AMERICAN ACADEMY
OF OPHTHALMOLOGY®
Protecting Sight. Empowering Lives.

Master Index

2019–2020
BCSC
Basic and Clinical Science Course™



American Academy of Ophthalmology Staff

Dale E. Fajardo, EdD, MBA, *Vice President, Education*
Beth Wilson, *Director, Continuing Professional Development*
Ann McGuire, *Acquisitions and Development Manager*
Stephanie Tanaka, *Publications Manager*
Teri Bell, *Production Manager*
Susan Malloy, *Acquisitions Editor and Program Manager*
Jasmine Chen, *Manager of E-Learning*
Beth Collins, *Medical Editor*
Eric Gerdes, *Interactive Designer*
Naomi Ruiz, *Publications Specialist*
Debra Marchi, *Permissions Assistant*

Index by Michael Ferreira, San Marcos, California

Cover image: From BCSC Section 9, *Uveitis and Ocular Inflammation*. Large mutton-fat keratic precipitates in a patient with sarcoidosis. *(Courtesy of Debra Goldstein, MD.)*

American Academy of Ophthalmology
655 Beach Street
Box 7424
San Francisco, CA 94120-7424

The 2019–2020 BCSC® Master Index is available at aao.org/bcscmi.

Copyright © 2019 American Academy of Ophthalmology. All rights reserved. No part of this publication may be reproduced without written permission.

Basic and Clinical Science Course 2019–2020

Louis B. Cantor, MD, Indianapolis, Indiana, *Senior Secretary for Clinical Education*
Christopher J. Rapuano, MD, Philadelphia, Pennsylvania, *Secretary for Lifelong Learning and Assessment*
Colin A. McCannel, MD, Los Angeles, California, *BCSC Course Chair*

Section 1 *Update on General Medicine*
Chair: Herbert J. Ingraham, MD, Danville, Pennsylvania
Section 2 *Fundamentals and Principles of Ophthalmology*
Chair: Vikram S. Brar, MD, Richmond, Virginia
Section 3 *Clinical Optics*
Chair: Scott E. Brodie, MD, PhD, New York, New York
Section 4 *Ophthalmic Pathology and Intraocular Tumors*
Chair: Robert H. Rosa, Jr, MD, Temple, Texas
Section 5 *Neuro-Ophthalmology*
Chair: M. Tariq Bhatti, MD, Durham, North Carolina
Section 6 *Pediatric Ophthalmology and Strabismus*
Chair: Robert W. Hered, MD, Maitland, Florida
Section 7 *Oculofacial Plastic and Orbital Surgery*
Chair: Bobby S. Korn, MD, PhD, La Jolla, California
Section 8 *External Disease and Cornea*
Chair: Robert W. Weisenthal, MD, De Witt, New York
Section 9 *Uveitis and Ocular Inflammation*
Chair: H. Nida Sen, MD, MHSc, Bethesda, Maryland
Section 10 *Glaucoma*
Chair: Christopher A. Girkin, MD, Birmingham, Alabama
Section 11 *Lens and Cataract*
Chair: Sharon L. Jick, MD, St Louis, Missouri
Section 12 *Retina and Vitreous*
Chair: Colin A. McCannel, MD, Los Angeles, California
Section 13 *Refractive Surgery*
Chair: M. Bowes Hamill, MD, Houston, Texas

Master Index

(*f* = figure; *t* = table. The BCSC Section number is indicated by the number preceding the period.)

A

A2E, 12.31
A constant, in IOL power determination/power prediction formulas, 11.85
A-pattern strabismus
clinical features of, 6.109
clinically significant, 6.109
definition of, 6.107
etiology of, 6.107–109, 6.108*f*
in exotropia, 6.108*f*, 6.109, 6.112
heterotopy as cause of, 6.28
horizontal rectus muscle transposition for, 6.112
identification of, 6.109
intorsion as cause of, 6.107, 6.110
medial rectus muscle displacement for, 6.110, 6.111*f*
palpebral fissure slanting associated with, 6.196
superior oblique muscle overaction associated with, 6.107
superior oblique tenotomy for, 6.112
surgical treatment of, 6.112, 6.112*t*
A-R syndrome. *See* Axenfeld-Rieger syndrome
A-scan ultrasonography/echography, 2.463*f*, 2.463*t*, 2.463–464, 7.31. *See also* Ultrasonography/ultrasound (echography)
for axial length measurement, 3.244–245, 3.245–246*f*
in IOL power determination/selection, 11.82–83, 11.83*f*, 11.85, 11.87
in primary congenital glaucoma, 10.160
in choroidal hemangioma, 4.281, 4.282*f*
in choroidal melanoma/ciliary body melanoma, 4.265, 4.266*f*
in metastatic eye disease, 4.307
a-wave
of ERG, 5.96, 12.46, 12.251. *See also* Electroretinography/electroretinogram
in rod–cone dystrophies, 12.261
AA. *See* Arachidonic acid
AAION. *See* Arteritic ischemic optic neuropathy, anterior
AAO. *See* American Academy of Ophthalmology
AAO Task Force on Genetic Testing, 2.240–241
AAP. *See* American Academy of Pediatrics
AAPOX. *See* Adult-onset asthma with periocular xanthogranuloma
AAV. *See* Adeno-associated virus
Ab externo approach
for IOL dislocation repair, 11.145, 11.147*f*
for trabeculotomy, in pediatric glaucoma, 10.160, 10.161–162, 10.162*f*, 10.163
Ab interno approach, for IOL dislocation repair, 11.145
Ab interno trabeculectomy, 6.287, 10.219
cataract surgery and, 11.186
Abatacept, 1.180, 2.406*t*, 6.322
for uveitis, 9.112
Abbe number
definition of, 3.195
of polycarbonate lenses, 3.196
ABC System (International Classification System for Intraocular Retinoblastoma), 4.297, 4.297*t*
ABC transporters/transporter protein. *See* ATP-binding cassette (ABC) transporters/transporter protein
ABCA4 gene, 6.339
description of, 2.308, 2.326, 2.328
retinopathy caused by, 12.31
in Stargardt disease, 4.168–169, 12.271
ABCC5 gene, in primary angle closure, 10.121
ABCC6 gene, 12.87
ABCDE mnemonic, for melanoma, 1.221
ABCR gene, 2.328
Abducens nerve. *See* Cranial nerve VI
Abduction
definition of, 6.33
extraocular muscles in, 5.46*f*
inferior oblique muscle, 5.46*f*
lateral rectus muscle, 5.46*f*
oblique muscles, 5.46*f*
superior oblique muscle, 5.46*f*
impaired, in younger patient, 5.201
lateral rectus muscle, 6.35*f*
nystagmus and (dissociated/disconjugate), 5.247
Aberrant nerve regeneration. *See also* specific nerve
cranial nerve III (oculomotor), 5.197–198, 5.198*f*
anisocoria and, 5.265–266
light-near dissociation and, 5.266*t*, 5.267
cranial nerve VII (facial), 5.277
superior oblique myokymia and, 5.250
synkinesis and, 5.197, 5.271, 5.271*f*, 5.277
Aberrations. *See also* Wavefront aberrations; *specific type*
astigmatism
irregular, 13.17–19, 13.18*f*, 13.19*f*. *See also* Irregular astigmatism
regular, 13.17, 13.18*f*
chromatic, 3.40, 3.72, 3.166, 3.199
coma, 3.275*f*, 3.275–276, 13.9, 13.12, 13.12*f*, 13.103*f*
definition of, 3.39, 3.69
first-order, 13.11
fourth-order, 13.12, 13.12*f*
higher-order, 13.11–13, 13.12*f*, 13.13*f*
keratorefractive surgery and, 3.276–277
after LASIK, 13.11, 13.12, 13.102–103, 13.103*f*
pupil size and, 3.106
after surface ablation, 13.11, 13.12, 13.13, 13.102
topography-guided laser ablation and, 13.32, 13.77
wavefront-guided/wavefront-optimized ablation and, 13.13, 13.31–32, 13.76–77
Zernike polynomials and, 3.139
after LASIK, 13.11, 13.12, 13.102–103, 13.103*f*
lower-order, 13.11, 13.11*f*
measurement/graphical representations of, 13.9–10, 13.10*f*
after photoablation, 13.11–13, 13.102–103, 13.103*f*
piston, 13.11

point spread function, 3.69–70
retinal reflex, 3.159
second-order, 13.11, 13.11*f*
Seidel, 3.41, 3.72, 3.72*f*
spherical, 3.42, 3.72, 3.72*f*, 3.74*f*, 3.159, 3.268–269, 3.272, 3.275–3.276*f*, 3.276, 13.9, 13.12, 13.12*f*, 13.102. *See also* Spherical aberration
after LASIK, 13.12, 13.102
after radial keratotomy, 13.50
after surface ablation, 13.12, 13.102
after surface ablation, 13.11, 13.12, 13.13, 13.102
third-order, 13.12, 13.12*f*
trefoil, 13.9, 13.12, 13.13*f*, 13.103*f*
wavefront. *See* Wavefront aberrations
zero-order, 13.11
Aberrometry/aberrometers, wavefront, 3.289–292, 3.290–3.291*f*
intraoperative, in IOL power determination/selection
astigmatism and, 11.124
after refractive surgery, 11.86
Abetalipoproteinemia, 2.236, 12.289–290
Ablepharon, 6.193
Ablepharon-macrostomia syndrome, 6.193
Abnormal head position (AHP), in torticollis, 6.82
AbobotulinumtoxinA, 5.281, 7.269. *See also* Botulinum toxin
ABPM. *See* Ambulatory blood pressure measurement
Abrasions, corneal, 4.13–14, 8.398–399
in mucous membrane pemphigoid, 8.300
posttraumatic recurrent corneal erosion and, 8.86, 8.87, 8.398
Absence seizures, 1.207
Absidia, 8.249*t*, 8.251
Absolute risk reduction (ARR), 1.22
Absolute scotomas, 12.327
Absorptive lenses, 3.192–194, 3.193*f*. *See also* Sunglasses
Abuse, elder, 1.185–187
Abusive head trauma (AHT), 1.299, 6.381–384, 6.382–383*f*, 12.365–366, 12.366*f*
AC. *See* Accommodative convergence/vergence
AC/A. *See* Accommodative convergence/accommodation (AC/A) ratio
AC/A ratio. *See* Accommodative convergence/accommodation (AC/A) ratio
ACA. *See* Anterior cerebral artery
ACAID. *See* Anterior chamber-associated immune deviation
Acanthamoeba, 2.437
cysts, 8.252, 8.252*f*
description of, 3.229, 8.252, 8.252*f*
keratitis/ocular infection caused by, 4.78–79, 4.79*f*, 8.208*t*, 8.252, 8.276–279, 8.277–278*f*
confocal microscopy in diagnosis of, 8.24, 8.277, 8.278*f*
contact lens wear and, 4.78–79, 8.276, 8.277
herpes simplex keratitis differentiated from, 8.278
isolation techniques for diagnosis of, 4.79, 8.211
pathogenesis and, 8.207, 8.276
stains and culture media for identification of, 4.79, 8.209*t*, 8.277
treatment of, 8.277–279
stains and culture media for identification of, 4.79, 8.209*t*, 8.277
Acantholysis, definition of, 4.202
Acanthosis
in actinic keratosis, 4.211*f*
definition of, 4.202
in seborrheic keratosis, 4.209
ACC. *See* Adenoid cystic carcinoma; American College of Cardiology
Accelerated corneal crosslinking, 13.134. *See also* Corneal (collagen) crosslinking
Accessory lacrimal glands
of Krause, 4.202
of Wolfring, 4.202
Accessory molecules, helper T cell expression of, 9.31
Accessory ophthalmic artery, 2.23*f*
Accidental trauma, 6.375–381, 6.377–378*f*, 6.380*f*. *See also* Trauma
Accommodating intraocular lenses, 3.261, 11.122, 11.122*f*, 13.8*t*, 13.154, 13.163–164, 13.164*f*
complications of, 11.151
Accommodation, 11.22–23, 11.23*t*, 13.159–162, 13.160*f*, 13.161*f*
age-related values for, 3.176*t*
aging effects on, 11.23, 13.159. *See also* Presbyopia
amplitude of, 6.188, 11.23
age-related changes in, 3.176, 3.176*t*
aging affecting, 11.23
definition of, 3.147
description of, 3.140
measurement of, 3.178–179
near point of accommodation for, 3.179
Prince rule for measuring, 3.179, 3.179*f*
spheres method for measuring, 3.179
changes with, 11.22–23, 11.23*t*
nonorganic disorders and, 5.310
in children, 2.79
contact lenses and, 3.178, 3.208–211, 3.209*f*, 3.210*t*
definition of, 3.34, 3.123, 3.140
direct-acting cholinergic agonists' effect on, 2.375
dynamic retinoscopy measurements of, 6.9
after fogging, 3.152, 3.160
Goldberg theory of reciprocal zonular action and, 13.162
Helmholtz hypothesis (capsular theory) of, 11.22, 13.159–160, 13.160*f*
hypoaccommodation, 6.9
in manifest refraction, 3.34–36
near point of
definition of, 3.140
measurement of, 3.179
pupil size effects on, 3.130
paralysis of, 3.174
presbyopia. *See* Presbyopia
range of, 3.140, 3.180
refractive error progression and, 3.144
relaxing of, 3.177. *See also* Cycloplegia/cycloplegics
Schachar theory of, 13.160–162, 13.161*f*
spasm of (ciliary muscle spasm), 3.176, 5.310
spectacle lens correction effects on, 3.178
stimulating of, 3.177
theories of, 13.159–162, 13.160*f*, 13.161*f*
zonular fibers in, 13.159, 13.160, 13.160*f*, 13.161, 13.161*f*

Accommodative control
definition of, 3.35
in manifest refraction, 3.34–36
"Rule-1" test for, 3.35
Accommodative convergence/accommodation (AC/A) ratio, 5.226–227
definition of, 6.71
description of, 3.175, 6.39
gradient method for, 3.177–178
heterophoria method for, 3.177
high
in accommodative esotropia, 6.90–92
accommodative esotropia and, 5.227
bifocal glasses for, 6.102
in intermittent exotropia, 6.100
measurement of, 6.71
response, 6.71
stimulus, 6.71
Accommodative convergence/vergence (AC), 5.226, 6.39, 6.59. *See also* Accommodative convergence/accommodation (AC/A) ratio
assessment of, 5.226–227
Accommodative demand, 3.208–210, 3.209*f*
Accommodative effort
asthenopic complaints associated with, 3.24
definition of, 3.140
Accommodative esodeviations
cycloplegic examinations for, 6.11
surgical treatment of, 6.102
Accommodative esotropia, 2.379, 5.227
amblyopia associated with, 6.91
definition of, 6.90
description of, 6.57
evaluation of, 6.91
high AC/A ratio, 5.227, 6.90–92
management of, 6.91–92
nonrefractive, 6.90
partially, 6.90–92
pathogenesis of, 6.90–91
refractive, 6.90–92
refractive surgery and, 13.188
types of, 6.86*t*, 6.90–91
Accommodative excess, 3.176
Accommodative insufficiency, 3.176
Accommodative intraocular lenses. *See* Accommodating intraocular lenses
Accommodative power, 2.79
Accommodative response, 3.140. *See also* Accommodation
Accommodative tone, situations that increase, 3.35
ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, 1.78, 12.98
Accuracy, saccadic eye movement, 5.221
ACD. *See* Anterior chamber depth
ACE. *See* Angiotensin-converting enzyme
ACE inhibitors. *See* Angiotensin-converting enzyme (ACE) inhibitors
ACED. *See* Assessment of Capacity for Everyday Decision-Making
Acephalgic migraine (aura without headache), 5.172, 5.177, 5.290, 5.291. *See also* Migraine headache
Acetazolamide sodium, 12.305, 12.393
for glaucoma, 10.172–173*t*, 10.180
in children, 10.165
for idiopathic intracranial hypertension, 5.112, 6.371
for intraocular pressure, 2.362, 2.391*t*, 2.392
Acetic acid (HAcetate/$CH_3CO_2H/C_2H_4O_2$), ocular injuries caused by, 8.376*t*
Acetylcholine (ACh)
degradation of, 2.377*f*
intracameral use of, 2.360*t*, 2.375–376
synthesis of, 2.377*f*
Acetylcholine receptor (AChR) antibody tests, for myasthenia gravis, 5.325–326
Acetylcholine receptors
antibodies, 6.142
description of, 2.374, 2.374*f*, 2.375*t*
drugs affecting. *See* Cholinergic agents
in myasthenia gravis, 5.323
Acetylcholinesterase, 2.375–376, 2.377*f*
Acetylcholinesterase inhibitors. *See* Cholinesterase/acetylcholinesterase inhibitors
Acetylcysteine, 2.371*t*
for filamentary keratopathy, 8.63, 8.304
N-Acetylgalactosamine-4-sulfatase deficiency, in Maroteaux-Lamy syndrome, 8.175*t*
Acetyltransferase, 2.233
ACh. *See* Acetylcholine
Achiasma, congenital, nystagmus caused by, 5.247
AChoA. *See* Anterior choroidal artery
AChR. *See* Anti–acetylcholine receptor (AChR) antibodies
Achromatic automated perimetry, 10.59. *See also* Perimetry
Achromatopsia (monochromatism), 6.337–338, 12.250, 12.250*t*
cerebral, 5.179
description of, 2.229
infantile nystagmus syndrome and, 5.236
Acid, ocular injuries caused by, 8.376*t*, 8.380–381, 8.380–381*f*. *See also* Chemical injury
cataract and, 11.59
Acid burns, 6.376, 8.376*t*, 8.380*f*, 8.380–381, 8.381*f*
Acid-fast stain, 8.244
ACIOLs (anterior chamber intraocular lenses). *See* Intraocular lenses (IOLs), anterior chamber
ACL (*a*cromegaly, *c*utis verticis gyrata, corneal *l*eukoma) syndrome, congenital corneal keloids in, 8.107
ACLS. *See* Advanced cardiac life support
Acne rosacea. *See* Rosacea
ACoA. *See* Anterior communicating artery
Acoustic neuromas/neurofibromas
description of, 5.330, 5.334*t*, 6.397, 10.156
seventh nerve (facial) palsy and, 5.279, 5.279*f*
Acquired (adaptive) immunity. *See* Adaptive immune response/adaptive immunity
Acquired aponeurotic ptosis, 7.245, 7.245*f*, 7.245*t*
Acquired distichiasis, 7.170
Acquired immunodeficiency syndrome (AIDS). *See* AIDS (acquired immunodeficiency syndrome); HIV (human immunodeficiency virus); HIV infection/AIDS
Acquired myogenic ptosis, 7.245

Acquired nonaccommodative esotropia
basic, 6.93
consecutive esotropia, 6.95
cyclic esotropia, 6.93
description of, 6.92
divergence insufficiency, 6.94
near reflex spasm, 6.94
sensory esotropia, 6.93–94
types of, 6.86*t*
Acquired ocular motor apraxia, 5.223
Acquired optic disc pit, 10.49–50
Acquired pendular nystagmus, 5.246–247
Acquired ptosis. *See* Ptosis
Acquired strabismus, 6.16
Acquired vasoproliferative lesions, 12.168
Acrocephalopolysyndactyly (Carpenter syndrome), 8.191*t*
Acrocephalopolysyndactyly type II, 8.191*t*
Acrocephalosyndactyly (Apert syndrome), 6.206–207, 6.207*f*, 6.209*f*, 7.39, 7.39*f*, 8.191*t*
Acrodermatitis chronica atrophicans, 9.228
Acromegaly, 1.48
*A*cromegaly, *c*utis verticis gyrata, corneal *l*eukoma (ACL) syndrome, congenital corneal keloids in, 8.107
Acropachy, 7.58
Acrylic, for IOLs, 11.120, 13.139*t*, 13.144. *See also* Foldable intraocular lenses
glistenings and, 11.151
ocular trauma and, 11.193
opacification and, 11.151
uveitis and, 11.140, 11.188
Acrylic intraocular lenses, 3.256
Acrysof ReSTOR bifocal IOLs, 3.262
ACS. *See* Acute coronary syndromes; American Cancer Society; Anterior ciliary sclerotomy
ACTA2 gene, 6.268
Actin, 2.285
in immunohistochemistry, 4.33
in adenoid cystic carcinoma, 4.231
"Actinic" band keratopathy, 4.83
Actinic injury. *See* Photochemical injury
Actinic (Labrador/climatic droplet) keratopathy (spheroidal degeneration), 4.83, 4.83*f*, 8.115–117, 8.116*f*
Actinic keratosis, 4.210–212, 4.211*f*, 4.212*f*, 7.198–199, 7.199*f*
squamous cell carcinoma and, 4.211
Actinomyces/Actinomyces israelii/actinomycetes, 7.305, 7.313, 8.208*t*, 8.244*t*, 8.248
Actinomycetes, infectious scleritis caused by, 9.119*f*
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, 1.78, 12.98
Activated neutrophils, 9.10
Activated partial thromboplastin time (aPTT), 1.139, 1.144
Activated protein C (APC), 1.139
Activated protein C resistance, 1.146–147
Active force generation test, 6.73
Active immunization, 1.223
Active medium, of lasers, 3.111, 3.112*f*
Active pulley hypothesis, 6.28
Active transport/secretion
in aqueous humor dynamics, 10.16
in lens, 11.21
epithelium as site of, 11.21
pump-leak theory and, 11.21, 11.22*f*
Activities of Daily Vision Scale (ADVS), 11.71
Acuity. *See* Visual acuity
Acuity meter, potential. *See* Potential acuity estimation/potential acuity meter (PAM) testing
Acular. *See* Ketorolac
Acular LS. *See* Ketorolac
Acular PF. *See* Ketorolac
Acute anterior uveitis. *See* Anterior uveitis, acute
Acute brainstem syndrome, 5.117*t*
Acute coronary syndromes (ACS). *See also* Coronary heart disease
anticoagulants for, 1.93–94
definition of, 1.83
myocardial infarction. *See* Myocardial infarction
treatment of, 1.93–95
troponins associated with, 1.87
Acute dacryocystitis, 7.313–314
Acute diencephalic syndrome, 5.117*t*
Acute disseminated encephalomyelitis, optic nerve involvement and, 4.244, 4.244*f*
Acute disseminated intravascular coagulation, 1.146
Acute exudative polymorphous vitelliform maculopathy, 12.287
Acute hemorrhagic conjunctivitis (AHC), 8.240, 8.240*t*
Acute idiopathic blind-spot enlargement (AIBSE), 5.100–101, 5.101*f*
fundus autofluorescence in identification of, 5.90
Acute idiopathic maculopathy (AIM), 12.228–229
Acute lymphoblastic leukemia, 6.413
Acute macular neuroretinopathy (AMN), 12.228, 12.229*f*, 12.277
fundus autofluorescence in identification of, 5.90
multiple evanescent white dot syndrome and, 9.189
OCT in identification of, 5.92, 5.93*f*
Acute multifocal posterior placoid pigment epitheliopathy (AMPPPE). *See* Acute posterior multifocal placoid pigment epitheliopathy
Acute myocardial infarction. *See also* Myocardial infarction
description of, 1.83
non–ST-segment elevation, 1.83
Acute paralytic strabismus, 6.175
Acute posterior multifocal placoid pigment epitheliopathy (APMPPE), 12.220*t*, 12.221*f*, 12.221–222
cerebral vasculitis and, 9.170
characteristics of, 9.162–164*t*
definition of, 9.169
diagnosis of, 9.170–172, 9.171–172*f*
fluorescein angiography findings in, 9.163*t*, 9.170, 9.171*f*
fundus autofluorescence findings in, 9.163*t*, 9.171, 9.172*f*
indocyanine green angiography findings in, 9.163*t*, 9.170–171, 9.171*f*
manifestations of, 9.170, 9.170*f*
medical management of, 9.93
optical coherence tomography findings in, 9.164*t*, 9.171, 9.172*f*
posterior uveitis in, 9.169–174, 9.170–173*f*
prognosis for, 9.172–173

relentless placoid chorioretinitis, 9.173*f*, 9.173–174
retinal pigment epithelium involvement by, 9.171
serpiginous choroiditis *versus*, 9.171
systemic conditions associated with, 9.169–170
vision loss risk factors in, 9.172–173
Acute respiratory distress, 6.230
Acute retinal necrosis (ARN), 4.145, 4.146*f*, 9.250, 9.251–252*f*, 9.324, 9.330, 12.236, 12.236*f*
Acute retinal pigment epitheliitis (ARPE), 9.162–164*t*, 9.189*f*, 9.189–190
Acute spastic entropion, 7.237
Acute symptomatic flap tears. *See* Flap tears
Acute syphilitic posterior placoid chorioretinitis (ASPPC), 12.241
Acute syphilitic retinitis, 9.222, 9.224*f*
Acute thyroiditis, 1.45
Acute zonal occult outer retinopathy (AZOOR), 5.101
characteristics of, 9.162–164*t*
complex of diseases, 9.192. *See also* White dot syndromes; *specific disorder*
course of, 9.191–192
definition of, 9.190
description of, 12.226–228, 12.227*f*
differential diagnosis of, 9.191–192
electro-oculography of, 12.51
fluorescein angiography findings in, 9.163*t*, 9.191
fundus autofluorescence findings in, 5.90, 9.163*t*, 9.191, 9.192*f*
optical coherence tomography findings in, 5.92, 9.164*t*, 9.191, 9.191*f*
retinal pigment epithelium findings in, 9.190, 9.190*f*
visual acuity in, 9.191
white dot syndromes *versus*, 9.192
Acuvail. *See* Ketorolac
Acyclovir, 8.215*t*
acute retinal necrosis treated with, 12.236
description of, 1.277–278, 2.432*t*, 2.433–434
Epstein-Barr virus treated with, 1.261
for herpes simplex virus
before cataract surgery, 11.175
description of, 1.260, 1.278, 8.215*t*, 8.219, 8.222, 8.223*t*, 9.249
for herpes zoster infections, 6.243, 8.229
for herpetic retinitis, 12.238*t*
for iridocyclitis, 8.222–224
progressive outer retinal necrosis syndrome treated with, 12.236
for stromal keratitis, 8.222, 8.223*t*
for varicella-zoster virus, 1.261, 9.252
Acyl ureidopenicillins, 1.272
AD. *See* Alzheimer disease
Adalimumab, 1.180, 2.405*t*, 6.322
for Behçet disease, 9.216, 9.218
for uveitis
description of, 9.110–111
intermediate, 9.150
sarcoidosis-associated uveitis, 9.199
treatment studies of, 9.100–101*t*
Adamantiades-Behçet disease. *See* Behçet disease
ADAMTS4 gene, 6.268
ADAMTS10 gene, 6.309
ADAMTS13, thrombotic thrombocytopenic purpura caused by, 1.142
ADAMTSL4 gene, 6.268
Adaptation
dark. *See also* Dark adaptation
in electro-oculography, 12.50
in full-field (Ganzfeld) electroretinography, 12.42
light. *See also* Light adaptation
in electro-oculography, 12.50
in full-field (Ganzfeld) electroretinography, 12.42
Adaptive immune response/adaptive immunity. *See also* Immune response; Immune response arc
conjunctiva and, 9.53
definition of, 9.1
description of, 1.246
effector responses of
antibody-dependent cellular cytotoxicity, 9.47–48
antibody-mediated, 9.39*f*, 9.39–42, 9.40*t*
lymphocyte-mediated, 9.42–46, 9.43*f*, 9.44*t*
natural killer cells in, 9.46
types of, 9.38*t*
innate immune response *versus*, 9.27
mechanisms of, 9.36, 9.36*f*, 9.38
mediator systems affecting. *See* Mediators
purpose of, 9.27–28
subclinical presence of, 9.6
Adaptive optics, 3.281, 3.305–306, 3.306*f*, 12.33
Adaptive optics scanning laser ophthalmoscope, of macula, 12.13*f*
Adaptive T regulatory cells, 9.34
ADC. *See* Apparent diffusion coefficient
ADC mapping. *See* Apparent diffusion coefficient (ADC) technique/mapping
ADCC. *See* Antibody-dependent cellular cytotoxicity
Add power
of bifocal lens, 3.178–180
higher, for low vision, 3.320
Additions
near-point, 3.37
progressive. *See* Progressive addition lenses
Additive interference, 3.100
Adduction
definition of, 6.33
extraocular muscles in, 5.46*f*
inferior rectus muscle, 5.46*f*
medial rectus muscle, 5.46*f*
superior rectus muscle, 5.46*f*
nystagmus and (dissociated/disconjugate), 5.247
overdepression in
causes of, 6.17, 6.116*t*, 6.116–118
description of, 6.17
pattern strabismus and, 6.107, 6.108*f*, 6.109
superior oblique muscle overaction as cause of, 6.118, 6.118*f*, 6.137
overelevation in
causes of, 6.17, 6.116*t*, 6.116–118
description of, 6.17
inferior oblique muscle overaction as cause of, 6.117*f*, 6.117–118
pattern strabismus and, 6.107, 6.108*f*, 6.109
underdepression in, 6.17
underelevation in, 6.17
Adefovir, 1.279
Adenine (DNA), 2.176
Adenine arabinoside. *See* Vidarabine

Adeno-associated virus (AAV)
  description of, 9.58
  vectors for, 2.194, 2.196
Adenocarcinoma, 4.10, 4.10*t*
  esophageal, 1.219
  paranasal sinuses, 7.102
  retinal pigment epithelium, 4.180, 4.279
  sebaceous, 4.210*t*, 4.215–218, 4.216*f*, 4.217*f*, 8.327, 8.337*f*, 8.337–338
Adenoid cystic carcinoma (ACC/cylindroma)
  description of, 7.100, 7.193, 7.193*f*
  of lacrimal gland, 4.230–231, 4.231*f*
Adenoma, 4.10, 4.10*t*
  Fuchs (pseudoadenomatous hyperplasia), 4.179, 4.279
  gonadotroph, 1.48
  lactotroph, 1.48
  null-cell, 1.48
  pituitary, 1.47–49
    chiasmal syndromes caused by, 5.147, 5.148*f*
    neuroimaging in evaluation of, 5.72*t*, 5.92*f*, 5.93–94*f*
    in pregnancy, 5.147, 5.333
  pleomorphic (benign mixed tumor)
    description of, 7.98–100, 7.99*f*, 7.192
    of lacrimal gland, 4.229–230, 4.230*f*
  plurihormonal, 1.48
  retinal pigment epithelium, 4.180, 4.279
  sebaceous (sebaceum), 4.210*t*, 4.215, 4.216*f*, 7.191
    in tuberous sclerosis, 5.331*f*, 10.30
  somatotroph, 1.47–48
  thyroid, 1.46
  of uvea/retina, 4.279
Adenomatous polyposis, familial (FAP/Gardner syndrome)
  description of, 6.349, 6.350*f*
  retinal manifestations of, 4.144–145, 4.269, 12.285–286
Adenosine triphosphate (ATP), 2.287, 2.290*f*, 2.311
Adenoviral conjunctivitis, 2.38
Adenoviruses (Adenoviridae)/adenoviral infection, 8.208*t*, 8.233–236, 9.272
  conjunctivitis, 4.52, 6.241–242, 8.208*t*, 8.233, 8.234*f*, 8.234–236, 8.235*f*
    acute hemorrhagic conjunctivitis, 8.240
    cicatricial conjunctivitis differentiated from, 8.301*t*
    epidemic keratoconjunctivitis, 8.233, 8.234*f*, 8.234–236, 8.235*f*
    follicular conjunctivitis, 8.233, 8.234
  herpes simplex infection differentiated from, 8.213–214
  keratitis caused by, 6.269
  pharyngoconjunctival fever caused by, 6.242, 8.233–234
Adenylate cyclase, 2.385
Adherence issues (therapy)
  in glaucoma management, 10.184
    in elderly patients
      glaucoma surgery and, 10.221
      medication use and, 10.186
  in ocular infection, 8.206
Adherence syndrome, 6.172
Adhesins, 8.206–207, 8.244
Adie tonic pupil, 5.256*f*, 5.263*f*, 5.263–265, 5.264*f*, 5.265*f*
  light-near dissociation and, 5.263, 5.264*f*, 5.266*t*
  pharmacologic testing for, 5.256*f*, 5.264–265, 5.265*f*
  pilocarpine for diagnosis of, 2.377
Adipose tissue, in orbit, 6.25
Adipose tumors, of orbit, 4.238
Adits, 7.274
Adjustable sutures, in extraocular muscle surgery, 6.165
Adjuvant chemotherapy, 1.239
Adnexa. *See* Ocular adnexa
ADOA. *See* Autosomal dominant optic atrophy
Adolescents. *See also* Children
  bacterial conjunctivitis in, 6.240*f*, 6.240–241
  glaucoma in, 10.147–167. *See also* Glaucoma, pediatric
  hypertension in, 1.68
  myopia in, 3.142
  perioperative management for ocular surgery in, 1.283
Adrenaline. *See* Epinephrine
Adrenergic agents. *See also* Alpha (α)-adrenergic agents; Beta (β)-blockers; *specific agent*
  angle closure caused by, 10.122
  β-, 2.387–390, 2.389*t*
  for glaucoma, 10.176–179
    agonists, 10.172*t*, 10.177–179, 10.178*f*
    antagonists/β-blockers, 10.164–165, 10.171–172*t*, 10.176–177
    ocular surface toxicity of, 8.90*t*
  inhibitors. *See* Alpha (α)-blockers; Beta (β)-blockers
  overview of, 2.382, 2.384
Adrenergic agonists
  α_1-, direct-acting, 2.384
  α_2-, 2.385–386
  β_2-, 1.128, 2.385*t*, 2.387–389
  indirect-acting, 2.387
Adrenergic receptors (adrenoceptors). *See also specific type*
  α_1, 2.382
  α_2, 2.382, 2.385
  β_1, 2.382, 2.383*f*
  β_2, 2.382, 2.383*f*
  β_3, 2.382
  categories of, 2.382
  drugs affecting. *See* Adrenergic agents
  sites of, 2.382, 2.384
Adrenoceptors. *See* Adrenergic receptors (adrenoceptors)
Adrenochrome deposition
  description of, 8.118*t*, 8.131*f*, 8.131–132
  epinephrine causing, 8.131, 10.31
ADRP. *See* Autosomal dominant retinitis pigmentosa
Adult cystinosis (nonnephropathic cystinosis), 8.181, 8.181*f*
Adult inclusion conjunctivitis, 6.241
Adult-onset asthma with periocular xanthogranuloma (AAPOX), 7.97
Adult-onset diabetes. *See* Diabetes mellitus (DM), type 2
Adult-onset foveomacular vitelliform dystrophy (AFMVD), 4.170, 4.171*f*, 12.272, 12.276
Adult-onset myopia, 3.143
Adult-onset vitelliform lesions, 12.272, 12.273*f*
Adult-onset vitelliform maculopathy
  fluorescein angiography of, 12.68
  spectral-domain optical coherence tomography of, 12.67–68, 12.68*f*
Adult-onset xanthogranuloma (AOX), 7.97

Adult T-cell leukemia/lymphoma, 9.265, 9.266*f*
Adult Treatment Panel (ATP), 1.71, 1.74
Advanced cardiac life support (ACLS), 1.299
Advanced Glaucoma Intervention Study (AGIS), 10.113–115
Advanced glycation cross-link breakers, 1.65
Advanced glycation end products (AGEs), 1.65, 2.345
Advanced surface ablation (ASA). *See* Photorefractive keratectomy
Advancement
  definition of, 6.164*t*
  of inferior oblique muscle, 6.166
  of plica semilunaris, 6.171
  of thickened Tenon capsule too close to limbus, 6.171
Advancement flaps, 8.359, 8.359*f*
ADVIRC. *See* Autosomal dominant vitreoretinochoroidopathy
ADVS (Activities of Daily Vision Scale), 11.71
AED. *See* Automated external defibrillator
Aedes aegypti mosquito, 1.265, 6.413, 9.267, 12.247
Aerial image, 3.298, 3.300, 3.300*f*
Aerobic glycolysis, in lens glucose/carbohydrate metabolism, 11.18
AF. *See* Atrial fibrillation; Autofluorescence
Affective disorders, 1.195–196
Afferent lymphatic channels. *See* Lymphatic system
Afferent phase, of immune response arc, 9.29*f*, 9.29–30
Afferent pupillary defects, 7.119, 12.352
  in amblyopia, 6.56
  in ocular trauma, 8.401
  relative (RAPD). *See* Relative afferent pupillary defect
Afferent signal error information, 5.40
Afferent visual pathways, 5.23–31, 5.24*f*, 5.212
  in cortex, 5.24*f*, 5.29*f*, 5.29–31, 5.30*f*
  light-near dissociation and, 5.266, 5.266*t*
  nonorganic disorders and, 5.301–305, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*
  optic chiasm, 5.23*f*, 5.27*f*, 5.27–28, 5.28*f*
  optic nerve, 5.24*f*, 5.26–27
  optic tract, 5.23*f*, 5.28–29
  in retina, 5.23–25, 5.24*f*, 5.25*f*
  visual evoked potential testing in evaluation of, 5.95
Affinity constant (K_m), sorbitol in cataract development and, 11.19
Aflibercept (VEGF Trap)
  branch retinal vein occlusion treated with, 12.135
  central retinal vein occlusion treated with, 12.135
  description of, 2.449, 12.82
  diabetic macular edema treated with, 12.113
  for macular edema, 4.152
  macular telangiectasia type 1 treated with, 12.161
  neovascular age-related macular degeneration treated with, 12.82–83
  retinal vein occlusion treated with, 12.135
AFMVD. *See* Adult-onset foveomacular vitelliform dystrophy
African Americans. *See also* Race
  sickle cell hemoglobinopathies and, 12.149, 12.154
  systemic lupus erythematosus in, 12.230
Afterimages/afterimage test
  description of, 6.51, 6.79, 6.79*f*
  in palinopsia, 5.176
  transient monocular visual loss and, 5.164
Against movement, in retinoscopy, 3.152, 3.153*f*, 3.155
Against-the-rule astigmatism, 3.123, 3.139, 3.250, 8.31, 8.32*t*, 8.33*f*
Age/aging
  accommodation affected by, 3.176*t*
  accommodative response/presbyopia and, 11.23, 13.159. *See also* Presbyopia
  angle-closure glaucoma and, 10.9, 10.81
  antiglaucoma medication/carbonic anhydrase inhibitor use and, 10.186
  cataracts associated with, 11.5, 11.43–48. *See also* Age-related cataracts
  central retinal vein occlusion and, 12.133
  central serous chorioretinopathy and, 12.189
  choroidal thickness affected by, 12.19, 12.212
  ciliary body hyalinization and, 4.189, 4.189*f*
  of conjunctiva, 8.112
  of cornea
    donor corneas and, 8.414, 8.416
    endothelial cell density and, 8.10, 8.23
    senile furrow degeneration and, 8.122
  depression associated with, 1.188–190
  eye changes secondary to, 1.183–184
  giant cell arteritis and, 5.288
  glaucoma and
    angle-closure, 10.9, 10.81
    antiglaucoma medication/carbonic anhydrase inhibitor use and, 10.186
    open-angle, 10.7, 10.81–82
    surgery and, 10.221
  intraocular pressure affected by, 10.22, 10.81–82
  lens changes associated with, 11.11, 11.43–48. *See also* Age-related cataracts; Presbyopia
  lens proteins affected by, 11.17
  macular changes associated with. *See* Age-related macular degeneration/maculopathy
  near-point additions based on, 3.37
  ocular hypertension and, 10.81
  open-angle glaucoma and, 10.7, 10.81–82
  outflow facility affected by, 10.19
  physiology, 1.183–184
  posterior vitreous detachment associated with, 4.129, 12.307–308
  presbyopia and. *See* Presbyopia
  pseudoexfoliation/exfoliation syndrome and, 10.91
  psychology of, 1.188–190
  ptosis and, 5.273
  refractive surgery and, 13.38
    epithelial defects in LASIK and, 13.112
    overcorrection in photoablation and, 13.101
    radial keratotomy and, 13.50
    re-treatments/enhancement and, 13.98
  of sclera, 4.111, 4.111*f*, 8.128, 8.129*f*
  syneresis and, 4.128, 4.129*f*
  trabecular meshwork and, 10.18
  transient visual loss and, 5.161
  wavefront aberrations and, 13.11
Age-related cataracts, 11.5, 11.43–48. *See also specific type*
  cortical, 11.45–46, 11.46*f*, 11.47*f*, 11.48*f*, 11.49*f*, 11.50*f*
  in diabetes mellitus, 11.60
  epidemiology of, 11.5
  genetic contributions to, 11.41–42

indications for surgery and, 11.72
nuclear, 4.123, 4.124*f*, 11.43–45, 11.45*f*
nutritional deficiency and, 11.7, 11.63–64
posterior subcapsular, 11.46–48, 11.51*f*
Age-related distance esotropia, 6.94
Age-Related Eye Disease Study (AREDS), 2.340, 2.346, 11.7, 11.63, 12.64, 12.69–71, 12.70*t*
Age-Related Eye Disease Study 2 (AREDS2), 1.79
Age-related macular degeneration/maculopathy (AMD/ARMD), 3.315, 4.160–166, 4.161–165*f*
adult-onset foveomacular vitelliform dystrophy *versus*, 12.272, 12.273*f*
aging as cause of, 12.61
antiangiogenic/anti-VEGF agents for, 4.164
blindness caused by, 12.61
Bruch membrane calcification in, 12.19
cataract surgery effects on, 12.71
central blindness progression of, 12.86
central serous chorioretinopathy *versus*, 12.67, 12.76, 12.79
choroidal neovascularization in, 12.64. *See also* Choroidal neovascularization
cigarette smoking and, 12.62
clinical studies of. *See specific study*
depression associated with, 1.188
drusen associated with, 4.160–163, 4.161*f*, 4.162*f*, 4.163*f*
exudative, 12.79
obstructive sleep apnea and, 1.127
genetic factors/testing in, 4.160, 12.63
genetics of, 12.62–63
genome-wide association studies for, 2.193
indocyanine green applications in, 2.444
low vision therapies and rehabilitation, 12.86
management of, 12.68–71, 12.79–86, 12.81*f*, 12.82*t*, 12.84*t*
Manhattan plot for, 2.193*f*
melanoma differentiated from, 4.269, 4.270*f*
neovascular ("wet"/exudative), 2.449, 4.154*f*, 4.164–166, 4.165*f*. *See also* Neovascular ("wet"/exudative) age-related macular degeneration
aflibercept for, 12.82–83
Amsler grid testing of, 12.71
antiangiogenic therapies for, 12.79–80
bevacizumab for, 12.83–85, 12.84*t*
choroidal neovascularization associated with, 12.71–79. *See also* Choroidal neovascularization
combination treatment for, 12.85
differential diagnosis of, 12.76, 12.79
intravitreal injections, 12.85
laser photocoagulation for, 12.79
low vision therapies for, 12.86
macular translocation surgery for, 12.85
management of, 12.79–86, 12.81*f*, 12.82*t*, 12.84*t*
pegaptanib for, 12.80
photodynamic therapy for, 12.79
polypoidal choroidal vasculopathy, 12.75
prevalence of, 12.61
ranibizumab for, 12.80–82, 12.82*t*
signs and symptoms of, 12.71
submacular hemorrhage in, 12.85, 12.385
surgical treatment for, 12.85–86
treatment effect modifiers, 12.85
verteporfin for, 12.79
nonneovascular ("dry"/nonexudative), 4.164, 4.164*f*. *See also* Nonneovascular ("dry"/nonexudative) age-related macular degeneration
Amsler grid testing for, 12.68–69
differential diagnosis of, 12.67–68
disproven treatment approaches for, 12.71
drusen associated with. *See* Drusen
education regarding, 12.68
focal atrophy in, 12.66
follow-up for, 12.68
geographic atrophy in, 12.64, 12.66, 12.67*f*, 12.68
hydrochloroquine toxicity *versus*, 12.68
hyperacuity testing for, 12.69
lifestyle changes for, 12.71
management of, 12.68–71
micronutrients for, 12.69–71
preferential hyperacuity perimetry for, 12.69
prevalence of, 12.61
retinal pigment epithelium abnormalities in, 4.164, 4.164*f*, 12.66–67
shape-discrimination hyperacuity for, 12.69
nonsubfoveal, 12.69
oxidative stress in, 2.345
pharmacogenomic testing for, 12.63
polypoidal choroidal vasculopathy and, 4.168
prevalence of, 12.61
race and, 12.62
risk factors for, 12.62, 12.70*t*
statins and, 1.78–79
susceptibility genes for, 12.63
vascular endothelial growth factor inhibitors for, 2.449
vision loss caused by, 1.184
Agenesis
corpus callosum, 6.361
definition of, 6.183*t*
AGEs. *See* Advanced glycation end products
Aggressive posterior retinopathy of prematurity (AP-ROP), 6.326, 6.327*t*, 6.330*f*, 6.333, 12.177, 12.178*t*
Aging. *See* Age/aging
Aging face
pathogenesis of, 7.267
physical examination of, 7.267–268
rejuvenation techniques for. *See* Facial rejuvenation
AGIS (Advanced Glaucoma Intervention Study), 10.113–115
AgKS. *See* Antigenic keratan sulfate
Agnosia
object, 5.179
parietal lobe lesions and, 5.156
Agonist (drug), 6.33
definition of, 2.367
direct-acting
acetylcholine, 2.375–377
actions of, 2.375
adverse effects of, 2.378
indications for, 2.378
pilocarpine, 2.377–378
indirect-acting, 2.379
mechanism of action, 2.374–375

muscarinic
adverse effects of, 2.378
direct-acting, 2.375–379, 2.376–377*f*
indirect-acting, 2.379
types of, 2.376*f*
Agraphia
alexia with, 5.179
alexia without, 5.179, 5.180*f*
AGV. *See* Ahmed glaucoma valve/implant
AHA. *See* American Heart Association
AHC. *See* Acute hemorrhagic conjunctivitis
Ahmed glaucoma valve/implant (AGV), 10.214, 10.214*t*
AHP. *See* Abnormal head position
AHT. *See* Abusive head trauma
AIBSE. *See* Acute idiopathic blind-spot enlargement
AICA. *See* Anterior inferior cerebellar artery
Aicardi syndrome, 2.210, 6.338–339, 6.339*f*
AIDS (acquired immunodeficiency syndrome). *See also* HIV (human immunodeficiency virus); HIV infection/AIDS
bacillary angiomatosis of, 9.240
bacterial keratitis in, 9.334
$CD4^+$ T cells in, 9.327
Cryptococcus neoformans choroiditis in, 9.333
cytomegalovirus retinitis associated with, 9.256, 9.328–329, 12.235–236
description of, 7.211
external eye manifestations of, 9.333–334
herpes zoster and, 9.334
immune recovery uveitis in, 9.329
Kaposi sarcoma associated with, 9.333, 9.333*f*
molluscum contagiosum associated with, 9.334
necrotizing herpetic retinitis in, 9.330, 9.330*f*
ocular toxoplasmosis in, 9.281–282, 9.282*f*
ophthalmic manifestations of, 9.327–333, 9.328*f*, 9.330*f*, 9.332*f*
opportunistic infections in, 9.328
pathophysiology of, 9.327
Pneumocystis jirovecii choroiditis in, 9.332, 9.332*f*
progressive outer retinal necrosis syndrome associated with, 12.236–237, 12.237*f*
toxoplasma retinochoroiditis in, 9.330*f*, 9.330–331
AIDS dementia complex (HIV encephalopathy/HIV-associated neurocognitive disorder), 5.348. *See also* HIV infection/AIDS
AIDS-related virus (ARV). *See* HIV (human immunodeficiency virus); HIV infection/AIDS
AIM. *See* Acute idiopathic maculopathy
AION. *See* Anterior optic neuropathy, ischemic
Air, refractive index of, 8.26
Air cells
ethmoid, 7.19–20, 7.282
ethmoid sinus, 5.8, 5.10*f*, 7.20
Air-puff (noncontact) tonometers, 10.26
Air–tear film interface, 8.6, 8.26
optical power of eye and, 13.7–9
reflection at, 8.6
Air–eye interface, 2.249, 2.249*f*
Airway
in asthma, 1.123
in cardiopulmonary resuscitation, 1.297
hyperreactivity of, 1.124
obstruction of, 1.126
Airway devices, 1.298
Airway inflammation, eosinophilic, 1.124
Airy disc, 3.106
AJCC (American Joint Committee on Cancer), on staging of ocular tumors, 4.253–254
AK. *See* Arcuate keratotomy; Astigmatic keratotomy
Ak-Cide. *See* Prednisolone; Prednisolone sodium phosphate/sulfacetamide sodium
in combination preparations
Ak-Con. *See* Naphazoline hydrochloride
Ak-Dex. *See* Dexamethasone
AK-Dilate. *See* Phenylephrine
Ak-Mycin. *See* Erythromycin
AK-Pentolate. *See* Cyclopentolate hydrochloride
Ak-Poly-Bac. *See* Polymyxin B sulfate/bacitracin zinc
Ak-Pred. *See* Prednisolone
Ak-Spore. *See* Hydrocortisone/neomycin sulfate/polymyxin B sulfate/bacitracin zinc
Ak-Sulf. *See* Sulfacetamide
Ak-T-Caine. *See* Tetracaine
Ak-Tob. *See* Tobramycin
Ak-Tracin. *See* Bacitracin zinc
Ak-Trol. *See* Dexamethasone/neomycin sulfate/polymyxin B sulfate
Akarpine. *See* Pilocarpine
AKC. *See* Atopic keratoconjunctivitis
Akinetopsia, 5.179
AL. *See* Axial length
Alagille syndrome (arteriohepatic dysplasia), 6.255, 8.97*t*, 8.102, 12.282*t*, 12.285
posterior embryotoxon and, 8.97*t*, 8.102
Alamast. *See* Pemirolast
Alaway. *See* Ketotifen
Albalon. *See* Naphazoline hydrochloride
Albendazole
for diffuse unilateral subacute neuroretinitis, 9.288
for visceral toxocariasis, 9.284
Albinism, 4.142, 4.142*f*, 12.288
definition of, 6.406
description of, 2.205
diagnosis of, 6.406–408
enzymes that cause, 2.204*t*
iris transillumination associated with, 4.142, 4.142*f*, 6.265, 6.406, 6.407*f*
ocular (OA), 2.230, 4.142, 4.142*f*, 6.406–407, 12.53, 12.288
oculocutaneous (OCA)
description of, 2.78, 2.215, 2.229, 4.142, 12.288
pattern-appearance visual evoked potentials in, 12.53
treatment of, 6.408
types of, 6.408*t*
Albinoidism, 12.288
Albright syndrome/hereditary osteodystrophy, 7.89, 8.191*t*
Albumin
in aqueous humor, 10.16
serum, 2.298
Alcaftadine, 2.412*t*
Alcaine. *See* Proparacaine
Alcian blue stain, 4.31*t*
Alcohol (ethanol)
as tissue fixative, 4.26, 4.26*t*

use/abuse of
cataract formation and, 11.63–64
intraocular pressure and, 10.22
optic neuropathy caused by, 5.137, 5.138
vitamin A deficiency and, 8.196
Alcohol withdrawal syndromes, 1.68
Aldehyde dehydrogenase, 2.260
Aldose reductase, 2.289–290
in cataract formation, 11.19
in lens glucose/carbohydrate metabolism, 11.18*f*, 11.19
Aldose reductase inhibitors
cataract prevention/management using, 11.72
description of, 1.40
Alemtuzumab, 1.180
for multiple sclerosis, 5.321*t*
Alexander's law, 5.240, 5.242, 6.147
Alexia
with agraphia, 5.179
without agraphia, 5.179, 5.180*f*
Alfentanil, 1.290
Alfuzosin, intraoperative floppy iris syndrome and, 11.74, 11.136, 11.137*t*
ALH. *See* Atypical lymphoid hyperplasia
Alignment, ocular
disorders of/unsatisfactory, 5.184–185. *See also* Diplopia
nonorganic, 5.309–310
refractive surgery and, 13.41
tests of, 5.184*f*, 5.184–185, 5.185*f*. *See also specific type*
Aliskiren, 1.63
Alizarin red stain, 4.31*t*
ALK. *See* Anterior lamellar keratoplasty
Alkalis (alkaline solutions), 6.376
ocular injuries caused by, 8.375–380, 8.376*t*, 8.379*f*, 8.380*f*. *See also* Chemical injury
cataract and, 11.59
glaucoma and, 10.103–104
vitamin C in management of, 8.383
Alkapton, corneal deposits of/pigmentation caused by, 8.118*t*, 8.184, 8.185*f*
Alkaptonuria, 2.204*t*, 8.183*t*, 8.184–185, 8.185*f*
Alkyl nitrites, 12.300, 12.300*f*
Alkylating agents, 1.240*t*, 2.404*t*
for Behçet disease, 1.173, 9.217–218
description of, 1.179
for uveitis, 9.109–110
All-*trans*-retinaldehyde, 2.308, 2.326
Allele(s)
definition of, 2.214
human leukocyte antigen. *See* Human leukocyte antigens
independent assortment of, 2.175
Allele-specific marking, 2.180
Allelic association. *See* Linkage disequilibrium
Allelic diversity, in human leukocyte antigens, 9.63
Allen figures, 6.7
Allen symbols, 3.23
Allergens. *See also* Allergic reactions/allergies
avoidance of
in atopic dermatitis, 8.287
in atopic keratoconjunctivitis, 8.293
in contact dermatoblepharitis, 8.287
in hay fever conjunctivitis, 8.288
Allergic aspergillosis
description of, 7.52
sinusitis, 5.353
Allergic conjunctivitis, 2.411–412, 2.412*t*, 6.246*f*, 6.246–248, 8.288–289, 9.2
cicatricial conjunctivitis differentiated from, 8.301*t*
perennial, 8.288–289
Allergic fungal sinusitis, orbital involvement and, 4.228
Allergic immune reactions, 9.2
Allergic keratoconjunctivitis
atopic, 8.292–294, 8.293*f*
vernal, 8.289–292, 8.290*f*, 8.291*f*
Allergic reactions/allergies. *See also* Hypersensitivity reactions; *specific reaction or allergy*
to adrenergic agonists, 10.178*f*, 10.178–179
to carbonic anhydrase inhibitors, 10.180
conjunctivitis, 8.288–289. *See also* Conjunctivitis, allergic
cicatricial conjunctivitis differentiated from, 8.301*t*
to contact lenses, 3.233–234
description of, 6.170, 6.171*f*, 6.246*f*, 6.246–249, 6.247*t*, 6.248*t*
drugs for. *See* Antihistamines
dry eye and, 8.54, 8.54*f*, 8.55*f*
in eyelid
atopic dermatitis, 8.287
contact dermatoblepharitis, 8.285–287, 8.286*f*
to topical medications, 8.285–287, 8.286*f*
Allergic shiners, 6.246
Allesthesia, visual, 5.180
Allogenic slings, 7.252
Allografts/allogeneic transplantation
corneal, 8.316, 8.411–451, 8.412*t*, 8.412–413*t*. *See also* Corneal grafts; Keratoplasty
rejection of, 8.316–318, 8.428–431. *See also* Rejection
immune privilege and, 8.316
limbal, 8.351*t*, 8.362–365. *See also* Limbal transplantation
indications for, 8.351*t*
stem cells, for thalassemias, 1.134
Alloplastic material addition techniques, 13.28, 13.28*f*
corneal effects of, 13.28, 13.28*f*
corneal inlays, 13.28, 13.60–61, 13.61*f*
intrastromal corneal ring segments, 13.28, 13.28*f*
Alloplastic orbital implants, 7.117
Alocril. *See* Nedocromil
Alomide. *See* Lodoxamide
Alpha (α)-adrenergic agents, 6.289*t*, 6.290
agonists
for glaucoma, 10.172*t*, 10.178*f*, 10.178–179
in children, 10.165
in elderly patients, 10.186
suppression of aqueous formation and, 10.17, 10.165
for hyphema, 8.395
for postoperative elevated intraocular pressure, 10.108
α_2-adrenergic agonists, 2.385–386
antagonists. *See also* Alpha (α)-blockers
direct-acting α_1-adrenergic agonists, 2.384
indirect-acting, 2.387

Alpha (α)-adrenergic receptors (adrenoceptors)
α_1-adrenergic receptors, 2.382
α_2-adrenergic receptors
description of, 2.382
ligand binding to, 2.385
Alpha (α)-antitrypsin
deficiency of, 1.124
description of, 2.276
Alpha (α)-blockers
α_1-blockers
"first-dose effect," 1.63
hypertension treated with, 1.62–63
intraoperative floppy iris syndrome and, 11.74, 11.136–137, 11.137*t*
Alpha chemokines, 9.23*t*
Alpha (α)-chymotrypsin, for ICCE, 11.195, 11.200
Alpha (α)-crystallins, 11.15, 11.15*f*, 11.15–16
Alpha (α)-galactosidase A, in Fabry disease, 8.176, 8.177, 8.178
Alpha (α)-hemolytic bacteria, infectious pseudocrystalline/crystalline keratopathy caused by, 4.79, 8.268, 8.268*f*
Alpha (α)-iduronidase, 2.214
in mucopolysaccharidoses, 8.174, 8.175*t*
Alpha (α)-L-fucosidase, defective/deficiency of, in fucosidosis, 8.179
Alpha (α)-interferon
for Mooren ulcer, 8.316
for ocular surface tumors, 8.327, 8.330, 8.330*f*, 8.331, 8.331*f*
conjunctival papilloma, 8.238–239, 8.239, 8.333
optic neuropathy caused by, 5.137
Alpha $(\alpha)_2$-Macroglobulin, 2.276
Alpha (α)-mannosidase, defective/deficiency of, in mannosidosis, 8.179
Alpha-tocopherol. *See* Vitamin E
Alpha (α)-zone peripapillary atrophy, 10.52
Alphagan/Alphagan P. *See* Brimonidine tartrate
Alphavirus, 12.247
Alport disease/syndrome, 4.118, 6.391
lenticonus in, 4.118, 11.30
pleiotropism in, 2.220
Alprazolam, 1.308*t*
Alrex. *See* Loteprednol etabonate
Alström syndrome, 6.391, 12.285
ALT (argon laser trabeculoplasty). *See* Argon laser therapy, for trabeculoplasty
Altacaine. *See* Tetracaine
Altafrin. *See* Phenylephrine
Alteplase. *See* Tissue plasminogen activator
Altered self, 9.30
Alternaria, 8.251
Alternate cover test
description of, 6.65–66, 6.66*f*
exodeviation evaluations, 6.100
prism, 6.65–66, 6.66*f*
Alternate occlusion, for binocular balance, 3.167–168
Alternating fixation, 6.16
Alternating heterotropia, 6.64
Alternating nystagmus, periodic (PAN), 5.243*t*, 5.245–246, 6.149
Alternating skew deviation, 5.216
Alternating suppression, 6.49
Alternating vision bifocal lenses, 3.224*f*, 3.224–225
Alternative hypothesis, 1.5
Alternative pathway activation, of complement, 9.17, 9.18*f*
Alternative payment models (APMs), 1.32
Alternative splicing, 2.179
Altitudinal defect, 5.103, 5.105*t*, 5.106*f*
in glaucoma, 10.69, 10.70*f*
ALTK. *See* Anterior lamellar keratoplasty (ALK), therapeutic
Alu sequence, 2.177
Aluminum, in intraocular foreign body, 12.362
Alveolar macrophages, 9.3
Alveolar nerves, posterior, 5.49
Alveolar rhabdomyosarcoma, 4.236, 4.237*f*, 7.88
Alzheimer disease (AD), 1.209–210
Amacrine cells, 2.316, 5.24
description of, 12.15
illustration of, 12.15*f*
Amalric triangles, 12.198
Amantadine, 1.205, 1.279
Amaurosis
fugax, 2.474*t*, 5.164, 5.167, 5.168–169, 5.171. *See also* Monocular transient visual loss
Horner syndrome and, 5.261
stroke and, 5.167, 5.168–169
Leber congenital (LCA), 6.335–336, 6.337*f*, 9.58. *See also* Leber congenital amaurosis
infantile nystagmus syndrome and, 5.236
Amblyopia, 7.180, 7.243
in accommodative esotropia, 6.91
afferent pupillary defects in, 6.56
anisometropic, 3.175
clinical features of, 6.54–55
critical period for, 6.45
occlusion therapy for, 6.58
refractive surgery and, 13.185–187
strabismus amblyopia *versus*, 6.54–55
bilateral, 3.175
cataracts as cause of
congenital, 6.55
removal of, 6.57
causes of, 6.45–46
classification of, 6.54–56
contrast sensitivity curve affected by, 3.136
corneal opacities as cause of, 6.262
corneal transplantation and, 8.450
crowding phenomenon associated with, 6.56
definition of, 6.5, 6.53
deprivation. *See* Amblyopia, visual deprivation
detection of, 6.56
diagnosis of, 6.56–57
epidemiology of, 6.53
evaluation of, 6.56–57. *See also* Ocular motility, assessment of
extraocular muscle surgery in, 6.160
fixation preference testing, 6.56–57
grating acuity associated with, 6.54, 6.56–57
infantile esotropia and, 6.87–89
isoametropic, 6.55
meridional, 6.46
monofixation syndrome and, 6.52
near vision *vs.* distance vision in, 3.25

occlusion therapy for, 6.58, 6.96, 6.102
optical defocus caused by, 6.45
pathophysiology of, 6.53–54
in pediatric glaucoma, 10.166
post–cataract surgery management of, 6.304
prevalence of, 6.53
recurrence of, 6.61
refractive, 3.175, 6.54–55
refractive surgery and, 13.185–187
reverse, 6.55–56, 6.59–60
screening for, 6.56
severity assessments, 6.56–57
strabismic
anisometropic amblyopia *versus*, 6.54–55
clinical features of, 6.54
critical period for, 6.45
development of, 6.46–47
eccentric fixation in, 6.54
grating acuity associated with, 6.54, 6.56
occlusion therapy for, 6.58
pathophysiology of, 6.54
visual acuity in, 6.54
with third nerve palsy, 6.138
trauma as cause of, 6.375
treatment of
atropine sulfate, 6.59
binocular, 6.59
cataract removal, 6.57
challenges associated with, 6.59–61
complications of, 6.59–61
cycloplegics, 6.59
lack of adherence to, 6.60
occlusion therapy, 6.58, 6.96
optical, 6.58–59
pharmacologic, 6.58–59
plus lenses, 6.59
recurrence of, 6.61
refractive correction, 6.57–58
strabismus secondary to, 6.59–60
termination of, 6.61
unresponsiveness to, 6.60–61
uncorrected anisometropia as cause of, 3.139
unresponsiveness of, to treatment, 6.60–61
vision development and, 6.53
vision loss associated with, 6.53, 6.56
visual acuity and, 3.23, 6.56
visual deficits caused by, 6.53–54
visual deprivation
causes of, 6.55
congenital cataracts as cause of, 6.55
congenital nevocellular nevi as cause of, 6.200
corneal blood staining as cause of, 6.379
critical period for, 6.53
reverse amblyopia, 6.55–56
Amblyopia ex anopsia. *See* Deprivation amblyopia
Amblyoscope, major, 6.70, 6.70*f*
Amblyoscope testing
description of, 6.51
sensory adaptation assessments using, 6.79–80
Ambulatory blood pressure measurement (ABPM), 1.52
Ambulatory surgical center, ocular surgery in, 1.281
AMD. *See* Age-related macular degeneration/maculopathy
Amebic keratitis, 4.78–79, 4.79*f*, 8.208*t*, 8.252, 8.276–279, 8.277*f*, 8.278*f*. *See also Acanthamoeba,* keratitis/ocular infection caused by
Amelanotic choroidal masses, 4.263, 4.264*f*, 4.306, 4.306*f*
differential diagnosis of, 4.272*t*
Amelanotic conjunctival nevus, 4.63, 8.340, 8.340*f*
Amelanotic melanoma, 4.68, 4.263, 4.264*f*, 4.272*t*, 8.343, 8.344*f*
Amelogenesis imperfecta, 12.286
American Academy of Ophthalmology (AAO)
Initiative in Vision Rehabilitation, 6.189
Initiative in Vision Rehabilitation page on the One Network, 1.185, 4.254, 6.189, 11.71, 12.68, 12.86, 12.260
IRIS (Intelligent Research in Sight) Registry of, 1.26
K-Card developed by, 13.194
Preferred Practice Pattern guidelines, 1.26, 1.196, 3.311, 3.329
retinopathy of prematurity screening guidelines, 6.329
vision rehabilitation guidelines from, 6.189
wrong-site surgery checklist, 1.289
American Academy of Pediatrics (AAP)
retinopathy of prematurity screening guidelines, 6.329
uveitis screening in juvenile idiopathic arthritis, 6.314
American Association for Pediatric Ophthalmology and Strabismus retinopathy of prematurity screening guidelines, 6.329
American Cancer Society (ACS)
colorectal cancer screening recommendations of, 1.219
mammography recommendations of, 1.217
American College of Cardiology (ACC)
blood pressure classification guidelines, 1.52
hypertension and
definition of, 1.214
treatment guidelines, 1.57
statin guidelines of, 1.76–77
American Heart Association (AHA)
advanced cardiac life support guidelines, 1.299
blood pressure classification guidelines, 1.52
hypertension and
definition of, 1.214
treatment guidelines, 1.57
statin guidelines of, 1.76–77
American Joint Committee on Cancer (AJCC), on staging of ocular tumors, 4.253–254
American National Standards Institute (ANSI), intraocular lens standards, 3.263–264
American Society of Anesthesiologists Physical Status (ASA-PS), 1.282
American Society of Cataract and Refractive Surgery (ASCRS), on IOL power calculation, 11.85
online post-refractive calculator, 13.52, 13.195–197, 13.196*f*
American Society of Ocularists, 7.141
American Uveitis Society, 9.250, 9.250t

Ametropia. *See also* Refractive errors
axial, 3.137
correction of
in children, 3.174–175
spectacle
cylindrical correcting lenses for, 3.173
far point, 3.170, 3.170*f*
spherical correcting lenses, 3.170, 3.170*f*
vertex distance, 3.170–173, 3.171–3.172*f*
definition of, 3.136, 3.170
refractive, 3.137, 3.257
undercorrection in photoablation and, 13.102
Amifampridine, for nystagmus, 5.245
Amikacin, 2.418*t*, 2.425, 12.300
for endophthalmitis, after cataract surgery, 11.163
for mycobacterial keratitis, 8.270*t*
Amino acid metabolism disorders. *See also specific disorder*
corneal changes and, 8.181*f*, 8.181–190, 8.182*t*, 8.183*t*, 8.184*f*, 8.185*f*, 8.186*t*, 8.187*f*, 8.188*f*, 8.189*f*
retinal manifestations of, 12.293
Aminocaproic acid/ε-aminocaproic acid, for hyphema, 8.395, 10.105
Aminoglycosides, 1.275, 2.425–426, 12.300. *See also specific agent*
for *Acanthamoeba* keratitis, 8.278
ocular surface toxicity of, 8.90*t*, 8.91
ototoxicity of, peripheral vestibular dysfunction and, 5.243
4-Aminopyridine, for nystagmus, 5.245
Amiodarone
cornea verticillata caused by, 8.130
lens changes caused by, 11.53
ocular adverse effects of, 1.106, 1.309*t*
optic neuropathy caused by, 1.106, 5.137
refractive surgery in patient taking, 13.37, 13.77–78
Amlodipine, for congestive heart failure, 1.99
Ammonia (NH_3), ocular injury caused by, 8.376*t*
AMN. *See* Acute macular neuroretinopathy
Amniocentesis, 2.239
Amniotic membrane transplantation (AMT)/graft, 8.351*t*
for chemical injuries, 8.384
for conjunctivochalasis, 8.86, 8.361
for corneal edema after cataract surgery, 11.129
for descemetocele, 8.369
for herpetic eye disease, 8.224–225
indications for, 8.351*t*
for neurotrophic keratopathy/persistent corneal epithelial defects, 8.82, 8.224
in pterygium surgery, 8.351, 8.355
recurrence rate and, 8.353*t*
for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.285, 8.297–298
for superior limbic keratoconjunctivitis, 8.84
after tumor removal surgery, 8.329
Amorphous corneal dystrophy, posterior (PACD), 8.135*t*, 8.136*t*, 8.154*f*, 8.154–155
Amoxicillin, 2.419
dental prophylaxis uses of, 1.248*t*
for Lyme disease, 9.231*t*
Amphotericin B, 2.429, 2.430*t*
for *Candida* fungal postoperative endophthalmitis, 9.298–299
for fungal endogenous endophthalmitis, 12.239
for fungal infections, 1.258, 1.277
for fungal keratitis, 8.275
Ampicillin
dental prophylaxis uses of, 1.248*t*
description of, 2.418*t*, 2.419
Amplitude
of accommodation, 11.23
age-related changes in, 3.176, 3.176*t*
definition of, 3.147
description of, 3.140
measurement of, 3.178–179
near point of accommodation for, 3.179
Prince rule for measuring, 3.179, 3.179*f*
spheres method for measuring, 3.179
convergence, 5.226
divergence, 5.226
of visual evoked potential, 5.95
AMPPPE (acute multifocal posterior placoid pigment epitheliopathy). *See* Acute posterior multifocal placoid pigment epitheliopathy
Ampullectomy, 7.311
Amsler grid testing, 3.315, 5.84
in age-related macular degeneration, 12.68–69, 12.71
in low vision evaluation, 5.84
in optic neuropathy *versus* maculopathy, 5.100*t*
Amsler sign, 10.101
AMT. *See* Amniotic membrane transplantation (AMT)/graft
Amyloid AA, 4.58
Amyloid AL, 4.58, 4.206
Amyloid degeneration. *See also* Amyloidosis/amyloid deposits
polymorphic, 8.122, 8.123*f*, 8.186*t*
Amyloidosis/amyloid deposits, 4.134*f*, 4.134–135, 4.206–207, 8.185–188, 8.186*t*, 8.187*f*, 8.188*f*, 12.348, 12.349*f*
conjunctival, 4.58*f*, 4.58–59, 8.185, 8.186*t*, 8.187*f*
corneal, 8.185–188, 8.186*t*, 8.188*f*
in gelatinous droplike dystrophy, 8.141, 8.141*f*, 8.185–187, 8.186*t*
in granular corneal dystrophy type 2, 8.148
in lattice corneal dystrophy, 4.89*f*, 4.89–90, 8.145, 8.146, 8.147*f*, 8.185–187
polymorphic amyloid degeneration and, 8.122, 8.123*f*, 8.186*t*
description of, 1.140
in eyelid, 4.206–207, 4.207*f*, 4.207*t*, 8.186*t*, 8.187
familial, 4.134, 4.134*f*, 4.206, 8.186*t*, 8.187
familial amyloid polyneuropathy (FAP), 4.134, 4.134*f*, 4.206
vitreous involvement/opacification and, 4.134, 4.134*f*
Finnish/gelsolin type (Meretoja syndrome), 4.206, 8.186*t*, 8.187, 8.188*f*
primary of cornea (subepithelial amyloidosis/gelatinous droplike dystrophy), 8.135*t*, 8.136*t*, 8.140–141, 8.141*f*, 8.185–187, 8.186*t*
orbital, 4.228
primary localized, 8.185–187, 8.186*t*

primary systemic, 8.186*t*, 8.187
secondary localized, 8.186*t*
secondary systemic, 8.186*t*
vitreous involvement in, 4.134*f*, 4.134–135
ANA. *See* Antinuclear antibody (ANA) testing
ANA testing. *See* Antinuclear antibody (ANA) testing
Anaerobes
as normal flora, 8.206*t*
stains and culture media for identification of, 8.209*t*
Anaerobic glycolysis, in glucose/carbohydrate metabolism in lens, 11.17–19, 11.18*f*
Anagrelide, for essential thrombocythemia, 1.143
Anakinra, 1.180
Analgesics. *See also specific agent*
ocular adverse effects of, 1.308*t*
rebound headache and, 5.293
Anaphase, 2.174, 2.174*f*
Anaphylactic hypersensitivity (immediate/type I) reactions. *See also* Allergic reactions/allergies; Anaphylaxis
atopic keratoconjunctivitis and, 8.292
contact dermatoblepharitis and, 8.285, 8.286*f*, 8.287
hay fever conjunctivitis and, 8.288
topical medications/substances and, 8.285, 8.286*f*, 8.287
Anaphylactoid reactions, 1.302, 2.417
Anaphylatoxins, 9.18
Anaphylaxis, 1.302–303. *See also* Anaphylactic hypersensitivity (immediate/type I) reactions
topical medications/substances and, 8.285, 8.286*f*, 8.287
Anaplastic carcinoma, 1.46
Anatomical reattachment surgery, for retinal detachment. *See* Retinal detachment, surgery for
ANCA. *See* Antineutrophil cytoplasmic autoantibody. *See also* Granulomatosis, with polyangiitis
ANCA-associated vasculitis. *See* Antineutrophil cytoplasmic autoantibody, vasculitis associated with
ANCA serum assay. *See* Antineutrophil cytoplasmic autoantibody, serum assay
ANCHOR study, 12.80–81
Ancobon. *See* Flucytosine
Ancylostoma caninum (dog hookworm), 9.287, 12.246
Anderson-Kestenbaum procedure, for nystagmus, 5.236, 5.237*f*
Anderson procedure, for nystagmus, 6.155
Andexanet alfa, 1.149
Androgen antagonists, tear production affected by, 8.62*t*
Anemia
antibody-mediated destruction as cause of, 1.135
aplastic
carbonic anhydrase inhibitors causing, 10.180
description of, 1.137
blood loss as cause of, 1.132–133
bone marrow disorders as cause of, 1.137
chronic hemolytic, 1.135
chronic renal failure as cause of, 1.137
classification of, 1.132
in congestive heart failure, 1.99
Coombs-positive hemolytic, 1.135
diabetic retinopathy and, 12.98
folate deficiency as cause of, 1.133–134
hemoglobin synthesis defects as cause of, 1.134–136
hemolytic, 1.135–137
inflammatory, 1.137
iron deficiency, 1.132–133
macrocytic, 1.132–133
megaloblastic, 1.133
microcytic, 1.132
normocytic, 1.132
nutritional deficiency as cause of, 1.132–134
pathophysiology of, 1.132
pernicious, 1.133
red blood cell destruction as cause of, 1.136–137
sickle cell, 1.135–136
sideroblastic, 1.137
thalassemias, 1.134–135
vitamin B_{12} deficiency as cause of, 1.133
Anemia of chronic disease, 1.159
Anestacaine. *See* Lidocaine
Anesthesia (anesthetics)
for cataract surgery, 11.91*f*, 11.91–92, 11.92*f*, 11.93*f*
retrobulbar hemorrhage and, 11.158, 11.171
examination under. *See* Examination, ophthalmic, under anesthesia
for extraocular muscle surgery, 6.174–175
general, 1.289–290, 6.174, 12.50
for cataract surgery, 11.92
in arthritis, 11.171
in claustrophobia, 11.169
in patient unable to communicate, 11.170
for penetrating and perforating trauma repair, 8.403
for intraocular pressure measurement in infants and children, 10.158–159
for intravitreal injections, 12.403
local (topical/regional)
abuse of, 8.89*f*, 8.89–90
adverse reactions to, 8.90*t*
for cataract surgery, 11.92
composition of, 2.438
intraocular surgery use of, 2.441–442
mechanism of action, 2.439
overview of, 2.437–440
for penetrating and perforating trauma repair, 8.403–404
peribulbar anesthesia, 2.442
for phakic IOL insertion, 13.141
for photoablation, 13.82
regional anesthetics, 2.438*t*
retrobulbar anesthesia, 2.442
topical, 2.439*t*, 2.439–440, 2.441–442
toxic manifestations of, 2.439
types of, 2.440–441
for penetrating and perforating trauma repair, 8.403–404
peribulbar, 6.174
for cataract surgery, 11.91
for phakic IOL insertion, 13.141
for photoablation, 13.82
for photocoagulation, 12.375
retrobulbar, 6.174
for cataract surgery, 11.91, 11.91*f*
hemorrhage and, 11.158, 11.171
tear production affected by, 8.62*t*
Anesthesia/hypoesthesia, corneal
congenital, 8.108

herpes simplex keratitis and, 8.217–218, 8.226*t*
herpes zoster and, 8.226*t*, 8.228
keratoplasty and, 8.418, 8.424
after LASIK, 13.172
neurotrophic keratopathy/persistent corneal defects and, 8.80, 8.224
Aneuploidy. *See also specific disorder*
of autosomes, 2.222–224
Aneurysm(s)
basilar artery, 5.338, 5.339*f*
berry (saccular), 1.121, 5.338
cerebral, 5.338–342, 5.339*f*, 5.340*f*, 5.341*f*
neuroimaging in diagnosis of, 5.69–70, 5.72*t*, 5.194*f*, 5.194–195, 5.340, 5.341*f*
ruptured, 5.338–339, 5.340, 5.340*f*, 5.341
third nerve (oculomotor) palsy and, 5.20, 5.339
aberrant regeneration and, 5.198
divisional palsy and, 5.197
pupil-involving, 5.194*f*, 5.194–195, 5.265
pupil-sparing, 5.196
in younger patients, 5.197
giant, 5.338, 5.339
internal carotid, 5.338, 5.339*f*
chiasmal syndromes caused by, 5.147, 5.150
third nerve (oculomotor) palsy and, 5.194, 5.194*f*, 5.196, 5.196*f*, 5.339
intracavernous carotid, 5.339–340
ophthalmic artery, 5.339
retinal arterial, 12.147–148, 12.148*f*
microaneurysms, 4.154, 4.155*f*
in diabetes mellitus, 4.155*f*, 4.159
in diabetic retinopathy, 4.159
in retinal vein occlusion, 4.158, 4.159
Aneurysmal bone cyst, 6.222
Aneurysmal subarachnoid hemorrhage, 1.121
Aneurysmal telangiectasia, 12.161
Angelman syndrome, 2.180–181
Angina pectoris. *See also* Ischemic heart disease
in congestive heart failure, 1.95
hypertension and, 1.65
manifestations of, 1.82–83
misinterpretation of, 1.83
Prinzmetal, 1.83
stable
coronary artery bypass grafting, 1.91–92
definition of, 1.83
hypertension and, 1.65
percutaneous coronary intervention for, 1.91–92
revascularization for, 1.91–93
treatment of, 1.91–93
treatment of, 1.91–93
unstable, 1.83
variant, 1.83
Angioedema
angiotensin-converting enzyme inhibitors as cause of, 1.106
description of, 1.61
Angiofibromas
facial
description of, 6.397
in tuberous sclerosis, 5.331*f*, 5.334*t*
giant cell, of orbit, 4.235
Angiogenesis
activators of, 12.80
in corneal transplant rejection, 8.317
definition of, 12.79
endothelial cells in, 12.79
inhibitors of, 1.240*t*, 1.241, 12.80. *See also* Antiangiogenic agents
vitreous effects on, 2.301
Angiographic cystoid macular edema, after cataract surgery, 11.163–164, 11.164*f*
Angiography/arteriography
cerebral, for carotid stenosis diagnosis, 1.116
computed tomography (CTA), 2.454, 2.455*t*, 2.458, 5.58, 5.69–70, 5.72*t*
advantages/disadvantages of/contraindications for, 5.61*t*
in aneurysm detection/evaluation, 5.69–70, 5.194, 5.194*f*, 5.340
in arterial dissection, 5.342
arteriovenous malformations on, 7.77*f*
in carotid artery evaluation, 5.167
for carotid stenosis, 1.116
description of, 7.32
in vertebrobasilar insufficiency, 5.338
for congestive heart failure, 1.97
conventional/catheter/contrast, 5.68, 5.68*f*
in aneurysm detection/evaluation, 5.195, 5.340, 5.341*f*
in arteriovenous malformations, 5.292*f*, 5.344, 5.344*f*
in reversible cerebral vasoconstriction syndrome, 5.347, 5.347*f*
in vertebrobasilar insufficiency, 5.337*f*, 5.338
in coronary heart disease diagnosis, 1.89
digital subtraction (DSA), 5.68
in arterial dissection, 5.342
dye injection in, 12.24
fluorescein. *See* Fluorescein angiography
indocyanine green. *See* Indocyanine green angiography
magnetic resonance (MRA), 2.455*t*, 2.458, 5.58, 5.68–69, 5.69*f*, 5.72*t*
advantages/disadvantages of/contraindications for, 5.61*t*
in aneurysm detection/evaluation, 5.194, 5.340, 5.341*f*
in arterial dissection, 5.342
in carotid artery evaluation, 5.167, 5.167*f*
carotid stenosis diagnosis using, 1.116
description of, 7.32, 7.79
in reversible cerebral vasoconstriction syndrome, 5.347
stroke evaluations, 1.112–113
in vertebrobasilar insufficiency, 5.338
optical coherence tomographic
artifacts in, 12.29, 12.30*f*
choroidal circulation abnormalities, 12.198
choroidal neovascularization on, 12.75–76, 12.76–12.78*f*, 12.192
depth resolution using, 12.29
diabetic retinopathy on, 12.93, 12.94*f*
fluorescein angiography *versus*, 12.29
macular telangiectasia type 2 on, 12.163, 12.164*f*

motion artifacts in, 12.29
projection artifacts in, 12.29, 12.30*f*
pseudoxanthoma elasticum on, 12.199*f*
retinal capillary layers on, 12.16
retinal disease evaluations using, 12.28–29
retinal vasculature on, 12.29, 12.30*f*
severity of, 12.93, 12.94*f*
retinal. *See* Fluorescein angiography; Indocyanine green angiography
scanning laser ophthalmoscopy *versus*, 12.24
Angioid streaks
choroidal neovascularization caused by, 12.87–89, 12.89*f*
definition of, 12.87
description of, 12.19
fluorescein angiography of, 12.87, 12.89*f*
pseudoxanthoma elasticum and, 1.141, 12.87, 12.89*f*
safety glasses for patients with, 12.88
in sickle cell disease, 12.154
visual disturbances caused by, 12.88
Angiokeratoma corporis diffusum (Fabry disease), 2.204*t*, 2.232*t*, 2.235, 6.270, 6.388*t*, 8.176–178, 8.177*f*, 12.291–292
Angiomas (angiomatosis). *See also* Hemangiomas (hemangiomatosis)
cavernous. *See* Cavernous hemangioma
cerebrofacial/encephalotrigeminal/encephalofacial. *See* Cerebrofacial (encephalotrigeminal/encephalofacial) angiomatosis/Sturge-Weber syndrome (SWS)
retinal (retinae). *See* Retinal angiomatosis
racemose (Wyburn-Mason syndrome/Bonnet-Dechaume-Blanc syndrome), 4.286*f*, 4.286–287, 5.331, 5.333*f*, 5.334*t*, 6.222, 6.394*t*, 6.405*t*, 6.405–406, 12.168
retinal, 12.168
Angiomatous tumors, 4.281–287. *See also* Angiomas; *specific tumor*
Angioplasty
for angina pectoris, 1.92
coronary. *See* Percutaneous coronary intervention
Angiopoietin 1, nevus flammeus and, 8.346
Angiosarcoma, conjunctival/ocular surface, 8.345*t*
Angiotensin-converting enzyme (ACE), 6.319, 7.34, 7.66
functions of, 1.61
in sarcoidosis, 1.163, 5.327
Angiotensin-converting enzyme (ACE) inhibitors
β-blockers and, in heart failure, 1.65
congestive heart failure treated with, 1.98
hypertension treated with, 1.59*t*, 1.61, 1.165
ocular adverse effects of, 1.106
pregnancy contraindications for, 1.68
Angiotensin I, 1.61
Angiotensin II, 1.61, 1.301
Angiotensin II receptor blockers (ARBs)
adverse effects of, 1.61
congestive heart failure treated with, 1.99
hypertension treated with, 1.59*t*, 1.61
mechanism of action, 1.61
pregnancy contraindications for, 1.68
Angle
anterior chamber. *See* Anterior chamber angle
kappa ([κ]). *See* Angle kappa
Angle alpha (α), 3.123, 3.129, 3.129*f*
Angle closure, 10.36, 10.117, 10.117*t*. *See also* Angle-closure glaucoma
acute, 10.123–125, 10.124*f*
management of, 10.184
anisocoria and, 5.263
chronic, 10.4*t*, 10.126–127
gonioscopic identification of/monitoring for, 10.36, 10.79
intermittent (subacute), 10.125–126
lens-induced, 10.96, 10.119, 10.128–132
mechanisms of, 10.118–120, 10.119*t*
ocular inflammation and, 10.138*f*, 10.138–139, 10.139*f*
pathogenesis and pathophysiology of, 10.118–120, 10.119*t*
plateau iris and, 10.4*t*, 10.9, 10.32, 10.120, 10.127
primary (PAC), 10.4*t*, 10.117*t*, 10.117–118, 10.120–122
acute, 10.123–125, 10.124*f*
management of, 10.184
chronic, 10.4*t*, 10.126–127
pupillary block causing, 10.118–119
secondary, 10.118
with pupillary block, 10.4*t*, 10.128–132
without pupillary block, 10.4*t*, 10.132–146
surgery for, 10.187. *See also* Glaucoma surgery
tumors causing, 10.99, 10.138
Angle-closure glaucoma, 2.387, 10.3, 10.4*t*, 10.6*t*, 10.117*t*, 10.117–146. *See also* Angle closure; Glaucoma
acute
description of, 10.123–125, 10.124*f*
management of, 10.184
age and, 10.9
aniridia and, 10.120, 10.155
aphakic, 10.130–132
in children, 10.156
after cataract surgery, 11.136
ciliary block/malignant glaucoma (aqueous misdirection) and, 11.139
central retinal vein occlusion and, 10.143–144
neovascularization and, 10.134–135
in children and adolescents. *See* Angle-closure glaucoma, pediatric
chronic, 10.4*t*, 10.126–127
classification of, 10.4*t*, 10.6*t*
combined-mechanism glaucoma and, 10.7
cornea plana and, 8.96*t*, 8.100–101
creeping, 10.126
drug-induced, 10.122–123, 10.145*f*, 10.145–146
ectopia lentis and, 10.129–130, 10.130*f*, 10.130*t*, 10.131*f*
epithelial and fibrous ingrowth and, 10.141–142, 10.142*f*, 10.143*f*
family history and, 10.121
flat anterior chamber and, 10.121, 10.144–145
malignant/ciliary block glaucoma (aqueous misdirection) and, 10.32, 10.140, 10.140*f*
gender and, 10.9, 10.121
genetic/hereditary factors in, 10.9
gonioscopic identification of, 10.36
inflammatory, 10.138*f*, 10.138–139, 10.139*f*

intermittent (subacute), 10.125–126
iridocorneal endothelial syndrome and, 4.101, 10.136*f*, 10.136–138, 10.137*f*
iris bombé and, 10.32, 10.129, 10.131*f*, 10.138, 10.139*f*
iris-induced, 10.120
lens-induced, 10.96, 10.119, 10.128–132
malignant (aqueous misdirection/ciliary block glaucoma), 10.32, 10.139–141, 10.140*f*
cataract surgery and, 10.139, 11.139
in children and adolescents, 10.149*t*
microcornea and, 8.95–99
microspherophakia and, 10.130, 10.131*f*, 11.33
nanophthalmos and, 4.108, 4.109, 10.144
ocular biometrics and, 10.121
open-angle glaucoma differentiated from, 10.3, 10.5*f*
outflow obstruction mechanisms in, 10.5, 10.6*t*, 10.118–120, 10.119*t*
pain caused by, 5.295
pathogenesis and pathophysiology of, 10.118–120, 10.119*t*
pediatric (childhood/congenital/infantile/juvenile), 10.149*t*
persistent fetal vasculature and, 10.144
phacomorphic, 10.119, 10.128, 10.129*f*, 11.67, 11.68*f*
plateau iris and, 10.4*t*, 10.9, 10.32, 10.120, 10.127
posterior polymorphous corneal dystrophy and, 8.159
prevalence of, 10.117
primary (PACG), 10.4*t*, 10.117*t*, 10.117–118, 10.120–122
acute, 10.123–125, 10.124*f*
management of, 10.184
epidemiology of, 10.9–10
prevalence of, 10.9, 10.117
with pupillary block, 10.119
iridotomy/iridectomy for, 10.124–125, 10.191–193, 10.192*f*
risk factors for, 10.9, 10.120–122
subacute/intermittent, 10.125–126
without pupillary block (plateau iris), 10.4*t*, 10.9, 10.120, 10.127*f*, 10.127–128
pseudophakic, 10.130–132
with pupillary block, 10.4*t*, 10.6*t*, 10.118–119
iridotomy/iridectomy for, 10.124, 10.125, 10.191–193, 10.192*f*
without pupillary block, 10.4*t*, 10.6*t*, 10.119*t*, 10.119–120
race and, 10.9, 10.117, 10.120
refraction/refractive errors and, 10.9, 10.122
retinal detachment and, 10.141
retinal surgery and, 10.143
retinal vascular disease and, 10.143–144
in retinopathy of prematurity, 12.181. *See also* Glaucoma
risk factors for, 10.9, 10.120–122
secondary, 9.318. *See also specific cause*
in children and adolescents, 10.149*t*
with pupillary block, 10.4*t*, 10.128–132
microspherophakia and, 11.33
phacomorphic glaucoma and, 11.67
without pupillary block, 10.4*t*, 10.132–146
subacute/intermittent, 10.125–126
surgical management of, 10.187. *See also* Glaucoma surgery
chamber deepening/goniosynechialysis, 10.220
incisional procedures. *See* Incisional surgery
laser gonioplasty/peripheral iridoplasty, 10.193–194
laser iridotomy, 10.124, 10.125, 10.126, 10.191–193, 10.192*f*
peripheral (surgical) iridectomy, 10.125, 10.220
topiramate causing, 10.145*f*, 10.145–146
transient visual loss and, 5.163*t*, 5.164
trauma and, 10.142
fibrous ingrowth and, 10.142, 10.143*f*
tumors causing, 10.99, 10.138
uveitic, 10.134, 10.139, 10.139*f*
Angle-closure suspect, primary, 10.4*t*, 10.117, 10.117*t*, 10.122–123
Angle kappa (κ)
definition of, 6.67
description of, 3.123, 3.129, 3.129*f*, 3.267, 3.272
negative, 6.67, 6.68*f*
pictorial representation of, 6.68*f*
positive, 6.67, 6.68*f*
Angle of deviation, 3.45, 3.46*f*
Angle of incidence
Brewster angle and, 3.99
definition of, 3.39
description of, 3.44*f*, 3.80
Angle of reflection, 3.80
Angle of refraction, 3.44*f*
Angle recession, 10.36, 10.107*f*
traumatic, 4.18, 4.19*f*, 4.103–104
glaucoma and, 4.18, 4.103–104, 10.39–40, 10.40–41*f*, 10.106–108, 10.107*f*
Angle-supported intraocular lenses, 13.137–138, 13.139*t*, 13.144
complications of, 13.146–147
Angle surgery, in Sturge-Weber syndrome, 6.402
Angular artery, 2.23*f*, 2.38*f*, 5.12, 5.13–15*f*
Angular gyrus, 5.32*f*
Angular magnification, 3.84. *See also* Magnification
Angular vein, 2.26*f*, 5.21*f*, 5.22–23
Anhedonia, 1.195
Anhidrosis
congenital insensitivity to pain with (CIPA), congenital corneal anesthesia and, 8.108
in Horner syndrome, 5.257–258
Anidulafungin, 2.431, 2.431*t*
Aniridia, 2.206, 2.225, 4.184, 6.266*f*, 6.266–267, 6.285, 10.150, 10.154–155, 11.33
cataract and, 11.33, 11.34*f*
surgery for, 11.184
glaucoma and (iris-induced angle closure), 10.120, 10.155
pediatric, 10.150, 10.155
Axenfeld-Rieger syndrome differentiated from, 10.154*t*
gonioscopic appearance of, 10.159
pupil irregularity and, 5.255
short arm 11 deletion syndrome/*PAX6* gene mutations and, 4.184, 10.150, 10.155, 11.33
Wilms tumor and, 4.184, 10.155, 11.33

Aniseikonia
definition of, 3.123, 3.139, 3.169, 3.255
meridional (meridional magnification), 3.147, 3.173. *See also* Distortion
spherical, 3.255
symptoms of, 3.199
Anisocoria, 5.253, 5.255–266, 6.275
cocaine in testing for, 5.256*f*
equal in dim and bright light, 5.256*f*, 5.257
evaluation of, 5.253–254, 5.256*f*
eyelid disorders and, 5.271
greater in bright light, 5.262–266, 5.263*f*, 5.264*f*, 5.265*f*
greater in dim light, 5.256*f*, 5.257–262, 5.258*t*, 5.259*f*, 5.260*t*, 5.261*f*, 5.262*f*
history in, 5.253
Horner syndrome and, 5.256*f*, 5.257–262, 5.259*f*, 5.260*t*, 5.261*f*, 5.262*f*
iris disorders and, 5.256*f*, 5.262–263
mechanical, 5.258*t*
pharmacologic, 5.258*t*, 5.263
physiologic (simple/essential), 5.256*f*, 5.257, 6.275
pupillary light reflex and, 5.255–257
third nerve (oculomotor) palsy/aberrant regeneration and, 5.256*f*, 5.265–266
tonic pupil/Adie tonic pupil and, 5.256*f*, 5.263*f*, 5.263–265, 5.264*f*, 5.265*f*
Anisometropia
abnormal visual experience caused by, 6.44
amblyopia caused by, 3.139
refractive surgery and, 13.185–187
anisophoria caused by correction of. *See* Anisophoria, induced
anterior polar cataracts associated with, 6.295
asymmetric lens-induced myopia causing, 11.70
in children, 3.175
contact lenses and, 3.206–208
definition of, 3.139
hyperopic, 3.140, 3.185*f*
management of, 3.197, 3.198*t*
after penetrating keratoplasty, 8.432
refractive surgery for, 13.179
second-eye cataract surgery for, 11.73
spectacle correction of
anisophoria induced by. *See* Anisophoria, induced
description of, 3.139
Anisometropic amblyopia, 3.175
clinical features of, 6.54–55
critical period for, 6.45
epibulbar dermoids as cause of, 6.256
occlusion therapy for, 6.58
refractive surgery and, 13.185–187
strabismus amblyopia *versus*, 6.54–55
Anisophoria
definition of, 3.139
induced
compensating for, 3.186–190, 3.187*f*
contact lenses for, 3.190
dissimilar segments for, 3.189, 3.189*f*
press-on prisms for, 3.188
refractive surgery for, 3.190
reverse slab-off for, 3.188–189
single-vision reading glasses with lowered optical centers for, 3.189–190
slab-off for, 3.188, 3.188*f*
symptomatic, 3.187
Ankyloblepharon, 6.193–194, 6.194*f*, 7.175–176, 7.176–177*f*
cataract surgery in patient with, 11.173
in mucous membrane pemphigoid, 8.300, 8.302*t*
Ankyloblepharon filiforme adnatum, 6.193–194, 6.194*f*, 7.175
Ankyloblepharon–ectodermal dysplasia–clefting syndrome. *See* Hay-Wells syndrome
Ankylosing spondylitis (AS)
acute anterior uveitis in, 9.130*f*, 9.131–132
cataract surgery in patient with, 11.171, 11.171*f*
description of, 1.154–155
human leukocyte antigen haplotype association with, 9.64
iridocyclitis in, 1.157
laboratory tests for, 9.125*t*
nonsteroidal anti-inflammatory drugs for, 9.132
treatment of, 9.132
ANNA-1 (anti-Hu) antibody, paraneoplastic-induced saccadic intrusions and, 5.249
ANNA-2 (anti-Ri) antibody, paraneoplastic-induced saccadic intrusions and, 5.249
Annular gap, 12.7
Annular keratopathy, traumatic, 8.388
Annular ring, 6.182
Annular zones, multifocal intraocular lens with, 3.259, 3.259*f*
Annulus of Zinn, 2.11, 2.17–18*f*, 2.18, 2.20*f*, 2.113–114, 2.125*f*, 2.128, 5.8*f*, 5.26, 5.45, 7.11, 7.13*f*, 7.13–14, 7.164
horizontal rectus muscles from, 6.20
inferior rectus muscle from, 6.20
superior oblique muscle from, 6.20
superior rectus muscle from, 6.20
vertical rectus muscles from, 6.20
Anomalies, congenital. *See* Congenital anomalies; *specific type*
Anomaloscope, 12.54
Anomalous binocular vision, 6.50
Anomalous retinal correspondence (ARC)
afterimage test for, 6.79*f*
definition of, 6.50
diplopia and visual confusion eliminated with, 6.49*f*
eccentric fixation *versus*, 6.51
harmonious, 6.76
Maddox rod testing in, 6.68
major amblyoscope for, 6.70
red-glass test findings in, 6.76*f*
after strabismus surgery, 6.50
testing for, 6.50–51
unharmonious, 6.76
Anomalous trichromatism, 12.249
Anophthalmia/anophthalmos, 6.209, 6.210*f*, 6.263. *See also* Anophthalmic socket surgery
congenital, 7.136
consecutive, 7.35
definition of, 7.35
primary, 7.35
secondary, 7.35
treatment of, 7.36–38

Anophthalmic ectropion, 7.144, 7.144*f*
Anophthalmic ptosis, 7.145, 7.145*f*
Anophthalmic socket. *See specific aspect*
Anophthalmic socket surgery
complications of
anophthalmic ectropion, 7.144, 7.144*f*
anophthalmic ptosis, 7.145, 7.145*f*
conjunctival cyst, 7.141, 7.141*f*
contracted fornices, 7.143
contracted sockets, 7.143–144, 7.144*f*
cosmetic optics, 7.145–146
deep superior sulcus, 7.141, 7.141*f*
giant papillary conjunctivitis, 7.142, 7.142*f*
lash margin entropion, 7.145, 7.145*f*
enucleation. *See* Enucleation
evisceration. *See* Evisceration
goals of, 7.135
indications for, 7.135
orbital implants
description of, 7.117, 7.139*f*, 7.139–141
exposure and extrusion of, 7.142*f*, 7.142–143
prostheses, 7.140–141, 7.147*f*
Ansa subclavia, 5.54
ANSI. *See* American National Standards Institute
Antagonist(s)
cholinergic, 2.380–381
definition of, 2.367
muscarinic, 2.380–381
nicotinic, 2.382, 2.383*t*
Antagonist (muscle)
contralateral, inhibitional palsy of, 6.120–121, 6.121*f*
definition of, 6.33
Anterior basement membrane dystrophy. *See* Basement membrane dystrophy
Anterior border, of iris, 4.181, 4.182*f*
Anterior capsule
description of, 6.302
opacification of, cataract surgery and, 11.152, 11.153
Anterior capsule fibrosis and phimosis, 11.153–154, 12.116
Nd:YAG laser capsulotomy for, 11.154, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser, capsulotomy
Anterior capsulotomy. *See* Capsulotomy, anterior
Anterior cerebral artery (ACA), 2.139*f*, 5.16*f*, 5.18, 5.27*f*
cranial nerve relationship and, 5.18–19, 5.42*f*
Anterior chamber, 4.97–106. *See also* Anterior chamber angle; Anterior segment
anatomy of, 2.48*f*, 2.59–62*f*, 2.59–63
aqueous humor of, 2.59
biomicroscopy in evaluation of, 10.31–32
before refractive surgery, 13.43–44
blunt trauma to, 10.39–40, 10.40, 10.41*f*, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*
congenital anomalies of, 4.98–99, 4.99*f*, 4.100*f*. *See also* Anterior segment, dysgenesis of
degenerations of, 4.100–105, 4.101*f*, 4.102*f*, 4.103*f*, 4.104*f*, 4.105*f*
development of, 2.161, 2.161*f*
dimensions of, 2.49*t*
disorders of, 4.97–106. *See also specific type*
double, after deep anterior lamellar keratoplasty, 8.435
dysgenesis of, 2.161
flat or shallow
angle-closure glaucoma and, 10.9, 10.31–32, 10.121, 10.144–145
malignant/ciliary block glaucoma (aqueous misdirection) and, 10.32, 10.140, 10.140*f*
cataract surgery and, 11.134–136
angle-closure glaucoma and, 10.144–145
intraoperative complications and, 11.134–135
posterior fluid misdirection syndrome and, 11.134–135
postoperative complications and, 11.135–136
preoperative considerations/IOL power determination and, 11.79, 11.84, 11.86–87
iridotomy contraindicated in, 10.191
after penetrating keratoplasty, 8.424
refractive surgery and, 13.43
after tube shunt surgery, 10.217, 10.218*t*
gonioscopy/evaluation of, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
assessment/documentation systems for, 10.36–40, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
before cataract surgery, 11.79
in glaucoma, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
growth and development of, 6.181
immunization in, 9.56
immunologic microenvironment of, 9.52*t*, 9.55–56
immunoregulatory systems of, 9.55–57
in leukemia, 4.315
melanoma of, 4.105*f*, 4.106, 4.106*f*, 4.194, 4.195*f*
glaucoma and, 4.105*f*, 4.106, 4.194
phacoemulsification in, 11.112
pigment dispersion affecting, 4.104–105, 4.105*f*
shallowing of, 9.318
structures of, 2.59–62*f*, 2.59–63
topography of, 4.97*f*, 4.97–98, 4.98*f*
ultrasound biomicroscopy of, 2.60*f*, 2.471–472*f*, 12.40
in uveitis. *See* Anterior uveitis
vitreous prolapse in, 11.143–144
volume of, 2.48
Anterior chamber angle, 4.97*f*, 4.97–98, 4.98*f*. *See also* Anterior chamber
anatomy of, 2.48*f*, 2.56*f*, 2.59–62*f*, 2.59–63, 2.62*f*
blood vessels in, 10.38*f*, 10.38–39
crowding of, retinopathy of prematurity as risk factor for, 6.334
development of
description of, 2.161
glaucoma and, 4.98, 4.99*f*, 10.6*t*
in glaucoma. *See* Angle closure; Angle-closure glaucoma
gonioscopy of, 4.97–98, 4.98*f*, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
in leukemia, 4.315
neovascularization of, 10.32, 10.38*f*, 10.38–39, 10.132*t*, 10.132–135, 10.133*f*, 10.134*f*, 10.135*f*. *See also* Neovascular glaucoma
in diabetes mellitus, 12.107
normal, 10.34*f*
in infants and children, 10.159
occludable/narrow, 10.34*f*, 10.122
OCT in evaluation of, 8.22, 8.22*f*

pigmentation in, in pseudoexfoliation/exfoliation syndrome, 10.39, 10.92, 10.92*f*
structures of, 2.59–62*f*, 2.59–63
traumatic recession of, 4.18, 4.19*f*, 4.103–104
glaucoma and, 4.18, 4.103–104, 10.39–40, 10.40–41*f*, 10.106–108, 10.107*f*
ultrasound biomicroscopy in evaluation of, 8.21
Anterior chamber-associated immune deviation (ACAID), 2.299, 9.56–57, 9.59
corneal graft tolerance and, 8.316
immune privilege and, 8.316
Anterior chamber cleavage syndrome. *See* Anterior segment, dysgenesis of
Anterior chamber depth (ACD), 2.48, 2.59, 3.248–249, 4.97
angle closure and, 10.9, 10.31–32, 10.121
in IOL power determination/selection, 11.84, 11.86–87. *See also* Estimated lens position
phakic IOL implantation and, 13.43, 13.141
Anterior chamber intraocular lenses (ACIOLs). *See* Intraocular lenses (IOLs), anterior chamber
Anterior chamber paracentesis
in bacterial endogenous endophthalmitis, 9.295
for central retinal artery occlusion, 12.146
description of, 6.414
technique for, 9.92
in uveitis, 9.90–92
Anterior chamber phakic intraocular lenses, 13.8*t*. *See also* Phakic intraocular lenses
Anterior choroidal artery (AChoA), 5.16*f*, 5.18, 5.18*f*
Anterior ciliary arteries, 2.22, 2.24*f*, 2.43, 5.14*f*, 5.14–15, 6.23
Anterior ciliary sclerotomy (ACS), for presbyopia, 13.162
Anterior clinoid process, 2.10*f*, 2.106*f*, 5.6*f*, 5.7*f*, 5.9*f*, 5.16*f*, 5.43*f*, 7.8*f*
Anterior colobomas, 2.153
Anterior communicating artery (ACoA), 2.106*f*, 5.16*f*, 5.18, 5.27*f*
aneurysm of, 5.339, 5.339*f*
cranial nerve relationship and, 5.42*f*, 5.43*f*
Anterior cortical gel, 12.7
Anterior cranial fossa, 2.459*t*, 5.6*f*, 5.8, 5.10*f*, 7.8*f*
Anterior crocodile shagreen (mosaic degeneration), 8.121
Anterior ethmoidal artery, 2.23*f*, 2.25*f*, 5.12, 5.13*f*, 5.14*f*, 5.16*f*, 7.9
Anterior ethmoidal foramen, 2.6*f*, 2.11, 5.11, 7.7–8*f*
Anterior facial vein, 2.26*f*
Anterior hyaloid, 12.8*f*
Anterior hyaloid face, 2.472*f*
Anterior inferior cerebellar artery (AICA), 5.19*f*, 5.20
cranial nerve relationship and, 5.42*f*
Anterior lacrimal crest, 2.6*f*
Anterior lamella
cicatrix of, 7.217*f*
deficiency of, 7.254
upper eyelid defects, 7.220
Anterior lamellar keratoplasty (ALK), 8.412, 8.412*t*, 8.433, 8.433*f*. *See also* Keratoplasty, lamellar
advantages of, 8.421–422*t*, 8.433, 8.433*f*
complications of, 8.435
intraoperative, 8.420*t*
postoperative, 8.421*t*
deep (DALK), 6.263, 6.270, 8.411–412, 8.412*t*, 8.433–435. *See also* Deep anterior lamellar keratoplasty
disadvantages of, 8.422*t*, 8.433
donor cornea contraindications and, 8.415*t*
femtosecond/femtosecond laser-assisted (FALK/FLAK), 8.412*t*, 8.431, 8.434
indications for, 8.412–413*t*, 8.420*t*, 8.433
layer-based approach to use of, 8.417*t*
preoperative evaluation/preparation and, 8.418
therapeutic (ALTK), 8.412*t*
Anterior lens capsule, 2.80
Anterior lens opacities, 6.295
Anterior lenticonus/lentiglobus, 4.118, 11.30
Anterior optic neuropathy
CMV infection causing, 5.349
ischemic (AION), 5.107*t*, 5.119–124, 5.120*t*, 5.121*f*, 5.123*t*
arteritic (AAION), 5.107*t*, 5.120, 5.120*t*, 5.120–122, 5.121*f*, 5.313
nonarteritic (NAION), 5.107*t*, 5.120, 5.120*t*, 5.121*f*, 5.122–124, 5.123*t*
nocturnal arterial hypotension and, 1.67
OCT in evaluation of, 5.91*f*
visual evoked potentials in, 12.52
perioperative, 5.124–125
with optic nerve/nerve head/disc edema, 5.104
Anterior orbitotomy, 7.87. *See also* Orbitotomy
Anterior persistent fetal vasculature, 12.341–342
Anterior pigmented epithelium, 2.70–71, 2.71*f*
Anterior polar cataracts (APCs), 6.55, 6.295, 6.295*f*, 11.35–36
Anterior pole, 11.9, 11.10*f*, 11.11*f*, 11.12*f*
Anterior pupillary membrane, 11.29, 11.29*f*
Anterior scleritis
diffuse, 9.116, 9.118
nodular, 9.116, 9.118–119, 9.119*f*
subtype of, 9.116*t*
Anterior segment, 2.459*t*. *See also* Anterior chamber; Cornea; Iris; *specific structure*
blood supply to
description of, 6.172
extraocular muscle blood supply and, 6.30
blunt trauma to, 12.353
disorders of
cataract and, 11.68
cataract surgery as cause of, 11.132–144, 11.137*t*. *See also specific type*
characteristics of, 6.320*t*
CMV-associated, 8.231–232, 8.232*f*
cornea. *See* Cornea, disorders of
description of, 6.253
developmental anomalies, 8.95–109, 8.96–98*t*. *See also* Anterior segment, dysgenesis of
globe anomalies, 6.263
inflammation. *See* Anterior uveitis
iris anomalies, 6.264–267, 267*f*
pupil abnormalities, 6.267–268, 6.268*f*
systemic disorders and, 8.173–203
toxic, 8.375–409
keratoconjunctivitis/keratopathy from medications, 8.80–81, 8.81*t*, 8.90*t*, 8.90–92, 8.91*f*

traumatic, 8.375–409, 10.39–40, 10.40*f*, 10.41*f*, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*, 11.190. *See also* Anterior segment, trauma to
dysgenesis of, 4.98–99, 4.99*f*, 4.100*f*, 8.95, 8.101–107. *See also specific disorder*
Peters anomaly and, 11.31–32. *See also* Peters anomaly
examination of. *See also* Slit-lamp biomicroscopy/examination
in children, 6.10, 6.187
in nystagmus evaluations, 6.154
OCT in, 8.21–22, 8.22*f*
in pediatric glaucoma, 10.158
before refractive surgery, 13.41–44, 13.42*f*, 13.43*f*
ultrasound biomicroscopy in, 4.265, 8.20–21, 8.21*f*. *See also* Ultrasonography/ultrasound (echography), anterior segment; Ultrasound biomicroscopy
imaging of, 3.292–306, 3.293–3.303*f*
inflammation of, in uveitis, 6.320
ischemia of (ASI), 6.172–173, 6.173*f*
leukemic infiltration of, 4.315
light wavelength transparency of, 3.118
Lyme disease-related inflammation of, corticosteroids for, 9.230
neovascularization of, 10.32, 10.38*f*, 10.38–39, 10.132*t*, 10.132–135, 10.133*f*, 10.134*f*, 10.135*f*. *See also* Neovascular glaucoma
in central retinal vein occlusion, 12.125
pigmentation in, in pseudoexfoliation/exfoliation syndrome, 10.39, 10.92, 10.92*f*
in primary congenital glaucoma, 6.282, 6.282*f*
surgery on
cystoid macular edema after, 12.393, 12.394*f*
endophthalmitis after. *See* Endophthalmitis, postoperative
posteriorly dislocated intraocular lenses after, 12.393
pupil irregularity and, 5.255
suprachoroidal hemorrhage after, 12.394–395, 12.395*f*
traumatic injury and, 10.108–109
vitrectomy for posterior segment complications of, 12.388–396
sympathetic ophthalmia findings in, 9.200
syphilis findings in, 9.221–222
systemic disorders affecting, 8.173–203
toxic injuries of, 8.375–409
trauma to, 8.375–409, 10.39–40, 10.40*f*, 10.41*f*, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*, 11.190
animal and plant substances causing, 8.386–387
chemical injuries, 8.375–384, 8.376*t*. *See also* Chemical injury
concussive (blunt), 8.387–396, 8.388*f*, 8.389*f*, 8.390*f*, 8.391*f*, 8.392*f*, 8.393*f*, 8.394*f*, 8.395*t*. *See also* Blunt (concussive) trauma
penetrating and perforating, 8.396–409. *See also* Penetrating and perforating ocular trauma; Trauma
surgical, 10.108–109
temperature and radiation causing, 8.384–386, 8.385*f*
tumors of, 6.271–274
metastatic, 4.305
ultrasound biomicroscopy of, 4.265, 8.20–21, 8.21*f*, 9.89
ultraviolet irradiation injury to, 3.118–119
in uveitis. *See* Anterior uveitis
Anterior segment developmental anomalies (ASDA). *See* Anterior segment, dysgenesis of
Anterior segment dysgenesis syndrome. *See also* Anterior segment, dysgenesis of
Peters anomaly and, 11.31–32
Anterior segment optical coherence tomography (OCT), 8.21–22, 8.22*f*. *See also* Optical coherence tomography
in glaucoma, 10.77
indications for, 9.85
in keratoconus, 8.165–166
in uveitis evaluations, 9.85
Anterior stromal puncture, for recurrent corneal erosions, 8.79, 8.87
Anterior subcapsular fibrous plaques, 4.120, 4.120*f*
Anterior synechiae, 9.318
in glaucoma
angle closure and, 10.117, 10.121
inflammation and, 10.138, 10.139*f*
anterior segment/iris neovascularization and, 10.39, 10.39*f*, 10.133, 10.133*f*, 10.134*f*
chamber deepening/goniosynechialysis in management of, 10.220
flat anterior chamber and, 10.144
gonioscopy in identification of, 10.34*f*, 10.39, 10.39*f*
iridocorneal endothelial syndrome and, 4.100–101, 4.101*f*, 10.136, 10.136*f*
plateau iris and, 10.128
traumatic hyphema and, 8.394, 8.395*t*
Anterior uvea. *See* Uvea
Anterior uveitis. *See also* Iridocyclitis; Iritis; Uveitis; *specific cause*
acute
in ankylosing spondylitis, 9.130*f*, 9.131–132
antimetabolites for, 9.130
characteristics of, 9.64, 9.65*t*, 9.79*f*, 9.130–131
chorioretinal scars with, 9.135*f*
corticosteroids for, 9.130
cycloplegics for, 9.131
drug-induced, 9.139–140*f*, 9.139–141
fibrinous exudate in, 9.130, 9.130*f*
in glaucomatocyclitic crisis, 9.135–136
herpes simplex virus as cause of, 9.247–250
HLA-B27 diseases associated with. *See* Anterior uveitis, HLA-B27–associated
hypopyon in, 9.130, 9.131*f*, 9.214*f*
in infectious endophthalmitis, 9.137
in inflammatory bowel disease, 9.133
intraocular lens-associated, 9.137–139, 9.138*f*
lens-associated uveitis, 9.136*f*, 9.136–137
in psoriatic arthritis, 9.133, 9.134*f*
in reactive arthritis syndrome, 9.132–133
seronegative spondyloarthropathies associated with, 9.131–134, 9.133–134*f*
in tubulointerstitial nephritis and uveitis syndrome, 9.134–135, 9.135*f*
tumor necrosis factor-α inhibitors for, 9.131
aqueous flare in, 9.77, 9.79*f*
in Behçet disease, 9.214
Busacca nodules in, 9.78, 9.80*f*

characteristics of, 9.70
chronic
diagnostic criteria for, 9.141
in juvenile idiopathic arthritis, 9.141–145
in pseudophakic bullous keratopathy, 9.138*f*
cytomegalovirus-related, 8.231–232, 8.232*f*, 9.248–249, 9.257
description of, 6.312
differential diagnosis of, 6.312*t*, 9.129
epidemiology of, 9.129
evaluation of, 9.71–72*t*
fibrin in, 9.19
glaucoma and, 10.100–102, 10.102*f*
granulomatous, 9.277
HLA-B27–associated
ankylosing spondylitis, 9.130*f*, 9.131–132
clinical presentation of, 9.130, 9.130*f*
description of, 9.64, 9.65*t*
inflammatory bowel syndrome, 9.133
pattern of, 9.130
psoriatic arthritis, 9.133, 9.134*f*
reactive arthritis syndrome, 9.132–133, 9.133*f*
idiopathic, 6.316
incidence of, 9.129
inflammatory cells in, 9.77, 9.79*f*
interstitial keratitis and, 9.220
intraocular pressure in, 9.80–81, 9.317
iris nodules in, 9.77–78, 9.80, 9.80*f*
juvenile idiopathic arthritis as cause of, 6.312–315, 6.313–314*t*, 6.314*f*, 6.322
juvenile spondyloarthropathies as cause of, 6.315, 6.315*t*
Kawasaki disease as cause of, 6.316
keratic precipitates in, 9.77–78, 9.79*f*
laboratory tests for, 6.321*t*
after laser trabeculoplasty, 10.190
muscarinic antagonists for, 2.380–381
posterior synechiae in, 9.77, 9.80*f*
postoperative. *See* Postoperative endophthalmitis
prevalence of, 9.68
in sarcoidosis, 9.195–196
scleritis and, 8.323
screening for, 6.314–315
signs of, 9.77–81, 9.79–80*f*
sudden-onset, 9.71*t*, 9.76
symptoms of, 9.76, 9.77*t*
traumatic, 6.316, 8.389–390
in tubulointerstitial nephritis and uveitis syndrome, 6.316
undifferentiated, 9.146–147
Anterior vitreous, patellar fossa of, 12.7
Anti–acetylcholine receptor (AChR) antibodies, in myasthenia gravis, 5.323
testing for, 5.325–326
Anti–basement membrane antibody, in mucous membrane pemphigoid, 8.301–302
Anti–CCP antibodies. *See* Anti–cyclic citrullinated peptide (CCP) antibodies
Anti–cyclic citrullinated peptide (CCP) antibodies, 1.152–153
Anti-dsDNA antibodies, in systemic lupus erythematosus, 1.161
Anti-elevation syndrome, 6.168–169
Anti-Hu (ANNA-1) antibody, paraneoplastic-induced saccadic intrusions and, 5.249
Anti-idiotypic antibodies, 9.41
Anti-inflammatory agents. *See also* Corticosteroid(s); Nonsteroidal anti-inflammatory drugs; *specific agent*
for cystoid macular edema, after cataract surgery, 11.164
for dry eye/keratoconjunctivitis sicca, 8.61*t*
glucocorticoids. *See* Glucocorticoids
for ocular allergies, 6.247*t*
for superior limbic keratoconjunctivitis, 8.84
types of, 2.400*t*
Anti-La (SS-B) autoantibodies, in Sjögren syndrome, 8.56, 8.58*t*
Anti-MCV antibody testing. *See* Anti–mutated citrullinated vimentin (anti-MCV) antibody testing
Anti–muscle-specific kinase (MuSK) antibodies, testing for, in myasthenia gravis, 5.325–326
Anti–mutated citrullinated vimentin (anti-MCV) antibody testing, 1.153
Anti–neuronal nuclear antibodies, paraneoplastic-induced saccadic intrusions and, 5.249
Anti-Parkinson agents, tear production affected by, 8.62*t*
Anti-Ri (ANNA-2) antibody, paraneoplastic-induced saccadic intrusions and, 5.249
Anti-RNA polymerase III, 1.165
Anti-Ro (SS-A) autoantibodies, in Sjögren syndrome, 8.56, 8.58*t*
Anti-Smith antibodies, in systemic lupus erythematosus, 1.161
Anti-SS-A (anti-Ro) autoantibodies, in Sjögren syndrome, 8.56, 8.58*t*
Anti-SS-B (anti-La) autoantibodies, in Sjögren syndrome, 8.56, 8.58*t*
Anti-TNF-α agents
optic neuropathy caused by, 5.137
for scleritis, 8.324, 8.325*t*
Anti–vascular endothelial growth factor, 2.360*t*, 9.274
Anti–vascular endothelial growth factor agents. *See* Anti-VEGF agents
Anti-VEGF agents, 3.317
adverse effects of, 12.113
for age-related macular degeneration/choroidal neovascularization, 4.164
bevacizumab, 12.83–85, 12.84*t*
central retinal artery occlusion treated with, 12.146
choroidal neovascularization treated with, 12.87–88, 12.212, 12.355
clinical trials of, 12.81
Coats disease treated with, 12.161
complications of, 12.104
for corneal transplantation rejection, 8.317
diabetic retinopathy treated with
description of, 12.101–102
nonproliferative, 12.101–102
proliferative, 12.103–104, 12.386
follow-up after, 12.134
intraocular pressure affected by, 10.110
intravitreal administration of, 12.404
low vision and, 12.86
for macular edema, 4.152–153, 4.153*f*

after cataract surgery, 11.165
in diabetes mellitus, 11.189, 12.101, 12.110–113, 12.112*f*
myopic choroidal neovascularization treated with, 12.212
neovascular age-related macular degeneration treated with, 12.80–81
for neovascular glaucoma, 10.135, 10.135*f*
nonproliferative diabetic retinopathy treated with, 12.101–102
pathologic myopia treated with, 12.89
polypoidal choroidal vasculopathy treated with, 12.76
proliferative diabetic retinopathy treated with, 12.103–104
for radiation-related adverse effects, 4.276
for radiation retinopathy, 1.4, 1.27, 1.239, 12.171
retinal arterial macroaneurysms treated with, 12.148
for retinal hemangioblastoma, 4.285
retinal vein occlusion treated with, 12.126
retinopathy of prematurity treated with, 6.333, 12.186–187
subretinal neovascularization treated with, 12.164
Antiallergic drugs, 2.411–413
Antiangiogenic agents. *See also* Anti-VEGF agents; *specific agent*
complications of, 12.85
for corneal transplantation rejection, 8.317
neovascular age-related macular degeneration treated with, 12.79–80
Antianxiety drugs
description of, 1.201*t*, 1.201–202
ocular adverse effects of, 1.308*t*
Antiarrhythmic drugs
cardiac rhythm disorders treated with, 1.102, 1.102*t*
implantable cardioverter-defibrillator and, combined therapy using, 1.104
tear production affected by, 8.62*t*
Vaughan Williams classification of, 1.102, 1.102*t*
ventricular fibrillation treated with, 1.104
Antibacterial agents. *See also* Antibiotics; *specific agent*
aminoglycosides, 1.275
β-lactam, 1.271–273
carbapenems, 1.273
cephalosporins, 1.272, 1.272*t*
classification of, 1.270
description of, 1.270
fluoroquinolones, 1.274
future directions for, 1.276
glycopeptides, 1.273–274
macrolides, 1.274–275
mechanism of action, 1.270
miscellaneous types of, 1.276
monobactams, 1.272–273
penicillins, 1.271–272
tetracyclines, 1.275–276
Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) study, 1.247
Antibiotics. *See also* Antibacterial agents; *specific type and agent*
for acute purulent conjunctivitis, 8.258
aminoglycosides, 1.275
for bacterial keratitis, 8.269–271, 8.270*t*
β-lactam, 1.271–273
blepharitis treated with, 6.245
carbapenems, 1.273
cephalosporins, 1.272, 1.272*t*
chalazion treated with, 7.182
congenital nasolacrimal duct obstruction treated with, 6.231–232, 6.234
for corneal abrasion, 6.376, 8.398, 8.399
dacryocystitis treated with, 7.314–315
description of, 1.270
for endophthalmitis, after cataract surgery, 11.162–163
fluoroquinolones, 1.274
future directions for, 1.276
glycopeptides, 1.273–274
for gonococcal conjunctivitis, 8.259
after LASIK, 13.93, 13.94
macrolides, 1.274–275
for meibomian gland dysfunction, 8.68
monobactams, 1.272–273
necrotizing fasciitis treated with, 7.49*f*
ocular adverse effects of, 1.308*t*
for penetrating and perforating ocular trauma, 8.402
postoperative, 8.409
preoperative, 8.403
penicillins, 1.271–272
perioperative, photoablation and, 13.81
before photoablation, 13.81–82
preseptal cellulitis treated with, 7.44–45
prophylactic
cataract surgery and, 11.93–95, 11.94*f*
corneal melting and, 11.132
for endophthalmitis, 11.93–95, 11.94*f*, 11.161–162
photoablation and, 13.81
for recurrent corneal erosions, 8.87
resistance to. *See specific agent and specific organism*
for staphylococcal blepharitis/blepharoconjunctivitis, 8.76
after surface ablation, 13.92, 13.108
tetracyclines, 1.275–276
for toxoplasmic retinochoroiditis, 12.243
Antibodies. *See also* Immunoglobulin(s)
anti-dsDNA, 1.161
anti-idiotypic, 9.41
anti-Smith, 1.161
anticentromere, 1.165
anti–cyclic citrullinated peptide (CCP), 1.152–153
aqueous humor production of, 9.91
in chronic inflammation, 9.42
classes of, 9.39
domains of, 9.39
Fab region of, 9.39
Fc portion of, 9.39
hypervariable region of, 9.39
idiotopes of, 9.41
local production of, 9.41–42
monoclonal, 1.144, 1.238, 1.242, 6.322. *See also* Monoclonal antibodies
description of, 9.41
recombinant, 9.41
plasma cell production of, 9.37
structural features of, 9.39, 9.39*f*, 9.40*t*
thyroglobulin, 1.42
Antibody-dependent cellular cytotoxicity (ADCC), 9.47–48

Antibody Fc receptors, 9.12
Anticentromere antibody, 1.165
Anticholinergic agents
angle closure caused by, 10.122
for lung disease, 1.128
mydriasis caused by, 5.263
Anticholinesterase agents. *See* Cholinesterase/acetylcholinesterase inhibitors
Anticipation, 2.218–219
Anticoagulant therapy, 12.346. *See also specific agent*
acute coronary syndromes treated with, 1.93–94
in atrial fibrillation, 1.103
cataract surgery and, 11.74, 11.157, 11.171–172, 11.172*t*
dilated cardiomyopathy treated with, 1.100
direct oral, 1.149–150, 1.286
heparin. *See* Heparin
natural, 1.138–139
ocular surgery and, 1.286
warfarin. *See* Warfarin/warfarin derivatives
Antidepressants
apraclonidine/brimonidine interactions and, 10.179
description of, 1.202–203, 1.203*t*
ocular effects of, 1.308*t*, 8.62*t*
Antidiabetic agents. *See* Insulin
Antiemetics, oculogyric crisis caused by, 5.231
Antiepileptic drugs, ocular side effects of, 1.208, 1.308*t*
Antifibrinolytic agents, 2.446–447
for hyphema, 8.395
Antifibrotic agents. *See also* Fluorouracil/5-fluorouracil; Mitomycin/mitomycin C
description of, 2.413–414
toxic keratoconjunctivitis caused by, 8.91
in trabeculectomy, 10.205–207, 10.207*f*, 10.208*f*
bleb-related endophthalmitis and, 10.163, 10.209
tube shunt implantation after failure of, 10.215
Antifungals, 1.277, 1.278*t*, 2.429–431, 2.430–431*t*. *See also specific type*
for *Candida* fungal postoperative endophthalmitis, 9.298
for chronic fungal postoperative endophthalmitis, 9.293
for zygomycosis, 7.52
Antigen
definition of, 9.27
immune privilege with, 9.56
immune processing of, 9.30, 9.33*f*
Antigen-presenting cells (APCs)
class I-dependent, 9.31*f*
class II-dependent, 9.30, 9.32*f*
in conjunctiva, 8.13, 9.53
in cornea, 8.13*f*, 8.13–14
transplant tolerance and, 8.316, 8.317
corneal lack of, 9.54
definition of, 9.29–30
in external eye defense, 8.12–13*f*, 8.13, 8.13*f*, 8.13–14
human leukocyte antigen type and, 9.63
in immune response arc, 9.29–30
interleukin-12 production by, 9.35
macrophages as, 9.14
monocytes as, 9.3
in phagocytosis, 9.30, 9.32*f*
Antigen-specific regulatory T (iTreg) cells, in external eye defense, 8.12–13*f*
Antigenic epitopes, 9.27, 9.41
Antigenic epitopic fragments, 9.30
Antigenic keratan sulfate (AgKS), macular corneal dystrophy and, 8.150–151
Antiglaucoma agents, 2.385*t*, 10.170–186, 10.171–174*t*. *See also* Glaucoma, management of
administration of eyedrops and, 10.184–185
adherence and, 10.186
in children, 10.165
adrenergic agonists, 10.172*t*, 10.177–179, 10.178*f*
α-, 10.165, 10.172*t*, 10.178*f*, 10.178–179
for angle-recession glaucoma, 10.108
anterior uveitis caused by, 9.141
β-blockers, 10.164–165, 10.171–172*t*, 10.176–177
carbonic anhydrase inhibitors, 10.165, 10.172–173*t*, 10.179–181
cataracts and, 11.52
in children, 10.153, 10.164–165
combined preparations, 10.174*t*, 10.182
conjunctiva affected by use of, 10.31
cornea affected by use of, 10.31
corneal graft failure and, 8.428
in elderly patients, 10.186
for elevated episcleral venous pressure, 10.103
for Fuchs heterochromic iridocyclitis, 10.101–102
general approach to use of, 10.183–186
generic agents and, 10.186
for hemolytic/ghost cell glaucoma, 10.106
hyperosmotic/osmotic agents, 10.174*t*
for hyphema, 10.105
for inflammatory glaucoma, 10.100
interrelationship between medical and surgical treatment and, 10.111
for iridocorneal endothelial syndrome, 10.137–138
latanoprost, 10.170–176, 10.171*t*
for lens particle glaucoma, 10.98
long-term therapy with, 10.183–184
for malignant glaucoma (aqueous misdirection/ciliary block glaucoma), 10.140
miotics, 10.166, 10.173*t*, 10.181–182
for neovascular glaucoma, 10.135
for normal-tension glaucoma, 10.88
for ocular hypertension, 10.89–90, 10.112
ocular surface toxicity of, 8.90*t*
for open-angle glaucoma, 10.113
parasympathomimetics, 10.173*t*, 10.181–182
for pediatric glaucoma, 10.153, 10.164–165
for phacoantigenic glaucoma, 10.98
for pigmentary glaucoma, 10.96
for postoperative elevated intraocular pressure, 10.108
during pregnancy/lactation, 10.185–186
preservative-free/alternatively preserved, 10.170–175, 10.175*t*
prostaglandins/prostaglandin analogues, 10.165–166, 10.170–176, 10.171*t*, 10.175*f*
after refractive surgery, 13.201
Antihistamines, 1.302, 1.308*t*. *See also specific agent*
for atopic dermatitis, 8.287
description of, 2.411–412
for hay fever conjunctivitis, 8.288, 8.289
mast-cell stabilizers and, 2.413
for ocular allergies, 6.247*t*
refractive surgery in patient taking, 13.37

tear production affected by, 8.62*t*
for vernal keratoconjunctivitis, 8.291
Antihypertensive therapy
agents used in. *See specific agent*
α_1-blockers, 1.62–63
in children, 1.68
combined α-adrenergic and β-adrenergic antagonists, 1.63
Conduit Artery Function Endpoint (CAFE) study findings on, 1.64
direct renin inhibitors, 1.63
direct vasodilators, 1.63
diuretics, 1.59*t*, 1.59–61
drugs used in, 1.59*t*
hypertension treated with, 1.52, 1.56–57, 1.59*t*, 1.59–64
for hyphema, 8.395
nighttime administration of, 1.66
in older adults, 1.67
parenteral, 1.64
in pregnancy, 1.68
stroke prevention uses of, 1.115
tear production affected by, 8.62*t*
Antimetabolites, 1.240*t*, 2.404*t*, 2.413–414
for acute anterior uveitis, 9.130
for scleritis, 8.324, 8.325*f*
for uveitis, 6.322, 9.106–108
Antimicrobial prophylaxis
for cataract surgery, 11.93–95, 11.94*f*
corneal melting and, 11.132
for endophthalmitis, 11.93–95, 11.94*f*, 11.161–162
for photoablation, 13.81–82
Antimicrobial therapy. *See also* Antibiotics; *specific agent*
aminoglycosides, 2.425–426
antifungal drugs, 2.429–431, 2.430–431*t*
cephalosporins, 2.417, 2.419–420
chloramphenicol, 2.425
fluoroquinolones, 2.420, 2.422–423
macrolide antibiotics, 2.427
penicillins, 2.417–419
sulfonamides, 2.423–424
tetracyclines, 2.424–425
types of, 2.418*t*
vancomycin, 2.426–427
Antineoplastic drugs, 1.240*t*. *See also* Chemotherapy
Antineutrophil cytoplasmic autoantibody (ANCA)
in granulomatosis with polyangiitis (Wegener granulomatosis). *See also* Granulomatosis, with polyangiitis
eyelid manifestations of, 4.207*t*
optic neuritis and, 5.115
serum assay, 7.34, 7.63
vasculitis associated with, 1.169*t*, 1.171–173
Antinuclear antibody (ANA) testing
description of, 1.153
in granulomatosis with polyangiitis, 9.159
in juvenile idiopathic arthritis, 1.157
in systemic lupus erythematosus, 1.160, 1.160*t*, 9.156
in systemic sclerosis, 1.165
Antioncogenes, 2.183. *See also* Tumor suppressor genes
Antioxidants
age-related macular degeneration and, 2.346, 4.160, 12.69
ascorbate, 2.342–343
carotenoids, 2.343
catalase, 2.342
cataract prevention and, 11.7, 11.20, 11.72
description of, 2.447
glutathione. *See* Glutathione
glutathione peroxidase, 2.341
macula localization of, 2.344*f*
pathways of, 2.337*f*
in retinal pigment epithelium, 2.341–343
selenium, 2.341
superoxide dismutase, 2.342
vitamin E, 2.340, 2.342, 2.344*f*
Antiphospholipid syndrome (APS), 1.148–149, 1.163–164
Antiplatelet therapy. *See also* Aspirin
cataract surgery and, 11.157, 11.171–172, 11.172*t*
coronary heart disease treated with, 1.90*t*
dual. *See* Dual antiplatelet therapy
ocular surgery and, 1.286
Antiporters, 2.271
Antiproliferative agents. *See* Antimetabolites
Antipsychotic drugs
adverse effects of, 1.200
description of, 1.199–201, 1.200*t*
extrapyramidal side effects of, 1.200
first-generation, 1.199–201, 1.200*t*
intraoperative floppy iris syndrome and, 11.136, 11.137*t*
oculogyric crisis caused by, 5.231
second-generation, 1.199, 1.200*t*
tardive dyskinesia caused by, 1.200
blepharospasm and, 5.281
facial movements and, 5.285
tear production affected by, 8.62*t*
Antireflection coatings, 3.103, 3.104*f*
Antiretinal antibody testing, in cancer-associated retinopathy, 5.102
Antiretroviral therapy (ART), 2.437
for cytomegalovirus retinitis, 9.256
description of, 2.436–437
for HIV, 1.268
Antiself-antibodies. *See* Autoantibodies
Antisense oligonucleotides, 2.197*f*
Antispasmodics, tear production affected by, 8.62*t*
Antithrombin (AT)
deficiency of, 1.147
description of, 1.139
Antithrombotic agents
coronary heart disease treated with, 1.89, 1.90–91*t*
stroke prevention using, 1.114–115
Antitumor antibiotics, 1.240*t*, 1.241
Antiulcer agents, tear production affected by, 8.62*t*
Antiviral agents, 1.277–279
acute retinal necrosis treated with, 12.236
for Bell palsy, 5.279
description of, 2.431, 2.433–434
for herpetic eye disease, 8.205, 8.215, 8.215*t*, 8.219, 8.222, 8.223*t*, 8.224
epithelial keratitis, 8.219, 8.223*t*
epitheliopathy caused by, 8.224
graft survival after keratoplasty and, 8.225
herpes zoster ophthalmicus, 8.229–230
before refractive surgery, 13.174
stromal keratitis, 8.222, 8.223*t*, 8.224

for HIV infection/AIDS. *See* Antiretroviral therapy
ocular surface toxicity of, 8.90*t*, 8.91
progressive outer retinal necrosis syndrome treated with, 12.236
systemic, 2.434–437
topical, 2.433–434
types of, 2.432–433*t*
Anton syndrome, 5.158, 5.180–181, 5.337
Antoni A pattern/Antoni B pattern, 7.86
in neurilemomas/schwannomas, 4.238, 4.239*f*
Anwar big-bubble technique, 8.434
Anxiolytics. *See* Antianxiety drugs
Aortic arch, 5.13*f*, 5.19
emboli from atheroma of, transient visual loss and, 5.166
Aortic arch (Takayasu) arteritis/aortitis syndrome, cataract caused by, 11.68
AOX. *See* Adult-onset xanthogranuloma
AP-ROP. *See* Aggressive posterior retinopathy of prematurity
APC. *See* Activated protein C
APC gene, 12.286
APCs. *See* Anterior polar cataracts; Antigen-presenting cells
Apert syndrome (acrocephalosyndactyly), 6.206–207, 6.207*f*, 6.209*f*, 7.39, 7.39*f*, 8.191*t*
Apertures
diffraction created by, 3.105, 3.105*f*
pinhole
double, 3.285, 3.286*f*
monocular diplopia and, 3.130
Apex, corneal, 8.25, 8.26*f*
Aphakia
congenital, 4.117, 6.305, 11.30
description of, 3.93, 3.119
epikeratoplasty (epikeratophakia) for, 13.62
glaucoma and. *See* Aphakic glaucoma
homoplastic corneal inlays for, 13.60
after ICCE, 11.201
infantile, 3.225
IOLs for, 11.118–122. *See also* Intraocular lenses
monocular, 3.191
post–cataract surgery management of, 6.304
as refractive hyperopia, 3.137
retinal detachment risks, 12.319
unilateral, 3.140, 3.207
Aphakic (pseudophakic) bullous keratopathy, after cataract surgery, 4.83–84, 4.84*f*, 11.129, 11.129*f*
IOL design and, 11.149
Aphakic glaucoma, 6.285, 10.130–132
in children, 10.156–157
tube shunt implantation for, 10.215
Aphakic spectacles
description of, 3.191*f*, 3.191–192
image magnification caused by, 3.255
Apical alignment fit, of rigid gas-permeable contact lenses, 3.218–219, 3.219*f*
Apical bearing, of rigid gas-permeable contact lenses, 3.218
Apical clearance, of rigid gas-permeable contact lenses, 3.218
Apical zone of cornea, 3.205, 3.215, 3.228, 8.25
Apixaban, 1.149
Aplastic anemia, 1.137, 2.393
carbonic anhydrase inhibitors causing, 10.180
APMPPE. *See* Acute posterior multifocal placoid pigment epitheliopathy
APMs. *See* Alternative payment models
Apnea. *See* Obstructive sleep apnea
Apocrine glands, of eyelid, 4.201, 4.202, 8.4. *See also* Glands of Moll
cyst arising in, 4.208, 4.208*f*
Apocrine hidrocystoma, 4.208, 4.208*f*, 7.193, 7.193*f*
Apodization, 3.239, 3.260
Apodized diffractive multifocal lenses, 13.166, 13.166*f*
Apolipoprotein(s)
D, 2.276
description of, 1.72
Apomorphine, for Parkinson disease, 1.205
Aponeurosis, levator. *See* Levator aponeurosis
Aponeurotic ptosis, 5.273, 5.273*t*, 7.245, 7.245*f*, 7.245*t*
Apoplexy, pituitary (Sheehan syndrome), 1.49, 5.149, 5.150*f*
Apoptosis
atrophy caused by, 2.182
cytotoxic T cell inducement of, 9.46
definition of, 2.171, 2.182
in embryogenesis, 2.182
Fas ligand (CD95 ligand/FasL) in
description of, 9.57
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
retinal ganglion cell, 6.44
Apparent diffusion coefficient (ADC), 2.461*t*
Apparent diffusion coefficient (ADC) technique/mapping, 1.112, 5.64*f*, 5.65*t*, 5.66, 5.67*f*, 5.75
Applanation head/plate, of microkeratome, 13.85*f*, 13.85–86
Applanation tonometry/tonometer, 3.282, 3.293–294, 3.294*f*, 10.22–25, 10.23*f*, 10.24*f*, 10.27
corneal thickness affecting, 10.25, 10.81, 10.82, 10.86, 13.105, 13.181
infection control and, 10.27
in normal-tension glaucoma, 10.86
portable electronic, 10.25
after refractive surgery, 13.105, 13.181, 13.200–201
LASIK, 13.105, 13.200–201
surface ablation, 13.105, 13.200–201
sources of error and, 10.23–24, 10.24*t*
Applanation ultrasonography, 3.245, 3.245*f*
for axial length measurement, in IOL power determination/selection, 11.83
Appositional suprachoroidal hemorrhage, 12.394–395
Approximations. *See specific type*
Apraclonidine hydrochloride, 2.385*t*, 2.385–386, 6.275, 6.289*t*, 6.290, 10.172*t*, 10.178–179
anisocoria/Horner syndrome diagnosis and, 5.256*f*, 5.259, 5.259*f*
in children, 10.165
Apraxia
of eyelid opening, 5.273*t*, 5.274
ocular motor, 5.221, 5.222–223
acquired, 5.223
congenital, 5.223
parietal lobe lesions and, 5.156, 5.223
APS. *See* Antiphospholipid syndrome
aPTT. *See* Activated partial thromboplastin time

AQP4-IgG (aquaporin-4 immunoglobulin G) antibody, in neuromyelitis optica spectrum disorder, 5.115, 5.117*t*, 5.118, 5.320, 5.322
AquaLase liquefaction device, 11.125
Aquaporin(s) (major intrinsic protein/MIP/water channels), 2.283, 2.285, 11.16, 11.20–21
Aquaporin-4 immunoglobulin G (AQP4-IgG) antibody. *See* AQP4-IgG (aquaporin-4 immunoglobulin G) antibody
Aquaporin channels, 2.294*f*
Aqueous drainage
  devices/shunts for. *See* Tube shunts
  for uveitic glaucoma, 9.320
Aqueous flare, in anterior uveitis, 9.77, 9.79*f*
Aqueous fluid polymerase chain reaction testing, in uveitis evaluations, 9.90–91
Aqueous humor
  antibody production in, 9.91
  ascorbate levels in, 2.274
  biological factors in, 9.55
  blood–aqueous barrier, 2.270, 2.279
  calcium in, 2.274
  carbohydrates in, 2.274–275
  carbon dioxide in, 2.278–279
  for CMV testing, 8.232
  composition of, 2.273*t*, 2.273–279
  dynamics of, 2.270–273, 10.5*f*, 10.13–19
  enzymes in, 2.276
  formation of. *See* Aqueous humor, production/composition of
  glucose concentration in, 2.274–275
  glutathione in, 2.275
  growth-modulatory factors in, 2.277
  immunosuppressive microenvironment of, corneal graft tolerance and, 8.316
  inorganic ions in, 2.274
  inositol in, 2.275
  insulin-like growth factor binding proteins in, 2.277
  intraocular pressure and, 10.5, 10.5*f*, 10.13, 10.14*f*
  in iris stroma, 2.68
  lactate in, 2.274
  magnetic resonance imaging of, 2.459*t*
  neuroendocrine proteins in, 2.276
  neurotrophic proteins in, 2.276
  nonpigmented epithelium secretion of, 2.271
  organic anions in, 2.274
  outflow of, 10.5*f*, 10.17–19, 10.18*f*
    facility of, 10.19
      classification of glaucomas and, 10.3–5, 10.4*t*, 10.6*t*
      intraocular pressure and, 10.5, 10.5*f*, 10.13, 10.14*f*
      tonography in measurement of, 10.19
    laser trabeculoplasty affecting, 10.188
    prostaglandin analogues affecting, 10.165–166, 10.170
    trabecular, 10.5*f*, 10.13, 10.17–18, 10.18*f*
    uveoscleral, 10.5*f*, 10.13, 10.19
  oxygen in, 2.278
  pH of, 2.279
  phosphate in, 2.274
  polymerase chain reaction testing of, in uveitis evaluations, 9.90–91
  production/composition of, 2.270–273, 2.272*f*, 10.5*f*, 10.13–17, 10.14–15*f*
    measurement of formation and, 10.17
    suppression of formation and, 10.16–17
      α_2-agonists in, 10.17, 10.165
      β-blockers in, 10.16–17, 10.164, 10.176
      carbonic anhydrase inhibitors in, 10.16, 10.165, 10.179
  production of, 2.59, 2.269, 2.272*f*
  proteinase inhibitors in, 2.276
  proteinases in, 2.276
  proteins in, 2.275–276
  refractive index of, 3.127*t*, 8.26
  secretion of, 2.270–273, 2.272*f*
  separation of, from blood. *See* Blood–aqueous barrier
  urea in, 2.275
  vascular endothelial growth factors in, 2.277–278
Aqueous layer (component), of tear film
  deficiency of. *See* Aqueous tear deficiency
  secretion tests, 8.38–39, 8.55–56
Aqueous misdirection, 2.378. *See also* Malignant glaucoma
Aqueous shunt implantation. *See* Tube shunts
Aqueous suppressants, for uveitic glaucoma, 9.319
Aqueous tear deficiency (ATD), 8.45, 8.53, 8.54*f*, 8.55*f*, 8.55–58. *See also* Dry eye
  blepharitis and, 8.76
  clinical presentation of, 8.55*f*, 8.55–58
  non-Sjögren syndrome, 8.55*f*
  refractive surgery and, 13.173
  Sjögren syndrome, 8.39, 8.55*f*, 8.56–58, 8.58*t*
  superior limbic keratoconjunctivitis and, 8.84
  tests of, 8.38–39, 8.55–56
  treatment of
    medical, 8.61*t*, 8.61–64, 8.62*t*
    surgical, 8.64–65, 8.65*f*
Aqueous vein, 2.67*f*
Arachidonic acid (AA)
  derivatives of, 2.407
  description of, 2.399
  eicosanoids from, 9.19
  prostaglandin synthesis from, 2.408*f*
Arachnids, ocular injury caused by, 8.386–387
Arachnodactyly, 6.307, 6.308*f*
  in Marfan syndrome, 11.40, 11.40*f*
Arachnoid mater, optic nerve, 4.241, 4.242*f*, 5.17*f*, 5.26
Arachnoid sheath, 2.114, 2.114*f*
Arachnoid villi, 5.22
ARB. *See* Autosomal recessive bestrophinopathy
ARBs. *See* Angiotensin II receptor blockers
ARC. *See* Anomalous retinal correspondence
Arc of contact, 6.32
Arc scanning, 8.35*t*
ARC-T (Astigmatism Reduction Clinical Trial), 13.57
Arcade retinal arteries, inferior/superior, 5.14
Arcade retinal veins, 5.21
Arcuate fibers, 5.103, 5.104*f*
  visual field defects and, 5.103, 5.106*f*
    glaucoma and, 10.42, 10.68, 10.68*f*
Arcuate incisions, for keratorefractive surgery, 13.27, 13.27*f*, 13.53, 13.54–55
  coupling and, 13.27, 13.27*f*, 13.54, 13.54*f*, 13.55
Arcuate keratotomy (AK), 13.8*t*, 13.53, 13.54–58

complications of, 13.58
instrumentation for, 13.55
ocular surgery after, 13.58
outcomes of, 13.57
refractive lens exchange and, 13.149
surgical technique for, 13.55–57
Arcuate (Bjerrum) scotoma, 5.103, 5.105*t*, 5.106*f*
in glaucoma, 10.68, 10.68*f*
Arcus (corneal), 1.78, 8.120–121, 8.121*f*, 8.179
in cornea plana, 8.100
in dyslipoproteinemia/hyperlipoproteinemia, 8.120, 8.121, 8.179
juvenilis, 8.121
in lecithin-cholesterol acyltransferase (LCAT) deficiency, 8.180, 8.180*f*
lipoides, in Schnyder corneal dystrophy, 8.151, 8.152*f*
senile furrow degeneration and, 8.122
senilis, 8.120–121, 8.121*f*
Arcus marginalis, 7.11
Arden index/ratio, 12.50
Area centralis, 12.9, 12.9*f*. *See also* Macula/macula lutea
Area of Martegiani, 12.7, 12.8*f*, 12.307
Area postrema syndrome, 5.117*t*
AREDS2. *See* Age-Related Eye Disease Study 2
AREDS. *See* Age-Related Eye Disease Study
ArF laser. *See* Argon-fluoride (ArF) excimer laser
Argon-fluoride (ArF) excimer laser, 13.29, 13.73–77, 13.74–75*f*. *See also* Excimer laser; Laser(s)
for photoablation, 13.29, 13.73–77, 13.74–75*f*. *See also* Photoablation
Argon laser therapy. *See also* Laser therapy; Photocoagulation
for diabetic retinopathy/macular edema, 4.160, 4.161*f*
for gonioplasty/iridoplasty, 10.194
in plateau iris, 10.127*f*, 10.128, 10.193–194
for iridotomy, 10.192, 10.193
for trabeculoplasty (ALT), 10.88, 10.113–115, 10.188–189, 10.190*f*
for trichiasis, 7.240
Argus II Retinal Prosthesis System, 12.264
Argyll Robertson-like pupil, 5.267
Argyll Robertson pupil, 5.267, 9.223
Argyria/argyriasis/argyrosis
description of, 8.118*t*, 8.132, 12.306
silver causing, 4.120
Arlt line, 8.261, 8.261*f*
ARMD. *See* Age-related macular degeneration/maculopathy
ARMOR study. *See* Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) study
ARMS2 gene, 12.63
in age-related macular degeneration, 4.160
ARN. *See* Acute retinal necrosis
Arnold-Chiari malformation, nystagmus caused by, 5.244, 5.245*f*, 5.246
ARPE. *See* Acute retinal pigment epitheliitis
ARR. *See* Absolute risk reduction
Arrestin, 2.313*t*, 12.253
in experimental autoimmune uveoretinitis, 9.61
Arrhythmias. *See also specific type*
bradyarrhythmias, 1.99, 1.101
in congestive heart failure, 1.99
tachyarrhythmias. *See* Tachyarrhythmias
ARS. *See* Axenfeld-Rieger syndrome
ART. *See* Antiretroviral therapy
Arterial circles, 5.15
Arterial macroaneurysms, retinal, 12.147–148, 12.148*f*
Arterial occlusive disease
carotid artery. *See* Carotid occlusive disease
retinal artery. *See also* Retinal artery occlusion
branch, 4.156
central, 4.156, 4.157*f*
Arterial retrobulbar hemorrhage. *See also* Retrobulbar hemorrhage
cataract surgery and, 11.158
Arteries, 5.11–20, 5.13–18*f*, 5.20*f*. *See also specific artery*
dissections in, 5.342–343
Arteriography. *See* Angiography/arteriography
Arteriohepatic dysplasia (Alagille syndrome), 6.255, 8.97*t*, 8.102, 12.282*t*, 12.285
posterior embryotoxon and, 8.97*t*, 8.102
Arteriosclerotic retinopathy, 12.122
Arteriovenous fistulas, 7.78, 7.78*f*
glaucoma associated with, 10.30
Arteriovenous malformations (AVMs), 5.343–345, 5.344*f*, 7.77*f*, 7.77–78
congenital retinal, 4.286*f*, 4.286–287
description of, 1.110
headache caused by, 5.291, 5.292*f*, 5.343
intracerebral hemorrhage from, 1.120
intracranial hemorrhage caused by, 5.343
neuro-ophthalmic signs of, 5.343–345, 5.344*f*
neuroimaging in evaluation of, 5.292*f*
occipital, 5.343
binocular transient visual loss and, 5.172
orbital, 6.222
subarachnoid hemorrhage caused by, 1.121–122
surgical excision of, 1.122
in Wyburn-Mason syndrome, 5.333*f*, 5.334*t*
Arteritic ischemic optic neuropathy
anterior (AAION), 5.107*t*, 5.120, 5.120*t*, 5.120–122, 5.121*f*, 5.313
posterior (PION), 5.107*t*, 5.119, 5.124
Arteritis
giant cell (GCA/temporal), 5.89, 5.89*f*, 5.313–315, 7.62–63, 9.125*t*
AAION and, 5.120, 5.313
central retinal artery occlusion caused by, 12.145
description of, 1.168, 12.195
diplopia in, 5.192, 5.313
facial pain associated with, 5.288, 5.297
headache in, 5.288, 5.313
indocyanine green angiography of, 12.196*f*
neuro-ophthalmic signs of, 5.313–315
occult, 5.120, 5.170
optic nerve affected in, 4.244*f*, 4.244–245, 5.120
polymyalgia rheumatica associated with, 1.168
transient monocular visual loss and, 1.119
transient visual loss and, 5.120, 5.161, 5.162, 5.169–170, 5.313–314
vasculitis, 7.62–63
Takayasu (aortic arch arteritis/aortitis syndrome/pulseless disease)
cataract caused by, 11.68
description of, 1.170, 9.125*t*

Artery of Percheron, 5.20, 5.229–230
Arthritis
cataract surgery in patient with, 11.171
enteropathic, 1.156, 6.315*t*
enthesitis-related, 1.154, 6.315*t*, 9.142
juvenile idiopathic, 1.157–158, 1.158*t*, 6.312–315, 6.313–314*t*, 6.314*f*, 6.322
psoriatic, 1.156–157
acute anterior uveitis in, 9.133
clinical presentation of, 9.133, 9.134*f*
laboratory tests for, 9.125*t*
reactive/Reiter syndrome, 1.155–156*f*, 1.157, 6.315*t*, 8.305–306
acute anterior uveitis in, 9.132–133
conjunctivitis/episcleritis associated with, 8.305–306
diagnostic criteria for, 9.132–133, 9.133*f*
human leukocyte antigen association with, 9.65*t*, 9.132
laboratory tests for, 9.125*t*
rheumatoid (RA)
cataract surgery in patient with, corneal melting/keratolysis and, 11.132
description of, 9.125*t*
extra-articular manifestations of, 1.152–153
hand deformities associated with, 1.152, 1.152*f*
juvenile. *See* Juvenile idiopathic arthritis
laboratory testing for, 1.153
ocular manifestations of, 1.153
peripheral ulcerative keratitis and, 8.311, 8.312, 8.312*f*
prevalence of, 1.152
refractive surgery contraindicated in, 13.191
scleritis/scleromalacia perforans and, 8.321–322, 8.322*f*
treatment of, 1.153–154
Arthritis mutilans, 1.156
Arthro-ophthalmopathy (Stickler syndrome), 12.282*t*. *See also* Stickler syndrome
Arthropods, 8.253, 8.254*f*
Artifacts
on automated perimetry, 10.66*f*, 10.66–67, 10.67*f*
in optical coherence tomography angiography, 12.29, 12.30*f*
projection, 12.29, 12.30*f*
Artificial insemination, 2.238
Artificial tears, 2.415. *See also* Lubricants
for corneal exposure in facial palsy, 5.280
for dry eye, 8.61*t*, 8.62–63
refractive surgery and, 13.173
for exposure keratopathy, 8.80
for hay fever conjunctivitis, 8.288
for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297, 8.298
for Thygeson superficial punctate keratitis, 8.307
ARV (AIDS-related virus). *See* HIV (human immunodeficiency virus); HIV infection/AIDS
AS. *See* Ankylosing spondylitis
ASA (advanced surface ablation). *See* Photorefractive keratectomy
ASA-PS. *See* American Society of Anesthesiologists Physical Status
Ascending optic atrophy, 4.245–246
Ascorbic acid (vitamin C)
in aqueous humor, 2.274
for chemical injuries, 8.383
corneal wound healing and, 13.33
description of, 2.340, 2.342–343
in phototherapeutic keratectomy, 8.367
in vitreous, 2.302, 2.303*f*, 12.9
ASCRS (American Society of Cataract and Refractive Surgery), on IOL power calculation, 11.85
online post-refractive calculator, 13.52, 13.195–197, 13.196*f*
ASDA (anterior segment developmental anomalies). *See* Anterior segment, dysgenesis of
Aseptic meningitis, in HIV infection/AIDS, 5.348
Aseptic thrombosis
cavernous sinus, 5.345
lateral (transverse) sinus, 5.69*f*, 5.345
Ash-leaf spot (hypopigmented macule), in tuberous sclerosis, 5.331*f*, 5.334*t*, 10.30
ASI. *See* Anterior segment, ischemia of
Aspergilloma (fungus ball), 5.353
Aspergillus (aspergillosis), 5.353–354, 5.354*f*, 7.52, 8.208*t*, 8.249*t*, 8.251, 9.301
allergic, 5.353
endophthalmitis caused by, 12.239
endogenous, 9.300–301
invasive, 5.353, 5.354
keratitis caused by, 4.78, 8.208*t*, 8.275
neuro-ophthalmic signs of, 5.353–354, 5.354*f*
ocular infection caused by, 8.208*t*
orbital infection caused by, 4.227–228, 4.228*f*, 5.353, 5.354*f*
retinal infection caused by, 4.147
sinus infection and, 5.353
Asphericity, corneal, 13.14
Aspiration. *See also* Irrigation/aspiration
in ECCE, 11.197
in manual small-incision cataract surgery, 11.198, 11.199*f*
in phacoemulsification, 11.102, 11.115
pumps for, 11.103*f*, 11.103–104, 11.104*f*
Aspiration biopsy. *See* Fine-needle aspiration biopsy
Aspirin, 2.409*t*, 2.409–410. *See also* Dual antiplatelet therapy
diabetic retinopathy and, 12.100
myocardial infarction prophylaxis using, 1.89
ocular adverse effects of, 1.308*t*
platelet aggregation inhibition using, 1.143
stroke prevention uses of, 1.114
ASPPC. *See* Acute syphilitic posterior placoid chorioretinitis
Assessment of Capacity for Everyday Decision-Making (ACED), 1.211
Association (genetic)
allelic. *See* Linkage disequilibrium
description of, 6.183
Asteroid bodies, 4.133, 4.133*f*
in sarcoidosis, 4.187
Asteroid hyalosis, 4.133, 4.133*f*, 12.346*f*, 12.346–347
Asthenopia, 6.101
Asthenopic complaints
definition of, 3.24

development of, 3.196
types of, 3.24
Asthma
bronchospasm in, 1.123–124
description of, 1.123–124
eosinophilic, 1.124
precipitating factors for, 1.124
treatment of, 1.128–130, 1.129*f*, 1.308*t*
Astigmatic dial technique, 3.148, 3.160–162, 3.161*f*, 3.166
Astigmatic keratotomy (AK)/incision, 13.8*t*
cataract surgery and, 11.123
coupling and, 13.54, 13.54*f*, 13.55
wound healing/repair and, 13.32
Astigmatic refractive errors. *See* Astigmatism
Astigmatism, 13.17–19
against-the-rule, 3.123, 3.139, 3.250, 8.31, 8.32*t*, 8.33*f*
autorefractor detection of, 3.273
in cataract patient, 11.174
corneal topography before surgery and, 11.84, 11.174
modification during surgery and, 11.123–124
toric IOLs for, 11.124, 13.151–153
after cataract surgery, 11.131–132
keratorefractive/refractive surgery and, 11.176, 11.177*f*, 13.53, 13.54–58
manual small-incision surgery and, 11.198
compound hyperopic, 3.138, 3.138*f*
compound myopic, 3.138, 3.138*f*
contact lenses for, 3.211–212
corneal
contact lens masking of, 3.225
description of, 3.19
spherical rigid contact lenses for, 3.211
toric intraocular lenses for, 3.257
in corneal ectasia, 8.32*t*
corneal topography in detection/management of, 8.15, 8.31–32, 8.32*t*, 13.17–19, 13.18–19*f*, 13.22–23, 13.44–45, 13.45*f*
after penetrating keratoplasty, 8.32, 8.431–432, 8.432*f*, 13.179–180
correction of. *See also* Astigmatism, surgical correction of
contact lenses for, 3.211–212, 3.222–223, 3.223*t*, 13.17
after refractive surgery, 13.199
cylindrical spectacle lenses for. *See* Cylindrical lenses distortion and. *See* Distortion
minus cylinder lens for, 3.19, 3.20*f*
quantities required for, 3.20
toric soft contact lenses for, 3.222–223, 3.223*t*
definition of, 3.3, 3.16, 3.39, 3.72, 3.123, 3.137
description of, 3.15–19
focal lines in, 3.137
induced, cataract surgery and, 11.131–132
irregular, 13.17–19, 13.18*f*, 13.19*f*. *See also* Wavefront aberrations
after arcuate keratotomy, 13.58
after cataract surgery, keratorefractive/refractive surgery and, 13.53
causes of, 3.277–278, 3.278*f*
corneal topography in detection/management of, 8.15, 8.31, 8.32, 13.17–19, 13.18*f*, 13.19*f*, 13.22–23, 13.44, 13.45, 13.45*f*
after penetrating keratoplasty, 8.431–432, 8.432*f*
definition of, 3.124, 3.267
description of, 3.130, 3.139
epithelial basement membrane dystrophy and, 3.277, 3.278*f*
keratorefractive/refractive surgery and, 3.272–278, 3.274–3.276*f*, 13.18–19, 13.22–23, 13.44, 13.45
cataract surgery outcome and, 11.176, 11.177*f*
after limbal relaxing incisions, 13.58
after penetrating keratoplasty, 8.426, 8.431–432
quantification of, 3.273
retinoscopy in detection/evaluation of, 8.163
wavefront analysis of, 3.273–277, 3.274–3.276*f*. *See also* Wavefront analysis
in keratoconus, 8.32*t*, 8.163, 8.164–165, 8.166
keratometry in evaluation of, 8.27
lenticular
description of, 3.19
refractive surgery and, 13.45, 13.149
as "residual" astigmatism, 3.211
in megalocornea, 8.100
mixed, 3.138, 3.138*f*
limbal relaxing incisions for, 13.57
wavefront-optimized laser ablation for, 13.97
after multifocal IOL implantation, 13.155
oblique, 3.139, 3.147
in pediatric glaucoma, 10.166
after penetrating keratoplasty, 8.426, 13.178–180
corneal keratoscopy in, 8.27
management of, 8.431–432, 8.432*f*
corneal topography in, 8.32, 8.431–432, 8.432*f*
IOLs for, 8.432, 13.179
refractive surgery in, 13.178–180
suture removal/adjustment and, 8.419*f*, 8.431–432, 8.432*f*
refractive surgery for, 13.178–180
toric IOLs for, 8.432, 13.179
phoropter detection of, 3.29
pictorial representation of, 3.138*f*
postoperative. *See specific procedure*
principal axes of, 3.138–139
pterygium and, 8.113
after radial keratotomy, 13.51, 13.51*f*, 13.51–52
refractive, 3.211
after refractive lens exchange, 13.149
regular, 3.124, 3.139, 3.276
corneal topography in detection/management of, 13.17, 13.18*f*
wavefront aberrations produced by, 13.11, 13.11*f*
retinoscopy in detection/evaluation of, 8.163
schematic diagram of, 3.72*f*
simple hyperopic, 3.138, 3.138*f*
simple myopic, 3.138, 3.138*f*
surgical correction of. *See also specific procedure*
arcuate keratotomy for, 13.8*t*, 13.53, 13.54–58
bioptics for, 13.137, 13.157
cataract surgery and, 11.123–124
incisional corneal surgery for, 13.53–58, 13.54*f*, 13.55*f*, 13.56*f*, 13.57*f*
light-adjustable IOLs for, 13.153–154, 13.154*f*
limbal relaxing incisions for, 11.123–124, 13.8*t*, 13.53–58, 13.54–57*f*, 13.56*t*
nonlaser, 13.8*t*
phakic IOLs for, 13.137, 13.140

photoablation for, 13.75*f*
preoperative patient preparation and, 13.82
refractive lens exchange for, 13.148–149
small-incision lenticule extraction for, 13.204
thermokeratoplasty for, 13.127
toric IOLs for, 11.124, 13.137, 13.148–149, 13.151–153
after penetrating keratoplastsy, 8.432, 13.179
transverse keratotomy for, 13.53, 13.54, 13.54*f*
wavefront-optimized/wavefront-guided laser ablation for, 13.31, 13.76–77
results of, 13.31–32, 13.97
tonometry accuracy and, 10.24
after toric IOL implantation, 13.153
toric lenses for, 3.257, 11.124, 13.137, 13.148–149, 13.151–153
after penetrating keratoplasty, 8.432, 13.179
types of, 3.277
wavefront analysis and, 13.11, 13.11*f*. *See also* Wavefront analysis
"with-the-rule," 8.31*f*
definition of, 3.19, 3.125
description of, 3.139
minus cylinder lens correction of, 3.20*f*
schematic diagram of, 3.19*f*
Astigmatism Reduction Clinical Trial (ARC-T), 13.57
Astrocytes, 2.111, 2.113
optic nerve, 4.241, 4.242*f*
retinal, 5.24
in healing/repair, 4.17
Astrocytoma (astrocytic hamartoma), 4.249, 4.249*f*, 5.108*f*, 6.353, 6.397, 6.399*f*
juvenile pilocytic, 4.249
optic. *See* Optic nerve glioma
pilocytic. *See* Optic nerve glioma
retinal, 4.295, 4.296*f*
optic nerve/nerve head/disc drusen differentiated from, 5.108*f*, 5.143
retinoblastoma differentiated from, 4.295, 4.296*f*
in tuberous sclerosis, 4.295, 5.143, 5.331*f*, 5.334*t*
Asymptomatic carotid stenosis, 1.116–117
Asymptomatic coronary heart disease, 1.86
Asymptomatic retinal breaks, 12.318
AT. *See* Antithrombin; Ataxia-telangiectasia
Ataxia
diplopia and, 5.191
optic, 5.223
Ataxia-telangiectasia (AT/Louis-Bar syndrome), 2.181, 5.330, 5.332*f*, 5.334*t*, 6.393*t*, 6.403*f*, 6.403*t*, 6.403–404, 8.115*t*, 8.346
ATD. *See* Aqueous tear deficiency
Athens protocol, 13.134
Atheroma
description of, 1.110
transient visual loss and, 5.165–166, 5.167*f*
Atherosclerosis
carotid
diagnosis of, 1.116
locations of, 1.115
coronary artery (coronary heart disease). *See* Ischemic heart disease
definition of, 1.72
fatty streak associated with, 1.81
ocular manifestations of, 1.78
plaque, 1.81
risk factors for, 1.89
screening for, 1.215
transient visual loss and, 5.165–166, 5.167*f*
Atkinson nerve block, for cataract surgery, 11.92, 11.93*f*
ATM gene, 2.181
ATOH7 gene, 12.341
Atopic dermatitis, 8.287
atopic keratoconjunctivitis and, 8.292
cataracts associated with, 11.66
eyelid involvement and, 8.287
vernal keratoconjunctivitis and, 8.289
Atopic keratoconjunctivitis (AKC), 6.249, 8.292–294, 8.293*f*
Atopy. *See specific Atopic entries*
Atorvastatin, 1.75*t*
ATP. *See* Adenosine triphosphate; Adult Treatment Panel
ATP-binding cassette (ABC) transporters/transporter protein, mutation in, in Stargardt disease, 4.168–169
ATPase-6 gene, 2.186
ATP7B gene, 6.270
in Wilson disease, 8.189
Atrial fibrillation (AF), 1.102–103, 1.103*f*
cardioembolic stroke caused by, 1.111
perioperative management for ocular surgery in patients with, 1.284
stroke caused by, 1.111
Atrial flutter, 1.102
Atrial thrombi, 1.102
Atrioventricular (AV) junction, 1.101
Atrophia bulbi
with shrinkage, 4.22
without shrinkage, 4.22
Atrophic retinal holes
definition of, 12.315
lattice degeneration and, 4.150, 12.310, 12.311*f*, 12.316*f*
retinal detachment secondary to, 12.310
Atrophy
chorioretinal
genes and loci associated with, 12.256*t*
in pathologic myopia, 12.214*f*
choroid, age-related, 12.200, 12.212
geographic
in Best vitelliform dystrophy, 12.271
description of, 12.64, 12.66, 12.67*f*, 12.68
in drusenoid retinal pigment epithelium detachment, 12.272
gyrate, 12.268–269, 12.269*f*
iris. *See* Iris, atrophy of
macula, 12.265, 12.265*f*
optic. *See* Optic atrophy
retinal, ischemic, 4.151, 4.151*f*, 4.156, 4.159
retinal pigment epithelium, 12.106*f*, 12.294*f*
geographic/nongeographic, 4.164, 4.164*f*
Atrophy creep, 12.89
Atropine
accommodation affected by, 11.23
amblyopia treated with, 6.59
in children, 6.11, 6.11*t*
description of, 1.306, 2.354, 2.380*t*
for edrophonium/neostigmine adverse effects, 5.324, 5.325

eyedrops, for refractive error prevention, 3.144
mydriasis caused by, 5.263
Atropine-Care. *See* Atropine
Atypia, cellular
conjunctival melanocytic intraepithelial neoplasia and, 4.66–68, 4.67*f*
primary acquired melanosis and, 4.65, 4.66, 4.67*f*, 8.342–343
Atypical granular corneal dystrophy. *See* Reis-Bücklers corneal dystrophy
Atypical lymphoid hyperplasia (ALH), of orbit, 4.231, 4.232
Atypical mole. *See* Nevi/nevus, dysplastic
Atypical mycobacteria, 8.248, 8.272–273, 8.273*f*
keratitis caused by, after photoablation, 13.106, 13.119
neuro-ophthalmic signs of infection with, 5.350
Aubagio. *See* Teriflunomide
Audio books, 3.323
Auditory artery, internal, 5.20
Auditory nerve. *See* Cranial nerve VIII
Augmentin, 1.273
Aura
with migraine headache, 5.171–172, 5.177, 5.290–291
seizures and, 5.172, 5.177
without migraine headache (acephalgic migraine), 5.172, 5.177, 5.290, 5.291
Auto-oxidation, 2.337
Autoantibodies. *See also specific type*
in Cogan syndrome, 8.310
in mucous membrane pemphigoid, 8.301–302
in Sjögren syndrome, 8.56, 8.58*t*
in systemic lupus erythematosus, 9.154
Autocrine signaling, of cytokines, 9.21
Autofluorescence (AF), 3.302–303. *See also* Hyperfluorescence
central serous chorioretinopathy findings, 12.192*f*
enhanced depth imaging optical coherence tomography and, 12.39
fluorescein angiography, 12.35
fundus (FAF), 2.330*f* 5.89–90, 5.90*f*
in acute posterior multifocal placoid pigment epitheliopathy, 9.163*t*, 9.171, 9.172*f*
in acute retinal pigment epitheliitis, 9.189
in acute zonal occult outer retinopathy, 5.90, 9.163*t*, 9.191, 9.192*f*
Best disease on, 6.343*f*
in birdshot chorioretinopathy, 9.163*t*, 9.166, 9.167*f*
in choroidal/ciliary body melanoma, 4.265, 4.266*f*
in cone dystrophies, 5.102
definition of, 12.29
description of, 12.23*f*
drusen demonstrating, 5.89, 5.90*f*, 5.141*f*, 5.142
fluorophores, 12.29
Gardner syndrome on, 6.350*f*
hyperspectral, 12.33
in low vision evaluation, 5.89–90, 5.90*f*
in multifocal choroiditis and panuveitis syndrome, 9.163*t*, 9.179, 9.180*f*, 9.186–187*f*
in multiple evanescent white dot syndrome, 9.163*t*, 9.186*f*
near-infrared, 12.32–33
optic disc drusen on, 6.373*f*, 6.374
in punctate inner choroiditis, 9.163*t*
retinal pigment epithelium tears on, 12.31, 12.32*f*
in serpiginous choroiditis, 9.163t, 9.176*f*
Stargardt disease on, 6.340, 12.270
in subretinal fibrosis and uveitis syndrome, 9.163*t*
in uveitis evaluations, 9.89
retinitis pigmentosa findings, 12.261
serpiginous choroidopathy findings, 12.223*f*
Autogenous tensor fascia lata, 7.252
Autografts/autologous transplantation
conjunctival, 8.351*t*, 8.353*t*, 8.353–355, 8.354*f*, 8.356
for chemical injuries, 8.384
indications for, 8.351*t*, 8.353
for limbal stem cell deficiency, 8.94
in pterygium surgery, 8.353*t*, 8.353–355, 8.354*f*
recurrence rate and, 8.353*t*
after tumor removal surgery, 8.329
conjunctival-limbal, in pterygium surgery recurrence rate and, 8.353*t*
corneal, 8.411, 8.451–452. *See also* Corneal grafts; Keratoplasty
limbal, 8.351*t*, 8.362–365, 8.363–364*f*. *See also* Limbal transplantation
indications for, 8.351*t*
Autoimmune diseases. *See also specific type*
Cogan syndrome as, 8.309, 8.310
conjunctivitis caused by, cicatricial conjunctivitis differentiated from, 8.301*t*
Mooren ulcer as, 8.314
mucous membrane pemphigoid as, 8.299, 8.301–302
peripheral ulcerative keratitis as, 8.51*f*, 8.311*t*, 8.311–313, 8.312*f*
refractive surgery in patient with, 13.191
retinopathy in, 5.103
scleritis in, 8.319, 8.323
Autoimmune hyperthyroidism, 7.57
Autoimmune regulator–deficient mice, 9.62
Autoimmune retinopathy, 5.103, 9.192–193, 12.286
Autoimmune uveitis. *See* Noninfectious ocular inflammatory diseases, uveitis/autoimmune uveitis
Autologous fat grafting, 7.271
Autologous serum drops
for dry eye, 8.61*t*, 8.63
for neurotrophic keratopathy/persistent corneal epithelial defects, 8.81, 8.224
for superior limbic keratoconjunctivitis, 8.84
Autologous transplantation. *See* Autografts/autologous transplantation
Automated external defibrillator (AED), 1.296–297, 1.297*t*
Automated optical biometers, 3.244
Automated perimetry. *See also* Perimetry
short-wavelength (SWAP), 10.75
standard (SAP/achromatic), 10.59
static, 5.84, 5.85*f*, 5.85–88, 5.87*f*, 10.59, 10.60–62
artifacts seen on, 10.66*f*, 10.66–67, 10.67*f*
in glaucoma, 10.59, 10.60–62
high false-positive rate in, 10.67, 10.67*f*
incorrect corrective lens used in, 10.66
learning effect and, 10.71
in nonorganic disorder evaluation, 5.306–307, 5.307*f*, 5.308*f*
screening tests and, 10.62
threshold tests and, 10.61*f*, 10.61–62, 10.63*f*
Automatic lensmeter, 3.285

Automatisms, 1.207
Autonomic cephalgias, trigeminal (TACs), 5.293–294
  Horner syndrome and, 5.260*t*, 5.261
Autonomic pathways, 5.52–56
  parasympathetic, 5.52, 5.54–56, 5.55*f*
  sympathetic, 5.52–54, 5.53*f*
  in tear secretion, 8.5, 8.5*f*
Autophagy
  description of, 2.283
  in retinal pigment epithelium, 2.332
Autorefractors. *See also* Retinoscope/retinoscopy
  astigmatism detection using, 3.273
  definition of, 3.147, 3.281
  description of, 3.285–286
  difficulties associated with, 3.286
  function of, 3.285
  initial estimate of refractive error obtained using, 3.28
  ray-deflection, 3.289
Autoregulation, vascular, disturbances of, in glaucoma, 10.85
Autosomal dominant inheritance, 2.206–208, 2.207*t*
Autosomal dominant optic atrophy (ADOA), 5.135, 5.136*f*
Autosomal dominant polyposis of the intestinal tract, 7.197
Autosomal dominant retinitis pigmentosa (ADRP), 2.312
Autosomal dominant vitreoretinochoroidopathy (ADVIRC), 6.341
Autosomal recessive bestrophinopathy (ARB)
  description of, 12.271
  electro-oculography of, 12.51
Autosomal recessive inheritance
  carrier heterozygotes, 2.205
  characteristics of, 2.207*t*
  consanguinity, 2.206
  description of, 2.203
  enzyme defects as cause of, 2.203, 2.205
  pseudodominance, 2.206
  retinitis pigmentosa, 2.312
Autosomes
  aneuploidy of, 2.222–224. *See also specific disorder*
  definition of, 2.213–214
Auxiliary lenses, for slit-lamp biomicroscope, 3.295–296, 3.296*t*
AV junction. *See* Atrioventricular (AV) junction
Avellino (granular type 2) corneal dystrophy, 4.90, 4.91*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.148–149, 8.149*f*
  amyloid deposits in, 8.148, 8.186*t*
  refractive surgery and, 13.43
AVMs. *See* Arteriovenous malformations
Avonex. *See* Beta (β)-interferon
Avulavirus, 8.240*t*
Awareness of vision, disorders of, 5.178*t*, 5.180–181
Axenfeld anomaly/syndrome, 4.100*f*, 8.102, 10.153. *See also* Axenfeld-Rieger syndrome
Axenfeld loop/Axenfeld nerve loop, 2.58, 2.58*f*, 4.108, 4.108*f*
Axenfeld-Rieger syndrome (A-R syndrome/ARS), 2.236, 4.98–99, 4.100*f*, 8.97*t*, 8.102, 8.103*f*, 10.31, 10.150, 10.153–154
  description of, 6.255, 6.255*f*, 6.264–265, 6.264–265*f*, 6.268*f*
  glaucoma associated with, 4.99, 6.285, 10.31, 10.153–154
  posterior embryotoxon in, 4.99, 4.99*f*, 4.100*f*, 8.97*t*, 8.102, 10.31, 10.153
Axes
  optic/optical, 11.9, 11.10*f*
  visual, Nd:YAG laser capsulotomy location and, 11.155
Axial ametropia, 3.137
Axial curvature/axial curvature map, 8.28, 8.29*f*, 13.16–17*f*. *See also* Cornea, topography of
"Axial distance," 13.16
Axial hyperopia, 2.470*f*
Axial length (AL), 11.84–85
  age-related changes in, 3.141
  angle closure and, 10.121
  in biometric formula for intraocular lens power calculation, 3.244–248
  in children, 3.254
  definition of, 3.244
  extremes in, cataract surgery in patient with, 11.184–185
  in IOL power determination, 11.82–83, 11.83*f*, 11.85
    hypotony and, 11.185
    optical measurement of, 11.82, 11.85
    refractive surgery and, 13.193
      staphylomas affecting, 13.150
    ultrasound measurement of, 11.82–83, 11.83*f*, 11.85, 11.87
    unexpected refractive results after surgery and, 11.150, 11.176
  optical measurement of, 3.247, 3.247*f*
  in primary congenital glaucoma, 6.283, 10.160
  ultrasonic measurement of, 3.244–246, 3.245–3.246*f*
Axial (longitudinal) magnification, 3.39, 3.63–64. *See also* Magnification
Axial plane, 7.27
Axial power, 13.16, 13.16*f*
Axial proptosis, 2.110
Axial refractive errors, correction of, 3.12–13
Axial resolution, of contact B-scan ultrasonography, 12.39
Axial scans
  B-scan ultrasound, 2.464–465, 2.464–465*f*
  computed tomography, 2.454, 2.456*f*
  ultrasound biomicroscopy, 2.468, 2.471*f*
Axonal transport system, of optic nerve, 5.26
  drusen and, 5.140
AZA. *See* Azathioprine
AzaSite. *See* Azithromycin
Azathioprine (AZA), 2.404*t*
  for Behçet disease, 9.217, 12.230
  dermatomyositis treated with, 1.168
  description of, 1.179
  polymyositis treated with, 1.168
  for uveitis, 6.322, 9.106–107
Azelaic acid, for rosacea, 8.71
Azelastine hydrochloride, 2.412*t*
Azithromycin, 2.421*t*, 2.427
  for chalazion, 7.182
  for chlamydial conjunctivitis, 8.263
  dental prophylaxis uses of, 1.248*t*
  indications for, 1.275
  for meibomian gland dysfunction, 8.68–69

for rosacea, 8.71
for trachoma, 8.262
Azlocillin, 2.419
AZOOR. *See* Acute zonal occult outer retinopathy
Azopt. *See* Brinzolamide
Aztreonam, 1.272–273

B

B&B stain (Brown and Brenn stain), 4.31*t*
B&H stain (Brown and Hopps stain), 4.31*t*
B cell(s), 4.9
activation of, 9.35
in anterior uvea, 9.56
antigen receptors of, 9.35
clonal expansion of, 9.37
clonality of, 9.41, 9.306
Fab fragment of, 9.41
homing of, 9.38
infiltration of, 9.41–42
monoclonal proliferation of, crystalline corneal deposits and, 8.198, 8.198*f*
in multifocal choroiditis and panuveitis syndrome, 9.179
in posterior segment, 9.57
priming of, 9.30
in resting state, 9.37
tissue infiltration of, 9.41–42
tuberculosis response by, 9.28
B-cell lymphomas. *See also* Lymphomas
conjunctival/ocular surface, 4.70, 4.71*f*, 8.348, 8.349–350, 8.350*f*
diffuse large, 7.92
extranodal marginal zone, 7.92, 7.95
in HIV infection/AIDS, 5.349
orbital, 4.232, 4.233*f*
primary central nervous system/intraocular, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
B lymphocytes. *See* B cell(s)
B-scan optical coherence tomography
definition of, 12.26
retinal pigment epithelium subretinal fluid on, 12.77*f*
volume rendering *versus*, 12.27
B-scan ultrasonography/echography, 7.31. *See also* Ultrasonography/ultrasound (echography)
anterior segment (ultrasound biomicroscopy/UBM), 4.265, 8.20–21, 8.21*f*
in choroidal melanoma/ciliary body melanoma, 4.265
before corneal transplantation, 8.418
in glaucoma, 10.77, 10.124*f*
pediatric glaucoma and, 10.160
axial scans, 2.464–465, 465*f*
before cataract surgery, 11.81
in choroidal hemangioma, 4.281
in choroidal melanoma/ciliary body melanoma, 4.265–267, 4.266*f*
dynamic, 2.467–468, 2.469*t*, 2.470–471*f*
intraocular foreign body evaluations using, 12.352
longitudinal scans, 2.464, 2.466*f*, 2.468–469*f*
in metastatic eye disease, 4.307, 4.307*f*
in optic nerve/nerve head/disc drusen
description of, 5.95, 5.141*f*, 5.142
versus papilledema, 5.141*f*, 5.142
for posterior scleritis, 9.124
probe for, 2.463*f*
tissue-specific gain setting for, 2.469*t*
transverse scans, 2.464–467, 2.466–467*f*
types of, 2.464, 2.465*f*
b-waves, 12.5, 12.42–44, 12.43*f*, 12.47*f*, 12.50, 12.261
of ERG, 5.96. *See also* Electroretinography/electroretinogram
BA. *See* Basilar artery
Babesiosis, 9.230
Bacampicillin hydrochloride, 2.419
Bacille Calmette-Guérin (BCG) vaccination. *See* BCG (Bacille Calmette-Guérin) vaccine
Bacilli (bacteria), 8.243
Bacillus, 8.244*t*, 8.247
cereus
description of, 8.247
endophthalmitis caused by, 12.363
hemolysin BL toxin derived from, 9.9
endogenous endophthalmitis caused by, 9.294
as normal flora, 8.206*t*
ocular infection caused by, 8.247
after ocular trauma, 8.247, 8.403
traumatic endophthalmitis caused by, 8.247, 8.403
Bacitracin zinc, 2.418*t*, 2.421*t*, 2.428
Background diabetic retinopathy. *See* Diabetic retinopathy, nonproliferative
Background luminance, perimetry results affected by, 10.60
Baclofen, for nystagmus, 5.245, 5.246
Bacteria, 8.208*t*, 8.243–249, 8.244*t*. *See also specific bacteria or type of infection*
cell wall of, 8.243–244
classification of, 8.243–244, 8.244*t*
conjunctivitis caused by, 4.52, 6.240*f*, 6.240–241, 8.208*t*, 8.255–265
in children, 8.243, 8.255–256
classification of, 8.257*t*
in neonates, 8.257*t*, 8.263–265
corneal infection caused by, 4.75–76, 4.76*f*, 8.208*t*, 8.267–273, 8.268*f*, 8.269*t*, 8.270*t*, 8.273*f*
corneal opacity and, 8.16*f*
endophthalmitis caused by
endogenous, 9.294–295, 12.237–239, 12.238*f*
lens affected in, 4.119, 4.119*f*
vitreous affected in, 4.127, 4.128*f*
eyelid margin and conjunctival infection caused by, 8.255–256
keratitis caused by, 4.75–76, 4.76*f*, 8.208*t*, 8.267–273, 8.268*f*, 8.269*t*, 8.270*t*, 8.273*f*. *See also* Keratitis, bacterial
contact lens wear and, 8.266–267, 8.268, 8.269, 8.269*t*
as normal flora, 8.205, 8.206*t*
ocular infection caused by, 8.208*t*, 8.243–249, 8.244*t*. *See also specific type or structure involved*
invasion and, 8.207
specimen collection/isolation techniques for diagnosis of, 8.209*t*, 8.211
optic nerve infection caused by, 4.243–244

orbital cellulitis caused by, 6.213, 6.214*f*
orbital infection caused by, 4.226
scleral infection/scleritis caused by, 4.75–76, 4.76*f*, 8.282–283, 8.283*f*
treatment of. *See* Antibiotics
Bacterial uveitis
bartonellosis as cause of. *See Bartonella* (bartonellosis)
leptospirosis as cause of, 9.232–233
Lyme disease as cause of. *See* Lyme disease
nocardiosis as cause of, 9.233
polymerase chain reaction for, 9.90
syphilis as cause of. *See* Syphilis
tuberculosis as cause of, 9.234–240, 9.235–238*f*. *See also* Tuberculosis
Whipple disease as cause of, 9.243–245, 9.244*f*
Bacteriology, 8.208*t*, 8.243–249, 8.244*t*. *See also* Bacteria
Bacteroides spp.
B fragilis, 1.275
description of, 2.419
Baerveldt glaucoma implant (BGI), 10.214, 10.214*t*, 10.215
Bagolini striated lenses
description of, 6.51–52
sensory adaptation testing using, 6.77*f*, 6.77–78
Bailey-Lovie eyecharts, 3.133, 6.8
BAK. *See* Benzalkonium
"Balance lens," 3.198
Balanced salt solution (BSS), 2.360*t*
in phacoemulsification, 11.110, 11.118
in surface ablation, 13.92
in trabeculectomy, 10.201
Balint syndrome, 5.180, 5.223
Balisacaris procyanos, 9.284
Balloon angioplasty. *See* Percutaneous coronary intervention
Balloon cells
in choroidal/ciliary body melanoma, 4.192, 4.193*f*
in choroidal/ciliary body nevus, 4.191
Balloon dacryoplasty, 6.234–235, 6.235*f*, 7.294
Baltimore Eye Survey, 10.81, 10.82, 10.83
Band atrophy
in optic tract syndrome, 5.153
in pituitary adenoma, 5.92*f*
Band keratopathy/calcific band keratopathy, 4.81–83, 4.82*f*, 6.322, 8.111, 8.117–120, 8.119*f*, 8.201
"actinic," 4.83
in aqueous tear deficiency, 8.56
calcific, 9.143*f*, 9.313. *See also* Calcific band keratopathy
in chronic uveitis, 9.78
gelatinous droplike corneal dystrophy and, 8.141, 8.141*f*
in gout, 8.119, 8.188
parathyroid disorders and, 8.201
Band-shaped and whorled microcystic dystrophy of the corneal epithelium. *See* Lisch epithelial corneal dystrophy
Bandage contact lenses, 3.227–228, 8.368
for chemical injuries, 8.383
contraindications to, in exposure keratopathy, 8.80
for corneal abrasion, 8.398
for dry eye, 8.61*t*, 8.63, 8.368
for graft-vs-host disease, 8.304, 8.305*f*
after LASIK, 13.93, 13.111, 13.200
for epithelial ingrowth, 13.122
for epithelial sloughing/defects, 13.112
microkeratome complications and, 13.111
for striae, 13.113
for penetrating and perforating ocular trauma, 8.402
for peripheral ulcerative keratitis, 8.313
for recurrent corneal erosions, 8.87, 8.368
for superior limbic keratoconjunctivitis, 8.84
after surface ablation, 13.92, 13.107, 13.200
sterile infiltrates and, 13.108, 13.108*f*
for Thygeson superficial punctate keratitis, 8.307
BAP1, in immunohistochemistry, 4.35
BAP1 gene, in choroidal/ciliary body melanoma, 4.197, 4.262, 4.278
Barbados Eye Study, 10.83, 11.6
Barbiturates, 1.201–202
Bardet-Biedl syndrome, 2.220, 6.391, 6.391*f*
clinical features of, 12.282*t*
genes and loci associated with, 12.256*t*
renal abnormalities associated with, 12.285
retinal degeneration associated with, 12.281, 12.284, 12.284*f*
Bare-metal stent (BMS), percutaneous coronary intervention with, 1.92
Bare sclera, wound closure after pterygium excision and, 8.351, 8.353*t*, 8.353–355, 8.354*f*
recurrence rate and, 8.353*t*
Bariatric surgery, in idiopathic intracranial hypertension, 5.112
Baricitinib, 1.180
Barkan membrane, 10.159
Baroreceptors, 2.384
Barr body. *See* Lyonization
Barrett formula, for IOL power determination/selection, 11.85
Bartonella (bartonellosis)
cat-scratch disease caused by, 5.119, 8.248, 8.265–266, 9.240–243, 9.242*f*
diagnosis of, 9.243
henselae (Rochalimaea henselae), 5.119, 6.240–241, 6.369, 8.244*t*, 8.248, 8.265, 8.266, 9.240–243, 12.243*f*
neuroretinitis and, 5.115, 5.119, 9.241, 9.242*f*
ocular involvement in, 9.241, 9.242*f*
ocular infection caused by, 8.248, 8.265–266
quintana, 5.119
treatment of, 9.243
Basal cell carcinoma (BCC), 7.200–205, 7.201–203*f*
of eyelid, 4.212*f*, 4.212–213, 4.213*f*
intraocular extension of, 4.310
Basal cell nevus syndrome (Gorlin syndrome), 7.201, 7.202*f*
eyelid manifestations of, 4.210*t*
Basal cells, of corneal epithelium, 2.261
Basal ganglia, 1.204, 5.30, 5.34
in blepharospasm, 5.281
Basal lamina (basal cell layer)
of cornea, 2.51, 2.52*f*
corneal. *See* Descemet membrane/layer
drusen of (cuticular drusen), 4.162, 12.274, 12.275*f*
lens. *See* Lens capsule

Basal laminar deposits, in age-related macular degeneration, 4.160, 4.162, 4.165, 4.165*f*
Basal linear deposits, in age-related macular degeneration, 4.160, 4.162
Basal (basic) secretors/basal (basic) tear secretion test, 7.296, 8.38
Base curve, of contact lens, 3.205, 3.215*f*, 3.216
Base-down prism, 3.188
  in relative cyclotropia evaluation, 5.185
Base-in prism, 3.211
  in fusional convergence evaluation, 5.226
Base-out prisms, 3.46, 3.211
  convergence insufficiency and, 6.103
  convergence paralysis and, 6.106
  dissociated vertical deviation and, 6.129
  in fusional convergence evaluation, 5.226
  in nonorganic disorder evaluation, 5.302–303
  for nystagmus, 5.236, 5.245, 6.155
Base pairs
  definition of, 2.182
  mutations of, 2.183
Base-up prism, 3.46, 3.188
Basedow disease. *See* Thyroid eye disease
Baseline probability of the outcome, 1.22
Basement membrane, corneal, 4.73, 4.74*f*, 8.9. *See also* Descemet membrane/layer
Basement membrane dystrophy, epithelial (EBMD/map-dot-fingerprint/Cogan microcystic/anterior basement membrane), 4.87, 4.87*f*, 8.135–136*t*, 8.135–138, 8.137–138*f*
  cataract surgery in patient with, 11.174*f*, 11.174–175
  recurrent corneal erosion and, 8.86–87, 8.133, 8.138
  reduced vision and, 5.99
  refractive surgery and, 13.42, 13.42*f*, 13.76, 13.78, 13.178
    multifocal IOLs, 13.155
Basement membrane zone (BMZ), in mucous membrane pemphigoid, 8.301*f*, 8.301–302
Basic acquired nonaccommodative esotropia, 6.93
Basic fibroblast growth factor (bFGF), 2.448. *See also* Fibroblast growth factors
Basic intermittent exotropia, 6.101
Basic life support (BLS), 1.299
Basic secretors/basic secretion test. *See* Basal (basic) secretors/basal (basic) tear secretion test
Basilar artery (BA), 5.12, 5.13*f*, 5.19, 5.19*f*, 5.20, 5.27*f*
  anatomy of, 2.106*f*, 2.124, 2.139
  aneurysm of, 5.338, 5.339*f*
  cranial nerve relationship and, 5.42*f*
  dissection of, 5.342
  median perforators of, 5.20
  stenosis of, 5.337*f*
  transient visual loss caused by ischemia of, 5.162, 5.336–337
Basilar laminar deposits
  age-related changes in, 12.61
  definition of, 12.64
  illustration of, 12.62*f*
Basilar linear deposits
  definition of, 12.64
  illustration of, 12.62*f*
Basilar plexus, 5.23*f*
Basilar-type migraine, 5.291. *See also* Migraine headache
Basilar vein of Rosenthal, 5.22
Basophils, 4.7, 4.8*f*
  characteristics of, 9.2–3
  histamine in, 9.19
Bathopsis, 6.43
Batten, Spielmeyer-Vogt disease, 6.389*t*
Batten disease, 12.283*t*, 12.290*f*
Battle sign, 5.280
Battlefield injuries, 7.122
Bausch + Lomb keratometer, 3.287
BAX expression, in adenoid cystic carcinoma, 4.231
BAX gene, 2.181
Bayes theorem, 1.19
Baylisascaris procyonis (raccoon roundworm), 12.246
BBG. *See* Brilliant blue G
BCC. *See* Basal cell carcinoma
BCG (Bacille Calmette-Guérin) vaccine, tuberculosis skin testing and, 9.238
Bcl-2 proteins, in adenoid cystic carcinoma, 4.231
BCVA/BCSVA. *See* Best-corrected visual/Snellen visual acuity
BD. *See* Behçet disease
BDUMP. *See* Bilateral diffuse uveal melanocytic proliferation
Beaded filaments, 11.16
Bear tracks (grouped pigmentation of retina), 4.269, 4.269*f*, 6.349
BEAT-ROP. *See* Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity
Beaver Dam Eye Study, 10.82, 10.83, 11.6
BEB. *See* Benign essential blepharospasm
Bee stings, ocular injury caused by, 8.386–387
Behavioral/psychiatric disorders. *See also specific disorder*
  bipolar disorder, 1.196, 1.203
  cataract surgery in patient with, 11.169–170
  conversion disorder, 1.197
  depression. *See* Depression
  factitious disorder, 1.197
  generalized anxiety disorder, 1.197
  hallucinations/illusions in, 5.174*t*
  illness anxiety disorder, 1.197
  informed consent in patients with, 1.211–212
  malingering, 1.197, 1.203
  mania, 1.195–196
  medical conditions as cause of, 1.194
  mood disorders, 1.195–196
  overview of, 1.194
  panic disorder, 1.198
  personality disorders, 1.198
  pharmacologic treatment of
    antianxiety drugs, 1.201*t*, 1.201–202
    antidepressants, 1.202–203, 1.203*t*
    antipsychotic drugs, 1.199–201, 1.200*t*
    barbiturates, 1.201–202
    benzodiazepines, 1.201–202
    hypnotic drugs, 1.201*t*, 1.201–202
    mood stabilizers, 1.203–204
  post-traumatic stress disorder, 1.198
  prevalence of, 1.194
  schizophrenia, 1.194–195, 1.200

somatic symptom and related disorders, 1.196–197
substance abuse disorders, 1.198–199
visual symptoms and. *See* Nonorganic (functional/nonphysiologic) ophthalmic disorders
Behçet disease (BD)
anterior uveitis in, 9.214
biologic agents for, 9.218
characteristics of, 9.211
corticosteroids for, 9.216–217
definition of, 9.211
description of, 1.173–174, 4.187, 12.230, 12.230*t*
diagnosis of, 9.212, 9.212*t*, 9.215–216
differential diagnosis of, 9.216
fluorescein angiography findings in, 9.216, 9.217*f*
genital ulcers associated with, 9.213
histologic findings in, 9.215, 9.216*f*
HLA associations with, 9.215
human leukocyte antigen association with, 9.65*t*
immunomodulatory therapy for, 9.216–218
neurologic involvement in, 9.213–214
nonocular systemic manifestations of, 9.213–214
ocular manifestations of, 9.214–215, 215*f*
optic nerve involvement in, 9.215
optical coherence tomography findings in, 9.216, 9.217*f*
oral aphthae associated with, 9.213, 9.213*f*
pathogenesis of, 9.215
posterior segment manifestations of, 9.214–215, 9.215*f*
prevalence of, 9.212
prognosis for, 9.218
skin lesions associated with, 9.213
systemic vasculitis associated with, 9.213
treatment of, 9.216–218
Behr optic atrophy, 6.368
Belimumab, 1.180
Bell palsy, 5.278*t*, 5.279
aberrant regeneration/facial nerve synkinesis and, 5.277, 5.279
Bell phenomenon, 6.126*f*, 6.197, 7.243
Bence Jones protein, corneal deposition of, 8.198
Benedikt syndrome, 5.191
Benign episodic unilateral mydriasis, 5.267
Benign epithelial lesions, 7.189–190, 190*f*
Benign essential blepharospasm (BEB), 5.281–283, 5.282*f*, 5.282*t*, 7.256–258. *See also* Blepharospasm
Benign eyelid myokymia, 5.282*t*, 5.284
Benign hereditary intraepithelial dyskeratosis, 8.332*t*
Benign lymphoid folliculosis, 8.48, 8.49*f*
Benign lymphoid hyperplasia, 4.70, 4.70*f*. *See also* Lymphoid hyperplasia
Benign lymphoid pseudotumor/pseudolymphoma. *See* Lymphoid hyperplasia
Benign melanocytic lesions
blue nevi, 7.198
dermal melanocytosis, 7.198, 7.198*f*
ephelis, 7.197
lentigo simplex, 7.197
nevi, 7.195–197, 7.196–197*f*
solar lentigo, 7.197–198, 7.198*f*
sources of, 7.194–195
Benign mixed tumor (pleomorphic adenoma)
description of, 7.98–100, 7.99*f*, 7.192
of lacrimal gland, 4.229–230, 4.230*f*
Benign monoclonal gammopathy, crystalline corneal deposits in, 8.198
Benign paroxysmal positional vertigo (BPPV), nystagmus and, 5.242–243
Benign prostatic hypertrophy, α-blockers for, intraoperative floppy iris syndrome and, 11.74, 11.136–137, 11.137*t*
Benign reactive lymphoid hyperplasia. *See* Lymphoid hyperplasia
Benoxinate, 2.441
Benzalkonium (BAK), 2.351
toxic reactions to, 8.80, 8.90, 8.90*t*, 8.91, 10.184
Benzodiazepines, 1.201–202
Benztropine, 1.205
Bepotastine besilate, 2.412*t*
Bepreve. *See* Bepotastine besilate
Berger space, 12.7, 12.8*f*
Bergmeister papilla, 4.126, 4.127*f*, 6.298, 6.366, 12.341. *See also* Hyaloid artery/system, persistence/remnants of
Berlin edema (commotio retinae), 4.18–19
Berlin nodules, 9.80
Berry (saccular) aneurysm, 1.121, 5.338
Besifloxacin, 2.421*t*
for bacterial keratitis, 8.270, 8.270*t*
Besivance. *See* Besifloxacin
Best-corrected visual/Snellen visual acuity (BCVA/BCSVA/corrected distance visual acuity/CDVA). *See also* Visual acuity
blindness and, 3.311
after Boston keratoprosthesis implantation, 8.452
after cataract surgery, 11.126
manual small-incision surgery and, 11.198–199
multifocal IOLs and, 11.121–122
corneal crosslinking and, 13.131
after endothelial keratoplasty (DMEK/DSEK), 8.438–440
flap folds/striae and, 13.112, 13.113, 13.114*t*, 13.115
as gold standard, 3.21
hard contact lens method for IOL power calculation and, 13.195
hyperopia correction and, 13.94
intrastromal corneal ring segment placement and, 13.67
irregular astigmatism affecting, 13.17
LASIK and, 13.95
in amblyopia/anisometropic amblyopia, 13.185–187
in diabetes mellitus, 13.190
after penetrating keratoplasty, 13.180
after retinal detachment surgery, 13.185
in low vision assessment, 5.78
photostress testing and, 5.88
multifocal intraocular lenses, 3.260
myopia correction and, 13.95
patient expectations/motivations for refractive surgery and, 13.36, 13.47
phakic IOL implantation and, 13.144
radial keratotomy and, 13.51–52
small-incision lenticule extraction and, 13.205
undercorrection after photoablation and, 13.102
Best disease (Best vitelliform dystrophy/vitelliform macular dystrophy), 6.340–342, 6.342*f*
characteristics of, 12.271, 12.272*f*

definition of, 12.51
electro-oculography of, 12.51, 12.271
BEST1 (*VMD2*/vitelliform macular dystrophy) gene, 6.340–342, 10.11*t*, 12.271
Bestrophin, 2.333*t*, 12.50
Bestrophinopathies, 6.341
Beta (β)-adrenergic antagonists, 2.389*t*, 2.389–390
Beta (β)-adrenergic agents. *See* Beta (β)-blockers
Beta $(\beta)_2$-adrenergic agonists, 2.385*t*, 2.387–389
for lung disease, 1.128
Beta (β)-adrenergic receptors (adrenoceptors)
β_1-, 2.382, 2.383*f*
β_2-, 2.382, 2.383*f*
β_3-, 2.382
drugs affecting. *See* Beta (β)-blockers
Beta (β)-blockers, 10.164–165, 10.171–172*t*, 10.176–177
adverse effects of, 1.62, 1.309*t*
angina pectoris treated with, 1.91
childhood glaucomas treated with, 6.288, 6.289*t*
congestive heart failure treated with, 1.98–99
dry eye and, 8.61
elevated intraocular pressure masked by, 10.86
for glaucoma, 10.171–172*t*, 10.176–177
in children, 10.164–165
in combination preparations, 10.174*t*, 10.182
in elderly patients, 10.186
normal-tension glaucoma and, 10.88
during pregnancy/lactation, 10.185
side effects of, 10.171–172*t*, 10.177
suppression of aqueous formation and, 10.16–17, 10.164, 10.176
for hemangiomas
description of, 6.220
infantile, 7.72
hypertension treated with, 1.62, 1.69
for hyphema, 8.395
myocardial infarction treated with, 1.93
ocular effects of, 1.106, 1.309*t*
for penetrating and perforating ocular trauma, 8.402
for postoperative elevated intraocular pressure, 10.108
prophylactic uses of, 1.285
Beta (β)-crystallins, 11.16
Beta (β)-Galactosidase, defective/deficiency of
in gangliosidoses, 8.176
in lysosomal storage diseases, 8.179
in Morquio syndrome, 8.175*t*
in sphingolipidoses, 8.176
Beta (β)-glucuronidase deficiency, in Sly syndrome, 8.175*t*
Beta (β)-interferon, for multiple sclerosis, 5.321*t*
Beta (β)-lactam antibiotics, 1.271–273. *See also specific agent*
Beta (β)-lactamases, 2.417
Beta (β) zone peripapillary atrophy, 10.48, 10.52
Beta chemokines, 9.23*t*
Betadine. *See* Povidone-iodine
Betagamma (β,γ)-crystallins, 11.15, 11.15*f*, 11.16
Betagan. *See* Levobunolol
Betaseron. *See* Beta (β)-interferon
Betaxolol, 2.389*t*, 2.390, 6.288, 6.289*t*, 10.88, 10.113, 10.172*t*, 10.176–177
in children, 10.165
Betimol. *See* Timolol
Betoptic S. *See* Betaxolol
Bevacizumab, 2.371*t*, 2.449
adverse effects of, 12.85
branch retinal vein occlusion treated with, 12.135
central retinal vein occlusion treated with, 12.135
choroidal neovascularization treated with, 12.73*f*, 12.213*f*
Coats disease treated with, 6.360
diabetic macular edema treated with, 12.113
endophthalmitis caused by, 12.404
for macular edema, 4.152
neovascular age-related macular degeneration treated with, 12.83–85, 12.84*t*
for neovascular glaucoma, 10.135, 10.135*f*
off-label uses of, 12.85
in pterygium excision, 8.356
ranibizumab and, comparison between, 12.83, 12.84*t*
retinal vein occlusion treated with, 12.135
retinopathy of prematurity treated with, 6.333, 12.186–187
Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP), 6.333, 12.186–187
Bezlotoxumab, 1.249
bFGF. *See* Basic fibroblast growth factor
BGI. *See* Baerveldt glaucoma implant
Biapenem, 1.273
Bias
in case series, 1.9
investigator, 1.5
missing medical records and, 1.26
recall, 1.11
selection, 1.4, 1.11
Biber-Haab-Dimmer (lattice type 1/LCD1/classic lattice) dystrophy, 4.88–90, 4.89*f*, 4.91*t*, 8.135–136*t*, 8.145*t*, 8.145–147, 8.146–147*f*. *See also* Lattice corneal dystrophy
Bicanalicular intubation, 6.234
Bicanalicular lacrimal stent, 7.293, 7.294*f*, 7.301*f*, 7.312
Bicarbonate
from carbonic anhydrase inhibitors, 2.391–392
in tear film, 2.251
Bicentric grinding, 3.188, 3.188*f*
Bichrome test. *See also* Duochrome; Worth 4-dot
in nonorganic disorder evaluation
monocular no light perception and, 5.303, 5.304*f*
monocular reduced vision and, 5.305
before refractive surgery, 13.39
Biconvex design, for IOLs, 11.120
Bielschowsky head-tilt test, 6.75, 6.122
Bietti crystalline dystrophy, 12.258, 12.269, 12.282*t*
Bietti nodular dystrophy (spheroidal degeneration), 4.83, 4.83*f*, 8.115–117, 8.116*f*
Bifocal add. *See* Add power; Bifocal lenses
Bifocal lenses. *See also* Multifocal lenses
accommodative amplitude for, 3.178–179
add power of, 3.178–180
contact
alternating vision, 3.224*f*, 3.224–225
presbyopia correction using, 3.224–225
simultaneous vision, 3.225, 3.225*f*
fused, 3.180

for high AC/A ratio accommodative esotropia, 6.91–92
image displacement, 3.184, 3.186*f*
image jump, 3.184–186, 3.187*f*
induced anisophoria, compensating for, 3.186–190, 3.187*f*
intraocular
description of, 3.258–259, 3.259*f*
modulation transfer function with, 3.262
lens design of, 3.190
plastic molded, 3.180
Prentice rule and, 3.184–190, 3.185–3.189*f*
prismatic effects of, 3.184, 3.185*f*
round segment, 3.180, 3.181*f*
types of, 3.180, 3.181*f*
Bifocal segments. *See also* Bifocal lenses
decentration of, 3.190–191
dioptric power of, 3.190
occupation and, 3.190–191
shape of, 3.190
width of, 3.190
Biguanides, for *Acanthamoeba* keratitis, 8.278–279
Bilateral acoustic/central (type 2) neurofibromatosis, 5.330, 5.334*t*, 6.393*t*, 6.397, 10.156
seventh nerve (facial) palsy and, 5.279, 5.279*f*
Bilateral amblyopia, 3.175
Bilateral diffuse uveal melanocytic proliferation (BDUMP), 9.309, 12.204–205, 12.205*f*, 12.287
Bilateral fourth nerve (trochlear) palsy, 5.199
Bilateral hilar adenopathy, 7.65*f*, 7.66
Bilateral no light perception testing, 5.301–302, 5.302*f*
Bilateral ptosis. *See* Ptosis
Bilateral vision/bilateral vision loss. *See* Binocular vision
Bile acid sequestrants, for hypercholesterolemia, 1.75*t*
Bimatoprost, 2.394*t*, 2.395, 10.170–176, 10.171*t*
in combination preparations, 10.174*t*
Bimatoprost/timolol maleate, 2.394*t*, 2.397*t*
Binocular balance
alternate occlusion for, 3.167–168
definition of, 3.34
Lancaster red-green test of, 3.35–36
in manifest refraction, 3.34–36
prism dissociation for, 3.168, 3.168*f*
in subjective refraction, 3.167–168, 3.168*f*
Binocular blur, 5.183
Binocular diplopia, 5.183
Binocular eye movements. *See also specific type*
conjugate (versions), 5.34–35, 5.35*f*. *See also specific type*
in diplopia, 5.184
disconjugate (vergences), 5.212, 5.212*t*, 5.226–228. *See also* Vergences/vergence system
Binocular function
field of single binocular vision assessment, 6.81–82, 6.82*f*
prism adaptation test, 6.82
Binocular fusion, 6.60, 6.91
Binocular indirect ophthalmoscopy/ophthalmoscopes (BIO). *See also* Ophthalmoscopy/ophthalmoscope
disadvantages of, 12.22
retinal disease evaluations using, 12.21–22
Binocular states, of eye, 3.139–140
Binocular transient visual loss, 5.161, 5.171–172
Binocular treatment, for amblyopia, 6.59
Binocular vision
abnormalities of. *See also specific type*
diplopia, 6.47–48
visual confusion, 6.47, 6.47*f*
anomalous, 6.50
assessment of
low vision evaluation and, 5.77
nonorganic disorder evaluation and, 5.301–302, 5.302*f*
in cyclic strabismus, 6.93
development of, 6.43
fusion, 6.42–43
monocular visual deprivation effects on, 6.45
no light perception, testing, 5.301–302, 5.302*f*
Panum's area of single, 6.42, 6.42*f*, 6.48
reduced, 5.77
nonorganic disorders and, 5.306–308, 5.307*f*, 5.308*f*, 5.309*f*
retinal correspondence, 6.41–42
single, 6.81–82, 6.82*f*
transient loss and, 5.161, 5.171–172
BIO. *See* Binocular indirect ophthalmoscopy/ophthalmoscopes
Bioavailability, 2.349
Biofilm, microbial, 8.207
keratitis and, 8.267
staphylococci forming, 8.244
Bioinformatics, 2.194
Biointegrated materials, 7.139
Biologic agents, 2.349
for rheumatoid disease, 1.153
Biologic response modifiers (BRMs/biological therapies). *See also* Immunomodulatory therapy/immunotherapy/immunosuppression
for cancer, 1.241–243
description of, 1.241–242, 2.405–406*t*
for scleritis, 8.324, 8.325*f*
Biomarkers
cardiac. *See* Cardiac enzymes
coronary heart disease, 1.86–87
Biomechanics of cornea, 8.43, 13.13–14
measurement of, 8.43
Biometry/biometrics
before cataract surgery, 11.82–83, 11.83*f*
hypotony and, 11.185
in IOL power determination/selection, 11.82–83, 11.83*f*, 11.84–85, 11.87
axial length, 11.82–83, 11.84–85, 11.87
hypotony affecting, 11.185
unexpected refractive results after surgery and, 11.150
hypotony and, 11.185
refractive surgery and, refractive lens exchange, 13.150
primary angle closure and, 10.121
Biomicroscopy
slit-lamp. *See* Slit-lamp biomicroscopy/examination
ultrasound (UBM)
of anterior chamber, 2.60*f*
anterior chamber evaluations, 12.40
axial scans, 2.468, 2.471*f*
characteristics of, 2.468

in choroidal/ciliary body melanoma, 4.265
ciliary body evaluations, 12.40
before corneal transplantation, 8.418
description of, 4.265, 8.20–21, 8.21*f*
in glaucoma, 10.77, 10.124*f*
pediatric glaucoma and, 10.160
ocular anatomy on, 2.471–472*f*
radial scans, 2.468–469, 2.472*f*
Biopsy
chorioretinal, in uveitis evaluations, 9.91
excisional, 7.203*f*, 7.204
eyelid, 7.203*f*, 7.203–204
fine-needle aspiration. *See* Fine-needle aspiration biopsy
incisional, 7.203, 7.203*f*
scleral, 9.91
sentinel lymph node
for melanoma, 7.210
for sebaceous carcinoma, 7.208
vitreous
indications for, 9.91–92
technique for, 9.92
Bioptic telescope, 3.309
Bioptics, 13.137, 13.157
Biosimilar agents, 1.180–181
Bioterrorism, ocular complications of smallpox vaccination and, 8.238
Biotherapy. *See* Biologic response modifiers; Immunomodulatory therapy/immunotherapy/immunosuppression
Bipedicle flap, 8.359*f*, 8.359–360
Biphakic eyes, axial length in, 3.245
Bipolar cells, 2.87, 2.315–318, 2.316*f*, 5.24
ganglion cells and, 12.13
illustration of, 12.15*f*
midget, 12.13
Bipolar dendrites, 2.87
Bipolar disorder, 1.196, 1.203
Birdshot uveitis (birdshot retinochoroidopathy/birdshot/vitiliginous chorioretinitis)
characteristics of, 9.162–164*t*, 12.220*t*, 12.224–225, 12.225*f*
course of, 9.168–169
definition of, 9.34, 9.165
differential diagnosis of, 9.168
electroretinogram evaluations, 9.168
fluorescein angiography findings in, 9.163*t*, 9.165–166, 9.166–167*f*
fundus autofluorescence findings in, 9.163*t*, 9.166, 9.167*f*
HLA-A29 and, 9.34, 9.64–65, 9.65*t*, 9.165
indocyanine green angiography findings in, 9.163*t*, 9.166, 9.167*f*, 9.179
manifestations of, 9.165–168, 9.166–168*f*
optical coherence tomography findings in, 9.164*t*, 9.168, 9.168*f*
posterior uveitis in, 9.165–169, 9.166–168*f*
retinal pigment epithelium findings in, 9.166
T helper cell-17 in, 9.34
treatment of, 9.169
uveal lymphoma and, 12.234
Birth defects. *See* Congenital anomalies; *specific type*
Birth trauma
congenital facial palsy and, 5.280
corneal edema and, 8.109
Horner syndrome and, 5.260*t*, 5.261
Bis-retinoids, 12.31
Bisphosphonates, 1.190, 1.308*t*
Bistratified cells (koniocellular neurons), 10.42
Bitemporal, definition of, 5.105*t*
Bitemporal hemianopia, 2.474*t*
chiasmal lesions causing, 5.146, 5.147*f*, 5.152
Bites, 7.218
Bitôt spot, 8.196–197, 8.197*f*
Corynebacterium xerosis and, 8.196–197, 8.246
Biventricular pacing, for congestive heart failure, 1.100
Bjerrum (arcuate) scotoma, 5.103, 5.105*t*, 5.106*f*
in glaucoma, 10.68, 10.68*f*
Blackbody radiometer, 3.107
Bladder cancer screening, 1.221
Bladder (Wedl) cells, 4.121, 4.121*f*, 11.48, 11.152
in phakomatous choristoma, 4.202, 4.203*f*
Blast injuries, corneal foreign bodies and, 8.400, 8.401*f*
Blau syndrome, 6.319, 9.197
Bleb, filtering. *See* Filtering bleb; Filtering procedures
Bleb-associated endophthalmitis, 10.163, 10.209, 10.209*t*, 10.210*f*, 12.390–391, 12.391*f*
Bleb leaks, after trabeculectomy, 10.209, 10.210, 10.211
Bleb pattern
Bron, in epithelial basement membrane dystrophy, 8.138
in Meesmann epithelial corneal dystrophy, 8.139
Blebitis, 12.390–391
after filtering surgery, 10.163, 10.209, 10.209*t*, 10.210*f*
Bleeding disorders. *See also* Hemostasis, disorders of
cataract surgery in patient with, 11.171–172
subconjunctival hemorrhages in, 8.388
Bleeding time, 1.139
Blend zone, 13.74*f*, 13.81
Bleph-10. *See* Sulfacetamide sodium
Blephamide. *See* Prednisolone acetate/sulfacetamide sodium
Blepharitis, 6.244–245, 6.244–245*f*, 8.72–75*f*, 8.72–76, 8.73*t*, 8.208*t*. *See also* Blepharoconjunctivitis
α-agonists causing, 10.178, 10.178*f*
cataract surgery in patient with, 11.172–173
dry eye and, 8.68, 8.72, 8.76
keratitis and, 8.72, 8.73*t*, 8.74
meibomian gland dysfunction and, 8.68, 8.72, 8.73*t*
refractive surgery and, 13.42, 13.43*f*, 13.172
multifocal IOLs, 13.155
in rosacea, 8.70, 8.73*t*
seborrheic, 8.72, 8.72*f*, 8.73*t*
staphylococcal, 8.72–75*f*, 8.208*t*, 8.254
keratitis and, 8.73*t*, 8.74, 8.76
marginal infiltrates in, 8.74, 8.74*f*
Blepharochalasis, 7.259
Blepharoconjunctivitis. *See also* Blepharitis; Conjunctivitis
α-agonists causing, 10.178, 10.178*f*
contact, 8.285–287, 8.286*f*
herpes simplex virus causing, 8.213, 8.214*f*, 8.216
marginal corneal infiltrates associated with, 8.74, 8.74*f*
staphylococcal, 8.74, 8.75, 8.76, 8.256, 8.257*t*
Blepharodermatitis, α-agonists causing, 10.178, 10.178*f*

Blepharophimosis syndrome. *See* Blepharophimosis–ptosis–epicanthus inversus syndrome
Blepharophimosis–ptosis–epicanthus inversus syndrome (BPES/congenital eyelid/blepharophimosis syndrome), 6.197–198, 6.198*f*, 7.173–174, 7.174–175*f*, 7.243
Blepharoplasty
complications of, 7.262–263
diplopia after, 7.262–263
exposure keratopathy and, 8.79
lower eyelid
description of, 7.260
infraciliary incision for, 7.262
laser skin resurfacing with, 7.268
midface rejuvenation with, 7.271–272, 7.272*f*
orbital fat redraping with, 7.272*f*
technique for, 7.261–262, 7.262*f*
transconjunctival incision for, 7.261, 7.262*f*
vision loss secondary to, 7.262
superior limbic keratoconjunctivitis and, 8.83
techniques for, 7.261–262, 262*f*
upper eyelid
brow ptosis and, 7.264
description of, 7.259
preoperative evaluation, 7.260
retraction caused by, 7.253*f*, 7.254
Blepharoptosis. *See* Ptosis
Blepharospasm, 2.359
benign essential (BEB), 5.281–283, 5.282*f*, 5.282*t*, 7.256–258
botulinum toxin for, 5.281–283
nonorganic, 5.310
in primary congenital glaucoma, 10.151, 10.152, 10.158
reflex, 5.281
superior limbic keratoconjunctivitis and, 8.84
transient visual loss and, 5.164
Blessig-Iwanoff cysts, 2.101
Blind loop syndrome, 12.290
Blind spot, 5.24
cortical area corresponding to, 5.29*f*
enlargement of, 5.103, 5.106*f*
acute idiopathic (AIBSE), 5.100–101, 5.101*f*
fundus autofluorescence in identification of, 5.90
Blindness. *See also* Low vision; Vision loss/impairment
age-related macular degeneration causing, 4.160
bilateral, testing, 5.301–302, 5.302*f*
cataract causing, 11.5
central, age-related macular degeneration progression to, 12.86
cerebral/cortical, 5.158, 5.336–337
blindsight and, 5.181
denial of (Anton syndrome), 5.158, 5.180–181, 5.337
color. *See* Color vision, defects in
congenital stationary night, spasmus nutans syndrome associated with, 6.151
cyclodestructive procedures for pain and, 10.195
day (hemeralopia), 12.264
in cone/cone-rod dystrophies, 5.102
diabetes mellitus/diabetic retinopathy causing, 4.159
functional. *See* Nonorganic (functional/nonphysiologic) ophthalmic disorders
in glaucoma, 10.7, 10.84
incisional surgery contraindicated in, 10.195, 10.198
primary congenital glaucoma and, 10.151, 10.152
race and, 10.82
herpetic stromal keratitis causing, 8.219
"hysterical." *See* Nonorganic (functional/nonphysiologic) ophthalmic disorders
legal, 3.310–311, 3.329
methanol toxicity as cause of, 12.301
monocular
testing, 5.302–305, 5.303*f*, 5.304*f*
transient. *See* Monocular transient visual loss
mucous membrane pemphigoid causing, 8.303
night. *See* Night blindness
nonorganic disorders and, 5.301–305, 5.302*f*, 5.303*f*, 5.304*f*. *See also* Nonorganic (functional/nonphysiologic) ophthalmic disorders
nystagmus after, 5.246
postmeasles, 8.239
prevalence of, 3.311
rehabilitation devices for, 3.325
retinopathy of prematurity as cause of, 6.335, 12.182
river (onchocerciasis), 8.252–253, 9.289*f*, 9.289–290
snow, 8.385
trachoma causing, 8.260
transient. *See* Transient visual loss
traumatic injury causing, 4.22–23, 4.23*f*
uveitis as cause of, 9.68
vitamin A deficiency causing, 8.196
Blindsight, 5.181
Blinking (blink reflex), 2.354, 5.52, 6.185, 7.283
abnormal, cranial nerve VII (facial) in, 5.49
excessive, 6.201–202
exposure keratopathy and, 8.79
protective/defensive function of, 8.3
tear secretion and, 8.3, 8.5
dry eye and, 8.55, 8.55*f*, 8.56
Bloch-Sulzberger syndrome (incontinentia pigmenti/IP), 2.209, 12.283*t*, 12.286. *See also* Incontinentia pigmenti
Block-and-replace therapy, 7.60
Blocked fluorescence, in fluorescein angiography, 12.35
Blood. *See also* Hemorrhage
clotting pathways of. *See* Coagulation
composition of, 1.131
cornea stained by, 4.86, 4.86*f*, 8.118*t*, 8.375, 8.394, 8.394*f*, 8.395, 8.395*t*, 10.104, 10.104*f*, 10.105
hyphema after cataract surgery and, 11.159
formed elements of, 1.131
in LASIK interface, 13.122, 13.123*f*
plasma of, 1.131
Blood–aqueous barrier
breakdown of, 2.279
description of, 2.270
functions of, 2.275
Blood–brain barrier, 12.16
Blood cells, 1.131
Blood dendritic cells, 9.4
Blood-derived macrophages, 9.3
Blood glucose, 1.40. *See also* Glucose
Blood–ocular barrier, 2.448. *See also specific type*
cytomegalovirus passage across, 9.256
description of, 9.56–57
fluorescein passage affected by, 12.33

Blood oxygenation level–dependent (BOLD) imaging, 5.70, 5.75
Blood pressure (BP). *See also* Hypertension
ambulatory measurement of, 1.52
classification of, 1.52*t*, 1.52–53, 1.214
coronary heart disease risks, 1.73*t*
diastolic, 1.52, 1.56
measurement of
ambulatory, 1.52
in hypertension evaluation, 1.55
phenylephrine hydrochloride effects on, 2.384
sleep-related decreases in, 1.53, 1.66–67
in stroke prevention, 1.115
in subarachnoid hemorrhage, 1.121
systolic, 1.52, 1.56
Blood–retina barrier, 2.88, 2.90*f*, 2.270, 2.321, 5.14
breakdown of, in diabetic retinopathy, 4.159
fluorescein passage affected by, 12.33
hyperglycemia-induced breakdown of, 12.108
ischemic damage to, hemorrhages and, 4.153–154, 4.155*f*
Blood vessels. *See* Vascular system
Blowout (indirect) fractures, orbital, 6.379
complications of, 7.117
delayed treatment of, 7.117
description of, 7.20
diagnosis of, 7.114–115
diplopia after, 5.206
hydraulic mechanism theory of, 7.114
indirect, 7.113
orbital cellulitis after, 7.48
physical examination of, 7.114–115
surgical management of, 7.117
white-eyed, 7.114
BLS. *See* Basic life support
Blue-blocking intraocular lenses, 11.120
Blue-cone (S-cone) monochromatism, 2.232*t*, 6.337–338
description of, 12.250, 12.250*t*
electroretinography findings in, 12.46, 12.47*f*
Blue cones. *See* S cones
Blue-dot (cerulean) cataract, 11.37, 11.38*f*
Blue dyschromatopsia, 6.368
Blue nevi/nevus, 4.64, 7.198
Blue sclera, 8.195*t*
in Ehlers-Danlos syndrome, 8.191*t*, 8.193
in keratoglobus, 8.171
in Marfan syndrome, 8.194
in osteogenesis imperfecta, 8.194, 8.194*f*
Blue-yellow color deficiency, 12.54
Blue-yellow color vision defects
in optic atrophy, 5.135
tests for, 5.78–79
Blue zone, 2.55
Blunt (concussive) trauma, 6.378–379, 8.387–396, 8.388–395*f*, 12.315, 12.353–358, 12.354–12.357*f*. *See also* Trauma
anisocoria caused by, 5.256*f*, 5.262–263
anterior segment, 8.387–396
anterior uveitis and, 8.389–390
corneal changes and, 8.388, 8.389*f*
cyclodialysis and, 8.391, 8.391*f*
hyphema and, 8.391–396, 8.392*f*, 8.393*f*, 8.394*f*, 8.395*t*
iridodialysis and, 8.390*f*, 8.390–391, 8.391*f*, 8.409
mydriasis and miosis and, 8.388–389, 8.389*f*
subconjunctival hemorrhage and, 8.387–388, 8.388*f*
in children, nonaccidental/abusive. *See* Abusive head trauma
commotio retinae and, 4.18–19
of eyelid, 7.213
glaucoma and, 4.103–104, 10.39–40, 10.41*f*, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*
hyphema caused by, 8.391–396, 8.392*f*, 8.393*f*, 8.394*f*, 8.395*t*
LASIK flap dislocation and, 13.115–116
lens injury/cataract caused by, 11.53–55, 11.54*f*
pupil irregularity caused by, 5.255
Blur circles. *See also* Point spread function
definition of, 3.69
description of, 3.5, 3.5*f*
formation of, 3.130*f*
size of, 3.129
Blurred vision/blurring. *See also* Vision loss/impairment
in corneal dystrophies, 8.133
in intermediate uveitis, 9.76
multifocal IOLs and, 13.156
ocular misalignment and, 5.183
in posterior uveitis, 9.76
vergence system and, 5.226
vertebrobasilar insufficiency and, 5.336
BMP. *See* Bone morphogenetic protein
BMS. *See* Bare-metal stent
BMZ. *See* Basement membrane zone
BNP. *See* Brain natriuretic peptide
Bobbing, ocular, 5.228
Bodily distress disorder, 1.196
Body dysmorphic disorder, 1.197
Body lice, ocular infection caused by, 8.255
BOLD (blood oxygenation level–dependent) imaging, 5.70, 5.75
Bone cyst, aneurysmal, 6.222
Bone disease, neuroimaging in evaluation of, 5.72*t*
Bone growth disorders, nonsynostotic, 6.212
Bone loss, corticosteroid-induced, 9.103
Bone marrow derived stem cells, hyalocytes from, 12.7
Bone marrow disorders, anemia caused by, 1.137
Bone marrow transplantation, graft-vs-host disease after, 8.304
Bone morphogenetic protein (BMP), lens placode formation and, 11.25
Bonnet-Dechaume-Blanc syndrome (Wyburn-Mason syndrome/racemose angioma/hemangioma), 4.286*f*, 4.286–287, 5.331, 5.333*f*, 5.334*t*, 6.222, 6.394*t*, 6.405*t*, 6.405–406, 12.168
Bony orbit. *See* Orbit
Bony tumors of orbit, 4.239, 4.240*f*
Borderline neoplastic proliferations, 4.10
Borrelia (borreliosis), 5.279–280, 5.352–353, 5.353*f*, 8.249. *See also* Lyme disease
burgdorferi, 1.254–255, 5.279, 8.249, 9.227, 9.230, 12.245
Boston keratoprosthesis, 8.452, 8.452*f*
Botryoid rhabdomyosarcomas, 4.236, 7.88
Botryoid tumors, 6.217

Bottom-up acuity testing, in nonorganic disorder evaluation, 5.306. *See also* Visual acuity, testing of
Botulinum toxin, 2.359
adverse effects of, 6.176
benign essential blepharospasm treated with, 7.256–257, 7.257*f*
for blepharospasm, 5.281–283
chemodenervation using, 6.175–176
complications of, 6.176
for corneal exposure, in facial palsy, 5.281
in extraocular muscle symmetric surgery, 6.160
in eyelids, 6.146
facial rejuvenation uses of, 7.269–270
for hemifacial spasm, 5.284, 7.258
indications for, 6.175–176
infantile esotropia treated with, 6.89
mechanism of action, 6.175
near reflex spasm treated with, 6.94
for nystagmus, 5.246
pharmacology of, 6.175
results of, 6.175–176
strabismus treated with, 6.175
techniques for, 6.175–176
type A, 2.443
as tarsorrhaphy alternative, 8.373
Botulism poisoning
ptosis/facial paralysis caused by, 5.273, 5.273*t*
tonic pupils in, 5.265
Bouin solution, as tissue fixative, 4.26*t*
Bourneville disease/syndrome (tuberous sclerosis/TS), 6.398*f*. *See also* Tuberous sclerosis
description of, 5.330, 5.331*f*, 5.334*t*, 6.393*t*, 6.397–399, 6.398*t*
glaucoma associated with, 10.30
Boutonnière deformity, 1.152
Bovine spongiform encephalopathy ("mad cow" disease), 5.357
Bow-tie optic atrophy, 5.25*f*, 5.153
Bow-tie pattern
keratoconus and, 13.175, 13.175*f*
regular astigmatism and, 8.31, 8.31*f*, 13.17, 13.18*f*, 13.22
Bowen disease, 7.199–200
Bowman layer/membrane
anatomy of, 2.50*f*, 2.51, 2.262–263, 8.7*f*, 8.8
Descemet membrane *versus*, 2.51
description of, 4.73, 4.74*f*, 8.7*f*, 8.8
healing/repair and, 4.16
in keratoconus, 8.162, 8.162*f*
in keratoglobus, 8.171
refractive surgery and, preparation of, 13.82–90
epithelial debridement techniques for, 13.82–84, 13.83*f*
epithelial preservation techniques for, 13.84
LASIK flap creation and, 13.84–90
with femtosecond laser, 13.87–90, 13.88*f*, 13.89*f*, 13.90*t*
with microkeratome, 13.84–87, 13.85*f*, 13.86*f*, 13.87*f*
in Reis-Bücklers corneal dystrophy (corneal dystrophy of Bowman layer type 1), 8.142, 8.142*f*, 8.143. *See also* Reis-Bücklers corneal dystrophy
in Thiel-Behnke corneal dystrophy (corneal dystrophy of Bowman layer type 2), 8.143, 8.144*f*. *See also* Thiel-Behnke corneal dystrophy
BP. *See* Blood pressure
BP180. *See* Bullous pemphigoid antigen II
BPD. *See* Butterfly-type pattern dystrophy
BPES. *See* Blepharophimosis–ptosis–epicanthus inversus syndrome
BPPV. *See* Benign paroxysmal positional vertigo
Brachial plexus injury, Horner syndrome and, 5.260*t*, 5.261
Brachium conjunctivum, 5.18*f*, 5.39
Brachycephaly, 6.205
Brachytherapy, 1.237–238
for choroidal hemangioma, 4.283
for choroidal melanoma/ciliary body melanoma, 4.253, 4.275*f*, 4.275–276
for iris melanoma, 4.261
for medulloepithelioma, 4.296
for metastatic eye disease, 4.310
for retinal hemangioblastoma, 4.285
for retinoblastoma, 4.301
Bradyarrhythmias
in congestive heart failure, 1.99
definition of, 1.101
Bradykinetic movement disorders. *See* Parkinson disease/parkinsonism
Bradyopsia, electroretinography findings in, 12.49
Bradyzoites, 9.275
Bragg peak effect, 4.276
Brain. *See specific structure and under Cerebral*
Brain lesions, in tuberous sclerosis, 5.331*f*, 5.334*t*, 6.398*f*
Brain natriuretic peptide (BNP), 1.97
Brain stones (calcified astrocytic hamartomas), in tuberous sclerosis, 5.331*f*, 5.334*t*
Brain tumors, retinoblastoma and, 4.302
Brainstem
anatomy of, 2.108*f*
lesions of
arteriovenous malformations, 5.343
facial weakness/paralysis caused by, 5.278, 5.278*t*
gaze palsy caused by, 5.228, 5.229*f*
Horner syndrome and, 5.260*t*
vestibular disorders and, 5.217
in ocular motility, 5.33, 5.34–40, 5.35*f*, 5.36*f*, 5.37*f*, 5.39*f*
Brainstem encephalitis, CMV infection causing, 5.349
Brainstem neural network, 5.33, 5.34
Brainstem saccade generators, 5.33
Brainstem syndrome, acute, 5.117*t*
Branch retinal artery occlusion (BRAO), 4.156, 9.160
emboli that cause, 12.141, 12.142*f*
hypertensive retinopathy and, 12.122
imaging of, 12.141*f*
management of, 12.142
multiple, 12.152*f*
in nonproliferative sickle cell retinopathy, 12.152*f*
retinal infarction caused by, 12.141
in Susac syndrome, 12.156
Branch retinal vein occlusion (BRVO), 1.148, 4.158–159
aflibercept for, 12.135
at arteriovenous crossing, 12.126
bevacizumab for, 12.135

clinical findings of, 12.125–127, 12.126*f*
corticosteroids for, 12.137–138
diabetes mellitus and, 12.128
fluorescein angiography of, 12.129*f*
glaucoma as risk factor for, 12.125
hypertensive retinopathy and, 12.122
intraretinal hemorrhages associated with, 12.125, 12.126*f*
macular laser surgery for, 12.128
neovascularization in, 4.159, 12.125, 12.128, 12.129*f*
pars plana vitrectomy for, 12.130
pharmacologic management of, 12.135–138
prognosis for, 12.128
ranibizumab for, 12.135
risk factors for, 12.127–128
scatter photocoagulation for, 12.128–130
spontaneous resolution of, 12.125
surgical management of, 12.128–130
treatment of, 12.128–130
triamcinolone for, 12.137
vision loss caused by, 12.128
Branchial arch syndromes, 6.210–211, 6.210–211*f*
BRAO. *See* Branch retinal artery occlusion
Brawny scleritis, 4.110, 4.110*f*
BRCA1, 1.216–217
BRCA2, 1.216–217
Breaks (retinal). *See* Retinal breaks
Breast cancer
eye involvement and, 4.197, 4.304*t*, 4.305*f*, 4.307*f*, 4.308, 4.308*f*, 4.309–310
hormone replacement therapy and, 1.215
mammographic detection of, 1.216–217
metastatic, 7.106, 7.106*f*
mortality rates for, 1.215
paraneoplastic-induced saccadic intrusions and, 5.249
prevalence of, 1.215
risk factors for, 1.215–216
screening for, 1.215–217
Breastfeeding
glaucoma medication use during, 10.185–186
refractive surgery contraindicated during, 13.37
Breslow thickness, 4.220
Brewster angle, 3.99
Brief psychotic disorder, 1.195
Brightness. *See* Radiance
Brightness sense testing, for relative afferent pupillary defect, 5.81
Brilliant blue G (BBG), 2.444
Brimonidine tartrate, 3.272, 6.289*t*, 6.290, 10.172*t*, 10.175*t*, 10.178–179
characteristics of, 2.385*t*
in children, 10.165
in combination preparations, 10.174*t*
in infants, 2.387
intraocular pressure reductions using, 2.386
neuroprotective effects of, 2.386
during pregnancy/lactation, 10.185
Brimonidine tartrate/timolol maleate, 2.385*t*, 2.389*t*, 2.397*t*
Brinzolamide, 2.356, 2.391*t*, 2.393, 10.173*t*, 10.179–180
in children, 10.165
in combination preparations, 10.174*t*
Brinzolamide/brimonidine tartrate suspension, 2.397*t*
British anti-Lewisite, 2.235
Brittle cornea syndrome, 6.262
Brivudine, 1.279
BRM. *See* Biologic response modifiers
Broad-beam illumination, for slit-lamp biomicroscopy, 8.17
Broad-beam lasers, for photoablation, 13.30, 13.31
Broad-spectrum penicillins, 2.419
Brodmann area, 2.115
Brodmann area 8, 5.33
Brodmann area 17 (striate cortex), 2.115, 2.116*f*, 5.24*f*, 5.29*f*, 5.29–30, 5.30*f*, 5.32*f*, 5.34*f*. *See also* Visual (calcarine/occipital/striate) cortex
description of, 6.44
disorders of, 5.158, 5.178*t*, 5.178–181
illusions and, 5.175
monocular visual deprivation in, 6.44, 6.45
Brodmann area 18 (parastriate cortex), 5.20*f*, 5.30*f*, 5.30–31. *See also* Visual (calcarine/occipital/striate) cortex
Bromday. *See* Bromfenac
Bromfenac, 2.400*t*
Bromocriptine, for Parkinson disease, 1.205
Bron (bleb) pattern, in epithelial basement membrane dystrophy, 8.138
Bronchiectasis, 1.124
Bronchitis, chronic, 1.124
Bronchodilators, for lung disease, 1.128
Bronchogenic carcinoma, 7.106. *See also* Lung cancer
Bronchospasm, 1.123–124
Brow- and forehead-lift, 7.264–265*f*, 7.265–266
Brow ptosis
brow- and forehead-lift for, 7.264–265*f*, 7.265–266
browpexy for, 7.264–265
definition of, 7.263
dermatochalasis and, 7.259, 7.263
direct brow elevation for, 7.265
illustration of, 7.263*f*
management of, 7.263–266, 7.264–265*f*
Brown and Brenn (B&B) stain, 4.31*t*
Brown and Hopps (B&H) stain, 4.31*t*
Brown-McLean syndrome, 11.128*t*, 11.130
Brown syndrome, 5.208
acquired, 6.136
clinical features of, 6.136–137, 6.137*f*
congenital, 6.136
as congenital cranial dysinnervation disorder, 6.131
description of, 6.117
diagnosis of, 6.137
forced duction test for, 6.137
iatrogenic, 6.168
inferior oblique muscle palsy *versus*, 6.124, 6.125*t*, 6.137
management of, 6.137–138
primary position hypotropia with, 6.137
rheumatoid arthritis and, 6.137
superior oblique muscle weakening for, 6.138, 6.166
surgical treatment of, 6.138
Brown tumor of bone, 6.222
Browpexy, 7.264–265
Bruch membrane, 2.97, 2.99, 2.100*f*, 2.322*f*, 4.141*f*
age-related macular degeneration/choroidal neovascularization and, 4.164, 4.165, 4.165*f*
anatomy of, 12.210–211

argyrosis effects on, 12.306
basilar laminar deposits effect on, 12.62*f*, 12.64
choroidal neovascularization after damage to, 12.355, 12.355*f*
degeneration of, 12.19, 12.71
disorders that affect, 12.89
embryologic development of, 12.210
histology of, 12.18*f*
layers of, 12.18*f*, 12.19
ocular expansion effects on, 12.211
outer lamella of, 12.211
photocoagulation-related rupture of, 12.378
remodeling of, 12.210
in retinal healing/repair, 4.17
rupture of, 4.22, 12.378
supertraction crescent, 12.210
tears in, 12.354
type 1 choroidal neovascularization in, 12.72*f*
Brückner test
in amblyopia screening, 6.56
description of, 6.9, 6.67–68
Bruits, carotid, 5.166. *See also* Carotid occlusive disease
Brunescent cataract, 4.123, 11.44. *See also* Cataract
lens proteins in, 11.17
surgery for, 11.180
hydrodelineation in, 11.110, 11.180
Bruns nystagmus, 5.243
Brushfield spots, 6.272
BRVO. *See* Branch retinal vein occlusion
BSCR (birdshot chorioretinopathy). *See* Birdshot uveitis (birdshot retinochoroidopathy/birdshot/vitiliginous chorioretinitis)
BSS. *See* Balanced salt solution
Buccal mucous membrane graft. *See also* Mucous membrane grafting
for mucous membrane pemphigoid, 8.303, 8.366
Buccal nerve, 5.51*f*, 5.52, 5.276–277*f*
Budge-Waller, ciliospinal center/nucleus of, 5.53*f*
Buerger disease (thromboangiitis obliterans), cataract caused by, 11.68
Bulbar conjunctiva, 2.28*f*, 2.43, 4.47, 4.48*f*, 8.6. *See also* Conjunctiva
fixation/plication of, for conjunctivochalasis, 8.86, 8.361
lymphoid lesions involving, 4.69, 4.70*f*
redundant. *See* Conjunctivochalasis
resection of, for conjunctivochalasis, 8.86, 8.362
in superior limbic keratoconjunctivitis, 8.83, 8.84
Bulbar (limbal) vernal keratoconjunctivitis, 6.248, 6.249*f*, 8.289–290, 8.290*f*
Bulla
conjunctival, in mucous membrane pemphigoid, 4.54, 4.54*f*, 8.299
corneal, 8.46*t*
in keratopathy, 4.84, 4.84*f*. *See also* Bullous keratopathy
eyelid, 8.45*t*
Bullous keratopathy, 4.83–84, 4.84, 4.84*f*, 4.85*f*
after cataract surgery, 4.83–84, 4.84*f*, 11.129, 11.129*f*
IOL design and, 11.149
disciform keratitis and, 8.225
DMET for, 8.449
in Fuchs endothelial corneal dystrophy, 4.92, 8.156
Bullous pemphigoid antigen II, in mucous membrane pemphigoid, 8.299
Bullous (reticular degenerative) retinoschisis, 4.148, 12.326, 12.327
Bull's-eye maculopathy/depigmentation
chloroquine toxicity as cause of, 12.295, 12.296*f*
clofazimine as cause of, 12.298
in cone dystrophies, 5.102
in neuronal ceroid lipofuscinoses, 12.289
Bull's-eye pattern
in acute idiopathic maculopathy, 12.229
in Bardet-Biedl syndrome, 12.284
in Lyme disease, 12.245
in macular atrophy, 12.265
in Stargardt disease, 12.270
Bull's-eye rash, 12.245, 12.265*f*
Bundle of His, 1.101
Buphthalmos, 6.283
in megalocornea, 8.99, 8.100
in primary congenital glaucoma, 8.100, 8.108, 10.151, 10.152*f*, 10.158, 10.166
Bupivacaine, 1.305, 2.438*t*, 2.440
Bupropion, 12.306
Burkitt lymphoma, 6.218
Burns, 6.376
chemical. *See* Chemical injury
eyelid, 7.218–219, 7.218–219*f*
thermal
anterior segment, 8.384–385, 8.385*f*
cataract surgery incision, 11.131
Burst cells/neurons, 5.35, 5.219, 5.220*f*
horizontal gaze and, 5.35, 5.37, 5.37*f*, 5.38
saccadic system and, 5.219, 5.220*f*, 5.221
vertical gaze and, 5.35, 5.36, 5.36*f*
Burst-mode phacoemulsification, 11.101
Busacca nodules
in anterior uveitis, 9.78, 9.80*f*
in sarcoidosis, 4.187, 9.196
Butterfly rash, 1.158, 1.159*f*
Butterfly-type pattern dystrophy (BPD), 4.170, 12.276, 12.276*f*
Buttonhole flap, 13.110, 13.110*f*
N-butylcyanoacrylate tissue adhesive. *See* Cyanoacrylate glue/adhesive
Butyrylcholinesterase, 2.379
Bypass Angioplasty Revascularization Investigation, 1.92

C

C4, 2.276
c-ANCA. *See* Cytoplasm-antineutrophil cytoplasmic autoantibody (c-ANCA)
C cells, 1.41, 1.46
C-MIN. *See* Conjunctival melanocytic intraepithelial neoplasia
C-reactive protein (CRP), 1.153
in AION
giant cell arteritis/AAION, 5.120, 5.120*t*, 5.314
nonarteritic (NAION), 5.120*t*
C-scan, 12.26
C-type lectin receptors, 9.46

c-wave, of ERG, 5.96. *See also* Electroretinography/electroretinogram
CA-MRSA. *See* Community-acquired (CA) methicillin-resistant *Staphylococcus aureus*
CABG. *See* Coronary artery bypass grafting
CACD. *See* Central areolar choroidal dystrophy
CAD (coronary artery disease). *See* Coronary heart disease; Ischemic heart disease
CADASIL. *See* Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
Café-au-lait spots, 6.392, 6.395*f*
  in neurofibromatosis, 5.330*f*, 5.334*t*
  in tuberous sclerosis, 5.331*f*, 5.334*t*
CAFE study. *See* Conduit Artery Function Endpoint (CAFE) study
Caffeine halothane contracture test, 1.292
CAIs. *See* Carbonic anhydrase inhibitors
Cajal, interstitial nucleus of (INC), 5.35, 5.35*f*
  saccadic eye movements and, 5.220–221
  vertical gaze and, 5.36, 5.36*f*, 5.38
Calcarine artery, 5.19*f*, 5.20
Calcarine cortex. *See* Occipital (primary visual/calcarine/striate) cortex
Calcarine fissure, 2.119, 5.29*f*, 5.29–30
Calcarine sulcus, 2.119
Calcific band keratopathy (band keratopathy), 4.81–83, 4.82*f*, 6.322, 8.111, 8.117–120, 8.119*f*, 8.201, 9.143*f*, 9.313
  "actinic," 4.83
  in aqueous tear deficiency, 8.56
  in chronic uveitis, 9.78
  gelatinous droplike corneal dystrophy and, 8.141, 8.141*f*
  in gout, 8.119, 8.188
  in juvenile idiopathic arthritis-related anterior uveitis, 9.143*f*, 9.313
  parathyroid disorders and, 8.201
Calcific drusen, 4.163, 12.66
Calcific plaques, senile scleral, 4.111, 4.111*f*
Calcified astrocytic hamartomas (brain stones), in tuberous sclerosis, 5.331*f*, 5.334*t*
Calcineurin inhibitors, 1.179
Calcitonin, 1.41
  in calcium regulation, 8.200
Calcitonin gene–related peptide (CGRP), 2.62, 2.251
Calcium
  antagonists of. *See* Calcium channel blockers
  in aqueous humor, 2.274
Calcium channel blockers (CCBs)
  adverse effects of, 1.61–62, 1.309*t*
  angina pectoris treated with, 1.91
  classification of, 1.61
  hypertension treated with, 1.59*t*, 1.61–62
  ocular adverse effects of, 1.309*t*
Calcium deposits, on IOLs, 11.151
Calcium embolus, transient visual loss and, 5.165, 5.165*f*, 5.166*t*
Calcium hydroxide ($Ca[OH]_2$), ocular injury caused by, 8.376*t*
Calcium oxalate crystals, in nuclear cataract, 4.123, 4.124*f*
Callender classification, of uveal melanomas, 4.194–196
  iris melanoma and, 4.190
Callosomarginal artery, 5.16*f*
CALT. *See* Conjunctiva-associated lymphoid tissue
Calvarium, 6.203
CAM. *See* Complexion-associated melanosis
Camera obscura, 3.3–7, 3.5–7*f*
cAMP (cyclic adenosine monophosphate), 2.388
  in α-agonist mechanism of action, 10.178
  in β-blocker mechanism of action, 10.176
Campbell-Robson contrast sensitivity grating, 3.135*f*
CAMs. *See* Cell adhesion molecules
Can-opener capsulotomy, 9.315
  for ECCE, 11.196
  for phacoemulsification, 11.109–110
Canakinumab, 1.180
Canal. *See also specific canal*
  in vitreous, 12.7
Canal of Dorello, 5.41, 5.42*f*
  sixth nerve (abducens) injury/palsy and, 5.201
Canalicular plugs, for dry eye, 8.64. *See also* Lacrimal plugs
Canaliculi, lacrimal, 2.42, 7.281
  accessory, 7.286*f*
  agenesis of, 7.288
  atresia, 6.227–228, 6.228*f*
  description of, 7.281
  duplication of, 7.286, 7.286*f*
  dysgenesis of, 7.288
  infection of. *See* Canaliculitis
  obstruction of
    canaliculodacryocystorhinostomy for, 7.303
    conjunctivodacryocystorhinostomy for, 7.304*f*, 7.304–305
    etiology of, 7.302–303
    evaluation of, 7.302
    illustration of, 7.299*f*
    infections that cause, 7.303
    inflammatory disease as cause of, 7.303
    lacrimal plugs as cause of, 7.302
    management of, 7.303–305, 7.304*f*
    medications that cause, 7.302
    neoplasm as cause of, 7.303
    partial, 7.302
    reconstruction of, 7.303
    stents for, 7.292–294, 7.294*f*, 7.303
    total, 7.298, 7.299*f*
    traumatic causes of, 7.303
  occlusion of, 7.298
  probing of, 7.291*f*, 7.291–292, 7.302
  stenosis of, 7.298
  traumatic injuries to, 7.311–312
Canaliculitis, 7.311, 7.313, 7.314*f*, 8.208*t*
Canaliculodacryocystorhinostomy, 7.303
Canaliculus, 6.378
  punctum of, 2.27
Canaloplasty, 10.217–219
  cataract surgery and, 11.186
Cancer, 2.183–184. *See also* Carcinoma; Intraocular tumors; Tumor(s); *specific cancer; specific type or organ or structure*
  in children, 1.235
  classification/growth patterns and, 4.10, 4.10*t*, 4.11*f*
  etiology of, 1.235–236, 1.237*t*
  familial clustering of, 1.236
  gene mutations associated with, 1.236, 1.237*t*

genetic profiling of, 1.242
global incidence of, 1.235
infiltrative optic neuropathy and, 5.131–132
ionizing radiation exposure as cause of, 1.236
mortality rates for, 1.235
orbital. *See* Orbital tumors
screening for, 1.215–221, 1.216*t*
treatment of
angiogenesis inhibitors, 1.240*t*, 1.241
biologic therapies, 1.241–243
chemotherapy, 1.239–241, 1.240*t*
monoclonal antibodies, 1.242
radiation therapy, 1.237–239
vaccines, 1.242
virus-associated, 1.236, 1.237*t*
Cancer-associated retinopathy (CAR), 5.102, 9.192–193
ERG in identification of, 5.96, 5.102
Cancer chemotherapy. *See* Chemotherapy
Candela (cd), 3.108
Candida (candidiasis), 8.208*t*, 8.249*t*, 8.250*f*, 8.250–251
albicans
adherence and, 8.206
description of, 1.258, 8.208*t*, 8.250, 8.250*f*, 9.296
chorioretinitis caused by, 9.297, 9.298*f*
diagnosis of, 9.297
endogenous fungal endophthalmitis caused by, 9.295–299, 9.296*f*, 9.299*f*
endophthalmitis caused by, 12.239–240, 12.240*f*
glabrata, 9.296
histologic features of, 9.297, 9.298*f*
keratitis caused by, 4.78, 8.208*t*, 8.251, 8.273, 8.274–275
as normal flora, 8.206*t*, 8.250
ocular infection caused by, 8.208*t*, 8.250–251
retinal infection caused by, 4.147
Candidate gene screening, 2.188–189
Candidemia, 9.296
Candidiasis, ocular, 9.297–298
"Candlewax drippings"
description of, 9.196, 9.197*f*
in sarcoidosis, 4.187, 5.327
Cannabis, intraocular pressure affected by, 10.22
Canthal reconstruction. *See* Eyelid(s), surgery/reconstruction of
Canthal tendons. *See also* Lateral canthal tendon; Medial canthal tendon
anatomy of, 7.168–169, 7.169*f*
trauma to, 7.214–215
Canthaxanthine, 12.303
$Ca(OH)_2$. *See* Calcium hydroxide
CAP. *See* Chromosome arm painting
Capacity to Consent to Treatment Instrument (CCTI), 1.211
Capillary hemangioblastoma, retinal, 4.283–285, 4.284*f*. *See also* Retinal angiomatosis
Capillary hemangioma, 7.71*f*, 7.71–73, 7.180–181
of conjunctiva/ocular surface, 8.345*t*
infantile. *See* Infantile (capillary) hemangiomas
Capillary nonperfusion. *See* Retinal capillaries, nonperfusion of
Capillary plexus
deep, 12.16
intermediate, 12.16
Capillary retinal arteriole obstruction. *See* Cotton-wool spots
Capillary telangiectasis, 1.121
Capsaicin cream, for postherpetic neuralgia, 8.230
Capsid (viral), 8.211, 8.212
Capsular block syndrome (CBS), 10.132, 11.148–149
Capsular/capsule opacification, 11.152–157, 11.184
IOLs and, 11.153
multifocal IOLs, 13.156, 13.167
Nd:YAG laser capsulotomy for, 11.152, 11.153, 11.154, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser, capsulotomy
multifocal IOLs and, 13.156, 13.167
Capsular cataracts, 11.38
Capsular fibrosis, 11.153–154
IOL decentration/dislocation and, 11.145
Nd:YAG laser capsulotomy for, 11.154, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser, capsulotomy
Capsular hooks, 11.182–183, 11.183*f*
Capsular phimosis, 11.153–154
Nd:YAG laser capsulotomy for, 11.154, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser, capsulotomy
in pseudoexfoliation/exfoliation syndrome, 11.184
Capsular rupture, cataract surgery and, 11.142–143, 11.180–181
Capsular tension rings (CTRs), for zonular incompetence, 11.180, 11.181*f*, 11.183
Capsular theory (Helmholtz hypothesis) of accommodation, 11.22, 13.159–160, 13.160*f*
Capsule, lens. *See* Lens capsule
Capsule staining, for cataract surgery, 11.178–179, 11.179*f*
Capsulopalpebral fascia, 2.35, 7.167
Capsulopalpebral head, 2.28*f*
Capsulopalpebral–orbital septum complex, 7.163
Capsulorrhexis, 6.302
advanced cataract and, 11.180
continuous curvilinear (CCC), 11.108–110, 11.109*f*
capsule staining for, 11.178–179, 11.179*f*
for ECCE, 11.196
for phacoemulsification, 11.108–110, 11.109*f*
for ECCE, 11.196, 11.197*f*
for phacoemulsification, 11.108–110, 11.109*f*
in zonular dehiscence with lens subluxation/dislocation, 11.182
Capsulotomy
anterior
for ECCE, 11.196, 11.197*f*
for phacoemulsification, 11.109–110
can-opener, 11.109–110, 11.196, 11.197*f*
lens particle glaucoma after, 10.98
Nd:YAG laser, 11.154*f*, 11.154–157, 11.156*f*
for anterior capsule fibrosis and phimosis, 11.154, 11.154*f*, 11.154–157, 11.156*f*
for capsular block syndrome, 11.149
for capsule opacification, 11.152, 11.153, 11.154, 11.154*f*, 11.154–157, 11.156*f*
multifocal IOLs and, 13.156, 13.167
complications of, 11.156–157
contraindications for, 11.155
indications for, 11.154–155

lens particle glaucoma and, 11.67
procedure for, 11.155–156, 11.156*f*
retinal detachment and, 11.157, 11.166
pupillary block after, 10.132
Captopril, 1.309*t*
CAR. *See* Cancer-associated retinopathy
CAR antigen (recoverin), 5.102
Carbachol
characteristics of, 2.378*t*
intracameral use of, 2.360*t*, 2.375–376
intraocular pressure affected by, 2.377
Carbamazepine, 1.203, 1.207–208
Carbapenems, 1.273. *See also specific agent*
Carbenicillin sodium, 2.418*t*, 2.419
Carbidopa, for Parkinson disease, 1.205
Carbocaine. *See* Mepivacaine
Carbogen, for central retinal artery occlusion, 12.146
Carbohydrate ("sugar") cataracts, 2.289–291
aldose reductase in development of, 11.19
Carbohydrate sulfotransferase 6 *(CHST6)* gene, in macular dystrophy, 4.91, 8.136*t*
Carbohydrates
in aqueous humor, 2.274–275
metabolism of, in lens, 11.17–19, 11.18*f*
Carbon, corneal deposits of/pigmentation caused by, 8.118*t*
Carbon dioxide, in aqueous humor, 2.278–279
Carbon dioxide (CO_2) lasers, 7.268. *See also* Laser(s); Laser therapy
Carbonic anhydrase, 2.271, 2.367
aqueous humor dynamics and, 10.16, 10.179
I, 1.167
Carbonic anhydrase inhibitors (CAIs), 2.391–393, 6.289*t*, 6.290
for acute intraocular pressure elevation, 10.184
in aqueous formation suppression, 10.16, 10.165
for cystoid macular edema, after cataract surgery, 11.165
for glaucoma, 10.172–173*t*, 10.179–181
in children, 10.165
for intraocular pressure control
in chemical injuries, 8.383
hyphema in sickle cell disease and, 8.396
for postoperative elevated intraocular pressure, 10.108
in sickle cell patients, 12.154–155
teratogenicity of, 10.185
for uveitis, 9.113
Carboplatin, for retinoblastoma, 4.299
Carcinoid, metastatic, immunohistochemistry in identification of, 4.34, 4.35*f*
Carcinoma, 4.10*t*, 4.11*f*. *See also* Adenocarcinoma; Carcinoma in situ; *specific type or structure*
adenoid cystic (ACC/cylindroma), 7.100, 7.193, 7.193*f*
of lacrimal gland, 4.230–231, 4.231*f*
basal cell. *See* Basal cell carcinoma
bronchogenic, 7.106
of conjunctiva, intraocular extension and, 4.310
of eyelid, 4.212*f*, 4.212–213, 4.213*f*, 4.214*f*
intraocular extension of, 4.310
metastatic, 4.197, 4.198*f*. *See also* Metastatic eye disease
ocular surface
mucoepidermoid, 8.332*t*, 8.336
squamous cell, 8.336*f*, 8.336–337
management of, 8.330*f*, 8.336–337
prostate, 7.107
retinoblastoma associated with, 4.302*t*
sebaceous, 4.210*t*, 4.215–218, 4.216*f*, 4.217*f*, 7.206–208, 7.207*f*, 8.327, 8.337*f*, 8.337–338
squamous cell. *See* Squamous cell carcinoma
thyroid, retinoblastoma associated with, 4.302*t*
Carcinoma in situ
of conjunctiva, 4.61, 4.63*f*
of eyelid, keratoacanthoma, 4.209–210, 4.210*t*, 4.211*f*
of ocular surface, 8.334. *See also* Conjunctival or corneal intraepithelial neoplasia
sebaceous, 4.217*f*, 4.218
CARD15, 6.319, 9.198
Cardiac arrest. *See* Cardiopulmonary arrest
Cardiac disease. *See* Coronary heart disease; Ischemic heart disease
Cardiac emboli, transient visual loss and, 5.165–166, 5.168
Cardiac enzymes, 1.86–87
Cardiac failure. *See* Congestive heart failure
Cardiac glycosides. *See* Digitalis/digitoxin/digoxin
Cardiac rhythm disorders. *See also* Arrhythmias
antiarrhythmic drugs for, 1.102, 1.102*t*
bradyarrhythmias, 1.99, 1.101
conduction block, 1.101
overview of, 1.101
tachyarrhythmias
atrial fibrillation, 1.102–103, 1.103*f*
atrial flutter, 1.102
in congestive heart failure, 1.99
definition of, 1.102
implantable cardioverter-defibrillators for, 1.104–106
supraventricular tachycardias, 1.102–103
ventricular, 1.104
ventricular fibrillation, 1.104
Cardiac transplantation, for congestive heart failure, 1.100
Cardiff Acuity Test, 6.9, 6.187
Cardinal positions of gaze, 6.31, 6.32*f*, 6.35, 6.64
Cardioembolic strokes, 1.111
Cardiogenic shock, 1.300. *See also* Shock
Cardiolite scintigraphy. *See* Technetium-99m
Cardiopulmonary arrest, 1.296–299, 1.297*t*
Cardiopulmonary resuscitation (CPR)
description of, 1.296–299, 1.297*t*
in ventricular fibrillation, 1.104
Cardiovascular disease (CVD). *See also specific type*
hypertension. *See* Hypertension
perioperative management for ocular surgery in patients with, 1.283
risk assessment for, 1.73
risk factors
cholesterol levels, 1.72
hypertension, 1.55, 1.56*t*
hypertensive retinopathy and, 1.69
list of, 1.56*t*
screening for, 1.214–215
Cardiovascular drugs. *See also* Digitalis/digitoxin/digoxin
ocular adverse effects of, 1.309*t*

Cardioverter-defibrillators, implantable. *See* Implantable cardioverter-defibrillator
Carney complex, eyelid manifestations of, 4.207*t*
Carotenoids (xanthophylls), 2.343
in macula, 4.140
Carotid arteries, 5.27*f*
common, 5.12, 5.13*f*
disorders of. *See* Carotid occlusive disease
dissection of, 5.342–343
Horner syndrome and, 5.162, 5.260*t*, 5.261, 5.262*f*, 5.297
neuroimaging in evaluation of, 5.72*t*, 5.342
external (ECA), 5.12, 5.13*f*, 5.15*f*, 7.170
internal (ICA), 5.10*f*, 5.12, 5.13*f*, 5.14, 5.15*f*, 5.16*f*, 5.18*f*, 5.27*f*, 7.14, 7.170
anatomy of, 2.106*f*
aneurysm of, 5.338, 5.339*f*
chiasmal syndromes caused by, 5.147, 5.150
third nerve (oculomotor) palsy and, 5.194, 5.194*f*, 5.196, 5.196*f*, 5.339
cranial nerve relationship and, 5.42*f*, 5.43*f*
dissection of, 5.342–343
Horner syndrome and, 5.162, 5.260*t*, 5.261, 5.262*f*, 5.297
pain caused by, 5.297, 5.342
neuroimaging in evaluation of, 5.72*t*, 5.167, 5.167*f*, 5.342
stenosis of. *See* Carotid stenosis
ultrasonography in evaluation of, 5.70, 5.167
Carotid artery stenting (CAS)
carotid endarterectomy *versus*, 1.118
carotid stenosis treated with, 1.118
prophylactic uses of, 1.117
Carotid bruits, 5.166. *See also* Carotid occlusive disease
asymptomatic, 1.116–117
Carotid canal, 2.106*f*
Carotid cavernous sinus, 2.476*t*
Carotid-cavernous sinus fistula, 5.203–206, 5.204*f*, 5.205*f*, 12.198
description of, 7.25
direct, 7.78, 7.78*f*
glaucoma associated with, 10.30
indirect, 7.79
neuroimaging in evaluation of, 5.70, 5.72*t*, 5.204, 5.204*f*, 5.205*f*
sixth nerve (abducens) palsy and, 5.201, 5.205–206
Carotid Doppler imaging, 5.70
Carotid duplex ultrasonography
carotid stenosis diagnosis using, 1.116
stroke evaluations using, 1.113
Carotid endarterectomy (CE)
carotid artery stenting *versus*, 1.118
carotid stenosis treated with, 1.117–119
Carotid occlusive disease. *See also* Carotid stenosis
clinical/laboratory evaluation of, 5.167, 5.167*f*
diagnosis of, 1.116
ischemic stroke caused by, 1.115–119
neuroimaging in evaluation of, 5.167, 5.167*f*
ocular ischemic syndrome and, 5.170
retinal hemorrhages in, 12.138
retinopathy of, 12.138
stroke/stroke risk and, 1.115–119, 5.167, 5.168, 5.169
transient visual loss caused by, 5.162, 5.165–168, 5.167*f*
treatment of, 5.169
Carotid Revascularization Endarterectomy Versus Stenting Trial-2 (CREST-2), 1.117
Carotid stenosis. *See also* Carotid occlusive disease
asymptomatic, 1.116–117
carotid endarterectomy for, 1.117–119
diagnosis of, 1.116
ischemic stroke caused by, 1.115–119
management of, 1.116–118
neuroimaging in evaluation of, 5.70, 5.72*t*, 5.167, 5.167*f*
ocular ischemic syndrome and, 5.170
stroke/stroke risk and, 1.115–119, 5.167, 5.168, 5.169
symptomatic, 1.117–118
transient monocular vision loss caused by, 1.118
transient visual loss caused by, 5.162, 5.165–166, 5.167, 5.167*f*, 5.168
treatment of, 5.169
Carotid territory ischemia. *See* Carotid occlusive disease; Carotid stenosis
Carpenter syndrome (acrocephalopolysyndactyly), 8.191*t*
Carteolol hydrochloride, 2.389*t*, 2.390, 10.171*t*, 10.176–177
Caruncle, 2.27*f*, 2.44, 4.47, 4.48*f*, 8.6
glandular lesions involving, 4.71–72, 4.72*f*
nevi in, 4.63
squamous papilloma in, 4.59, 4.60*f*
CAS. *See* Carotid artery stenting; Clinical Activity Score
Cascade ionization, 3.115–116, 3.116*f*
Case-control series, 1.10–12, 1.11*f*
Case reports, 1.9
Case series, 1.9–10
Caseating granulomas, 4.7, 4.9*f*
Caspofungin, 2.431, 2.431*t*
Cat-scratch disease (CSD), 5.119, 6.240, 6.369, 8.248, 8.265–266, 9.240–243, 9.242*f*, 12.242–243, 12.243*f*
neuroretinitis and, 5.119
Parinaud oculoglandular syndrome and, 8.248, 8.265–266
Cat-scratch fever, 9.240
Catalase, 2.342
in lens, 11.20
Cataract, 4.120–123, 4.120–123*f*, 11.43–68. *See also* Cataract surgery; *specific type*
acquired, 6.293
advanced, surgery for, 11.180
age-related, 11.5, 11.43–48. *See also* Age-related cataracts
epidemiology of, 11.5
genetic contributions to, 11.41–42
alcohol use/abuse and, 11.63–64
amblyopia caused by, 6.55, 6.57
anterior polar (APC), 6.55, 6.295, 6.295*f*, 11.35–36
anterior subcapsular. *See* Cataract, subcapsular, anterior
astigmatism caused by, 11.123
atopic dermatitis and, 11.66
autosomal dominant transmission of, 6.294
bilateral, 6.293, 6.294*t*
brunescent, 4.123, 11.44
lens proteins in, 11.17
surgery for, 11.180
hydrodelineation in, 11.110, 11.180

capsular, 11.38
carbohydrate ("sugar")
aldose reductase in development of, 11.19
description of, 2.289–291
cerulean, 11.37, 11.38*f*
chemical injuries causing, 11.59
in children, 11.34–39, 11.35*t*, 11.36*f*, 11.37*f*, 11.38*f*, 11.39*f*. *See also* Cataract, congenital; Cataract, pediatric
genetic contributions to, 11.41–42
"Christmas tree," in myotonic dystrophy, 5.330
complete (total), 11.38
congenital, 6.293, 11.34–39, 11.35*t*, 11.36–39*f*. *See also* Cataract, pediatric
aniridia and, 11.33, 11.34*f*
bilateral, 11.35*t*
genetic/hereditary factors in, 11.41–42
surgical management of. *See* Cataract surgery, in children
unilateral, 11.35*t*
contrast sensitivity affected by, 11.70
contusion, 11.54, 11.54*f*
coronary, 11.37
cortical, 2.235, 4.122, 4.122*f*, 11.45–46, 11.46–50*f*
characteristics and effects of, 11.45, 11.70*t*
genetic contributions to, 11.41
race and, 11.6
uveitis and, 11.64*f*, 11.64–66
corticosteroid use and, 6.321, 11.51–52, 11.64, 11.188
degenerative ocular disorders and, 11.68
diabetic, 11.60*f*, 11.60–61
carbohydrate ("sugar"), aldose reductase in development of, 11.19
surgery for, 11.170
preoperative evaluation and, 11.80–81
drug-induced, 11.51–53, 11.52*f*
duplication, 4.120, 4.120*f*
electrical injury causing, 11.59, 11.59*f*
after endothelial keratoplasty (DMEK/DSEK), 8.446–447
epidemiology of, 11.5–7
etiology of, 6.294, 6.294–295*t*, 11.35*t*
evaluation of, 6.299*t*, 6.299–301, 11.69–88, 11.70*t*
fundus evaluation in patient with, 11.80–81
galactose metabolism defects as cause of, 2.289
in galactosemia, 11.61, 11.61*f*
general features of, 6.293–294
glassblower's, 11.57
glaucoma and, 4.103, 10.97*f*, 10.97–98, 10.128, 10.211–212, 11.67, 11.186*f*, 11.186–187
in children, 10.156
management of, 10.211–213, 11.186–187
preoperative evaluation/care and, 11.186*f*, 11.186–187
glaucoma surgery and, 10.187
history in, 6.299*t*, 6.300, 11.69–71, 11.70*t*
surgery evaluation and, 11.74–76
hypermature, 11.46, 11.49*f*
phacolytic glaucoma/uveitis and, 4.103, 10.97*f*, 10.97–98, 11.67
hypocalcemic, 11.61–62
illusions caused by, 5.174
incidence/prevalence of, 11.5, 11.6
infantile, 6.293, 11.34–39, 11.35*t*, 11.36*f*, 11.37*f*, 11.38*f*, 11.39*f*. *See also* Cataract, congenital
intralenticular foreign body causing, 11.57
intumescent, 11.46
surgery for, 11.179–180
IOL implantation and. *See* Cataract surgery
ischemia causing, 11.68
after keratoplasty, 11.176
laboratory workup for, 6.299*t*, 6.301
lamellar (zonular), 6.55, 6.296, 6.296*f*, 11.34–35, 11.36*f*
lens proteins and, 11.17
management of, 11.71–88. *See also* Cataract surgery
in glaucoma, 10.211–213, 11.186*f*, 11.186–187
low vision aids in, 11.71
nonsurgical, 11.71–72
pharmacologic, 11.72
in Marfan syndrome, 8.194
mature, 11.46, 11.48*f*
phacolytic glaucoma/uveitis and, 10.97*f*, 10.97–98, 11.67
megalocornea and, 8.100
membranous, 11.38, 11.39*f*
metabolic, 11.60*f*, 11.60–62, 11.61*f*, 11.62*f*
morgagnian, 4.122, 4.123*f*, 11.46, 11.50*f*
phacolytic glaucoma and, 10.97*f*, 10.97–98
morphology of, 6.294–299, 6.295*t*, 6.295–298*f*
in myotonic dystrophy, 11.62, 11.62*f*
next-generation gene sequencing for, 6.301
nuclear, 4.123, 4.124*f*, 11.43–45, 11.45*f*, 12.402, 12.402*t*
characteristics and effects of, 11.43, 11.44, 11.70, 11.70*t*
in children/congenital, 11.38, 11.39*f*
genetic contributions to, 11.42
hyperbaric oxygen therapy and, 11.20, 11.65
infantile, 6.295, 6.296*f*
race and, 11.6
in rubella, 6.410
vitrectomy and, 11.55, 11.190
nutritional disease and, 11.7, 11.63–64
ocular anomalies associated with, 6.293, 6.294*t*
ocular examination of, 6.300
oil droplet, 11.44, 11.61, 11.61*f*
oxidative damage and, 11.19–20
in pars planitis, 9.151
pediatric, 11.34–39, 11.35*t*, 11.36–39*f*. *See also* Cataract, congenital
bilateral, 11.35*t*
persistent fetal vasculature and, 4.126, 11.42
surgery for. *See* Cataract surgery, in children
unilateral, 11.35*t*
penetrating and perforating injuries causing, 11.55, 11.55*f*, 11.56*f*. *See also* Cataract, traumatic
after penetrating keratoplasty, 8.432
perimetry interpretation and, 10.71
peripheral vacuolar, 6.298
persistent fetal vasculature and, 4.126, 6.298*f*, 6.298–299, 11.42
phacolytic glaucoma/uveitis and, 4.103, 10.97*f*, 10.97–98, 11.67
phacomorphic glaucoma and, 10.128, 11.67, 11.68*f*
after phakic IOL insertion
iris-fixated lenses, 13.145
posterior chamber lenses, 13.138, 13.145–146, 13.146

pinhole vision in patients with, 3.24
polar, 6.55, 11.35–36, 11.37*f*
surgery for, 11.180–181
hydrodissection/nucleus rotation and, 11.111, 11.181
posterior capsular, 6.387*f*
posterior lenticonus/lentiglobus and, 6.296–297, 6.297*f*, 11.30
posterior polar, 11.36
surgery for, 11.180–181
hydrodissection/nucleus rotation and, 11.111, 11.181
posterior subcapsular (PSC). *See* Cataract, subcapsular, posterior
postvitrectomy, 11.55, 11.190
in pseudoexfoliation syndrome, 11.65
race and, 11.6
radiation-induced, 1.239, 11.57–58
after refractive surgery, 11.176–177, 11.177*f*
refractive surgery in patient with, 13.43–44
removal of, 6.57. *See also* Cataract surgery
retinoscopy evaluations, 6.299
risk factors for development of, 11.6–7
rosette, 11.54, 11.54*f*
rubella, 6.410, 11.38–39
scleritis and, 8.323
sectoral, 6.297–298
in siderosis bulbi, 11.58*f*, 11.58–59
silicone oil use and, 11.83, 11.120, 11.190
slit-lamp examination of, 6.300
smoking/tobacco use and, 11.6–7, 11.63–64
"snowflake," 11.60, 11.60*f*
statins and, 1.79, 11.53
steroid-induced, 11.51–52, 11.64, 11.188
subcapsular
anterior (subcapsular fibrous plaques), 4.120, 4.120*f*
after posterior chamber phakic IOL insertion, 13.146
posterior (PSC), 2.283, 4.120*f*, 4.120–121, 4.121*f*, 6.297, 11.46–48, 11.51*f*
chamber phakic IOL insertion, 13.146
characteristics and effects of, 11.47, 11.70*t*
corticosteroids causing, 11.51–52
ischemia causing, 11.68
in myotonic dystrophy, 11.62
race and, 11.6
silicone oil use and, 11.190
uveitis and, 11.64
vitrectomy and, 11.55, 11.190
subtypes of, distribution of, 11.6
"sugar"
aldose reductase in development of, 11.19
description of, 2.289–291
"sunflower," in chalcosis/Wilson disease, 8.189, 11.59, 11.62
surgery for. *See* Cataract surgery
sutural (stellate), 11.37, 11.37*f*
tetanic, 11.61–62
total (complete), 11.38
traumatic. *See also specific type*
description of, 4.18, 11.53–59, 11.54–56*f*, 11.59*f*, 11.190–193, 11.192*f*
surgery for, 11.192
treatment-induced. *See* Cataract, drug-induced
types of, 6.293
ultrasonographic findings in, 2.470*f*
uveitis and, 9.313–317, 11.64*f*, 11.64–65, 11.139–140
visual acuity and, 11.69–70, 11.70*t*
postoperative outcome and, 11.126
preoperative evaluation and, 11.75–76
visual deprivation amblyopia caused by, 6.55
visual function affected by, 6.300
visual impairment caused by, 1.184
vitrectomy and, 11.55, 11.190
in Wilson disease, 8.189, 11.62
workup for, 6.299*t*, 6.301
zonular (lamellar), 6.55, 6.296, 6.296*f*, 11.34–35, 11.36*f*
Cataract surgery, 11.89–126. *See also* Lensectomy; Phacoemulsification; *specific procedure*
in acne rosacea, 11.172–173
age-related macular degeneration progression affected by, 12.71
α-blocker use and, 11.74
amblyopia managed with, 6.57, 6.304
anesthesia for, 11.91*f*, 11.91–92, 11.92*f*, 11.93*f*
anterior capsule fibrosis and phimosis and, 11.153–154
anterior capsule management in, 6.302
anterior segment complications of, 11.132–144, 11.137*t*
anticoagulant use and, 11.74, 11.157, 11.171–172, 11.172*t*
antimicrobial prophylaxis for, 11.93–95, 11.94*f*
corneal melting and, 11.132
aphakia management after, 6.304
aphakic glaucoma after, 10.156
arcuate keratotomy with, 13.58
astigmatism and
arcuate keratotomy and, 13.53–54, 13.54–58
induced, 11.131–132
limbal relaxing incisions for, 13.8*t*, 13.27*f*, 13.53–54, 13.54, 13.54*f*, 13.54–58, 13.55*f*, 13.56*f*, 13.56*t*, 13.57*f*
modification of preexisting, 11.123–124
toric IOLs for, 11.124, 13.151–153
axial length extremes and, 11.184–185
biometry before, 11.82–83, 11.83*f*
hypotony affecting, 11.185
IOL power determination/selection and, 11.82–85, 11.83*f*, 11.87
in bleeding diathesis, 11.171–172
in blepharitis, 11.172–173
Brown-McLean syndrome after, 11.128*t*, 11.130
bullous keratopathy after, 4.83–84, 4.84*f*, 11.129, 11.129*f*
IOL design and, 11.149
capsular block syndrome and, 10.132, 11.148–149
capsular opacification and contraction and, 11.152–157, 11.184
Nd:YAG laser capsulotomy for, 11.152–157, 11.154*f*, 11.156*f*. *See also* Nd:YAG laser, capsulotomy
capsular rupture and, 11.142–143
capsule staining and, 11.178–179, 11.179*f*
capsulorrhexis in, 11.108–110, 11.109*f*
capsule staining for, 11.178–179, 11.179*f*
in children, 6.301–305
glaucoma after, 10.149*t*
choroidal hemorrhage and. *See* Cataract surgery, suprachoroidal hemorrhage/effusion and

ciliary block (malignant) glaucoma and, 10.139, 11.139
in claustrophobia, 11.169
clear corneal incision for, 11.106*f*, 11.106–107
with trabeculectomy, 10.213
communication with patient and, 11.169–170, 11.170
complications of, 6.304–305, 11.127–167. *See also specific type*
anterior segment, 11.132–144, 11.137*t*
antimicrobial prophylaxis in prevention of, 11.93–95, 11.94*f*
capsular opacification and contraction and, 11.152–157
corneal, 11.128*t*, 11.128–132, 11.129*f*
endophthalmitis, 4.119, 4.119*f*, 11.127, 11.140, 11.160–163, 11.161*f*
hemorrhage, 11.157–160
intraoperative, 11.127
IOL implantation and, 11.144*f*, 11.144–152, 11.146–148*f*
retinal, 11.163–167, 11.164*f*
conjunctival evaluation before, 11.78
corneal complications of, 11.128*t*, 11.128–132, 11.129*f*
corneal conditions and, 11.174*f*, 11.174–177, 11.177*f*
corneal decompensation after, 6.304
corneal edema and, 11.128*t*, 11.128–130
corneal evaluation before, 11.78–79
pachymetry, 11.84
topography, 11.84, 11.86, 11.174
corneal melting/keratolysis after, 11.132
in patient with dry eye, 11.132
cyclodialysis and, 11.139
cystoid macular edema and, 11.163–165, 11.164*f*, 11.187, 12.157, 12.159, 12.260
in glaucoma, 11.164, 11.187
after Nd:YAG capsulotomy, 11.157
vitreous prolapse and, 11.143–144
delirium after, 1.187
in dementia/mental disability, 11.169–170
Descemet membrane detachment and, 11.131
in diabetes mellitus, 11.170
preoperative evaluation and, 11.80–81
diplopia after, 5.207
donor cornea suitability and, 8.414
elevated intraocular pressure after, 11.75, 11.128*t*, 11.129, 11.136. *See also* Elevated intraocular pressure
endophthalmitis after, 4.119, 4.119*f*, 6.305, 11.127, 11.140, 11.160–163, 11.161*f*. *See also* Postoperative endophthalmitis
prevention of, 11.93–95, 11.94*f*, 11.161–162
Propionibacterium acnes causing, 4.119, 4.119*f*, 11.140, 11.162
with endothelial keratoplasty (DMEK/DSEK), 8.446–447, 11.175–176
epithelial/fibrous ingrowth and, 11.128*t*, 11.132–133
external eye examination before, 11.77–78
external ocular abnormalities and, 11.172–174
extracapsular cataract extraction (ECCE), 11.90, 11.90*f*, 11.196–198, 11.197*f*. *See also* Extracapsular cataract extraction
fall reduction after, 1.192
femtosecond laser, 11.125–126
filtering bleb (inadvertent) after, 11.130–131
filtering surgery and
cataract surgery combined with, 10.211–213
cataract surgery following, 11.187
flat or shallow anterior chamber and, 11.134–136
angle-closure glaucoma and, 10.144–145
intraoperative complications and, 11.134–135
posterior fluid misdirection syndrome and, 11.134–135
postoperative complications and, 11.135–136
preoperative considerations/IOL power determination and, 11.79, 11.84, 11.86–87
fluid-based phacolysis, 11.125
Fuchs heterochromic uveitis/iridocyclitis and, 11.64–65
functional visual status after, 1.192
fundus evaluation before, 11.80–81
glaucoma and
description of, 6.285, 6.304, 10.98, 10.128, 10.139, 10.156, 10.213, 11.186*f*, 11.186–187
filtering surgery before, 11.187
filtering surgery combined with, 10.211–213
phacomorphic glaucoma and, 10.128
preoperative evaluation and, 11.186*f*, 11.186–187
trabeculectomy combined with, 10.211–213
globe exposure for, 11.105, 11.105*f*, 11.199
hemorrhage and, 11.157–160
high hyperopia and, 11.185
high myopia and, 11.184–185
historical overview/key developments in, 11.89*f*, 11.89–91, 11.90*f*, 11.195
hyphema after, 11.149, 11.158–159
in hypotony, 11.185
hypotony/flat anterior chamber after, 11.135
suprachoroidal effusion/hemorrhage and, 11.159, 11.160
illusions caused by, 5.174
incisions for. *See also specific type of incision and type of surgery*
complications related to, 11.130–131, 11.134
for ECCE, 11.196
for ICCE, 11.199–200
leaking, 11.118, 11.130–131
flat anterior chamber and, 11.135
for phacoemulsification
clear corneal, 11.106*f*, 11.106–107
scleral tunnel, 11.107*f*, 11.107–108
indications for, 11.72–74
inflammation control after, 9.138
informed consent for, 11.87–88
intracapsular cataract extraction (ICCE), 3.240, 11.90, 11.199–201, 11.200*f*. *See also* Intracapsular cataract extraction
intraocular lens. *See also* Intraocular lenses
complications of, 11.144*f*, 11.144–152, 11.146*f*, 11.147*f*, 11.148*f*
description of, 11.115–117, 11.118–122
placement of
description of, 6.301
issues associated with, 6.303–304
lensectomy with, 6.302–304
posterior capsulectomy/vitrectomy with, 6.303
power calculations, 6.303

intraoperative floppy iris syndrome and, 11.74, 11.178
iridodialysis and, 11.138
iris trauma and
in patient with preexisting iris trauma, 11.191, 11.192*f*
as surgical complication, 11.138
in keratoconjunctivitis sicca, 11.173
keratoplasty and, 11.175–176
with IOL insertion (triple procedure), 11.175–176
key developments in, 11.195
laser photolysis, 11.125
lens anatomy alterations and, 11.179–184, 11.181*f*, 11.182*f*, 11.183*f*
lens-iris diaphragm retropulsion syndrome and, 11.138, 11.184
lens particle glaucoma after, 10.98
lens visualization and, 11.177–179, 11.178*f*, 11.179*f*
trauma affecting, 11.191
lensectomy, 6.302
limbal relaxing incisions and, 11.123–124, 13.58
macular edema after, 6.304–305
macular function evaluation before, 11.82
retinal disease and, 11.189
malignant glaucoma (aqueous misdirection/ciliary block glaucoma) and, 10.139, 11.139
manifest refraction delays after, 3.26
manual small-incision (MSICS), 11.198, 11.199*f*
in eye with functioning filter, 11.187
in glaucoma, 11.186, 11.187
measurements taken before, 11.82–84, 11.83*f*
medical status and, 11.72, 11.170–171
medical therapy after, 6.304
in megalocornea, 8.100
in mucous membrane pemphigoid, 11.173
in nanophthalmos, 11.185
necrotizing scleritis after, 9.121
in neurocognitive/neurodevelopmental disorders, 11.169–170
nucleus removal in
in ECCE, 11.196–197
in ICCE, 11.200, 11.200*f*
in phacoemulsification, 11.111, 11.112–114, 11.113*f*. *See also* Phacoemulsification
ophthalmic viscosurgical devices (viscoelastic agents) in, 11.95–97. *See also* Ophthalmic viscosurgical devices
outcomes of, 11.126
improving, 11.87
paracentesis for, 11.105
patient preparation for, 11.87–88
in patient with communication obstacles, 11.169–170, 11.170
after penetrating keratoplasty, 8.432
with penetrating keratoplasty and IOL insertion (triple procedure), 11.175
phacoemulsification, 11.90–91, 11.98–118. *See also* Phacoemulsification
photic retinopathy after, 12.368
for plateau iris, 10.128
posterior capsule opacification and, 11.152–153, 12.260
Nd:YAG laser capsulotomy for, 11.152, 11.153, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser, capsulotomy
posterior capsule rupture and, 11.142–143
posterior fluid misdirection syndrome and, 11.134–135
postoperative care and, 6.304
after ECCE, 11.198
after ICCE, 11.201
potential acuity estimation before, 11.81–82
preoperative evaluation/preparation for, 11.74–76, 11.87–88
primary posterior capsulectomy, 6.303
in pseudoexfoliation/exfoliation syndrome, 11.79, 11.184
pseudophakic/aphakic bullous keratopathy after, 4.83–84, 4.84*f*, 11.129, 11.129*f*
IOL design and, 11.149
psychosocial considerations in, 11.72, 11.76, 11.169–170
pupil expansion and, 11.177–178, 11.178*f*
in uveitis, 11.191
pupil irregularity caused by, 5.255
pupillary capture and, 11.148, 11.148*f*
IOL decentration and, 11.145
after radial keratotomy, 13.52–53
rate of, 11.5–6
red reflex and, 11.178–179, 11.179*f*
refraction before, 11.76
refractive errors after, 11.86
after refractive surgery, 11.176–177, 11.177*f*
IOL power calculation and, 11.85–87, 11.176, 11.177*f*, 13.44, 13.194
with refractive surgery, 11.123–124. *See also* Cataract surgery, astigmatism and
retained foreign matter and, 11.191
retained lens material and, 11.140–141
retinal complications and, 11.163–167, 11.164*f*
retinal detachment after, 6.304, 11.127, 12.319
family history as risk factor and, 11.75
Nd:YAG laser capsulotomy and, 11.157, 11.166
in retinal disease, 11.189
retinal light toxicity and, 11.166
retrobulbar hemorrhage and, 11.158, 11.171
same-day bilateral, 11.73
scleral tunnel incisions for
ECCE and, 11.196
phacoemulsification and, 11.107*f*, 11.107–108
second-eye, 11.73
shallow anterior chamber and. *See* Cataract surgery, flat or shallow anterior chamber and
slit-lamp examination before, 11.78–80
small pupil and, 11.177–178, 11.178*f*
specular microscopy before, 11.84
strabismus after, 6.304
suprachoroidal hemorrhage/effusion and, 11.159, 11.171
delayed, 11.160
expulsive, 11.159–160
flat anterior chamber and, 11.134
systemic conditions and, 11.170–172, 11.171*f*
tamsulosin use and, 11.74, 11.136, 11.137, 11.137*t*
timing of, 6.301
toxic anterior segment syndrome and, 11.129, 11.133–134
after trauma, 11.190–193, 11.192*f*

in triple procedure, 11.175–176
uveitis and, 6.323, 9.313–314, 11.64–65, 11.75, 11.139–140
postoperative, 11.139–140
pupil expansion and, 11.191
visual function evaluation after, 11.126
visual function evaluation before, 11.71, 11.72, 11.76–77
vitreal complications/vitreous abnormalities and, 12.349
with ICCE, 11.200
posterior detachment, 11.166
prolapse, 11.142, 11.143–144
vitreocorneal adherence, 11.130
vitreous loss during, 12.349
wound closure for
complications associated with, 11.130–131
after ECCE, 11.197–198
after ICCE, 11.200–201
postoperative endophthalmitis and, 11.161
wound dehiscence/rupture and, 11.131
wound management in, 12.349
zonular abnormalities and, 11.179–184
iris coloboma/corectopia and, 11.180
nucleus rotation and, 11.111
zonular dehiscence with lens subluxation or dislocation and, 11.181–183, 11.182*f*, 11.183*f*
zonular anatomy alterations and, 11.179–184
Cataractous lens, B-scan ultrasonography of, 12.40*f*
Catarrhal (marginal corneal) infiltrates, 8.310–311
staphylococcal blepharitis/blepharoconjunctivitis and, 8.74, 8.74*f*
Catastrophic antiphospholipid syndrome, 1.164
Caterpillar hairs, ocular inflammation caused by, 8.387
Cathelicidins, in rosacea, 8.69
Cathepsin, 1.167
in Goldberg syndrome, 8.179
Cathepsin D, 2.276
Catheter/conventional/contrast angiography, 5.68, 5.68*f*
in aneurysm detection/evaluation, 5.195, 5.340, 5.341*f*
in arteriovenous malformations, 5.292*f*, 5.344, 5.344*f*
in reversible cerebral vasoconstriction syndrome, 5.347, 5.347*f*
in vertebrobasilar insufficiency, 5.337*f*, 5.338
Catheter-based reperfusion. *See* Percutaneous coronary intervention
Cation balance, in lens maintenance, 11.21, 11.22*f*
Cats, *Bartonella henselae* transmitted by, 8.248, 8.265
CATT clinical trial, 12.83, 12.84*t*
Cause-and-effect diagram, 1.30–31
Caustic chemicals, ocular injury caused by, 8.375–384, 8.376*t*. *See also* Chemical injury
Caustic soda, ocular injury caused by, 8.376*t*
Cautery, thermal
for conjunctivochalasis, 8.86, 8.361
for punctal occlusion, 8.65
for superior limbic keratoconjunctivitis, 8.84
Cavernous hemangioma, 4.6
cerebrofacial. *See* Sturge-Weber syndrome
of conjunctiva/ocular surface, 8.345, 8.345*t*, 8.346
description of, 7.75
optic neuropathy caused by, 5.126
orbital, 4.6, 4.233, 4.234*f*
retinal, 4.285*f*, 4.285–286, 12.168, 12.169*f*
Cavernous optic atrophy of Schnabel, 4.246, 4.247*f*
Cavernous sinus, 2.133, 2.135–136, 2.138*f*, 5.6*f*, 5.11, 5.21*f*, 5.22, 5.23*f*
carotid artery fistulas and, 5.203–206, 5.204*f*, 5.205*f*
neuroimaging in evaluation of, 5.70, 5.72*t*, 5.204, 5.204*f*, 5.205*f*
cranial nerve IV (trochlear) in, 5.42*f*, 5.43, 5.43*f*
cranial nerve VI (abducens) in, 5.41, 5.42*f*, 5.43*f*
Horner syndrome caused by lesions of, 5.260*t*
inflammation in (Tolosa-Hunt syndrome), 5.203
multiple cranial nerve paresis caused by lesions of, 5.202
ophthalmoplegia caused by lesions of, 5.202–206, 5.204*f*, 5.205*f*
pain caused by lesions of, 5.296
Cavernous sinus syndrome, 2.475*t*, 5.339
Cavernous sinus thrombosis (CST), 5.345, 6.214, 7.48, 7.51
orbital infection/cellulitis and, 5.345
Cavernous venous malformations (CVMs), 7.75–77, 7.76*f*
Cavitation, 11.99
CBS. *See* Capsular block syndrome
CCBs. *See* Calcium channel blockers
CCC. *See* Continuous curvilinear capsulorrhexis
CCD. *See* Charge-coupled device
CCDDs. *See* Congenital cranial dysinnervation disorders
CCL. *See* Corneal (collagen) crosslinking
CCN1 gene, in neurofibromatosis, 4.238
CCRS. *See* Co-contractive retraction with jaw-eyelid synkinesis syndrome
CCT. *See* Central cornea, thickness of
CCTA. *See* Coronary computed tomography angiography
CCTI. *See* Capacity to Consent to Treatment Instrument
CCTVs, 3.323
cd. *See* Candela
CD antigens. *See also specific type*
in immunohistochemistry, 4.35
CD4, in adaptive immune response, 9.30
$CD4^+$ helper-induced T lymphocytes, 1.266
$CD4^+$ T cells. *See also* Helper T cells; T cell(s)
in AIDS, 9.327
in cytomegalovirus retinitis, 12.235
development of, 9.43*f*
in external eye defense, 8.12*f*
in HIV infection/AIDS, 8.241
in immune processing, 9.30–31
in sympathetic ophthalmia, 9.45
in tubulointerstitial nephritis and uveitis syndrome, 9.135
CD8
in adaptive immune response, 9.30
cytotoxic T cell expression of, 9.36, 9.44
$CD8^+$ T cells. *See also* T cell(s)
cytotoxicity mechanisms of, 9.47*f*
in external eye defense, 8.12*f*
major histocompatibility class I molecules and, 9.30
regulatory (suppressor). *See* Regulatory (Treg/suppressor) T cells
in sympathetic ophthalmia, 9.45

CD19, in lymphoma, 4.232
CD20
in lymphoma, 4.232
in nonspecific orbital inflammation, 4.225
CD25, in nonspecific orbital inflammation, 4.225
CD34, in orbital solitary fibrous tumors, 4.235
CD40 receptors, 7.57
CD52, 1.180
CD154, 7.57
CD340, in immunohistochemistry, 4.35
CD95 ligand. *See* Fas ligand
CD95 receptor, 9.46
CDB1 (corneal dystrophy of Bowman layer type 1). *See* Reis-Bücklers corneal dystrophy
CDB2 (corneal dystrophy of Bowman layer type 2). *See* Thiel-Behnke corneal dystrophy
CDC (Centers for Disease Control), 1.223, 1.226, 1.227, 1.232
cataract epidemiology and, 11.5
CDCR. *See* Conjunctivodacryocystorhinostomy
CDKs. *See* Cyclin-dependent kinases
CDS (Cornea Donor Study), 8.416
CDVA. *See* Corrected distance visual acuity
CE (Conformité Européene) marking, 13.3
for intrastromal corneal ring segments, 13.65
for small-incision lenticule extraction, 13.203
CEA. *See* Carotid endarterectomy
Cecocentral scotoma, 5.103, 5.105*t*, 5.106*f*, 6.368
Cefaclor, 1.308*t*
Cefadroxil, 2.419
Cefamandole, 2.419
Ceftazidime, 2.418*t*, 2.426
Cefazolin
for bacterial keratitis, 8.270*t*
for dental prophylaxis, 1.248*t*
description of, 2.418*t*, 2.419
Cefepime hydrochloride, 2.420
Cefoperazone, 2.420
Cefotaxime, 2.420
for Lyme disease, 9.231*t*
Cefoxitin, 2.419
Cefpirome, 2.420
Ceftazidime, 2.420
for bacterial keratitis, 8.270*t*
after corneoscleral laceration repair, 8.409
for endophthalmitis, after cataract surgery, 11.162
for postoperative endophthalmitis, 12.389
for pseudomonal infections, 1.251
Ceftriaxone
for bacterial keratitis, 8.270*t*
Borrelia burgdorferi treated with, 1.255
dental prophylaxis uses of, 1.248*t*
description of, 2.418*t*
for gonococcal conjunctivitis, 8.259
in neonates, 8.264
gonococcal infections treated with, 1.251
for Lyme disease, 9.231*t*
Cefuroxime axetil
description of, 1.308*t*, 2.360*t*, 2.419
intracameral, during cataract surgery, 11.94, 11.162
for Lyme disease, 9.231*t*
"Ceiling effect," 1.25
Celecoxib, 2.409*t*
Cell adhesion molecules (CAMs), 9.38
description of, 9.10
types of, 9.11
Cell cycle
checkpoints in, 2.175–176, 2.183
cytokinesis, 2.173–174
meiosis, 2.174–175
mitosis, 2.173
phases of, 2.173–174, 2.174*f*
regulation of, 2.175–176
Cell-free fetal DNA, 2.239
Cell-marker studies, 7.33–34
Cell-mediated immunity. *See* Cellular immunity/immune system
Cell wall
bacterial, 8.243–244
fungal, 8.249
Cellophane maculopathy, 2.300, 12.335
Cellular atypia
conjunctival melanocytic intraepithelial neoplasia and, 4.66–68, 4.67*f*
primary acquired melanosis and, 4.65, 4.66, 4.67*f*, 8.342–343
Cellular immunity/immune system (cell-mediated immunity), 1.245
mast cells in, 9.3
in mucous membrane pemphigoid, 8.299
Cellular retinol-binding protein 1 (CRBP1), 2.326
Cellulitis, 4.204, 4.204*f*
orbital, 6.213–215, 6.214*f*, 7.46*t*, 7.46–48, 7.47*f*
pain in, 5.295
preseptal, 4.204, 4.204*f*, 6.170, 6.212–214, 7.43–46, 7.44*t*
Haemophilus causing, 8.256
Cellulose sponge, in surface ablation, 13.92
"CEMAS (The Classification of eye movement abnormalities and strabismus)," 5.234
Center for Quality Assessment and Improvement in Mental Health, 1.190
Center-involved diabetic macular edema
description of, 12.92
imaging of, 12.109, 12.110*f*
Centers for Disease Control (CDC), 1.223, 1.226, 1.227, 1.232
cataract epidemiology and, 11.5
Central, Steady, and Maintained (CSM) method, 6.6
Central areolar choroidal dystrophy (CACD), 12.277
Central blindness, age-related macular degeneration progression to, 12.86
Central colobomas, 2.153
Central cornea, 2.51, 8.25, 8.25*f*
healing in, 4.14–16, 4.15*f*
thickness of (CCT), 6.181, 6.281, 8.25, 8.41–42. *See also* Cornea, thickness/rigidity of
glaucoma and, 10.25, 10.31, 10.81, 10.82, 10.90
in infants and children, 10.159
normal-tension glaucoma and, 10.86–87
in infants and children
normal, 10.159
in primary congenital glaucoma, 10.159
ocular hypertension and, 8.41, 10.25, 10.90, 10.112
tonometry measurements affected by, 10.25, 10.81, 10.82, 10.86
transparency disorders, 6.257–258*t*, 6.257–263, 6.258*f*

Central corneal power *(K)*, 8.26. *See also* Cornea, refractive power of
description of, 3.243, 3.248
errors in, 3.252
in keratoconus/corneal ectasia, 8.32*t*
measurement of, 8.26–27, 8.27*f*, 13.7–9. *See also* Keratometry/keratometer
after refractive surgery, 13.193
simulation measurements (SIM K), 13.19
Central dysacusia, 9.205
Central epithelial edema, 3.232
Central fat compartment, 7.261
Central fusion, 6.42
Central fusion disruption, 6.48, 6.79, 6.104
Central islands, after photoablation, 13.103–104, 13.104*f*
Central macular atrophic lesions, 12.266
Central nervous system (CNS)
Behçet disease involvement of, 12.230
cryptococcosis of, 5.356
disorders of. *See* Neurologic disorders
incontinentia pigmenti involvement of, 12.286
local anesthesia toxic reactions effect on, 1.304
lymphoma/intraocular lymphoma of, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
metabolic abnormalities of
abetalipoproteinemia, 12.289–290
lysosomal, 12.291–292, 12.292*f*
mucopolysaccharidoses, 12.290–291
neuronoid ceroid lipofuscinoses, 12.289, 12.290*f*
peroxisomal disorders, 12.290
Refsum disease, 12.290
retinal degeneration caused by, 12.288–292
vitamin A deficiency, 12.289–290
metastatic lesions in, ocular metastases associated with, 4.304, 4.304*f*
primary vitreoretinal lymphoma involvement of, 12.234
zygomycosis of, 5.355
Central (type 2) neurofibromatosis, 5.300, 5.334*t*, 6.393*t*, 6.397, 10.156
seventh nerve (facial) palsy and, 5.279, 5.279*f*
Central optical clear zone. *See also* Optical zone, corneal
arcuate keratotomy and, 13.54–55, 13.56
radial keratotomy and, 13.50, 13.50*f*, 13.51
IOL power calculations affected by, 13.193
Central posterior keratoconus, 6.259
Central posterior surface. *See* Base curve
Central retinal artery (CRA), 5.12, 5.13*f*, 5.14, 5.14*f*, 5.16*f*, 5.17*f*, 10.44–45, 10.45*f*
anatomy of, 12.16
description of, 2.111
lumen of, 2.119
occlusion of. *See* Central retinal artery occlusion
optic nerve supplied by, 5.17*f*, 5.26, 10.44–45, 10.45*f*
retinal inner layers supplied by, 12.140
Central retinal artery occlusion (CRAO), 4.156, 4.157*f*, 7.271
anti-VEGF therapy for, 12.146
causes of, 12.144
ciliary artery occlusion with, 12.144, 12.145*f*
electroretinography findings in, 12.50
emboli as cause of, 12.144
giant cell arteritis as cause of, 12.145
illustration of, 12.16*f*, 12.144*f*
iris neovascularization in, 12.146
management of, 12.146
retinal infarction caused by, 12.143
spectral-domain optical coherence tomography of, 12.144*f*
symptoms and signs of, 12.143
transient visual loss and, 5.161
vision loss caused by, 12.143–144
Central retinal vein (CRV), 2.26*f*, 2.111, 2.120, 5.17*f*, 5.21, 5.21*f*, 10.44, 10.45*f*, 10.46
occlusion of. *See* Central retinal vein occlusion
optic nerve drained by, 5.17*f*, 10.45*f*, 10.46
Central retinal vein occlusion (CRVO), 1.148, 4.156–158, 4.158*f*
aflibercept for, 12.135
age and, 12.133
angle-closure glaucoma and, 10.143–144
neovascularization and, 10.134–135
bevacizumab for, 12.135
causes of, 12.133–134
chronic changes caused by, 12.127*f*
cilioretinal artery occlusion caused by, 12.143
clinical findings of, 12.127*f*, 12.130
complications of, 12.135
corticosteroids for, 12.137–138
cystoid macular edema caused by, 12.136*f*
differential diagnosis of, 12.134
diuretic and, 12.134
electroretinography findings in, 12.50
evaluation of, 12.134–135
follow-up for, 12.134
hypercoagulable conditions presenting with, 12.134
hypertensive retinopathy and, 12.122
hyperviscosity retinopathy *versus*, 12.134
intraocular pressure in, 12.133
iris neovascularization in, 12.133, 12.135
ischemic/complete/nonperfused, 4.156, 4.157–158, 4.158*f*, 12.132*f*
macular laser surgery for, 12.135
management of, 12.134–135
neovascularization in, 12.125
nonischemic, 12.130, 12.131*f*
ocular ischemic syndrome *versus*, 12.134
open-angle glaucoma in, 10.84, 12.133
oral contraceptives and, 12.134
panretinal photocoagulation for, 12.135
papillophlebitis and, 5.125–126, 5.126*f*
pars plana vitrectomy for, 12.135
pharmacologic management of, 12.135–138
progression of, follow-up for, 12.134
ranibizumab for, 12.135
retinal microvascular changes in, 12.125, 12.127*f*
risk factors for, 12.133–134
spontaneous resolution of, 12.125
transient visual loss and, 5.170
treatment of, 12.135
vision loss caused by, 12.130
vitreous hemorrhage secondary to, 12.135
Central scotoma, 5.103, 5.105*t*, 5.106*f*, 6.368, 12.86, 12.265
nonorganic disorders and, 5.306

Central serous chorioretinopathy (CSC)
age and, 12.189
age-related macular degeneration *versus*, 12.67, 12.76, 12.79
autofluorescence abnormalities in, 12.192*f*
choroidal thickening in, 12.191
corticosteroids as cause of, 12.300
demographics of, 12.189–191, 12.190*f*
differential diagnosis of, 12.193–194
discovery of, 12.189
enhanced depth imaging optical coherence tomography findings, 12.67, 12.191, 12.193*f*
fluorescein angiography findings in, 12.190, 12.191*f*
fundus autofluorescence of, 12.32
historical descriptions of, 12.189
imaging of, 12.190–192, 12.191–12.193*f*
indocyanine green angiography of, 12.38, 12.192, 12.194*f*
neovascularization associated with, 12.194
nonneovascular age-related macular degeneration *versus*, 12.67, 12.76
optical coherence tomography of, 12.32
photodynamic therapy for, 12.194
polypoidal choroidal vasculopathy *versus*, 12.193
retinal detachment caused by, 12.189, 12.191
retinal pigment epithelium pigmentation in, 12.190, 12.190*f*
sildenafil as cause of, 12.299
stress and, 12.191
symptoms and signs of, 12.189–190
systemic conditions associated with, 12.191
systemic corticosteroids as risk factor for, 12.191
treatment of, 12.194
visual acuity in, 12.190
white dots with, 12.191, 12.191*f*
Central serous retinopathy (CSR). *See* Central serous chorioretinopathy
Central stromal inflammation, 8.50–52
Central supporting connective tissue strand, 2.112*f*
Central suppression, 6.48
Central suppression scotoma, 4Δ base-out prism test for, 6.79
Central surgical space, 7.12
Central toxic keratopathy, after photoablation, 13.105*f*, 13.105–106
Central Vein Occlusion Study (CVOS), 4.157
Central vestibular instability nystagmus, 6.149
Central vestibular nystagmus, 5.216, 5.243*t*, 5.243–246, 5.245*f*
instability (periodic alternating/PAN), 5.243*t*, 5.245–246, 6.149
Central vision loss. *See* Vision loss/impairment
Central visual field, 3.315, 3.317
in low vision, 5.85, 5.85*f*
Central vitreous, 12.7
Central zone, of cornea, 8.25, 8.25*f*. *See also* Central cornea
Centration, for photoablation, 13.91–92
decentered ablation and, 13.104
Cephalexin, 2.419
for dental prophylaxis, 1.248*t*
Cephalgias, trigeminal autonomic (TACs), 5.293–294
Horner syndrome and, 5.260*t*, 5.261
Cephalosporins, 2.417, 2.419–420. *See also specific agent*
description of, 1.272, 1.272*t*
Haemophilus influenzae treated with, 1.250
after penetrating and perforating trauma repair, 8.409
Cephalothin, 2.420
Cephradine, 2.419
Ceramide trihexoside, 2.235, 12.291
in Fabry disease, 8.176
Cerebellar arteries
anterior inferior (AICA), 5.19*f*, 5.20
cranial nerve relationship and, 5.42*f*
posterior inferior (PICA), 5.19, 5.19*f*, 5.20
superior (SCA), 2.107*f*, 5.18*f*, 5.19*f*, 5.20
cranial nerve relationship and, 5.42*f*
Cerebellar hemangioblastoma, with retinal angiomatosis (von Hippel–Lindau disease), 4.284–285, 5.330, 5.331*f*, 5.334*t*
Cerebellopontine angle tumors
Bruns nystagmus and, 5.243
seventh nerve (facial) palsy and, 5.276–277*f*, 5.278, 5.278*t*, 5.279
sixth nerve (abducens) palsy and, 5.200–201
Cerebellum, 5.33, 5.39–40, 5.41*f*
dysfunction of, in multiple sclerosis, 5.317
saccadic eye movement control and, 5.221
Cerebral achromatopsia, 5.179
Cerebral amyloid angiopathy, 1.120
Cerebral aneurysm, 5.338–342, 5.339*f*, 5.340*f*, 5.341*f*
neuroimaging in diagnosis of, 5.69–70, 5.72*t*, 5.194*f*, 5.194–195, 5.340, 5.341*f*
ruptured, 5.338–339, 5.340, 5.341
third nerve (oculomotor) palsy and, 5.20, 5.339
aberrant regeneration and, 5.198
divisional palsy and, 5.197
pupil-involving, 5.194*f*, 5.194–195, 5.265
pupil-sparing, 5.196
in younger patients, 5.197
Cerebral (intracerebral) angiography/arteriography. *See* Angiography/arteriography
Cerebral aqueduct (Sylvius), 2.107*f*, 5.36*f*, 5.41*f*, 5.192
Cerebral arterial circle, 2.139, 2.139*f*
Cerebral artery
anterior (ACA), 2.139*f*, 5.16*f*, 5.18, 5.27*f*
cranial nerve relationship and, 5.18–19, 5.42*f*
middle (MCA), 5.16*f*, 5.18, 5.18*f*, 5.19, 5.27*f*
anatomy of, 2.106*f*, 2.139*f*
aneurysm of, 1.122, 5.339*f*
cranial nerve relationship and, 5.42*f*
posterior (PCA), 2.106*f*, 2.108*f*, 2.139*f*, 5.12, 5.18, 5.18*f*, 5.19*f*, 5.20
aneurysm of, 5.339*f*
cranial nerve relationship and, 5.42*f*
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 1.111, 5.295
migrainelike headache in, 5.295
Cerebral/cortical blindness, 5.158, 5.336–337
blindsight and, 5.181
denial of (Anton syndrome), 5.158, 5.180–181, 5.337
Cerebral circulation, 1.110
Cerebral (cortical/retrogeniculate) visual impairment (CVI), 6.186–187. *See also* Cerebral/cortical blindness
Cerebral diplopia, 5.185

Cerebral edema, MRI in evaluation of, 5.64*f*, 5.65*t*, 5.66, 5.67*f*, 5.75
Cerebral hemisphere abnormalities, 6.361
Cerebral hypoperfusion, 1.299
Cerebral ischemia. *See also* Ischemic stroke; Stroke
causes of, 1.110–111
MRI in evaluation of, 5.64*f*, 5.65*t*, 5.66, 5.67*f*, 5.75, 5.167
pathogenesis of, 1.110
transient, 1.110
Cerebral palsy, hypoaccommodation in, 6.9
Cerebral peduncles, 2.107*f*, 5.18*f*, 5.34*f*, 5.41*f*
Cerebral ptosis, 5.273
Cerebral vascular system
cavernous sinus, 2.135–136, 2.138*f*
description of, 2.135
venous sinuses, 2.136, 2.138, 2.138*f*
Cerebral vasculitis, 9.170, 12.222
Cerebral vasoconstriction syndrome, reversible (RCVS), 5.346–348, 5.347*f*
Cerebral venography, in cerebral venous thrombosis, 5.346
Cerebral venous thrombosis (CVT), 5.345–346
in idiopathic intracranial hypertension, 5.111
neuroimaging in, 5.69, 5.69*f*, 5.72*t*, 5.346
Cerebrofacial (encephalotrigeminal/encephalofacial) angiomatosis/Sturge-Weber syndrome (SWS), 5.331, 5.332*f*, 5.334*t*, 10.30, 10.155
choroidal hemangioma in, 4.197, 4.281, 5.332*f*, 5.334*t*
description of, 5.331, 5.332*f*, 5.334*t*, 6.199, 6.251, 6.285, 6.349, 6.394*t*, 6.401*t*, 6.401–403, 6.402*f*, 10.30, 10.155, 12.202
port-wine stain (nevus flammeus) in, 8.346
glaucoma associated with, 5.332*f*, 5.334*t*, 10.30, 10.155
in children, 5.332*f*, 10.155
port-wine stain (port-wine nevus/nevus flammeus) in, 5.332*f*, 5.334*t*, 8.346, 10.30, 10.155
Cerebrospinal fluid (CSF)
magnetic resonance imaging of, 2.459*t*
in multiple sclerosis, 5.319
in neuromyelitis optica, 5.322
for syphilis testing, 9.225
Cerebrotendinous xanthomatosis, 6.387*f*
Cerebrovascular accident. *See* Stroke
Cerebrovascular disease. *See also* Ischemia; Stroke
fourth nerve (trochlear) palsy caused by, 5.199
hyperlipidemia and, 1.78
hypertension and, 1.66
internuclear ophthalmoplegia caused by, 5.190
neuro-ophthalmic signs of, 5.335–348
neuroimaging in evaluation of, 5.60*f*, 5.67–71, 5.68*f*, 5.72*t*
sixth nerve (abducens) palsy caused by, 5.200, 5.201, 5.345–346
third nerve (oculomotor) palsy caused by, 5.195, 5.198
transient visual loss caused by, 5.36, 5.161, 5.162, 5.164–165
Cerivastatin, 1.77
Certolizumab, 1.180, 9.110
Cerulean cataract, 11.37, 11.38*f*
Ceruloplasmin, in Wilson disease, 8.189
Cervical cancer
human papillomavirus and, 1.217–218
mortality rates for, 1.217
prevalence of, 1.217
risk factors for, 1.217–218
screening for, 1.216*t*, 1.217–218
Cervical ganglia, 5.53*f*, 5.54
Horner syndrome caused by lesions of, 5.260*t*
Cervical nerve, 5.51*f*, 5.52, 5.276–277*f*
Cervicitis, 1.255
Cervicofacial division, of cranial nerve VII (facial), 5.52
Cervicoplasty, 7.276*f*
Cetamide. *See* Sulfacetamide
Cevimeline, for dry eye, 8.64
C_3F_8. *See* Perfluoropropane
CFEOM. *See* Congenital fibrosis of the extraocular muscles
CFH (complement factor H) gene, 2.183, 12.63
in age-related macular degeneration, 4.160
CGH. *See* Comparative genomic hybridization
CGRP. *See* Calcitonin gene–related peptide
CH_3CO_2H. *See* Acetic acid
CHADS2 risk calculator, 1.103
Chair rotation fixation test, vestibular-ocular response suppression/smooth-pursuit deficits and, 5.225, 5.225*f*, 5.226
Chalasis/conjunctivochalasis, 8.45*t*, 8.85*f*, 8.85–86, 8.114
surgical management of, 8.86, 8.361–362
Chalazion (chalazia), 4.204, 4.206*f*, 6.198–199, 6.199*f*, 6.244, 7.181–183, 7.182–183*f*, 7.191, 7.207, 7.248, 7.248*f*, 8.77
internal hordeolum and, 8.77
in rosacea, 8.70
Chalcosis, 4.120, 11.59, 12.362
corneal deposits/pigmentation in, 8.118*t*
glaucoma and, 10.103
Challenge testing
in contact dermatoblepharitis, 8.287
in hay fever conjunctivitis, 8.288
Chamber angle. *See* Anterior chamber angle
Chamber deepening. *See also* Anterior chamber, flat or shallow
for angle-closure glaucoma, 10.220
Chandler syndrome, 4.100, 8.111, 8.126, 10.136, 10.137*f*. *See also* Iridocorneal endothelial (ICE) syndrome
Chaperone-mediated autophagy, 2.283
Charcot-Marie-Tooth disease, 12.282*t*
Charge-coupled device (CCD), 3.289, 13.10*f*
CHARGE syndrome, 6.364
Charged-particle radiation
for choroidal hemangioma, 4.283
for choroidal melanoma/ciliary body melanoma, 4.276
Charles Bonnet syndrome, 1.206, 3.309, 3.312, 5.177–178, 12.86
Chatter, 11.99, 11.100
Chavasse theory, of infantile esotropia, 6.87
CHD. *See* Coronary heart disease
Checkpoint inhibitors, 7.206, 7.210–211
Checkpoints, in cell cycle, 2.175–176
CHED. *See* Congenital hereditary endothelial dystrophy
CHED1. *See* Posterior polymorphous corneal dystrophy
CHED2. *See* Congenital hereditary endothelial dystrophy
Chédiak-Higashi syndrome (CHS), 6.407, 12.288
Chelation therapy, for band keratopathy, 8.119

Chemical conjunctivitis, 6.239
Chemical energy, 3.106
Chemical injury (burns), 6.376, 8.375–384, 8.376*t*
  acid burns, 8.376*t*, 8.380*f*, 8.380–381, 8.381*f*
  alkali burns, 8.375–380, 8.376*t*, 8.379*f*, 8.380*f*
  amniotic membrane transplantation for, 8.384
  during cataract surgery, corneal edema and, 11.128*t*
  cataracts caused by, 11.59
  classification/grading schemes for, 8.376*t*, 8.376–379, 8.377–378*t*, 8.379*f*
  clinical findings in, 8.376*t*, 8.376–379, 8.377–378*t*, 8.379*f*
  glaucoma and, 10.103–104
  limbal transplantation for, 8.380, 8.384
  management of, 8.381–384, 8.382*f*
  prognostic features of, 8.376*t*
Chemodenervation. *See* Botulinum toxin
Chemokines
  alpha, 9.23*t*
  beta, 9.23*t*
  description of, 9.21
  in external eye defense, 8.12*f*
Chemoreduction. *See* Chemotherapy (cancer)
Chemosis, 8.46*t*
  insect/arachnid injuries causing, 8.386
Chemotactic factors
  definition of, 9.12
  in neutrophil transmigration, 9.12
Chemotaxis, 9.2
Chemotherapy (cancer). *See also specific agent*
  adjuvant, 1.239
  for choroidal/ciliary body melanoma, 4.277
  curative, 1.239
  description of, 1.239–241, 1.240*t*
  for lymphoma, 4.312
  MEK inhibitors, 12.299
  for metastatic eye disease, 4.310
  neoadjuvant, 1.239
  for optic nerve glioma, 5.130
  optic nerve glioma treated with, 7.82–83
  palliative, 1.239, 1.241
  primary vitreoretinal lymphoma treated with, 12.234
  for retinoblastoma, 4.253, 4.299–300, 4.300*f*, 6.356–357
  rhabdomyosarcomas treated with, 7.88–89
  topical
    ocular surface toxicity of, 8.90*t*
    for ocular surface tumors, 8.330*f*, 8.330–332, 8.331*f*
Cherry-red spot
  in central retinal artery occlusion, 4.156, 12.143
  in commotio retinae, 12.353
  in mucolipidoses, 8.178
  ophthalmic artery occlusion and, 12.146
  in Tay-Sachs disease, 12.291, 12.292*f*
Cherry-red spot myoclonus syndrome, 6.388*t*, 6.390
Chest compressions, 1.296–297
Chest radiographs
  congestive heart failure findings, 1.97
  lung disease evaluations, 1.126
CHF. *See* Congestive heart failure
Chi-square test, 1.7
Chiasm (optic), 5.23*f*, 5.27*f*, 5.27–28, 5.28*f*
  anatomy of, 2.108*f*, 2.115–116
  blood supply of, 2.122*t*
  gliomas involving, 5.129, 5.129*f*, 5.130
  lesions of, 5.146–152
    etiology of, 5.147–152
    extrinsic lesions, 5.147–151, 5.149*f*, 5.150*f*
    field loss patterns in, 5.146–147, 5.147*f*, 5.148*f*
    intrinsic lesions, 5.151–152, 152*f*
    in multiple sclerosis, 5.318
    neuroimaging in evaluation of, 5.72*t*, 5.91, 5.148*f*, 5.149*f*, 5.150*f*, 5.152*f*
    in neuromyelitis optica, 5.320
    parasellar lesions, 5.146, 5.150. *See also* Parasellar region, lesions of
Chiasmal glioma, 6.396
Chiasmal neuritis, 5.151–152*f*
Chibroxin. *See* Norfloxacin
Chickenpox. *See* Varicella (chickenpox)
Chikungunya fever, 9.268*f*, 9.268–269
Chikungunya virus retinitis, 12.247
Child abuse
  abusive head trauma, 1.299, 6.381–384, 6.382–383*f*, 12.365–366, 12.366*f*
  ocular trauma caused by, 6.381, 6.384
Childhood absence epilepsy, 1.207
Children. *See also* Infant(s); *specific topic*
  abuse of. *See* Child abuse
  accommodation in, 2.79
  amblyopia in, 6.5
  ametropia correction in, 3.174–175
  anisometropia in, 3.175
    amblyopia caused by. *See* Anisometropic amblyopia
  aspirin in, 2.410
  axial length measurements in, 3.254
  bacterial conjunctivitis in, 6.240*f*, 6.240–241, 8.243, 8.255–256
  cancer in, 1.235
  cardiopulmonary arrest in, 1.296–299, 1.297*t*
  cataract in, 11.34–39, 11.35*t*, 11.36*f*, 11.37*f*, 11.38*f*, 11.39*f*. *See also* Cataract, congenital; Cataract, pediatric
  cataract surgery in, 6.301–305
  clinical/cycloplegic refraction in. *See specific disorder*
  Coats disease in, 4.143, 4.143*f*, 4.295, 4.295*f*, 12.159
    retinoblastoma differentiated from, 4.295, 4.295*f*
  computed tomography in, 7.31
  confrontation visual field testing in, 6.4, 6.10
  congenital toxoplasmosis in, 12.243
  conjunctivitis in, 6.240*f*, 6.240–241. *See also* Conjunctivitis, in children
  corneal transplantation in, 8.450–451
  cytomegalovirus retinitis in, 9.255–256
  decreased/low vision in. *See* Low vision, in infants
  difficult, eye examination in, 6.5
  electroretinography applications in, 12.50
  emmetropia in, 3.141
  enucleation in, 7.137
  examination of, glaucoma and, 10.157*t*, 10.157–160
  eye development abnormalities in. *See specific type and under Congenital*
  eye examination in
    anterior segment examination, 6.10
    Brückner test, 6.9
    communication during, 6.4

cycloplegic refraction, 6.10–12
difficult child, 6.5
distance fixation targets, 6.3, 6.4*f*
dynamic retinoscopy, 6.9
fundus, 6.12
general consideration and strategies for, 6.3–5
intraocular pressure measurement, 6.10
1 toy, 1 look rule, 6.3, 6.4*f*
in outpatient setting, 6.3, 6.4*f*
practitioner positioning during, 6.4
pupil testing, 6.10
red reflex, 6.9
"safe" environment for, 6.4
slit-lamp examination, 6.4–5
tonometry, 6.10
visual acuity assessment. *See* Children, visual acuity assessment in
visual field testing, 6.10
vocabulary during, 6.4
eyedrop administration in, 6.11–12
glaucoma in, 10.4*t*, 10.147–167. *See also* Glaucoma, pediatric
history-taking in, 6.3–5
Horner syndrome in, 5.259, 5.261–262
hyperopia in, 3.141, 3.174–175
hypertension in, 1.68
idiopathic intracranial hypertension in, 5.113
intraocular lens in, 9.315
intraocular pressure in
measurement of, 6.181
normal level of, 6.282
iris heterochromia in, 6.274, 6.274*f*, 6.274*t*
low vision in, 3.327–328
medulloepithelioma in, 4.296
metastatic neuroblastoma in, 7.22*f*
myopia in, 3.142, 3.174
nasolacrimal duct obstruction in, 6.235
nystagmus in, 5.235–239, 5.237*f*, 6.147–157. *See also* Nystagmus
obesity in, 1.68
ocular motor apraxia in, 5.222–223
optic nerve gliomas in, 4.249, 5.129
optic nerve sheath meningioma in, 5.129
optic neuritis in, 6.369, 6.369*f*
orbital floor fractures in, 7.115, 7.116*f*
orbital inflammation in, 6.215–216
orbital tumors in, 4.228, 4.229. *See also* Orbital tumors
overrefraction in, 3.169
perioperative management for ocular surgery in, 1.283
preoperative fasting by, 1.287
preseptal cellulitis in, 8.256
preverbal, visual acuity assessment in, 6.8–9, 6.154
ptosis in, 6.198
refractive surgery in, 13.187–188
rhabdomyosarcoma in, 7.87
slit-lamp examination in, 6.4–5
staphylomas in, 4.112
tetracycline contraindications in, 2.424–425
third nerve (oculomotor) palsy in, 5.197
trauma in, 12.316–317, 12.365–366, 12.366*f*
uveitis in, 9.320
varicella-zoster infection in, 8.225, 8.227
vision impairment in, 3.327
vision rehabilitation in, 6.188–189, 6.189*t*, 9.325
visual acuity assessment in
age-specific approaches, 6.5
alternative methods, 6.8–9
Central, Steady, and Maintained method of, 6.6
eye charts for, 6.6*t*, 6.6–8, 6.7*f*
fixation and following behavior for, 6.5
fixation behavior, 6.5–6
HOTV test, 6.6, 6.6*t*, 6.7*f*
induced tropia test, 6.6
in nystagmus, 6.8
occluders used in, 6.8
optotypes for, 6.6*t*, 6.6–8, 6.7*f*
preferential looking, 6.5, 6.8–9, 6.9*f*, 6.182, 6.300
preverbal children, 6.8–9, 6.154
sequence of, 6.8
symbol charts for, 6.7
visual evoked potential for, 6.9, 6.182, 6.300
visual acuity testing in, 3.38
visual evoked potentials application in, 12.53
visual impairment in, 6.186–187
Children's Oncology Group (COG), 4.301
Chip, in microarray, 4.41
Chlamydia, 8.248–249
conjunctivitis caused by, 4.52, 4.54*f*, 8.208*t*, 8.257*t*, 8.260*t*, 8.260–263, 8.261*f*, 8.262*f*
in adults, 8.257*t*, 8.260, 8.263
in neonates, 8.257*t*, 8.265
gonococcal coinfection and, 8.259
ocular infection/inflammation caused by, 8.208*t*, 8.257*t*, 8.260*t*, 8.260–263, 8.261*f*, 8.262*f*, 8.265
persistence/chronic infection and, 8.207
specimen collection/isolation techniques for diagnosis of, 8.209*t*, 8.211
pneumoniae, 1.155
psittaci. See Chlamydophila psittaci
trachoma caused by, 8.260–263, 8.261*f*, 8.262*f*
trachomatis, 8.208*t*, 8.257*t*, 8.260, 8.260*t*
conjunctivitis caused by, 6.238–239, 6.239*f*, 6.241
gonorrhea and, 1.251
reactive arthritis associated with, 1.155
trachoma caused by, 6.241
transmission of, 1.255
treatment of, 1.255
Chlamydophila psittaci, 8.260
Chloasma, 7.195
Chlorambucil, 1.179, 2.404*t*
for uveitis, 9.110
Chloramphenicol, 1.276, 2.421*t*, 2.425
Chlorhexidine, for *Acanthamoeba* keratitis, 8.278, 8.279
Chloride (Cl), in lens, 11.21
Chloroma (granulocytic sarcoma), 4.316, 6.218
Chloroquine
bull's-eye maculopathy caused by, 12.295, 12.296*f*
indications for, 12.295
retinal pigment epithelium abnormalities caused by, 12.295–297, 12.296*f*
toxicity of, cornea verticillata and, 8.130

Chlorpromazine, 12.297
corneal pigmentation/verticillata caused by, 8.130, 8.132
intraoperative floppy iris syndrome and, 11.136, 11.137*t*
lens changes caused by, 11.52
Chlortetracycline, 2.424
Chlorthalidone, 1.59, 1.65
CHM gene, 12.268
$C_2H_4O_2$. *See* Acetic acid
"Chocolate cysts," 7.74, 8.348
Choking, 1.299
Cholera vaccination, 1.232
Cholesterol, 2.284
drugs for modification of. *See* Lipid-lowering therapy
elevated levels of. *See* Hyperlipidemia
in lecithin-cholesterol acyltransferase deficiency, 8.180
lipoprotein transport of, 1.72
National Cholesterol Education Program guidelines for, 1.71
Cholesterol absorption inhibitor, for hypercholesterolemia, 1.75*t*
Cholesterol crystals, vitreous hemorrhage and, 4.133
Cholesterol emboli (Hollenhorst plaques), 12.141, 12.142*f*, 12.144
in branch retinal artery occlusion, 4.156
transient visual loss and, 5.165, 5.165*f*, 5.166*t*
Cholesterolosis, 12.348
Cholinergic agents. *See also* Muscarinic drugs; Nicotinic drugs; *specific agent*
agonists
direct-acting
acetylcholine, 2.375–377
actions of, 2.375
for acute angle closure, 10.124
adverse effects of, 2.378
for glaucoma, 10.173*t*, 10.181–182
in children, 10.166
indications for, 2.378
pilocarpine, 2.377–378
for dry eye, 8.61*t*, 8.64
indirect-acting, 2.379
mechanism of action, 2.374–375
types of, 2.376*f*
antagonists, 2.380–381
nicotinic
antagonists, 2.382
indirect-acting agonists, 2.381
Cholinergic receptors
description of, 2.374, 2.374*f*, 2.375*t*
drugs affecting. *See* Cholinergic agents
Cholinesterase/acetylcholinesterase inhibitors (anticholinesterase agents)
for Alzheimer disease, 1.210
angle closure caused by, 10.122
cataracts caused by, 11.52
characteristics of, 2.378*t*
for glaucoma, 10.173*t*, 10.181–182
irreversible, 2.379
for myasthenia gravis, 5.324–326
pralidoxime reversal of, 2.379
reversible, 2.379
Chondroid syringoma, 7.192
Chondroitin sulfate, 2.297
in mucopolysaccharidoses, 8.175*t*
as viscoelastic, 11.95
Chondrosarcoma, 7.91
Chopping techniques, in phacoemulsification, 11.114
Chorda tympani, 5.51*f*, 5.276–277*f*
seventh nerve lesions and, 5.276–277*f*
Chordlin-like 1 *(CHRDL1)* gene, in megalocornea, 6.254, 8.96*t*, 8.99
Choriocapillaris, 4.141*f*, 4.182–183
age-related changes in, 12.61
anatomy of, 2.76, 2.77–78*f*, 12.17, 12.19, 12.20*f*
atrophy of, in choroideremia, 12.258
blood flow abnormalities in, 12.198
development of, 2.160–161
ghost vessels in, 12.198
hypertensive choroidopathy findings, 12.123
immune responses of, 9.57–59
immunologic microenvironment of, 9.57
immunoregulatory systems of, 9.59
optical coherence tomography angiography of, 12.30*f*
in pseudoxanthoma elasticum, 12.199*f*
retinal pigment epithelium and, 2.322*f*
in type 1 choroidal neovascularization, 12.71
Chorioretinal atrophy
genes and loci associated with, 12.256*t*
in pathologic myopia, 12.214*f*
Chorioretinal biopsy, 9.91
Chorioretinal coloboma, 6.364
Chorioretinal disruption
traumatic, 12.357*f*, 12.357–358
traumatic (sclopetaria), 4.22
Chorioretinal edema, 12.379
Chorioretinal folds, 12.200–201, 12.201*f*
Chorioretinal inflammation. *See* Chorioretinitis; Chorioretinopathy; *specific disorder*
Chorioretinal lacunae, 6.338, 6.339*f*
Chorioretinal lesions, 9.271, 9.272*f*
Chorioretinal scars/scarring, 9.135*f*
in congenital toxoplasmosis, 12.243
in ocular histoplasmosis syndrome, 12.87
ocular toxoplasmosis/toxoplasmic chorioretinitis and, 4.147, 4.148*f*
Chorioretinal spots, 9.264*f*
Chorioretinitis
acute syphilitic
description of, 9.222, 9.222*f*
posterior placoid, 12.241
Candida, 9.297, 9.298*f*
in Ebola virus survivor, 9.272*f*
focal, 12.238, 12.238*f*
fungal, 4.147, 4.147*f*. *See also specific type*
in neuroretinitis, 12.242
posterior placoid, 9.222, 9.223*f*
relentless placoid, 9.173*f*, 9.173–174
sclopetaria, 4.22
syphilitic, 6.412, 12.241–242, 12.242*f*
Toxoplasma, 6.409, 6.410*f*
toxoplasmic, 4.147–148, 4.148*f*
with uveitis. *See* Posterior uveitis
vitiliginous. *See* Birdshot uveitis
with vitritis, 9.72–73*t*

West Nile virus, 12.246, 12.247*f*
without vitritis, 9.73*t*
Zika virus, 12.247
Chorioretinopathy. *See also* Retinopathy; *specific type*
birdshot, 12.49
central serous
age and, 12.189
age-related macular degeneration *versus*, 12.67, 12.76, 12.79
autofluorescence abnormalities in, 12.192*f*
choroidal thickening in, 12.191
corticosteroids as cause of, 12.300
demographics of, 12.189–191, 12.190*f*
differential diagnosis of, 12.193–194
discovery of, 12.189
enhanced depth imaging optical coherence tomography findings, 12.67, 12.191, 12.193*f*
fluorescein angiography findings in, 12.190, 12.191*f*
fundus autofluorescence of, 12.32
historical descriptions of, 12.189
imaging of, 12.190–192, 12.191–12.193*f*
indocyanine green angiography of, 12.38, 12.192, 12.194*f*
neovascularization associated with, 12.194
nonneovascular age-related macular degeneration *versus*, 12.67, 12.76
optical coherence tomography of, 12.32
photodynamic therapy for, 12.194
polypoidal choroidal vasculopathy *versus*, 12.193
retinal detachment caused by, 12.189, 12.191
retinal pigment epithelium pigmentation in, 12.190, 12.190*f*
sildenafil as cause of, 12.299
stress and, 12.191
symptoms and signs of, 12.189–190
systemic conditions associated with, 12.191
systemic corticosteroids as risk factor for, 12.191
treatment of, 12.194
visual acuity in, 12.190
white dots with, 12.191, 12.191*f*
inflammatory (white dot syndromes). *See specific disorder*
peripheral exudative hemorrhagic (PEHCR), 4.270*f*, 4.271
Choristomas, 4.6, 4.47, 4.49*f*, 5.332, 7.40. *See also* Dermoids
complex, 4.48, 4.49*f*
conjunctival, 4.47, 4.49*f*
description of, 6.223, 6.256
orbital. *See specific type*
osseous, 4.48, 4.49*f*
phakomatous (Zimmerman tumor), 4.202–203, 4.203*f*
Choristomatous tumors, 6.225–226
Choroid, 4.181, 4.181*f*, 4.182–183, 4.183*f*, 5.17*f*. *See also* Uvea (uveal tract)
age-related atrophy of, 12.200, 12.212
amelanotic masses of, 4.263, 4.264*f*, 4.306, 4.306*f*
differential diagnosis of, 4.272*t*
anatomy of, 4.181*f*, 4.182–183, 4.183*f*, 5.17*f*, 12.19–20, 12.20*f*, 12.193*f*
arterial supply to, 12.194, 12.195*f*
autoimmune conditions of
Behçet disease, 12.230, 12.230*t*
inflammatory vasculitis, 12.230–231
intermediate uveitis, 12.231–232
intraocular lymphoma, 12.233–234, 12.234*f*
lupus vasculitis, 12.230–231, 12.231*f*
overview of, 12.229
sympathetic ophthalmia, 12.233
Vogt-Koyanagi-Harada disease, 12.232*f*, 12.232–233
bilateral diffuse uveal melanocytic proliferation effects on, 12.204
blood circulation in, 12.19–20, 12.20*f*, 12.194, 12.195*f*
blood flow in, 2.76
abnormalities of, 12.198
capillary arrangement in, 12.19
choriocapillaris, 2.76, 2.77–78*f*
in choroidal neovascularization, 12.36, 12.37*f*
coloboma of, 4.184, 4.184*f*
detachment of, 4.270, 12.379, 12.379*f*
melanoma differentiated from, 4.270–271
development of, 2.160–161
diseases of. *See also* Chorioretinitis; Chorioretinopathy; Choroiditis; Choroidopathy; *specific type*
bilateral diffuse uveal melanocytic proliferation, 12.204–205, 12.205*f*
central serous chorioretinopathy. *See* Central serous chorioretinopathy
hemangiomas, 12.202*f*, 12.202–203
inflammatory, posttraumatic granulomatous, 4.22, 4.22*f*
nonarteritic, 12.195–196, 12.197*f*
perfusion abnormalities, 12.194, 12.195–12.197*f*, 12.199–12.200*f*
uveal effusion syndrome, 12.203, 12.204*f*
edema of, 2.378
enhanced depth imaging optical coherence tomography of, 12.25, 12.193*f*
filling defects in, 12.198
focal posttraumatic granulomatous inflammation of, 4.22, 4.22*f*
folds in, 12.200–201, 12.201*f*
functions of, 2.76, 12.212
gyrate atrophy of, 2.204*t*
Haller layer, 12.19
healing/repair and, 4.16
as heat sink, 12.20
hemangiomas of, 4.197, 4.198*f*, 4.281–283, 4.282*f*, 4.283*f*
in Sturge-Weber syndrome, 4.197, 4.281, 5.332*f*, 5.334*t*
immune responses of, 9.57–59
immunologic microenvironment of, 9.52*t*, 9.57–58
immunoregulatory systems of, 9.59
inflammation of
infectious causes, 12.235–247
noninfectious causes, 12.219–234
white dot syndromes as cause of. *See* White dot syndromes
inner structure of, 12.193*f*
innervation of, 2.76
ischemia of, illusions and, 5.175
layers of, 2.76

in leukemia, 4.315
lymphoma of (uveal lymphoid proliferation/hyperplasia/infiltration), 4.199, 4.199*f*, 4.313–314
magnetic resonance imaging of, 2.459*t*
mast cells in, 9.58
melanocytoma of, 4.192, 4.258
melanoma of, 2.471*f*, 4.106, 4.106*f*, 4.192*f*, 4.192–197, 4.193*f*, 4.194*f*, 4.195*f*, 4.196*f*, 4.253, 4.262–279. *See also* Choroidal melanoma/ciliary body melanoma
classification of, 4.194, 4.271–272, 4.272*t*
clinical characteristics of, 4.262–263, 4.264*f*
diagnosis of, 4.263*f*, 4.264*f*, 4.264–267, 4.266*f*, 4.267*f*
differential, 4.267–271, 4.269*f*, 4.270*f*
enucleation for, 4.196, 4.274–275
glaucoma caused by, 4.105*f*, 4.106, 4.194, 10.99, 10.99*f*
metastatic, 4.196, 4.272–274, 4.273*t*, 4.306
prognosis/prognostic factors for, 4.194–197, 4.273*t*, 4.277–279
transpupillary thermotherapy for, 4.276
treatment of, 4.253, 4.274–277, 4.275*f*
nevus of, 4.191, 4.192*f*, 4.256–258, 4.257*f*, 4.267–268
melanoma differentiated from, 4.267–268
osteoma of, 4.198–199, 4.270*f*, 4.271
melanoma differentiated from, 4.270*f*, 4.271
in pathologic myopia, 12.212–216, 12.214–12.215*f*
perfusion of, 2.76
posttraumatic granulomatous inflammation of, focal, 4.22, 4.22*f*
retinal metabolic needs supplied by, 12.20
retinoblastoma invading, 4.177, 4.177*f*
rupture of, 4.22, 4.22*f*, 12.88, 12.354–12.356*f*, 12.354–355
Sattler layer, 12.19
stroma of, 2.77, 4.182
in Sturge-Weber syndrome, 4.197, 4.281
subfoveal thickness of, 12.19
thickness of
description of, 12.19
measurement of, 12.212
subfoveal, 12.212, 12.214*f*
thinning of, 12.214
topography of, 4.181*f*, 4.182–183, 4.183*f*
trauma-related rupture of, 12.354–12.356*f*, 12.354–355
tuberculosis involvement of, 9.236–237*f*
tumors of, 4.191–197. *See also* Choroidal melanoma/ciliary body melanoma; *specific type*
glaucoma caused by, 10.99, 10.99*f*
metastatic, 4.197, 4.198*f*, 4.303, 4.304*t*, 4.306*f*, 4.307*f*, 4.308*f*, 4.308*t*
melanoma differentiated from, 4.270*f*, 4.271, 4.306
ultrasound biomicroscopy of, 2.472*f*
in uveitis. *See* Posterior uveitis
vasculature of, retina supplied by, 4.139–140
ischemia and, 4.140, 4.151, 4.151*f*
venous pressure increases in, 12.198
vessels of, 2.76–77
vortex veins in, 12.19
Choroidal arteries
anterior, 5.16*f*, 5.18, 5.18*f*
posterior/posterior lateral, 5.18*f*, 5.19*f*
Choroidal detachment, 12.379, 12.379*f*
Choroidal dystrophies
Bietti crystalline dystrophy, 12.258, 12.269, 12.282*t*
central areolar, 12.277
choroidemia, 12.267–268, 12.268*f*
classification of, 12.255
gyrate atrophy, 12.268–269, 12.269*f*
Choroidal effusions
angle-closure glaucoma and, 10.141, 10.142*f*, 10.144, 10.145, 10.145*f*
bupropion as cause of, 12.306
in carotid-cavernous fistula, 5.205, 5.205*f*
contact B-scan ultrasonography of, 12.39*f*
after filtering surgery, 10.210–211
Choroidal granuloma, 12.241*f*
Choroidal hemangioma, 6.401
Choroidal hemorrhage/suprachoroidal hemorrhage, 4.18, 4.19*f*
angle-closure glaucoma and, 10.141, 10.142*f*, 10.144, 10.145, 10.145*f*
cataract surgery and, 11.159, 11.171
delayed, 11.160
expulsive, 11.159–160
flat or shallow anterior chamber and, 11.134
expulsive, 4.18, 4.19*f*
cataract surgery and, 11.159–160
after filtering surgery, 10.210–211
Choroidal lesions, 6.349–350
Choroidal melanoma/ciliary body melanoma (posterior uveal melanoma), 4.106, 4.106*f*, 4.192*f*, 4.192–197, 4.193*f*, 4.194*f*, 4.195*f*, 4.196*f*, 4.253, 4.262–279, 7.136, 9.308
age-related macular degeneration differentiated from, 4.269, 4.270*f*
chemotherapy for, 4.277
classification of, 4.194, 4.271–272, 4.272*t*
clinical characteristics of, 4.262–263, 4.263*f*, 4.264*f*
congenital hypertrophy of retinal pigment epithelium differentiated from, 4.144, 4.268–269, 4.269*f*
diagnosis of, 4.263*f*, 4.264*f*, 4.264–267, 4.266*f*, 4.267*f*
differential, 4.267–271, 4.269*f*, 4.270*f*
enucleation for, 4.196, 4.274–275
epithelioid cell, 4.192, 4.193*f*, 4.194, 4.195
exenteration for, 4.277
fine-needle aspiration biopsy in identification/evaluation of, 4.42, 4.43*f*, 4.253
glaucoma caused by, 4.105*f*, 4.106, 4.194, 10.99, 10.99*f*, 10.138
immunotherapy for, 4.277
melanocytoma differentiated from, 4.268
metastatic, 4.196, 4.272–274, 4.273*t*, 4.306
mixed-cell type, 4.194, 4.195
nevus differentiated from, 4.267–268
observation in management of, 4.274
ocular surface/conjunctival involvement and, 4.68, 4.69*f*, 8.343
prognosis/prognostic factors for, 4.194–197, 4.273*t*, 4.277–279
risk factors for, 4.262, 4.268
spindle cell, 4.192*f*, 4.192–193, 4.194, 4.195
staging of, 4.271–272, 4.273*t*
surgical excision of, 4.277

transpupillary thermotherapy for, 4.276
treatment of, 4.253, 4.274–277, 4.275*f*
Choroidal neovascular membranes (CNVMs), 6.342, 6.343*f*
Choroidal neovascularization (CNV), 2.99, 2.449, 3.115. *See also* Neovascularization
in acute posterior multifocal placoid pigment epitheliopathy, 12.222
in age-related macular degeneration, 4.161*f*, 4.164–166, 4.165*f*, 12.64
anatomical classification of, 12.71–75
angioid streaks as cause of, 12.87–89, 12.89*f*
anti-VEGF therapy for, 12.87–88, 12.212, 12.355
bevacizumab for, 12.73*f*, 12.213*f*
after Bruch membrane damage, 12.355, 12.355*f*
classic, 12.72, 12.73*f*
conditions associated with, 12.90*t*
fluorescein angiography of, 12.36, 12.37*f*, 12.72–73, 12.73–12.74*f*
green laser for, 12.373
idiopathic, 12.89–90
indocyanine green angiography of, 12.73
laser photocoagulation for, 12.376
late leakage from an undetermined source, 12.72
miscellaneous causes of, 12.89–90
in multifocal choroiditis and panuveitis syndrome, 9.180*f*, 9.181
multifocal choroiditis in, 12.226, 12.226*f*
occult, 12.72–73
ocular histoplasmosis syndrome-associated, 9.274, 12.86–87, 12.88*f*
optical coherence tomographic angiography of, 12.75–76, 12.76–12.78*f*, 12.192
optical coherence tomography of, 12.192, 12.194
in pathologic myopia, 12.89, 12.211*f*, 12.211–212
photocoagulation for, 12.376
photodynamic therapy for, 12.212, 12.213*f*, 12.380
polypoidal choroidal vasculopathy and, 4.166
prevalence of, 9.325
in punctate inner choroiditis, 9.182
retinal pigment epithelium tears in, 12.31
scar tissue *versus*, 12.73
serpiginous choroiditis and, 9.175
signs and symptoms of, 12.71
spectral-domain optical coherence tomography of, 12.73–75, 12.75*f*
subfoveal, 12.355, 12.380
subretinal hemorrhages *versus*, 12.211
susceptibility genes for, 12.63
treatment of, 9.325
type 1, 4.165, 4.165*f*, 12.71–72, 12.72*f*, 12.76*f*
type 2, 4.165, 4.165*f*, 12.72, 12.75, 12.77*f*
type 3, 12.72–73, 12.75, 12.78*f*
in uveitis, 9.324–325
vascular endothelial growth factor concentrations in, 12.80
vitelliform exudative macular detachment *versus*, 12.272
vitreous hemorrhage secondary to, 12.231*f*
Choroidal nevi
description of, 6.349
scanning laser ophthalmoscopy of, 12.24
Choroidal osteoma, 6.349
Choroidal scars, 9.274
Choroidal tubercles, 9.236, 9.237*f*
Choroidal vasculitis, 1.171
Choroidal vasculopathy, polypoidal (PCV/posterior uveal bleeding syndrome), 4.166*f*, 4.166–168, 4.167*f*. *See also* Polypoidal choroidal vasculopathy
Choroidal vein, 5.21
Choroideremia, 2.232*t*, 12.267–268, 12.268*f*
choriocapillaris atrophy in, 12.258
electroretinography findings in, 12.50
Choroiditis. *See also* Choroidopathy; Posterior uveitis
birdshot uveitis in, 12.225, 12.225*f*
Cryptococcus neoformans, 9.333
geographic. *See* Serpiginous choroiditis
macular, 9.274*f*
multifocal (MFC), 6.319, 12.220*t*, 12.225–226, 12.226*f*
with panuveitis (MCP/MFCPU), 12.226*f*. *See also* Multifocal choroiditis and panuveitis syndrome
Pneumocystis jirovecii, 9.332, 9.332*f*
punctate inner (PIC), 12.225. *See also* Multifocal choroiditis; Punctate inner choroiditis/choroidopathy
serpiginous. *See* Serpiginous choroiditis
serpiginous-like, 9.177, 9.236, 9.237*f*
Choroidopathy. *See also* Choroiditis
central serous. *See* Chorioretinopathy, central serous
geographic. *See* Serpiginous choroidopathy
helicoid peripapillary. *See* Serpiginous choroidopathy
hypertension, 12.123–124*f*
punctate inner (PIC), 12.225. *See also* Multifocal choroiditis; Punctate inner choroiditis/choroidopathy
CHRDL1 gene, 6.254
in megalocornea, 8.96*t*, 8.99
"Christmas tree" cataracts, in myotonic dystrophy, 5.330
Chromatic aberration, 3.40, 3.72, 3.166, 3.199
Chromogens, in immunohistochemistry, 4.33, 4.35*f*
Chromogranin, in immunohistochemistry, 4.34
Chromophores, 3.115, 3.119
ultraviolet-absorbing, IOLs with, 11.120
Chromosomal aneuploidy. *See specific disorder*
Chromosomal crossing over, 2.175
Chromosomal defects, 2.221
Chromosomal nondisjunction, 2.216*f*
Chromosome analysis
aneuploidy of autosomes, 2.222–224
chromosome arm painting, 2.221–222, 2.222*f*
description of, 2.221
fluorescence in situ hybridization for, 2.221–222
indications for, 2.221
mosaicism, 2.224–225
types of, 2.221–222
Chromosome arm painting (CAP), 2.221–222, 2.222*f*
Chromosomes
abnormalities of, 6.385, 6.386*t*. *See also specific type*
in aniridia, 2.225–226
ocular manifestations of diseases due to. *See specific disease*
description of, 2.213
gene assignments, 2.187
homologous, 2.215–216
nonhomologous, 2.216
numbering of, 2.176

sex
aneuploidy of, 2.223
mosaicism, 2.225
structure of, 2.177*f*
Chronic anterior uveitis. *See* Anterior uveitis, chronic
Chronic Arthus reaction, 9.42
Chronic bronchitis, 1.124
Chronic cyclitis. *See* Pars planitis
Chronic dacryocystitis, 7.315
Chronic disseminated intravascular coagulation, 1.146
Chronic fungal postoperative endophthalmitis, 9.292–293
Chronic hemolytic anemia, 1.135
Chronic hypertension, 1.67–68
Chronic inflammation, local antibody production in, 9.42
Chronic kidney disease. *See* Renal diseases
Chronic necrotizing aspergillosis, 7.52
Chronic obstructive pulmonary disease (COPD)
description of, 1.124
Global Initiative for Chronic Obstructive Lung Disease resources on, 1.124
obstructive sleep apnea and, 1.124–125
ocular surgery in patient with, cataract surgery, 11.170
perioperative management for ocular surgery in patients with, 1.284
Chronic papillary conjunctivitis, 7.185
Chronic peripheral rhegmatogenous retinal detachment, 9.311
Chronic progressive external ophthalmoplegia (CPEO), 5.328–329, 5.329*f*, 6.141–142, 6.143*t*, 12.293–294
description of, 2.185
mitochondrial DNA mutations in, 2.185
ptosis in, 5.273, 5.273*t*, 5.328, 5.329*f*
Chronic relapsing inflammatory optic neuropathy (CRION), 5.116
Chronic renal disease, 1.65
Chronic renal failure, 1.137
Chronic thyroiditis, 1.45
Chronic uveitis
calcific band keratopathy associated with, 9.313
definition of, 9.75–76
signs and symptoms of, 9.72*t*
systemic corticosteroids for, 9.102–103
Chronic Uveitis Evaluation of the Intravitreal Dexamethasone Implant study, 9.99*t*
CHRPE. *See* Congenital hypertrophy of retinal pigment epithelium
Chrysiasis, corneal deposits/pigmentation in, 8.118*t*
CHS. *See* Chédiak-Higashi syndrome
CHSD. *See* Congenital hereditary stromal dystrophy
CHST6 (carbohydrate sulfotransferase 6) gene, in macular dystrophy, 4.91, 8.136*t*
Churg-Strauss syndrome, 9.125*t*. *See also* Eosinophilic granulomatosis with polyangiitis
Chylomicrons, 1.72
Chymotrypsin (α-chymotrypsin), for ICCE, 11.195, 11.200
CI. *See* Convergence insufficiency
Ciancia syndrome, 6.88, 6.95
Cicatricial ectropion
clinical features of, 7.230*f*
surgical repair of, 7.233*f*, 7.233–234
Cicatricial entropion, 7.237–238*f*, 239
Cicatricial pemphigoid. *See* Mucous membrane (ocular cicatricial) pemphigoid
Cicatricial retinal detachment, 12.286
Cicatrization, 7.219
conjunctival, 8.47*t*. *See also* Conjunctivitis, cicatrizing; Mucous membrane (ocular cicatricial) pemphigoid
Cidofovir, 2.432*t*, 2.436
for herpes simplex virus, 1.260
Cigarette burns, 6.376
Cigarette smoking. *See* Smoking
CIGTS (Collaborative Initial Glaucoma Treatment Study), 10.81, 10.111, 10.187
Cilastatin, 1.273
Cilia (eyelashes), 2.28, 4.201, 7.170, 8.3, 8.4*f*
accessory. *See* Distichiasis
entropion/ptosis of. *See* Trichiasis
lice infestation of, 8.255
misdirection of. *See* Trichiasis
in staphylococcal blepharitis, 8.72*f*, 8.73*t*, 8.74, 8.254
Ciliary arteries. *See also* Cilioretinal artery
anatomy of, 2.22
anterior, 2.22, 2.24*f*, 5.14*f*, 5.14–15
description of, 6.23
long, 5.13*f*, 5.14*f*, 5.15, 5.15*f*
occlusion of, 12.144, 12.145*f*
optic nerve supplied by, 10.44–46, 10.45*f*
posterior, 2.23–24*f*, 5.15–17, 5.17*f*
short, 5.13*f*, 5.14*f*, 5.15–17, 5.17*f*
Ciliary block, after cataract surgery, flat or shallow anterior chamber and, 11.135
Ciliary block glaucoma (malignant glaucoma/aqueous misdirection), 2.378, 10.32, 10.139–141, 10.140*f*
cataract surgery and, 10.139, 11.139
in children and adolescents, 10.149*t*
after penetrating keratoplasty, 8.424
Ciliary body, 4.97*f*, 4.98*f*, 4.181, 4.181*f*, 4.182, 4.183*f*, 12.40. *See also* Uvea (uveal tract)
anatomy of, 2.48*f*, 4.97*f*, 4.98*f*, 4.181*f*, 4.182, 4.183*f*
apex of, 2.72
aqueous humor production by, 2.269
arterial supply to, 2.75
cyclodestruction of, 10.194–196, 10.195*f*
cytochrome P450, 2.270
definition of, 2.72
development of, 2.157, 2.159*f*, 2.160
drug targeting of, for glaucoma, 2.269
epithelial cells of, 2.72, 2.73f
epithelium of. *See* Ciliary epithelium
fenestrated capillaries in, 9.56
functions of, 2.72, 2.269
healing/repair and, 4.16
hyalinization of, 4.189, 4.189*f*
medulloepithelioma arising in, 4.296, 4.296*f*
melanocytoma of, 4.192, 4.258, 4.268
melanoma of, 4.106, 4.106*f*, 4.192*f*, 4.192–197, 4.193*f*, 4.194*f*, 4.195*f*, 4.196*f*, 4.253, 4.262–279, 7.136, 9.308. *See also* Choroidal melanoma/ciliary body melanoma
classification of, 4.194, 4.271–272, 4.272*t*
clinical characteristics of, 4.262, 4.263*f*
diagnosis of, 4.263*f*, 4.264*f*, 4.264–267, 4.266*f*, 4.267*f*
differential, 4.267–271, 4.269*f*, 4.270*f*

glaucoma caused by, 4.105*f*, 4.106, 4.194, 10.99, 10.99*f*, 10.138
metastatic, 4.196, 4.272–274, 4.273*t*
prognosis/prognostic factors for, 4.194–197, 4.273*t*, 4.277–279
treatment of, 4.253, 4.274–277, 4.275*f*
neoplastic disorders of, 4.191–197. *See also* Choroidal melanoma/ciliary body melanoma; *specific type*
glaucoma and, 10.99, 10.99*f*
metastatic, 4.303, 4.304
neuroendocrine peptides in, 2.276
nevus of, 4.191, 4.256
oxidation-reduction enzymes in, 2.270
oxidative stress and, 2.269
pars plana of, 2.72
pars plicata of, 2.72, 2.73*f*, 2.100*f*, 2.472*f*
physiology of, 2.269–270
pigmented epithelium of, 2.73
protein synthesis in, 2.275
smooth muscle fibers in, 2.75*f*
stroma of, 2.73
supraciliary space, 2.76
tear in (angle recession), 4.18, 4.19*f*, 4.103–104
glaucoma and, 4.18, 4.103–104, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*
topography of, 4.181*f*, 4.182, 4.183*f*
tumors of, 6.273*f*, 6.273–274
ultrasound biomicroscopy of, 2.471–472*f*, 8.21
in uveitis. *See* Intermediate uveitis
Ciliary body band, 10.33*t*, 10.34*f*
Ciliary epithelium
aqueous humor formation/dynamics and, 10.5*f*, 10.13–16, 10.14–15*f*
description of, 2.270, 2.273
neuroendocrine properties of, 2.274, 2.276
nonpigmented, benign adenomas of, 4.279
pigmented
acquired hyperplasia of, 4.279, 4.280*f*
benign adenomas of, 4.279
secretory properties of, 2.273
Ciliary flush, in herpetic epithelial keratitis, 8.217
Ciliary ganglion, 5.45, 5.48*f*, 5.55, 5.55*f*, 8.5*f*
Adie tonic pupil and, 5.263, 5.264, 5.264*f*, 5.265
anatomy of, 2.16*f*, 2.107*f*, 2.128*f*
branches of, 2.15–16
motor root of, 2.15, 2.16*f*
parasympathetic fibers in, 2.15
roots of, 2.15, 2.16*f*
sensory root of, 2.15, 2.16*f*
sympathetic fibers in, 2.15
sympathetic root of, 2.15, 2.16*f*
Ciliary margin, 7.170
Ciliary muscle, 6.20
in accommodation, 11.22–23, 11.23*t*, 13.159, 13.160, 13.160*f*, 13.161*f*
contraction of, 2.79
development of, 2.160
direct-acting cholinergic agonists' effect on, 2.375
fibers of, 2.75–76, 2.375
layers of, 2.75–76
miotic/muscarinic agents affecting, 10.181
muscarinic antagonists' effect on, 2.380–381
stimulation of, for accommodative esotropia, 2.379
Ciliary muscle spasm (spasm of accommodation), 3.176, 5.310
Ciliary nerves
branches of, 2.58
long, 2.254*f*, 5.53*f*
lacrimal functional unit innervated by, 8.5*f*
posterior, 5.55
short, 2.16, 5.55*f*
Adie tonic pupil and, 5.263, 5.264, 5.264*f*, 5.265
Ciliary neurotrophic factor, 2.332
Ciliary processes, 10.13, 10.15*f*
in aqueous humor formation, 10.5*f*, 10.13–16, 10.14–15*f*
description of, 2.72
development of, 2.159*f*
plateau iris and, 10.120
Ciliary spasm, 6.94
Ciliary sulcus, 2.60*f*
Ciliochoroidal effusion, 6.284
Ciliopathies, 6.336, 6.391–392, 6.391–392*f*
Cilioretinal artery, 5.17
anatomy of, 12.16, 12.16*f*
occlusion of, 12.143
Ciliospinal center of Budge-Waller, 5.53*f*
Ciloxan. *See* Ciprofloxacin
Cimetidine, for conjunctival papillomas, 8.238, 8.239, 8.333
CIN. *See* Conjunctival or corneal intraepithelial neoplasia; Corneal intraepithelial neoplasia
Cingulate gyrus, 5.52
CIPA. *See* Congenital insensitivity to pain with anhidrosis
Ciprofloxacin, 1.274, 1.308*t*
for bacterial keratitis, 8.269, 8.270*t*
corneal deposits caused by, 8.131, 8.131*f*
description of, 2.421*t*, 2.422
for gonococcal conjunctivitis, 8.259
Ciraparantag, 1.149
Circadian variation, in intraocular pressure, 10.3, 10.8, 10.22, 10.80–81, 10.81*t*, 10.86, 10.87
Circinate balanitis, 9.133
Circle of least confusion, 3.76, 3.76*f*
Circle of Willis, 2.138–139, 2.139*f*, 5.18
subarachnoid hemorrhage from, 1.121
Circle of Zinn-Haller (circle of Haller and Zinn/circle of Zinn), 2.120, 2.122*f*, 5.17, 10.44, 10.46, 12.217
Circular aperture, diffraction created by, 3.105, 3.105*f*
Circular ciliary muscle, 2.25*f*
Circular venous plexus, 5.23*f*
Circularly polarized light, 3.98
Circulation
choroid, 12.19–20
retinal, 12.16*f*, 12.16–17
Circumcorneal conjunctival hyperemia, 9.232
Circumscribed (localized) choroidal hemangioma, 4.197, 4.198*f*, 4.281, 4.282*f*
Circumscribed iris nevus, 4.255, 4.256*f*
CIS. *See* Clinically isolated syndrome
11-*cis*-retinaldehyde, 2.307, 2.326, 2.333*t*, 12.17
11-*cis*-retinol dehydrogenase, 12.252
Cisterns, in vitreous, 12.7
Citric acid/sodium citrate, for chemical injuries, 8.383
Citrobacter, 8.247

CJD. *See* Creutzfeldt-Jakob disease
CK. *See* Conductive keratoplasty
Cl. *See* Chloride
CLs. *See* Contact lenses
Clarithromycin, 2.427
  for bacterial keratitis, 8.270*t*
  dental prophylaxis uses of, 1.248*t*
  indications for, 1.275
Clarity, optical, of ophthalmic viscosurgical device, 11.97
Class I–dependent antigen-presenting cells, 9.31*f*
Class II–dependent antigen-presenting cells, 9.30, 9.32*f*
Classic granular corneal dystrophy (granular corneal dystrophy type 1/GCD1), 4.88–90, 4.89*f*, 4.90, 4.90*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.145–148, 8.146–148*f*
Classic pathway activation, of complement, 9.17, 9.18*f*
"The Classification of eye movement abnormalities and strabismus (CEMAS)," 5.234
Claude syndrome, 5.191
Claudication, jaw/tongue, in giant cell arteritis, 5.313
Claustrophobia, cataract surgery in patient with, 11.169
Clavulanic acid, 1.273. *See also specific antibiotic combination*
"Claw" haptics, for iris-fixated phakic IOL, 13.141
Clear corneal incision
  for cataract surgery, 11.106*f*, 11.106–107
    in glaucoma, 11.186
    after radial keratotomy, 11.177, 13.53
    with trabeculectomy, 10.213
  for posterior chamber phakic IOL implantation, 13.142–143
Cleft syndromes. *See* Craniofacial malformations
Cleocin. *See* Clindamycin
Climatic droplet (actinic/Labrador) keratopathy (spheroidal degeneration), 4.83, 4.83*f*, 8.115–117, 8.116*f*
Climatotherapy, for vernal keratoconjunctivitis, 8.291
Clindamycin, 2.418*t*
  dental prophylaxis uses of, 1.248*t*
  indications for, 1.275
  for necrotizing fasciitis, 7.49
  for ocular toxoplasmosis, 9.281
  for toxoplasmic retinochoroiditis, 12.243
  for toxoplasmosis, 6.410
Clinical Activity Score (CAS), 7.58, 7.59*t*
Clinical genetics
  chromosome analysis. *See* Chromosome analysis
  chromosomes, 2.213–217
  expressivity, 2.220
  genes, 2.213–217
  inheritance patterns. *See* Inheritance
  lyonization, 2.230–231, 2.231*f*
  meiosis, 2.215, 2.216*f*
  mitosis, 2.215
  mutations, 2.217–220. *See also* Mutation
  overview of, 2.199–200
  pedigree analysis in, 2.200–201, 2.201*f*
  penetrance, 2.219
  pleiotropism, 2.220
  terminology associated with, 2.210–212
Clinical history method, for IOL power calculation after refractive surgery, 13.194. *See also* Historical methods
Clinical Laboratories Improvement Amendments, 2.241
Clinical questions
  examples of, 1.3
  researching answers to
    information sources used in, 1.3
    overview of, 1.3–4
Clinical refraction. *See* Refraction, clinical
Clinical studies
  absolute risk reduction, 1.22
  case-control series, 1.10–12, 1.11*f*
  case reports, 1.9
  case series, 1.9–10
  clinical practice measurements and improvements using
    continuous quality improvement, 1.28–31
    data used in, 1.23–24
    lean techniques for, 1.31–32
    measurement system, 1.24–25
    monitoring system implementation, 1.25–27
    quality improvements, 1.25
    results analysis, 1.27–28
  cohort studies, 1.11*f*, 1.12–13
  conflict of interest, 1.7–8
  control groups in, 1.4
  critical reading of
    recruitment strategy for, 1.4–5
    study population, 1.4–5
  cross-sectional studies, 1.12
  data from
    continuous, 1.7
    extrapolation of, 1.5
    normal distribution of, 1.7
  design of. *See specific type of study*
  diagnostic and screening test interpretation
    clinical acceptance, 1.21
    combination use of tests, 1.20–21
    complicating factors in, 1.16–21
    ethics of testing, 1.21
    generalizability, 1.21
    overview of, 1.15–16
    pretest probability of disease, 1.18–21, 1.20*t*
    receiver operating characteristic curves, 1.16–18, 1.18*f*
  experimental, 1.8
  follow-up, 1.6
  hierarchy of, 1.9*f*
  "intention to treat" analysis, 1.6
  investigator bias in, 1.5
  meta-analyses, 1.3, 1.8
  nonexperimental, 1.8
  number needed to treat, 1.22
  observational, 1.8
  odds ratios, 1.22–23
  outcomes of
    baseline probability of, 1.22
    as clearly defined, 1.6
    clinical relevance of, 1.5
    reliability of, 1.6
  population used in
    evaluation of, 1.4–5
    random assignment of, 1.4
    recruitment strategy for, 1.4–5
    vulnerable, 1.4

relative risk, 1.22
reproducibility of, 1.5
risk difference, 1.22
sample size of, 1.5
selection bias in, 1.4
validity of
criteria for, 1.6
follow-up and, 1.6
Clinical trials
case series *versus*, 1.9
cohort studies *versus*, 1.13, 1.13*f*
evaluation of, 1.14
meta-analyses of, 1.14
random assignment in, 1.13
in retinoblastoma treatment, 4.301
Clinically isolated syndrome (CIS), 5.114. *See also* Optic neuritis
multiple sclerosis treatment and, 5.320
Clinically significant diabetic macular edema (CSME), 12.92, 12.110, 12.114. *See also* Diabetic macular edema
Clinically significant retinopathy of prematurity (CSROP), 12.184*t*. *See also* Retinopathy of prematurity
Clinoid process, anterior, 5.6*f*, 5.7*f*, 5.9*f*, 5.16*f*, 5.43*f*
Clivus (umbo), 5.5
anatomy of, 12.9, 12.9*f*
characteristics of, 12.10*t*
Clobetasone, for atopic dermatitis, 8.287
Clofazimine, 12.298
corneal pigmentation caused by, 8.132
Clomiphene, 1.309*t*
Clonazepam, for nystagmus, 5.245
Clopidogrel. *See also* Dual antiplatelet therapy
for stroke prevention, 1.114
Cloquet (hyaloid) canal, 2.157, 4.125
anatomy of, 12.7, 12.8*f*
formation of, 12.341
Closed-circuit televisions, 3.310, 3.323
Closed-loop intraocular lenses, pseudophakic bullous keratopathy and, 11.149
Closed-loop speculum, for globe exposure, in cataract surgery, 11.105*f*
Clostridium
botulinum, 2.443
toxin derived from. *See* Botulinum toxin
difficile, 1.249
reactive arthritis associated with, 1.155
vancomycin for, 1.273
Clotting. *See* Coagulation
Cloverleaf visual field (artifact), in perimetry, 10.66, 10.66*f*
Clozapine, 1.200
Clump cells, in iris, 4.181
Cluster A, B, and C personality disorders, 1.198
Cluster headache, 5.289*t*, 5.294
Horner syndrome and, 5.260*t*, 5.261, 5.294
CME. *See* Cystoid macular edema
CMN. *See* Congenital motor nystagmus
CMV. *See* Cytomegalovirus
CN. *See* Congenital nystagmus
CNLDO. *See* Congenital nasolacrimal duct obstruction
CNS. *See* Central nervous system
CNs. *See* Cranial nerve(s)
CNTGS (Collaborative Normal-Tension Glaucoma Study), 10.87–88
CNV. *See* Choroidal neovascularization
CNVMs. *See* Choroidal neovascular membranes
Co-contractive retraction with jaw-eyelid synkinesis syndrome (CCRS/Marcus Gunn jaw-winking syndrome/ptosis), 5.272, 5.272*f*
CO_2 lasers. *See* Carbon dioxide (CO_2) lasers
Coagulation. *See also* Hemostasis
disorders of. *See* Coagulation disorders; Hemostasis, disorders of; Hypercoagulable states
laboratory evaluation of, 1.139–140
Coagulation cascade
description of, 1.89, 1.90*f*
extrinsic pathway of, 1.138*f*
intrinsic pathway of, 1.138*f*
schematic diagram of, 1.138*f*
Coagulation disorders
acquired, 1.145–146
cataract surgery in patient with, 11.171–172
disseminated intravascular coagulation, 1.142, 1.145–146
hemophilia A, 1.144
hereditary, 1.144–145
liver disease, 1.145
thrombotic disorders, 1.146
transient visual loss and, 5.171
vitamin K deficiency, 1.145
von Willebrand disease, 1.144–145
Coagulation factors, 1.138
Coarctation of the aorta, 1.54
Coatability, of ophthalmic viscosurgical device, 11.97
Coats disease, 2.470*f*, 4.143, 4.143*f*, 4.295, 4.295*f*, 12.159–161, 12.160*f*, 12.326
clinical findings of, 6.358, 6.359*f*
diagnosis of, 6.359–360
differential diagnosis of, 6.360
fluorescein angiography findings, 6.359, 6.359*f*
gender predilection of, 6.358
retinoblastoma *versus*, 4.295, 4.295*f*, 6.352–353, 6.360
treatment of, 6.360
Coats reaction, 12.260
Coats white ring, 8.115, 8.116*f*
"Coaxial" illumination, 3.294
Cobblestone (paving-stone) degeneration, 4.150, 4.150*f*, 12.313, 12.314*f*
Cocaine, 2.439*t*, 2.441
anisocoria/Horner syndrome diagnosis and, 5.256*f*, 5.258, 5.259
optic neuropathy caused by, 1.199
Cocci (bacteria), 8.243, 8.244*t*
gram-negative, 8.244*t*, 8.245, 8.246*f*
therapy for infection caused by, 8.270*t*
gram positive, 8.243, 8.244*t*, 8.244–245, 8.245*f*
therapy for infection caused by, 8.270*t*
Coccidioides immitis (coccidioidomycosis), 9.301–302
optic nerve infection caused by, 4.243–244
Cochet-Bonnet esthesiometer, 8.42–43
Cochlear nerve, 5.38
Cochrane Library, 1.3
Cockayne syndrome (CS), 8.191*t*

Coefficient of variation, specular microscopy in evaluation of, 8.23
COG (Children's Oncology Group), 4.301
Cogan lid-twitch sign, 5.271, 5.324
Cogan microcystic epithelial dystrophy. *See* Basement membrane dystrophy
Cogan plaque, 8.128, 8.129*f*
Cogan-Reese (iris nevus) syndrome/Cogan-Reese variant, 4.100, 4.101*f*, 4.259, 8.111, 8.127, 10.136. *See also* Iridocorneal endothelial (ICE) syndrome
Cogan syndrome, 1.174, 6.269, 8.285, 8.309–310, 9.125*t*
Cogwheel (saccadic) pursuit, 5.219, 5.224, 5.225, 5.226
Coherence
  definition of, 3.91, 3.99
  description of, 3.99–102
  pictorial representation of, 3.100*f*
  spatial, 3.101
  temporal, 3.100*f*, 3.101
Coherence length
  description of, 3.101–102
  of laser light, 3.111
  spectral bandwidth and, 3.102, 3.103*f*
Coherence time, 3.101–102
Coherence tomography, optical. *See* Optical coherence tomography
Cohesive ophthalmic viscosurgical devices/viscoelastics, 2.445, 11.96. *See also* Ophthalmic viscosurgical devices
Cohort studies
  description of, 1.12–13
  schematic diagram of, 1.11*f*
COL1A1/COL1A2 genes, in osteogenesis imperfecta, 8.194
COL2A1, 2.302
COL4A3–5 genes, in Alport syndrome, 4.118
COL2A1 gene, 6.345, 12.343
COL8A2 gene, in posterior polymorphous corneal dystrophy, 8.136*t*
COL18A1 gene, 6.346–347
COL25A1 gene, 6.133
Colchicine, for Behçet disease, 1.173
Cold (temperature), anterior segment injuries caused by, 8.385
Cold remedies, tear production affected by, 8.62*t*
Colistimethate sodium, 2.418*t*
Collaborative Initial Glaucoma Treatment Study (CIGTS), 10.81, 10.111, 10.187
Collaborative Normal-Tension Glaucoma Study (CNTGS), 10.87–88
Collaborative Ocular Melanoma Study (COMS), 4.253, 4.271, 4.278–279
Collagen
  corneal, 8.8, 8.9, 8.9*f*, 13.13
    surgical procedures affecting character of, 13.127–135. *See also* Collagen shrinkage
  in Ehlers-Danlos syndrome, 8.193
  in lens capsule, 11.11
  in megalocornea, 8.99
  in osteogenesis imperfecta, 8.194
  scleral, 4.107–108
  stromal, 8.9, 8.9*f*
    corneal haze after surface ablation and, 13.33, 13.109
Collagen corneal shields, 2.365
Collagen (corneal) crosslinking (CCL/CXL), 13.8*t*, 13.130–135, 13.131*f*, 13.133*f*, 13.133*t*
  for *Acanthamoeba* keratitis, 8.279
  accelerated, 13.134
  for bacterial keratitis, 8.272
  combined techniques for, 13.134–135
  complications of, 13.135
  for ectasia/postoperative ectasia, 13.124, 13.130, 13.131, 13.206
  for fungal keratitis, 8.275
  with intracorneal ring segment implantation, 13.134, 13.207
  for keratoconus, 8.166
  for neurotrophic keratopathy/persistent corneal epithelial defects, 8.82
  patient selection/indications/contraindications for, 13.131–132
  with photorefractive or phototherapeutic keratectomy, 13.134, 13.206–207
  with refractive procedures, 13.206–208
  surgical technique for, 13.131*f*, 13.132–135, 13.133*f*, 13.133*t*
  transepithelial, 13.132–134, 13.133*f*
Collagen (corneal) crosslinking plus, 13.206
Collagen fibers
  in Bowman layer, 2.262
  in corneal stroma, 2.263, 2.264–265*f*
  in Descemet membrane, 2.266
  scleral, 2.58–59
  in vitreous, 12.7, 12.344
    age-related breakdown of, 2.300
    description of, 2.101, 2.294–297, 2.295–296*f*
    proteins associated with, 2.298
Collagen plugs, for dry eye, 8.64. *See also* Lacrimal plugs
Collagen shrinkage, 13.8*t*, 13.28, 13.28*f*, 13.127–129, 13.128*f*, 13.129*f*. *See also specific procedure*
  conductive keratoplasty for, 13.8*t*, 13.28, 13.28*f*, 13.128*f*, 13.128–129, 13.129*f*, 13.165
  corneal effects of, 13.28, 13.28*f*
  thermokeratoplasty for, 13.8*t*, 13.28, 13.28*f*, 13.127–128
Collagen vascular diseases. *See also* Connective tissue disorders; *specific type*
  immune-related eye disorders and, 8.285
  polyarteritis nodosa, 9.156–158
  refractive surgery in patient with, 13.37, 13.171, 13.191
  systemic lupus erythematosus. *See* Systemic lupus erythematosus
Collagenase, 8.207
  in inflammation, 9.25
  in ocular infections, 8.207
Collagenase inhibitors, for peripheral ulcerative keratitis, 8.313
Collagenolysis, in conjunctivochalasis, 8.85
Collagenous layer, posterior (retrocorneal fibrous membrane/RCFM), 2.267, 4.84, 4.85*f*
Collamer, for posterior chamber phakic IOLs, 13.138, 13.139*t*, 13.142, 13.142*f*
Collarettes (cilia), in blepharitis, 8.72*f*, 8.73

Collateral vessels, retinochoroidal/retinociliary venous (optociliary shunt vessels), 5.22
in optic nerve sheath meningioma, 5.127*f*, 5.128
in papilledema, 5.109
Collector channels, 2.64, 2.67*f*, 10.5*f*, 10.13
Colliculus
facial, 5.49
superior (SC), 5.18*f*, 5.33–34
saccadic control and, 5.219
Collier sign
in convergence-retraction nystagmus, 5.250
in dorsal midbrain (Parinaud) syndrome, 5.229, 5.250, 5.267, 5.274
Colloid bodies, optic disc/nerve. *See* Optic disc (optic nerve head/ONH), drusen of
Colloidal iron stain, 4.31*t*
Coloboma, 2.153
chorioretinal, 6.364
congenital, 7.179–180, 7.180*f*
as craniofacial malformation, 6.209
eyelid, 6.193, 6.193*f*
in Treacher Collins syndrome (mandibulofacial dysostosis), 4.207*t*
globe, 6.263
inferonasal disc, 6.365*f*
iris, 4.184, 6.266, 6.266*f*
cataract surgery in patient with, 11.180
lens, 6.305*f*, 6.305–306, 11.30–31, 11.31*f*
optic nerve/nerve head/disc, 4.242, 4.243*f*, 5.145, 6.364–365*f*
pupil irregularity and, 5.255
uveal, 4.184, 4.184*f*
Colobomatous cyst, 6.224
Colon cancer. *See* Colorectal cancer
Colonoscopy
colorectal cancer screening uses of, 1.218–219
computed tomography, 1.219
Colony-stimulating factors, 1.242
in mucous membrane pemphigoid, 8.299
Color blindness. *See* Color vision, defects in
Color photography, in uveitis evaluations, 9.89
Color plate testing, pseudoisochromatic, in low vision evaluation, 5.78
Color vision
abnormalities of
achromatopsia, 12.250, 12.250*t*
acquired, 12.249, 12.250*t*
congenital, 12.249–251, 12.250*t*
description of, 12.249
drugs that cause, 12.304–305
blue-yellow deficiency, 12.54
defects in. *See also specific type*
cataract and, 11.44, 11.70
in cone dystrophies, 5.102
cortical lesions and, 5.30
in optic atrophy, 5.135, 5.146
in optic neuritis, 5.78, 5.114
in optic neuropathy *versus* maculopathy, 5.78–79, 5.99
retina as source of, 5.175
simultanagnosia and, 5.180
description of, 12.54
digoxin effects on, 1.106
in NAION, 5.122
red-green deficiency, 12.54
Color vision defects, 2.312. *See also* Color vision, defects in
Color vision tests
Farnsworth-Munsell 100-hue test, 12.55
Farnsworth Panel D-15 test, 12.55*f*, 12.55–56
Hardy-Rand-Rittler plates, 12.54
Ishihara plates, 12.54, 12.55*f*
in low vision evaluation, 5.78–79
panel tests, 12.55
pseudoisochromatic plates, 12.54, 12.55*f*
Colorectal cancer
colonoscopy screening for, 1.218–219
flexible sigmoidoscopy screening for, 1.218–219
mortality rates for, 1.218
polyps, 1.218
risk factors for, 1.218
screening for, 1.216*t*, 1.218–219
Coma (wavefront aberration), 3.40, 3.72, 3.72*f*, 3.275*f*, 3.275–276, 13.9, 13.12, 13.12*f*
after LASIK, 13.103*f*
Combigan. *See* Brimonidine tartrate, in combination preparations; Brimonidine tartrate/timolol maleate
Combined α-adrenergic and β-adrenergic antagonists, 1.63
Combined hamartoma of retina and retinal pigment epithelium, 4.179, 4.180*f*, 4.280, 4.280*f*, 6.350
Combined interrupted and continuous sutures
for penetrating keratoplasty, 8.419*f*
suture removal/adjustment and, 8.419*f*, 8.431–432, 8.432*f*
Combined lymphatic venous malformations, 7.74
Combined-mechanism glaucoma, 10.7
Combined nevus, 4.218
Comitance, spread of, 5.186
Comitant (concomitant) deviations, 5.183, 5.184, 5.186. *See also specific type*
definition of, 6.16
in infantile esotropia, 6.88
Comma sign, 12.154
Commissure, posterior (PC), 5.35, 5.35*f*, 5.55*f*
vertical gaze and, 5.36, 5.36*f*
Common carotid artery, 5.12, 5.13*f*
Common cause factors, 1.28
Commotio retinae, 4.18–19, 12.353, 12.354*f*
Communicating arteries
anterior (ACoA), 2.106*f*, 5.16*f*, 5.18, 5.27*f*
aneurysm of, 5.339, 5.339*f*
cranial nerve relationship and, 5.42*f*, 5.43*f*
posterior (PCoA), 5.16*f*, 5.18, 5.18*f*, 5.19*f*, 5.20
anatomy of, 2.106–107*f*, 2.124, 2.139*f*
aneurysm of, 5.339*f*
third nerve (oculomotor) palsy and, 2.125, 5.20, 5.194, 5.194*f*, 5.339
cranial nerve relationship and, 5.42*f*
Communication
between clinician and pathologist, 4.25–26
between clinician and patient, cataract surgery and, 11.169–170
between clinician and radiologist, 5.57, 5.73
Community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA), 7.45

Comparative genomic hybridization (CGH), 4.38*t*
Complement
activation pathways for, 9.17, 9.18*f*
in external eye defense, 8.11
functions of, 9.17
in inflammation, 9.17–19
in uveitis-glaucoma-hyphema syndrome, 9.10
Complement factor H *(CFH)* gene, 2.183, 12.63
in age-related macular degeneration, 4.160
Complement receptors, 9.12
Complementary DNA, 2.189
Complete achromatopsia, 6.337–338
Complete cataract, 11.38
Complete third nerve (oculomotor) palsy, 5.195
CompleteMoisturePlus contact lens solution, *Acanthamoeba* keratitis and, 8.276
Complex choristomas, 4.48, 4.49*f*
Complex partial seizures, 1.206–207
Complexion-associated melanosis (CAM/racial melanosis/primary conjunctival/hypermelanosis) 4.63t, 4.65, 4.66, 4.66*f*, 8.338*t*, 8.339*t*, 8.341, 8.341*f*
Compliance, 2.373
Compliance with therapy. *See* Adherence issues (therapy)
Compound hyperopic astigmatism
astigmatic dial technique applied to, 3.160, 3.161*f*
description of, 3.138, 3.138*f*
fogging to produce, 3.161*f*
Compound myopic astigmatism, 3.138, 3.138*f*
Compound nevi, 7.196, 7.196*f*
of conjunctiva, 4.64
conjunctival/ocular surface, 8.338*t*
of eyelid, 4.219, 4.219*f*
Compounded pharmaceuticals, 2.372–373
Compounding, 2.372
Compression (dynamic) gonioscopy, 10.35, 10.35*f*, 10.36
in acute primary angle closure, 10.123
Compressive optic neuropathy, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*, 7.60–61
intraorbital/intracanalicular, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*
optic glioma causing, 5.126, 5.128*t*, 5.129*f*, 5.129–131
optic nerve sheath meningioma causing, 5.126, 5.127*f*, 5.127–129, 5.128*t*
in pituitary apoplexy, 5.149, 5.150*f*
in thyroid eye disease, 5.131, 5.132*f*
Compromised host. *See also* Immunocompromised host
refractive surgery in, 13.37, 13.171
Computed tomography (CT), 5.58, 5.58*f*, 5.60, 5.61*t*, 5.72*t*
advantages/disadvantages of/contraindications for, 5.60, 5.61*t*
in aneurysm detection/evaluation, 5.340
axial scans, 2.454, 2.456*f*
cavernous venous malformations on, 7.76*f*
in children, 7.31
in choroidal melanoma/ciliary body melanoma, 4.267
contrast agents with, 2.457
corneal, 13.19–22, 13.20–21*f*, 13.194
after refractive/keratorefractive surgery, 13.23
IOL power determination/selection and, 13.194
coronal scans, 2.456*f*
in coronary heart disease diagnosis, 1.88
dacryocystocele on, 7.290*f*
dermoid cysts on, 7.41
description of, 2.453–454
disadvantages of, 2.456–457
epilepsy diagnosis using, 1.207
fibrous dysplasia on, 7.89, 7.90*f*
immunoglobulin G4–related disease on, 7.66*f*
indications for, 2.454, 2.473*t*, 2.476*t*, 7.300
intraocular foreign body evaluations, 12.352
iodinated contrast agents with, 2.457
Langerhans cell histiocytosis on, 7.96*f*
lung disease evaluations, 1.126
lymphoproliferative disorders on, 7.93*f*
magnetic resonance imaging *versus*, 2.455*t*, 2.457, 7.29*t*, 7.29–31
multimodal, 1.112
necrotizing fasciitis on, 7.49*f*
nonspecific orbital inflammation on, 7.68*f*
optic nerve glioma, 7.80–81
in optic nerve/nerve head/disc drusen, 5.141*f*, 5.142
orbital compartment syndrome on, 7.118*f*, 7.120*f*
orbital disorders evaluated using, 7.26*f*, 7.26–27
in orbital evaluation, 5.58, 5.58*f*, 5.60, 5.61*t*, 5.72*t*, 5.73*f*
orbital floor fractures on, 7.116
orbital foreign bodies on, 7.117–118, 7.118*f*
periorbital sinuses, 2.14*f*
posterior fossa on, 2.456
radiation exposure from, 2.456
in retinoblastoma, 4.293
sarcoidosis on, 7.65*f*
silent sinus syndrome on, 7.103*f*
single-photon emission (SPECT), 2.454, 5.70
solitary fibrous tumor, 7.89
sphenoid wing meningioma on, 7.84*f*
stroke evaluations using, 1.112
uveal lymphoma evaluations, 12.234
zygomycosis on, 7.51*f*
Computed tomography angiography (CTA), 2.454, 2.455*t*, 2.458, 5.58, 5.69–70, 5.72*t*
advantages/disadvantages of/contraindications for, 5.61*t*
in aneurysm detection/evaluation, 5.69–70, 5.194, 5.194*f*, 5.340
in arterial dissection, 5.342
arteriovenous malformations on, 7.77*f*
in carotid artery evaluation, 5.167
for carotid stenosis, 1.116
description of, 7.32
in vertebrobasilar insufficiency, 5.338
Computed tomography colonoscopy, for colorectal cancer screening, 1.219
Computed tomography venography (CTV), 2.454, 2.455*t*, 5.58, 5.70, 5.72*t*, 5.75
advantages/disadvantages of/contraindications for, 5.61*t*
in cerebral venous thrombosis, 5.346
Computerized corneal topography. *See* Cornea, topography of
Computerized videokeratoscopy. *See* Videokeratoscopy
COMS (Collaborative Ocular Melanoma Study), 4.253, 4.271, 4.278–279

Concave lenses
combining of, 3.11
description of, 3.11
ray tracing for, 3.64, 3.65–3.66*f*
spherical, description of, 3.11
Concave mirrors
ray tracing for, 3.82*f*, 3.83
retinoscope setting, 3.150, 3.151*f*
Concentric contact lenses, 3.225
Concizumab, 1.144
Concomitant deviations. *See* Comitant (concomitant) deviations
Concretions, conjunctival, 8.113–114
Concussive (blunt) trauma, anterior segment, 8.387–396. *See also* Blunt (concussive) trauma
Condensing lens, 3.298*f*, 3.299
Conduction block, 1.101
Conductive keratoplasty (CK), 13.8*t*, 13.28, 13.28*f*, 13.128*f*, 13.128–129, 13.129*f*, 13.165
corneal transplantation after, 13.198
for presbyopia, 13.128, 13.128*f*, 13.165
Conduit Artery Function Endpoint (CAFE) study, 1.64
Cone dystrophies/degenerations, 5.102
bull's-eye pattern associated with, 12.265, 12.265*f*
description of, 12.264–265
electroretinography findings in, 12.46, 12.47*f*, 12.265
ERG in, 5.102
genes and loci associated with, 12.256*t*
in optic neuropathy *versus* maculopathy, 5.99
with supernormal rod ERG, 12.49
Cone inner segments, 4.140*f*. *See also* Cones; Photoreceptor(s), inner segments of
Cone outer segments, 4.140*f*. *See also* Cones; Photoreceptor(s), outer segments of
Cone response, single-flash (photopic/light-adapted electroretinogram), in cone dystrophies, 5.102
Cone–rod dystrophies. *See also* Retinitis pigmentosa
ERG in, 5.96
genes and loci associated with, 12.256*t*
Jalili syndrome, 12.286
retinitis punctata albescens, 12.258, 12.258*f*
in Stargardt disease, 6.340
Cones, 4.140, 4.140*f*, 5.24
abnormalities of. *See* Color vision, defects in
anatomy of, 2.86*f*
bipolar cells, 2.315–316, 2.315–316*f*, 12.13
cells of, 2.315–316, 2.315–316*f*
circuitry of, 2.316*f*
foveal, 2.95, 12.11
foveal density of, 6.44
gene defects associated with, 2.314*f*
inner segments of, 12.11–12, 12.12*f*
L, 2.312, 2.315, 2.317, 12.54
light effects on, 2.318, 2.318*f*
light-sensitive molecules in, 12.12
M, 2.312, 2.315, 2.318, 12.54
neurally mediated negative feedback of, 2.311
neuronal elements of, 2.88
number of, 2.84
outer segments of, 12.11, 12.12*f*
pedicle of, 2.87
photoreceptors in, 12.13
phototransduction of, 2.311
retinoblastoma and, 4.172
rods *versus*, 2.306
S, 2.312, 12.54
schematic diagram of, 12.14*f*
synaptic body of, 2.87
trivariant color vision, 2.312
types of, 12.54
Conflict of interest, 1.7–8
Confluent drusen, 12.65
Confocal microscopy, 8.24, 8.24*f*
in *Acanthamoeba* keratitis diagnosis, 8.24, 8.277, 8.278*f*
in fungal keratitis diagnosis, 8.275
before phakic IOL insertion, 13.141
Confocal scanning laser microscope, 3.302
Confocal scanning laser ophthalmoscopy/ophthalmoscope (CSLO/SLO), 3.302, 3.302*f*
in optic nerve/nerve head/disc evaluation, 10.56
for retinal disease evaluations, 12.24
Conformité Européene (CE) marking, 13.3
for intrastromal corneal ring segments, 13.65
for small-incision lenticule extraction, 13.203
Confounding factors, 1.12–13
Confrontation testing, 5.83–84, 6.4, 6.10
before cataract surgery, 11.82
in hemispatial neglect, 5.181
in nonorganic disorder evaluation, 5.307–308
before refractive surgery, 13.41
Confusion, in older adults, 1.187
Confusion tests, in nonorganic disorder evaluation
monocular no light perception and, 5.303*f*, 5.303–305, 5.304*f*
monocular reduced vision and, 5.305
Congenital, 2.210. *See also* Genetics
Congenital anomalies, 4.6, 4.7*f*, 4.12*t*. *See also specific type*
anophthalmia. *See* Anophthalmia/anophthalmos
of anterior segment/chamber, 4.98–99, 4.99*f*, 4.100*f*, 8.95–109, 8.96–98*t*
of conjunctiva, 4.47–50, 4.49*f*
of cornea, 4.73–74, 4.74*f*, 4.75*f*, 8.95–109, 8.96–98*t*
secondary abnormalities and, 8.107–109
craniofacial clefts, 7.38–39
distichiasis, 7.170, 7.179, 7.179*f*
ectropion, 7.174, 7.176*f*
entropion, 7.179, 7.179*f*
of eyelid, 4.202–203, 4.203*f*
glaucoma associated with, 4.98, 4.99*f*, 10.4*t*, 10.6*t*, 10.147, 10.148*t*, 10.151. *See also* Glaucoma, pediatric
Horner syndrome, 7.246
of lens, 4.117–118, 4.118*f*, 11.30*f*, 11.30–39, 11.31*f*, 11.32*f*, 11.33*f*, 11.34*f*, 11.35*t*, 11.36*f*, 11.37*f*, 11.38*f*, 11.39*f*. *See also* Cataract, congenital
microphthalmia, 7.36–38
myogenic ptosis, 7.244, 7.244*f*, 7.245*t*
nasolacrimal duct obstruction. *See* Nasolacrimal duct obstruction, congenital
oculomotor nerve palsy, 7.246
of optic nerve/nerve head/disc, 4.241–242, 4.243*f*, 5.143*f*, 5.143–145, 5.144*f*
transient visual loss and, 5.164
of orbit, 4.223–224, 4.224*f*
orbital tumors. *See* Orbital tumors, congenital
overview of, 7.35

of retina and retinal pigment epithelium, 4.142*f*, 4.142–145, 4.143*f*, 4.144*f*, 4.145*f*
of sclera, 4.108–109, 8.95–109, 8.96–98*t*
syndromic craniosynostosis, 7.39, 7.39*f*
of trabecular meshwork, 4.98–99, 4.99*f*, 4.100*f*
tumors, 7.40–42
of uveal tract, 4.184, 4.184*f*
of vitreous, 4.125–127, 4.126*f*, 4.127*f*
Congenital anterior staphyloma, 8.98*t*, 8.106*f*, 8.106–107
Congenital aphakia, 4.117, 6.305, 11.30. *See also* Aphakia
Congenital cataract, 6.293, 11.34–39, 11.35*t*, 11.36*f*, 11.37*f*, 11.38*f*, 11.39*f*. *See also* Cataract, congenital; *specific type*
genetic/hereditary factors in, 11.41–42
Congenital cranial dysinnervation disorders (CCDDs)
Brown syndrome as, 6.131
congenital fibrosis of the extraocular muscles, 6.134–135
definition of, 6.131
Duane retraction syndrome. *See* Duane retraction syndrome
Möbius syndrome, 6.97, 6.135–136, 6.136*f*
Congenital Epstein-Barr virus infection, 9.257
Congenital esotropia, 6.86*t*. *See also* Infantile esotropia
amblyopia associated with, 6.87–89
botulinum toxin injections for, 6.89
Chavasse theory of, 6.87
Ciancia syndrome, 6.88, 6.95
clinical features of, 6.87–88
cross-fixation associated with, 6.87–88, 6.88*f*
cyclopegic refraction for, 6.88
definition of, 6.87
evaluation of, 6.87–88
management of, 6.88–89
medial rectus muscle recession for, 6.89
mental illness and, 6.87
ocular alignment in, 6.88–89
pathogenesis of, 6.87
prematurity as risk factor for, 6.87
smooth-pursuit asymmetry associated with, 6.88
surgical treatment of, 6.89
Worth "sensory" concept of, 6.87
Congenital Esotropia Observational Study, 6.89
Congenital eyelid syndrome. *See* Blepharophimosis–ptosis–epicanthus inversus syndrome
Congenital fibrosis of the extraocular muscles (CFEOM), 6.134–135
Congenital fourth nerve (trochlear) palsy, 5.199, 5.199*f*
Congenital glaucoma (primary congenital glaucoma/PCG), 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147, 10.148*t*, 10.151*f*, 10.151–153, 10.152*f*, 10.152*t*. *See also* Glaucoma, pediatric; Primary congenital glaucoma
corneal opacities associated with, 6.257*t*, 6.260, 6.261*f*, 8.108–109
differential diagnosis of, 6.281*t*, 10.151–152, 10.152*t*
genetics of, 6.277–278, 10.11*t*, 10.150
megalocornea and, 8.95, 8.96*t*, 8.99–100, 8.108
treatment of, 10.153
medical, 10.153
surgical, 10.153, 10.160–164, 10.161*f*, 10.162*f*, 10.187
Congenital hereditary endothelial dystrophy (CHED/CHED2), 4.92–93, 4.94*f*, 6.257*t*, 6.258*f*, 6.258–259, 8.135*t*, 8.136*t*, 8.160, 8.161*f*
Congenital hereditary stromal dystrophy (CHSD), 6.257*t*, 6.259
Congenital hypertrophy of retinal pigment epithelium (CHRPE)
description of, 4.144–145, 4.145*f*, 4.268–269, 4.269*f*, 6.349, 6.349*f*
in familial adenomatous polyposis, 2.201, 2.202*f*
melanoma differentiated from, 4.144, 4.268–269, 4.269*f*
Congenital insensitivity to pain with anhidrosis (CIPA), congenital corneal anesthesia and, 8.108
Congenital iris ectropion syndrome, 6.267
Congenital lacrimal fistula, 6.228, 6.229*f*
Congenital miosis, 6.267–268
Congenital motor nystagmus (CMN), 6.148–149, 6.149*t*, 6.153–154
Congenital mydriasis, 6.268
Congenital myopia, 3.174
Congenital nasolacrimal duct obstruction (CNLDO)
antibiotics for, 6.231–232, 6.234
balloon dacryoplasty for, 6.234–235, 6.235*f*, 7.294
bilateral, 6.232*f*
canalicular obstruction, 7.298, 7.300*f*
causes of, 7.283, 7.287–288
clinical features of, 6.230, 6.232*f*
complex, 6.230, 6.233–234
dacryocystitis associated with, 7.289
description of, 6.227, 6.230
diagnosis of, 7.300
evaluation, 7.287–288
examination of, 6.230
infantile glaucoma *versus*, 6.230
intubation for, 6.234–235
lacrimal intubation stents for, 7.292–294, 7.294*f*
massage for, 6.231–232
nasolacrimal probing for, 6.232–235, 6.233*f*, 7.289, 7.291*f*, 7.291–292, 7.298, 7.300
nonsurgical management of, 6.231–232
prevalence of, 6.230
recurrence of, 6.234
simple, 6.230, 6.231*f*
spontaneous resolution of, 6.231
stents for, 6.234–235
surgical management of, 6.232–233
tearing caused by, 6.230
turbinate infracture for, 7.294
valve of Hasner in, 7.288–289
Congenital nevocellular nevi, 6.200–201, 6.201*f*
Congenital nystagmus (CN), 5.234*f*, 5.235–237, 5.237*f*
latent/manifest latent. *See* Latent nystagmus; Fusion maldevelopment nystagmus syndrome
periodic alternating (PAN), 5.245
pregeniculate visual impairment and, 5.235–236
Congenital ocular motor apraxia, 5.223
Congenital ptosis. *See* Ptosis, congenital
Congenital retinal arteriovenous malformations, 4.286*f*, 4.286–287. *See also* Racemose angioma/hemangioma (Wyburn-Mason syndrome/Bonnet-Dechaume-Blanc syndrome)
Congenital retinal disease. *See specific disorder and under Hereditary*
Congenital rubella syndrome (CRS), 8.240, 8.240*t*, 9.258–259, 9.259*f*
aphakia and, 4.117

cataracts and, 11.38–39
glaucoma and, 10.150*t*
Congenital sensory nystagmus, 6.149, 6.150*t*, 6.154
Congenital sixth nerve (abducens) palsy, 5.201
Congenital stationary night blindness (CSNB)
Duchenne muscular dystrophy and, 12.285
electroretinography findings in, 6.338, 12.46, 12.47*f*, 12.251, 12.252*f*
genes and loci associated with, 12.256*t*
with myopia, 2.232*t*
retinitis pigmentosa *versus*, 12.251
spasmus nutans syndrome associated with, 6.151
subtypes of, 12.251
X-linked, 12.252
Congenital strabismus, 6.16. *See also* Strabismus
Congenital (congenital hereditary) stromal corneal dystrophy (CHSD/CSCD), 8.135*t*, 8.136*t*, 8.152, 8.153*f*. *See also* Congenital hereditary stromal dystrophy
Congenital superior oblique palsy, 6.69
Congenital syphilis, 1.222, 6.269, 6.412–413, 8.107, 8.308–309, 8.309*f*, 9.220, 9.226
corneal manifestations of/interstitial keratitis, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*
Congenital tarsal kink, 6.194–195
Congenital tilted disc syndrome, 5.144, 5.144*f*
Congenital toxoplasmosis, 9.276–277, 9.277*f*, 12.243
Congenital Zika syndrome, 1.265, 9.269
Congestive heart failure (CHF)
arrhythmias in, 1.99
bradyarrhythmias in, 1.99
brain natriuretic peptide in, 1.97
cardiac transplantation for, 1.100
chest radiograph findings in, 1.97
classification of, 1.95, 1.96*f*
coronary angiography of, 1.97
diagnostic evaluation of, 1.97
echocardiography of, 1.97
electrocardiography of, 1.97
epidemiology of, 1.95
etiology of, 1.98
hypertension and, 1.65
left-sided, 1.95, 1.96*f*
management of
implantable cardioverter-defibrillator, 1.100
invasive, 1.100
medical, 1.98–100
nonsurgical, 1.98–100
surgical, 1.100
in myocardial infarction, 1.85
palliative care in, 1.100
pathophysiology of, 1.95
perioperative management for ocular surgery in patients with, 1.283–284
precipitating factors for, 1.99
with preserved ejection fraction
description of, 1.95, 1.96*f*
management of, 1.99
with reduced ejection fraction
description of, 1.95, 1.96*f*
management of, 1.98–99
right-sided, 1.95, 1.96*f*
signs and symptoms of, 1.95, 1.97
stages of, 1.95, 1.96*f*
tachyarrhythmias in, 1.99
in women, 1.95
Congo red stain, 4.31*t*
Congruous, definition of, 5.105*t*
Congruous visual field defects, 5.29, 5.105*t*
retrochiasmal lesions producing, 5.153
occipital lobe lesions, 5.156, 5.157*f*
Conidia, 8.249
Conidiophores, 8.249
Conjugacy, saccadic eye movement, 5.221
Conjugate eye movements (versions), 5.34–35, 5.35*f*. *See also specific type*
in diplopia, 5.184
smooth-pursuit system and, 5.224
Conjugate horizontal gaze, 6.182
Conjugate nystagmus, 1.208
Conjugate planes, in indirect ophthalmoscope, 3.299*f*
Conjugate points, 3.40, 3.64
Conjunctiva, 4.47–72, 8.4*f*. *See also under Conjunctival*
age-related changes in, 1.183, 8.112
anatomy of, 2.36, 2.37*f*, 2.43–44, 4.47, 4.48*f*, 7.168, 8.4*f*, 8.6–7
biopsy of, 8.360–361
in granulomatous conjunctivitis, 4.52
in lymphoid lesions, 4.69, 4.70
in mucous membrane (cicatricial) pemphigoid, 4.54, 4.54*f*, 8.301*f*, 8.301–302
in neoplastic disorders, 8.329
in peripheral ulcerative keratitis, 8.311
in pseudopemphigoid (drug-induced pemphigoid), 8.301
in superior limbic keratoconjunctivitis, 8.84
blood under, 8.387–388, 8.388*f*
bulbar, 2.28*f*, 2.43, 4.47, 4.48*f*, 8.6
fixation/plication of, for conjunctivochalasis, 8.86, 8.361
lymphoid lesions involving, 4.69, 4.70*f*
redundant. *See* Conjunctivochalasis
resection of, for conjunctivochalasis, 8.86, 8.362
in superior limbic keratoconjunctivitis, 8.83, 8.84
capillary hemangioma of, 4.50
carcinoma of. *See also* Conjunctiva, tumors of
intraocular extension and, 4.310
squamous cell, 8.336, 8.336*f*. *See also* Ocular surface squamous neoplasia
in situ, 4.61, 4.63*f*
invasive, 4.61, 4.62*f*, 4.63*f*
caruncular, 4.48*f*. *See also* Caruncle
cicatrization of, 8.47*t*. *See also* Conjunctivitis, cicatrizing; Mucous membrane (ocular cicatricial) pemphigoid
circumcorneal hyperemia of, 9.232
concretions of, 8.113–114
congenital anomalies of, 4.47–50, 4.49*f*
cysts of, 4.59, 4.59*f*, 7.141, 7.141*f*, 8.114, 8.114*f*. *See also* Epithelial inclusion cysts
nevi and, 4.64, 8.340
degenerations of, 4.56*f*, 4.56–59, 4.57*f*, 4.58*f*, 4.59*f*, 8.111*t*, 8.111–114, 8.115*t*
deposits in
amyloid, 4.58*f*, 4.58–59, 8.185, 8.186*t*, 8.187*f*
in hematologic disorders, 8.198

discharge from, 8.46*t*
disorders of, 4.47–72, 8.45–46*t*, 8.47, 8.47*t*. *See also* Conjunctivitis; Keratoconjunctivitis; *specific type*
common clinical findings in, 8.45–46*t*, 8.47, 8.47*t*
epithelial inclusion cysts, 6.250
in glaucoma, 10.31
immune-mediated, 8.288–306
ionizing radiation causing, 8.386
neoplastic, 4.59–72, 8.327–350. *See also* Conjunctiva, tumors of
nevi, 6.250, 6.250*f*
ocular melanocytosis, 6.250–251, 6.251*f*
papillomas, 6.250
Stevens-Johnson syndrome, 6.251–252, 6.252*f*
therapeutic/surgical interventions for, 8.352–366
toxic epidermal necrolysis, 6.251–252
dysplasia of (conjunctival intraepithelial neoplasia/CIN), 4.61, 4.63*f*, 8.37, 8.38*f*, 8.332*t*, 8.334, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia; Ocular surface squamous neoplasia
melanocytic, 4.63*t*, 4.65, 4.66, 4.67*f*
effector cells in, 9.53
eosinophils in, 9.2
epithelium of, 2.44, 4.47, 4.48*f*, 7.296, 8.7, 8.7*f*
cysts of, 4.59, 4.59*f*, 8.114, 8.114*f*. *See also* Epithelial inclusion cysts
nevi and, 4.64
dysplasia of (conjunctival intraepithelial neoplasia/CIN), 4.61, 4.63*f*, 8.37, 8.38*f*, 8.332*t*, 8.334, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia; Ocular surface squamous neoplasia
melanocytic, 4.63*t*, 4.65, 4.66, 4.67*f*
in external eye defense, 8.13
tumors of, 8.332*t*, 8.332–337
erosions of, 8.47*t*
punctate epithelial, 8.46*t*
examination of
before cataract surgery, 11.78
in glaucoma, 10.31
before refractive surgery, 13.41–42
in external eye defense, 8.13
fixation/plication of
for conjunctivochalasis, 8.86, 8.361
for superior limbic keratoconjunctivitis, 8.84
follicles of, 8.46*t*, 8.47*t*, 8.48–49, 8.49*f*
in chlamydial conjunctivitis/trachoma, 8.261, 8.262, 8.263
foreign body on, 4.52, 4.53*f*, 8.397, 8.397*f*, 8.398*f*
insect stingers/hairs, 8.386–387
radioactive, 8.386
forniceal, 4.47, 4.48*f*, 8.6
lymphoid lesions involving, 4.69, 4.70*f*
fornices of, 2.28*f*, 2.36, 2.37*f*, 2.43
glaucoma/glaucoma therapy affecting, 10.31
granuloma of, 8.46*t*, 8.47*t*
foreign-body, 4.52, 4.53*f*
in Parinaud oculoglandular syndrome, 4.51, 8.265
in sarcoidosis, 4.52, 4.52*f*, 8.347
hemangiomas of, 4.50, 8.345*t*, 8.345–346
immunologic microenvironment of, 9.52*t*, 9.53
immunoregulatory systems of, 9.53
inadequate, tube shunt implantation for, 10.215
incision through. *See* Transconjunctival incisions
infection/inflammation of, 4.50*f*, 4.50–55, 4.51*f*, 4.52*f*, 4.53*f*, 4.54*f*, 4.55*f*. *See also* Conjunctivitis; Keratoconjunctivitis
in graft-vs-host disease, 8.303, 8.304
inflammatory vascular lesions of, 8.346*f*, 8.346–347
innervation of, 2.43
intraepithelial neoplasia of (CIN), 4.61, 4.63*f*, 8.37, 8.38*f*, 8.332*t*, 8.334, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia; Ocular surface squamous neoplasia
melanocytic, 4.63*t*, 4.65, 4.66, 4.67*f*
laceration of, 8.396–397
lymphoid tissue associated with (CALT), 2.43, 4.47, 4.69, 8.7
lymphoma arising in, 8.349–350, 8.350*f*
lymphoma of, 4.70*f*, 4.70–71, 4.71*f*, 8.349–350, 8.350*f*
mast cells in, 9.3
melanocytic/pigmented lesions of, 4.61–69, 4.63*t*, 4.64*f*, 4.65*f*, 4.66*f*, 4.67*f*, 4.68*f*, 4.69*f*
melanoma of, 4.68*f*, 4.68–69, 8.338*t*, 8.339*t*, 8.343–345, 8.344*f*
in situ, 4.65, 4.67*f*, 4.68
intraocular extension of, 4.310
ocular melanocytosis and, 8.349–350
primary acquired melanosis and, 4.66–68, 4.67*f*, 4.68, 4.68*f*, 8.327, 8.342, 8.343
membrane of, 8.46*t*, 8.47*t*
in epidemic keratoconjunctivitis, 8.234, 8.234*f*, 8.235
in gonococcal conjunctivitis, 8.258
in ligneous conjunctivitis, 8.294
mucosa-associated lymphoid tissue of, 9.53
nevus of, 4.61–64, 4.63*t*, 4.64*f*, 4.65*f*, 8.338*t*, 8.339*t*, 8.340*f*, 8.340–341
malignant transformation/melanoma and, 4.64, 4.68, 8.340, 8.341, 8.343
normal flora of, 8.205, 8.206*t*
palpebral, 2.36, 2.37*f*, 2.43, 4.47, 4.48*f*, 4.201, 4.201*f*, 4.202, 8.6
papillae of, 8.46*t*, 8.47*f*, 8.47*t*, 8.47–48, 8.48*f*. *See also* Papillae, conjunctival
papillomas of, 4.59–60, 4.60*f*, 8.238–239, 8.239*f*, 8.332*t*, 8.332–334, 8.333*f*
pH of, chemical injury management and, 8.382
pigmented lesions of, 8.338*t*, 8.338–345, 8.339*t*, 8.340*f*
benign, 8.338*t*, 8.338–341, 8.339*f*, 8.339*t*, 8.340*f*, 8.341*f*
malignant, 8.338*t*, 8.339*t*, 8.343–345, 8.344*f*
preinvasive, 8.338*t*, 8.339*t*, 8.342*f*, 8.342–343
primary melanosis of, 4.63*t*, 4.65, 4.66–68, 4.67*f*
pseudomembrane of, 8.46*t*, 8.47*t*
in epidemic keratoconjunctivitis, 8.234
in ligneous conjunctivitis, 8.294
redundant. *See* Conjunctivochalasis
resection of, for conjunctivochalasis, 8.86, 8.362
sarcoidosis involvement of, 9.195, 9.195*f*
scrapings/swabbings from, 8.210–211
specimen collection from, 8.209*t*, 8.209–210
stem cells of, 8.92, 8.362
stroma of (substantia propria), 4.47, 4.48*f*, 8.7
age-related changes in, 8.112
in external eye defense, 8.13
immune and inflammatory cells in, 8.13

in superior limbic keratoconjunctivitis, 8.83–84, 8.84*f*
tarsal, 8.6
telangiectasia of, in ataxia-telangiectasia, 5.332*f*, 5.334*t*
topical agent absorption in, 2.355
topography of, 4.47, 4.48*f*
transplantation of, 8.351, 8.351*t*, 8.353*t*, 8.353–355, 8.354*f*, 8.356
for chemical injuries, 8.384
indications for, 8.351*t*, 8.353, 8.356
for limbal stem cell deficiency, 8.94
in pterygium surgery, 8.351, 8.353*t*, 8.353–355, 8.354*f*, 8.356
recurrence rate and, 8.353*t*
after tumor removal surgery, 8.329
tumors of, 4.59–72, 8.327–350. *See also* Ocular surface, tumors of
approach to patient with, 8.328
epithelial, 8.332*t*, 8.332–337
glandular, 4.71–72, 4.72*f*, 8.337*f*, 8.337–338
human papillomavirus causing, 4.59–60, 4.60*f*, 8.238–239, 8.239*f*, 8.332*t*, 8.332–334, 8.333*f*
inflammatory, 8.346*f*, 8.346–347
Kaposi sarcoma, 8.239, 8.345*t*, 8.347*f*, 8.347–348
lymphoid/lymphatic/lymphocytic, 4.69–71, 4.70*f*, 4.71*f*, 8.348–350, 8.349*f*, 8.350*f*
malignant, 8.338*t*, 8.339*t*
management of, 8.328–332, 8.330*f*, 8.331*f*
surgical, 8.329–330, 8.330*f*
melanocytic/pigmented lesions, 4.61–69, 4.63*t*, 4.64*f*, 4.65*f*, 4.66*f*, 4.67*f*, 4.68*f*, 4.69*f*
metastatic, 8.350
neurogenic and smooth muscle, 8.345
pigmented, 8.338*t*, 8.338–345, 8.339*t*, 8.340*f*, 8.341*f*, 8.342*f*
preinvasive, 8.332*t*. *See also* Conjunctival or corneal intraepithelial neoplasia
pigmented, 8.338*t*, 8.339*t*, 8.342*f*, 8.342–343
squamous lesions, 4.59–61, 4.60*f*, 4.62*f*, 4.63*f*
topical chemotherapy for, 8.330*f*, 8.330–332, 8.331*f*
vascular and mesenchymal, 8.345*t*, 8.345–348, 8.346*f*, 8.347*f*
ulceration of, 8.47*t*
Conjunctiva-associated lymphoid tissue (CALT/conjunctival MALT), 2.43, 4.47, 4.69, 8.7
lymphoma arising in, 8.349–350, 8.350*f*
Conjunctival artery, 2.24*f*
Conjunctival autograft/autologous transplantation, 8.351*t*, 8.353*t*, 8.353–355, 8.354*f*, 8.356
for chemical injuries, 8.384
indications for, 8.351*t*, 8.353
for limbal stem cell deficiency, 8.94
in pterygium surgery, 8.353*t*, 8.353–355, 8.354*f*
recurrence rate and, 8.353*t*
after tumor removal surgery, 8.329
Conjunctival filtering blebs, endophthalmitis associated with, 12.390–391, 12.391*f*
Conjunctival fixation sutures
for conjunctivochalasis, 8.86, 8.361
for superior limbic keratoconjunctivitis, 8.84
Conjunctival flaps, 8.354*f*, 8.356–360, 8.357*f*, 8.358*f*, 8.359*f*
for bare sclera after pterygium excision, 8.353, 8.354*f*
cataract surgery and
for ECCE, 11.196
for ICCE, 11.199
leak causing inadvertent filtering bleb and, 11.130–131
for postoperative corneal edema, 11.129–130
for herpetic eye disease, 8.225
for neurotrophic keratopathy/persistent corneal epithelial defects, 8.82, 8.357
for peripheral ulcerative keratitis, 8.313
removal of, 8.360
for trabeculectomy, 10.200, 10.201*f*, 10.202*f*
closure of, 10.204, 10.206*f*
in elderly patients, 10.221
management of, 10.207–208
for trabeculotomy, in children, 10.161–162
Conjunctival hyperemia/congestion, 6.237, 6.238*t*, 8.45*t*, 8.114, 8.115*t*
in glaucoma, 10.31
insect/arachnid injuries causing, 8.386
prostaglandin analogues causing, 10.175
Conjunctival inclusion cysts, 4.59, 4.59*f*, 8.114, 8.114*f*
concretions and, 8.113–114
nevi and, 4.64, 8.340
Conjunctival-limbal autograft. *See* Autografts/autologous transplantation
Conjunctival melanocytic intraepithelial neoplasia (C-MIN), 4.63*t*, 4.65, 4.66, 4.67*f*
Conjunctival or corneal intraepithelial neoplasia (CIN), 2.414, 4.61, 4.63*f*, 8.37, 8.38*f*, 8.332*t*, 8.334–335, 8.335*f*. *See also* Ocular surface squamous neoplasia
melanocytic, 4.63*t*, 4.65, 4.66, 4.67*f*
Conjunctival scarring, 6.146
Conjunctival telangiectasia, 6.303*f*, 6.403
Conjunctival vascular tortuosity, 8.114, 8.115*t*
Conjunctivalization of cornea, 8.362
Conjunctivitis, 4.50, 8.208*t*. *See also* Keratoconjunctivitis
acute, 8.257*t*
hemorrhagic (AHC), 8.240, 8.240*t*
purulent, 8.256, 8.257*t*
adenoviral, 4.52, 6.241–242, 8.208*t*, 8.233, 8.234*f*, 8.234–236, 8.235*f*
adult inclusion, 6.241
allergic, 2.411–412, 2.412*t*, 6.246*f*, 6.246–248, 8.288–289
perennial, 8.288–289
seasonal, 8.288–289
bacterial, 4.52, 6.240*f*, 6.240–241, 8.208*t*, 8.255–265
in children, 8.243, 8.255–256
classification of, 8.257*t*
in neonates, 8.257*t*, 8.263–265
blepharitis and, 6.244–245, 6.244–245*f*, 8.72, 8.73*t*, 8.74–76. *See also* Blepharoconjunctivitis
chemical, 6.239
in children, 6.240*f*, 6.240–241, 8.243, 8.255–256
preseptal cellulitis caused by, 8.256
Chlamydia trachomatis as cause of, 6.238–239, 6.239*f*
chlamydial, 1.244, 4.52, 4.54*f*, 8.208*t*, 8.257*t*, 8.260*t*, 8.260–263, 8.261*f*, 8.262*f*
in adults, 8.257*t*, 8.260, 8.263
in neonates, 8.257*t*, 8.265
chronic papillary, 7.185

cicatrizing, 4.53, 4.54*f*, 8.47*t*, 8.299, 8.300–301, 8.301*t*, 8.303. *See also* Mucous membrane (ocular cicatricial) pemphigoid
differential diagnosis of, 8.300–301, 8.301*t*
Corynebacterium causing, 8.245
coxsackievirus, 8.240, 8.240*t*
enterovirus, 8.240, 8.240*t*
Epstein-Barr virus causing, 6.243, 8.230–231
follicular, 4.50, 4.50*f*, 4.51, 4.51*f*, 6.241, 6.243, 7.190, 7.190*f*, 8.47*t*, 8.48–49, 8.49*f*
in acute hemorrhagic conjunctivitis, 8.240
adenoviral, 8.233, 8.234
Epstein-Barr virus causing, 8.230–231
in influenza, 8.240*t*
in measles, 8.239, 8.240*t*
in mumps, 8.240, 8.240*t*
rhinovirus causing, 8.240*t*
RNA viruses causing, 8.239
toxic, 8.90*t*, 8.91, 8.91*f*
varicella-zoster virus causing, 8.225, 8.226
giant papillary (GPC), 3.231*f*, 3.234, 7.142, 7.142*f*
after penetrating keratoplasty, 8.426
gonococcal/hyperacute gonococcal, 8.208*t*, 8.245, 8.257*t*, 8.258–260, 8.259*f*, 8.260*t*
in neonates, 8.257*t*, 8.258, 8.264
in graft-vs-host disease, 8.303
granulomatous, 4.51–52, 4.52*f*
in Parinaud oculoglandular syndrome, 8.265–266
Haemophilus causing, 4.52, 8.208*t*, 8.256, 8.257*t*
hay fever, 8.288–289
hemorrhagic, 1.264
herpes simplex, 4.52, 6.239, 6.242, 8.208*t*, 8.213, 8.214*f*, 8.216, 8.226*t*, 8.257*t*, 8.260*t*
herpes zoster, 4.52, 8.225–230, 8.226*t*. *See also* Herpes zoster ophthalmicus
in HIV infection/AIDS, 8.240*t*, 8.241, 8.260*t*, 9.334
hyperacute, 8.257*t*
gonococcal, 8.208*t*, 8.245, 8.257*t*, 8.258–260, 8.259*f*, 8.260*t*
in infants, 8.257*t*, 8.263–265. *See also* Ophthalmia neonatorum
infectious, 4.52–53, 4.54*f*, 6.237–243. *See also specific type and causative agent*
ligneous, 6.249, 8.294*f*, 8.294–295
Loa loa causing, 8.282, 8.282*f*
measles virus causing, 8.239, 8.240*t*
medication toxicity causing, 8.80–81, 8.81*t*, 8.90*t*, 8.90–91
meningococcal, 8.257*t*
microsporidial, 8.280*f*, 8.280–281
molluscum contagiosum as cause of, 6.243, 6.244
mumps virus causing, 8.240, 8.240*t*
in neonates
chlamydial, 1.244
description of, 8.257*t*, 8.263–265. *See also* Ophthalmia neonatorum
inclusion, 6.238
noninfectious, 4.52–55, 4.54*f*
ophthalmia neonatorum, 8.257*t*, 8.263–265
Chlamydia trachomatis as cause of, 6.238–239, 6.239*f*, 8.257*t*, 8.265
definition of, 6.237
epidemiology of, 6.237
etiology of, 6.237
herpes simplex virus as cause of, 6.239
Neisseria gonorrhoeae as cause of, 6.238*f*, 6.238–239
Neisseria meningitidis as cause of, 6.238
prevalence of, 6.237
prophylaxis for, 6.239
papillary, 4.50, 4.50*f*, 4.51*f*, 8.47*t*, 8.48*f*, 8.426
in Parinaud oculoglandular syndrome, 4.51, 8.265–266
perennial allergic, 6.246–248
pneumococcal, 8.256, 8.257*t*
in reactive arthritis/Reiter syndrome, 1.157, 8.305–306, 9.133
RNA viruses causing, 8.239
in rosacea, 8.70
rubella as cause of, 9.260
in sarcoidosis, 4.52, 4.52*f*
seasonal allergic, 6.246*f*, 6.246–248, 8.288–289
seroconversion, in HIV infection/AIDS, 8.240*t*, 8.241
signs and symptoms of, 6.237
solitary granulomatous, 9.334
staphylococcal/staphylococcal blepharitis and, 8.73*t*, 8.74, 8.75, 8.76, 8.254, 8.256, 8.257*t*
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296*f*, 8.296–297
streptococcal, 8.208*t*, 8.256, 8.257*t*
subacute, 8.257*t*
toxic, 3.232
medications causing, 8.80–81, 8.81*t*, 8.90*t*, 8.90–91
varicella-zoster virus as cause of, 6.242–243, 8.225–230, 8.226*t*. *See also* Herpes zoster ophthalmicus
viral, 4.52, 6.241–243, 6.243–244*f*, 8.208*t*. *See also specific virus*
Conjunctivochalasis, 7.297*f*, 7.302, 8.45*t*, 8.85*f*, 8.85–86, 8.114
surgical management of, 8.86, 8.361–362
Conjunctivodacryocystorhinostomy (CDCR), 6.227–228, 7.288, 7.304*f*, 7.304–305, 7.307, 7.311
Conjunctivoplasty, 6.172
Connective tissue disorders. *See also* Collagen vascular diseases; *specific disorder*
cataract surgery in patient with, 11.170–171, 11.171*f*
corneal changes in, 8.190–196, 8.191–192*t*, 8.193*f*, 8.194*f*, 8.195*f*, 8.195*t*
peripheral ulcerative keratitis in, 8.312
refractive surgery in patient with, 13.37, 13.171, 13.191
scleritis in, 8.323, 8.325*f*
tumors, 6.222
Connective tissue mast cells, 9.2–3
Conoid of Sturm, 3.40, 3.76, 3.76*f*, 3.160, 3.161*f*
Consanguinity, 2.206, 2.237
Consecutive anophthalmia, 7.35
Consecutive esotropia, 6.95
Consecutive exotropia, 6.16, 6.104
Consecutive hyperopia, 13.101–102
Consecutive myopia, 13.101–102
Consecutive strabismus, 6.16
Consensual response, in pupillary reaction to light, 5.254

Consent, informed. *See also* Informed consent
for cataract surgery, 11.87–88
for refractive surgery, 13.36*t*, 13.46–48, 13.47*t*
in patient with ocular or systemic disease, 13.171–172
phakic IOL insertion and, 13.140–141
refractive lens exchange and, 13.147–148
CONSORT (Consolidated Standards of Reporting Trials) Statement, 1.14
Constant exotropia, 6.103–105, 6.104*f*
Constant suppression, 6.49
Constructive interference, 3.100, 3.119
Contact applanation, for axial length measurement, in IOL power determination/selection, 11.83
Contact B-scan ultrasonography, 12.39, 12.39*f*
Contact dermatoblepharitis/dermatitis/conjunctivitis, 8.285–287, 8.286*f*
Contact inhibition, in corneal wound repair, 4.13
Contact lens method, for IOL power calculation after refractive surgery, 13.195
Contact lens solutions
Acanthamoeba keratitis and, 8.276, 8.277
Fusarium keratitis and, 8.273–274
ocular surface toxicity and, 8.91
Contact lenses (CLs), 1.269. *See also* Rigid gas-permeable (RGP) contact lenses; Soft (flexible) contact lenses; *specific type*
Acanthamoeba keratitis associated with, 4.78–79, 8.276, 8.277
accommodation and, 3.178, 3.208–211, 3.209*f*, 3.210*t*
accommodative demand through, 3.210*t*
amblyopia treated with, 6.304
anisometropia and, 3.139, 3.206–208
astigmatism correction using, 3.211–212, 3.222–223, 3.223*t*, 13.17
after refractive surgery, 13.199
bacterial keratitis associated with, 8.266–267
orthokeratology and, 13.71
bandage, 3.227–228, 8.368
for chemical injuries, 8.383
contraindications to, in exposure keratopathy, 8.80
for corneal abrasion, 8.398
for dry eye, 8.61*t*, 8.63, 8.368
for graft-vs-host disease, 8.304, 8.305*f*
after LASIK, 13.93, 13.111, 13.200
for epithelial ingrowth, 13.122
for epithelial sloughing/defects, 13.112
microkeratome complications and, 13.111
for striae, 13.113
for penetrating and perforating ocular trauma, 8.402
for peripheral ulcerative keratitis, 8.313
for recurrent corneal erosion, 8.87, 8.368
for superior limbic keratoconjunctivitis, 8.84
after surface ablation, 13.92, 13.107, 13.200
sterile infiltrates and, 13.108, 13.108*f*
for Thygeson superficial punctate keratitis, 8.307
base curve of, 3.205, 3.215*f*, 3.216
bifocal
alternating vision, 3.207*t*, 3.224*f*, 3.224–225
presbyopia correction using, 3.224–225
simultaneous vision, 3.207*t*, 3.225, 3.225*f*
care of, 3.229–230
complications/problems associated with
allergic reactions, 3.233–234
corneal abrasions, 3.233
corneal warpage, 3.232–233
dry eye, 3.234–235
giant papillary conjunctivitis, 3.231*f*, 3.234
hypoxic/metabolic, 3.230–232, 3.231*t*
infections, 3.230, 3.231*f*, 3.231*t*
inflammation, 3.231*t*, 3.233–234
keratoconjunctivitis, 3.233
mechanical, 3.231*t*, 3.232–233
9-o' clock staining, 3.233, 3.233*f*
ptosis, 3.233
punctate keratitis, 3.232–233
risk factors for, 3.214
sterile corneal infiltrates, 3.231*f*, 3.234
3-o' clock staining, 3.233, 3.233*f*
toxic, 3.231*t*, 3.232
toxic conjunctivitis, 3.232
concentric, 3.225
contraindications for, 3.214
convergence affected by, 3.178
corneal abnormalities corrected using, 3.225–226
corneal abrasion caused by, 8.399
custom, 3.228–229
daily-wear, 3.214–215
description of, 2.365–366
diameter of, 3.205, 3.215*f*, 3.216
discontinuing use of before refractive surgery, 13.22–23, 13.38
disinfection of, 3.229
Dk, 3.213, 3.215
Dk/t, 3.213
dry eye and, 8.54, 8.55*f*
extended-wear
deep stromal neovascularization associated with, 3.232
description of, 3.215
FAP-SAM rules for, 3.220, 3.220*f*
Federal Fairness to Contact Lens Consumers Act, 3.235
federal laws regarding, 3.235
filtering bleb and, 10.211
fitting of. *See also* Fitting (contact lens)
goals for, 3.215
LARS rule for, 3.223, 3.224*f*
rigid gas-permeable lens, 3.218–3.221*f*, 3.218–222, 3.220*t*
soft contact lens, 3.216–217, 3.217*f*, 3.217–3.218*t*
terminology associated with, 3.215*f*, 3.215–216
toric soft lens, 3.222–223, 3.224*f*
flexible. *See* Soft (flexible) contact lenses
fundus on, 12.22
fungal keratitis associated with, 4.78, 8.273–274
gas-permeable scleral, 3.226–227
geometry of, 3.215*f*, 3.215–216
history of use of, refractive surgery evaluation and, 13.38
hybrid
description of, 3.226
indications for, 3.207*t*
ideal characteristics of, 3.212–213

image magnification by, 3.255
image size and, 3.206–208
induced anisophoria corrected using, 3.190
keratitis/keratoconjunctivitis associated with use of, 3.233, 4.78–79, 8.84, 8.266–267, 8.273–274, 8.276–277
orthokeratology and, 13.71
for keratoconus, 3.225–226, 8.166, 8.167*f*
for keratoglobus, 8.171
after LASIK, 13.199, 13.200
lens dislocation treated with, 6.310
materials used in, 3.212–214
monovision and, 13.164
as trial for surgery, 13.39, 13.165, 13.198
for myopia reduction (orthokeratology), 3.228, 13.70–71
ocular surface problems/complications with, 8.84, 8.266–267, 8.273–274, 8.276, 8.277
optical zone of, 3.215*f*, 3.216
optics of, 3.206–212
for orthokeratology, 3.228, 13.70–71
over-the-counter, 3.235
overrefraction of, 3.227
overwear syndromes, 3.230
oxygen permeability of, 3.213, 3.215
parts of, 3.215*f*
patient education about, 3.230
patient history-taking for, 3.214
for pellucid marginal degeneration, 8.169
after penetrating keratoplasty, 8.432, 13.178
peripheral curve of, 3.205, 3.215*f*, 3.216
in photocoagulation delivery, 12.375
physical examination before, 3.214
piggyback, 3.226
polymethylmethacrylate, 3.213
power of, 3.220–3.221*f*, 3.220–222
Prentice rule and, 3.206
for presbyopia, 3.223–225
prevalence of, 3.206
after radial keratotomy, 13.52, 13.199, 13.199*f*, 13.199–200
reading glasses over, 3.223
rear vertex power of, 3.216, 3.216*t*
after refractive/keratorefractive surgery, 13.198–200, 13.199*f*
rigid gas-permeable (RGP). *See also* Rigid gas-permeable (RGP) contact lenses
advantages of, 3.214*t*, 3.215
apical alignment fit of, 3.218–219, 3.219*f*
apical bearing of, 3.218
apical clearance of, 3.218
base curve of, 3.218, 3.219*f*
central fit of, 3.219
characteristics of, 3.213–214
corneal abnormalities corrected using, 3.226
corneal reshaping uses of, 3.228
disadvantages of, 3.215
fitting of, 3.218–3.221*f*, 3.218–222, 3.220*t*
fluorescein patterns for fitting evaluations, 3.219*f*, 3.219–220
indications for, 3.207*t*, 3.227
interpalpebral fit of, 3.219
keratoconus correction using, 3.226
orthokeratology, 3.228
pannus associated with, 3.232
parameters of, 3.220*t*
ptosis secondary to, 3.233
scleral, 3.226–227
soft lenses *versus*, 3.218
tear layer created by, 3.221
tear lens, 3.218, 3.218*f*
rigid (hard). *See* Rigid gas-permeable (RGP) contact lenses
sagittal depth or vault of, 3.205, 3.215*f*, 3.216
scleral
description of, 3.226
for dry eye, 8.61*t*, 8.63
gas-permeable, 3.226–227
for graft-vs-host disease, 8.304, 8.305*f*
indications for, 3.207*t*
for limbal stem cell deficiency, 8.94
segmented, 3.224–225
selection of, 3.214–215
semi-scleral, 3.227
soft. *See* Soft (flexible) contact lenses
solutions for, 3.229*t*, 3.229–230
spectacle lenses and, 3.206, 3.216
after surface ablation, 13.200
therapeutic, 8.368. *See also* Contact lenses, bandage
therapeutic uses of, 3.227–228
toric soft, 3.207*t*, 3.222–223, 3.224*f*
discontinuing use of before refractive surgery, 13.38
after radial keratotomy, 13.200
tube shunt implantation and, 10.215
vault of. *See* Contact lenses, sagittal depth or vault of
wettability of, 3.213, 3.213*f*
wetting angle of, 3.213
Contact specular microscopy, 3.295, 8.23
Contiguous gene-deletion syndrome, 2.225
Continuous curvilinear capsulorrhexis (CCC), 11.108–110, 11.109*f*. *See also* Capsulorrhexis
capsule staining for, 11.178–179, 11.179*f*
for ECCE, 11.196
for phacoemulsification, 11.108–110, 11.109*f*
Continuous data, 1.6
Continuous positive airway pressure (CPAP)
description of, 1.126–127
obstructive sleep apnea treated with, 1.127
Continuous quality improvement
data presentation to facilitate, 1.28, 1.29–30*f*
features of, 1.28, 1.30–31
fishbone diagram for, 1.30–31
flowchart for, 1.30, 1.31f
Continuous sutures, for penetrating keratoplasty, 8.419*f*
postoperative problems and, 8.419*f*, 8.426, 8.426*f*, 8.431–432, 8.432*f*
Continuous-wave lasers, 3.112
Contour interaction bars, 6.7*f*, 6.8
Contour stereopsis, 6.81
Contraceptives (oral), central retinal vein occlusion risks, 12.134
Contracted fornices, 7.143
Contracted sockets, 7.143–144, 7.144*f*
Contraction, wound, 4.13
eyelid/orbit scarring and, 4.17

Contralateral antagonist, inhibitional palsy of, 6.120–121, 6.121*f*
Contralateral corneal autograft, 8.451–452
Contrast. *See also* Contrast sensitivity
  measurement of, 3.134
Contrast/catheter/conventional angiography, 5.68, 5.68*f*, 5.337*f*
  in aneurysm detection/evaluation, 5.195, 5.340, 5.341*f*
  in arteriovenous malformations, 5.292*f*, 5.344, 5.344*f*
  in reversible cerebral vasoconstriction syndrome, 5.347, 5.347*f*
  in vertebrobasilar insufficiency, 5.337*f*, 5.338
Contrast dacryocystography, 7.300
Contrast media
  adverse effects of, 2.458
  for angiography, 5.68, 5.68*f*
  for CT studies, 5.60
  gadolinium-based, for magnetic resonance imaging, 2.458
  iodinated, for computed tomography, 2.457
  for MRI studies, 5.60
Contrast sensitivity, 12.56–57, 12.57*f*
  cataracts and, 11.70, 11.77
  definition of, 3.123
  description of, 3.134–136, 3.136*f*
  higher-order aberrations affecting, 13.12, 13.76
  illumination requirements for, 3.318
  low vision/vision rehabilitation and, 3.314–315, 5.88
  with multifocal IOLs, 13.156
  with phakic IOLs, 13.144
  poor levels of, 3.314
  posterior subscapular lens opacity effects on, 3.67
  sunglasses' effect on, 3.192
  testing, 5.88, 11.77
    in low vision evaluation, 5.88
  testing of, 3.315, 3.316*f*
  with wavefront-guided/optimized and topography-guided ablations, 13.77
Contrast sensitivity function (CSF), 3.123, 3.134–136, 3.260
Contrast threshold, 3.124, 3.135
Contrecoup, 12.315
Control charts, 1.28, 1.30*f*
Control group, 1.4–6, 1.11
Contusion cataract, 11.54, 11.54*f*
Contusion injury. *See also* Blunt (concussive) trauma; Trauma
  lens damage caused by, 11.53–55, 11.54*f*
Convergence, 5.226
  accommodative, 6.39, 6.59
  assessment of, 5.226–227, 6.71
  contact lens correction effects on, 3.178, 3.212*f*
  definition of, 6.39
  dysfunction of, 5.227
  fusional, 6.39, 6.43, 6.72
  near point of, 6.71
  proximal (instrument), 6.39
  spectacle lens correction effects on, 3.178
  symmetric, 6.41
  tonic, 6.40
  voluntary, 6.40
Convergence amplitude, 5.226
  in convergence insufficiency, 5.227
Convergence insufficiency (CI), 5.227, 6.103
Convergence paralysis, 6.105–106
Convergence-retraction nystagmus (CRN/induced convergence-retraction), 5.243*t*, 5.250, 6.152–153
Convergence spasm, 5.227, 6.94
Convergent nystagmus, 1.208
Convergent rays. *See* Convergence
Converging lens, for hyperopia correction, 3.170, 3.170*f*
Conversion disorder, 1.197
Convex lenses
  description of, 3.8–9
  image formation, 3.9*f*
  ray tracing for, 3.62*f*
  spherical lens combined with, 3.17
Convex mirrors, ray tracing for, 3.82*f*
Coombs and Gell hypersensitivity classification. *See* Hypersensitivity reactions
Coombs-positive hemolytic anemia, 1.135
Copaxone. *See* Glatiramer
COPD. *See* Chronic obstructive pulmonary disease
Copeland retinoscope, 3.150, 3.156
Copeland streak projection system, 3.150
Copper, 12.362
  in aqueous humor, 2.274
  corneal deposition of, 11.59
    Kayser-Fleischer ring and, 8.118*t*, 8.173, 8.189, 8.189*f*, 11.62
  deficiency of, optic neuropathy caused by, 5.138
  foreign body of, 11.59
  "sunflower" cataract and
    in chalcosis/Wilson disease and, 8.189
    description of, 11.59
  in Wilson disease/chalcosis, 1.136, 8.189, 11.59, 11.62
Copper-zinc superoxide dismutase (CuZnSOD), 2.342
Cor pulmonale, 1.126
Core therapy, for glaucoma, indications for surgery and, 10.197
Corectopia, 5.255, 6.268
  cataract surgery in patient with, 11.180
  in iridocorneal endothelial syndrome, 10.136, 10.137*f*
  iridodialysis repair and, 8.375
Cornea, 4.73–96, 4.74*f*. *See also under Corneal*
  abrasions of, 3.233, 4.13–14, 7.214, 8.398–399
    contact lenses causing, 8.399
    description of, 6.376
    in mucous membrane pemphigoid, 8.300
    posttraumatic recurrent corneal erosion and, 8.86, 8.87, 8.398
  age-related changes in, 8.115
  air–tear film interface, 2.49
  aldehyde dehydrogenase in, 2.260
  amyloid deposits in. *See* Cornea, deposits in
  anatomy of, 2.48, 2.48*f*, 3.268–271, 3.269–3.271*f*, 4.73, 4.74*f*, 8.7*f*, 8.7–10, 8.9*f*
  anesthesia/hypoesthesia of
    congenital, 8.108
    herpes simplex epithelial keratitis and, 8.217–218, 8.226*t*
    herpes zoster and, 8.226*t*, 8.228
    keratoplasty and, 8.418, 8.424

after LASIK, 13.172
neurotrophic keratopathy/persistent corneal defects and, 8.80, 8.224
anterior surface of, 3.270
apex of, 8.25, 8.26*f*
apical zone of, 3.205, 3.215, 3.228, 8.25
aspheric, 3.269, 3.279, 13.14
avascularity of, 2.259
axial map of, 3.269*f*
basal lamina of, 2.51, 2.52*f*
biochemistry of, 2.259–260
biomechanics of, 8.43, 13.13–14
measurement of, 8.43
biopsy of, 8.210, 8.211*f*, 8.366–367
blood staining of, 4.86, 4.86*f*, 8.118*t*, 8.375, 8.394, 8.394*f*, 8.395, 8.395*t*, 10.104, 10.104*f*, 10.105
hyphema after cataract surgery and, 11.159
Bowman layer/membrane of, 4.73, 4.74*f*, 8.7*f*, 8.8. *See also* Bowman layer/membrane
healing/repair of, 4.16
preparation for refractive surgery and, 13.82–90
calcification of. *See* Band keratopathy/calcific band keratopathy
central, 2.51, 8.25, 8.25*f*. *See also* Central cornea
healing in, 4.14–16, 4.15*f*
chemical injury of, 8.375–384, 8.376*t*. *See also* Chemical injury
clouding of, 6.179, 6.385, 6.387*f*
collagen fibrils of, 2.53
congenital/developmental anomalies of, 4.73–74, 4.74*f*, 4.75*f*, 8.95–109, 8.96–98*t*. *See also specific type*
in hereditary syndromes and dystrophies, 8.107
opacities, 8.16*f*, 8.107. *See also* Cornea, opacification of
secondary abnormalities causing, 8.107–109
of size and shape, 8.95–101, 8.96*t*, 8.99*f*
structural, 8.101–107, 8.102*f*, 8.103*f*, 8.105*f*, 8.106*f*
conjunctivalization of, 8.362
curvature of, 8.25–26. *See also* Cornea, topography of
axial, 8.28, 8.29*f*, 13.16, 13.16*f*, 13.17*f*
in cornea plana, 8.96*t*, 8.100
evaluation of, 8.25–36. *See also* Cornea, topography of; Keratometry/keratometer; Keratoscopy
corneal zones and, 8.25, 8.25*f*, 8.26*f*
keratometry for, 8.26–27, 8.27*f*
keratoscopy for, 8.27–28, 8.28*f*
Placido disk-based topography for, 8.27–28, 8.35*t*
shape/curvature/power and, 8.25–26
tomography for, 8.33–36, 8.34*f*, 8.35*f*, 8.35*t*
topography for, 8.28–36, 8.29*f*, 8.30*f*, 8.31*f*, 8.32*f*, 8.32*t*, 8.33*f*, 8.35*t*
after keratorefractive surgery, 3.269
mean, 8.28
measurement of, 13.14–19, 13.15–19*f*, 13.44–45, 13.45*f*
power and, 8.25–26, 13.7–9
radius of, 8.8, 8.27
in cornea plana, 8.100
instantaneous (meridional/tangential power), 13.16–17, 13.17*f*
keratometry in measurement of, 8.27
in schematic eye, 3.127*t*
refractive surgery affecting, 13.9, 13.26–28, 13.27*f*, 13.28*f*
IOL power calculation and, 13.193–197, 13.196*f*
in schematic eye, 3.127*t*
defense mechanisms of, 8.11–14, 8.12–13*f*, 8.13*f*
degenerations/dystrophies of, 4.81–94. *See also* Corneal degenerations; Corneal dystrophies; *specific type*
degenerations, 4.81–86, 8.115–128
dystrophies, 4.86–94, 8.133–160, 8.134*t*, 8.135*t*, 8.136*t*
delle of, 6.172, 6.172*f*
deposits in, 8.16*f*
amyloid. *See also* Amyloidosis/amyloid deposits
in gelatinous droplike corneal dystrophy, 8.141, 8.141*f*, 8.185–187, 8.186*t*
in granular corneal dystrophy type 1 (GCD2/Avellino), 8.148, 8.186*t*
in lattice corneal dystrophy, 4.89*f*, 4.89–90, 8.145, 8.146, 8.147*f*, 8.185–187
in polymorphic amyloid degeneration, 8.122, 8.123*f*, 8.186*t*
copper/Wilson disease causing, 8.118*t*, 8.173, 8.189, 8.189*f*, 11.59, 11.62
crystalline, 8.182*t*
in cystinosis, 8.181*f*, 8.181–182
in hematologic disorders, 8.197–199, 8.198*f*, 8.199*f*
in cystinosis, 8.181*f*, 8.181–182
drug-induced, 8.129*t*, 8.129–132, 8.130*f*, 8.131*f*
dystrophies and, 8.133
pigment, 4.86, 8.118*t*
drug-induced, 8.129*t*, 8.129–132, 8.130*f*, 8.131*f*
Descemet membrane/layer of, 4.73, 4.74*f*, 8.7*f*, 8.9. *See also* Descemet membrane/layer
development of, 2.161–162*f*
diameter of, 6.179, 6.281, 8.7
in infants and children, 10.158
glaucoma and, 10.151, 10.156, 10.158
disorders of, 4.73–96, 8.46*t*, 8.49–53, 8.50*t*. *See also* Keratitis; Keratoconjunctivitis; Keratopathy; *specific type*
acquired, 6.269
blunt trauma causing, 8.388, 8.389*f*
as cataract surgery complication, 11.128*t*, 11.128–132, 11.129*f*
cataract surgery in patient with, 11.174*f*, 11.174–177, 11.177*f*, 11.191–192
central corneal transparency, 6.257–258*t*, 6.257–263, 6.258*f*
common clinical findings in, 8.46*t*, 8.49–53, 8.50*f*, 8.50*t*, 8.51*f*, 8.52*f*
congenital hereditary endothelial dystrophy, 6.257*t*
congenital hereditary stromal dystrophy, 6.257*t*, 6.259
conjunctival flap for, 8.354*f*, 8.356–360, 8.357*f*, 8.358*f*, 8.359*f*
contact lens-related, 8.84, 8.266–267, 8.273–274
cornea plana, 6.255, 6.255*f*
in cystinosis, 6.270, 6.387*f*
decreased vision and, 5.99
degenerations/dystrophies, 4.81–94. *See also* Corneal degenerations; Corneal dystrophies; *specific type*

degenerations, 4.81–86, 8.115–128
dystrophies, 4.86–94, 8.133–160, 8.134*t*, 8.135*t*, 8.136*t*
dermatologic diseases and, 8.201–203
dermolipoma, 6.256–257
diffuse corneal transparency, 6.257–258*t*, 263, 6.258*f*
ectatic, 4.95*f*, 4.95–96, 8.161–171. *See also* Ectatic disorders/ectasia
endocrine diseases and, 8.199–201, 8.200*t*, 8.201*f*
epibulbar dermoid, 6.256, 6.256*f*, 6.257*t*
in Fabry disease, 6.270, 6.388*t*
in familial dysautonomia, 6.270
forceps injury, 6.257*t*
hematologic disorders and, 8.197–199, 8.198*f*, 8.199*f*
illusions caused by, 5.174
immune-mediated, 8.306–318
transplant rejection and, 8.316–318, 8.428–431
infections, 6.257*t*
ionizing radiation causing, 8.386
keratitis, 6.269
keratoconus, 6.254
keratoglobus, 6.254
keratoplasty for, 6.262–263
medications causing, 8.80–81, 8.81*t*, 8.90*t*, 8.90–91
crystalline deposits, 8.182*t*
megalocornea, 6.253*f*, 6.253–254
metabolic disorders and, 8.174–190. *See also specific disorder*
amino acid/nucleic acid/protein/mineral metabolism and, 8.181*f*, 8.181–190, 8.182*t*, 8.183*t*, 8.184*f*, 8.185*f*, 8.186*t*, 8.187*f*, 8.188*f*, 8.189*f*
lipoprotein metabolism and, 8.179–181, 8.180*f*
lysosomal storage diseases and, 8.174–179, 8.175*t*, 8.176*f*, 8.177*f*
microcornea, 6.254, 6.254*f*
in mucopolysaccharidoses, 6.257*t*, 6.270, 6.385, 6.387*f*, 6.388*t*
neoplastic, 4.96, 8.327–350. *See also* Cornea, tumors of; *specific tumor*
nutritional disorders and, 8.196–197, 8.197*f*
peripheral corneal transparency, 6.255–256*f*, 6.255–257
posterior corneal defect, 6.257*t*
posterior embryotoxon, 6.255, 6.255*f*
in rosacea, 8.70, 8.70*f*
in Schnyder corneal dystrophy, 6.270, 6.387*f*
sclerocornea, 6.257*t*
size- or shape-related, 6.253–254, 6.253–254*f*
skeletal/connective tissue disorders and, 8.190–196, 8.191–192*t*, 8.193*f*, 8.194*f*, 8.195*f*, 8.195*t*
systemic conditions that cause, 6.269–271
systemic disorders and, 8.173–203
therapeutic/surgical interventions/transplantation for, 8.366–373, 8.417*t*, 8.417–419. *See also* Cornea, transplantation of; Keratoplasty; *specific procedure*
layer-based approach to, 8.417, 8.417*t*
preoperative evaluation/preparation and, 8.418–419
thermal burns causing, 8.384–385, 8.385*f*
treatment of, 6.262–263
in tyrosinemia type II, 6.270
ulcers, 6.248, 6.249*f*, 6.262–263
ultraviolet radiation causing, 8.385–386
vitamin A deficiency and, 8.196–197, 8.197*f*
in Waardenburg syndrome, 6.270
in Wilson disease, 6.270
donor. *See* Donor cornea
dysplasia of (corneal intraepithelial neoplasia/CIN), 2.414, 4.61, 4.63*f*, 4.96, 8.37, 8.38*f*, 8.332*t*, 8.334–8.335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
dystrophies of. *See* Corneal dystrophies
ectasia of. *See* Ectatic disorders/ectasia
ectatic, 4.95*f*, 4.95–96, 8.161–171. *See also* Ectatic disorders/ectasia
edema of, 2.251, 8.41–42, 9.54*f*
acute, 6.254, 8.41
biomechanics and, 13.13–14
birth trauma causing, 8.109
after cataract surgery, 11.128*t*, 11.128–130
ECCE, 11.198
ICCE, 11.201
persistent, with vitreocorneal adherence, 11.130
cataract surgery in patient with, 11.191–192
chronic, 8.41–42
cold-induced, 8.385
in congenital hereditary endothelial dystrophy, 8.160
in Fuchs endothelial dystrophy, 8.156, 8.157, 8.157*f*
illusions and, 5.174
intraocular surgery and, 8.42
in iridocorneal endothelial syndrome, 10.136
in keratoconus, 8.163–164, 8.164*f*, 8.167–168
in primary congenital glaucoma, 6.279–280, 8.108–109, 10.151, 10.158
refractive surgery contraindicated in, 13.43
tonometry accuracy and, 10.24
effector cells in, 9.54
endothelium of, 4.73, 4.74*f*, 8.7*f*, 8.10
anatomy of, 2.54–55*f*, 8.7*f*, 8.10
cells of, 2.54, 2.266–267, 2.267*f*, 2.267*t*
definition of, 2.266
dysfunction of, 8.52
keratoplasty for, 8.411, 8.436–450. *See also* Keratoplasty, endothelial
healing/repair of, 4.16
keratorefractive surgery and, 13.32–33
multifocal IOL implantation and, 13.155
phakic IOL implantation and, 13.141
angle-supported lenses, 13.146
iris-fixated lenses, 13.145
posterior chamber lenses, 13.146
pigmentation of/deposits in, 8.118*t*, 8.132
enlargement of, 8.95, 8.96*t*, 8.99*f*, 8.99–100. *See also* Megalocornea
in pediatric/primary congenital glaucoma, 8.95, 8.96*t*, 8.99–100, 8.108, 10.31, 10.147, 10.158
epithelial cells of, 2.261–262, 2.262*f*
epithelium of, 2.51, 2.52*f*, 2.260–262, 2.261–262*f*, 2.375, 4.73, 4.74*f*, 7.296, 8.7*f*, 8.8
anatomy of, 8.7*f*, 8.8
cysts of, 8.130

debridement of
for epithelial defects
after LASIK, 13.112
after surface ablation, 13.108
for surface ablation, 13.82–84, 13.83*f*
defects/persistent defects of, 6.376, 8.46*t*, 8.80–82, 8.81*t*, 8.82*f*
acid burns causing, 8.380, 8.380*f*
after cataract surgery, 11.132, 11.173
glaucoma medication toxicity and, 10.31
after LASIK, 13.93, 13.112
in diabetes mellitus, 13.190
management of, 8.368
after penetrating/deep anterior lamellar keratoplasty, 8.80, 8.424
after surface ablation, 13.107–108
topical anesthetic use/abuse and, 8.80–81, 8.81*t*, 8.89, 8.89*f*
in toxic keratoconjunctivitis, 8.80–81, 8.81*t*
drug-induced deposits in, 8.129*t*, 8.130*f*, 8.130–132, 8.131*f*
dysplasia of (corneal intraepithelial dysplasia/CIN), 2.414, 4.96, 8.37, 8.38*f*, 8.332*t*, 8.334–8.335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
external eye defense and, 8.12*f*, 8.13*f*, 8.13–14, 8.207
healing/repair of, 4.13–14, 4.15*f*
keratorefractive surgery and, 13.32–33
delayed, 13.93–94, 13.108
preparation of, for refractive surgery, 13.82–84, 13.83*f*
preservation techniques for
in epi-LASIK, 13.84
in LASEK, 13.84
tumors of, 8.332*t*, 8.332–337
erosions of
in epidemic keratoconjunctivitis, 8.234
punctate epithelial, 8.46*t*, 8.50, 8.50*f*, 8.50*t*
in exposure keratopathy, 8.80
in herpetic eye disease/neurotrophic keratopathy, 8.224
in vernal keratoconjunctivitis, 8.290
recurrent, 8.79, 8.86–88
dystrophic, 8.86, 8.87, 8.133, 8.135*t*
in epithelial basement membrane dystrophy, 8.86, 8.87, 8.133, 8.138
in lattice corneal dystrophy type 1, 8.147
in Reis-Bücklers corneal dystrophy, 8.143
eye pain and, 5.295, 8.86, 8.87
management of, 8.368
posttraumatic, 8.86, 8.87
examination of, 8.15–43. *See also* Examination, ophthalmic
before cataract surgery, 11.78–79, 11.84
in glaucoma, 10.31, 10.33*t*, 10.34*f*
in infants and children, 10.158
before refractive surgery, 13.42–43
exposure of, in facial palsy, 5.280–281
in external eye defense, 8.11–14, 8.12–13*f*, 8.13*f*
farinata, 8.121–122, 8.122*f*
fetal, secondary abnormalities affecting, 8.107–109
flat (cornea plana), 6.255, 6.255*f*, 8.96*t*, 8.100–101
flap creation and, 13.44–45, 13.79
microcornea and, 8.95, 8.96*t*, 8.100
in Peters anomaly, 4.74, 4.75*f*
posterior amorphous corneal dystrophy and, 8.154–155
sclerocornea and, 8.96*t*, 8.98*t*, 8.100, 8.105
foreign body in, 6.376, 8.399–400, 8.400*f*, 8.401*f*, 8.403
insect stingers/hairs, 8.386–387
plant/vegetation, 8.387, 8.399
radioactive, 8.386
removal of, 8.403
glaucoma/glaucoma therapy affecting, 10.31
glucose metabolism by, 2.259
glycosaminoglycans in, 2.263
ground substance of, 2.53
growth and development of, 6.181
guttae/guttata, 8.23*f*, 8.128
age-related, 8.115
Brown-McLean syndrome and, 11.130
cataract surgery and, 11.79
in Fuchs endothelial corneal dystrophy, 4.92, 4.93*f*, 8.23*f*, 8.156, 8.157*f*
in luetic keratitis, 4.80
peripheral (Hassall-Henle bodies/warts), 2.53, 8.115, 8.128
refractive surgery and, 13.43
healing/repair of, 4.13–16, 4.15*f*
keratorefractive surgery and, 13.32–33
delays in, 13.93–94, 13.108
herpes simplex latency in, 8.215
hydration of, 8.9, 8.41–42. *See also* Cornea, edema of
pachymetry in measurement of, 8.41–42
hypoesthesia of. *See* Cornea, anesthesia/hypoesthesia of
imaging of. *See also* Cornea, topography of; *specific type*
for keratorefractive surgery, 13.14–26, 13.44–45, 13.45*f*. *See also* Cornea, topography of; *specific type*
indications for, 13.22–24, 13.23*f*, 13.24*f*
postoperative evaluation and, 13.23*f*, 13.23–24, 13.24*f*
preoperative evaluation and, 13.14–26, 13.44–45, 13.45*f*, 13.79–80
immunologic microenvironment of, 9.52*t*, 9.54*f*, 9.54–55
immunoregulatory systems of, 9.54–55
infection/inflammation of, 4.75–81, 4.76*f*, 4.77*f*, 4.78*f*, 4.79*f*, 4.80*f*, 4.81*f*, 8.266–283. *See also* Keratitis; Keratoconjunctivitis
contact lens wear and, 8.84, 8.266–267, 8.273–274
signs of, 8.49–53, 8.50*f*, 8.50*t*, 8.51*f*, 8.52*f*
innervation of, 8.8. *See also* Corneal nerves
intraepithelial neoplasia of (CIN), 4.96, 8.37, 8.38*f*, 8.332*t*, 8.335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
keloids of, 8.125
congenital, 8.107–108, 8.125
keratitis-related scarring of, 6.245*f*
keratocytes of, 2.53
Khodadoust line of endothelial rejection, 9.54, 9.54*f*
lacerations of. *See* Corneoscleral lacerations
lactic acid accumulation in, 2.260
layers of, 2.50*f*, 2.50–55, 2.52–54*f*, 4.73, 4.74*f*

marginal (catarrhal) infiltrates of, 8.310–311
staphylococcal blepharitis/blepharoconjunctivitis and, 8.74, 8.74*f*
matrix metalloproteinases in, 2.264
melting (keratolysis) of, 9.25
cataract surgery and, 11.132
in patient with dry eye, 11.132
management of, 8.369*f*, 8.369–370
neurotrophic keratopathy/persistent corneal epithelial defects and, 8.81, 8.82
peripheral ulcerative keratitis and, 8.311, 8.312
refractive surgery and, 13.94
topical medication toxicity and, 4.80–81
meridional map of, 3.269*f*
neovascularization/vascularization of
in atopic keratoconjunctivitis, 8.292, 8.293*f*
corneal transplantation and, 8.317, 8.435
pediatric, 8.451
inflammation and, 8.52
after lamellar keratoplasty, 8.435
in rosacea, 8.70, 8.70*f*
in stem cell deficiency, 8.92, 8.93
in vernal keratoconjunctivitis, 8.290
oblate shape of, 13.14, 13.26
after radial keratotomy, 13.50
opacification of, 8.16*f*
acid burn causing, 8.381, 8.381*f*
in cornea farinata, 8.121–122, 8.122*f*
in Fleck corneal dystrophy, 8.153, 8.154*f*
flowchart for diagnosis of, 8.16*f*
in ichthyosis, 8.202
infantile/congenital, 8.16*f*
differential diagnosis/classification of, 8.16*f*
glaucoma and, 8.108–109
in hereditary syndromes, 8.107
inflammatory, 8.16*f*, 8.52
in keratectasia and congenital anterior staphyloma, 8.98*t*, 8.106*f*, 8.106–107
lamellar keratoplasty for, 8.434
noninflammatory, 8.16*f*
in Peters anomaly, 4.74, 4.75*f*, 8.97*t*, 8.102–103, 8.103*f*, 10.154, 11.31
polymorphic amyloid degeneration and, 8.122, 8.123*f*, 8.186*t*
in posterior amorphous corneal dystrophy, 8.154, 8.154*f*
in pre-Descemet corneal dystrophy, 8.155
in primary congenital glaucoma, 8.108–109, 10.151, 10.158
in Reis-Bücklers corneal dystrophy, 4.88, 4.88*f*, 8.143
in Schnyder corneal dystrophy, 8.151, 8.152*f*
in Thiel-Behnke corneal dystrophy, 4.88, 4.89*f*, 8.143
optical zone of. *See* Optical zone, corneal
pachymetry of, 13.21*f*, 13.45–46. *See also* Pachymetry/pachymeter
corneal thickness measurement and, 13.45–46, 13.125
forme fruste keratoconus and, 13.176, 13.177*f*
paracentral zone of, 8.25, 8.25*f*
penetrating injury to, 6.376
perforation of. *See also* Corneoscleral lacerations; Penetrating and perforating ocular trauma; Trauma
foreign-body removal and, 8.403
in keratoconus, 8.163
LASIK and, 13.111
management of, 8.369*f*, 8.369–370, 8.370*f*, 8.402–403
nonsurgical, 8.402–403
surgical repair in, 8.403. *See also* Corneoscleral lacerations
radial keratotomy and, 13.52
Seidel test in identification of, 8.36, 8.38*f*
peripheral zone of, 2.51, 8.25, 8.25*f*
photoablation applications in, 3.115
physiology of, 2.259–260
pigmentation/pigment deposits in, 4.86, 8.118*t*
drug-induced, 8.129*t*, 8.129–132, 8.130*f*, 8.131*f*
plana (flat cornea), 6.255, 6.255*f*, 8.96*t*, 8.100–101
flap creation and, 13.44–45, 13.79
microcornea and, 8.95, 8.96*t*, 8.100
in Peters anomaly, 4.74, 4.75*f*
posterior amorphous corneal dystrophy and, 8.154–155
sclerocornea and, 8.96*t*, 8.98*t*, 8.100, 8.105
plasma-derived proteins in, 9.54
posterior surface of, 2.54*f*, 3.270
power of, nominal value for, 3.12
precorneal tear film of, 2.49–50, 2.259
preparation of, for refractive surgery, 13.82–90, 13.83*f*, 13.85*f*, 13.86*f*, 13.87*f*, 13.88*f*, 13.89*f*, 13.90*t*
in primary congenital glaucoma, 6.280*f*, 6.280–281
prolate shape of, 3.268, 13.9, 13.14, 13.26
proteinase inhibitors of, 2.264
proteoglycans in, 2.53
Q value of, 13.14
radius of curvature of, 2.50
refractive index of, 2.50, 3.127*t*, 8.8, 8.26
refractive power of, 8.25–26, 13.7–9
age-related changes in, 3.141
central. *See also* Central corneal power
description of, 3.243, 3.248
errors in, 3.252
measurement of, 3.270, 8.26–27, 8.27*f*, 13.7–9. *See also* Keratometry/keratometer
after penetrating keratoplasty, 3.253
in schematic eye, 3.127*t*
reshaping of
orthokeratology and, 13.70–71
using rigid gas-permeable contact lenses, 3.228
sarcoidosis involvement of, 9.196
in schematic eye, 3.127*t*
sensation in, 8.8
measurement of (esthesiometry), 8.42–43
reduction/absence of
congenital, 8.108
in herpes simplex epithelial keratitis, 8.217–218, 8.226*t*
in herpes zoster, 8.226*t*, 8.228
keratoplasty and, 8.418, 8.424
after LASIK, 13.172
in neurotrophic keratopathy/persistent corneal epithelial defects, 8.80, 8.224
shape of, 3.268–271, 3.269–3.271*f*, 8.25–26, 13.9
aspheric, 13.14
curvature and power and, 8.25–26, 13.7–9

disorders of, 8.96*t*, 8.100
orthokeratology and, 13.70–71
refractive surgery and, 13.9
tomography in evaluation of, 13.19–22, 13.20–21*f*
shield ulcer of, 6.248, 6.249*f*
size of, 8.7
disorders of, 8.95–101, 8.96*t*, 8.99*f*
specimen collection from, 8.209*t*, 8.210, 8.210*f*
staphyloma of, congenital anterior, 8.98*t*, 8.106*f*, 8.106–107
steep, flap creation and, 13.79
stem cells of, 8.8, 8.10–11, 8.92. *See also* Limbal stem cells
culture of, 8.365
sterile infiltrates, 3.231*f*, 3.234
stroma of, 4.73, 4.74*f*, 8.7*f*, 8.8–9, 8.9*f*
anatomy of, 2.53, 8.7*f*, 8.8–9, 8.9*f*
biomechanics and, 13.13–14
collagen fibers in, 2.263, 2.264–265*f*
composition of, 2.53, 2.58
degenerations of, 8.120–126
dystrophies of. *See* Stromal corneal dystrophies
healing/repair of, 4.14, 4.15*f*
inflammation of, 8.50*t*, 8.50–52, 8.51*f*
in systemic infections, 8.279
keratocytes, 2.263
neovascularization of, 8.52
pigmentation of/deposits in, 8.118*t*
drug-induced, 8.129*t*, 8.132
refractive index of, 8.26
subepithelial infiltrates of, 8.46*t*
in epidemic keratoconjunctivitis, 8.234*f*, 8.234–235, 8.235*f*
surgery on. *See* Keratorefractive surgery
systemic disorders affecting, 8.173–203
thermal injury to, 6.376
thickness/rigidity of, 4.73, 4.74*f*, 8.7, 8.25, 8.41, 8.42
corneal crosslinking and, 13.130, 13.132
glaucoma and, 10.25, 10.31, 10.81, 10.82, 10.90
in infants and children, 10.159
normal-tension glaucoma and, 10.86–87
in infants and children
normal, 10.159
in primary congenital glaucoma, 10.159
intraocular pressure/pressure measurement and, 8.41, 10.25, 10.81, 10.82, 10.86–87, 10.90, 13.105, 13.181, 13.200
in infants and children, 10.159
measurement of, 8.41–42. *See also* Pachymetry/pachymeter
before cataract surgery, 11.78–79
in keratoconus screening, 13.24, 13.26
minimum requirements for LASIK and, 13.45–46, 13.79–80
corneal perforation and, 13.111
ectasia and, 13.79
pachymetry in, 13.45–46, 13.125
before refractive surgery, 13.45–46
topography in, 13.26, 13.79–80
ocular hypertension and, 10.25, 10.90, 10.112
tonometry measurements affected by, 10.25, 10.81, 10.82, 10.86, 13.105, 13.181
thinning of
in ectatic disorders, 8.133, 8.161, 8.170*f*
in keratoconus, 8.161, 8.162, 8.163, 8.165, 8.165*f*, 8.166, 8.170*f*
in keratoglobus, 8.170*f*, 8.171
in macular dystrophy, 8.150, 8.150*f*
management of, 8.368–369
over intrastromal corneal ring segments/Intacs, 13.67, 13.68*f*
in pellucid marginal degeneration, 8.168, 8.168*f*, 8.169, 8.169*f*, 8.170*f*
in posterior amorphous corneal dystrophy, 8.154, 8.154*f*
tight junctions of, 2.51
tomography of, 8.33–36, 8.34*f*, 8.35*f*, 8.35*t*, 13.19–22, 13.20–21*f*, 13.194
in keratoconus, 8.35, 8.35*f*, 8.165*f*, 8.165–166
after refractive/keratorefractive surgery, 13.23
IOL power determination/selection and, 13.194
topography of, 3.281, 3.288–289, 4.73, 8.15, 8.28–36, 8.29–33*f*, 8.35*t*, 13.14–19, 13.15–19*f*, 13.24–26, 13.25*f*, 13.44–45, 13.45*f*
astigmatism detection/management and, 8.31, 8.32, 8.32*t*, 13.17–19, 13.18*f*, 13.19*f*, 13.22–23, 13.44, 13.45, 13.45*f*
after penetrating keratoplasty, 8.32, 8.431–432, 8.432*f*, 13.179–180
cataract surgery and, 11.84, 11.86, 11.174
central islands after surface ablation and, 13.103–104, 13.104*f*
computerized, 13.14–19, 13.15*f*, 13.16*f*, 13.17*f*, 13.18*f*, 13.19*f*, 13.44–45, 13.45*f*
in decentered ablation, 13.104, 13.104*f*
IOL power determination/selection and, 11.86
after refractive surgery, 11.86, 13.193, 13.194
in keratoconus, 8.29*f*, 8.30*f*, 8.31, 8.32*f*, 8.32*t*, 8.165*f*, 8.165–166, 13.23, 13.24, 13.25*f*, 13.44, 13.175, 13.175*f*, 13.176*f*, 13.177*f*
keratorefractive surgery and. *See* Cornea, topography of
laser ablation guidance and, 13.32
before LASIK, 13.79
limitations of, 13.19
maps generated by, 8.28–33, 8.29*f*, 8.30*f*, 8.31*f*, 8.32*f*, 8.33*f*, 13.14–19, 13.15*f*, 13.17*f*, 13.19*f*, 13.44–45, 13.45*f*. *See also* Corneal power maps
postoperative, 13.23, 13.24*f*
in pellucid marginal degeneration, 8.31, 8.33*f*, 8.169, 8.170*f*, 13.24, 13.44, 13.45*f*, 13.79, 13.176, 13.176*f*
photoablation and, 13.32
Placido-based, 13.7–9, 13.14–16, 13.15*f*, 13.17, 13.20–21*f*, 13.25*f*
IOL power calculation after refractive surgery and, 13.193
Placido disk-based, 8.27–28, 8.28, 8.35*t*
in corneal biomechanics evaluation, 8.43
after radial keratotomy, 13.50–51
refractive/keratorefractive surgery and, 13.14–19, 13.15*f*, 13.16*f*, 13.17*f*, 13.18*f*, 13.19*f*, 13.24–26, 13.25*f*, 13.44–45, 13.45*f*, 13.79
dry eye and, 13.173
indications for, 13.22–23, 13.23*f*, 13.24*f*

postoperative evaluation and, 13.23*f*, 13.23–24, 13.24*f*
preoperative evaluation and, 13.14–19, 13.15*f*, 13.16*f*, 13.17*f*, 13.18*f*, 13.19*f*, 13.24–26, 13.25*f*, 13.44–45, 13.45*f*, 13.79–80
refractive lens exchange and, 13.149
toric IOLs and, 13.151–152
transitional zone of, 8.25
transketolase in, 2.260
transparency of, 8.9
transplantation of, 8.316, 8.411–452, 8.412*t*, 8.412–413*t*. *See also* Donor cornea; Keratoplasty; Keratoplasty, penetrating; *specific procedure*
allografts/allogeneic transplantation, 8.316, 8.411–451, 8.412*t*, 8.412–413*t*
arcuate keratotomy and, 13.56–57
autografts/autologous transplantation, 8.411, 8.451–452
cataract/cataract surgery and, 11.56, 11.175, 11.176
for chemical injuries, 8.384
for corneal edema after cataract surgery, 11.129
definition of/terminology and, 8.411–412
disease transmission and, 8.414, 8.415*t*, 8.416*t*
Creutzfeldt-Jakob disease, 8.254, 8.416*t*
rabies virus, 8.240, 8.240*t*, 8.416*t*
donor selection and, 8.414, 8.415*t*, 8.416*t*
eye banking and, 8.413–417, 8.415*t*, 8.416*f*, 8.416*t*
immune privilege and, 8.316
indications for, 8.412–413*t*
intraocular lens implantation after, 3.253–254
patient selection and, 8.418
pediatric, 8.450–451
preoperative evaluation/preparation and, 8.418–419
rabies virus, 8.240, 8.240*t*, 8.416*t*
after refractive surgery, 13.197–198
refractive surgery after, 13.37, 13.178–180
rejection and, 4.84, 4.85*f*, 8.316–318, 8.428–431. *See also* Rejection
in triple procedure, 11.175–176
tumors of, 4.96, 6.271, 8.327–350. *See also* Ocular surface, tumors of; *specific type*
approach to patient with, 8.328
epithelial, 8.332*t*, 8.332–337
management of, 8.328–332, 8.330*f*, 8.331*f*
surgical, 8.329–330, 8.330*f*
topical chemotherapy for, 8.330*f*, 8.330–332, 8.331*f*
ultrasound biomicroscopy of, 2.471*f*
vertex of, 8.25, 8.26*f*
verticillata (hurricane/vortex keratopathy), 8.90, 8.129*t*, 8.130, 8.130*f*, 8.176, 8.177*f*
in chloroquine/hydroxychloroquine toxicity, 8.130
in Fabry disease, 6.270, 8.176, 8.177*f*
warpage of
contact lens wear causing, refractive surgery and, 13.22, 13.38, 13.44, 13.79
topography in identification of, 13.44, 13.79
zones of, 8.25, 8.25*f*, 8.26*f*
Cornea Donor Study (CDS), 8.416
Cornea plana, 6.255, 6.255*f*. *See also* Cornea, flat
Corneal alignment tool, 3.171*f*
Corneal allografts. *See* Corneal grafts
Corneal apex, 3.228
Corneal arcus, 1.78, 8.120–121, 8.121*f*, 8.179
in cornea plana, 8.100
in dyslipoproteinemia/hyperlipoproteinemia, 8.120, 8.121, 8.179
juvenilis, 8.121
in lecithin-cholesterol acyltransferase (LCAT) deficiency, 8.180, 8.180*f*
lipoides, in Schnyder corneal dystrophy, 8.151, 8.152*f*
senile furrow degeneration and, 8.122
senilis, 8.120–121, 8.121*f*
Corneal astigmatism. *See also* Astigmatism
contact lens masking of, 3.225
description of, 3.19
spherical rigid contact lenses for, 3.211
toric intraocular lenses for, 3.257
Corneal autografts. *See* Corneal grafts
Corneal contact lenses. *See* Contact lenses
Corneal (collagen) crosslinking (CCL/CXL), 13.8*t*, 13.130–135, 13.131*f*, 13.133*f*, 13.133*t*
for *Acanthamoeba* keratitis, 8.279
accelerated, 13.134
for bacterial keratitis, 8.272
combined techniques for, 13.134–135
complications of, 13.135
for ectasia/postoperative ectasia, 13.124, 13.130, 13.131, 13.206
for fungal keratitis, 8.275
with intracorneal ring segment implantation, 13.134, 13.207
for keratoconus, 8.166
for neurotrophic keratopathy/persistent corneal epithelial defects, 8.82
patient selection/indications/contraindications for, 13.131–132
with photorefractive or phototherapeutic keratectomy, 13.134, 13.206–207
with refractive procedures, 13.206–208
surgical technique for, 13.131*f*, 13.132–135, 13.133*f*, 13.133*t*
transepithelial, 13.132–134, 13.133*f*
Corneal (collagen) crosslinking plus, 13.206
Corneal decompensation, after cataract surgery, 6.304
Corneal degenerations, 4.81–86, 4.82*f*, 4.83*f*, 4.84*f*, 4.85*f*, 4.86*f*, 8.115–128. *See also* Keratopathy; *specific type*
age-related changes and, 8.115
dystrophies differentiated from, 8.111, 8.111*t*
endothelial, 8.126–128
age-related, 8.115
epithelial and subepithelial, 8.115–120
peripheral hypertrophic subepithelial, 8.124–125, 8.125*f*
stromal, 8.120–126
Corneal depression, 3.245*f*
Corneal dystrophies, 4.81–94, 8.133–160, 8.134*t*, 8.135*t*, 8.136*t*. *See also* Corneal degenerations; *specific type*
cataract/cataract surgery in patient with, 11.84, 11.174*f*, 11.174–175
classification of, 8.133–134, 8.134*t*, 8.135*t*
degenerations differentiated from, 8.111, 8.111*t*
endothelial, 4.92–94, 4.93*f*, 4.94*f*, 8.135*t*. *See also* Endothelial dystrophies
cataract surgery in patient with, 11.84, 11.175

epithelial and subepithelial, 4.87, 4.87*f*, 8.135*t*, 8.135–141. *See also* Epithelial dystrophies, epithelial and subepithelial
epithelial-stromal *TGFBI*, 4.88*f*, 4.88–91, 4.89*f*, 4.90*f*, 4.91*t*, 4.91*f*, 8.133, 8.134, 8.135*t*, 8.136*t*, 8.142–149
genetic/hereditary factors and, 8.133, 8.134, 8.136*t*
macular (MCD), 4.91, 4.91*t*, 4.92*f*, 8.135*t*, 8.136*t*, 8.145*t*, 8.149–151, 8.150*f*
recurrence of, after corneal transplantation, 8.425, 8.425*f*
recurrent erosion (EREDs), 8.86, 8.87, 8.133, 8.135*t*
refractive surgery and, 13.42–43, 13.43*f*, 13.76, 13.78, 13.178
multifocal IOLs, 13.155
stromal, 4.91, 4.92*f*, 8.135*t*, 8.149–156. *See also* Stromal corneal dystrophies
Corneal dystrophy of Bowman layer type 1 (CDB1). *See* Reis-Bücklers corneal dystrophy
Corneal dystrophy of Bowman layer type 2 (CDB2). *See* Thiel-Behnke corneal dystrophy
Corneal endothelial rings, traumatic, 8.388
Corneal exposure, 6.207
Corneal flap folds, after LASIK, 13.112–115, 13.114*t*, 13.115*f*. *See also* Striae
Corneal grafts, 8.316. *See also* Cornea, transplantation of; Donor cornea; Keratoplasty
allografts (allogeneic transplantation), 8.316, 8.411–451, 8.412*t*, 8.412–413*t*
rejection of, 4.84, 4.85*f*, 8.316–318, 8.428–431, 9.55. *See also* Rejection
arcuate keratotomy incisions in, 13.56–57
autografts (autologous transplantation), 8.411, 8.451–452
disease recurrence in, 8.225, 8.232
dislocation/decentration of, after endothelial keratoplasty, 8.440–444, 8.441*f*, 8.442*f*, 8.443*f*
DMEK, 8.442*f*, 8.442–443, 8.443*f*
DSEK, 8.441, 8.442*f*
endothelial failure of, 4.84, 4.85*f*
late non–immune-mediated, 8.427–428
primary
after endothelial keratoplasty (DMEK/DSEK), 8.447
after penetrating keratoplasty, 8.423, 8.423*f*
rejection of, 4.84, 4.85*f*, 8.316–318, 8.428–431. *See also* Rejection
Corneal haze, 2.263, 6.270. *See also* Haze formation
Corneal hydrops, in keratoconus, 4.95*f*, 4.96, 8.163–164, 8.164*f*
management of, 8.167–168
Corneal hysteresis, 8.43
Corneal incision, clear, for cataract surgery, 11.106*f*, 11.106–107
in glaucoma, 11.186
with trabeculectomy, 10.213
Corneal inlays, 13.59–71, 13.169
alloplastic, 13.28, 13.60–61, 13.61*f*
homoplastic, 13.60
KAMRA, 3.175, 3.271
in keratophakia, 13.60–61, 13.61*f*
for presbyopia, 13.59–71, 13.169
Corneal intraepithelial neoplasia (CIN), 4.96, 8.37, 8.38*f*, 8.332*t*, 8.335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
Corneal intrastromal femtosecond laser treatment, for presbyopia, 13.168
Corneal irritation, 7.296
Corneal lacerations, 12.359
Corneal light reflex, corneal vertex and, 8.25, 8.26*f*
Corneal light reflex tests
Hirschberg test, 6.67, 6.68*f*
Krimsky test, 6.67, 6.68*f*, 6.104*f*
ocular alignment assessments using, 6.67–68, 6.68*f*
Corneal light wedge (parallelepiped) technique, in gonioscopy, 10.36
Corneal neovascularization, 3.231*f*, 3.232
Corneal nerves, 8.8
confocal microscopy in evaluation of, 8.24, 8.24*f*
enlarged/prominent, 8.173, 8.200*t*
in multiple endocrine neoplasia, 8.200, 8.200*t*
in multiple endocrine neoplasia type 2B, 1.50
Corneal nodules, Salzmann, 4.81, 4.82*f*, 8.124*f*, 8.124–125, 8.125*f*
Corneal onlays, 13.59–71. *See also* Corneal inlays
Corneal opacities
congenital hereditary endothelial dystrophy as cause of, 6.257*t*, 6.258*f*, 6.258–259
congenital hereditary stromal dystrophy as cause of, 6.259
differential diagnosis of, 6.257*t*
infantile glaucoma as cause of, 6.257*t*, 6.260, 6.261*f*
Peters anomaly, 6.259, 6.260*f*
posterior corneal depression, 6.259
primary, 6.258*t*
sclerocornea, 6.260, 6.261*f*
secondary, 6.258*t*
STUMPED mnemonic for, 6.257*t*, 6.257–258
total, 6.260, 6.261*f*
Corneal optics, 13.7–9
Corneal pachymetry. *See* Pachymetry/pachymeter
Corneal power. *See* Cornea, refractive power of
Corneal power maps, 8.28–33, 8.29*f*, 8.30*f*, 8.31*f*, 8.32*f*, 8.33*f*, 13.14–19, 13.15*f*, 13.17*f*, 13.19*f*, 13.44–45, 13.45*f*. *See also* Cornea, topography of
interpretation of, 8.28–31
in keratoconus, 8.165, 8.165*f*, 8.167*f*
in pellucid marginal degeneration, 8.31, 8.33*f*, 8.169, 8.170*f*
postoperative, 13.23, 13.24*f*
Corneal power simulation measurements (SIM K), 13.19
astigmatism after penetrating keratoplasty and, 8.431, 8.432*f*
Corneal refractive power, 3.287
Corneal refractive surgery, 13.7, 13.8*t*. *See also* Keratorefractive surgery
Corneal refractive therapy, 13.70–71. *See also* Orthokeratology
Corneal resistance factor (CRF), 8.43
Corneal ring segments, intrastromal (ICRS), 13.8*t*, 13.28, 13.28*f*, 13.62*f*, 13.62–70, 13.63*f*, 13.64*f*, 13.65*f*, 13.67*f*, 13.68*f*, 13.69*f*
complications of, 13.67–70, 13.68*f*, 13.69*f*
contraindications for, 13.63

corneal crosslinking with, 13.134, 13.207
corneal transplantation after, 13.198
instrumentation for, 13.63
for keratoconus, 13.62, 13.65*f*, 13.65–66, 13.69–70, 13.176
after LASIK, 13.70
limitations of, 13.47*t*
number of segments used and, 13.66–67, 13.67*f*
outcomes of, 13.64–65
removal of, 13.63, 13.65
LASIK after, 13.70
surgical technique for, 13.64, 13.64*f*
Corneal storage media, 8.414–417, 8.416*f*
Corneal surgery, refractive. *See* Keratorefractive surgery
Corneal tattoo, 8.118*t*, 8.371*f*, 8.371–372
Corneal topography. *See* Cornea, topography of
Corneal transplant. *See* Cornea, transplantation of; Donor cornea; Keratoplasty
Corneal ulcers, 6.248, 6.249*f*, 6.262–263, 8.46*t*, 8.82*f*. *See also* Keratitis
bacterial, 4.75–76, 4.76*f*
in gonococcal conjunctivitis, 8.258, 8.259*f*
in herpes simplex infection, 4.76–78, 4.77*f*. *See also* Herpes simplex virus (HSV), keratitis caused by
Mooren, 8.313–316, 8.315*f*
neurotrophic. *See* Neurotrophic keratopathy/ulcers
specimen collection from, 8.210, 8.211*f*
in vernal keratoconjunctivitis, 8.290, 8.291*f*
in vitamin A deficiency, 8.197
von Hippel internal, 4.74, 4.75*f*
Corneal verticillata (hurricane/vortex keratopathy), 8.90, 8.129*t*, 8.130, 8.130*f*, 12.295
in chloroquine/hydroxychloroquine toxicity, 8.130
in Fabry disease, 6.270, 8.176, 8.177*f*
Corneal warpage, 3.232–233
Corneoscleral junction, 2.55
Corneoscleral lacerations, 8.388. *See also* Anterior segment, trauma to; Penetrating and perforating ocular trauma; Trauma
description of, 6.377
repair of, 8.404*f*, 8.404–409, 8.405*f*, 8.407*f*, 8.408*f*
Corneoscleral limbus, 8.10, 8.11*f*
Corneoscleral meshwork, 10.17, 10.18*f*
Corneoscleral trabecular meshwork, 2.63–64
Corona, lymphoid follicle, 4.50*f*, 4.51*f*, 4.69, 4.70*f*
Coronal plane, 7.27
Coronal suture, 5.5
Coronary angiography/arteriography. *See* Angiography/arteriography
Coronary angioplasty. *See* Percutaneous coronary intervention
Coronary artery aneurysm, 6.316
Coronary artery bypass grafting (CABG)
angina pectoris treated with, 1.91–92
percutaneous coronary intervention *versus*, 1.92
Coronary artery disease (CAD). *See* Coronary heart disease; Ischemic heart disease
Coronary artery stenosis, 1.89
Coronary cataract, 11.37
Coronary computed tomography angiography (CCTA), in coronary heart disease diagnosis, 1.88
Coronary heart disease (CHD), 1.40, 1.284. *See also* Ischemic heart disease
acute coronary syndromes, 1.83–85
angina pectoris, 1.82–83
aspirin therapy in, 1.89
asymptomatic, 1.86
atherosclerotic
angina pectoris caused by, 1.83
deaths caused by, 1.81, 1.215
clinical syndromes of, 1.82–86
deaths caused by, 1.71
diagnosis of
cardiac enzymes, 1.86–87
computed tomography, 1.88
coronary arteriography, 1.89
coronary computed tomography angiography, 1.88
echocardiography, 1.87
electrocardiography, 1.86
electron beam computed tomography, 1.88
exercise stress testing, 1.88
intravascular ultrasound, 1.89
invasive procedures for, 1.89
magnetic resonance imaging, 1.88
multiple gated acquisition scans, 1.89
myoglobin levels, 1.87
noninvasive procedures for, 1.86–89
positron emission tomography, 1.88
radionuclide scintigraphy and scans, 1.88
serum biomarkers, 1.86–87
single-photon emission computed tomography, 1.88
troponin levels, 1.87
ventriculography, 1.89
management of
antithrombotic agents, 1.89, 1.90–91*t*
direct oral antithrombotic agents, 1.90*t*
goals for, 1.89
percutaneous coronary intervention, 1.100
surgery, 1.100
pathophysiology of, 1.81–82
risk factors for, 1.72, 1.73*t*, 1.82
screening for, 1.215
sudden cardiac death, 1.85–86
in women, 1.82
Coronary syndrome, acute. *See* Acute coronary syndromes; Myocardial infarction
Coronary thrombus, 1.83
Corpus callosum agenesis, 6.361
Corrected distance visual acuity (CDVA/best-corrected visual/Snellen visual acuity/BCVA/BCSVA), 3.260. *See also* Visual acuity
after cataract surgery, 11.126
manual small-incision surgery and, 11.198–199
multifocal IOLs and, 11.121–122
corneal crosslinking and, 13.131
flap folds/striae and, 13.112, 13.113, 13.114*t*, 13.115
hard contact lens method for IOL power calculation and, 13.195
hyperopia correction and, 13.94
intrastromal corneal ring segment placement and, 13.67
irregular astigmatism affecting, 13.17
LASIK and, 13.95
in amblyopia/anisometropic amblyopia, 13.185–186, 13.187

in diabetes mellitus, 13.190
after penetrating keratoplasty, 13.180
after retinal detachment surgery, 13.185
in low vision assessment, 5.78
photostress testing and, 5.88
myopia correction and, 13.95
patient expectations/motivations for refractive surgery and, 13.36, 13.47
phakic IOL implantation and, 13.144
radial keratotomy and, 13.51–52
after small-incision lenticule extraction, 13.205
undercorrection after photoablation and, 13.102
Correcting lens
retinal reflex neutralization with, 3.153, 3.154*f*
in retinoscopy, 3.153–155, 3.154*f*
Correspondence. *See* Retinal correspondence
Corrugator supercilii muscle, 2.31*f*, 7.153, 7.154*f*
Cortex
lens, 4.116*f*, 4.117, 11.10*f*, 11.12*f*, 11.13
degenerations of, 4.121–122, 4.122*f*, 4.123*f*
topography of, 4.116*f*, 4.117
occipital/visual. *See* Occipital (primary visual/calcarine/striate) cortex
Cortical cataracts, 4.122, 4.122*f*, 11.45–46, 11.46*f*, 11.47*f*, 11.48*f*, 11.49*f*, 11.50*f*
characteristics and effects of, 11.45, 11.70*t*
genetic contributions to, 11.41
race and, 11.6
uveitis and, 11.64*f*, 11.64–65
Cortical/cerebral blindness, 5.158, 5.336–337
blindsight and, 5.181
denial of (Anton syndrome), 5.158, 5.180–181, 5.337
Cortical inattention, 6.186
Cortical pathways. *See* Supranuclear (cortical) pathways
Cortical potential, visual evoked (visual evoked potential/response [VECP/VEP/VER]), 5.95
in low vision evaluation, 5.95
in nonorganic disorder evaluation, 5.302
Cortical spokes, 11.46, 11.47*f*
Cortical spreading depression, 5.177
Cortical syndromes, 5.178*t*, 5.178–181
recognition disorders and, 5.178*t*, 5.179, 5.180*f*
vision/visual deficit awareness disorders and, 5.178*t*, 5.180–181
visual-spatial relationship disorders and, 5.178*t*, 5.180
Cortical vision loss, 2.475*t*
Cortical visual impairment, 6.186
Cortical vitreous, 2.296
Corticobulbar tract, 5.50*f*
Corticosteroid(s) (steroids). *See also specific drug*
Acanthamoeba keratitis treatment and, 8.279
acute posterior multifocal placoid pigment epitheliopathy treated with, 12.222
acute retinal necrosis treated with, 12.236
for adenovirus infection, 8.236
adrenal function after, 1.175
adverse effects of, 1.175–176, 1.308*t*, 9.94, 9.103, 9.143, 9.150
for allergic eye disease, 8.289
for atopic dermatitis, 8.287
for autoimmune retinopathy, 9.193
for bacterial keratitis, 8.271–272
for Behçet disease, 1.173, 9.216–217
for Bell palsy, 5.279
branch retinal vein occlusion treated with, 12.137–138
for cataracts, 9.314
cataracts caused by, 6.321, 11.51–52, 11.64, 11.188
central retinal vein occlusion treated with, 12.137–138
central serous chorioretinopathy caused by, 12.300
cessation of, 1.175
for chalazion, 7.183, 8.77
for chemical injuries, 8.383
for Cogan syndrome, 1.174, 8.310
for contact dermatoblepharitis, 8.287
for corneal graft rejection, 8.429–430, 8.447, 8.448
for cystoid macular edema, 4.152, 12.159, 12.393
after cataract surgery, 11.165
cytomegalovirus retinitis and, 12.236
for descemetocele, 8.369
diabetic macular edema treated with, 12.113–114
for diffuse unilateral subacute neuroretinitis-related inflammation, 9.288
for dry eye, 8.61*t*
for Epstein-Barr keratitis, 8.231
fungal keratitis associated with use of, 4.78, 8.273
for giant cell arteritis/AAION, 5.120*t*, 5.121–122, 5.314–315, 12.145
glaucoma caused by, 6.284, 6.321, 10.109–110
in children and adolescents, 10.149*t*
refractive surgery and, 13.41, 13.182, 13.201
after glaucoma surgery, 10.208
herpes simplex keratitis and, 8.217, 8.219, 8.223*t*
for herpes simplex virus, 9.249
for herpes zoster, 8.222, 8.229–230
for human T-lymphocytic virus type 1, 9.267
for hyphema, 8.394–395, 10.105
in idiopathic intracranial hypertension, 5.112
idiopathic thrombocytopenia purpura treated with, 1.141
immunoglobulin G4–related disease treated with, 7.67
infantile (capillary) hemangioma treated with, 7.72, 7.181
infectious pseudocrystalline keratopathy associated with use of, 4.79
inhaled, intraocular pressure affected by, 1.130
for insect/arachnid injuries, 8.387
intraocular pressure affected by, 10.100, 10.108, 10.109–110
inflammatory glaucoma treatment and, 10.100
optic nerve damage and, 10.110
after refractive surgery, 13.41, 13.92, 13.104–105, 13.182, 13.201
in uveitis, 10.110
intravitreal administration, 2.360*t*. *See also* Intravitreal injections, corticosteroids
intravitreal implants, 6.321
for iridocyclitis, 9.127
for limbic stem cell deficiency, 8.94
lung disease treated with, 1.128
for Lyme disease-related anterior segment inflammation, 9.230

for meibomian gland dysfunction, 8.68
monitoring of, 1.176
for Mooren ulcer, 8.315
for multifocal choroiditis and panuveitis syndrome, 9.181
for multiple sclerosis, 5.319–320
for neuromyelitis optica, 5.323
nonspecific orbital inflammation treated with, 7.69–70
ocular adverse effects of, 1.308*t*
for ocular allergies/inflammation, 2.411, 6.247*t*, 6.248, 8.289
ocular hypertension caused by, 9.317, 9.319. *See also* Corticosteroid(s) (steroids), intraocular pressure affected by
for ocular toxoplasmosis, 9.281
for optic neuritis, 5.116, 6.369
orbital cellulitis treated with, 7.48
osteoporosis caused by, 1.175
for pars planitis, 9.149–150
after penetrating and perforating trauma repair, 8.409
for peripheral ulcerative keratitis, 8.313
after photoablation, 13.92
complications associated with, 13.104–105
corneal haze reduction and, 13.33, 13.94, 13.108–109
for diffuse lamellar keratitis, 13.117
elevated intraocular pressure/glaucoma and, 13.41, 13.104–105, 13.182, 13.201
fungal keratitis and, 13.106
herpes simplex keratitis and, 13.174
LASIK, 13.93, 13.94
for transient light sensitivity, 13.123
pressure-induced stromal keratopathy and, 13.119
regression in overcorrection and, 13.101, 13.108–109
regression in undercorrection and, 13.102
surface ablation, 13.92, 13.94, 13.108–109
posterior sub-Tenon injection of, 9.95–96, 9.96*f*, 9.322
progressive outer retinal necrosis syndrome treated with, 12.237
after pterygium excision, 8.356
ptosis caused by eyedrops containing, 5.273, 5.273*t*
for recurrent corneal erosions, 8.87
after refractive surgery, elevated intraocular pressure/glaucoma and, 13.41, 13.92, 13.104–105, 13.182, 13.201
refractive surgery in patient taking, 13.37
for relentless placoid chorioretinitis, 9.173–174
retinal vein occlusion treated with, 12.137–138
rheumatic disorders treated with, 1.174–176, 1.175*t*
risks associated with long-term use of, 6.321
for rosacea, 8.71
for sarcoidosis, 9.199
for scleritis, 8.324, 8.325*f*, 9.126
for staphylococcal blepharitis/blepharoconjunctivitis, 8.76
for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297, 8.298
for stromal keratitis, 8.222, 8.223*t*
sub-Tenon injections of, 6.320
supratarsal injection of, for vernal keratoconjunctivitis, 8.291
for sympathetic ophthalmia, 9.203
for syphilitic uveitis-related inflammation, 9.227
for thermal injuries, 8.385
for Thygeson superficial punctate keratitis, 6.269, 8.307
for thyroid eye disease, 5.131
topical
for iridocyclitis, 9.127
for uveitis, 9.94–95, 9.130
toxoplasmic retinochoroiditis treated with, 12.244
toxoplasmosis treated with, 6.409–410
for traumatic vision loss, 5.140
types of, 2.400*t*
for uveitis, 6.320–321
adverse effects of, 9.94, 9.103, 9.143, 9.150
in children, 9.143
dose and duration of, 9.94, 9.102
intermediate, 9.149–150
intraocular pressure elevation and, 10.100
intravitreal, 9.97–98, 9.102
local, 9.95
nonsteroidal anti-inflammatory drugs and, 9.103
osteoporosis prevention strategies, 9.103
periocular, 9.95–96, 9.96–97*f*
phacoantigenic, 9.137
sustained-release, 9.95
systemic, 9.102–103, 9.150
tapering of, 9.94
topical, 9.94–95
traumatic anterior, 8.389–390
for vernal keratoconjunctivitis, 6.249, 8.291
for visceral toxocariasis, 9.284
wound healing affected by, 13.33
Corticosteroid-sparing, in uveitis. *See* Immunomodulatory therapy/immunotherapy/immunosuppression
Cortisol deficiency, corticosteroid-induced, 9.94
Cortisone, 1.175*t*
Cortisporin. *See* Hydrocortisone
Cortisporin suspension. *See* Hydrocortisone/neomycin sulfate/polymyxin B sulfate
Corynebacterium, 8.244*t*, 8.245–246
diphtheriae, 8.207, 8.245
invasive capability of, 8.207
as normal flora, 8.206*t*, 8.246
ocular infection caused by, 8.245–246
cicatricial conjunctivitis differentiated from, 8.301*t*
xerosis, 8.196–197, 8.246
Cosmetic blepharoplasty, 7.253*f*
Cosmetic facial surgery. *See* Facial surgery; *specific procedure*
Cosopt Ocumeter Plus. *See* Dorzolamide hydrochloride/timolol maleate
Cotransport, 2.271
Cotton-wool spots, 4.152, 9.154, 9.155*f*, 9.256, 9.297, 9.327, 9.328*f*, 12.122
in AAION/NAION, 5.120
in branch retinal vein occlusion, 4.159
in central retinal vein occlusion, 4.156, 4.157
cytomegalovirus retinitis and, 12.235
in diabetic retinopathy, 4.159, 12.140–141

in hypertensive retinopathy, 12.122, 12.122*f*
in leukemia, 4.315
in Purtscher retinopathy, 12.171
in systemic lupus erythematosus, 12.230
Couching, 11.89, 11.89*f*
Cough, 1.124
cataract surgery in patient with, 11.170
Counseling. *See* Patient education
genetic. *See* Genetic testing/counseling
Coup, 12.315
Coupling/coupling ratio, 13.27, 13.27*f*, 13.54, 13.54*f*, 13.55
arcuate incisions/keratotomy and, 13.27, 13.27*f*, 13.54, 13.54*f*
astigmatic keratotomy and, 11.123, 13.27, 13.27*f*, 13.54, 13.54*f*, 13.55
limbal relaxing incisions and, 13.54, 13.54*f*, 13.55
Cover tests
alternate, 6.65–66, 6.66*f*
before cataract surgery, 11.77–78
cover-uncover test, 6.64, 6.65*f*
ocular alignment assessments using, 6.64–67, 6.65–66*f*
Cowden disease, eyelid manifestations of, 4.210*t*
COX. *See* Cyclooxygenase (COX) pathway
COX-1. *See* Cyclooxygenase
COX-2. *See* Cyclooxygenase
COX-1/COX-2. *See* Cyclooxygenase
Coxsackieviruses, acute hemorrhagic conjunctivitis caused by, 8.240, 8.240*t*
CPAP. *See* Continuous positive airway pressure
CPC. *See* Cyclophotocoagulation/cycloablation
CPEO. *See* Chronic progressive external ophthalmoplegia
CPR. *See* Cardiopulmonary resuscitation
CR-39, 3.194–195
CRA. *See* Central retinal artery
"Crab claw" pattern
keratoconus and, 13.24, 13.176, 13.176*f*
in pellucid marginal degeneration, 8.31, 8.33*f*, 8.169, 8.170*f*
Crab louse *(Phthirus pubis)*, 8.253, 8.254*f*
ocular infection caused by, 8.208*t*, 8.253, 8.255
Crack cocaine, 1.199. *See also* Cocaine
Cranial dysinnervation disorders, congenital. *See specific disorder*
Cranial fossae
anterior, 5.6*f*, 5.8, 5.10*f*
middle, 5.6*f*, 5.10*f*, 5.11
neuroimaging in evaluation of, 5.72*t*
posterior, 5.6*f*
neuroimaging in evaluation of, 5.72*t*
Cranial nerves (CNs), 5.40*f*, 5.40–45, 5.41*f*, 5.42–43*f*, 5.44*f*. *See also specific nerve*
anatomic relationships of, 2.106*f*
anatomy of, 2.15, 5.40*f*, 5.40–45, 5.41*f*, 5.42–43*f*, 5.44*f*
cerebrovascular system effects on, 2.135
extraocular muscles supplied by, 5.40*f*, 5.40–45, 5.41*f*, 5.42–43*f*, 5.44*f*
intracavernous course of, 2.137*f*
ocular motor, 5.40–44*f*, 5.40–45
palsy of, 2.135, 2.475*t*
in cryptococcosis, 5.356
diplopia caused by, 5.192, 5.193*f*, 5.193–201, 5.194*f*, 5.196*f*, 5.198*f*, 5.199*f*, 5.200*f*, 5.202
multiple nerve involvement and, 5.202
herpes infection and, 5.350
isolated. *See also specific type*
in multiple sclerosis, 5.318
localization of lesions causing, 5.187*f*, 5.187–188
in multiple sclerosis, 5.318
neuroimaging in evaluation of, 5.70
pain associated with, 5.192
radiation therapy and, 5.358
in sarcoidosis, 5.280, 5.327
saccadic system and, 5.33
Cranial nerve II. *See* Optic nerve
Cranial nerve III (oculomotor nerve), 5.8*f*, 5.35, 5.35*f*, 5.40–44*f*, 5.44–45, 5.48*f*, 5.55*f*
aberrant regeneration of, 5.197–198, 5.198*f*
anisocoria and, 5.265–266
light-near dissociation and, 5.266*t*, 5.267
in accommodation, 11.23
anatomy of, 2.108*f*, 2.123–126, 5.8*f*, 5.35, 5.35*f*, 5.40, 5.40*f*, 5.41–44*f*, 5.44–45, 5.48*f*, 5.55*f*
congenital palsy of, 7.246
divisions of, 6.19
extraocular muscles innervated by, 2.21, 6.19–20, 7.12
eyelid disorders and, 5.271
fascicular portion of, 2.124
gaze palsy caused by lesions of, 5.228
horizontal gaze and, 5.36, 5.37*f*
inferior division of, 2.125
intra-axial lesions of, 5.191
muscles innervated by, 2.123
nucleus complex of, 2.123, 2.123*f*
in ocular motility disorders, 5.188, 5.191, 5.193*f*, 5.193–198, 5.194*f*, 5.196*f*, 5.198*f*
cavernous sinus/superior orbital fissure lesions and, 5.202–206
palsy of. *See* Third nerve (oculomotor) palsy
subnuclei of, 2.123
superior division of
description of, 2.125
palsy of, 6.128
vertical gaze and, 5.36*f*, 5.36–37
Cranial nerve IV (trochlear nerve), 5.8*f*, 5.35, 5.35*f*, 5.40, 5.40*f*, 5.41*f*, 5.42*f*, 5.43*f*, 5.43–44, 5.48*f*, 7.13
anatomy of, 2.12*f*, 2.127–128, 5.8*f*, 5.35, 5.35*f*, 5.40, 5.40*f*, 5.41*f*, 5.42*f*, 5.43*f*, 5.43–44, 5.48*f*
extraocular muscles innervated by, 2.21, 6.19
fascicles of, 2.128
horizontal gaze and, 5.37*f*
Horner syndrome in lesions of, 5.260*t*
intra-axial lesions of, 5.191, 5.192
in ocular motility disorders, 5.185, 5.186, 5.188–189, 5.198–200, 5.199, 5.199*f*
cavernous sinus/superior orbital fissure lesions and, 5.202–206
palsy of. *See* Fourth nerve (trochlear) palsy
superior oblique myokymia and, 5.250
vertical gaze and, 5.36*f*, 5.36–37
Cranial nerve V (trigeminal nerve), 5.41*f*, 5.42*f*, 5.43*f*, 5.47*f*, 5.47–49, 5.48*f*, 5.55
anatomy of, 2.107–108*f*, 2.128–129, 5.41*f*, 5.42*f*, 5.43*f*, 5.55

branches of, 2.107*f*
cold-induced anterior segment trauma and, 8.385
corneal sensation and, 8.42
divisions of, 2.131–133, 5.16*f*, 5.42*f*, 5.43*f*, 5.47*f*, 5.48–49, 7.9–10, 7.14
efferent pathway of, 7.280
facial pain caused by lesions of, 5.297, 5.298, 5.298*f*
in herpes simplex infection, 8.213
in herpes zoster, 8.226, 8.227
innervations by, 2.128, 2.129*f*
intracranial pathway of, 2.131
lacrimal functional unit innervated by, 8.5*f*
main sensory nucleus of, 2.129–130
mandibular division of, 2.133. See also Cranial nerve V (trigeminal nerve), V_3 (mandibular nerve)
maxillary division of, 2.132, 7.14. See also Cranial nerve V (trigeminal nerve), V_2 (maxillary nerve)
mesencephalic nucleus of, 2.129
in migraine, 5.291
motor nucleus of, 2.131
nasociliary branch of, 7.13
neurotrophic keratopathy/persistent corneal epithelial defects caused by damage to, 8.42, 8.80, 8.81*t*
nuclear complex of, 2.129
in ocular motility disorders, cavernous sinus/superior orbital fissure lesions and, 5.202–206
ophthalmic division of, 2.130, 2.131–132, 2.132*f*, 7.14. See also Cranial nerve V (trigeminal nerve), V_1 (ophthalmic nerve)
pathways of, 2.129*f*
sensory nucleus of, 2.129–130
spinal nucleus and tract of, 2.130–131
V_1 (ophthalmic nerve), 5.16*f*, 5.43*f*, 5.47*f*, 5.48
V_2 (maxillary nerve), 5.16*f*, 5.42*f*, 5.43*f*, 5.47*f*, 5.48*f*, 5.49
V_3 (mandibular nerve), 5.16*f*, 5.42*f*, 5.47*f*, 5.49
Cranial nerve VI (abducens nerve), 5.8*f*, 5.35, 5.35*f*, 5.40, 5.40*f*, 5.40–41, 5.41*f*, 5.42*f*, 5.43*f*, 5.48*f*, 5.53*f*
anatomy of, 2.107*f*, 2.133, 5.8*f*, 5.35, 5.35*f*, 5.40–41, 43*f*, 5.48*f*, 5.53*f*, 7.13*f*
extraocular muscle innervation by, 6.19, 7.12
gaze palsy caused by lesions of, 5.228
horizontal gaze and, 5.36, 5.37, 5.37*f*, 5.38
in one-and-a-half syndrome, 5.191
intra-axial lesions of, 5.192
in ocular motility disorders, 5.189
cavernous sinus/superior orbital fissure lesions and, 5.202–206
palsy of, 2.475*t*. *See also* Sixth nerve (abducens) palsy
pregnancy affecting, 5.333
pursuit system and, 5.34*f*, 5.224
Cranial nerve VII (facial nerve), 5.12, 5.41*f*, 5.42*f*, 5.49–52, 5.50–51*f*, 5.55, 5.56, 5.276–277*f*
aberrant regeneration of
Bell palsy and, 5.277, 5.279
synkinesis in, 5.271, 5.271*f*, 5.277
anatomy of, 2.133–135, 5.41*f*, 5.42*f*, 5.49–52, 5.50–51*f*, 5.55, 5.56, 5.276–277*f*, 7.152*f*, 7.153, 7.155–156*f*
autonomic function of, testing, 5.275, 5.276–277*f*
brainstem lesions involving, 5.278, 5.278*t*
branches of, 2.134, 7.156*f*
cervicofacial division of, 5.52
distribution of, 5.276–277*f*
evaluation of, 5.275–277, 5.276–277*f*
facial movement abnormalities caused by disorders of, 5.275–277, 5.276–277*f*, 5.277–285
overactivity and, 5.281–285, 5.282*f*, 5.282*t*, 5.283*f*
underactivity and, 5.275, 5.276–277*f*, 5.277–281, 5.278*t*, 5.279*f*. *See also* Facial paralysis/weakness
horizontal gaze and, in one-and-a-half syndrome, 5.191
intra-axial lesions of, 5.192
mandibular branch of, 5.51*f*, 5.52, 5.276–277*f*
motor nucleus of, 2.133
muscles innervated by, 7.155
nonmotor pathways of, 7.280*f*
palsy of, 6.136*f*. *See also* Facial paralysis/weakness
aberrant regeneration after, 7.258
brow ptosis after, 7.263
lacrimal pump function affected by, 7.296, 7.297*f*
paralytic ectropion secondary to, 7.297*f*
parasympathetic fibers of, 7.280
peripheral lesions involving, 5.278–280, 5.279*f*
pregnancy affecting, 5.333
sarcoidosis involving, 5.280, 5.327
supranuclear lesions involving, 5.276*f*, 5.277–278
surgical ablation of, 7.258
surgical decompression of, for hemifacial spasm, 5.284
synkinesis caused by disorders of, 5.271, 5.271*f*, 5.277
temporal (frontal) branch of, 2.134, 5.51*f*, 5.52, 5.276–277*f*, 7.155*f*
temporofacial division of, 5.52
terminal branches of, 5.51*f*, 5.52, 5.276–277*f*
zygomatic branch of, 5.51*f*, 5.52, 5.276–277*f*
Cranial nerve VIII (auditory nerve), 5.35, 5.38
anatomy of, 5.35, 5.38
horizontal gaze and, 5.37*f*
vertical gaze and, 5.36*f*
vestibular imbalance caused by lesions of, 5.217
in vestibular-ocular reflex, 5.214, 5.217
Cranial neuropathy syndrome, idiopathic multiple, 5.202
Cranial sutures, 6.203–204, 6.204*f*
Craniofacial anomalies, syndromic, 7.38–39
Craniofacial bones, 5.6–7, 5.9*f*
Craniofacial clefts, 7.38–39. *See also* Craniofacial malformations; *specific type*
Craniofacial development, 2.145*f*
Craniofacial dysostosis (Crouzon syndrome), 8.191*t*. *See also* Crouzon syndrome
Craniofacial malformations, 6.211, 6.211*f*. *See also specific type*
anophthalmia, 6.209, 6.210*f*
Apert syndrome (acrocephalosyndactyly), 6.206–207, 6.207*f*, 6.209*f*, 7.39, 7.39*f*, 8.191*t*
branchial arch syndromes, 6.210–211, 6.210–211*f*
Crouzon syndrome, 6.206, 6.206*f*, 7.38*f*, 8.191*t*
fetal alcohol syndrome, 6.211–212, 6.212*f*
mandibulofacial dysostosis. *See* Craniofacial malformations, Treacher Collins/Treacher Collins-Franceschetti syndrome
nonsynostotic, 6.209–212
oculoauriculovertebral spectrum/sequence /syndrome (OAVS), 6.210, 8.191*t*, 8.195*f*, 8.195–196
Pfeiffer syndrome, 6.207

Pierre Robin sequence (anomaly/deformity), 6.211, 8.192*t*
Saethre-Chotzen syndrome, 6.207, 6.208*f*
Treacher Collins/Treacher Collins-Franceschetti syndrome (mandibulofacial dysostosis), 6.196, 6.211, 6.211*f*, 7.38*f*, 8.192*t*
eyelid manifestations of, 4.207*t*
Craniometaphyseal dysplasia, 6.212
Craniopharyngiomas, 5.147, 5.150
nystagmus caused by, 5.247
Craniosynostosis
anatomy of, 6.203–204
Apert syndrome, 6.206–207, 6.207*f*, 6.209*f*
brachycephaly, 6.205
complications of
corneal exposure, 6.207
globe luxation, 6.207–208
ocular adnexal abnormalities, 6.209
optic nerve abnormalities, 6.208–209
proptosis, 6.207
strabismus, 6.208
Crouzon syndrome, 6.206, 6.206*f*, 7.38*f*, 8.191*t*
definition of, 6.203
dolichocephaly, 6.205
etiology of, 6.205–206
Kleeblattschädel, 6.205
Pfeiffer syndrome, 6.207
plagiocephaly, 6.204–205
Saethre-Chotzen syndrome, 6.207, 6.208*f*
scaphocephaly, 6.205
syndromic, 6.206–207, 7.39, 7.39*f*
CRAO. *See* Central retinal artery occlusion
Crash cart, 1.298
CRAVE study, 12.135
Crawford stent and hook, 7.293, 7.293*f*
CRB1 mutations, 12.258
CRBP1. *See* Cellular retinol-binding protein 1
Creases (eyelid). *See* Eyelid(s), creases of
Creatine kinase MB, 1.87
Creeping angle closure, 10.126. *See also* Angle-closure glaucoma
"Crescent moon sign," in internal carotid artery dissection, 5.262*f*, 5.342
Crest cells. *See* Neural crest cells
CREST syndrome, 1.164
CREST trial. *See* Carotid Revascularization Endarterectomy Versus Stenting Trial-2
Cretinism, 1.41
Creutzfeldt-Jakob disease (CJD)
corneal transplant in transmission of, 8.254, 8.416*t*
description of, 1.211, 5.357
CRF. *See* Corneal resistance factor
Cri-du-chat syndrome, 6.386*t*
Cribriform plate, 5.6*f*. *See also* Lamina cribrosa
Cricothyrotomy, 1.299, 1.302
Crigler-Najjar syndrome, 2.204*t*
CRION. *See* Chronic relapsing inflammatory optic neuropathy
CRISPR–Cas9, 2.198
Critical angle, 3.40, 3.50–51
Crizanlizumab, for sickle cell disease, 1.135
CRN. *See* Convergence-retraction nystagmus
Crocodile shagreen, 8.121
Crocodile tears, 5.277
Crohn disease, 1.156
Crolom. *See* Cromolyn
Cromolyn
description of, 2.412*t*
for hay fever conjunctivitis, 8.289
for lung disease, 1.128
Cross cylinder technique
Jackson. *See* Jackson cross cylinder
for refraction, 3.163–165, 3.164*f*, 3.165*t*
Cross-fixation, in infantile esotropia, 6.87–88, 6.88*f*
Cross-sectional studies, 1.12
Crossed diplopia, 6.75
Crossing over, 2.175, 2.216–217
Crosslinking. *See* Corneal (collagen) crosslinking
Crouzon syndrome, 6.206, 6.206*f*, 7.38*f*, 8.191*t*
Crowding phenomenon
in amblyopia, 6.56
definition of, 6.54
CRP. *See* C-reactive protein
CRS. *See* Congenital rubella syndrome
CRV. *See* Central retinal vein
CRVO. *See* Central retinal vein occlusion
CRYO-ROP. *See* Cryotherapy for Retinopathy of Prematurity
Cryoablation, for retinopathy of prematurity, 12.185–186
Cryoglobulin deposition, ophthalmic findings in, 8.198–199
Cryopexy
transconjunctival, 12.398
transscleral, 12.398
Cryoprobe, for lens extraction, 11.195
in ICCE, 11.200
Cryotherapy, 7.205, 7.210, 7.240
for conjunctival papillomas, 8.239, 8.333
for intermediate uveitis, 9.150
for ligneous conjunctivitis, 8.295
with ocular surface surgery for neoplasia, 8.329
retinal cavernous hemangioma treated with, 12.168
for retinal hemangioblastoma/von Hippel–Lindau disease/syndrome, 4.285
for retinoblastoma, 4.300
for trichiasis/distichiasis, 8.88
von Hippel–Lindau syndrome treated with, 12.167
Cryotherapy for Retinopathy of Prematurity (CRYO-ROP), 6.326, 6.331
Cryptococcal meningitis, 1.277
Cryptococcosis, 9.299–300
Cryptococcus neoformans/gatti (cryptococcosis), 5.356, 8.249*t*, 8.251
choroiditis, 9.333
in HIV infection/AIDS, 5.356
ocular infection caused by, 5.356
optic nerve infection caused by, 4.243, 4.243*f*, 5.356
retinal infection caused by, 4.147
Cryptogenic stroke, 1.119
Cryptophthalmos, 6.191, 6.193, 6.193*f*, 7.180, 7.181*f*
Cryptophthalmos-syndactyly (Fraser syndrome), 4.207*t*, 6.193
Crystal deposition, corneal, 8.173, 8.182*t*
in cystinosis, 8.181*f*, 8.181–182
in hematologic disorders, 8.197–199, 8.198*f*, 8.199*f*

Crystal violet stain, 4.31*t*
Crystalline corneal/stromal dystrophy, Schnyder (SCD), 6.270, 6.387*f*, 8.135*t*, 8.136*t*, 8.145*t*, 8.151–152, 8.152*f*. *See also* Schnyder corneal dystrophy
hyperlipoproteinemia and, 8.151, 8.179
Crystalline keratopathy, infectious, 8.268, 8.268*f*
corneal deposits and, 8.182*t*
after penetrating keratoplasty, 8.427, 8.427*f*
Crystalline lens. *See* Lens
Crystalline/pseudocrystalline keratopathy, infectious, 4.79–80, 4.80*f*
after penetrating keratoplasty, 4.79
Crystalline retinopathy
cause of, 12.302–304, 12.303*t*
drugs that cause, 12.302–304
tamoxifen as cause of, 12.303, 12.304*f*
West African, 12.303–304, 12.305*f*
Crystallins, 11.15*f*, 11.15–16. *See also* Lens proteins
α, 2.284, 11.15, 11.15*f*, 11.15–16
β, 11.16
β,γ-, 2.284–285, 11.15, 11.15*f*, 11.16
description of, 2.281, 2.284–285
γ, 11.16
taxon-specific, 2.285
CS. *See* Cockayne syndrome
CSC. *See* Central serous chorioretinopathy
CSCD (congenital stromal corneal dystrophy). *See* Congenital (congenital hereditary) stromal corneal dystrophy
CSD. *See* Cat-scratch disease
CSF. *See* Cerebrospinal fluid; Contrast sensitivity function
CSLO. *See* Confocal scanning laser ophthalmoscopy/ophthalmoscope
CSM method. *See* Central, Steady, and Maintained (CSM) method
CSME. *See* Clinically significant diabetic macular edema
CSNB. *See* Congenital stationary night blindness
CSR (central serous retinopathy). *See* Central serous chorioretinopathy
CSROP. *See* Clinically significant retinopathy of prematurity
CST. *See* Cavernous sinus thrombosis
CT/CT scan. *See* Computed tomography
CT angiography. *See* Computed tomography angiography
CT venography. *See* Computed tomography venography
CTA. *See* Computed tomography angiography
CTLs. *See* Cytotoxic T cells
CTNS gene, 6.270
in cystinosis, 8.181
CTRs. *See* Capsular tension rings
CTV. *See* Computed tomography venography
Culex mosquitoes, 12.246
Cultured epithelial stem cells, for transplantation, 8.365. *See also* Limbal transplantation
Cuneiform opacities, 11.46, 11.47*f*
Cup, optic. *See* Cupping of optic nerve/nerve head/disc; Optic cup
Cup-disc ratio
in AAION/NAION, 5.120, 5.121*f*
in glaucoma evaluation, 10.48, 10.53
in infants and children, 10.160
Cupping of optic nerve/nerve head/disc
asymmetry of, 10.48–49, 10.49*f*
description of, 6.187, 6.402*f*
glaucomatous, 10.46, 10.47*f*, 10.48–49, 10.49*t*
in infants and children, 10.46
visual field changes correlated with, 10.74–75
physiologic, 10.48
vertical elongation and, 10.49, 10.50*f*
Curative chemotherapy, 1.239
Curly fibers, in Thiel-Behnke corneal dystrophy, 8.143, 8.144*f*. *See also* Thiel-Behnke corneal dystrophy
Curvature
corneal, 8.25–26. *See also* Cornea, topography of
axial, 8.28, 8.29*f*, 13.16, 13.16*f*, 13.17*f*
in cornea plana, 8.96*t*, 8.100
evaluation of, 8.25–36
corneal zones and, 8.25, 8.25*f*, 8.26*f*
keratometry for, 8.26–27, 8.27*f*
keratoscopy for, 8.27–28, 8.28*f*
Placido disk-based topography for, 8.27–28, 8.28, 8.35*t*
shape/curvature/power and, 8.25–26
tomography for, 8.33–36, 8.34*f*, 8.35*f*, 8.35*t*
topography for, 8.28–36, 8.29*f*, 8.30*f*, 8.31*f*, 8.32*f*, 8.32*t*, 8.33*f*, 8.35*t*
after keratorefractive surgery, 3.269
mean, 8.28
measurement of, 13.14–19, 13.15*f*, 13.16*f*, 13.17*f*, 13.18*f*, 13.19*f*, 13.44–45, 13.45*f*
power and, 8.25–26, 13.7–9
radius of, 3.127*t*, 8.8, 8.27
in cornea plana, 8.100
instantaneous (meridional/tangential power), 13.16–17, 13.17*f*
keratometry in measurement of, 8.27
refractive surgery affecting, 13.9, 13.26–28, 13.27*f*, 13.28*f*
IOL power calculation and, 13.193–197, 13.196*f*
in schematic eye, 3.127*t*
radius of, 3.127*t*
Curvature maps, 8.28–33, 8.29*f*, 8.30*f*, 8.31*f*, 8.32*f*, 8.33*f*, 13.14–19, 13.15*f*, 13.17*f*, 13.19*f*, 13.44–45, 13.45*f*. *See also* Cornea, topography of
interpretation of, 8.28–31
in keratoconus, 8.165, 8.165*f*, 8.167*f*
in pellucid marginal degeneration, 8.31, 8.33*f*, 8.169, 8.170*f*
postoperative, 13.23, 13.24*f*
Curvature of field
definition of, 3.72
schematic diagram of, 3.72*f*
Curvilinear capsulorrhexis, 9.315
Curvularia, 8.249*t*, 8.251
Cushing syndrome
corticotroph adenomas associated with, 1.48
elevated intraocular pressure in, 10.110
hypertension associated with, 1.54
Custom (wavefront-guided) ablation, 13.31, 13.46, 13.76–77
higher-order aberrations and, 13.13, 13.31–32, 13.76–77
for LASIK re-treatment/enhancement, 13.99
for mixed astigmatism, 13.97
multifocal, 13.167, 13.168*f*
outcomes of, 13.31–32, 13.97

overcorrection and, 13.102
patient selection/relative contraindications and, 13.80
postoperative aberrations and, 13.13, 13.102
preoperative planning/laser programming for, 13.31, 13.46, 13.81
for presbyopia, 13.167, 13.168*f*
wavefront analysis before, 13.31, 13.46, 13.80
Cutaneous horn (exuberant hyperkeratosis), 4.211, 7.188–189
Cutaneous leishmaniasis, 8.252
Cuticular (basal laminar) drusen, 4.162, 12.274, 12.275*f*
Cutler-Beard flap, 7.221, 7.223*f*
Cutting head, of microkeratome, 13.84, 13.85, 13.85*f*
CuZnSOD. *See* Copper-zinc superoxide dismutase
CVD. *See* Cardiovascular disease
CVI. *See* Cerebral (cortical/retrogeniculate) visual impairment
CVMs. *See* Cavernous venous malformations
CVOS (Central Vein Occlusion Study), 4.157
CVT. *See* Cerebral venous thrombosis
CXL. *See* Corneal (collagen) crosslinking
Cyanoacrylate glue/adhesive
for corneal perforation/corneoscleral laceration, 8.369*f*, 8.369–370, 8.402, 8.406
for descemetocele, 8.369
for peripheral ulcerative keratitis, 8.313
as tarsorrhaphy alternative, 8.373
Cyclic adenosine monophosphate (cAMP), 2.388
in α-agonist mechanism of action, 10.178
in β-blocker mechanism of action, 10.176
Cyclic esotropia, 6.93
Cyclic nucleotide-gated channels, 2.307, 2.309*f*
Cyclic strabismus, 6.93
Cyclin-dependent kinases (CDKs), 1.236, 2.176
Cyclins, 2.176
Cyclitis, chronic. *See* Intermediate uveitis; Pars planitis
Cycloablation. *See* Cyclophotocoagulation/cycloablation
Cyclocryotherapy, 6.287, 10.194
for pediatric glaucoma, 10.163–164
Cyclodestructive procedures, 9.320. *See also* Cyclophotocoagulation/cycloablation
Cyclodeviations
double Maddox rod test for, 6.69, 6.69*f*
fusion affected by, 6.79
Cyclodialysis, 4.18, 4.19*f*, 4.103, 8.391, 8.391*f*
after cataract surgery, 11.139
gonioscopic appearance of, 10.40, 10.41*f*
ultrasound biomicroscopy in evaluation of, 8.21, 8.391, 8.391*f*
Cyclogyl. *See* Cyclopentolate hydrochloride
Cyclomydril. *See* Cyclopentolate hydrochloride/phenylephrine hydrochloride
Cyclooxygenase (COX-1/COX-2), 2.409
COX-1, 9.19
COX-2, 9.19
Cyclooxygenase (COX) pathway, in arachidonic acid oxidation, 9.19
Cyclopentolate hydrochloride, 2.380*t*, 6.11, 6.11*t*
Cyclopentolate hydrochloride/phenylephrine hydrochloride, 2.380*t*
Cyclophosphamide, 2.404*t*
Behçet disease treated with, 1.173
description of, 1.179
for mucous membrane pemphigoid, 8.303
for peripheral ulcerative keratitis, 8.313
for uveitis, 9.109–110, 9.158, 9.160
Cyclophotocoagulation/cycloablation (CPC/cyclodestruction), 10.194–196, 10.195*f*
endoscopic, 10.194, 10.195, 10.196
cataract surgery and, 11.186
for neovascular glaucoma, 10.135
for pediatric glaucoma, 10.161, 10.163–164
Cycloplegia/cycloplegics, 2.380*t*, 11.23
adverse effects of, 6.11–12
amblyopia treated with, 6.59
for chemical injuries, 8.383
in children, 6.11–12
corneal abrasion treated with, 6.376
for corneal abrasions, 8.398
description of, 2.381
for hyphema, 8.394, 10.105
indications for, 3.38
for insect/arachnid injuries, 8.387
intraocular pressure affected by, 10.110
near reflex spasm treated with, 6.94
ocular surface toxicity and, 8.90*t*
after penetrating and perforating trauma repair, 8.409
for recurrent corneal erosions, 8.87
refraction with. *See* Cycloplegic refraction
for thermal injuries, 8.385
for traumatic anterior uveitis, 8.389–390
for uveitis, 9.113, 9.131
for vegetative injuries, 8.387
Cycloplegic refraction. *See also* Refraction; Refraction, clinical
agents used in, 6.11–12
in amblyopia treatment, 6.57
in children, 3.174, 6.10–12
description of, 3.168–169
in infantile esotropia, 6.88
before refractive surgery, 13.40
laser programming and, 13.40, 13.81
technique of, 6.11
Cyclosporine/cyclosporine A, 1.179, 2.258, 2.371*t*, 2.404*t*, 2.415
for atopic keratoconjunctivitis, 8.294
for Behçet disease, 9.217, 12.230
for corneal graft rejection prophylaxis, 8.430
for dry eye, 8.61*t*, 8.63
before refractive surgery, 13.173
for graft-vs-host disease, 8.304
for hay fever conjunctivitis, 8.289
for Mooren ulcer, 8.315, 8.316
for peripheral ulcerative keratitis, 8.313
for scleritis, 8.324
for superior limbic keratoconjunctivitis, 8.84
for Thygeson superficial punctate keratitis, 8.307
topical, 8.61*t*, 8.63
for uveitis, 9.108
for vernal keratoconjunctivitis, 6.249, 8.291, 8.292
Cyclothymic disorder, 1.196
Cyclotropia, relative, 5.185
Cyclovergence, fusional, 6.40
Cyclovertical strabismus, 6.162
Cylate. *See* Cyclopentolate hydrochloride

Cylinder axis
cross cylinder technique for determining, 3.163–166
finding of, for regular astigmatism, 3.156–158, 3.157–3.158*f*
locating of, 3.156, 3.157*f*
minus cylinder phoropter refinement of, 3.29–30, 3.30*f*
plus cylinder phoropter refinement of, 3.30
refinement of, 3.29–30, 3.30*f*, 3.163
straddling, 3.158, 3.158*f*
Cylinder power
cross cylinder technique for determining, 3.163–166
finding of, for regular astigmatism, 3.158
lensmeter measurement of, 3.284, 3.284*f*
minus cylinder phoropter refinement of, 3.31
plus cylinder phoropter refinement of, 3.31–32
refinement of, 3.31–32, 3.163–165, 3.164*f*
Cylindrical lenses
axis orientation in, 3.17–18
minus, 3.17*f*
plus, 3.17*f*
Cylindroma (adenoid cystic carcinoma/ACC), 7.100, 7.193, 7.193*f*
of lacrimal gland, 4.230–231, 4.231*f*
CYP1B1 gene, 6.259, 6.277
in glaucoma, 10.11*t*, 10.150
primary congenital, 8.108
in Peters anomaly, 8.97*t*, 8.103, 10.150
CYP2D6, 2.270
CYP4V2, 12.257*t*, 12.258, 12.269
Cyst(s). *See also specific type*
colobomatous, 6.224
dermoid, 6.223–224, 6.223–224*f*. *See also* Dermoids
epithelial inclusion, 6.250
iris, 6.272*f*, 6.272–273
microphthalmia with, 6.224, 6.225*f*
Cystadenoma (oncocytoma), 4.71–72, 4.72*f*, 8.337
Cystathionine β-synthase, 6.308
Cysteamine, 6.270, 12.293
for cystinosis, 8.182
Cysteine-rich proteins, in neurofibromatosis, 4.238
Cystic carcinoma, adenoid (ACC/cylindroma),
description of, 7.100, 7.193, 7.193*f*
of lacrimal gland, 4.230–231, 4.231*f*
Cystic fibrosis, 1.124
Cysticercosis, 7.53, 9.285–286, 9.285–286*f*
orbital involvement and, 4.228
Cysticercus cellulosae, 9.285
Cystine, 2.235
Cystine accumulation/crystals, in cystinosis, 8.181*f*, 8.181–182
Cystinosis, 2.235, 6.270, 6.387*f*, 6.389*t*, 8.181–182, 8.183*t*, 12.293
corneal changes in, 8.181*f*, 8.181–182, 8.183*t*
cysteamine for, 8.182
in infants and children, 8.181
Cystoid degeneration, peripheral, 4.148, 4.149*f*, 12.326
reticular (RPCD), 4.148, 4.149*f*, 12.326
typical (TPCD), 4.148, 4.149*f*, 12.326
Cystoid macular edema (CME), 2.359, 2.391, 2.394, 2.410, 4.140, 4.152–153, 4.153*f*, 4.154*f*. *See also* Macular edema
angiographic, after cataract surgery, 11.163–164, 11.164*f*
birdshot uveitis in, 12.224
cataract surgery as cause of, 12.157, 12.159, 12.260
central retinal vein occlusion as cause of, 12.136*f*
characteristics of, 12.156–157
corticosteroids for, 12.159, 12.393
after cataract surgery, 11.165
in cytomegalovirus retinitis, 12.235
differential diagnosis of, 12.157
drugs that cause, 12.301
edema sources in, 12.156–157
etiologies of, 12.157
fingolimod as cause of, 12.302
fluorescein angiography of, 12.36*f*, 12.157
incidence of, 12.157, 12.159
in Irvine-Gass syndrome, 12.157
nicotinic acid as cause of, 12.301
optical coherence tomography of, 12.132*f*, 12.157, 12.158*f*
petaloid, 12.157
postoperative, cataract surgery and, 11.163–165, 11.164*f*, 11.187
in glaucoma, 11.164, 11.187
after Nd:YAG laser capsulotomy, 11.157
vitreous prolapse and, 11.143–144
predisposing factors for, 12.157, 12.159
pseudophakic
definition of, 12.157
imaging of, 12.394*f*
optical coherence tomography of, 12.158*f*
pars plana vitrectomy for, 12.394*f*
in retinal dystrophies, 12.260, 12.260*f*
retinal vein occlusion as cause of, 12.135. *See also* Retinal vein occlusion
retinitis pigmentosa and, 12.260
spontaneous resolution of, 12.159
subretinal diseases that cause, 12.157
taxanes as cause of, 12.301
treatment of, 12.159
vision loss caused by, 12.225
vitrectomy for, 12.159, 12.393, 12.394*f*
Cystotome, for ECCE, 11.196
Cytarabine, epithelial cysts caused by, 8.130
Cytobrush, 8.210
Cytochrome P450, 2.351
Cytogenetics, 2.221
Cytoid bodies, 4.151–152, 4.152*f*
Cytokeratins, in immunohistochemistry, 4.33
Cytokines, 1.241, 7.210. *See also specific type*
in birdshot chorioretinopathy, 9.34
definition of, 9.21
in external eye defense, 8.11–13, 8.12*f*
growth factors, 9.21, 9.24*t*
in inflammation, 9.21, 9.22–24*t*
inhibitors of. *See* Biologic response modifiers
intercellular signaling of, 9.21
interferons, 9.21, 9.24*t*
interleukins, 9.21, 9.22–23*t*
lipopolysaccharide effects on, 9.7
mast cell–derived, 9.49
retinal pigment epithelium synthesis of, 9.58
in tear film, 2.252, 8.11–13, 8.12*f*
types of, 9.21, 9.22–24*t*

Cytology (ocular), 4.34*t*. *See also* Fine-needle aspiration biopsy
impression, in superior limbic keratoconjunctivitis, 8.84
Cytomegalovirus (CMV), 1.237*t*, 1.261–262, 1.279, 6.411, 6.411*f*, 8.231
anterior uveitis caused by, 8.231–233, 9.248–249
in HIV infection/AIDS, 5.349, 5.349*f*
keratitis caused by, 8.231–232, 8.232*f*
Posner-Schlossman syndrome caused by, 9.135
retinitis caused by, 2.364, 2.435–436, 4.145, 4.146*f*, 5.349, 12.235–236, 12.238*t*
characteristics of, 9.254–257
in children, 9.255–256
in HIV infection/AIDS, 5.349, 5.349*f*, 9.256, 9.328–329
imaging of, 9.255*f*
retinal detachments secondary to, 9.324, 9.329
treatment of, 9.256–257
Cytoplasm-antineutrophil cytoplasmic autoantibody (c-ANCA), 7.63
Cytoplasmic antinuclear antibody testing, 9.160
Cytosine, 2.176
Cytoskeletal (urea-soluble) lens proteins, 2.285, 11.15*f*, 11.16–17
Cytotoxic edema, 2.461*t*
Cytotoxic hypersensitivity (type II) reaction. *See also* Cytotoxic T cells
in mucous membrane pemphigoid, 8.299
Cytotoxic T cells (CTLs)
apoptosis inducement by, 9.46
assassination by, 9.46
autoimmunity and, 9.44
CD8 expression by, 9.36, 9.44
cytotoxicity mechanisms of, 9.46, 9.47*f*
description of, 9.44, 9.46
precursor, 9.46
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
suicide induction by, 9.46
Cytotoxicity
antibody-dependent cellular, 9.47–48
$CD8^+$ T cell, 9.47*f*
Cytovene. *See* Ganciclovir
Cytovene IV. *See* Ganciclovir

D

D. *See* Diopter
D-15 test, in low vision evaluation, 5.79
D-penicillamine, for Wilson disease, 8.189
Daclizumab, 2.406*t*
for multiple sclerosis, 5.321*t*, 9.152
Dacryoadenitis, 4.224, 7.68, 7.98, 7.312–313, 8.208*t*
Epstein-Barr virus causing, 8.208*t*, 8.230–231
mumps virus causing, 8.208*t*, 8.240
Dacryocystectomy, 7.317
Dacryocystitis
acute, 6.229
description of, 7.289, 7.313–315, 7.315*f*, 8.208*t*, 9.158
Dacryocystocele, 6.213, 6.225, 6.228–230, 6.229*f*, 7.289, 7.290*f*
Dacryocystography, 7.300
Dacryocystorhinostomy (DCR)
dacryocystitis treated with, 7.315
for nasolacrimal duct obstruction, 6.236, 7.286, 7.295, 7.307–310, 7.308–309*f*
Dacryolith, 7.305*f*, 7.305–306, 7.313
Dacryops, 4.208
Dacryoscintigraphy, 7.300
Dactylitis, 1.154
DAISY digital format, of audio books, 3.323
Dalen-Fuchs nodules/spots, 9.200, 9.202
in sympathetic ophthalmia, 4.185, 4.186*f*
Dalfampridine, for nystagmus, 5.245
DALK. *See* Deep anterior lamellar keratoplasty
DALYs. *See* Disability-adjusted life years
Danazol, 1.309*t*
Dantrolene, for malignant hyperthermia, 1.292
Dapiprazole hydrochloride, 2.387
Daraprim. *See* Pyrimethamine
Dark adaptation
absorptive lenses for, 3.192
in congenital stationary night blindness, 6.338
in electro-oculography, 12.50
in full-field (Ganzfeld) electroretinography, 12.42
in Oguchi disease, 12.253
spectral luminous efficiency function in, 3.109
Dark adaptometry, 12.57–58
Darkroom prone-position test, for primary angle-closure suspect, 10.122
DASH diet, 1.57, 1.58*t*
DAT. *See* Dual antiplatelet therapy
Data
clinical practice improvements using, 1.23–24
continuous, 1.6
normal distribution of, 1.6, 1.28
Data presentation
continuous quality improvement through, 1.28, 1.29–30*f*
control charts for, 1.28, 1.30*f*
histograms for, 1.28, 1.29*f*
Pareto chart for, 1.28, 1.30*f*
run charts for, 1.28, 1.30*f*
scatter diagrams for, 1.28, 1.29*f*
Dawson fingers, 5.67*f*
Day blindness (hemeralopia), 12.264
in cone/cone-rod dystrophies, 5.102
DC cardioversion. *See* Direct-current (DC) cardioversion
DCCT. *See* Diabetes Control and Complications Trial
DCN (decorin) gene
in congenital stromal corneal dystrophy, 8.136*t*
in posterior amorphous corneal dystrophy, 8.136*t*
DCR. *See* Dacryocystorhinostomy
DCs. *See* Dendritic cells
DDT. *See* Dye disappearance test
de Morsier syndrome (septo-optic dysplasia), 5.143–144, 6.361, 6.363*f*
Deafness (hearing loss)
cataract surgery in patient with, 11.170
pigmentary retinopathy and, 12.284. *See also* Usher syndrome
vestibular nystagmus and, 5.241, 5.241*t*, 5.242

Debridement
for *Acanthamoeba* keratitis, 8.278
for chemical injuries, 8.383
for epithelial defects
after LASIK, 13.112
after surface ablation, 13.108
for fungal keratitis, 8.275
for herpes simplex epithelial keratitis, 8.219
layer-based approach to use of, 8.417*t*
for limbal stem cell deficiency, 8.94
for recurrent corneal erosions, 8.79, 8.87
for surface ablation, 13.82–84, 13.83*f*
for thermal injuries, 8.385
Decadron. *See* Dexamethasone
Decamethonium, 2.382
Decentered ablation, 13.104, 13.104*f*
Decentration/dislocation (IOL), 11.127, 11.144*f*, 11.144–147, 11.146*f*, 11.147*f*
angle-supported lenses and, 13.146
bifocal segments, 3.190–191
iris-fixated lenses and, 13.145
laser application during photoablation and, 13.91
laser capsulotomy and, 11.156
multifocal lenses and, 3.258, 11.144, 11.145, 13.155
prism correction through, 3.197
Decision-making capacity assessments, 1.211
Decongestants
ocular, 2.416–417
tear production affected by, 8.62*t*
Decorin, 8.9
Decorin *(DCN)* gene
in congenital stromal corneal dystrophy, 8.136*t*
in posterior amorphous corneal dystrophy, 8.136*t*
Decreased vision. *See* Low vision; Vision loss/impairment
Decussation, optic nerve, 6.43
Deep anterior lamellar keratoplasty (DALK), 6.263, 6.270, 8.411, 8.412, 8.412*t*, 8.433, 8.434–435
advantages of, 8.421–422*t*
in children, 8.451
complications of, 8.435
intraoperative, 8.420*t*
postoperative, 8.421*t*
disadvantages of, 8.422*t*
for herpetic eye disease, 8.225
indications for, 8.420*t*
for keratoconus, 8.167
layer-based approach to use of, 8.417*t*
neurotrophic cornea after, 8.80
preoperative evaluation/preparation and, 8.418
rejection and, 8.411, 8.435, 8.435*f*
Deep-brain stimulation, for Parkinson disease, 1.205
Deep capillary plexus, 12.16
Deep cervical fascia, 7.153
Deep lamellar endothelial keratoplasty (DLEK), 8.412*t*, 8.436, 8.437*t*
Deep mimetic muscles, 7.153
Deep plexus, 2.57
Deep stromal neovascularization, 3.232
Deep superior sulcus, 7.141, 7.141*f*
Deep temporal artery, 5.15*f*
Deep temporal fascia, 7.155
Deep venous thrombosis, 5.345. *See also* Thromboembolism; Thrombosis/thrombotic disorders
in activated protein C resistance, 1.146–147
in antiphospholipid syndrome, 1.163–164
treatment of, 1.139, 1.164
Defense mechanisms
of external eye, 8.11–14, 8.12–13*f*, 8.13*f*
impaired. *See* Immunocompromised host
Defensins, in tear film, 8.6*f*
Deferoxamine, 12.298–299
Defibrillator-cardioverter, implantable (ICD). *See* Implantable cardioverter-defibrillator
Defibrillators, implanted, laser surgery in patient with, 13.37
Defocus, 3.40, 3.276, 3.276*f*
Defocus aberrations, positive and negative, 13.11, 13.11*f*
Deformable intraocular lenses, 13.170
Deformational plagiocephaly, 6.204–205
Degenerations, 4.9–10, 4.12*t*. *See also specific type*
anterior chamber/trabecular meshwork, 4.100–105, 4.101*f*, 4.102*f*, 4.103*f*, 4.104*f*, 4.105*f*
cataracts associated with, 11.68
conjunctival, 4.56*f*, 4.56–59, 4.57*f*, 4.58*f*, 4.59*f*, 8.111*t*, 8.111–114, 8.115*t*
corneal, 4.81–86, 4.82*f*, 4.83*f*, 4.84*f*, 4.85*f*, 4.86*f*, 8.115–128. *See also* Corneal degenerations
dystrophies differentiated from, 8.111, 8.111*t*
elastotic (elastosis)
in pinguecula/pterygium, 4.56*f*, 4.56–58
solar, of eyelid, 4.211–212, 4.212*f*
eyelid, 4.206*f*, 4.206–207, 4.207*f*, 4.207*t*
lens, 4.120*f*, 4.120–124, 4.121*f*, 4.122*f*, 4.123*f*, 4.124*f*. *See also* Cataract
macular. *See* Macular degeneration
optic nerve, 4.245*f*, 4.245–247, 4.246*f*, 4.247*f*
orbital, 4.228
peripheral cystoid, 4.148, 4.149*f*
reticular (RPCD), 4.148, 4.149*f*, 12.326
typical (TPCD), 4.148, 4.149*f*, 12.326
retinal, 4.148–170, 4.171–172*f*, 6.385. *See also* Retinal degeneration; Retinal dystrophies
scleral, 4.111*f*, 4.111–112, 4.112*f*, 8.128, 8.129*f*
uveal tract, 4.188, 4.189*f*
vitreous, 4.128–135, 4.129*f*, 4.130*f*, 4.131*f*, 4.132*f*, 4.133*f*, 4.134*f*
Degenerative retinoschisis, reticular (bullous) and typical, 4.148, 12.326, 12.327
Dehiscences, in lamina cribrosa, 12.218, 12.218*f*
Delayed hypersensitivity (DH). *See also* Delayed hypersensitivity (DH) T lymphocytes
contact dermatoblepharitis/dermatitis as, 8.286, 8.286*f*, 8.287
definition of, 9.42
in graft rejection, 8.316, 8.317
granulomatous form of, 9.44
in scleritis, 9.116
subtypes of, 9.42
T helper cell-17 in, 9.44
topical medications/substances and, 8.286, 8.286*f*, 8.287
tuberculin form of, 9.28
Delayed hypersensitivity (DH) T lymphocytes
description of, 9.36, 9.42–44

inflammatory diseases mediated by, 9.44*t*
in sympathetic ophthalmia, 9.45–46
T helper-cell 2, 9.43
in toxocara granuloma, 9.45
Delayed suprachoroidal hemorrhage, after cataract surgery, 11.160
Delayed visual maturation (DVM), 6.186–187
Deletion 4p, 6.386*t*
Deletion 5p, 6.386*t*
Deletion 18p, 6.386*t*
Deletion 18q, 6.386*t*
Delirium, 1.187
hallucinations and, 5.173
Delivery (birth), difficult, corneal edema caused by, 8.109
Delle, 6.172, 6.172*f*
Dellen, 8.79, 8.92, 8.368
management of, 8.368
DEM. *See* Diagnostic electron microscopy
Demarcation lines
pigmented, in rhegmatogenous retinal detachment, 12.324
in retinopathy of prematurity, 6.328*f*
in retinoschisis, 12.328
Dementia
AIDS-associated (HIV encephalopathy/HIV-associated neurocognitive disorder), 5.348. *See also* HIV infection/AIDS
Alzheimer disease as cause of, 1.209–210
cataract surgery in patient with, 11.169–170
hallucinations and, 5.173
Lewy body, 1.210
vascular, 1.210
visual symptoms of, 1.210
Demodex, 6.245, 8.253, 8.254*f*, 8.254–255, 8.255*f*
blepharitis/blepharoconjunctivitis and, 8.72, 8.72*f*, 8.73*f*, 8.253, 8.255
brevis, 8.205, 8.253
folliculorum, 8.205, 8.253
as normal flora, 8.205, 8.206*t*, 8.253
ocular infection caused by, 8.208*t*, 8.253, 8.254–255, 8.255*f*
rosacea and, 8.69, 8.253
Demodicosis, 6.245
de Morsier syndrome (septo-optic dysplasia), 5.143–144, 6.361, 6.363*f*
Demulcents, 8.62–63
Demyelination/demyelinating disease
internuclear ophthalmoplegia and, 5.190
multiple sclerosis, 5.315–320, 5.316*f*. *See also* Multiple sclerosis
neuroimaging in evaluation of, 5.72*t*
neuromyelitis optica and, 5.320–323
optic nerve involvement/optic neuritis and, 2.474*t*, 4.244, 4.244*f*, 5.114, 5.114*f*, 5.115, 5.317–318, 12.52
illusions and, 5.175
pain in, 5.295–296
Dendrites/dendritic keratitis, 4.76, 4.77*f*, 8.46*t*
herpes simplex, 4.76, 4.77*f*, 8.216–219, 8.218*f*, 8.226*t*
herpes zoster, 8.226, 8.226*t*, 8.227
Dendritic cells (DCs)
characteristics of, 9.4–5
in choroidal/ciliary body nevus, 4.191
conjunctival, 8.13
corneal, 8.13*f*, 8.13–14
in external eye defense, 8.13, 8.13*f*, 8.13–14
major histocompatibility class II molecule expression by, 9.30
pattern recognition receptors used by, 9.4
primed macrophages and, 9.14
Denervation and extirpation, 6.164*t*
Denervation anisocoria, 5.258*t*
Dengue fever, 9.267*f*, 9.267–268
Dense media
images in, 3.12
vergence equation for, 3.12
Dental diseases, retinal degeneration associated with, 12.286
Dentate processes
definition of, 12.10
illustration of, 12.11*f*
Deorsumduction, 6.33. *See also* Depression of eye
Deorsumversion, 6.37
Deoxyribonucleic acid. *See* DNA
Depigmentation, bull's-eye. *See also* Bull's-eye maculopathy/depigmentation
in cone dystrophy, 5.102
Depo-Medrol. *See* Methylprednisolone
Depolarizing agents, 2.382
Depression
chronic medical conditions as cause of, 1.194
Diagnostic and Statistical Manual of Mental Disorders criteria, 1.188
medications that cause, 1.204
in older adults, 1.188–190, 1.195–196
Patient Health Questionnaire-2 screening for, 1.189–190
prevalence of, 1.196
screening for, 1.189, 1.194
signs and symptoms of, 1.189, 1.195
subclinical, 1.189
Depression of eye (downgaze)
description of, 5.230–231, 6.33, 6.38
disorders/limitation of, 5.228–229
in newborn, 5.230–231
extraocular muscles controlling, 5.36*f*, 5.46*f*
inferior rectus muscle, 5.36*f*, 5.46*f*
superior oblique muscle, 5.36*f*, 5.46*f*
Depression (perimetry), generalized, in glaucoma, 10.69
Depressor supercilii muscle, 2.31*f*
Deprivation amblyopia, 6.55, 6.379
Depth of field
in camera obscura, 3.5, 3.5*f*
definition of, 3.40, 3.57, 3.58*f*
reduced, 3.8*f*
Depth of focus, 3.40, 3.57, 3.58*f*
Depth perception, stereopsis *versus*, 6.43
Dermal appendages of eyelid, neoplasms of, 4.214–218, 4.215*f*, 4.216*f*, 4.217*f*
Dermal fillers, for facial rejuvenation, 7.270*f*, 7.270–271
Dermal (intradermal) nevus, 4.219, 4.220*f*, 7.196
Dermal melanocytosis, 7.198, 7.198*f*, 8.339
Dermal/dermal orbital/oculodermal (nevus of Ota) melanocytosis, 4.63*t*, 4.64, 8.339
glaucoma associated with, 10.30
of iris, 4.259

Dermal orbital melanocytosis. *See* Dermal/dermal orbital/oculodermal (nevus of Ota) melanocytosis
Dermatan sulfate
in cornea, 8.9
in mucopolysaccharidoses, 8.175*t*
Dermatitis. *See also* Dermatoblepharitis
α-agonists causing, 10.178, 10.178*f*
atopic, 8.287
atopic keratoconjunctivitis and, 8.292
cataracts associated with, 11.66
eyelid involvement and, 8.287
vernal keratoconjunctivitis and, 8.289
contact, eyelid involvement and, 8.285–287, 8.286*f*
zoster, 8.227, 8.229
Dermatoblepharitis, 8.208*t*
contact, 8.285–287, 8.286*f*
herpes simplex virus causing, 8.208*t*, 8.213, 8.214*f*, 8.216
varicella-zoster virus causing, 8.208*t*, 8.225–230, 8.226*t*. *See also* Herpes zoster ophthalmicus
Dermatochalasis
brow ptosis and, 7.259, 7.263
description of, 7.249, 7.249*f*
Dermatologic diseases. *See also* Skin, disorders of
retinal degeneration associated with, 12.286
Dermatomyositis, 1.167*f*, 1.167–168
eyelid manifestations of, 4.207*t*
Dermis, eyelid, 4.201, 4.201*f*
neoplasms of, 4.214, 4.215*f*
Dermis-fat grafts, 7.36, 7.37*f*, 7.137, 7.141, 7.143, 7.143*f*
Dermoids (dermoid cysts/tumors), 4.6, 4.47, 4.49*f*, 6.223–224, 6.223–224*f*, 7.40–41
congenital, 4.203
conjunctival, 4.47, 4.49*f*
corneal, 4.73, 8.196
epibulbar/limbal, 4.6, 4.47, 4.49*f*
of eyelid, congenital, 4.203
Goldenhar syndrome and, 4.47
limbal, Goldenhar-Gorlin syndrome and, 8.195, 8.195*f*
orbital, 4.223, 4.224*f*
Dermolipomas (lipodermoids), 7.41, 7.42*f*
description of, 4.47–48, 4.48*f*, 6.210, 6.256–257
Goldenhar syndrome and, 4.48
Derry disease, 6.389*t*
DES. *See* Drug-eluting stent; Dry eye syndrome
Descemet membrane/layer, 4.73, 4.74*f*, 8.7*f*, 8.9
age-related changes in, 8.115
age-related thickening of, 2.266*f*
anatomy of, 2.53, 2.54*f*, 8.7*f*, 8.9
Bowman layer *versus*, 2.51
breaks in
description of, 6.260
in primary congenital glaucoma, 6.280, 6.280*f*
traumatic, 6.262, 6.262*f*
chalcosis findings in, 12.362
in congenital hereditary endothelial dystrophy, 8.160
in congenital stromal corneal dystrophy, 8.152
copper deposits/Kayser-Fleischer ring and, 8.118*t*, 8.173, 8.189, 8.189*f*
definition of, 2.266
deposits in/pigmentation of, 8.118*t*, 8.132
in Wilson disease, 8.189, 8.189*f*
detachment of
after cataract surgery, 11.131
after deep anterior lamellar keratoplasty, 8.435
folds in, 8.41–42
in Fuchs endothelial corneal dystrophy, 4.92, 4.93*f*, 8.156, 8.157
guttae in, in luetic keratitis, 4.80
Hassall-Henle warts of, 2.53
healing/repair of, 4.16
in macular dystrophy, 8.150
in posterior amorphous corneal dystrophy, 8.154, 8.154*f*, 8.155
in posterior polymorphous corneal dystrophy, 4.93, 4.94*f*, 8.158
rupture of/tears in, 4.17, 4.18*f*
birth trauma and, 8.109, 8.389*f*
after deep anterior lamellar keratoplasty, 8.435
in keratoconus, 4.17, 4.18*f*, 4.95*f*, 4.96, 8.163–164, 8.164*f*
in keratoglobus, 8.171
ocular trauma and, 4.17, 4.18*f*, 8.388, 8.389*f*
tears in, 6.254
thickness of, 2.53
Descemet membrane endothelial keratoplasty (DMEK), 8.412, 8.412*t*, 8.436, 8.436*t*, 8.437*t*
advantages of, 8.421–422*t*, 8.438
cataract surgery and, 8.446–447
complications of, 8.437*t*
intraoperative, 8.420–421*t*, 8.440
postoperative, 8.421*t*, 8.440–449
disadvantages of, 8.422*t*, 8.438–440
endothelial cell loss after, 8.448–449
for Fuchs endothelial corneal dystrophy, 4.92, 4.93*f*
graft dislocation/decentration after, 8.442*f*, 8.442–443, 8.443*f*
hemi, 8.449–450
indications for, 8.420*t*
primary graft failure and, 8.447
pupillary block after, 8.444*f*, 8.444–445
rejection and, 8.437*t*, 8.448
results, 8.437*t*
visual acuity after, 8.438–440
Descemet membrane endothelial transfer (DMET), 8.449
Descemet stripping/Descemet stripping automated endothelial keratoplasty (DSEK/DSAEK), 8.412, 8.412*t*, 8.436, 8.436*t*, 8.437*t*
advantages of, 8.421–422*t*, 8.438, 8.439*f*
cataract formation and, 11.56
cataract surgery and, 8.446–447
complications of, 8.437*t*
intraoperative, 8.420–421*t*, 8.440, 8.441*f*
postoperative, 8.421*t*, 8.440–449
disadvantages of, 8.422*t*, 8.438–440
endothelial cell loss after, 8.448–449
epithelial ingrowth after, 8.445, 8.445*f*
graft dislocation/decentration and, 8.441, 8.442*f*
graft failure and, 4.85*f*
indications for, 8.420*t*
primary graft failure and, 8.447
pupillary block after, 8.444*f*, 8.444–445
rejection and, 8.437*t*, 8.447, 8.447*f*
results of, 8.437*t*
visual acuity after, 8.438–440

Descemetocele, management of, 8.369
lamellar keratoplasty for, 8.433, 8.433*f*
Descemetorrhexis
in DMET, 8.449
in DSEK, 8.436
for Fuchs endothelial corneal dystrophy, 8.157–158, 8.449
Descending optic atrophy, 4.246
Desmin, in immunohistochemistry, 4.33
Desmoid tumors, 6.222
Desmopressin, for von Willebrand disease, 1.144
Desmosomes, 2.51, 2.52*f*, 2.73*f*
Destructive interference, 3.100, 3.119
Deutan red-green color deficiency, 12.54
Deuteroanomalous dichromatism, 12.250*t*
Deuteroanomalous trichromatism, 12.250*t*
Developmental defects. *See also* Congenital anomalies; *specific type*
of lens, 11.39–42, 11.40*f*
Developmental glaucomas, 10.153–156. *See also* Glaucoma, pediatric
Developmental hyperopia, 3.143
Developmental myopia, 3.142–143, 3.174
Deviation maps, 10.65, 10.65*f*
Deviations, 5.230–231. *See also* Esodeviations; Exodeviations; Horizontal deviations; Strabismus; Vertical deviations; *specific type*
comitant (concomitant), 5.183, 5.184, 5.186
definition of, 6.16
in infantile esotropia, 6.88
esodeviations
accommodative, 6.90. *See also* Accommodative esotropia
definition of, 6.85
in divergence insufficiency, 6.94
epidemiology of, 6.85
extraocular muscle surgery amounts for, 6.160, 6.160*t*
risk factors for, 6.85
types of, 6.86*t*
exodeviations
control of, 6.100
convergence insufficiency, 6.103
definition of, 6.99
exotropia. *See* Exotropia
extraocular muscle surgery amounts for, 6.160, 6.161*t*
latent, 6.99
manifest, 6.99
risk factors for, 6.99
head tilt and, 5.185
incomitant, 6.16
incomitant (noncomitant), 5.183, 5.184, 5.187. *See also specific type*
primary, 6.38
secondary, 6.39
seizure activity and, 5.230
skew. *See* Skew deviation
strabismic amblyopia and, 6.46–47
terminology used to describe, 6.15–16
tonic, 5.230–231
in gaze preference, 5.228
variations in size of, 6.16
vertical. *See* Vertical deviations
Devic disease (neuromyelitis optica/NMO), 5.107*t*, 5.116–118, 5.117*t*, 5.320–323
clinical presentation of, 5.320–322
diagnosis of, 5.322–323
treatment of, 5.323
Dexacidin. *See* Dexamethasone/neomycin sulfate/polymyxin B sulfate
Dexamethasone, 1.175*t*
for corneal graft rejection
prophylaxis, 8.430
treatment, 8.430
elevated intraocular pressure after photoablation associated with, 13.105
intravitreal implant of, 9.97, 9.150
pellet formulation of, for uveitis, 9.97–98
for toxoplasmosis, 6.410
for vernal keratoconjunctivitis, 8.291
Dexamethasone implant, 2.364
complications of, 12.404
retinal vein occlusion treated with, 12.137
Dexamethasone/neomycin sulfate/polymyxin B sulfate, 2.422*t*
Dexamethasone sodium phosphate, 2.400*t*, 2.402*t*
Dexamethasone/tobramycin, 2.422*t*
Dexasporin. *See* Dexamethasone/neomycin sulfate/polymyxin B sulfate
Dextrocycloversion, 6.38
Dextroversion, 6.37
DFP. *See* Diisopropyl phosphofluoridate
DH. *See* Delayed hypersensitivity
DHA. *See* Docosahexaenoic acid
DHD. *See* Dissociated horizontal deviation
DI. *See* Divergence insufficiency/paralysis
Diabetes Control and Complications Trial (DCCT), 1.35, 2.345, 12.96
Diabetes insipidus, diabetes mellitus, optic atrophy, and deafness (DIDMOAD/Wolfram) syndrome, 2.220
pleiotropism in, 6.408–409
Diabetes mellitus (DM), 6.408–409. *See also specific Diabetic entries*
asteroid hyalosis and, 12.346
blood glucose testing in, 1.40
cataract surgery in, 12.116, 12.117–12.120*t*
cataracts associated with
carbohydrate ("sugar"), aldose reductase in development of, 11.19
description of, 11.19, 11.60*f*, 11.60–61
surgery for, 11.170
preoperative evaluation and, 11.80–81
characteristics of, 1.33
classification of, 1.33–34
complications of
acute, 1.38–39
coronary artery disease, 1.40
glycemic control effects on, 1.36
ketoacidosis, 1.38–39
large-vessel disease, 1.40
long-term, 1.39–40
macrovascular, 1.36
myocardial infarction, 1.40
nephropathy, 1.39
neuropathy, 1.39–40

nonketotic hyperglycemic hyperosmolar coma, 1.38–39
ophthalmic, 1.40–41. *See also* Diabetes mellitus, cataracts associated with; Diabetic macular edema; Diabetic retinopathy
retinopathy, 1.36, 1.40
corneal changes in, 4.159, 8.173, 8.199–200
neurotrophic keratopathy/persistent corneal defects and, 8.81, 8.81*t*, 8.199
definition of, 1.33
Diabetes Control and Complications Trial, 1.35, 2.345, 12.96
diagnosis of, 1.34–35
gestational, 1.34
glaucoma and, 10.83
glycemic control in, 1.35–36
hemoglobin A_{1c} in
as diagnostic marker, 1.34
retinopathy progression relative to, 1.36*f*
hyperglycemia associated with, 1.33
hypertension in, 1.56, 1.65
insulin-dependent, 12.91
latent autoimmune diabetes in adults, 1.34
lifestyle modifications for, 1.35
metabolic syndrome as risk factor for, 1.35
microvascular complications of, 1.33
non–insulin-dependent, 12.91
ocular surgery considerations in, 1.284, 1.286–287
ophthalmic considerations and. *See* Diabetes mellitus, cataracts associated with; Diabetic macular edema; Diabetic retinopathy
ophthalmic examinations for, 12.93–94, 12.95*t*
perioperative management for ocular surgery in patients with, 1.284
prediabetes, 1.34–35
preoperative fasting considerations in, 1.287
prevalence of, 1.33
refractive surgery in patient with, 13.37, 13.190–191
retinal vein occlusion risks, 12.128
retinopathy of. *See* Diabetic retinopathy
risk reduction methods, 1.35–36
signs and symptoms of, 1.34
treatment of, 1.36–38, 1.286–287
type 1, 1.34, 12.91
glycemic control in, 1.35–36
insulin administration for, 1.37
pancreas transplantation for, 1.37–38
pathogenesis of, 1.33–34
prevalence of, 1.33
quality-of-life improvements in, 1.37
treatment of, 1.36–38
type 2, 1.34, 12.91
cardiovascular risk reduction in, 1.36
characteristics of, 1.34
in children, 1.34
glycemic control in, 1.35–36
hypertension associated with, 1.33
impaired glucose tolerance progression to, 1.35
insulin resistance associated with, 1.34
metformin for, 1.38
noninsulin therapy for, 1.38
prevalence of, 1.33
thiazolidinediones for, 1.38
treatment of, 1.38
United Kingdom Prospective Diabetes Study, 12.96–97
Diabetic keratopathy, refractive surgery in patient with, 13.190
Diabetic ketoacidosis (DKE), 1.38–39
Diabetic macular edema (DME)
cataract surgery and, 11.80, 11.189, 12.116
center-involved, 12.92, 12.109, 12.110*f*
classification of, 12.109–110, 12.110*f*
clinically significant (CSME), 12.92, 12.110, 12.114
contrast sensitivity issues in, 12.56
definition of, 12.92
focal, 12.110
mechanism of, 12.108, 12.109*f*
non–center-involved, 12.109, 12.111*f*
optical coherence tomography of, 12.111*f*
spectral-domain optical coherence tomography of, 12.109*f*, 12.125
treatment of
aflibercept, 12.113
anti-VEGF therapy, 12.101, 12.110, 12.111–113
bevacizumab, 12.113
corticosteroids, 12.113–114
Diabetic Retinopathy Clinical Research Network findings, 12.112*f*, 12.113
intravitreal steroids, 12.101
laser surgery, 12.114–115, 12.376
overview of, 12.110–111
pars plana vitrectomy, 12.115
ranibizumab, 12.111–112, 12.112*f*
surgery, 12.114–115, 12.388
vitrectomy, 12.388
vision loss caused by, 12.94
Diabetic nephropathy, 12.98
Diabetic neuropathy, neurotrophic keratopathy/persistent corneal defects and, 8.81, 8.81*t*, 8.199
Diabetic papillopathy, 5.125, 5.125*f*
Diabetic retinopathy, 4.155*f*, 4.159–160, 4.160*f*, 4.161*f*, 6.408–409
anemia and, 12.98
aspirin and, 12.100
background. *See* Diabetic retinopathy, nonproliferative
cataract surgery and, 11.80–81, 11.189
cotton-wool spots associated with, 12.140–141
description of, 12.91
diabetic nephropathy associated with, 12.98
epidemiology of, 12.92–93
4:2:1 rule for, 12.99
glycemic control for, 12.96–98
hemoglobin A_{1c} levels in, 12.96, 12.98
iris neovascularization and, 4.159, 4.160*f*
ischemic heart disease and, 1.105
medical management of, 12.96–98
neurotrophic keratopathy/persistent corneal epithelial defect and, 8.81, 8.81*t*
nonproliferative (NPDR/background). *See also* Diabetic macular edema
anti-VEGF therapy for, 12.101–102
clinical findings in, 12.99
definition of, 12.91

intraretinal hemorrhages associated with, 12.100*f*
intraretinal microvascular abnormalities in, 12.100*f*
microaneurysms associated with, 12.100*f*
optical coherence tomography angiography of, 12.94*f*
panretinal photocoagulation for, 12.101
posterior vitreous detachment creation for, 12.102
progression of, to proliferative diabetic retinopathy, 12.101
ranibizumab for, 12.102
scatter photocoagulation for, 12.116
severity of, 12.95*t*, 12.99
treatment of, 12.101–102
venous beading associated with, 12.100*f*
vision loss in, 12.101
in older adults, 1.184
ophthalmic examinations for, 12.93–94, 12.95*t*
papillopathy and, 5.125
pathogenesis of, 12.93
photocoagulation for, 4.160, 4.161*f*
pregnancy-related progression of, 12.93–94
prevalence of, 1.184
progression of, 1.36, 1.40
fenofibrate effects on, 12.102
hypertension as risk factor for, 12.98
pregnancy-related, 12.93–94
proliferative (PDR), 2.301
anti-VEGF therapy for, 12.103–104, 12.386
complications of, 12.103–108
definition of, 12.91–92
extraretinal fibrovascular proliferation associated with, 12.102
high-risk characteristics of, 12.103
laser surgery for, 12.104–107
management of, 12.103–108
neovascular proliferation associated with, 12.102
neovasculization in, 12.151
nonproliferative diabetic retinopathy progression to, 12.101
nonsurgical management of, 12.103–104
optical coherence tomography angiography of, 12.94*f*
panretinal photocoagulation for, 12.104, 12.106, 12.106*f*
photocoagulation for, 12.94
in pregnancy, 12.94
proangiogenic factors in, 12.102
proliferative sickle cell retinopathy *versus*, 12.151
ranibizumab for, 12.104
scatter photocoagulation for, 12.116
severe carotid artery occlusive disease associated with, 12.98
severity of, 12.95*t*
stages of, 12.102
steroids for, 12.103–104
surgical management of, 12.104–107
tractional retinal detachment caused by, 12.103, 12.108, 12.387–388
treatment of, 2.414
vitreous hemorrhage caused by, 12.103, 12.103*f*, 12.107–108, 12.386–387
reactive oxygen species in, 2.345
refractive surgery in patient with, 13.190
retinal capillary nonperfusion associated with, 12.101
severity of, 12.95*t*, 12.101
studies of, 1.78
Diabetes Control and Complications Trial, 1.35, 2.345, 12.96
Early Treatment Diabetic Retinopathy Study, 12.99–101
United Kingdom Prospective Diabetes Study, 12.96–97
systemic medical management of, 12.96–98
terminology associated with, 12.91–92
vision loss from
abnormalities associated with, 12.98
lipid levels and, 12.98
mechanisms of, 12.101
Diabetic Retinopathy Clinical Research Network
cataract surgery in diabetes mellitus studies, 12.116, 12.117–12.120*t*
diabetic macular edema treatment, 12.112*f*, 12.113
Diabetic Retinopathy Study (DRS), 12.104–105
Diagnostic and Statistical Manual of Mental Disorders (DSM) depression criteria, 1.188
Diagnostic electron microscopy (DEM), 4.34*t*, 4.42
Diagnostic positions of gaze, 6.64
Diagnostic/screening tests. *See* Screening
Diagnostic ultrasonography. *See* Ultrasonography/ultrasound (echography)
Dialyses, 4.19–20, 4.20*f*
Diameter
of contact lenses, 3.205, 3.215*f*, 3.216
of pupil, 3.105
Diamidines, for *Acanthamoeba* keratitis, 8.278
3,4-Diaminopyridine. *See* Amifampridine
Diamox. *See* Acetazolamide
Diamox Sequels. *See* Acetazolamide
"Diaphragm pattern," 5.170
Diaphragm pump, for phacoemulsification aspiration, 11.103, 11.104*f*
Diarrhea, *Clostridium difficile,* 1.249
Diastolic blood pressure, 1.52, 1.56, 1.214
Diastolic dysfunction, 1.99
Diathermy, for hyphema, 8.396
Diazoxide, 1.64
DIC. *See* Disseminated intravascular coagulation
DICER1 gene mutation, in medulloepithelioma, 4.179
Dichromacy, 12.250
Diclofenac sodium, 2.400*t*, 2.409*t*
Dideoxyinosine, 12.299
DIDMOAD syndrome, 2.220, 6.408–409
Dieffenbachia keratitis, 8.387
Diencephalic syndrome, acute, 5.117*t*
Diet/diet therapy
DASH, 1.57, 1.58*t*
for dry eye, 8.61*t*, 8.64, 8.68
genetic diseases managed with, 2.235
hypercholesterolemia managed with, 1.74
retinopathy of prematurity and, 12.184–185
in vitamin A deficiency, 8.196, 8.197
Diethylcarbamazine, for loiasis, 8.282
Difference map, after keratorefractive surgery, 13.23, 13.23*f*
Diffraction of light, 3.91, 3.104–106, 3.105*f*
Diffractive multifocal intraocular lenses, 3.259*f*, 3.259–260, 13.166, 13.166*f*

Diffuse anterior scleritis, 8.320, 8.320*f*, 8.320*t*, 8.321*f*, 8.325*f*, 9.116, 9.118
Diffuse choroidal hemangioma, 4.197, 4.198*f*, 4.281–283, 4.283*f*
Diffuse corneal transparency disorders, 6.257–258*t*, 6.257–263, 6.258*f*
Diffuse drusen, 4.160, 4.161*f*
Diffuse illumination, for slit-lamp biomicroscopy, 8.16, 8.17*f*
Diffuse infiltrative retinoblastoma, 6.353
Diffuse injection (simple) episcleritis, 4.109, 8.318
Diffuse iris nevus, 4.255, 4.256*f*
Diffuse lamellar keratitis (DLK), after LASIK, 13.116*f*, 13.116–117, 13.117*t*
  infectious keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
  pressure-induced stromal keratopathy differentiated from, 13.119
Diffuse large B-cell lymphomas (DLBCLs), 7.92
Diffuse macular edema, 12.110, 12.111*f*
Diffuse neonatal hemangiomatosis, 6.220
Diffuse photoreceptor dystrophies, 4.170, 4.172*f*. *See also* Cone dystrophies/degenerations; Cone-rod dystrophies; Retinitis pigmentosa
Diffuse soft-tissue histiocytosis, 6.219
Diffuse superficial keratitis, 6.242
Diffuse toxic goiter, 1.43. *See also* Graves disease, hyperthyroidism associated with
Diffuse unilateral subacute neuroretinitis (DUSN), 9.287–288*f*, 9.287–289, 12.246
Diffuse uveitis. *See* Panuveitis
Diffusible ligands, 2.165–166
Diffusion, 2.271
  in aqueous humor dynamics/formation, 10.16
  glucose transport into lens and, 11.17
Diffusion-weighted magnetic resonance imaging (DWI), 1.112, 2.458, 2.461*t*, 5.64*f*, 5.65*t*, 5.66, 5.67*f*, 5.72*t*, 5.75
  in cerebral ischemia detection/evaluation, 5.167, 5.168
Diflucan. *See* Fluconazole
Diflunisal, 2.409*t*
Difluprednate, 2.356, 2.400*t*, 2.403
  for corneal graft rejection prophylaxis, 8.430
  for uveitis, 9.94
Digital eversion, for cicatricial entropion, 7.237
Digital pressure, for intraocular pressure estimation, 10.26
Digital rectal examination (DRE), for prostate cancer, 1.221
Digital resolution, of scanning laser ophthalmoscopy, 12.24
Digital subtraction angiography (DSA), 5.68
  in arterial dissection, 5.342
Digitalis/digitoxin/digoxin
  description of, 12.305
  ocular effects of, 1.106, 5.175
  visual changes caused by, 5.175
Digitalis glycosides, 1.309*t*
Dihydropyridine calcium channel blockers, 1.61
Diisopropyl phosphofluoridate (DFP), 2.379
Diktyoma (medulloepithelioma), 4.178*f*, 4.178–179, 4.296*f*, 4.296–297, 6.273*f*, 6.273–274
  retinoblastoma differentiated from, 4.296*f*, 4.296–297
  teratoid, 4.179
Dilated cardiomyopathy, anticoagulation therapy for, 1.100
Dilated fundus examination, before refractive surgery, 13.44
Dilator muscle (iris), 4.182
  in Horner syndrome, 5.258
  innervation of, 5.53, 5.54
  tadpole pupil caused by spasm of, 5.255
Dimethyl fumarate, for multiple sclerosis, 5.321*t*
Dimorphic fungi, 8.249
Dinitrophenol, 2.330
Diode laser. *See also* Laser(s)
  for choroidal/ciliary body melanoma, 4.276
  for cyclodestruction, 10.194, 10.195–196
    in children, 10.163
  for retinoblastoma, 4.300
  for trabeculoplasty, 10.189–190
Diopter (D), 8.3, 8.8, 8.26, 8.27, 13.7
  definition of, 3.40, 3.51
  prism, 3.46, 3.47*f*
  values for, 3.52*t*
Dioptric power. *See also* Diopter; Power (optical)
  of bifocal segments, 3.190
  description of, 8.3, 8.8
Diphenhydramine hydrochloride, 1.302
Diphtheria-tetanus-pertussis (DTP), 1.229
Diphtheroids, 8.246
  as normal flora, 8.205, 8.206*t*, 8.246
Dipivefrin (DPE) hydrochloride, 2.385*t*
  for glaucoma, 10.177
Diplopia, 5.183–209
  binocular, 5.183
  after blepharoplasty, 7.262–263
  in Brown syndrome, 5.208
  carotid-cavernous fistula causing, 5.203–206, 5.204*f*, 5.205*f*
  after cataract surgery, 5.207
  cavernous sinus/superior orbital fissure lesions causing, 5.202–206, 5.204*f*, 5.205*f*
  cerebral, 5.185
  comitant deviations and, 5.183, 5.184, 5.186
  cranial nerve palsies causing, 5.192, 5.193*f*, 5.193–201, 5.194*f*, 5.196*f*, 5.198*f*, 5.199*f*, 5.200*f*, 5.202
    multiple nerve involvement and, 5.202
  crossed, 6.75
  description of, 6.47–48
  esotropia and, 6.102
  extraocular muscle surgery as cause of, 6.168
  fixation switch, 5.209
  fourth nerve (trochlear) palsy causing, 5.185, 5.186, 5.188–189, 5.198–200, 5.199*f*
  in foveal displacement syndrome, 5.209
  in heavy eye syndrome, 5.208
  heteronymous, 6.75
  history in, 5.183
  homonymous, 6.75
  incomitant deviations and, 5.183, 5.184, 5.187
  infranuclear causes of, 5.191–206, 5.193*f*, 5.194*f*, 5.198*f*, 5.199*f*, 5.200*f*, 5.204*f*
  internuclear causes of, 5.189–191, 5.190*f*, 5.191*f*

after LASIK, 13.125
in amblyopia patient, 13.186
localization of lesions causing, 5.187*f*, 5.187–188
monocular, 5.174, 5.185
in cataracts, 11.43–44, 11.45, 11.47, 11.70–71
in multiple sclerosis, 5.318
in myasthenia gravis, 5.192, 5.206, 5.324
myopathic/restrictive/orbital causes of, 5.186, 5.206–209, 5.207*f*
neuroimaging evaluation of, 5.73*f*
neuromuscular junction causes of, 5.206
neuromyotonia causing, 5.202
nuclear causes of, 5.188–189
one-and-a-half syndrome and, 5.191, 5.191*f*
in orbital floor/blowout fracture, 5.206, 6.127–128, 7.114, 7.115–116
orbital myositis causing, 5.207*f*, 5.207–208
orbital neoplasia causing, 5.208
paradoxical, 6.50, 6.50*f*
paretic syndromes causing, 5.186
multiple cranial nerve involvement and, 5.202
restrictive syndromes differentiated from, 5.186, 5.186*f*
physical examination in, 5.184*f*, 5.184–185, 5.185*f*
physiologic, 6.48
postoperative, 5.207, 5.209, 6.168
posttraumatic, 5.186, 5.206
press-on prisms for, 6.96
prisms for, 6.72
red-glass test for, 6.75
refractive procedure-induced, 5.209
restrictive syndromes causing, 5.186, 5.206–209, 5.207*f*
paretic syndromes differentiated from, 5.186, 5.186*f*
postsurgical, 5.207
posttraumatic, 5.186, 5.206
in sagging eye syndrome, 5.209
sixth nerve (abducens) palsy causing, 5.200*f*, 5.200–201, 6.96
in superior oblique myokymia, 5.250, 5.251
suppression of, 6.49*f*
supranuclear causes of, 5.188, 5.188*t*
testing for, 6.75
third nerve (oculomotor) palsy causing, 5.188, 5.191, 5.193*f*, 5.193–198, 5.194*f*, 5.196*f*, 5.198*f*, 6.139
in thyroid eye disease, 5.186, 5.206, 6.140–141, 7.61–62
Tolosa-Hunt syndrome and, 5.203
uncrossed, 6.75
vergence dysfunction causing. *See* Vergences/vergence system
vertebrobasilar insufficiency causing, 5.337, 5.337*f*
Diquafosol tetrasodium, 2.416
Direct-acting agonists
α_1-adrenergic agonists, 2.384
cholinergic
acetylcholine, 2.375–377
actions of, 2.375
adverse effects of, 2.378
indications for, 2.378
pilocarpine, 2.377–378
Direct carotid-cavernous fistulas, 7.78, 7.78*f*
Direct coronal scans, 7.27
Direct-current (DC) cardioversion
atrial fibrillation treated with, 1.103
ventricular tachycardia treated with, 1.104
Direct illumination, 3.292
Direct ophthalmoscope/ophthalmoscopy, 3.281, 3.297–3.298*f*, 3.297–298, 3.307. *See also* Ophthalmoscopy/ophthalmoscope
limitations of, 12.21
retinal disease evaluations using, 12.21
Direct oral anticoagulants, 1.149–150, 1.286
Direct oral antithrombotic agents, for coronary heart disease, 1.90*t*
Direct renin inhibitors (DRIs), for hypertension, 1.63
Direct response, in pupillary reaction to light, 5.254
Direct sequencing, 2.189
Direct thrombin inhibitors
coronary heart disease treated with, 1.90–91*t*
indications for, 1.149
Direct-to-consumer genetic testing, 2.241
Direct traumatic optic neuropathy, 5.139, 5.139*f*, 7.121*f*
Direct vasodilators, for hypertension, 1.63
Direct visualization, in ophthalmic examination, 8.15–20, 8.16*f*, 8.17*f*, 8.18*f*, 8.19*f*, 8.20*f*. *See also* Slit-lamp biomicroscopy/examination
Disability-adjusted life years (DALYs), 1.193
"Disc at risk," 5.121*f*, 5.122
Disc edema. *See* Optic nerve head (ONH/optic disc), edema of
Disciform keratitis (endotheliitis), 8.51*f*
CMV causing, 8.232, 8.232*f*
herpes simplex virus causing, 4.77*f*, 4.78, 8.220, 8.221*f*, 8.222
persistent bullous keratopathy and, 8.225
Disciform macular degeneration, ultrasonographic findings in, 2.471*f*
Disconjugate eye movements (vergences), 5.212, 5.212*t*, 5.226–228. *See also specific type*
dysfunction of, 5.227–228
Disconjugate (dissociated) nystagmus, 5.234, 5.247
Disconnection syndromes, 5.178
Discrete neurofibromas, 7.83
Disease
posttest probability of, 1.19–20
pretest probability of, 1.18–21, 1.20*t*
risk factors and, cohort studies regarding associations between, 1.13
Disease-modifying antirheumatic drugs (DMARDs), 9.103. *See also* Immunomodulatory therapy/immunotherapy/immunosuppression
alkylating agents, 1.179
ankylosing spondylitis treated with, 1.155
azathioprine, 1.179
biologic, 1.177*t*, 1.180–181
biosimilar agents, 1.180–181
calcineurin inhibitors, 1.179
hydroxychloroquine, 1.178–179
interleukin inhibitors, 1.180
Januse kinase inhibitors, 1.180
leflunomide, 1.178
methotrexate, 1.178
mycophenolate mofetil, 1.179
nonbiologic, 1.177*t*, 1.178–179

ocular adverse effects of, 1.308*t*
rheumatoid disease treated with, 1.153
sulfasalazine, 1.179
tumor necrosis factor-α inhibitors, 1.180
types of, 1.177*t*
Disease-modifying therapy (DMT), for multiple sclerosis, 5.320, 5.321*t*
neuromyelitis optica and, 5.323
Disjunctive nystagmus, 5.234
Disk-diffusion susceptibility testing, 1.271
Dislocated lens, 11.40. *See also* Ectopia lentis
cataract surgery in patient with, 11.181–183, 11.182*f*, 11.183*f*
conditions associated with, 6.306*t*
description of, 6.306
ectopia lentis et pupillae, 6.267–268, 6.307, 6.307*f*
in homocystinuria, 6.308–309
illustration of, 6.306*f*
inborn errors of metabolism and, 6.306
iridodonesis with, 6.306
isolated/simple ectopia lentis, 6.307
in Marfan syndrome, 6.307–308, 6.308*f*
refractive error caused by, 6.310
in sulfite oxidase deficiency, 6.310
traumatic, 11.40, 11.54*f*, 11.54–55
treatment of, 6.310
in Weill-Marchesani syndrome, 6.309
Dislocation/decentration (IOL), 11.127, 11.144*f*, 11.144–147, 11.146*f*, 11.147*f*
angle-supported lenses and, 13.146
iris-fixated lenses and, 13.145
laser capsulotomy and, 11.156
multifocal lenses and, 11.144–145, 13.155
Dislocation (LASIK flap), 13.113, 13.115–116
striae and, 13.113
traumatic, 13.115–116
Disodium ethylenediaminetetraacetic acid (EDTA). *See* Ethylenediaminetetraacetic acid
Dispersion, definition of, 3.45
Dispersive ophthalmic viscosurgical devices/viscoelastics, 2.445, 11.96. *See also* Ophthalmic viscosurgical devices
elevated intraocular pressure and, 10.108
Dissection
arterial, 5.342–343. *See also specific type or artery affected*
gross, for pathologic examination, 4.28*f*, 4.28–30, 4.29*f*
Disseminated intravascular coagulation (DIC), 1.142, 1.145–146, 12.196
Dissimilar segments, induced anisophoria corrected using, 3.189, 3.189*f*
Dissociated horizontal deviation (DHD), 6.17, 6.105, 6.129
Dissociated (disconjugate) nystagmus, 5.234, 5.247
Dissociated strabismus complex (DSC), 6.17, 6.105*f*, 6.129
Dissociated torsional deviation (DTD), 6.17, 6.129
Dissociated vertical deviation (DVD)
age at onset, 6.129
clinical features of, 6.129, 6.129*f*
definition of, 6.129
description of, 6.17, 6.105, 6.111, 6.115–116
hypertropia and, 6.115
inferior oblique anterior transposition for, 6.166
inferior oblique muscle overaction *versus*, 6.129–130
management of, 6.130
Distance vision
multifocal intraocular lenses for, 3.258
near vision *versus*, in amblyopia, 3.25
Distance visual acuity. *See also* Visual acuity
corrected (best-corrected visual acuity). *See* Corrected distance visual acuity
testing
in low vision, 5.78
before refractive surgery, 13.39
Distance–near incomitance, 6.162
Distant objects, principal planes and, 3.59
Distensible venous malformations, 7.74–75, 7.75*f*
Distichiasis, 4.202, 6.195, 6.195*f*, 7.170, 7.179, 7.179*f*, 8.88
congenital, 4.202
Distometer, 3.171, 3.171*f*
Distortion
definition of, 3.40, 3.72
schematic diagram of, 3.72*f*
Distraction test, for horizontal eyelid laxity, 7.231
Distributive shock, 1.300. *See also* Shock
Disuse anopsia. *See* Deprivation amblyopia
Diuretics, 12.134
hypertension treated with, 1.59*t*, 1.59–61
loop, 1.59*t*, 1.59–60
ocular adverse effects of, 1.309*t*
potassium-sparing, 1.59*t*, 1.60
side effects of, 1.60–61
thiazide-type, 1.59, 1.59*t*
Diurnal fluctuation of vision, after radial keratotomy, 13.51
Diurnal variation
in intraocular pressure, 10.3, 10.8, 10.22, 10.80–81, 10.81*t*, 10.86, 10.87
in vision, after radial keratotomy, 13.51
Divergence
fusional, 6.40, 6.72
fusional vertical, 6.40
synergistic, 6.133
Divergence amplitude, 5.226
Divergence insufficiency/paralysis (DI), 5.227–228, 6.94
Divergent strabismus, 6.15
Diverging lens, for myopia correction, 3.170, 3.170*f*
"Divide and conquer nucleofractis," 11.112–114, 11.113*f*
Divisional third nerve (oculomotor) palsy, 5.197
Dix-Hallpike maneuver, 5.242–243
Dk, 3.213, 3.215
Dk/t, 3.213
DKA. *See* Diabetic ketoacidosis
DLBCLs. *See* Diffuse large B-cell lymphomas
DLEK. *See* Deep lamellar endothelial keratoplasty
DLK. *See* Diffuse lamellar keratitis
DLPN. *See* Dorsolateral pontine nuclei
DM. *See* Diabetes mellitus
DMARDs. *See* Disease-modifying antirheumatic drugs
DME. *See* Diabetic macular edema
DMEK. *See* Descemet membrane endothelial keratoplasty
DMET. *See* Descemet membrane endothelial transfer

DMT. *See* Disease-modifying therapy
DNA (deoxyribonucleic acid)
amplification of, in polymerase chain reaction, 4.36–40, 4.38*t*, 4.39*t*, 4.40*f*
coding region of, 2.178
damage to, 2.181–182
direct sequencing of, 2.189
methylation of, 2.180
mitochondrial (mtDNA), diseases associated with deletions/mutations of
chronic progressive external ophthalmoplegia, 5.328–329, 5.329*f*
Leber hereditary optic neuropathy, 5.133
mutations in, 2.182–183
noncoding, 2.177–178
plasmid, 8.243
repair of, 2.181–182. *See also* Mutation
sequencing of, 2.189
next-generation (NGS/massively parallel), 4.39*t*
telomeric, 2.178
virus, 8.211, 8.212. *See also* DNA viruses
DNA gyrase, 2.420
DNA probes, 4.41
in microarray, 4.41
multiplex ligation-dependent amplification of (MLPA), 4.39*t*
DNA viruses, 1.236, 1.237*t*, 8.211, 8.212–239
adenoviruses (Adenoviridae), 8.233–236
herpesviruses (Herpesviridae), 8.212–233
papovaviruses, 8.238–239
poxviruses (Poxviridae), 8.236–238
Docetaxel, 12.301
Docosahexaenoic acid (DHA), 2.324, 12.70
Dog bites, 7.218
Dog tapeworm *(Echinococcus granulosus)*, orbital infection caused by, 4.228
Dolichocephaly, 6.205
Dolichoectasia, intracavernous carotid aneurysm as, 5.339
Doll's head maneuver/phenomenon, 5.221, 5.228, 6.88
Dominance, ocular, 13.39
Dominant diseases, gene therapy for, 2.197–198
Dominant inheritance
autosomal, 2.206–208, 2.207*t*
description of, 2.202–203
X-linked, 2.209, 2.210*t*
Dominant-negative effect, 2.197
Dominant optic atrophy, 5.135, 5.136*f*, 6.367–368, 6.368*f*
Donder's law, 6.31
Donepezil, for Alzheimer disease, 1.210
Donor cornea, 8.411. *See also* Corneal grafts; Keratoplasty
contraindications to use of, 8.414, 8.415*t*, 8.416*t*
criteria for acceptability of, 8.414, 8.415*t*, 8.416*t*
disease transmission and, 8.414, 8.415*t*, 8.416*t*
Creutzfeldt-Jakob disease, 8.254, 8.416*t*
rabies virus, 8.240, 8.240*t*, 8.416*t*
dislocation/decentration of, after endothelial keratoplasty, 8.440–444, 8.441*f*, 8.442*f*, 8.443*f*
DMEK, 8.442*f*, 8.442–443, 8.443*f*
DSEK, 8.441, 8.442*f*
endothelial failure of, 4.84, 4.85*f*
late non–immune-mediated, 8.427–428
primary
after endothelial keratoplasty (DMEK/DSEK), 8.447
after penetrating keratoplasty, 8.423, 8.423*f*
for epikeratoplasty (epikeratophakia), 13.62
eye banking and, 8.413–417, 8.415*t*, 8.416*f*, 8.416*t*
for homoplastic corneal inlay, 13.60
prior LASIK affecting, 13.198
rejection of, 4.84, 4.85*f*, 8.316–318, 8.428–431. *See also* Rejection
selection/screening of, 8.414, 8.415*t*, 8.416*t*
storage of, 8.413–417, 8.415*t*, 8.416*f*, 8.416*t*
Dopamine agonists, for Parkinson disease, 1.205
Dopamine–norepinephrine reuptake inhibitors, 1.203*t*
Doppler imaging, 5.70, 7.31. *See also* Ultrasonography/ultrasound
carotid, 5.70
orbital, 5.70–71
Dorello canal, 2.133, 5.41, 5.42*f*
sixth nerve (abducens) injury/palsy and, 5.201
Doripenem, 1.273
Dorsal midbrain (Parinaud) syndrome, 5.37, 5.229, 5.230*f*
in children, 5.231
convergence-retraction nystagmus in, 5.229, 5.250
description of, 2.475*t*, 6.105
eyelid retraction in, 5.229, 5.250, 5.274, 5.275*t*
light-near dissociation in, 5.229, 5.230*f*, 5.266*t*, 5.266–267
multiple sclerosis and, 5.319
Dorsal nasal artery, 2.23*f*, 2.38*f*
Dorsal subnucleus, of cranial nerve VII (facial), 5.49
Dorsal vermis, 5.33, 5.40
Dorsal visual processing stream, 5.224
Dorsolateral pontine nuclei (DLPN), 5.33, 5.34*f*, 5.35, 5.224
Dorsum sella, 5.6*f*
Dorzolamide, 2.391*t*, 2.393, 10.173*t*, 10.175*t*, 10.179–180
in children, 10.165
in combination preparations, 10.174*t*
Dorzolamide hydrochloride/timolol maleate, 2.389*t*, 2.391*t*, 2.397*t*
Dot-and-blot hemorrhages, ischemia causing, 4.153–154, 4.155*f*, 5.170, 5.171*f*
Dots, in epithelial basement membrane dystrophy, 8.137–138, 8.138*f*
Double anterior chamber, after deep anterior lamellar keratoplasty, 8.435
Double-elevator palsy. *See* Monocular elevation deficiency
Double freeze–thaw technique, 7.240
Double heterozygotes, 2.215
"Double hump" sign, in plateau iris, 10.127, 10.127*f*
Double-*K* method, 3.252
Double Maddox rod test, 5.184–185, 5.185*f*, 6.69, 6.69*f*, 6.120
in fourth nerve (trochlear) palsy, 5.198
Double pinhole apertures, 3.285, 3.286*f*

Double-ring sign
description of, 6.361, 6.362*f*
in optic nerve hypoplasia, 5.143, 5.143*f*
Double simultaneous stimulation, in confrontation testing, in hemispatial neglect, 5.181
Double-slit experiments, 3.94, 3.101, 3.101*f*, 3.105
Double vision. *See* Diplopia
Down syndrome
clinical features of, 2.223, 2.224*t*
genetic errors in, 2.223
hypoaccommodation in, 6.9
idiopathic intracranial hypertension associated with, 6.372
ocular findings in, 2.224*t*, 6.386*t*
pharmacogenetics and, 2.233–234
pseudopapilledema associated with, 6.372
Downbeat nystagmus, 5.243*t*, 5.244–245, 5.245*f*, 6.152
Downgaze (depression of eye/deorsumversion/deorsumduction)
description of, 5.230–231, 6.38
disorders/limitation of, 5.228–229
in newborn, 5.230–231
extraocular muscles controlling, 5.36*f*, 5.46*f*
inferior rectus muscle, 5.36*f*, 5.46*f*
superior oblique muscle, 5.36*f*, 5.46*f*
Downward-slanting palpebral fissure
description of, 6.196
pattern strabismus and, 6.107, 6.108*f*
syndromes with, 6.196
Doxazosin, intraoperative floppy iris syndrome and, 11.74, 11.136–137, 11.137*t*
Doxycycline, 1.308*t*
for bartonellosis, 9.243
for cat-scratch disease, 9.243, 12.242–243
for chlamydial conjunctivitis, 8.263
description of, 2.371*t*, 2.424
for Lyme disease, 9.231*t*
for meibomian gland dysfunction, 8.68
ocular rosacea treated with, 2.370
for recurrent corneal erosions, 8.87
for rosacea, 8.71
Doyne honeycomb dystrophy, 12.275. *See also* Drusen
DPE. *See* Dipivefrin
Dragged-fovea diplopia syndrome, 6.145
DRE. *See* Digital rectal examination
"Dresden protocol," 13.130, 13.132, 13.133*t*. *See also* Corneal (collagen) crosslinking
DRIs. *See* Direct renin inhibitors
Drop attacks, 5.336
DRS. *See* Diabetic Retinopathy Study
Drug abuse. *See* Substance abuse disorders
Drug delivery
collagen corneal shields for, 2.365
contact lenses for, 2.365–366
encapsulated cell technology for, 2.366
gel-forming drops for, 2.366
implants for, 2.364
intracameral, 2.359–360, 2.360*t*
intraocular, 2.359–361
intraocular lenses for, 2.364–365
intravitreal, 2.360*t*, 2.361
liposomes for, 2.366
local administration, 2.359–361
microelectromechanical systems for, 2.367
nanotechnology for, 2.366–367
ocular inserts for, 2.363–364
periocular injections, 2.359
punctal plug–mediated, 2.366
routes for, 2.353*f*
sustained-release, 2.363–365
systemic administration, 2.361–362
topical. *See* Topical anesthesia/anesthetics
Drug dependence, 1.198–199
Drug-eluting stent (DES), percutaneous coronary intervention with, 1.92
Drug-induced cicatricial pemphigoid (pseudopemphigoid), 8.91, 8.92, 8.299
Drug-induced thrombocytopenia, 1.141–142
Drug-induced uveitis, 9.139–140*f*, 141
Drug Quality and Security Act (2013), 2.372
Drug resistance. *See specific agent and specific organism*
Drug withdrawal syndromes, 1.68–69
Drugs. *See also specific drug or drug group*
allergic reaction to. *See* Allergic reactions/allergies; *specific drug*
color-vision abnormalities caused by, 12.304–305
compliance with, 2.373
compounding of, 2.372–373
crystalline retinopathy caused by, 12.302–304, 12.304*t*
as diagnostic agents, 2.444–445
dry eye and, 2.415–416, 8.61–62, 8.62*t*
fixed, dilated pupil caused by, 5.310
ganglion cell toxicity caused by, 12.301
glaucoma caused by
angle closure/angle-closure glaucoma and, 10.122–123, 10.145*f*, 10.145–146
open-angle glaucoma and, 10.109–111
hallucinations/illusions caused by, 5.175
hyaloidal separation effects on, 12.85
lens changes caused by, 11.51–53, 11.52*f*
macular edema caused by, 12.301–302, 12.302*f*
microvasculopathy caused by, 12.300–301
noncompliance with, 2.373, 2.373*t*
occlusive retinopathy caused by, 12.300–301
ocular. *See also specific agent*
conjunctivitis/keratoconjunctivitis/keratopathy caused by, 8.80–81, 8.81*t*, 8.90*t*, 8.90–91
contact dermatoblepharitis caused by, 8.285–287, 8.286*f*
corneal deposits and pigmentation caused by, 8.129*t*, 8.129–132, 8.130*f*, 8.131*f*
crystalline deposits, 8.182*t*
mucous membrane (cicatricial) pemphigoid (pseudopemphigoid) caused by, 8.91, 8.92, 8.299
neurotrophic keratopathy/persistent corneal epithelial defects caused by, 8.80–81, 8.81*t*
refractive surgery and, 13.37
topical. *See* Eyedrops
toxic ulcerative keratopathy/keratoconjunctivitis caused by, 8.80–81, 8.81*t*, 8.90*t*, 8.90–91
toxicity of, 8.80–81, 8.81*t*, 8.90*t*, 8.90–92, 8.91*f*, 8.129*t*. *See also specific disorder*
corneal crystalline deposition and, 8.182*t*
viscoelastics. *See* Ophthalmic viscosurgical devices
ocular adverse effects of, 1.307–309, 1.308–309*t*

ocular toxicity and
description of, 12.305–306
NAION and, 5.123
optic neuropathy caused by, 5.107*t*, 5.137–139
optic nerve toxicity caused by, 12.301
retinal toxicity caused by
alkyl nitrites, 12.300, 12.300*f*
chloroquine derivatives, 12.295–297, 12.296*f*
clofazimine, 12.298
deferoxamine, 12.298–299
dideoxyinosine, 12.299
hydroxychloroquine, 12.295–297, 12.296*f*
MEK inhibitors, 12.299, 12.299*f*
nucleoside reverse transcriptase inhibitors, 12.299
phenothiazines, 12.297–298, 12.298*f*
scleral delivery of, 12.20
Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis) caused by, 8.295
thrombocytopenia induced by, 1.141–142
topical. *See* Topical anesthetics/anesthesia
toxicity caused by, retinal signs of, 12.68
Drusen
in age-related macular degeneration, 4.160–163, 4.161*f*, 4.162*f*, 4.163*f*
boundaries of, 12.65
calcific, 4.163, 12.66
categorization of, 12.64–65
choroidal nevi and, 4.256, 4.257*f*, 4.268
confluent, 12.65
cuticular (basal laminar), 4.162, 12.274, 12.275*f*
definition of, 12.63
diffuse, 4.160, 4.161*f*
early-onset, 12.273, 12.274*f*
fluorescein angiography of, 12.65
fundus camera imaging of, 12.23, 12.23*f*
geographic atrophy and, 12.66
giant, 4.295, 5.108*f*, 5.143
retinoblastoma differentiated from, 4.295
in tuberous sclerosis, 4.295
hard (hyaline), 4.162, 4.162*f*, 12.65
histologic appearance of, 12.63, 12.64*f*
large colloid, 12.274
optic nerve/nerve head/disc (ODD), 4.247, 4.247*f*, 5.108*f*, 5.140–143, 5.141*f*, 6.373*f*, 6.373–374
astrocytic hamartoma differentiated from, 5.108*f*, 5.143
autofluorescence in identification of, 5.89, 5.90*f*, 5.141*f*, 5.142
papilledema/pseudopapilledema and, 4.247, 5.107, 5.108*f*, 5.141*f*, 5.142–143
transient visual loss and, 5.141, 5.161, 5.164
ultrasonography in identification of, 5.95, 5.141*f*, 5.142
optical coherence tomography of, 12.65–66
photoreceptors affected by, 12.64
pigment epithelial detachment associated with, 12.64
refractile, 12.23*f*
soft, 4.162, 4.162*f*, 12.65, 12.68, 12.75, 12.200*f*, 12.272
spectral-domain optical coherence tomography of, 12.64*f*
subretinal deposits, 12.200
Drusenoid deposits, subretinal (reticular pseudodrusen/RPD), 4.162, 4.163, 4.163*f*, 4.171*f*, 12.65*f*, 12.65–66
Drusenoid pigment epithelial detachment, 12.64, 12.272, 12.274*f*
"Dry" age-related macular degeneration. *See* Nonneovascular ("dry"/nonexudative) age-related macular degeneration
Dry eye disease, 7.310
Dry eye (keratoconjunctivitis/keratitis sicca [KCS]), 3.234–235, 8.45, 8.53–69. *See also* Ocular surface, disorders of; *specific causative factor*
aqueous tear deficiency causing, 8.45, 8.53, 8.54*f*, 8.55*f*, 8.55–58, 8.61*t*, 8.61–65, 8.62*t*, 8.65*f*. *See also* Aqueous tear deficiency
blepharitis and, 8.68, 8.72, 8.76
cataract surgery in patient with, 11.173
corneal melting/keratolysis and, 11.132
clinical approach to, 8.53–69, 8.54*f*, 8.55*f*
decreased vision/transient visual loss and, 5.99, 5.164
definition of, 8.53
diagnostic classification of, 8.53–54, 8.55*f*
evaporative, 8.45, 8.53–54, 8.54–55*f*, 8.58–60, 8.59*f*, 8.60*f*, 8.66–67*t*, 8.66–69
in graft-vs-host disease, 8.303
illusions and, 5.174
keratoprosthesis for, 8.452–453
lacrimal plugs for, 8.61*t*
after LASIK, 13.78–79, 13.172
mechanisms of, 8.53–55, 8.54*f*, 8.55*f*
medications causing, 8.61–62, 8.62*t*
in mucous membrane pemphigoid, 8.303
mucus-fishing syndrome and, 8.89
multifocal IOLs and, 13.155
non-Sjögren syndrome, 8.55*f*
pain and, 5.295
in peripheral ulcerative keratitis, 8.312–313
after photoablation, 13.76, 13.78–79, 13.172
after photorefractive keratectomy, 13.79
refractive surgery and, 13.42, 13.78–79, 13.172–173
severity of, 8.57*t*
Sjögren syndrome, 8.39, 8.55*f*, 8.56–58, 8.58*t*
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298
after surface ablation, 13.76
epithelial defect and, 13.107–108
systemic diseases associated with, 8.59*t*
tear film evaluation in, 8.38–41, 8.40*f*, 8.55–56
stains used in, 8.36–37, 8.37*f*, 8.38*f*, 8.56
tear film osmolarity and, 8.39, 8.53
treatment of, 8.61*t*, 8.61–69, 8.62*t*, 8.65*f*, 8.66*t*, 8.66–67*t*
medical management
of aqueous tear deficiency, 8.61*t*, 8.61–64, 8.62*t*
of evaporative dry eye, 8.66*t*, 8.66–67*t*, 8.66–69
surgical management, of aqueous tear deficiency, 8.64–65, 8.65*f*
Dry eye syndrome (DES)
cyclosporine A for, 2.258
description of, 2.250, 2.253
lifitegrast for, 2.258
medications for, 2.415–416
neural feedback loop in, 2.255*f*
ocular surface inflammation in, 2.257*f*, 2.257–258

tear substitutes for, 2.258
vicious circle theory of, 2.254, 2.256*f*
"Dry"/nonexudative age-related macular degeneration. *See* Nonneovascular ("dry"/nonexudative) age-related macular degeneration
DSA. *See* Digital subtraction angiography
DSC. *See* Dissociated strabismus complex
DSEK/DSAEK. *See* Descemet stripping/Descemet stripping automated endothelial keratoplasty
DSM. *See Diagnostic and Statistical Manual of Mental Disorders*
DTD. *See* Dissociated torsional deviation
DTP. *See* Diphtheria-tetanus-pertussis
Dual antiplatelet therapy (DAT)
for angina pectoris, 1.91–92
ocular surgery considerations, 1.286
Dual-optic intraocular lenses, 13.170, 13.170*f*
Duane retraction syndrome, 7.243
bilateral, 6.132
classification of, 6.132–133
clinical features of, 6.132–133
definition of, 6.131
electromyographic studies of, 6.132
esotropic, 6.95–97, 6.132*f*, 6.133
exotropic, 6.105, 6.132, 6.132*f*
genetics of, 6.132
globe retraction in, 6.134
incomitant hypertropia associated with, 6.125
management of, 6.133–134
"ocular splits," 6.133
overdepression in adduction caused by, 6.117
overelevation in adduction caused by, 6.117
prevalence of, 6.133
surgical treatment of, 6.133–134
synergistic divergence associated with, 6.133
systemic/syndromic defects associated with, 6.131
type 1, 6.132*f*, 6.132–133
type 2, 6.132, 6.132*f*
type 3, 6.132–134, 6.133*f*
Dua's (pre-Descemet) layer, 4.73, 4.74*f*, 8.9
Duchenne muscular dystrophy, 2.210, 12.285
Ductal cysts of eyelid, 4.208, 4.208*f*
Ductions, 5.184. *See also specific type*
description of, 6.33, 6.83
in diplopia, 5.184
forced, 5.186, 5.186*f*
forced. *See* Forced duction test (traction test)
in infantile esotropia, 6.37
Duke Activity Status Index, 1.283
Dulcitol (galactitol), in cataract formation, 11.61
Duochrome (red-green/bichrome) test. *See also* Worth 4-dot
basis of, 3.36
in nonorganic disorder evaluation
monocular no light perception and, 5.303, 5.304*f*
monocular reduced vision and, 5.305
pictorial representation of, 3.167*f*
before refractive surgery, 13.39
spherical endpoint verified using, 3.166, 3.167*f*
Duodenal biopsy, for Whipple disease, 9.244
DuoTrav. *See* Travoprost, in combination preparations; Travoprost/timolol maleate
Duplex ultrasonography. *See also* Ultrasonography/ultrasound (echography)
in carotid artery evaluation/disease, 5.70, 5.167
Duplication cataract, 4.120, 4.120*f*
Dura mater, optic nerve, 4.241, 4.242*f*, 5.17*f*
Dural arteriovenous/arterial malformations, 5.343, 12.198, 12.199*f*
Dural-cavernous fistula, glaucoma associated with, 10.30
Dural fistula, 2.476*t*
Dural rings, 5.14, 5.16*f*
Dural sheath, optic nerve, 5.26
Dural tail, 7.85
Durezol. *See* Difluprednate
DUSN. *See* Diffuse unilateral subacute neuroretinitis
Duty cycle, in phacoemulsification, 11.100
DVD. *See* Dissociated vertical deviation
DVM. *See* Delayed visual maturation
DWI. *See* Diffusion-weighted magnetic resonance imaging
Dye disappearance test (DDT), 7.297, 7.298*f*, 8.36
Dynamic B-scan ultrasonography, 2.467–468, 2.469*t*, 2.470–471*f*
Dynamic contour tonometry/tonometer, 10.26
Dynamic gonioscopy, 10.35, 10.35*f*, 10.36
in acute primary angle closure, 10.123
Dynamic retinoscopy
accommodation measurements using, 6.9
in children, 6.9
Dynamic skiascopy. *See* Retinoscope/retinoscopy
Dynamic visual acuity, vestibular-ocular reflex evaluation and, 5.216
Dysautonomia, familial (FD/Riley-Day syndrome), congenital corneal anesthesia and, 8.108
description of, 2.204*t*, 2.229, 6.271
Dyschromatopsia, 12.249, 12.265. *See also* Color vision, defects in
Dysconjugate nystagmus, 6.151–152
Dyscoria, 6.267
Dysgeusia, Horner syndrome and, 5.261
Dyskeratosis
in actinic keratosis, 4.211
benign hereditary intraepithelial, 8.332*t*
definition of, 4.202
Dyskinesia, tardive
blepharospasm and, 5.281
facial movements and, 5.285
Dysmetric saccades, 5.222
Dysmorphic sialidosis (ML I), 8.178
Dysphotopsias, 3.239, 3.255
IOLs and, 5.174, 11.150–151
Dysplasia
ectodermal, 8.202
ocular surface (conjunctival or corneal intraepithelial neoplasia/CIN), 2.414, 4.61, 4.63*f*, 4.96, 8.37, 8.38*f*, 8.332*t*, 8.334–335, 8.335*f*. *See also* Ocular surface squamous neoplasia
melanocytic, 4.63*t*, 4.65, 4.66, 4.67*f*
of orbit
fibro-osseous, 4.239, 4.240*f*
fibrous, 4.239, 4.240*f*
Dysplastic nevus
description of, 1.220
melanoma arising from, 4.220, 4.262

Dyspnea, 1.124
Dysraphism, 6.183*t*
Dysthymic disorder, 1.195
Dysthyroid ophthalmopathy/orbitopathy. *See* Thyroid eye disease
Dystopia canthorum, 6.191, 6.192*f*
Dystrophic lipidization, 12.66
Dystrophies, 4.10, 4.12*t*. *See also specific type*
adult-onset foveomacular vitelliform, 4.170, 4.171*f*, 12.272, 12.276
butterfly-type pattern, 12.276, 12.276*f*
choroidal
Bietti crystalline dystrophy, 12.258, 12.269, 12.282*t*
central areolar, 12.277
choroideremia, 12.267–268, 12.268*f*
classification of, 12.255
gyrate atrophy, 12.268–269, 12.269*f*
cone
bull's-eye pattern associated with, 12.265, 12.265*f*
description of, 12.264–265
electroretinography findings in, 12.46, 12.47*f*, 12.265
genes and loci associated with, 12.256*t*
with supernormal rod ERG, 12.49
cone–rod
genes and loci associated with, 12.256*t*
Jalili syndrome, 12.286
retinitis punctata albescens, 12.258, 12.258*f*
corneal, 4.81–94, 8.133–160, 8.134*t*, 8.135*t*, 8.136*t*. *See also* Corneal dystrophies; *specific type*
cataract/cataract surgery in patient with, 11.84, 11.174*f*, 11.174–175
refractive surgery and, 13.42–43, 13.43*f*, 13.76, 13.78, 13.178
multifocal IOLs, 13.155
degenerations differentiated from, 8.111, 8.111*t*
hereditary. *See* Hereditary dystrophies
macular, 4.168–169*f*, 4.168–170, 4.171*f*. *See also* Macular dystrophies
adult-onset vitelliform lesions, 12.272, 12.273*f*
atypical, 12.277
Best disease, 12.271, 12.272*f*
early-onset "drusenoid," 12.273–276, 12.274–12.275*f*
electroretinography findings in, 12.46, 12.47*f*
North Carolina, 12.277, 12.278*f*
occult, 12.277
pattern dystrophies, 12.276*f*, 12.276–277
Sorsby, 12.275*f*, 12.275–276
Stargardt disease. *See* Macular dystrophies
macular corneal (MCD), 4.91, 4.91*t*, 4.92*f*, 8.135*t*, 8.136*t*, 8.145*t*, 8.149–151, 8.150*f*
panretinal
clinical findings of, 12.261, 12.263*f*
Coats reaction associated with, 12.260
nonsyndromic, 12.258–259
syndromic, 12.259
pattern, 4.170, 4.171*f*, 12.67, 12.272, 12.276*f*, 12.276–277
adult-onset foveomacular vitelliform, 4.170, 4.171*f*
butterfly-type (BPD), 4.170, 12.276, 12.276*f*
photoreceptor (diffuse), 4.170, 4.172*f*
retinal. *See* Retinal degeneration; Retinal dystrophies
rod–cone. *See also* Retinitis pigmentosa
in Bardet-Biedl syndrome, 12.284
characteristics of, 12.261–264, 12.262–12.264*f*
conventional testing of, 12.261
electroretinography evaluations, 12.46, 12.47*f*, 12.261
imaging of, 12.262–12.264*f*
macula-spared, 12.46, 12.47*f*
stromal, 4.91, 4.91*t*, 4.92*f*
Dystrophin, 2.180, 12.285

E

E_e. *See* Irradiance
E_v. *See* Illuminance
E coli. See Escherichia/Escherichia coli
E-Selectin, 9.11–12
Eagle Vision glaucoma implant, 10.214*t*
Eales disease, 9.237, 9.238*f*, 9.324, 12.156, 12.241
Early macular telangiectasia, 12.277
Early Manifest Glaucoma Trial (EMGT), 10.88, 10.113
Early-onset "drusenoid" macular dystrophies, 12.273–276, 12.274–12.275*f*
Early-onset (childhood) nystagmus, 5.235–239. *See also* Nystagmus
Early Treatment Diabetic Retinopathy Study (ETDRS), 12.99–101, 12.110
eyechart, 3.23*f*, 3.133, 3.133*f*, 3.313, 3.313*f*, 6.8
Early Treatment for Retinopathy of Prematurity (ETROP), 6.326, 6.331*t*, 6.332, 12.179, 12.185
EAU. *See* Experimental autoimmune uveoretinitis
EB. *See* Elementary body
EBAA (Eye Bank Association of America), 8.414
EBMD. *See* Epithelial dystrophies, epithelial and subepithelial, basement membrane
Ebola virus
description of, 1.264–265, 9.270–271, 9.271*f*
panuveitis, 12.247
EBRT. *See* External-beam radiotherapy
EBV. *See* Epstein-Barr virus
EBV-HLH. *See* Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis
ECA. *See* External carotid artery
ECCE. *See* Extracapsular cataract extraction
Eccentric fixation, 3.310
anomalous retinal correspondence *versus*, 6.51
definition of, 6.54
in strabismic amblyopia, 6.54
Eccentric gaze, 5.38
gaze-evoked nystagmus and, 5.222, 5.240
rebound, 5.240–241
saccadic dysfunction and, 5.222
Ecchymoses. *See also* Purpura
eyelid, 7.22, 7.22*f*, 7.23*t*
Eccrine hidrocystoma, 4.208, 7.191
Eccrine spiradenomas, 7.193
Eccrine sweat glands
anatomy of, 7.191
of eyelid, 4.201, 4.202, 8.4
cyst arising in, 4.208
syringoma associated with malformation of, 4.214, 4.215*f*
tumors of, 7.191–192
ECD. *See* Erdheim-Chester disease

ECDC. *See* European Centre for Disease Prevention and Control
ECG. *See* Electrocardiography/electrocardiogram
Echinocandins, 2.431, 2.431*t*
Echinococcus granulosus (echinococcosis)
description of, 7.53
orbital infection caused by, 4.228
Echo time (TE), 2.457
Echocardiography
cardiac emboli identification and, 5.168
in cerebral ischemia/stroke, 5.168
congestive heart failure evaluations, 1.97
coronary heart disease diagnosis using, 1.87
ejection fraction evaluations, 1.97
stress, 1.87
stroke evaluations, 1.112
Echography. *See* Ultrasonography/ultrasound (echography)
Echothiophate, 2.378*t*, 10.173*t*
cataract and, 11.52
for glaucoma, 10.173*t*
Eclampsia, 1.67, 12.196
neuro-ophthalmic signs of, 5.333
transient visual loss and, 5.161
Eclipse retinopathy. *See* Solar retinopathy
Econopred. *See* Prednisolone
Econopred Plus. *See* Prednisolone acetate
ECP. *See* Endoscopic cyclophotocoagulation; Endoscopic photocoagulation
Ectatic disorders/ectasia. *See also specific type*
corneal, 4.95*f*, 4.95–96, 8.161–171. *See also* Keratoconus; Pellucid marginal degeneration
corneal crosslinking for, 13.124, 13.130–131, 13.176, 13.206
intrastromal corneal ring segments for, 13.63
after LASIK, 8.166, 13.124–125
corneal crosslinking for, 13.124, 13.130, 13.131
intrastromal corneal ring segments for, 13.70
opacities in, 8.16*f*
refractive lens exchange and, 13.149
refractive surgery contraindicated in, 13.23, 13.24–25, 13.25*f*, 13.78
corneal topography and, 13.23, 13.24, 13.25*f*, 13.78
topography in evaluation of, 8.31, 8.32*t*, 8.33*f*
retinal. *See* Coats disease
Ectoderm
derivatives of, 2.149*t*
description of, 2.143–144, 2.145*f*
in embryologic development, 2.150*f*
in lens development, 11.25, 11.26*f*
ocular structures derived from, lens, 11.25, 11.26*f*
Ectodermal dysplasia, 6.194, 8.202
Ectomesenchymal cells, 2.161
Ectomesenchyme, 2.149
Ectopia lentis, 10.129–130, 10.130*f*, 10.130*t*, 10.131*f*, 11.39–41, 11.40*f*
angle-closure glaucoma and, 10.129–130, 10.130*f*, 10.130*t*, 10.131*f*
cataract surgery in patient with, 11.181–183, 11.182*f*, 11.183*f*
in Ehlers-Danlos syndrome, 1.141
et pupillae, 6.267–268, 6.307, 6.307*f*, 11.42
Axenfeld-Rieger syndrome differentiated from, 10.154*t*
in homocystinuria, 11.41
in hyperlysinemia, 11.41
isolated/simple, 6.307, 11.40
in Marfan syndrome, 1.141, 8.193, 8.193*f*, 8.194, 11.40*f*, 11.40–41
traumatic, 11.40
Ectopic lacrimal gland, 6.226
Ectopic tissue masses, 6.223–225*f*, 226
Ectropion, 2.72
anophthalmic, 7.144, 7.144*f*
cicatricial
clinical features of, 7.230*f*
surgical repair of, 7.233*f*, 7.233–234
classification of, 7.229, 7.231
congenital, 7.174, 7.176*f*
of eyelid, 6.194
of iris, 6.267
definition of, 7.229
involutional
clinical features of, 7.230*f*
horizontal eyelid laxity as cause of, 7.231
lateral tarsal strip procedure for, 7.231, 7.232*f*
lower eyelid tightening surgery for, 7.231, 7.232*f*
medial spindle procedure for, 7.231, 7.232*f*
mechanical, 7.230*f*, 7.234
paralytic, 7.230*f*, 7.254–255
tarsal, 7.232
types of, 7.229–231, 7.230*f*
uveae, 2.72, 4.188, 4.189*f*, 4.255, 4.256*f*, 4.259, 4.259*f*, 6.267, 10.137*f*
Eczema, of eyelid, 8.45*t*
ED (epithelial debridement). *See* Debridement
Edema
corneal. *See* Cornea, edema of
epithelial, 8.42, 8.46*t*
cataract surgery and, 11.128*t*, 11.128–130
intraocular surgery and, 8.42
macular. *See* Macular edema
optic disc, in bartonellosis, 9.241
optic nerve/nerve head/disc. *See* Optic nerve head (ONH/optic disc), edema of
retinal, 4.152–153, 4.153*f*, 4.154*f*
stromal, 8.42
cataract surgery and, 11.128*t*, 11.128–130
Edetate disodium, 2.371*t*
for band keratopathy, 8.119
EDI-OCT. *See* Enhanced depth imaging optical coherence tomography
Edinger-Westphal (EW) nucleus, 2.15, 2.71, 2.124, 2.126, 2.127*f*, 5.44*f*, 5.54, 5.55*f*
EDOF. *See* Extended-depth-of-focus
Edrophonium, 2.381
description of, 1.305
in myasthenia gravis diagnosis, 5.324–325
toxic reaction to/side effects of, 5.324–325
EDS. *See* Ehlers-Danlos syndrome
EDTA (ethylenediaminetetraacetic acid), 9.313
for band keratopathy, 8.119
Edwards syndrome, 6.386*t*
EEG. *See* Electroencephalography

EF. *See* Ejection fraction
Efalizumab, 2.406*t*
EFEMP1 gene, 2.333*t*, 12.275
Effectivity of lenses, 3.40, 3.60
Effector blockade, 9.57
Effector lymphocytes, 9.36
Effector T (Teff) cells, in external eye defense, 8.12–13*f*
Efference copy information, 5.40
Efferent visual pathways/efferent visual system, 5.31–46, 5.211. *See also* Ocular motility, control of; Ocular motor pathways
Effusion
  suprachoroidal
    angle-closure glaucoma and, 10.141, 10.142*f*, 10.144, 10.145, 10.145*f*
    cataract surgery and, 11.159
      flat or shallow anterior chamber and, 11.134
    after filtering surgery, 10.210–211
  uveal, angle-closure glaucoma and, 10.138–139
Eflone. *See* Fluorometholone
EGF. *See* Epidermal growth factor
"Egg yolk" stage, of Best disease, 6.341, 6.342*f*
EGPA. *See* Eosinophilic granulomatosis with polyangiitis
Ehlers-Danlos syndrome (EDS), 1.140–141, 2.204*t*, 8.190–193, 8.191*t*
  blue sclera in, 8.191*t*, 8.193
  corneal changes in, 8.191*t*, 8.193
  keratoglobus in, 8.171, 8.191*t*, 8.193
Eicosanoids
  in inflammation, 9.19–20, 9.20*f*
  posterior diffusion of, 9.19–20
  schematic diagram of, 9.20*f*
Eicosapentaenoic acid (EPA), 12.70
EIF1AX gene, in choroidal/ciliary body melanoma, 4.197, 4.278
Eight-and-a-half syndrome, 5.191
Eight-ball (total) hyphema, 8.393, 8.393*f*
Eighth cranial nerve. *See* Cranial nerve VIII
Eighth nerve tumors, in neurofibromatosis, 10.156. *See also* Acoustic neuromas/neurofibromas
Einstein, Albert, 3.95
Ejection fraction (EF)
  in congestive heart failure, 1.95, 1.96*f*
  echocardiography of, 1.97
EK (endothelial keratoplasty). *See* Keratoplasty, endothelial
EKC. *See* Epidemic keratoconjunctivitis
Elastases, in ocular infections, 8.207
Elastin, in pseudoexfoliation/exfoliation syndrome, 10.91, 10.93
Elastotic degeneration/elastosis
  in pinguecula/pterygium, 4.56, 4.56*f*
  solar, of eyelid, 4.211–212, 4.212*f*
Elderly patients. *See* Age/aging; Older adults
Electrical injuries
  corneal injury caused by, 8.385
  description of, 12.357
  lens damage/cataracts caused by, 11.59, 11.59*f*
Electro-oculography/electro-oculogram (EOG), 2.330. *See also specific disorder*
  acute zonal occult outer retinopathy evaluations, 12.51
  autosomal recessive bestrophinopathy evaluations, 12.51
  Best disease evaluations, 6.342, 12.51, 12.271
  bestrophin mutation evaluations, 12.51
  hereditary retinal disease evaluations using, 6.335
  illustration of, 12.52*f*
  purpose of, 12.50
  technique of, 12.50
  vitelliform macular dystrophy evaluations, 12.51
Electroablation, 10.213
Electrocardiography/electrocardiogram (ECG)
  atrial fibrillation findings, 1.103*f*
  congestive heart failure evaluations, 1.97
  myocardial infarction findings, 1.83–84, 1.86
  nomenclature of, 1.84–85*f*
  non–ST-segment elevation myocardial infarction findings, 1.83–84
  ST-segment elevation myocardial infarction findings, 1.84
  unstable angina findings, 1.83
Electroencephalography (EEG), epilepsy diagnosis using, 1.207
Electrolysis
  for trichiasis, 7.240
  for trichiasis/distichiasis, 8.88
Electrolytes
  in lens, maintenance of balance of, 11.21, 11.22*f*
  in tear film, 2.251
Electromagnetic spectrum, 3.93, 3.93*f*
Electromagnetism theory, 3.94
Electromyography/electromyogram (EMG)
  definition of, 6.32
  motor units on, 6.32
  in myasthenia gravis, 5.326
  in myotonic dystrophy, 5.330
Electron beam computed tomography, in coronary heart disease diagnosis, 1.88
Electron microscopy, diagnostic, 4.34*t*, 4.42
Electron transport chain, 2.336
Electrons, quantum theory of, 3.110
Electrophysiologic testing
  International Society for Clinical Electrophysiology of Vision standards for, 12.41
  purpose of, 12.41
  of retina, 12.41–42. *See also specific test*
    in low vision evaluation, 5.95–97, 5.96*f*
    in nonorganic disorder evaluation, 5.302
  in ventricular arrhythmias, 1.104
Electroretinography/electroretinogram (ERG), 2.318, 2.318*f*, 5.96*f*, 5.96–97. *See also specific type*
  a-waves, 12.46, 12.251, 12.261
  ABCA4 retinopathy findings, 12.48*f*
  achromatopsia, 6.337, 12.250
  acute zonal occult outer retinopathy findings, 12.227
  b-waves, 12.5, 12.42–44, 12.43*f*, 12.47*f*, 12.50, 12.261
  Best disease findings, 12.271
  birdshot chorioretinopathy findings, 9.168, 12.49
  bradyopsia findings, 12.49
  c-waves, 5.96
  central retinal artery occlusion findings, 12.50
  central retinal vein occlusion findings, 12.50
  in children, 12.50
  choroideremia findings, 12.50
  clinical considerations for, 12.46, 12.49–50

in cone dystrophies, 5.102
findings associated with, 12.46, 12.47*f*, 12.265
with supernormal rod ERG findings, 12.49
cone–rod dystrophy phenotype in, 12.44
congenital stationary night blindness findings, 6.338, 12.46, 12.47*f*, 12.251, 12.252*f*
dark adaptometry and, 12.58
drugs that cause abnormalities in, 12.304–305
electrodes used in, 12.42
enhanced S-cone disease/syndrome findings, 12.49, 12.266, 12.267*f*
full-field (Ganzfeld), 5.96
in cone dystrophies, 5.102
in melanoma-associated retinopathy, 5.102–103
in multiple evanescent white dot syndrome, 5.101
functions of, 12.42
fundus albipunctatus findings, 12.252
hereditary retinal disease evaluations, 6.335
hydrochloroquine toxicity findings, 12.45, 12.49*f*
inherent noise in, 12.44
Knobloch syndrome findings, 6.347
Leber congenital amaurosis findings, 6.336, 12.266
in low vision evaluation, 5.96*f*, 5.96–97
macular dystrophy findings, 12.44, 12.46, 12.47*f*
melanoma-associated retinopathy findings, 12.286
multifocal (mfERG), 5.96*f*, 5.96–97, 12.45, 12.48–12.49*f*
in melanoma-associated retinopathy, 5.102–103
in multiple evanescent white dot syndrome, 5.101
multiple evanescent white dot syndrome on, 5.101, 12.224
in newborn, 12.44
night blindness findings, 12.46
in nonparaneoplastic autoimmune retinopathy, 5.103
ocular ischemic syndrome findings, 12.138, 12.139*f*
pattern, 12.45–46, 12.46–12.49*f*
peak-time shift in, 12.44
photophobia findings, 12.46
retinitis pigmentosa evaluations, 9.310
rod monochromatism findings, 12.250
S-cone monochromatism findings, 12.250
siderosis bulbi findings, 12.362
uveitis evaluations, 9.90
vigabatrin-related abnormalities of, 12.305
X-linked retinitis pigmentosa findings, 12.50
Elementary body (EB), 8.248–249
Elestat. *See* Epinastine
Elevated episcleral venous pressure, 10.102*t*, 10.102–103, 10.103*f*
adnexal signs of, 10.31
in children and adolescents, 10.150*t*
intraocular pressure and, 10.20, 10.102
open-angle glaucoma caused by, 10.102*t*, 10.102–103, 10.103*f*
Sturge-Weber syndrome and, 10.30, 10.155
Elevated intraocular pressure, 10.3, 10.89–90. *See also* Intraocular pressure
in angle closure/angle-closure glaucoma, 10.117–118
acute, 10.123–125
management of, 10.184
chronic, 10.126
subacute/intermittent, 10.125
in angle-recession glaucoma, 10.106–108
aqueous humor dynamics and, 10.5, 10.5*f*, 10.13–19, 10.14*f*
cataract surgery and, 10.211, 10.213, 11.75, 11.128*t*, 11.129, 11.136
corneal edema and, 11.129
ECCE, 11.198
epithelial ingrowth and, 11.133
expulsive suprachoroidal hemorrhage and, 11.159, 11.160
flat or shallow anterior chamber and, 11.134, 11.135–136
in glaucoma, 11.67, 11.75, 11.187
postoperative hyphema and, 11.159
retained lens material and, 11.141
retrobulbar hemorrhage and, 11.158
stromal/epithelial corneal edema and, 11.129
in central retinal artery occlusion, 12.146
in central retinal vein occlusion, 10.84, 12.133
in chemical injury, management and, 8.383
in children, 10.158–159
circadian/diurnal variation and, 10.3, 10.8, 10.22, 10.80–81, 10.81*t*, 10.86, 10.87
in combined-mechanism glaucoma, 10.7
conjunctiva affected by, 10.31
corneal blood staining and, 4.86
corticosteroids causing, 10.100, 10.108, 10.109–110
optic nerve damage and, 10.110
refractive surgery and, 13.41, 13.92, 13.104–105, 13.182, 13.201
uveitis and, 10.110
drugs for. *See* Antiglaucoma agents; Glaucoma, management of; *specific agent*
episcleral venous pressure and, 10.20, 10.102
factors causing, 10.21*t*, 10.21–22
frequency of, 10.20*f*, 10.20–21
in glaucoma, 10.3, 10.79–81, 10.81*t*
angle closure/angle-closure glaucoma, 10.117, 10.118
acute, 10.123–124
management of, 10.184
chronic, 10.126
subacute/intermittent, 10.125
angle-recession glaucoma, 10.106–108
cataract surgery and, 11.75
combined-mechanism glaucoma, 10.7
corticosteroids after refractive surgery and, 13.41, 13.182, 13.201
ghost cell glaucoma, 10.106
glaucoma risk and, 10.3, 10.8, 10.79–81, 10.81*t*
glaucomatocyclitic crisis (Posner-Schlossman syndrome) and, 10.101
hemolytic glaucoma, 10.106
indications for surgery and, 10.197
open-angle glaucoma, 10.79–81, 10.81*t*
optic neuropathy and, 10.46–47
pediatric glaucoma, 10.147, 10.166
phacolytic glaucoma/uveitis, 11.67
pigmentary glaucoma, 10.95
postoperative, 10.108
refractive surgery and, 13.41, 13.180–183, 13.182*f*, 13.200–201
uveitis and, 10.100
glaucoma risk and, 10.3, 10.8, 10.79–81, 10.81*t*

glaucoma without, 10.3, 10.4*t*, 10.85*f*, 10.85–88, 10.86*t*. *See also* Glaucoma, normal-tension
in glaucomatocyclitic crisis (Posner-Schlossman syndrome), 10.101
in hyphema, 8.394, 8.395, 10.104–105
sickle cell disease and, 8.395, 8.395*t*, 8.396
surgery and, 8.395, 8.395*t*, 8.396
indications for surgery and, 10.197
after intravitreal injection of anti-VEGF drugs, 12.404
after LASIK, 13.181, 13.182, 13.200–201
pressure-induced stromal keratopathy and, 13.119, 13.120*f*
LASIK flap creation and, 13.181, 13.201
lens epithelium affected by, 4.120
Nd:YAG laser capsulotomy and, 11.156
optic neuropathy and, 10.46–47
after penetrating keratoplasty, 8.424–426
phacoemulsification lowering, 11.186
after photoablation, 13.104–105, 13.200–201
postoperative, 10.108–109
after combined cataract surgery and trabeculectomy, 10.212
after laser trabeculoplasty, 10.108, 10.190, 10.191
after trabeculectomy, 10.208–209
after tube shunt implantation, 10.217
in pseudoexfoliation/exfoliation syndrome, 10.93
refractive surgery and, 13.41, 13.181, 13.200–201
retinal detachment and, 10.109, 10.141
sickle cell hemoglobinopathies/retinopathy and, 10.104, 10.105
after surface ablation, 13.104–105, 13.181, 13.200–201
trauma and, 10.103–108
in uveitis
corticosteroid-induced, 10.110
glaucoma and, 10.100–102, 10.102*f*
Elevation-based tomography, 13.22, 13.22*f*
Elevation of eye (upgaze), 6.33, 6.37–38
disorders/limitation of, 5.228–229
in Brown syndrome, 5.208
in dorsal midbrain (Parinaud) syndrome, 5.229, 5.230*f*
in newborns, 5.230
saccadic dysfunction and, 5.222
extraocular muscles controlling, 5.36*f*, 5.46*f*
inferior oblique muscle, 5.36*f*, 5.46*f*
superior rectus muscle, 5.36*f*, 5.46*f*
11p13 syndrome (short arm 11 deletion syndrome/*PAX6* gene mutation), in aniridia, 4.184, 10.150, 11.33
ELISA. *See* Enzyme-linked immunosorbent assay
Ellipsoid, 12.12
Ellipsoid zone, 4.141*f*
Ellipsoidal mirror, scanning laser ophthalmoscopy use of, 12.24
Elliptical phacoemulsification, 11.101
Elliptically polarized light, 3.98
ELM. *See* External limiting membrane
ELOVL4 gene, in Stargardt disease, 4.168
ELP. *See* Estimated lens position
Elschnig pearls, 4.121, 4.121*f*, 11.152
Elschnig ring, 10.43
Elschnig spots, 9.157, 12.123, 12.123*f*, 12.196
Emadine. *See* Emedastine; Epinastine hydrochloride
Emanation theory of vision, 11.3
Emboli
cholesterol (Hollenhorst plaques), 12.141, 12.142*f*, 12.144
in branch retinal artery occlusion, 4.156
transient visual loss and, 5.165, 5.165*f*, 5.166*t*
retinal vasculitis *versus*, 12.156
transient visual loss caused by, 5.161, 5.162, 5.163*t*, 5.165, 5.165*f*, 5.165–169, 5.166*t*
clinical/laboratory evaluation in, 5.166–168
prognosis/treatment and, 5.168–169
Embryogenesis. *See also* Eye, development of
early stages of, 2.143, 2.144*f*
steps involved in, 2.143
Embryology. *See* Congenital anomalies; Eye, development of
Embryonal rhabdomyosarcoma, 4.236, 7.88
Embryonic lens nucleus, 4.117, 11.13, 11.27*f*
opacification of (congenital nuclear cataract), 11.38, 11.39*f*
Embryotoxon, posterior, 4.99, 4.99*f*, 4.100*f*, 8.97*t*, 8.101–102, 8.102*f*. *See also* Anterior segment, dysgenesis of
in Axenfeld-Rieger syndrome, 4.99, 4.99*f*, 4.100*f*, 8.97*t*, 8.102, 10.31, 10.153
isolated, Axenfeld-Rieger syndrome differentiated from, 10.154*t*
Emedastine difumarate, 2.411, 2.412*t*
Emergencies. *See* Medical emergencies
Emergency Medical Services (EMS), 1.296
EMG. *See* Electromyography/electromyogram
EMGT (Early Manifest Glaucoma Trial), 10.88, 10.113
Emicipizumab, 1.144
Emissaria, 2.58
Emissary channels, scleral, 4.107*f*, 4.108, 4.108*f*
melanoma spread via, 4.194, 4.195*f*
Emmetropia
accommodative demand, 3.208
in children, 3.141
definition of, 3.124, 3.136, 3.137*f*
model of, 3.12, 3.13*f*
pictorial representation of, 3.140*f*
retinal reflex in, 3.152
Emmetropization, 3.141, 6.180
Emotional lacrimation, 2.135
Emphysema, 1.124
orbital, 7.115
Empirical horopter, 6.41, 6.42*f*
EMS. *See* Emergency Medical Services
Emtansine, 1.242
Emulsification. *See also* Phacoemulsification
locations of, 11.111–112
Emulsion, 2.349, 2.356
EMZL. *See* Extranodal marginal zone B-cell lymphoma
En face scan
definition of, 12.26
retinal disease evaluations, 12.26, 12.29
Enalapril, 1.64, 1.309*t*
Encapsulated cell technology, for drug delivery, 2.366
Encephalitis
brainstem, CMV infection causing, 5.349
herpes, 5.350, 5.350*f*
Encephalitozoon, 8.252
keratoconjunctivitis caused by, 8.280

Encephalocele, 6.225, 7.39
Encephalofacial angiomatosis/encephalofacial cavernous hemangiomatosis. *See* Encephalotrigeminal/encephalofacial angiomatosis/hemangiomatosis (Sturge-Weber syndrome/SWS)
Encephalomyelitis, acute disseminated, optic nerve involvement and, 4.244, 4.244*f*
Encephalopathy
  HIV (AIDS dementia complex/HIV-associated neurocognitive disorder), 5.348
  inherited, migrainelike headache and, 5.294–295
  posterior reversible (PRES) syndrome, 5.333–335, 5.335*f*
  transmissible spongiform, 5.357
Encephalotrigeminal/encephalofacial angiomatosis/hemangiomatosis (Sturge-Weber syndrome/SWS), 5.331, 5.332*f*, 5.334*t*, 10.30, 10.155
  choroidal hemangioma in, 4.197, 4.281, 5.332*f*, 5.334*t*
  description of, 5.331, 5.332*f*, 5.334*t*, 6.199, 6.251, 6.285, 6.349, 6.394*t*, 6.401*t*, 6.401–403, 6.402*f*, 10.30, 10.155, 12.202
    port-wine stain (nevus flammeus) in, 8.346
  glaucoma associated with, 5.332*f*, 5.334*t*, 10.30, 10.155
    in children, 5.332*f*, 10.155
  port-wine stain (port-wine nevus/nevus flammeus) in, 5.332*f*, 5.334*t*, 8.346, 10.30, 10.155
Enclavation, 13.141
End-stage renal disease
  diabetic nephropathy as cause of, 1.39
  hypertension as cause of, 1.214
Endocrine diseases and disorders. *See also specific type*
  corneal changes in, 8.199–201, 8.200*t*, 8.201*f*
  multiple endocrine neoplasia syndromes, 8.200
Endocrine signaling, of cytokines, 9.21
Endoderm, 2.143, 2.145*f*
Endogenous endophthalmitis. *See* Endophthalmitis, endogenous
Endogenous infection, uveal, 4.185
Endonasal dacryocystorhinostomy, 7.307, 7.309, 7.309*f*
Endoperoxides, 2.408
Endophthalmitis, 1.199, 7.138
  acute postoperative, 9.291–292
  Bacillus, 8.247, 8.403, 12.363
  bacterial, vitreous affected in, 4.127, 4.128*f*
  bacterial toxin induction in, 9.9
  bevacizumab and, 12.85
  bleb-associated, 10.163, 10.209, 10.209*t*, 10.210*f*, 12.390–391, 12.391*f*
  Candida, 9.295–299, 9.296*f*, 9.299*f*
  after cataract surgery, 6.305
  chronic postoperative
    bacterial causes of, 9.292
    clinical findings of, 9.292, 9.292*f*
    diagnosis of, 9.293
    fungal causes of, 9.292–293
    Nd:YAG laser capsulotomy triggering of, 9.292
    overview of, 9.291–292
    Propionibacterium acnes as cause of, 9.292, 9.292*f*
    treatment of, 9.293
  definition of, 9.291
  endogenous, 12.237–239, 12.238*f*
    bacterial, 9.294–295
    fungal, 9.295–302, 9.296*f*, 9.298*f*, 9.300*f*
  fungal, 12.239, 12.239*f*
    Aspergillus as cause of, 9.300–301
    Candida, 9.295–299, 9.296*f*, 9.299*f*
    coccidioidomycosis as cause of, 9.301–302
    cryptococcosis as cause of, 9.299–300
    endogenous, 9.295–302, 9.296*f*, 9.298*f*, 9.300*f*
    manifestations of, 9.295
    "string of pearls" in, 9.296*f*
  hypopyon of, 9.6
  infectious, 4.119, 4.119*f*, 4.127, 4.128*f*. *See also specific type and causative agent*
    acute anterior uveitis associated with, 9.137
    after cataract surgery, 11.127, 11.140, 11.160–163, 11.161*f*
  innate immune response in, 9.5
  after intravitreal injections, 12.404
  after penetrating and perforating ocular trauma, 8.247, 8.403
  phacoanaphylactic/lens-induced granulomatous (phacoantigenic/lens-associated uveitis), 4.118–119, 4.119*f*, 11.66
  postoperative, 2.428
    acute-onset, 11.162, 12.388–390, 12.390*f*
    bleb-associated, 10.163, 10.209, 10.209*t*, 10.210*f*, 12.390–391, 12.391*f*
    after cataract surgery, 4.119, 4.119*f*, 11.127, 11.140, 11.160–163, 11.161*f*
      prevention of, 11.93–95, 11.94*f*, 11.161–162
    chronic (delayed-onset), 11.162, 11.163, 12.390, 12.391*f*
    after penetrating keratoplasty, 8.424
    prophylaxis of, 11.93–95, 11.94*f*, 11.161–162
    Propionibacterium acnes causing, 4.119, 4.119*f*, 8.246, 11.140, 11.162
  posttraumatic, 12.362–363
  Propionibacterium acnes causing, 4.119, 4.119*f*, 8.246, 11.140, 11.162
  Streptococcus viridans as cause of, 12.404
  yeast, 12.239–240, 12.240*f*
Endophthalmitis Study Group of the European Society of Cataract and Refractive Surgeons (ESCRS), on postoperative endophthalmitis, 11.94, 11.162
Endophthalmitis Vitrectomy Study (EVS), 11.161, 11.162, 12.389–390
Endophytic retinoblastoma, 6.352, 6.352*f*
Endoplasmic reticulum aminopeptidase (ERAP), 9.65
Endoscopic brow- and forehead-lift, 7.264*f*, 7.265
Endoscopic cyclophotocoagulation (ECP)/endoscopic laser delivery, 10.194, 10.195, 10.196. *See also* Cyclophotocoagulation/cycloablation
  cataract surgery and, 11.186
  for pediatric glaucoma, 10.163–164
Endoscopic dacryocystorhinostomy, 7.309
Endoscopic photocoagulation (ECP), for childhood glaucomas, 6.287–288, 6.288*f*
Endoscopic transnasal surgery, 7.132
Endothelial cell density, 8.10
  age-related decrease in, 8.10, 8.23
  reduction of after endothelial keratoplasty (DMEK/DSEK), 8.448–449
  specular microscopy in evaluation of, 8.23
Endothelial cell migration, DMEK and, 8.449

Endothelial cells
activation of, 9.10, 9.12
in angiogenesis, 12.79
of cornea, 2.54, 2.266–267, 2.267*f*, 2.267*t*
Endothelial degenerations, 8.126–128
age-related, 8.115
Endothelial dystrophies, 4.92–94, 4.93*f*, 4.94*f*, 8.135*t*
cataract surgery in patient with, 11.84, 11.175
congenital hereditary (CHED/CHED2), 4.92–93, 4.94*f*, 8.135*t*, 8.136*t*, 8.160, 8.161*f*
Fuchs (FECD), 4.92, 4.93*f*, 8.23*f*, 8.135*t*, 8.136*t*, 8.156–158, 8.157*f*
descemetorrhexis/DMET for, 8.157–158, 8.449
IOL implantation and, 11.149, 13.155
refractive surgery and, 13.43, 13.178
multifocal IOL implantation, 13.155
posterior polymorphous (PPCD/PPMD), 4.93–94, 4.94*f*
glaucoma and, 8.159, 10.31
posterior polymorphous (PPCD/PPMD/CHED1), 8.135*t*, 8.136*t*, 8.158–160, 8.159*f*, 8.160*f*
Endothelial failure. *See also* Endothelial graft rejection
after endothelial keratoplasty (DMEK/DSEK), 8.447
after penetrating keratoplasty, 4.84, 4.85*f*
late non-immune-mediated, 8.427–428
primary, 8.423, 8.423*f*
Endothelial graft rejection. *See also* Endothelial failure; Rejection
after endothelial keratoplasty (DMEK/DSEK), 8.437*t*, 8.447*f*, 8.447–448
epithelial edema with, 9.54*f*
Khodadoust line, 9.54, 9.54*f*
after penetrating keratoplasty, 8.429, 8.430*f*
stromal edema with, 9.54*f*
Endothelial keratoplasty (EK). *See* Keratoplasty, endothelial
Endothelial meshwork, 2.64, 2.65*f*
Endothelial nitric oxide synthase (eNOS), 2.394–395
Endothelial pump, corneal hydration and, 8.9
pachymetry in evaluation of, 8.41–42
Endothelial rings, corneal, traumatic, 8.388
Endotheliitis (disciform keratitis), 8.51*f*
CMV causing, 8.232, 8.232*f*
herpes simplex virus causing, 4.77*f*, 4.78, 8.220, 8.221*f*, 8.222
persistent bullous keratopathy and, 8.225
Endothelium, corneal, 4.73, 4.74*f*, 8.7*f*, 8.10. *See also under Endothelial*
anatomy of, 8.7*f*, 8.10
deposits in, 8.118*t*, 8.132
dysfunction of, 8.52
keratoplasty for, 8.411, 8.436–450. *See also* Keratoplasty, endothelial
novel methods for treatment of, 8.449–450
healing/repair of, 4.16
keratorefractive surgery and, 13.32–33
multifocal IOL implantation and, 13.155
phakic IOL implantation and, 13.141
angle-supported lenses, 13.146
iris-fixated lenses, 13.145
posterior chamber lenses, 13.146
pigmentation of/deposits in, 8.118*t*
drug-induced, 8.132
Endotoxin. *See also* Lipopolysaccharide
in innate immune response activation, 9.7
microbial, 8.244
uveitis induced by, 9.8, 9.62
Endovascular coiling, for carotid-cavernous fistula, 7.79*f*
Energy
definition of, 3.106
kinetic, 3.106
phaco, 11.99. *See also* Power
potential, 3.106
transfer of, 3.106
Enhanced depth imaging optical coherence tomography (EDI/EDI-OCT)
autofluorescence imaging and, 12.39
central serous chorioretinopathy findings, 12.67, 12.191, 12.193*f*
in choroidal/ciliary body melanoma, 4.265, 4.268
choroidal layer on, 12.79, 12.193*f*
choroidal-scleral interface on, 12.66
description of, 12.25
in metastatic eye disease, 4.307
in optic nerve/nerve head/disc drusen, 5.142
pachychoroid on, 12.76
in posterior scleritis, 9.124
in uveitis, 9.85, 9.88*f*
Enhanced S-cone disease (ESCD), 12.266, 12.267*f*
Enhanced S-cone syndrome, 12.49
Enophthalmos, 5.271, 7.24
cataract surgery in patient with, 11.77
definition of, 7.23
in metastatic breast carcinoma, 7.106*f*
in orbital blowout/floor fractures, 7.114–115, 7.116
eNOS. *See* Endothelial nitric oxide synthase
Entacapone, for Parkinson disease, 1.205
Enterobacter/Enterobacteriaceae, 8.244*t*, 8.247
aerogenes, 2.419
conjunctivitis caused by, 8.257*t*
Enterococcus, 8.244*t*, 8.245
faecalis, 8.245
postoperative endophthalmitis caused by, 11.161
vancomycin-resistant, 8.245
Enterocytozoon, 8.252
Enteropancreatic tumors, 1.50
Enteropathic arthritis, 1.156, 6.315*t*, 9.125*t*
Enteroviruses, 8.240*t*
acute hemorrhagic conjunctivitis caused by, 8.240, 8.240*t*
Enthesitis, 1.154
Enthesitis-related arthritis (ERA), 1.154, 6.315*t*, 9.142
Entrance pupil, 3.124, 3.130–131
Entropion
acute spastic, 7.237
cicatricial, 7.237–238*f*, 239
congenital, 6.194, 7.179, 7.179*f*
involutional
causes of, 7.234
clinical features of, 7.235*f*
retractor disinsertion as cause of, 7.234–235
surgical repair of, 7.236, 7.236*f*
temporizing measures for, 7.235*f*, 7.235–236
transconjunctival approach to, 7.236, 7.236*f*
lower eyelid, 7.234
marginal, 7.238
spastic, 7.235*f*, 7.237
upper eyelid, 7.234

Enucleation
in children, 7.137
complications of, 7.138–139
conjunctival cyst after, 7.141*f*
definition of, 7.135
description of, 7.36
indications for, 7.136
for medulloepithelioma, 4.296
for melanoma, 4.196, 4.274–275
for penetrating and perforating ocular trauma, 8.404, 12.233
prostheses after, 7.140–141, 7.147*f*
removal of wrong eye, 7.138
for retinoblastoma, 4.299
rubeosis iridis and, 4.188, 4.189*f*
for sympathetic ophthalmia prevention, 8.404
for uveal lymphoid proliferation/infiltration, 4.314
Envelope (virus)/enveloped viruses, 8.212
Environment/environmental factors
in dry eye, 8.54*f*, 8.55, 8.55*f*, 8.61
in glaucoma, 10.10
Enzymatic cleaners, for contact lens, 3.229, 3.229*t*
Enzyme(s)
in aqueous humor, 2.276
posterior vitreous detachment induced by, 2.304
vitreolysis using, 2.304
Enzyme-linked immunosorbent assay (ELISA)
for *Borrelia burgdorferi,* 1.254
for HIV, 1.267
for leptospirosis, 9.232
in Lyme disease, 5.353, 12.246
for syphilis, 9.225
in toxocariasis, 12.245
Enzyme replacement therapy, for genetic diseases, 2.235
EOG. *See* Electro-oculography/electro-oculogram
EOMs. *See* Extraocular muscles
Eosinophilic airway inflammation, 1.124
Eosinophilic granuloma, 6.219, 6.219*f*
Eosinophilic granulomatosis with polyangiitis (EGPA), 1.172
Eosinophils, 4.7, 4.8*f*
characteristics of, 9.2
granule products of, 9.2
EPA. *See* Eicosapentaenoic acid
EPHA2 gene, in age-related cataracts, 11.41–42
Ephelis, 4.219, 7.197. *See also* Freckle
Epi-LASIK. *See* Epipolis laser in situ keratomileusis
"Epi-off" ("epithelium-off") corneal crosslinking, 13.130, 13.132, 13.133*t*. *See also* Corneal (collagen) crosslinking
"Epi-on" ("epithelium-on") corneal crosslinking, 13.133*f*. *See also* Transepithelial corneal crosslinking
Epiblepharon, 6.194, 6.195*f*, 7.176*f*, 7.178–179
Epibulbar (limbal) dermoids
description of, 4.6, 4.47, 4.49*f*, 6.210, 6.256, 6.256*f*, 6.257*t*
Goldenhar syndrome and, 8.195, 8.195*f*
Epicanthus, 6.196, 6.196*f*, 7.176–177, 177*f*
Epicanthus inversus, 6.196, 7.177
Epicanthus palpebralis, 6.196, 6.196*f*, 7.177
Epicanthus supraciliaris, 6.196, 7.177
Epicanthus tarsalis, 6.196, 6.196*f*, 7.177–178*f*
Epicapsular star, 11.31, 11.32*f*
Epidemic keratoconjunctivitis (EKC), 6.213, 6.242, 8.233, 8.234*f*, 8.234–236, 8.235*f*
Epidermal/epidermoid cysts
of eyelid, 4.208, 4.208*f*
inclusion, 7.189, 7.189*f*
of orbit, 4.223–224
Epidermal growth factor (EGF), 2.449
in tear film, 8.6*f*
Epidermal necrolysis, toxic (Stevens-Johnson syndrome and Stevens-Johnson syndrome/toxic epidermal necrolysis overlap/SJS-TEN), 8.285, 8.295–298, 8.296*f*, 8.297*f*
Epidermis, eyelid, 4.201, 4.201*f*, 8.3–4
neoplasms of, 4.209*f*, 4.209–213, 4.210*f*, 4.210*t*, 4.211*f*, 4.212*f*, 4.213*f*, 4.214*f*. *See also* Eyelid(s), tumors of
premalignant (actinic keratosis), 4.210–212, 4.211*f*, 4.212*f*
Epidermoid/epidermal cysts, 6.223, 7.40
of eyelid, 4.208, 4.208*f*
inclusion, 7.189, 7.189*f*
of orbit, 4.223–224
Epifrin. *See* Epinephrine
Epigastric thrusts, 1.299
Epigenetics, 2.173, 2.179
Epikeratoplasty (epikeratophakia), 13.8*t*, 13.27, 13.59, 13.62
Epilation, for trichiasis/distichiasis, 8.88
Epilepsy. *See also* Seizures
characteristics of, 1.206
diagnosis of, 1.207
etiology of, 1.206–207
hallucinations and, 5.177
seizures associated with, 1.206–209
surgery for, 1.208
transient visual loss and, 5.161, 5.162, 5.172
treatment of, 1.207–209
Epimerase deficiency, galactosemia/cataract formation and, 11.61
Epimyoepithelial islands, 7.101
Epinastine hydrochloride, 2.412*t*
Epinephrine
acute allergic reaction treated with, 1.302–303
acute asthma attacks treated with, 1.128
adrenochrome deposition caused by, 8.118*t*, 8.131
description of, 2.385
dipivalyl. *See* Dipivefrin
for glaucoma, 10.177
intracameral administration of, 2.360*t*
for intraoperative floppy iris syndrome, 11.138
L-, 2.388
local anesthesia uses of, 1.305
Epipapillary vessels, 10.45
Epiphora, 7.292, 7.296, 7.301, 7.301*f*, 8.46*t*. *See also* Tearing/epiphora
in primary congenital glaucoma, 10.151, 10.152, 10.152*t*, 10.158
differential diagnosis and, 10.151, 10.152*t*
Epiphycan *(EPYC)* gene, in posterior amorphous corneal dystrophy, 8.136*t*
Epipolis laser in situ keratomileusis (epi-LASIK), 13.8*t*, 13.73. *See also* Surface ablation

corneal preparation for, 13.83, 13.83*f*, 13.84
epithelial debridement, 13.83, 13.83*f*
epithelial preservation, 13.84
glaucoma/ocular hypertension and, 13.181, 13.182
immediate postablation measures for, 13.92–93
outcomes of, 13.84
Epiretinal membranes (ERMs), 9.323
asymptomatic, 12.336
causes of, 12.332
contracture of, 12.335
definition of, 12.332
fluorescein angiography findings, 12.335
in idiopathic macular holes, 4.132
incidence of, 12.333
optical coherence tomography of, 12.335, 12.383*f*
prevalence of, 12.333
"pseudohole" appearance with, 12.334
retinal distortion caused by, 6.145
scanning laser ophthalmoscopy of, 12.334*f*
secondary, 12.333
signs and symptoms of, 12.334–12.335*f*, 12.334–336
spectral-domain optical coherence tomography of, 12.335*f*
treatment of, 12.336, 12.382, 12.383*f*
vitrectomy for, 12.382, 12.383*f*
vitreomacular traction syndrome *versus*, 12.382–383
Episclera, 2.58, 4.107, 4.107*f*. *See also* Episcleritis
in glaucoma, 10.31, 10.102*t*, 10.102–103, 10.103*f*
healing/repair of, 4.16
immune-mediated disorders of, 8.318–326
melanosis of, 8.338*t*, 8.338–340, 8.339*f*, 8.339*t*
nodular fasciitis causing tumor of, 4.112
Episcleral arterial circle, 2.24*f*
Episcleral implants, radioactive, 1.238
Episcleral plexus, 5.21, 10.5*f*
Episcleral venous pressure (EVP), 10.19–20
elevated, 10.102*t*, 10.102–103, 10.103*f*
adnexal signs of, 10.31
in children and adolescents, 10.150*t*
intraocular pressure and, 10.20, 10.102
open-angle glaucoma caused by, 10.102*t*, 10.102–103, 10.103*f*
Sturge-Weber syndrome and, 10.30, 10.155
normal, 10.20, 10.102
Episcleral vessels, 2.57, 2.57*f*
Episcleritis, 4.109, 8.46*t*, 8.318*f*, 8.318–319
in herpes zoster, 8.227
immune-mediated, 8.318*f*, 8.318–319
nodular, 4.109, 8.318, 8.318*f*
nonsteroidal anti-inflammatory drugs for, 9.113
in reactive arthritis/Reiter syndrome, 8.305–306
in rosacea, 8.70, 8.70*f*
scleritis *versus*, 9.117
simple (diffuse injection), 4.109, 8.318
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296–297
Epithelial basement membrane dystrophy, 3.277, 3.278*f*
Epithelial cells. *See also* Epithelium
keratinization of (keratinized/degenerated)
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297
in superior limbic keratoconjunctivitis, 8.84
in vitamin A deficiency, 8.196
Epithelial cysts. *See also* Epithelial inclusion cysts
of cornea, drug-induced, 8.130
description of, 6.170–171
of orbit, 4.223–224
Epithelial debridement (ED). *See* Debridement
Epithelial defects
conjunctival, 8.46*t*
corneal/persistent corneal, 8.46*t*, 8.80–82, 8.81*t*, 8.82*f*
acid burns causing, 8.380, 8.380*f*
after cataract surgery, 11.132, 11.173
glaucoma medication toxicity and, 10.31
after LASIK, 13.93, 13.112
in diabetes mellitus, 13.190
management of, 8.368
after penetrating/deep anterior lamellar keratoplasty, 8.80, 8.424
after small-incision lenticule extraction, 13.205
after surface ablation, 13.107–108
topical anesthetic use/abuses and, 8.80–81, 8.81*t*, 8.89, 8.89*f*
in toxic keratoconjunctivitis, 8.80–81, 8.81*t*
Epithelial degenerations, 8.115–120, 8.116*f*, 8.117*f*, 8.118*t*, 8.119*f*
Epithelial downgrowth. *See* Epithelial ingrowth
Epithelial dystrophies
epithelial and subepithelial, 4.87, 4.87*f*, 8.135*t*, 8.135–141
basement membrane (EBMD/map-dot-fingerprint/Cogan microcystic/anterior basement membrane), 4.87, 4.87*f*, 8.135*t*, 8.135–138, 8.136*t*, 8.137*f*, 8.138*f*
cataract surgery in patient with, 11.174*f*, 11.174–175
recurrent corneal erosion and, 8.86, 8.87, 8.133, 8.138
reduced vision and, 5.99
refractive surgery and, 13.42, 13.42*f*, 13.76, 13.78, 13.178
multifocal IOLs, 13.155
gelatinous droplike (GDLD), 8.135*t*, 8.140–141, 8.141*f*
Lisch (LECD), 8.135*t*, 8.136*t*, 8.140, 8.140*f*
Meesmann/Stocker-Holt variant, 8.135*t*, 8.136*t*, 8.139, 8.139*f*
mucinous (SMCD), 8.135*t*
recurrent erosion (EREDs), 8.86, 8.87, 8.133, 8.135*t*
epithelial-stromal *TGFBI*, 4.88*f*, 4.88–91, 4.89*f*, 4.90*f*, 4.91*t*, 4.91*f*, 8.133, 8.134, 8.135*t*, 8.136*t*, 8.142–149
granular, 8.135*t*
type 2 (GCD2/Avellino), 4.90, 4.91*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.148–149, 8.149*f*
amyloid deposits in, 8.148, 8.186*t*
refractive surgery and, 13.43
type 1 (GCD1/classic), 4.90, 4.90*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.147–148, 8.148*f*
lattice, 4.88–90, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.145–147, 8.146*f*, 8.147*f*
recurrence of after corneal transplantation, 8.425
Reis-Bücklers (RBCD/CDB1/atypical granular), 4.88, 4.88*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.142*f*, 8.142–143
Thiel-Behnke (TBCD/CDB2), 4.88, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.143–144, 8.144*f*

Epithelial edema, 8.42, 8.46*t*. *See also* Cornea, edema of
after cataract surgery, 11.128*t*, 11.128–130
Epithelial erosions, punctate (PEEs)
of conjunctiva, 8.46*t*
of cornea, 8.46*t*, 8.50, 8.50*f*, 8.50*t*
in exposure keratopathy, 8.80
in herpetic eye disease/neurotrophic keratopathy, 8.224
refractive surgery and, 13.42, 13.42*f*
vernal keratoconjunctivitis and, 8.290
Epithelial graft rejection, 8.428, 8.428*f*. *See also* Rejection
Epithelial hyperplasia, 7.187–189, 7.188*f*
Epithelial inclusion cysts, 6.250
conjunctival, 4.59, 4.59*f*, 7.141, 7.141*f*, 8.114, 8.114*f*
concretions and, 8.113–114
nevi and, 4.64, 8.340
Epithelial ingrowth (downgrowth)
angle-closure glaucoma and, 10.141–142, 10.142*f*, 10.143*f*
cataract surgery and, 11.128*t*, 11.132–133
corneal graft failure and, 4.84, 4.85*f*
after DSEK, 8.445, 8.445*f*
after LASIK, 13.120–122, 13.121*f*
in diabetes mellitus, 13.190
pannus and, 8.52, 8.52*f*
Epithelial keratitis/keratopathy
adenovirus causing, 8.234, 8.235, 8.235*f*
CMV causing, 8.232
dry eye and, 8.56
in epidemic keratoconjunctivitis, 8.235, 8.235*f*
herpes simplex virus causing, 8.213, 8.214*f*, 8.216*f*, 8.216–219, 8.217*f*, 8.218*f*, 8.223*t*, 8.226*t*
measles virus causing, 8.239
punctate (PEK), 8.46*t*, 8.50, 8.50*f*, 8.50*t*
adenoviruses causing, 8.234
blepharitis/blepharoconjunctivitis and, 8.72, 8.73*t*, 8.74
exposure causing, 8.80
herpes simplex virus causing, 8.216, 8.216*f*
in herpes zoster, 8.227, 8.228
microsporidial, 8.280, 8.280*f*
superficial Thygeson (SPK), 8.306–307, 8.307*f*
varicella-zoster virus causing, 8.226, 8.226*t*
Epithelial slough, LASIK and, 13.112
Epithelial-stromal *TGFBI* dystrophies, 4.88*f*, 4.88–91, 4.89*f*, 4.90*f*, 4.91*t*, 4.91*f*, 8.133, 8.134, 8.135*t*, 8.136*t*, 8.142–149
granular, 8.135*t*
type 2 (GCD2/Avellino), 4.90, 4.91*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.148–149, 8.149*f*
amyloid deposits in, 8.148, 8.186*t*
refractive surgery and, 13.43
type 1 (GCD1/classic), 4.90, 4.90*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.147–148, 8.148*f*
lattice, 4.88–90, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.145–147, 8.146*f*, 8.147*f*
recurrence of after corneal transplantation, 8.425
Reis-Bücklers (RBCD/CDB1/atypical granular), 4.88, 4.88*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.142*f*, 8.142–143
Thiel-Behnke (TBCD/CDB2), 4.88, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.143–144, 8.144*f*
Epithelial tumors, 4.10*t*, 4.11*f*
ocular surface, 8.332*t*, 8.332–337
benign, 8.322*t*, 8.322–324, 8.333*f*
malignant, 8.334–337, 8.335*f*, 8.336*f*
preinvasive, 8.332*t*. *See also* Conjunctival or corneal intraepithelial neoplasia
pigmented, of uvea and retina, 4.279–280, 4.280*f*
Epithelial ulcer, geographic, in herpes simplex keratitis, 8.217, 8.217*f*, 8.218*f*
Epithelioid cells, macrophage activation into, 9.4
Epithelioid histiocytes, 4.7, 4.8*f*
Epithelioid (Leber) cells. *See also* Macrophage(s)
in choroidal/ciliary body melanoma, 4.192, 4.193*f*, 4.194–195
Epithelioid melanoma, 4.192, 4.193*f*, 4.194–195
Epitheliopathy
in herpetic keratitis, 8.224
in microsporidiosis, 8.280, 8.280*f*
in toxic keratoconjunctivitis, 8.90
Epithelium. *See also under Epithelial*; Ocular surface
ciliary
nonpigmented, benign adenomas of, 4.279
pigmented
acquired hyperplasia of, 4.279, 4.280*f*
benign adenomas of, 4.279
conjunctival, 4.47, 4.48*f*, 8.7, 8.7*f*
corneal resurfacing by (conjunctivalization), 8.362
cysts of, 4.59, 4.59*f*, 8.114, 8.114*f*. *See also* Epithelial inclusion cysts
nevi and, 4.64
dysplasia of (conjunctival intraepithelial neoplasia/CIN), 4.61, 4.63*f*, 8.37, 8.38*f*, 8.332*t*, 8.334, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia; Ocular surface squamous neoplasia
melanocytic, 4.63*t*, 4.65, 4.66, 4.67*f*
in external eye defense, 8.13
tumors of, 8.332*t*, 8.332–337
cornea. *See* Cornea, epithelium of
debridement of
for epithelial defects
after LASIK, 13.112
after surface ablation, 13.108
for surface ablation, 13.82–84, 13.83*f*
in external eye defense, 8.12*f*, 8.13, 8.13*f*, 8.13–14, 8.207
healing of, keratorefractive surgery and, 13.32–33
delayed, 13.93–94, 13.108
iris pigment. *See* Iris pigment epithelium
lens, 4.116*f*, 4.117, 11.10*f*, 11.12*f*, 11.12–13
active transport and, 11.21
degenerations of, 4.120–121, 122*f*. *See also* Cataract
development of, 11.27, 11.27*f*
opacification of (capsular cataract), 11.38
topography of, 4.116*f*, 4.117
preparation of, for refractive surgery, 13.82–84, 13.83*f*
preservation techniques for
in epi-LASIK, 13.84
in LASEK, 13.84
retinal pigment. *See* Retinal pigment epithelium
tumors of. *See* Epithelial tumors

"Epithelium-off" ("epi-off") corneal crosslinking, 13.130, 13.132, 13.133*t*. *See also* Corneal (collagen) crosslinking
"Epithelium-on" ("epi-on") corneal crosslinking, 13.133*f*. *See also* Transepithelial corneal crosslinking
Epitope(s)
in adaptive immune response, 9.27, 9.30
antigenic, 9.27, 9.41
definition of, 9.27
idiotopes *versus*, 9.41
Epley procedure, for benign paroxysmal positional vertigo, 5.243
e-Aminocaproic acid, 2.446–447
Epstein-Barr virus (EBV), 1.237*t*, 1.262, 6.243, 7.313, 8.230, 9.257–258
dacryoadenitis caused by, 8.208*t*, 8.230–231
ocular infection caused by, 8.208*t*, 8.230–231, 8.231*f*
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH), 1.262
EPYC gene, in posterior amorphous corneal dystrophy, 8.136*t*
Equator (lens), 4.116*f*, 4.117, 11.9, 11.10*f*, 11.12*f*
Equatorial lens bow, 4.116*f*, 4.117
Equatorial retina, 12.9–10
Equine recurrent uveitis, 9.62
Equivalent optical system, 3.67–68, 3.68–3.69*f*
ERA. *See* Enthesitis-related arthritis
Erbium:yttrium-aluminum-garnet (Er:YAG) lasers, 7.268
Erdheim-Chester disease (ECD), 7.97, 7.98*f*
eyelid manifestations of, 4.207*t*
EREDs. *See* Recurrent erosion corneal dystrophies
ERG. *See* Electroretinography/electroretinogram
Ergot alkaloids, 12.300
ERMs. *See* Epiretinal membranes
Erosions
conjunctival, 8.47*t*
punctate epithelial, 8.46*t*
corneal
in epidemic keratoconjunctivitis, 8.234
epithelial, punctate, 8.46*t*, 8.50, 8.50*f*, 8.50*t*
in exposure keratopathy, 8.80
in herpetic eye disease/neurotrophic keratopathy, 8.224
refractive surgery and, 13.42, 13.42*f*
vernal keratoconjunctivitis and, 8.290
recurrent, 8.79, 8.86–88
dystrophic, 8.86, 8.87, 8.133, 8.135*t*
in epithelial basement membrane dystrophy, 8.86, 8.87, 8.133, 8.138
in lattice corneal dystrophy type 1, 8.147
in Reis-Bücklers corneal dystrophy, 8.143
eye pain in, 5.295, 8.86, 8.87
management of, 8.368
posttraumatic, 8.86, 8.87
eyelid, 8.45*t*
Ertapenem, 1.273
Er:YAG lasers. *See* Erbium:yttrium-aluminum-garnet (Er:YAG) lasers
Erysiphakes, 11.195
Erythema migrans/erythema chronicum migrans, 9.227–228, 9.228*f*, 12.245
in Lyme disease, 5.352, 5.353*f*
Erythema nodosum, 1.155, 1.156*f*, 1.162
Erythrocyte sedimentation rate (ESR), 1.153
in giant cell arteritis/AAION, 5.120, 5.120*t*, 5.314
in NAION, 5.120*t*
in optic neuritis, 5.115
Erythrocytes, mean corpuscular volume of, 1.132. *See also* Red blood cells (RBCs)
Erythromycin, 1.274–275, 2.418*t*, 2.421*t*, 2.427
for chlamydial conjunctivitis, 8.263
in neonates, 8.265
for chlamydial infections, 6.239
for meibomian gland dysfunction, 8.68
for rosacea, 8.71
for trachoma, 8.262–263, 8.263
Erythropoiesis, 1.131
Erythropoietin, 1.136
ESCD. *See* Enhanced S-cone disease
Escherichia/Escherichia coli (E coli)
description of, 2.419, 8.247
as normal flora, 8.205
ocular infection caused by, 8.247
reactive arthritis associated with, 1.155
Shiga toxin-producing, 1.142
urinary tract infections caused by, 12.238
ESCRS (Endophthalmitis Study Group of the European Society of Cataract and Refractive Surgeons), on postoperative endophthalmitis, 11.94, 11.162
ESCS. *See* Enhanced S-cone syndrome
Eserine. *See* Physostigmine
Esmolol, 1.64
Eso- (prefix), 6.15
Esodeviations. *See also* Esotropia; *specific type*
accommodative, 6.90. *See also* Accommodative esotropia
definition of, 6.85
in divergence insufficiency, 6.94
epidemiology of, 6.85
extraocular muscle surgery amounts for, 6.160, 6.160*t*
risk factors for, 6.85
types of, 6.86*t*
Esophageal cancer, 1.219
Esophoria, 3.142
Esotropia. *See also* Esodeviations
accommodative, 2.379, 5.227
amblyopia associated with, 6.91
definition of, 6.90
description of, 6.57
evaluation of, 6.91
high AC/A ratio, 5.227, 6.90–92
management of, 6.91–92
nonrefractive, 6.90
partially, 6.90–92
pathogenesis of, 6.90–91
refractive, 6.90–92
refractive surgery and, 13.188
types of, 6.86*t*, 6.90–91
acquired nonaccommodative
basic, 6.93
consecutive esotropia, 6.95
cyclic esotropia, 6.93
description of, 6.92
divergence insufficiency, 6.94
near reflex spasm, 6.94

sensory esotropia, 6.93–94
types of, 6.86*t*
age-related distance, 6.94
botulinum toxin injection for, 6.97
congenital. *See* Esotropia, infantile
in congenital fibrosis of the extraocular muscles (CFEOM), 6.135
consecutive, 6.16, 6.95
contact lens trial before refractive surgery and, 13.199
cyclic, 6.93
diplopia and, 6.102
in Duane retraction syndrome, 6.95–97, 6.132*f*, 6.133
exotropia following, 6.16
high myopia and, 6.97, 6.143–144
Hirschberg test for, 6.67, 6.68*f*
hyperopia and, 3.175
incomitant, 6.95–97, 6.96*f*
infantile, 6.86*t*
amblyopia associated with, 6.87–89
botulinum toxin injections for, 6.89
Chavasse theory of, 6.87
Ciancia syndrome, 6.88, 6.95
clinical features of, 6.87–88
cross-fixation associated with, 6.87–88, 6.88*f*
cyclopegic refraction for, 6.88
definition of, 6.87
evaluation of, 6.87–88
management of, 6.88–89
medial rectus muscle recession for, 6.89
mental illness and, 6.87
ocular alignment in, 6.88–89
pathogenesis of, 6.87
prematurity as risk factor for, 6.87
smooth-pursuit asymmetry associated with, 6.88
surgical treatment of, 6.89
V-pattern strabismus associated with, 6.109, 6.112*t*
Worth "sensory" concept of, 6.87
large-angle, 6.87
negative angle kappa and, 6.67, 6.68*f*
nystagmus and, 6.86*t*, 6.95. *See also* Nystagmus
latent, 5.238
nystagmus blockage syndrome as cause of, 6.155
postoperative, 6.102
postsurgical, 6.102
postsurgical consecutive, 6.95
prevalence of, 6.85
primary inferior oblique muscle overaction associated with, 6.117
pseudoesotropia, 6.85–87, 6.86*f*
risk factors for, 6.85
sensory, 6.93–94
small-angle, 6.102
spontaneous consecutive, 6.95
strabismus surgery for, 6.91
types of, 6.86*t*
V-pattern strabismus associated with, 6.109, 6.112*t*
ESR. *See* Erythrocyte sedimentation rate
Essential (physiologic/simple) anisocoria, 5.256*f*, 5.257
Essential blepharospasm, benign (BEB), 5.281–283, 5.282*f*, 5.282*t*, 7.256–258
Essential/progressive iris atrophy, 4.100, 4.101*f*, 8.111, 8.126, 8.127*f*, 10.136, 10.137*f*. *See also* Iridocorneal endothelial (ICE) syndrome
cataract and, 11.68
Essential thrombocythemia (ET), 1.142–143
Esthesiometry, 8.42–43
Estimated lens position (ELP), 3.239, 3.243, 3.248–250, 3.249*f*, 3.252–253
Estradiol, 1.309*t*
Estrogen/hormone replacement therapy (HRT)
breast cancer and, 1.215
refractive surgery in patient taking, 13.37
tear production affected by, 8.62*t*
Estrogen receptors, in immunohistochemistry, 4.35
ET. *See* Essential thrombocythemia
Etanercept, 1.180, 2.405*t*, 6.322
for sarcoidosis, 9.199
ETDRS. *See* Early Treatment Diabetic Retinopathy Study
Ethambutol
screening recommendations for, 1.257
tuberculosis treated with, 1.257
Ethanol. *See also* Alcohol
as tissue fixative, 4.26, 4.26*t*
Ethmoid air cells, 7.19–20, 7.282
Ethmoid/ethmoidal arteries, 5.12, 5.13*f*, 5.14*f*, 5.16*f*
Ethmoid/ethmoidal bone, 2.6*f*, 2.8, 5.7*f*, 5.8, 5.9*f*, 7.7–8*f*
Ethmoid sinus, 2.12, 2.14*f*
air cells of, 5.8, 5.10*f*, 7.20
bacterial infections of, 7.8
squamous cell carcinoma of, 7.102, 7.103*f*
Ethmoidal complex, 5.8
Ethmoidal foramen
anterior/posterior, 5.11
description of, 7.9
Ethmoidal suture, frontal, 5.8
Ethnic background. *See also* Race
multiple sclerosis and, 5.315
oculopharyngeal dystrophy and, 5.329
sarcoidosis and, 5.327
spasmus nutans and, 5.239
Vogt-Koyanagi-Harada syndrome and, 4.186
Ethosuximide, 1.207
Ethylene glycol, 12.303
optic neuropathy caused by, 5.137
Ethylenediaminetetraacetic acid (EDTA), 9.313
for band keratopathy, 8.119
Etodolac, 2.409*t*
Etoposide, for retinoblastoma, 4.299
Etoricoxib, 1.176
ETROP. *See* Early Treatment for Retinopathy of Prematurity
European Centre for Disease Prevention and Control (ECDC), 1.224
European Glaucoma Prevention Study, 10.89
European Glaucoma Society, angle closure definitions and, 10.117
Euryblepharon, 6.195, 7.174–175, 7.176–177*f*, 7.178*f*, 7.178–179
Evaporative dry eye, 8.45, 8.53–54, 8.54*f*, 8.55*f*, 8.58–60, 8.59*f*, 8.60*f*. *See also* Dry eye
blepharitis and, 8.68, 8.72
meibomian gland dysfunction and, 8.40–41, 8.53–54, 8.54*f*, 8.55*f*, 8.58–59, 8.60*f*, 8.66*t*, 8.66–67*t*, 8.66–69

rosacea and, 8.60, 8.70
treatment of, 8.66*t*, 8.66–67*t*, 8.66–69
Event-based analysis, of visual field progression, 10.71
Evisceration
advantages of, 7.138
complications of, 7.138–139
definition of, 7.135, 7.137
disadvantages of, 7.138
for penetrating ocular injury, 12.233
prostheses after, 7.140–141, 7.147*f*
Evoked cortical potential, visual. *See* Visual evoked potential/cortical potential/response
EVP. *See* Episcleral venous pressure
EVR1 gene, 12.346*t*
EVR2 gene, 12.346*t*
EVR3 gene, 12.346*t*
EVR4 gene, 12.346*t*
EVR5 gene, 12.346*t*
EVS. *See* Endophthalmitis Vitrectomy Study
EW. *See* Edinger-Westphal (EW) nucleus
Ewing sarcoma, 6.218
retinoblastoma associated with, 4.302*t*
Exact ray tracing. *See* Ray tracing
Examination
ocular
anterior segment examination, 6.10
Brückner test, 6.9
communication during, 6.4
cycloplegic refraction, 6.10–12
difficult child, 6.5
distance fixation targets, 6.3, 6.4*f*
dynamic retinoscopy, 6.9
fundus, 6.12
general considerations and strategies for, 6.3–5
intraocular pressure measurement, 6.10
1 toy, 1 look rule, 6.3, 6.4*f*
in outpatient setting, 6.3, 6.4*f*
practitioner positioning during, 6.4
pupil testing, 6.10
red reflex, 6.9
"safe" environment for, 6.4
slit-lamp examination, 6.4–5
tonometry, 6.10
visual acuity assessment. *See* Children, visual acuity assessment in
visual field testing, 6.10
vocabulary during, 6.4
ophthalmic, 8.15–43. *See also* Refraction, clinical; *specific method used*
under anesthesia
for infants and children, 10.157, 10.157*t*
for pediatric glaucoma, 10.157, 10.157*t*
gonioscopy and, 10.159
for retinoblastoma, 4.292, 4.292*f*
before cataract surgery, 11.77–78, 11.78–80
confocal microscopy in, 8.24, 8.24*f*
corneal biomechanics measurement in, 8.43
corneal curvature evaluation in, 8.25–36, 13.14–19, 13.15*f*, 13.16*f*, 13.17*f*, 13.18*f*, 13.19*f*, 13.44–45, 13.45*f*. *See also* Cornea, curvature of
corneal pachymetry in, 8.41–42. *See also* Pachymetry/pachymeter
before corneal transplantation, 8.418
diabetes mellitus-related, 12.93–94, 12.95*t*
in diplopia, 5.184*f*, 5.184–185, 5.185*f*
direct visualization in, 8.15–20, 8.16*f*, 8.17*f*, 8.18*f*, 8.19*f*, 8.20*f*
esthesiometry in, 8.42–43
in glaucoma, 10.48, 10.49*t*, 10.157*t*, 10.157–160
in infants and children, 10.157*t*, 10.157–160
in low vision evaluation, 5.78–97. *See also* Low vision, assessment of
in nonorganic disorders, 5.301–311, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*, 5.307*f*, 5.308*f*, 5.309*f*
OCT in, 8.21–22, 8.22*f*
in ocular surface neoplasia, 8.328
in penetrating and perforating ocular trauma, 8.401–402, 8.402*t*
in primary congenital glaucoma, 10.151–152, 10.152*t*, 10.157*t*, 10.157–160
before refractive surgery, 13.36*t*, 13.39–44, 13.42*f*, 13.43*f*
ancillary tests and, 13.44–46, 13.45*f*
in retinoblastoma, 4.292, 4.292*f*
scanning in, 8.20–24, 8.21*f*, 8.22*f*, 8.23*f*, 8.24*f*
slit-lamp biomicroscopy in, 8.15–20, 8.16*f*, 8.17*f*, 8.18*f*, 8.19*f*, 8.20*f*
specular microscopy in, 8.23, 8.23*f*
stains used in, 8.36–37, 8.37*f*, 8.38*f*, 8.56
tear film/tear production evaluation and, 8.38–41, 8.40*f*
stains used in, 8.36–37, 8.37*f*, 8.38*f*, 8.56
in transient visual loss evaluation, 5.163
ultrasound biomicroscopy in, 8.20–21, 8.21*f*
Excavated optic nerve/nerve head/disc, 5.137*f*
congenital, 5.145
in glaucoma, 5.136, 5.137*f*
Excessive blinking, 6.201–202
Excimer laser, 13.8*t*, 13.29, 13.73–77, 13.74–75*f*. *See also* Laser(s)
for photoablation, 13.8*t*, 13.29, 13.73–77, 13.74–75*f*. *See also* Photoablation; *specific procedure*
aberrations and, 13.13, 13.102–103, 13.103*f*
application of treatment and, 13.91*f*, 13.91–93
calibration of, 13.80
complications/adverse effects of, 13.101–126
corneal preparation for, 13.82–90, 13.83*f*, 13.85*f*, 13.86*f*, 13.87*f*, 13.88*f*, 13.89*f*, 13.90*t*
corneal transplantation after, 13.198
elevated intraocular pressure after, 13.104–105, 13.180–183, 13.182*f*, 13.200–201
herpes simplex virus keratitis and, 13.173–174
outcomes of, 13.95–97
preoperative programming of, 13.31, 13.40, 13.81
for presbyopia, 13.167, 13.168*f*
tracking/centration/ablation and, 13.91*f*, 13.91–92
for phototherapeutic keratectomy, 8.367
for recurrent corneal erosions, 8.87
Excision repair, 2.181
Excisional biopsy, 7.203*f*, 7.204
in conjunctival nevi, 8.341
in primary acquired melanosis, 8.342

Exciting eye, 4.185, 9.199–200. *See also* Sympathetic ophthalmia
Excretory lacrimal system. *See* Lacrimal drainage system
Excyclo- (prefix), 6.16
Excycloduction. *See* Extorsion
Exenatide, 1.205
Exenteration
basal cell carcinoma treated with, 7.204
considerations for, 7.146
definition of, 7.135
extended, 7.146
lacrimal drainage system tumors treated with, 7.317
for melanoma, 4.277, 8.344
rhabdomyosarcomas treated with, 7.89
sebaceous carcinoma treated with, 7.207
subtotal, 7.146
total, 7.146, 7.147*f*
types of, 7.146–147, 7.147*f*
Exercise, coronary heart disease risk modification using, 1.73*t*
Exercise stress testing, for coronary heart disease diagnosis, 1.88
Exfoliation. *See also* Exfoliation/pseudoexfoliation syndrome
true, infrared radiation/heat causing, 4.102, 11.57
Exfoliation/pseudoexfoliation syndrome, 4.101–103, 4.102*f*, 4.124, 10.11*t*, 10.31, 10.91*f*, 10.91–93, 10.92*f*, 10.130, 10.131*f*, 11.65*f*, 11.65–66
cataract surgery in patient with, 11.79, 11.184
glaucoma and (pseudoexfoliation glaucoma), 10.11*t*, 10.31, 10.91, 10.93, 10.130, 10.131*f*
IOL decentration/dislocation and, 11.144
postoperative hyphema and, 11.158
zonular incompetence and, 10.92, 10.93, 10.130, 10.131*f*, 11.65–66, 11.181, 11.182*f*, 11.184
Exo- (prefix), 6.15
Exodeviations. *See also* Exotropia; *specific type*
control of, 6.100
convergence insufficiency, 6.103
definition of, 6.99
exotropia. *See* Exotropia
extraocular muscle surgery amounts for, 6.160, 6.161*t*
latent, 6.99
manifest, 6.99
risk factors for, 6.99
Exogenous infection, uveal, 4.185
Exogenous inoculation, 8.206
Exons, 2.176–177
Exophoria
definition of, 6.99
diagnosis of, 6.99
Exophthalmometers, 7.24, 7.24*f*
Exophthalmometry, 7.24, 7.24*f*, 7.116
Exophthalmos, 5.271, 7.23, 7.112. *See also* Proptosis
thyrotoxic. *See* Thyroid eye disease
Exophytic retinoblastoma, 6.352–353, 6.353*f*
Exorbitism, 6.203, 7.23. *See also* Proptosis
Exotoxins
definition of, 9.9
innate immune response triggered by, 9.9
microbial, virulence and, 8.207
Exotropia
A-pattern strabismus associated with, 6.109
alternate cover test for, 6.66*f*, 6.99
angle kappa and, 6.67
consecutive, 6.16, 6.104
constant, 6.103–105, 6.104*f*
contact lens trial before refractive surgery and, 13.199
in craniosynostosis, 6.208
in Duane retraction syndrome, 6.105, 6.132, 6.132*f*
esotropia after, 6.95
high myopia and, 6.143–144
hypertropias associated with, 6.100
infantile, 6.103–104, 6.104*f*
intermittent
age at onset, 6.99
basic, 6.101
characteristics of, 6.99–100
control of, 6.100
course of, 6.99
dissociated horizontal deviation and, 6.105
evaluation of, 6.100–101
nonsurgical management of, 6.101–102
normal retinal correspondence in, 6.99
occlusion therapy for, 6.102
patch test for, 6.101
postoperative alignment, 6.102
prisms for, 6.102
recurrence of, 6.103
refractive errors in, 6.101
surgical treatment of, 6.102–103
tenacious proximal fusion in, 6.71
treatment of, 6.101–103
Krimsky test, 6.67, 6.68*f*, 6.104*f*
large-angle, 6.116
neuromuscular abnormalities as cause of, 6.105
postsurgical, 6.104
primary inferior oblique muscle overaction associated with, 6.117
pseudoexotropia, 6.99
risk factors for, 6.99
sensory, 6.104
V-pattern strabismus with, 6.108*f*, 6.112
Experimental autoimmune uveoretinitis (EAU), 9.61–62
Experimental studies, 1.8
Expiration dates on biologics, 2.372
Exposure keratitis/keratopathy, 8.79–80
cataract surgery in patient with, 11.174
tarsorrhaphy for, 8.80
Exposure keratopathy, 7.254
Exposure staining, 8.56
Expressivity, 2.220
Expulsive choroidal/suprachoroidal hemorrhage, 4.18, 4.19*f*
cataract surgery and, 11.159–160
Extavia. *See* Beta (β)-interferon
Extend plug, for dry eye, 8.64
Extended-depth-of-focus (EDOF) intraocular lenses
description of, 3.262–263, 3.263*f*
for multifocal IOLs, 13.165–166
Extended exenteration, 7.146
External adnexa. *See* Ocular adnexa

External-beam radiotherapy (EBRT)
for choroidal hemangioma, 4.283
for choroidal melanoma/ciliary body melanoma, 4.276
description of, 1.237–238
for lymphoma, 4.312
for metastatic eye disease, 4.310
for retinoblastoma, 4.301
secondary tumors and, 4.302, 4.302*t*
for uveal lymphoid proliferation/infiltration, 4.314
External carotid artery (ECA), 5.12, 5.13*f*, 5.15*f*, 7.170
External dacryocystorhinostomy, 7.307, 7.308*f*
External hordeolum (stye), 4.203–204, 7.183, 8.76, 8.76*f*
External jugular vein, 5.23
External limiting membrane (ELM), 4.140*f*, 4.141*f*
anatomy of, 12.15
definition of, 2.91
development of, 2.155
histology of, 12.11, 12.12*f*
External (outer) eye. *See also specific structure*
anatomy of, 8.3–14
cataract surgery in patient with abnormalities of, 11.172–174
common clinical findings in disorders of, 8.45–46*t*
defense mechanisms of, 8.11–14, 8.12–13*f*
examination of, 8.15–43. *See also* Examination; Examination, ophthalmic
before cataract surgery, 11.77–78
in primary congenital glaucoma, 10.158
immune-related disorders of, 8.285–326. *See also* Immune response (immunity)
infections of. *See* Infection (ocular)
External validity, 1.26
Extinction, 5.84
Extorsion (excycloduction), 6.33
definition of, 6.33
extraocular muscles in, 5.46*f*
oblique muscles, 5.46*f*
rectus muscles, 5.46*f*
V-pattern strabismus caused by, 6.107, 6.110
Extra-areal periphery, 12.9
Extracapsular cataract extraction (ECCE), 11.90, 11.90*f*, 11.196–198, 11.197*f*. *See also* Cataract surgery
for advanced cataract, 11.180
anterior capsulotomy in, 11.196, 11.197*f*
complications of, 11.135–136, 11.195, 11.198
flat or shallow anterior chamber and, 11.134, 11.135
intraoperative complications and, 11.134–135
posterior fluid misdirection syndrome and, 11.134–135
postoperative complications and, 11.135–136
historical overview/key developments in, 11.90, 11.90*f*, 11.119, 11.195
incisions for, 11.196
IOLs for, 11.197
lens particle glaucoma and, 11.67
manual small-incision cataract surgery and, 11.198, 11.199*f*
nucleus removal in, 11.196–197
ocular trauma affecting visualization and, 11.191
patient preparation for, 11.196
posterior capsule opacification and, 11.152–153
Nd:YAG laser capsulotomy for, 11.152, 11.153, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser, capsulotomy
postoperative course and, 11.198
retained lens fragments after, 11.141
retinal detachment and, 11.166
suture-induced astigmatism after, 11.132
wound closure and, 11.197–198
in zonular dehiscence with lens subluxation or dislocation, 11.182
Extracapsular IOL dislocation, 11.144, 11.144*f*, 11.145
Extraconal fat, 7.12
Extraconal fat pads, 6.28
Extracoronal surgical space, 7.123*f*, 7.123–124
Extracranial to intracranial bypass surgery, for ocular ischemic syndrome, 12.140
Extracranial trunk, of cranial nerve VII (facial), 5.52
Extranodal marginal zone B-cell lymphoma (EMZL), 7.92, 7.95
Extranodal marginal zone lymphoma (MALToma)
of conjunctiva, 4.70, 4.71*f*, 8.349–350, 8.350*f*
of orbit, 4.232, 4.233*f*
Extraocular muscle(s) (EOMs), 5.45–46, 5.46*f*. *See also* Ocular motility; *specific muscle*
action of
description of, 6.31–32
gaze position and, 6.34–37, 6.35–37*f*
primary, 6.34
secondary, 6.34
tertiary, 6.34
anatomy of, 2.17–18*f*, 5.45–46, 5.46*f*, 7.12, 7.12*f*
arc of contact, 6.32
arterial system of, 6.23
assessment of, 7.243
blood supply of, 2.21, 6.23–24, 6.30
congenital cranial dysinnervation disorders involving, 2.163
congenital fibrosis of, 6.134–135
in convergence-retraction nystagmus, 5.250
course of, 6.19–22
damage to, 7.139
development of, 2.162–163
fascial relationships of, 6.25–28, 6.26–27*f*
fiber structure in, 6.24
fibrosis of
congenital, 6.134–135
in thyroid eye disease, 6.140
fine structure of, 2.22
formation of, 2.162–163
function of, 7.11–12, 7.243
global layer of, 6.24
growth and development of, 6.181–182
inflammation of. *See* Myositis
inherited conditions affecting, 5.328–330, 5.329*f*
innervation of, 2.21, 5.40*f*, 5.40–45, 5.41*f*, 5.42–43*f*, 5.44*f*, 6.19–22, 7.12–13. *See also* Cranial nerve(s)
insertion of, 2.20, 2.21*f*, 6.19–22, 6.31
lost, 6.162, 6.169
magnetic resonance imaging of, 2.459*t*
myasthenia gravis effects on, 6.142
names of, 2.17
ophthalmic artery supply of, 6.23

orbital distribution of, 2.20
orbital implant migration caused by displacement of, 7.140*f*
orbital layer of, 6.24
orbital relationships of, 6.25–28, 6.26–27*f*
origin of, 2.18, 2.20*f*, 6.19–22
pulley system of, 6.28, 6.32
retrobulbar injection–related damage to, 6.146
slipped, 6.162, 6.169, 6.169*f*
structure of, 6.24, 6.25*f*
surgery of. *See* Extraocular muscle surgery; Strabismus surgery
3-step test of, 6.73–75, 6.74*f*
in thyroid eye disease, 4.226, 4.227*f*, 5.131, 5.206
optic neuropathy and, 5.131, 5.132*f*
thyroid eye disease effects, 6.140
venous system of, 6.23–24
yoke muscles, 6.38
Extraocular muscle surgery, 6.155–157, 6.156*f*. *See also specific type or disorder*
adjustable sutures used in, 6.165
in amblyopia, 6.160
anesthesia for, 6.174–175
in awake patients, 6.165
complications of, 6.168–174
adherence syndrome, 6.172
alignment issues, 6.168
allergic reactions, 6.170, 6.171*f*
anterior segment ischemia, 6.172–173, 6.173*f*
anti-elevation syndrome, 6.168–169
conjunctival scarring, 6.171–172, 6.172*f*
delle, 6.172, 6.172*f*
diplopia, 6.168
epithelial cyst, 6.170–171
eyelid position changes, 6.173, 6.173*f*
foreign-body granuloma, 6.170
iatrogenic Brown syndrome, 6.168
infections, 6.170, 6.170*f*
lost muscles, 6.169
orbital cellulitis, 6.170, 6.170*f*
pulled-in-two syndrome, 6.169–170
pyogenic granuloma, 6.170, 6.171*f*
refractive changes, 6.173–174
scleral perforation, 6.170
slipped muscles, 6.169, 6.169*f*
unsatisfactory alignment, 6.168
cyclovertical strabismus, 6.162
distance–near incomitance and, 6.162
for esodeviations, 6.160, 6.160*t*
esotropia correction with, 6.159
evaluation before, 6.159
for exodeviations, 6.160, 6.161*t*
exotropia after, 6.17
formulas for, 6.160–161*t*
fornix incision for, 6.162–163
hangback recession, 6.163
horizontal deviations, 6.161
horizontal incomitance and, 6.161
hypertropia treated with, 6.164–165
hypotropia treated with, 6.164–165
incisions for, 6.162–163
incomitance and, 6.161–162
indications for, 6.159–160
limbal incision for, 6.163
malignant hyperthermia secondary to, 6.174–175
monocular horizontal recession-resection procedures, 6.161
for nystagmus, 5.236
oblique muscles
inferior, 6.164*t*, 6.165–166
tightening procedures, 6.164*t*, 6.166–167
weakening procedures, 6.164*t*, 6.165–166
oculocardiac reflex, 6.174
planning of, 6.160–162
posterior fixation, 6.167
postoperative nausea and vomiting secondary to, 6.174
prior surgery and, 6.162
reasons for, 6.159
rectus muscles
hypertropia, 6.164–165
hypotropia, 6.164–165
slipped, 6.169, 6.169*f*
tightening procedures, 6.163–164, 6.164*t*
weakening procedures, 6.163, 6.164*t*
stay sutures used in, 6.167
for superior oblique myokymia, 5.251
sutures used in
adjustable, 6.165
posterior fixation, 6.167
stay, 6.167
symmetric, 6.160–161*t*
techniques for, 6.164*t*
tightening procedures
for inferior oblique muscle, 6.166
for oblique muscles, 6.164*t*, 6.166–167
for rectus muscles, 6.163–164, 6.164*t*
for superior oblique muscle, 6.167
transposition procedures, 6.167
vertical incomitance and, 6.161
weakening procedures
for inferior oblique muscle
bilateral, 6.165
indications for, 6.118
for superior oblique muscle palsy, 6.123, 6.123*t*
surgical procedures for, 6.164*t*, 6.165–166
for V-pattern strabismus, 6.111
for oblique muscles, 6.164*t*, 6.165–166
for rectus muscles, 6.163, 6.164*t*
Extraocular myopathy. *See also specific disorder*
inherited conditions causing, 5.328–330, 5.329*f*
in thyroid eye disease, 4.226, 4.227*f*, 5.206
Extrastriate cortex, 5.34*f*
Extrinsic pathway, of coagulation cascade, 1.138*f*
Exuberant granulation tissue (pyogenic granuloma), 4.55, 4.55*f*
Exuberant hyperkeratosis (cutaneous horn), 4.211, 7.188
Exudates
hard, 4.140, 4.152, 4.153*f*, 12.122, 12.160
in leukemia, 4.315
macular, 12.124*f*
soft. *See* Cotton-wool spots
Exudative hemorrhagic chorioretinopathy, peripheral (PEHCR), 4.270*f*, 4.271

Exudative retinal detachment
causes of, 12.320
diagnostic features of, 12.321*t*
in familial exudative vitreoretinopathy, 12.343
imaging of, 12.325*f*
management of, 12.325–326
photocoagulation as cause of, 12.379
retinal surface in, 12.326
subretinal fluid findings in, 12.326
Exudative/"wet" age-related macular degeneration. *See* Neovascular ("wet"/exudative) age-related macular degeneration
Eye. *See also specific ocular entries*
age-related changes in, 1.183–184
anatomy of. *See also specific structure*
early conceptions of, 11.3, 11.3*f*, 11.4*f*
axes of, 3.128–129, 3.129*f*
axial length of
angle closure and, 10.121
extremes of, cataract surgery in patient with, 11.184–185
in infants and children, in primary congenital glaucoma, 10.160
in IOL power determination, 11.82–83, 11.83*f*, 11.85
hypotony affecting, 11.185
unexpected refractive results after surgery and, 11.150, 11.176
in primary congenital glaucoma, 10.160
compartments of, 2.48
congenital anomalies of, 4.6, 4.7*f*, 4.12*t*, 6.182–183, 6.183*t*. *See also* Congenital anomalies; *specific type*
glaucoma associated with, 10.4*t*, 10.6*t*, 10.147, 10.148*t*, 10.151. *See also* Glaucoma, pediatric
curvature of, 3.268
depression of (downgaze). *See* Depression of eye (downgaze)
development of. *See also specific structure*
abnormalities of, 4.6, 4.7*f*, 4.12*t*. *See also* Congenital anomalies; *specific type*
glaucoma associated with, 10.4*t*, 10.6*t*, 10.153–156. *See also* Glaucoma, pediatric
dimensions of, 6.179*t*, 6.179–180
disorders of
atopic keratoconjunctivitis, 6.249
blepharitis, 6.244–245, 245*f*
conjunctivitis. *See* Conjunctivitis
ligneous conjunctivitis, 6.249
ocular allergies, 6.246*f*, 6.246–249, 6.247–248*t*
ophthalmia neonatorum. *See* Ophthalmia neonatorum
vernal keratoconjunctivitis, 6.248–249, 249*f*
dry. *See* Dry eye
elevation of (upgaze). *See* Elevation of eye
embryologic development of, 2.143–144, 2.144–146*f*, 2.148*f*, 2.152*t*. *See also* Ocular development
examination of, 8.15–43. *See also* Examination
before refractive surgery, 13.36*t*, 13.39–44, 13.42*f*, 13.43*f*
ancillary tests and, 13.44–46, 13.45*f*
external. *See* External (outer) eye
fellow. *See* Fellow eye
fluid transport in, 2.294*f*
glands of, 2.30*t*
growth and development of
abnormal, 6.182–183, 6.183*t*
normal, 6.179–182
Gullstrand mathematical model of, 3.59, 3.124, 3.125, 3.126*f*, 3.127*t*, 3.243, 3.270
hereditary diseases of. *See* Hereditary dystrophies
infection of. *See* Infection (ocular)
information about position of (efference copy information), 5.40
injury to. *See* Trauma
malformation of, 6.182–183
normal flora of, 8.205–206, 8.206*t*
optics of
accommodation, 3.140–141
axes, 3.128–129, 3.129*f*
binocular states, 3.139–140
contrast sensitivity, 3.134–136, 3.135–136*f*
contrast sensitivity function, 3.134–136
developmental hyperopia, 3.143
developmental myopia, 3.142–143
mathematical models of, 3.125, 3.126*f*
pupil size effects on visual resolution, 3.129–131
refractive errors, 3.141*f*, 3.141–142
refractive states, 3.136–139, 3.137–138*f*
schematic eye and, 3.125–128, 3.126*f*, 3.127*t*, 3.128*f*. *See also* Schematic eye
visual acuity, 3.131–134, 3.132–133*f*
phthisical (phthisis bulbi), 4.22, 4.23, 4.23*f*
retinoblastoma regression and, 4.301
physical examination of. *See* Examination
refractive state of, 3.136–139, 3.137–138*f*, 6.180*f*, 6.180–181
removal of. *See* Anophthalmic socket surgery; Enucleation; Evisceration; Exenteration
schematic, 3.127*t*
in systemic malignancies, 4.197, 4.303–316
traumatic injury of. *See* Trauma
tumors of. *See* Intraocular tumors
Eye Bank Association of America (EBAA), 8.414
Eye banking, 8.413–417, 8.415*t*, 8.416*f*, 8.416*t*. *See also* Cornea, transplantation of; Donor cornea
screening for prior LASIK and, 13.198
Eye drops. *See* Eyedrops
Eye fields
frontal (FEFs), 5.32*f*, 5.33, 5.34*f*, 5.37*f*
saccadic control and, 5.219, 5.220
seizures/tonic deviations and, 5.230
parietal, 5.32*f*
supplementary (SEFs), 5.32*f*, 5.33
Eye marking, before phacoemulsification, 11.104
Eye movements. *See also* Ocular motility
abnormalities of
National Eye Institute classification of, 6.147
nystagmus. *See* Nystagmus
active force generation test, 6.73
binocular
vergences, 6.37, 6.39–40
versions, 6.37–39
electromyography of, 6.32–33
forced duction test, 6.73

monocular
ductions, 6.33
field of action, 6.33–34
gaze position effects on extraocular muscle action, 6.34–37, 6.35–37*f*
primary action, 6.34
secondary action, 6.34
terminology associated with, 6.33
tertiary action, 6.34
motor units, 6.32–33
optical coherence tomography tracking of, 12.27
optokinetic system of, 6.40
saccadic system of, 6.40
saccadic velocity, 6.73
smooth-pursuit system of, 6.40
supranuclear control systems for, 6.40
vergence system of, 6.40
vestibular-ocular system of, 6.40
Eye muscles. *See* Extraocular muscle(s)
Eye pain. *See* Pain
Eye patches. *See* Patching
Eye-popping reflex, 5.274
"Eye strain," pain and, 5.295
Eyeball. *See* Globe
Eyebrow
botulinum toxin injection in, 7.269
ptosis. *See* Brow ptosis
Eyecharts
Bailey-Lovie, 3.133
for children, 3.38
contrast sensitivity testing, 3.315, 3.316*f*
distance from patient to, 3.149
Early Treatment Diabetic Retinopathy Study (ETDRS), 3.23*f*, 3.133, 3.133*f*, 3.313*f*
pictorial representation of, 3.23*f*
Snellen
disadvantages of, 3.132–133
letters on, 3.131–134, 3.132*f*
visual acuity testing using, 3.22, 3.23*f*
Eyedrops (topical medications)
administration of, 10.184–185
adherence and, 10.186
in children, 10.165
anesthetic
abuse of, 8.89*f*, 8.89–90
for cataract surgery, 11.92
antibiotic, after cataract surgery, 11.95
corneal melting and, 11.132
corneal melting and, 4.80–81, 11.132
corticosteroid. *See also* Corticosteroid(s)
ptosis caused by, 5.273, 5.273*t*
for glaucoma. *See also* Antiglaucoma agents
administration of, 10.184–185
adherence and, 10.186
in children, 10.165
ocular allergies treated with, 6.247*t*
ocular toxicity of, 8.80–81, 8.81*t*, 8.90*t*, 8.90–91
contact dermatoblepharitis, 8.285–287, 8.286*f*
pediatric administration of, 6.11–12
Eyeglasses. *See* Spectacle lenses (spectacles)
Eyelashes (cilia), 2.28, 4.201, 7.170, 8.3, 8.4*f*
accessory. *See* Distichiasis
entropion/ptosis of. *See* Trichiasis
lice infestation of, 8.255
misdirection of. *See* Trichiasis
in staphylococcal blepharitis, 8.72*f*, 8.73*t*, 8.74, 8.254
Eyelid(s), 4.201–221, 5.52, 8.3–4, 8.4*f*. *See also* Lower eyelids; Upper eyelids
age-related changes in, 1.183
amyloid deposits in, 4.206–207, 4.207*f*, 4.207*t*, 8.186*t*, 8.187
anatomy of, 2.26–37, 2.28*f*, 4.201*f*, 4.201–202, 5.52, 8.3–4, 8.4*f*
apraxia of opening of, 5.273*t*, 5.274
arterial supply of, 2.38*f*, 7.170
in atopic dermatitis, 8.287
basal cell carcinoma of
description of, 4.212*f*, 4.212–213, 4.213*f*
intraocular extension of, 4.310
biopsy of, 7.203*f*, 7.203–204
blepharoptosis of. *See* Ptosis
blood supply to, 2.37–38, 2.38*f*
botulinum toxin injection into, 6.146
canthal tendons of, 7.168–169, 7.169*f*
coloboma of
description of, 7.179–180, 7.180*f*
in Treacher Collins syndrome (mandibulofacial dysostosis), 4.207*t*
conjunctiva of. *See* Conjunctiva
connective tissue of, 7.168–169
in contact dermatoblepharitis, 8.285–287, 8.286*f*
creases of, 5.52, 6.197, 7.160, 8.4*f*
cysts of, 4.208, 4.208*f*
congenital dermoid, 4.203
ductal, 4.208, 4.208*f*
epidermoid/epidermal, 4.208, 4.208*f*
inclusion/sebaceous, 4.208, 4.208*f*
degenerations of, 4.206*f*, 4.206–207, 4.207*f*, 4.207*t*
disorders of, 4.201–221, 5.269–275, 8.45*t*
ablepharon, 6.193
ankyloblepharon, 6.193–194, 6.194*f*
cataract surgery in patient with, 11.174
chalazia, 6.198–199, 6.199*f*
chalazion, 7.181–183, 7.182–183*f*, 7.191, 7.207
coloboma, 6.193, 6.193*f*
common clinical findings in, 8.45*t*
congenital, 4.202–203, 4.203*f*, 6.191–198
ankyloblepharon, 7.175–176, 7.176–177*f*
blepharophimosis–ptosis–epicanthus inversus syndrome, 7.173–174, 7.174–175*f*
coloboma, 7.179–180, 7.180*f*
cryptophthalmos, 7.180, 7.181*f*
distichiasis, 7.179, 7.179*f*
ectropion, 7.174, 7.176*f*
entropion, 7.179, 7.179*f*
epiblepharon, 7.176*f*, 7.178–179
epicanthus, 7.176–177, 177*f*
euryblepharon, 7.174–175, 7.176–177*f*, 7.178*f*, 7.178–179
infantile (capillary) hemangioma, 7.180–181
congenital tarsal kink, 6.194–195
cryptophthalmos, 6.191, 6.193, 6.193*f*
distichiasis, 6.195, 6.195*f*
dystopia canthorum, 6.191, 6.192*f*
ectropion, 6.194
edema, 7.184, 7.184*f*

entropion, 6.194
epiblepharon, 6.194, 6.195*f*
epicanthus, 6.196, 6.196*f*
epithelial lesions, 6.200
euryblepharon, 6.195
evaluation of, 5.169*f*, 5.269–272, 5.270*f*, 5.271*f*
excessive blinking, 6.201–202
eyelid imbrication syndrome, 7.185–186
floppy eyelid syndrome, 7.184–185, 7.185*f*
hemangiomas, 6.199
hordeolum, 6.198–199, 7.183–184, 7.184*f*, 7.191
immune-mediated, 8.285–287, 8.286*f*
infectious, 6.198–199
inflammatory, 6.198–199
lice infestation, 8.255
lymphedema, 7.184, 7.184*f*
Marcus Gunn jaw-winking syndrome, 6.198
in myasthenia gravis, 5.324
neoplasms, 4.209–221, 4.210*t*, 6.199–200. *See also* Eyelid(s), tumors of
nevi, 6.200–201, 6.201*f*
noninflammatory, 6.199–201
nonorganic, 5.310–311
palpebral fissure slants, 6.196
pilomatricoma, 6.200, 6.200*f*
port-wine stain, 6.199
ptosis, 6.196–198, 6.197*t*, 6.198*f*
pyogenic granuloma, 6.199, 6.199*f*
in thyroid eye disease, 4.226, 4.227*f*. *See also* Thyroid eye disease
traumatic. *See* Eyelid(s), trauma to
trichotillomania, 6.201, 6.201*f*, 7.186, 7.186*f*
vascular, 6.199
drooping. *See* Ptosis
ecchymosis of, 7.22, 7.22*f*, 7.23*t*
ectropion of. *See* Ectropion
edema of, 7.84, 7.184, 7.184*f*
emphysema of, 7.115
entropion of. *See* Entropion
in evaporative dry eye, 8.55*f*, 8.58
eversion of, 7.174, 7.176*f*. *See also* Ectropion
examination of, 5.269*f*, 5.269–271, 5.270*f*
before refractive surgery, 13.41, 13.42, 13.43*f*
fibrous anatomy of, 7.165*f*
floppy, 8.79, 8.82–83, 8.83*f*
fold of, 7.160–161
function of, 8.3
fusion of (ankyloblepharon), in mucous membrane pemphigoid, 8.300, 8.302*t*
glands of, 4.202, 8.4. *See also specific type*
healing/repair of, 4.17
in herpes simplex blepharoconjunctivitis/dermatoblepharitis, 8.213, 8.214*f*, 8.216
in herpes zoster ophthalmicus, 8.227, 8.227*f*
horizontal laxity of, 7.231, 7.234
horizontal shortening/tightening of, for exposure keratopathy, 8.80
infection/inflammation of, 4.203–204, 4.204–206*f*, 8.254–255, 8.255*f*. *See also* Blepharitis
fungal and parasitic, 8.254–255, 8.255*f*
staphylococcal, 8.72–75*f*, 8.72–76, 8.73*t*, 8.208*t*, 8.254
inversion of. *See* Entropion
keratosis of, 8.46*t*
actinic, 4.210–212, 4.211*f*, 4.212*f*
seborrheic, 4.209, 4.209*f*, 4.210*f*
lacerations of
description of, 6.378
repair of. *See* Eyelid(s), surgery/reconstruction of
lower. *See* Lower eyelids
lymphatic supply of, 2.38, 2.39*f*, 7.170–171
lymphedema of, 7.184, 7.184*f*
malformations of, 6.191
malpositions of
blepharoptosis. *See* Ptosis
ectropion. *See* Ectropion
entropion. *See* Entropion
history-taking for, 7.229
nonorganic disorders and, 5.310–311
physical examination of, 7.229
symblepharon, 7.239
trichiasis, 7.239*f*, 7.239–240
margin of, 2.27, 2.30*f*, 4.201*f*, 8.3
anatomy of, 7.163, 7.163*f*, 7.170, 7.170*f*
disease of, 8.45
ectropion of. *See* Ectropion
in evaporative dry eye, 8.55*f*, 8.58
infections of, 8.254–255, 8.255*f*
inspection of, 7.288
inversion of, 7.179. *See also* Entropion
lacerations of, 7.214, 7.215–216*f*
nevus of, 7.196*f*
reconstruction for defects involving, 7.220–225
in rosacea, 8.70
sebaceous carcinoma of, 7.207
upper eyelid crease to, measurement of, 7.242
vascular and mesenchymal tumors of, 8.345*t*, 8.345–348
meibomian glands of, 7.170
melanoma of, 4.220, 4.221*f*
milia of, 7.189, 7.189*f*
in molluscum contagiosum, 8.236–237, 8.237*f*, 8.238*f*
morphologic measurements of, 6.191, 6.192*f*
movement of, 2.255
muscles of, 2.28, 2.31*f*, 2.33–35, 5.52
levator, 7.165, 7.165*f*
for protraction, 7.161–163, 7.162–163*f*
for retraction, 7.164–167, 7.165–167*f*
neoplasms of. *See* Eyelid(s), tumors of
nevi involving, 4.218*f*, 4.218–220, 4.219*f*
normal flora of, 8.205, 8.206*t*
orbital fat, 7.164, 7.164*f*
orbital septum, 7.163–164
orbital tumors from, 7.101
palpebral fissure of, 2.26, 2.27*f*, 2.36*f*
in Parkinson disease patients, 1.206
perforating injury of, 6.377*f*
plexiform neurofibroma involving, 5.269*f*
positional changes in, 6.173, 6.173*f*
protraction of
muscles for, 7.161–163, 7.162–163*f*
spasm (benign essential blepharospasm/BEB). *See* Blepharospasm
ptosis of. *See* Ptosis
racial variations in, 2.27, 2.29*f*, 7.160–161, 7.161*f*
redundancy of. *See* Dermatochalasis

retraction of, 5.274, 5.275*f*, 5.275*t*
bilateral, 7.253, 7.254*f*
causes of, 7.253
congenital, 7.253
definition of, 7.252
in dorsal midbrain (Parinaud) syndrome, 5.229, 5.250, 5.274, 5.275*t*
iatrogenic, 7.253
lower, 7.252, 7.253*f*, 7.254
management of, 7.253
muscles for, 7.164–167, 7.165–167*f*
pseudoptosis/ptosis and, 5.274, 5.275*t*
in thyroid eye disease, 4.226, 4.227*f*, 5.131, 5.274, 5.275*f*, 5.275*t*, 7.253
upper, 7.253, 7.254*f*
in rosacea, 8.70
in scleroderma, 4.207*t*
sebaceous adenocarcinoma/sebaceous gland carcinoma of, 4.210*t*, 4.215–218, 4.216*f*, 4.217*f*, 8.327, 8.337*f*, 8.337–338
skin of, 2.27–29, 2.29–30*f*, 4.201, 4.210, 7.159–161, 7.160–161*f*, 8.3–4
amyloid deposits in, 4.206–207, 4.207*f*, 4.207*t*, 8.186*t*, 8.187
healing/repair of, 4.17
melanoma arising in, 4.220, 4.221*f*
tumors of. *See also* Eyelid(s), tumors of
melanoma, 4.220, 4.221*f*
in SLE, 4.207*t*
specimen collection from, 8.208–209, 8.209*t*
squamous cell carcinoma of, 4.213, 4.214*f*
actinic keratosis and, 4.211
well-differentiated (keratoacanthoma), 4.209–210, 4.210*t*, 4.211*f*
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297, 8.297*f*, 8.298
structural layers of, 7.159–171
subcutaneous connective tissue of, 7.159–161
suborbicular fat pads of, 7.168
surgery/reconstruction of
eyelid defects
lower eyelid, 7.222–225, 7.223–224*f*
not involving eyelid margin, 7.220, 7.221*f*
upper eyelid, 7.220–221, 7.222*f*
for eyelid trauma. *See* Eyelid(s), trauma to
indications for, 7.205
lateral canthal defects, 7.225, 7.226–227*f*
medial canthal defects, 7.226, 7.227*f*, 7.228
for mucous membrane pemphigoid, 8.303
principles of, 7.220
priorities in, 7.219–220
suspensory anatomy of, 7.165*f*
systemic diseases manifesting in, 4.206–207, 4.207*t*
in systemic sclerosis, 4.207*t*
tarsus of, 7.168, 7.169*f*
in thyroid eye disease, 4.226, 4.227*f*, 5.131, 5.274, 5.275*f*, 5.275*t*. *See also* Thyroid eye disease
topography of, 4.201*f*, 4.201–202
trauma to
blunt, 7.213
burns, 7.218–219, 7.218–219*f*
canthal soft tissue, 7.214–216
dog bites as cause of, 7.218
human bites as cause of, 7.218
lacerations, 7.214–216*f*
management of, 7.213
margin, 7.214, 7.215–216*f*
penetrating, 7.213–216
repair of. *See* Eyelid(s), surgery/reconstruction of
secondary repair of, 7.216–218, 7.217*f*
tarsoconjunctival flaps for, 7.218
tumors of, 4.209–221, 4.210*t*, 8.327
actinic keratosis, 7.198–199, 7.199*f*
adnexal lesions, 7.190–194, 7.191–192*f*
apocrine hidrocystoma, 7.193, 7.193*f*
basal cell carcinoma, 4.212*f*, 4.212–213, 4.213*f*
intraocular extension of, 4.310
benign, 4.209*f*, 4.209–210, 4.210*f*, 4.214–215, 4.215*f*, 4.216*f*, 4.218*f*, 4.218–220, 4.219*f*, 4.221*f*, 8.327
epithelial lesions, 7.189–190, 190*f*
melanocytic, 4.218*f*, 4.218–220, 4.219*f*
blue nevi, 7.198
dermal melanocytosis, 7.198, 7.198*f*
ephelis, 7.197
lentigo simplex, 7.197
nevi, 7.195–197, 7.196–197*f*
solar lentigo, 7.197–198, 7.198*f*
sources of, 7.194–195
clinical evaluation of, 7.186–187
cutaneous horn, 7.188–189
cylindroma, 7.193, 7.193*f*
dermal, 4.214, 4.215*f*
dermal appendage, 4.214–218, 4.215*f*, 4.216*f*, 4.217*f*
eccrine hidrocystoma, 7.191
epidermal, 4.209*f*, 4.209–213, 4.210*f*, 4.210*t*, 4.211*f*, 4.212*f*, 4.213*f*, 4.214*f*
premalignant (actinic keratosis), 4.210–212, 4.211*f*, 4.212*f*
epithelial hyperplasia, 7.187–189, 7.188*f*
frozen section/Mohs surgery for, 4.44*f*, 4.44–45
in situ epithelial malignancies, 7.199–200
keratoacanthoma, 4.209–210, 4.210*t*, 4.211*f*, 7.199–200
lentigo maligna, 7.200
malignant, 4.210*t*, 4.212*f*, 4.212–213, 4.213*f*, 4.215–218, 4.216*f*, 4.217*f*, 4.220, 4.221*f*, 8.327
basal cell carcinoma, 4.212*f*, 4.212–213, 4.213*f*, 7.200–205, 7.201–203*f*
intraocular extension of, 4.310
intraocular extension of, 4.310
Kaposi sarcoma, 5.349, 7.211, 7.211*f*, 8.345*t*, 8.347–348
melanocytic (melanoma), 4.220, 4.221*f*
melanoma, 7.208–211, 7.209*f*
Merkel cell carcinoma, 7.212, 7.212*f*
sebaceous adenocarcinoma/sebaceous gland carcinoma, 4.210*t*, 4.215–218, 4.216*f*, 4.217*f*, 7.206–208, 7.207*f*, 8.327, 8.337*f*, 8.337–338
squamous cell carcinoma, 4.213, 4.214*f*, 7.205–206, 7.206*f*
actinic keratosis and, 4.211
in situ, 7.199
well-differentiated (keratoacanthoma), 4.209–210, 4.210*t*, 4.211*f*

melanocytic
benign, 4.218*f*, 4.218–220, 4.219*f*, 4.221*f*
malignant (melanoma), 4.220, 4.221*f*
pilomatricoma, 7.194, 7.195*f*
premalignant
epidermal, 7.198–199, 7.199*f*
epidermal (actinic keratosis), 4.210–212, 4.211*f*, 4.212*f*
melanocytic, 7.200
pseudoepitheliomatous hyperplasia, 7.188
sebaceous adenoma, 7.191
sebaceous hyperplasia, 7.191
syringomas, 7.192, 7.192*f*
systemic malignancies and, 4.209, 4.210*t*
trichilemmoma, 7.194
trichoepithelioma, 7.193, 7.194*f*
trichofolliculoma, 7.193, 7.194*f*
vascular and mesenchymal, 8.345*t*, 8.345–348
verruca vulgaris, 7.188, 7.188*f*
vascular supply of, 2.37–38, 2.38*f*, 5.12, 5.13*f*, 5.14*f*, 5.17, 7.157, 7.158–159*f*, 7.170–171
venous drainage of, 5.21*f*, 5.23, 7.171
vertical rectus muscle attachment of, 6.30*f*
Eyelid artifact, in perimetry, 10.66
Eyelid droop. *See* Ptosis
Eyelid hygiene
in blepharitis/meibomian gland dysfunction, 8.66–68, 8.72, 8.76
in chalazion/hordeolum, 8.77
Eyelid imbrication syndrome, 7.185–186
Eyelid myokymia, 5.282*t*, 5.284
Eyelid retractor/speculum
for examination in conjunctival foreign body, 8.397
for examination/management in chemical injury, 8.381, 8.382*f*
for globe exposure, in cataract surgery, 11.105, 11.105*f*
Eyelid taping
for exposure keratopathy, 8.80
for floppy eyelid syndrome, 8.83
as tarsorrhaphy alternative, 8.373
Eyelid weights
for corneal exposure in facial palsy, 5.281
for exposure keratopathy, 8.80
Eyelid–globe incongruity, 2.257

F

F_3. *See* Trifluridine
FA. *See* Facial artery; Fluorescein angiography
Fab fragment, of B cells, 9.41
Fabry disease (angiokeratoma corporis diffusum), 2.204*t*, 2.232*t*, 2.235, 6.270, 6.388*t*, 8.176–178, 8.177*f*, 12.291–292
Face. *See also under Facial*
aging. *See* Aging face
anatomy of, sensory and motor components and, 5.47–52
arterial network of, 7.157, 7.158–159*f*
mimetic muscles of, 7.153, 7.154*f*
rejuvenation techniques for. *See* Facial rejuvenation
sensory innervation of, 7.155
superficial musculoaponeurotic system of, 7.151–153, 7.152*f*
temporoparietal fascia of, 7.151, 7.153
vascular supply of, 7.157, 7.158–159*f*
Face-lift. *See* Facial rejuvenation
Facial angiofibromas, 2.229, 6.397
in tuberous sclerosis, 5.331*f*, 5.334*t*
Facial angioma. *See* Nevi/nevus, flammeus
Facial artery (FA), 2.23*f*, 2.38*f*, 5.12, 5.13*f*, 5.14*f*, 5.15*f*
Facial asymmetry, torticollis and, 6.82
Facial clefts. *See* Craniofacial malformations
Facial colliculus, 2.134, 5.49
Facial colliculus syndrome, 5.189
Facial contracture, spastic paretic, 5.284
Facial defects. *See* Craniofacial malformations
Facial description, in confrontation testing, 5.83
Facial diplegia
in Guillain-Barré syndrome, 5.280
in pontine lesions, 5.278
Facial dystonia
benign essential blepharospasm, 7.256–258
hemifacial spasm, 7.258
Facial genu, 5.40, 5.41*f*, 5.49, 5.192
Facial grimacing, blepharospasm associated with, 5.281, 5.282*f*
Facial hemiatrophy, progressive (Parry-Romberg syndrome), 8.192*t*
Facial motor pathways, 5.49–52, 5.50–51*f*. *See also* Cranial nerve VII
disorders of, 5.275–285. *See also* Facial movement abnormalities
Facial movement abnormalities, 5.269, 5.275–285
cranial nerve VII (facial) disorders causing, 5.275–277, 5.276–277*f*, 5.277–285
overactivity and, 5.281–285, 5.282*f*, 5.282*t*, 5.283*f*
underactivity and, 5.275, 5.276–277*f*, 5.277–281, 5.278*t*, 5.279*f*. *See also* Facial paralysis/weakness
evaluation of, 5.269, 5.271*f*, 5.271–272
Facial muscles, innervation of, 5.49–52, 5.50–51*f*. *See also* Cranial nerve VII
Facial myokymia, 5.282*t*, 5.284
Facial nerve. *See* Cranial nerve VII (facial nerve)
Facial nerve block, for cataract surgery, 11.92, 11.93*f*
Facial numbness, pain associated with, 5.298
Facial pain, 5.289*t*, 5.296–298. *See also* Headache; Neuralgia; Pain
Facial paralysis/weakness, 5.275, 5.276–277*f*, 5.277–281, 5.278*t*, 5.279*f*
bilateral, 5.280
brainstem lesions causing, 5.278, 5.278*t*
cataract surgery in patient with, 11.174
in HIV infection/AIDS, 5.280
nuclear lesions causing, 5.276*f*
paralytic ectropion, 7.254–255
peripheral lesions causing, 5.278–280, 5.279*f*
progressive, 5.280
recurrent, 5.280
in sarcoidosis, 5.280, 5.327
seventh nerve lesions causing, 5.275, 5.276–277*f*
supranuclear lesions causing, 5.276*f*, 5.277–278
treatment of, 5.280–281
upper eyelid paralysis, 7.255–256

Facial rejuvenation
autologous fat grafting for, 7.271
botulinum toxin for, 7.269–270
dermal fillers for, 7.270*f*, 7.270–271
hyaluronic acid fillers for, 7.270, 7.270*f*
laser skin resurfacing for, 7.268–269
nonsurgical, 7.268–271, 7.270*f*
soft-tissue dermal fillers for, 7.270*f*, 7.270–271
surgical techniques for, 7.271–276, 7.272–275*f*
Facial surgery, 7.271–276, 7.272–275*f*. *See also* Eyelid(s), surgery/reconstruction of; *specific procedure*
Facial synkinesis, 5.271, 5.271*f*
Facial tic (habit spasm), 5.285
Facial vein, 5.21*f*, 5.22, 5.23
eyelids drained by, 5.21*f*, 5.23
Facial venous system, 5.23
Facilitated diffusion, glucose transport into lens and, 11.17
Factitious disorders, 1.197
ocular surface, 8.88–90, 8.89*f*
Factor IX
activation of, 1.138
deficiency of, 1.144
Factor V, 1.146
Factor V Leiden, 1.146–147
Factor VII, 1.138
Factor VIII deficiency. *See* Hemophilia A
Factor Xa inhibitors, 1.90*t*, 1.149
Facultative suppression, 6.49
Fadenoperation, 6.128, 6.164*t*
FAF. *See* Fundus autofluorescence
Falciform ligament, 5.26
FALK. *See* Femtosecond anterior lamellar keratoplasty
Fallopian canal, 5.52, 5.56
seventh nerve lesions and, 5.276–277*f*
Falls, 1.191–192
False-negative responses, in perimetry, 5.86, 10.62
False-positive responses
in confrontation testing, 5.84
in perimetry, 5.86, 10.62, 10.67, 10.67*f*
Famciclovir, 2.432*t*, 2.435, 8.215*t*
for herpes simplex virus, 1.260, 1.278, 8.215*t*, 9.249
for herpes zoster virus infections, 8.229
varicella-zoster treated with, 1.261
FAME. *See* Fingolimod-associated macular edema
Familial adenomatous polyposis (FAP/Gardner syndrome), 12.285–286
congenital hypertrophy of retinal pigment epithelium in, 2.201, 2.202*f*
description of, 6.349, 6.350*f*
retinal manifestations of, 4.144–145, 4.269
Familial amyloid polyneuropathy (FAP), 4.134, 4.134*f*, 4.206
vitreous involvement/opacification and, 4.134, 4.134*f*
Familial amyloidosis, 4.134, 4.134*f*, 4.206, 8.186*t*, 8.187
Finnish/gelsolin type (Meretoja syndrome), 4.206, 8.186*t*, 8.187, 8.188*f*
with lattice corneal changes, 8.146, 8.185–187
primary of cornea (subepithelial amyloidosis/gelatinous droplike dystrophy), 8.135*t*, 8.136*t*, 8.140–141, 8.141*f*, 8.185–187, 8.186*t*
Familial cerebello retinal angiomatosis. *See* von Hippel–Lindau (VHL) disease/syndrome
Familial Creutzfeldt-Jakob disease (fCJD), 5.357
Familial disorder, 2.210
Familial dysautonomia (FD/Riley-Day syndrome)
congenital corneal anesthesia and, 8.108
description of, 2.204*t*, 2.229, 6.271
Familial exudative vitreoretinopathy (FEVR), 6.347–348, 6.348*f*, 12.343–344, 12.345*f*
Familial glaucoma iridogoniodysplasia. *See* Axenfeld-Rieger syndrome
Familial hemiplegic migraine, 5.291
Familial juvenile nephronophthisis, 12.285
Familial juvenile systemic granulomatosis, 6.319
Familial oculorenal syndromes, 6.391–392, 6.391–392*f*
Family history/familial factors. *See also under Genetic*
in genetic counseling, 2.237
in glaucoma, 10.10, 10.82, 10.121
angle closure/angle-closure glaucoma and, 10.121
open-angle glaucoma and, 10.82
in ocular hypertension, 10.90
Famotidine, 1.288
Famvir. *See* Famciclovir
Famvir HZV. *See* Famciclovir
Fanconi syndrome, 2.425
FAP. *See* Familial adenomatous polyposis; Familial amyloid polyneuropathy
Far point
ametropia correction using spectacles, 3.170, 3.170*f*
cylindrical correcting lenses and, 3.173
refractive states and, 3.136
spherical correcting lenses and, 3.170, 3.170*f*
Farkas canthal index, 6.191
Farnsworth-Munsell 100-hue test, 12.55
in low vision evaluation, 5.79
Farnsworth Panel D-15 test, 12.55*f*, 12.55–56
in low vision evaluation, 5.79
Faropenem, 1.273
FAS. *See* Fetal alcohol syndrome
Fas ligand (CD95 ligand/FasL)
in apoptosis
description of, 9.57
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
corneal transplant tolerance and, 8.316
in effector blockade, 9.57
Fasanella-Servat procedure, 7.250
Fascia, orbital, 6.27
Fascia bulbi, 2.44, 6.26. *See also* Tenon capsule
Fascia lata, 7.255
Fascia solitarius, 5.51*f*
Fascicles
cranial nerve III (oculomotor), 5.44–45
cranial nerve IV (trochlear), 5.43
cranial nerve V (trigeminal), 5.48
cranial nerve VI (abducens), 5.41
cranial nerve VII (facial), 5.49
Fascicular ocular motor nerve palsies, 5.191
Fasciitis, nodular, 4.112, 4.113*f*, 8.347
episcleral tumor caused by, 4.112
FasL. *See* Fas ligand
Fastigial nucleus, 5.40
Fasting, preoperative, 1.287–288
Fasting hypoglycemia, 1.300

Fasting plasma glucose (FPG), in diabetes mellitus diagnosis, 1.34
Fat decompression, 7.130
Fat emboli/embolism
  description of, 12.141, 12.173
  transient visual loss caused by, 5.165
Fat-suppression/saturation techniques, in MRI, 5.58, 5.58*f*, 5.62–65, 5.65*f*, 5.66*f*, 5.67*f*
Fatal familial insomnia (FFI), 1.211, 5.357
Fatty acid supplements, for dry eye, 8.61, 8.61*t*, 8.64, 8.68
Fatty streak, 1.81
FAZ. *See* Foveal avascular zone
FBN1 gene, 6.307
  in Marfan syndrome, 8.194
Fc receptors
  antibody, 9.12
  description of, 9.3
  mast-cell, 9.19
  types of, 9.47
FCD. *See* Fleck corneal dystrophy
fCJD. *See* Familial Creutzfeldt-Jakob disease
FD. *See* Familial dysautonomia
FD-OCT. *See* Fourier-domain optical coherence tomography; Frequency-domain optical coherence tomography
FDA. *See* Food and Drug Administration
FDCA. *See* Food, Drug, and Cosmetic Act
FDF perimetry. *See* Flicker-defined form (FDF) perimetry
FDG-PET (fluorodeoxyglucose positron emission tomography) in sarcoidosis, 5.328
FDT perimetry. *See* Frequency-doubling technology (FDT) perimetry
Fecal immunochemical test (FIT), for colorectal cancer screening, 1.218–219
FECD. *See* Fuchs endothelial corneal dystrophy
Federal Fairness to Contact Lens Consumers Act, 3.235
FEFs. *See* Frontal eye fields
Feiz and Mannis formula, for IOL power determination/selection, 11.86
Fellow eye. *See also* Sympathetic ophthalmia
  macular hole risks, 12.339
  in patient with AAION, 5.120, 5.120*t*, 5.121–122
  in patient with acute angle closure, 10.123, 10.125
  in patient with exfoliation syndrome, 10.91
  in patient with malignant optic glioma of adulthood, 5.130
  in patient with NAION, 5.120*t*, 5.123
  in patient with optic neuritis, 5.115
  in patient with traumatic/angle-recession glaucoma, 10.108
  retinal detachment in, 12.319
  sympathetic ophthalmia and. *See* Sympathetic ophthalmia
Fells modification of Harada-Ito procedure, 6.167
Felty syndrome, 1.152
Femto-LASIK. *See* Femtosecond laser in situ keratomileusis
Femtosecond anterior lamellar keratoplasty (FALK), 8.412*t*, 8.431, 8.434
Femtosecond laser, 13.29
  for anterior/deep anterior lamellar keratoplasty, 8.412*t*, 8.431, 8.434
  for arcuate keratotomy incisions, 13.54, 13.55
  for cataract extraction, 11.125–126
  for corneal inlay insertion, 13.61, 13.169
  for corneal intrastromal treatment, 13.168
  for intrastromal corneal ring segment incisions/channels, 13.64
  for LASIK flap creation, 13.8*t*, 13.87–90, 13.88*f*, 13.89*f*, 13.90*t*
    aberrations and, 13.102–103
    advantages/disadvantages/complications of, 13.88, 13.90*t*, 13.122–124, 13.123*f*
    re-treatment/enhancements and, 13.98
    steep or flat corneas and, 13.44–45, 13.79
  for lenticule extraction, 13.8*t*, 13.27–28, 13.203
  for photodisruption, 13.29
  for presbyopia treatment, 13.168
  for relaxing incisions after penetrating keratoplasty, 8.432
  for small-incision lenticule extraction, 13.204
Femtosecond laser-assisted keratoplasty (FLAK), 8.412*t*, 8.431, 8.434
Femtosecond laser in situ keratomileusis (Femto-LASIK), 13.8*t*. *See also* Femtosecond laser, for LASIK flap creation
Femtosecond lenticule extraction (FLEx), 13.8*t*, 13.27–28, 13.203
Fenofibrate, diabetic retinopathy progression affected by, 12.102
Fenoprofen, 2.409*t*
Fenoterol, 1.128
Fentanyl, 1.290, 1.306
Fermat principle
  definition of, 3.40, 3.70
  description of, 3.86–88, 3.274
  point spread function and, 3.275
  wavefront analysis based on, 3.274
Ferrara rings, 13.62–63. *See also* Intrastromal corneal ring segments
Ferrous sulfate, for iron deficiency anemia, 1.133
Ferry lines, 8.118*t*
Fetal alcohol syndrome (FAS), 1.199, 6.183, 6.211–212, 6.212*f*, 6.361
Fetal lens nucleus, 4.117, 11.13, 11.27–28*f*, 11.28–29
  opacification of (congenital nuclear cataract), 11.38, 11.39*f*
Fetal vasculature, persistent. *See* Persistent fetal vasculature
Fetus
  irradiation effects on, 1.239
  maternal antiglaucoma agents affecting, 10.185–186
FEV_1. *See* Forced expiratory volume over 1 second
FEV_1/FVC ratio. *See* Forced expiratory volume over 1 second/forced vital capacity (FEV_1/FVC) ratio
FEVR. *See* Familial exudative vitreoretinopathy
Feynman, Richard, 3.96
FFI. *See* Fatal familial insomnia
FGFs. *See* Fibroblast growth factors
FHU. *See* Fuchs heterochromic uveitis
Fiber layer of Henle (HFL), 2.84, 2.92, 2.94*f*, 4.140, 4.141*f*, 5.24. *See also* Nerve fiber layer
Fibric acids, for hypercholesterolemia, 1.75*t*
Fibrillin, 2.298
  defects in, in Marfan syndrome, 8.193–194, 11.40
Fibrillin-1, 6.307

Fibrin, 1.146
dissolution of, 9.18
in inflammation, 9.18–19
in uveitis-glaucoma-hyphema syndrome, 9.10
Fibrin clots, 6.377
Fibrin degradation products, 1.146
Fibrin glue/sealant/tissue adhesive, 2.371*t*, 2.446, 8.355
for conjunctivochalasis, 8.86
for corneal autograft fixation, 8.351, 8.355
in pterygium excision, 8.355
recurrence rate and, 8.353*t*
off-label use of, 8.355
Fibrinogen, 9.18
Fibrinolytic agents, 2.445–446
Fibro-osseous dysplasia (juvenile ossifying fibroma)
description of, 6.222
of orbit, 4.239, 4.240*f*
Fibroblast(s)
keratocytes as, 8.8, 8.9*f*. *See also* Keratocytes
orbital, 7.57
in thyroid eye disease, 4.226
Fibroblast growth factor receptor genes, 6.206
Fibroblast growth factors (FGFs), 2.166, 2.449
Fibrocellular proliferation, intraocular, 4.20–22, 4.21*f*
Fibrocytes (stromal keratocytes), 4.73
corneal haze after surface ablation and, 13.33, 13.109
in wound healing/repair, 4.14–15, 4.15*f*, 4.16
Fibroma/fibromatosis
juvenile ossifying, of orbit, 4.239, 4.240*f*
molluscum, 5.334*t*
Fibronectin, 2.304, 12.7
Fibroplasia, retrolental. *See* Retinopathy of prematurity
Fibrosarcoma, 7.91
retinoblastoma associated with, 4.302*t*
Fibrous downgrowth. *See* Fibrous ingrowth (downgrowth)
Fibrous dysplasia, 6.222, 7.89, 7.90*f*
of orbit, 4.239, 4.240*f*
Fibrous histiocytoma (fibroxanthoma)
description of, 7.89, 8.347
malignant, 4.112
orbital, 4.235
scleral, 4.112, 4.113*f*
Fibrous ingrowth (downgrowth)
angle-closure glaucoma and, 10.141–142, 10.143*f*
corneal edema after cataract surgery and, 11.128*t*, 11.133
corneal graft failure and, 4.84, 4.85*f*
Fibrous tumor, solitary, of orbit, 4.235*f*, 4.235–236
Fibrovascular pigment epithelial detachment, 12.72–73
Fibrovascular plaque, anterior, in persistent fetal vasculature, 4.125, 4.126*f*
Fibroxanthoma. *See* Fibrous histiocytoma
Field defects. *See* Visual field defects
Field loss, vision rehabilitation for, 3.325–326
Field of vision. *See* Visual field
Fifth cranial nerve. *See* Cranial nerve V
Filamentary keratopathy, 8.56, 8.56*f*
in graft-vs-host disease, 8.304
treatment of, 8.63
Filamentous fungi, 8.249, 8.249*t*, 8.250*f*, 8.251
keratitis caused by, 8.251, 8.273, 8.274*f*, 8.275
as normal flora, 8.206*t*
ocular infection caused by, 8.251
Filaments, corneal, 8.46*t*
in aqueous tear deficiency, 8.56, 8.56*f*
Filaments (bacteria), gram-positive, 8.244*t*, 8.248–249
Filariae
Loa loa, 8.282
orbital involvement and, 4.228
onchocercal, 8.252–253
Filensin, 2.285, 11.16
Filtering bleb
cataract surgery in eye with, 11.187
endophthalmitis associated with, 10.163, 10.209, 10.209*t*, 10.210*f*
evaluation for, before glaucoma surgery, 10.31
inadvertent, after cataract surgery, 11.130–131
LASIK and, 13.182
in trabeculectomy, 10.200, 10.206–207, 208*f*
postoperative complications and, 10.209, 10.209*t*, 10.210, 10.210*f*, 10.211
Filtering procedures, 10.197–211. *See also* Trabeculectomy
cataract surgery after, 10.211–213, 11.186, 11.187
conjunctival evaluation before, 10.31
flat or shallow anterior chamber/angle-closure glaucoma and, 10.144–145
LASIK and, 13.182
for neovascular glaucoma, 10.135
for pigmentary glaucoma, 10.96
Fimbriae, bacterial, 8.244
Fine-needle aspiration biopsy (FNAB), 4.34*t*, 4.42–43, 4.43*f*, 4.253, 7.132, 7.132*f*
in lymphoma, 4.42
in metastatic eye disease, 4.253, 4.307
of orbit, 4.43
in uveal lymphoid proliferation/infiltration, 4.314
Finger comparison test, in confrontation testing, 5.83–84
Finger counting, in confrontation testing, 5.83
Finger-touching test, nonorganic disorder evaluation and, 5.301, 5.302*f*
Fingerprint lines, in epithelial basement membrane dystrophy, 8.137
Fingolimod, 12.301
for multiple sclerosis, 5.320, 5.321*t*, 9.152
macular edema and, 5.320, 5.322*f*
Fingolimod-associated macular edema (FAME), 5.320, 5.322*f*
Finnish (gelsolin) type amyloidosis (Meretoja syndrome), 4.206, 8.186*t*, 8.187, 8.188*f*
Finnish Twin Cohort Study, 10.10
Finoff transilluminator, 3.33
FIPTs. *See* Focal intraretinal periarteriolar transudates
First-generation antipsychotics, 1.199–201, 1.200*t*
First-generation cephalosporins, 2.419
First nodal point, 3.66
First-order aberrations, 13.11
First-order approximation. *See* Paraxial rays
First-order neuron, 5.52, 5.53, 5.53*f*
Horner syndrome caused by lesions of, 5.257, 5.259, 5.260*t*
First principal plane, 3.56, 3.58
FISH. *See* Fluorescence in situ hybridization
Fish eye disease, 8.180
Fishbone diagram, 1.30–31

Fissures
calcarine, 5.29*f*, 5.29–30
orbital, 5.6*f*, 5.7*f*, 5.9*f*, 5.11
inferior, 5.7*f*, 5.9*f*, 5.11
superior, 5.6*f*, 5.7*f*, 5.9*f*, 5.11
ophthalmoplegia caused by lesions of, 5.203
Fistulas
arteriovenous, 7.78, 7.78*f*
glaucoma associated with, 10.30
carotid-cavernous, 5.203–206, 5.204*f*, 5.205*f*, 7.78–79*f*, 80
neuroimaging in evaluation of, 5.70, 5.72*t*, 5.204, 5.204*f*, 5.205*f*
congenital lacrimal, 6.228, 6.229*f*
lacrimal–cutaneous, 7.286, 7.286*f*
Fistulizing procedures, 10.197–211. *See also* Filtering procedures
FIT. *See* Fecal immunochemical test
Fite-Faraco stain, 4.31*t*
Fitting (contact lens), after refractive surgery, 13.199, 13.200. *See also* Contact lenses, fitting of
Fitzpatrick skin type, 7.268
5-Fluorocytosine, 2.431
5-FU. *See* Fluorouracil/5-fluorouracil
Fixation (visual), 5.212, 5.212*t*, 5.213–214
alternating, 6.16
amblyopia evaluations, 6.56–57
assessments of, in preverbal children, 6.300
dysfunction of, 5.214
eccentric
anomalous retinal correspondence *versus*, 6.51
definition of, 6.54
maintained, 6.6
monocular, 6.16
near, 6.64
in normal vision, 3.313–314
nystagmus and, 5.215, 5.240, 5.241*t*
for retinoscopy, 3.152
spasm of. *See* Ocular motor apraxia
steady, 6.6
uncentral, 6.6
unsteady, and unmaintained, 6.6
vestibular-ocular reflex suppression and, 5.225, 5.225*f*
in visual acuity assessment in children, 6.5–6
Fixation loss, in perimetry, 5.86
Fixation reflex, 6.300
Fixation switch diplopia, 5.209
Fixatives, for tissue preservation, 4.26, 4.26*t*
Fixed, dilated pupil, nonorganic causes of, 5.310
Fixed-combination medications, 2.397, 2.397*t*
FKHL7 gene. *See FOXC1 (FKHL7)* gene
FL. *See* Follicular lymphoma
Flagella, bacterial, 8.244
FLAIR (fluid-attenuated inversion recovery) images, 5.62, 5.63*t*, 5.65, 5.66*f*, 5.67*f*, 5.72*t*, 5.75, 7.28
in multiple sclerosis, 5.65, 5.66*f*, 5.316*f*, 5.319
FLAK. *See* Femtosecond laser-assisted keratoplasty
Flame hemorrhages, ischemia causing, 4.153, 4.155*f*
Flap(s)
advancement, 8.359, 8.359*f*
bipedicle, 8.359*f*, 8.359–360
conjunctival, 8.354*f*, 8.356–360, 8.357*f*, 8.358*f*, 8.359*f*
for bare sclera after pterygium excision, 8.353, 8.354*f*
cataract surgery and
for ECCE, 11.196
for ICCE, 11.199
leak causing inadvertent filtering bleb and, 11.130–131
for postoperative corneal edema, 11.129–130
for herpetic eye disease, 8.225
for neurotrophic keratopathy/persistent corneal epithelial defects, 8.82, 8.357
for peripheral ulcerative keratitis, 8.313
removal of, 8.360
for trabeculectomy, 10.200, 10.201*f*, 10.202*f*
closure of, 10.204, 10.206*f*
management of, 10.207–208
for trabeculotomy, in children, 10.161–162
Cutler-Beard, 7.221, 7.223*f*
epi-LASIK, 13.84
eyelid defects reconstructed using, 7.220
Gundersen, 8.357*f*, 8.357–358, 8.358*f*, 11.129
LASIK, 13.30, 13.73, 13.75*f*, 13.79, 13.82, 13.84–90
aberrations associated with creation of, 13.102–103, 13.103*f*
buttonhole, 13.110, 13.110*f*
corneal inlay insertion and, 13.60, 13.169
corneal transplantation and, 13.198
dislocation of, 13.113, 13.115–116
striae and, 13.113
traumatic, 13.115–116
femtosecond, 13.8*t*, 13.87–90, 13.88*f*, 13.89*f*, 13.90*t*
aberrations and, 13.102–103
advantages/disadvantages/complications of, 13.88, 13.90*t*, 13.122–124, 13.123*f*
re-treatment/enhancements and, 13.98
steep or flat corneas and, 13.44–45, 13.79
glaucoma/elevated intraocular pressure and, 13.181, 13.201
haze formation and, 13.33
immediate postablation care of, 13.92–93
infected, 13.107, 13.107*f*, 13.117–119
diffuse lamellar keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
microkeratome, 13.84–87, 13.85*f*, 13.86*f*, 13.87*f*
aberrations and, 13.102
complications associated with, 13.110*f*, 13.110–112, 13.111*f*
re-treatment/enhancements and, 13.98
penetrating keratoplasty and, 13.180
re-treatment/enhancements and, 13.98–99, 13.99*f*
retinal detachment repair and, 13.185, 13.197
steep or flat corneas and, 13.44–45, 13.79
striae in, 13.112–115, 13.114*t*, 13.115*f*
modified Hughes, 7.223–224*f*, 7.224
Mustardé, 7.224, 7.225*f*
scleral, for trabeculectomy, 10.200–201, 10.203*f*
closure of, 10.202–204, 10.205*f*
management of, 10.207–208
single pedicle, 8.359*f*, 8.359–360
Flap folds, after LASIK, 13.112–115, 13.114*t*, 13.115*f*. *See also* Striae
Flap tears, of retina, 12.315, 12.318–319
Flarex. *See* Fluorometholone

Flash visual evoked potential, 5.95
in nonorganic disorder evaluation, 5.302
Flashing lights. *See* Photopsias
Flat anterior chamber. *See* Anterior chamber, flat or shallow
Flat refracting surface, optics of, 3.44–45
Flattening
in myopia surgery, 13.26, 13.80
progressive, after radial keratotomy, 13.51
Flaviviridae, 12.247
Flavivirus, 1.265
Flecainide, 1.309*t*
Fleck corneal dystrophy (FCD), 8.135*t*, 8.136*t*, 8.153, 8.154*f*
Fleischer rings, 4.95*f*, 4.96, 6.254, 8.117, 8.118*t*, 8.163, 8.163*f*
Fleurettes
in retinoblastoma, 4.175, 4.175*f*
in retinocytoma, 4.178
FLEx. *See* Femtosecond lenticule extraction
Flexible contact lenses. *See* Soft (flexible) contact lenses
Flexible-loop anterior chamber intraocular lenses, 11.119, 11.120*f*
Flexible sigmoidoscopy, for colorectal cancer screening, 1.218–219
Flexivue Microlens, 13.169
Flexner-Wintersteiner rosettes, 6.353
in medulloepithelioma, 4.178*f*, 4.179
in primary intracranial pinealoblastoma, 4.298
in retinoblastoma, 4.174–175, 4.175*f*
FlexOptic intraocular lens, 13.170
Flicker-defined form (FDF) perimetry, 10.75, 10.76*f*
Flicker fusion threshold, 2.311
Floaters
description of, 12.344
in intermediate uveitis, 9.76
in posterior vitreous detachment, 12.308–309
in retinal tears, 5.175
in rhegmatogenous retinal detachment, 12.320
in toxocariasis, 12.244
in toxoplasmic retinochoroiditis, 12.243
vitrectomy for, 12.386
Flocculus, 5.34*f*
"Floor effect," 1.25
Floor of orbit. *See* Orbital floor
Floppy eyelid syndrome, 7.184–185, 7.185*f*, 8.79, 8.82–83, 8.83*f*
Floppy iris syndrome, intraoperative (IFIS), 2.384, 11.74, 11.136–138, 11.137*t*
pupil expansion devices for, 11.178
Flow cytometry, 4.34*t*, 4.36, 4.37*f*
Flow rate, in phacoemulsification, 11.102
vacuum rise time and, 11.102
Flowchart, 1.30, 1.31f
Flt-3L. *See* Fms-like tyrosine kinase 3 ligand
Flu. *See* Influenza virus
Flucaine. *See* Fluorescein sodium/proparacaine
Fluconazole, 2.429, 2.430*t*
for coccidioidomycosis, 9.302
for fungal keratitis, 8.275
for yeast endophthalmitis, 12.240
Flucytosine, 2.431, 2.431*t*
Fluence, 3.107*t*
Fluid-attenuated inversion recovery (FLAIR), 5.62, 5.63*t*, 5.65, 5.66*f*, 5.67*f*, 5.72*t*, 5.75, 7.28
in multiple sclerosis, 5.65, 5.66*f*, 5.316*f*, 5.319
Fluid-based phacolysis, 11.125
Fluidics, terminology used in, 11.102–103
FLuidVision intraocular lens, 13.170
Fluocinolone acetonide implant, 2.364, 2.403
for birdshot chorioretinopathy, 9.169
for multifocal choroiditis and panuveitis syndrome, 9.181
for sympathetic ophthalmia, 9.203
for uveitis
description of, 9.97–98
macular edema caused by, 9.322
Fluor-Op. *See* Fluorometholone
Fluoracaine. *See* Fluorescein sodium/proparacaine
Fluorescein, 2.362, 2.444, 8.36
absorption properties of, 3.301
angiography with. *See* Fluorescein angiography
for applanation tonometry, 10.22–23
accuracy and, 10.23–24
for aqueous deficiency diagnosis, 8.56
characteristics of, 12.33
for dye disappearance test, 8.36
for fluorophotometry, 10.17
intravenous administration of. *See* Fluorescein angiography
leakage of, 12.35
in ocular surface evaluation, 8.36–37, 8.37*f*, 8.38*f*
pooling of, 12.35, 12.36*f*
punctate staining patterns and, 8.36, 8.37*f*
rigid gas-permeable contact lens fitting evaluations using, 3.219*f*, 3.219–220
for tear breakup time testing, 8.36, 8.57*t*, 8.60
Fluorescein angiography (FA), 5.89, 5.89*f*
in AAION, 5.120, 5.120*t*
acute idiopathic maculopathy on, 12.228
in acute posterior multifocal placoid pigment epitheliopathy, 9.163*t*, 9.170, 9.171*f*, 12.221*f*, 12.222
in acute retinal pigment epitheliitis, 9.189, 9.189*f*
in acute zonal occult outer retinopathy, 9.163*t*, 9.191, 12.227
adult-onset vitelliform maculopathy on, 12.68
adverse effects of, 12.36
in age-related macular edema/melanoma differentiation, 4.269, 4.270*f*
angioid streaks on, 12.87, 12.89*f*
asteroid hyalosis on, 12.347
autofluorescence, 12.35
in Behçet disease, 9.216, 9.217*f*
Best disease on, 6.342, 6.343*f*
bilateral diffuse uveal melanocytic proliferation on, 12.205*f*
in birdshot chorioretinopathy/birdshot uveitis, 9.163*t*, 9.165–166, 9.166–167*f*, 12.224–225, 12.225*f*
blocked fluorescence in, 12.35
branch retinal artery occlusions on, 12.152*f*
in cataract surgery evaluation, 11.82, 11.188, 11.189
central retinal artery occlusion on, 12.144*f*
central retinal vein occlusion on, 12.130, 12.131*f*
central serous chorioretinopathy on, 12.190, 12.191*f*
in choroidal hemangioma, 4.281, 4.282*f*

in choroidal melanoma/ciliary body melanoma, 4.265
choroidal neovascularization on, 12.36, 12.37*f*, 12.72–73, 12.73–12.74*f*
in choroidal nevus, 4.257
choroidemia on, 12.268
in Coats disease, 4.295, 4.295*f*, 6.359, 6.359*f*, 12.160*f*
cystoid macular edema on, 12.36*f*, 12.157
in Dengue fever, 9.267
description of, 3.303
drusen on, 12.65
epiretinal membranes on, 12.335
familial exudative vitreoretinopathy on, 12.345*f*
fluorescein dye used in, 12.33
fovea in, 12.34
foveal avascular zone in, 12.9
fundus camera for, 3.301, 12.23, 12.36
in granulomatous necrotizing scleritis, 9.120*f*
hyperfluorescence in, 12.35
hypertensive choroidopathy findings, 12.123, 12.124*f*
illustration of, 12.34*f*
in intermediate uveitis, 9.148
in iris melanoma, 4.260–261
ischemic central retinal vein occlusion on, 12.132*f*
laser therapy for diabetic macular edema guided using, 12.115
in low vision evaluation, 5.89, 5.89*f*
lupus vasculitis on, 12.231*f*
in lymphoma, 4.311
macular telangiectasia type 2 on, 12.163, 12.163*f*
in metastatic eye disease, 4.306
in multifocal choroiditis and panuveitis syndrome, 9.163*t*, 9.179, 9.179*f*
in multiple evanescent white dot syndrome, 5.101, 9.163*t*, 9.185, 9.186*f*, 12.223–224
in NAION, 5.120*t*, 5.123*t*
narrow-band interference filters in, 3.103
nonischemic central retinal vein occlusion on, 12.130, 12.131*f*
in ocular ischemic syndrome, 9.310, 12.138, 12.139*f*
in optic nerve/nerve head/disc drusen *versus* papilledema, 5.142
in optic neuritis, 5.123*t*
optical coherence tomography angiography *versus*, 12.29
in pars planitis, 9.148
in pregnancy, 12.36
prepapillary vascular loops on, 12.341
in primary vitreoretinal lymphoma, 9.305
in punctate inner choroiditis, 9.163*t*, 9.182, 9.183*f*
radiation retinopathy on, 12.170, 12.170*f*
recirculation phase of, 12.34
retinal cavernous hemangioma on, 12.169*f*
in retinal disease, 12.33–38, 12.34*f*, 12.36–12.37*f*. *See also specific disease*
cavernous hemangioma, 4.286
hemangioblastoma, 4.284, 4.284*f*
retinal pigment epithelium cells on, 12.34
in serpiginous choroiditis, 9.163*t*, 9.175*f*
skin yellowing caused by, 12.36
Stargardt disease on, 12.269–270, 12.270*f*
in subretinal fibrosis and uveitis syndrome, 9.163*t*, 9.184
in sympathetic ophthalmia, 9.200, 9.201*f*
technique for, 12.33–34, 12.34*f*
in tubercular uveitis, 9.236, 9.237*f*
uveal effusion syndrome on, 12.204*f*
in uveitis, 9.88, 9.89*f*
vascular filling defects in, 12.35
vitreoretinal traction syndrome on, 12.337
in Vogt-Koyanagi-Harada disease/syndrome, 9.208–209, 9.209*f*, 12.232
in West Nile virus, 9.263, 9.264*f*
wide-angle, 12.36, 12.37*f*
Fluorescein sodium/benoxinate, 2.439*t*
Fluorescein sodium/proparacaine, 2.439*t*
Fluorescence, 3.111
Fluorescence in situ hybridization (FISH), 2.221–222, 4.38*t*
Fluorescent polymerase chain reaction, 2.239
Fluorescent treponemal antibody absorption (FTA-ABS) test, 1.253, 9.224–225, 12.241
Fluorexon, 8.36
5-Fluorocytosine. *See* Flucytosine
Fluorodeoxyglucose positron emission tomography (FDG-PET), in sarcoidosis, 5.328
Fluorometholone (FML)
description of, 2.400*t*, 2.402, 2.402*t*
elevated intraocular pressure after photoablation associated with, 13.182
for Thygeson superficial punctate keratitis, 8.307
Fluorometholone/sulfacetamide, 2.422*t*
Fluorophores, in fundus autofluorescence, 12.29
Fluorophotometry, 10.17
Fluoroquinolones, 2.420, 2.422–423
adverse effects of, 1.274
for bacterial conjunctivitis, 6.240
for bacterial keratitis, 8.269, 8.270*t*, 8.271
corneal deposits caused by, 8.131
description of, 1.274
for gonococcal conjunctivitis, 8.259
in neonates, 8.264
for gonococcal infections, 1.251
Fluorouracil/5-fluorouracil (5-FU)
bleb-associated endophthalmitis and, 10.209
description of, 2.359, 2.371*t*, 2.413–414
for ocular surface tumors, 8.327, 8.330*f*, 8.331
in trabeculectomy, 10.205–207
Fluoxetine, 1.308*t*
Fluphenazine, oculogyric crisis caused by, 5.231
Flurbiprofen sodium, 2.400*t*, 2.409*t*
Fluress. *See* Fluorescein sodium/benoxinate
Flurox. *See* Fluorescein sodium/benoxinate
Flutter
ocular, 5.243*t*, 5.248, 5.248*f*, 5.249
voluntary, 5.249–250, 5.309
Fluvastatin, 1.75*t*
"Flying spot" excimer lasers, 3.277
Flying spot lasers, for photoablation, 13.31
FML. *See* Fluorometholone
FML Forte Liquifilm. *See* Fluorometholone
FML Liquifilm. *See* Fluorometholone
FML-S. *See* Fluorometholone/sulfacetamide
FML S.O.P. *See* Fluorometholone
FMN/FMNS. *See* Fusion/fusional maldevelopment nystagmus syndrome
fMRI. *See* Functional magnetic resonance imaging

Fms-like tyrosine kinase 3 ligand (Flt-3L), 1.167
FNAB. *See* Fine-needle aspiration biopsy
Foam cells, 1.81
Focal chorioretinitis, 12.238, 12.238*f*
Focal illumination, for slit-lamp biomicroscopy, 8.17, 8.18*f*
Focal intraretinal periarteriolar transudates (FIPTs), 12.121–122, 12.122*f*
Focal length, 3.3, 3.8
Focal line, 3.76*f*
  in astigmatism, 3.137, 3.160
Focal macular edema, 12.110, 12.111*f*
Focal point
  posterior, 3.140
  refractive states and, 3.136
  secondary, 3.170
  "virtual," 3.11, 3.11*f*
Focal stromal infiltrates, 8.50
Focimeter. *See* Lensmeter
Fogging
  description of, 3.286
  for nonorganic disorder evaluation
    monocular no light perception and, 5.303, 5.304*f*
    monocular reduced vision and, 5.305
  for retinoscopy, 3.152, 3.160–161
Folate/folic acid
  deficiency of
    anemia caused by, 1.133–134
    causes of, 1.134
    optic neuropathy caused by, 5.138
    vitamin B_{12} deficiency *versus*, 1.134
  supplementation of, in methotrexate therapy, 6.322
Foldable intraocular lenses, 11.116, 11.120, 11.120*f*, 11.121*f*
  insertion of, 11.116
  posterior chamber phakic, 13.138
Folic acid. *See* Folate/folic acid
Follicles, conjunctival, 8.46*t*, 8.47*t*, 8.48–49, 8.49*f*
  in chlamydial conjunctivitis/trachoma, 8.261, 8.262, 8.263
Follicular carcinoma, 1.46
Follicular conjunctivitis, 4.50*f*, 4.50–51, 4.51*f*, 6.241, 6.243, 7.94, 7.190, 7.190*f*, 8.47*t*, 8.48–49, 8.49*f*
  in acute hemorrhagic conjunctivitis, 8.240
  adenoviral, 4.52, 8.233, 8.234
  Epstein-Barr virus causing, 8.230–231
  in influenza, 8.240*t*
  in measles, 8.239, 8.240*t*
  in mumps, 8.240, 8.240*t*
  rhinovirus causing, 8.240*t*
  RNA viruses causing, 8.239
  toxic, 8.90*t*, 8.90*f*, 8.91
  varicella-zoster virus causing, 8.225, 8.226
Follicular keratosis, 7.188, 7.188*f*
  inverted, 4.209, 4.210*f*
Follicular lymphoma (FL), 7.92, 7.95
Folliculosis, benign lymphoid, 8.48, 8.49*f*
Followability, in phacoemulsification, 11.102
Fondaparinux, 1.149
Fontanelles, 6.204*f*
Food, Drug, and Cosmetic Act (FDCA), 2.372
Food and Drug Administration (FDA)
  description of, 2.370
  expiration dates on biologics, 2.372
Foot-pedal controls, phaco machine, 11.99
Footplates of Müller cells, 12.15, 12.15*f*
Foramen (foramina)
  ethmoidal, anterior/posterior, 5.11
  lacerum, 5.6*f*
  magnum, 5.5
  optic, 5.7*f*
  orbital, 2.10–11
  ovale, 5.6*f*
  rotundum, 2.106*f*, 5.6*f*, 5.11, 7.7*f*
  spinosum, 5.6*f*
  supraorbital, 5.9*f*
  zygomaticotemporal, 5.11
Forced duction test (traction test), 7.114
  for Brown syndrome, 6.137
  for consecutive esotropia, 6.95
  description of, 6.73
  in diplopia, 5.186, 5.186*f*
  for orbital floor fractures, 6.379
Forced expiratory volume over 1 second (FEV_1), 1.126
Forced expiratory volume over 1 second/forced vital capacity (FEV_1/FVC) ratio, 1.126
Forced vital capacity (FVC), 1.126
Forehead rejuvenation, 7.271
Foreheadplasty, 7.265
Foreign bodies
  aluminum, 12.362
  chalcosis secondary to, 12.362
  composition of, 12.362
  conjunctival, 4.52, 4.53*f*, 8.397, 8.397*f*, 8.398*f*
    insect stingers/hairs, 8.386–387
    radioactive, 8.386
  copper, 12.362
  corneal, 6.376, 8.399–400, 8.400*f*, 8.401*f*, 8.403
    insect stingers/hairs, 8.386–387
    iron, 8.118*t*, 8.399
    plant/vegetation, 8.387, 8.399
    radioactive, 8.386
    removal of, 8.403
  evaluation of, 12.351
  imaging of, 12.352–353, 12.360, 12.361*f*
  intralenticular, 11.57
  intraocular (IOFBs), 9.311
  intraorbital, 7.117–118, 7.118*f*
  of iris, 4.259
  iron, 12.362
  magnetic resonance imaging of, 12.353
  migration of, 12.362
  neuroimaging in evaluation of, 5.72*t*
  ocular reaction to, 12.362
  penetrating and perforating trauma and, 8.396, 8.397, 8.397*f*, 8.398*f*, 8.399–400, 8.400*f*, 8.401*f*, 8.403. *See also* Penetrating and perforating ocular trauma
    removal and, 8.408
  plain-film x-ray studies of, 12.352–353
  retained, 12.362
    cataract surgery and, 11.191
    glaucoma and, 10.32, 10.103
    siderosis and, 4.120, 11.58*f*, 11.58–59

siderosis bulbi secondary to, 12.362, 12.363*t*
surgical removal of, 12.360–362
zinc as, 12.362
Foreign body giant cells, 4.7, 4.9*f*
Foreign-body granuloma, 6.170
Foreign-body sensation, in corneal abrasion, 8.398
Forkhead genes/forkhead transcription factor
Axenfeld-Rieger syndrome and, 8.97*t*, 8.102, 10.150
glaucoma and, 10.150
in Peters anomaly, 8.97*t*, 8.103
Form-deprivation errors, 12.216
Form-vision deprivation amblyopia, 6.55. *See also* Visual deprivation, amblyopia
Formalin, as tissue fixative, 4.26, 4.26*t*
Forme fruste (subclinical keratoconus), 8.166, 13.124. *See also* Keratoconus
refractive surgery contraindicated in, 13.23, 13.25–26, 13.79, 13.124
LASIK, 13.79, 13.124, 13.175*f*, 13.175–176, 13.177*f*
topography in detection and, 8.31, 8.166, 13.23, 13.25–26, 13.79, 13.175*f*, 13.175–176, 13.177*f*
Formed elements. *See* Blood cells
Formed hallucinations, 5.158, 5.175, 5.176. *See also* Hallucinations
Formoterol, 1.128
Forniceal conjunctiva, 4.47, 4.48*f*, 8.6. *See also* Conjunctiva; Fornices
lymphoid lesions involving, 4.69, 4.70*f*
Fornices, 4.47, 4.48*f*, 8.6, 8.7
lymphoid lesions involving, 4.69, 4.70*f*
in mucous membrane pemphigoid, 8.285, 8.299–300, 8.300*f*, 8.302, 8.302*t*, 8.303
reconstruction of, for mucous membrane pemphigoid, 8.303
sterilization of, during cataract surgery, 11.94
Fornix-based conjunctival flap, for trabeculectomy, 10.200, 10.201*f*
closure of, 10.204, 10.206*f*
in elderly patients, 10.221
Fornix incision, 6.162–163
Fortification spectrum, in migraine, 5.162
Foscarnet
acute retinal necrosis treated with, 12.236
for cytomegalovirus retinitis, 9.256, 12.235, 12.238*t*
description of, 2.360*t*, 2.432*t*, 2.436
for herpes simplex virus, 1.260, 9.252
progressive outer retinal necrosis syndrome treated with, 12.236
Foscavir. *See* Foscarnet
Fossae
anterior cranial, 5.6*f*, 5.8, 5.10*f*
lacrimal/lacrimal gland, 5.7*f*, 5.9*f*, 7.6, 7.7*f*
middle cranial, 5.6*f*, 5.10*f*, 5.11
neuroimaging in evaluation of, 5.72*t*
pituitary, 5.6*f*, 7.8*f*
posterior cranial, 5.6*f*
neuroimaging in evaluation of, 5.72*t*
pterygopalatine, 5.12, 7.8, 7.8*f*, 7.10
temporal, 5.8, 5.10*f*
Fostamatinib, 1.141
Foster-Kennedy/pseudo-Foster-Kennedy syndrome, 5.122
Foster modification, 6.167
Foster staging system, for mucous membrane pemphigoid, 8.299–300, 8.300*f*, 8.302, 8.302*t*
4Δ base-out prism test, 6.78*f*, 6.78–79
Four-E Model of Health Care Communication, 3.326*f*
454 next-generation sequencing method. *See* Next-generation sequencing
4:2:1 rule, for diabetic retinopathy, 12.99
Fourier analysis, 13.10
Fourier-domain optical coherence tomography (FD-OCT), 3.304–305, 8.22, 10.54
Fourth cranial nerve. *See* Cranial nerve IV
Fourth-generation cephalosporins, 2.419
Fourth nerve (trochlear) palsy, 5.185–186, 5.188–189, 5.198–200, 5.199*f*, 6.140
description of, 2.475*t*, 6.140
diplopia and, 5.185–186, 5.188–189, 5.198–200, 5.199*f*
isolated, 5.199, 5.200
in multiple sclerosis, 5.318
skew deviation differentiated from, 5.198–199, 5.216
Fourth-order aberrations, 13.12, 13.12*f*
Fourth-order wavefront aberrations, 3.276*f*
Fovea (fovea centralis), 3.314*f*, 4.140, 5.24
anatomy of, 2.83, 12.9, 12.9*f*
characteristics of, 12.10*t*
cone density in, 6.44
cones in, 12.11
definition of, 2.94
description of, 12.9, 12.9*f*
development of, 6.44
fluorescein angiography of, 12.34
hypoplasia of, 6.154, 6.338, 6.406
nystagmus associated with, 5.236
inner cellular layers in, 12.12*f*
in metabolic disorders. *See* Cherry-red spot
optical coherence tomography of, 2.96*f*
parafovea, 2.85
perifovea, 2.97
photocoagulation-related burns of, 12.378
retinoschisis, 6.344
schematic section of, 2.93*f*
Fovea ethmoidalis, 2.14, 2.14*f*
Foveal avascular zone (FAZ), 2.95, 2.97*f*
definition of, 12.9
optical coherence tomography angiography of, 12.77*f*
Foveal center, rods in, 12.11
Foveal cones, 2.87
Foveal displacement syndrome, diplopia caused by, 5.209
Foveal-sparing scotomas, 3.314, 3.315*f*
Foveation periods, 5.234
Foveola, 4.140, 4.141*f*
anatomy of, 12.9, 12.9*f*, 12.11
borders of, 2.94
characteristics of, 12.10*t*
definition of, 2.94
photoreceptor layer of, 2.95
Foveomacular retinitis. *See* Solar retinopathy
Foveomacular vitelliform dystrophy, adult-onset (AFMVD), 4.170, 4.171*f*, 12.272, 12.276
Foville syndrome, 5.192
FOXC1 (FKHL7) gene, 2.187, 6.265
in Axenfeld-Rieger syndrome, 8.97*t*, 8.102, 10.150

in glaucoma, 10.11*t*
in Peters anomaly, 8.97*t*, 8.103, 10.150, 11.32
FOXE3 gene
in congenital aphakia, 4.117
in Peters anomaly, 8.97*t*, 8.103
FOXL2 gene, 6.197, 7.173
FOXO1 gene, in orbital rhabdomyosarcoma, 4.236
FOXO1A gene, in Axenfeld-Rieger syndrome, 8.97*t*
FPG. *See* Fasting plasma glucose
Fractionated stereotactic radiotherapy, for optic nerve sheath meningioma, 7.86
Fractures. *See also specific type or structure affected*
blowout, 6.379. *See also* Blowout (indirect) fractures
orbital floor, 6.127–128, 6.128*f*, 6.379–380, 6.380*f*
orbital roof, 6.380, 6.380*f*
osteoporotic, 1.190
Francisella tularensis, 6.240
François-Neetens speckled corneal dystrophy (Fleck corneal dystrophy/FCD), 8.135*t*, 8.136*t*, 8.153, 8.154*f*
Fraser syndrome, 6.193
eyelid manifestations of, 4.207*t*
Freckle, 4.219. *See also* Ephelis
iris, 4.259, 4.260*f*
ocular surface, 8.338*t*
Free cap formation, in LASIK, 13.111, 13.111*f*
Free iron, 2.339
Free radicals (oxygen radicals), lens damage and, 11.19–20
Free tarsoconjunctival graft and skin flap, for lower eyelid defects, 7.223*f*
Freezing, anterior segment injuries caused by, 8.385
Frenzel goggles, in nystagmus assessment, 5.234
Frequency
of light, 3.93
in phacoemulsification, 11.99
Frequency-domain optical coherence tomography (FD-OCT), 3.304, 8.22
Frequency-doubling technology (FDT) perimetry, 10.75
in glaucoma suspect screening, 10.89
Fresnel prisms. *See also* Prism(s)
advantages of, 3.197
description of, 3.49, 3.49*f*
induced anisophoria correction using, 3.188
Press-On, 3.49
Frisby Davis Distance Stereotest, 6.81
FRMD7 gene, 6.149, 6.153
Frontal artery, 5.14
Frontal bone
anatomy of, 2.6–7*f*, 2.9–10*f*, 5.5, 5.7, 5.7*f*, 5.9*f*, 7.7–8*f*
pneumatization of, 7.19
Frontal branch of facial nerve. *See* Temporal nerve
Frontal ethmoidal suture, 5.8
Frontal eye fields (FEFs), 5.32*f*, 5.33, 5.34*f*, 5.37*f*
saccadic control and, 5.219, 5.220
seizures/tonic deviations and, 5.230
Frontal gyri, 5.32*f*
Frontal lobe, 5.24*f*
Frontal nerve, 2.12*f*, 2.131, 5.8*f*, 5.43*f*, 5.48, 5.48*f*, 7.14
lacrimal functional unit innervated by, 8.5*f*
Frontal pontine pathway, 5.34*f*
Frontal sinus
anatomy of, 7.8*f*, 7.19*f*
description of, 5.8, 5.10*f*
development of, 7.19
Frontalis muscle, 2.28*f*, 2.31*f*, 7.152*f*, 7.153, 7.154*f*
Frontalis suspension
description of, 7.145, 7.250, 7.251*f*
for eyelid ptosis, 6.197
Frontoethmoidal suture, 2.6*f*, 2.9*f*, 5.9*f*, 7.7
Frontosphenoid suture, 2.10*f*, 5.9*f*
Frontotemporal-orbitozygomatic (FTOZ) approach, 7.132
Frontozygomatic suture, 2.10, 2.10*f*, 5.7, 5.9*f*, 7.6, 7.7*f*, 7.40, 7.40*f*
Frost suture, 8.372, 8.372*f*
"Frosted-branch" angiitis, 9.254, 9.255*f*, 9.304
Frozen section, for pathologic examination, 4.34*t*, 4.43–45, 4.44*f*
Frozen section analysis, 7.33
FTA-ABS. *See* Fluorescent treponemal antibody absorption (FTA-ABS) test
FTOZ approach. *See* Frontotemporal-orbitozygomatic (FTOZ) approach
5-FU. *See* Fluorouracil/5-fluorouracil
FUCA1 gene, in fucosidosis, 8.179
Fuchs adenoma (pseudoadenomatous hyperplasia), 4.179, 4.279
Fuchs endothelial corneal dystrophy (FECD), 2.54, 4.92, 4.93*f*, 8.23*f*, 8.135*t*, 8.136*t*, 8.156–158, 8.157*f*
descemetorrhexis/DMET for, 8.157–158, 8.449
IOL implantation and, 11.149, 13.155
refractive surgery and, 13.43, 13.178
multifocal IOL implantation, 13.155
Fuchs heterochromic uveitis (FHU/Fuchs heterochromic iridocyclitis/Fuchs uveitis syndrome)
cataracts/cataract surgery and, 11.64*f*, 11.64–65
description of, 9.145–146, 9.146*f*
glaucoma and, 10.101–102, 10.102*f*
Goldmann-Witmer coefficient for, 9.41–42
keratic precipitates in, 9.248
medical management of, 9.93
Fuchs superficial marginal keratitis, 8.123
Fucosidosis, 6.388*t*, 8.179
Full-field (Ganzfeld) electroretinogram/electroretinography, 5.96
ABCA4 retinopathy findings, 12.48*f*
in cone dystrophies, 5.102, 12.265
cone–rod dystrophies, 12.265
description of, 12.42–45, 12.43*f*
in melanoma-associated retinopathy, 5.102–103
mixed rod-cone, 12.43
in multiple evanescent white dot syndrome, 5.101
normal response in, 12.43*f*, 12.44
photoptic flicker, 12.44
photoptic single-flash, 12.44
quinine toxicity on, 12.302*f*
rod-specific, 12.42
Full-thickness pentagonal resection, for trichiasis, 7.240
Full-thickness skin grafts
for medial canthal defects, 7.226, 7.227*f*
for upper eyelid defects, 7.220, 7.221*f*
Full-time occlusion
amblyopia treated with, 6.58
reverse amblyopia caused by, 6.60

Fumagillin, for microsporidial keratoconjunctivitis, 8.280
Functional imaging, 5.70
Functional magnetic resonance imaging (fMRI), 5.70, 5.75
Functional vision loss. *See* Nonorganic (functional/nonphysiologic) ophthalmic disorders
Fundus
  arteriolar narrowing of, 12.261
  color photograph of, 12.23, 12.23*f*
  evaluation of, 8.19. *See also* Fundus autofluorescence; Fundus photography; Ophthalmoscopy/ophthalmoscope; Slit-lamp biomicroscopy/examination
    before cataract surgery, 11.80–81
    in choroidal melanoma/ciliary body melanoma, 4.263*f*, 4.265
    in conjunctival neoplasia, 8.328
    in glaucoma, 10.32
    in infants and children, 10.160
    in ischemic optic neuropathy, 5.120, 5.121*f*
    in low vision evaluation, 5.81–82, 5.82*f*, 5.83*f*
    in ocular ischemic syndrome, 5.170, 5.171*f*
    in optic neuropathy *versus* maculopathy, 5.100, 5.100*t*
    before refractive surgery, 13.44
  examination of, in children, 6.12
  Leber congenital amaurosis findings, 6.336, 6.337*f*
  in Leber hereditary optic neuropathy, 5.133, 5.134*f*
  in multiple sclerosis, 5.318
  ocular, 3.296
  ocular torticollis findings, 6.84
  optic disc drusen evaluations, 6.374
  primary congenital glaucoma–related findings, 6.284
  relative depth of, 3.64
  retinitis pigmentosa findings, 12.261, 12.262*f*
  "sunset glow" appearance of, 12.232*f*, 12.232–233
  tomato ketchup, 4.281, 4.283*f*
Fundus albipunctatus, 12.252, 12.253*f*
Fundus autofluorescence (FAF), 2.330*f*, 5.89–90, 5.90*f*
  in acute posterior multifocal placoid pigment epitheliopathy, 9.163*t*, 9.171, 9.172*f*
  in acute retinal pigment epitheliitis, 9.189
  in acute zonal occult outer retinopathy, 5.90, 9.163*t*, 9.191, 9.192*f*
  Best disease on, 6.343*f*
  in birdshot chorioretinopathy, 9.163*t*, 9.166, 9.167*f*
  in choroidal melanoma/ciliary body melanoma, 4.265, 4.266*f*
  in cone dystrophies, 5.102
  definition of, 12.29
  description of, 12.23*f*
  drusen demonstrating, 5.89, 5.90*f*, 5.141*f*, 5.142
  fluorophores, 12.29
  Gardner syndrome on, 6.350*f*
  hyperspectral, 12.33
  in low vision evaluation, 5.89–90, 5.90*f*
  in multifocal choroiditis and panuveitis syndrome, 9.163*t*, 9.179, 9.180*f*, 9.186–187*f*
  in multiple evanescent white dot syndrome, 9.163*t*, 9.186*f*
  near-infrared, 12.32–33
  optic disc drusen on, 6.373*f*, 6.374
  in punctate inner choroiditis, 9.163*t*
  retinal disease evaluations, 12.29, 12.31–33
  retinal pigment epithelium tears on, 12.31, 12.32*f*
  in serpiginous choroiditis, 9.163*t*, 9.176*f*
  Stargardt disease on, 6.340, 12.270
  in subretinal fibrosis and uveitis syndrome, 9.163*t*
  in uveitis evaluations, 9.89
Fundus biomicroscopy. *See* Slit-lamp biomicroscopy/examination
Fundus camera, 3.301
  disadvantages of, 12.23
  flash illumination used by, 12.23
  for fluorescein angiography, 12.23, 12.36
  for indocyanine green angiography, 12.23
  operating principles of, 12.22–23
  retinal disease evaluations using, 12.22–23, 12.23*f*
Fundus coloboma, 2.470*f*
Fundus flavimaculatus (Stargardt disease/juvenile macular degeneration), 4.168–169*f*, 4.168–170, 6.339, 12.269. *See also* Stargardt disease
  ATP-binding cassette (ABC) transporter protein mutations causing, 4.168–169
  description of, 12.44
  electroretinography findings in, 12.48*f*
  retinal pigment epithelium in, 4.168–169*f*, 4.169–170
Fundus oculi, 2.83
Fundus photography
  in choroidal melanoma/ciliary body melanoma, 4.263*f*, 4.265
  exudative retinal detachment on, 12.325*f*
  lattice degeneration on, 12.310–12.311*f*
  retinopathy of prematurity screening uses of, 12.184
Fundus pulverlentus, 12.276–277
Fundus-related perimetry, 3.317
Fungal cell wall, 8.249
Fungal endophthalmitis, 12.239, 12.239*f*
  Aspergillus as cause of, 9.300–301
  Candida, 9.295–299, 9.296*f*, 9.299*f*
  coccidioidomycosis as cause of, 9.301–302
  cryptococcosis as cause of, 9.299–300
  endogenous, 9.295–302, 9.296*f*, 9.298*f*, 9.300*f*
  manifestations of, 9.295
  "string of pearls" in, 9.296*f*
Fungal infections
  antifungal agents for, 1.277, 1.278*t*
  description of, 1.258
Fungal orbital cellulitis, 6.215
Fungal uveitis
  ocular histoplasmosis syndrome, 9.272–275, 9.273–274*f*
  polymerase chain reaction for, 9.90
Fungemia, 12.239
Fungi, 8.208*t*, 8.249*t*, 8.249–251. *See also specific organism or type of infection*
  allergic sinusitis caused by, orbital involvement and, 4.228
  chorioretinitis caused by, 4.147, 4.147*f*
  eyelid infections caused by, 8.254–255, 8.255*f*
  isolation techniques for identification of, 8.211
  keratitis caused by, 4.78, 4.78*f*, 8.208*t*, 8.273–276, 8.274*f*
    after photoablation, 13.106–107

plant/vegetable materials and, 4.78, 8.273, 8.387, 8.399
as normal flora, 8.206*t*
ocular infection caused by, 8.208*t*, 8.249–251, 8.254–255, 8.255*f*, 8.282–283
corneal opacity and, 8.16*f*
neuro-ophthalmic signs of, 5.353–356, 5.354*f*, 5.355*f*
optic nerve infection caused by, 4.243*f*, 4.243–244
orbital infection caused by, 4.226–228, 4.228*f*
aspergillosis, 4.227–228, 4.228*f*
mucormycosis/zygomycosis/phycomycosis, 4.226–227, 4.228*f*
retinal infection caused by, 4.146–147, 4.147*f*
scleritis caused by, 8.282–283
stains and culture media for identification of, 8.209*t*, 8.275
Fungizone. *See* Amphotericin B
Fungus ball (aspergilloma), 5.353
Furosemide, for idiopathic intracranial hypertension, 5.112
Furrow degeneration, senile, 8.122
Fusarium, 8.207, 8.208*t*, 8.249*t*, 8.251
endophthalmitis, 12.239
keratitis caused by, 4.78, 4.78*f*, 8.208*t*, 8.251, 8.273–274, 8.274*f*, 8.275
oxysporum, 8.251
solani, 8.251, 8.274*f*, 8.275
Fusiform dendritic cells, in choroidal/ciliary body nevus, 4.191
Fusion
binocular, 6.60, 6.91
central, 6.42
in cyclic strabismus, 6.93
definition of, 6.42
motor, 6.43
peripheral, 6.51–52
sensory, 6.43
stereopsis, 6.43
Fusion/fusional maldevelopment nystagmus syndrome (FMN/FMNS/latent/manifest latent nystagmus/LN/MLN), 5.237–238, 6.83, 6.88, 6.95, 6.129, 6.148, 6.150–151, 6.151*f*, 6.154
Fusion/fusional vergence
description of, 5.226, 6.72, 6.72*t*
stereopsis. *See* Stereopsis
Fusional convergence, 5.226, 6.39, 6.43, 6.72
Fusional cyclovergence, 6.40
Fusional divergence, 6.40, 6.72
Fusional vertical divergence, 6.40
FVC. *See* Forced vital capacity

G

G-W adaptometer. *See* Goldmann-Weekers (G-W) adaptometer
G6P. *See* Glucose-6-phosphate
G6PD deficiency. *See* Glucose-6-phosphate dehydrogenase (G6PD) deficiency
G_0 phase, 2.174, 2.176
G_1 phase, 2.175
G_2 phase, 2.175–176
G protein α-subunit *(GNAQ/GNA11)* genes
in nevus of Ota, 4.64
in uveal melanoma, 4.197
GA. *See* Geographic atrophy
GABA (gamma [γ]-aminobutyric acid) agonists, for nystagmus, 5.245, 5.246
Gabapentin
for nystagmus, 5.236, 5.245, 5.246
for postherpetic neuralgia, 8.230
GAD. *See* Generalized anxiety disorder; Glutamic acid decarboxylase
Gadolinium, 5.60, 5.75
description of, 2.458
in MR angiography, 5.68
in multiple sclerosis imaging, 5.316*f*, 5.319
T1-weighted magnetic resonance imaging enhanced with, 7.28, 7.28*f*
GAGs. *See* Glycosaminoglycans
Gail model, 1.217
Gain/gain adjustment (eye movement), 5.39–40
pursuit system and, 5.224, 5.225
vestibular-ocular reflex (VOR), 5.215–216
in toxic vestibular dysfunction, 5.243
Gal-1-PUT (galactose-1-phosphate uridyltransferase), defective/deficiency of, in galactosemia, 11.61
Galactitol (dulcitol), in cataract formation, 11.61
Galactokinase
defective/deficiency of, 2.204*t*
galactosemia/cataract formation and, 11.61
description of, 2.289
Galactose, in cataract formation, 11.61
Galactose-6-sulfatase deficiency, in Morquio syndrome, 8.175*t*
Galactose-1-phosphate uridyltransferase (Gal-1-PUT), defective/deficiency of, in galactosemia, 11.61
Galactosemia, 6.389*t*, 11.61
cataracts in, 11.61, 11.61*f*
description of, 2.203, 2.204*t*, 2.289
dietary therapy for, 11.61
galactose-free diet for, 2.235
Galactosialidoses, 6.389*t*, 8.179
Galen, vein of, 5.22
Galilean telescopes, 3.40, 3.83–84, 3.84*f*, 3.140, 3.166, 3.255, 3.292, 3.298, 3.322
Galilei system, 3.248
Gallamine, 2.382
Gallium scanning, in sarcoidosis, 5.328
Gametes, 2.215
Gamma (γ)-aminobutyric acid (GABA) agonists, for nystagmus, 5.245, 5.246
Gamma (γ)-crystallins, 11.16
Gamma knife technique, 5.357
Gammopathy, benign monoclonal, crystalline corneal deposits in, 8.198
Ganciclovir, 8.215*t*
acute retinal necrosis treated with, 12.236
for cytomegalovirus
anterior segment, 8.232
description of, 9.256
retinitis, 12.235, 12.238*t*
description of, 2.360*t*, 2.432*t*, 2.434–435
for Epstein-Barr virus, 1.261
for herpes simplex virus, 8.215*t*, 8.219, 9.252

progressive outer retinal necrosis syndrome treated with, 12.236
Ganfort. *See* Bimatoprost/timolol maleate
Ganglion-blocking drugs, 2.383*t*
Ganglion cell complex (GCC), OCT in evaluation of, 5.92, 10.54
Ganglion cell layer with the inner plexiform layer (GCIPL), spectral domain-OCT in evaluation of, 10.54
Ganglion cells/ganglion cell layer (GCL), 2.92
anatomy of, 12.15
axons of, 2.87
bipolar cells and, 12.13
description of, 2.317
drug toxicity affecting, 12.301
histology of, 12.11, 12.12*f*
quinine effects on, 12.301
retinal, 4.140*f*, 4.141*f*, 5.24, 5.25*f*, 5.26. *See also* Retinal ganglion cells
in optic nerve, 5.103, 5.104*f*, 10.41–42
in optic neuropathy, glaucomatous, 10.46–47
in optic nerve head pallor, 5.81
ratio of, to photoreceptors, 5.24
spectral domain-OCT in evaluation of, 10.54–56, 10.55*f*, 10.56*f*
superficial vascular plexus in, 12.16
Ganglioneuromas, 1.50
Gangliosidoses, 6.388–389*t*, 8.176–178. *See also specific type under GM*
Ganzfeld bowl, 12.42
Ganzfeld ERG. *See* Full-field (Ganzfeld) electroretinogram/electroretinography
Gap junctions, in lens, 11.20
Garamycin. *See* Gentamicin
Gardner syndrome (familial adenomatous polyposis/FAP). *See also* Familial adenomatous polyposis
description of, 6.349, 6.350*f*
retinal manifestations of, 4.144–145, 4.269, 12.285–286
Gas-permeable contact lenses. *See* Rigid gas-permeable (RGP) contact lenses; Scleral contact lenses; Soft (flexible) contact lenses
Gas-permeable scleral contact lenses, 3.226–227
Gasserian ganglion (semilunar/trigeminal ganglion), 2.131, 5.42*f*, 5.48, 5.48*f*
herpes simplex/varicella zoster virus latency and, 8.205, 8.207, 8.212, 8.213, 8.226
Gastric bypass surgery, for weight loss, in idiopathic intracranial hypertension, 5.112
Gastric cancer, 1.219
Gastrinomas, 1.50
Gastroenteritis, 1.230
Gastroesophageal reflux disease (GERD), 1.219
Gastrointestinal cancer screening, 1.219–220
Gastrointestinal carcinoma, metastatic eye disease and, 4.304*t*
Gastrointestinal diseases, retinal degeneration associated with, 12.285–286
Gastrulation, 2.143–144
GAT. *See* Goldmann applanation tonometry
GATA3 transcription factor, 9.32
Gatifloxacin, 2.421*t*
for bacterial keratitis, 8.269, 8.270*t*
Gaucher disease, 6.388*t*, 12.291
Gaussian optics, 3.40, 3.60, 3.66
Gaussian reduction formulas, 3.243
Gaze. *See also* Ocular motility
cardinal positions of, 6.31, 6.32*f*, 6.35, 6.64
direction of, 6.147
downgaze, 6.38
horizontal, 5.37*f*, 5.37–38
left, 6.37
positions of, 6.31
cardinal, 6.31, 6.32*f*, 6.35, 6.64
definition of, 6.64
diagnostic, 6.64
extraocular muscle action and, 5.46, 5.46*f*, 6.34–37
field of action, 6.33
nystagmus affected by, 5.240–241
ocular alignment assessment using, 6.64
primary, 6.31, 6.64
secondary diagnostic, 6.31
for strabismus, 6.64
tertiary diagnostic, 6.31
for vertical strabismus, 6.64
right, 6.37
upgaze, 6.37
vertical, 5.36, 5.36*f*, 5.36–37
Gaze deviations
description of, 1.208
seizure activity and, 5.230
Gaze-evoked nystagmus, 5.38, 5.222, 5.234*f*, 5.240–241. *See also* Nystagmus
in internuclear ophthalmoplegia, 5.189, 5.190*f*
rebound, 5.240–241
substance abuse as cause of, 1.199
Gaze-evoked transient visual loss, 5.164
Gaze palsy, 5.228–230, 5.229*f*, 5.230*f*
in ataxia-telangiectasia, 5.334*t*
horizontal, 5.228
in one-and-a-half syndrome, 5.191
in sixth nerve palsy, 5.189, 5.200, 5.200*f*
ipsilateral, 5.41, 5.200, 5.200*f*
in multiple sclerosis, 5.318
nonorganic, 5.309
in sarcoidosis, 5.327
vertical, 5.228
Gaze preference, 5.228
GBD. *See* Global Burden of Disease Study
GCA. *See* Giant cell arteritis
GCC. *See* Ganglion cell complex
GCD1. *See* Granular corneal dystrophy, type 1
GCD2. *See* Granular corneal dystrophy, type 2
GCIPL. *See* Ganglion cell layer with the inner plexiform layer
GCL. *See* Ganglion cells/ganglion cell layer
GDLD. *See* Gelatinous droplike corneal dystrophy
GDx. *See* Scanning laser polarimetry/polarimeter
Gel-forming drops, for drug delivery, 2.366
Gelatinase, 2.294
Gelatinous droplike corneal dystrophy (GDLD/primary familial amyloidosis), 8.135*t*, 8.136*t*, 8.140–141, 8.141*f*, 8.185–187, 8.186*t*
Gelsolin gene mutation
amyloidosis/amyloid deposits (Meretoja syndrome) and, 4.206, 8.186*t*, 8.187, 8.188*f*
lattice corneal dystrophy and, 4.206

Gelsolin (Finnish) type familial amyloidosis (Meretoja syndrome), 4.206, 8.186*t*, 8.187, 8.188*f*
Gender, in glaucoma, 10.9, 10.121
Gene(s)
cancer, 2.183–184
definition of, 2.176, 2.213
disease association for, 2.187–188
expression of. *See* Gene transcription and translation; Genetic/hereditary factors; Genetics
independent assortment of, 2.216–217
linkage studies of, 2.187
recessive, 2.202
segregation of, 2.215–216
size variations among, 2.213
structure of, 2.176–177
word origin of, 2.213
Gene assignments, 2.187–188
Gene dosage, 2.187
Gene expression profile, 4.40
in choroidal/ciliary body melanoma, 4.197
Gene mapping, 2.188
Gene therapy
adeno-associated virus vectors, 2.194, 2.196
for choroidemia, 12.268
dominant diseases treated with, 2.197–198
genetic diseases treated with, 2.236
for Leber congenital amaurosis, 6.337, 12.266
replacement of absent gene product in X-linked and recessive diseases, 2.194, 2.196
retinal, 9.58
for retinal dystrophies, 12.260, 12.266
Stargardt disease treated with, 6.340
Gene transcription and translation
definition of, 2.179
overview of, 2.178–179
General anesthesia, 1.289–290, 6.174, 12.50. *See also* Anesthesia
for cataract surgery, 11.92
in arthritis, 11.171
in claustrophobia, 11.169
in patient unable to communicate, 11.170
for penetrating and perforating trauma repair, 8.403
Generalized anxiety disorder (GAD), 1.197
Generalized gangliosidosis (GM_1 gangliosidosis type I), 8.176
Generalized seizures, 1.207
Generalized tonic-clonic seizures, 1.207
Generic drugs, antiglaucoma, 10.186
Genetic, 2.210–211
Genetic counseling. *See* Genetic testing/counseling
Genetic diseases and disorders. *See also specific disease or disorder*
chelation of excessive metabolites, 2.235
clinical management of, 2.234–236
complications of, 2.236
dietary control of, 2.235
drug therapy for, 2.236
enzyme replacement therapy for, 2.235
ethnic concentration of, 2.229
explanation of, 2.234
gene therapy for, 2.236
genetic testing for, 2.238
multifactorial inheritance of, 2.232–233
polygenic inheritance of, 2.232–233
prevalence of, 2.171
racial concentration of, 2.229
sequelae of, 2.236
single-gene, 2.218
treatment of, 2.235–236
variability of, 2.218–219
vitamin therapy for, 2.236
vitreous affected by, 2.302, 2.304
Genetic/hereditary factors. *See also* Family history/familial factors; Genetics, clinical; Inborn errors of metabolism
in age-related cataracts, 11.41–42
in choroidal melanoma, 4.253
in corneal dystrophies, 8.133, 8.134, 8.136*t*
in glaucoma, 10.10, 10.11, 10.11*t*
in children and adolescents, 10.150
in multiple sclerosis, 5.315
in retinoblastoma, 4.172–173, 4.253, 4.289–291, 4.290*f*
Genetic heterogeneity, 2.212, 2.213*f*, 12.255
Genetic linkage, 2.175
Genetic map, 2.213
Genetic markers, 2.187. *See also specific type*
Genetic testing/counseling
AAO Task Force on Genetic Testing recommendations for, 2.240–241
for age-related macular degeneration, 12.63
description of, 2.205, 2.236–237, 2.238
direct-to-consumer, 2.241
family history in, 2.237
in glaucoma, 10.11
issues in, 2.237–238
of minors, 2.241
preimplantation genetic diagnosis, 2.221, 2.239–240
prenatal diagnosis, 2.239
referrals for providers of support for persons with disabilities, 2.240
reproductive issues, 2.238–240
requirements of, 2.237
in retinoblastoma, 4.289–291, 4.290*f*
in von Hippel–Lindau syndrome, 4.285
Genetic therapy. *See* Gene therapy
Genetics
clinical. *See also* Family history/familial factors; Genetic/hereditary factors; *specific disorder*
chromosome analysis. *See* Chromosome analysis
chromosomes, 2.213–217
expressivity, 2.220
genes, 2.213–217
genetic counseling and. *See* Genetic testing/counseling
inheritance patterns. *See* Inheritance
lyonization, 2.230–231, 2.231*f*
meiosis, 2.215, 2.216*f*
mitosis, 2.215
mutations, 2.217–220. *See also* Mutation
overview of, 2.199–200
pedigree analysis in, 2.200–201, 2.201*f*
penetrance, 2.219
pleiotropism, 2.220
terminology associated with, 2.210–212
definition of, 2.171

molecular
cell cycle, 2.173–176, 2.174*f*
DNA damage and repair, 2.181–182
gene structure, 2.176–177
gene therapy. *See* Gene therapy
gene transcription and translation. *See* Gene transcription and translation
mitochondrial diseases. *See* Mitochondrial diseases
mutations
disease and, 2.182–183
screening for, 2.189–194, 2.190–193*f*
noncoding DNA, 2.177–178
myopia and, 3.143
pharmacogenetics, 2.233–234
Geniculate body/nucleus/ganglion, 5.51*f*, 5.56, 5.276–277*f*
lateral (LGB/LGN), 5.18, 5.18*f*, 5.24*f*, 5.28–29, 5.55*f*, 5.154. *See also* Lateral geniculate body/nucleus
lesions of, 5.154, 5.154*f*, 8.5*f*
medial, 5.18*f*
Geniculate ganglionitis, facial paralysis/weakness caused by, 5.276–277*f*
Geniculocalcarine pathways (optic radiations), 2.116, 2.118*f*, 2.122*t*, 5.18*f*, 5.19, 5.24*f*, 5.29, 5.30
lesions of, 5.153, 5.155
in multiple sclerosis, 5.318
Geniculocalcarine radiation, 2.116*f*
Genome, 2.210, 2.218
Genome editing, 2.198
Genome-wide association studies (GWAS), 2.182, 2.189–191, 2.193–194, 2.218
Genoptic. *See* Gentamicin
Genotype, 2.218
Genotyping, 9.63
Gentak. *See* Gentamicin
Gentamicin sulfate, 2.418*t*, 2.425, 12.300
Gentasol. *See* Gentamicin
Geographic atrophy (GA), of retinal pigment epithelium, 4.164, 4.164*f*
in Best vitelliform dystrophy, 12.271
description of, 12.64, 12.66, 12.67*f*, 12.68
in drusenoid retinal pigment epithelium detachment, 12.272
Geographic epithelial ulcer, in herpes simplex keratitis, 8.217, 8.217*f*, 8.218*f*
Geographic map lines, in epithelial basement membrane dystrophy, 8.137, 8.137*f*
Geometric optics, 3.43–89. *See also specific aspect*
aberrations. *See* Aberrations
axial (longitudinal) magnification, 3.63–64
basic rules of, 3.86
conjugate points, 3.64
conoid of Sturm, 3.76, 3.76*f*
critical angle, 3.50–51
definition of, 3.43
depth of field, 3.57, 3.58*f*
depth of focus, 3.57, 3.58*f*
description of, 3.54–57
general refracting system, 3.58–67
IOLs and, 11.120, 11.121*f*
Jackson cross cylinder. *See* Jackson cross cylinder
mirrors. *See* Mirror(s)
nodal points, 3.66–67, 3.67*f*
physical optics and, 3.119
power cross, 3.16, 3.17*f*, 3.77, 3.77–3.78*f*
power-*versus*-meridian graph, 3.79*f*, 3.79–80
principal planes, 3.56–57, 3.57*f*
principles of, 3.43
prisms. *See* Prism(s)
ray tracing. *See* Ray tracing
real objects, 3.61
reduced optical system, 3.67–68, 3.68–3.69*f*
refraction by single curved surface, 3.51–54
refractive index, 3.43–44
spherical equivalent, 3.76
telescopes. *See* Telescopes
"thick-lens formula," 3.54–55
total internal reflection, 3.50, 3.50*f*
transverse magnification, 3.62
two-sided lenses. *See* Two-sided lenses
virtual objects, 3.61
Geometric scattering, 3.91, 3.97–98
Geometric wavefront, 3.70–71, 3.274
GERD. *See* Gastroesophageal reflux disease
Geriatrics. *See* Age/aging; Older adults
German measles, 6.410. *See also* Rubella
Germinal center, lymphoid follicle, 4.50*f*, 4.51, 4.51*f*, 4.69, 4.70, 4.70*f*, 4.71*f*
Germinative zone, 11.12, 11.12*f*
Germline mutations, 6.358
Gerstmann syndrome, 5.156, 5.179
Gerstmann-Sträussler-Scheinker (GSS) syndrome, 5.357
Gestational age, retinopathy and. *See* Retinopathy of prematurity
Gestational diabetes mellitus, 1.34
GFR. *See* Glomerular filtration rate
Ghost cells/ghost cell glaucoma, 4.103, 4.104*f*, 10.105–106, 10.106*f*, 12.347
vitreous hemorrhage and, 4.133, 10.105, 10.106
Ghost dendrites, in herpes simplex keratitis, 8.217, 8.218*f*
Ghost images
with multifocal IOLs, 13.156
after photoablation, 13.102
after small-incision lenticule extraction, 13.205
GHT. *See* Glaucoma Hemifield Test
Giant aneurysm, 5.338, 5.339
Giant cell(s)
foreign body, 4.7, 4.9*f*
Langhans, 4.7, 4.9*f*
macrophage activation into, 9.4
multinucleated, 4.7, 4.9*f*
in focal posttraumatic choroidal granulomatous inflammation, 4.22*f*
in granulomatous conjunctivitis, 4.52, 4.52*f*
in sarcoidosis, 4.187, 4.187*f*
Touton, 4.7, 4.9*f*
in juvenile xanthogranuloma, 4.187, 4.188*f*
Giant cell arteritis (GCA/temporal arteritis), 5.89, 5.89*f*, 5.313–315, 7.62–63, 9.125*t*
AAION and, 5.120, 5.313
central retinal artery occlusion caused by, 12.145
description of, 1.168, 12.195
diplopia in, 5.192, 5.313
facial pain associated with, 5.288, 5.297
headache in, 5.288, 5.313
indocyanine green angiography of, 12.196*f*

neuro-ophthalmic signs of, 5.313–315
occult, 5.120, 5.170
optic nerve affected in, 4.244*f*, 4.244–245, 5.120
polymyalgia rheumatica associated with, 1.168
transient monocular visual loss and, 1.119
transient visual loss and, 5.120, 5.161, 5.162, 5.169–170, 5.313–314
vasculitis, 7.62–63
Giant congenital melanocytic nevi, 4.218
Giant drusen, 4.295, 5.108*f*, 5.143
retinoblastoma differentiated from, 4.295
in tuberous sclerosis, 4.295
Giant fornix syndrome, 7.141
Giant papillae, conjunctival, 8.48, 8.48*f*
Giant papillary conjunctivitis (GPC), 3.231*f*, 3.234, 7.142, 7.142*f*
after penetrating keratoplasty, 8.426
Giant tears, of retina, 12.315
Giemsa stain, 4.31*t*
Gigantism, 1.47
Gilenya. *See* Fingolimod
Gillespie syndrome
aniridia in, 10.155
description of, 2.225
Glands of Krause, 2.28*f*, 2.30*t*, 2.41, 2.251, 2.253, 4.202, 7.168, 7.280
Glands of Moll, 2.29, 2.30*f*, 2.30*t*, 4.201, 7.191, 8.4, 8.4*f*
Glands of Wolfring, 2.30*t*, 2.41, 2.251, 2.253, 4.202, 7.168, 7.280, 8.4*f*
Glands of Zeis, 2.28, 2.30*f*, 2.30*t*, 2.250, 4.201, 7.183, 7.191, 8.4, 8.4*f*
chalazion/hordeolum and, 4.204, 4.206*f*, 8.76, 8.77
hordeolum caused by infection of, 4.203–204
sebaceous adenocarcinoma arising in, 4.215
Glare
assessment of, 3.318
cataracts and, 11.45, 11.47, 11.70, 11.70*t*, 11.77
definition of, 3.318
digoxin as cause of, 1.106
with IOLs, 11.144, 11.150–152
angle-supported lenses, 13.146
iris-fixated lenses, 13.145
multifocal lenses, 13.156
in optic neuropathy *versus* maculopathy, 5.100*t*
after photoablation, 13.102
polarized sunglasses for reduction of, 3.99, 3.192–193
as positive dysphotopsia, 11.150
pupil size and, 13.40
after radial keratotomy, 13.51
rainbow, after LASIK with femtosecond laser flap creation, 13.123–124
before refractive surgery, 13.41
Glare testing, in cataract evaluation, 11.77
Glass foreign body, 8.399, 8.400*f*
Glass lenses
high-index, 3.195
standard, 3.195
tempering of, 3.195
Glass prisms in Prentice position, 3.45, 3.46*f*
Glassblower's cataract, 11.57
Glasses. *See also* Spectacle lenses (spectacles)
anisometropia correction with, 3.139
in bright light, 3.130
existing initial estimate of refractive error from, 3.27
Glatiramer, for multiple sclerosis, 5.321*t*
Glaucoma, 10.3–11, 10.10. *See also* Angle-closure glaucoma; Elevated intraocular pressure; Open-angle glaucoma; Uveitis-glaucoma-hyphema (UGH) syndrome
age affecting development of
angle-closure glaucoma and, 10.9
open-angle glaucoma and, 10.7, 10.81–82
angle-recession, 4.18, 4.103–104
posttraumatic, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*
aniridia and, 10.120, 10.150, 10.154–155
anterior chamber evaluation in, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*. *See also* Gonioscopy
aphakic, 6.285, 10.130–132, 10.156–157
tube shunt implantation for, 10.215
aqueous misdirection and. *See* Glaucoma, malignant
Axenfeld-Rieger syndrome and, 4.99, 8.97*t*, 8.102, 10.31, 10.150, 10.153–154
biomicroscopy in evaluation of
slit-lamp, 10.30–32
ultrasound, 10.77, 10.124*f*
pediatric glaucoma and, 10.160
cataracts and, 4.103, 10.97*f*, 10.97–98, 10.128, 10.211, 10.212, 11.52, 11.56, 11.186*f*, 11.186–187
management of, 10.211–213, 10.213, 11.186*f*, 11.186–187. *See also* Cataract surgery, glaucoma and
preoperative evaluation/care and, 11.75
childhood. *See* Glaucoma, pediatric
ciliary block. *See* Glaucoma, malignant
classification of, 10.3–5, 10.4*t*, 10.6*t*
in children, 10.4*t*, 10.6*t*, 10.147–150, 10.148*t*, 10.149–150*t*
clinical evaluation of, 10.29–77. *See also specific type*
gonioscopy in, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
history and general examination in, 10.29–32
in infants and children, 10.157
in infants and children, 10.151–152, 10.152*t*, 10.157*t*, 10.157–160
optic nerve and, 10.41–46, 10.43*f*, 10.44*f*, 10.45*f*
in infants and children, 10.160
optic neuropathy and, 10.46–59, 10.47*f*, 10.49*f*, 10.50*f*, 10.51*f*, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
visual field examination in, 10.59–77. *See also* Perimetry; Visual field testing, in glaucoma
combined-mechanism, 10.7
congenital, 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147, 10.148*t*, 10.151*f*, 10.151–153, 10.152*f*, 10.152*t*. *See also* Glaucoma, pediatric; Primary congenital glaucoma
conjunctiva affected in, 10.31
cornea affected in, 10.31
cornea plana and, 8.96*t*, 8.100–101
enlargement/megalocornea and, 8.95, 8.96*t*, 8.99–100, 8.108, 10.31, 10.147, 10.158
opacities and, 8.108–109
corneal thickness and, 10.25, 10.31, 10.81, 10.82, 10.86–87, 10.90, 10.159

corticosteroid-induced, 6.321, 9.319, 10.109–110
refractive surgery and, 13.41, 13.182, 13.201
definitions and, 10.3
developmental, 10.153–156. *See also* Glaucoma, pediatric
diabetes mellitus and, 10.83
drug-induced
angle-closure glaucoma and, 10.122–123, 10.145*f*, 10.145–146
open-angle glaucoma and, 10.109–111
drugs for, 10.170–186, 10.171–174*t*. *See also* Antiglaucoma agents
environmental factors in, 10.10
epidemiology of, 10.7–10, 10.9*t*
episclera affected in, 10.31, 10.102*t*, 10.102–103, 10.103*f*
external adnexae affected in, 10.29–30
Fuchs heterochromic uveitis/iridocyclitis and, 10.101–102, 10.102*f*
fundus examination in, 10.32
gender affecting risk of, 10.9, 10.121
genetic/hereditary factors in, 8.108, 10.10, 10.11, 10.11*t*
ghost cell, 4.103, 4.104*f*, 10.105–106, 10.106*f*, 12.347
hemolytic, 4.103, 4.104*f*, 10.105, 10.106
hemorrhage/hyphema and, 4.103, 4.104*f*, 8.394, 10.50, 10.51*f*, 10.85*f*, 10.85–86. *See also* Uveitis-glaucoma-hyphema (UGH) syndrome
hemosiderin in, 4.103, 4.104*f*
incidence of, 1.184, 10.7, 10.8
infantile, 6.230, 10.4*t*, 10.147, 10.148*t*. *See also* Glaucoma, pediatric
inflammatory
angle-closure glaucoma and, 10.138*f*, 10.138–139, 10.139*f*
open-angle glaucoma and, 10.100–102, 10.102*f*
intraocular pressure in. *See also* Elevated intraocular pressure
description of, 10.3, 10.20–21, 10.46–47, 10.79, 10.80–81, 10.81*t*
monitoring of, 1.130
IOL implantation and, 11.149
iridocorneal endothelial syndrome and, 4.101, 8.127, 10.136*f*, 10.136–138, 10.137*f*
iris bombé and, 10.32, 10.129, 10.131*f*, 10.138, 10.139*f*
juvenile open-angle, 10.4*t*, 10.147, 10.148*t*, 10.153. *See also* Glaucoma, pediatric
lens evaluation in, 10.32
lens-induced, 4.103, 4.103*f*, 4.122, 10.96–98, 10.97*f*, 10.119, 11.67–68, 11.68*f*
angle-closure glaucoma and, 10.96, 10.119, 10.128–132
in children and adolescents, 10.149*t*
open-angle glaucoma and, 10.96–98, 10.97*f*
lens particle, 10.98, 11.67
leukemia and, 4.315
low-tension, 10.3, 10.4*t*, 10.85*f*, 10.85–88, 10.86*t*. *See also* Glaucoma, normal-tension
systemic nocturnal hypotension as risk factor for, 1.66–67
malignant (aqueous misdirection/ciliary block glaucoma), 10.32, 10.139–141, 10.140*f*
cataract surgery and, 10.139, 11.139
in children and adolescents, 10.149*t*
after penetrating keratoplasty, 8.424
management of
in children, 10.160–166
clinical trials in evaluation of, 10.111–115
interrelationship between medical and surgical treatment and, 10.111
medical, 10.169–186. *See also* Antiglaucoma agents
adherence and, 10.186
agents used in, 10.170–186, 10.171–174*t*. *See also* Antiglaucoma agents; *specific drug*
in children, 10.153
combined medications in, 10.182
in elderly patients, 10.186
general approach to, 10.183–186
long-term therapy and, 10.183–184
during pregnancy/lactation, 10.185–186
prognosis and, 10.84
after refractive surgery, 13.201
surgical, 10.187–212. *See also* Glaucoma surgery; *specific procedure*
cataract surgery and, 10.211–213, 10.213, 11.186*f*, 11.186–187
in children, 10.160–164, 10.161*f*, 10.162*f*
in elderly patients, 10.221
in Marfan syndrome, 8.194
megalocornea and, 8.95, 8.96*t*, 8.99–100, 8.108
melanocytoma and, 4.106, 4.258
melanomalytic, 4.105*f*, 4.106, 4.194
microcornea and, 8.95–99
microspherophakia and, 10.130, 10.131*f*, 11.33
nanophthalmos and, 4.108, 4.109, 10.144
neovascular, 4.188, 10.38*f*, 10.38–39, 10.132*t*, 10.132–135, 10.133*f*, 10.134*f*, 10.135*f*
iris examination in, 10.32, 10.39, 10.135*f*
rubeosis iridis and, 4.188
tube shunt implantation for, 10.215
nerve damage caused by, 12.328
nerve fibers/nerve fiber layer in, 10.48, 10.49*t*
diffuse/focal loss and, 10.50–52, 10.51*f*
patterns of loss and, 10.67–69, 10.68*f*, 10.69*f*, 10.70*f*
neurofibromatosis and, 10.156
in children, 10.156
neuroretinal rim changes in, 10.48–50, 10.49*t*, 10.50*f*
normal-tension (NTG), 10.3, 10.4*t*, 10.85*f*, 10.85–88, 10.86*t*
diagnostic evaluation of, 10.87
differential diagnosis of, 10.86*t*, 10.86–87
disc hemorrhages in, 10.85*f*, 10.85–86
genetic/hereditary factors in, 10.11*t*
prognosis/therapy of, 10.87–88
risk factors/clinical features of, 10.85*f*, 10.85–86
open-angle. *See* Open-angle glaucoma
ophthalmoscopic signs of, 10.48, 10.49*t*
optic neuropathy/optic nerve changes in, 5.107*t*, 5.136, 5.137*f*, 10.3, 10.46–59, 10.47*f*, 10.49*f*, 10.50*f*, 10.51*f*, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
imaging in evaluation of, 10.53–59, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
optic nerve/nerve head/disc evaluation and, 10.32, 10.41–46, 10.43*f*, 10.44*f*, 10.45*f*, 10.48–59, 10.49*t*, 10.49*f*, 10.50*f*, 10.51*f*, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
normal-tension glaucoma and, 10.86

perimetry changes correlated with, 10.74–75
recording findings and, 10.53
patterns of nerve loss and, 10.67–69, 10.68*f*, 10.69*f*, 10.70*f*
outflow facility in, 10.19
classification of glaucomas and, 10.3–5, 10.4*t*, 10.6*t*
intraocular pressure and, 10.5, 10.5*f*, 10.13, 10.14*f*, 10.19
laser trabeculoplasty affecting, 10.188
tonography in measurement of, 10.19
outflow obstruction mechanisms in, 10.5, 10.6*t*
oxidative stress in, 2.345
pain caused by, 5.295
in pars planitis, 9.151
in pathologic myopia, 12.218, 12.218*f*
pediatric (childhood/congenital/infantile/juvenile), 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147–167
algorithm for, 6.279*f*
aniridia and, 10.150, 10.155
gonioscopic appearance of, 10.159
anomalies associated with, 10.4*t*, 10.6*t*, 10.147, 10.148*t*, 10.151
anterior segment examination in, 10.158
aphakic, 6.285, 10.156–157
Axenfeld-Rieger syndrome and, 4.99, 8.97*t*, 8.102, 10.31, 10.150, 10.153–154
axial length measurements in, 10.160
cataract surgery and, 10.149*t*, 10.156
central corneal thickness in, 10.159
classification of, 6.277, 6.278*t*, 6.279*f*, 10.4*t*, 10.6*t*, 10.147–150, 10.148*t*, 10.149–150*t*
corneal edema and, 8.108–109
corneal enlargement and, 8.95, 8.96*t*, 8.99–100, 8.108, 10.31, 10.147, 10.158
corneal opacities and, 8.108–109
corticosteroids as cause of, 6.284
definition of, 6.277
developmental, 10.153–156
diagnosis/differential diagnosis of, 10.151–152, 10.152*t*
examination/evaluation in, 10.151–152, 10.152*t*, 10.157*t*, 10.157–160
external examination in, 10.158
follow-up of, 6.290–291, 10.167
genetic/hereditary factors in, 10.11*t*, 10.150
genetics of, 6.277–278
gonioscopy in, 10.159
history in, 10.157
juvenile open-angle, 6.278, 6.284, 10.4*t*, 10.147, 10.148*t*, 10.153
medical therapy for, 10.153, 10.164–165
megalocornea and, 8.95, 8.96*t*, 8.99–100, 8.108
neurofibromatosis and, 10.156
optic nerve/fundus evaluation in, 10.160
pachymetry in, 10.159
Peters anomaly and, 4.74, 10.150, 10.154
primary, 10.4*t*, 10.147–148, 10.148*t*
congenital, 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147, 10.148*t*, 10.151*f*, 10.151–153, 10.152*f*, 10.152*t*. *See also* Primary congenital glaucoma
anterior segment findings in, 6.282, 6.282*f*
axial length in, 6.283
central corneal thickness in, 6.281
clinical manifestations of, 6.279–280, 6.280*f*
corneal edema in, 6.279–280
corneal findings in, 6.280*f*, 6.280–281
definition of, 6.278
diagnostic examination for, 6.280–283, 6.282–283*f*
differential diagnosis of, 6.281*t*
genetics of, 6.277–278
gonioscopy for, 6.282, 6.282*f*
goniotomy for, 6.285, 6.286*f*
incidence of, 6.278
natural history of, 6.283–284
optic nerve findings in, 6.282–283, 6.283*f*
optical coherence tomography of, 6.283
pathophysiology of, 6.278
surgical treatment of, 6.285–287, 6.286*f*
tonometry in, 6.281–282
trabeculotomy, 6.286*f*, 6.286–287
genetics of, 10.11*t*, 10.150
infantile, 10.151
juvenile open-angle, 10.4*t*, 10.147, 10.148*t*, 10.153
prognosis for, 6.290–291, 10.166–167
secondary, 10.4*t*, 10.148, 10.149–150*t*, 10.156–157
acquired condition, 6.284
after cataract surgery, 6.285
classification of, 6.278*t*
nonacquired conditions associated with, 6.284*t*
Sturge-Weber syndrome and, 5.332*f*, 10.155
surgery for, 10.153, 10.164–165
strabismus and, 10.166–167
tonometry in, 10.158–159
treatment of, 10.153, 10.160–166
β-blockers, 6.288, 6.289*t*
cyclocryotherapy, 6.287
description of, 6.285
endoscopic photocoagulation, 6.287–288, 6.288*f*
goniotomy for, 6.285, 6.286*f*
medical, 10.153, 10.164–165
medical/medications, 6.288–290, 6.289*t*
surgery, 6.285–288, 6.286*f*, 6.288*f*
surgical, 10.153, 10.160–164, 10.161*f*, 10.162*f*, 10.187
trabeculotomy, 6.286*f*, 6.286–287
tube shunt implantation surgery, 6.287
tumors causing, 10.149*t*
vision loss caused by, 6.290
visual acuity and, 10.158
penetrating keratoplasty and, 8.424–425, 10.109
graft failure and, 8.428
peripapillary atrophy in, 10.48, 10.52
persistent fetal vasculature and, 10.144
Peters anomaly and, 4.74, 10.150, 10.154
phacoantigenic, 10.98
phacolytic (phacolytic uveitis), 4.103, 4.103*f*, 4.122, 9.13, 9.137, 10.97*f*, 10.97–98, 11.67
phacomorphic, 10.119, 10.128, 10.129*f*, 11.67, 11.68*f*
pigmentary/pigment dispersion syndrome and, 4.105, 4.105*f*, 10.93–96, 10.94*f*, 10.95*f*, 10.96*f*
port-wine stain and, 6.199
posterior polymorphous corneal dystrophy and, 8.159
preperimetric, 10.3

prevalence of, 10.7–8, 10.9
primary, 10.3–5. *See also* Angle-closure glaucoma, primary; Open-angle glaucoma, primary
congenital, 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147, 10.148*t*, 10.151*f*, 10.151–153, 10.152*t*, 10.152*f*. *See also* Primary congenital glaucoma
anterior segment findings in, 6.282, 6.282*f*
axial length in, 6.283
central corneal thickness in, 6.281
clinical manifestations of, 6.279–280, 6.280*f*
corneal edema in, 6.279–280
corneal findings in, 6.280*f*, 6.280–281
definition of, 6.278
diagnostic examination for, 6.280–283, 6.282–283*f*
differential diagnosis of, 6.281*t*
genetics of, 6.277–278
gonioscopy for, 6.282, 6.282*f*
goniotomy for, 6.285, 6.286*f*
incidence of, 6.278
natural history of, 6.283–284
optic nerve findings in, 6.282–283, 6.283*f*
optical coherence tomography of, 6.283
pathophysiology of, 6.278
surgical treatment of, 6.285–287, 6.286*f*
tonometry in, 6.281–282
trabeculotomy, 6.286*f*, 6.286–287
juvenile open-angle, 10.4*t*, 10.147, 10.148*t*, 10.153
management of. *See* Antiglaucoma agents; Glaucoma surgery
open-angle, 2.233, 2.345, 2.377–378, 2.381, 2.387
pseudoexfoliation/exfoliation syndrome and (pseudoexfoliation glaucoma), 4.101–103, 4.102*f*, 10.11*t*, 10.31, 10.91, 10.93, 10.130, 10.131*f*
pseudophakic, 10.130–132
pupillary-block, in retinopathy of prematurity, 12.181
pupils affected in, 10.30, 10.33*t*
race affecting risk of, 10.7–8, 10.9, 10.81, 10.82, 10.120
in angle-closure glaucoma, 10.9, 10.117, 10.120
in open-angle glaucoma, 10.7–8, 10.81, 10.82
radiation-related, 4.276
reactive oxygen species in, 2.345
refraction/refractive errors in, 10.9, 10.29, 10.122
refractive surgery and, 13.41, 13.180–183, 13.182*f*, 13.200–201
retinal vein occlusion risks secondary to, 12.125
retinoblastoma and, 4.292
retinopathy of prematurity as risk factor for, 6.334
risk factors for
in angle-closure glaucoma, 10.9, 10.120–122
in open-angle glaucoma, 10.8, 10.9*t*, 10.80–83
rubeosis iridis and, 4.188
scleral involvement/scleritis and, 8.323, 10.31
screening perimetry in, 10.62
secondary, 4.101–106, 4.102*f*, 4.103*f*, 4.104*f*, 4.105*f*, 4.106, 10.5. *See also* Angle-closure glaucoma, secondary; Open-angle glaucoma, secondary
in infants and children, 10.4*t*, 10.148, 10.149–150*t*
management of. *See* Antiglaucoma agents; Glaucoma surgery
rubeosis iridis and, 4.188
slit-lamp biomicroscopy in evaluation of, 10.30–32
spatial frequencies affected by, 3.136
Sturge-Weber syndrome and, 5.332*f*, 5.334*t*, 6.401–402, 10.30, 10.155
surgery for, 10.187–221. *See also* Glaucoma surgery; *specific procedure*
tests for, 10.29–77. *See also* Glaucoma, clinical evaluation of
threshold perimetry in, 10.61*f*, 10.61–62, 10.63*f*
topiramate causing, 10.145*f*, 10.145–146
transient visual loss and, 5.163*t*, 5.164
trauma and, 4.103–104, 4.104*f*, 10.39–40, 10.40*f*, 10.41*f*, 10.98, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*
in children and adolescents, 10.149*t*
tube shunt implantation for, 10.213–217, 10.214*t*, 10.218*t*
tumors causing, 4.105*f*, 4.106, 10.98–100, 10.99*f*, 10.138
in children and adolescents, 10.149*t*
ultrasound biomicroscopy in evaluation of, 10.77, 10.124*f*
pediatric glaucoma and, 10.160
uveal lymphoid proliferation/infiltration and, 4.314
uveitis and, 9.317, 10.100–102, 10.102*f*, 10.134, 10.139, 10.139*f*. *See also* Uveitis-glaucoma-hyphema (UGH) syndrome
in children and adolescents, 10.149*t*
optical coherence tomography of, 9.85
visual field changes in, 10.59–77. *See also* Visual field defects, in glaucoma
evaluation of. *See also* Perimetry; Visual field testing, in glaucoma
patterns of field loss and, 10.67–69, 10.68*f*, 10.69*f*, 10.70*f*
serial fields/progression and, 10.71–75, 10.72*f*, 10.73*f*, 10.74*f*
single field and, 10.62–67, 10.64*f*, 10.65*f*, 10.66*f*, 10.67*f*
vitrectomy and, 10.143
Glaucoma diagnosis (GDx) test. *See* Scanning laser polarimetry/polarimeter
Glaucoma drainage devices (tube shunts), 10.196–197, 10.213–217, 10.214*t*, 10.218*t*
cataract extraction combined with, 10.213
complications associated with, 10.217, 10.218*t*
corneal graft failure and, 8.428
description of, 6.146, 6.287, 6.323
in iridocorneal endothelial syndrome, 8.127
LASIK and, 13.182
neovascular glaucoma and, 10.135
pediatric glaucoma and, 10.161, 10.163
strabismus and, 10.166–167
uveitis/uveitic glaucoma and, 10.214
Glaucoma filtering surgery, 9.319
Glaucoma genes, 10.10, 10.11, 10.11*t*
Glaucoma Hemifield Test (GHT), 10.65, 10.65*f*
Glaucoma Laser Trial (GLT), 10.188
Glaucoma surgery, 10.187–221. *See also specific procedure*
for angle-closure glaucoma, 10.220
cataract development after, 11.56
cataract surgery and, 10.211–213, 10.213, 11.186–187, 11.187
chamber deepening/goniosynechialysis, 10.220

in children, 10.160–164, 10.161*f*, 10.162*f*
strabismus and, 10.166–167
corneal graft failure and, 8.428
deep sclerectomy, 10.217–219
in elderly patients, 10.221
electroablation, 10.219
filtering procedures, 10.197–211. *See also* Filtering procedures; Trabeculectomy
goniotomy, 10.160, 10.161, 10.161*f*, 10.163
incisional surgery, 10.196–220. *See also* Trabeculectomy
for angle-closure glaucoma, 10.220
cataract surgery, 10.213
with trabeculectomy, 10.211–213
complications of, 10.187
for open-angle glaucoma, 10.113–115
trabeculectomy, 10.197–211
with cataract surgery, 10.211–213
tube shunt implantation, 10.213–217, 10.214*t*, 10.218*t*
interrelationship between medical and surgical treatment and, 10.111
laser surgery, 10.188–196
cyclodestruction, 10.194–196, 10.195*f*
gonioplasty/iridoplasty, 10.193–194
iridotomy, 10.191–193, 10.192*f*
trabeculoplasty, 10.88, 10.113–115, 10.188–191, 10.190*f*
LASIK and, 13.182, 13.201
microshunts, 10.219–220
minimally invasive, 10.219–220
nonpenetrating, 10.217–219
peripheral (surgical) iridectomy, 10.125, 10.220
peripheral iridoplasty, 10.193–194
after refractive surgery, 13.201
shunting surgeries, 10.213–217, 10.214*t*, 10.218*t*, 10.219–220. *See also* Microshunts; Tube shunts
trabeculotomy, 10.160, 10.161–162, 10.162*f*, 10.219
in uveitis patients, 6.323
viscocanalostomy, 10.217–219
Glaucoma suspect, 10.4*t*, 10.89
angle-closure, 10.4*t*, 10.117, 10.117*t*, 10.122–123
open-angle, 10.4*t*, 10.89
screening tests for, 10.62
Glaucoma tube shunts. *See* Tube shunts
Glaucomatocyclitic crisis (Posner-Schlossman syndrome)
acute anterior uveitis in, 9.135–136
description of, 10.100–101
Glaucomatous cupping. *See* Cupping of optic nerve/nerve head/disc, glaucomatous
Glauctabs. *See* Methazolamide
Glaukomflecken, 4.120, 10.124, 11.68
GLC1A gene, 10.10, 10.11*t*
GLC3A gene, 10.11*t*
GLC1A myocilin gene, 10.150
GLC1B gene, 10.11*t*
GLC3B gene, 10.11*t*
GLC1C gene, 10.11*t*
GLC3C gene, 10.11*t*
GLC1D gene, 10.11*t*
GLC3D gene, 10.11*t*
GLC1E gene, 10.11*t*
GLC1F gene, 10.11*t*
GLC1G gene, 10.11*t*
GLC1I gene, 10.11*t*
GLC1J gene, 10.11*t*
GLC1K gene, 10.11*t*
Glial cells, 2.317
optic nerve, 4.241, 4.242*f*
retinal, 5.24
in healing/repair, 4.17
ischemia and, 4.152
Glioblastoma/glioblastoma multiforme, optic nerve (malignant optic glioma of adulthood/MOGA), 4.249, 5.130–131
Gliomas, optic nerve/pathway/chiasm (OPGs), 4.249, 4.249*f*, 4.295, 5.126, 5.128*t*, 5.129*f*, 5.129–131
in children (juvenile), 4.249
malignant (malignant optic gliomas of adulthood/MOGAs/glioblastomas), 4.249, 5.130–131
malignant (malignant optic gliomas of childhood/MOGAs/glioblastomas), 4.249
in neurofibromatosis, 5.130, 5.334*t*
Gliosis, retinal, 4.157, 4.158, 4.158*f*
of peripapillary nerve fiber layer, 5.109
Gliotic (sclerotic) lesions, in multiple sclerosis, 5.316, 5.316*f*
Glistenings, IOL, 11.151
Global Burden of Disease Study (GBD), 1.193
Global Initiative for Chronic Obstructive Lung Disease (GOLD), 1.124
Global layer, of extraocular muscles, 6.24, 6.27
Globe
atrophy/disorganization of (atrophia/phthisis bulbi), 4.22–23, 4.23*f*
retinoblastoma regression and, 4.301
congenital and developmental anomalies of, 6.263
displacement of, 4.223, 7.23–24
exposure of
for ICCE, 11.199
for phacoemulsification, 11.105, 11.105*f*
gross dissection of, for pathologic examination, 4.28*f*, 4.28–30, 4.29*f*
injuries to
lacerating, 12.358
needle perforation/penetration of, 12.358, 12.395*f*, 12.395–396
perforating, 12.358
primary repair of, 12.359
scleral rupture, 12.352, 12.358
surgical management of, 12.359–360
vitrectomy for, 12.359–360
wound closure of, 12.359
layers of, 2.48–49
luxation of, 6.207–208
orbital tumors from, 7.101
orientation of, pathologic examination and, 4.27, 4.27*f*
palpation of, 7.25
penetrating injuries of, 12.358
description of, 6.376
needle penetration/perforation and. *See* Penetrating and perforating ocular trauma; Trauma
position of, 7.24

posterior view of, 2.24*f*
ptosis of, 7.114
retraction of
in Duane retraction syndrome, 6.134
in induced convergence-retraction, 6.153
rupture/traumatic injury of, surgical repair of, 8.403–409, 8.404*f*, 8.405*f*, 8.407*f*, 8.408*f*. *See also* Corneoscleral lacerations
stabilization of, for clear corneal incision, 11.106
suspensory ligament of. *See* Lockwood ligament
topographic features of, 2.48–49
Globe-conserving therapy, for retinoblastoma, 4.299
Globe tenting, 7.5
Glomerular filtration rate (GFR), 2.351–352
Glomus tumor, 8.345*t*
GLP-1. *See* Glucagon-like peptide 1
GLT (Glaucoma Laser Trial), 10.188
Glucagon-like peptide-1 (GLP-1), 1.205
Glucocorticoids. *See also* Corticosteroid(s)
administration of, 2.403, 2.407*t*
adverse effects of, 2.401–403
cell-specific effects of, 2.399
in elderly patients, 2.401
granulomatosis with polyangiitis treated with, 1.172
immune-mediated inflammation effects of, 2.399
indications for, 2.399
intraocular pressure elevation by, 2.401–402, 2.402*t*
potency of, 1.175*t*
regimens for, 2.403–407
rheumatic disorders treated with, 1.174–176, 1.175*t*
for thyroid eye disease, 7.60–61
types of, 2.403–407
Glucose
aqueous humor concentration of, 2.274–275
in cataract formation, 11.19, 11.60. *See also* Diabetes mellitus
lens metabolism of, 2.290
metabolism of, in lens, 11.17–19, 11.18*f*
plasma levels of, in diabetes mellitus. *See* Glycemic control
in retinal pigment epithelium, 2.323
in tear film, 2.252
Glucose-6-phosphate (G6P), in lens glucose/carbohydrate metabolism, 11.17, 11.18*f*
Glucose-6-phosphate dehydrogenase (G6PD) deficiency, 1.136
Glucose control. *See* Glycemic control
Glucose surveillance. *See* Glycemic control
β-Glucuronidase deficiency, in Sly syndrome, 8.175*t*
Glutamic acid decarboxylase (GAD), downbeat nystagmus and, 5.244
Glutaraldehyde, as tissue fixative, 4.26, 4.26*t*
Glutathione (GSH)
in aqueous humor, 2.275
description of, 2.341
in lens, oxidative changes and, 11.17, 11.20
oxidation-reduction cycle, 2.340
reactive oxygen species and, 2.339
Glutathione peroxidase (GSH-Px), 2.341
in lens, 11.20
Glycemic control
in diabetes mellitus, 1.35–36
for diabetic retinopathy, 12.96–98
Glycerin, 2.397, 2.398*t*
Glycerol, 10.174*t*, 10.182–183
Glycocalyx, 2.260, 2.261*f*
Glycolysis, in glucose/carbohydrate metabolism, in lens, 11.17–19, 11.18*f*
Glycopeptides, 1.273–274
Glycoprotein IIb/IIIa inhibitors
coronary heart disease treated with, 1.91*t*
myocardial infarction treated with, 1.94
Glycoproteinosis. *See* Sialidoses
Glycoproteins
in lipid keratopathy, 8.125
viral, 8.207, 8.212
Glycosaminoglycans (GAGs)
corneal haze after surface ablation and, 13.109
corneal hydration and, 8.9
description of, 2.53, 2.263, 2.297, 7.57
in Fleck corneal dystrophy, 8.153
in macular corneal dystrophy, 8.149–150
in mucolipidoses, 8.178
in mucopolysaccharidoses, 8.174
in thyroid eye disease, 4.226
Glyrol. *See* Glycerin
GM_1 gangliosidoses
description of, 2.204*t*, 6.389*t*
I (generalized), 8.176
GM_2 gangliosidosis (Tay-Sachs disease)
description of, 2.204*t*, 6.389*t*, 8.176–178, 12.291, 12.291*f*
type I, 2.204*t*, 12.291
type II, 2.204*t*
GMS (Gomori or Grocott methenamine silver) stain, 4.31*t*, 9.298*f*
GNA11 gene
in nevus of Ota, 4.64
in uveal melanoma, 4.197
GNAQ gene
in nevus of Ota, 4.64
in uveal melanoma, 4.197
Goblet cells, 4.47, 4.48*f*, 8.5, 8.6*f*
description of, 2.30*t*, 2.43, 2.44
mucin production by, 2.253
in mucous membrane pemphigoid, 8.299, 8.300
Goiter. *See also* Hyperthyroidism; Thyroid eye disease
diffuse toxic, 1.43
in Graves hyperthyroidism, 1.43
GOLD. *See* Global Initiative for Chronic Obstructive Lung Disease
Gold compounds/salts, corneal deposits of/pigmentation caused by, 8.118*t*, 8.132
Gold eyelid weights
for corneal exposure in facial palsy, 5.281
for exposure keratopathy, 8.80
Gold standard, 1.15–16
Goldberg syndrome, 8.179
Goldberg theory of reciprocal zonular action, 13.162
"Golden ring" sign, 11.110
Goldenhar-Gorlin syndrome (oculoauriculovertebral (OAV) syndrome), 6.210, 8.191*t*, 8.195*f*, 8.195–196
Goldenhar syndrome/oculoauriculovertebral dysplasia, 2.144
craniofacial malformations associated with, 6.210*f*, 6.210–211

dermoids/dermolipomas/lipodermoids and, 4.47, 4.48
dermolipomas associated with, 6.256
description of, 4.47, 6.131
epibulbar dermoids associated with, 6.256, 6.256*f*
Goldman (kinetic) perimetry, 5.84, 5.85*f*. *See also* Perimetry
in nonorganic disorder evaluation, 5.308, 5.308*f*
Goldmann applanation, 6.281
Goldmann applanation tonometry (GAT), 3.282, 3.293, 10.22–23, 10.23*f*, 10.24*f*. *See also* Applanation tonometry/tonometer
corneal thickness affecting, 13.105, 13.181
infection control and, 10.27
after refractive surgery, 13.105, 13.181, 13.200–201
LASIK, 13.105, 13.200–201
surface ablation, 13.105, 13.200–201
Goldmann equation, 2.271, 2.273, 10.13
Goldmann-Favre syndrome. *See* Enhanced S-cone disease (ESCD)
Goldmann lenses, for gonioscopy, 10.33, 10.34*f*, 10.35
Goldmann perimetry, 3.315
Goldmann 3-mirror contact gonioscopy lens, 3.295–296, 3.296*f*
Goldmann-Weekers (G-W) adaptometer, 12.57–58
Goldmann-Witmer (GW) coefficient
calculation of, 9.41–42
description of, 9.251–253
for Fuchs heterochromic uveitis, 9.41–42
polymerase chain reaction and, 9.91
for toxoplasmosis, 9.91
Golimumab, 1.180, 9.110
Gomori methenamine silver (GMS) stain, 4.31*t*, 9.298*f*
Gonadotroph adenomas, 1.48
Gonadotropin-producing pituitary tumors, 1.48
Goniolenses, 10.33–35, 10.35*f*. *See also* Gonioscopy
in children and adolescents, 10.159
Gonioplasty, laser, 10.193–194
Gonioscopy, 6.282, 6.282*f*, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
assessment/documentation systems for, 10.36–40, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
before cataract surgery, 11.79
chamber angle, 4.97–98, 4.98*f*, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
in traumatic/angle-recession glaucoma, 10.39–40, 10.40*f*, 10.41*f*, 10.107, 10.107*f*
in choroidal/ciliary body melanoma, 4.262, 4.263*f*, 4.265
direct, 10.33, 10.35*f*
dynamic (compression/indentation), 10.35, 10.35*f*, 10.36,10.123
in elevated episcleral venous pressure, 10.102
in Fuchs heterochromic uveitis/iridocyclitis, 10.101, 10.102*f*
in glaucoma, 10.32–40, 10.33*t*, 10.34*f*, 10.35*f*, 10.37*f*, 10.38*f*, 10.39*f*, 10.40*f*, 10.41*f*
angle-closure, 10.123, 10.124*f*, 10.125
in infants and children, 10.159
inflammatory, 10.100
lens particle, 11.67
neovascular, 10.38*f*, 10.38–39, 10.134
normal-tension, 10.87
primary open-angle, 10.79
traumatic/angle-recession, 10.39–40, 10.40*f*, 10.41*f*, 10.107, 10.107*f*
indirect, 10.33–36, 10.35*f*
in pediatric glaucoma, 10.159
in iris nevus, 4.255
Koeppe-type lenses in, 10.33
normal angle landmarks in, 10.34*f*
in pigment dispersion syndrome, 10.94, 10.94*f*
trabecular meshwork, 4.97–98, 4.98*f*, 10.33*t*, 10.34*f*
in trauma evaluation, 10.39–40, 10.40*f*, 10.41*f*, 11.190
Goniosynechialysis
for angle-closure glaucoma, 10.220
with cataract extraction, 10.213
for subacute/intermittent angle closure, 10.126
Goniotomy, 9.320, 10.160, 10.161, 10.161*f*, 10.163
primary congenital glaucoma treated with, 6.285, 6.286*f*
in uveitis patients, 6.323
Gonococcus (*Neisseria gonorrhoeae*/gonorrhea), 6.238*f*, 6.238–239, 8.207, 8.208*t*, 8.245, 8.246*f*
conjunctivitis/hyperacute conjunctivitis caused by, 8.208*t*, 8.245, 8.257*t*, 8.258–260, 8.259*f*, 8.260*t*
in neonates, 8.257*t*, 8.258, 8.264
invasive capability of, 8.207
l infections, 1.250–251
resistant strains of, 8.259, 8.264
Gorlin syndrome (basal cell nevus syndrome), 7.201, 7.202*f*
eyelid manifestations of, 4.210*t*
Gottron sign, 1.167
Gout, 8.188
corneal changes in, 8.119, 8.188
GPA. *See* Granulomatosis, with polyangiitis; Guided Progression Analysis
GPC. *See* Giant papillary conjunctivitis
G6PD deficiency. *See* Glucose-6-phosphate dehydrogenase (G6PD) deficiency
GPDS1 genes, 10.11*t*
GPR143 gene, 6.407
Graded-density sunglasses, 3.192–193
Gradenigo syndrome, 5.201, 5.345
Gradient echo sequences, 7.28–29
Gradient method, for accommodative convergence/accommodation ratio measurement, 3.177–178, 6.71
Graft(s)
conjunctival, 8.351*t*
for chemical injuries, 8.384
indications for, 8.351*t*, 8.353, 8.356
for limbal stem cell deficiency, 8.94
in pterygium surgery, 8.351, 8.353*t*, 8.353–355, 8.354*f*, 8.356
recurrence rate and, 8.353*t*
after tumor removal surgery, 8.329
conjunctival-limbal, for pterygium, 8.353*t*
corneal, 8.316. *See also* Cornea, transplantation of; Donor cornea; Keratoplasty
allografts (allogeneic transplantation), 8.316, 8.411–451, 8.412*t*, 8.412–413*t*
arcuate keratotomy incisions in, 13.56–57
autografts (autologous transplantation), 8.411, 8.451–452
disease recurrence in, 8.225, 8.232

dislocation/decentration of, after endothelial keratoplasty, 8.440–444, 8.441*f*, 8.442*f*, 8.443*f*
DMEK, 8.442*f*, 8.442–443, 8.443*f*
DSEK, 8.441, 8.442*f*
endothelial failure of, 4.84, 4.85*f*
late non-immune-mediated, 8.427–428
primary
after endothelial keratoplasty (DMEK/DSEK), 8.447
after penetrating keratoplasty, 8.423, 8.423*f*
rejection of, 4.84, 4.85*f*, 8.316–318, 8.428–431. *See also* Rejection
for eyelid repair, in burn patients, 8.385
immune privilege and, 8.316
limbal, 8.351*t*. *See also* Limbal transplantation
for chemical injuries, 8.380, 8.384
indications for, 8.351*t*
mucous membrane, 8.351*t*, 8.365–366
indications for, 8.351*t*, 8.366
for mucous membrane pemphigoid, 8.303, 8.366
rejection of. *See* Rejection
Graft-host interface
arcuate keratotomy incisions in, 13.56–57
pathology in
after DSEK, 8.445–446, 8.446*f*
after lamellar keratoplasty, 8.435
Graft-vs-host disease (GVHD), 8.303–305, 8.305*f*
superior limbic keratoconjunctivitis and, 8.83
Gram-negative bacteria, 8.243, 8.244*t*
cocci, 8.244*t*, 8.245, 8.246*f*
therapy for infection caused by, 8.270*t*
as normal flora, 8.206*t*
rods, 8.244*t*, 8.247*f*, 8.247–248
therapy for infection caused by, 8.270*t*
Gram-positive bacteria, 8.243, 8.244*t*
cocci, 8.243, 8.244*t*, 8.244–245, 8.245*f*
therapy for infection caused by, 8.270*t*
filaments, 8.244*t*, 8.248–249
rods, 8.244*t*, 8.245–247, 8.246*f*
Gram stain, 4.31*t*, 8.243–244, 8.244*t*
Granular corneal dystrophy, 8.135*t*, 8.145*t*. *See also specific type*
atypical. *See* Reis-Bücklers corneal dystrophy
genetics of, 8.136*t*
recurrence of after corneal transplantation, 8.425, 8.425*f*
refractive surgery and, 13.43
type 1 (GCD1/classic), 4.88–4.90, 4.89*f*, 4.90*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.145–148, 8.146–148*f*
type 2 (GCD2/Avellino), 4.90, 4.91*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.148–149, 8.149*f*
amyloid deposits in, 8.148, 8.186*t*
refractive surgery and, 13.43
Granular cytomegalovirus retinitis, 9.255*f*
Granular-lattice corneal dystrophy. *See* Granular corneal dystrophy, type 2
Granulocytic sarcoma (chloroma), 4.316, 6.218
Granulomas, 4.7, 4.8*f*, 4.9*f*. *See also* Granulomatosis; Granulomatous disease/inflammation
chalazia, 8.77
choroidal, 12.241*f*
conjunctival/ocular surface, 8.46*t*, 8.47*t*
foreign-body, 4.52, 4.53*f*
in Parinaud oculoglandular syndrome, 4.51, 8.265
pyogenic, 4.55, 4.55*f*, 8.345*t*, 8.346, 8.346*f*
after pterygium excision, 8.356
in sarcoidosis, 4.52, 4.52*f*, 8.347
foreign-body, 4.52, 4.53*f*, 6.170
iris, 9.300*f*, 9.302
macular, 6.317*f*
necrobiotic
in episcleritis, 4.109
in scleritis, 4.110, 4.110*f*
posterior pole, 12.245
pyogenic, 4.55, 4.55*f*, 6.170, 6.171*f*, 8.345*t*, 8.346, 8.346*f*
after pterygium excision, 8.356
in sarcoidosis, 4.52, 4.52*f*, 4.187, 4.187*f*, 5.126*f*, 5.327, 8.347
toxocara, 9.45
in toxocariasis, 12.244, 12.245*f*
unifocal eosinophilic, 6.219, 6.219*f*
zonal, 4.119, 4.119*f*
Granulomatosis. *See also* Granulomas; Granulomatous disease/inflammation
eosinophilic, with polyangiitis, 1.172
with polyangiitis (GPA/Wegener granulomatosis)
definition of, 9.158
description of, 1.171–172, 7.34, 7.63–64, 7.64*f*, 12.195, 12.196*f*
diagnosis of, 9.159–160
eyelid manifestations of, 4.207*t*
laboratory investigations for, 9.125*t*
manifestations of, 9.158–159, 9.159*f*
nasolacrimal duct obstruction associated with, 7.306, 7.306*f*
necrotizing scleritis in, 9.120*f*
ocular involvement in, 9.159
optic neuritis and, 5.115
treatment of, 9.160
vision loss in, 9.159
Granulomatous arthritis, pediatric, 6.318
Granulomatous colitis. *See* Crohn disease
Granulomatous conjunctivitis, 4.51–52, 4.52*f*
in Parinaud oculoglandular syndrome, 8.265–266
Granulomatous disease/inflammation, 4.7. *See also* Granulomas; Granulomatosis
conjunctivitis, 4.51–52, 4.52*f*
in Parinaud oculoglandular syndrome, 8.265
focal posttraumatic choroidal, 4.22, 4.22*f*
Granulomatous hypersensitivity reaction, 1.125
Granulomatous ileocolitis. *See* Crohn disease
Granulomatous inflammatory infiltrate, necrobiotic, in episcleritis, 4.109
Granulomatous necrotizing scleritis, 9.120*f*, 9.120–121
Granulysin, in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
Grating acuity
contrast sensitivity and, 5.88
definition of, 6.54
in strabismic amblyopia, 6.54
testing for, 6.8, 6.9*f*, 6.56–57
Graves disease, 7.54. *See also* Thyroid eye disease
hyperthyroidism associated with, 1.43–44
radioactive iodine uptake testing for, 1.42
thyroid-stimulating immunoglobulins in, 1.42

Graves ophthalmopathy. *See* Thyroid eye disease
Graves orbitopathy, 2.470*f*
Gray (Gy), 1.237
Gray line, 2.28
Gray matter, 2.458, 2.459*t*, 2.460*f*
Gray zone, 2.55
Grayscale map, 5.86, 5.87*f*
Greater (major) arterial circle, 5.15
Greater superficial petrosal nerve, 2.135, 5.276–277*f*, 5.277
Greater wing of sphenoid bone, 2.6–7*f*, 2.9–10*f*, 2.11
Green cones. *See* M cones
Green laser, 12.373
GRK1 gene, 12.253
Grocott methenamine silver (GMS) stain, 4.31*t*
Groenouw dystrophy type I (granular corneal dystrophy, type 1/GCD1/classic), 4.90, 4.90*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.147–148, 8.148*f*
Groenouw dystrophy type II (macular corneal dystrophy/MCD), 8.135*t*, 8.136*t*, 8.145*t*, 8.149–151, 8.150*f*
Grönblad-Strandberg syndrome, 12.87. *See also* Pseudoxanthoma elasticum
Gross dissection, for pathologic examination, 4.28*f*, 4.28–30, 4.29*f*
Ground-in prisms, for nystagmus, 6.155
Ground substance, of cornea, 2.53
Group A β-hemolytic streptococci, 1.247
Grouped pigmentation of retina (bear tracks), 4.269, 4.269*f*, 6.349
Growth factors
  in aqueous humor, 2.277
  bioavailability of, 2.277
  definition of, 2.448, 9.21
  in ocular development, 2.165–166
  in tear film, 2.252
  types of, 2.448–449, 9.24*t*
Gruber (petroclinoid) ligament, 5.41
GSH. *See* Glutathione
GSH-Px. *See* Glutathione peroxidase
GSS syndrome. *See* Gerstmann-Sträussler-Scheinker (GSS) syndrome
Guaiac-based fecal occult blood test, for colorectal cancer screening, 1.218–219
Guanine, 2.176
Guanine nucleotide-binding proteins, 2.395
Guanylate cyclase, 2.308, 2.313*t*
Guided Progression Analysis (GPA), in visual field progression identification, 10.71–72, 10.72*f*, 10.73*f*
Guillain-Barré syndrome
  facial diplegia in, 5.280
  Miller Fisher variant of, 5.273, 5.273*t*, 5.280
Guillain-Mollaret triangle lesion, oculopalatal myoclonus and, 5.247
Gullstrand mathematical model, of human eye, 3.59, 3.124, 3.125, 3.126*f*, 3.127*t*, 3.243, 3.270
Gundersen flap, 8.357*f*, 8.357–358, 8.358*f*, 11.129
"Guttering," 12.79
GVHD. *See* Graft-vs-host disease
GW coefficient. *See* Goldmann-Witmer (GW) coefficient
GWAS. *See* Genome-wide association studies
Gy. *See* Gray
Gyrate atrophy, 12.268–269, 12.269*f*
Gyrus
  angular, 5.32*f*
  cingulate, 5.52
  frontal, 5.32*f*
  postcentral, 5.47*f*
  precentral, 5.49
    facial weakness/paralysis caused by lesion of, 5.277
  rectus, 2.105, 2.108*f*, 5.26
  supramarginal, 5.32*f*

H

H_e. *See* Fluence
H_2 blockers, 1.288
H_1-receptor blockers, for ocular allergy. *See* Antihistamines
H&E (hematoxylin-eosin) stain, 4.31*t*
HA-MRSA. *See* Hospital-associated (HA) methicillin-resistant *Staphylococcus aureus*
Haab striae, 6.260, 6.261*f*, 6.280*f*, 6.280–281, 8.109, 10.31, 10.147, 10.151, 10.152*f*, 10.158, 10.166
HAART (highly active antiretroviral therapy). *See* Antiretroviral therapy
Habit spasm, 5.285
HAcetate. *See* Acetic acid
Haemophilus/Haemophilus influenzae, 2.419, 7.46, 8.208*t*, 8.244*t*, 8.248
  biotype III *(H aegyptius)*, 8.207
    conjunctivitis caused by, 8.208*t*, 8.256, 8.257*t*
    invasive capability of, 8.207
  bleb-associated endophthalmitis caused by, 8.248, 12.391
  characteristics of, 1.249–250
  conjunctivitis caused by, 4.52, 8.208*t*, 8.256, 8.257*t*
  as normal flora, 8.206*t*
  preseptal cellulitis caused by, 8.256
  treatment of, 1.250
  type b (Hib), 1.249–250, 8.248
  vaccines for, 1.231, 1.250
Hagberg-Santavuori disease, infantile, 6.389*t*
Haigis formula, 3.249*f*, 3.249–250
  for IOL power determination/selection, 11.85
Hair cells, 5.38, 5.39*f*, 5.214
Hair follicle tumors, 7.193–194
Haldol. *See* Haloperidol
Haller and Zinn, circle of (circle of Zinn), 2.120, 2.122*f*, 5.17, 10.44, 10.46, 12.217
Haller layer, 2.76, 2.77*f*, 12.19
Hallermann-Streiff-François syndrome (oculomandibulodyscephaly), 8.191*t*
Hallucinations, 5.158, 5.173, 5.175–178
  cortical origin of, 5.158, 5.176–178
  hypnagogic, 5.177
  hypnopompic, 5.177
  nonvisual causes of, 5.174*t*
  occipital lobe lesions causing, 5.158, 5.176–178
  ocular origin of, 5.175
  optic nerve origin of, 5.176
  parietal lobe lesions causing, 5.175, 5.177
  sleep-associated, 5.177
  temporal lobe lesions causing, 5.155, 5.176–177

in visually impaired patient (Charles Bonnet syndrome), 5.177–178
Hallucinosis, peduncular, 5.176
Haloperidol, oculogyric crisis caused by, 5.231
Halos
with IOLs
angle-supported lenses, 13.146
iris-fixated lenses, 13.145
multifocal lenses, 13.156
after photoablation, 13.102
pupil size and, 13.40
after radial keratotomy, 13.51
spherical aberrations causing, 13.12, 13.102
with transient monocular visual loss, 5.164
Hamartin, 5.334*t*
Hamartomas, 4.6, 4.50, 5.331–332, 7.40
astrocytic (astrocytomas), 4.249, 4.249*f*, 5.108*f*, 6.353, 6.397, 6.399*f*
juvenile pilocytic, 4.249
optic. *See* Optic nerve glioma
pilocytic. *See* Optic nerve glioma
retinal, 4.295, 4.296*f*
optic nerve/nerve head/disc drusen differentiated from, 5.108*f*, 5.143
retinoblastoma differentiated from, 4.295, 4.296*f*
in tuberous sclerosis, 4.295, 5.143, 5.331*f*, 5.334*t*
combined, of retina and retinal pigment epithelium, 4.179, 4.180*f*, 4.280, 4.280*f*
of conjunctiva/eyelid/ocular surface, 4.50, 8.345*t*
of retinal pigment epithelium
combined, 4.179, 4.180*f*, 4.280, 4.280*f*
in Gardner syndrome, 4.145
simple, 4.279, 4.280*f*
Hamartomatous angiofibromas. *See also* Adenoma, sebaceous (sebaceum)
in tuberous sclerosis, 5.331*f*, 5.334*t*
Hand deformities, rheumatoid arthritis-related, 1.152, 1.152*f*
Handheld esthesiometer, 8.42–43
Handheld laser-pointer injury, 12.369
Handheld magnifiers, 3.321, 3.321*f*
Handpiece, phaco, 11.98, 11.98*f*
Hangback recession, 6.163
Haploid, 2.215
Haploid insufficiency, 2.197
Haploinsufficiency, 2.226
Haplotype, 9.63
HapMap, 2.189–190, 2.190*f*
Haptic of IOL, insertion of lens and, 11.116, 11.117, 11.119, 11.119*f*
Harada-Ito procedure
description of, 6.124
Fells modification of, 6.167
HARBOR study, 12.82
Harboyan syndrome, 6.259
Hard contact lens method, for IOL power calculation after refractive surgery, 13.195
Hard contact lenses. *See* Rigid gas-permeable (RGP) contact lenses
Hard-design progressive addition lenses, 3.182, 3.183*f*
Hard drusen, 4.162, 4.162*f*, 12.65
Hard exudates, 4.140, 4.152, 4.153*f*, 12.122, 12.160
in leukemia, 4.315
"Hard" tubercles, 4.7, 4.8*f*. *See also* Tubercles
Hardy-Rand-Rittler (HRR) plates
for color vision testing, 12.54
in low vision evaluation, 5.78–79
Harlequin syndrome, 5.257
Harmonious anomalous retinal correspondence, 6.76
Hartmann screen, 3.286
Hartmann-Shack wavefront sensor/aberrometry, 3.277, 3.289, 3.290*f*, 13.9, 13.10*f*
Hashimoto thyroiditis, 1.45–46, 7.54, 7.57
Hassall-Henle bodies/warts (peripheral corneal guttae), 2.53, 8.115, 8.128
"Hatchet face," in myotonic dystrophy, 5.329
HATTS. *See* Hemagglutination treponemal test for syphilis
HAV. *See* Hepatitis, A
Hay fever conjunctivitis, 8.288–289
Hay-Wells syndrome, 6.194
Haze formation
after corneal crosslinking, 13.135
after LASIK, 13.33
diffuse lamellar keratitis and, 13.116
pressure-induced stromal keratopathy and, 13.119
surface ablation re-treatment/enhancements and, 13.98
late-onset, 13.109
regression after surgery and, 13.109
after small-incision lenticule extraction, 13.205
after surface ablation, 13.33, 13.52, 13.92, 13.108–110, 13.109*f*
corticosteroids in reduction of, 13.33, 13.94, 13.108–109
mitomycin C in reduction of, 13.33, 13.92, 13.109
undercorrection and, 13.102, 13.108–109
vitreous, in intermediate uveitis, 9.81*f*, 9.81–82, 9.82*t*
wound healing and, 13.33
Hb. *See* Hemoglobin
HbA_{1c}. *See* Hemoglobin A_{1c}
HBV. *See* Hepatitis, B
HCl. *See* Hydrochloric acid
HCO_3. *See* Bicarbonate
HCT. *See* Hematopoietic stem cell transplantation
HCV. *See* Hepatitis, C
HDE. *See* Humanitarian device exemption
HDL-C. *See* High-density-lipoprotein cholesterol
HDL cholesterol. *See* High-density-lipoprotein cholesterol
Head
bony anatomy of, 5.5–11, 5.6*f*, 5.7–8*f*, 5.9*f*, 5.10*f*
torticollis of. *See* Torticollis
vascular anatomy of, 5.11–23
arterial, 5.11–20, 5.13–14*f*, 5.15*f*, 5.16*f*, 5.17*f*, 5.18*f*, 5.20*f*
venous, 5.21*f*, 5.21–23, 5.22*f*, 5.23*f*
Head lice, ocular infection caused by, 8.255
Head movements
abnormal, spasmus nutans and, 5.239
vestibular-ocular reflex and, 5.214, 5.215
Head thrusts
in ocular motor apraxia patients, 5.223
vestibular-ocular reflex gain evaluation and, 5.215–216
Head-tilt, chin-lift maneuver, 1.297

Head trauma, 7.119. *See also* Trauma
abusive, 6.381–384, 6.382–383*f*
anisocoria caused by, 5.256*f*, 5.262–263
chiasmal injury caused by, 5.152
convergence insufficiency caused by, 5.227
fourth nerve (trochlear) palsy caused by, 5.199, 5.200
optic nerve damage caused by, 5.139*f*, 5.139–140
pupil irregularity caused by, 5.255
restrictive syndromes caused by, 5.186, 5.206
seventh nerve (facial) palsy caused by, 5.280
sixth nerve (abducens) palsy caused by, 5.201
Headache, 5.287–295, 5.288*t*
analgesic rebound, 5.293
in arteriovenous malformations, 5.291, 5.292*f*, 5.343
in carotid dissection, 5.342
classification of, 5.287
cluster, 5.289*t*, 5.294
Horner syndrome and, 5.260*t*, 5.261, 5.294
evaluation of, 5.287–288, 5.288*t*
in giant cell (temporal) arteritis, 5.288, 5.313
in hemicrania continua, 5.289*t*, 5.294
history in, 5.287, 5.288*t*
ice pick, 5.294
idiopathic stabbing, 5.294
intracranial hemorrhage causing, 5.288
intracranial hypertension causing, 5.107, 5.288
idiopathic, 5.110, 5.112, 5.113, 5.288
migraine. *See* Migraine headache
primary, 5.287
in recurrent painful oculomotor neuropathy, 5.197
refractive errors and, 3.25
ruptured aneurysm causing, 5.340
secondary, 5.287
in subarachnoid hemorrhage, 1.121
tension-type, 5.292–293
"thunderclap," 5.346
transient visual loss and, 5.161, 5.162, 5.171–172, 5.177, 5.287. *See also* Migraine headache
treatment of, 5.292–293
trigeminal autonomic cephalgias, 5.289*t*, 5.293–294
trochlear (trochleitis), 5.296
Healing, ophthalmic wound. *See* Wound(s), healing/repair of
Healon/Healon-GV/Healon5, 2.445, 11.96, 11.97
Hearing loss
cataract surgery in patient with, 11.170
pigmentary retinopathy and, 12.284. *See also* Usher syndrome
retinitis pigmentosa and, 12.284
vestibular nystagmus and, 5.241, 5.241*t*, 5.242
Heart block, 1.101
Heart disease. *See* Coronary heart disease; Ischemic heart disease
Heart failure. *See* Congestive heart failure
Heat, anterior segment injuries caused by, 8.384–385, 8.385*f*
Heavy-chain disease, crystalline corneal deposits and, 8.198
Heavy chains, immunoglobulin, overproduction of, crystalline corneal deposits and, 8.198
Heavy eye syndrome (strabismus fixus), 5.208
HEDS (Herpetic Eye Disease Study), 8.216, 8.222, 8.223*t*, 11.175
Heerfordt syndrome, 1.162, 9.195
Heidenhain variant of Creutzfeldt-Jakob disease, 5.357
Height maps, 13.22, 13.22*f*
Heimann-Bielschowsky phenomenon, 5.238–239, 6.152
Heimlich maneuver, 1.299
Helical CT scanners, 7.27
Helicases, 2.181
Helicobacter pylori, 7.92
gastric cancer and, 1.219
Helicoid peripapillary choroidopathy. *See* Serpiginous choroidopathy
Heliotrope rash, 1.167, 1.167*f*
HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, 12.197*f*
Helmholtz hypothesis (capsular theory) of accommodation, 11.22, 13.159–160, 13.160*f*
Helmholtz type keratometer, 8.27
Helminths, 8.252–253
Helper T cells. *See also* CD4$^+$ T cell(s); T cell(s); *specific T helper cell*
accessory molecules expressed by, 9.31
in adaptive immune response, 9.30, 9.32*f*
antigen receptor on, 9.30
classification of, 9.32
differentiation of, 9.32–35
priming of, 9.31
subsets of, 9.32
Th1, 9.32–33
Th2, 9.32
Th17, 9.33–34
Hemagglutination treponemal test for syphilis (HATTS), 1.253
Hemangioblastomas, 6.353, 6.400, 6.400*t*
cerebellar, with retinal angiomatosis (von Hippel–Lindau disease), 4.284–285, 5.330, 5.331*f*, 5.334*t*
retinal, 4.144, 4.144*f*, 4.283–285, 4.284*f*. *See also* Retinal angiomatosis
in von Hippel–Lindau disease/syndrome, 5.330, 5.331*f*, 5.334*t*, 12.165–166, 12.166*f*, 12.168
Hemangiomas (hemangiomatosis), 4.281–286. *See also* Angiomas (angiomatosis)
capillary, 8.345*t*, 8.345–346. *See also* Infantile (capillary) hemangioma
cavernous, 4.6, 8.345, 8.345*t*, 8.346, 12.168, 12.169*f*. *See also* Cavernous hemangioma
choroidal, 4.197, 4.198*f*, 4.281–283, 4.282*f*, 4.283*f*, 12.202*f*, 12.202–203
in Sturge-Weber syndrome, 4.197, 4.281, 5.332*f*, 5.334*t*
of conjunctiva, 4.50, 8.345*t*, 8.345–346
definition of, 6.219
eyelid, 4.214, 4.215*f*, 5.271, 6.199, 8.345*t*, 8.345–346
infantile (capillary). *See* Infantile (capillary) hemangioma
of orbit, 4.6, 4.233, 4.234*f*, 6.219–221
cavernous, 4.6, 4.233, 4.234*f*
infantile (capillary), 4.233
transient visual loss and, 5.164
plaque, 6.220, 6.220*f*
propranolol for, 6.220, 6.221*f*

racemose (Wyburn-Mason syndrome/Bonnet-Dechaume-Blanc syndrome), 4.286*f*, 4.286–287, 5.331, 5.333*f*, 5.334*t*, 6.222, 6.394*t*, 6.405, 6.405–406, 12.168
of retina, 4.283–286, 4.284*f*, 4.285*f*
capillary (retinal capillary hemangioblastoma/angiomatosis retinae). *See* Capillary hemangioblastoma; Retinal angiomatosis
cavernous, 4.285*f*, 4.285–286
systemic disease associated with, 6.220
treatment of, 6.220–221
Hemangiopericytomas
description of, 7.89
of orbit, 4.235, 4.235*f*
Hematogenous seeding, 8.206
Hematologic disorders. *See also specific type*
anemia. *See* Anemia
blood composition, 1.131
corneal changes in, 8.197–199, 8.198*f*, 8.199*f*
erythropoiesis, 1.131
hemostasis disorders. *See* Hemostasis, disorders of
Hematopoietic growth factors, 1.242
Hematopoietic stem cell transplantation (HCT)
allogeneic, for thalassemias, 1.134
complications of, 1.135
sickle cell disease treated with, 1.135
Hematopoietic tissue, tumors arising in, 4.10*t*, 4.11*f*
Hematoxylin-eosin (H&E) stain, 4.31*t*
Hemeralopia (day blindness), 12.264
in cone/cone-rod dystrophies, 5.102
Hemi-Descemet membrane endothelial keratoplasty (hemi-DMEK), 8.449–450
Hemiachromatopsia, 5.179
Hemianopia, 5.105*t*
chiasmal lesions causing, 5.146, 5.147*f*, 5.151*f*, 5.152
homonymous
arteriovenous malformations causing, 5.343, 5.344*f*
cortical injury causing, 5.29
hallucinations within, 5.177
lateral geniculate body lesions causing, 5.154, 5.154*f*
in migraine headache, 5.171–172
in neuromyelitis optica, 5.320
occipital lobe lesions causing, 5.156–158, 5.157*f*, 5.158*f*, 5.159*f*
optic tract lesions causing, 5.147*f*, 5.153
optokinetic nystagmus (OKN) testing in evaluation of, 5.219
in palinopsia, 5.176
parietal lobe lesions causing, 5.156
retrochiasmal lesions causing, 5.153
temporal lobe lesions causing, 5.155, 5.155*f*
in vertebrobasilar disease, 5.336
Hemiatrophy, progressive facial (Parry-Romberg syndrome), 8.192*t*
Hemicrania
continua, 5.289*t*, 5.294
paroxysmal, 5.289*t*, 5.294
Hemidesmosomes, 2.51, 2.52*f*
Hemifacial microsomia, 6.210, 6.210*f*, 7.27*f*
in Goldenhar-Gorlin syndrome, 8.191*t*, 8.195–196
Hemifacial spasm (HFS), 2.359, 2.475*t*, 5.282*t*, 5.283*f*, 5.283–284, 6.202, 7.256, 7.257*f*, 7.258, 7.269
Hemiretinal vein occlusion (HRVO), 12.130, 12.133*f*
Hemispatial neglect (hemineglect), 5.181
Hemispheric transient ischemic attack (HTIA), stroke and, 5.168–169
Hemoglobin (Hb), 12.373, 12.374*f*
normal level of, 1.132
synthesis defects involving, 1.134–136
Hemoglobin A_{1c} (HbA_{1c})
in diabetes mellitus, 1.34
diabetic retinopathy and, 12.96, 12.98
Hemoglobin S, 1.135, 12.149
Hemoglobinopathies, sickle cell. *See* Sickle cell anemia/sickle cell disease; Sickle cell retinopathy
Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome, 12.197*f*
Hemolysis, renal response to, 1.136
Hemolytic anemia
characteristics of, 1.135–137
microangiopathic, 1.142
Hemolytic glaucoma, 4.103, 4.104*f*, 10.105, 10.106
Hemolytic-uremic syndrome (HUS), 1.136, 1.142
Hemophilia A, 1.144
Hemophilia B, 1.144
Hemorrhage. *See also* Hyphema
cataract surgery and, 11.157–160
flat anterior chamber and, 11.134
patient receiving anticoagulation therapy and, 11.74, 11.157, 11.171–172
choroidal. *See* Hemorrhage, suprachoroidal/choroidal
conjunctival, in acute hemorrhagic conjunctivitis, 8.240
dot-and-blot, ischemia causing, 4.153–154, 4.155*f*, 5.170, 5.171*f*
flame, ischemia causing, 4.153, 4.155*f*
glaucoma and, 4.103, 4.104*f*, 10.50, 10.51*f*, 10.85*f*, 10.85–86
histologic sequelae of, 4.22
intracerebral, 1.120
intracranial, 1.120–122
arteriovenous malformations causing, 5.343
headache caused by, 5.288
ruptured aneurysm causing, 5.340
intralesional, 6.221, 6.221*f*
intraretinal, 9.157*f*
intraventricular, 1.120–121
nerve fiber layer, in glaucoma, 10.50, 10.51*f*
neuroimaging in evaluation of, 5.72*t*
ocular, ruptured aneurysm causing, 5.340, 5.340*f*
peripapillary, 6.373
retinal. *See also specific type*
in abusive head trauma, 6.382–383, 383*f*, 12.366, 12.366*f*
in branch retinal vein occlusion, 4.159
in carotid occlusive disease, 12.138
in central retinal vein occlusion, 4.156, 4.158*f*
in glaucoma, 10.50, 10.51*f*
ischemia causing, 4.153–154, 4.155*f*
in leukemia, 4.315, 4.315*f*, 6.414
in ocular ischemic syndrome, 5.170, 5.171*f*
retrobulbar, cataract surgery and, 11.158, 11.171
salmon-patch
description of, 12.150, 12.150*f*
syphilitic keratitis and, 8.107, 8.308, 8.309*f*
subarachnoid, 1.121, 6.382
arteriovenous malformations causing, 5.343

with ocular hemorrhage, 5.340, 5.340*f*
ruptured aneurysm causing, 5.340
subconjunctival, 8.115*t*, 8.387–388, 8.388*f*
submacular
in neovascular age-related macular degeneration, 12.85, 12.385
posttraumatic, 12.354*f*
vitrectomy for, 12.385, 12.386*f*
subretinal, 6.373
choroidal neovascularization *versus*, 12.211
in polypoidal choroidal vasculopathy, 12.76
suprachoroidal/choroidal, 4.18, 4.19*f*, 12.394–395, 12.395*f*
angle-closure glaucoma and, 10.141
cataract surgery and, 11.159, 11.171
delayed, 11.160
expulsive, 11.159–160
flat anterior chamber and, 11.134
expulsive, 4.18, 4.19*f*
cataract surgery and, 11.159–160
after filtering surgery, 10.210–211
vitreous, 2.302, 4.132–133
in central retinal vein occlusion, 12.135
echography for, 12.347
hemolytic/ghost cell glaucoma and, 4.133, 10.105, 10.106
peripheral neovascularization, 12.232
photocoagulation as cause of, 12.379
in polypoidal choroidal vasculopathy, 12.75
posterior vitreous detachment and, 12.309
in proliferative diabetic retinopathy, 12.103, 12.103*f*, 12.107–108
trauma-related, 12.357
treatment of, 12.309
in Valsalva retinopathy, 12.171
vision loss caused by, 12.346
Hemorrhagic chorioretinopathy, peripheral exudative (PEHCR), 4.270*f*, 4.271
Hemorrhagic choroidal detachment, melanoma differentiated from, 4.170–171
Hemorrhagic conjunctivitis, 1.264
acute (AHC), 8.240, 8.240*t*
Hemorrhagic disease of the newborn, 1.145
Hemorrhagic occlusive retinal vasculitis (HORV), 2.361, 12.300–301
Hemorrhagic stroke. *See* Stroke
Hemosiderin
corneal blood staining and, 4.86, 4.86*f*
in glaucoma, 4.103, 4.104*f*
Hemosiderosis/siderosis bulbi, 4.103, 4.120, 11.58*f*, 11.58–59
glaucoma and, 4.103, 10.103
Hemostasis
clot formation in, 1.138
disorders of
amyloidosis, 1.140
cataract surgery in patient with, 11.171–172
causes of, 1.138
clinical manifestations of, 1.140
Ehlers-Danlos syndrome, 1.140
essential thrombocythemia, 1.142–143
essential thrombocytopenia, 1.142–143
hemophilia A, 1.144
hemophilia B, 1.144
hereditary hemorrhagic telangiectasia, 1.140
idiopathic thrombocytopenic purpura, 1.141
laboratory tests for, 1.139–140
Marfan syndrome, 1.140–141
osteogenesis imperfecta, 1.140
platelet disorders, 1.141–144
pseudoxanthoma elasticum, 1.140
scurvy, 1.140
thrombocytopenia, 1.141–142
thrombocytosis, 1.142–143
thrombotic thrombocytopenic purpura, 1.142
vascular disorders, 1.140–141
von Willebrand disease, 1.144–145
laboratory evaluation of, 1.139–140
pathways of, 1.138*f*
physiology of, 1.138–139
Henderson-Patterson bodies, 8.237
Henle fiber layer/Henle layer (HFL), 2.84, 2.92, 2.94*f*, 4.140, 4.141*f*, 5.24. *See also* Nerve fiber layer
definition of, 12.9
histology of, 12.11, 12.12*f*
myopia macular schisis of, 12.209
HEP. *See* Hepatoerythropoietic porphyria
Heparan sulfate
in microbial adherence, 8.207
in mucopolysaccharidoses, 8.175*t*
Heparin
coronary heart disease treated with, 1.91*t*
indications for, 1.150
low-molecular-weight
coronary heart disease treated with, 1.91*t*
description of, 1.149
stroke prevention uses of, 1.114
unfractionated, 1.149
Hepatic disease. *See* Hepatitis; Liver disease
Hepatitis
A, 1.224, 1.232
B, 1.224, 1.226, 1.232, 1.237*t*
C, 1.226, 1.237*t*, 1.263
D, 1.263
E, 1.263
G, 1.263
immunization for, 1.224–226, 1.225*t*, 1.232
Hepatocellular cancer, 1.220, 1.224
Hepatoerythropoietic porphyria (HEP), 8.190
Hepatolenticular degeneration (Wilson disease), 8.189*f*, 8.189–190, 11.62. *See also* Wilson disease
cataracts associated with, 8.189, 11.62
oculogyric crisis in, 5.231
penicillamine for, 8.189
Hepcidin
ferrous sulfate effects on, 1.133
in iron deficiency anemia, 1.132
Herbert pits, 8.261, 8.261*f*
Hereditary, 2.210–211. *See also* Genetics
Hereditary benign intraepithelial dyskeratosis, 8.332*t*
Hereditary dystrophies. *See also specific type*
choroidal
Bietti crystalline dystrophy, 12.258, 12.269, 12.282*t*
choroidemia, 12.267–268, 12.268*f*
classification of, 12.255
gyrate atrophy, 12.268–269, 12.269*f*

endothelial, congenital (CHED/CHED2), 4.92–93, 4.94*f*, 8.135*t*, 8.136*t*, 8.160, 8.161*f*
photoreceptor (diffuse), 4.170, 4.172*f*
retinal
bilateral symmetric involvement of, 12.258
blindness concerns of patients with, 12.260
cystoid macular edema in, 12.260, 12.260*f*
diagnostic considerations for, 12.258–259
enhanced S-cone disease, 12.266, 12.267*f*
gene therapy for, 12.260, 12.266
genes and loci associated with, 12.256–12.257*t*
genetic considerations for, 12.259
inheritance patterns for, 12.259
Leber congenital amaurosis, 12.265–266
management of, 12.259–260, 12.260*f*
molecular genetic testing for, 12.259
photoreceptor, 4.170, 4.172*f*
rod–cone dystrophies, 12.261–264, 12.262–12.264*f*
stem cell therapy for, 12.260
stromal, congenital (CHSD/CSCD), 8.135*t*, 8.136*t*, 8.152, 8.153*f*
Hereditary factors. *See* Genetic/hereditary factors
Hereditary hemorrhagic telangiectasia, 1.140
Hereditary hyaloideoretinopathies with optically empty vitreous, 12.342–343, 12.343*f*
Hereditary macular dystrophies
Best disease, 6.340–342, 6.342*f*
Stargardt disease, 6.339–340, 6.340–341*f*
Hereditary optic neuropathy, 5.107*t*, 5.133–135, 5.134*f*, 5.136*f*
Leber (LHON), 5.133–135, 5.134*f*, 6.368
description of, 2.185–186
family history of, 2.200
mitochondrial DNA mutations and, 5.133
optic neuritis and, 5.115, 5.133
Hereditary retinoblastomas, 2.226–227
Hereditary sensory and autonomic neuropathy, type III. *See* Familial dysautonomia
Hereditary spherocytosis, 1.136
Hereditary vitreoretinopathies, familial exudative, 6.347–348, 6.348*f*
Hering's law of equal innervation/motor correspondence
description of, 2.124, 6.38, 6.115–116, 6.121, 7.242, 7.242*f*, 7.253
eyelid retraction and, 5.274
horizontal gaze and, 5.36*f*
nystagmus and, 5.247
ptosis enhancement and, 5.270*f*, 5.310
Heritability, 2.210
Hermansky-Pudlak syndrome, 1.144, 2.229, 6.407, 12.288
Her2Neu, in immunohistochemistry, 4.35
Herpes simplex keratitis, 2.447
Herpes simplex virus (HSV), 2.434, 7.269, 8.212–225
acute retinal necrosis/progressive outer retinal necrosis/nonnecrotizing herpetic retinitis caused by, 4.145, 5.350. *See also* Herpes simplex virus, retinitis caused by
acyclovir for infection caused by, 8.215*t*, 8.219, 8.222, 8.223*t*
anterior uveitis associated with, 9.247–250
antiviral agents for, 8.205, 8.215, 8.215*t*, 8.219, 8.222, 8.223*t*, 8.224, 8.225
blepharitis/blepharoconjunctivitis/conjunctivitis caused by, 8.208*t*, 8.213, 8.214*f*, 8.216, 8.226*t*, 8.257*t*, 8.260*t*
characteristics of, 1.259–260
conjunctivitis caused by, 4.52, 6.239, 6.242, 8.208*t*, 8.213, 8.214*f*, 8.216, 8.226*t*, 8.257*t*, 8.260*t*
dermatoblepharitis caused by, 8.208*t*, 8.213, 8.214*f*, 8.216
famciclovir for infection caused by, 8.215*t*
infectious scleritis caused by, 9.124
iridocyclitis caused by, 8.222–224
keratitis caused by, 4.76–78, 4.77*f*, 4.80, 6.269, 8.208*t*, 8.213, 8.214*f*, 8.216*f*, 8.216–222, 8.217*f*, 8.218*f*, 8.220*f*, 8.221*f*, 9.334
Acanthamoeba keratitis differentiated from, 8.278
disciform, 4.77*f*, 4.78, 8.220, 8.221*f*, 8.222
persistent bullous keratopathy and, 8.225
epithelial, 8.213, 8.214*f*, 8.216*f*, 8.216–219, 8.217*f*, 8.218*f*, 8.226*t*
interstitial, 4.77*f*, 4.78, 4.80, 8.219–220, 8.220*f*, 8.222
necrotizing, 8.219, 8.220–221, 8.221*f*, 8.222, 8.223*t*
neurotrophic keratopathy/ulcers/persistent corneal epithelial defects and, 4.77*f*, 8.80, 8.81*t*, 8.217–218, 8.224, 8.225
nonnecrotizing, 8.219, 8.220*f*, 8.221*f*, 8.223*t*
after penetrating keratoplasty, 8.424, 8.425*f*
penetrating keratoplasty for, 8.225
recurrence of in graft, 8.225
recurrent corneal erosion and, 8.86
refractive surgery and, 13.173–174
stromal, 4.77*f*, 4.78, 8.219–222, 8.220*f*, 8.221*f*
treatment of, 8.219, 8.222
latency/recurrent infection and, 8.205, 8.207, 8.212, 8.213, 8.215–224, 8.216*f*, 8.217*f*, 8.218*f*, 8.220*f*, 8.221*f*, 8.223*t*, 8.226*t*
neonatal, 6.412
ocular hypertension associated with, 9.248–249
ocular infection/inflammation caused by, 6.412, 8.208*t*, 8.212–225
adenovirus infection differentiated from, 8.213–214
cataract surgery and, 11.175
complications of, 8.224–225
iridocorneal endothelial syndrome and, 8.127
neuro-ophthalmic signs of, 5.350, 5.350*f*
pathogenesis of, 8.213
primary infection, 8.213–215, 8.214*f*
recurrent infection, 8.215–224, 8.216*f*, 8.217*f*, 8.218*f*, 8.220*f*, 8.221*f*, 8.223*t*, 8.226*t*. *See also* Herpes simplex virus, latency/recurrent infection and
excimer laser exposure and, 13.173–174
refractive surgery and, 13.37, 13.173–174
treatment of, 8.205, 8.215, 8.215*t*, 8.219, 8.222, 8.223*t*
surgical, 8.225
varicella-zoster virus infection differentiated from, 8.225, 8.226*t*
ophthalmia neonatorum caused by, 6.239
perinatal infection caused by, 8.213
retinitis caused by, 4.145, 5.350
necrotizing, 4.145, 12.236–12.237*f*, 12.236–237, 12.238*t*
transmission of, 8.213
type 1, 1.237*t*, 8.213
type 2, 1.237*t*, 8.213

valacyclovir for infection caused by, 8.215*t*, 8.219, 8.222
Herpes zoster, 6.243, 6.243*f*, 8.225, 8.226–227, 9.248, 9.334. *See also* Herpes zoster ophthalmicus; Varicella-zoster virus
acute retinal necrosis/progressive outer retinal necrosis/nonnecrotizing herpetic retinitis caused by, 5.350
acyclovir for, 8.229
conjunctivitis and, 4.52, 8.225–230, 8.226*t*
cranial nerve VII (facial) involvement and, 5.280
description of, 2.434
famciclovir for, 8.229
ophthalmic manifestations in, 5.298, 5.298*f*, 5.350, 8.226*t*, 8.226–230, 8.227*f*, 8.228*f*
retinitis caused by, necrotizing, 4.145, 5.350
scleritis/episcleritis and, 8.227, 8.282
vaccine in prevention of, 5.298, 8.229
valacyclovir for, 8.229
without vesicles (zoster sine herpete), 5.298
Herpes zoster ophthalmicus (HZO), 1.278, 5.298, 5.298*f*, 5.350, 8.226*t*, 8.226–230, 8.227–228*f*, 8.228*f*, 9.248
acyclovir for, 8.229
lipid keratopathy and, 8.125, 8.228, 8.228*f*
neurotrophic keratopathy/persistent corneal epithelial defects and, 8.80, 8.81*t*, 8.227
refractive surgery and, 13.174
Herpesviruses (Herpesviridae)/herpesvirus infection, 8.212–233. *See also specific virus*
cytomegalovirus, 1.237*t*, 1.261–262, 1.279
Epstein-Barr virus, 1.262
herpes simplex virus. *See* Herpes simplex virus
neuro-ophthalmic signs of, 5.350, 5.350*f*
refractive surgery and, 13.37, 13.173–174
types of, 1.259
varicella-zoster, 1.260–261
Herpetic choroiditis, 9.177
Herpetic encephalitis, 9.251
Herpetic Eye Disease Study (HEDS), 8.216, 8.222, 8.223*t*, 11.175
Herpetic keratitis, 2.394
Herpetic retinitis
necrotizing, 9.330, 9.330*f*
nonnecrotizing, 9.250–254
Herpex. *See* Idoxuridine
hESC. *See* Human embryonic stem cells
Hess screen, 6.120
Heterochromia (heterochromia iridis)
in Fuchs heterochromic uveitis/iridocyclitis, 10.101
in Fuchs uveitis syndrome, 9.145, 9.146*f*
in Horner syndrome, 5.258
pediatric iris, 6.274, 6.274*f*, 6.274*t*
in siderosis bulbi, 11.58*f*
Heteronymous diplopia, 6.75
Heterophoria method, for accommodative convergence/accommodation ratio measurement, 3.177, 5.226, 5.227, 6.71
Heteroplasmy, 2.176
in Leber hereditary optic neuropathy, 5.133
Heterotopy, 6.28
Heterotropias/tropias
alternating, 6.64
bifocal segment decentration and, 3.191
definition of, 6.15
heterophoria *versus*, 6.64
heterotropia *versus*, 6.64
horizontal, 3.196–197
in monofixation syndrome, 6.51
refractive surgery and, 13.41
vertical, 3.197
Heterozygous, 2.214
Hex K. *See* Hexagonal keratotomy
Hexagonal cells, specular microscopy in evaluation of percentage of, 8.23
Hexagonal keratotomy (Hex K), 13.8*t*
Hexokinase, in lens glucose/carbohydrate metabolism, 11.17, 11.18*f*, 11.19
Hexosaminidase, defective/deficiency of, in gangliosidoses, 8.176
Hexosaminidase activator deficiency, 6.389*t*
Hexose monophosphate (HMP) shunt
description of, 2.289
in glucose/carbohydrate metabolism, in lens, 11.17, 11.18*f*, 11.19
Hexose monophosphate pathway, 2.260
HF. *See* Hydrofluoric acid
HFAs. *See* Humphrey perimeters/Humphrey Field Analyzers
HFL. *See* Henle fiber layer/Henle layer
HFS. *See* Hemifacial spasm
HGD gene, in alkaptonuria, 8.184
HGP. *See* Human Genome Project
Hib (*Haemophilus influenzae* type b), 1.249–250, 8.248
Hidrocystoma
apocrine, 4.208, 4.208*f*
eccrine, 4.208, 7.191
High AC/A ratio
in accommodative esotropia, 6.90–92
bifocal glasses for, 6.102
in intermittent exotropia, 6.100
High-density-lipoprotein cholesterol (HDL-C). *See also* Cholesterol
coronary heart disease prevention in, 1.71
pathogenesis of, 1.72
High-frequency ultrasound, 2.462
High hyperopia, cataract surgery in patient with, 11.185
High-index glass, 3.195
High-index lens, 3.196
High (pathologic) myopia
cataract surgery in patient with, 11.184–185
chorioretinal atrophy in, 12.214*f*
choroid in, 12.212–216, 12.214–12.215*f*
choroidal neovascularization caused by, 12.89, 12.90*f*, 12.211*f*, 12.211–212
criteria for, 3.143
definition of, 12.207
description of, 3.143
esotropia associated with, 6.97, 6.143–144
exotropia associated with, 6.143–144
factors associated with, 12.207
glaucoma and, 10.82, 10.122, 12.218, 12.218*f*
global prevalence of, 12.207
macular holes in, 12.209
ocular expansion related to, 12.216
optic nerve in, 12.217–218, 12.218*f*
prevalence of, 12.207

prevention of, 12.207–208
retina in, 12.207–216, 12.209–215
sclera in, 12.216–217, 12.217*f*
surgical correction of
bioptics for, 13.157
phakic IOLs for, 13.140
refractive lens exchange for, 13.148, 13.150
retinal detachment and, 13.44, 13.183–184, 13.184, 13.197
swept-source optical coherence tomography of, 12.209*f*
traction effects on retinal vessels in, 12.209
High-plus-power lenses, 12.375
High-power intraocular lenses, 3.264
Higher-order aberrations, 13.11–13, 13.12*f*, 13.13*f*. *See also* Aberrations; Irregular astigmatism; Wavefront aberrations; *specific type*
keratorefractive surgery and, 3.276–277
after LASIK, 13.11, 13.12, 13.102–103, 13.103*f*
point spread function and, 3.305
pupil size and, 3.106
after radial keratotomy, 13.11, 13.12
after surface ablation, 13.11, 13.12, 13.13, 13.102
topography-guided laser ablation and, 13.32, 13.77
wavefront-guided/wavefront-optimized ablation and, 13.13, 13.31–32, 13.76–77
Zernike polynomials and, 3.139
Highly active antiretroviral therapy (HAART). *See* Antiretroviral therapy
Hilar adenopathy, 7.65*f*, 7.66
Hip fractures, 1.190
Hippus, 5.254
Hirschberg test, 6.67, 6.68*f*
Histamine
in basophils, 9.19
in connective tissue mast cells, 9.3
hay fever conjunctivitis and, 8.288
in mast cells, 9.19
in mucosal mast cells, 9.3
Histiocytes, 4.7
epithelioid, 4.7, 4.8*f*
Histiocytic disorders, 7.95–97, 7.96*f*
Histiocytic lymphoma. *See* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma; Primary vitreoretinal lymphoma
Histiocytoma, fibrous, 8.347
malignant, 4.112
orbital, 4.235
scleral, 4.112, 4.113*f*
Histiocytosis X. *See* Langerhans cell histiocytosis
Histo spots, 9.273, 9.273*f*
Histocompatibility antigens. *See* Human leukocyte antigens
Histocryl. *See* Cyanoacrylate glue/adhesive
Histograms
description of, 1.28, 1.29*f*
for flow cytometry results, 4.36, 4.37*f*
Histoplasma capsulatum, 9.272, 12.86–87
Histoplasmosis, 12.86–87
Historical methods, for IOL power calculation after refractive surgery, 11.86–87, 13.194
History
in cataract, 11.69–71, 11.70*t*
evaluation for surgery and, 11.74–76
before corneal transplantation, 8.418
in diplopia, 5.183
family. *See also under Genetic*
in glaucoma, 10.10, 10.82, 10.121
angle-closure glaucoma and, 10.121
open-angle glaucoma and, 10.82
in ocular hypertension, 10.90
glaucoma evaluation and, 10.29–32
in infants/children/adolescents, 10.157
in headache, 5.287, 5.288*t*
in low vision assessment, 5.78–79
in ocular surface neoplasia, 8.328
in penetrating and perforating ocular trauma, 8.401
in refractive surgery evaluation, 13.35–39, 13.36*t*
in trauma, 8.401
HIV (human immunodeficiency virus), 6.348, 8.240*t*, 8.241. *See also* HIV infection/AIDS
antiretroviral therapy for, 1.268
clinical syndromes of, 1.267
conjunctivitis caused by, 8.240*t*, 8.241, 8.260*t*
description of, 1.266
etiology of, 1.266–267
opportunistic infections in, 1.269
pathogenesis of, 1.266–267
risk factors for, 1.267
syphilis involvement in, 1.253
transmission of, excimer laser ablation and, 13.189
treatment of, 1.268
HIV-1. *See* HIV infection/AIDS
HIV-2. *See* HIV infection/AIDS
HIV-associated neurocognitive disorder (HIV encephalopathy/AIDS dementia complex), 5.348
HIV-associated neuroretinal disorder (HIV-RND), 5.348
HIV infection/AIDS, 5.348–350, 8.240*t*, 8.241. *See also* AIDS (acquired immunodeficiency syndrome); HIV (human immunodeficiency virus)
CMV infection in, 5.349, 5.349*f*
retinitis, 5.349, 9.256, 12.235
conjunctivitis in, 8.240*t*, 8.241, 8.260*t*
cryptococcosis in, 5.356
encephalopathy in (AIDS dementia complex/HIV-associated neurocognitive disorder), 5.348
herpes simplex keratitis in, 8.222
herpes zoster and, 9.334
herpesvirus infection in, 8.222
intraocular lymphoma risks, 12.234
Kaposi sarcoma in, 5.349, 8.347
lymphoma in, 5.349
microsporidiosis in, 8.280, 8.280*f*
molluscum contagiosum in, 8.237, 8.238*f*
neuro-ophthalmic signs of, 5.348–350, 5.349*f*
neuroretinal disorder in, 5.348
ocular infection/manifestations and, 5.348, 8.240*t*, 8.241, 8.260*t*
ocular surface squamous neoplasia in, 4.61
ocular toxoplasmosis in, 9.281–282, 9.282*f*
ophthalmic manifestations of, 9.327–333, 9.328*f*, 9.330*f*, 9.332*f*
progressive multifocal leukoencephalopathy in, 5.351
refractive surgery in patient with, 13.188–190
retinitis in, 4.145, 5.349, 9.256, 12.235
retinopathy associated with, 9.327, 9.328*f*

seventh nerve (facial) palsy in, 5.280
syphilis and, 9.219–220, 9.331–332
Toxoplasma retinochoroiditis/toxoplasmosis in, 5.352, 12.243
HIV-RND. *See* HIV-associated neuroretinal disorder
Hives, fluorescein angiography as cause of, 12.36
HLA(s). *See* Human leukocyte antigens
HLA-A29
birdshot chorioretinopathy and, 9.34, 9.64–65, 9.65*t*, 9.165
prevalence of, 9.64
HLA-B5, 12.230
HLA-B12, 9.215
HLA-B27, 1.154, 1.156
characteristics of, 9.131
diseases associated with
ankylosing spondylitis, 9.130*f*, 9.131–132
clinical presentation of, 9.130, 9.130*f*
inflammatory bowel syndrome, 9.133
pattern of, 9.130
psoriatic arthritis, 9.133, 9.134*f*
reactive arthritis syndrome, 9.132–133, 9.133*f*
uveitis and, 9.64, 9.65*t*
HLA-B51, 9.215
HLA-D, 9.63
HLA-DM, 9.63
HLA-DR4
Lyme disease and, 9.228
Vogt-Koyanagi-Harada syndrome and, 9.204
HMB-45, in immunohistochemistry, 4.34
melanoma diagnosis and, 4.68
HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme-A) reductase inhibitors. *See also* Statins
cataracts and, 11.53
hypercholesterolemia treated with, 1.75*t*, 1.76
lipid-lowering uses of, 1.75*t*, 1.76
HMP shunt. *See* Hexose monophosphate (HMP) shunt
HMS. *See* Medrysone
Hoffer Q formula, 3.249*f*, 3.249–250
for IOL power determination/selection, 11.85, 11.86
Holes
macular, 4.131–132, 4.132*f*
contusion injury as cause of, 12.315
fellow-eye risk for development of, 12.339
formation of, 12.339, 12.340*f*
idiopathic
description of, 12.337–339, 12.338*f*
vitrectomy for, 12.384–385, 12.385*f*
International Vitreomacular Traction Study Classification System for, 12.336*t*
lamellar, 12.28*f*
management of, 12.339–340
optical coherence tomography of, 12.27*f*
in pathologic myopia, 12.209
posttraumatic, 12.355–357, 12.356*f*
rhegmatogenous retinal detachment caused by, 12.330, 12.330*f*
spontaneous resolution of, 12.340
stage 0, 12.339
stage 1, 12.339–340
stage 2, 12.339
stage 3, 12.339
stage 4, 12.339
surgical management of, 12.339–340
optic (optic pits, optic nerve/disc pits, optic pit maculopathy), 5.145
acquired, 10.49–50
outer-schisis-layer, 12.327, 12.327*f*
retinal
atrophic
definition of, 12.315
lattice degeneration and, 4.150, 12.310, 12.311*f*, 12.316*f*
retinal detachment secondary to, 12.310
description of, 12.378
lattice degeneration and, 4.150
operculated, 12.315–316
Holladay formulas, 3.249*f*, 3.250
for IOL power determination/selection, 11.85, 11.87
Hollenhorst plaques (cholesterol emboli), 12.141, 12.142*f*, 12.144
in branch retinal artery occlusion, 4.156
transient visual loss and, 5.165, 5.165*f*, 5.166*t*
Holmes-Adie syndrome, 5.264. *See also* Adie tonic pupil
Holmium:yttrium-aluminum-garnet (Ho:YAG) laser
photothermal effects of, 13.29
for thermokeratoplasty, 13.127–128
Holocrine glands, of eyelid, 8.4
Homatropaire. *See* Homatropine hydrobromide
Homatropine hydrobromide, 2.380*t*
Homeobox genes/homeotic selector genes
in Axenfeld-Rieger syndrome, 8.97*t*, 8.102
description of, 2.164–165
functions of, 2.171
in Peters anomaly, 8.97*t*, 8.103
Homeotic selector genes, 2.171
Homer Wright rosettes, 6.353
in medulloepithelioma, 4.179
in retinoblastoma, 4.175, 4.175*f*
Homing, 9.38
Homocysteine, 1.148
Homocystinuria, 2.204*t*, 6.308–309, 6.389*t*, 11.41, 12.282*t*
ectopia lentis in, 11.41
lens disorders in, 11.41
vitamin B_6 replacement therapy for, 11.41
Homogentisate 1,2-dioxygenase, in alkaptonuria, 8.184
Homogentisic acid/homogentisic acid oxidase, alkaptonuria and, 8.184
Homologous chromosomes, 2.175, 2.215–216
Homonymous, 5.105*t*
Homonymous diplopia, 6.75
Homonymous hemianopia, 2.474*t*, 6.83
arteriovenous malformations causing, 5.343, 5.344*f*
cortical injury causing, 5.29
hallucinations within, 5.177
lateral geniculate body lesions causing, 5.154, 5.154*f*
in migraine headache, 5.171–172
in neuromyelitis optica, 5.320
occipital lobe lesions causing, 5.156–158, 5.157*f*, 5.158*f*, 5.159*f*
optic tract lesions causing, 5.147*f*, 5.153
optokinetic nystagmus (OKN) testing in evaluation of, 5.219

in palinopsia, 5.176
parietal lobe lesions causing, 5.156
retrochiasmal lesions causing, 5.153
temporal lobe lesions causing, 5.155, 5.155*f*
in vertebrobasilar disease, 5.336
Homoplastic corneal inlays, 13.60
Homoplastic lenticule, in epikeratoplasty, 13.62
Homozygous, 2.214
Honeycomb-shaped corneal dystrophy. *See* Thiel-Behnke corneal dystrophy
Hordeolum (hordeola)
description of, 6.198–199, 7.183–184, 7.184*f*, 7.191, 8.76*f*, 8.76–77
external (stye), 4.203–204, 8.76, 8.76*f*
internal, 8.76, 8.77. *See also* Chalazion
HORIZON study, 12.81–82
Horizontal cells, 2.315*f*, 2.316, 5.24
Horizontal deviations. *See also* A-pattern strabismus; V-pattern strabismus
in craniosynostosis, 6.208
dissociated, 6.17, 6.105, 6.105*f*, 6.129
extraocular muscle surgery for, 6.161
Maddox rod test for, 6.69
Horizontal eyelid shortening/tightening, for exposure keratopathy, 8.80
Horizontal gaze
description of, 5.37*f*, 5.37–38
deviation of, seizures and, 1.208
palsy of, 5.228, 5.229*f*
in one-and-a-half syndrome, 5.191
in sixth nerve palsy, 5.189, 5.200, 5.200*f*
Horizontal heterophorias, 3.196–197
Horizontal phaco chop technique, 11.114
Horizontal rectus muscles. *See also* Lateral rectus (LR) muscle; Medial rectus (MR) muscle
anatomy of, 6.20, 6.35*f*
inferior zone of, 6.24
innervation of, 6.34
in pattern strabismus, 6.109–110
primary position of, 6.35, 6.35*f*
recession/resection of
description of, 6.139
for esodeviations, 6.160
monocular, 6.161
for nystagmus correction, 6.157
superior zone of, 6.24
transposition of, 6.110, 6.112
Horizontal rotations, 6.31
Horizontal strabismus. *See* Horizontal deviations
Hormone(s)
in cancer chemotherapy, metastatic eye disease and, 4.310
hypothalamic, 1.47, 1.47*t*
ocular adverse effects of, 1.309*t*
thyroid. *See* Thyroid hormones
Hormone replacement therapy (HRT)
breast cancer and, 1.215
refractive surgery in patient taking, 13.37
tear production affected by, 8.62*t*
Horner muscle, 2.29, 2.32*f*, 7.163, 7.282
Horner syndrome, 5.256*f*, 5.257–262, 5.259*f*, 5.260*t*, 5.261*f*, 5.262*f*, 6.274–275, 6.415*f*
apraclonidine for diagnosis of, 2.386
carotid artery dissection causing, 5.162, 5.260*t*, 5.261, 5.262*f*, 5.297
cluster headache and, 5.260*t*, 5.261, 5.294
congenital, 5.261–262, 7.246
description of, 7.104, 7.243–244
imaging studies for, 2.475*t*
pharmacologic testing for, 5.258–259, 5.259*f*
ptosis and, 5.257, 5.259*f*, 5.272, 5.273*t*
vertebrobasilar insufficiency and, 5.337
Horner-Trantas dots, 6.248, 6.249*f*, 8.289–290, 8.290*f*
Horopter
definition of, 6.41
empirical, 6.41, 6.42*f*
Horror fusionis, 6.48
Horseshoe-shaped retinal tears, 12.316, 12.323*f*
HORV. *See* Hemorrhagic occlusive retinal vasculitis
Hospital-associated (HA) methicillin-resistant *Staphylococcus aureus,* 7.45
Host defenses, 8.11–14, 8.12–13*f*, 8.206
impaired. *See* Immunocompromised host
Host–microbe interactions, 1.245
Hot nodules, 1.44
"HOTV" character set, 3.23
HOTV optotypes, 3.133*f*
HOTV test, 6.6, 6.6*t*, 6.7*f*
Houseplants, ocular injuries caused by, 8.387
Ho:YAG laser (holmium:yttrium-aluminum-garnet laser)
photothermal effects of, 13.29
for thermokeratoplasty, 13.127–128
HPMC. *See* Hydroxypropyl methylcellulose
HPMPC. *See* Cidofovir
HPS. *See* Hermansky-Pudlak syndrome
HPV. *See* Human papillomavirus
HRR plates. *See* Hardy-Rand-Rittler (HRR) plates
HRT. *See* Hormone replacement therapy
HRVO. *See* Hemiretinal vein occlusion
H_2SO_3. *See* Sulfurous acid
H_2SO_4. *See* Sulfuric acid
HSV. *See* Herpes simplex virus
HTIA. *See* Hemispheric transient ischemic attack
HTLV-1. *See* Human T-lymphotropic virus type 1
HTRA1 gene, in age-related macular degeneration, 4.160
HU (HTLV-1 uveitis). *See* HTLV-1 (human T-lymphotropic virus type 1)
Hudson-Stähli line, 8.117, 8.118*t*
Hughes classification, for chemical injury of eye, 8.376, 8.376*t*
Human bites, 7.218
Human embryonic stem cells, 2.166
Human Genome Project (HGP), 2.187
Human granulocytic anaplasmosis, 9.230
Human granulocytic ehrlichiosis, 9.230
Human herpesvirus 4. *See* Epstein-Barr virus
Human herpesvirus 8, 9.333
Kaposi sarcoma caused by, 8.239, 8.347
Human herpesviruses, 8.212–233. *See also* Herpesviruses; *specific type*
Human immunodeficiency virus. *See* HIV (human immunodeficiency virus)
Human immunodeficiency virus (HIV) infection. *See* HIV infection/AIDS

Human leukocyte antigens (HLAs). *See also specific HLA*
allelic variation, 9.63–64
disease associations with, 9.64–66, 9.65*t*
function of, 9.63
genotyping of, 9.63
haplotype of
definition of, 9.63
disease associations with, 9.64–66, 9.65*t*
in Mooren ulcer, 8.314
in mucous membrane pemphigoid, 8.299
in multiple sclerosis, 5.315
in reactive arthritis/Reiter syndrome, 8.305–306
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
"Human optical bench," 3.14*f*
Human papillomavirus (HPV), 8.238
cancer associated with
cervical, 1.217–218, 1.237*t*
conjunctival intraepithelial neoplasia, 8.238
characteristics of, 1.264
conjunctival papillomas caused by, 4.59–60, 4.60*f*, 8.238–239, 8.239*f*, 8.332*t*, 8.332–334, 8.333*f*
eyelid infection/wart caused by, 4.204, 4.205*f*
ocular infection/papillomas caused by, 4.59–60, 4.60*f*, 4.204, 4.205*f*, 8.238–239, 8.239*f*, 8.332*t*, 8.332–334, 8.333*f*
ocular surface squamous neoplasia and, 4.61
transmission of, 1.231
vaccination for, 1.225*t*, 1.231–232, 1.236
Human T-lymphotropic virus type 1 (HTLV-1), 1.237*t*
description of, 9.265–267, 9.266*f*
keratopathy associated with, 9.266
uveitis associated with, 9.263–264
Humanitarian device exemption (HDE), for Intacs use in keratoconus, 13.65–66
Humoral immune system/humoral immunity, 1.245
Humphrey perimeters/Humphrey Field Analyzers (HFAs), 5.87*f*, 10.60, 10.61, 10.61*f*, 10.64*f*, 10.64–65
visual field progression evaluation with, 10.71–74, 10.72*f*, 10.73*f*, 10.74*f*
Humphrey perimetry, 3.315
Humphrey Visual Field Index, 10.72–74, 10.74*f*
Hunter syndrome (MPS II), 2.204*t*, 6.388*t*, 8.174, 8.175*t*, 12.283*t*, 12.291
Hurler-Scheie syndrome (MPS IH/S), 8.174, 8.175*t*
Hurler syndrome (MPS IH/MPS1-H), 2.204*t*, 2.214, 6.270, 6.388*t*, 8.174, 8.175*t*, 8.176*f*, 12.282*t*, 12.290
Hurricane (vortex) keratopathy (cornea verticillata), 8.90, 8.129*t*, 8.130, 8.130*f*, 8.176, 8.177*f*
in chloroquine/hydroxychloroquine toxicity, 8.130
in Fabry disease, 6.270, 8.176, 8.177*f*
HUS. *See* Hemolytic-uremic syndrome
Hutchinson melanotic freckle, 7.200
Hutchinson sign, 5.49, 9.248
Hutchinson triad, 6.412, 8.308, 9.220
Huygens, Christiaan, wave theory of light, 3.94–95, 3.95*f*
Hyaline bodies, optic disc/nerve. *See* Optic disc (optic nerve head/ONH), drusen of
Hyaline deposits
in granular corneal dystrophy type 1, 8.147
in granular corneal dystrophy type 2, 8.148
Hyaline (hard) drusen, 4.162, 4.162*f*
Hyalocytes, 2.101, 2.294, 2.299*f*, 2.299–300, 4.125, 9.56
oxygen consumption by, 12.7
in vitreous, 12.7
Hyaloid artery/system, 2.158*f*, 6.366, 12.340–341
persistence/remnants of, 4.125–126, 4.126*f*. *See also* Persistent fetal vasculature
optic nerve/nerve head/disc edema differentiated from, 5.107
tunica vasculosa lentis development and, 11.29, 11.29*f*
Hyaloid (Cloquet) canal, 2.157, 4.125
Hyaloid corpuscle (Mittendorf dot), 4.126, 11.29, 11.31, 11.32*f*
Hyaloideocapsular ligament, 2.157
Hyalosis, asteroid, 4.133, 4.133*f*
Hyaluronan/hyaluronic acid, 2.293, 2.371*t*, 12.331
description of, 2.293
in thyroid eye disease, 4.226
in vitreous, 2.297
Hyaluronate/sodium hyaluronate, as viscoelastic, 11.95
elevated intraocular pressure and, 10.108
Hyaluronic acid fillers, 7.270, 7.270*f*
Hyaluronidase, 2.440
in Natowicz syndrome, 8.175*t*
Hybrid contact lenses, after radial keratotomy, 13.200
Hybridization
comparative genomic (CGH), 4.38*t*
fluorescence in situ (FISH), 4.38*t*
Hybridomas, 1.242
Hydatid cyst, orbital infection associated with, 4.228
Hydralazine, 1.64
Hydraulic mechanism theory, 7.114
Hydrochloric acid (HCl), ocular injuries caused by, 8.376*t*
Hydrocortisone, 1.175*t*, 2.402*t*
Hydrocortisone/neomycin sulfate/polymyxin B sulfate, 2.422*t*
Hydrocortisone/neomycin sulfate/polymyxin B sulfate/bacitracin zinc, 2.422*t*
Hydrodelineation, in phacoemulsification, 11.110
for advanced cataract, 11.180
for posterior polar cataract, 11.181
for zonular dehiscence with lens subluxation or dislocation, 11.182
Hydrodissection, in phacoemulsification, 11.110
for advanced cataract, 11.180
for posterior polar cataract, 11.111, 11.181
for traumatic cataract, 11.192
for zonular dehiscence with lens subluxation or dislocation, 11.182
Hydrofluoric acid (HF), ocular injuries caused by, 8.376*t*, 8.380
Hydrogel contact lenses, 3.213
Hydrogel polymers
for IOLs, capsular opacification and, 11.153
in material addition techniques, 13.28
corneal inlays, 13.59, 13.60
Hydrogen peroxide (H_2O_2), 2.336, 2.337*t*, 9.16. *See also* Free radicals
Hydrogen peroxide solution, for contact lens, 3.229, 3.229*t*
Hydrops, in keratoconus, 4.95*f*, 4.96, 8.163–164, 8.164*f*
management of, 8.167–168

3-Hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitors. *See also* Statins
cataracts and, 11.53
hypercholesterolemia treated with, 1.75*t*, 1.76
lipid-lowering uses of, 1.75*t*, 1.76
Hydroxyamphetamine
description of, 2.380*t*
in Horner syndrome diagnosis, 5.259–260, 5.261*f*
Hydroxyamphetamine hydrobromide/tropicamide, 2.380*t*
Hydroxyapatite orbital implant. *See* Orbital implants
Hydroxychloroquine, 1.164, 1.178–179, 1.308*t*
cornea verticillata caused by, 8.130
toxicity
description of, 12.295–297
multifocal electroretinography findings in, 12.45, 12.49*f*
nonneovascular age-related macular degeneration *versus*, 12.68
Hydroxyl/hydroxy radicals, 2.337*t*, 9.16. *See also* Free radicals
9-2-Hydroxypropoxymethylguanine. *See* Ganciclovir
Hydroxypropyl cellulose inserts, for dry eye, 8.63
Hydroxypropyl methylcellulose (HPMC), as viscoelastic, 11.95
Hydroxyurea
essential thrombocythemia treated with, 1.143
sickle cell disease treated with, 1.135
Hyfrecator, for punctal occlusion, 8.65
Hyper- (prefix), 6.15
Hyperacuity testing, in age-related macular degeneration, 12.69
Hyperaldosteronism, hypertension caused by, 1.54
Hyperautofluorescence, in chloroquine toxicity, 12.297
Hyperbaric oxygen therapy, oxidative lens damage/cataracts and, 11.20, 11.65
Hypercalcemia
corneal changes in, 8.118, 8.198. *See also* Band keratopathy/calcific band keratopathy
in sarcoidosis, 5.327
Hypercalciuria, in sarcoidosis, 5.327
Hypercapnia, 1.124
Hypercholesterolemia. *See also* Hyperlipidemia; Hyperlipoproteinemias
corneal arcus and, 8.120, 8.121, 8.179
management of. *See* Lipid-lowering therapy
in Schnyder corneal dystrophy, 8.151, 8.179
Hyperchromic heterochromia, 6.274*t*
Hypercoagulable states (hypercoagulability). *See also* Thrombosis/thrombotic disorders
cerebral venous thrombosis and, 5.346
description of, 1.146
NAION and, 5.123
in pregnancy, 1.148
primary, 1.146–148
secondary, 1.146, 1.148
transient visual loss and, 5.171
Hyperemia
conjunctival, 6.237, 6.238*t*, 8.45*t*, 8.114, 8.115*t*
in glaucoma, 10.31
prostaglandin analogues causing, 10.175
insect/arachnid injuries causing, 8.386
in scleritis, 9.117, 9.117*f*
Hyperfluorescence, in fluorescein angiography, 12.35
Hyperglobus, 7.23
Hyperglycemia. *See also* Diabetes mellitus; Glycemic control
blood–retina barrier breakdown caused by, 12.108
cataract formation and. *See* Diabetes mellitus (DM), cataracts associated with
control of. *See* Glycemic control
in diabetes mellitus, 1.33
Hyperglycinemia, 2.204*t*
Hyperhomocysteinemia, 1.148, 12.134
Hyperkeratosis
in actinic keratosis, 4.211
definition of, 4.202
exuberant (cutaneous horn), 4.211
Hyperlipidemia
cerebrovascular disease and, 1.78
ischemic heart disease and, 1.78
lifestyle modifications for, 1.74
management of, 1.74–79
peripheral arterial disease and, 1.78
statins for, 1.75*t*, 1.76–77
Hyperlipoproteinemias, 8.179. *See also* Hypercholesterolemia
corneal changes in, 8.179
arcus and, 8.120, 8.121, 8.179
Schnyder corneal dystrophy and, 8.151, 8.179
xanthelasma associated with, 4.206, 4.207*t*
Hyperlysinemia, 11.41
Hypermature cataract, 11.46, 11.49*f*
phacolytic glaucoma/uveitis and, 4.103, 10.97*f*, 10.97–98, 11.67
Hypermelanosis (complexion-associated melanosis), 4.63*t*, 4.65, 4.66, 4.66*f*
Hypermetric saccades, 5.221, 5.222, 5.248, 5.248*f*
Hyperopia, 6.180, 12.201
age-related increases in, 3.143
angle closure/angle-closure glaucoma and, 10.29, 10.122
anisometropic, 3.185*f*
after cataract surgery, prior refractive surgery and, 11.177
cataract surgery in patient with, 11.185
in children, 3.141, 3.174–175
consecutive, 13.101–102
converging lens for, 3.170, 3.170*f*
cornea plana and, 8.96*t*, 8.100
definition of, 3.3, 3.13, 3.124
developmental, 3.143
esotropia and, 3.175
glaucoma and, 10.29, 10.122
high, cataract surgery in patient with, 11.185
high accommodative convergence/accommodative (AC/A) esotropia and, refractive surgery and, 13.188
in infants, 3.141
isometropic, 3.185*f*
latent, refraction at near to detect, 3.36–38
microcornea and, 8.96*t*, 8.99
model of, 3.13, 3.13*f*
myopia overcorrection and, 13.101–102
conductive keratoplasty for, 13.129
pictorial representation of, 3.138*f*

prismatic effects of bifocal lenses in, 3.185*f*
after radial keratotomy, 13.51, 13.52
correction of, 13.52
retinal reflex in, 3.152
spectacle lenses for, 3.211, 3.212*f*
surgical correction of, 13.30
bioptics for, 13.137, 13.157
conductive keratoplasty for, 13.128, 13.129*f*, 13.165
corneal curvature steepening and, 13.26, 13.80, 13.96
homoplastic corneal inlays and, 13.60
keratophakia for, 13.59–62, 13.62*f*
LASIK for, 3.271, 3.271*f*, 13.96, 13.97
light-adjustable IOLs for, 13.153–154, 13.154*f*
monovision for, 13.165
myopia after (consecutive myopia), 13.101–102
nonlaser, 13.8*t*
overcorrection and, 13.101–102
phakic IOLs for, 13.137, 13.138–140, 13.140
photoablation for, 13.74*f*
outcomes of, 13.96
photorefractive keratectomy for, 13.94, 13.96
phototherapeutic keratectomy for, 8.367
photothermal therapy for, 13.29
refractive lens exchange for, 13.148, 13.150
thermokeratoplasty for, 13.127
wavefront-optimized/wavefront-guided laser ablation for, 13.31
outcomes of, 13.31–32, 13.97
wavefront aberration produced by (negative defocus), 13.11
Hyperopic anisometropia, 3.140
Hyperopic astigmatism, 3.138, 3.138*f*
outcomes of photoablation for, 13.96
Hyperosmolar drugs, 2.443
Hyperosmolarity, tear film, dry eye and, 8.39, 8.53
Hyperosmotic/osmotic agents, 10.174*t*, 10.182–183
for acute angle closure, 10.124–125, 10.184
Hyperparathyroidism, corneal changes and, 8.200–201
Hyperplasia, 4.10*t*, 6.183*t*
epithelial, ciliary pigmented, 4.279, 4.280*f*
intravascular papillary endothelial, 8.345*t*
lymphoid/reactive lymphoid (RLH)
of conjunctiva/ocular surface, 4.69–70, 4.70*f*, 8.327, 8.348–349, 8.349*f*
lymphoma and, 8.327, 8.348, 8.349
of orbit, 4.231, 4.232. *See also* Lymphomas, orbital; Lymphoproliferative disorders
of uveal tract (primary choroidal lymphoma/uveal lymphoid proliferation/infiltration/lymphoma), 4.199, 4.199*f*, 4.313–314
pseudoadenomatous (Fuchs adenoma), 4.179, 4.279
pseudoepitheliomatous, 8.332*t*
sebaceous, 4.215, 4.216*f*
Hyperprolactinemia, 1.48
Hypersensitivity
delayed
definition of, 9.42
granulomatous form of, 9.44
subtypes of, 9.42
T cells
description of, 9.36, 9.42–44
inflammatory diseases mediated by, 9.44*t*
in sympathetic ophthalmia, 9.45–46
T helper-cell 2, 9.43
in toxocara granuloma, 9.45
T helper cell-17 in, 9.44
tuberculin form of, 9.28
immediate, 9.48–49
Hypersensitivity reactions. *See also* Allergic reactions/allergies
anaphylactic (immediate/type I)
atopic keratoconjunctivitis and, 8.292
contact dermatoblepharitis and, 8.285, 8.286*f*, 8.287
hay fever conjunctivitis and, 8.288
topical medications/substances and, 8.285, 8.286*f*, 8.287
cytotoxic (type II), in mucous membrane pemphigoid, 8.299
delayed (type IV)
contact dermatoblepharitis as, 8.286, 8.286*f*, 8.287
in graft rejection, 8.316, 8.317
topical medications/substances and, 8.286, 8.286*f*, 8.287
immediate (type I/anaphylactic). *See* Hypersensitivity reactions, anaphylactic (immediate/type I)
Hypersplenism, 1.134, 1.136
Hypertelorism, 6.191, 7.23, 7.39
Hypertension. *See also* Pulmonary hypertension
in adolescents, 1.68
ambulatory blood pressure monitoring in, 1.53
angina pectoris and, 1.65
arteriosclerotic vascular disease and, 12.122
asteroid hyalosis and, 12.346
in black patients, 1.52, 1.57
blood pressure in
ambulatory monitoring of, 1.53
classifications of, 1.52*t*, 1.52–53, 1.214
as cardiovascular risk factor, 1.55, 1.56*t*
cerebrovascular disease and, 1.66
characteristics of, 1.51–52
in children, 1.68
choroidopathy caused by, 12.123, 12.123–12.124*f*
chronic, 1.67–68
chronic renal disease and, 1.65
classification of, 12.121
coronary heart disease risks, 1.73*t*
definition of, 1.214
in diabetes mellitus, 1.56, 1.65
diabetic retinopathy progression associated with, 12.98
end-stage renal disease secondary to, 1.214
etiology of, 1.53–55
evaluation of, 1.55–56
focal intraretinal periarteriolar transudates caused by, 12.121–122, 12.122*f*
glaucoma and, 10.83
health risks associated with, 1.51, 1.214
heart failure and, 1.65
intracerebral bleeding secondary to, 1.120
intracranial. *See* Intracranial hypertension
in intraventricular hemorrhage, 1.120
left ventricular hypertrophy and, 1.66
lifestyle modifications for, 1.57, 1.58*t*

malignant, 12.196
masked, 1.51, 1.53
metabolic syndrome and, 1.66
obesity as risk factor for, 1.66, 1.68
obstructive sleep apnea syndrome and, 1.66
ocular (OHT), 10.4*t*, 10.89–90. *See also* Elevated intraocular pressure; Ocular hypertension
refractive surgery and, 13.104–105, 13.180–183, 13.182*f*, 13.200–201
in older adults, 1.67
optic neuropathy caused by, 12.123, 12.125
oral contraceptives and, 1.67
pathogenesis of, 1.53–55
patient education and assessment in, 1.69–70
perioperative management for ocular surgery in patients with, 1.284
peripheral arterial disease and, 1.66
physical examination of, 1.55
in pregnancy, 1.67–68
prevalence of, 1.51, 1.214, 12.121
primary, 1.53
race and, 1.51–52
rebound, 1.69
renin-angiotensin-aldosterone system in, 1.53, 1.54*f*
resistant, 1.54, 1.55*t*, 1.64
retinal complications of, 1.69–70, 1.70*t*
retinal vascular diseases associated with, 12.121–125, 12.122–12.124*f*
retinopathy caused by, 12.121–123, 12.122*f*, 12.124*f*
screening for, 1.214
secondary
causes of, 1.53–54, 1.55*t*
in children, 1.68
laboratory tests for, 1.55
stage 1, 1.52
stage 2, 1.52–53
stroke and, 1.66, 1.115
transient, 1.68
treatment of
advanced glycation cross-link breakers, 1.65
algorithm for, 1.60*f*
α_1-blockers, 1.62–63
angiotensin-converting enzyme inhibitors, 1.59*t*, 1.61, 1.165
angiotensin II receptor blockers, 1.59*t*, 1.61
antihypertensives, 1.52, 1.56–57, 1.59–64
β-blockers, 1.62, 1.69
blood pressure thresholds as guidelines for, 1.60*f*
calcium channel blockers, 1.59*t*, 1.61–62
combination therapy, 1.63
combined α-adrenergic and β-adrenergic antagonists, 1.63
comorbidities, 1.65–66
considerations in, 1.57
DASH diet, 1.57, 1.58*t*
direct renin inhibitors, 1.63
direct vasodilators, 1.63
diuretics, 1.59*t*, 1.59–61
future, 1.64–65
lifestyle modifications, 1.57, 1.58*t*
nonpharmacologic, 1.57, 1.58*t*, 1.64
in older adults, 1.67
pharmacologic, 1.51–52. *See also* Antihypertensive therapy
radiofrequency ablation, 1.64–65
ventricular dysfunction and, 1.65
"white coat," 1.53
withdrawal syndromes as cause of, 1.68–69
in women, 1.67–68
Hypertensive crisis, 1.69
Hypertensive retinopathy, 1.69, 1.70*t*
Hyperthyroidism
Graves, 1.43–44. *See also* Thyroid eye disease
orbitopathy/ophthalmopathy and. *See* Thyroid eye disease
radioactive iodine for, 7.60
Hypertonic medications, for recurrent corneal erosions, 8.87
Hypertrichosis, prostaglandin analogues/latanoprost causing, 10.175, 10.175*f*
Hypertrophic subepithelial corneal degeneration, peripheral, 8.124–125, 8.125*f*
Hypertropia
dissociated vertical deviation and, 6.115
exotropia associated with, 6.100
extraocular muscle surgery for, 6.164–165
incomitant, 6.125
inferior rectus muscle weakness as cause of, 6.128
rectus muscle surgery for, 6.164–165
superior oblique muscle palsy associated with, 6.123
Hypertyrosinemia/tyrosinemia, 8.183*t*, 8.183–184, 8.184*f*
alkaptonuria and, 8.184
corneal changes in, 8.183–184, 8.184*f*
Hyperuricemia, 8.188
band keratopathy and, 8.119, 8.188
Hyperviscosity, transient visual loss and, 5.171
Hyperviscosity retinopathy, central retinal vein occlusion *versus*, 12.134
Hyphae, 8.249, 8.250*f*
Hyphema, 6.378*f*, 6.378–379
after cataract surgery, 11.149, 11.158–159
corneal blood staining and, 4.86
after cataract surgery, 11.159
glaucoma/elevated intraocular pressure and, 4.103, 4.104*f*, 8.395, 10.104*f*, 10.104–105. *See also* Uveitis-glaucoma-hyphema (UGH) syndrome
normal-tension glaucoma and, 10.85*f*, 10.85–86
iris-fixated phakic IOL insertion and, 13.145
layered, 8.392, 8.393*f*
microscopic, 8.392, 8.392*f*
sickle cell disease and, 8.395*t*, 8.396
elevated intraocular pressure and, 8.395, 8.395*t*, 8.396
sickle cell disease/retinopathy/elevated intraocular pressure and, 10.104, 10.105
spontaneous, 8.393
total/eight-ball, 8.393, 8.393*f*
transient visual loss and, 5.164
traumatic, 8.391–396, 8.392*f*, 8.393*f*, 8.394*f*, 8.395*t*, 12.154
glaucoma/elevated intraocular pressure and, 8.395, 10.104*f*, 10.104–105
medical management of, 8.394–395
rebleeding after, 8.394, 8.394*f*, 10.104, 10.105

sickle cell disease and, 8.395, 8.395*t*, 8.396
elevated intraocular pressure and, 8.395, 8.395*t*, 8.396
sickle cell disease/retinopathy/elevated intraocular pressure and, 10.104, 10.105
surgery for, 8.395*t*, 8.395–396, 8.396, 10.105
Hypnagogic hallucinations, 5.177
Hypnopompic hallucinations, 5.177
Hypnotic drugs, 1.201*t*, 1.201–202
Hypo- (prefix), 6.16
Hypoaccommodation, 6.9
Hypoautofluorescence, in chloroquine toxicity, 12.297
Hypocalcemia, cataracts associated with, 11.61–62
Hypochondriasis. *See* Illness anxiety disorder
Hypochromic heterochromia, 6.274*t*
Hypoesthesia/anesthesia, corneal
congenital, 8.108
herpes simplex keratitis and, 8.217–218, 8.226*t*
herpes zoster and, 8.226*t*, 8.228
keratoplasty and, 8.418, 8.424
after LASIK, 13.172
in neurotrophic keratopathy/persistent corneal epithelial defects, 8.80, 8.224
Hypoglobus, 7.23
Hypoglycemia
agents for. *See* Insulin
description of, 1.300
Hypokalemia, carbonic anhydrase inhibitors causing, 10.180
Hypolipoproteinemias, corneal changes in, 8.180*f*, 8.180–181
Hypometric saccades, 5.221, 5.222
Hypoperfusion. *See also* Ischemia
scotomata caused by, 5.157–158, 5.159*f*
transient visual loss caused by, 5.161, 5.162, 5.170, 5.171*f*
Hypophosphatasia, 8.192*t*
Hypophysitis, lymphocytic, 5.335
Hypopigmented macule (ash-leaf spot), in tuberous sclerosis, 5.331*f*, 5.334*t*, 10.30
Hypoplasia, 6.183*t*. *See also specific structure affected*
Hypoplasminogenemia, in ligneous conjunctivitis, 8.294
Hypopyon, 12.390
in acute anterior uveitis, 9.130, 9.131*f*
in *Aspergillus* endophthalmitis, 9.300
in Behçet disease, 9.214, 9.214*f*
after cataract surgery, 11.140
endophthalmitis, 9.6
lens-associated uveitis, 9.6
in leukemia, 9.308
Hypotelorism
ocular, 6.191
orbital, 6.203
Hypotension
glaucoma and, 10.87
ocular. *See* Hypotony
phenylephrine hydrochloride for, 2.384
Hypotensive lipids. *See* Prostaglandin (PG) analogues
Hypothalamic-pituitary-adrenal suppression, 1.175
Hypothalamic-pituitary axis
disorders of, 1.46–49
functions of, 1.46–47
Hypothalamus, 5.52, 5.53*f*
functions of, 1.46
hormones secreted from, 1.47, 1.47*t*
Hypothyroidism, 1.44–45
thyroid eye disease and. *See* Thyroid eye disease
Hypotony, 9.321
cataract/cataract surgery in patient with, 11.68, 11.185
during/after surgery
filtering surgery and, 10.210
flat anterior chamber and, 11.135
angle-closure glaucoma and, 10.144
suprachoroidal effusion/hemorrhage and, 11.159, 11.160
tube shunt implantation and, 10.216–217, 10.217, 10.218*t*
Hypotony maculopathy, 10.210, 12.201
antifibrotic use and, 10.205
Hypotropia
extraocular muscle surgery for, 6.164–165
high myopia associated with, 6.143–144
in monocular elevation deficiency, 6.126, 6.126*f*
primary position, with Brown syndrome, 6.137
pseudoptosis/superior rectus muscle anatomy and, 5.270, 5.270*f*, 5.274, 6.30
rectus muscle surgery for, 6.164–165
Hypovolemic shock, 1.300. *See also* Shock
Hypoxemia, 1.124
Hypoxia inducible factor, 2.228
Hysteresis, corneal, 8.43
Hysteria, 5.299
"Hysterical blindness." *See* Nonorganic (functional/nonphysiologic) ophthalmic disorders
HZO. *See* Herpes zoster ophthalmicus

I

I_e. *See* Radiant intensity
I_v. *See* Luminous intensity
I-cell (inclusion-cell) disease (ML II), 6.388*t*, 8.178
I-S (inferior-superior) values, 8.31, 13.4
after intrastromal corneal ring segment implantation, 13.66
in keratoconus/corneal ectasia, 8.32*t*, 8.165, 8.165*f*
IA. *See* Irrigation/aspiration
IADLs. *See* Instrumental activities of daily living
IAPB (International Agency for the Prevention of Blindness), 11.6
Iatrogenic Brown syndrome, 6.168
IBD. *See* Inflammatory bowel disease
Ibuprofen, 1.308*t*, 2.409*t*
for scleritis, 8.324
ICA. *See* Internal carotid artery
ICAM-1. *See* Intercellular adhesion molecule-1
Icare tonometer, 6.10, 6.281
ICCE. *See* Intracapsular cataract extraction
ICD. *See* Implantable cardioverter-defibrillator
IC3D (International Committee for the Classification of Corneal Dystrophies), 8.133–134, 8.134*t*, 8.135*t*
"ICE" cells, 8.127
Ice-pack test, for myasthenia gravis, 5.324, 5.325, 5.325*f*

Ice pick headache, 5.294
ICE syndrome. *See* Iridocorneal endothelial (ICE) syndrome
ICG. *See* Indocyanine green
ICG angiography. *See* Indocyanine green angiography
Ichthyosis, 8.201–202
  pre-Descemet corneal dystrophy and, 8.155
  vulgaris, 8.201–202
ICP. *See* Intracranial pressure
ICRB. *See* International Classification of Retinoblastoma
ICROP. *See* International Classification of Retinopathy of Prematurity
ICRS. *See* Intrastromal corneal ring segments
ICSI. *See* Intracytoplasmic sperm injection
Idarucizumab, 1.149
IDDM (insulin-dependent diabetes mellitus). *See* Diabetes mellitus (DM), type 1
Idebenone, for Leber hereditary optic neuropathy, 5.135
Idiopathic enlargement of blind spot syndrome, acute (AIBSE), 5.100–101, 5.101*f*
  fundus autofluorescence in identification of, 5.90
Idiopathic intracranial hypertension (IIH/pseudotumor cerebri/PTC), 5.110–113, 5.111*t*, 6.370*f*, 6.370–371
  in children, 5.113
  headache and, 5.110, 5.112, 5.113, 5.288
Idiopathic macular holes, 4.131–132, 4.132*f*
  description of, 12.337–339, 12.338*f*
  vitrectomy for, 12.384–385, 12.385*f*
Idiopathic multifocal choroiditis. *See* Multifocal choroiditis
Idiopathic multiple cranial neuropathy syndrome, 5.202
Idiopathic orbital inflammation/inflammatory syndrome. *See* Nonspecific orbital inflammation
Idiopathic polypoidal choroidal vasculopathy. *See* Polypoidal choroidal vasculopathy
Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN), 12.156
Idiopathic stabbing headache, 5.294
Idiopathic stellate maculopathy, 9.241
Idiopathic thrombocytopenic purpura (ITP), 1.141
Idiotopes, 9.41
Idoxuridine, 2.432*t*, 2.433
Iduronate-2-sulfatase, in Hunter syndrome, 8.175*t*
α-L-Iduronidase, in mucopolysaccharidoses, 8.174, 8.175*t*
IEP. *See* Individualized Education Plan
IFIS. *See* Intraoperative floppy iris syndrome
IFNs. *See* Interferons
Ig. *See* Immunoglobulin(s); *specific Immunoglobulin entries*
IGA. *See* Indocyanine green angiography
IgA. *See* Immunoglobulin A
IgA dermatosis, linear, 8.301
IgE. *See* Immunoglobulin E
IgE-mediated hypersensitivity reaction. *See* Immunoglobulin E (IgE)–mediated hypersensitivity reaction
IGF-I. *See* Insulin-like growth factor I (IGF-I)
IGF-IR. *See* Insulin-like growth factor I receptor
IGFBPs. *See* Insulin-like growth factor binding proteins
IgG. *See* Immunoglobulin G
IgG4-RD. *See* Immunoglobulin G4–related disease
IGRA. *See* Interferon-gamma release assay
IGT. *See* Impaired glucose tolerance
IHD. *See* Ischemic heart disease
Ihh, 2.166
IIH. *See* Idiopathic intracranial hypertension
IIVs. *See* Inactivated influenza vaccines
IK. *See* Interstitial keratitis
IKBKAP gene, 6.271
IL. *See specific Interleukin entries*
IL-1RA. *See* Interleukin-1 receptor antagonist
Ilevro. *See* Nepafenac
Illness anxiety disorder, 1.197
Illuminance (E_v), 3.109, 3.109*t*
Illumination
  in indirect ophthalmoscope/ophthalmoscopy, 12.21
  for slit-lamp biomicroscope
    direct, 8.16–18, 8.17*f*, 8.18*f*, 8.19*f*
    indirect, 8.17*f*, 8.18–19, 8.20*f*
Illusions, 5.173–175, 5.174*t*
  cortical origin of, 5.175
  nonvisual causes of, 5.174*t*
  ocular origin of, 5.174–175
  optic nerve origin of, 5.175
ILM. *See* Internal limiting membrane
Ilotycin. *See* Erythromycin
IM. *See* Infectious mononucleosis
Image(s)
  in dense media, 3.12
  magnification of. *See also* Magnification
    contact lenses, 3.255
    intraocular lenses, 3.255
  paraxial theory of, 3.69
  real, 3.41, 3.60–61
  relocation of, 3.62
  virtual
    definition of, 3.42
    formation of, 3.11, 3.11*f*
    Maddox rod and, 3.75, 3.75*f*
    real images *versus*, 3.61
Image displacement
  through bifocal lenses, 3.184, 3.186*f*
  definition of, 3.147
Image distance, definition of, 3.3, 3.10
Image jump
  definition of, 3.147
  through bifocal lenses, 3.184–186, 3.187*f*
Image size, contact lenses and, 3.206–208
Image vergence, 3.51
Imaging, of nearby objects, 3.9–10, 3.10*f*
Imaging studies
  computed tomography. *See* Computed tomography
  indications for, 2.454, 2.457, 2.473–476*t*
  magnetic resonance imaging. *See* Magnetic resonance imaging
  ordering of, 2.472, 2.473–476*t*
  radiographic. *See* Neuroimaging; *specific modality*
  ultrasound/ultrasonography. *See* Ultrasonography/ultrasound (echography)
Imbert-Fick principle, 10.22
Imbibition pressure (IOP-SP), 8.9
Imidazoles, 2.429–431, 2.430*t*
  for *Acanthamoeba* keratitis, 8.278
Imipenem/cilastatin, 1.273, 2.418*t*

Imipramine, 1.308*t*
Immediate hypersensitivity (type I) reaction, 9.48–49. *See also* Allergic reactions/allergies
atopic keratoconjunctivitis and, 8.292
contact dermatoblepharitis and, 8.285, 8.286*f*, 8.287
hay fever conjunctivitis and, 8.288
topical medications/substances and, 8.285, 8.286*f*, 8.287
Immersion ultrasonography, 3.245, 3.246*f*
for axial length measurement, in IOL power determination/selection, 11.83, 11.83*f*
Immune-checkpoint inhibitors
description of, 7.206, 7.210–211
Vogt-Koyanagi-Harada syndrome caused by, 9.140*f*
Immune deficiency, in HIV infection/AIDS. *See* HIV infection/AIDS
Immune hypersensitivity reactions. *See* Hypersensitivity reactions
Immune privilege
in anterior chamber/anterior uvea/vitreous, corneal allograft immunity and, 8.316
corneal, 8.316, 9.54
definition of, 9.51
Immune processing
antigen in, 9.30, 9.33*f*
$CD4^+$ T cells in, 9.30–31
Immune reconstitution inflammatory syndrome (IRIS), 1.269–270
Immune recovery uveitis (IRU), 1.269, 9.329
Immune-related disorders. *See* Immune response (immunity), disorders of
Immune response (immunity). *See also* Immune response arc
of anterior chamber, 9.55–57
of anterior uvea, 9.55–57
cellular. *See* Adaptive immune response, lymphocyte-mediated immune effector responses
of choriocapillaris, 9.57–59
of choroid, 9.57–59
of conjunctiva, 9.53
of cornea, 9.54*f*, 9.54–55
definition of, 9.1, 9.6
disorders of. *See also specific type and specific structure affected*
in HIV infection/AIDS. *See* HIV infection/AIDS
neuro-ophthalmic signs of, 5.313–318
ocular disease and, 8.285–326
inflammation *versus*, 9.6
innate. *See* Innate immune response/innate immune system
mediator systems that amplify. *See also* Mediators
complement, 9.17–19
eicosanoids, 9.19–20, 9.20*f*
fibrin, 9.18–19
histamine, 9.18
overview of, 9.17
plasma-derived enzyme systems, 9.17–19
plasminogen, 9.18
platelet-activating factors, 9.20–21
neutrophils in, 9.2
ocular
disorders of, 8.285–326. *See also specific structure affected and specific type*
conjunctival involvement and, 8.288–306
corneal involvement and, 8.306–318
transplant rejection and, 8.316–318, 8.428–431
episcleral/scleral involvement and, 8.318–326
eyelid involvement and, 8.285–287, 8.286*f*
graft-vs-host disease and, 8.303–305
mediators of. *See* Mediators
ocular surface immunoregulation and, 8.11–13, 8.12–13*f*
primary, 9.37–38
regional, 9.51, 9.52*t*. *See also* Immunologic microenvironment
of retina, 9.57–59
of retinal pigment epithelium, 9.57–59
secondary, 9.37–38
of vitreous, 9.55–57
Immune response arc. *See also* Immune response
mucosa-associated lymphoid tissue, 9.53
phases of, 9.28–37, 9.29*f*, 9.31–33*f*
afferent, 9.29*f*, 9.29–30
effector, 9.36–37
processing, 9.30–35, 9.33*f*
regional immunity and, 9.51, 9.52*t*
Immune ring, corneal, 8.51*f*
Immune system. *See also* Immune response; Immune response arc
components of, 9.2–5
leukocytes of. *See* Leukocytes (white blood cells)
Immunization schedules, 1.223
Immunizations. *See also* Vaccines/vaccinations; *specific disease*
active, 1.223
contraindications for, 1.223–224
development of, 1.223
Haemophilus influenzae, 1.231–232
hepatitis, 1.224–226, 1.225*t*
hepatitis A, 1.224
hepatitis B, 1.224, 1.226, 1.232
hepatitis C, 1.226
influenza, 1.225*t*, 1.226–227
measles/mumps/rubella, 1.225*t*, 1.228–229
meningococcal, 1.231
passive, 1.223, 1.233
pneumococcal pneumonia, 1.230–231
polio, 1.229
in pregnancy, 1.224
recommendations for, 1.225*t*
rotavirus, 1.230
tetanus and diphtheria, 1.225*t*, 1.229–230
travel-related, 1.232
varicella-zoster, 1.225*t*, 1.227–228
yellow fever, 1.232
Immunocompromised host. *See also* HIV infection/AIDS
CMV infection in, 4.145, 4.146*f*
herpes zoster in, 8.225, 8.226–227
ocular infection in
microsporidia causing, 8.280, 8.280*f*
yeasts causing, 8.250
ocular surface squamous cell carcinoma in, 8.336
refractive surgery and, 13.37, 13.171

Immunofluorescence assay, in mucous membrane pemphigoid, 4.55
Immunoglobulin(s). *See also* Antibodies; *specific type*
classes of, 9.39
description of, 9.11
disorders of, corneal crystal deposition and, 8.182*t*, 8.197–199, 8.198*f*, 8.199*f*
functional properties of, 9.39, 9.41
intravenous (IVIg), for neuromyelitis optica, 5.323
isotypes of, 9.39, 9.40*t*
plasma cell production of, 9.37
structural features of, 9.39, 9.39*f*
Immunoglobulin A (IgA), 2.252
in conjunctiva, 9.53
dermatosis, linear, 8.301
molecular size of, 9.39
in tear film, 8.6*f*
Immunoglobulin A1, 9.41
Immunoglobulin A2, 9.41
Immunoglobulin E (IgE), 2.399
inflammatory reactions mediated by
Fc receptors for, 9.3
mast cells in, 9.3
mast-cell degranulation mediated by, 9.48–49
in tear film, 8.39
in type I hypersensitivity/anaphylactic reactions, 8.285
Immunoglobulin E (IgE)–mediated hypersensitivity reaction, 2.351
Immunoglobulin G (IgG), 2.399
κ-chain deposition, corneal, 8.198
in multiple sclerosis, 5.319
in neuromyelitis optica/neuromyelitis optica spectrum disorder, 5.117*f*, 5.118, 5.320, 5.322
Immunoglobulin G4, 9.41
Immunoglobulin G4 (IgG4)–positive plasmacytic infiltrates, in nonspecific orbital inflammation, 4.225
Immunoglobulin G4–related disease (IgG4-RD), 7.66*f*, 7.66–67
Immunoglobulin M
description of, 9.35
molecular size of, 9.39
primary immune response production of, 9.37
Immunohistochemistry, 4.33–35, 4.35*f*
in melanoma diagnosis, 4.68
in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma diagnosis, 4.136, 4.312
Immunologic microenvironment
of anterior chamber, 9.55–56
of anterior uvea, 9.55–56
of choriocapillaris, 9.57–58
of choroid, 9.57–58
of conjunctiva, 9.52*t*, 9.53
of cornea, 9.54*f*, 9.54–55
of retina, 9.57–58
of retinal pigment epithelium, 9.52*t*, 9.57–58
of vitreous, 9.52*t*, 9.55–56, 9.56
"Immunologic privilege," corneal, 8.316
Immunologic tolerance, corneal transplantation and, 8.316
Immunology (ocular). *See* Immune response (immunity); Immune response arc
Immunomodulatory therapy/immunotherapy/immunosuppression (IMT), 2.403, 2.404–406*t*
for atopic keratoconjunctivitis, 8.294
for Behçet disease, 9.216–218
for birdshot chorioretinopathy, 9.169
for choroidal/ciliary body melanoma, 4.277
for Cogan syndrome, 1.174
for corneal graft rejection prophylaxis, 8.430
for dermatomyositis, 1.168
for graft-vs-host disease, 8.304
for hay fever conjunctivitis, 8.289
infectious pseudocrystalline keratopathy associated with, 4.79
for lung disease, 1.128
for melanoma, 7.210
for Mooren ulcer, 8.316
for mucous membrane pemphigoid, 8.303
for multiple sclerosis, 5.116
for neuromyelitis optica, 5.323
for peripheral ulcerative keratitis, 8.313
for polymyositis, 1.168
for sarcoidosis, 9.199
for scleritis, 8.324, 8.325*f*, 9.126
for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297
for systemic sclerosis, 1.166
for uveitis
abatacept, 9.112
adalimumab, 9.110–111
alkylating agents, 9.105, 9.109–110
antimetabolites, 9.106–108
azathioprine, 9.106–107
biologic agents, 9.104, 9.110–113
chlorambucil, 9.110
complications of, 9.105
cyclophosphamide, 9.109–110
cyclosporine, 9.108
description of, 9.103
evaluations before initiating, 9.104–105
indications for, 9.104
infliximab, 9.111–112
interferon alfa-2a/2b, 9.112
methotrexate, 9.107
monitoring during, 9.105
mycophenolate mofetil, 9.107
nonbiologic agents, 9.104, 9.106–110
onset of action, 9.105
pregnancy contraindications for, 9.105
in psoriatic arthritis, 9.133
rituximab, 9.112
T-cell inhibitors, 9.108–109
tacrolimus, 9.108
tumor necrosis factor inhibitors, 9.105, 9.110–112, 9.130–131
Immunophenotyping, flow cytometry for, 4.36
Immunoregulatory systems
of anterior chamber, 9.56–57
of anterior uvea, 9.56–57
of choriocapillaris, 9.59
of choroid, 9.59

of conjunctiva, 9.53
of cornea, 9.54–55
of retina, 9.59
of retinal pigment epithelium, 9.59
of vitreous, 9.56–57
Immunosuppression. *See* Immunomodulatory therapy/immunotherapy/immunosuppression
Immunotherapy. *See* Immunomodulatory therapy/immunotherapy/immunosuppression
Impact resistance, of spectacle lenses, 3.195
Impaired glucose tolerance (IGT), 1.35
Implantable cardioverter-defibrillator (ICD)
antiarrhythmic therapy with, 1.105
congestive heart failure treated with, 1.100
current-generation, 1.105
ocular surgery preoperative discussions, 1.282
sudden cardiac death prevention using, 1.86, 1.105
tachyarrhythmias treated with, 1.104–106
transvenous system, 1.105
Implanted defibrillators, laser surgery in patient with, 13.37
Implants
for drug delivery, 2.364
intrastromal corneal ring segment/Intacs, extrusion, 13.67, 13.68*f*
orbital
description of, 7.117, 7.139*f*, 7.139–141
exposure and extrusion of, 7.142*f*, 7.142–143
osseointegrated magnetic, 7.147*f*
Impression cytology, in superior limbic keratoconjunctivitis, 8.84
Imprinting
definition of, 2.180
diseases caused by abnormalities in, 2.180–181
IMT. *See* Immunomodulatory therapy/immunotherapy/immunosuppression
In situ hybridization, fluorescence (FISH), 4.38*t*
In vitro fertilization, 2.238
Inactivated influenza vaccines (IIVs), 1.227
Inborn errors of metabolism, 2.203, 2.205
lens dislocation and, 6.306
ocular findings in, 6.385, 6.387*f*, 6.388–389*t*, 6.390*f*
prevalence of, 6.385
INC. *See* Interstitial nucleus of Cajal
Incision(s). *See also* Incisional surgery
for arcuate keratotomy, 13.27, 13.27*f*, 13.53, 13.54–55
for cataract surgery. *See also specific type of incision and type of surgery*
clear corneal, 11.106*f*, 11.106–107
closure of
complications associated with, 11.130–131
after ECCE, 11.197–198
postoperative endophthalmitis and, 11.161
complications associated with, 11.130–131
flat or shallow anterior chamber, 11.134
dehiscence/rupture of, 11.131
for ECCE, 11.196
wound closure and, 11.197–198
for ICCE, 11.199–200
induced astigmatism and, 11.131–132
for manual small-incision surgery, 11.198
modification of preexisting astigmatism and, 11.123–124
for phacoemulsification
clear corneal, 11.106*f*, 11.106–107
scleral tunnel, 11.107*f*, 11.107–108
postoperative leaking and, 11.118, 11.130–131
flat anterior chamber and, 11.135
angle-closure glaucoma and, 10.144–145
after radial keratotomy, 13.53
for radial keratotomy, 13.50, 13.50*f*
traumatic rupture of, 13.52
scleral tunnel
for ECCE, 11.196
for phacoemulsification, 11.107*f*, 11.107–108
self-sealing, beveled/biplanar, clear corneal incisions and, 11.106*f*, 11.106–107
thermal wounds of, 11.131
fornix, 6.162–163
for intrastromal corneal ring segment placement, 13.64
for keratorefractive surgery, 13.26–27, 13.27*f*
limbal, 6.163
limbal relaxing (LRIs), 13.8*t*, 13.27*f*, 13.53–54, 13.54*f*, 13.54–58, 13.55*f*, 13.56*f*, 13.56*t*, 13.57*f*
for trabeculectomy, 10.200, 10.201*f*, 10.202*f*
Incision leaks, after cataract surgery, 11.118, 11.130–131
flat anterior chamber and, 11.135
angle-closure glaucoma and, 10.144–145
Incisional biopsy, 7.203, 7.203*f*
Incisional surgery
corneal (keratorefractive), 13.8*t*, 13.26–27, 13.27*f*, 13.49–58. *See also specific procedure*
for astigmatism, 13.53–58, 13.54*f*, 13.55*f*, 13.56*f*, 13.57*f*
corneal effects of, 13.26–27, 13.27*f*
for myopia, 13.49–53, 13.50*f*, 13.51*f*
for glaucoma, 10.187, 10.196–220. *See also* Trabeculectomy
angle-closure glaucoma and, 10.220
cataract surgery, with trabeculectomy, 10.211–213
complications of, 10.187
open-angle glaucoma and, 10.113–115
trabeculectomy, 10.197–211
with cataract surgery, 10.211–213
tube shunt implantation, 10.213–217, 10.214*t*, 10.218*t*
Inciting eye. *See* Exciting eye
Inclusion-cell disease (ML II), 8.178
Inclusion conjunctivitis, chlamydial, 8.260, 8.263, 8.265
in adults, 8.260, 8.263
in neonates, 8.260, 8.265
Inclusion cysts, 6.250
epidermal, of eyelid, 4.208, 4.208*f*
epithelial, conjunctival, 4.59, 4.59*f*, 8.114, 8.114*f*
concretions and, 8.113–114
nevi and, 4.64, 8.340
IncobotulinumtoxinA, 5.281. *See also* Botulinum toxin
Incomitant deviation, 6.16
Incomitant esotropia, 6.95–97, 6.96*f*
Incomitant (noncomitant) deviations, 5.183, 5.184, 5.187. *See also specific type*
Incomitant strabismus
abnormal head position caused by, 6.83
prism alternate cover test for, 6.66
Incomplete achromatopsia, 6.337

Incomplete penetrance, 2.207
Incongruous visual field defects, 5.29
retrochiasmal lesions producing, 5.153
Incontinentia pigmenti (IP), 2.209–210, 6.393*t*, 6.404*t*, 6.404–405, 6.404–405*f*, 12.283*t*, 12.286
Incorrect corrective lens artifact, in perimetry, 10.66
Increased intracranial pressure. *See* Intracranial hypertension
Increased intraocular pressure. *See* Elevated intraocular pressure; Ocular hypertension
Incyclo- (prefix), 6.16
Incyclodiplopia, 6.119
Incycloduction. *See* Intorsion
Indentation (dynamic) gonioscopy, 10.35, 10.35*f*, 10.36
in acute primary angle closure, 10.123
Indentation (Schiøtz) tonometry, 10.19, 10.26
Independent assortment, 2.175, 2.216–217
Indeterminate neoplastic proliferations, 4.10
Index features, in diagnosis, 4.11
Index of refraction. *See* Refractive index
Indirect-acting agonists
cholinergic, 2.379
description of, 2.387
nicotinic, 2.381
Indirect (blowout) fractures. *See also* Blowout (indirect) fractures
description of, 7.113
of orbital floor, diplopia after, 5.206
Indirect carotid-cavernous fistulas, 7.79
Indirect illumination, 3.292
Indirect ophthalmoscope/ophthalmoscopy
definition of, 3.281
description of, 3.298–300*f*, 3.298–301, 3.307
illumination in, 12.21
posterior vitreous detachment diagnosed using, 12.309, 12.331
retinal disease evaluations using, 12.21–22
transverse magnification of, 3.63
Indirect traumatic optic neuropathy, 2.115, 5.139
Individualized Education Plan (IEP), 6.188
Indocyanine green (ICG)
description of, 2.362, 2.444
intravenous administration of. *See* Indocyanine green angiography
Indocyanine green angiography (IGA), 5.89
acute idiopathic maculopathy on, 12.228
in acute posterior multifocal placoid pigment epitheliopathy, 9.163*t*, 9.170–171, 9.171*f*, 12.222
in acute zonal occult outer retinopathy, 9.163*t*, 12.227
adverse effects of, 12.39
applications of, 12.38–39
in birdshot chorioretinopathy, 9.163*t*, 9.166, 9.167*f*, 9.179
central serous chorioretinopathy on, 12.38, 12.192, 12.194*f*
in choroidal hemangioma, 4.281, 4.282*f*, 12.202*f*
in choroidal melanoma/ciliary body melanoma, 4.265
choroidal neovascularization on, 12.73
definition of, 12.38
description of, 3.303
fundus camera for, 12.23
giant cell arteritis findings, 12.196*f*
in granulomatous necrotizing scleritis, 9.120*f*
in low vision evaluation, 5.89
in multifocal choroiditis and panuveitis syndrome, 9.163*t*
in multiple evanescent white dot syndrome, 5.101, 9.163*t*, 9.188*f*, 12.223–224
narrow-band interference filters in, 3.103
polypoidal choroidal vasculopathy on, 12.38, 12.38*f*
in punctate inner choroiditis, 9.163*t*, 9.182, 9.183*f*
in serpiginous choroiditis, 9.163*t*, 9.175
in subretinal fibrosis and uveitis syndrome, 9.163*t*
in sympathetic ophthalmia, 9.201, 9.202*f*
in tubercular uveitis, 9.236, 9.237*f*
in uveitis, 9.89
in Vogt-Koyanagi-Harada syndrome, 9.209
Indomethacin, 2.409*t*, 2.410
cornea verticillata caused by, 8.130
for scleritis, 8.324
INDs. *See* Investigational new drugs
Induced anisophoria
compensating for, 3.186–190, 3.187*f*
contact lenses for, 3.190
dissimilar segments for, 3.189, 3.189*f*
press-on prisms for, 3.188
refractive surgery for, 3.190
reverse slab-off for, 3.188–189
single-vision reading glasses with lowered optical centers for, 3.189–190
slab-off for, 3.188, 3.188*f*
Induced convergence-retraction (convergence-retraction nystagmus/CRN), 5.243*t*, 5.250, 6.152–153
Induced pluripotent stem cells
CRISPR–Cas9 and, 2.198
description of, 2.166
Induced tropia test, 6.6
Inducible nitric oxide synthase (iNOS), 2.394, 9.16
Inducible T regulatory cells, 9.34
Inert orbital implant. *See* Orbital implants
Infant(s). *See also* Children; Newborns; *specific Infantile entries*
abusive head trauma in, 6.381–384, 6.382–383*f*, 12.365–366, 12.366*f*
aphakia in, 3.225
chlamydial infection in, 6.239
congenital toxoplasmosis in, 12.243
conjunctivitis in, 8.257*t*, 8.263–265. *See also* Ophthalmia neonatorum
corneal transplantation in, 8.450–451
cystinosis in, 8.181
cytomegalovirus infection in, 6.411, 6.411*f*
decreased/low vision in. *See* Low vision, in infants
delayed visual maturation in, 6.186–187
extraocular muscles in, 6.181–182
eye examination in, glaucoma and, 10.157, 10.157*t*
eyelid retraction in, 5.274
herpes simplex infection in, 8.213
Horner syndrome in, 5.261–262
hyperopia in, 3.141
intraocular pressure in
measurement of, 6.181
normal level of, 6.282
Leber congenital amaurosis in, 12.265–266
low vision in, 3.327–328
neuronoid ceroid lipofuscinoses in, 12.289

normal flora in, 8.205
nystagmus in, 5.235–237, 5.237*f*
ocular infections in, 8.257*t*, 8.263–265. *See also specific type*
ophthalmia neonatorum in, 8.257*t*, 8.263–265. *See also* Ophthalmia neonatorum
Refsum disease in, 12.290
retinal hemorrhage in, 6.382–383, 383*f*
retinopathy of prematurity in, 12.175
trauma in, 12.316–317, 12.365–366, 12.366*f*
vision in
decreased, 6.187–188
development of, 6.185
impairments in, 6.186–187
visual evoked potentials in, 5.95, 12.53
decreased vision and, 5.95
Infantile (capillary) hemangioma, 7.71*f*, 7.71–73, 7.180–181. *See also* Hemangiomas
of conjunctiva/ocular surface, 4.50, 8.345*t*, 8.345–346
of eyelid, 4.214, 4.215*f*, 8.345*t*, 8.345–346
of orbit, 4.233
of retina. *See* Capillary hemangioblastoma; Retinal angiomatosis
Infantile (capillary) hemangiomas, 7.71*f*, 7.71–73, 7.180–181
Infantile cataract, 6.293, 11.34–39, 11.35*t*, 11.36*f*, 11.37*f*, 11.38*f*, 11.39*f*
Infantile esotropia, 6.86*t*
amblyopia associated with, 6.87–89
botulinum toxin injections for, 6.89
Chavasse theory of, 6.87
Ciancia syndrome, 6.88, 6.95
clinical features of, 6.87–88
cross-fixation associated with, 6.87–88, 6.88*f*
cyclopegic refraction for, 6.88
definition of, 6.87
evaluation of, 6.87–88
management of, 6.88–89
medial rectus muscle recession for, 6.89
mental illness and, 6.87
ocular alignment in, 6.88–89
pathogenesis of, 6.87
prematurity as risk factor for, 6.87
smooth-pursuit asymmetry associated with, 6.88
surgical treatment of, 6.89
V-pattern strabismus associated with, 6.109, 6.112*t*
Worth "sensory" concept of, 6.87
Infantile exotropia, 6.103–104, 6.104*f*
Infantile glaucoma, 4.98, 4.99*f*, 10.4*t*, 10.147, 10.148*t*, 10.151. *See also* Glaucoma, pediatric; Primary congenital glaucoma
corneal opacities associated with, 6.257*t*, 6.260, 6.261*f*
description of, 6.230
Infantile Hagberg-Santavuori disease, 6.389*t*
Infantile malignant osteopetrosis, 6.212
Infantile nystagmus syndrome (INS), 5.235–237, 5.237*f*, 6.83, 6.148–149, 6.149*t*, 6.156*f*, 6.187, 6.335. *See also* Congenital nystagmus
Infantile primary congenital glaucoma. *See* Infantile glaucoma; Primary congenital glaucoma
Infantile strabismus. *See also* Strabismus
description of, 6.16
dissociated vertical deviation associated with, 6.129
fusion maldevelopment nystagmus syndrome associated with, 6.151, 6.154
primary inferior oblique muscle overaction associated with, 6.117
Infarction. *See also specific type/tissue or organ involved*
neuroimaging in evaluation of, 5.64*f*, 5.65*t*, 5.66, 5.67*f*, 5.75
Infection (ocular), 8.208*t*. *See also specific type*, *structure affected*, *causative agent and under Infectious*
Acanthamoeba causing, 8.208*t*, 8.252, 8.276–279, 8.277*f*, 8.278*f*
bacterial/bacteriology, 8.208*t*, 8.243–249, 8.244*t*. *See also* Bacteria
corneal and scleral involvement and, 8.208*t*, 8.267–273, 8.268*f*, 8.269*t*, 8.270*t*, 8.273*f*, 8.282–283, 8.283*f*
eyelid margin and conjunctival involvement and, 8.255–266
basic concepts and, 8.205–211, 8.208*t*, 8.209*t*, 8.211*f*
canaliculitis, 7.313, 7.314*f*
contact lens–related, 3.230, 3.231*f*, 8.84, 8.266–267, 8.273–274, 8.276, 8.277
corneal, 6.257*t*, 8.266–283. *See also* Keratitis; Scleritis
corneal opacity and, 8.16*f*
dacryoadenitis, 7.312–313
dacryocystitis, 7.313–315, 7.315*f*
defense mechanisms and, 8.11–14, 8.12–13*f*, 8.13*f*, 8.206
diagnostic laboratory techniques in, 8.208–211, 8.209*t*, 8.211*f*
eyelid disorders caused by, 6.198–199
eyelid margin and conjunctival involvement and, 8.254–266. *See also* Conjunctivitis; Eyelid(s)
fungal/mycology, 8.208*t*, 8.249–251
corneal and scleral involvement and, 8.282–283
eyelid margin involvement and, 8.254–255, 8.255*f*
in infants and children
intrauterine and perinatal, corneal anomalies and, 8.107
ophthalmia neonatorum, 8.257*t*, 8.263–265
Loa loa causing, 4.228, 8.253, 8.282, 8.282*f*
microbiology of, 8.207–211, 8.208*t*, 8.209*t*, 8.211*f*. *See also specific causative factor*
microsporidia causing, 8.280*f*, 8.280–281, 8.281*f*
mycobacterial, 8.248
atypical organisms and, 8.248, 8.272–273, 8.273*f*
neuroimaging in evaluation of, 5.72*t*
normal flora and, 8.205–206, 8.206*t*
orbital inflammation caused by. *See* Orbital inflammation, infectious causes of
parasitic/parasitology, 8.208*t*, 8.252–253
corneal and scleral involvement and, 8.208*t*, 8.266–283
eyelid margin involvement and, 8.254–255, 8.255*f*
pathogenesis of, 8.206–207
pediatric glaucoma and, 10.150*t*
after penetrating keratoplasty, 8.426, 8.426*f*
postoperative, 6.170, 6.170*f*
preseptal cellulitis caused by, 6.212–213
prions causing, 8.254
scleral involvement, 8.266–283

Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis) and, 8.295
viral/virology, 8.208*t*, 8.211–241
Infection control, in clinical tonometry, 10.27
Infectious conjunctivitis, 4.52–53, 4.54*f*. *See also specific type and causative agent*
Infectious crystalline keratopathy, 8.268, 8.268*f*
corneal deposits and, 8.182*t*
after penetrating keratoplasty, 8.427, 8.427*f*
Infectious diseases. *See also* Infection; *specific organism and disorder*
Borrelia burgdorferi, 1.254–255
Candida albicans, 1.258
Chlamydia trachomatis. *See Chlamydia, trachomatis*
Clostridium difficile, 1.249
cytomegalovirus, 1.237*t*, 1.261–262, 1.279
Ebola virus, 1.264–265
external eye, 8.208*t*. *See also* Infection; *specific causative agent*
bacterial, 8.208*t*, 8.243–249, 8.244*t*, 8.255–266
basic concepts and, 8.205–211, 8.208*t*, 8.209*t*, 8.211*f*
corneal and scleral involvement and, 8.266–283. *See also* Keratitis; Scleritis
diagnostic laboratory techniques in, 8.208–211, 8.209*t*, 8.211*f*
eyelid margin and conjunctival involvement and, 8.254–266. *See also* Conjunctivitis; Eyelid(s)
fungal, 8.208*t*, 8.249–251, 8.254–255, 8.255*f*, 8.282–283
microbiology of, 8.207–211, 8.208*t*, 8.209*t*, 8.211*f*. *See also specific causative factor*
normal flora and, 8.205–206, 8.206*t*
parasitic, 8.208*t*, 8.252–253, 8.254–255, 8.255*f*, 8.266–283
pathogenesis of, 8.206–207
prions causing, 8.254
viral, 8.208*t*, 8.211–241
fungal, 1.258
Haemophilus influenzae, 1.231, 1.249–250
hepatitis. *See* Hepatitis
herpes simplex virus. *See* Herpes simplex virus
human papillomavirus. *See* Human papillomavirus
influenza, 1.225*t*, 1.226–227
measles, 1.228–229
meningococcus, 1.231
microbiology of, 1.245–246
mumps, 1.228–229
Mycobacterium tuberculosis, 1.222, 1.256–257
Mycoplasma pneumoniae, 1.256
Neisseria, 1.250–251, 1.276
neuro-ophthalmic signs of, 5.348–357
ocular inflammatory. *See* Infectious ocular inflammatory disease
polio, 1.229
Pseudomonas aeruginosa, 1.251–252
rotavirus, 1.230
rubella, 1.229
screening for, 1.222–223
seventh nerve pathology caused by, 5.278*t*, 5.279–280
Staphylococcus, 1.246–247
Streptococcus, 1.247–249, 1.248*t*
syphilis. *See* Syphilis
Toxoplasma gondii, 1.258–259
varicella-zoster, 1.225*t*, 1.227–228
Zika virus, 1.265–266
Infectious endocarditis, community-acquired, 1.248
Infectious endophthalmitis, 4.119, 4.119*f*, 4.127, 4.128*f*
acute anterior uveitis associated with, 9.137
Infectious/microbial keratitis, 2.426, 4.75–80, 4.76*f*, 4.77*f*, 4.78*f*, 4.79*f*, 4.80*f*, 4.81*f*, 8.208*t*, 8.266–279, 8.307–309, 8.309*f*. *See also specific type and causative agent*
clinical presentation of, 8.267–268, 8.268*f*, 8.274*f*, 8.274–275, 8.276–277, 8.277*f*
contact lens wear and, 8.266–267, 8.273–274
for orthokeratology, 13.71
interstitial disease and, 8.307–309, 8.309*f*
intrauterine, 8.107
syphilitic, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*
laboratory evaluation/causes of, 8.268–269, 8.269*t*, 8.275, 8.277, 8.278*f*
after LASIK, 13.106*f*, 13.106–107, 13.107*f*, 13.117–119, 13.118*f*, 13.118*t*
diffuse lamellar keratitis differentiated from, 13.117–118, 13.118*f*, 13.119*t*
management of, 8.269–272, 8.270*t*, 8.275–276, 8.277–279
orthokeratology and, 13.71
pathogenesis of, 8.267, 8.273–274, 8.276
after penetrating keratoplasty, 8.427
after photoablation, 13.106*f*, 13.106–107, 13.107*f*
recurrence of in graft, 8.225, 8.232
specimen collection in evaluation of, 8.210, 8.211*f*
stains and culture in identification of, 8.209*t*, 8.269, 8.273, 8.275
Infectious mononucleosis (IM), ocular involvement in, 8.230–231, 8.231*f*
Infectious ocular inflammatory disease. *See also specific type and causative agent*
endophthalmitis, 4.119, 4.119*f*, 4.127, 4.128*f*
protozoal, 4.147–148, 4.148*f*, 8.252
Acanthamoeba keratitis, 8.208*t*, 8.252, 8.276–279, 8.277*f*, 8.278*f*
corneal opacity and, 8.16*f*
retinitis, 4.147–148, 4.148*f*
Infectious pseudocrystalline/crystalline keratopathy, 4.79–80, 4.80*f*
after penetrating keratoplasty, 4.79
Infectious scleritis
actinomycetes as cause of, 9.119*f*
clinical presentation of, 9.124
description of, 9.116
microbiological examination for, 9.125
pathophysiology of, 9.123–124
treatment of, 9.127
vision loss risks, 9.128
Infectious uveitis
acute retinal necrosis, 9.250, 9.251*f*
adenovirus as cause of, 9.272
bartonellosis as cause of. *See Bartonella* (bartonellosis)
Chikungunya fever as cause of, 9.268–269
cytomegalovirus as cause of, 9.248–249, 9.254–257, 9.255*f*
Dengue fever as cause of, 9.267*f*, 9.267–268

Ebola virus as cause of, 9.270–271, 9.271*f*
Epstein-Barr virus as cause of, 9.257–258
herpes simplex virus as cause of, 9.247–250, 9.248–249*f*
human T-lymphocytic virus type 1 as cause of, 9.265–267, 9.266*f*
immunologic uveitis *versus*, 9.311
leptospirosis as cause of, 9.232–233
Lyme disease as cause of. *See* Lyme disease
lymphocytic choriomeningitis virus as cause of, 9.261
measles as cause of, 9.261–263
mumps as cause of, 9.261
nocardiosis as cause of, 9.233
periocular injection contraindications in, 9.96
progressive outer retinal necrosis, 9.250–254, 9.253*f*
rhegmatogenous retinal detachment associated with, 9.324
Rift Valley fever as cause of, 9.265, 9.265*f*
rubella as cause of, 9.258–261
subacute sclerosing panencephalitis as cause of, 9.262–263
syphilis as cause of. *See* Syphilis
tuberculosis as cause of, 9.234–240, 9.235–238*f*. *See also* Tuberculosis
West Nile virus as cause of, 9.263–264
Whipple disease as cause of, 9.243–245, 9.244*f*
Zika fever as cause of, 9.269–270, 9.270*f*
Inferior canaliculus, 2.32*f*
Inferior conchae, 7.19
Inferior meatus, 5.11. *See also* Inferior turbinate
Inferior muscular artery, 5.14–15
Inferior oblique (IO) muscle, 5.36*f*, 5.46, 5.46*f*, 7.262
action of, 6.34*t*, 6.38*f*
advancement of, 6.166
anatomy of, 2.17*f*, 2.28*f*, 2.107*f*, 5.36*f*, 5.46, 5.46*f*, 6.19*f*
anteriorization/anterior transposition of
anti-elevation syndrome caused by, 6.168
description of, 6.166
characteristics of, 2.19*t*, 6.21*t*
elevator function of, 6.73
field of action for, 6.33
innervation of, 5.40, 5.44, 5.44*f*
description of, 6.19
surgical considerations and, 6.29
magnetic resonance imaging of, 2.460*f*
origins of, 2.18, 6.20, 6.21*t*, 6.28
overaction of
bilateral, 6.117
clinical features of, 6.117–118
in craniosynostosis, 6.208
description of, 6.17
latent dissociated vertical deviation *versus*, 6.129–130
management of, 6.118
overelevation in adduction caused by, 6.117*f*, 6.117–118
primary, 6.117
secondary, 6.117
in superior oblique muscle paralysis, 6.166
V-pattern strabismus caused by, 6.107
Y-pattern strabismus caused by, 6.113
palsy of
Brown syndrome *versus*, 6.124, 6.125*t*, 6.137
clinical features of, 6.124, 6.124*f*, 6.125*t*
management of, 6.124–125
pseudo-overaction of, 6.109, 6.113
pulley system, 6.28
tightening of, 6.166
transposition of, anterior, 6.166
underaction of, 6.17
weakening of
bilateral, 6.165
indications for, 6.118
for superior oblique muscle palsy, 6.123, 6.123*t*
surgical procedures for, 6.164*t*, 6.165–166
for V-pattern strabismus, 6.111
Inferior ophthalmic vein, 2.12, 2.12*f*, 2.26*f*, 2.34*f*, 5.8*f*, 5.21*f*, 5.22, 5.22*f*, 5.23*f*, 7.13*f*
Inferior orbital fissure, 2.6*f*, 2.10*f*, 2.12, 5.7*f*, 5.9*f*, 5.11, 7.7–8*f*, 7.9–10, 7.130*f*
Inferior orbital groove, 5.9*f*
Inferior orbital vein, 6.23
Inferior orbitotomy
transconjunctival incisions for, 7.126–127, 7.127*f*
transcutaneous incisions for, 7.126, 7.126*f*
Inferior palpebral artery, 5.13*f*
Inferior palpebral vein, 5.21*f*
Inferior petrosal sinus, 5.22, 5.23*f*
Inferior punctum, 2.27
Inferior rectus (IR) muscle, 5.8*f*, 5.36*f*, 5.45, 5.46*f*
action of, 6.34*t*, 6.36*f*
anatomy of, 2.17*f*, 2.20*f*, 2.28*f*, 2.107*f*, 5.8*f*, 5.36*f*, 5.45, 5.46*f*, 7.12, 7.13*f*
characteristics of, 2.19*t*
computed tomography of, 2.456*f*
depressor function of, 6.73
flap tears of, 6.127–128
hydatid cyst of, 7.53*f*
innervation of, 5.44, 5.44*f*, 6.19
lateral border of, 6.29
magnetic resonance imaging of, 2.460*f*
neurofibrovascular bundle, 6.29
origin of, 6.20, 6.22*f*
recession/resection of
description of, 6.29
eyelid position affected by, 6.173
surgery considerations for, 6.29
weakening of
for nystagmus, 6.156
procedures for, 6.163, 6.164*t*
Inferior rectus tendon, 6.19*f*
Inferior retinal arcade, 5.14
Inferior sagittal sinus, 5.22*f*
Inferior staphyloma syndrome, 12.217, 12.217*f*
Inferior-superior (I-S) values, 8.31, 13.4
after intrastromal corneal ring segment implantation, 13.66
in keratoconus/corneal ectasia, 8.32*t*, 8.165, 8.165*f*
Inferior tarsal muscle, 2.35, 7.167
Inferior transseptal injection, of periocular corticosteroids, 9.96, 9.97*f*
Inferior turbinate, 2.14*f*
Inferior turbinate infracture, 7.294
Inferolateral trunk, 5.12

Inferomedial orbital strut, 2.14
Inferonasal disc coloboma, 6.365*f*
Inferotemporal fossa, 2.12
Infiltrative lesions, orbital, 5.126*f*, 5.126–127
Infiltrative optic neuropathy, 5.107*t*, 5.126*f*, 5.126–127, 5.131–133
Inflamase Forte. *See* Prednisolone; Prednisolone sodium phosphate
Inflammation (ocular), 3.231*t*, 3.233–234, 4.6–9, 4.8*f*, 4.9*f*, 4.12*t*. *See also* Endophthalmitis; Uveitis; *specific type or structure affected*
  acute, 4.6, 4.13
  angle-closure glaucoma and, 10.138*f*, 10.138–139, 10.139*f*
  anisocoria and, 5.258*t*
  cataracts/cataract surgery and, 11.64*f*, 11.64–66, 11.139–140, 11.170–171
    postoperative, 11.139–140
      retained lens material and, 11.141
    trauma and, 11.191
  in chemical injury, management and, 8.382–384
  choroidal. *See also* Chorioretinitis; Chorioretinopathy; Choroidopathy
    posttraumatic, 4.22, 4.22*f*
  chronic, 4.6–7
  conjunctival, 4.50*f*, 4.50–55, 4.51*f*, 4.52*f*, 4.53*f*, 4.54*f*, 4.55*f*
  corneal, 4.75–81, 4.76*f*, 4.77*f*, 4.78*f*, 4.79*f*, 4.80*f*, 4.81*f*
  cytokines in, 9.21, 9.22–24*t*
  eicosanoids in, 9.19–20, 9.20*f*
  eyelid, 4.203–204, 4.204*f*, 4.205*f*, 4.206*f*, 6.198–199
  glaucoma and, 10.100–102, 10.102*f*, 10.138*f*, 10.138–139, 10.139*f*
  granulomatous, 4.7
    focal posttraumatic choroidal, 4.22, 4.22*f*
  immune response *versus*, 9.6
  infectious diseases and, protozoal, 4.147–148, 4.148*f*, 8.252
    Acanthamoeba keratitis, 8.208*t*, 8.252, 8.276–279, 8.277*f*, 8.278*f*
    corneal opacity and, 8.16*f*
    retinitis, 4.147–148, 4.148*f*
  lens-related, 4.118–119, 4.119*f*
  leukotrienes in, 9.20
  mediators of. *See* Mediators
  nongranulomatous, 4.7
  noninfectious. *See* Noninfectious ocular inflammatory diseases
  nonspecific orbital, 6.215–216, 6.216*f*
  open-angle glaucoma and, 10.100–102, 10.102*f*
  optic nerve, 4.243*f*, 4.243–245, 4.244*f*, 4.245*f*
  orbital. *See* Nonspecific orbital inflammation; Orbital inflammation
  pain in, 5.295
  pathologic findings associated with, 9.6
  pupil irregularity and, 5.255
  retinal, 4.145–148, 4.146*f*, 4.147*f*, 4.148*f*
  in retinoblastoma, 4.291, 4.291*t*
  scleral, 4.109–110, 4.110*f*, 4.111*f*
  treatment of. *See* Anti-inflammatory agents
  uveal tract, 4.185–187, 4.186*f*, 4.187*f*, 4.188*f*. *See also* Uveitis
  in uveitis, 6.320–322
  vitreal, 4.127, 4.128*f*. *See also* Endophthalmitis; Vitritis
  in wound healing/repair, 4.13
Inflammatory anemia, 1.137
Inflammatory anisocoria, 5.258*t*
Inflammatory bowel disease (IBD)
  acute anterior uveitis in, 9.133
  ocular manifestations of, 1.157
  spondylarthritis associated with, 1.156
Inflammatory cells, in anterior uveitis, 9.77, 9.79*f*
Inflammatory chorioretinopathies
  acute posterior multifocal placoid pigment epitheliopathy. *See* Acute posterior multifocal placoid pigment epitheliopathy
  acute retinal pigment epitheliitis, 9.162–164*f*, 9.189*f*, 9.189–190
  acute zonal occult outer retinopathy. *See* Acute zonal occult outer retinopathy
  birdshot chorioretinopathy. *See* Birdshot uveitis (birdshot retinochoroidopathy/birdshot/vitiliginous chorioretinitis)
  definition of, 9.161
  multifocal choroiditis and panuveitis syndrome. *See* Multifocal choroiditis and panuveitis syndrome
  multiple evanescent white dot syndrome. *See* Multiple evanescent white dot syndrome
  punctate inner choroiditis. *See* Punctate inner choroiditis/choroidopathy
  serpiginous choroiditis. *See* Serpiginous choroiditis
  subretinal fibrosis and uveitis syndrome. *See* Subretinal fibrosis and uveitis syndrome
Inflammatory dendritic cells, 9.4
Inflammatory infiltrate, necrobiotic granulomatous, in episcleritis, 4.109
Inflammatory mediators. *See* Mediators
Inflammatory optic neuropathy, 5.113–118, 5.114*f*, 5.117*t*. *See also* Optic neuritis
  chronic relapsing, 5.116
  pain in, 5.295–296
Inflammatory pseudoguttae, 8.52
Inflammatory pseudotumor. *See* Nonspecific orbital inflammation
Inflammatory response. *See also* Endophthalmitis; Inflammation (ocular); Uveitis; *specific type or structure*
  clinical manifestations of, 9.6
  definition of, 9.6
  lipopolysaccharide-induced, 9.8–9
Inflammatory vascular tumors, conjunctival/ocular surface, 8.346*f*, 8.346–347
Inflammatory vasculitis, 12.230, 12.230*t*. *See also* Vasculitis/vasculitides
Infliximab, 1.180, 2.405*t*, 6.322
  anti-idiotypic antibodies' effect on, 9.41
  for Behçet disease, 9.216
  for Mooren ulcer, 8.316
  for peripheral ulcerative keratitis, 8.313
  sarcoidosis-associated uveitis treated with, 9.199
  for scleritis, 8.324
  for uveitis, 9.111–112
Infliximab-dyyb, 1.181

Influenza virus
antiviral agents for, 1.279
description of, 8.239, 8.240*t*
immunization for, 1.225*t*, 1.226–227
Informed consent
in behavioral disorder patients, 1.211–212
for cataract surgery, 11.87–88
ethical considerations in, 1.212
in neurologic disorder patients, 1.211–212
before ocular surgery, 1.282
in older adults, 1.187
for refractive surgery, 13.36*t*, 13.46–48, 13.47*t*
in patient with ocular or systemic disease, 13.171–172
phakic IOL insertion and, 13.140–141
refractive lens exchange and, 13.147–148
Infraduction, 6.33. *See also* Depression of eye (downgaze)
Infranuclear pathways, 5.40–45, 5.40–44*f*, 5.211
disorders of, 5.191–206, 5.193*f*, 5.194*f*, 5.198*f*, 5.199*f*, 5.200*f*, 5.204*f*. *See also* Diplopia
Infraorbital artery, 2.23*f*, 5.12, 5.13*f*, 5.14*f*, 5.15*f*, 6.23, 7.8
Infraorbital canal, 2.11, 5.11, 7.8
Infraorbital foramen, 2.9*f*, 5.9*f*, 7.7*f*
Infraorbital groove, 2.6*f*, 2.8, 2.9*f*, 7.8
Infraorbital nerve, 5.48*f*, 5.49, 7.12*f*, 7.20
lacrimal functional unit innervated by, 8.5*f*
Infraorbital vein, 2.26*f*, 5.21*f*
Infrared laser, 12.374. *See also* Laser(s)
Infrared meibography, 8.40, 8.40*f*
Infrared (IR) radiation. *See also* Radiation
lens affected by, 11.57
Infratrochlear artery, 5.12
Infundibulum, 2.108*f*
Inheritance. *See also* Genetics; *specific disorder*
codominant patterns of, 2.203
dominant
autosomal, 2.206–208, 2.207*t*
description of, 2.202–203
X-linked, 2.209, 2.210*t*
maternal, 2.210, 2.218
multifactorial, 2.232–233
polygenic, 2.232–233
recessive
autosomal, 2.203–206
description of, 2.202–203
X-linked, 2.208–209, 2.209*t*
X-linked
description of, 2.208
disorders associated with, 2.210
dominant, 2.209, 2.210*t*
recessive, 2.208–209, 2.209*t*
Inherited disorders
migrainelike headache and, 5.294–295
neuro-ophthalmic signs of, 5.328–333, 5.334*t*. *See also specific disorder*
Inherited metabolic disorders. *See* Metabolic disorders
Initiative in Vision Rehabilitation on the ONE Network, 1.185
Injection drug use. *See* Substance abuse disorders
INL. *See* Inner nuclear layer
Inlays, corneal, 13.59–71, 13.169
alloplastic, 13.28, 13.60–61, 13.61*f*
homoplastic, 13.60
in keratophakia, 13.60–61, 13.61*f*
for presbyopia, 13.59–71, 13.169
Innate immune response/innate immune system
adaptive immune response *versus*, 9.27
conjunctiva and, 9.53
definition of, 9.1
macrophage activation by, 9.14
mediator systems in. *See* Mediators
overview of, 9.5
subclinical presence of, 9.6
summary of, 9.7*t*
triggers of
bacterial-derived molecules, 9.7*t*, 9.7–9
exotoxins, 9.9
lipopolysaccharide, 9.7–8
overview of, 9.6–7, 9.7*t*
Innate immunity, 1.245
Inner ischemic retinal atrophy, 4.151, 4.151*f*
in diabetic retinopathy, 4.159
in retinal arterial and venous occlusions, 4.156, 4.159
Inner neuroblastic layer, 2.155*f*
Inner nuclear layer (INL), 2.92, 4.140*f*, 4.141*f*
histology of, 12.11, 12.12*f*, 12.15*f*
paracentral acute middle maculopathy of, 12.143
Inner-outer segment junction, 12.12
Inner plexiform layer (IPL), 2.92, 4.140*f*, 4.141*f*, 12.11, 12.12*f*
Inner segments (IS), 2.85, 4.140*f*. *See also* Photoreceptor(s), inner segments of
of cones, 12.11, 12.12*f*
ellipsoid, 12.12
of rods, 12.11, 12.12*f*
Innominate artery, 5.12, 5.13*f*, 5.19
INO. *See* Internuclear ophthalmoplegia
Inoculum, 8.206
iNOS. *See* Inducible nitric oxide synthase
Inositol, 2.275
INR. *See* International normalized ratio
INS. *See* Infantile nystagmus syndrome
Insect hairs/stings, ocular injury/infection caused by, 8.386–387
Insomnia, fatal, 5.357
Instantaneous radius of curvature (meridional/tangential power), 13.16–17, 13.17*f*
Instrument myopia, 3.282, 3.286
Instrumental activities of daily living (IADLs), 1.187
Instrumentation. *See* Ophthalmic instrumentation; Surgical instruments
Insulin
continuous subcutaneous infusion of, 1.37
type 1 diabetes mellitus treated with, 1.37
Insulin-dependent diabetes mellitus, 6.408, 12.91. *See also* Diabetes mellitus (DM), type 1
Insulin growth factor-1 (IGF-1), retinopathy of prematurity screening and, 12.182
Insulin-like growth factor, 2.448
Insulin-like growth factor binding proteins, 2.277
Insulin-like growth factor I (IGF-I)
description of, 7.56
in retinopathy of prematurity pathophysiology, 6.325, 6.326*t*

Insulin-like growth factor I receptor (IGF-IR), 7.57
Insulin resistance
metabolic syndrome and, 1.77
in type 2 diabetes mellitus, 1.34
Insulinomas, 1.50
Intacs, 13.63. *See also* Intrastromal corneal ring segments
corneal crosslinking with, 13.207
Integrins, 9.11
Candida virulence and, 8.206
in external eye defense, 8.12–13*f*
Intense pulsed-light (IPL) therapy
for meibomian gland dysfunction, 8.69
for rosacea, 8.71
"Intention to treat" analysis, 1.6
Intercellular adhesion molecules (ICAMs). *See* Cell adhesion molecules
Intercellular adhesion molecule-1 (ICAM-1), 2.252, 2.415, 9.11
Intercellular signaling, of cytokines, 9.21
Interdigitation zone, 4.141*f*
Interdigitations, 2.286, 2.287*f*
Interface. *See* Graft-host interface
Interface debris, after LASIK, 13.122, 13.123*f*
Interference, 3.99–103
applications of, 3.103
constructive, 3.100, 3.119
definition of, 3.91
destructive, 3.100, 3.119
pictorial representation of, 3.101*f*
subtractive, 3.100
Interference filters, narrow-band, 3.103, 3.104*f*
Interferogram, 12.25
Interferometry
coherence length and, 3.101–102
coherence time and, 3.101–102
concept of, 3.102*f*
description of, 3.303
low-coherence, 3.102, 3.304, 8.21
in meibomian gland dysfunction, 8.40, 8.40*f*
Interferons (IFNs), 1.308*t*
α (interferon-alfa), 1.261, 2.448, 9.24*t*, 12.300
for Behçet disease, 9.218
for Mooren ulcer, 8.316
for ocular surface tumors, 8.327, 8.330, 8.330*f*, 8.331, 8.331*f*
conjunctival papilloma, 8.238–239, 8.239, 8.333
optic neuropathy caused by, 5.137
for uveitis, 9.112
β, for multiple sclerosis, 5.321*t*
definition of, 9.21
description of, 2.447–448
gamma
characteristics of, 9.24*t*
macrophage activation by, 9.42
T helper cell-1 production of, 9.35
for Mooren ulcer, 8.316
for ocular surface tumors, 8.327, 8.330, 8.330*f*, 8.331, 8.331*f*
conjunctival papilloma, 8.238–239, 8.239, 8.333
types of, 9.24*t*
Interferon-gamma release assay (IGRA)
for tuberculosis detection, 1.222
tuberculosis testing using, 9.29
INTERHEART study, 1.72
Interlenticular membranes, piggyback IOLs and, 13.150
Interlenticular opacifications, IOL, 11.151
Interleukin(s), 1.242
definition of, 9.21
in external eye defense, 8.6*f*, 8.11–13, 8.12*f*
types of, 9.22–23*t*
Interleukin-1
in dry eye, 8.53
in external eye defense, 8.11–13, 8.12*f*
in tear film, 8.11–13, 8.12*f*
Interleukin-1 receptor antagonist (IL-1RA), in external eye defense, 8.6*f*, 8.12*f*
Interleukin-1β, 9.22*t*
Interleukin-2, 7.210
characteristics of, 9.22*t*
T-cell synthesis and release of, 9.31
Interleukin-4
in B-cell activation, 9.35, 9.43
characteristics of, 9.22*t*
Interleukin-5
characteristics of, 9.22*t*
eosinophils and, 9.2
Interleukin-6
characteristics of, 9.22*t*
in inflammatory uveitis, 9.306
Interleukin-8, 9.23*t*
Interleukin-10
in intraocular lymphoma, 9.306
in T regulatory cell effector function, 9.35
Interleukin-12
antigen-presenting cell production of, 9.35
characteristics of, 9.23*t*
Interleukin-17A, 9.23*t*
Interleukin inhibitors, 1.180
Intermarginal sulcus, 2.28
Intermediate capillary plexus, 12.16
Intermediate uveitis (IU), 6.312*t*, 6.316, 6.316*f*, 6.320, 6.321*t*, 12.231–232. *See also* Pars planitis; Uveitis; *specific cause*
characteristics of, 9.70
chronic, 9.82
conditions associated with, 9.147
evaluation of, 9.72*t*
floaters in, 9.76
human leukocyte antigen association with, 9.65*t*
in human T-lymphocytic virus type 1, 9.266
immune recovery and, 9.257
in Lyme disease, 9.229
in multiple sclerosis, 9.151–152
multiple sclerosis and, 5.318
pars planitis. *See* Pars planitis
peripheral vascular sheathing in, 9.75
signs of, 9.81–82, 82*f*
snowball opacities in, 9.82, 9.147, 9.148*f*
snowbanks in, 9.82, 9.147
symptoms of, 9.76, 9.77*t*
vitreous cells in, 9.81–82, 9.82*t*
vitreous haze in, 9.81*f*, 9.81–82
Intermittent ataxia, 2.204*t*

Intermittent exotropia
age at onset, 6.99
basic, 6.101
characteristics of, 6.99–100
control of, 6.100
course of, 6.99
dissociated horizontal deviation and, 6.105
evaluation of, 6.100–101
nonsurgical management of, 6.101–102
normal retinal correspondence in, 6.99
occlusion therapy for, 6.102
patch test for, 6.101
postoperative alignment, 6.102
prisms for, 6.102
recurrence of, 6.103
refractive errors in, 6.101
surgical treatment of, 6.102–103
tenacious proximal fusion in, 6.71
treatment of, 6.101–103
Intermittent strabismus, 6.182
Intermuscular septum, 2.44, 6.28–29, 7.12
Internal auditory artery, 5.20
Internal carotid artery (ICA), 5.10*f*, 5.12, 5.13*f*, 5.14, 5.15*f*, 5.16*f*, 5.18*f*, 5.27*f*, 7.14, 7.170
anatomy of, 2.106*f*
aneurysm of, 5.338, 5.339*f*
chiasmal syndromes caused by, 5.147, 5.150
third nerve (oculomotor) palsy and, 5.194, 5.194*f*, 5.196, 5.196*f*, 5.339
cranial nerve relationship and, 5.42*f*, 5.43*f*
description of, 2.138
dissection of, 5.342–343
Horner syndrome and, 5.162, 5.260*t*, 5.261, 5.262*f*, 5.297
pain caused by, 5.297, 5.342
magnetic resonance imaging of, 2.460*f*
Internal hordeolum, 7.183, 8.77. *See also* Chalazion
Internal jugular vein, 5.22, 5.22*f*, 5.23
lesions of, Horner syndrome and, 5.260*t*
Internal limiting membrane (ILM), 4.140*f*
amacrine cells in, 12.15
anatomy of, 2.73*f*, 12.15
development of, 2.155
epiretinal membranes, 12.332
hemorrhagic detachment of, 12.171
histology of, 12.11, 12.12*f*
nonproliferative sickle cell retinopathy findings, 12.150
peeling of, 12.209
in retinal healing/repair, 4.17
vitreoretinal interface, 2.296
vitreous detachment and, 4.129
vitreous remnants on, 12.332
Internal medullary lamina, 5.34
Internal posterior hordeolum. *See* Chalazion
Internal radiation therapy. *See* Brachytherapy
Internal reflectivity, 2.463
Internal scleral sulcus, 4.98
Internal ulcer of von Hippel, 4.74, 4.75*f*
International Agency for the Prevention of Blindness (IAPB), 11.6
International Classification of Retinoblastoma (ICRB), 6.354, 6.356*t*
International Classification of Retinopathy of Prematurity (ICROP), 6.325, 6.327*t*
International Classification System for Intraocular Retinoblastoma (ABC System), 4.297, 4.297*t*
International Committee for the Classification of Corneal Dystrophies (IC3D), 8.133–134, 8.134*t*, 8.135*t*
International Federation for Clinical Neurophysiology electrophysiologic testing standards, 12.41
International HapMap Project, 2.189–190
International League of Associations of Rheumatology, 1.157, 1.158*t*
International normalized ratio (INR), 1.140, 1.276
International Reading Speed Texts (iReST), 3.318
International Society for Clinical Electrophysiology of Vision (ISCEV)
electrophysiologic testing standards of, 12.41
full-field electroretinography standards, 12.42, 12.43*f*
International Society of Refractive Surgery (ISRS), K-Card developed by, 13.194
International Standards Organization (ISO), intraocular lens standards of, 3.263–264
International Study Group for Behçet disease, 9.212, 9.212*t*
International Vitreomacular Traction Study Classification System, 12.336*t*
Internuclear lesions, diplopia caused by, 5.189–191, 5.190*f*, 5.191*f*
Internuclear ophthalmoplegia (INO), 2.475*t*, 5.38, 5.189–190, 5.190*f*, 5.247, 6.144
bilateral/wall-eyed bilateral (WEBINO), 5.189, 5.190*f*
in multiple sclerosis, 5.318
in multiple sclerosis, 5.318
in neuromyelitis optica, 5.322
nystagmus in, 5.189, 5.190*f*, 5.247
pursuit dysfunction in, 5.226
Interphotoreceptor retinoid-binding protein (IRBP), 2.326, 4.172
Interphotoreceptor retinoid-binding protein–specific T-cell receptor transgenic mice, 9.62
Interplexiform cells, 5.24
Interpulse time (TI), 5.75
Interpupillary distance, 6.203
bifocal segment decentration and, 3.191
in spectacle lens prescription, 3.198
Interrater reliability, 1.24
Interrupted sutures, for penetrating keratoplasty, 8.419*f*
removal/adjustment of, 8.419*f*, 8.431–432, 8.432*f*
Intersaccadic interval, 5.213
saccadic intrusions/oscillations and
normal, 5.247–248, 5.248*f*
not normal, 5.248*f*, 5.248–249
Intersexes, 2.225
Interstitial keratitis (IK), 4.80, 4.81*f*, 8.46*t*, 9.220, 9.221*f*. *See also* Keratitis
Epstein-Barr, 8.230, 8.231*f*
glaucoma and, 10.139
herpetic, 4.77*f*, 4.78, 4.80, 8.219–220, 8.220*f*, 8.222
in infectious disease, 8.307–309, 8.309*f*
syphilitic, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*
intrauterine infection and, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*

Interstitial nucleus of Cajal (INC), 5.35, 5.35*f*
saccadic eye movements and, 5.220–221
vertical gaze and, 5.36, 5.36*f*, 5.38
Interstitial nucleus of medial longitudinal fasciculus, rostral (riMLF), 5.33, 5.35, 5.35*f*, 5.220
saccadic eye movements and, 5.220
vertical gaze and, 5.36, 5.36*f*, 5.220
Intervening sequence. *See* Introns
Intorsion (incycloduction), 6.33
A-pattern strabismus caused by, 6.107, 6.110
definition of, 6.33
extraocular muscles in, 5.46*f*
oblique muscles, 5.46*f*
rectus muscles, 5.46*f*
Intra-arterial chemotherapy, for retinoblastoma, 4.299–300, 4.300*f*
Intra-axial ocular motor nerve course, 5.41*f*
Intra-axial ocular motor nerve palsies, 5.191
Intracameral drug delivery, 2.359–360, 2.360*t*
Intracameral injections
cefuroxime, during cataract surgery, 11.94, 11.162
lidocaine, during cataract surgery, 11.92, 11.137
Intracanalicular plugs, for dry eye, 8.64
Intracanalicular region of optic nerve, 4.241
compressive lesions of, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*. *See also specific lesion*
one-and-a-half syndrome and, 5.191
Intracapsular cataract extraction (ICCE), 3.240, 11.90, 11.199–201, 11.200*f*. *See also* Cataract surgery
globe exposure for, 11.199
historical overview/key developments in, 11.90, 11.119, 11.120*f*, 11.195
incision for, 11.199–200
IOLs for, 11.200
iridectomy/lens delivery in, 11.200, 11.200*f*
patient preparation for, 11.199
postoperative course for, 11.201
postoperative flat or shallow anterior chamber and, 11.135
retinal detachment and, 11.166
suture-induced astigmatism after, 11.131–132
wound closure and, 11.200–201
in zonular dehiscence with lens subluxation or dislocation, 11.182
Intracapsular IOL dislocation, 11.144, 11.144*f*, 11.145
Intracavernous carotid aneurysms, 5.339–340
Intracavernous ocular motor nerve course, 5.43*f*
Intracerebral hemorrhage, 1.120. *See also* Intracranial hemorrhage
Intraconal fat, 7.12
Intraconal fat pads, 6.28
Intraconal orbital abscesses, 6.214
Intraconal surgical space, 7.124
IntraCor (corneal intrastromal femtosecond laser treatment), 13.168
Intracorneal inlays. *See* Corneal inlays
Intracranial aspergilloma, 5.353–354
Intracranial hemorrhage, 1.120–122
arteriovenous malformations causing, 5.343
headache caused by, 5.288
neuroimaging in evaluation of, 5.72*t*
ruptured aneurysm causing, 5.340
Intracranial hypertension (increased intracranial pressure/ICP)
description of, 7.80
headache caused by, 5.107, 5.110, 5.112, 5.113, 5.288
idiopathic (IIH/pseudotumor cerebri/PTC), 5.110–113, 5.111*t*
in children, 5.113
headache and, 5.110, 5.112, 5.113, 5.288
optic nerve/nerve head/disc edema and. *See* Papilledema
ruptured aneurysms causing, 5.340
symptoms associated with, 5.107, 5.110–111, 5.111*t*
Intracranial pinealoblastoma, primary, retinoblastoma and, 4.298, 4.302
Intracranial pressure (ICP), 6.209, 6.370
Intracranial region of optic nerve, 4.241, 5.26–27
meningioma involving, 5.127–129, 5.128*f*
Intracranial retinoblastoma, ectopic, 4.298
Intracytoplasmic sperm injection (ICSI), 2.239
Intradermal (dermal) nevus, 4.219, 4.220*f*, 7.196
Intraepithelial dyskeratosis, benign hereditary, 8.332*t*
Intraepithelial lymphocytes, 9.5
Intraepithelial melanosis, 4.65–68, 4.66*f*, 4.67*f*
Intraepithelial neoplasia
conjunctival or corneal (CIN), 2.414, 4.61, 4.63*f*, 4.96, 8.37, 8.38*f*, 8.332*t*, 8.334–335, 8.335*f*. *See also* Ocular surface squamous neoplasia
melanocytic, 4.63*t*, 4.65, 4.66, 4.67*f*
corneal, 4.96
Intraepithelial (junctional) nevus, 8.338*t*, 8.340
Intralenticular fibrosis, 3.241
Intralenticular foreign bodies, 11.57
Intralesional hemorrhage, 6.221, 6.221*f*
Intramuscular injections, 2.362
Intranasal cysts, 6.229
Intraocular chemotherapy, for lymphoma, 4.312
Intraocular fine-needle aspiration biopsy (FNAB), 4.34*t*, 4.42–43, 4.43*f*, 4.253. *See also* Fine-needle aspiration biopsy
Intraocular gases, 2.360*t*
Intraocular inflammation. *See* Endophthalmitis; Inflammation (ocular); Uveitis; *specific type or structure*
Intraocular injections, 2.359–361
Intraocular foreign bodies (IOFBs). *See* Foreign bodies
Intraocular lenses (IOLs), 11.115–117, 11.118–122. *See also* Cataract surgery
accommodating, 3.261, 11.122, 11.122*f*, 13.8*t*, 13.154, 13.163–164, 13.164*f*
complications of, 11.151
acrylic, 3.256
American National Standards Institute standards for, 3.263–264
angle kappa in evaluation of, 8.33
angle-supported, 13.137, 13.138, 13.139*t*, 13.144
complications of, 13.146–147
anterior chamber, 11.117, 11.119, 11.120*f*
anterior uveitis caused by, 9.138, 9.138*f*
after capsular rupture, 11.142–143
closed-loop, pseudophakic bullous keratopathy and, 11.149
complications of, 11.146
fixed-haptic, 9.138*f*
flexible-loop, 11.119, 11.120*f*
history of development of, 11.119, 11.120*f*

after ICCE, 11.200
insertion of, 11.117
phakic, 13.8*t*. *See also* Phakic intraocular lenses
pictorial representation of, 3.241*f*
pupillary block and, 10.131–132
anterior chamber (ACIOLs), 11.117, 11.119, 11.120*f*
anterior uveitis caused by, 9.138, 9.138*f*
after capsular rupture, 11.142–143
closed-loop, pseudophakic bullous keratopathy and, 11.149
complications of, 11.146
fixed-haptic, 9.138*f*
flexible-loop, 11.119, 11.120*f*
history of development of, 11.119, 11.120*f*
after ICCE, 11.200
insertion of, 11.117
phakic, 13.8*t*. *See also* Phakic intraocular lenses
pictorial representation of, 3.241*f*
pupillary block and, 10.131–132
apodized diffractive, 13.166, 13.166*f*
biconvex, 3.241*f*
bifocal
description of, 3.258–259, 3.259*f*
modulation transfer function with, 3.262
biocompatibility of, 9.138
biometry in power calculation/selection of, 11.82–83, 11.83*f*, 11.84–85, 11.87
axial length, 11.82–83, 11.83*f*, 11.84–85, 11.87
hypotony affecting, 11.185
unexpected refractive results after surgery and, 11.150
refractive lens exchange and, 13.150
blue-blocking, 11.120
capsular block syndrome and, 10.132, 11.148–149
capsular opacification and, 11.153, 13.156, 13.167
after capsular rupture, 11.142–143
in children, 9.315
closed-loop, pseudophakic bullous keratopathy and, 11.149
complications of, 11.144*f*, 11.144–152, 11.146*f*, 11.147*f*, 11.148*f*
induced-astigmatism, 11.132
corneal disease and, 11.128*t*
cystoid macular edema and, 11.165
decentration and dislocation of, 11.127, 11.144*f*, 11.144–147, 11.146*f*, 11.147*f*
angle-supported lenses and, 13.146
bifocal segments, 13.190–191
iris-fixated lenses and, 13.145
laser application during photoablation and, 13.91
laser capsulotomy and, 11.156
multifocal IOLs and, 3.258, 11.144, 11.145, 13.155
prism correction through, 3.197
deformable, 13.170
description of, 6.301
designs of
innovations in, 13.170, 13.170*f*
modifications of, 11.119–122, 11.120*f*, 11.121*f*, 11.122*f*
diffractive multifocal, 13.166, 13.166*f*
for drug delivery, 2.364–365
dual-optic, 13.170, 13.170*f*
dysphotopsias caused by, 3.255
estimated lens position for, 3.239, 3.243, 3.248–250, 3.249*f*, 3.252–253
extended-depth-of-focus, 3.262–263, 3.263*f*
flexible-loop, 11.119, 11.120*f*
foldable, 11.116, 11.120, 11.120*f*, 11.121*f*. *See also* Foldable intraocular lenses
insertion of, 11.116
posterior chamber phakic, 13.138
glare and, 11.144, 11.150–152
glaucoma and, 10.108
high-power, 3.264
history of, 11.118*f*, 11.118–119
hyphema after cataract surgery and, 11.159
illusions caused by, 5.174
image magnification, 3.255
in infants and children, 13.187
innovations in, 13.170, 13.170*f*
insertion of, 11.115–117
anterior chamber, 11.117
after capsular rupture, 11.142–143
complications of, 11.144*f*, 11.144–152, 11.146*f*, 11.147*f*, 11.148*f*
after ECCE, 11.197
after ICCE, 11.200
posterior chamber, 11.116–117
procedures after, 11.117–118
International Standards Organization standards for, 3.263–264
iris-fixated/supported, 11.116–117, 11.119, 11.119*f*, 13.8*t*, 13.137, 13.138, 13.139*t*, 13.141–142, 13.142*f*
after ICCE, 11.200
insertion of, 11.116–117, 11.119*f*
after keratoplasty, 11.176
pseudophakic bullous keratopathy and, 11.149
uveitis and, 11.188
issues associated with, 6.303–304
in juvenile idiopathic arthritis–associated uveitis cataracts, 9.315
after keratoplasty, 11.176
with keratoplasty and cataract surgery (triple procedure), 11.175–176
laser capsulotomy affecting, 11.155–156, 11.156
lens dislocation treated with, 6.310
lensectomy with, 6.302–304
light-adjustable, 13.153–154, 13.154*f*
for manual small-incision cataract surgery, 11.198
materials for, 3.240
megalocornea and, 8.100
meniscus, 3.240, 3.241*f*
minus-power, 3.240
modulation transfer function, 3.261–263, 3.262–3.263*f*
monofocal, 3.257, 3.260, 13.151
multifocal (MFIOLs), 11.121*f*, 11.121–122, 13.8*t*, 13.155–156, 13.165–167, 13.166*f*
annular zones, 3.259, 3.259*f*
best-corrected visual acuity with, 3.260
bifocal, 3.258–259, 3.259*f*
capsular decentration and, 11.183
clinical results of, 3.260–261
complications of, 11.151
decentration effects on, 3.258
description of, 3.257–258
diffractive, 3.259*f*, 3.259–260

disadvantages of, 3.258
dry eye therapy before use of, 11.173
extended-depth-of-focus lenses *versus*, 3.262–263, 3.263*f*
indications for, 3.258
multiple-zone, 3.259, 3.259*f*
patient selection for, 3.260
power calculation for, 3.258
for presbyopia, 13.165–167, 13.166*f*
three-zone, 3.259, 3.259*f*
types of, 3.258–260
in myopia, 11.184–185
nonspherical optics with, 3.257
after ocular trauma, 11.193
opacification of, 11.151
optical performance standards for, 3.264
overview of, 3.240–241
partial-ridge, 3.240
after penetrating keratoplasty, 8.432, 13.179
with penetrating or endothelial keratoplasty and cataract surgery (triple procedure), 11.175–176
phacoemulsification with, 9.315
phakic (PIOLs), 13.8*t*, 13.47*t*, 13.137, 13.138–147, 13.139*t*, 13.142*f*, 13.143*f*. *See also* Phakic intraocular lenses
advantages/disadvantages/limitations of, 13.47*t*, 13.138–140
for amblyopia/anisometropic amblyopia/strabismus, 13.185–186, 13.187
in children, 13.187
corneal crosslinking with, 13.134, 13.207–208
retinal detachment and, 13.138, 13.145, 13.146
piggyback
definition of, 3.240
intralenticular fibrosis after placement of, 3.241
power calculations for, 3.251
refractive lens exchange and, 13.150
planoconvex, 3.241*f*
plus-power, 3.250
posterior capsule opacification and, 3.240
posterior capsulectomy/vitrectomy with, 6.303
posterior chamber (PCIOLs), 11.116–117, 11.118*f*, 11.119*f*, 11.119–122, 11.120*f*, 11.121*f*, 12.393
anterior chamber depth prediction formula for, 3.249
capsular block syndrome and, 10.132
after capsular rupture, 11.143
decentration/dislocation of, 11.145
dislocated, 12.393
after ECCE, 11.197
history of development of, 11.118–119, 11.119*f*
image magnification with, 3.255
insertion of, 11.116–117
after keratoplasty, 11.176
light-adjustable, 13.153–154, 13.154*f*
near-addition power for, 3.259
after ocular trauma, 11.193
pachymetry studies of, 3.249
phakic, 13.8*t*, 13.138, 13.142*f*, 13.142–144, 13.143*f*. *See also* Phakic intraocular lenses
complications with, 13.145–146
corneal crosslinking with, 13.207–208
sizing, 13.144
pictorial representation of, 3.241*f*
pupillary capture of, 11.148, 11.148*f*
in retinal disease, 11.189
scleral/iris-fixated (sutured), 11.116–117, 11.119, 11.119*f*, 13.8*t*, 13.137, 13.138, 13.139*t*, 13.141–142, 13.142*f*
after ICCE, 11.200
insertion of, 11.116–117, 11.119*f*
after keratoplasty, 11.176
pseudophakic bullous keratopathy and, 11.149
uveitis and, 11.188
uveitis and, 11.188
posteriorly dislocated, 12.393
power calculation and determination for, 6.303, 11.84–87
axial length, 3.243–248
biometry in, 11.82–83, 11.83*f*, 11.84–85, 11.87, 13.150. *See also* Intraocular lenses (IOLs), biometry in power calculation/selection of
hypotony affecting, 11.185
central corneal power, 3.243, 3.248
in children, 3.254–255
contact lens method for, 13.195
in corneal transplant eyes, 3.253–254
double-*K* method, 3.252
formulas for, 11.84, 11.85–87
biometric, 3.244–250
errors in, 3.252
for post–keratorefractive procedure eye, 3.252–253
prediction, 3.243–244
regression formulas, 11.85–87
theoretical, 3.243
geometric optics and, 3.243
historical methods for, 11.86–87, 13.194
improving outcomes of surgery and, 11.87
incorrect, 11.85
multifocal lenses, 3.258
in myopia, 11.184
online post-refractive calculator for (ASCRS), 13.52, 13.195–197, 13.196*f*
piggyback lenses, 3.251
preventing errors in, 11.87
after radial keratotomy, 13.51, 13.52–53, 13.193
refraction and, 11.76
refractive lens exchange and, 13.150
after refractive surgery, 3.251–253
refractive surgery and, 11.85–87, 11.176, 11.177*f*, 13.44, 13.193–197, 13.196*f*
in silicone oil–filled eyes, 3.254
sulcus placement adjustments, 3.250*t*
topographical method for, after refractive surgery, 13.193, 13.194
triple procedure and, 11.175
unexpected refractive results after surgery and, 11.86, 11.149–150
power labeling of, 3.263–264
for presbyopia, 13.8*t*, 13.154, 13.163–164, 13.164*f*, 13.170, 13.170*f*
pressure on, 3.242*f*
pseudoaccommodating, 11.122
complications of, 11.151
for pseudophakia, 13.163–164, 13.164*f*
pseudophakic bullous keratopathy and, 11.149
pupil evaluation and, 11.78

pupillary block and, 10.131–132
pupillary capture of, 11.148, 11.148*f*
for refractive errors. *See also specific type*
accommodating, 13.8*t*, 13.154, 13.163–164, 13.164*f*
deformable, 13.170
dual-optic, 13.170, 13.170*f*
innovations in, 13.170, 13.170*f*
light-adjustable, 13.153–154, 13.154*f*
monocular, 13.151
multifocal (MFIOLs), 13.155–156, 13.165–167, 13.166*f*
complications of, 13.156, 13.167
for presbyopia, 13.165–167, 13.166*f*
phakic, 13.137, 13.138–147, 13.139*t*, 13.142*f*, 13.143*f*. *See also* Phakic intraocular lenses
advantages/disadvantages/limitations of, 13.47*t*, 13.138–140
retinal detachment and, 13.138, 13.145, 13.146
power determination of
refractive lens exchange and, 13.150
refractive surgery and, 13.44, 13.193–197, 13.196*f*
after radial keratotomy, 13.51, 13.52–53
with refractive lens exchange, 13.8*t*, 13.150. *See also* Refractive lens exchange
piggybacking and, 13.150
toric, 13.8*t*, 13.137, 13.148–149, 13.151–153
with refractive lens exchange, 13.8*t*, 13.150. *See also* Refractive lens exchange
piggybacking and, 13.150
retained fragments of, 9.90
in retinal disease, 11.189
in silicone oil eyes, 3.254, 11.83, 11.120, 11.190
split bifocal, 3.258, 3.259*f*
square edge design of, 3.242*f*
standards for, 3.263–264
sulcus-supported, 13.137, 13.139*t*
supplemental, power calculations for, 3.251
sutured-in, 3.250
TECNIS Symfony, 3.263
tilt of, 3.250
toric, 11.124, 13.8*t*, 13.137, 13.148–149, 13.151–153. *See also* Toric intraocular lenses
astigmatism correction using, 3.257
complications of, 11.151
contraindication for, capsular decentration and, 11.183
corneal crosslinking with, 13.134, 13.207–208
dry eye therapy before use of, 11.173
after penetrating keratoplasty, 8.432, 13.179
traumatic cataract and, 11.193
types of, 3.240, 3.241*f*
with UV-absorbing chromophores, 11.120
in uveitis, 9.137–139, 9.138*f*, 11.188
postoperative inflammation and, 11.140
uveitis-glaucoma-hyphema (UGH) syndrome and, 9.10, 9.137, 10.108–109, 11.149
decentration and, 11.145
vision disturbances related to, 3.255–256, 3.256*f*
zonal refractive, 13.166, 13.166*f*
Intraocular lymphoma, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349, 12.233–234, 12.234*f*. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
Intraocular medications. *See specific drug*
Intraocular melanomas, 7.146
Intraocular pressure (IOP), 10.3, 10.20*f*, 10.20–27. *See also* Ocular hypertension
age affecting, 10.81–82
in anterior uveitis, 9.80–81, 9.317
applanation tonometry of, 3.293
apraclonidine hydrochloride effects on, 2.385
aqueous humor dynamics and, 10.5, 10.5*f*, 10.13, 10.14*f*
β-agonist effects on, 2.390
brimonidine effects on, 2.386
carbachol effects on, 2.377
carbonic anhydrase inhibitors' effect on, 2.392
in chemical injury, management and, 8.383
in childhood glaucoma, 6.277, 6.279, 6.290–291
circadian/diurnal variation in, 10.3, 10.8, 10.22, 10.80–81, 10.81*t*, 10.86, 10.87
corneal thickness/rigidity and, 8.41, 10.25, 10.81, 10.82, 10.86–87, 10.90, 13.105, 13.181, 13.200
in infants and children, 10.159
corticosteroids affecting, 10.100, 10.108, 10.109–110
optic nerve damage and, 10.110
after refractive surgery, 13.41, 13.92, 13.201
in uveitis, 10.110
decreased
after cataract surgery, flat anterior chamber and, 11.135
factors causing, 10.21*t*, 10.22
digital palpation of, 6.10
digital pressure in estimation of, 10.26
distribution in population and, 10.20*f*, 10.20–21
drugs for lowering, 3.144. *See also* Antiglaucoma agents
elevated/increased. *See* Elevated intraocular pressure
episcleral venous pressure and, 10.20, 10.102
factors affecting, 10.21*t*, 10.21–22
flap creation affected by, 13.181
follow-up for, 6.290–291
in glaucoma, 10.3, 10.20–21, 10.46–47, 10.79–81, 10.81*t*. *See also* Elevated intraocular pressure; Glaucoma
glucocorticoid-induced elevation of, 2.401–402, 2.402*t*
Goldmann equation and, 2.271, 2.273
in hyphema, 6.378, 8.394, 8.395, 10.104, 10.105
sickle cell disease and, 8.395, 8.395*t*, 8.396
surgery and, 8.395, 8.395*t*, 8.396
increased
difluprednate as cause of, 9.94
periocular corticosteroids as cause of, 9.96
inhaled corticosteroids' effect on, 1.130
lens epithelium affected by, 4.120
lowering of, in glaucoma management. *See also* Antiglaucoma agents
clinical trials in study of, 10.111–115
normal-tension glaucoma and, 10.87–88
target range for, 10.169, 10.183
maintenance of, 2.271
measurement of, 10.22–27, 10.23*f*, 10.24*f*. *See also* Tonometry

artifact in, normal-tension glaucoma and, 10.86
in children
description of, 6.10, 6.181
tonometry for, 6.281
in infants and children, 10.158–159
after refractive surgery, 13.105, 13.181, 13.200–201
pressure-induced stromal keratopathy after LASIK and, 13.119
before refractive surgery, 13.41
during refractive surgery, suction ring placement and, 13.86
medications for reducing, 6.288, 6.289*t*
monitoring of, in glaucoma patients using corticosteroids, 1.130
netarsudil effects on, 2.396
normal range for, 6.282, 10.20–21, 10.80, 10.85
in infants and children, 10.159
in orbital compartment, 7.119
pregnancy affecting, 10.185
in rhegmatogenous retinal detachment, 12.320
rimexolone effects on, 2.403
scleral buckling effects on, 12.399
in sickle cell retinopathy, 12.154
statins and, 1.78
swelling pressure and, 8.9
target, in glaucoma treatment, 10.169, 10.183
in trauma patients, 12.352
in uveitis, corticosteroids affecting, 10.110
Intraocular region of optic nerve, 4.241
Intraocular surgery. *See* Ocular surgery
Intraocular tumors. *See also specific type of tumor and structure affected*
angiomatous, 4.281–287
glaucoma caused by, 4.105*f*, 4.106, 10.98–100, 10.99*f*, 10.138
in children and adolescents, 10.149*t*
gross dissection in identification of, 4.29*f*, 4.29–30
leukemia and, 4.315*f*, 4.315–316, 4.316*f*
lymphoma, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
melanocytic, 4.255–280
metastatic, 4.197, 4.303–316. *See also* Metastatic eye disease
molecular pathology in identification/evaluation of, 4.34*t*, 4.36–42, 4.38–39*t*, 4.40*f*, 4.41*f*
retinoblastoma, 4.172–177, 4.253, 4.289–302. *See also* Retinoblastoma
in systemic malignancies, 4.197, 4.303–316. *See also* Metastatic eye disease
direct extension from extraocular tumors and, 4.310
leukemia and, 4.315*f*, 4.315–316, 4.316*f*
lymphomatous, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–314, 4.313*f*
secondary, 4.303–310
transillumination in identification of, 4.28*f*, 4.28–29
Intraoperative floppy iris syndrome (IFIS), 2.384, 11.74, 11.136–138, 11.137*t*
pupil expansion devices for, 11.178
Intraoperative optical coherence tomography (OCT), 8.22
Intraoral trauma/tumor, Horner syndrome caused by, 5.260*t*
Intraorbital optic nerve, 7.11
Intraorbital region of optic nerve, 4.241, 5.26, 10.42
compressive lesions of, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*. *See also specific lesion*
Intrapapillary drusen, 6.373*f*, 6.373–374
Intraparenchymal hematomas, 1.122
Intrarater reliability, 1.24
Intraretinal hemorrhage, 9.157*f*
in branch retinal vein occlusion, 12.125, 12.126*f*
in nonproliferative diabetic retinopathy, 12.100*f*
in systemic lupus erythematosus, 12.230–231
Intraretinal microvascular abnormalities (IRMAs), 4.153*f*, 4.154, 4.155*f*
in diabetic retinopathy, 4.159
in nonproliferative diabetic retinopathy, 12.100*f*
Intrascleral fixation, 12.393
Intrastromal corneal femtosecond laser treatment, for presbyopia, 13.168
Intrastromal corneal ring segments (ICRS), 13.8*t*, 13.28, 13.28*f*, 13.62–65*f*, 13.62–70, 13.67–69*f*. *See also* Corneal ring segments, intrastromal
complications of, 13.67–70, 13.68–69*f*
contraindications for, 13.63
corneal crosslinking with, 13.134, 13.207
corneal transplantation after, 13.198
instrumentation for, 13.63
for keratoconus, 13.62, 13.65*f*, 13.65–66, 13.69–70, 13.176
after LASIK, 13.70
limitations of, 13.47*t*
number of segments used and, 13.66–67, 13.67*f*
outcomes of, 13.64–65
removal of, 13.63, 13.65
LASIK after, 13.70
surgical technique for, 13.64, 13.64*f*
Intrauterine ocular infections. *See also specific type*
corneal anomalies and, 8.107
keratectasia, 8.107
cytomegalovirus, 6.411, 6.411*f*
description of, 6.409
herpes simplex virus, 6.412
lymphocytic choriomeningitis, 6.413
rubella, 6.410*f*, 6.410–411
syphilitic, 4.80, 4.81*f*, 6.412–413, 8.107, 8.308–309, 8.309*f*
toxoplasmosis, 6.409–410, 6.410*f*
Zika virus, 6.413
Intravascular papillary endothelial hyperplasia, 8.345*t*
Intravascular ultrasound, in coronary heart disease diagnosis, 1.89
Intravenous drug use. *See* Substance abuse disorders
Intravenous immunoglobulin (IVIg)
for neuromyelitis optica, 5.323
for uveitis, 9.113
Intravenous injections, 2.362
Intraventricular hemorrhage (IVH), 1.120–121. *See also* Intracranial hemorrhage
Intravitreal corticosteroids, for uveitis, 9.97–98, 9.102
Intravitreal cysts, 9.286*f*
Intravitreal drug delivery, 2.360*t*, 2.361
Intravitreal injections
for age-related macular degeneration, 4.164
anesthesia for, 12.403

anti-VEGF drugs, 12.404
aseptic technique for, 12.403–404
cataract formation and, 11.56
chemotherapy for retinoblastoma and, 4.299–300
complications of, 12.404
corticosteroids
after cataract surgery, 11.163
for cystoid macular edema, 4.152, 11.165
diabetic macular edema treated with, 12.101
elevated intraocular pressure and, 10.110
proliferative diabetic retinopathy treated with, 12.104
retinopathy of prematurity treated with, 12.187
for endophthalmitis, postoperative, 11.162
endophthalmitis after, 12.404
indications for, 12.403
prevalence of, 12.403
technique for, 12.403, 12.403*f*
Intravitreal triamcinolone acetonide (IVTA). *See* Triamcinolone
Intrinsic pathway, of coagulation cascade, 1.138*f*
Intrinsic sympathomimetic activity (ISA), 1.62
Intrinsically photosensitive retinal ganglion cells (ipRGCs), 5.24, 5.28. *See also* Ganglion cells/ganglion cell layer (GCL), retinal
Introns
description of, 2.176
excision of, 2.179. *See also* Splicing
Intrusions, saccadic. *See* Saccadic intrusions/oscillations
Intubation, lacrimal stent, 7.292–294, 7.294*f*
Intumescent cortical cataract, 11.46
surgery for, 11.179–180
Invasion, as microbial virulence factor, 8.207
Invasive aspergillosis, 5.353–354, 7.52
Inverse Knapp procedure, 6.128
Inversion recovery (IR) imaging, 5.75
Inverted follicular keratosis, 4.209, 4.210*f*
Investigational new drugs (INDs), 2.371
Investigator bias, 1.5
Involutional ectropion
clinical features of, 7.230*f*
horizontal eyelid laxity as cause of, 7.231
lateral tarsal strip procedure for, 7.231, 7.232*f*
lower eyelid tightening surgery for, 7.231, 7.232*f*
medial spindle procedure for, 7.231, 7.232*f*
Involutional entropion
causes of, 7.234
clinical features of, 7.235*f*
retractor disinsertion as cause of, 7.234–235
surgical repair of, 7.236, 7.236*f*
temporizing measures for, 7.235*f*, 7.235–236
transconjunctival approach to, 7.236, 7.236*f*
Involutional stenosis, 7.305
IO. *See* Inferior oblique (IO) muscle
Iodinated contrast agents, 2.457
Iodine, radioactive. *See* Radioactive iodine
Iodine-125
for retinoblastoma, 4.301
for uveal melanoma, 4.275
Iodine-131, for Graves hyperthyroidism, 1.44
IOFBs (intraocular foreign bodies). *See* Foreign bodies
IOL power calculator, online post-refractive (ASCRS), 13.52, 13.195–197, 13.196*f*
IOLs. *See* Intraocular lenses
Ionization constant, 2.262
Ionizing radiation. *See also* Radiation; Radiation therapy
anterior segment injury caused by, 8.386
cancer caused by exposure to, 1.236
cataracts caused by, 11.57
ocular effects of, 1.238, 1.238*t*
retinopathy caused by exposure to, 12.170*f*, 12.170–171
tissue damage caused by, 1.238*t*
treatment uses of, 1.237
Iontophoresis, 2.367
IOP. *See* Intraocular pressure
IOP-SP. *See* Imbibition pressure
Iopidine. *See* Apraclonidine
IP. *See* Incontinentia pigmenti
IPE. *See* Iris pigment epithelium
Ipilimumab, 7.210
IPL. *See* Inner plexiform layer; Intense pulsed-light (IPL) therapy
Ipratropium bromide, 1.128
ipRGCs. *See* Intrinsically photosensitive retinal ganglion cells
Ipsilateral gaze palsy, 5.41, 5.200, 5.200*f*
IR. *See* Inferior rectus (IR) muscle
IR (index of refraction). *See* Refractive index
IR (inversion recovery) imaging, 5.75
IR radiation. *See* Infrared radiation
IRBP. *See* Interphotoreceptor retinoid-binding protein
iReST. *See* International Reading Speed Texts
IRID1 gene, 10.11*t*
Iridectomy
for angle-closure glaucoma, 10.125, 10.220
acute angle closure and, 10.125
for anterior chamber IOL insertion, 11.117, 11.136
in ICCE, 11.200
for phakic IOL insertion, 13.141
in trabeculectomy, 10.202, 10.204*f*
Irides. *See* Iris
Iridocorneal adhesions (Peters anomaly), 4.74, 4.75*f*, 4.98, 8.97*t*, 8.102–104, 8.103*f*, 10.150, 10.154, 11.31–32. *See also* Axenfeld-Rieger syndrome
Axenfeld-Rieger syndrome differentiated from, 10.154*t*
glaucoma and, 4.74, 10.150, 10.154
pediatric keratoplasty for, 8.450
Iridocorneal endothelial (ICE) syndrome, 4.100–101, 4.101*f*, 4.259, 6.268, 8.111, 8.126–128, 8.127*f*, 10.31, 10.136*f*, 10.136–138, 10.137*f*
Axenfeld-Rieger syndrome differentiated from, 10.154*t*
glaucoma and, 4.101, 10.31, 10.136–137*f*, 10.136–138
posterior polymorphous corneal dystrophy differentiated from, 8.159
Iridocyclitis, 2.380–381, 2.434, 3.176, 6.412. *See also* Anterior uveitis; Iritis; *specific cause*
in ankylosing spondylitis, 1.157
in Behçet disease, 1.174
corticosteroids for, 9.127
definition of, 9.70

Fuchs heterochromic (Fuchs heterochromic uveitis [FHU]/uveitis syndrome). *See also* Fuchs heterochromic uveitis
cataracts/cataract surgery and, 11.64*f*, 11.64–65
glaucoma and, 10.101–102, 10.102*f*
herpetic, 8.222–224, 8.223*t*
in reactive arthritis/Reiter syndrome, 8.305–306
in rosacea, 8.70, 8.70*f*
Iridodialysis, 4.18, 4.20*f*, 4.103, 5.255, 8.390*f*, 8.390–391, 8.391*f*, 10.41*f*
during cataract surgery, 11.138
cataract surgery in patient with, 11.191
pupil irregularity and, 5.255
repair of, 8.375, 8.390*f*, 8.390–391, 8.391*f*, 8.409
Iridodonesis, 6.306, 6.308
cataract surgery and, 11.79, 11.181–182
in pseudoexfoliation/exfoliation syndrome, 10.92
Iridogoniodysgenesis, gene for, 10.11*t*
Iridogoniodysgenesis anomaly/syndrome. *See* Axenfeld-Rieger syndrome
Iridogoniodysplasia, familial glaucoma. *See* Axenfeld-Rieger syndrome
Iridolenticular diaphragm, 9.123
Iridoplasty
for angle-closure glaucoma, 10.193–194
for plateau iris, 10.127*f*, 10.128, 10.193–194
Iridoschisis, 4.98
Axenfeld-Rieger syndrome differentiated from, 10.154*t*
Iridotomy
for acute angle closure, 10.124, 10.125, 10.191–193, 10.192*f*
for angle-closure glaucoma, 10.124–126, 10.191–193, 10.192*f*
cataract extraction after, 10.213
for chronic angle closure, 10.126
for ectopia lentis, 10.129–130
laser, 10.191–193, 10.192*f*
for malignant/ciliary block glaucoma (aqueous misdirection), 10.140
for phacomorphic glaucoma, 10.128
for phakic IOL insertion, 13.141
for pigmentary glaucoma, 10.96, 10.96*f*
for plateau iris, 10.128, 10.191
for primary angle-closure suspect, 10.122, 10.191
for subacute/intermittent angle closure, 10.126
IRIS. *See* Immune reconstitution inflammatory syndrome
Iris, 4.97–98*f*, 4.181–182, 4.181–182*f*. *See also* Uvea (uveal tract)
abnormalities of, 6.264–266*f*, 6.264–267
anisocoria and, 5.256*f*, 5.262–263
pupil irregularity caused by, 5.255
absence of/rudimentary (aniridia), 4.184, 10.150, 10.154–155, 11.33
cataract and, 11.33, 11.34*f*
surgery for, 11.184
glaucoma and (iris-induced angle closure), 10.120, 10.155
pediatric, 10.150, 10.155
Axenfeld-Rieger syndrome differentiated from, 10.154*t*
gonioscopic appearance of, 10.159
pupil irregularity and, 5.255
short arm 11 deletion syndrome/*PAX6* gene mutations and, 4.184, 10.150, 10.155, 11.33
Wilms tumor and, 4.184, 10.155, 11.33
anatomy of, 2.48*f*, 2.69–70*f*, 4.97*f*, 4.98*f*, 4.181–182, 4.181–182*f*
angle closure and, 10.120
aniridia, 6.266*f*, 6.266–267
anterior border of, 4.181, 4.182*f*
anterior pigmented epithelium of, 2.70–71, 2.71*f*
atrophy of, 4.100, 4.101*f*, 8.111, 8.126, 8.127*f*, 10.136, 10.137*f*. *See also* Iridocorneal endothelial (ICE) syndrome
in acute angle closure, 10.123–124
cataract and, 11.68
in herpetic eye disease, 8.226*t*, 8.227
in Axenfeld-Rieger syndrome, 6.264–265, 6.264–265*f*
blood vessels of, 2.69
bowing of
with pupillary block, 10.119
with reverse pupillary block, in pigment dispersion syndrome/pigmentary glaucoma, 10.93, 10.96*f*
Brushfield spots of, 6.272
collarette of, 2.69
coloboma of, 4.184, 6.266, 6.266*f*
cataract surgery in patient with, 11.180
congenital ectropion of, 6.267
cysts of, 4.259, 4.260*f*, 6.272*f*, 6.272–273
development of, 2.157, 2.159–160*f*, 2.160
dilator muscles of
description of, 2.70–71, 2.160*f*
phenylephrine hydrochloride effects on, 2.384
evaluation of
before cataract surgery, 11.79
in glaucoma, 10.32, 10.33*t*, 10.34*f*
in pupillary examination, 5.254
in familial dysautonomia, 6.270
functions of, 2.269
growth and development of, 6.181
healing/repair of, 4.16
heterochromia of (heterochromia iridis), 6.274, 6.274*f*, 6.274*t*
in Fuchs heterochromic uveitis/iridocyclitis, 10.101
in Horner syndrome, 5.258
in siderosis bulbi, 11.58*f*
hypoplasia of, 6.264–267, 6.264–267*f*
Axenfeld-Rieger syndrome and. *See* Axenfeld-Rieger syndrome
incarceration of, after penetrating keratoplasty, 8.424
intramuscular circle of, 2.22
juvenile xanthogranuloma of, 4.187, 4.260, 6.271
laceration of, repair of, 8.406, 8.408*f*, 8.409
layers of, 2.71*f*
in leukemia, 4.315
Lisch nodules of, 6.271–272, 6.272*f*, 6.392, 6.395*f*, 6.397
malformation of, pupil irregularity and, 5.255
mammillations of, 6.271–272, 6.272*f*
melanocytoma of, 4.192, 4.258
melanoma of, 4.106, 4.190, 4.191*f*, 4.258–261, 4.259*f*, 4.260*f*, 4.261*f*
glaucoma caused by, 4.106, 4.194

neoplastic disorders of, 4.189–190, 4.190*f*, 4.191*f*
fine-needle aspiration biopsy in identification/evaluation of, 4.42
metastatic, 4.260, 4.260*f*, 4.303, 4.304, 4.305*f*
neovascularization of (rubeosis iridis), 4.188, 4.189*f*
in branch retinal vein occlusion, 12.128–129, 12.129*f*
in central retinal artery occlusion, 12.146
in central retinal vein occlusion, 12.133, 12.135
in diabetes mellitus, 4.159, 4.160*f*, 12.107
glaucoma and, 4.188, 10.32, 10.39, 10.132*t*, 10.133, 10.133*f*, 10.135*f*. *See also* Neovascular glaucoma
in children and adolescents, 10.149*t*
incisional surgery contraindicated in, 10.198
laser iridotomy contraindicated in, 10.191
in radiation retinopathy, 12.170
in retinoblastoma, 4.174, 4.174*f*, 4.292
nerves of, 2.69
nodules of. *See* Iris nodules
parasympathetic innervation of, 2.71
persistent pupillary membrane, 6.264, 6.264*f*, 6.266*f*
physiology of, 2.269–270
pigment epithelium of. *See* Iris pigment epithelium
pigmentation of
prostaglandin analogues/latanoprost affecting, 10.175
pseudoexfoliation syndrome/glaucoma and, 10.39, 10.92
plateau, 10.4*t*, 10.9, 10.32, 10.120, 10.127*f*, 10.127–128
laser iridotomy for, 10.128, 10.191
posterior pigmented epithelium of, 2.71–72
prolapse of, after DSEK, 8.439*f*
prostaglandin analogues effect on, 2.393–394
pupillary abnormalities and, 5.254
sectoral palsy of, 5.254
anisocoria/Adie tonic pupil and, 5.256*f*, 5.263, 5.263*f*
smooth muscle in, 4.182
sphincter muscles of
anatomy of, 2.71*f*, 2.160*f*
direct-acting cholinergic agonists' effect on, 2.375
stroma of, 2.68–69, 4.181
structures of, 2.68
surfaces of, 2.71*f*
sympathetic innervation of, 2.71
systemic conditions that affect, 6.269–270
topography of, 4.181*f*, 4.181–182, 4.182*f*
transillumination of, 6.265, 6.406, 6.407*f*
in albinism, 4.142, 4.142*f*
in pigment dispersion syndrome, 10.94, 10.94*f*
traumatic damage to
anisocoria and, 5.256*f*, 5.262–263
during cataract surgery, 11.138
cataract surgery in patient with, 11.191
iridodialysis, 4.18, 4.20*f*, 4.103, 8.390*f*, 8.390–391, 8.391*f*
cataract surgery and, 11.138, 11.191
repair of, 8.375, 8.390*f*, 8.390–391, 8.391*f*, 8.409
laceration, 8.406, 8.408*f*, 8.409
mydriasis and miosis, 8.388–389, 8.389*f*
pupil irregularity and, 5.255
repair of, 4.16, 8.406, 8.408*f*, 8.409
tumors of, 4.189–190, 4.190*f*, 4.191*f*, 6.271–273, 6.272*f*
fine-needle aspiration biopsy in identification/evaluation of, 4.42
metastatic, 4.260, 4.260*f*, 4.303, 4.304, 4.305*f*
ultrasound biomicroscopy of, 2.471–472*f*
in uveitis. *See* Iridocyclitis; Iritis
vitreous adhesions to, 12.159
in Waardenburg syndrome, 6.270
Iris bombé
description of, 6.285, 9.81, 9.130, 9.196
after endothelial keratoplasty (DMEK/DSEK), 8.444*f*, 8.444–445
glaucoma and, 10.32, 10.129, 10.131*f*, 10.138, 10.139*f*
Iris chafing, 9.137
Iris-claw lenses, 6.310
Iris-clip intraocular lenses, pseudophakic bullous keratopathy and, 11.149
Iris dilator. *See* Dilator muscle (iris)
Iris-fixated/supported posterior chamber intraocular lenses, 11.116–117, 11.119, 11.119*f*, 13.8*t*, 13.137, 13.138, 13.139*t*, 13.141–142, 13.142*f*
after ICCE, 11.200
insertion of, 11.116–117, 11.119*f*
after keratoplasty, 11.176
phakic, 13.8*t*, 13.137, 13.138, 13.139*t*, 13.141–142, 13.142*f*. *See also* Phakic intraocular lenses
complications of, 13.145
sizing, 13.142, 13.142*f*
pseudophakic bullous keratopathy and, 11.149
uveitis and, 11.188
Iris fixation, 12.393
Iris freckle, 4.259, 4.260*f*
Iris granulomas, 9.300*f*, 9.302
Iris heterochromia, in Ebola virus, 9.271*f*
Iris hooks
for pupil expansion, 11.177, 11.178*f*
for zonular incompetence, 11.180
Iris-induced angle closure, 10.120, 10.155
IRIS (Intelligent Research in Sight) Registry, 1.26
Iris nevus, 4.106, 4.189–190, 4.190*f*, 4.255, 4.256*f*, 4.259
Iris nevus syndrome (Cogan-Reese syndrome/variant), 4.100, 4.101*f*, 4.259, 8.111, 8.127, 10.136. *See also* Iridocorneal endothelial (ICE) syndrome
Iris nodules, 6.271–272, 6.272*f*. *See also* Lisch nodules
in anterior uveitis, 9.77–78, 9.80, 9.80*f*
in leukemia, 4.315
in neurofibromatosis, 5.330*f*, 5.334*t*
in ocular tuberculosis, 9.235*f*
in sarcoidosis, 4.187
Iris pigment epithelium (IPE), 2.71–72, 4.181
cysts of, 4.259, 4.260*f*, 6.272, 6.272*f*
in diabetic retinopathy, 4.159, 4.160*f*
in healing/repair, 4.16
in pigment dispersion syndrome, 10.94, 10.94*f*
proliferation of, 4.259
Iris plane, phacoemulsification at, 11.112
Iris sphincter. *See* Sphincter muscle (iris)
Iris stromal atrophy, 9.249*f*
Iris suture fixation, peripheral, for IOL decentration, 11.145, 11.146*f*
Iritis, 6.412, 9.70. *See also* Anterior uveitis; Iridocyclitis; *specific cause*
CMV, 8.232

herpetic, 8.222–224, 8.223*t*
after iris-fixated phakic IOL insertion, 13.145
IRMAs. *See* Intraretinal microvascular abnormalities
Iron
in aqueous humor, 2.274
colloidal, for tissue staining, 4.31*t*
corneal deposits of, 8.117, 8.117*f*, 8.118*t*
in keratoconus, 4.95*f*, 4.96, 8.117, 8.162, 8.163, 8.163*f*
foreign body of, 8.118*t*, 8.399
siderosis caused by, 4.120, 11.58*f*, 11.58–59
in hemosiderosis bulbi, glaucoma and, 4.103
Iron chelation, for thalassemias, 1.134
Iron deficiency anemia, 1.132–133
Iron lines, 8.117, 8.117*f*, 8.118*t*
in keratoconus, 8.117, 8.162, 8.163, 8.163*f*
in pterygium, 8.113
Irradiance (E_e), 3.107*t*, 3.108
Irregular astigmatism, 13.17–19, 13.18*f*, 13.19*f*. *See also* Astigmatism
after arcuate keratotomy, 13.58
after cataract surgery, keratorefractive/refractive surgery and, 13.53
causes of, 3.277–278, 3.278*f*
corneal topography in detection/management of, 8.15, 8.31, 8.32, 13.17–19, 13.18*f*, 13.19*f*, 13.22–23, 13.44, 13.45, 13.45*f*
after penetrating keratoplasty, 8.431–432, 8.432*f*
definition of, 3.124, 3.267
description of, 3.130, 3.139
epithelial basement membrane dystrophy and, 3.277, 3.278*f*
keratorefractive/refractive surgery and, 3.272–278, 3.274–276*f*, 13.18–19, 13.22–23, 13.44, 13.45
cataract surgery outcome and, 11.176, 11.177*f*
after limbal relaxing incisions, 13.58
after penetrating keratoplasty, 8.426, 8.431–432, 8.432*f*
quantification of, 3.273
retinoscopy in evaluation of, 8.163
wavefront analysis of, 3.273–277, 3.274–276*f*. *See also* Wavefront analysis
Irreversible cholinesterase inhibitors, 2.379
Irreversible obstructive lung diseases, 1.124
Irrigating solutions, 2.443
Irrigation/aspiration (IA). *See also* Aspiration
for chemical injuries, 8.381–382
for conjunctival foreign body, 8.397
in ECCE, 11.197
for hyphema, 8.395
of lacrimal drainage system, 7.291–292, 7.291–292*f*, 7.297–298, 7.299–300*f*
in manual small-incision cataract surgery, 11.198
in phacoemulsification, 11.101–102, 11.115
posterior fluid misdirection and, 11.134–135
toxic solutions exposure and, corneal edema caused by, 11.129, 11.133–134
for plant materials, 8.387
Irritated follicular keratosis, 7.188, 7.188*f*
IRU. *See* Immune recovery uveitis
IRVAN. *See* Idiopathic retinal vasculitis, aneurysms, and neuroretinitis
Irvine-Gass syndrome, 11.163–165, 11.164*f*, 12.157, 12.349. *See also* Cystoid macular edema
IS. *See* Inner segments
ISA. *See* Intrinsic sympathomimetic activity
ISCEV. *See* International Society for Clinical Electrophysiology of Vision
Ischemia, 1.81. *See also* Cerebrovascular disease; Stroke; *specific territory affected*
cardiac. *See* Ischemic heart disease
carotid territory. *See also* Carotid occlusive disease
transient visual loss and, 5.162, 5.165–166, 5.167, 5.167*f*, 5.168
cataracts caused by, 11.68
cerebral. *See* Stroke
choroidal, 12.196, 12.196*f*
diplopia caused by, 5.192
fourth nerve (trochlear) palsy and, 5.199
intraocular pressure-induced, in acute angle closure, 10.123–124
macular, 12.98, 12.101, 12.115
MRI in evaluation of, 5.64*f*, 5.65*t*, 5.66, 5.67*f*, 5.75
occipital, transient visual loss caused by, 5.162, 5.172
ocular (ocular ischemic syndrome/OIS), 5.170, 5.171*f*
posterior circulation. *See* Vertebrobasilar system, disorders of
retinal, 4.140, 4.150–160. *See also* Retinal ischemia
stroke and, 5.167, 5.168–169
transient visual loss and, 5.161, 5.164, 5.167, 5.168–169
sixth nerve (abducens) palsy and, 5.200, 5.201
third nerve (oculomotor) palsy and, 5.195, 5.198
time course of vision loss and, 5.77
Ischemic/complete/nonperfused central retinal vein occlusion, 4.156, 4.157–158, 4.158*f*
Ischemic heart disease (IHD). *See also* Acute coronary syndromes; Angina pectoris; Coronary artery disease
asymptomatic, 1.86
clinical syndromes associated with, 1.82–86
diabetic retinopathy and, 1.105
diagnosis of
cardiac enzymes, 1.86–87
computed tomography, 1.88
coronary arteriography, 1.89
coronary computed tomography angiography, 1.88
echocardiography, 1.87
electrocardiography, 1.86
electron beam computed tomography, 1.88
exercise stress testing, 1.88
intravascular ultrasound, 1.89
invasive procedures for, 1.89
magnetic resonance imaging, 1.88
multiple gated acquisition scans, 1.89
myoglobin levels, 1.87
noninvasive procedures for, 1.86–89
positron emission tomography, 1.88
radionuclide scintigraphy and scans, 1.88
serum biomarkers, 1.86–87
single-photon emission computed tomography, 1.88
troponin levels, 1.87
ventriculography, 1.89

hyperlipidemia and, 1.78
management of
antithrombotic agents, 1.89, 1.90–91*t*
direct oral antithrombotic agents, 1.90*t*
goals for, 1.89
pathophysiology of, 1.81–82
risk factors for, 1.82
Ischemic optic neuropathy, 5.107*t*, 5.119–125, 5.120*t*, 5.121*f*, 5.123*t*
anterior (AION), 5.107*t*, 5.119–124, 5.120*t*, 5.121*f*, 5.123*t*
arteritic (AAION), 5.107*t*, 5.120, 5.120*t*, 5.120–122, 5.121*f*, 5.313
giant cell arteritis and, 5.120, 5.313
nonarteritic (NAION), 5.107*t*, 5.120, 5.120*t*, 5.121*f*, 5.122–124, 5.123*t*
OCT in evaluation of, 5.91*f*
perioperative, 5.124–125
posterior (PION), 5.107*t*, 5.119, 5.124
Ischemic stroke. *See also* Cerebral ischemia; Stroke
blood pressure control for prevention of, 1.115
cardioaortic causes of, 1.118–119
carotid duplex ultrasonography for, 1.113
carotid occlusive disease as cause of, 1.115–119
causes of, 1.111
cerebral arteriography for, 1.113
clinical manifestations of, 1.110–111
diagnosis of, 1.111–112
helical computed tomography angiography for, 1.113
imaging studies for, 1.112–113
magnetic resonance angiography evaluations, 1.112–113
magnetic resonance imaging evaluations, 1.112–113
management of, 1.111–112
mechanical thrombectomy for, 1.113–114
multimodal computed tomography for, 1.112
nonarteriosclerotic causes of, 1.111
penumbra, 1.110
prevention of, 1.114–115
recombinant tissue plasminogen activator for, 1.113
reperfusion techniques, 1.114
risk factors for, 1.111
statins for prevention of, 1.115
thrombolytic agents, 1.113
transcranial Doppler ultrasonography for, 1.113
treatment of, 1.113–114
Ischemic uveitis, 5.170
Ishihara plates
for color vision testing, 12.54, 12.55*f*
in low vision evaluation, 5.78
in simultanagnosia, 5.180
Island of vision, in perimetry, 5.84
Islet cell transplantation, 1.37
ISNT rule, 10.49
ISO. *See* International Standards Organization (ISO)
Isoametropic amblyopia, 6.55
Isochrone, 3.71
Isoetharine, 1.128
Isoforms, 2.179–180
Isolated optic neuritis, 5.113–115, 5.114*f*
Isolated/simple ectopia lentis, 6.307
Isolated stromal rejection, 8.429. *See also* Rejection
Isolation techniques, in ocular microbiology, 8.211
Isometropic hyperopia, 3.185*f*
Isoniazid, 2.233
for tuberculosis, 1.257, 9.239–240
Isopter, 5.84
Isopto Atropine. *See* Atropine
Isopto Carbachol. *See* Carbachol
Isopto Carpine. *See* Pilocarpine
Isopto Cetamide. *See* Sulfacetamide
Isopto Eserine. *See* Physostigmine
Isopto Homatropine. *See* Homatropine hydrobromide
Isopto Hyoscine. *See* Scopolamine hydrobromide
Isotretinoin, 1.308*t*, 12.305
corneal pigmentation caused by, 8.132
refractive surgery in patient taking, 13.37, 13.77–78
ISRS. *See* International Society of Refractive Surgery
Istalol. *See* Timolol
ITP. *See* Idiopathic thrombocytopenic purpura
Itraconazole, 2.429, 2.430*t*
for fungal keratitis, 8.275
iTreg cells. *See* Antigen-specific regulatory T (iTreg) cells
IU. *See* Intermediate uveitis
Ivermectin
for loiasis, 8.282
for onchocerciasis, 9.290
IVF. *See* In vitro fertilization
IVH. *See* Intraventricular hemorrhage
IVIg. *See* Intravenous immunoglobulin
IVTA (intravitreal triamcinolone acetonide). *See* Triamcinolone
Ixekizumab, 1.180
Ixodes, 1.254
pacificus, 9.227
scapularis, 9.227

J

"Jabs and jolts" syndrome, 5.294
"Jack-in-the-box" phenomenon, 3.191
Jackson cross cylinder
definition of, 3.40, 3.80, 3.147
hand-held, 3.32, 3.32*f*
minus cylinder phoropter with
cylinder axis refinement using, 3.29, 3.30*f*
cylinder power refinement using, 3.31, 3.31*f*
for refraction, 3.163–165, 3.164*f*
for regular astigmatism, 3.163–165, 3.164*f*
Jalili syndrome, 12.286
Janus kinase inhibitors
description of, 1.180
rheumatoid disease treated with, 1.153
Jarisch-Herxheimer reaction, 9.226, 9.230
Javal-Schiøtz-style keratometer, 3.287, 8.27
Jaw claudication, in giant cell arteritis, 5.313
Jaw-winking syndrome/ptosis, Marcus Gunn, 5.272, 5.272*f*
JC virus, in progressive multifocal leukoencephalopathy, 5.351
Jenner, Edward, 1.223
Jerk nystagmus, 5.214, 5.233, 5.234, 6.147. *See also* Nystagmus
in multiple sclerosis, 5.319

JIA. *See* Juvenile idiopathic arthritis
JNC7/JNC8. *See* Joint National Committee on Prevention, Detection, Evaluation, and Treatment of Blood Pressure
JOAG. *See* Juvenile open-angle glaucoma
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of Blood Pressure (JNC7)
  blood pressure classification, 1.52
  hypertension treatment guidelines, 1.57
Jones I test, 7.297
Jones II test, 7.297
Joubert syndrome, 6.144, 6.392, 6.392*f*, 12.285
Joules, 3.106
Jowling, 7.267
JRA (juvenile rheumatoid arthritis). *See* Juvenile idiopathic arthritis
Jugular bulb, 5.22
Jugular veins
  external, 5.23
  internal, 5.22, 5.22*f*, 5.23
    lesions of, Horner syndrome and, 5.260*t*
Junctional nevus, 7.196
  of conjunctiva, 4.64
  conjunctival/ocular surface, 8.338*t*, 8.340
  of eyelid, 4.219, 4.219*f*
Junctional scotoma, 2.474*t*
"Junctional scotomas," 2.474*t*, 5.146–147, 5.148*f*, 5.151*f*
Juvenile ankylosing spondylitis, 6.315*t*
Juvenile chronic arthritis. *See* Juvenile idiopathic arthritis (JIA)
Juvenile fibromatosis, 6.222
Juvenile glaucoma. *See* Glaucoma, pediatric; Juvenile open-angle glaucoma
Juvenile idiopathic arthritis (JIA), 1.157–158, 1.158*t*, 6.312–315, 6.313–314*t*, 6.314*f*, 6.322
  calcific band keratopathy in, 9.143*f*, 9.313
  chronic anterior uveitis in
    description of, 9.76, 9.141–145
    methotrexate for, 9.107
  classification of, 9.141–142
  differential diagnosis of, 9.142
  human leukocyte antigen association with, 9.65*t*
  laboratory tests for, 9.125*t*
  ocular involvement in, 9.141–142, 9.143*f*
  oligoarticular, 9.142
  polyarticular, 9.141–142
  prognosis for, 9.142
  treatment of, 9.142–145
Juvenile macular degeneration (Stargardt disease/fundus flavimaculatus), 4.168–169*f*, 4.168–170
  ATP-binding cassette (ABC) transporter protein mutations causing, 4.168–169
  retinal pigment epithelium in, 4.168–169*f*, 4.169–170
Juvenile-onset diabetes mellitus. *See* Diabetes mellitus (DM), type 1
Juvenile-onset myopia, 3.142
Juvenile-onset vitelliform macular dystrophy. *See* Best disease
Juvenile open-angle glaucoma (JOAG), 6.278, 6.284, 10.4*t*, 10.147, 10.148*t*, 10.153. *See also* Glaucoma, pediatric
  genetics of, 10.11*t*, 10.150
Juvenile ossifying fibroma (fibro-osseous dysplasia)
  description of, 6.222
  of orbit, 4.239, 4.240*f*
Juvenile pilocytic astrocytoma, 4.249
Juvenile psoriatic arthritis, 6.315*t*
Juvenile retinal dystrophy, 6.390*f*
Juvenile retinoschisis. *See* Retinoschisis, X-linked
Juvenile rheumatoid arthritis (JRA). *See* Juvenile idiopathic arthritis (JIA)
Juvenile spondyloarthropathies, 6.315, 6.315*t*
Juvenile xanthogranuloma (JXG), 6.271, 7.97, 8.347, 9.309
  glaucoma associated with, 10.30
  of iris, 4.187, 4.260
  uveal tract/uveitis and, 4.187, 4.188*f*
Juxtacanalicular meshwork/tissue, 10.17, 10.18*f*
Juxtacanalicular trabecular meshwork
  definition of, 2.64
  Schlemm canal and, 2.65*f*
Juxtafoveal telangiectasia, 12.161
JXG. *See* Juvenile xanthogranuloma

K

K. *See* Potassium
K. *See* Central corneal power
K-Card, 13.194
K_m (Michaelis/affinity constant), sorbitol in cataract development and, 2.391, 11.19
K (keratometry) reading. *See* Keratometry/keratometer
K system (koniocellular system/neurons/bistratified cells), 10.42
Kabuki syndrome, 6.195
KAMRA corneal inlay, 3.175, 3.271, 13.28, 13.61, 13.61*f*, 13.169
Kanamycin sulfate, 2.418*t*, 2.425
Kaposi sarcoma, 7.211, 7.211*f*, 8.239, 8.345*t*, 8.347*f*, 8.347–348, 9.333, 9.333*f*
  ocular adnexal, 5.349
Kaposi sarcoma–associated herpesvirus/human herpesvirus (KSHV) 8, 8.239, 8.347
Kartagener syndrome, 1.124
Karyotype, 2.221
Karyotyping, 2.221
Kasabach-Merritt syndrome, 6.220, 7.72
Kawasaki disease, 1.171, 6.316
Kayser-Fleischer ring, 6.270, 8.118*t*, 8.173, 8.189, 8.189*f*, 11.62, 12.362
KC. *See* Keratoconus
K_{cat}, 2.391
KCS (keratoconjunctivitis sicca). *See* Aqueous tear deficiency; Dry eye
Kearns-Sayre syndrome, 2.185, 5.329, 6.142, 12.283*t*, 12.294
Kelman phaco tip, 11.101
Keloids
  corneal, 8.125
    congenital, 8.107–108, 8.125
  refractive surgery in patient with history of, 13.77
Kenalog. *See* Triamcinolone
Keplerian telescopes, 3.40, 3.83–84, 3.84*f*

KERA gene, 6.255
in cornea plana, 8.96*t*, 8.100
posterior amorphous corneal dystrophy and, 8.136*t*, 8.155
Keratan sulfate
antigenic (AgKS), macular corneal dystrophy and, 8.150–151
in cornea, 8.9
cornea plana and, 8.96*t*, 8.100
mucopolysaccharidoses and, 8.175*t*
Keratectasia, 8.98*t*, 8.106–107
Keratectomy, 8.366–367, 8.412*t*, 13.30*f*
for corneal haze after surface ablation, 13.109
lamellar, for keratophakia, 13.59, 13.60
mechanical, 8.367
multizone, 13.30, 13.30*f*
photorefractive (PRK). *See* Photorefractive keratectomy
phototherapeutic (PTK). *See* Phototherapeutic keratectomy
superficial (SK), 8.366–367, 8.412*t*
layer-based approach to use of, 8.417*t*
in trabeculectomy, 10.201–202, 10.204*f*
Keratic precipitates (KPs), 8.52
in anterior uveitis, 9.77–78, 9.79*f*
in CMV infection, 8.232
in Fuchs heterochromic uveitis, 9.248
in Fuchs uveitis syndrome, 9.146*f*
in glaucomatocyclitic crisis (Posner-Schlossman syndrome), 10.101
in inflammatory glaucoma, 10.100
mutton-fat, 9.78, 9.79*f*, 9.196
in phacoantigenic glaucoma, 10.98
in sarcoidosis, 9.196, 9.196*f*
in sympathetic ophthalmia, 4.185
in uveitic glaucoma, 10.31
in Vogt-Koyanagi-Harada syndrome, 9.205, 9.207
Keratin
in adenoid cystic carcinoma, 4.231
in squamous cell carcinoma, 4.213, 4.214*f*
Keratin gene mutation, in Meesmann corneal dystrophy, 8.136*t*
Keratinization (keratinized/degenerated epithelial cells)
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297
in superior limbic keratoconjunctivitis, 8.84
in vitamin A deficiency, 8.196
Keratitis, 8.46*t*, 8.49–53, 8.50*f*, 8.50*t*, 8.51*f*, 8.52*f*, 8.208*t*
Acanthamoeba
contact lens wear and, 4.78–79, 8.276, 8.277
description of, 4.78–79, 4.79*f*, 8.208*t*, 8.252, 8.276–279, 8.277*f*, 8.278*f*
herpes simplex keratitis differentiated from, 8.278
isolation techniques for diagnosis of, 4.79, 8.211
stains and culture media for identification of, 4.79, 8.209*t*, 8.277
treatment of, 8.277–279
adenovirus caused by, 6.269
bacterial, 4.75–76, 4.76*f*, 8.208*t*, 8.267–273, 8.268*f*, 8.269*t*, 8.270*t*, 8.273*f*. *See also* Keratitis, infectious/microbial
clinical presentation of, 8.267–268, 8.268*f*
contact lens wear and, 8.266–267, 8.268, 8.269, 8.269*t*
for orthokeratology, 13.71
intrauterine, 8.107
syphilitic, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*
laboratory evaluation/causes of, 8.268–269, 8.269*t*
management of, 8.269–272, 8.270*t*
pathogenesis of, 8.267
stains and culture media for identification of, 8.209*t*, 8.269
blepharitis and, 8.72, 8.73*t*, 8.74
Candida causing, 8.208*t*, 8.251, 8.273, 8.274–275
chlamydial infection and, 8.263
CMV, 8.231–232, 8.232*f*
in Cogan syndrome, 8.309–310
congenital syphilis as cause of, 6.269
contact lens wear and, 4.78–79, 8.84, 8.266–267, 8.273–274
for orthokeratology, 13.71
corneal involvement, 6.269
corneal scarring caused by, 6.245*f*
dendritic, 4.76, 4.77*f*
herpes simplex virus causing, 4.76, 4.77*f*, 8.216–219, 8.218*f*, 8.226*t*
herpes zoster, 8.226, 8.226*t*, 8.227
Dieffenbachia, 8.387
diffuse lamellar (DLK), after LASIK, 13.116*f*, 13.116–117, 13.117*t*
infectious keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
pressure-induced stromal keratopathy differentiated from, 13.119
diffuse superficial, 6.242
disciform (endotheliitis), 8.51*f*
CMV causing, 8.232, 8.232*f*
herpes simplex virus causing, 4.77*f*, 4.78, 8.220, 8.221*f*, 8.222
persistent bullous keratopathy and, 8.225
Enterobacteriaceae causing, 8.247
epithelial. *See also* Epithelial keratitis/keratopathy
adenovirus causing, 8.234, 8.235, 8.235*f*
CMV causing, 8.232
in epidemic keratoconjunctivitis, 8.235, 8.235*f*
herpes simplex virus causing, 8.213, 8.214*f*, 8.216*f*, 8.216–219, 8.217*f*, 8.218*f*, 8.223*t*, 8.226*t*
measles virus causing, 8.239
varicella-zoster virus causing, 8.226, 8.226*t*
Epstein-Barr virus, 8.230–231, 8.231*f*
exposure, 8.79–80
cataract surgery in patient with, 11.174
Fuchs superficial marginal, 8.123
fungal, 4.78, 4.78*f*, 8.208*t*, 8.273–276, 8.274*f*, 12.239
plant/vegetable materials and, 4.78, 8.273, 8.387, 8.399
gonococcal conjunctivitis and, 8.258
herpes simplex, 4.76–78, 4.77*f*, 6.412, 8.208*t*, 8.213, 8.214*f*, 8.216*f*, 8.216–222, 8.217*f*, 8.218*f*, 8.220*f*, 8.221*f*, 8.226*t*, 9.334. *See also* Herpes simplex virus (HSV), keratitis caused by
Acanthamoeba keratitis differentiated from, 8.278
description of, 6.269

neurotrophic keratopathy/ulcers/persistent corneal epithelial defects caused by, 4.77*f*, 8.80, 8.81*t*, 8.217–218, 8.224, 8.225
after penetrating keratoplasty, 8.424, 8.425*f*
refractive surgery and, 13.173–174
herpes zoster, 8.226, 8.226*t*. *See also* Herpes zoster ophthalmicus
in HIV infection/AIDS, after LASIK, 13.189
immune-mediated corneal disease and, 8.306–318
infectious/microbial, 4.75–80, 4.76*f*, 4.77*f*, 4.78*f*, 4.79*f*, 4.80*f*, 4.81*f*, 6.269, 8.208*t*, 8.266–279, 8.307–309, 8.309*f*. *See also specific infectious agent*
clinical presentation of, 8.267–268, 8.268*f*, 8.274*f*, 8.274–275, 8.276–277, 8.277*f*
contact lens wear and, 8.266–267, 8.273–274, 13.71
for orthokeratology, 13.71
interstitial disease and, 8.307–309, 8.309*f*
intrauterine, 8.107
syphilitic, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*
laboratory evaluation/causes of, 8.268–269, 8.269*t*, 8.275, 8.277, 8.278*f*
after LASIK, 13.106*f*, 13.106–107, 13.107*f*, 13.117–119, 13.118*f*, 13.118*t*
diffuse lamellar keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
management of, 8.269–272, 8.270*t*, 8.275–276, 8.277–279
orthokeratology and, 13.71
pathogenesis of, 8.267, 8.273–274, 8.276
after penetrating keratoplasty, 8.427
after photoablation, 13.106*f*, 13.106–107
recurrence of in graft, 8.225, 8.232
specimen collection in evaluation of, 8.210, 8.211*f*
stains and culture in identification of, 8.209*t*, 8.269, 8.273, 8.275
interstitial (IK), 4.80, 4.81*f*, 6.269, 8.46*t*
Epstein-Barr, 8.230, 8.231*f*
glaucoma and, 10.139
herpetic, 4.77*f*, 4.78, 4.80, 8.219–220, 8.220*f*, 8.222
in infectious disease, 8.307–309, 8.309*f*
syphilitic, 4.80, 4.81*f*, 8.308–309, 8.309*f*
intrauterine infection and, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*
intrauterine, 8.107
keratectasia caused by, 8.107
syphilitic, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*
lipid keratopathy and, 8.125
in Lyme disease, 9.229
measles virus causing, 8.239
microsporidial, 8.280–281
mycobacterial, 8.248
noninfectious, 4.80–81, 6.269
nummular, 6.243
herpes zoster, 8.228, 8.228*f*
in onchocerciasis, 8.253
pain caused by, 5.295
peripheral, 8.50*t*
scleritis and, 8.323
ulcerative (PUK), 8.51*f*, 8.311*t*, 8.311–313, 8.312*f*. *See also* Keratitis, ulcerative/peripheral ulcerative
Propionibacterium acnes causing, 8.246
punctate epithelial, 6.269, 8.46*t*, 8.50, 8.50*f*, 8.50*t*, 9.334*f*
adenoviruses causing, 8.234
blepharitis/blepharoconjunctivitis and, 8.72, 8.73*t*, 8.74
exposure causing, 8.80
herpes simplex causing, 8.216, 8.216*f*
in herpes zoster, 8.227, 8.228
microsporidial, 8.280, 8.280*f*
superficial Thygeson (SPK), 8.306–307, 8.307*f*
topical anesthetic abuse causing, 8.89
Pythium insidiosum causing, 8.251, 8.275
in reactive arthritis syndrome/Reiter syndrome, 8.305–306
in rosacea, 8.70, 8.70*f*
Salzmann nodular degeneration and, 8.124*f*, 8.124–125, 8.125*f*
scleritis and, 8.323
sicca. *See* Dry eye
staphylococcal, 8.73*t*, 8.74, 8.76
stromal, 8.46*t*, 8.50*t*, 8.50–52, 8.51*f*
CMV causing, 8.232
in Cogan syndrome, 8.309–310
Epstein-Barr virus, 8.230–231, 8.231*f*
herpes simplex virus causing, 4.77*f*, 4.78, 8.219–222, 8.220*f*, 8.221*f*, 8.223*t*
penetrating keratoplasty for, 8.225
recurrence of, in graft, 8.225
in herpes zoster ophthalmicus, 8.228, 8.228*f*
microsporidial, 8.280–281
necrotizing, 8.52, 8.219, 8.220–221, 8.221*f*, 8.222, 8.223*t*
nonnecrotizing, 8.51*f*, 8.219, 8.220*f*, 8.221*f*, 8.223*t*
nonsuppurative, 8.46*t*, 8.50, 8.50*t*, 8.51*f*, 8.52
in rosacea, 8.70, 8.70*f*
suppurative, 8.46*t*, 8.50, 8.50*t*, 8.51*f*, 8.52
syphilitic, 8.308–309, 8.309*f*
syphilitic, 4.80, 4.81*f*, 8.308–309, 8.309*f*
intrauterine, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*
Thygeson superficial punctate (SPK), 6.269, 8.306–307, 8.307*f*
toxic, 8.91. *See also* Keratoconjunctivitis, toxic
ulcerative/peripheral ulcerative (PUK), 8.51*f*, 8.311*t*, 8.311–313, 8.312*f*
differential diagnosis of, 8.311, 8.311*t*
in rosacea, 8.71
in systemic immune-mediated diseases, 8.51*f*, 8.311*t*, 8.311–313, 8.312*f*
varicella-zoster virus, 8.225–230, 8.226*t*. *See also* Herpes zoster ophthalmicus
yeast, 8.208*t*, 8.251, 8.273, 8.274–275
Kerato-irido-lenticular dysgenesis. *See* Peters anomaly
Keratoacanthoma, 7.199–200, 7.200*f*
eyelid, 4.209–210, 4.210*t*, 4.211*f*
Keratocan, mutation in gene for, in cornea plana, 8.96*t*, 8.100
posterior amorphous corneal dystrophy and, 8.136*t*
Keratoconjunctivitis. *See also* Conjunctivitis
adenoviral, 8.233, 8.234*f*, 8.234–236, 8.235*f*
atopic (AKC), 6.249, 8.292–294, 8.293*f*
chlamydial, 8.260
contact lens-induced (CLIK/CLK), 3.233, 8.84
epidemic (EKC), 8.233, 8.234*f*, 8.234–236, 8.235*f*

microsporidial, 8.280–281
plants causing, 8.387
superior limbic (SLK), 8.83–85, 8.84*f*
toxic, medications causing, 8.80–81, 8.81*t*, 8.90*t*, 8.90–91
vernal (VKC), 6.248–249, 6.248–249*f*, 8.289–292, 8.290*f*, 8.291*f*
atopic keratoconjunctivitis differentiated from, 8.292–293, 8.293*f*
Keratoconjunctivitis sicca. *See also* Aqueous tear deficiency; Dry eye
in systemic lupus erythematosus, 1.161
Keratoconjunctivitis sicca-like syndrome, 1.106
Keratoconus (KC), 4.95*f*, 4.95–96, 8.161*f*, 8.161–168, 8.162*f*, 8.163*f*, 8.164*f*, 8.165*f*, 8.167*f*, 8.170*f*, 13.175*f*, 13.175–178, 13.176*f*, 13.177*f*
contact lenses for, 3.225–226, 8.166, 8.167*f*
corneal (collagen) crosslinking for, 8.166, 13.130–131, 13.131, 13.176, 13.206–208
corneal opacity caused by, 8.16*f*
Descemet membrane rupture and, 4.17, 4.18*f*, 4.95*f*, 4.96
description of, 6.254, 6.259
ectasia after LASIK and, 13.124, 13.175
intrastromal corneal ring segments for, 13.70, 13.124
Fleischer ring in, 4.95*f*, 4.96, 8.117, 8.118*t*, 8.163, 8.163*f*
in floppy eyelid syndrome, 8.79, 8.82
illusions and, 5.174
intrastromal corneal ring segments for, 13.62, 13.65*f*, 13.65–66, 13.66, 13.69–70, 13.176
keratoscopy in, 8.28, 8.167*f*
Marfan syndrome and, 8.194
posterior, 4.98, 8.97*t*, 8.104, 8.105*f*
refractive lens exchange and, 13.149
refractive surgery contraindicated in, 8.31, 8.166, 13.23, 13.24, 13.25*f*, 13.38, 13.42–43, 13.44, 13.175*f*, 13.175–178, 13.176*f*, 13.177*f*
corneal topography and, 8.31, 8.166, 13.23, 13.24, 13.25*f*, 13.44, 13.175, 13.175*f*, 13.176*f*, 13.177*f*
subclinical (forme fruste), 8.166, 13.124
refractive surgery contraindicated in, 13.23, 13.25–26, 13.79, 13.124, 13.175*f*, 13.175–176, 13.177*f*
LASIK, 13.79, 13.124, 13.175*f*, 13.175–176, 13.177*f*
topography in detection and, 8.31, 8.166, 13.23, 13.25–26, 13.79, 13.175*f*, 13.175–176, 13.177*f*
thermokeratoplasty for, 13.127–128
tomography in, 8.35, 8.35*f*, 8.165*f*, 8.165–166
topography in, 8.29*f*, 8.30*f*, 8.31, 8.32*f*, 8.32*t*, 8.165*f*, 8.165–166, 13.23, 13.24, 13.25*f*, 13.44, 13.175, 13.175*f*, 13.176*f*, 13.177*f*
Keratocystic odontogenic tumors, 7.201
Keratocytes, 2.53, 2.259, 2.263, 8.8–9, 8.9*f*
apoptosis of, in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.295–296
in Fleck corneal dystrophy, 8.153
stromal (fibrocytes), 4.73
corneal haze after surface ablation and, 13.33, 13.109
wound healing and, 4.14–15, 4.15*f*, 4.16, 13.33
Keratoderma blennorrhagicum, 1.155, 1.155*f*, 9.133, 9.134*f*
Keratoectasias, corneal, 4.95*f*, 4.95–96
Keratoepithelin gene, in corneal dystrophies, 4.88, 8.133, 8.134, 8.136*t*. *See also TGFBI* dystrophies
Reis-Bücklers, 8.142
Thiel-Behnke, 8.143
Keratoglobus, 4.95, 6.254, 8.169–171, 8.170*f*
in Ehlers-Danlos syndrome, 8.171, 8.191*t*, 8.193
Keratolenticular adhesions (Peters anomaly), 4.74, 4.75*f*, 4.98, 8.97*t*, 8.102–104, 8.103*f*, 10.150, 10.154, 11.31–32. *See also* Axenfeld-Rieger syndrome
Axenfeld-Rieger syndrome differentiated from, 10.154*t*
glaucoma and, 4.74, 10.150, 10.154
pediatric keratoplasty for, 8.450
Keratolimbal allograft, 8.362–365. *See also* Limbal transplantation
Keratolysis (corneal melting), 9.25
cataract surgery and, 11.132
in patient with dry eye, 11.132
management of, 8.369*f*, 8.369–370
neurotrophic keratopathy/persistent corneal epithelial defects and, 8.81, 8.82
peripheral ulcerative keratitis and, 8.311, 8.312
refractive surgery and, 13.94
topical medication toxicity and, 4.80–81
Keratomalacia, in vitamin A deficiency, 8.197
Keratometry/keratometer, 3.282, 3.286–288, 3.287*f*, 3.307, 8.26–27, 8.27*f*, 13.7–9
astigmatism after penetrating keratoplasty and, 8.431
in IOL power determination/selection, 11.84, 11.174
corneal irregularities and, 11.174
refractive surgery and, 11.86, 13.193
unexpected refractive results after surgery and, 11.150
in keratoconus, 8.164–165
refractive surgery and, 13.44, 13.45
IOL power calculation and, 11.86, 13.193
postoperative, 13.193
radial keratotomy, 13.50–51, 13.52
toric IOLs, 13.152
Keratomileusis, 13.27, 13.76. *See also* LASEK; LASIK
Keratoneuritis/perineuritis, radial, in *Acanthamoeba* keratitis, 4.79, 8.277
Keratopathy
actinic (Labrador/climatic droplet/spheroidal degeneration), 4.83, 4.83*f*, 8.115–117, 8.116*f*
annular, traumatic, 8.388
band/calcific band, 4.81–83, 4.82*f*, 8.111, 8.117–120, 8.119*f*, 8.201
"actinic," 4.83
in aqueous tear deficiency, 8.56
gelatinous droplike corneal dystrophy and, 8.141, 8.141*f*
in gout, 8.119, 8.188
parathyroid disorders and, 8.201
bullous, 4.83–84, 4.84*f*, 4.85*f*
after cataract surgery, 4.83–84, 4.84*f*, 11.129, 11.129*f*
IOL design and, 11.149
disciform keratitis and, 8.225
DMET for, 8.449
in Fuchs endothelial corneal dystrophy, 4.92, 8.156

central toxic, after photoablation, 13.105*f*, 13.105–106
climatic droplet. *See* Spheroidal degeneration
diabetic, refractive surgery in patient with, 13.190
exposure, 8.79–80
tarsorrhaphy for, 8.80
filamentary, 8.56, 8.56*f*
in graft-vs-host disease, 8.304
treatment of, 8.63
infectious crystalline/pseudocrystalline, 4.79–80, 4.80*f*, 8.268, 8.268*f*
corneal deposits and, 8.182*t*
after penetrating keratoplasty, 4.79, 8.427, 8.427*f*
Labrador (actinic/climatic droplet/spheroidal degeneration), 4.83, 4.83*f*, 8.115–117, 8.116*f*
lipid, 8.125–126, 8.126*f*
corneal crystal deposition and, 8.182*t*
in herpes zoster, 8.125, 8.228, 8.228*f*
measles, 8.239, 8.240*t*
medications causing, 8.80–81, 8.81*t*, 8.90*t*, 8.90–91
neurotrophic, 8.42, 8.80–82, 8.81*t*, 8.82*f*
diabetic neuropathy and, 8.81, 8.81*t*, 8.199
esthesiometry in evaluation of, 8.42
herpetic/postherpetic eye disease and, 4.77*f*, 4.78, 8.80, 8.81*t*, 8.217–218, 8.224, 8.225, 8.227
after penetrating/deep anterior lamellar keratoplasty, 8.80
pressure-induced stromal (PISK), after LASIK, 13.119, 13.120*f*
punctate epithelial, 8.46*t*, 8.50, 8.50*f*, 8.50*t*
adenoviruses causing, 8.234
blepharitis/blepharoconjunctivitis and, 8.72, 8.73*t*, 8.74
exposure causing, 8.80
herpes simplex causing, 8.216, 8.216*f*
in herpes zoster, 8.227
microsporidial, 8.280, 8.280*f*
superficial Thygeson (SPK), 8.306–307, 8.307*f*
topical anesthetic abuse causing, 8.89
toxic
central, after photoablation, 13.105*f*, 13.105–106
ulcerative, 8.80–81, 8.81*t*. *See also* Keratoconjunctivitis, toxic
urate, 8.119, 8.188
vortex (hurricane/cornea verticillata), 8.90, 8.129*t*, 8.130, 8.130*f*, 8.176, 8.177*f*
in chloroquine/hydroxychloroquine toxicity, 8.130
in Fabry disease, 6.270, 8.176, 8.177*f*
Keratophakia, 13.27, 13.59–62, 13.61*f*
Keratoplasty, 8.411–412, 8.412*t*, 8.412–413*t*
cataract formation after, 11.176
cataract surgery and IOL implantation combined with (triple procedure), 11.175–176
in children, 8.450–451
conductive (CK), 13.8*t*, 13.28, 13.28*f*, 13.128*f*, 13.128–129, 13.129*f*, 13.165
corneal transplantation after, 13.198
for presbyopia, 13.128, 13.128*f*, 13.165
for corneal disorders, 6.262–263
for corneal edema after cataract surgery, 11.129
donor cornea contraindications and, 8.414, 8.415*t*, 8.416*t*
endothelial (EK), 8.411, 8.412, 8.412*t*, 8.436*t*, 8.436–450, 8.437*t*, 8.439*f*, 8.441*f*, 8.442*f*, 8.443*f*, 8.444*f*, 8.445*f*, 8.446*f*, 8.447*f*
advantages of, 8.421–422*t*, 8.438, 8.439*f*
cataract surgery and, 8.446–447, 11.175–176
in children, 8.451
complications of, 8.437*t*
intraoperative, 8.420–421*t*, 8.440, 8.441*f*
postoperative, 8.421*t*, 8.440–449
for corneal edema after cataract surgery, 11.129
Descemet membrane (DMEK), 8.412, 8.412*t*, 8.436, 8.436*t*, 8.437*t*
advantages of, 8.421–422*t*, 8.438
cataract surgery and, 8.446–447
complications of, 8.437*t*
intraoperative, 8.420–421*t*, 8.440
postoperative, 8.421*t*, 8.440–449
disadvantages of, 8.422*t*, 8.438–440
endothelial cell loss after, 8.448–449
for Fuchs endothelial corneal dystrophy, 4.92, 4.93*f*
graft dislocation/decentration after, 8.442*f*, 8.442–443, 8.443*f*
hemi, 8.449–450
indications for, 8.420*t*
primary graft failure and, 8.447
pupillary block after, 8.444*f*, 8.444–445
rejection and, 8.437*t*, 8.438
results of, 8.437*t*
visual acuity after, 8.438–440
Descemet stripping/Descemet stripping automated (DSEK/DSAEK), 8.412, 8.412*t*, 8.436, 8.436*t*, 8.437*t*
advantages of, 8.421–422*t*, 8.438, 8.439*f*
cataract surgery and, 8.446–447
complications of, 8.437*t*
intraoperative, 8.420–421*t*, 8.440, 8.441*f*
postoperative, 8.421*t*, 8.440–449
disadvantages of, 8.422*t*, 8.438–440
endothelial cell loss after, 8.448–449
epithelial ingrowth after, 8.445, 8.445*f*
graft dislocation/decentration after, 8.441, 8.442*f*
graft failure and, 4.85*f*
indications for, 8.420*t*
primary graft failure and, 8.447
pupillary block after, 8.444*f*, 8.444–445
rejection and, 8.437*t*, 8.447, 8.447*f*
results of, 8.437*t*
visual acuity after, 8.438–440
disadvantages of, 8.422*t*, 8.438–440
donor cornea contraindications and, 8.415*t*
endothelial cell loss after, 8.448–449
epithelial ingrowth after, 8.445, 8.445*f*
for Fuchs endothelial corneal dystrophy, 8.157
graft dislocation/decentration after, 8.440–444, 8.441*f*, 8.442*f*, 8.443*f*
graft rejection and, 4.84, 4.85*f*
indications for, 8.412–413*t*, 8.420*t*, 8.436
layer-based approach to use of, 8.417*t*
preoperative evaluation/preparation and, 8.418
primary graft failure and, 8.447
pupillary block after, 8.444*f*, 8.444–445
rejection and, 8.437*t*, 8.447*f*, 8.447–448

short-term results of, 8.437*t*
in triple procedure, 11.175–176
visual acuity after, 8.438–440
eye banking and, 8.413–417, 8.415*t*, 8.416*f*, 8.416*t*
indications for, 8.412–413*t*
lamellar (LK), 8.411, 8.433*f*, 8.433–436, 8.435*f*
for *Acanthamoeba* keratitis, 8.279
anterior (ALK), 8.412, 8.412*t*, 8.433, 8.433*f*
advantages of, 8.421–422*t*, 8.433
complications of, 8.435
intraoperative, 8.420*t*
postoperative, 8.421*t*
disadvantages of, 8.422*t*, 8.433
donor cornea contraindications and, 8.415*t*
femtosecond/femtosecond laser-assisted (FALK/FLAK), 8.412*t*, 8.431, 8.434
indications for, 8.412–413*t*, 8.420*t*, 8.433
layer-based approach to use of, 8.417*t*
preoperative evaluation/preparation and, 8.418
therapeutic (ALTK), 8.412*t*
complications of, 8.420*t*, 8.421*t*, 8.435–436
conjunctival flap removal and, 8.360
for corneoscleral lacerations, 8.406
deep anterior (DALK), 8.411, 8.412, 8.412*t*, 8.433, 8.434–435
advantages of, 8.421–422*t*
in children, 8.451
complications of, 8.435
intraoperative, 8.420*t*
postoperative, 8.421*t*
for corneal changes in mucopolysaccharidoses, 8.174–176
disadvantages of, 8.422*t*
for herpetic eye disease, 8.225
indications for, 8.420*t*, 8.434
for keratoconus, 8.167
layer-based approach to use of, 8.417*t*
neurotrophic cornea after, 8.80
preoperative evaluation/preparation and, 8.418
rejection and, 8.411, 8.435, 8.435*f*
deep (DLEK), 8.412*t*, 8.436, 8.437*t*
graft rejection and, 4.84
rejection and, 8.411, 8.435, 8.435*f*
wound healing/repair and, 13.32–33
patient selection and, 8.418
penetrating (PK/PKP), 8.411, 8.412, 8.419–432, 8.437*t*
for *Acanthamoeba* keratitis, 8.279
advantages of, 8.421*t*
arcuate keratotomy and, 13.56–57, 13.58
astigmatism after
control of, 8.431–432, 8.432*f*
refractive surgery for, 13.178–180
suture removal/adjustment and, 8.419*f*, 8.431–432, 8.432*f*
corneal keratoscopy and, 8.28
corneal topography and, 8.32, 8.431–432, 8.432*f*
for bacterial keratitis, 8.272
bullous keratopathy after, 4.83–84, 4.84, 4.84*f*, 4.85*f*
cataract/cataract surgery and, 11.56, 11.175, 11.176
for chemical injuries, 8.379–380
in children, 8.450–451
CMV recurrence after, 8.232
complications of, 8.437*t*
intraoperative, 8.419, 8.420–421*t*
postoperative, 8.421*t*, 8.423–430
conjunctival flap removal and, 8.360
for corneal changes in mucopolysaccharidoses, 8.174–176
for corneal edema after cataract surgery, 11.129
corneal topography after, 13.179–180
disadvantages of, 8.422*t*
disease recurrence in graft and, 8.225, 8.232, 8.425, 8.425*f*
donor cornea contraindications and, 8.415*t*
endophthalmitis after, 8.424
for Fuchs endothelial dystrophy, 8.157
for fungal keratitis, 8.276
glaucoma after, 8.424–425, 10.109
graft rejection and, 4.84, 4.85*f*, 8.316–318, 8.428–431, 8.437*t*. *See also* Rejection
prevention of, 8.430–431
treatment of, 8.429–430
for herpetic eye disease, 8.225
recurrence of, in graft, 8.225
indications for, 8.412–413*t*, 8.419, 8.420*t*
infectious/microbial keratitis after, 8.427
infectious pseudocrystalline/crystalline keratopathy after, 4.79
for keratoconus, 8.167
for keratoglobus, 8.171
layer-based approach to use of, 8.417*t*
for microsporidial stromal thinning, 8.281
for mucous membrane pemphigoid, 8.303
neurotrophic cornea after, 8.80
for peripheral ulcerative keratitis, 8.313
postoperative care and, 8.423–430
preoperative evaluation/preparation and, 8.418
after radial keratotomy, 13.52
refractive error after, control of, 8.431–432, 8.432*f*
after refractive surgery, 13.197–198
refractive surgery after, 13.37, 13.178–180
results of, 8.423–429, 8.437*t*
in rosacea patients, 8.71
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298
sutures for, 8.419*f*
corneoscleral laceration repair and, 8.406, 8.407*f*, 8.408*f*
postoperative problems and, 8.426*f*, 8.426–427, 8.431–432, 8.432*f*
removal/adjustment and, for astigmatism control, 8.419*f*, 8.431–432, 8.432*f*
tectonic
for herpetic eye disease, 8.225
keratoglobus, 8.171
for peripheral ulcerative keratitis, 8.313
in triple procedure, 11.175
preoperative evaluation/preparation and, 8.418–419
Keratoprosthesis, 8.452*f*, 8.452–453, 8.453*t*
for chemical injuries, 8.380, 8.384
complications of, 8.452–453, 8.453*t*
for graft-vs-host disease, 8.304
for herpetic eye disease, 8.225
for limbal stem cell deficiency, 8.94

for mucous membrane pemphigoid, 8.303, 8.453*t*
for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298, 8.452
Keratorefractive surgery (KRS), 13.7, 13.8*t*. *See also* Refractive surgery; *specific procedure*
abbreviations and acronyms used in, 13.3–5
ablation zones used in, 3.272
amblyopia/anisometropic amblyopia and, 13.185–187
angle kappa, 3.272
astigmatism and
corneal topography in detection/management of, 8.32, 13.18–19, 13.22–23, 13.44, 13.45, 13.45*f*
penetrating keratoplasty and, 13.178–180
in autoimmune disease, 13.191
cataract/cataract surgery and, 11.123–124, 11.176–177, 11.177*f*, 13.43–44
IOL power calculation and, 11.85–87, 11.176, 11.177*f*, 13.44, 13.194
preoperative evaluation/planning and, 11.76, 11.79
in children, 13.187–188
collagen shrinkage, 13.8*t*, 13.28, 13.28*f*, 13.127–129, 13.128*f*, 13.129*f*
in collagen vascular/connective tissue diseases, 13.37, 13.171, 13.191
contact lens use after, 13.198–200, 13.199*f*
contraindications to
corneal topography in identification of, 13.23, 13.24–26, 13.25*f*
in ocular and systemic disease, 13.171
corneal biomechanics affected by, 13.13–14
corneal crosslinking, 13.8*t*, 13.130–135, 13.131*f*, 13.133*f*, 13.133*t*
corneal effects of, 13.9, 13.26–28, 13.27*f*, 13.28*f*
corneal imaging/evaluation and, 13.14–26, 13.44–45, 13.45*f*. *See also* Cornea, topography of; *specific type*
indications for, 13.22–24, 13.23*f*, 13.24*f*
postoperative, 13.23*f*, 13.23–24, 13.24*f*
preoperative, 13.14–26, 13.44–45, 13.45*f*, 13.79–80
dry eye and, 13.173
corneal optics and, 13.7–9
corneal shape and, 3.268–271, 3.269–3.271*f*, 13.9
corneal topography and, 13.14–19, 13.15*f*, 13.16*f*, 13.17*f*, 13.18*f*, 13.19*f*, 13.24–26, 13.25*f*, 13.44–45, 13.45*f*, 13.79. *See also* Cornea, topography of
dry eye and, 13.173
indications for, 13.22–23, 13.23*f*, 13.24*f*
postoperative evaluation and, 13.23*f*, 13.23–24, 13.24*f*
preoperative evaluation and, 13.14–19, 13.15*f*, 13.16*f*, 13.17*f*, 13.18*f*, 13.19*f*, 13.24–26, 13.25*f*, 13.44–45, 13.45*f*, 13.79–80
refractive lens exchange and, 13.149
toric IOLs and, 13.151–152
after corneal transplant, 13.37, 13.178–180
corneal transplant after, 13.197–198
corneal wound healing and, 13.32–33
in diabetes mellitus, 13.37, 13.190–191
donor cornea suitability and, 8.414
emerging technologies in, 13.203–208
excimer laser, 13.8*t*, 13.29, 13.73–77, 13.74–75*f*
glaucoma/ocular hypertension and, 13.41, 13.180–183, 13.182*f*, 13.200–201
herpes simplex virus infection and, 13.173–174
higher-order aberrations from, 3.276–277
in HIV infection/AIDS, 13.188–190
incisional, 13.8*t*, 13.26–27, 13.27*f*, 13.49–58
for astigmatism, 13.53–58, 13.54*f*, 13.55*f*, 13.56*f*, 13.57*f*
corneal effects of, 13.26–27, 13.27*f*
for myopia, 13.49–53, 13.50*f*, 13.51*f*
informed consent for, 13.36*t*, 13.46–48, 13.47*t*
inlays/onlays, 13.59–71, 13.169
with intraocular refractive surgery (bioptics), 13.137, 13.157
IOL power calculations after, 13.44, 13.193–197, 13.196*f*
iron lines associated with, 8.117
irregular astigmatism and, 3.272–278, 3.274–3.276*f*, 13.18–19, 13.22–23, 13.44, 13.45
keratoconus and, 13.23, 13.24, 13.25*f*, 13.38, 13.42–43, 13.44, 13.175*f*, 13.175–178, 13.176*f*, 13.177*f*. *See also* Keratoconus
keratometric power measurements affected by, 13.193
in large-pupil patients, 3.272
laser biophysics and, 13.29–32, 13.30*f*
laser-tissue interactions and, 13.29
limitations of, 13.47*t*
medical history and, 13.36*t*, 13.37
monovision and, 13.39, 13.164–165
myopia treated with, 3.275
night vision problems after, 3.272
nonlaser lamellar, 13.8*t*
in ocular and systemic disease, 13.171–191. *See also specific disorder*
ocular history and, 13.36*t*, 13.37–38
optical considerations/principles and, 13.9–13, 13.10*f*, 13.11*f*, 13.12*f*, 13.13*f*
overview of, 3.268
overview of procedures used in, 13.7, 13.8*t*
patient age and, 13.38–39
patient evaluation for, 13.35–48, 13.36*t*. *See also* Keratorefractive surgery (KRS), preoperative evaluation for
after penetrating keratoplasty, 8.432, 13.37, 13.178–180
penetrating keratoplasty after, 13.197–198
photoablation, 13.29–32, 13.30*f*, 13.73–74, 13.74–75*f*, 13.101–126. *See also* Photoablation
postoperative considerations and, 13.193–201
contact lens use and, 13.198–200, 13.199*f*
corneal imaging and, 13.23*f*, 13.23–24, 13.24*f*
corneal transplantation and, 13.197–198
glaucoma and, 13.200–201
IOL power calculations and, 13.193–197, 13.196*f*
retinal detachment repair and, 13.197
preoperative evaluation for, 13.35–48, 13.36*t*
corneal imaging/ancillary tests and, 13.14–26, 13.44–46, 13.45*f*, 13.79–80. *See also* Cornea, topography of; *specific type*
discussion of findings/informed consent and, 13.36*t*, 13.46–48, 13.47*t*
history and, 13.35–39, 13.36*t*

ocular examination and, 13.36*t*, 13.39–44, 13.42*f*, 13.43*f*
patient expectations/motivations and, 13.35–36, 13.36*t*, 13.47
in presbyopia, 13.38–39, 13.159–170
pupil size and, 3.272–273
after radial keratotomy, 13.52
retinal disease/detachment and, 13.44, 13.183–185, 13.197
social/occupational history and, 13.36*t*, 13.36–37
spherical aberrations in, 3.272
strabismus and, 13.41, 13.185–187
techniques used in, 3.268
topography-guided, 13.32, 13.77, 13.97
wavefront aberrations/analysis and, 13.9–13, 13.10*f*, 13.11*f*, 13.12*f*, 13.13*f*, 13.46, 13.102–103, 13.103*f*
wavefront-guided/wavefront-optimized, 13.31–32, 13.76–77, 13.97. *See also* Wavefront-guided (custom) laser ablation; Wavefront-optimized laser ablation
Keratoscopy, 8.27–28, 8.28*f*, 8.35*t*. *See also* Videokeratoscopy
in keratoconus, 8.28, 8.167*f*
Keratosis, 8.45*t*
actinic, 4.210–212, 4.211*f*, 4.212*f*
squamous cell carcinoma and, 4.211
inverted follicular, 4.209, 4.210*f*
seborrheic, 4.209, 4.209*f*, 4.210*f*
Keratotomy
arcuate (AK), 13.8*t*, 13.53–58
complications of, 13.58
instrumentation for, 13.55
ocular surgery after, 13.58
outcomes of, 13.57
refractive lens exchange and, 13.149
surgical technique for, 13.55–57
astigmatic (AK), 13.8*t*
cataract surgery and, 11.123
wound healing/repair and, 13.32
hexagonal (Hex K), 13.8*t*
incisional, 13.49. *See also* Radial keratotomy
radial (RK). *See* Radial keratotomy
transverse (tangential/straight), 13.53–54, 13.54*f*
Keratouveitis, 9.70, 9.220, 9.247
varicella, 8.226, 8.229
Kerlone. *See* Betaxolol
Kestenbaum-Anderson procedure, for nystagmus, 5.236, 5.237*f*
Kestenbaum procedure, for nystagmus, 6.155, 6.156*t*, 6.156*f*
Kestenbaum rule, 3.320
Ketoconazole, 1.277, 2.429, 2.430*t*
for fungal keratitis, 8.275
Ketoprofen, 2.409*t*
Ketorolac, 1.289–290
for cystoid macular edema, after cataract surgery, 11.165
description of, 2.400*t*, 2.409*t*, 2.410
for intraoperative floppy iris syndrome, 11.138
Ketotifen fumarate, 2.412*t*, 2.413
Khodadoust line of endothelial rejection, 8.429, 8.430*f*, 9.54, 9.54*f*
Ki-67
in orbital solitary fibrous tumors, 4.236
in pingueculae/pterygia, 4.57
Kidney cancer, metastatic eye disease and, 4.304*t*
Kidneys. *See under Renal*
Killer cells, 9.48
natural, in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
Killer immunoglobulin-like receptors, 9.46
Kinase inhibitors, 1.177*t*, 1.180
Kinetic energy, 3.106
Kinetic perimetry, 5.84, 5.85*f*, 10.59. *See also* Visual field testing
in nonorganic disorder evaluation, 5.308, 5.308*f*
Kinetic red target test, in confrontation testing, 5.83
"Kissing nevus," 4.218, 4.218*f*, 7.196, 7.197*f*
Klebsiella spp
description of, 2.419, 8.247
pneumoniae endophthalmitis, 12.238
Kleeblattschädel, 6.205
Klippel-Trénaunay syndrome (KTS), 6.406
Klippel-Trénaunay-Weber syndrome (KTWS)
description of, 6.199, 6.251, 6.394*t*, 6.406
glaucoma associated with, 10.30
K_m (Michaelis/affinity constant), sorbitol in cataract development and, 2.391, 11.19
Knapp procedure, 6.127
inverse, 6.128
Knobloch syndrome, 6.346*f*, 6.346–347
Knudson's hypothesis, retinoblastoma and, 2.227
Koeppe lens/Koeppe-type lenses, for gonioscopy/funduscopy, 10.33
in children and adolescents, 6.282, 6.282f, 10.159
Koeppe nodules
in anterior uveitis, 9.78
in sarcoidosis, 4.187, 9.196, 9.196*f*
Koganei, clump cells of, 4.181
KOH. *See* Potassium hydroxide
Kohn shell, 3.246*f*
Koilocytosis, in human papillomavirus infection, 4.204, 4.205*f*
Koniocellular (K) system/neurons/bistratified cells, 10.42
KPro. *See* Boston keratoprosthesis
KPs. *See* Keratic precipitates
Krabbe disease, 2.204*t*, 6.388*t*
Krause, glands of, 4.202
Krill disease. *See* Acute retinal pigment epitheliitis
Krimsky test, 6.67, 6.68*f*, 6.104*f*
KRS. *See* Keratorefractive surgery
KRT3/KRT12 mutation, in Meesmann corneal dystrophy, 8.136*t*
Krukenberg spindles, 4.105, 8.118*t*, 8.128, 10.31, 10.92, 10.94, 10.94*f*. *See also* Pigment/pigmentary dispersion syndrome
KSHV. *See* Kaposi sarcoma-associated herpesvirus
KTS. *See* Klippel-Trénaunay syndrome
KTWS. *See* Klippel-Trénaunay-Weber syndrome
Kuglen hook, for pupil expansion, 11.177

Kupffer cells, 9.3
Kuru, 1.211, 5.357
Kyrieleis plaques, 12.244*f*
Kyrielesis arteriolitis, 9.278

L

L_e. *See* Radiance
L_v. *See* Luminance
L cones, 2.312, 2.315, 12.54
L-Selectin, 9.11–12
LA. *See* Lacrimal artery
"La belle indifference," 5.299
LA 3.0 (photopic single-flash) electroretinogram, in cone dystrophies, 5.102
Labbé, vein of, 5.22
Labetalol, 1.64
  intraoperative floppy iris syndrome and, 11.137, 11.137*t*
Labrador (actinic/climatic droplet) keratopathy (spheroidal degeneration), 4.83, 4.83*f*, 8.115–117, 8.116*f*
Labyrinth, 5.38, 5.39*f*, 6.40
  in vestibular-ocular reflex, 5.214
Labyrinthine segment, of cranial nerve VII (facial), 5.52
Lacerations. *See also* Trauma
  conjunctival, 8.396–397
  corneal, 12.359
  corneoscleral, 6.377, 8.388. *See also* Anterior segment, trauma to; Penetrating and perforating ocular trauma; Trauma
    repair of, 8.404*f*, 8.404–409, 8.405*f*, 8.407*f*, 8.408*f*
  eyelid
    description of, 6.378, 7.214–216*f*
    repair of. *See* Eyelid(s), surgery/reconstruction of
  globe, 12.358
  iris, repair of, 8.406, 8.408*f*, 8.409
  medial rectus muscle, 6.146
  scleral, 12.359
Lacquer cracks, 12.211, 12.211*f*
Lacrimal artery (LA), 2.23*f*, 2.25*f*, 2.40, 5.13*f*, 5.14, 5.14*f*, 5.15*f*, 6.23, 7.12*f*
Lacrimal bone, 2.9*f*, 5.7*f*, 5.8, 5.9*f*, 7.7*f*, 7.8*f*
Lacrimal canaliculi. *See* Canaliculi
Lacrimal crests, 2.9*f*, 5.9*f*, 7.282
Lacrimal drainage system, 2.32*f*, 2.40*f*, 2.42*f*, 2.42–43. *See also* Nasolacrimal duct; *specific structure*
  abnormalities of
    congenital, 6.227–230
    congenital lacrimal fistula, 6.228, 6.229*f*
    dacryocystocele, 6.213, 6.225, 6.228–230, 6.229*f*, 7.289, 7.290*f*
    developmental, 7.285–287
    duplication, 7.286
    lacrimal puncta or canaliculi atresia, 6.227–228, 6.228*f*
    obstruction. *See* Nasolacrimal duct obstruction
  acquired obstruction of
    canalicular obstruction, 7.298, 7.299*f*
    diagnostic tests for, 7.297–300, 7.298–300*f*
    evaluation of, 7.294–300
    history-taking for, 7.294
    nasolacrimal duct, 7.305–310
    physical examination for, 7.295–296
    probing for, 7.298, 7.300
    pseudoepiphora, 7.296
  anatomy of, 7.162*f*, 7.281*f*, 7.281–282
  congenital obstruction of
    balloon dacryoplasty for, 7.294
    canalicular agenesis and dysgenesis, 7.288
    dacryocystocele, 7.289, 7.290*f*
    dacryocystorhinostomy for, 7.295
    evaluation, 7.287–288
    lacrimal intubation stents for, 7.292–294, 7.293–294*f*
    nasolacrimal duct. *See* Nasolacrimal duct obstruction
    probing and irrigation for, 7.291–292, 292*f*
    punctal agenesis and dysgenesis, 7.288
  defects of, 7.226
  development of
    abnormalities of, 7.285–287
    normal, 7.283
  diagnostic tests of, 7.297–300, 7.298–300*f*
  disorders of. *See* Tearing/epiphora
  dye disappearance test of, 7.297, 7.298*f*
  excretory apparatus of. *See* Lacrimal drainage system
  healing/repair of, 4.17
  irrigation of, 7.291–292, 292*f*, 7.297–298, 7.299–300*f*
  neoplasm of, 7.316–317
  obstruction of. *See* Tearing/epiphora
  outflow examination, 7.296, 7.297*f*
  secretory apparatus/function of. *See* Lacrimal gland
  therapeutic closure of, 7.310–311
Lacrimal ducts. *See also* Lacrimal drainage system
  cyst arising from, 4.208
Lacrimal fistula, congenital, 6.228, 6.229*f*
Lacrimal fossa/lacrimal gland fossa, 5.7*f*, 5.9*f*, 6.181, 7.98
Lacrimal functional unit (LFU), 8.4–5, 8.5*f*
  disturbance of
    dry eye caused by, 8.53, 8.54*f*. *See also* Dry eye
    immunoregulation in reduction of, 8.12*f*
Lacrimal gland, 4.202, 4.223, 5.51*f*, 8.5, 8.6*f*
  accessory, 2.41, 2.253, 4.202. *See also specific gland*
  agenesis of, 7.285
  anatomy of, 2.39–41, 7.279–281, 7.280*f*
  canaliculi of. *See* Canaliculi, lacrimal
  cells of, 2.40
  characteristics of, 2.30*t*
  congenital abnormalities of, 7.285
  cyst arising from duct of, 4.208
  development of, 2.163
  drainage system of. *See* Lacrimal drainage system
  dysfunction of, 2.255*f*
    in Sjögren syndrome, 8.57
    tests of, 8.38–41, 8.40*f*
  ectopic, 6.226
  Epstein-Barr virus infection and, 8.230–231
  in external eye defense, 8.11
  fistula of, 7.285
  fossa of, 2.7*f*, 2.8, 7.6, 7.7*f*
  hypoplasia of, 7.285
  infection of, 7.312–315. *See also* Dacryoadenitis
  innervation of, 2.251, 5.52, 5.55, 5.276–277*f*, 8.5, 8.5*f*
  ionizing radiation damaging, 8.386
  lobule of, 2.41*f*
  magnetic resonance imaging of, 2.459*t*

malignant epithelial tumors of, 7.146
neurotransmitters in, 2.251
oncocytoma arising in, 4.71–72, 4.72*f*, 8.337
orbital lobe of, 2.251
outflow examination, 7.296, 7.297*f*
palpebral, 2.39
palpebral lobe of, 2.251
pump mechanism of, 7.283, 7.284*f*
sarcoidosis involvement of, 9.195
secretions produced by, 2.40
secretory system of. *See* Lacrimal secretory system
tear production from, 2.163
tumors of, 4.229–231, 4.230*f*, 4.231*f*
adenoid cystic carcinoma, 7.100
description of, 7.98
epithelial, 4.229–231, 4.230*f*, 4.231*f*, 7.98–100, 7.99*f*
malignant mixed tumor, 7.100
nonepithelial, 7.101
pleomorphic adenomas, 4.229–230, 4.230*f*, 7.98–100, 7.99*f*
Lacrimal intubation stents, 7.292–294, 7.294*f*
Lacrimal nerve, 2.12*f*, 2.131, 5.8*f*, 5.43*f*, 5.48, 5.48*f*, 7.14, 8.5*f*
Lacrimal plugs, 7.302, 7.306
for dry eye, 8.61*t*, 8.64–65, 8.65*f*
Lacrimal punctum. *See also* Punctum
agenesis of, 7.288
anatomy of, 7.281, 7.284*f*
aplasia, 7.287, 7.287*f*
atresia of, 6.227–228, 6.228*f*
description of, 2.41, 2.43
dilatation of, 7.291*f*
disorders of, 7.300–302
duplication of, 7.286
dysgenesis of, 7.288
epiphora, 7.301, 7.301*f*
occlusion of, 7.300
plugs, 7.302, 7.306, 7.310
stenosis of, 7.301
thermal obliteration of, 7.311
Lacrimal reflex arc, 2.136*f*
Lacrimal sac (tear sac), 2.42
anatomy of, 2.32*f*
dacryocystitis findings in, 7.314
description of, 7.282
fossa of, 2.6*f*, 2.8
inflammation of. *See* Dacryocystitis
neoplasm of, 7.295*f*, 7.316*f*
palpation of, 7.296
squamous cell carcinoma of, 7.316*f*, 7.317
traumatic injuries to, 7.312
tumors of, 4.229, 7.316–317
Lacrimal secretory system
anatomy of, 7.279–281, 7.280*f*
development of
abnormalities involving, 7.285
normal, 7.283
Lacrimal vein, 5.21*f*, 7.12*f*
Lacrimal–cutaneous fistula, 7.286, 7.286*f*
Lacrimation. *See* Tearing/epiphora
Lactate, in aqueous humor, 2.274
Lactation
glaucoma medication use during, 10.185–186
refractive surgery contraindicated during, 13.63
Lactoferrin, in tear film, 8.6*f*, 8.39
Lacus lacrimalis, 8.6
LADA. *See* Latent autoimmune diabetes in adults
Lagophthalmos, 7.242, 7.246, 7.255, 7.263
assessment for, 5.271
causes of, 8.79
exposure keratopathy and, 8.79
Laherparepvec, 7.210
LAIV. *See* Live-attenuated influenza vaccine
LAL. *See* Light Adjustable Lens
Lambda (λ)-pattern strabismus
clinical features of, 6.110
surgical treatment of, 6.113
Lambdoid suture, 5.5
Lamellae
corneal, 8.8, 8.9*f*
zonular, 11.11
Lamellar (zonular) cataracts, 11.34–35, 11.36*f*
Lamellar channels, for intrastromal corneal ring segment placement, 13.62, 13.62*f*, 13.63*f*, 13.64
deposits in, 13.69, 13.69*f*
Lamellar flaps, LASIK, 13.73, 13.79, 13.82, 13.84–90. *See also* Flap(s), LASIK
after penetrating keratoplasty, 13.180
Lamellar macular hole, 12.28*f*
Lamellar surgery, 13.8*t*. *See also* LASIK
corneal wound healing and, 13.32–33
keratectomy, for keratophakia, 13.59, 13.60
keratoplasty. *See* Keratoplasty; Keratoplasty, lamellar
nonlaser, 13.8*t*
Lamellar (zonular) cataracts, 6.55, 6.296, 6.296*f*
Lamina cribrosa
anatomy of, 2.111, 2.113
dehiscences in, 12.218, 12.218*f*
description of, 4.107, 4.242*f*, 5.17*f*, 6.364, 10.43–44, 10.44*f*, 10.45*f*, 10.46
Lamina fusca, 2.58, 4.107, 4.107*f*, 4.108, 4.182
Lamina papyracea, 2.8, 5.7*f*, 5.8, 7.7
Lamina terminalis, 5.27*f*
Laminar area of optic nerve, 10.42, 10.43, 10.46
Laminar deposits, basal, in age-related macular degeneration, 4.160, 4.162, 4.165, 4.165*f*
Laminin, 2.304, 8.8, 12.7
Lamotrigine, 1.203, 1.207
Lampalizumab, 12.71
Lancaster red-green test, 3.35–36, 6.69, 6.120
Lancefield groups, 8.244–245
Landolt C optotypes, 3.133*f*, 3.134
Lang stereopsis tests, 6.81
Langerhans cell histiocytosis (LCH), 6.218–219, 7.95, 7.96*f*
Langerhans cells
characteristics of, 9.4–5
conjunctival, 8.13
corneal, 8.13*f*, 8.13–14
in external eye defense, 8.13*f*, 8.13–14
functions of, 9.4–5
Langhans giant cells, 4.7, 4.9*f*
Large-angle esotropias, 6.87
Large cell (primary central nervous system/intraocular) lymphoma, 4.135–136*f*, 4.135–137, 4.311*f*, 4.311–313, 4.313*f*, 5.349. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma

Large colloid drusen, 12.274
Large-vessel vasculitis, 1.169*t*, 1.170
Larval migrans. *See also Toxocara* (toxocariasis)
ocular, 8.253
visceral, 8.253
Laryngotracheobronchial disease, in relapsing polychondritis, 1.168
LASEK (laser subepithelial keratomileusis), 2.263, 13.8*t*, 13.73. *See also* Keratorefractive surgery; Photorefractive keratectomy; Surface ablation
in children, 13.187
corneal preparation/epithelial preservation for, 13.84
glaucoma/ocular hypertension and, 13.182
immediate postablation measures for, 13.92–93
Laser(s), 13.73–74. *See also* Laser therapy; *specific type*
active medium used by, 3.111–112, 3.112*f*
biophysics of, 13.29–32, 13.30*f*
carbon dioxide, 7.268
coagulation uses of, 3.115
continuous-wave, 3.112
definition of, 3.92
description of, 3.110
excimer, 13.8*t*, 13.29, 13.73–77, 13.74–75*f*
fundamentals of, 3.110–112
green, 12.373
infrared, 12.374
light produced by, 3.111
mode-locking, 3.112
Nd:YAG, 3.112, 3.115
photochemical effect caused by, 12.374
photocoagulation using. *See* Photocoagulation
Q-switching, 3.112
red, 12.374
stimulated emission, 3.111, 3.111*f*
tissue interactions and, 13.29
topography-guided, 13.32, 13.77
transpupillary thermotherapy using, 12.380
ultrashort laser pulses, 3.117–118
vaporization caused by, 12.374–375
wavefront-guided/wavefront-optimized, 13.31–32, 13.76–77. *See also* Wavefront-guided (custom) laser ablation; Wavefront-optimized laser ablation
programming, 13.31, 13.81
wavelength of
description of, 3.115
for photocoagulation, 12.373–375
yellow, 12.374
Laser capsulotomy (Nd:YAG), 11.154*f*, 11.154–157, 11.156*f*
for anterior capsule fibrosis and phimosis, 11.154, 11.154*f*, 11.154–157, 11.156*f*
for capsular block syndrome, 11.149
for capsule opacification, 11.152, 11.153, 11.154, 11.154*f*, 11.154–157, 11.156*f*
multifocal IOLs and, 13.156, 13.167
complications of, 11.156–157
contraindications for, 11.155
indications for, 11.154–155
lens particle glaucoma and, 11.67
procedure for, 11.155–156, 11.156*f*
retinal detachment and, 11.157, 11.166
Laser gonioplasty, 10.193–194
Laser in situ keratomileusis. *See* LASIK
Laser iridotomy, 3.115. *See also* Iridotomy
for acute angle closure, 10.124, 10.125, 10.191–193, 10.192*f*
for angle-closure glaucoma, 10.124, 10.125, 10.126, 10.191–193, 10.192*f*
cataract extraction after, 10.213
for angle-closure suspect, 10.122, 10.191
for ectopia lentis, 10.129–130
for malignant/ciliary block glaucoma (aqueous misdirection), 10.140
for phacomorphic glaucoma, 10.128
for phakic IOL insertion, 13.141
for pigmentary glaucoma, 10.96, 10.96*f*
for subacute/intermittent angle closure, 10.126
Laser ophthalmoscopy/ophthalmoscope, in optic nerve/nerve head/disc evaluation, 10.56
Laser photoablation. *See* Photoablation
Laser photocoagulation, for intermediate uveitis, 9.150
Laser photolysis, 11.125
Laser-pointer injury, 12.369
Laser pupilloplasty
for cataracts, 11.71–72
for IOL decentration/dislocation, 11.145
Laser retinopexy, 12.376–377
Laser scanning confocal microscope, 8.24. *See also* Confocal microscopy
Laser skin resurfacing, 7.268–269
Laser subepithelial keratomileusis. *See* LASEK
Laser surgery
adverse effects of, 12.114
branch retinal vein occlusion treated with, 12.128
central retinal vein occlusion treated with, 12.135
diabetic macular edema treated with, 12.114–115
proliferative diabetic retinopathy treated with, 12.104–107
retinopathy of prematurity treated with, 12.185–186
Laser suture lysis (LSL), scleral flap closure/management and, 10.202–203, 10.207–208
Laser therapy. *See also* Laser surgery; Photocoagulation; Photodynamic therapy; *specific procedure*
for choroidal hemangioma, 4.283
for choroidal melanoma/ciliary body melanoma, 4.276
for diabetic retinopathy, 4.160, 4.161*f*
for glaucoma, 10.188–196. *See also specific procedure*
malignant/ciliary block glaucoma (aqueous misdirection) and, 10.139
trabeculoplasty and, 10.88, 10.93, 10.96, 10.96*f*, 10.113–115, 10.188–191, 10.190*f*
light–tissue interactions and, 13.29
for retinoblastoma, 4.300
Laser thermokeratoplasty (LTK). *See also* Thermokeratoplasty
corneal transplantation after, 13.198
description of, 13.8*t*, 13.127–128
hyperopia treated with, 3.115
Laser trabeculoplasty (LTP), 3.115, 10.113–115, 10.188–191, 10.190*f*
for normal-tension glaucoma, 10.88
for open-angle glaucoma, 10.113–115, 10.188–191
for pigmentary glaucoma, 10.96, 10.96*f*
for pseudoexfoliation glaucoma, 10.93
selective (SLT), 10.188, 10.189, 10.190, 10.190*f*

LaserACE procedure, 13.162
Laser–tissue interactions
overview of, 3.112–113
photoablation, 3.113, 3.113*t*, 3.113*f*, 3.115
photochemical, 3.113*t*, 3.113–114
photodisruption, 3.113, 3.113*t*, 3.113*f*, 3.116–117, 3.117*f*
plasma-induced ablation, 3.113, 3.113*t*, 3.113*f*, 3.115–116, 3.116–117*f*
thermal, 3.113–114*t*, 3.113–114*f*, 3.113–115
types of, 3.113, 3.113*t*, 3.113*f*
Lash margin entropion, 7.145, 7.145*f*
Lashes. *See* Eyelashes
LASIK (laser in situ keratomileusis), 13.8*t*, 13.73, 13.74, 13.75*f*, 13.76. *See also* Keratorefractive surgery; Photoablation
aberrations after, 13.11, 13.12, 13.102–103, 13.103*f*
for accommodative esotropia, 13.188
for amblyopia/anisometropic amblyopia, 13.186, 13.187
application of laser treatment and, 13.30, 13.91*f*, 13.91–93
arcuate keratotomy and, 13.54, 13.58
in astigmatism, 13.97
after penetrating keratoplasty, 8.432, 13.179, 13.180
bandage contact lenses after, 13.93, 13.111, 13.200
for epithelial ingrowth, 13.122
for epithelial sloughing/defects, 13.112
for microkeratome complications, 13.111
for striae, 13.113
bioptics with, 13.157
calibration of excimer laser for, 13.80
cataract surgery after, 11.177
IOL power calculation and, 11.86
central toxic keratopathy after, 13.105*f*, 13.105–106
in children, 13.187
complications/adverse effects of, 13.110–124. *See also specific type*
in diabetes mellitus, 13.190
rare, 13.125–126
in connective tissue/autoimmune diseases, 13.191
contact lens use after, 13.199, 13.200
contraindications/relative contraindications to, 13.78–80
forme fruste/keratoconus and, 13.79, 13.124, 13.175*f*, 13.175–176, 13.177*f*
ocular and systemic disease and, 13.171
"pellucid suspect" pattern and, 13.176, 13.176*f*
residual stromal bed thickness and, 13.30, 13.45–46, 13.79–80. *See also* LASIK (laser in situ keratomileusis), residual stromal bed thickness and
corneal biomechanics affected by, 13.14
corneal perforation and, 13.111
corneal preparation for, 13.84–90, 13.85*f*, 13.86*f*, 13.87*f*, 13.88*f*, 13.89*f*
corneal thickness and, 13.45–46, 13.79–80
corneal transplantation after, 13.198
corneal wound healing/repair and, 13.33
corticosteroids after, 13.93, 13.94
complications associated with, 13.105
in diabetes mellitus, 13.190
diffuse lamellar keratitis after, 13.116*f*, 13.116–117, 13.117*t*
infectious keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
pressure-induced stromal keratopathy differentiated from, 13.119
drugs affecting success of, 13.37
dry eye after, 13.78–79, 13.172
in dry eye disorders, 13.78–79, 13.172–173
ectasia/keratoconus and, 13.124–125, 13.175–177*f*, 178
corneal crosslinking and, 13.124, 13.130–131, 13.176
intrastromal corneal ring segment placement and, 13.70
ectatic disorders after, 8.166
elevated intraocular pressure after, 13.105, 13.119, 13.181, 13.182, 13.200–201
epipolis. *See* Epipolis laser in situ keratomileusis
epithelial ingrowth after, 13.120–122, 13.121*f*
epithelial sloughing/defects after, 13.112
filtering surgery and, 13.182
flap creation for, 13.30, 13.73, 13.75*f*, 13.79, 13.82, 13.84–90
aberrations and, 13.102–103, 13.103*f*
corneal inlay insertion and, 13.60, 13.169
femtosecond, 13.8*t*, 13.87–90, 13.88*f*, 13.89*f*, 13.90*t*
aberrations and, 13.102–103
advantages/disadvantages/complications of, 13.88, 13.90*t*, 13.122–124, 13.123*f*
re-treatment/enhancements and, 13.98
steep or flat corneas and, 13.44–45, 13.79
glaucoma/elevated intraocular pressure and, 13.181, 13.201
infection and, 13.107, 13.107*f*, 13.117–119
diffuse lamellar keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
microkeratome, 13.84–87, 13.85*f*, 13.86*f*, 13.87*f*
aberrations and, 13.102
complications associated with, 13.110*f*, 13.110–112, 13.111*f*
re-treatment/enhancements and, 13.98
after penetrating keratoplasty, 13.180
retinal detachment surgery and, 13.185, 13.197
steep or flat corneas and, 13.44–45, 13.79, 13.80
flap dislocation and, 13.113, 13.115–116
striae and, 13.113
traumatic, 13.115–116
flap folds and, 13.112–115, 13.114*t*, 13.115*f*
glaucoma/ocular hypertension and, 13.105, 13.181, 13.182, 13.200–201
haze formation and, 13.33
herpes simplex virus keratitis and, 13.174
herpes zoster ophthalmicus and, 13.174
in HIV infection/AIDS, 13.189
for hyperopia, 13.96, 13.97
hyperopia correction using, 3.271, 3.271*f*
infectious keratitis after, 13.106*f*, 13.106–107, 13.107*f*, 13.117–119, 13.118*f*, 13.118*t*
diffuse lamellar keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
interface complications and, 13.116–122
interface debris after, 13.122, 13.123*f*

intraocular pressure elevation/measurement after, 10.25, 13.105, 13.119, 13.181, 13.200–201
after intrastromal corneal ring segment removal, 13.70
keratitis after
atypical mycobacteria causing, 8.272–273, 8.273*f*, 13.106, 13.119
diffuse lamellar, 13.116*f*, 13.116–117, 13.117*t*
infectious keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
pressure-induced stromal keratopathy differentiated from, 13.119
herpes simplex, 13.174
infectious, 13.106*f*, 13.106–107, 13.107*f*, 13.117–119, 13.118*f*, 13.118*t*
diffuse lamellar keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
keratopathy after
central toxic, 13.105*f*, 13.105–106
pressure-induced stromal, 13.119, 13.120*f*
limbal relaxing incisions and, 13.54, 13.58
limitations of, 13.47*t*
microkeratome for, 13.84–87, 13.85*f*, 13.86*f*, 13.87*f*
aberrations and, 13.102
complications associated with, 13.110*f*, 13.110–112, 13.111*f*
re-treatment/enhancements and, 13.98
for mixed astigmatism, 13.97
for myopia, 13.95, 13.97
intraocular pressure measurements and, 13.181, 13.182*f*
spherical aberrations after, 13.11, 13.12, 13.102
OCT in evaluation and, 8.22
outcomes of, 13.95
for hyperopia correction, 13.96, 13.97
for myopia correction, 13.95, 13.97
small-incision lenticule extraction compared with, 13.204, 13.205
for wavefront-guided/wavefront-optimized/topography-guided treatment, 13.31–32, 13.97
overcorrection and, 13.101–102
conductive keratoplasty for, 13.129
patient selection and, 13.78–80
after penetrating keratoplasty, 13.179, 13.180
postoperative care for, 13.94–95
immediate postablation measures and, 13.93
preoperative care for
patient preparation and, 13.81–82
patient selection/relative contraindications and, 13.78–80
planning/laser programming and, 13.81
pressure-induced stromal keratopathy after, 13.119, 13.120*f*
after radial keratotomy, 13.52
re-treatment/enhancements and, 13.97–100, 13.99*f*
for refractive errors after penetrating keratoplasty, 8.432
refractive lens exchange and, 13.149
residual myopia after, intrastromal corneal ring segments for, 13.70
residual stromal bed thickness and, 13.30, 13.45–46, 13.79–80
calculation of, 13.46, 13.79
corneal perforation and, 13.111
ectasia and, 13.79
retinal detachment/retinal detachment repair and, 13.183, 13.184, 13.185, 13.197
small-incision lenticule extraction compared with, 13.205, 13.206
striae and, 13.112–115, 13.114*t*, 13.115*f*
stromal bed preparation for, 13.84–90. *See also* LASIK (laser in situ keratomileusis), flap creation for
surface ablation for enhancement of, 13.98–99
surgical technique for, 13.80–95
tracking/centration/ablation and, 13.91*f*, 13.91–92
undercorrection and, 13.102
wavefront aberrations after, 13.11, 13.12, 13.102–103, 13.103*f*
wavefront analysis before, 13.80
wavefront-guided. *See* Wavefront-guided (custom) laser ablation
LASIK-interface complications, 13.116–122
diffuse lamellar keratitis, 13.116*f*, 13.116–117, 13.117*t*
epithelial ingrowth, 13.120–122, 13.121*f*
infectious keratitis, 13.117–119, 13.118*f*, 13.118*t*
interface debris, 13.122, 13.123*f*
pressure-induced stromal keratopathy, 13.119, 13.120*f*
LASIK line, 8.118*t*
Lastacaft. *See* Alcaftadine
Latanoprost, 2.363, 2.368, 2.393, 2.394*t*, 10.170–176, 10.171*t*
in combination preparations, 10.174*t*
Latanoprost/timolol maleate, 2.394*t*, 2.397*t*
Latanoprostene bunod (LBN), 2.394*t*, 2.395, 10.170
Late-diagnosed primary congenital glaucoma, 10.147, 10.148*t*. *See also* Glaucoma, pediatric
Late non-immune-mediated endothelial failure, 8.427–428
Late-onset corneal haze, 13.109
Latency (saccadic), 5.219, 5.221, 5.222
Latency (viral), herpesvirus/recurrent infection and, 8.205, 8.207, 8.212, 8.213, 8.215–224, 8.216*f*, 8.217*f*, 8.218*f*, 8.220*f*, 8.221*f*, 8.223*t*, 8.226*t*
Latency (visual evoked potential), 5.95
Latent autoimmune diabetes in adults (LADA), 1.34
Latent exodeviations, 6.99
Latent/manifest latent nystagmus (LN/MLN) (fusion/fusional maldevelopment nystagmus syndrome/FMN/FMNS), 5.237–238, 6.83, 6.88, 6.95, 6.129, 6.150–151, 6.151*f*, 6.154
Latent strabismus, 6.15
Latent syphilis, 1.252
Latent transforming growth factor beta-binding protein 2 (LTBP2), 6.306
Lateral canthal tendon
defects of, eyelid reconstruction for, 7.225, 7.226–227*f*
description of, 7.169
trauma to, 7.214–215
Lateral canthotomy, 7.119, 7.223*f*
Lateral canthus, 2.27*f*
Lateral geniculate body/nucleus (LGB/LGN)
anatomy of, 2.116–117*f*, 2.124*f*
blood supply of, 2.122*t*
description of, 5.18, 5.18*f*, 5.24*f*, 5.28–29, 5.55*f*, 5.154, 6.43
lesions of, 5.154, 5.154*f*
neurons of, 6.44

Lateral lenticulostriate artery, 5.16*f*
Lateral long posterior ciliary arteries, 5.15
Lateral magnification, 3.62. *See also* Transverse magnification
Lateral medullary syndrome of Wallenberg (Wallenberg syndrome), 5.20, 5.180, 5.217, 5.337
  Horner syndrome and, 5.260*t*, 5.337
  MRI in, 5.64*f*
Lateral orbital tubercle of Whitnall, 7.6, 7.7–8*f*
Lateral orbital wall, 2.10, 2.10*f*, 5.9*f*
Lateral orbitotomy. *See* Orbitotomy
Lateral palpebral artery, 2.38*f*
Lateral rectus (LR) muscle, 5.8*f*, 5.45, 5.46*f*, 7.12, 7.12*f*
  abduction of, 6.35*f*
  action of, 6.34*t*, 6.35*f*
  anatomy of, 2.34*f*, 2.107*f*, 5.8*f*, 5.45, 5.46*f*
  anomalous innervation of, 6.109
  blood supply to, 2.21
  characteristics of, 2.19*t*, 6.21*t*
  computed tomography of, 2.456*f*
  contracture of, 6.109
  field of action, 6.33
  horizontal gaze and, 5.37*f*, 5.38
  innervation of, 2.21, 5.38, 6.19
  lost, 6.95
  magnetic resonance imaging of, 2.460*f*
  origin of, 6.20, 6.21*t*
  recession/resection of
    for Duane retraction syndrome, 6.134
    for exodeviations, 6.160
    for high myopia, 6.143
    for intermittent exotropia, 6.102
    for third nerve palsy, 6.139
    for X-pattern strabismus, 6.113
  slipped, 6.95
  superior transposition of, 6.113
Lateral rectus tendon, 6.19*f*
Lateral (transverse) sinus thrombosis, 5.69*f*, 5.345–346
Lateral subnucleus
  of cranial nerve III (oculomotor), 5.44, 5.44*f*
  of cranial nerve VII (facial), 5.49
Lateral tarsal strip procedure, 7.231, 7.232*f*
Lateral transverse B-scan, 2.466*f*, 2.466–467
Lateral wall of orbit
  anatomy of, 7.6
  decompression of, 7.130, 7.131*f*
Lateropulsion/ocular lateropulsion, in Wallenberg syndrome, 5.217
Latex allergies, 1.288
Lattice corneal dystrophy (LCD), 4.88–90, 4.89*f*, 4.91*t*, 8.135*t*
  classic (LCD1/type 1), 4.88–90, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.145–147, 8.146*f*, 8.147*f*
  recurrence of, after corneal transplantation, 8.425
  variant, 8.135*t*, 8.146–147, 8.147*f*
Lattice degeneration, 4.148–150, 4.149*f*
  prophylactic treatment of, 12.319
  radial perivascular, 4.150
  retinal detachment and, 12.309–311, 12.310–12.311*f*, 12.316*f*, 12.319
Lattice lines, 8.145, 8.146, 8.146*f*, 8.147*f*
  in amyloidosis, 8.187–188, 8.188*f*
LAV (lymphadenopathy-associated virus). *See* HIV (human immunodeficiency virus)
Law of equal innervation/motor correspondence, Hering's
  eyelid retraction and, 5.274
  horizontal gaze and, 5.36*f*
  nystagmus and, 5.247
  ptosis enhancement and, 5.270*f*, 5.310
Law of reflection
  definition of, 3.40
  description of, 3.80–81
  vergence equation for mirrors derived from, 3.88–89, 3.89*f*
Law of refraction (Snell's law), 8.26
Law of specular reflection, 3.80
Layered hyphema, 8.392, 8.393*f*
LBD. *See* Lewy body dementia
LBN. *See* Latanoprostene bunod
LCA. *See* Leber congenital amaurosis
LCAT deficiency. *See* Lecithin-cholesterol acyltransferase (LCAT) deficiency
LCD. *See* Lattice corneal dystrophy
LCD1. *See* Lattice corneal dystrophy (LCD), classic (LCD1/type 1)
LCH. *See* Langerhans cell histiocytosis
LCMV. *See* Lymphocytic choriomeningitis virus
LCPUFAs. *See* Long-chain polyunsaturated fatty acids
LCs. *See* Langerhans cells
LD. *See* Lyme disease
LDL-C. *See* Low-density-lipoprotein cholesterol
LDL cholesterol (LDL-C). *See* Low-density-lipoprotein cholesterol
Le Fort fractures, 7.109, 7.110*f*
LEA Grating Acuity Test, 6.8
LEA symbols, 3.23, 3.133*f*, 3.134, 6.6, 6.7*f*
Lead ingestion, optic neuropathy caused by, 5.137
Leakage, hyperfluorescence and, 12.35
Lean techniques, 1.31–32
Learning effect, in automated perimetry, 10.71
Leber congenital amaurosis (LCA), 6.335–336, 6.337*f*, 9.58
  characteristics of, 12.265–266
  genes and loci associated with, 2.213*f*, 12.256*t*
  genetic heterogeneity of, 2.212, 2.213*f*
  infantile nystagmus syndrome and, 5.236
  retinal degeneration associated with, 12.281
  RPE65 mutations as cause of, 2.196, 2.333
Leber (epithelioid) cells. *See also* Macrophage(s)
  in choroidal/ciliary body melanoma, 4.192, 4.193*f*, 4.194, 4.195
Leber hereditary optic neuropathy (LHON), 5.133–135, 5.134*f*, 6.368
  description of, 2.185–186
  family history of, 2.200
  mitochondrial DNA mutations and, 5.133
  optic neuritis and, 5.115, 5.133
Leber idiopathic stellate maculopathy, 9.241
Leber stellate neuroretinitis, 12.242
LECD. *See* Lisch epithelial corneal dystrophy
Lecithin-cholesterol acyltransferase (LCAT) deficiency, 8.180*f*, 8.180–181
Lecithin retinol acyltransferase, 2.326, 2.327*f*
LED bulb, 3.108

Ledipasvir/sofosbuvir, 1.261
Left hypotropia (LHoT), 6.17
Left jerk nystagmus, 6.148*f*, 6.150
Left ventricular hypertrophy, hypertension and, 1.66
Legal blindness, 3.310–311, 3.329
Legionella pneumophila, 2.427
Legionnaires' disease, 2.427
Leigh necrotizing encephalopathy, 2.204*t*
Leiomyoma
of ciliary body, 4.199
of iris, 4.260
mesectodermal, 4.199
of orbit, 4.236–237
Leiomyosarcoma
ocular surface, 8.338*t*, 8.345
of orbit, 4.237
Leishmania (leishmaniasis), 8.252
Lemtrada. *See* Alemtuzumab
Lens (crystalline), 4.114*f*, 4.115–124, 4.116*f*
absence of, 4.117. *See also* Aphakia
age-related changes in, 11.43–48. *See also* Age-related cataracts
alcohol use/abuse and, 11.63–64
anatomy of, 2.79, 4.115*f*, 4.115–117, 4.116*f*, 11.9*f*, 11.9–13, 11.10*f*, 11.11*f*, 11.12*f*
altered, cataract surgery and, 11.179–184, 11.181*f*, 11.182*f*, 11.183*f*
early conceptions of, 11.3, 11.3*f*, 11.4*f*
biochemistry and metabolism of, 11.11, 11.14–23
bow zone/bow region of, 2.283
capsule of. *See* Lens capsule
carbohydrate metabolism in, 11.17–19, 11.18*f*
changing shape of. *See* Accommodation
chemical composition of, 2.284–286
chemical injuries affecting, 11.59
colobomas of, 11.30–31, 11.31*f*
coloration change in, 4.121–122, 11.43, 11.44*f*
congenital anomalies and abnormalities of, 4.117–118, 4.118*f*, 11.30–39, 11.30–39*f*
cortex of, 2.283, 4.116*f*, 4.117, 11.10*f*, 11.12*f*, 11.13
degenerations of, 4.121–122, 4.122*f*, 4.123*f*
topography of, 4.116*f*, 4.117
crystallins in, 2.281, 2.284–285, 11.15*f*, 11.15–16. *See also* Crystallins
cytoskeletal proteins in, 2.285
definition of, 2.79, 2.281
degenerations/degenerative ocular disorders and, 4.120*f*, 4.120–124, 4.121*f*, 4.122*f*, 4.123*f*, 4.124*f*, 11.68. *See also* Cataract
development/embryology of, 11.25–42
cataract development and. *See* Cataract, congenital
congenital anomalies and abnormalities and, 4.117–118, 4.118*f*, 11.30–39, 11.30–39*f*
developmental defects and, 11.39–42, 11.40*f*
normal, 11.25–29, 11.26–29*f*
diabetes mellitus affecting, 11.60*f*, 11.60–61. *See also* Cataract, diabetic
dislocation of, 11.39–40. *See also* Ectopia lentis
cataract surgery in patient with, 11.181–183, 11.182–183*f*
conditions associated with, 6.306*t*
description of, 6.306
ectopia lentis et pupillae, 6.267–268, 6.307, 6.307*f*
in homocystinuria, 6.308–309
illustration of, 6.306*f*
inborn errors of metabolism and, 6.306
iridodonesis with, 6.306
isolated/simple ectopia lentis, 6.307
in Marfan syndrome, 6.307–308, 6.308*f*
refractive error caused by, 6.310
in sulfite oxidase deficiency, 6.310
traumatic, 11.40, 11.54*f*, 11.54–55
treatment of, 6.310
in Weill-Marchesani syndrome, 6.309
disorders of, 4.115–124, 11.43–68. *See also* Cataract; *specific disorder*
coloboma, 6.305*f*, 6.305–306
congenital aphakia, 6.305
illusions caused by, 5.174
spherophakia, 6.305
systemic disorders and, 4.124
drug-induced changes in, 11.51–53, 11.52*f*
ectopic. *See* Ectopia lentis
electrical injury to, 11.59, 11.59*f*
embryologic development of, 2.153–155, 2.154*f*
epithelium of, 2.80, 2.82, 4.116*f*, 4.117, 11.10*f*, 11.12–13
active transport and, 11.21
degenerations of, 4.120*f*, 4.120–121, 4.121*f*, 4.122*f*
development of, 2.154*f*, 11.27, 11.27*f*
opacification of (capsular cataract), 11.38
structure of, 2.282–283
topography of, 4.116*f*, 4.117
evaluation of
before cataract surgery, 11.79–80
in glaucoma, 10.32. *See also* Lens-induced glaucoma; Lens particle glaucoma
before refractive surgery, 13.43–44
focal opacifications and, 4.121, 4.122, 4.122*f*, 4.123*f*
foreign body in, 11.57
formation of, 2.153–155, 2.154*f*
free radicals affecting, 11.19–20
generalized discoloration with loss of transparency and, 4.121–122
germinative zone of, 2.82
glaucoma and. *See* Lens-induced glaucoma; Lens particle glaucoma
glucose metabolism in, 2.290
healing/repair of, 4.17
in homocystinuria, 11.41
hyperbaric oxygen therapy associated with changes in, 11.20, 11.65
in hyperlysinemia, 11.41
infection/inflammation of, 4.118–119, 4.119*f*. *See also* Lens (crystalline), uveitis and
interdigitations, 2.286, 2.287*f*
iris-claw, 6.310
ischemic damage to, 11.68
luxed/luxated, 6.268, 6.306, 6.390*f*, 11.40. *See also* Ectopia lentis
cataract surgery in patient with, 11.181–183, 11.182*f*, 11.183*f*
traumatic, 11.40, 11.54*f*, 11.54–55
magnetic resonance imaging of, 2.459*t*, 2.460*f*
major intrinsic protein expression by, 2.283, 2.285

in Marfan syndrome, 8.193, 8.193*f*, 8.194, 11.40*f*, 11.40–41
in megalocornea, 8.100
metabolic diseases affecting, 11.60*f*, 11.60–62, 11.61*f*, 11.62*f*
metabolism in, 2.289–291
microscopic appearance of, 2.80*f*
molecular biology of, 11.15*f*, 11.15–17
nucleus of, 2.283, 4.116*f*, 4.117, 11.10*f*, 11.12*f*, 11.13
congenital cataract of, 11.38, 11.39*f*
degenerations of, 4.123, 4.123*f*, 4.124*f*
embryonic, 11.13, 11.27*f*
opacification of (congenital nuclear cataract), 11.38, 11.39*f*
emulsification of. *See* Phacoemulsification
fetal, 11.13, 11.27*f*, 11.28, 11.28*f*, 11.28–29
opacification of (congenital nuclear cataract), 11.38, 11.39*f*
opacification of. *See* Nuclear cataracts
removal/disassembly of, 11.111, 11.112–114, 11.113*f*. *See also* Cataract surgery; Lensectomy; Phacoemulsification
in ECCE, 11.196–197
in ICCE, 11.200*f*, 11.200–201
in manual small-incision cataract surgery, 11.198, 11.199*f*
in phacoemulsification, 11.111, 11.112–114, 11.113*f*
chopping techniques for, 11.114
phaco fracture for, 11.112–114, 11.113*f*
rotation of, in phacoemulsification, 11.111
topography of, 4.116*f*, 4.117
nutritional diseases affecting, 11.63–64
opacification of. *See* Cataract
organization of, 2.81*f*
oxidative damage to, 2.339–340, 11.19–20
perforating and penetrating injury of, 11.55, 11.55*f*, 11.56*f*
glaucoma and, 11.67
physiology of, 2.286, 11.20–23
plasma membranes of, 2.284
potassium in, 2.287
proteins of
description of, 2.284–285
posttranslational modifications to, 2.286
pseudoexfoliation/exfoliation syndrome and, 11.65*f*, 11.65–66
pump–leak hypothesis of solute movement in, 2.288*f*
radiation affecting, 11.57–58
radiation sensitivity of, 1.238–239
refractive index of, 2.281
removal of. *See* Cataract surgery; Lensectomy; Phacoemulsification; Refractive lens exchange
retained, cataract surgery and, 11.140–141
ruptured, removal of, 8.408–409
in schematic eye, 3.127*t*
size of, 11.11
smoking/tobacco use and, 11.63–64
sodium in, 2.287
sorbitol accumulation in, 2.291
structure of, 2.281–283, 2.282*f*
subluxed/subluxated, 11.39–40, 11.40*f*. *See also* Ectopia lentis
angle closure/pupillary block and, 10.119, 10.129–130, 10.130*f*, 10.130*t*
cataract surgery in patient with, 11.181–183, 11.182*f*, 11.183*f*
description of, 6.268, 6.306
in homocystinuria, 6.309
in Marfan syndrome, 6.308*f*
surgery for, 6.310
traumatic, 11.40, 11.54*f*, 11.54–55
sutures of, 2.82, 11.13
development of, 11.27*f*, 11.28–29
opacification of (sutural/stellate cataract), 11.37, 11.37*f*
topography of, 4.115*f*, 4.115–117, 4.116*f*
transparency of, 2.286
transport functions in, 11.21, 11.22*f*
traumatic damage to, 11.53–59, 11.54*f*, 11.55*f*, 11.56*f*, 11.58*f*, 11.59*f*
glaucoma and, 10.98
phacoantigenic uveitis and, 4.118–119, 4.119*f*, 11.66, 11.191
surgery and, 11.190–193, 11.192*f*
uveitis associated with, 4.103, 4.103*f*, 4.118–119, 4.119*f*, 4.122, 11.64*f*, 11.64–65, 11.66. *See also* Phacoantigenic (lens-associated) uveitis; Phacolytic glaucoma
hypopyon in, 9.6
types of, 9.136*f*, 9.136–137
water and cation balance in, maintenance of, 11.21, 11.22*f*
zonular fibers/zonules of, 2.82–83, 2.83*f*, 2.282, 4.115, 4.117, 11.9, 11.10*f*, 11.12
absent/abnormal
cataract surgery and, 11.179–184
iris coloboma/corectopia and, 11.180
nucleus rotation and, 11.111
in glaucoma, 10.33*t*, 10.119
in accommodation, 13.159, 13.160, 13.160*f*, 13.161, 13.161*f*
degenerations of, 4.124
development of, 11.29
evaluation of
before cataract surgery, 11.80
in glaucoma, 10.33*t*
pigment deposits on, in pigment dispersion syndrome, 10.94, 10.95*f*
in pseudoexfoliation/exfoliation syndrome, 10.92, 10.93, 10.130, 10.131*f*, 11.65–66, 11.181, 11.182*f*, 11.184
as tertiary vitreous, 4.125
topography of, 4.115, 4.117
Lens block, 10.119
Lens capsule, 2.79–80, 2.80*f*, 4.115, 4.116*f*, 11.10–12*f*, 11.11. *See also* Capsulorrhexis; Capsulotomy
anatomy of, 2.281–282, 2.282*f*, 4.115, 4.116*f*
degenerations of, 4.120
development of, 11.27, 11.27*f*
exfoliation of, infrared radiation/heat causing, 11.57
formation of, 2.154, 2.154*f*
healing/repair of, 4.17
pigment deposits in, in pigment dispersion syndrome, 10.94, 10.95*f*

rupture of
cataract formation and, 4.18. *See also* Cataract, traumatic
cataract surgery and, 11.142–143
staining, in cataract surgery, 11.178–179, 11.179*f*
structure of, 2.281–282, 2.282*f*
topography of, 4.115, 4.116*f*
ultrasound biomicroscopy of, 2.471*f*
Lens equator, 2.283
Lens-extraction procedures. *See* Refractive lens exchange
Lens fibers, 4.117
accommodation and, 11.22
description of, 2.82, 2.283
development of, 11.12*f*, 11.12–13
primary fibers, 11.26–27, 11.27*f*
secondary fibers, 11.27*f*, 11.27–28
microspherophakia and, 11.33
opacities of, 4.122, 4.122*f*
zonular (zonules of Zinn), 4.115, 4.117, 11.9, 11.10*f*, 11.12
absent/abnormal
cataract surgery and, 11.179–184
iris coloboma/corectopia and, 11.180
nucleus rotation and, 11.111
in glaucoma, 10.33*t*, 10.119
in accommodation, 13.159, 13.160, 13.160*f*, 13.161, 13.161*f*
degenerations of, 4.124
development of, 11.29
evaluation of
before cataract surgery, 11.80
in glaucoma, 10.33*t*
pigment deposits on, in pigment dispersion syndrome, 10.94, 10.95*f*
in pseudoexfoliation/exfoliation syndrome, 10.92, 10.93, 10.130, 10.131*f*, 11.65–66, 11.181, 11.182*f*, 11.184
as tertiary vitreous, 4.125
topography of, 4.115, 4.117
Lens gradient method, for accommodative convergence measurement, 5.226–227
Lens-induced glaucoma, 4.103, 4.103*f*, 4.122, 10.96–98, 10.97*f*, 10.119, 11.67–68, 11.68*f*
angle-closure glaucoma and, 10.96, 10.119, 10.128–132
in children and adolescents, 10.149*t*
open-angle glaucoma and, 10.96–98, 10.97*f*
Lens-induced granulomatous (phacoanaphylactic) endophthalmitis (phacoantigenic uveitis), 4.103, 4.103*f*, 4.118–119, 4.119*f*, 4.122, 11.66. *See also* Phacolytic glaucoma
Lens-iris diaphragm retropulsion syndrome (LIDRS), 11.138, 11.184
Lens-iris interface, angle closure/angle-closure glaucoma and, 10.118–119
Lens particle glaucoma, 10.98, 11.67
Lens pit, 2.153, 11.25, 11.26*f*
Lens placode, 11.25, 11.26*f*
Lens power, bifocal segment decentration and, 3.191
Lens proteins, 11.15*f*, 11.15–17. *See also specific type*
aging affecting, 11.17
crystallins, 11.15*f*, 11.15–16. *See also* Crystallins
cytoskeletal and membrane, 11.15*f*, 11.16–17
in phacoantigenic glaucoma, 10.98
in phacoantigenic uveitis/endophthalmitis, 10.98, 11.66, 11.191
in phacolytic glaucoma/uveitis, 4.103, 4.103*f*, 4.122, 10.96, 11.67
traumatic cataract and, 11.66, 11.192
urea-insoluble (membrane structural), 11.15*f*, 11.16–17
urea-soluble (cytoskeletal), 2.285, 11.15*f*, 11.16–17
in uveitis, 4.103, 4.103*f*, 4.122, 11.67
water-insoluble, 11.15, 11.15*f*
age affecting, 11.17
water-soluble, 11.15, 11.15*f*. *See also* Crystallins
conversion of to water-insoluble, 11.17
Lens rim artifact, in perimetry, 10.60, 10.66, 10.66*f*
Lens vesicle, 2.153–154, 2.154*f*
formation of, 11.25, 11.26*f*
Lensectomy, 6.302, 6.410. *See also* Cataract surgery
for acute angle closure, 10.125
for chronic angle closure, 10.126
for ectopia lentis, 10.130
in Marfan syndrome, 11.41
for plateau iris, 10.128
for subacute/intermittent angle closure, 10.126
Lenses. *See also* Bifocal lenses; Contact lenses; Intraocular lenses
absorptive, 3.192–194, 3.193*f*
balance, 3.198
combining of, 3.9, 3.11
contact. *See* Contact lenses
cylindrical. *See* Cylindrical lenses
effectivity of, 3.40, 3.60
high-plus-power, 12.375
intraocular. *See* Intraocular lenses
materials used in
glass, 3.195
high-index, 3.196
polycarbonate, 3.195–196
standard plastic, 3.195
Trivex, 3.196
multifocal. *See* Multifocal lenses
photochromic, 3.193, 3.193*f*
for photocoagulation, 12.375, 12.376*f*
spectacle. *See* Spectacle lenses
spherocylindrical. *See* Cylindrical lenses
ultraviolet-absorbing, 3.193–194
Lensmaker's equation (LME)
definition of, 3.41
derivation of, from Snell's law, 3.85–86
description of, 3.51–52
power comparisons using, 3.52
thin-lens approximation and, 3.54
Lensmeter, 3.169
automatic, 3.285
cylinder power measurements, 3.284, 3.284*f*
definition of, 3.282
manual, 3.283–3.284*f*, 3.283–285
pictorial representation of, 3.283*f*
prism detection using, 3.285
Lensometers. *See* Lensmeter
Lenticonus/lentiglobus, 6.296, 11.30, 11.30*f*
anterior, 4.118, 11.30
posterior, 4.118, 4.118*f*, 11.30, 11.30*f*

Lenticular astigmatism. *See also* Astigmatism
description of, 3.19
refractive surgery and, 13.45, 13.149
toric IOLs and, 13.152
as "residual" astigmatism, 3.211
Lenticular irregularities, decreased vision and, 5.99
Lenticular myopia (myopic shift), 11.43, 11.70
Lenticular optics, 3.8*f*
Lenticular refractive procedures. *See* Intraocular lenses (IOLs), for refractive errors
Lenticules, 13.59
in epikeratoplasty, 13.62
femtosecond extraction of (FLEx), 13.8*t*, 13.27–28, 13.203
graft failure and, 4.84, 4.85*f*
in keratophakia, 13.59, 13.60
refractive extraction of (ReLEx), 13.8*t*, 13.27, 13.203–206
complications of, 13.205
indications and preoperative evaluation for, 13.204
LASIK compared with, 13.206
outcomes of, 13.205
re-treatment and, 13.206
surgical technique for, 13.204–205
small-incision extraction of (SMILE), 13.8*t*, 13.28, 13.203–206. *See also* Lenticules, refractive extraction of
Lenticulostriate artery, lateral, 5.16*f*
Lentiglobus. *See* Lenticonus/lentiglobus
Lentigo maligna, 7.200
Lentigo maligna melanoma, 4.220, 4.221*f*, 7.209, 7.209*f*
Lentigo simplex, 7.197
LENTIS Mplus intraocular lens, 3.258, 13.166, 13.166*f*
"Leopard spots," 4.306, 4.308*f*
Leptochoroid, 12.19
Leptomeningeal vascular malformation, 6.401*t*
Leptospira interrogans, 9.232
Leptospirosis, 9.232–233
Leser-Trélat sign, 4.209
Lesser (minor) arterial circle, 5.15
Lesser wing of sphenoid bone, 2.6–7*f*, 2.11
Lester hooks, for pupil expansion, 11.177
Letter chart visual acuity. *See* Visual acuity
Letter tests, of contrast sensitivity, 5.88
Leukemia, 4.10, 4.10*t*, 4.11*f*, 6.218, 6.413–414
essential thrombocythemia transformation into, 1.143
neoplastic masquerade syndromes secondary to, 9.308
ocular involvement in, 4.315*f*, 4.315–316, 4.316*f*
choroid, 4.315
iris, 4.315
optic nerve/nerve head/disc, 4.316, 4.316*f*
orbit, 4.316
retina, 4.315, 4.315*f*
uvea, 4.315
vitreous, 4.315
Leukemic retinopathy, 4.315, 4.315*f*
Leukocoria, 6.299, 6.351, 6.351*f*, 6.351*t*, 12.342. *See also specific cause*
in Coats disease, 4.143*f*
in retinoblastoma, 4.291, 4.291*f*
Leukocytes (white blood cells). *See also specific cell*
basophils, 9.2–3
classification of, 9.2
cytokine effects on, 9.25
dendritic cells, 9.4–5
eosinophils, 9.2
Fc receptor expression by, 9.47
immunophenotyping of, flow cytometry for, 4.36
in inflammation, 4.7, 4.8*f*
Langerhans cells, 9.4–5
lymphocytes, 9.5
macrophages, 9.3–4
mast cells, 9.2–3
monocytes, 9.3–4
neutrophils, 9.2
oxygen metabolism by, 9.16
platelet-activating factor activation of, 9.21
Leukocyte common antigen, in immunohistochemistry, 4.34
Leukocytoclastic vasculitis, 9.125*t*
Leukoencephalopathy
with cerebral autosomal dominant arteriopathy and subcortical infarcts (CADASIL), 5.295
migrainelike headache in, 5.295
progressive multifocal (PML), 5.351*f*, 5.351–352
natalizumab causing, 5.318, 5.351
Leukomas, in Peters anomaly, 10.154, 11.31
Leukotriene inhibitors, for lung disease, 1.128
Leukotrienes, 2.408*f*
in inflammation, 9.20
Leuprolide, 1.309*t*
Levator aponeurosis, 2.28*f*, 2.34–35, 2.35*f*, 5.52, 7.165*f*, 7.165–166, 8.4*f*
ptosis and, 5.273, 5.273*t*
Levator muscle (levator palpebrae superioris/LPS), 4.202, 5.8*f*, 5.52, 7.12, 7.166
action of, 6.34*t*, 8.3
anatomy of, 2.17*f*, 2.20*f*, 2.28*f*, 2.33–35, 2.34*f*, 2.107*f*, 5.8*f*, 6.19*f*, 6.26*f*, 8.4*f*, 8.8
characteristics of, 2.19*t*, 6.21*t*, 6.22
computed tomography of, 2.456*f*
congenital ptosis caused by dystrophic development of, 5.272
innervation of, 2.21, 2.124, 5.44, 5.44*f*, 6.19
magnetic resonance imaging of, 2.460*f*
origin of, 6.21*t*, 6.22
origins of, 2.18
superior rectus muscle attachment to, 6.29
Levator palpebrae muscle, 8.3, 8.4*f*
Levobunolol, 10.171*t*, 10.176–177
in children, 10.165
description of, 2.389*t*, 2.390
Levocabastine hydrochloride, 2.412, 2.412*t*
Levocycloversion, 6.38
Levodopa, for Parkinson disease, 1.205
Levofloxacin, 2.421*t*
for bacterial keratitis, 8.269, 8.270*t*
Levothyroxine, for hypothyroidism, 1.45
Levoversion, 6.37
Lewy body dementia (LBD), 1.210
LFU. *See* Lacrimal functional unit
LGB. *See* Lateral geniculate body/nucleus
LGN. *See* Lateral geniculate body/nucleus
Lhermitte sign, in multiple sclerosis, 5.317
LHON. *See* Leber hereditary optic neuropathy

LHoT. *See* Left hypotropia
Libman-Sacks endocarditis, 1.163
Lice, ocular infection caused by, 8.255
Lid lag, in thyroid eye disease, 5.131, 5.271
Lid margin. *See* Eyelid(s), margin of
Lid-twitch sign, Cogan, 5.271, 5.324
Lidocaine, 1.291, 2.360*t*, 2.438*t*, 2.440–441
  for cataract surgery, 11.92
  for intraoperative floppy iris syndrome, 11.137
LIDRS. *See* Lens-iris diaphragm retropulsion syndrome
Lids. *See* Eyelid(s)
Lieberman speculum, for globe exposure, in cataract surgery, 11.105*f*
Life-support techniques, 1.295
Lifestyle changes, for age-related macular degeneration, 12.71
Lifestyle modifications
  for congestive heart failure, 1.99
  for diabetes mellitus, 1.35
  for hyperlipidemia, 1.74
  for hypertension, 1.57, 1.58*t*
Lifitegrast, 8.63
  for dry eye syndrome, 2.258, 2.415
Ligament of Wieger, 2.157, 12.7, 12.8*f*
Ligaments. *See specific ligament*
Light. *See also specific aspect*
  coherence of, 3.99–102
  corneal reflex to, corneal vertex and, 8.25, 8.26*f*
  definition of, 3.93
  diffraction of, 3.104–106, 3.105*f*
  eye injury caused by. *See* Light toxicity/photic damage/phototoxicity
  frequency of, 3.93
  hazards of, 3.118–119
  interference, 3.99–102
  from lasers. *See* Laser(s)
  measurement of. *See also* Photometry; Radiometry
    candela as unit for, 3.108
    overview of, 3.106–107
    photometry, 3.108–110, 3.109*t*
    radiometry, 3.107*t*, 3.107–108, 3.110
  particle theory of, 3.94
  paths for, 3.119
  phenomena of, 3.98–106
  polarization of, 3.98–99
  propagation of, 3.119
  properties of, 3.106
  pupillary response to. *See* Pupillary light reflex
  reflection of, 3.96. *See also* Reflection
  refraction of, 3.96
  scattering of
    age-related increase in, 3.98
    definition of, 3.96–97
    geometric, 3.97–98
    Mie, 3.92, 3.97–98
    Rayleigh, 3.92, 3.97
    Tyndall effect and, 3.97
  spectral bandwidth of, 3.102
  unpolarized, 3.98
  visible, 3.93, 3.94*t*
  wave nature of, 3.71
  wave theory of, 3.94–95, 3.95*f*
  wavelength of, 3.93, 3.94*t*
  wave–particle duality of, 3.94
Light adaptation
  in electro-oculography, 12.50
  in full-field (Ganzfeld) electroretinography, 12.42
  spectral luminous efficiency function in, 3.109
Light-adjustable intraocular lenses, 13.153–154, 13.154*f*
Light Adjustable Lens (LAL), 13.170
Light amplification by stimulated emission of radiation (LASER). *See* Laser(s)
Light chains, immunoglobulin, overproduction of, crystalline corneal deposits and, 8.198
Light-gathering power. *See* Transverse magnification
Light-near dissociation, 5.254, 5.266*t*, 5.266–267
  Adie tonic pupil and, 5.263, 5.264*f*, 5.266*t*
  in dorsal midbrain (Parinaud) syndrome, 5.229, 5.230*f*, 5.266*t*, 5.266–267
Light rays. *See* Ray(s)
Light reflex. *See* Pupillary light reflex
Light sensitivity. *See also* Photophobia
  after LASIK with femtosecond laser flap creation, 13.123
Light toxicity/photic damage/phototoxicity
  cataract surgery and, 11.166
  ophthalmic instrumentation causing, cataract surgery and, 11.166
Lighthouse chart, 6.7
Lightning injuries, 12.357
Lightning streaks of Moore, 5.175
Ligneous conjunctivitis, 6.249, 8.294*f*, 8.294–295
Lignocaine. *See* Lidocaine
Likelihood ratio, 1.19, 2.188
Limbal dermoids, Goldenhar-Gorlin syndrome and, 8.195, 8.195*f*
Limbal (epibulbar) dermoids, 4.6, 4.47, 4.49*f*
Limbal groove, for ECCE, 11.196
Limbal incision, 6.163
Limbal palisades of Vogt, 2.56*f*
Limbal relaxing incisions (LRIs), 13.8*t*, 13.27*f*, 13.53–58, 13.54*f*, 13.55*f*, 13.56*f*, 13.56*t*, 13.57*f*
  cataract surgery and, 11.123–124
  complications of, 13.58
  instrumentation for, 13.55, 13.56*f*
  ocular surgery after, 13.58
  outcomes of, 13.57
  refractive lens exchange and, 13.149
  technique for, 13.55–57, 13.56*t*, 13.57*f*
Limbal stem cells, 8.8, 8.10–11, 8.92. *See also* Limbal transplantation
  in aniridia, 10.155
  in corneal epithelium maintenance, 8.8, 8.362
  deficiency of, 8.92–94, 8.93*t*, 8.94*f*, 8.362
  in graft-vs-host disease, 8.304
  repopulation and. *See* Limbal transplantation
  toxic insults/toxic keratoconjunctivitis from medications and, 8.91, 8.224
  transplantation of. *See* Limbal transplantation
Limbal transplantation (limbal autograft/allograft/stem cell transplantation), 8.94, 8.351*t*, 8.362–365, 8.363–364*f*
  for chemical injuries, 8.380, 8.384
  indications for, 8.351*t*

simple epithelial (SLET), 8.365
for chemical injury, 8.384
for pterygium, 8.355
Limbal vernal keratoconjunctivitis, 6.248, 6.249*f*, 8.289–290, 8.290*f*
Limbal zone, corneal, 8.25, 8.25*f*. *See also* Limbus
Limbic system (cingulate gyrus), 5.52
Limbus, 8.10–11, 8.11*f*, 8.25, 8.25*f*. *See also under Limbal*
alkali burns affecting, 8.379, 8.379*f*, 8.380*f*
anatomy of, 2.55–56, 2.56*f*
definition of, 2.49
marginal corneal infiltrates and, 8.310–311
blepharoconjunctivitis and, 8.74, 8.74*f*
squamous cell carcinoma of, 8.336, 8.336*f*
Limbus-based conjunctival flap, for trabeculectomy, 10.200, 10.202*f*
closure of, 10.204, 10.206*f*
in elderly patients, 10.221
Lime, ocular injury caused by, 8.376*t*
Limiting membranes
external (ELM), 4.140*f*, 4.141*f*
anatomy of, 12.15
histology of, 12.11, 12.12*f*
internal (ILM), 4.140*f*
amacrine cells in, 12.15
anatomy of, 12.15
epiretinal membranes, 12.332
hemorrhagic detachment of, 12.171
histology of, 12.11, 12.12*f*
nonproliferative sickle cell retinopathy findings, 12.150
peeling of, 12.209
in retinal healing/repair, 4.17
vitreous detachment and, 4.129
vitreous remnants on, 12.332
middle
anatomy of, 12.15
definition of, 12.16
histology of, 12.11, 12.12*f*
Lincoff rules, 12.320, 12.322*f*
Linear deposits, basal, in age-related macular degeneration, 4.160, 4.162
Linear IgA dermatosis, 8.301
Linear incisions, for keratorefractive surgery, 13.27
Linear magnification, 3.62. *See also* Transverse magnification
Linear nevus sebaceous syndrome, 4.47, 4.48
Linearly polarized light, 3.95*f*, 3.98
LINEs. *See* Long interspersed elements
Lingua plicata, in Melkersson-Rosenthal syndrome, 5.280
Lingual nerve, 5.276–277*f*
Linkage disequilibrium, 2.175, 9.64
Lipid keratopathy, 8.125–126, 8.126*f*
corneal crystal deposition in, 8.182*t*
in herpes zoster, 8.125, 8.228, 8.228*f*
Lipid layer of tear film, 2.249–250, 2.250*f*, 8.5, 8.6*f*
interferometry in evaluation of, 8.40, 8.40*f*
Lipid-lowering therapy. *See also specific agent*
agents used in, 1.75*t*, 1.76–77
atherosclerotic lesions reduced with, 1.89
low-density-lipoprotein cholesterol reductions using, 1.74, 1.75*t*
statins for, 1.75*t*, 1.76–77
Lipid management, coronary heart disease risk modification using, 1.73*t*
Lipid peroxidation, 2.336–338
in lens opacification, 11.19
Lipid solubility, 2.357
Lipid strip, 2.249
Lipidoses, 6.388*t*. *See also* Lipids, metabolism and storage of
Lipids
disorders of, xanthelasma associated with, 4.206
in Fleck corneal dystrophy, 8.153
metabolism and storage of, disorders of (lipidoses), 8.179–181, 8.180*f*
corneal changes in, 8.179–181, 8.180*f*
arcus and, 8.120, 8.121, 8.179
in Schnyder corneal dystrophy, 8.151, 8.179
mucolipidoses and, 8.178
as ocular hypotensive agents. *See* Prostaglandin (PG) analogues
in retinal pigment epithelium, 2.324
in tear film. *See* Lipid layer of tear film
Lipodermoids (dermolipomas), 7.41, 7.42*f*
description of, 4.47–48, 4.48*f*, 6.210, 6.256–257
Goldenhar syndrome and, 4.48
Lipofuscin, 2.98, 2.328, 6.340, 9.89
accumulation of, in cornea farinata, 8.122
fundus autofluorescence and, 5.89–90
in lysosomes, 12.31
in retinal pigment epithelium, 4.141, 12.32
Lipofuscin-like material/lipoprotein, in pre-Descemet corneal dystrophy, 8.155
Lipomas, of orbit, 4.238
Lipopolysaccharide (LPS)
animal models of, 9.8
bacterial, 8.244. *See also* Endotoxin
components of, 9.7
gut release of, 9.8
inflammatory response induced by injection of, 9.8–9
in innate immune response activation, 9.7–8
in neutrophil activation, 9.12
ocular effects induced by, 9.8
Lipoproteins
cholesterol transport by, 1.72
corneal arcus and, 8.120, 8.121, 8.179
corneal changes in disorders of metabolism of, 8.179–181, 8.180*f*
definition of, 1.72
drugs affecting metabolism of. *See* Lipid-lowering therapy
Liposarcomas, 7.91
of orbit, 4.238
Liposomes, for drug delivery, 2.366
Liposuction, neck, 7.274–275, 7.275*f*
Lipoxin, 9.20
5-Lipoxygenase
in arachidonic acid oxidation, 9.19
derivatives of, 9.20
Lisch epithelial corneal dystrophy (LECD), 8.135*t*, 8.136*t*, 8.140, 8.140*f*

Lisch nodules, 2.220, 4.259, 4.260*f*, 5.330*f*, 5.334*t*, 6.271–272, 6.272*f*, 6.392, 6.395*f*, 6.397
Lissajous figures, 3.98
Lissamine green, 8.37, 8.38*f*
in ocular surface evaluation, 8.37, 8.38*f*
in tear film/dry eye evaluation, 8.37, 8.56
Listeria monocytogenes, invasive capability of, 8.207
Listing's law, 6.31
Listing's plane, 6.31
Lithium carbonate, 1.203
Live-attenuated influenza vaccine (LAIV), 1.227
Liver abscesses, endogenous bacterial endophthalmitis and, 12.238
Liver disease, 1.145. *See also* Hepatitis
metastatic uveal melanoma causing, 4.196, 4.272, 4.273
retinal degeneration associated with, 12.285
Liver transplantation, 1.226
Livostin. *See* Levocabastine
LK (lamellar keratoplasty). *See* Keratoplasty, lamellar
LME. *See* Lensmaker's equation
LMs. *See* Lymphatic malformations
LMWH. *See* Low-molecular-weight heparin
LMX1B gene, 10.11*t*
LN. *See* Latent/manifest latent nystagmus (LN/MLN)
Loa loa (loiasis), 8.253, 8.282, 8.282*f*, 9.290
orbital involvement and, 4.228
Lobular capillary hemangioma. *See* Pyogenic granuloma
LOC387715 gene, in age-related macular degeneration, 4.160
Local administration, of drugs, 2.359–361
Local anesthesia/anesthetics. *See also* Anesthesia (anesthetics), local
abuse of, 8.89*f*, 8.89–90
adverse reactions to, 8.90*t*
agents for
description of, 1.290–291
dosing of, 1.305*t*
toxic reactions to, 1.304–306
for cataract surgery, 11.92
composition of, 2.438
epinephrine added to, 1.305
intraocular surgery use of, 2.441–442
intraoperative considerations for, 1.290–291
mechanism of action, 2.439
overview of, 2.437–440
for penetrating and perforating trauma repair, 8.403–404
peribulbar anesthesia, 2.442
peribulbar injection of, 1.304
for phakic IOL insertion, 13.141
for photoablation, 13.82
regional anesthetics, 2.438*t*
retrobulbar anesthesia, 2.442
retrobulbar injection of, 1.290–291, 1.304
topical, 2.439*t*, 2.439–440, 2.441–442
toxic manifestations of, 2.439
types of, 2.440–441
Localized (circumscribed) choroidal hemangioma, 4.197, 4.198*f*, 4.281, 4.282*f*
Lockwood ligament, 2.34*f*, 2.35, 6.28, 7.165
Locus vacuus, 11.3, 11.3*f*
Lodoxamide
description of, 2.412*t*, 2.412–413
for hay fever conjunctivitis, 8.289
Löfgren syndrome, 1.162, 9.195
Logarithm of odds score, 2.188
LogMAR, 3.132
cystoid macular edema after cataract surgery and, 11.164
visual acuity chart, 6.7*f*, 6.8
LoGTS (Low-Pressure Glaucoma Treatment Study), 10.88
Long arm 13 deletion syndrome, 2.226–227
Long-chain polyunsaturated fatty acids (LCPUFAs), 12.70
Long ciliary arteries, 5.13*f*, 5.14*f*, 5.15, 5.15*f*
Long ciliary nerve, 5.53*f*, 7.14
lacrimal functional unit innervated by, 8.5*f*
Long interspersed elements (LINEs), 2.177
Long posterior ciliary artery, 2.24*f*
Long-wavelength sensitive cones. *See* L cones
Longitudinal (axial) magnification, 3.39, 3.63–64. *See also* Magnification
Longitudinal ciliary muscle, 2.25*f*
Longitudinal fasciculus, medial (MLF), 5.35, 5.35*f*, 5.38
diplopia caused by disruption of, 5.189–191, 5.190*f*
dissociated nystagmus caused by lesions of, 5.247
horizontal gaze and, 5.37, 5.38
rostral interstitial nucleus of (riMLF), 5.33, 5.35, 5.35*f*, 5.220
saccadic eye movements and, 5.220
vertical gaze and, 5.36, 5.36*f*
vertical gaze and, 5.36, 5.36*f*
Longitudinal scans, 2.464, 2.466*f*, 2.468–469*f*
Longitudinal (spin-lattice) relaxation time (T1), 5.62, 5.63*t*, 5.76
Loop diuretics, 1.59*t*, 1.59–60
Loop of Meyer, 5.24*f*, 5.29, 5.155
lesions affecting, 5.155, 5.155*f*
Loracarbef, 1.273
Los Angeles Latino Eye Study, 1.12
Loss of heterozygosity, 2.184
Lotemax. *See* Loteprednol etabonate
Loteprednol etabonate, 2.400*t*, 2.403, 2.411
Loteprednol etabonate/tobramycin, 2.422*t*
Louis-Bar syndrome (ataxia-telangiectasia/AT), 2.181, 5.330, 5.332*f*, 5.334*t*, 6.393*t*, 6.403*f*, 6.403*t*, 6.403–404, 8.115*t*, 8.346
Loupes, 3.322
Louse. *See* Lice
Lovastatin, 1.75*t*
Low birth weight, retinopathy and. *See* Retinopathy of prematurity
Low-coherence interferometry, 3.102, 3.304, 8.21
Low-coherence light, in optical coherence tomography, 12.25
Low-density DNA microarray, 4.41
Low-density-lipoprotein cholesterol (LDL-C). *See also* Cholesterol
corneal arcus and, 8.121, 8.179
coronary heart disease prevention in, 1.71
lipid-lowering therapies for, 1.74–77, 1.75*t*
pathogenesis of, 1.72
reducing levels of. *See* Lipid-lowering therapy

Low-frequency ultrasound, 2.462
Low-molecular-weight heparin (LMWH). *See also* Heparin
coronary heart disease treated with, 1.91*t*
description of, 1.149
Low-order Zernike polynomials, 3.73, 3.73*f*
Low-Pressure Glaucoma Treatment Study (LoGTS), 10.88
Low-tension glaucoma, 1.66–67, 10.3, 10.4*t*, 10.85*f*, 10.85–88, 10.86*t*. *See also* Glaucoma, normal-tension
Low vision, 3.311–325. *See also* Blindness; Vision loss/impairment; Vision rehabilitation
assessment of, 5.77–97
adjunct testing in, 5.88–97
Amsler grid testing in, 5.84
associated symptoms and, 5.78
color vision and, 5.78–79
confrontation testing in, 5.83–84
contrast sensitivity and, 5.88
electrophysiologic testing in, 5.95–97, 5.96*f*
electroretinography in, 5.96*f*, 5.96–97
fluorescein angiography in, 5.89, 5.89*f*
fundus examination in, 5.81–82, 5.82*f*, 5.83*f*
history in, 5.78–79
neuroimaging in, 5.71
nonorganic disorders and, 5.301–311, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*, 5.307*f*, 5.308*f*, 5.309*f*
OCT in, 5.90–94, 5.91*f*, 5.92*f*, 5.93*f*, 5.93–94*f*
perimetry in, 5.84–88, 5.85*f*, 5.87*f*
photostress recovery testing in, 5.88
potential acuity meter testing in, 5.88–89
pupillary testing in, 5.79*f*, 5.79–81
refraction in, 5.78
time course and, 5.77–78
ultrasonography in, 5.95
visual acuity testing in, 5.78
visual evoked potential testing in, 5.95
visual field testing in, 5.83–88, 5.85*f*, 5.87*f*. *See also* Visual field testing
central visual field and, 5.85, 5.85*f*
bilateral/binocular, 5.77
nonorganic disorders and, 5.306–308, 5.307*f*, 5.308*f*, 5.309*f*
central visual field and, 5.85, 5.85*f*
chiasmal lesions causing, 5.146–152. *See also specific disorder*
in children, 3.327–328
classification of, 5.99–159. *See also specific causative factor*
communication with patients with, 3.326*f*, 3.326–327
definition of, 3.310
evaluation of
central visual field, 3.315, 3.317
Charles Bonnet syndrome, 3.312
contrast sensitivity, 3.314–315, 3.316*f*
elements of, 3.311–312
fixation, 3.313, 3.314*f*
glare assessments, 3.318
history-taking in, 3.312
ocular history, 3.312
ophthalmic evaluation *versus*, 3.311–312
peripheral visual field, 3.318
refraction, 3.314, 3.315*f*
visual function assessments, 3.313–318*f*, 3.313–318
visual task performance, 3.318–319
fundus autofluorescence in, 5.89–90, 5.90*f*
in infants, 3.327–328
information sources on, 6.189*t*
interventions for
devices, 3.318–325, 3.321–3.322*f*
electronic devices, 3.323, 3.324*f*
higher adds, 3.320
magnifiers, 3.320–322, 3.321*f*
nonoptical aids, 3.323
telescopes, 3.322*f*, 3.322*t*, 3.322–323
video magnifiers, 3.323, 3.324*f*
management of, 5.99–159. *See also* Low vision aids; Vision rehabilitation; *specific causative factor*
nonorganic disorders causing, 5.299*t*, 5.299–312
afferent visual pathways and, 5.301–305, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*
clinical profile of patient with, 5.300
examination techniques in, 5.301–311, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*, 5.307*f*, 5.308*f*, 5.309*f*
eyelid position/function and, 5.310–311
malingering and, 5.299
management of, 5.311
ocular motility/alignment and, 5.309–310
organic disorders misdiagnosed as, 5.299, 5.299*t*
pupils/accommodation and, 5.310
optic neuropathy causing, 5.103–146. *See also* Optic neuropathy
overview of, 3.311
rehabilitation for, 6.188–189, 6.189*t*, 12.86, 12.260
retrochiasmal lesions causing, 5.152–158
therapies for, 12.86
unilateral/monocular, 5.77
nonorganic disorders and, 5.302–305, 5.303*f*, 5.304*f*, 5.305*t*
Low vision aids. *See also* Vision rehabilitation
for cataract, 11.71
Lowe disease/syndrome (oculocerebrorenal syndrome)
congenital corneal keloids in, 8.107, 8.125
description of, 2.232*t*, 4.118, 6.391
Lower eyelids. *See also* Eyelid(s); *specific disorders*
anatomy of, 2.26, 7.160*f*
arterial arcade of, 7.171
blepharoplasty of
infraciliary incision for, 7.262
laser skin resurfacing with, 7.268
midface rejuvenation with, 7.271–272, 7.272*f*
orbital fat redraping with, 7.272*f*
technique for, 7.261–262, 7.262*f*
transconjunctival incision for, 7.261, 7.262*f*
vision loss secondary to, 7.262
cicatricial entropion of, 7.237*f*
defects involving, reconstruction of, 7.222–225, 7.223–224*f*
development of, 2.163
entropion of, 7.234
epiblepharon of, 7.178*f*
hyaluronic acid filler application to, 7.270*f*
inferior rectus muscle attachment to, 6.30*f*
laceration of, 7.217*f*
milia of, 7.189, 7.189*f*

muscles of, 2.35
orbital septum, 7.163
punctum of, 2.42
retractors of
anatomy of, 7.167, 7.167*f*
surgical repair of, 7.232, 7.236*f*
sebaceous hyperplasia of, 7.191*f*
squamous cell carcinoma of, 7.206*f*
tightening surgery for, 7.231, 7.232*f*
transcutaneous incision of, 7.126*f*
xanthelasmas of, 7.190, 7.190*f*
Lower face rejuvenation, 7.272–273
Lower-order aberrations, 13.11, 13.11*f*
LOXL1 (lysyl oxidase–like) gene
description of, 2.183
in pseudoexfoliation/exfoliation syndrome, 4.102, 10.11*t*, 10.91
LPS. *See* Lipopolysaccharide
LPS (levator palpebrae superioris). *See* Levator muscle
LR. *See* Lateral rectus (LR) muscle
LRAT. *See* Lecithin retinol acyltransferase
LRIs. *See* Limbal relaxing incisions
LRP5 gene, 12.345*f*
LSL. *See* Laser suture lysis
LTBP2. *See* Latent transforming growth factor beta-binding protein 2
LTBP2 gene, 6.277
in glaucoma, 10.150
LTK. *See* Laser thermokeratoplasty
LTP. *See* Laser trabeculoplasty
Lubricants. *See also* Artificial tears
for chemical injuries, 8.383
for conjunctivochalasis, 8.86
for dellen, 8.79, 8.92
for graft-vs-host disease, 8.304
for neurotrophic keratopathy/persistent corneal epithelial defects, 8.81, 8.224, 8.230
for peripheral ulcerative keratitis, 8.312–313
for recurrent corneal erosions, 8.87
for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297, 8.298
for thermal injuries, 8.385
Lucentis. *See* Ranibizumab
Luetic keratitis/interstitial keratitis, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*. *See also* Syphilis
LUM (lumican) gene
in cornea plana, 8.100
in posterior amorphous corneal dystrophy, 8.136*t*
Lumbar puncture, in aneurysm evaluation, 5.195, 5.340–341
Lumboperitoneal shunting, for idiopathic intracranial hypertension, 5.112, 5.113
Lumen (lm), 3.108
Lumican, 8.9
mutation in gene for
in cornea plana, 8.100
in posterior amorphous corneal dystrophy, 8.136*t*
Lumigan. *See* Bimatoprost/timolol maleate
Luminance (L_v)
description of, 3.109, 3.109*t*
perimetry results affected by, 10.60
Luminous exitance, 3.108
Luminous flux, 3.108
Luminous intensity, 3.108
Lung cancer
cancer-associated retinopathy and, 5.102
eye involvement and, 4.197, 4.198*f*, 4.304, 4.304*t*, 4.308–309, 4.309*f*
mortality rates for, 1.220
paraneoplastic-induced saccadic intrusions and, 5.249
screening for, 1.216*t*, 1.220
Lung diseases. *See also* Pulmonary diseases
asthma, 1.123–124, 1.128–130, 1.129*f*
evaluation of, 1.125–126
obstructive, 1.123–125
chronic obstructive pulmonary disease, 1.124, 1.285
description of, 1.123
irreversible, 1.124
reversible, 1.123–124
pathologic processes, 1.123
perioperative management for ocular surgery in patients with, 1.284
restrictive, 1.125
symptoms of, 1.124
treatment of
algorithm for, 1.129*f*
anticholinergics, 1.128
β_2-adrenergic agonists, 1.128
bronchodilators, 1.128
corticosteroids, 1.128
inflammation inhibitors, 1.128
leukotriene inhibitors, 1.128
noninvasive pressure support ventilation, 1.126–127
nonpharmacologic, 1.126–127
pharmacologic, 1.127–130
Lupus choroidopathy, 9.154, 9.155*f*
Lupus erythematosus. *See* Systemic lupus erythematosus (SLE)
Lupus retinopathy, 9.154, 9.155*f*
Lupus vasculitis, 12.230–231, 12.231*f*
Lutein, 2.94
age-related macular degeneration managed with, 12.70*t*
cataract risk affected by, 11.7
description of, 12.367
Luxed/luxated lens, 11.40. *See also* Ectopia lentis
cataract surgery in patient with, 11.181–183, 11.182*f*, 11.183*f*
traumatic, 11.40, 11.54*f*, 11.54–55
Lye, ocular injury caused by, 8.376*t*
Lyme disease (LD)/Lyme borreliosis, 5.352–353, 5.353*f*, 8.249, 12.245–246
antibiotics for, 9.230, 9.231*t*
clinical features of, 9.227–229, 9.228*f*
corticosteroids for, 9.230
definition of, 9.227
diagnosis of, 9.230
epidemiology of, 9.227
erythema chronicum migrans associated with, 9.227–228, 9.228*f*
facial palsies and, 5.279–280

HLA-DR4 and, 9.228
keratitis in, 9.229
neuro-ophthalmic manifestations of, 9.229
ocular involvement in, 9.229, 9.229*f*
ocular manifestations of, 5.115, 5.352
optic neuritis and, 5.115
stage 1, 9.227–228, 9.228*f*
stage 2, 9.228
stage 3, 9.228–229
treatment of, 9.230, 9.231*t*
vitritis in, 9.229, 9.229*f*
Lymph node biopsy, in conjunctival/ocular surface melanoma, 8.344
Lymphadenopathy, in ocular surface neoplasia, 8.328
Lymphadenopathy-associated virus (LAV). *See* HIV (human immunodeficiency virus)
Lymphangiectasia, conjunctival/ocular surface, 8.348
Lymphangiogenesis, in corneal transplant rejection, 8.317
Lymphangiomas. *See also* Lymphatic malformations
conjunctival/ocular surface, 8.348
description of, 6.221, 7.14
Lymphatic malformations (LMs), 7.73*f*, 7.73–74
conjunctival/ocular surface, 8.348
orbital, 4.233, 4.234*f*, 6.221–222
Lymphatic system
description of, 9.30
of eyelids, 2.38, 2.39*f*, 7.170–171
of orbit, 7.14
Lymphatic/lymphocytic/lymphoid tumors. *See also* Lymphoproliferative disorders; *specific type*
conjunctival/ocular surface, 4.69–71, 4.70*f*, 4.71*f*, 8.348–350, 8.349*f*, 8.350*f*
Lymphedema, 7.184, 7.184*f*
Lymphocyte(s), 4.8*f*, 4.9
activation of, 9.30
B. *See* B cell(s)
characteristics of, 9.5
effector, 9.36
homing of, 9.38
sensitization of, 9.30
surface markers of, 9.5
T. *See* T cell(s)
Lymphocyte function–associated antigen-1 (LFA-1), 2.258, 2.415
Lymphocyte inhibitors, 2.406*t*
Lymphocytic choriomeningitis virus (LCMV), 6.413, 9.261
Lymphocytic hypophysitis, 5.335
Lymphogranuloma venereum, 8.260
Lymphoid follicle, conjunctival, 4.47, 4.50*f*, 4.51, 4.51*f*, 4.69, 4.70, 4.70*f*
Lymphoid folliculosis, benign, 8.48, 8.49*f*
Lymphoid hyperplasia (lymphoid infiltration/reactive lymphoid hyperplasia [RLH]/benign lymphoid pseudotumor/pseudolymphoma). *See also* Lymphoproliferative disorders
of conjunctiva/ocular surface, 4.69–70, 4.70*f*, 8.327, 8.348–349, 8.349*f*
lymphoma and, 8.327, 8.348, 8.349
description of, 7.94
of orbit, 4.231, 4.232. *See also* Lymphomas, orbital
atypical, 4.231, 4.232
of uveal tract (primary choroidal lymphoma/uveal lymphoid proliferation/infiltration/lymphoma), 4.199, 4.199*f*, 4.313–314
Lymphoid proliferation, uveal, 4.199, 4.199*f*, 4.313–314
Lymphoid pseudotumor/pseudolymphoma, benign. *See* Lymphoid hyperplasia
Lymphoid tissues
immunoregulation in, 8.12–13*f*
mucosa-associated (MALT), 4.47, 4.69
of conjunctiva (conjunctiva-associated/CALT), 4.47, 4.69, 8.7
lymphoma of (extranodal marginal zone lymphoma/MALToma)
of conjunctiva, 4.70, 4.71*f*, 8.349–350, 8.350*f*
of orbit, 4.232, 4.233*f*
Lymphoid/lymphocytic/lymphatic tumors. *See also* Lymphoproliferative disorders; *specific type*
conjunctival/ocular surface, 4.69–71, 4.70*f*, 4.71*f*, 8.348–350, 8.349*f*, 8.350*f*
Lymphomas, 4.10, 4.10*t*, 4.11*f*, 4.231
adnexal, 4.231, 4.232, 4.233*f*
Burkitt, 6.218
choroidal (uveal lymphoid hyperplasia/proliferation/infiltration), 4.199, 4.199*f*, 4.313–314
conjunctival/ocular surface, 4.70*f*, 4.70–71, 4.71*f*, 8.349–350, 8.350*f*
lymphoid hyperplasia and, 8.327, 8.348, 8.349
extranodal marginal zone (mucosa-associated/MALToma)
of conjunctiva, 4.70, 4.71*f*, 8.349–350, 8.350*f*
of orbit, 4.232, 4.233*f*
in HIV infection/AIDS, 5.349
intraocular, 12.233–234, 12.234*f*. *See also* Lymphomas, primary central nervous system/intraocular/vitreoretinal/retinal
mucosa-associated (MALToma/extranodal marginal zone)
of conjunctiva, 4.70, 4.71*f*, 8.349–350, 8.350*f*
of orbit, 4.232, 4.233*f*
ocular adnexal, 4.231, 4.232, 4.233*f*
orbital, 4.231, 4.232, 4.233*f*, 6.218
diffuse large B-cell, 7.92
extranodal marginal zone B-cell, 7.92, 7.95
follicular, 7.92, 7.95
malignant, 7.94
mantle cell, 7.92
non-Hodgkin. *See* Non-Hodgkin lymphoma
orbital inflammatory syndrome differentiated from, 4.225
primary central nervous system/intraocular/vitreoretinal/retinal, 4.135–136*f*, 4.135–137, 4.311*f*, 4.311–313, 4.313*f*, 5.349, 9.303, 9.304*f*. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
primary vitreoretinal, 12.233–234
age of onset, 9.303
clinical features and findings of, 9.304–305, 9.305*f*
diagnostic testing for, 9.305–306
fluorescein angiography findings in, 9.305
histology of, 9.306, 9.307*f*
incidence of, 9.303
systemic, secondary eye involvement and, 4.135*f*, 4.135–137, 4.136*f*, 4.314

uveal, 4.199, 4.199*f*, 4.313–314, 12.234, 12.235*f*
of vitreous, 4.135*f*, 4.135–137, 4.136*f*
Lymphoproliferative disorders. *See also* Lymphoid hyperplasia; Lymphomas; *specific type*
biopsy of, 7.94
of choroid, 4.199, 4.199*f*, 4.313–314
clinical presentation of, 7.93, 7.93*f*
diagnosis of, 7.93
histiocytic disorders, 7.95–97, 7.96*f*
management of, 7.94–95
non-Hodgkin lymphoma. *See* Non-Hodgkin lymphoma
of orbit, 4.231–232, 4.233*f*
lymphoid hyperplasia/lymphomas, 4.231–232, 4.233*f*
plasma cell tumors, 7.95
salmon-patch subconjunctival lesion, 7.94*f*
uveal, 4.199, 4.199*f*, 4.313–314
xanthogranuloma, 7.97
Lyonization, 2.180, 2.230–231, 2.231*f*
Lysosomal acid hydrolase, in mucolipidoses, 8.178
Lysosomal metabolic diseases, 12.291–292, 12.292*f*
Lysosomal storage disorders, 8.174–179. *See also* Mucopolysaccharidoses
corneal changes in, 8.174–179, 8.175*t*, 8.176*f*, 8.177*f*
Lysosomes
in eosinophils, 9.2
lipofuscin in, 12.31
in neutrophils, 9.2
outer segment digestion by, 12.17
Lysozyme, 7.34
serum levels of, in sarcoidosis, 5.327
Lysyl hydroxylase, in Ehlers-Danlos syndrome, 8.193
Lysyl oxidase–like *(LOXL1)* gene
description of, 2.183
in pseudoexfoliation/exfoliation syndrome, 4.102, 10.11*t*, 10.91

M

M cells (magnocellular neurons/system), 5.28, 5.32, 10.42
smooth-pursuit system and, 5.224
M cones, 2.312, 2.317, 12.54
M-*flex* T intraocular lens, 13.166
M2 protein inhibitors, 1.279
M proteins, plasma cell overproduction of, 8.198
mAbs. *See* Monoclonal antibodies
MAC. *See* Microphthalmia, anophthalmia, coloboma
MAC (*Mycobacterium avium* complex) infections, neuro-ophthalmic signs of, 5.350
MacArthur Competence Assessment Tool for Treatment (MacCAT-T), 1.211
MacCAT-T. *See* MacArthur Competence Assessment Tool for Treatment
Mackay-Marg type tonometer/tonometry, 10.25
MACRA. *See* Medicare Access and CHIP Reauthorization Act
Macroadenomas, pituitary, 1.47
Macroalbuminuria, 1.39
Macroaneurysms, retinal arterial, 12.147–148, 12.148*f*
Macroautophagy, 2.283
Macrocystic, 7.73
Macrocytic anemia, 1.132–133
Macroglia, 2.317
Macroglobulinemia, Waldenström, crystalline corneal deposits in, 8.198, 8.199*f*
Macrolides. *See also specific agent*
for blepharitis, 6.245
description of, 1.274–275, 2.427
for Lyme disease, 9.231*t*
Macrophage(s), 4.7, 4.13
activation of, 9.13–16, 9.15*f*, 9.21
as antigen-presenting cells, 9.14
characteristics of, 9.3–4
epithelioid cell activation of, 9.4
functions of, 9.3
giant cell activation of, 9.4
interferon-gamma activation of, 9.42
major histocompatibility class II molecule expression by, 9.30
mediators synthesized by, 9.15
primed, 9.14, 9.15*f*
recruitment of, 9.13–16
reparative, 9.16
resting, 9.13, 9.15*f*
scavenging, 9.13
stimulated, 9.14–16, 9.15*f*
tuberculosis response by, 9.28
in wound healing/repair, 4.13
Macrophage-activating factor, 9.42
Macrophage chemotactic protein-1, 9.23*t*
Macrophage colony-stimulating factor, in mucous membrane pemphigoid, 8.299
Macropsia, 5.175
migraine and, 5.177
Macrosaccadic oscillations, 5.248, 5.248*f*
in multiple sclerosis, 5.319
Macrosquare-wave jerks, 5.248*f*
Macrostriae, in LASIK flaps, 13.113, 13.114*t*, 13.115*f*. *See also* Striae
Macugen. *See* Pegaptanib
Macula acoustica, 5.38, 5.39*f*
Macula/macula lutea, 2.93, 4.140, 4.141*f*. *See also specific Macular entries*
adaptive optics scanning laser ophthalmoscope of, 12.13*f*
age-related changes in. *See* Age-related macular degeneration/maculopathy
aminoglycoside effects on, 12.300
anatomy of, 2.83, 2.93–94, 12.9
antioxidant localization in, 2.344*f*
atrophy of
in cone dystrophies, 5.102
description of, 12.265, 12.265*f*
B-scan ultrasonography of, 2.469*f*
characteristics of, 12.10*t*
detachment of. *See* Macular detachment
diseases of, 5.99–103, 5.100*t*. *See also* Retinopathy; *specific type*
fingolimod and, 5.320, 5.322*f*
illusions and, 5.174–175
transient visual loss and, 5.164
evaluation of function of. *See* Macular function tests
fibers of, 2.111
fovea of. *See* Fovea
in glaucoma, imaging in evaluation of, 10.54

length of, 12.9
photic lesions of, 12.369
photocoagulation applications, 12.375–376
puckering of, 12.335
retinal pigment epithelium in, 4.141
schisis of, 12.328
superior, rods in, 12.12
Macula-sparing homonymous hemianopia, 5.157
Macular choroiditis, 9.274*f*
Macular colobomas, 12.266
Macular corneal dystrophy (MCD). *See* Macular dystrophies
Macular cube optical coherence tomography (OCT), 5.92, 5.93*f*
Macular degeneration. *See also* Macular dystrophies
age-related. *See* Age-related macular degeneration/maculopathy
cataract surgery in patient with, 11.80
disciform, 2.471*f*
exudative, 12.68
fall risks associated with, 1.191
genes and loci associated with, 12.256*t*
juvenile (Stargardt disease/fundus flavimaculatus), 4.168–169*f*, 170
ATP-binding cassette (ABC) transporter protein mutation causing, 4.168–169
retinal pigment epithelium in, 4.168–169*f*, 4.169–170
pinhole vision in patients with, 3.24
ultrasonographic findings in, 2.470*f*
vitelliform. *See* Macular dystrophies, vitelliform
Macular detachment
optic nerve pit with, 12.329*f*
optic pits and, 5.145
vitelliform exudative, 12.272, 12.274*f*
Macular dragging, in retinopathy of prematurity, 6.334, 6.334*f*
Macular dystrophies, 4.168–169*f*, 4.168–170, 4.171*f*. *See also specific type*
adult-onset vitelliform lesions, 12.272, 12.273*f*
atypical, 12.277
Best disease, 6.340–342, 6.342*f*, 12.51, 12.271, 12.272*f*
corneal (MCD), 4.91, 4.91*t*, 4.92*f*, 8.135*t*, 8.136*t*, 8.145*t*, 8.149–151, 8.150*f*
early-onset "drusenoid," 12.273–276, 12.274–275*f*
electroretinography findings in, 12.46, 12.47*f*
hereditary. *See specific type*
North Carolina, 12.277, 12.278*f*
occult, 12.277
pattern, 4.170, 4.171*f*, 12.276*f*, 12.276–277
Sorsby, 12.275*f*, 12.275–276
Stargardt disease, 4.168–170, 6.339–340, 6.340–341*f*
vitelliform, adult-onset, 4.170, 4.171*f*
Macular edema, 4.140, 4.152–153, 4.153–154*f*
after cataract surgery, 6.304–305
cystoid (CME). *See also* Cystoid macular edema
angiographic, after cataract surgery, 11.163–164, 11.164*f*
birdshot uveitis in, 12.224
cataract surgery as cause of, 12.157, 12.159, 12.260
central retinal vein occlusion as cause of, 12.136*f*
characteristics of, 12.156–157
corticosteroids for, 12.159, 12.393
after cataract surgery, 11.165
in cytomegalovirus retinitis, 12.235
differential diagnosis of, 12.157
drugs that cause, 12.301
edema sources in, 12.156–157
etiologies of, 12.157
fingolimod as cause of, 12.302
fluorescein angiography of, 12.36*f*, 12.157
incidence of, 12.157, 12.159
in Irvine-Gass syndrome, 12.157
nicotinic acid as cause of, 12.301
optical coherence tomography of, 12.132*f*, 12.157, 12.158*f*
petaloid, 12.157
postoperative, cataract surgery and, 11.163–165, 11.164*f*, 11.187
in glaucoma, 11.164, 11.187
after Nd:YAG laser capsulotomy, 11.157
vitreous prolapse and, 11.143–144
predisposing factors for, 12.157, 12.159
pseudophakic
definition of, 12.157
imaging of, 12.394*f*
optical coherence tomography of, 12.158*f*
pars plana vitrectomy for, 12.394*f*
in retinal dystrophies, 12.260, 12.260*f*
retinal vein occlusion as cause of, 12.135. *See also* Retinal vein occlusion (RVO)
retinitis pigmentosa and, 12.260
spontaneous resolution of, 12.159
subretinal diseases that cause, 12.157
taxanes as cause of, 12.301
treatment of, 12.159
vision loss caused by, 12.225
vitrectomy for, 12.159, 12.393, 12.394*f*
diabetic (DME)
cataract surgery and, 11.80, 11.189, 12.116
center-involved, 12.92, 12.109, 12.110*f*
classification of, 12.109–110, 12.110*f*
clinically significant, 12.92, 12.110, 12.114
contrast sensitivity issues in, 12.56
definition of, 12.92
focal, 12.110
mechanism of, 12.108, 12.109*f*
non–center-involved, 12.109, 12.111*f*
optical coherence tomography of, 12.111*f*
spectral-domain optical coherence tomography of, 12.109*f*, 12.125
treatment of
aflibercept, 12.113
anti-VEGF therapy, 12.101, 12.110, 12.111–113
bevacizumab, 12.113
corticosteroids, 12.113–114
Diabetic Retinopathy Clinical Research Network findings, 12.112*f*, 12.113
intravitreal steroids, 12.101
laser surgery, 12.114–115, 12.376
overview of, 12.110–111
pars plana vitrectomy, 12.115
ranibizumab, 12.111–112, 12.112*f*
surgery, 12.114–115, 12.388
vitrectomy, 12.388
vision loss caused by, 12.94

diffuse, 12.110, 12.111*f*
drugs that cause, 12.301–302, 12.302*f*
Early Treatment Diabetic Retinopathy Study findings for, 12.99–100
focal, 12.110, 12.111*f*
in gyrate atrophy, 12.268
in intermediate uveitis, 9.70
nonsteroidal anti-inflammatory drugs for, 9.113
panretinal photocoagulation effects on, 12.106, 12.379
in pars planitis, 9.147
in tubulointerstitial nephritis and uveitis syndrome, 9.134
uveitic
description of, 9.19
fluorescein angiography of, 9.88, 9.89*f*
optical coherence tomography of, 9.85, 9.88*f*
in phacoemulsification, 9.316
postoperative, 9.316
smoking as risk factor for, 9.321
treatment of, 9.322
Macular epiretinal membranes. *See* Epiretinal membranes
Macular exudates, 12.124*f*
Macular function tests
before cataract surgery, 11.82
retinal disease and, 11.189
before multifocal IOL implantation, 13.155, 13.166–167
Macular granuloma, 6.317*f*
Macular halo, 12.292*f*
Macular holes, 2.300, 4.131–132, 4.132*f*, 9.323
contusion injury as cause of, 12.315
fellow-eye risk for development of, 12.339
formation of, 12.339, 12.340*f*
idiopathic
description of, 12.337–339, 12.338*f*
vitrectomy for, 12.384–385, 12.385*f*
International Vitreomacular Traction Study Classification System for, 12.336*t*
lamellar, 12.28*f*
management of, 12.339–340
optical coherence tomography of, 12.27*f*
in pathologic myopia, 12.209
posttraumatic, 12.355–357, 12.356*f*
rhegmatogenous retinal detachment caused by, 12.330, 12.330*f*
spontaneous resolution of, 12.340
stage 0, 12.339
stage 1, 12.339–340
stage 2, 12.339
stage 3, 12.339
stage 4, 12.339
surgical management of, 12.339–340
Macular laser surgery. *See* Photocoagulation
Macular line scans, 5.92, 5.93*f*
Macular microperimetry, 3.310, 3.317, 3.317*f*
Macular neuroretinopathy, acute (AMN)
fundus autofluorescence in identification of, 5.90
OCT in identification of, 5.92, 5.93*f*
Macular pits, 12.356
Macular pucker, 2.300
Macular star
in neuroretinitis, 5.118, 5.118*f*, 5.119
in toxoplasmic optic neuritis, 5.352
Macular telangiectasia
early, 12.277
type 1, 12.161
type 2, 12.161–164, 12.162–164*f*
type 3, 12.164–165
volume rendering of, 12.31
Macular translocation surgery, 12.85
Macule
of eyelid, 8.45*t*
hypopigmented (ash-leaf spot), in tuberous sclerosis, 5.331*f*, 5.334*t*, 10.30
Maculopathies, 5.99–103, 5.100*t*. *See also* Retinopathy; *specific type*
acute exudative polymorphous vitelliform, 12.287
acute idiopathic (AIM), 12.228–229
adult-onset vitelliform
fluorescein angiography of, 12.68
spectral-domain optical coherence tomography of, 12.67–68, 12.68*f*
age-related. *See* Age-related macular degeneration/maculopathy
bull's-eye
chloroquine toxicity as cause of, 12.295, 12.296*f*
clofazimine as cause of, 12.298
in cone dystrophies, 5.102
in neuronal ceroid lipofuscinoses, 12.289
cellophane, 12.335
color vision testing in, 5.78–79, 5.99
hypotony, 10.210, 12.201
antifibrotic use and, 10.205
optic neuropathy differentiated from, 5.78–79, 5.99–100, 5.100*t*
optic pit, 12.328–329, 12.329*f*
paracentral acute middle (PAMM), 12.143
MAD. *See* Minimum deviation position
"Mad cow" disease (bovine spongiform encephalopathy), 5.357
Madarosis, 7.187, 7.202, 7.202*f*
in staphylococcal blepharitis, 8.74
Maddox rod/Maddox rod test, 3.75, 3.75*f*, 5.184, 5.184*f*
double, 5.184–185, 5.185*f*, 6.69, 6.69*f*, 6.120
in fourth nerve (trochlear) palsy, 5.198
in fourth nerve (trochlear) palsy, 5.198
in myasthenia gravis, 5.325
ocular alignment assessments using, 6.68–69, 6.69*f*
Magnesium hydroxide ($Mg[OH]_2$), ocular injury caused by, 8.376*t*
Magnetic resonance angiography (MRA), 2.455*t*, 2.458, 5.58, 5.68–69, 5.69*f*, 5.72*t*
advantages/disadvantages of/contraindications for, 5.61*t*
in aneurysm detection/evaluation, 5.194, 5.340, 5.341*f*
in arterial dissection, 5.342
in carotid artery evaluation, 5.167, 5.167*f*
carotid stenosis diagnosis using, 1.116
description of, 7.32, 7.79
in reversible cerebral vasoconstriction syndrome, 5.347
stroke evaluations, 1.112–113
in vertebrobasilar insufficiency, 5.338

Magnetic resonance imaging (MRI), 5.58–59*f*, 5.60–67, 5.61*t*, 5.62*f*, 5.63*f*, 5.63*t*, 5.64*f*, 5.65*f*, 5.65*t*, 5.66*f*, 5.67*f*, 5.72*t*
advantages/disadvantages of/contraindications for, 5.61*t*
in aneurysm detection/evaluation, 5.194–195, 5.340, 5.341*f*
in arterial dissections, 5.342
in arteriovenous malformations, 5.292*f*, 5.343–344, 5.344*f*, 7.77*f*
in carotid artery evaluation, 5.167, 5.167*f*
carotid-cavernous fistulas on, 7.78*f*
in cerebral ischemia detection/evaluation, 5.167, 5.168
in choroidal melanoma/ciliary body melanoma, 4.267
computed tomography *versus*, 2.455*t*, 2.457, 7.29*t*, 7.29–31
concerns regarding, 2.458, 2.460
contraindications for, 7.30
in coronary heart disease diagnosis, 1.88
description of, 2.453
diffusion-weighted, 1.112, 2.458, 2.461*t*
disadvantages of, 2.458
echo time, 2.457
epilepsy diagnosis using, 1.207
Erdheim-Chester disease on, 7.98*f*
ethmoid sinus squamous cell carcinoma on, 7.103*f*
fibrous dysplasia on, 7.89
functional (fMRI), 5.70, 5.75
gadolinium-enhanced T1-weighted, 7.28*f*
gray matter on, 2.458, 2.459*t*, 2.460*f*
in idiopathic intracranial hypertension, 5.111
indications for, 2.457, 2.473–476*t*, 7.300
infantile hemangiomas on, 7.72
in infiltrative optic neuropathy, 5.132
intraocular foreign body evaluations, 12.353
Langerhans cell histiocytosis on, 7.96*f*
metallic foreign bodies and, 2.458
metastatic breast carcinoma on, 7.106*f*
metastatic neuroblastoma on, 7.105*f*
microphthalmia with orbital cysts on, 7.37*f*
in multiple sclerosis, 5.65, 5.114*f*, 5.316*f*, 5.319
in NAION, 5.123, 5.123*t*
ocular anatomy on, 2.459*t*, 2.460*f*
in optic atrophy, 5.146
optic nerve glioma on, 7.80–81, 7.81*f*
optic nerve on, 6.363*f*
optic nerve sheath meningioma on, 7.85*f*
in optic neuritis/neuromyelitis optica, 5.66*f*, 5.115, 5.116, 5.123*t*, 5.322–323
orbital cellulitis on, 7.47*f*
orbital disorders on, 7.27–31, 7.28*f*, 7.29*t*, 7.30*f*
in orbital evaluation, 5.58–59*f*, 5.60–67, 5.61*t*, 5.62*f*, 5.63*f*, 5.63*t*, 5.64*f*, 5.65*f*, 5.65*t*, 5.66*f*, 5.67*f*, 5.72*t*
perfusion-weighted imaging, 1.113
pituitary tumor evaluations using, 1.48
primary vitreoretinal lymphoma evaluations, 12.234
principles of, 2.457, 7.27–28
in progressive multifocal leukoencephalopathy, 5.351, 5.351*f*
repetition time, 2.457
in retinoblastoma, 4.293
in reversible cerebral vasoconstriction syndrome, 5.347*f*
rhabdomyosarcoma on, 7.87, 7.87*f*
in sarcoidosis, 5.327
solitary fibrous tumor on, 7.89, 7.90*f*
sphenoid wing meningioma on, 7.84*f*
stroke evaluations, 1.112–113
Sturge-Weber syndrome findings, 6.402*f*
T1-weighted, 2.457, 2.460*f*, 5.58*f*, 5.62, 5.62*f*, 5.63*f*, 7.28*f*, 7.30*f*
T2-weighted, 2.457–458, 2.460*f*, 5.58*f*, 5.62, 5.62*f*, 5.63*f*, 7.28*f*, 7.30*f*
zygomycosis on, 7.51*f*
Magnetic resonance spectroscopy (MRS), 5.70
Magnetic resonance venography (MRV), 5.58, 5.69, 5.69*f*, 5.72*t*, 5.75
advantages/disadvantages of/contraindications for, 5.61*t*
in cerebral venous thrombosis, 5.69, 5.69*f*, 5.346
description of, 2.455*t*
in idiopathic intracranial hypertension, 5.111
Magnification
angular, 3.84
axial (longitudinal), 3.39, 3.63–64
devices for, 3.319–320
in indirect ophthalmoscope/ophthalmoscopy, 12.21
meridional (meridional aniseikonia). *See* Aniseikonia; Distortion
trade, 3.321–322
transverse, 3.42, 3.62, 3.300
video magnifiers for, 3.323, 3.324*f*
Magnifiers, 3.320–322, 3.321*f*. *See also* Vision rehabilitation
Magnocellular neurons (M cells/system), 5.28, 5.32, 10.42
smooth-pursuit system and, 5.224
Magnocellular nevus. *See* Melanocytoma
MAHA. *See* Microangiopathic hemolytic anemia
MAI (*Mycobacterium avium-intracellulare* complex) infections, neuro-ophthalmic signs of, 5.350
Main sensory nucleus, 2.129–130
of cranial nerve V (trigeminal), 5.47, 5.47*f*
Main sequence, 5.219
Maintained fixation, 6.6
Major amblyoscope, 6.70, 6.70*f*
Major arterial circle, 2.24*f*, 2.72, 5.15
Major depressive disorder, 1.189, 1.195, 1.202. *See also* Depression
Major histocompatibility class I molecules
$CD8^+$ T cells and, 9.30
definition of, 9.63
Major histocompatibility class II molecules
cellular expression of, 9.30
definition of, 9.63
expression of, 9.4
Langerhans cell expression of, 9.5
retinal pigment epithelium expression of, 9.57
Major histocompatibility complex (MHC). *See* Human leukocyte antigens
Major intrinsic protein (MIP/aquaporin), 2.283, 2.285, 11.16, 11.20–21
MAK-associated retinitis pigmentosa, 2.229
Malabsorption, folate deficiency caused by, 1.134

Malar rash, in systemic lupus erythematosus, 1.158, 1.159*f*
Malaria vaccination, 1.232
Malassezia furfur
as normal flora, 8.206*t*
ocular infection caused by, 8.255
Malattia Leventinese, 12.275. *See also* Drusen
Malformation. *See* Congenital anomalies; *specific type*
Malherbe calcifying epitheliomas. *See* Pilomatricoma
Malignancy. *See* Cancer
Malignant fibrous histiocytoma, 4.112
Malignant glaucoma (aqueous misdirection/ciliary block glaucoma), 2.378, 10.32, 10.139–141, 10.140*f*
cataract surgery and, 10.139, 11.139
in children and adolescents, 10.149*t*
after penetrating keratoplasty, 8.424
Malignant hypertension, 12.196
Malignant hyperthermia (MH), 1.291–292, 1.293*t*, 6.174–175
Malignant Hyperthermia Association of the United States (MHAUS), 1.292, 1.293*t*
Malignant lymphomas. *See* Lymphomas
Malignant melanoma. *See* Melanoma
Malignant meningioma, 7.86
Malignant mixed tumor, 7.100
Malignant optic gliomas of adulthood (MOGAs/glioblastomas), 4.249, 5.130–131
Malignant osteopetrosis, infantile, 6.212
Malingering, 1.197, 1.203, 5.299
Malnutrition. *See also* Nutritional deficiency
corneal changes in, 8.196–197, 8.197*f*
MALT. *See* Mucosa-associated lymphoid tissue
MALT lymphoma/MALToma. *See* Mucosa-associated lymphoid tissue (MALT) lymphoma
Malyugin ring, for pupil expansion, 11.178*f*
Mammillary body, 2.108*f*
Mammillations, iris, 6.271–272, 6.272*f*
Mammography, breast cancer detection using, 1.216–217
Mandibular branch of cranial nerve VII (facial), 5.51*f*, 5.52, 5.276–277*f*
Mandibular division of cranial nerve V (trigeminal). *See* Cranial nerve V (trigeminal nerve)
Mandibulofacial dysostosis (Treacher Collins/Treacher Collins-Franceschetti syndrome)
description of, 6.196, 6.211, 6.211*f*, 7.38*f*, 8.192*t*
eyelid manifestations of, 4.207*t*
Manganese superoxide dismutase (MnSOD), 2.342
Manhattan plot, 2.190–191, 2.192–193*f*
Mania, 1.195–196
Manic depression. *See* Bipolar disorder
Manifest exodeviations, 6.99
Manifest latent nystagmus (MLN), 5.238, 6.88, 6.95, 6.151. *See also* Latent/manifest latent nystagmus
Manifest (noncycloplegic) refraction. *See also* Refraction
after cataract surgery, 3.26
definition of, 3.21
indications for, 3.25–26
IOL power calculation and, 13.194, 13.195
pacing of, 3.38
after penetrating keratoplasty, 8.431–432, 8.432*f*
before refractive surgery, 13.39, 13.40
laser programming and, 13.40, 13.81
steps involved in, 3.21–38
accommodative control, 3.34–36
binocular balance, 3.34–36
cylinder axis refinements, 3.29–30, 3.30*f*
cylinder power refinements, 3.30–33, 3.32*f*
initial estimate of refractive error, 3.27*f*, 3.27–29
occluding of left eye and refracting of right eye, 3.26–27
occluding of right eye and refracting of left eye, 3.33–34
overview of, 3.21–22
preliminary, 3.22–26
refinements, 3.33
visual acuity testing, 3.22–25, 3.23–3.24*f*
visual history, 3.25
summary of, 3.38
Manifest strabismus, 6.15
Mann-Whitney U test, 1.7
Mannitol, 2.275, 2.397–398, 2.398*t*, 10.174*t*, 10.182–183
Mannose-binding lectin pathway, 9.17, 9.18*f*
Mannose-induced protein (MIP-133), *Acanthamoeba* keratitis and, 8.276
Mannosidosis
description of, 2.204*t*, 6.389*t*, 8.179, 12.282*t*
Mantle cell lymphoma (MCL), 7.92
Mantle zone, 4.51, 4.51*f*, 4.69
Manual lensmeter, 3.283–3.284*f*, 3.283–285
Manual small-incision cataract surgery (MSICS), 11.198, 11.199*f*
in eye with functioning filter, 11.187
in glaucoma, 11.186, 11.187
MAO inhibitors. *See* Monoamine oxidase (MAO) inhibitors
Map-dot-fingerprint dystrophy. *See* Basement membrane dystrophy, epithelial
Map lines, in epithelial basement membrane dystrophy, 8.137, 8.137*f*
Maple syrup urine disease, 2.204*t*
MAR. *See* Melanoma-associated retinopathy
MAR (minimum angle of resolution), logarithm of (logMAR), cystoid macular edema after cataract surgery and, 11.164. *See also* LogMAR
Marcaine. *See* Bupivacaine
Marcus Gunn jaw-winking syndrome/ptosis, 5.272, 5.272*f*, 6.198, 7.243, 7.246, 7.247*f*
Marcus Gunn pupil (relative afferent pupillary defect/RAPD), 5.253
in acute idiopathic blind-spot enlargement/acute zonal occult outer retinopathy/multiple evanescent white dot syndrome, 5.101
cataract surgery on patient with, 11.78
in NAION, 5.122
in ocular trauma, 8.401
in optic neuropathy *versus* maculopathy, 5.81, 5.99, 5.100*t*
in optic tract syndrome, 5.153
testing for, 5.79*f*, 5.79–81
in glaucoma evaluation, 10.30
nonorganic disorders and, 5.302
Marfan syndrome, 1.140–141, 2.212, 8.192*t*, 8.193*f*, 8.193–194, 11.40*f*, 11.40–41
cardiovascular abnormalities associated with, 6.307–308

clinical features of, 6.307, 6.308*f*
corneal changes in, 8.192*t*, 8.193*f*, 8.194
fibrillin defects in, 2.298, 8.193–194, 11.40
lens defects/ectopia lentis and, 8.193, 8.193*f*, 8.194, 10.130, 11.40*f*, 11.40–41
lens dislocation associated with, 6.307–308, 6.308*f*
lens zonular fibers in, 2.82
megalocornea and, 8.96*t*, 8.194
ocular abnormalities associated with, 6.308, 6.308*f*
pleiotropism in, 2.220
Margin, eyelid. *See* Eyelid(s), margin of
Marginal arterial arcades, 5.13*f*, 7.171
eyelids supplied by, 8.4*f*
Marginal arterial cascades, 2.34*f*, 2.37
Marginal cicatricial entropion, 7.239
Marginal corneal (catarrhal) infiltrates, 8.310–311
staphylococcal blepharitis/blepharoconjunctivitis and, 8.74, 8.74*f*
Marginal degeneration
pellucid (PMD), 4.95, 8.16*f*, 8.168*f*, 8.168–169, 8.169*f*, 8.170*f*
corneal topography in evaluation of, 8.31, 8.33*f*, 8.169, 8.170*f*
refractive lens exchange and, 13.149
refractive surgery contraindicated in, 13.24, 13.44, 13.79, 13.176, 13.176*f*
corneal topography and, 13.24, 13.44, 13.45*f*, 13.79, 13.176, 13.176*f*
Terrien, 8.122–124, 8.123*f*
Marginal entropion, 7.238
Marginal keratitis
Fuchs superficial, 8.123
in rosacea, 8.70, 8.70*f*
Marginal myotomy, 6.164*t*
Marginal tear strip (tear meniscus), inspection of, 8.56
Marginal zone, 4.69
extranodal lymphoma (MALToma) involving
of conjunctiva, 4.70, 4.71*f*, 8.349–350, 8.350*f*
of orbit, 4.232, 4.233*f*
Margin–reflex distance (MRD), 6.197
Margin–reflex distance 1 (MRD_1), 7.241–242
Margin–reflex distance 2 (MRD_2), 7.242
Marijuana, intraocular pressure affected by, 10.22
MARINA study, 12.80–81
Markers (gene). *See specific type*
Maroteaux-Lamy syndrome (MPS VI), 6.388*t*, 8.175*t*
Marsupialization, of chalazion, 7.182
MART-1 (Melan-A), in immunohistochemistry, 4.34
melanoma diagnosis and, 4.67*f*, 4.68
Masked bilateral superior oblique muscle palsy, 6.122
Masked hypertension, 1.51, 1.53
Masquerade syndromes, 9.84
chronic peripheral rhegmatogenous retinal detachment, 9.311
intraocular foreign bodies, 9.311
juvenile xanthogranuloma, 9.309
leukemia as cause of, 9.308
metastatic tumors as, 9.309
neoplastic, 9.303–309
nonneoplastic, 9.310–311
ocular ischemic syndrome, 9.310
pigment dispersion syndrome, 9.311
primary vitreoretinal lymphoma. *See* Primary vitreoretinal lymphoma
retinitis pigmentosa, 9.310
retinoblastoma, 9.308–309
systemic lymphoma as cause of, 9.307
uveal lymphoid proliferations, 9.308
uveal melanoma, 9.308
Mass casualty incidents (MCIs), 7.122
Massively parallel DNA sequencing (next-generation sequencing/NGS), 2.189, 4.39*t*
Masson trichrome stain, 4.31*t*
Mast cell(s), 2.411, 4.7
acute immunoglobulin E–mediated degranulation of, 9.48–49
characteristics of, 9.2–3
in choroid, 9.58
in conjunctival substantia propria, 9.3, 9.53
connective tissue, 9.2–3
cytokines derived from, 9.49
histamine in, 9.19
mucosal, 9.2–3
Mast-cell stabilizers, 2.411–413. *See also specific agent*
for atopic dermatitis, 8.287
for hay fever conjunctivitis, 8.288–289
for ocular allergies, 6.247*t*, 6.248
for ocular allergy, 8.287
for vernal keratoconjunctivitis, 8.291
Mastoid segment, of cranial nerve VII (facial), 5.52
Maternal infection transmission. *See specific infection*
Maternal inheritance, 2.210, 2.218. *See also* Mitochondrial DNA
Maternally inherited diabetes and deafness (MIDD), 2.185, 12.283*t*, 12.294, 12.294*f*
Matrix metalloproteinases (MMPs)
-9
description of, 2.252
in ligneous conjunctivitis, 8.294
in tear film, 8.6*f*, 8.39
in cornea, 2.264
in ligneous conjunctivitis, 8.294
in neurotrophic keratopathy/persistent corneal epithelial defects, 8.81
in recurrent corneal erosion, 8.87
in tear film, 2.252, 8.6*f*, 8.39
in vitreous from myopia patients, 2.301
Mature cataract, 11.46, 11.48*f*
phacolytic glaucoma/uveitis and, 10.97*f*, 10.97–98, 11.67
Maxidex. *See* Dexamethasone; Dexamethasone sodium phosphate
Maxilla/maxillary bone, 5.5, 5.6*f*, 5.8, 5.9*f*
Maxillary antrum, 2.8
Maxillary artery, 2.23*f*, 5.12, 5.15*f*
Maxillary bone, 2.6*f*, 2.9–10*f*, 7.7–8*f*
Maxillary division of cranial nerve V (trigeminal). *See* Cranial nerve V (trigeminal nerve)
Maxillary nerve, 7.10
Maxillary sinuses, 2.10*f*, 2.12, 2.14*f*, 5.8, 5.9*f*, 5.10*f*, 7.8*f*, 7.20
Maxilloethmoidal suture, 2.9*f*, 5.9*f*
Maxitrol. *See* Dexamethasone/neomycin sulfate/polymyxin B sulfate

Maxwell, James Clerk
electromagnetism theory by, 3.94
equations created by, 3.94, 3.96
Maze procedure, 1.103
Mazzocco foldable intraocular lens, 11.120, 11.120*f*
MCA. *See* Middle cerebral artery
McCannel sutures/technique
for IOL decentration, 11.145
for iris laceration/iridodialysis repair, 8.406, 8.408*f*
McCarey-Kaufman (MK) medium, for donor corneas, 8.414
MCD. *See* Macular dystrophies, corneal
McDonald criteria, for multiple sclerosis, 5.319
MCIs. *See* Mass casualty incidents
MCL. *See* Mantle cell lymphoma
MCP. *See* Multifocal choroiditis and panuveitis syndrome
MCP-1. *See* Macrophage chemotactic protein-1
MCV. *See* Mean corpuscular volume
MD index. *See* Mean Deviation (MD) index
MDRTB. *See* Multidrug-resistant tuberculosis
M_e. *See* Radiant exitance
Mean corpuscular volume (MCV), 1.132
Mean curvature/mean curvature map, 8.28, 8.30*f*. *See also* Cornea, topography of
Mean Deviation (MD) index, 10.65
in visual field progression identification, 10.71
Mean of the ten largest melanoma cell nuclei (MLN), 4.196, 4.196*f*
Measles (rubeola), 8.239, 8.240*t*, 9.261–263
ocular infection caused by, 8.239, 8.240*t*
Measles/mumps/rubella vaccination, 1.225*t*, 1.228–229
MECD. *See* Meesmann epithelial corneal dystrophy
Mechanical anisocoria, 5.258*t*
Mechanical epilation, 7.239
Mechanical ptosis, 7.248, 7.248*f*
Mechanical thrombectomy, for stroke, 1.113–114
Meckel cave, 2.131, 5.48
Media
ocular. *See* Optical (ocular) medium/media
refractive indices of, 3.43, 3.44*t*
Medial canthal fold, 7.176
Medial canthal tendon
anatomy of, 7.168–169, 7.282
avulsion of, 7.215
defects of, eyelid reconstruction for, 7.226, 7.227*f*, 7.228
lower limb laxity, 7.231
repositioning of, 7.174
trauma to, 7.214–215
Medial canthus, 2.27*f*
Medial geniculate nucleus, 5.18*f*
Medial lemniscus, 2.107*f*, 5.41*f*
Medial long posterior ciliary arteries, 5.15
Medial longitudinal fasciculus (MLF), 2.133, 5.35, 5.35*f*, 5.38, 6.144
diplopia caused by disruption of, 5.189–191, 5.190*f*
dissociated nystagmus caused by lesions of, 5.247
horizontal gaze and, 5.37, 5.38
rostral interstitial nucleus of (riMLF), 5.33, 5.35, 5.35*f*, 5.220
saccadic eye movements and, 5.220
vertical gaze and, 5.36, 5.36*f*
vertical gaze and, 5.36, 5.36*f*
Medial margin, of orbit, 2.8
Medial orbital fractures, 7.112–114
Medial orbital wall, 2.8, 2.9*f*, 5.7, 5.9*f*
Medial orbitotomy. *See also* Orbitotomy
description of, 7.113, 7.127
retrocaruncular incision for, 7.128–129*f*
transconjunctival incisions for, 7.128
transcutaneous incisions for, 7.128
Medial palpebral artery, 2.23*f*
Medial rectus (MR) muscle, 5.8*f*, 5.45–46, 5.46*f*, 7.12–13*f*
action of, 6.31, 6.34*t*, 6.35*f*
adduction of, 6.35*f*
anatomy of, 2.17*f*, 2.107*f*, 5.8*f*, 5.45, 5.46, 5.46*f*
botulinum toxin injection of, 6.97
characteristics of, 2.19*t*, 6.21*t*
computed tomography of, 2.456*f*
in convergence-retraction nystagmus, 5.250
displacement of, for A-pattern strabismus, 6.110, 6.111*f*
excision of, 6.146
field of action, 6.33
horizontal gaze and, 5.37*f*, 5.38
inadvertent excision of, 6.146
innervation of, 5.38, 5.44, 5.44*f*, 6.19
laceration of, 6.146
magnetic resonance imaging of, 2.460*f*
origin of, 6.20, 6.21*t*
recession/resection of
for convergence insufficiency, 6.103
for Duane retraction syndrome, 6.133
for esotropia from nystagmus blockage syndrome, 6.155
for infantile esotropia, 6.89
for internuclear ophthalmoplegia, 6.144
for Möbius syndrome, 6.136
restriction of, 6.97
slipped, 6.169, 6.169*f*
surgery considerations for, 6.29
Medial rectus tendon, 6.19*f*
Medial spindle procedure, 7.231, 7.232*f*
Medial superior temporal (MST) area, 5.32*f*, 5.33, 5.34*f*, 5.224
Medial temporal (MT) area, 5.30*f*, 5.32*f*, 5.33, 5.34*f*, 5.224
Median perforators, of basilar artery, 5.20
Mediators. *See also specific type*
hay fever conjunctivitis and, 8.288
reactive nitrogen products, 9.16
reactive oxygen intermediates, 9.16
Medical emergencies
anaphylaxis, 1.302–303
cardiopulmonary arrest, 1.296–299, 1.297*t*
crash cart for, 1.298
hypoglycemia, 1.300
opioid overdose, 1.306–307
seizures. *See* Seizures
shock. *See* Shock
status epilepticus, 1.303–304
syncope, 1.299

Medical history. *See also* History
cataract surgery evaluation and, 11.72, 11.170–171
glaucoma evaluation and, 10.29
refractive surgery evaluation and, 13.36*t*, 13.37
Medical therapy, 2.370–371
Medicare, 3.325
Medicare Access and CHIP Reauthorization Act (MACRA), 1.32
Medication adherence, 2.373
Medication compliance, 2.373
Medications. *See* Drugs; *specific medication*
Medium. *See* Optical (ocular) medium/media
Medium-sized–vessel vasculitis, 1.169*t*, 1.170–171
Medium-wavelength sensitive cones. *See* M cones
Medroxyprogesterone, for chemical injuries, 8.383
Medrysone, 2.400*t*, 2.402*t*
Medullary epithelium, medulloepithelioma arising from, 4.178, 4.296
Medullary lamina, internal, 5.34
Medullary thyroid cancer, 1.46, 1.50
Medulloepithelioma (diktyoma), 4.178*f*, 4.178–179, 4.296*f*, 4.296–297, 6.273*f*, 6.273–274
retinoblastoma differentiated from, 4.296*f*, 4.296–297
teratoid, 4.179
Meesmann epithelial corneal dystrophy (MECD), 8.135*t*, 8.136*t*, 8.139, 8.139*f*
Megaloblastic anemia, 1.133
Megalocornea, 6.253*f*, 6.253–254, 8.95, 8.96*t*, 8.99*f*, 8.99–100
congenital glaucoma and, 8.95, 8.96*t*, 8.99–100, 8.108
Marfan syndrome and, 8.96*t*, 8.194
Megalopapilla, 6.366
Meibography, infrared, 8.40, 8.40*f*
Meibomian (tarsal) glands, 4.201*f*, 4.202, 8.4, 8.4*f*, 8.5
anatomy of, 2.28*f*, 2.30*t*, 2.37*f*, 7.170, 7.182
atrophy of, 8.60
blepharitis with dysfunction of, 6.244, 6.244*f*
chalazion/hordeolum and, 4.203–204, 4.204, 4.206*f*, 8.76, 8.77
description of, 2.249
distichiasis of, 6.195, 6.195*f*
dysfunction of (MGD), 2.250, 8.40*f*, 8.40–41, 8.53–54, 8.54*f*, 8.55*f*, 8.58–59, 8.60*f*, 13.173
blepharitis in, 8.68, 8.72, 8.73*t*
cataract surgery and, 11.172–173
dry eye and, 8.40–41, 8.53–54, 8.54*f*, 8.55*f*, 8.58–59, 8.60*f*
refractive surgery and, 13.42, 13.173
rosacea and, 8.70
staging of, 8.67*t*
treatment of, 8.66–67*t*, 8.66–69
hordeolum of, 7.183
innervation of, 2.254
lesions of, 7.191
phospholipid secretion by, 2.249
sebaceous adenocarcinoma arising in, 4.215
in tear film lipids/tear production, 8.5
Meibomitis. *See also* Meibomian (tarsal) glands, dysfunction of
refractive surgery and, 13.42
Meibum, 2.35
Meige syndrome, 5.281, 5.282*f*
Meiosis, 2.174–175, 2.215, 2.216*f*
nondisjunction during. *See* Nondisjunction
MEK inhibitors, 12.299, 12.299*f*
Melan-A (MART-1), in immunohistochemistry, 4.34
melanoma diagnosis and, 4.67*f*, 4.68
Melanin, 12.32–33, 12.367, 12.373, 12.374*f*
corneal deposits of/pigmentation caused by, 8.118*t*, 8.128
magnetic resonance imaging of, 2.457
in retinal pigment epithelium, 2.331
albinism and, 4.142
hypertrophy and, 4.144, 4.145*f*
Melanin-like pigment, corneal deposits of/pigmentation caused by, 8.118*t*, 8.131*f*, 8.131–132
Melanocytes
description of, 2.78, 2.161, 2.393, 7.195
tumors arising from, 8.338*t*, 8.338–345, 8.339*t*. *See also* Melanocytic tumors; Pigmented (melanocytic) lesions
Melanocytic nevus
of anterior chamber/trabecular meshwork, 4.106
congenital, 4.218, 4.218*f*
conjunctival, 4.61–64, 4.64*f*, 4.65*f*
malignant transformation of, 4.64, 4.68
of eyelid, 4.218*f*, 4.218–220, 4.219*f*
glaucoma and, 4.106
malignant transformation/melanoma risk and, 4.64, 4.68, 4.218, 4.263, 4.267–268
Melanocytic tumors, 4.255–280, 6.392, 6.395*f*. *See also* Nevus; *specific type*
of anterior chamber/trabecular meshwork, 4.106, 4.106*f*
benign
blue nevi, 7.198
dermal melanocytosis, 7.198, 7.198*f*
ephelis, 7.197
lentigo simplex, 7.197
nevi, 7.195–197, 7.196–197*f*
solar lentigo, 7.197–198, 7.198*f*, 7.200
sources of, 7.194–195
classification of, 7.195*t*
conjunctival/ocular surface, 4.61–69, 4.63*t*, 4.64*f*, 4.65*f*, 4.66*f*, 4.67*f*, 4.68*f*, 4.69*f*, 8.338*t*, 8.338–345
benign, 8.338*t*, 8.338–341, 8.339*f*, 8.339*t*, 8.340*f*, 8.341*f*
malignant, 8.338*t*, 8.339*t*, 8.343–345, 8.344*f*
preinvasive, 8.338*t*, 8.339*t*, 8.342*f*, 8.342–343
of eyelid
benign, 4.218*f*, 4.218–220, 4.219*f*, 4.221*f*
malignant (melanoma), 4.220, 4.221*f*
melanoma risk and, 4.262, 4.268
of ocular surface, 4.61–69, 4.63*t*, 4.64*f*, 4.65*f*, 4.66*f*, 4.67*f*, 4.68*f*, 4.69*f*
premalignant, 7.200
Melanocytoma
glaucoma and, 4.106, 4.258, 10.99, 10.99*f*
of iris/ciliary body/choroid, 4.192, 4.258, 4.268
melanoma differentiated from, 4.268
ocular surface, 8.338*t*
of optic nerve/nerve head/disc, 4.248, 4.248*f*, 4.257*f*, 4.258, 4.268, 6.367, 6.367*f*
Melanocytosis
dermal/dermal orbital/oculodermal (nevus of Ota), 4.63*t*, 4.64, 8.339

glaucoma associated with, 10.30
of iris, 4.259
ocular (melanosis oculi), 4.63*t*, 4.64, 4.65*f*, 6.250–251, 6.251*f*, 8.338*t*, 8.338–340, 8.339*f*, 8.339*t*
choroidal nevus resembling, 4.257, 4.257*f*
congenital, 8.338–340, 8.339*f*
of iris, 4.259, 4.260*f*
oculodermal (nevus of Ota), 8.339, 8.339*t*
Melanogenesis, 2.331
Melanokeratosis, striate, 4.65, 8.341
Melanolipofuscin, 12.33
Melanolysosomes, 12.32
Melanoma
amelanotic, 4.68, 4.263, 4.264*f*, 4.272*t*
of anterior chamber/trabecular meshwork, 4.106, 4.106*f*, 4.195*f*
chemotherapy for, 4.277
choroidal/ciliary body (uveal), 4.106, 4.106*f*, 4.192*f*, 4.192–197, 4.193*f*, 4.194*f*, 4.195*f*, 4.196*f*, 4.253, 4.262–279, 7.136, 9.308
age-related macular degeneration differentiated from, 4.269, 4.270*f*
chemotherapy for, 4.277
classification of, 4.194, 4.271–272, 4.272*t*
clinical characteristics of, 4.262–263, 4.264*f*
congenital hypertrophy of retinal pigment epithelium differentiated from, 4.144, 4.268–269, 4.269*f*
diagnosis of, 4.263*f*, 4.264*f*, 4.264–267, 4.266*f*, 4.267*f*
differential, 4.267–271, 4.269*f*, 4.270*f*
enucleation for, 4.196, 4.274–275
epithelioid cell, 4.192, 4.193*f*, 4.194, 4.195
exenteration for, 4.277
fine-needle aspiration biopsy in identification/evaluation of, 4.42, 4.43*f*, 4.253
glaucoma caused by, 4.105*f*, 4.106, 4.194, 10.99, 10.99*f* , 10.138
immunotherapy for, 4.277
melanocytoma differentiated from, 4.268
metastatic, 4.196, 4.197, 4.272–274, 4.273*t*, 4.306
mixed-cell type, 4.194, 4.195
nevus differentiated from, 4.267–268
observation in management of, 4.274
ocular surface/conjunctival involvement and, 4.68, 4.69*f*, 8.343
prognosis/prognostic factors for, 4.194–197, 4.273*t*, 4.277–279
risk factors for, 4.262, 4.268
spindle cell, 4.192*f*, 4.192–193, 4.194, 4.195
staging of, 4.271–272, 4.273*t*
surgical excision of, 4.277
transpupillary thermotherapy for, 4.276
treatment of, 4.253, 4.274–277, 4.275*f*
congenital hypertrophy of retinal pigment epithelium differentiated from, 4.144, 4.268–269, 4.269*f*
conjunctival/ocular surface, 4.68*f*, 4.68–69, 8.338*t*, 8.339*t*, 8.343–345, 8.344*f*
in situ, 4.65, 4.67*f*, 4.68
intraocular extension of, 4.310
ocular melanocytosis and, 8.349–350
primary acquired melanosis and, 4.66–68, 4.67*f*, 4.68, 4.68*f*, 8.327, 8.342, 8.343
enucleation for, 4.196, 4.274–275
exenteration for, 4.277, 8.344
eyelid, 4.220, 4.221*f*, 7.208–211, 7.209*f*
glaucoma and, 4.105*f*, 4.106, 4.194, 10.99, 10.99*f*, 10.138
immunotherapy for, 4.277
of iris, 4.106, 4.190, 4.191*f*, 4.258–261, 4.259*f*, 4.260*f*, 4.261*f*
melanomalytic glaucoma caused by, 4.106, 4.194
lentigo maligna, 4.220, 4.221*f*, 7.209, 7.209*f*
metastatic, 4.196, 4.197, 4.272–274, 4.273*t*, 4.306, 9.309
nevi and, 4.64, 4.68, 4.218, 4.262, 4.263, 4.267–268
nodular, 4.220, 4.221*f*, 7.209–210
oncolytic virus treatment for, 1.242
retinoblastoma and, 4.302, 4.302*t*
retinopathy and, 5.102–103
ERG in identification of, 5.96, 5.102–103
ring, 4.193, 4.194*f*, 4.262, 4.263*f*
screening for, 1.220–221
superficial spreading, 4.220, 4.221*f*
treatment of, 7.210–211
uveal, 4.106, 4.106*f*, 4.192–196*f*, 4.192–197, 4.253, 4.262–279, 7.136, 9.308. *See also* Melanoma, choroidal/ciliary body
Melanoma-associated retinopathy (MAR), 5.102–103, 9.192–193, 12.286
ERG in identification of, 5.96, 5.102–103
Melanomalytic glaucoma, 4.105*f*, 4.106, 4.194, 10.99, 10.99*f*
Melanopsin, in intrinsically photosensitive retinal ganglion cells, 5.24
Melanosis, 8.338
acquired
primary (PAM), 8.327, 8.338*t*, 8.339*t*, 8.342*f*, 8.342–343
melanoma and, 8.327, 8.342, 8.343
secondary, 8.342
complexion-associated (CAM/racial melanosis/primary conjunctival/hypermelanosis), 4.63*t*, 4.65, 4.66, 4.66*f*, 8.338*t*, 8.339*t*, 8.341, 8.341*f*
congenital episcleral, 8.338, 8.338*t*, 8.338–340, 8.339*f*, 8.339*t*
intraepithelial, 4.65–68, 4.66*f*, 4.67*f*
ocular (ocular melanocytosis/melanosis oculi), 4.63*t*, 4.64, 4.65*f*, 6.250–251, 8.338*t*, 8.338–340, 8.339*f*, 8.339*t*
choroidal nevus resembling, 4.257, 4.257*f*
of iris, 4.259, 4.260*f*
primary acquired (PAM), 4.63*t*, 4.65, 4.66–68, 4.67*f*
secondary acquired, 4.65–66
Melanosomes, 2.98, 2.393
MELAS (mitochondrial myopathy and encephalomyopathy, lactic acidosis, and strokelike episodes), 5.294–295
migrainelike headache and, 5.294–295
Melasma, 7.195
Melkersson-Rosenthal syndrome, 5.280
Melles technique, 8.434
Meloxicam, 2.409*t*
Melphalan, 6.357
for retinoblastoma, 4.300

Memantine, 1.210
for nystagmus, 5.236, 5.245, 5.246
Membrane(s). *See also specific type*
Bowman, 4.73, 4.74*f*. *See also* Bowman layer/membrane
Bruch. *See* Bruch membrane
conjunctival, 8.46*t*, 8.47*t*
in epidemic keratoconjunctivitis, 8.234, 8.234*f*, 8.235
in gonococcal conjunctivitis, 8.258
in ligneous conjunctivitis, 8.294
Descemet, 4.73, 4.74*f*. *See also* Descemet membrane/layer
limiting
external (ELM/XLM), 4.140*f*, 4.141*f*
internal (ILM), 4.140*f*
in retinal healing/repair, 4.17
vitreous detachment and, 4.129
neovascular. *See also* Choroidal neovascularization; Neovascularization
in age-related macular degeneration, 4.165*f*, 4.165–166
retrocorneal fibrous (RCFM/posterior collagenous layer), 4.84, 4.85*f*
Membrane proteins, in lens, 2.285
Membrane-spanning mucins, 2.253
Membrane structural (urea-insoluble) lens proteins, 11.15*f*, 11.16–17
Membrane-type frizzled protein *(MFRP)* gene
in glaucoma, 10.11*t*
in nanophthalmos, 4.108, 10.11*t*
Membranous cataract, 11.38, 11.39*f*
Membranous conjunctivitis, 6.251
Memory cells, 9.37
MEMS. *See* Microelectromechanical systems
MEN. *See* Multiple endocrine neoplasia
Mendel, Gregor, 2.202
Mendelian diseases, 2.218
Mendelian Inheritance in Man, Online (OMIM), for corneal dystrophies, 8.191–192*t*
Ménière disease, 5.242
Meningeal artery
middle (MMA), 5.12, 5.14*f*, 5.15*f*
recurrent, 5.14, 5.14*f*, 5.15*f*
Meningeal nerve, middle, 5.49
Meningeal sheaths, 2.114*f*, 2.114–115
Meninges
neuroimaging in evaluation of, 5.72*t*
optic nerve, 4.241, 4.242*f*
Meningiomas, 2.105
cerebellopontine angle
Bruns nystagmus and, 5.243
seventh nerve (facial) palsy and, 5.279
intracranial, 5.127*f*, 5.127–129, 5.128*t*
MRI of, 5.65*f*, 5.66*f*, 5.127*f*
optic nerve sheath (ONSM), 4.250, 4.250*f*, 5.65*f*, 5.66*f*, 5.126, 5.127–128*f*, 5.127–129
orbital, 4.250, 5.127, 6.223
transient visual loss and, 5.164
parasellar, 5.147, 5.150
Meningitis
cryptococcal, 1.277, 5.356
facial palsies and, 5.279
headache and, 5.288
in HIV infection/AIDS, 5.348
meningococcal, 1.250
tuberculous, 5.350
neuro-ophthalmic signs of, 5.350
Meningocele, 6.225, 7.38
Meningococcus *(Neisseria meningitidis)*, 8.207, 8.245
conjunctivitis caused by, 8.257*t*
invasive capability of, 8.207
meningitis caused by, 1.250
vaccinations for, 1.231
Meningoencephalitis, in HIV infection/AIDS, 5.348
Meningoencephalocele, 7.39
Meningohypophyseal trunk, 5.12–14
Meningomas, 7.84–85*f*, 86
Meningothelial optic meningioma, 4.250, 4.250*f*
Meniscus lenses, principal planes for, 3.56
Mental acuity disturbances, in multiple sclerosis, 5.317
Mental disorders due to general medical condition (organic mental syndromes). *See* Alzheimer disease; Behavioral/psychiatric disorders
Mepivacaine, 2.438*t*, 2.440
Mepolizumab, for eosinophilic asthma, 1.124
6-Mercaptopurine (6-MP), 9.106
Meretoja syndrome (Finnish/gelsolin type familial amyloidosis), 4.206, 8.186*t*, 8.187, 8.188*f*
Meridian
definition of, 3.4, 3.15
description of, 11.9
notation symbol for, 3.18
power-cross, 3.77
principal
definition of, 3.4, 3.16
in irregular astigmatism, 3.139
refractive powers of, 3.16
toric surface curvature variation along, 3.16*f*
Meridional aniseikonia, 3.147, 3.173
Meridional complex
definition of, 12.10
illustration of, 12.10*f*
Meridional folds
definition of, 12.10, 12.312
retinal detachment and, 12.312
Meridional magnification (meridional aniseikonia). *See* Distortion
Meridional power (instantaneous radius of curvature), 13.16–17, 13.17*f*
Merit-based Incentive Payment System (MIPS), 1.32
Merkel cell, 7.212
Merkel cell carcinoma, 7.212, 7.212*f*
Merlin, 2.228
Merlin (neurofibromin 2), 5.334*t*
MESA (Multi-Ethnic Study of Atherosclerosis), 12.62
Mesectodermal dysgenesis. *See* Anterior segment, dysgenesis of
Mesectodermal leiomyoma, 4.199
Mesencephalic nucleus, 2.129
of cranial nerve V (trigeminal), 5.47, 5.47*f*
Mesencephalic reticular formation (MRF), 5.35*f*
Mesencephalon, 2.123, 2.145*f*
Mesenchymal dysgenesis. *See* Anterior segment, dysgenesis of

Mesenchymal tumors
chondrosarcoma, 7.91
of eyelid and conjunctiva, 8.345*t*, 8.345–348
fibrosarcoma, 7.91
fibrous dysplasia, 7.89, 7.90*f*
fibrous histiocytoma, 7.89
liposarcoma, 7.91
malignant, 7.91
miscellaneous, 7.89–91, 7.90–91*f*
osteomas, 7.89, 7.91, 7.91*f*
osteosarcoma, 7.91
rhabdomyosarcoma, 7.87*f*, 7.87–89
solitary fibrous tumor, 7.89, 7.90*f*
Mesoderm
derivatives of, 2.149*t*
description of, 2.143, 2.145*f*
in embryologic development, 2.150*f*
hyaloid artery arising from, 2.158*f*
Mesodermal dysgenesis, Peters anomaly and, 11.31–32
Messenger RNA (mRNA)
description of, 2.176
intron excision, 2.179
proteins, 2.273
Meta-analyses, 1.3, 1.8, 1.14
Metabolic acidosis, 2.392
Metabolic disorders. *See also* Inborn errors of metabolism; *specific disorder*
cataracts and, 11.60*f*, 11.60–62, 11.61*f*, 11.62*f*
corneal changes and, 8.174–190
amino acid/nucleic acid/protein/mineral metabolism and, 8.181*f*, 8.181–190, 8.182*t*, 8.183*t*, 8.184*f*, 8.185*f*, 8.186*t*, 8.187*f*, 8.188*f*, 8.189*f*
lipoprotein metabolism and, 8.179–181, 8.180*f*
lysosomal storage diseases, 8.174–179, 8.175*t*, 8.176*f*, 8.177*f*
Metabolic imaging, 5.70
Metabolic syndrome
definition of, 1.77
diabetes mellitus risks, 1.35
diagnostic criteria for, 1.35
hypertension and, 1.66
insulin resistance and, 1.77
management of, 1.77–78
Metachromatic leukodystrophy, 2.204*t*, 6.388*t*
Metaherpetic ulcer, 8.224
Metalloproteinases, matrix (MMPs). *See* Matrix metalloproteinases
Metallosis, lens damage/cataracts caused by, 11.58*f*, 11.58–59
Metamorphopsia, 5.174–175, 9.273
in optic neuropathy *versus* maculopathy, 5.100, 5.100*t*
Metaphase, 2.174, 2.174*f*
Metarhodopsin II, 2.308
Metastatic eye disease, 4.197, 4.303–310, 9.309. *See also specific type and structure affected*
carcinoma, 4.303–310
ancillary tests in evaluation of, 4.306–308, 4.309*f*
clinical features of, 4.304–306, 4.305*f*, 4.306*f*, 4.307*f*, 4.308*f*, 4.308*t*
diagnostic factors in, 4.308–309
direct intraocular extension and, 4.310
mechanisms of intraocular metastasis and, 4.303–304, 4.304*f*
primary sites and, 4.303, 4.304*t*
prognosis for, 4.309–310
treatment of, 4.310
of choroid, 4.197, 4.198*f*, 4.303, 4.304*t*, 4.306*f*, 4.307*f*, 4.308*f*, 4.308*t*
melanoma differentiated from, 4.270*f*, 4.271, 4.306
of conjunctiva/ocular surface, 8.350
of iris, 4.260, 4.260*f*, 4.303, 4.304, 4.305*f*
of optic nerve/nerve head/disc, 4.303, 4.307–308
of orbit, 4.228, 4.240
in adults, 7.105–107
from breast carcinoma, 7.106, 7.106*f*
from bronchogenic carcinoma, 7.106
in children, 7.104–105
leukemia, 7.104
management of, 7.107
neuroblastoma, 6.415*f*
in children, 7.22*f*, 7.104, 7.105*f*
description of, 6.414
tumors, 6.218
of retina, 4.303, 4.308, 4.309*f*
retinoblastoma and, 4.177, 4.177*f*, 4.293–294
of uvea, 4.197, 4.198*f*, 4.303, 4.304–306, 4.305*f*, 4.306*f*, 4.307*f*, 4.308*f*, 4.309*t*
prognosis for, 4.309–310
Metastatic melanoma, 9.309
Metformin, 1.38
Methanol
as tissue fixative, 4.26*t*
toxicity of, 12.301
optic neuropathy caused by, 5.137
Methazolamide (MZM), 2.391*t*, 2.392, 10.173*t*, 10.180
in children, 10.165
Methenamine silver stain, Gomori or Grocott (GMS), 4.31*t*
Methicillin-resistant *Staphylococcus aureus* (MRSA), 1.246, 2.359, 2.426, 6.213, 6.240, 8.244, 8.271
dacryoadenitis caused by, 7.313
keratitis caused by, after photoablation, 13.106
orbital cellulitis caused by, 7.48
preseptal cellulitis caused by, 7.45
Methicillin sodium, 2.418*t*
Methimazole, thyroid secretion suppression using, 1.44
Methionine, in homocystinuria, 11.41
dietary restriction in management of, 11.41
Methotrexate (MTX), 2.404*t*
dermatomyositis treated with, 1.168
description of, 1.178
dosing of, 1.178
for intraocular (primary central nervous system) lymphoma, 4.312
for polymyalgia rheumatica, 1.168
for polymyositis, 1.168
for primary vitreoretinal lymphoma, 12.234
rheumatoid disease treated with, 1.153
for scleritis, 8.324
for uveitis, 6.322
adverse effects of, 9.107
dosing of, 9.107
treatment studies involving, 9.100*t*

Methoxyflurane, 12.303
Methylation, 2.180
Methylcellulose
hydroxypropyl (HPMC), as viscoelastic, 11.95
Methyldopa, 1.63
Methylenetetrahydrofolate reductase gene, 1.148
Methylmalonic acid, 1.133
Methylprednisolone, 2.399
acute allergic reaction treated with, 1.302
for corneal graft rejection, 8.430
for giant cell arteritis/AAION, 5.121, 5.314
for neuromyelitis optica, 5.323
for optic neuritis, 5.116
potency of, 1.175*t*
for scleritis, 9.126–127
for uveitis, 9.95, 9.96*f*, 9.102–103
Metipranolol, 2.389*t*, 2.390, 10.171*t*, 10.176–177
Metoclopramide, oculogyric crisis caused by, 5.231
Metronidazole, for rosacea, 8.71
MEWDS. *See* Multiple evanescent white dot syndrome
Meyer loop, 2.116, 2.116*f*, 5.24*f*, 5.29, 5.155
lesions affecting, 5.155, 5.155*f*
Mezlocillin sodium, 2.419
MFC. *See* Multifocal choroiditis
MFCPU (multifocal choroiditis with panuveitis). *See* Multifocal choroiditis and panuveitis syndrome
mfERG. *See* Multifocal electroretinogram/electroretinography
MFIOLs. *See* Multifocal lenses, intraocular
MFRP (membrane-type frizzled protein) gene
description of, 6.263
in glaucoma, 10.11*t*
in nanophthalmos, 4.108, 10.11*t*
MG. *See* Myasthenia gravis
MGD. *See* Meibomian (tarsal) glands, dysfunction of
MGDA. *See* Morning glory disc anomaly
$Mg(OH)_2$. *See* Magnesium hydroxide
mGy. *See* Milligray
MH. *See* Malignant hyperthermia
MHA-TP. *See* Microhemagglutination assay for *T. pallidum* antibodies
MHAUS. *See* Malignant Hyperthermia Association of the United States
MI. *See* Myocardial infarction
MIC. *See* Minimal inhibitory concentration
Micafungin, 2.431, 2.431*t*
for *Candida* fungal postoperative endophthalmitis, 9.299
Michaelis/affinity constant (K_m), sorbitol in cataract development and, 11.19
Michel medium, as tissue fixative, 4.26, 4.26*t*
Miconazole nitrate, 2.429, 2.430*t*
Micro-lenslet array, 3.291*f*
Microadenomas, pituitary, 1.47
Microalbuminuria, 1.39
Microaneurysms
in nonproliferative diabetic retinopathy, 12.100*f*
retinal, 4.154, 4.155*f*
in diabetes mellitus, 4.155*f*, 4.159
in diabetic retinopathy, 4.159
in retinal vein occlusion, 4.158, 4.159
Microangiopathic hemolytic anemia (MAHA), 1.142
Microarrays, 4.40–41, 4.41*f*
clinical use of, 4.41–42
SNP oligonucleotide (SOMA), 4.39*t*
tissue (TMAs), 4.40, 4.41*f*
Microautophagy, 2.283
Microbial keratitis. *See* Infectious/microbial keratitis
Microbiology, 1.245–246, 8.207–211, 8.208*t*, 8.209*t*, 8.211*f*. *See also* Infection; Infectious diseases; *specific organism*
bacteriology, 8.208*t*, 8.243–249, 8.244*t*
diagnostic laboratory techniques in, 8.208–211, 8.209*t*, 8.211*f*
mycology (fungal infection), 8.208*t*, 8.249–251
parasitology, 8.208*t*, 8.252–253
prions, 8.254
virology, 8.208*t*, 8.211–241
Micrococcus, as normal flora, 8.206*t*
Microcornea, 6.254, 6.254*f*, 8.95–99, 8.96*t*
cornea plana and, 8.95, 8.96*t*, 8.100
in Ehlers-Danlos syndrome, 1.141
Microcystic, 7.73
Microcystic dystrophy
band-shaped and whorled. *See* Lisch epithelial corneal dystrophy
Cogan (epithelial basement membrane). *See* Basement membrane dystrophy
Microcystic epitheliopathy, 3.232
Microcysts
in bullous keratopathy, 4.84
in Lisch epithelial corneal dystrophy, 8.140, 8.140*f*
Microcytic anemia, 1.132
Microelectromechanical systems (MEMS)
description of, 2.367
in swept-source optical coherence tomography, 12.25–26
Microenvironments, immunologic. *See* Immunologic microenvironment
Microexplosions, 12.375
Microfilariae
Loa loa, 8.282
onchocercal, 8.253
Microglia/microglial cells
description of, 2.317, 9.3
optic nerve, 4.241, 4.242*f*
retinal, ischemia and, 4.152
β_2-Microglobulin, 9.31*f*
Micrographic surgery, Mohs, for eyelid tumors, 4.44*f*, 4.44–45
basal cell carcinoma, 4.213
sebaceous adenocarcinoma, 4.218
squamous cell carcinoma, 4.213
Microhemagglutination assay for *T pallidum* antibodies (MHA-TP), 9.224, 12.241
Microinvasive glaucoma surgery (MIGS)
cataract surgery and, 11.186
Schlemm canal in, 2.6464
Microkeratomes, for LASIK, 13.84–87, 13.85*f*, 13.86*f*, 13.87*f*
aberrations and, 13.102
complications associated with, 13.110*f*, 13.110–112, 13.111*f*
re-treatment/enhancements and, 13.98

Micronutrients. *See also specific type*
for age-related macular degeneration, 12.69–71
Micropannus. *See* Pannus/micropannus
Microphthalmia, anophthalmia, coloboma (MAC), 6.263
Microphthalmia/microphthalmos, 4.109, 7.36–38, 7.136
with cyst, 6.224, 6.225*f*
description of, 6.209
persistent fetal vasculature associated with, 4.126
Micropinocytotic vesicles, 2.64
Micropsia, 5.175
migraine and, 5.177
Microsaccadic refixation movements, 5.213
Microsatellites, 2.177
Microscope
confocal, 3.302, 8.24, 8.24*f*
in *Acanthamoeba* keratitis diagnosis, 8.24, 8.277, 8.278*f*
examination before phakic IOL insertion and, 13.141
slit-lamp. *See* Slit-lamp biomicroscopy/examination
specular, 3.295, 8.23, 8.23*f*
examination before cataract surgery and, 11.84
examination before phakic IOL insertion and, 13.141
examination in iridocorneal endothelial syndrome and, 10.137
in Fuchs endothelial corneal dystrophy, 8.23*f*, 8.158
surgical/operating, 3.294, 3.295*f*
for manual small-incision cataract surgery, 11.198
phototoxicity and, 11.166
Microscopic hyphema, 8.392, 8.392*f*
Microscopic polyangiitis (MPA), 1.172–173, 9.125*t*, 9.158
Microshunts, 10.219–220
Microsomal triglyceride transfer protein, 2.314*t*
Microsomia, hemifacial, in Goldenhar-Gorlin syndrome, 8.191*t*, 8.195–196
Microspherophakia, 6.307, 11.32–33, 11.33*f*
pupillary block/angle-closure glaucoma caused by, 10.130, 10.131*f*, 11.33
in Weill-Marchesani syndrome, 11.33
Microsporidia (microsporidiosis), 8.252, 8.280*f*, 8.280–281, 8.281*f*
conjunctivitis/keratitis/keratoconjunctivitis caused by, 8.280–281
in HIV infection/AIDS, 8.280, 8.280*f*
Microstriae, in LASIK flaps, 13.113, 13.114*t*, 13.115*f*. *See also* Striae
Microtrauma, ocular infection and, fungal keratitis, 4.78
Microtropia, 6.51
Microvascular abnormalities, intraretinal (IRMAs), 4.153*f*, 4.154, 4.155*f*
in diabetic retinopathy, 4.159
Microvascular decompression surgery, for hemifacial spasm, 5.284
Microvasculopathy, in diabetes mellitus. *See* Diabetic retinopathy
Midazolam, 1.290
Midbrain, 5.27*f*, 5.30
lesions of
convergence insufficiency caused by, 5.227
corectopia caused by, 5.255
eyelid retraction in, 5.229, 5.250, 5.274, 5.275*t*
gaze palsies caused by, 5.228–229
light-near dissociation and, 5.229, 5.230*f*, 5.266*t*, 5.266–267
vertical eye movements and, 5.36, 5.36*f*, 5.36–37
Midbrain corectopia, 5.255
MIDD. *See* Maternally inherited diabetes and deafness
Middle cerebral artery (MCA), 5.16*f*, 5.18*f*, 5.18–19, 5.27*f*
anatomy of, 2.106*f*, 2.139*f*
aneurysm of, 1.122, 5.339*f*
cranial nerve relationship and, 5.42*f*
Middle cervical ganglion, 5.54
Middle conchae, 7.19
Middle cranial fossa, 2.106*f*, 2.460*f*, 5.6*f*, 5.10*f*, 5.11
neuroimaging in evaluation of, 5.72*t*
Middle lamellar deficiency, 7.254
Middle limiting membrane (MLM), 2.92, 4.140*f*
anatomy of, 12.15
definition of, 12.16
histology of, 12.11, 12.12*f*
Middle meningeal artery (MMA), 5.12, 5.14*f*, 5.15*f*
Middle meningeal nerve, 5.49
Middle turbinate, 2.14*f*
Midface
fractures of, 7.109, 7.110*f*
rejuvenation of, 7.271–272, 7.273*f*
Midget bipolar cell, 12.13
Mie scattering, 3.92, 3.97–98
Migraine attacks, stroke-like, after radiation therapy (SMART), 5.358
Migraine headache, 5.171–172, 5.177, 5.288–292, 5.290*f*, 5.292*f*
with aura, 5.171–172, 5.177, 5.290–291
aura without (acephalgic migraine), 5.172, 5.177, 5.290, 5.291
basilar-type, 5.291
evaluation of, 5.291–292, 5.292*f*
familial hemiplegic, 5.291
hallucinations and, 5.177
inherited encephalopathies resembling, 5.294–295
ophthalmoplegic, 5.197
persistent positive visual phenomena and, 5.177, 5.201, 5.290
prophylaxis for, 5.293
transient visual loss and, 5.161, 5.162, 5.171–172, 5.177, 5.291
treatment of, 5.292–293
visual phenomena of, 5.177, 5.290–291
without aura, 5.290
Migration inhibitory factor, in mucous membrane pemphigoid, 8.299
Migratory dendritic cells, 9.4
MIGS. *See* Microinvasive glaucoma surgery
Mikulicz syndrome, 1.166
Milia, 7.189, 7.189*f*
Miliary disease, 9.234
Milk-alkali syndrome, corneal changes in, 8.201
"Milky Way" sign, in Vogt-Koyanagi-Harada disease, 12.232
Millard-Gubler syndrome, 5.192
Miller Fisher syndrome, 5.273, 5.273*t*, 5.280

Milligray (mGy)
description of, 2.456
radiation dose measurement, 5.60, 5.75
Millisievert (mSv), 2.456
Mimecan, mutation in gene for, in cornea plana, 8.96*t*, 8.100
Mimetic muscles, of face, 7.153, 7.154*f*
Mineral metabolism, disorders of, corneal changes in, 8.181*f*, 8.181–190, 8.182*t*, 8.183*t*, 8.184*f*, 8.185*f*, 8.186*t*, 8.187*f*, 8.188*f*, 8.189*f*
Mini- (modified) monovision, 13.39, 13.164–165
accommodating IOLs and, 13.154
Minimal inhibitory concentration (MIC), 1.271
Minimal lethal concentration (MLC), 1.271
Minimum angle of resolution (MAR), logarithm of (logMAR), cystoid macular edema after cataract surgery and, 11.164. *See also* LogMAR
Minimum deviation position (MAD), 3.45, 3.46*f*
Minimum legible threshold, 3.131
Minimum separable threshold, 3.131
Minimum visible threshold, 3.131
Minnesota Low-Vision Reading Test (MNREAD), 3.318, 3.319*f*
Minocycline, 1.308*t*, 2.424
adrenochrome deposition caused by, 8.118*t*, 8.131
for meibomian gland dysfunction, 8.68
for rosacea, 8.71
Minor (lesser) arterial circle, 5.15
Minors, genetic testing of, 2.241
Minus cylinder
description of, 3.148–149
for against movement, 3.155
plus cylinder conversion to, 3.149
Minus cylinder lens
pictorial representation of, 3.17*f*
"with-the-rule" astigmatism correction using, 3.19, 3.20*f*
Minus cylinder phoropter
advantages of, 3.148
astigmatism detection using, 3.29
cylinder axis refinement using, 3.29–30, 3.30*f*
with Jackson cross cylinder, 3.29, 3.30–3.31*f*
Minus lenses. *See* Concave lenses
Miochol. *See* Acetylcholine
Miosis/miotic agents
for acute angle closure, 10.124
angle closure caused by, 10.124, 10.182
contrast sensitivity affected by, 3.136
for glaucoma, 10.173*t*, 10.181–182
anterior uveitis and, 10.100
cataract/cataract surgery and, 11.52
in children, 10.166
in Horner syndrome, 5.257, 5.258, 5.258*t*, 5.259*f*, 5.261*f*
pharmacologic, 5.259*f*, 5.261*f*, 5.265*f*
toxic keratoconjunctivitis and, 8.90*t*, 8.91
traumatic injury and, 5.262, 8.389
Miostat. *See* Carbachol
Miotics, 2.378, 2.378*t*
MIP. *See* Major intrinsic protein
MIP-133 (mannose-induced protein), *Acanthamoeba* keratitis and, 8.276
MIPS. *See* Merit-based Incentive Payment System
Mires
in applanation tonometry, 10.23, 10.24*f*
astigmatism evaluation and, 8.15
in keratometry, 8.27, 8.27*f*
in keratoscopy, 8.27, 8.28, 8.28*f*
in topography, 8.28, 13.14, 13.16, 13.25*f*
Mirror(s)
description of, 3.80–83
examination room use of, 3.149–150
plane, 3.81
ray tracings and, 3.81, 3.82*f*, 3.83
vergence equation for, 3.81, 3.88–89, 3.89*f*
Mirror test, nonorganic disorders and, 5.302
Misdirection, in nonorganic disorder evaluation, 5.300
Mismatch repair, 2.181
Missense mutations, 2.183
"Missing half" field defect, in nonorganic disorder, 5.307, 5.307*f*
Mitochondria, 2.176
Mitochondrial diseases, 12.293–294
causes of, 2.184–185
chronic progressive external ophthalmoplegia, 2.185
Leber hereditary optic neuropathy, 2.185–186
maternally inherited diabetes and deafness, 2.185
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, 2.185
neuropathy, ataxia, and retinitis pigmentosa, 2.186
phenotype of, 2.184
severity of, 2.184
Mitochondrial DNA (mtDNA)
acquisition of, 2.176
diseases associated with deletions/mutations of
chronic progressive external ophthalmoplegia, 5.328–329, 5.329*f*
Leber hereditary optic neuropathy, 5.133
replicative segregation of, 2.184
ribosomal RNA encoded by, 2.184
spontaneous deletions and mutations of, 2.184
Mitochondrial myopathy
description of, 12.293*f*, 12.293–294
with encephalopathy, lactic acidosis, and strokelike episodes (MELAS), 2.185, 5.294–295, 12.283*f*, 12.294
migrainelike headache and, 5.294–295
neuro-ophthalmic signs of, 5.328–330, 5.329*f*
Mitomycin/mitomycin C (MMC), 2.371*t*, 2.413–414, 9.319
for ocular surface tumors, 8.327, 8.330, 8.330*f*, 8.331
in phototherapeutic keratectomy, 8.367
in pterygium surgery, 8.355
recurrence rate and, 8.353*t*, 8.355
after radial keratotomy, 13.52
in surface ablation, 13.92
corneal haze prevention/corneal wound healing and, 13.33, 13.92, 13.109
for undercorrection, 13.102
toxic reactions to, 8.91
in trabeculectomy, 10.205, 10.207
bleb-associated endophthalmitis and, 10.163, 10.209
in children, 10.163
scleral flap closure and, 10.203, 10.205*f*
Mitophagy, 2.283

Mitosis
description of, 2.173, 2.215
nondisjunction during. *See* Nondisjunction
Mitotic inhibitors, 1.240*t*
Mitotic nondisjunction, 2.224
Mitten deformity, 6.206, 6.207*f*
Mittendorf dot, 4.126, 6.298, 11.29, 11.31, 11.32*f*, 12.340
Mixed astigmatism, 3.138, 3.138*f*
limbal relaxing incisions for, 13.57
wavefront-optimized laser ablation for, 13.97
Mixed-cell type melanoma, 4.194, 4.195
Mixed macrocystic/microcystic lymphatic malformations, 7.73
Mixed tumor, benign (pleomorphic adenoma)
description of, 7.98–100, 7.99*f*, 7.192
of lacrimal gland, 4.229–230, 4.230*f*
Mizuo-Nakamura phenomenon, 12.253, 12.253*f*
MK medium. *See* McCarey-Kaufman (MK) medium
ML I. *See* Dysmorphic sialidosis
ML II. *See* Inclusion-cell disease
ML III. *See* Pseudo–Hurler polydystrophy
ML IV, 8.178
MLC. *See* Minimal lethal concentration
MLF. *See* Medial longitudinal fasciculus
MLM. *See* Middle limiting membrane
MLN. *See* Manifest latent nystagmus; Mean of the ten largest melanoma cell nuclei
MLPA. *See* Multiplex ligation-dependent probe amplification
MLs. *See* Mucolipidoses
MMA. *See* Middle meningeal artery
MMC. *See* Mitomycin/mitomycin C
MMCR. *See* Müller muscle-conjunctival resection
MMP. *See* Mucous membrane (ocular cicatricial) pemphigoid
MMPs. *See* Matrix metalloproteinases
MNREAD. *See* Minnesota Low-Vision Reading Test
MnSOD. *See* Manganese superoxide dismutase
MOABs. *See* Monoclonal antibodies
Möbius syndrome/sequence, 5.228, 5.278, 6.97, 6.135–136, 6.136*f*
Mode-locking, 3.112
Modified Hughes flaps, 7.223–224*f*, 7.224
Modified (mini-) monovision, 13.39, 13.164–165
accommodating IOLs and, 13.154
Modulation transfer function (MTF)
definition of, 3.124, 3.239, 3.261
description of, 3.135
intraocular lenses, 3.261–263, 3.262–3.263*f*
Moebius syndrome. *See* Möbius syndrome/sequence
MOGAs. *See* Malignant optic gliomas of adulthood
Mohs micrographic surgery, 7.204–207, 7.228
for eyelid tumors, 4.44*f*, 4.44–45
basal cell carcinoma, 4.213
sebaceous adenocarcinoma, 4.218
squamous cell carcinoma, 4.213
Moisture-retaining eyewear (moisture chambers/shields), 8.61*t*, 8.63–64
"Molar tooth" sign, 6.392*f*
Molds, 5.353, 8.249, 8.249*t*, 8.251
Molecular genetics
cell cycle, 2.173–176, 2.174*f*
DNA damage and repair, 2.181–182
gene structure, 2.176–177
gene therapy. *See* Gene therapy
gene transcription and translation. *See* Gene transcription and translation
mitochondrial diseases. *See* Mitochondrial diseases
mutations
disease and, 2.182–183
screening for, 2.189–194, 2.190–193*f*
noncoding DNA, 2.177–178
Molecular pathology, 4.34*t*, 4.36–42, 4.38–39*t*, 4.40*f*, 4.41*f*
Moles. *See* Nevi/nevus
Moll, glands of, 4.201, 8.4, 8.4*f*
Molluscum contagiosum/molluscum nodule, 6.199, 6.243, 6.244, 7.190, 8.208*t*, 8.236–237, 8.237*f*, 8.238*f*, 9.334
of eyelid, 4.204, 4.205*f*, 8.236–237, 8.237*f*, 8.238*f*
Molteno implant, 10.214, 10.214*t*
Molybdenum cofactor deficiency. *See* Sulfite oxidase deficiency
Mondino and Brown staging system, for mucous membrane pemphigoid, 8.302, 8.302*t*
Monitoring system, for clinical practice, 1.25–27
Monoamine oxidase (MAO) inhibitors
α_2-adrenergic agonist interactions with, 2.386
drug interactions and, apraclonidine/brimonidine interactions, 10.179
Parkinson disease treated with, 1.205
types of, 1.203*t*
Monobactams, 1.272–273
Monocanalicular stents, 6.234
Monochromatism/achromatopsia, 12.250*t*
blue-cone, 6.337–338
cerebral, 5.179
description of, 2.229
infantile nystagmus syndrome and, 5.236
rod, 6.337
Monoclonal antibodies (mAbs/MOABs), 1.144, 1.238, 1.242, 6.322
description of, 9.41
recombinant, 9.41
Monoclonal gammopathy, benign, crystalline corneal deposits in, 8.198
Monocular aphakia, 3.191
Monocular cover-uncover test, 6.64, 6.65*f*
Monocular diplopia, 5.174, 5.185
in cataracts, 11.43–44, 11.45, 11.47, 11.70–71
multifocal intraocular lenses as cause of, 3.258
pinhole aperture testing for, 3.130
Monocular distortion. *See* Distortion
Monocular elevation deficiency, 6.125–127, 6.126*f*, 7.245
Monocular eye movements, 5.184. *See also* Ductions; Forced duction test; *specific type*
ductions, 6.33
field of action, 6.33–34
gaze position effects on extraocular muscle action, 6.34–37, 6.35–37*f*
primary action, 6.34
secondary action, 6.34
terminology associated with, 6.33
tertiary action, 6.34
Monocular fixation, 6.16

Monocular nystagmus, 6.152
in Heimann-Bielschowsky phenomenon, 5.238–239
seizures and, 1.208
Monocular transient visual loss (transient monocular visual loss/TMVL), 5.161, 5.163*t*, 5.163–171. *See also* Transient visual loss
carotid artery disease and, 5.162, 5.165–166, 5.167, 5.167*f*, 5.168
carotid stenosis as cause of, 1.118
embolic causes of, 5.161, 5.162, 5.163*t*, 5.165, 5.165*f*, 5.165–169, 5.166*t*
clinical/laboratory evaluation in, 5.166–168
prognosis/treatment and, 5.168–169
giant cell arteritis presenting as, 1.119
hypoperfusion causing, 5.161, 5.162, 5.170, 5.171*f*
ocular causes of, 5.163*t*, 5.163–164
ocular ischemic syndrome causing, 5.170, 5.171*f*
optic nerve disorders causing, 5.161, 5.164
orbital causes of, 5.164
postural changes causing, 5.161, 5.164, 5.170
systemic causes of, 5.169–171, 5.171*f*
vascular disease causing, 5.163*t*, 5.164–171
vasospasm/hyperviscosity/hypercoagulability causing, 5.161, 5.162, 5.171
Monocular vision
no light perception, testing, 5.302–305, 5.303*f*, 5.304*f*
reduced, 5.161, 5.163*t*, 5.163–171. *See also* Monocular transient visual loss; Unilateral vision loss
in low vision evaluation, 5.77
in nonorganic disorders, 5.305, 5.305*t*
Monocular visual deprivation
binocularity affected by, 6.45
description of, 6.44
visual cortex affected by, 6.45
Monocytes, 4.7, 4.8*f*. *See also* Macrophage(s)
as antigen-presenting cells, 9.3
characteristics of, 9.3–4
lipopolysaccharide effects on, 9.7
Monofixation syndrome
amblyopia and, 6.52
definition of, 6.51
diagnosis of, 6.51–52
management of, 6.52
Worth 4-dot test for, 6.81
Monofocal intraocular lenses, 13.151
Monogenic diseases, 2.218
Mononeuritis multiplex, 1.171, 9.158
Mononucleosis, infectious (IM), ocular involvement in, 8.230–231, 8.231*f*
Monosomy, 2.223
Monosomy 3, in choroidal/ciliary body melanoma, 4.197, 4.253, 4.268, 4.278
Monosomy X, 6.386*t*
Monovision, 3.224, 3.240, 3.258, 13.39, 13.164–165
with contact lenses, 13.164
as trial before surgery, 13.39, 13.165, 13.198
modified (mini), 13.39, 13.164–165
accommodating IOLs and, 13.154
Mood disorders, 1.195–196. *See also* Depression
Mood stabilizers, 1.203–204
Moore, lightning streaks of, 5.175
Mooren ulcer, 8.313–316, 8.315*f*
Moraxella
blepharitis/blepharoconjunctivitis caused by, 8.74, 8.208*t*
catarrhalis, 7.46
conjunctivitis caused by, 8.208*t*, 8.257*t*
keratitis caused by, 8.208*t*
lacunata, 8.257*t*
as normal flora, 8.206*t*
Morgagnian cataract, 4.122, 4.123*f*, 11.46, 11.50*f*
phacolytic glaucoma and, 10.97*f*, 10.97–98
Morgagnian globules, 4.122, 4.122*f*, 4.123*f*, 4.124*f*, 11.46
Morning glory disc anomaly (MGDA), 6.362–363, 6.364*f*
Morning glory optic nerve head anomaly, 5.145
Morpheaform (sclerosing) basal cell carcinoma, 4.212–213, 4.213*f*, 7.202, 7.202*f*. *See also* Basal cell carcinoma
Morphogenic gradients, 2.164–166
Morphogens, 2.165
Morquio syndrome (MPS IV), 6.270, 8.175*t*
Mosaic degeneration (anterior crocodile shagreen), 8.121
Mosaicism, 2.224–225
Mosaics, 2.224
Mosquito-borne diseases, 12.246–247
Mossy fiber input, 5.40
Motility, ocular. *See* Ocular motility
Motility disorders. *See* Ocular motility, disorders of
Motility examination. *See* Ocular motility, assessment of
Motion artifacts, in optical coherence tomography angiography, 12.29
Motion contrast, 12.28
Motor apraxia, ocular. *See* Ocular motor apraxia
Motor correspondence, Hering's law of (Hering's law of equal innervation), 6.38, 6.115–116, 6.121
eyelid retraction and, 5.274
horizontal gaze and, 5.36*f*
nystagmus and, 5.247
ptosis enhancement and, 5.270*f*, 5.310
Motor fusion, 6.43
Motor nucleus
of cranial nerve V (trigeminal), 5.47–48
of cranial nerve VI (abducens), 5.51*f*
of cranial nerve VII (facial), 5.49, 5.50*f*, 5.51*f*, 5.276–277*f*
Motor pathways, facial, 5.49–52, 5.50–51*f*. *See also* Cranial nerve VII
Motor physiology
eye movements. *See* Eye movements
gaze positions, 6.31
ocular rotations, 6.31
principles of, 6.31–32
terminology associated with, 6.31–32
Motor system disorders. *See* Parkinson disease/parkinsonism
Motor tracking systems, ocular, 5.212*t*, 5.212–213
Motor units
description of, 6.32–33
recruitment of, during fixation or following movement, 6.33
Mouth-to-mouth ventilation, 1.298
Moxeza. *See* Moxifloxacin
Moxifloxacin, 1.308*t*, 9.139
for bacterial keratitis, 8.269, 8.270*t*
description of, 2.360*t*, 2.421*t*
after penetrating and perforating trauma repair, 8.409

Moxisylyte, 2.387. *See also* Thymoxamine hydrochloride
Moyamoya disease, 6.363
6-MP. *See* 6-Mercaptopurine
MPA. *See* Microscopic polyangiitis
MPO-ANCA. *See* Myeloperoxidase-antineutrophil cytoplasmic autoantibody
MPS. *See* Mucopolysaccharidoses
MPS I H. *See* Hurler syndrome
MPS I HS. *See* Hurler-Scheie syndrome
MPS I S. *See* Scheie syndrome
MPS IH/MPS1-H. *See* Hurler syndrome
MPS IH/S. *See* Hurler-Scheie syndrome
MPS IS/MPS1-S. *See* Scheie syndrome
MPS II. *See* Hunter syndrome
MPS III. *See* Sanfilippo syndrome
MPS III A–D. *See* Sanfilippo syndrome
MPS IV. *See* Morquio syndrome
MPS IV A–B. *See* Morquio syndrome
MPS VI. *See* Maroteaux-Lamy syndrome
MPS VII. *See* Sly syndrome
MPS IX. *See* Natowicz syndrome
MPSs. *See* Mucopolysaccharidoses
MR. *See* Medial rectus (MR) muscle
MRA. *See* Magnetic resonance angiography
MRD. *See* Margin–reflex distance
MRD_1. *See* Margin–reflex distance 1
MRD_2. *See* Margin–reflex distance 2
MRD_1/MRD_2. *See* Margin–reflex distance
MRF. *See* Mesencephalic reticular formation
MRI. *See* Magnetic resonance imaging
MRI angiography. *See* Magnetic resonance angiography
mRNA. *See* Messenger RNA
MRS. *See* Magnetic resonance spectroscopy
MRSA. *See* Methicillin-resistant *Staphylococcus aureus*
MRV. *See* Magnetic resonance venography
MS. *See* Multiple sclerosis
MSICS. *See* Manual small-incision cataract surgery
MST area. *See* Medial superior temporal (MST) area
mSv. *See* Millisievert
MT area. *See* Medial temporal (MT) area
mtDNA. *See* Mitochondrial DNA
MTF. *See* Modulation transfer function
MTS. *See* Muir-Torre syndrome
MTX. *See* Methotrexate
Mucin glycoproteins, 2.260
Mucinous corneal dystrophy, subepithelial (SMCD), 8.135*t*
Mucins, 2.253
  tear film, 8.5, 8.6*f*
    dry eye and, 8.54, 8.54*f*
    secretion of, 8.5, 8.6*f*
Mucoceles, 6.224, 7.101–102, 7.102*f*
Mucocutaneous lymph node syndrome. *See* Kawasaki disease
Mucoepidermoid carcinoma, 4.61
  ocular surface, 8.332*t*, 8.336
Mucolipidoses (MLs), 6.388*t*, 8.178
  corneal changes in, 8.178
    congenital/infantile opacities and, 8.107
Mucomyst. *See* Acetylcysteine
Mucopolysaccharides
  deposit of. *See also* Glycosaminoglycans
    in macular dystrophy, 8.149
  in hypothyroidism, 1.45
Mucopolysaccharidoses (MPSs), 2.204*t*, 8.174–176, 8.175*t*, 8.176*f*, 12.282–12.283*t*, 12.290–291. *See also specific type*
  corneal changes in, 8.174–176, 8.175*t*, 8.176*f*
    congenital/infantile opacities and, 8.107
  corneal disorders in, 6.257*t*, 6.270, 6.385, 6.387*f*, 6.388*t*
Mucopyoceles, 7.101
Mucor infection (mucormycosis/zygomycosis/phycomycosis), 5.355*f*, 5.355–356, 6.215, 6.215*f*, 7.51, 8.249*t*, 8.251
  cornea involved in (keratitis), 4.78
  optic nerve involved in, 4.243
  orbit involved in, 4.226–227, 4.228*f*, 5.355
Mucosa-associated lymphoid tissue (MALT)
  of conjunctiva (conjunctiva-associated/CALT), 2.43, 4.47, 4.69, 8.7
    lymphoma arising in, 8.349–350, 8.350*f*
  description of, 2.43, 4.47, 4.69, 7.92, 9.53
Mucosa-associated lymphoid tissue (MALT) lymphoma (MALToma/extranodal marginal zone lymphoma)
  of conjunctiva, 4.70, 4.71*f*, 8.349–350, 8.350*f*
  of orbit, 4.232, 4.233*f*
Mucosal mast cells, 9.2–3
Mucous membrane grafting (transplantation), 8.351*t*, 8.365–366
  indications for, 8.351*t*, 8.366
  for mucous membrane pemphigoid, 8.303, 8.366
Mucous membrane (ocular cicatricial) pemphigoid (MMP), 4.53–55, 4.54*f*, 8.285, 8.299–303, 8.300*f*, 8.301*f*, 8.301*t*, 8.302*t*
  cataract surgery in patient with, 11.173
  drug-induced (pseudopemphigoid), 8.91, 8.92, 8.299
  mucous membrane grafting for, 8.303, 8.366
  staging of, 8.299–300, 8.300*f*, 8.302, 8.302*t*
Mucus, tear film, 8.5
Mucus excess, conjunctival, 8.46*t*
Mucus-fishing syndrome, 8.89
MUGA. *See* Multiple gated acquisition
Muir-Torre syndrome (MTS)
  description of, 7.191, 7.207
  eyelid manifestations of, 4.210*t*, 4.215, 4.216*f*
Mulberry lesions (astrocytic hamartomas), 4.295, 4.296*f*, 5.108*f*, 5.143
Müller cells
  defect of, 12.162
  description of, 2.88–89, 2.92, 2.111, 2.112*f*
  development of, 2.155*f*
  footplates of, 12.15, 12.15*f*, 12.326
  outer extent of, 12.15
  retinal, 5.24
    in healing/repair, 4.17
  retinoschisin and, 12.279
Müller muscle (superior tarsal muscle), 4.202, 8.3, 8.4*f*
  description of, 2.26, 2.33, 2.35, 7.166, 7.167*f*, 7.171, 7.254
  eyelid control and, 8.3, 8.4*f*
  in Horner syndrome, 5.257
  innervation of, 5.53, 5.53*f*, 5.54
Müller muscle–conjunctival resection (MMCR), 7.145, 7.250
Multi-Ethnic Study of Atherosclerosis (MESA), 12.62
Multi-lenslet array, 3.291*f*

Multicenter Uveitis Steroid Treatment Trial, 9.98, 9.99*t*
Multicentric basal cell carcinoma, 7.203. *See also* Basal cell carcinoma
Multidrug-resistant tuberculosis (MDRTB), 1.257, 9.239
Multifactorial inheritance, 2.232–233
Multifocal ablation, for presbyopia, 13.167, 13.168*f*
Multifocal chorioretinitis
  in West Nile virus, 9.263
  in Whipple disease, 9.244, 9.244*f*
Multifocal choroiditis (MFC), 6.319, 12.220*t*, 12.225–226, 12.226*f*
  in AIDS patients, 9.332
  peripheral, 9.229
  in systemic lupus erythematosus, 9.155*f*
  tubercular, 9.236*f*
Multifocal choroiditis and panuveitis syndrome (MCP), 12.226f
  characteristics of, 9.162–164*t*, 9.177–178
  definition of, 9.178
  diagnosis of, 9.181
  fluorescein angiography findings in, 9.163*t*, 9.179, 9.179*f*
  fundus autofluorescence findings in, 9.163*t*, 9.179, 9.180*f*
  lesions in, 9.178, 9.178*f*
  manifestations of, 9.178–180*f*, 9.178–181
  optical coherence tomography findings in, 9.164*t*, 9.179, 9.180*f*
  prognosis for, 9.181
  treatment of, 9.181
Multifocal electroretinogram/electroretinography (mfERG), 5.96*f*, 5.96–97, 12.45, 12.48–12.49*f*
  in melanoma-associated retinopathy, 5.102–103
  in multiple evanescent white dot syndrome, 5.101
Multifocal eosinophilic granuloma, 6.219
Multifocal lenses. *See also* Bifocal lenses
  bifocal
    accommodative amplitude for, 3.178–179
    add power of, 3.178–180
    fused, 3.180
    image displacement, 3.184, 3.186*f*
    image jump, 3.184–186, 3.187*f*
    induced anisophoria, compensating for, 3.186–190, 3.187*f*
    lens design of, 3.190
    plastic molded, 3.180
    Prentice rule and, 3.184–190, 3.185–3.189*f*
    prismatic effects of, 3.184, 3.185*f*
    round segment, 3.180, 3.181*f*
    types of, 3.180, 3.181*f*
  definition of, 3.178
  intraocular (MFIOLs), 11.121*f*, 11.121–122, 13.8*t*, 13.155–156, 13.165–167, 13.166*f*
    adverse effects of/complications/patient dissatisfaction and, 11.151, 13.156, 13.167
    annular zones, 3.259, 3.259*f*
    apodized diffractive, 13.166, 13.166*f*
    best-corrected visual acuity with, 3.260
    bifocal, 3.258–259, 3.259*f*
    bilateral implantation of, 13.155
    capsular decentration and, 11.183
    clinical results of, 3.260–261
    decentration effects on, 3.258
    description of, 3.257–258
    diffractive, 3.259*f*, 3.259–260, 13.166, 13.166*f*
    disadvantages of, 3.258
    dry eye therapy before use of, 11.173
    extended-depth-of-focus lenses *versus*, 3.262–263, 3.263*f*
    indications for, 3.258
    multiple-zone, 3.259, 3.259*f*
    outcomes of, 13.155–156
    patient selection for, 3.260, 13.155, 13.166–167
    power calculation for, 3.258
    for presbyopia, 13.165–167, 13.166*f*
    refractive, 13.166, 13.166*f*
    surgical technique for insertion of, 13.155
    three-zone, 3.259, 3.259*f*
    types of, 3.258–260
    zonal refractive, 13.166, 13.166*f*
  progressive addition, 3.182–184, 3.183*f*
  trifocal, 3.180–182
Multifocal serpiginous choroiditis, 9.177
Multifocal stromal infiltrates, 8.50
Multimodal computed tomography, stroke evaluations, 1.112
Multinucleated giant cells, 4.7, 4.9*f*
  in focal posttraumatic choroidal granulomatous inflammation, 4.22*f*
  in granulomatous conjunctivitis, 4.52, 4.52*f*
  in sarcoidosis, 4.187, 4.187*f*
Multiplanar incisions, clear corneal, 11.106, 11.106*f*
Multiple endocrine neoplasia (MEN), 8.200
  conjunctival neurogenic/smooth muscle tumors in, 8.345
  corneal nerve enlargement in, 8.200, 8.200*t*
  MEN1, 1.49–50, 1.236
  MEN2, 1.49–50, 1.236
  ophthalmologic findings in, 1.49*f*
Multiple evanescent white dot syndrome (MEWDS), 5.101, 12.220*t*, 12.223–224, 12.224*f*
  acute macular neuroretinopathy and, 9.189
  characteristics of, 9.162–164*t*
  definition of, 9.185
  description of, 9.161
  diseases associated with, 9.189
  early receptor potential amplitudes in, 9.187
  fluorescein angiography findings in, 9.163*t*, 9.185, 9.186–187*f*
  fundus autofluorescence findings in, 5.90, 9.163*t*, 9.186–187*f*, 9.187
  indocyanine green angiography findings in, 9.163*t*, 9.188*f*
  manifestations of, 9.185–188, 188*f*
  medical management of, 9.93
  OCT in identification of, 5.92, 5.101
  prognosis for, 9.188
Multiple gated acquisition (MUGA) scans, in coronary heart disease diagnosis, 1.89
Multiple myeloma, 7.95
  crystalline corneal deposits and, 8.198, 8.198*f*
Multiple sclerosis (MS), 5.315–320, 5.316*f*
  chiasmal/retrochiasmal abnormalities in, 5.318
  course and prognosis of, 5.315
  diagnosis of, 5.319
  epidemiology and genetics of, 5.315

funduscopic abnormalities in, 5.318
HLA association in, 5.315
human leukocyte antigen association with, 9.65*t*
intermediate uveitis associated with, 9.151–152, 12.231
laboratory evaluation of, 5.319
neuro-ophthalmic signs of, 5.315–320, 5.316*f*
neuroimaging in, 5.65, 5.72*t*, 5.92, 5.316*f*, 5.319
nonocular symptoms of, 5.317
ocular motility disturbances in, 5.246, 5.248, 5.249, 5.318–319
optic nerve conduction delay in, 12.52
optic nerve involvement and, 5.107*t*, 5.114, 5.114*f*, 5.115, 5.116, 5.317–318
pathology in, 5.315–316, 5.316*f*
presentation of, 5.316–317
progressive, 5.315
relapsing-remitting course of, 5.315
treatment of, 5.319–320, 5.321*t*
uveitis in, 5.318
Multiple sulfatase deficiency, 8.177
Multiple-zone multifocal intraocular lens, 3.259, 3.259*f*
Multiplex ligation-dependent probe amplification (MLPA), 4.39*t*
Multipurpose solutions, for contact lens, 3.229*t*, 3.230
Multizone keratectomies, 13.30, 13.30*f*
Mumps virus, 8.239, 8.240*t*
description of, 1.228–229, 9.261
ocular infection caused by, 8.208*t*, 8.239, 8.240, 8.240*t*
Munchausen syndrome, 5.299. *See also* Factitious disorders
Munnerlyn formula, 3.279, 13.29
Munson sign, 8.163, 8.163*f*
Murine models
autoimmune regulator–deficient mice, 9.62
interphotoreceptor retinoid-binding protein-specific T-cell receptor transgenic mice, 9.62
Muro 128. *See* Sodium chloride
Muscarinic drugs
adverse effects of, 2.378
agonists
adverse effects of, 2.378
direct-acting, 2.375–379, 2.376–377*f*
indirect-acting, 2.379
antagonists, 2.380–381
Muscarinic receptors
description of, 2.374, 2.374*f*, 2.375*t*
drugs affecting. *See* Muscarinic drugs
Muscle cone, 6.26, 6.26*f*
Muscle of Riolan, 2.29, 2.30*f*, 2.32*f*, 7.163, 7.163*f*, 7.170
Muscle relaxants and sedatives, for benign essential blepharospasm, 7.258
Muscle-specific kinase (MuSK) antibodies, in myasthenia gravis, 5.325–326
Muscle-weakening procedures. *See* Weakening procedures
Muscles. *See* Extraocular muscles; *specific muscle*
Muscular arteries, inferior/superior, 5.14–15, 5.15*f*
MuSK antibodies. *See* Muscle-specific kinase (MuSK) antibodies
Mustardé flap, 7.224, 7.225*f*
Mutagens, 2.217
Mutamycin. *See* Mitomycin/mitomycin C
Mutation. *See also specific type*
definition of, 2.182–183, 2.217
gain of function caused by, 2.183
missense, 2.183
nonsense, 2.183
null, 2.183
point, 2.217
polymorphisms *versus*, 2.182–183
screening methods for, 2.189–194, 2.190–193*f*
single base-pair, 2.183
Mutton-fat keratic precipitates, 8.52, 9.78, 9.79*f*, 9.196. *See also* Keratic precipitates
in sympathetic ophthalmia, 4.185
MVA. *See* Magnetic resonance venography
Myasthenia gravis (MG), 5.323–326, 5.325*f*, 6.142*f*, 6.142–143, 6.143*t*
clinical presentation of, 5.324
description of, 7.58
diagnosis of, 5.324–326, 5.325*f*
edrophonium in, 5.324–325
extraocular motor dysfunction/diplopia in, 5.192, 5.206, 5.324
neostigmine methylsulfate for, 2.381
neuro-ophthalmic signs of, 5.323–326, 5.325*f*
ocular, 7.248
prostigmine for diagnosis of, 2.362
pseudo-internuclear ophthalmoplegia caused by, 5.190, 5.324
ptosis associated with, 5.206, 5.270*f*, 5.271, 5.273, 5.273*t*, 5.324, 7.244, 7.247–248
saccadic dysfunction in, 5.221–222
treatment of, 5.326
Mycelium, 8.249
MYCN oncogene, in retinoblastoma, 4.173, 4.290
Mycobacterium (mycobacteria), 1.256–257, 7.50, 7.50*f*, 8.244*t*, 8.248, 8.272–273, 8.273*f*
abscessus, 1.256
avium/avium-intracellulare, 5.350
chelonei, 7.50, 8.248, 8.272
fortuitum, 7.50, 8.248, 8.272
keratitis caused by, after photoablation, 13.106, 13.119
leprae, 1.256, 6.240, 8.248
lepromatosis, 1.256
neuro-ophthalmic signs of infection with, 5.350
nontuberculous (atypical) infection caused by, 8.248, 8.272–273, 8.273*f*
ocular infection/inflammation caused by, 8.248, 8.272–273, 8.273*f*
therapy for, 8.270*t*
stains and culture media for identification of, 8.209*t*, 8.273
tuberculosis. See also Tuberculosis
description of, 1.222, 1.256–257, 5.350, 6.240, 8.248, 9.234, 12.240
interferon-gamma release assays for, 9.29
nucleic acid amplification techniques for, 9.239
phlyctenulosis associated with, 8.75
serpiginous-like choroiditis caused by, 9.177
Mycology, 8.208*t*, 8.249–251. *See also* Fungi
Mycophenolate mofetil, 1.179, 2.404*t*
for corneal graft rejection prophylaxis, 8.430
for uveitis, 6.322, 9.107
Mycoplasma pneumoniae, 1.256, 2.427

Mycotic (fungal) keratitis, 4.78, 4.78*f*, 8.208*t*, 8.273–276, 8.274*f*
after photoablation, 13.106–107
plant/vegetable materials and, 4.78, 8.273, 8.387, 8.399
Mydfrin. *See* Phenylephrine
Mydral. *See* Tropicamide
Mydriacyl. *See* Tropicamide
Mydriasis/mydriatics, 2.380, 2.380*t*
angle closure caused by, 10.122, 10.123
benign episodic, 5.267
after cataract surgery, 11.138
congenital, 6.268
in Horner syndrome, 5.259
multifocal IOLs and, 13.156
pharmacologic, 5.263
seizures and, 1.208
traumatic, 5.262, 8.388, 8.389*f*
for uveitis, 9.113
Myectomy, 6.164*t*
for benign essential blepharospasm, 5.283
surgical, 7.257–258
Myelin sheaths, 6.44
Myelinated retinal nerve fiber layer, 6.365, 6.365*f*
Myelinated retinal nerve fibers, 2.62, 4.143
Myelination
of nerve fiber layer, optic nerve/nerve head/disc edema differentiated from, 5.107–109, 5.108*f*
of optic nerve, 5.26
Myelitis, with optic neuritis (neuromyelitis optica/NMO/Devic disease), 5.107*t*, 5.116–118, 5.117*t*, 5.320–323. *See also* Neuromyelitis optica
Myelodysplastic syndrome, 1.137
Myeloid stem cells, 1.131
Myeloma, crystalline corneal deposits and, 8.198, 8.198*f*
Myeloperoxidase, 9.158, 9.160
Myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA), 7.64
Myeloproliferative disorders, 1.142, 1.148
MYOC (TIGR/myocilin *[TIGR/MYOC])* gene, 10.10, 10.11*t*, 10.150
in pediatric glaucoma, 8.108
Myocardial infarction (MI). *See also* Acute coronary syndromes; Ischemic heart disease
aspirin prophylaxis in, 1.89
complications of, 1.85
congestive heart failure after, 1.85
coronary thrombus as cause of, 1.83
definition of, 1.83
in diabetes mellitus, 1.40
diagnosis of
biomarkers, 1.86–87
cardiac enzymes, 1.86
electrocardiogram, 1.83–84, 1.85*f*, 1.86
myoglobin levels, 1.87
troponin levels, 1.87
mortality rate for, 1.85
non–ST-segment elevation
description of, 1.83
treatment of, 1.93–94
onset of, 1.83
prognosis for, 1.84–85
signs and symptoms of, 1.84
ST-segment elevation
description of, 1.83
reperfusion therapies for, 1.94
thrombolysis for, 1.94–95
treatment of, 1.94
treatment of
medical therapy, 1.93–94
percutaneous coronary intervention, 1.85, 1.94
thrombolysis, 1.94–95
Myocardial ischemia, 1.83
Myocardial oxygen demand, 1.81
Myocilin gene (*TIGR*/myocilin/*TIGR/MYOC*) gene, 10.10, 10.11*t*, 10.150
in pediatric glaucoma, 8.108
Myoclonus
oculopalatal, pendular nystagmus and, 5.246–247
opsoclonus and, 5.249
voluntary nystagmus and, 5.250
Myoepithelial cells, 5.54
Myofibromas, 6.222
Myogenic ptosis, 5.273*t*, 7.240, 7.244*f*, 7.244–245
Myoglobin
in immunohistochemistry, 4.33
serum, 1.87
Myoid, 12.12
Myoid zone, 4.141*f*
Myokymia
eyelid, 5.282*t*, 5.284
facial, 5.282*t*, 5.284
superior oblique (SOM), 5.250–251, 6.145
Myopathies
diplopia caused by, 5.206–209, 5.207*f*
extraocular
inherited conditions causing, 5.328–330, 5.329*f*
in thyroid eye disease, 4.226, 4.227*f*, 5.206
mitochondrial, with encephalopathy, lactic acidosis, and strokelike episodes (MELAS), 5.294–295
migrainelike headache and, 5.294–295
Myopia
accommodative demand, 3.208
in adolescents, 3.142
adult-onset, 3.143
cataract causing, 11.43, 11.70, 11.70*t*
cataract surgery in patient with, 11.184–185
retinal detachment and, 11.166
in children, 3.142, 3.174
congenital, 3.174
consecutive, 13.101–102
contact lenses for, orthokeratology and, 13.70–71
definition of, 3.4, 3.124
description of, 3.12–13, 3.137
developmental, 3.142–143, 3.174
diverging lens for, 3.170, 3.170*f*
educational achievement and, 3.143
etiology of, 3.143
genetic factors, 3.143
glaucoma and, 10.9, 10.29, 10.82, 10.87, 10.122
high. *See* High (pathologic) myopia
historical treatments for, 12.208
hyperopia overcorrection and, 13.101–102
conductive keratoplasty for, 13.129
instrument, 3.282, 3.286
juvenile-onset, 3.142

keratorefractive surgery for, 3.275
lenticular (myopic shift), 11.43, 11.70
megalocornea and, 8.100
model of, 3.12–13, 3.13*f*
night, spherical aberrations and, 13.12, 13.102
orthokeratology for correction of, 13.70–71
pathologic. *See* High (pathologic) myopia
photorefractive keratectomy for, 3.271, 3.271*f*
pictorial representation of, 3.137*f*
positive defocus caused by, 3.276
prevalence of, 6.180
prismatic effects of bifocal lenses in, 3.185*f*
progression of, methods for reducing, 3.144
residual
after intrastromal corneal ring segment placement, 13.65
after LASIK, intrastromal corneal ring segments for, 13.70
retinal detachment and, 13.44, 13.183–184, 13.184, 13.197
retinal reflex in, 3.152, 3.152*f*
in retinopathy of prematurity, 6.334
spectacle lenses for, 3.211, 3.212*f*
squinting by persons with, 3.130
surgical correction of, 13.30, 13.30*f*. *See also specific procedure*
aberrations after, 13.11, 13.12
bioptics for, 13.137, 13.157
corneal curvature flattening and, 13.26, 13.51, 13.80
examination before, 13.40
hyperopia after (consecutive hyperopia), 13.101–102
incisional corneal surgery for, 13.49–53, 13.50*f*, 13.51*f*
intraocular pressure measurement and, 13.181, 13.182*f*
intrastromal corneal ring segments for, 13.62, 13.62*f*, 13.63, 13.63*f*, 13.64–65
LASIK for, 13.95, 13.97. *See also* LASIK
light-adjustable IOLs for, 13.153–154, 13.154*f*
monovision for, 13.164, 13.165
nonlaser, 13.8*t*
overcorrection and, 13.101–102
phakic IOLs for, 13.137, 13.138, 13.140
photoablation for, 13.74*f*
outcomes of, 13.95–96
photorefractive keratectomy for, 13.95
radial keratotomy for, 13.49–53, 13.50*f*, 13.51*f*. *See also* Radial keratotomy
refractive lens exchange for, 13.148, 13.150
retinal detachment/retinal detachment repair and, 13.44, 13.183–184, 13.184, 13.197
small-incision lenticule extraction for, 13.204
wavefront-optimized/wavefront-guided laser ablation for, 13.31
outcomes of, 13.31–32, 13.97
topiramate as cause of, 12.305
vitreous affected by, 2.301
wavefront aberration produced by (positive defocus), 13.11, 13.11*f*
wavefronts in, 3.73, 3.73*f*
Myopic astigmatism, 3.138, 3.138*f*
Myopic keratomileusis, 13.8*t*. *See also* LASIK
Myopic macular schisis, 12.209, 12.210*f*
Myopic shift, in cataracts (lenticular myopia), 11.43, 11.70
Myorhythmia, oculomasticatory, 5.251
Myosin VIIA, 2.313*t*
Myositis, 2.470*f*, 7.68, 7.69*f*
orbital, 4.224, 4.225*f*, 5.207*f*, 5.207–208
nonspecific orbital inflammation and, 4.225, 4.225*f*
Myotomy, 6.164*t*
Myotonic dystrophy, 2.218, 5.329–330, 12.282*t*
lens disorders/cataracts in, 11.62, 11.62*f*
ptosis in, 5.273, 5.273*t*, 5.329, 5.330
Myxedema, 1.44
MZM. *See* Methazolamide

N

N95, 12.45
N-MYC gene, in retinoblastoma, 4.173, 4.290
N-retinylidene-phosphatidylethanolamine, 2.328
Na. *See* Sodium
Na^+/I symporter (NIS), 7.307
Nabumetone, 2.409*t*
Nadbath-Ellis block, for cataract surgery, 11.93*f*
Nadbath facial nerve block, 1.291
NADH reductase. *See* Nicotinamide adenine dinucleotide (NADH) reductase
NADP, in lens glucose/carbohydrate metabolism, 11.18*f*, 11.19
NADPH, 2.311, 2.336
in lens glucose/carbohydrate metabolism, 11.18*f*, 11.19
Nafcillin, 2.418
Nail-patella syndrome (onycho-osteodysplasia), 8.192*t*
gene for, 10.11*t*
NAION. *See* Nonarteritic ischemic optic neuropathy, anterior
Na^+,K^+-ATPase (sodium-potassium pump)
in aqueous humor secretion/suppression, 10.16–17
cold affecting, 8.385
corneal hydration and, 8.9
description of, 2.266, 2.271, 2.287
in Fuchs endothelial corneal dystrophy, 8.156
in lens active transport, 11.21
pump-leak theory and, 11.21, 11.22*f*
in retinal pigment epithelium, 2.324
Nalidixic acid, 2.420
Nanophthalmos, 4.108–109, 6.263
angle-closure glaucoma and, 4.108, 4.109, 10.144
cataract surgery in patient with, 11.185
genetic/hereditary factors in, 10.11*t*
Nanopore sequencing technology, in next-generation sequencing. *See* Next-generation sequencing
Nanotechnology, for drug delivery, 2.366–367
NaOH. *See* Sodium hydroxide
Naphazoline hydrochloride, 2.412*t*
Naphazoline hydrochloride/antazoline phosphate, 2.412*t*
Naphazoline hydrochloride/pheniramine maleate, 2.412*t*
Naphcon-A. *See* Naphazoline hydrochloride/pheniramine maleate

Naproxen, 1.308*t*, 2.409*t*
Narcolepsy, in neuromyelitis optica spectrum disorder, 5.117*t*
NARP. *See* Neurogenic muscle weakness, ataxia, and retinitis pigmentosa; Neuropathy, ataxia, and retinitis pigmentosa
Narrow-band interference filters, 3.103, 3.104*f*
Narrow complex tachycardias, 1.102
Nasal bone, 7.7*f*
Nasal cavity, 7.19
Nasal endoscopy, for nasolacrimal duct obstruction, 6.235
Nasal/nasal radiating fibers, 5.25, 5.25*f*, 5.103, 5.104*f*
  visual field defects and, 5.103, 5.106*f*
Nasal retina, 5.24*f*, 5.25, 5.27
Nasal step, 5.103, 5.106*f*
  in glaucoma, 10.68, 10.69*f*
Nasal vein, 2.26*f*
Naso-orbital-ethmoidal (NOE) fractures, 7.112, 7.113*f*
Naso-orbital fractures, 7.306
Nasociliary nerve, 2.12*f*, 2.132, 2.132*f*, 5.8*f*, 5.43*f*, 5.48, 5.48*f*, 5.54, 7.12–13*f*
  lacrimal functional unit innervated by, 8.5*f*
Nasofrontal vein, 2.26*f*
Nasolabial folds, 7.270*f*
Nasolacrimal canal, 2.9, 7.11, 7.20
Nasolacrimal duct (NLD), 2.42, 5.9*f*, 5.11. *See also* Lacrimal drainage system
  anatomy of, 2.9*f*, 2.11, 7.19, 7.281–282
  canalization of, 7.283
  description of, 2.8
  development of, 7.283
  imperforate, 7.288
  occlusion of, ocular medication absorption and, 10.184–185
    in children, 10.165
  physiology of, 7.283
  probing of, 7.292
  traumatic injuries to, 7.312
Nasolacrimal duct obstruction (NLDO). *See also* Tearing/epiphora
  complete, 7.298
  congenital
    antibiotics for, 6.231–232, 6.234
    balloon dacryoplasty for, 6.234–235, 6.235*f*, 7.294
    bilateral, 6.232*f*
    canalicular obstruction, 7.298, 7.300*f*
    causes of, 7.283, 7.287–288
    clinical features of, 6.230, 6.232*f*
    complex, 6.230, 6.233–234
    dacryocystitis associated with, 7.289
    description of, 6.227, 6.230
    diagnosis of, 7.300
    evaluation, 7.287–288
    examination of, 6.230
    infantile glaucoma *versus*, 6.230
    intubation for, 6.234–235
    lacrimal intubation stents for, 7.292–294, 7.294*f*
    lacrimal sac palpation in examination for, 7.296
    management of, 7.288–289
    massage for, 6.231–232
    nasolacrimal probing for, 6.232–235, 6.233*f*
    nonsurgical management of, 6.231–232
    prevalence of, 6.230
    probing for, 7.289, 7.291*f*, 7.291–292, 7.298, 7.300
    recurrence of, 6.234
    simple, 6.230, 6.231*f*
    spontaneous resolution of, 6.231
    stents for, 6.234–235
    surgical management of, 6.232–233
    tearing caused by, 6.230
    treatment of, 7.287
    turbinate infracture for, 7.294
    valve of Hasner in, 7.288–289
  dacryocystitis associated with, 7.313–315, 7.315*f*
  dacryocystorhinostomy for, 6.236, 7.307–310, 7.308–309*f*
  dacryolith as cause of, 7.305*f*, 7.305–306
  description of, 7.300
  diagnosis of, 7.305
  endoscopic lacrimal duct recanalization for, 7.310
  etiology of, 7.305–307
  granulomatosis with polyangiitis as cause of, 7.306, 7.306*f*
  inflammatory diseases as cause of, 7.306
  intubation and stenting for, 7.292–294, 7.294*f*, 7.307
  involutional stenosis as cause of, 7.305
  lacrimal plugs as cause of, 7.306
  lacrimal–cutaneous fistula and, 7.286
  management of, 7.307–310
  nasal disease as cause of, 7.306
  nasal endoscopy for, 6.235
  neoplasms as cause of, 7.307
  in older children, 6.235
  primary congenital glaucoma differentiated from, 10.152, 10.152*t*
  radioactive iodine as cause of, 7.307
  recurrent, 6.234
  sinus disease as cause of, 7.306
  traumatic causes of, 7.306
Nasolacrimal probing, for congenital nasolacrimal duct obstruction, 6.232–235, 6.233*f*
Natacyn. *See* Natamycin
Natalizumab, for multiple sclerosis, 5.318, 5.321*t*
  progressive multifocal leukoencephalopathy caused by, 5.318, 5.351
Natamycin, 2.429, 2.430*t*
  for fungal keratitis, 8.275
National Cholesterol Education Program (NCEP)
  Adult Treatment Panel, 1.71, 1.74
  blood cholesterol guidelines, 1.71
National Elder Abuse Incidence Study, 1.185
National Eye Institute (NEI) classification of eye movement abnormalities, 6.147
National Eye Institute Visual Function Questionnaire (NEI-VFQ), 11.71
National Health and Nutrition Examination Surveys (NHANES), 1.52
National Institutes of Health Stroke Scale (NIHSS), 1.111
National Institutes of Health vitreous haze grading system, 9.82
National Registry of Drug-Induced Ocular Side Effects, 1.309
Natowicz syndrome (MPS IX), 8.175*t*

Natural (innate) immunity. *See* Innate immune response/innate immune system
Natural killer (NK) cells
description of, 9.5, 9.46
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
Natural regulatory T (nTreg) cells, in external eye defense, 8.12–13*f*
Naturally occurring T regulatory cells, 9.34
Naugle exophthalmometer, 7.24, 7.24*f*
Nausea and vomiting, fluorescein angiography as cause of, 12.36
NBX. *See* Necrobiotic xanthogranuloma
NCEP. *See* National Cholesterol Education Program
NCLs. *See* Neuronal ceroid lipofuscinoses
NDP gene, 2.212, 6.347
Nd:YAG laser. *See also* Laser(s)
capsulotomy, 11.154*f*, 11.154–157, 11.156*f*
for anterior capsule fibrosis and phimosis, 11.154, 11.154*f*, 11.154–157, 11.156*f*
for capsular block syndrome, 11.149
for capsule opacification, 11.152, 11.153, 11.154, 11.154*f*, 11.154–157, 11.156*f*
multifocal IOLs and, 13.156, 13.167
chronic postoperative endophthalmitis triggered by, 9.292
complications of, 11.156–157
contraindications for, 11.155
description of, 6.302
indications for, 11.154–155
lens particle glaucoma and, 11.67
procedure for, 11.155–156, 11.156*f*
retinal detachment and, 11.157, 11.166
uveitis and, 9.316
for cyclodestruction, 10.194, 10.195
in children, 10.163, 10.164
cystoid macular edema treated with, 12.159
description of, 3.112, 3.115
for iridotomy, 10.192, 10.193
mechanism of, 12.367
ocular injury caused by, 12.367
photolysis, 11.125
for trabeculoplasty (selective), 10.188, 10.189, 10.190, 10.190*f*
vitreolysis
for cystoid macular edema, after cataract surgery, 11.165
for vitreous prolapse in anterior chamber, 11.143
"Near clear" incision, for cataract surgery, 11.107
Near fixation, 6.64
Near-infrared fundus autofluorescence, 12.32–33
Near periphery, 12.9
Near-point chart, phoropter with, 3.37*f*
Near point of accommodation
definition of, 3.140
measurement of, 3.179
pupil size effects on, 3.130
Near point of convergence (NPC), 5.226, 6.71
in convergence insufficiency, 5.227
Near reflex, 2.126
spasm of, 5.227, 5.309–310, 6.94
Near response, in pupillary examination, 5.254
light-near dissociation and, 5.254, 5.266*t*, 5.266–267
Near synkinesis, 2.126, 6.39
Near triad, 2.126, 6.39
Near vision
distance vision *versus*, in amblyopia, 3.25
multifocal intraocular lenses for, 3.258
refraction at, 3.36–38
Near visual acuity. *See also* Visual acuity
age-related loss of, 11.23. *See also* Presbyopia
testing
indications for, 3.24
in low vision, 5.78
before refractive surgery, 13.39
Neck rejuvenation
cervicoplasty, 7.276*f*
liposuction, 7.274–275, 7.275*f*
platysmaplasty, 7.276, 7.276*f*
Necrobiotic granuloma
in episcleritis, 4.109
in scleritis, 4.110, 4.110*f*
Necrobiotic granulomatous inflammatory infiltrate, in episcleritis, 4.109
Necrobiotic xanthogranuloma (NBX), 7.97, 8.347
Necrotizing fasciitis, 7.48–50, 7.49*f*
Necrotizing herpetic retinitis, 4.145, 9.330, 9.330*f*, 12.236–12.237*f*, 12.236–237, 12.238*t*
Necrotizing retinochoroiditis, 12.243
Necrotizing retinopathies
acute retinal necrosis, 9.250, 9.251–252*f*
cytomegalovirus-related anterior uveitis, 9.248–249
definition of, 9.250
progressive outer retinal necrosis, 9.250–254
Necrotizing scleritis, 4.110, 4.110*f*, 8.46*t*, 8.320*t*, 8.320–322, 8.321*f*, 8.322*f*, 8.325*f*
anterior, 9.118*f*
clinical presentation of, 9.118*f*, 9.119–122
delayed hypersensitivity response in, 9.116
description of, 9.115
diagnosis of, 9.124
granulomatous, 9.120*f*, 9.120–121
with inflammation, 8.320*t*, 8.320–321, 8.321*f*, 9.120–121, 121*f*
laboratory tests for, 9.124
mortality rates for, 9.119
pathophysiology of, 9.116
postsurgical, 9.121, 9.121*f*
surgically induced (SINS), 8.282
vaso-occlusive, 9.120, 9.121*f*
vision loss risks, 9.128
without inflammation (scleromalacia perforans), 4.110, 8.320*t*, 8.321–322, 8.322*f*, 9.121–122, 9.122*f*
Necrotizing stromal keratitis, 8.52
herpes simplex causing, 8.219, 8.220–221, 8.221*f*, 8.222, 8.223*t*
Nedocromil sodium, 2.412*t*
Needle perforation/penetration injuries, of globe, 12.358, 12.395*f*, 12.395–396
Negative angle kappa, 6.67, 6.68*f*
Negative defocus, 3.276, 13.11
Negative dysphotopsias, 3.255–256
IOLs and, 5.174, 11.150–151
Negative lenses. *See* Concave lenses

Negative likelihood ratio, 1.19
Negative numbers, in vergence equation, 3.10
Negative predictive value (NPV)
of diagnostic and screening test, 1.15–16
pretest probability effects on, 1.20*t*
Negative staining (fluorescein), 8.36
NEI classification of eye movement abnormalities, 6.147
NEI-VFQ (National Eye Institute Visual Function Questionnaire), 11.71
Neisseria, 8.244*t*, 8.245
description of, 1.250–251, 1.276, 2.419
gonorrhoeae (gonococcus), 6.238*f*, 6.238–239, 8.207, 8.208*t*, 8.245, 8.246*f*
conjunctivitis/hyperacute conjunctivitis caused by, 8.208*t*, 8.245, 8.257*t*, 8.258–260, 8.259*f*, 8.260*t*
in neonates, 8.257*t*, 8.258, 8.264
invasive capability of, 8.207
I infections, 1.250–251
resistant strains of, 8.259, 8.264
meningitidis (meningococcus), 6.238, 8.207, 8.245
conjunctivitis caused by, 8.257*t*
invasive capability of, 8.207
NEMO gene. *See IKBKAP* gene
Neo-Synephrine. *See* Phenylephrine
Neoadjuvant chemotherapy, 1.239
Neodymium:yttrium-aluminum-garnet laser. *See* Nd:YAG laser
Neofrin. *See* Phenylephrine
Neomycin sulfate, 2.418*t*, 2.426
Neomycin sulfate/polymyxin B sulfate/prednisolone acetate, 2.422*t*
Neonatal adrenoleukodystrophy, 12.283*t*, 12.290, 12.291*f*
Neonatal inclusion conjunctivitis, 6.238
Neonatal ophthalmia. *See* Ophthalmia neonatorum
Neonates. *See also* Infant(s)
chlamydial conjunctivitis in, 1.244
conjunctivitis in, 8.257*t*, 8.263–265
corneal transplantation in, 8.450–451
herpes simplex infection in, 1.260, 8.213
normal ocular flora in, 8.205
ocular deviations in, 5.230–231
ocular infections in, 8.257*t*, 8.263–265. *See also specific type*
ophthalmia neonatorum. *See* Ophthalmia neonatorum
Neoplasia, 4.10, 4.10*t*, 4.11*f*, 4.12*t*. *See also* Cancer; Intraocular tumors; Tumor(s); *specific type or structure*
classification of, 4.10*t*, 4.11*f*
diplopia caused by, 5.208
facial pain associated with, 5.298
neuroimaging in evaluation of, 5.64*f*, 5.65*f*, 5.72*t*
ocular flutter/opsoclonus caused by, 5.249
ocular surface. *See* Ocular surface, tumors of
Neoplasms. *See also* Tumor(s)
benign, 6.219–223
canalicular obstruction caused by, 7.303
differential diagnosis of, 6.216–217
eyelid, 6.199–200. *See also* Eyelid(s), tumors of
hemangiomas, 6.219–221
hematopoietic, 6.218–219
histiocytic, 6.218–219
lacrimal drainage system, 7.316–317
lacrimal sac, 7.295*f*
Langerhans cell histiocytosis, 6.218–219
leukemia, 6.218
lymphoma, 6.218
lymphoproliferative, 6.218–219
metastatic, 6.218, 7.316
nasolacrimal duct obstruction caused by, 7.307
neuroblastoma, 6.218
primary malignant, 6.217–218
rhabdomyosarcoma, 6.217*f*, 6.217–218
sarcomas, 6.218
vascular, 6.219–221, 6.220–221*f*
Neosporin. *See* Polymyxin B sulfate/neomycin sulfate/gramicidin
Neostigmine
description of, 2.381
in myasthenia gravis, 5.325, 5.326
Neovascular glaucoma, 4.188, 10.38*f*, 10.38–39, 10.132*t*, 10.132–135, 10.133*f*, 10.134*f*, 10.135*f*
iris examination in, 10.32, 10.39, 10.135*f*
tube shunt implantation for, 10.215
Neovascular membrane. *See also* Choroidal neovascularization; Neovascularization
in age-related macular degeneration, 4.165*f*, 4.165–166
Neovascular proliferation, in proliferative diabetic retinopathy, 12.102
Neovascular ("wet") age-related macular degeneration, 2.449, 4.154*f*, 4.164–166, 4.165*f*
aflibercept for, 12.82–83
Amsler grid testing of, 12.71
antiangiogenic therapies for, 12.79–80
bevacizumab for, 12.83–85, 12.84*t*
choroidal neovascularization associated with, 12.71–79. *See also* Choroidal neovascularization
combination treatment for, 12.85
differential diagnosis of, 12.76, 12.79
intravitreal injections, 12.85
laser photocoagulation for, 12.79
low vision therapies for, 12.86
macular translocation surgery for, 12.85
management of, 12.79–86, 12.81*f*, 12.82*t*, 12.84*t*
pegaptanib for, 12.80
photodynamic therapy for, 12.79
polypoidal choroidal vasculopathy, 12.75
prevalence of, 12.61
ranibizumab for, 12.80–82, 12.82*t*
signs and symptoms of, 12.71
submacular hemorrhage in, 12.85, 12.385
surgical treatment for, 12.85–86
treatment effect modifiers, 12.85
verteporfin for, 12.79
Neovascularization
of anterior chamber angle, in glaucoma, 10.32, 10.38*f*, 10.38–39, 10.132*t*, 10.132–135, 10.133*f*, 10.134*f*, 10.135*f*. *See also* Neovascular glaucoma
in branch retinal vein occlusion, 4.159, 12.125, 12.128, 12.129*f*
in central retinal vein occlusion, 4.158, 12.125
in central serous chorioretinopathy, 12.194
choroidal. *See* Choroidal neovascularization
corneal
in atopic keratoconjunctivitis, 8.292, 8.293*f*

corneal transplantation and, 8.317
pediatric, 8.451
inflammation and, 8.52
after lamellar keratoplasty, 8.435
in rosacea, 8.70, 8.70*f*
stem cell deficiency and, 8.92, 8.93
in vernal keratoconjunctivitis, 8.290
in diabetes mellitus, 4.159, 4.160*f*. *See also* Diabetic retinopathy, proliferative
in glaucoma, 4.188, 10.38*f*, 10.38–39, 10.132*t*, 10.132–135, 10.133*f*, 10.134*f*, 10.135*f*. *See also* Neovascular glaucoma
incisional surgery contraindicated in, 10.198
laser iridotomy contraindicated in, 10.191
tube shunt implantation and, 10.215
of iris (rubeosis iridis), 4.188, 4.189*f*
in branch retinal vein occlusion, 12.128–129, 12.129*f*
in central retinal artery occlusion, 12.146
in central retinal vein occlusion, 12.133, 12.135
in diabetes mellitus, 4.159, 4.160*f*, 12.107
glaucoma and, 4.188, 10.32, 10.39, 10.132*t*, 10.133, 10.133*f*, 10.135*f*. *See also* Neovascular glaucoma
in children and adolescents, 10.149*t*
incisional surgery contraindicated in, 10.198
laser iridotomy contraindicated in, 10.191
in radiation retinopathy, 12.170
in retinoblastoma, 4.174, 4.174*f*, 4.292
optic nerve/nerve head/disc (NVD), 12.128, 12.129*f*
in diabetic retinopathy, papillopathy and, 5.125
peripheral, 12.232
peripheral retinal, 12.154*t*
in proliferative sickle cell retinopathy, 12.151, 12.153*f*
pupillary reactivity disorders and, 5.255
retinal. *See also* Retinal disease, vascular
in age-related macular degeneration, 4.161*f*, 4.164–166, 4.165*f*
ischemia causing, 4.154, 4.156*f*
in uveitis, 9.324–325
in retinopathy of prematurity, 12.180–181
sea fan, 12.151, 12.153*f*
stromal, inflammation and, 8.52
subretinal, 12.162
Nepafenac, 2.400*t*, 2.410
Nephroblastoma. *See* Wilms tumor
Nephrogenic systemic fibrosis (NSF), 2.458
gadolinium causing, 5.60
Nephropathic cystinosis, 8.181
Nephropathy, diabetic, 1.39
Neptazane. *See* Methazolamide
Nerve block, facial, for cataract surgery, 11.92, 11.93*f*
Nerve fiber layer (NFL/RNFL), 3.99, 3.303, 4.139, 4.140*f*, 4.141*f*, 5.17*f*, 5.25, 5.25*f*, 5.103, 5.104*f*, 10.42–43, 10.43*f*, 10.45*f*
anatomy of, 12.15
atrophy of, in glaucoma, 10.48, 10.52
cotton-wool spots, 12.122, 12.122*f*, 12.140, 12.140*f*
in glaucoma, 10.48, 10.49*t*
diffuse/focal loss and, 10.50–52, 10.51*f*
hemorrhages in, 10.50, 10.51*f*
patterns of loss and, 10.67–69, 10.68*f*, 10.69*f*, 10.70*f*
gliosis of, 5.109
of Henle (HFL), 2.84, 2.92, 2.94*f*, 4.140, 4.141*f*, 5.24
histology of, 12.11, 12.12*f*
imaging in evaluation of, 10.53–59, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
infarction of, 12.140. *See also* Cotton-wool spots
measurement of, 12.26
in multiple sclerosis, 5.318
myelination of, optic nerve/nerve head/disc edema differentiated from, 5.107–109, 5.108*f*
OCT in assessment of, 5.91, 5.91*f*, 5.92, 5.92*f*, 5.94, 5.94*f*
OCT measurement of, 12.218
optic nerve/nerve head/disc, 10.42–43, 10.43*f*, 10.45*f*
edema and, 5.82, 5.82*f*, 5.83*f*, 5.105
pallor of, 5.82, 5.82*f*, 5.91*f*
Nerve fibers, 4.140. *See also* Nerve fiber layer
distribution of, 10.42–43, 10.43*f*
myelinated, 4.143
Nerve head sign of sickling, 12.154
Nerve loop (Axenfeld loop), 4.108, 4.108*f*
Nerve (neural) sheath tumors
conjunctival/ocular surface, 8.345
of orbit, 4.237–238, 4.238*f*, 4.239*f*
of uveal tract, 4.199, 4.200*f*
Nervus intermedius, 5.49, 5.51*f*, 5.55–56, 5.276–277*f*
Netarsudil, 2.396
Nettleship-Falls ocular albinism, 2.230, 6.407
Neural crest cells
definition of, 2.143
ectomesenchymal cells derived from, 2.162*f*
migration of, 2.146–147*f*, 2.161*f*
types of, 2.144
Neural integrator/integration, 5.36, 5.37*f*, 5.38, 5.220
in gaze-evoked nystagmus, 5.38, 5.240
in saccadic eye movement, 5.220, 5.220*f*, 5.222
Neural network, brainstem, 5.33, 5.34
Neural retina
anatomy of, 2.48*f*
development of, 2.155, 2.155*f*
lamination of, 2.155
Neural (neuroretinal) rim, 10.48
changes in, in glaucoma, 10.48–50, 10.49*t*, 10.50*f*
Neural sheath tumors, 6.223. *See also specific type*
conjunctival/ocular surface, 8.345
meningomas, 7.84–85*f*, 7.84–86
neurofibroma, 7.83*f*, 7.83–84
optic nerve glioma. *See* Optic nerve glioma
of orbit, 4.237–238, 4.238*f*, 4.239*f*
schwannoma, 7.86–87
of uveal tract, 4.199, 4.200*f*
Neuralgia
occipital, 5.296, 5.297
postherpetic (PHN), 5.280, 5.298, 8.226*t*, 8.227, 8.229, 8.230
trigeminal (tic douloureux), 5.289*t*, 5.297
Neurilemoma (neurinoma/schwannoma)
conjunctival/ocular surface, 8.345
description of, 7.86
of orbit, 4.238, 4.239*f*
of uveal tract, 4.199
vestibular, Bruns nystagmus and, 5.243
Neuritis
chiasmal, 5.151–152*f*
optic. *See* Optic neuritis

Neuro-oculocutaneous syndromes. *See also* Phakoma/phakomatoses
ataxia-telangiectasia, 6.393*t*, 6.403*f*, 6.403*t*, 6.403–404
characteristics of, 6.392
clinical features of, 6.393–394*t*
incontinentia pigmenti, 6.393*t*, 6.404*t*, 6.404–405, 6.404–405*f*
Klippel-Trénaunay syndrome (KTS), 6.406
neurofibromatosis type 1. *See* Neurofibromatosis 1 (NF1/von Recklinghausen)
neurofibromatosis type 2, 6.393*t*, 6.397
tuberous sclerosis, 6.393*t*, 6.397–399, 6.398*f*, 6.398*t*
von Hippel–Lindau syndrome, 6.393*t*, 6.399–401, 6.400*f*, 6.400*t*
Wyburn-Mason syndrome, 6.222, 6.394*t*, 6.405*t*, 6.405–406
Neuro-ophthalmology
anatomy in, 5.5–56
afferent visual pathways, 5.23–31, 5.24*f*
autonomic pathways, 5.52–56
bony anatomy, 5.5–11
efferent visual system (ocular motor pathways), 5.31–46, 5.211
sensory and facial motor pathways, 5.47–52
vascular anatomy, 5.11–23
neuroimaging in, 5.57–76, 5.72*t*. *See also* Neuroimaging
pregnancy and, 5.333–335
radiation therapy complications and, 5.357–358, 5.358*f*
systemic conditions and, 5.313–358
cerebrovascular disorders, 5.335–348
immunologic disorders, 5.313–318
infectious disorders, 5.348–357
inherited disorders, 5.328–333, 5.334*t*
Neuroblastoma, 6.218, 6.414–415, 6.415*f*
Horner syndrome and, 5.261–262
metastatic, 7.22*f*, 7.104, 7.105*f*
paraneoplastic-induced saccadic intrusions caused by, 5.249
Neurocognitive/neurodevelopmental disorders, cataract surgery in patient with, 11.169–170
Neurocristopathy, 4.98–99, 4.99*f*, 4.100*f*. *See also* Anterior segment, dysgenesis of; Axenfeld-Rieger syndrome
Peters anomaly and, 11.31–32
Neurocutaneous syndromes (phakomatoses), 5.330–333, 5.330–334*f*. *See also* Neurofibromatosis; *specific type*
Neuroectoderm, 2.149*t*, 2.150*f*, 2.160
tumors arising in, 8.338*t*, 8.338–345, 8.339*t*
Neuroectodermal cells, 2.157
Neuroectodermal tumor, primitive (PNET), retinoblastoma associated with, 4.298, 4.302, 4.302*t*
Neuroendocrine proteins, in aqueous humor, 2.276
Neurofibromas. *See also* Neurofibromatosis
acoustic, 5.330, 5.334*t*, 10.156
seventh nerve (facial) palsy and, 5.279, 5.279*f*
cutaneous, 5.330*f*
description of, 7.83*f*, 7.83–84
eyelid involvement/ptosis and, 5.269, 5.269*f*, 5.271
ocular surface, 8.338*t*, 8.345
of orbit, 4.237–238, 4.238*f*
plexiform, 10.30, 10.156
eyelid involvement/ptosis and, 5.269*f*
glaucoma and, 10.30, 10.156
of orbit, 4.238, 4.238*f*
of uveal tract, 4.199, 4.200*f*
Neurofibromatosis (NF). *See also* Neurofibromas; Neurofibromatosis 1 (NF1/von Recklinghausen); Neurofibromatosis 2 (NF2/bilateral acoustic/central)
conjunctival neurofibroma and, 8.345
description of, 7.80
eyelid abnormalities/ptosis caused by, 5.269*f*
Neurofibromatosis 1 (NF1/von Recklinghausen), 5.330, 5.330*f*, 5.334*t*, 7.83–84, 10.156
clinical features of, 6.393*t*
expressivity in, 2.220
eyelid involvement/ptosis and, 5.269*f*
genetics of, 2.227–228
glaucoma and, 10.30, 10.156
Lisch nodules associated with, 4.259, 4.260*f*
manifestations of, 6.396–397
melanocytic lesions in, 6.392, 6.395*f*
neuroglial lesions in, 6.395*f*, 6.395–396
optic nerve meningiomas and, 4.250
optic pathway/optic nerve gliomas and, 4.249, 5.130, 5.334*t*
orbital involvement and, 4.238, 4.238*f*
plexiform neurofibromas in, 5.334*t*, 6.395*f*, 6.395–396, 10.30, 10.156
eyelid involvement/ptosis and, 5.269*t*
sphenoid dysplasia associated with, 6.397
uveal/choroidal involvement and, 4.199, 4.200*f*
Neurofibromatosis 2 (NF2/bilateral acoustic/central)
description of, 5.330, 5.334*t*, 6.393*t*, 6.397, 10.156
seventh nerve (facial) palsy and, 5.279, 5.279*f*
Neurofibromin/neurofibromin 1, 5.334*t*
Neurofibromin 2 (merlin), 5.334*t*
Neurofibrovascular bundle, 6.29
Neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP), 12.294
Neurogenic ptosis, 5.273, 5.273*t*
acquired, 7.246–248
congenital, 5.272–273, 7.246
myasthenia gravis as cause of, 7.247–248
temporary, 7.247
Neurogenic/neural tumors. *See also specific type*
conjunctival/ocular surface, 8.345
Neurogenic vision loss, 7.119
Neuroglial lesions, 6.395*f*, 6.395–396
Neuroimaging, 5.57–76, 5.72*t*. *See also specific modality*
in aneurysm detection/evaluation, 5.69–70, 5.194*f*, 5.194–195, 5.340, 5.341*f*
in arteriovenous malformations, 5.292*f*
in cerebral venous thrombosis, 5.69, 5.69*f*, 5.72*t*, 5.346
cerebral visual impairment evaluations, 6.188
clinical principles and, 5.57–59, 5.71–73, 5.72*t*
how to order studies and, 5.73
interpretive errors and, 5.57
modality selection and, 5.57, 5.71–73, 5.72*t*
prescriptive errors and, 5.57
what studies to order and, 5.57, 5.71–73, 5.72*t*
when to order studies and, 5.57, 5.71
in cranial nerve palsy, 5.70

CT, 5.58, 5.58*f*, 5.60, 5.61*t*, 5.72*t*
in headache evaluation, 5.287
migraine headache and, 5.291, 5.292*f*
metabolic and functional, 5.70
MRI, 5.58–59*f*, 5.60–67, 5.61*t*, 5.62*f*, 5.63*f*, 5.63*t*, 5.64*f*, 5.65*f*, 5.65*t*, 5.66*f*, 5.67*f*, 5.72*t*
in multiple sclerosis, 5.65, 5.72*t*, 5.92, 5.316*f*, 5.319
negative studies and, 5.73–75, 5.74*f*
in optic atrophy, 5.146
in optic nerve glioma, 5.128*t*, 5.130
in optic nerve/nerve head/disc drusen, 5.89, 5.90*f*, 5.141*f*, 5.142
in optic nerve sheath meningioma, 5.128*t*
in optic neuritis/neuromyelitis optica, 5.66*f*, 5.72*t*, 5.115, 5.322–323
in papilledema, 5.109
in retinoblastoma, 4.292–293
in reversible cerebral vasoconstriction syndrome, 5.347, 5.347*f*
in sarcoidosis, 5.327
superior oblique muscle palsy evaluations, 6.119
terminology used in, 5.75–76
in traumatic optic neuropathy, 5.139*f*, 5.140
vascular, 5.60*f*, 5.67–71, 5.68*f*, 5.72*t*
in vertebrobasilar insufficiency, 5.337*f*, 5.338
Neuroleptic malignant syndrome (NMS), 1.200
Neuroleptics (antipsychotic drugs)
oculogyric crisis caused by, 5.231
tardive dyskinesia caused by
blepharospasm and, 5.281
facial movements and, 5.285
Neurologic disorders. *See also specific type*
Alzheimer disease, 1.209–210
behavioral changes caused by, 1.194
cataract surgery in patient with, 11.169–170
decision-making capacity assessments in, 1.211
epilepsy. *See* Epilepsy
hallucinations/illusions caused by, 5.174*t*
informed consent in patients with, 1.211–212
Lewy body dementia, 1.210
Parkinson disease, 1.204–205
in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.312
prion-associated, 1.211
stroke. *See* Stroke
in syphilis. *See* Neurosyphilis
vascular dementia, 1.210
Neuromas. *See also* Neurofibromas
acoustic, 5.330, 5.334*t*, 10.156
seventh nerve (facial) palsy and, 5.279, 5.279*f*
conjunctival/ocular surface, 8.345
Neuromuscular blocking agents, 2.383*t*, 6.174
Neuromuscular disorders. *See also specific type*
retinal degeneration associated with, 12.285
Neuromuscular junction disease
diplopia in, 5.206
ptosis in, 5.206, 5.273*t*
Neuromyelitis optica (NMO/Devic disease), 5.107*t*, 5.116–118, 5.117*t*, 5.320–323
clinical presentation of, 5.320–322
diagnosis of, 5.322–323
treatment of, 5.323
Neuromyelitis optica (NMO)-IgG (AQP4-IgG) antibody, 5.115, 5.117*t*, 5.118, 5.320, 5.322
Neuromyelitis optica spectrum disorder (NMOSD), 5.115, 5.116–118, 5.117*t*, 5.322, 5.323
Neuromyotonia, 5.202, 5.358
Neuronal ceroid lipofuscinoses (NCLs), 6.389*t*, 12.283*t*, 12.289, 12.290*f*
Neuronal nitric oxide synthase (nNOS), 2.394
Neuronitis, vestibular, peripheral vestibular dysfunction and, 5.242
Neurons, retinal, 2.315–317, 2.328
ischemia affecting, 4.151*f*, 4.151–152, 4.152*f*
Neuropathic pain, 1.40
Neuropathy, ataxia, and retinitis pigmentosa, 2.186
Neuropathy
diabetic, 1.39–40
neurotrophic keratopathy/persistent corneal defects and, 8.81, 8.81*t*, 8.199
hereditary sensory and autonomic. *See* Familial dysautonomia
optic. *See* Optic neuropathy
Neuropeptide Y (NPY), 2.249
Neuropeptides, 9.24*t*
Neuroretinal disorder, HIV-associated (HIV-RND), 5.348
Neuroretinal (neural) rim, 10.48
changes in, in glaucoma, 10.48–50, 10.49*t*, 10.50*f*
Neuroretinitis, 5.118*f*, 5.118–119, 6.369, 6.369*f*
bartonellosis as cause of, 9.241, 9.242*f*
cat-scratch disease causing (*Bartonella*-associated), 5.119
differential diagnosis of, 9.242*t*
diffuse unilateral subacute, 9.287–288*f*, 9.287–289
in sarcoidosis, 5.327
syphilis *versus*, 9.223
in toxoplasmosis, 5.352
Neuroretinopathy, acute macular (AMN)
fundus autofluorescence in identification of, 5.90
OCT in identification of, 5.92, 5.93*f*
Neurosarcoidosis, 5.327–328. *See also* Sarcoidosis
Neurosensory retina, 4.139–140, 4.140*f*, 4.141*f*. *See also* Retina
anatomy of, 4.139–140, 4.140*f*, 4.141*f*
cells of, 2.305
definition of, 2.84
description of, 2.83
external limiting membrane of, 2.91
ganglion cell layer of, 2.92
glial elements of, 2.88
inner nuclear layer of, 2.92
inner plexiform layer of, 2.92
internal limiting membrane of, 2.92
layers of, 2.84, 2.85*f*
melanoma invading, 4.194, 4.195*f*
middle limiting membrane of, 2.92
nerve fiber layer of, 2.92
neuronal elements of, 2.84–88, 2.86*f*
ischemia affecting, 4.151*f*, 4.151–152, 4.152*f*
outer nuclear layer of, 2.91–92
outer plexiform layer of, 2.91–92
retinal pigment epithelium and, 2.91
stratification of, 2.91–93, 2.93*f*
vascular elements of, 2.88–90, 2.90–91*f*. *See also* Retina, blood vessels of

Neurosyphilis, 1.252–253, 9.226
Neurotransmitters, 2.374, 2.374*f*
Neurotrophic keratopathy/ulcers, 8.42, 8.80–82, 8.81*t*, 8.82*f*
diabetic neuropathy and, 8.81, 8.81*t*, 8.199
esthesiometry in evaluation of, 8.42
herpetic/postherpetic eye disease and, 4.77*f*, 4.78, 8.80, 8.81*t*, 8.217–218, 8.224, 8.225, 8.227
after penetrating/deep anterior lamellar keratoplasty, 8.80
Neurotrophic proteins, in aqueous humor, 2.276
Neutral density filter effect, 6.54
Neutrality, retinoscopy, 3.152, 3.153–3.154*f*, 3.155
Neutrophil(s), 4.7
activation of, 9.10, 9.11*f*, 9.12
adhesion of, 9.11*f*, 9.12
characteristics of, 9.2
in chemical injuries, 8.383
in external eye defense, 8.13
granule products of, 9.25
in inflammation, 4.7
in innate immune response, 9.10–12
lipopolysaccharide effects on, 9.7
recruitment and activation of, 9.10–12, 9.11*f*
resting, 9.10
transmigration of, 9.11*f*, 9.12
in wound healing/repair, 4.14, 4.15*f*
Neutrophil rolling, 9.10, 9.11*f*
Nevanac. *See* Nepafenac
Nevi/nevus, 7.195–197, 7.196*f*
anterior chamber/trabecular meshwork affected by, 4.106
blue, 4.64
of choroid, 4.191, 4.192*f*, 4.256–258, 4.257*f*, 4.267–268
melanoma differentiated from, 4.267–268
of ciliary body, 4.191, 4.256
compound, 8.338*t*
of conjunctiva, 4.64
of eyelid, 4.219, 4.219*f*
congenital, 4.218, 4.218*f*
conjunctival/ocular surface, 4.61–64, 4.63*t*, 4.64*f*, 4.65*f*, 6.250, 6.250*f*, 8.338–339*t*, 8.340*f*, 8.340–341
malignant transformation and, 4.64, 4.68
melanoma and, 4.64, 4.68, 8.340, 8.341, 8.343
dermal (intradermal), 4.219, 4.220*f*
dysplastic, melanoma arising from, 4.220, 4.262
of eyelid, 4.218*f*, 4.218–220, 4.219*f*, 6.200–201, 6.201*f*
flammeus (port-wine nevus/stain/PWS)
description of, 8.345*t*, 8.346
increased episcleral venous pressure and, 10.30
in Sturge-Weber syndrome, 5.332*f*, 5.334*t*, 8.346, 10.30, 10.155
intradermal (dermal), 4.219, 4.220*f*
intraepithelial (junctional), 8.338*t*, 8.340
iris, 4.106, 4.189–190, 4.190*f*, 4.255, 4.256*f*, 4.259
junctional
of conjunctiva, 4.64
of eyelid, 4.219, 4.219*f*
"kissing," 4.218, 4.218*f*
magnocellular. *See* Melanocytoma
melanocytic
of anterior chamber/trabecular meshwork, 4.106
congenital, 4.218, 4.218*f*
conjunctival, 4.61–64, 4.63*t*, 4.64*f*, 4.65*f*
malignant transformation of, 4.64, 4.68
of eyelid, 4.218*f*, 4.218–220, 4.219*f*
glaucoma and, 4.106
malignant transformation/melanoma risk and, 4.64, 4.68, 4.218, 4.263, 4.267–268
of Ota (dermal/oculodermal melanocytosis), 4.63*t*, 4.64, 6.251, 7.198, 7.198*t*, 8.339, 8.339*t*
glaucoma associated with, 10.30
of iris, 4.259
port-wine. *See* Nevus, flammeus
stromal, 4.64, 8.340
subepithelial, 4.64, 8.338*t*, 8.340
uveal tract, 4.191, 4.192*f*
Nevus cells, 4.218, 4.219*f*, 4.219–220, 4.220*f*, 7.195
tumors arising from, 4.218, 8.338*t*, 8.338–345, 8.339*t*. *See also* Melanocytic tumors; Nevi/nevus; Pigmented (melanocytic) lesions
Newborn primary congenital glaucoma, 10.147, 10.148*t*, 10.151. *See also* Glaucoma, pediatric; Primary congenital glaucoma
Newborns. *See also* Infant(s)
conjunctivitis in, 8.257*t*, 8.263–265
corneal transplantation in, 8.450–451
dysconjugate eye movements in, 6.185
extraocular muscles in, 6.182
glaucoma in, 10.147, 10.148*t*, 10.151. *See also* Glaucoma, pediatric; Primary congenital glaucoma
herpes simplex infection in, 8.213
maternal antiglaucoma agents affecting, 10.185–186
normal ocular flora in, 8.205
ocular deviations in, 5.230–231
ocular infections in, 8.257*t*, 8.263–265. *See also specific type*
ophthalmia neonatorum in, 8.257*t*, 8.263–265
pupils in, 6.10
skew deviation in, 6.185
sunsetting in, 6.185
visual acuity of, 6.44
visual development in, 6.185
Newcastle Control Score for Intermittent Exotropia, 6.100
Newcastle disease, 8.240*t*
Newton, Isaac
description of, 3.94
third law of motion, 3.293
Next-generation sequencing (NGS/massively parallel DNA sequencing), 4.39*t*, 6.301
NF. *See* Neurofibromatosis
NF1. *See* Neurofibromatosis 1 (NF1/von Recklinghausen)
NF1 gene, 5.334*t*
NF2. *See* Neurofibromatosis 2 (NF2/bilateral acoustic/central)
NF2 gene, 5.334*t*
NF-κB. *See* Nuclear factor κB
NFL. *See* Nerve fiber layer
NGS. *See* Next-generation sequencing
NH_3. *See* Ammonia
NHANES. *See* National Health and Nutrition Examination Surveys

NHL. *See* Non-Hodgkin lymphoma
NIA imaging. *See* Near-infrared fundus autofluorescence
Nicotinamide adenine dinucleotide (NADH) reductase, 2.343
Nicotinamide adenine dinucleotide phosphate (NADPH), 2.311, 2.336
  in lens glucose/carbohydrate metabolism, 11.18*f*, 11.19
Nicotine. *See* Nicotinic drugs
Nicotinic acid, 12.301
  for hypercholesterolemia, 1.75*t*
Nicotinic drugs
  antagonists, 2.382, 2.383*t*
  indirect-acting agonists, 2.381
Nicotinic receptors, 2.374, 2.374*f*, 2.375*t*
  drugs affecting. *See* Nicotinic drugs
NIDDM (non-insulin-dependent diabetes mellitus). *See* Diabetes mellitus (DM), type 2
Niemann-Pick disease, 2.204*t*, 6.388*t*, 12.291
Night blindness
  in choroideremia, 12.267
  congenital stationary
    electroretinography findings in, 12.46, 12.47*f*, 12.251, 12.252*f*
    retinitis pigmentosa *versus*, 12.251
    subtypes of, 12.251
  dark adaptometry evaluations, 12.58
  electroretinography evaluations, 12.46
  fundus albipunctatus, 12.252, 12.253*f*
  in gyrate atrophy, 12.268
  in vitamin A deficiency, 8.196
Night myopia, spherical aberrations and, 13.12, 13.102
Night vision, 3.272
Night-vision abnormalities. *See also* Night blindness
  description of, 12.251–253*f*, 12.251–253
  after refractive/keratorefractive surgery
    contact lens use for, 13.199
    phakic IOLs
      angle-supported lenses, 13.146
      iris-fixated lenses, 13.145
      multifocal lenses, 13.156
      posterior chamber lenses, 13.146
    photoablation, 13.102
    radial keratotomy, 13.51
  spherical aberrations and, 13.12, 13.102
NIHSS. *See* National Institutes of Health Stroke Scale
9-o'clock staining, 3.233, 3.233*f*
NIS. *See* Na^+/I symporter
Nitrates, 1.91
Nitric oxide (NO), 2.394–395, 9.16
  in eosinophilic airway inflammation, 1.124
Nitric oxide donors, 2.394–395
Nitric oxide synthetase (NOS), 9.16
Nitroglycerin, 1.64, 1.91
Nitrosoureas, 1.240*t*
Nivolumab, 7.210
  Vogt-Koyanagi-Harada syndrome caused by, 9.140*f*
Nizoral. *See* Ketoconazole
NK cells. *See* Natural killer (NK) cells
NLD. *See* Nasolacrimal duct
NLDO. *See* Nasolacrimal duct obstruction
NLP. *See* No light perception
NMO. *See* Neuromyelitis optica
NMO (neuromyelitis optica)-IgG (AQP4-IgG) antibody, 5.115, 5.117*t*, 5.118, 5.320, 5.322
NMOSD. *See* Neuromyelitis optica spectrum disorder
NMS. *See* Neuroleptic malignant syndrome
NNO1 gene, 10.11*t*
nNOS. *See* Neuronal nitric oxide synthase
NNT. *See* Number needed to treat
NO. *See* Nitric oxide
No light perception (NLP). *See also* Blindness
  testing
    bilateral, 5.301–302, 5.302*f*
    monocular, 5.302–305, 5.303*f*, 5.304*f*
Nocardia/*Nocardia asteroides* (nocardiosis), 9.233
  description of, 8.244*t*, 8.248, 9.233, 9.311
  keratitis caused by
    corticosteroid treatment and, 8.271
    after photoablation, 13.106
Nocardiosis, 9.233
Nociceptors, in lacrimal functional unit/tear secretion, 8.5
Nocturnal arterial hypotension, 1.66–67
NOD2 gene, 6.319
Nodal points, 3.41, 3.66–67, 3.67*f*
Nodular anterior scleritis, 8.320, 8.320*t*, 8.321*f*, 8.325*f*, 9.116, 9.118–119, 9.119*f*
Nodular basal cell carcinoma, 4.212, 4.212*f*. *See also* Basal cell carcinoma
Nodular episcleritis, 4.109, 8.318, 8.318*f*
Nodular fasciitis, 4.112, 4.113*f*, 8.347
  episcleral tumor caused by, 4.112
Nodular melanoma, 4.220, 4.221*f*, 7.209–210. *See also* Melanoma
Nodules. *See specific type*
Nodulus, 5.39
NOE fractures. *See* Naso-orbital-ethmoidal fractures
Non–center-involved diabetic macular edema, 12.109, 12.111*f*
Non-contact lens, indirect ophthalmoscopy using, 12.22
Non-Hodgkin lymphoma (NHL). *See also* Lymphomas
  conjunctival, 8.349
  description of, 7.91–92
  orbital, 4.232, 4.233*f*
  primary central nervous system/intraocular, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
  risk for, 7.92
Non-Hodgkin lymphoma of the central nervous system. *See* Primary vitreoretinal lymphoma
Non-insulin-dependent diabetes mellitus (NIDDM). *See* Diabetes mellitus (DM), type 2
Non–Sjögren syndrome dry eye (NSSDE), 8.55*f*
Non–ST-segment elevation myocardial infarction (NSTEMI). *See* Acute coronary syndrome
Nonaccidental trauma
  abusive head trauma, 6.381–384, 6.382–383*f*
  ocular injury secondary to, 6.384
Nonadherence to therapy, in older patients, 10.186
Nonalternating suppression, 6.49
Nonarteritic ischemic optic neuropathy
  anterior (NAION)
    description of, 5.107*t*, 5.120, 5.120*t*, 5.121*f*, 5.122–124, 5.123*t*
    nocturnal arterial hypotension and, 1.67

OCT in evaluation of, 5.91*f*
visual evoked potentials in, 12.52
posterior (PION), 5.107*t*, 5.124
Noncaseating granulomas, 4.8*f*, 7.65
in granulomatous conjunctivitis, 4.52, 4.52*f*
in sarcoidosis, 4.187, 4.187*f*
Noncoding DNA, 2.177–178
Noncomitant deviations. *See* Incomitant (noncomitant) deviations
Noncompliance, 2.373, 2.373*t*
Noncontact specular microscopy, 8.23
Noncontact (air-puff) tonometers, 10.26
Noncycloplegic (manifest) refraction. *See also* Refraction, clinical
IOL power calculation and, 13.194, 13.195
after penetrating keratoplasty, 8.431–432, 8.432*f*
before refractive surgery, 13.39, 13.40
laser programming and, 13.40, 13.81
Noncycloplegic refraction, 3.168–169
Nondepolarizing agents, 2.382
Nondihydropyridine calcium channel blockers, 1.61
Nondisjunction
meiotic, 2.223
mitotic, 2.224
Nonenveloped viruses, 8.212
Nonexperimental studies, 1.8
Nonexudative/"dry" age-related macular degeneration. *See* Nonneovascular ("dry"/nonexudative) age-related macular degeneration
Nongranulomatous inflammation, 4.7
Non–Hodgkin lymphoma of the central nervous system. *See* Primary vitreoretinal lymphoma
Nonhomologous chromosomes, 2.216
Noninfectious ocular inflammatory diseases. *See also specific type and specific cause*
conjunctivitis, 4.52–55, 4.54*f*
sarcoidosis and, 4.52, 4.52*f*
keratitis, 4.80–81
optic nerve involvement and, 4.244*f*, 4.244–245, 4.245*f*
orbital, 4.224–226, 4.225*f*
uveitis/autoimmune uveitis, 4.127, 4.128*f*. *See also specific cause*
vitreous infiltrate in, 4.127, 4.128*f*
Noninvasive prenatal screening, 2.239
Noninvasive pressure support ventilation, 1.126–127
Nonketotic hyperglycemic hyperosmolar coma, 1.38–39
Nonlaser lamellar keratorefractive surgery, 13.8*t*
Nonnecrotizing herpetic retinitis, 9.250–254
Nonnecrotizing herpetic retinopathy, 9.250
Nonnecrotizing scleritis, 4.110, 8.46*t*, 8.320*t*, 8.320–322, 8.321–322*f*
Nonnecrotizing stromal keratitis, 8.51*f*
herpes simplex causing, 8.219, 8.220*f*, 8.221*f*, 8.223*t*
Nonneovascular ("dry"/nonexudative) age-related macular degeneration, 4.164, 4.164*f*
Amsler grid testing for, 12.68–69
contrast sensitivity issues in, 12.56
differential diagnosis of, 12.67–68
disproven treatment approaches for, 12.71
drusen in, 4.160–163, 4.161–163*f*
education regarding, 12.68
focal atrophy in, 12.66
follow-up for, 12.68
geographic atrophy in, 12.64, 12.66, 12.67*f*, 12.68
hydrochloroquine toxicity *versus*, 12.68
hyperacuity testing for, 12.69
lifestyle changes for, 12.71
management of, 12.68–71
micronutrients for, 12.69–71
preferential hyperacuity perimetry for, 12.69
prevalence of, 12.61
retinal pigment epithelium abnormalities in, 4.164, 4.164*f*, 12.66–67
shape-discrimination hyperacuity for, 12.69
Nonnephropathic cystinosis, 8.181, 8.181*f*
Nonorganic (functional/nonphysiologic) ophthalmic disorders, 5.299*t*, 5.299–312
afferent visual pathways and, 5.301–305, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*
clinical profile of patient with, 5.300
examination techniques in, 5.301–311, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*, 5.307*f*, 5.308*f*, 5.309*f*
eyelid position/function and, 5.310–311
malingering and, 5.299
management of, 5.311
ocular motility/alignment and, 5.309–310
organic disorders misdiagnosed as, 5.299, 5.299*t*
pupils/accommodation and, 5.310
Nonorganic overlay, 5.299, 5.311
Nonparaneoplastic autoimmune retinopathy (NpAIR), 5.103
Nonparaneoplastic autoimmune retinopathy (NpAIR)-associated antibody, 5.103
Nonpenetrance, 2.219
Nonpenetrating glaucoma surgery, 10.217–219
Nonperfused/complete/ischemic central retinal vein occlusion, 4.156, 4.157–158, 4.158*f*
Nonphysiologic ophthalmic disorders. *See* Nonorganic (functional/nonphysiologic) ophthalmic disorders
Nonpigmented epithelium (NPE)
definition of, 2.270
tight junctions of, 2.270, 2.275
Nonproliferative diabetic retinopathy (NPDR)
anti-VEGF therapy for, 12.101–102
clinical findings in, 12.99
definition of, 12.91
intraretinal hemorrhages associated with, 12.100*f*
intraretinal microvascular abnormalities in, 12.100*f*
microaneurysms associated with, 12.100*f*
optical coherence tomography angiography of, 12.94*f*
panretinal photocoagulation for, 12.101
posterior vitreous detachment creation for, 12.102
progression of, to proliferative diabetic retinopathy, 12.101
ranibizumab for, 12.102
scatter photocoagulation for, 12.116
severity of, 12.95*t*, 12.99
treatment of, 12.101–102
venous beading associated with, 12.100*f*
vision loss in, 12.101
Nonproliferative sickle cell retinopathy (NPSR). *See also* Sickle cell retinopathy
branch retinal artery occlusions in, 12.152*f*
characteristics of, 12.149–150

imaging of, 12.150–12.152*f*
retinal arteriolar occlusions in, 12.151*f*
salmon-patch hemorrhage in, 12.150*f*
Nonrefractive accommodative esotropia, 6.90
Nonrhegmatogenous retinal detachment. *See* Retinal detachment
Nonsense mutations, 2.183
Nonseptate filamentous fungi, 8.249*t*, 8.251. *See also* Filamentous fungi; Fungi
Nonspecific orbital inflammation (NSOI/orbital pseudotumor/idiopathic orbital inflammation/orbital inflammatory syndrome [OIS])
corticosteroids for, 7.69–70
description of, 4.224–226, 4.225*f*, 6.215–216, 6.216*f*, 7.22, 7.24
diagnosis of, 7.68–70
orbital lymphoma differentiated from, 4.225
pain in, 5.295
pathogenesis of, 7.67
sclerosing, 7.70
symptoms of, 7.68
treatment of, 7.70
Nonspherical optics, 3.257
Non–ST-segment elevation myocardial infarction (NSTEMI). *See* Acute coronary syndrome
Nonsteroidal anti-inflammatory drugs (NSAIDs). *See also specific drugs*
for ankylosing spondylitis, 1.155, 9.132
for corneal abrasion, 8.398–399
corneal complications of, 2.411
corneal melting after cataract surgery associated with, 11.132, 11.173
corticosteroids and, concomitant use of, 9.103
cyclooxygenase inhibition by, 2.409
for cystoid macular edema, 2.410
after cataract surgery, 11.165
derivatives of, 2.407–409
after LASIK, 13.93
for diffuse lamellar keratitis, 13.117
macular edema treated with, 9.322
ocular adverse effects of, 1.308*t*
for ocular allergies
description of, 6.247*t*
hay fever conjunctivitis, 8.289
platelet function inhibition using, 1.143
rheumatic disorders treated with, 1.176
rheumatoid arthritis treated with, 1.153
for scleritis, 8.324, 8.325*f*, 9.126
after surface ablation, 13.92, 13.93–94, 13.108
delayed re-epithelialization and, 13.93–94, 13.108
sterile infiltrates and, 13.108
types of, 2.400*t*, 2.409*t*, 2.409–411
uveitis treated with, 9.113, 9.315
Nonsyndromic panretinal dystrophies, 12.258–259
Nontuberculous (atypical) mycobacteria, 7.50, 7.50*f*, 8.248, 8.272–273, 8.273*f*
neuro-ophthalmic signs of infection with, 5.350
Nonulcerative stromal interstitial keratitis, 9.220, 9.221*f*
Nonvalved tube shunts, 10.214, 10.214*t*
Norflox. *See* Norfloxacin
Norfloxacin, 2.421*t*
Normal distribution, 1.6
Normal flora, ocular, 8.205–206, 8.206*t*
Normal retinal correspondence (NRC)
afterimage test for, 6.79*f*
in intermittent exotropia, 6.100
strabismus and, 6.48, 6.49*f*
testing for, 6.51
Normal-tension glaucoma (NTG), 10.3, 10.4*t*, 10.85*f*, 10.85–88, 10.86*t*. *See also* Glaucoma, normal-tension
Normocytic anemia, 1.132
Norrie disease, 2.212, 6.347
North Carolina macular dystrophy, 12.277, 12.278*f*
NOS. *See* Nitric oxide synthetase
Nose. *See also specific Nasal entries*
anatomy of, 7.19, 7.282*f*
bony projections of, 7.19
inferior meatus of, 5.11
physical examination of, 7.296
Nosema, 8.252
stromal keratitis caused by, 8.280
NOTCH3 gene mutation, in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, 5.295
Nothnagel syndrome, 5.191
Novocain. *See* Procaine penicillin
Nozik technique, for uveitis, 9.95–96, 9.97*f*
NpAIR. *See* Nonparaneoplastic autoimmune retinopathy
NPC. *See* Near point of convergence
NPDR. *See* Nonproliferative diabetic retinopathy
NPE. *See* Nonpigmented epithelium
NPH. *See* Nucleus prepositus hypoglossi
NPS gene, 10.11*t*
NPSR. *See* Nonproliferative sickle cell retinopathy
NPV. *See* Negative predictive value
NPY. *See* Neuropeptide Y
NRC. *See* Normal retinal correspondence
NR2E3 gene, 12.49, 12.266
Nrf2. *See* Nuclear factor erythroid 2–related factor
Nrl, 2.155
NRTIs. *See* Nucleoside reverse transcriptase inhibitors
NSAIDs. *See* Nonsteroidal anti-inflammatory drugs
NSF. *See* Nephrogenic systemic fibrosis
NSOI. *See* Nonspecific orbital inflammation
NSSDE. *See* Non–Sjögren syndrome dry eye
NSTEMI. *See* Non–ST-segment elevation myocardial infarction
NTG. *See* Normal-tension glaucoma
nTreg cells. *See* Natural regulatory T (nTreg) cells
NTRK1 gene, in congenital insensitivity to pain with anhidrosis, 8.108
Nuclear cataracts, 4.123, 4.124*f*, 11.43–45, 11.45*f*
characteristics and effects of, 11.43, 11.44, 11.70, 11.70*t*
in children/congenital, 11.38, 11.39*f*
genetic contributions to, 11.42
hyperbaric oxygen therapy and, 11.20, 11.65
infantile, 6.295, 6.296*f*
after posterior chamber phakic IOL insertion, 13.146
race and, 11.6
in rubella, 6.410
sclerotic, 12.402
vitrectomy and, 11.55, 11.190

Nuclear disassembly/removal, 11.111, 11.112–114, 11.113*f*. *See also* Cataract surgery; Lensectomy; Phacoemulsification
in ECCE, 11.196–197
in ICCE, 11.200*f*, 11.200–201
in manual small-incision cataract surgery, 11.198, 11.199*f*
in phacoemulsification, 11.111, 11.112–114, 11.113*f*
chopping techniques for, 11.114
phaco fracture for, 11.112–114, 11.113*f*
Nuclear facial palsy, 5.276*f*
Nuclear factor erythroid 2–related factor (Nrf2), 2.338
Nuclear factor κB (NF-κB), 7.92
Nuclear layer. *See* Inner nuclear layer; Outer nuclear layer
Nuclear lesions, diplopia caused by, 5.188–189. *See also specific nerve*
Nuclear sclerosis, 11.43, 11.45*f*, 11.48*f*, 11.50*f*. *See also* Nuclear cataracts
myopic shift associated with, 3.143
refractive surgery and, 13.44
smoking and, 11.6–7
Nucleic acids. *See also* DNA; RNA
disorders of metabolism of, corneal changes and, 8.181*f*, 8.181–190, 8.182*t*, 8.183*t*, 8.184*f*, 8.185*f*, 8.186*t*, 8.187*f*, 8.188*f*, 8.189*f*
in retinal pigment epithelium, 2.324
viral, 8.211
Nucleofractis, "divide and conquer," 11.112–114, 11.113*f*
Nucleoside reverse transcriptase inhibitors (NRTIs), 12.299
Nucleotides, 2.176. *See also* Nucleic acids
Nucleus (lens). *See* Lens (crystalline), nucleus of
Nucleus prepositus hypoglossi (NPH), 5.35, 5.35*f*, 5.220
horizontal gaze and, 5.37*f*, 5.38
NuLens accommodating intraocular lens, 13.170
Null allele, 2.194
Null-cell adenomas, 1.48
Null hypothesis
definition of, 1.5
rejection of, 1.5
Null mutations, 2.183
Null point/zone, 5.234
in congenital motor nystagmus, 6.148, 6.156
in jerk nystagmus, 6.147
surgical adjustment of for nystagmus, 5.236, 5.237*f*
Number needed to treat (NNT), 1.22
Numbness, facial pain and, 5.298
Nummular keratitis, 6.243
herpes zoster, 8.228, 8.228*f*
Nursing (breastfeeding)
glaucoma medication use during, 10.185–186
refractive surgery contraindicated during, 13.37
Nutritional deficiency
anemia caused by, 1.132–134
cataract formation and, 11.7, 11.63–64
corneal changes in, 8.196–197, 8.197*f*
optic neuropathy and, 5.107*t*, 5.137–139, 5.138*f*
Nutritional supplements. *See also specific type*
for dry eye, 8.61*t*, 8.64, 8.68
NVD. *See* Neovascularization, optic nerve/nerve head/disc
Nyctalopia, 12.290. *See also* Night blindness
in vitamin A deficiency, 8.196
Nystagmus, 2.475*t*, 5.214, 5.215, 5.233–251, 5.234*f*
acquired, 5.233, 6.151–152
pendular, 5.246–247
Alexander's law and, 5.240, 5.242
amplitude of, gaze position affecting, 5.234
Anderson procedure for, 6.155
assessment of, 5.215, 5.233–235, 5.234*f*
Bruns, 5.243
central vestibular instability, 6.149
childhood (early-onset), 5.235–239
chin-down position, 6.156
chin-up position, 6.156
congenital (CN)
description of, 5.234*f*, 5.235–237, 5.237*f*
motor, 6.148–149, 6.149*t*, 6.153–154
sensory, 6.149, 6.150*t*, 6.154
convergence-retraction (CRN/induced convergence-retraction), 5.243*t*, 5.250, 6.152–153
definition of, 6.147
diagnosis of, 6.84
dissociated (disconjugate/dysconjugate), 5.234, 5.247, 6.151–152
downbeat, 5.243*t*, 5.244–245, 5.245*f*, 6.152
esotropia and, 6.86*t*, 6.95
evaluation of, 6.153–154
features of, 6.147
fixation and, 5.240, 5.241*t*
fusion maldevelopment nystagmus syndrome, 6.83, 6.88, 6.95, 6.148, 6.150–151, 6.151*f*, 6.154
gaze direction and, 6.147
gaze-evoked, 5.38, 5.222, 5.234*f*, 5.240–241
in internuclear ophthalmoplegia, 5.189, 5.190*f*
rebound, 5.240–241
gaze positions affecting, 5.240
head-tilt correction in, 6.156
in hereditary retinal disease, 6.335
history-taking for, 6.153
horizontal rectus muscle surgery for, 6.157
induced convergence-retraction, 6.152–153
infantile nystagmus syndrome, 6.83, 6.148–149, 6.149*t*, 6.156*f*, 6.187, 6.335
inheritance patterns, 6.153
in internuclear ophthalmoplegia, 5.189, 5.190*f*, 5.247
jerk, 5.214, 5.233, 5.234, 6.147
in multiple sclerosis, 5.319
Kestenbaum procedure for, 6.155, 6.156*f*, 6.156*t*
latent/manifest latent (LN/MLN/fusion/fusional maldevelopment nystagmus syndrome/FMN/FMNS), 5.237–238, 6.83, 6.88, 6.95, 6.129, 6.148, 6.150–151, 6.151f, 6.154
monocular, 6.152
in Heimann-Bielschowsky phenomenon, 5.238–239
monocular occlusion effects on intensity of, 6.154
in multiple sclerosis, 5.246, 5.319
in neuromyelitis optica, 5.320–322
nomenclature for, 6.147
occluding of one eye as cause of, 3.27
ocular examination for, 6.153–154
oculopalatal myoclonus/tremor and, 5.246–247
optic nerve gliomas causing, 5.130

optokinetic (OKN/optokinetic system), 5.212, 5.212*t*, 5.218–219, 6.40
dysfunction of, 5.218–219
in congenital nystagmus, 5.235
parietal lobe lesions and, 5.156, 5.219
nonorganic disorders and, 5.301–302
pendular, 5.214, 5.233, 5.234*f*, 5.246–247, 6.147
acquired, 5.246–247
in multiple sclerosis, 5.246, 5.319
periodic alternating (PAN), 5.243*t*, 5.245–246, 6.149
prevalence of, 6.147
prisms for, 6.155
pupil responses in, 6.154
rebound, 5.240–241
retinal dystrophy and, 6.391*f*
saccadic intrusions, 5.233, 5.247–250, 5.248*f*
see-saw (vision loss), 5.243*t*, 5.247, 6.152
sensory, 6.187
spasmus nutans, 5.239, 6.151–152
strabismus associated with, 6.154, 6.156–157
surgery for, 6.155–157, 6.156*f*, 6.156*t*
torsional, 5.245
treatment of, 6.155–157
upbeat, 5.243*t*, 5.245
vertical, 6.152
vestibular, 5.215, 5.234*f*, 5.241*t*, 5.241–246, 5.243*t*, 5.245*f*
central, 5.216, 5.243*t*, 5.243–246, 5.245*f*
peripheral, 5.216, 5.241*t*, 5.241–243
visual acuity assessments in, 6.8, 6.153–154
visual evoked potentials in, 12.53
voluntary, 5.249–250, 5.309
wandering, 12.266
Nystagmus blockage syndrome, 6.95, 6.148, 6.155
Nystagmus-like disorders, 6.152–153
Nystatin, 1.277

O

OA. *See* Ocular albinism
OA1 (albinism). *See* Ocular albinism
OAT gene, 12.269
OAVS. *See* Oculoauriculovertebral syndrome
Obesity
in children, 1.68
floppy eyelid syndrome and, 8.82
hypertension risks associated with, 1.66, 1.68
in idiopathic intracranial hypertension, 5.111, 5.112
Object agnosia, 5.179
Object distance, 3.4, 3.10
Object vergence, 3.51
Objective refraction. *See* Retinoscope/retinoscopy
OBL. *See* Opaque bubble layer
Oblate, 3.267
Oblate cornea, 13.14, 13.26
Q value and, 13.14
after radial keratotomy, 13.50
Oblique astigmatism, 3.139, 3.147
Oblique muscles, 5.8*f*, 5.45–46, 5.46*f*. *See also* Inferior oblique (IO) muscle; Superior oblique (SO) muscle
anatomy of, 5.8*f*, 5.45, 5.46, 5.46*f*, 6.20–22, 6.21*t*
innervation of, 5.40, 5.44, 5.44*f*
myokymia affecting, 5.250–251
overactions of, 6.17, 6.117
pseudo-overactions, 6.116
tightening procedures for, 6.164*t*, 6.166–167
weakening procedures. *See* Weakening procedures
O'Brien nerve block, for cataract surgery, 11.92, 11.93*f*
Observation
in management of choroidal/ciliary body melanoma, 4.274
in management of medulloepithelioma, 4.296
in management of ocular surface tumor, 8.328–329
Observational studies, 1.8
Obstructive lung diseases
chronic obstructive pulmonary disease, 1.124
description of, 1.123
irreversible, 1.124
reversible, 1.123–124
Obstructive shock, 1.300. *See also* Shock
Obstructive sleep apnea (OSA)
characteristics of, 1.124–125
continuous positive airway pressure for, 1.127
ocular conditions associated with, 1.127
Obstructive sleep apnea syndrome (OSAS)
floppy eyelids and, 8.79, 8.82
hypertension and, 1.66
nonarteritic anterior ischemic optic neuropathy associated with, 1.67
retinal findings secondary to, 1.67
OCA. *See* Albinism
Occipital artery, 5.12
Occipital bone, 5.5
Occipital ischemia, transient visual loss and, 5.162, 5.172
Occipital lobe, 5.24*f*
lesions of, 5.147*f*, 5.156–158, 5.157*f*, 5.158*f*, 5.159*f*. *See also* Occipital (primary visual/calcarine/striate) cortex, disorders of
hallucinations and, 5.158, 5.177
transient visual loss/seizures and, 5.161, 5.162, 5.172
Occipital nerves, facial pain and, 5.296
Occipital neuralgia, 5.296, 5.297
Occipital (primary visual/calcarine/striate) cortex, 5.24*f*, 5.29*f*, 5.29–31, 5.30*f*, 5.32*f*, 5.34*f*
disorders of, 5.158, 5.178*t*, 5.178–181
hallucinations and, 5.158, 5.176–178
illusions and, 5.175
recognition disorders and, 5.178*t*, 5.179, 5.180*f*
vision/visual deficit awareness disorders and, 5.178*t*, 5.180–181
visual-spatial relationship disorders and, 5.178*t*, 5.180
ocular motor control and, 5.32*f*, 5.32–33, 5.34*f*
vascular supply of
arterial supply, 5.20, 5.20*f*
venous drainage, 5.22*f*, 5.22–23, 5.23*f*
Occipital seizures, transient visual loss and, 5.161, 5.162, 5.172
Occipitoparietal pathway, 5.30*f*
Occipitotemporal pathway, 5.30*f*
Occlusion, in phacoemulsification, 11.102
Occlusion therapy. *See also* Patching
adherence to, 6.60
amblyopia treated with, 6.58, 6.96, 6.102

basic acquired nonaccommodative esotropia secondary to, 6.93
full-time, 6.58, 6.60
intermittent exotropia treated with, 6.102
part-time, 6.58
reverse amblyopia caused by, 6.60
Occlusive arterial disease
branch retinal artery
emboli that cause, 12.141, 12.142*f*
hypertensive retinopathy and, 12.122
imaging of, 12.141*f*
management of, 12.142
multiple, 12.152*f*
in nonproliferative sickle cell retinopathy, 12.152*f*
retinal infarction caused by, 12.141
in Susac syndrome, 12.156
branch retinal vein
aflibercept for, 12.135
at arteriovenous crossing, 12.126
bevacizumab for, 12.135
clinical findings in, 12.125–127, 12.126*f*
corticosteroids for, 12.137–138
diabetes mellitus and, 12.128
fluorescein angiography of, 12.129*f*
glaucoma as risk factor for, 12.125
hypertensive retinopathy and, 12.122
intraretinal hemorrhages associated with, 12.125, 12.126*f*
macular laser surgery for, 12.128
neovascularization in, 12.125, 12.128, 12.129*f*
pars plana vitrectomy for, 12.130
pharmacologic management of, 12.135–138
prognosis for, 12.128
ranibizumab for, 12.135
risk factors for, 12.127–128
scatter photocoagulation for, 12.128–130
spontaneous resolution of, 12.125
surgical management of, 12.128–130
treatment of, 12.128–130
triamcinolone for, 12.137
vision loss caused by, 12.128
central retinal artery
anti-VEGF therapy for, 12.146
causes of, 12.144
ciliary artery occlusion with, 12.144, 12.145*f*
electroretinography findings in, 12.50
emboli as cause of, 12.144
giant cell arteritis as cause of, 12.145
illustration of, 12.16*f*, 12.144*f*
iris neovascularization in, 12.146
management of, 12.146
retinal infarction caused by, 12.143
spectral-domain optical coherence tomography of, 12.144*f*
symptoms and signs of, 12.143
vision loss caused by, 12.143–144
central retinal vein occlusion. *See* Central retinal vein occlusion
Occlusive retinal disease
arterial. *See also* Retinal artery occlusion
branch retinal artery occlusion, 4.156
central retinal artery occlusion, 4.156, 4.157*f*
venous. *See also* Retinal vein occlusion
branch retinal vein occlusion, 4.158–159
central retinal vein occlusion, 4.156–158, 4.158*f*
angle-closure glaucoma and, 10.143–144
neovascularization and, 10.134–135
open-angle glaucoma and, 10.84
Occlusive retinopathy, 12.300–301
Occult choroidal neovascularization, 12.72–73
Occult giant cell arteritis, 5.120, 5.170
Occult macular dystrophies, 12.277
Occupation, refractive surgery selection and, 13.36–37
Occupational light toxicity, 12.369
Occupational therapists, 3.325
Ochronosis, 8.118*t*, 8.184, 8.185*f*
Ocriplasmin, 2.304, 12.337, 12.340
OCRL1 gene, in oculocerebrorenal (Lowe) syndrome, 4.118, 6.391
OCS. *See* Orbital compartment syndrome
OCT. *See* Optical coherence tomography
OCTA. *See* Optical coherence tomographic angiography
Octopus perimeters, 10.61
visual field progression evaluation with, 10.74
Ocu-Dex. *See* Dexamethasone sodium phosphate
Ocufen. *See* Flurbiprofen sodium
Ocuflox. *See* Ofloxacin
Ocular adnexa. *See also specific structure*
abnormalities of, in craniosynostosis, 6.209
anatomy of, 2.5–15, 2.6–15*f*
arterial supply of, 5.13–14*f*
in cryptophthalmos, 6.191
description of, 6.181
development of, 2.163, 2.164*f*
in external eye defense, 8.11
extraocular muscles. *See* Extraocular muscles
glands of, 2.30*t*
in glaucoma evaluation, 10.29–30
Kaposi sarcoma of, 5.349, 9.333, 9.333*f*
lesions of, 7.190–194, 7.191–192*f*
lymphoma/lymphoproliferative lesions of, 4.231, 4.232, 4.233*f*. *See also* Lymphomas
lymphoproliferative lesions of, 7.91
orbit. *See* Orbit
Ocular albinism (OA), 6.406–407. *See also* Albinism
characteristics of, 12.288
description of, 2.78, 4.142, 4.142*f*
pattern-appearance visual evoked potentials in, 12.53
X-linked, 2.230
Ocular alignment
assessment of
alternate cover test, 6.65–66, 6.66*f*
corneal light reflex tests, 6.67–68, 6.68*f*
cover tests, 6.64–67, 6.65–66*f*
diagnostic positions of gaze, 6.64
Lancaster red-green test for, 6.69
Maddox rod test, 6.68–69, 6.69*f*
major amblyoscope for, 6.70, 6.70*f*
monocular cover test, 6.64, 6.65*f*
prism alternate cover test, 6.65–66, 6.66*f*
red reflex tests, 6.67–68
simultaneous prism and cover test, 6.66–67
subjective tests for, 6.68–70
disorders of/unsatisfactory, 5.184–185. *See also* Diplopia
nonorganic, 5.309–310

after extraocular muscle surgery, 6.168
in infantile esotropia, 6.88–89
refractive surgery and, 13.41
tests of, 5.184*f*, 5.184–185, 5.185*f*. *See also specific type*
Ocular allergies, 6.246*f*, 6.246–249, 6.247*t*, 6.248*t*. *See also* Allergic reactions/allergies
Ocular argyrosis/argyria/argyriasis, 12.306
silver causing, 4.120
Ocular autonomic pathways, 5.52–56
parasympathetic, 5.52, 5.54–56, 5.55*f*
sympathetic, 5.52–54, 5.53*f*
Ocular biometrics. *See* Biometry/biometrics
Ocular bobbing, 5.228
Ocular cicatricial pemphigoid. *See* Mucous membrane (ocular cicatricial) pemphigoid
Ocular cysticercosis. *See* Cysticercosis
Ocular cytology. *See* Cytology
Ocular decongestants, 2.416–417
Ocular development. *See also* Eye, development of
adnexa, 2.163, 2.164*f*
anterior chamber, 2.161, 2.161*f*
choroid, 2.160–161
ciliary body, 2.157, 2.159*f*, 2.160
cornea, 2.161–162*f*
diffusible ligands in, 2.165–166
embryogenesis in, 2.143–144, 2.144–146*f*, 2.148*f*
extraocular muscles, 2.162–163
genetic cascades, 2.164–166
growth factors in, 2.165–166
homeobox genes, 2.164–165
iris, 2.157, 2.159–160*f*, 2.160
lacrimal gland, 2.163
lens, 2.153–155, 2.154*f*
morphogenic gradients, 2.164–166
morphogens in, 2.165
neural crest cell migration in, 2.146–147*f*, 2.161*f*
optic nerve, 2.156*f*, 2.157
orbit, 2.164
retina, 2.155, 2.155*f*
retinal pigment epithelium, 2.157
sclera, 2.162
timeline of, 2.148, 2.150–151*f*, 2.152*t*
uvea, 2.157
vitreous, 2.157, 2.158*f*
Ocular deviations. *See* Deviations
Ocular dominance, determining, 13.39
Ocular drug design, 2.363–365
Ocular emollients, 2.415
Ocular examination. *See* Examination
Ocular expansion, pathologic myopia as cause of, 12.216
Ocular fixation system, 5.212, 5.212*t*, 5.213–214. *See also* Fixation
dysfunction of, 5.214
Ocular flutter, 5.243*t*, 5.248, 5.248*f*, 5.249
Ocular foreign bodies, 2.458
Ocular fundus, 3.296
Ocular graft-vs-host disease (GVHD), 8.303–305, 8.305*f*
superior limbic keratoconjunctivitis and, 8.83
Ocular hemorrhage. *See also* Hemorrhage
ruptured aneurysm causing, 5.340, 5.340*f*
Ocular histoplasmosis syndrome (OHS), 12.87
choroidal neovascularization caused by, 12.86–87, 12.88*f*
description of, 9.272–275, 9.273–274*f*
Ocular history. *See also* History
in cataract, 11.69–71, 11.70*t*
evaluation for surgery and, 11.75–76
diabetes mellitus and, 10.83
glaucoma evaluation and, 10.29
in low vision evaluation, 3.312
refractive surgery evaluation and, 13.36*t*, 13.37–38
Ocular hypertelorism, 6.191
Ocular hypertension (OHT), 10.4*t*, 10.89–90, 10.112. *See also* Elevated intraocular pressure; Intraocular pressure
age/aging and, 10.81
corneal thickness and, 10.25, 10.90, 10.112
corticosteroid-induced, 9.317, 9.319
glaucoma risk and, 10.8, 10.81, 10.89, 10.90, 10.112
glaucoma suspect and, 10.89–90
herpes simplex virus and, 9.248–249
race and, 10.82
refractive surgery and, 13.104–105, 13.180–183, 13.182*f*, 13.200–201
uveitic, 9.317
Ocular Hypertension Treatment Study (OHTS), 1.22–23, 10.65, 10.81, 10.82, 10.83, 10.89–90, 10.112
Ocular hypotelorism, 6.191
Ocular hypotension. *See* Hypotony
Ocular hypotony, 2.470*f*
Ocular immune privilege
antigens, 9.56
definition of, 9.51
regulators involved in, 9.57
Ocular immunology. *See* Immune response; Immune response arc
Ocular infection. *See* Infection; Infectious diseases
Ocular inflammation. *See* Endophthalmitis; Inflammation (ocular); Uveitis; *specific organ or structure affected*
Ocular injury. *See* Penetrating and perforating ocular trauma; Trauma
Ocular inserts, 2.363–364
Ocular instability of infancy, 6.87
Ocular ischemic syndrome (OIS), 5.170, 5.171*f*, 9.310
central retinal vein occlusion *versus*, 12.134
course of, 12.139
definition of, 12.138
etiology of, 12.139
ischemic cardiovascular disease associated with, 12.139
retinopathy caused by, 12.138
stroke rate in, 12.139
symptoms and signs of, 12.138–139
treatment of, 12.140
Ocular larval migrans, 8.253. *See also Toxocara* (toxocariasis)
Ocular lateropulsion, in Wallenberg syndrome, 5.217
Ocular melanocytosis (melanosis oculi), 4.63*t*, 4.64, 4.65*f*, 6.250–251, 6.251*f*, 8.338*t*, 8.338–340, 8.339*f*, 8.339*t*
choroidal nevus resembling, 4.257, 4.257*f*
congenital, 8.338–340, 8.339*f*
of iris, 4.259, 4.260*f*
Ocular microbiology. *See* Microbiology

Ocular motility. *See also specific type of eye movement*
abnormal, 5.183–209. *See also* Ocular motility, disorders of
assessment of, 5.233–235, 5.234*f*
before cataract surgery, 11.77–78
in nonorganic disorders, 5.309–310
before refractive surgery, 13.41
binocular eye movements and. *See also specific type*
conjugate (versions), 5.34–35, 5.35*f*
in diplopia, 5.184
disconjugate (vergences), 5.212, 5.212*t*, 5.226–228. *See also* Vergences/vergence system
contact lens trial before refractive surgery and, 13.199
control of, 5.31–46, 5.211, 5.212*t*, 5.212–213. *See also* Ocular motor pathways
brainstem in, 5.34–40, 5.35*f*, 5.36*f*, 5.37*f*, 5.39*f*
cerebellum in, 5.39–40
cortical/supranuclear pathways in, 5.32*f*, 5.32–33, 5.34*f*. *See also* Supranuclear (cortical) pathways
disorders of, 5.188, 5.188*t*, 5.211–231
cranial nerves/infranuclear pathways in, 5.40*f*, 5.40–45, 5.41*f*, 5.42–43*f*, 5.44*f*, 5.211
disorders of, 5.191–206, 5.193*f*, 5.194*f*, 5.198*f*, 5.199*f*, 5.200*f*, 5.204*f*. *See also* Diplopia
extraocular muscles in, 5.45–46, 5.46*f*
ocular fixation system in, 5.212, 5.212*t*, 5.213–214
optokinetic system/nystagmus in, 5.212, 5.212*t*, 5.218–219
saccades/saccadic system in, 5.32–33, 5.38, 5.212, 5.212*t*, 5.219–223, 5.220*f*
smooth-pursuit system in, 5.32, 5.33, 5.34*f*, 5.212, 5.212*t*
subcortical structures in, 5.33–34
vergence system in, 5.212, 5.212*t*, 5.226–228
vestibular-ocular system in, 5.38–39, 5.39*f*, 5.212, 5.212*t*
disorders of, 5.183–209, 5.211–231. *See also specific disorder*
chronic progressive external ophthalmoplegia (CPEO), 6.141–142, 6.143*t*
diplopia, 5.183–209. *See also* Diplopia
esotropia and hypotropia associated with high myopia, 6.143–144
gaze palsy/preference and, 5.228–230, 5.229*f*, 5.230*f*
infranuclear, 5.191–206, 5.193*f*, 5.194*f*, 5.198*f*, 5.199*f*, 5.200*f*, 5.204*f*
internuclear ophthalmoplegia, 6.144
localization of lesions causing, 5.187*f*, 5.187–188
in multiple sclerosis, 5.246, 5.248, 5.249, 5.318–319
myasthenia gravis, 6.142*f*, 6.142–143, 6.143*t*
nonorganic, 5.309–310
nystagmus/spontaneous, 5.233–251, 5.234*f*. *See also* Nystagmus
ocular fixation system dysfunction and, 5.214
ocular motor apraxia, 6.144–145
optokinetic nystagmus dysfunction and, 5.218–219
saccadic dysfunction and, 5.221–223, 5.233, 5.247–250, 5.248*f*
intrusions, 5.233, 5.247–250, 5.248*f*
ocular motor apraxia and, 5.221, 5.222–223
seizure activity and, 5.230
smooth-pursuit system dysfunction and, 5.224, 5.225–226
superior oblique myokymia, 6.145
supranuclear, 5.188, 5.188*t*, 5.211–231
thyroid eye disease, 6.140–141, 6.141*f*, 6.143*t*, 6.215
in thyroid eye disease, 4.226
tonic deviations and, 5.230–231
vergence dysfunction and, 5.227–228
in vertebrobasilar insufficiency, 5.337, 5.337*f*
vestibular/vestibular-ocular dysfunction and, 5.216*f*, 5.216–218, 5.234*f*, 5.241*t*, 5.241–246, 5.243*t*, 5.245*f*
ductions and, 5.184
efferent visual system and, 5.31–46, 5.211. *See also* Ocular motility, control of; Ocular motor pathways
fundamental principles of, 5.212*t*, 5.212–213
vergences and, 5.212, 5.212*t*, 5.226–228. *See also* Vergences/vergence system
versions and, 5.34–35, 5.35*f*
in diplopia, 5.184
Ocular motor apraxia, 5.221, 5.222–223, 6.144–145
acquired, 5.223
congenital, 5.223
Ocular motor pathways, 5.31–46, 5.211, 5.212*t*, 5.212–213. *See also* Ocular motility; *specific nerve*
brainstem and, 5.34–40, 5.35*f*, 5.36*f*, 5.37*f*, 5.39*f*
cerebellum and, 5.39–40
cortical input and, 5.32*f*, 5.32–33, 5.34*f*
cranial nerves and, 5.40*f*, 5.40–45, 5.41*f*, 5.42–43*f*, 5.44*f*. *See also specific nerve*
diplopia and, 5.187*f*, 5.187–206
extraocular muscles and, 5.45–46, 5.46*f*
ocular fixation system and, 5.212*t*, 5.213–214
optokinetic system/nystagmus and, 5.212, 5.212*t*, 5.218–219
saccades/saccadic system and, 5.32–33, 5.38, 5.212, 5.212*t*, 5.219–223, 5.220*f*
smooth-pursuit system and, 5.32, 5.33, 5.34*f*, 5.212, 5.212*t*
subcortical structures in, 5.33–34
supranuclear, 5.212*t*, 5.213–231
vergence system and, 5.212, 5.212*t*, 5.226–228
vestibular-ocular system and, 5.38–39, 5.39*f*, 5.212, 5.212*t*
Ocular motor tracking systems, 5.212*t*, 5.212–213
Ocular myasthenia gravis, 7.248. *See also* Myasthenia gravis
Ocular neuromyotonia, 5.202, 5.358
Ocular nocardiosis. *See Nocardia*/*Nocardia asteroides* (nocardiosis)
Ocular (optical) media
abnormalities of, 5.99
diplopia and, 5.185
fundus examination in evaluation of, 5.81
perimetry affected by, 5.86
transient visual loss and, 5.164
opaque. *See* Cataract; Opacities
refractive index of. *See* Refractive index
Ocular pain, 5.295–296. *See also* Pain
in ocular ischemic syndrome, 5.170
Ocular perfusion pressure (OPP), glaucoma and, 10.83

Ocular pharmacology. *See* Drugs; *specific agent*
Ocular pharmacotherapeutics. *See* Pharmacotherapeutics
Ocular prostheses
for graft-vs-host disease, 8.304
for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298
Ocular Response Analyzer (ORA), 10.26
Ocular-retinal developmental disease, genes and loci associated with, 12.256*t*
Ocular rotations
assessment of, 6.71
definition of, 6.31
horizontal, 6.31
torsional, 6.31
tube shunt effects on, 6.146
vertical, 6.31
Ocular-scoliotic type Ehlers-Danlos syndrome, 8.193
Ocular sensory pathways, 5.47*f*, 5.47–49, 5.48*f*. *See also* Cranial nerve V
"Ocular splits," 6.133
Ocular surface. *See also* Conjunctiva; Cornea; Epithelium
disorders of. *See also specific structure affected and specific type*
clinical approach to, 8.45–77. *See also specific structure and disorder*
common clinical findings and, 8.45–46*t*, 8.45–53
contact lens wear and, 8.84, 8.266–267, 8.273–274, 8.276, 8.277
corneal transplantation success and, 8.418
dry eye, 8.45, 8.53–69. *See also* Dry eye
aqueous tear deficiency, 8.45, 8.53, 8.54*f*, 8.55*f*, 8.55–58, 8.61*t*, 8.61–65, 8.62*t*, 8.65*f*
evaporative, 8.45, 8.53–54, 8.54*f*, 8.55*f*, 8.58–60, 8.59*f*, 8.60*f*, 8.66*t*, 8.66–67*t*, 8.66–69
eyelid disease associated with, 8.69–77
factitious, 8.88–90, 8.89*f*
immune-mediated, 8.285–326. *See also* Immune response (immunity), ocular, disorders of
limbal stem cell deficiency and, 8.92–94, 8.93*t*, 8.94*f*, 8.362. *See also* Limbal transplantation
neoplastic, 8.327–350. *See also* Ocular surface, tumors of
refractive surgery and, 13.172–173
structural/exogenous, 8.79–94
systemic conditions associated with, 8.173–203
tear film/tear production evaluation and, 8.38–41, 8.40*f*
therapeutic/surgical interventions for, 8.351*t*, 8.352–373. *See also specific procedure*
conjunctival interventions, 8.352–366
corneal interventions, 8.366–373
indications for, 8.351*t*
toxic, 8.90*t*, 8.90–92, 8.91*f*
evaluation of, 8.36–41
staining in, 8.36–37, 8.37*f*, 8.38*f*, 8.56
tear production and, 8.38–39
qualitative tests of, 8.40*f*, 8.40–41
quantitative tests of, 8.39
immunoregulation of, 8.11–13, 8.12–13*f*
infectious. *See* Infection
trauma to, 8.375–409. *See also* Anterior segment, trauma to
tumors of, 8.327–350
approach to patient with, 8.328
epithelial origin of, 8.332*t*, 8.332–337
glandular origin of, 8.337*f*, 8.337–338
incidence of, 8.327
lymphoid/lymphatic/lymphocytic, 4.69–71, 4.70*f*, 4.71*f*, 8.348–350, 8.349*f*, 8.350*f*
management of, 8.328–332, 8.330*f*, 8.331*f*
surgical, 8.329–330, 8.330*f*
topical chemotherapy, 8.330*f*, 8.330–332, 8.331*f*
melanocytic, 4.61–69, 4.63*t*, 4.64*f*, 4.65*f*, 4.66*f*, 4.67*f*, 4.68*f*, 4.69*f*
metastatic, 8.350
neuroectodermal origin of, 8.338*t*, 8.338–345, 8.339*t*
pigmented, 8.338*t*, 8.338–345
benign, 8.338*t*, 8.338–341, 8.339*f*, 8.339*t*, 8.340*f*, 8.341*f*
malignant, 8.338*t*, 8.339*t*, 8.343–345, 8.344*f*
preinvasive, 8.338*t*, 8.339*t*, 8.342*f*, 8.342–343
squamous neoplasia, 4.60–61, 4.62*f*, 4.63*f*, 8.334–337, 8.335*f*, 8.336*f*
invasive, 8.336, 8.336*f*. *See also* Squamous cell carcinoma
management of, 8.330*f*, 8.336–337
noninvasive, 8.334–335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
vascular and mesenchymal, 8.345*t*, 8.345–348, 8.346*f*, 8.347*f*
Ocular surface prosthesis
for graft-vs-host disease, 8.304
for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298
Ocular surface squamous neoplasia (OSSN), 4.60–61, 4.62*f*, 4.63*f*, 8.334–337, 8.335*f*, 8.336*f*. *See also under Squamous*
invasive, 8.336, 8.336*f*. *See also* Squamous cell carcinoma
management of, 8.330*f*, 8.336–337
noninvasive, 8.334–335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
Ocular surgery. *See also* Cataract surgery; *specific procedure*
in ambulatory surgical center, 1.281
American Society of Anesthesiologists Physical Status, 1.282
anesthetics in, 2.441–442
after arcuate keratotomy, 13.58
bullous keratopathy after, 4.83–84, 4.84, 4.84*f*, 4.85*f*
cataract and, 11.55–57
for choroidal/ciliary body melanoma, 4.275*f*, 4.277
with corneal surgery (bioptics), 13.137, 13.157
after corneal transplantation, 8.432
after corneoscleral laceration repair, 8.407–408
diplopia after, 5.207
endophthalmitis after. *See also* Postoperative endophthalmitis
Propionibacterium acnes causing, 4.119, 4.119*f*, 8.246, 11.140, 11.162

epithelial and fibrous ingrowth after, 10.141–142, 10.142*f*
fasting before, 1.287–288
informed consent before, 1.282
intraoperative considerations
general anesthesia, 1.289–290
local anesthesia, 1.290–291
malignant hyperthermia, 1.291–292, 1.293*t*
lens particle glaucoma and, 11.67
after limbal relaxing incisions, 13.58
malignant/ciliary block glaucoma (aqueous misdirection) and, 10.139
ocular surface, 8.351*t*
for ocular surface tumors, 8.329–330, 8.330*f*
perioperative management in
in adolescents, 1.283
anticoagulants, 1.286
antiplatelet agents, 1.286
atrial fibrillation, 1.284
cardiovascular disease, 1.283–284
in children, 1.283
complications prevention as focus of, 1.282
diabetes mellitus, 1.284, 1.286–287
fasting, 1.287–288
hypertension, 1.284
implantable cardioverter-defibrillator, 1.282
latex allergies, 1.288
medications, 1.285–287
preoperative assessment, 1.281–283
pulmonary medications, 1.287
respiratory diseases, 1.284–285
risk status assessments, 1.281
Universal Protocol, 1.288–289
after radial keratotomy, 13.52–53
refractive, 13.7, 13.8*t*, 13.137–157. *See also* Keratorefractive surgery; Refractive surgery; *specific procedure*
accommodating IOLs, 13.8*t*, 13.154, 13.163–164, 13.164*f*
bioptics, 13.137, 13.157
light-adjustable IOLs, 13.153–154, 13.154*f*
limitations of, 13.47*t*
monofocal IOLs, 13.151
multifocal IOLs, 13.8*t*, 13.155–156, 13.165–167, 13.166*f*
phakic/phakic IOLs, 13.8*t*, 13.137, 13.138–147, 13.139*t*, 13.142*f*, 13.143*f*. *See also specific procedure*
pseudophakic, 13.8*t*. *See also specific procedure*
refractive lens exchange, 13.8*t*, 13.137, 13.147–151
toric IOLs, 13.8*t*, 13.137, 13.148–149, 13.151–153
suprachoroidal hemorrhage and, 11.159–160, 11.171
sympathetic ophthalmia and, 4.185, 12.233. *See also* Surgery
Ocular tics, 6.201–202
Ocular tilt reaction, 5.216*f*, 5.216–217
torsional nystagmus in, 5.245
Ocular torsion, 6.107
Ocular torticollis, 6.82–84, 6.83*t*
Ocular toxocariasis (OT). *See Toxocara* (toxocariasis)
Ocular toxoplasmosis. *See Toxoplasma* (toxoplasmosis)
Ocular trauma. *See* Trauma
Ocular Trauma Score, 12.364, 12.364*t*
Ocular tumors. *See* Intraocular tumors; Tumor(s)
Oculoauriculovertebral syndrome (OAVS/Goldenhar-Gorlin syndrome), 6.210, 8.191*t*, 8.195*f*, 8.195–196
Oculocardiac reflex, 2.130, 6.174
Oculocerebrorenal syndrome (Lowe disease/syndrome), 4.118, 6.391
congenital corneal keloids in, 8.107, 8.125
Oculocutaneous albinism (OCA). *See* Albinism
Oculodento-osseous dysplasia, 8.192*t*
Oculodentodigital dysplasia
Axenfeld-Rieger syndrome differentiated from, 10.154*t*
description of, 12.282*t*
Oculodermal/dermal/dermal orbital melanocytosis (nevus of Ota), 4.63*t*, 4.64, 8.339
glaucoma associated with, 10.30
of iris, 4.259
Oculodermal melanocytosis (nevus of Ota), 6.251, 7.198, 7.199*f*, 8.339, 8.339*t*
Oculodigital reflex, 6.185, 12.266
Oculoglandular syndrome, Parinaud, 4.51, 8.265–266. *See also* Cat-scratch disease
Oculogyric crisis, 5.231
Oculomandibulodyscephaly (Hallermann-Streiff-François syndrome), 8.191*t*
Oculomasticatory myorhythmia, 5.251
Oculomotor foramen, 2.20*f*, 7.13
Oculomotor nerve. *See* Cranial nerve III
Oculomotor nerve palsy. *See* Third nerve (oculomotor) palsy
Oculomotor neuropathy, recurrent painful, 5.197
Oculomycosis, 8.249–251. *See also* Fungi
trauma and, 8.251
Oculopalatal myoclonus/tremor, pendular nystagmus and, 5.246–247
Oculopharyngeal dystrophy, 5.329
ptosis in, 5.273, 5.273*t*, 5.329
Ocumeter, 2.389*t*
Ocupress. *See* Carteolol; Carteolol hydrochloride
Ocusert delivery system. *See* Pilocarpine
ODAd. *See* Overdepression in adduction
ODD. *See* Optic disc (optic nerve head/ONH), drusen of
Odds ratio, 1.22–23
Odontogenic cysts, 7.202*f*
Odontogenic infections, 7.48
OEAd. *See* Overelevation in adduction
Off-axis object point, 3.72
Off-bipolar cells, 2.315
Off-label drug use
for conductive keratoplasty, 13.129
description of, 2.370–371, 2.371t
refractive surgery in ocular and systemic disease and, 13.171
"Off-pump bypass surgery," 1.92
Ofloxacin, 2.421*t*, 2.422
for bacterial keratitis, 8.269, 8.270*t*
for gonococcal conjunctivitis, 8.259
OGTT. *See* Oral glucose tolerance test
Oguchi disease, 2.229, 12.253
"Ohno" sign, 12.233
OHS. *See* Ocular histoplasmosis syndrome

OHT. *See* Ocular hypertension
OHTS (Ocular Hypertension Treatment Study), 1.22–23, 10.65, 10.81, 10.82, 10.83, 10.89–90, 10.112
Oil droplet appearance/cataract, 11.44
  in galactosemia, 11.61, 11.61*f*
  in lenticonus/lentiglobus, 11.30
Oil glands, of eyelid. *See specific Sebaceous entries*
Ointments
  description of, 2.358–359
  ocular. *See* Lubricants
OIS. *See* Ocular ischemic syndrome
OIS (orbital inflammatory syndrome). *See* Nonspecific orbital inflammation
OKN. *See* Optokinetic system/nystagmus
Olanzapine, 1.200
Older adults. *See also* Age/aging
  abuse of, 1.185–187
  antihypertensive therapy in, 1.67
  cataracts in, 1.184
  confusion in, 1.187
  delirium in, 1.187
  depression in, 1.188–190, 1.195
  diabetic retinopathy in, 1.184
  falls in, 1.191–192
  financial abuse of, 1.186
  functional assessment of, 1.187
  glaucoma in, 1.184
  global statistics regarding, 1.183
  hip fractures in, 1.190
  hypertension in, 1.67
  informed consent in, 1.187
  instrumental activities of daily living assessment in, 1.187
  losses experienced by, 1.188
  maltreatment of, 1.185
  office environment for, 1.184–185
  orthostatic hypotension in, 1.67
  osteoporosis in, 1.190
  perioperative considerations in, 1.187–188
  pharmacologic principles in, 2.351–352
  physical abuse of, 1.186
  physiologic aging in, 1.183–184
  population growth, 1.183
  preoperative discussions with, 1.188
  psychological abuse of, 1.186
  sensory systems in, 1.184
  suicide rates in, 1.188
  varicella-zoster virus in, 1.228
  vision loss in, 1.184
Olfactory bulb, 2.108*f*
Olfactory fossa, 2.460*f*
Olfactory nerve (cranial nerve I), 2.105, 2.108*f*
Olfactory tract, 2.105
Oligemic shock. *See* Shock
Oligoarthritis, 9.143*f*
Oligoarticular (pauciarticular)-onset juvenile idiopathic (chronic/rheumatoid) arthritis (oligoarthritis). *See* Juvenile idiopathic arthritis
Oligodendrocytes, 2.157, 4.241, 4.242*f*
Oligonucleotide microarray analysis, SNP (SOMA), 4.39*t*
Olivopontocerebellar atrophy, 12.282*t*
Olopatadine hydrochloride, 2.413
Omega-3 fatty acids
  description of, 2.250, 12.70
  supplements, for dry eye, 8.61, 8.61*t*, 8.64, 8.68
Omidria, 2.384
OMIM (Online Mendelian Inheritance in Man), 2.187–188, 6.294, 12.255
  for corneal dystrophies, 8.191–192*t*
Omnipause cells/neurons, 5.38, 5.219, 5.220*f*
  saccadic intrusions and, 5.248, 5.249
  saccadic system and, 5.219, 5.220*f*
Omnipred. *See* Prednisolone
On-bipolar cells, 2.315–317
"On-label" prescribing, 2.370
OnabotulinumtoxinA, 5.281. *See also* Botulinum toxin
  as tarsorrhaphy alternative, 8.373
Onchocerca/*Onchocerca volvulus* (onchocerciasis), 8.252–253, 9.289
Onchocerciasis, 8.252–253, 9.289*f*, 9.289–290
Oncocytoma, 4.71–72, 4.72*f*, 8.337
Oncogenes, 1.235, 2.183
Oncologist, ophthalmic, 4.42
Oncolytic virus therapy, for melanoma, 7.210
One-and-a-half syndrome, 5.191, 5.191*f*
100-hue test (Farnsworth-Munsell), in low vision evaluation, 5.79
1-piece foldable intraocular lens, insertion of, 11.116
1 toy, 1 look rule, for pediatric eye examination, 6.3, 6.4*f*
ONH. *See* Optic nerve (cranial nerve II), hypoplasia of; Optic nerve head
ONL. *See* Outer nuclear layer
Onlays, corneal, 13.59–71. *See also* Inlays, corneal
Online Mendelian Inheritance in Man (OMIM), 2.187–188, 6.294, 12.255
  for corneal dystrophies, 8.191–192*t*
Online post-refractive intraocular lens power calculator (ASCRS), 13.52, 13.195–197, 13.196*f*
ONSF. *See* Optic nerve sheath, fenestration of
ONSM. *See* Optic nerve sheath meningioma
Onycho-osteodysplasia (nail-patella syndrome), 8.192*t*
  gene for, 10.11*t*
OPA1 gene, 6.367
  in optic atrophy, 5.135
Opacities
  corneal. *See* Cornea, opacification of
  fundus evaluation with, 11.81
  IOL, 11.151
  lens. *See* Cataract
  lens fiber, 4.122, 4.122*f*
  vitreous
    amyloidosis, 12.348, 12.349*f*
    in amyloidosis, 4.134
    asteroid hyalosis, 12.346*f*, 12.346–347
    bilateral, 12.348
    cholesterolosis, 12.348
    pigment granules, 12.348
    vitrectomy for, 12.386
    vitreous degeneration and detachment associated, 12.344
    vitreous hemorrhage, 12.347
Opaque bubble layer (OBL), femtosecond laser flap creation and, 13.88, 13.122–123

Opcon-A. *See* Naphazoline hydrochloride/pheniramine maleate
Open-angle glaucoma, 10.3–5, 10.4*t*, 10.6*t*, 10.79–115. *See also* Glaucoma
age and, 10.7
angle-closure glaucoma differentiated from, 10.3, 10.5*f*
aphakic, 6.285
in central retinal vein occlusion, 12.133
central retinal vein occlusion and, 10.84
childhood. *See* Open-angle glaucoma, pediatric
classification of, 10.3–5, 10.4*t*, 10.6*t*
combined-mechanism, 10.7
cornea plana and, 8.101
corneal thickness and, 10.81, 10.82, 10.86–87, 10.90
corticosteroids causing, 10.109–110
diabetes mellitus and, 10.83
drug-induced, 10.109–111
episcleral venous pressure elevation and, 10.102*t*, 10.102–103, 10.103*f*
family history and, 10.82
Fuchs heterochromic iridocyclitis/uveitis and, 10.101–102, 10.102*f*
genetic/hereditary factors in, 10.10, 10.11*t*
glaucoma suspect and, 10.4*t*, 10.89
glaucomatocyclitic crisis (Posner-Schlossman syndrome) and, 10.100–101
hemorrhage/hyphema and, 10.85*f*, 10.85–86
intraocular pressure in, 10.79, 10.80–81, 10.81*t*
intraocular tumors and, 10.98–100, 10.99*f*
juvenile, 6.278, 6.284
lens-induced, 10.96–98, 10.97*f*
management of
clinical trials in evaluation of, 10.111–115
medical, 10.183–184. *See also* Antiglaucoma agents; *specific drug*
surgical, 10.187. *See also* Glaucoma surgery; *specific procedure*
incisional, 10.113–115. *See also* Filtering procedures
laser trabeculoplasty, 10.113–115, 10.188–191, 10.190*f*
minimally invasive procedures/microshunts, 10.219–220
nonpenetrating procedures and, 10.217–219
microcornea and, 8.95–99
myopia and, 10.82, 10.87
normal-tension (NTG). *See* Glaucoma, normal-tension
ocular hypertension and, 10.89–90, 10.112
ocular inflammation and, 10.100–102, 10.102*f*
optic nerve/nerve head/disc appearance in, 5.136, 5.137*f*, 10.79–80
outflow obstruction mechanisms in, 10.5, 10.6*t*
pediatric (childhood/congenital/infantile/juvenile), 10.4*t*, 10.147, 10.148*t*
genetics of, 10.11*t*, 10.150
primary
congenital, 4.98, 4.99*f*, 10.4*t*, 10.147, 10.148*t*, 10.151–152*f*, 10.151–153, 10.152*t*. *See also* Primary congenital glaucoma
genetics of, 10.11*t*, 10.150
juvenile, 10.4*t*, 10.148*t*, 10.153
penetrating keratoplasty and, 10.109
pigmentary/pigment dispersion syndrome and, 4.105, 4.105*f*, 10.93–96, 10.94*f*, 10.95*f*, 10.96*f*
posterior polymorphous corneal dystrophy and, 8.159
primary (POAG), 10.3–5, 10.4*t*, 10.79–84, 10.81*t*
clinical features of, 10.79–80
clinical trials in, 10.111–115. *See also specific study*
congenital, 4.98, 4.99*f*
description of, 2.233, 2.345, 2.377–378, 2.381, 2.387
disorders associated with, 10.83–84
epidemiology of, 10.7–8, 10.9*t*
genetic/hereditary factors in, 10.10, 10.11*t*
incidence of, 10.7, 10.8
juvenile, 10.4*t*, 10.148*t*, 10.153
management of. *See* Antiglaucoma agents; Glaucoma surgery
prevalence of, 10.7–8
prognosis/therapy for, 10.84
refractive surgery and, 13.180–183, 13.182*f*, 13.200–201
risk factors for, 10.8, 10.9*t*, 10.80–83
without elevated intraocular pressure, 10.3, 10.4*t*, 10.85*f*, 10.85–88, 10.86*t*. *See also* Glaucoma, normal-tension
pseudoexfoliation/exfoliation syndrome and (pseudoexfoliation glaucoma), 10.91–92*f*, 10.91–93
race and, 10.7–8, 10.81, 10.82
refractive surgery and, 13.180–183, 13.182*f*, 13.200–201
risk factors for, 10.8, 10.9*t*, 10.80–83
Schwartz (Schwartz-Matsuo) syndrome and, 10.109
secondary, 9.318–319, 10.4*t*, 10.5, 10.79, 10.91–111. *See also specific cause*
trauma causing, 4.103–104, 4.104*f*, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*
traumatic, 4.103–104, 4.104*f*, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*
visual field loss in, 10.79–80
vitrectomy as risk factor for, 12.402
without elevated intraocular pressure, 10.3, 10.4*t*, 10.85*f*, 10.85–88, 10.86*t*. *See also* Glaucoma, normal-tension
Open-loop speculum, for globe exposure, in cataract surgery, 11.105*f*
Open-loop trackers, 13.91
Open reading frame (ORF), 2.176
Open reduction and fixation, for zygomatic fractures, 7.111
Operating/surgical microscope
for manual small-incision cataract surgery, 11.198
phototoxicity and, 11.166
Operculated retinal holes, 12.315–316
OPGs. *See* Optic nerve (optic pathway/chiasm) gliomas
OphA. *See* Ophthalmic artery
Ophthacet. *See* Sulfacetamide
Ophthalmia, sympathetic (SO), 4.185, 4.186*f*
enucleation in prevention of, 8.404
glaucoma/glaucoma surgery and, 10.195, 10.196, 10.198
histologic/histopathologic features of, 4.185, 4.186*f*
surgical procedures/injuries leading to, 4.185

Ophthalmia neonatorum, 8.257*t*, 8.263–265
chlamydia/*Chlamydia trachomatis* as cause of, 6.238–239, 6.239*f*, 8.257*t*, 8.265
definition of, 6.237
epidemiology of, 6.237
etiology of, 6.237
gonococcal, 8.257*t*, 8.258, 8.264
herpes simplex virus as cause of, 6.239. *See also* Conjunctivitis, herpes simplex
Neisseria gonorrhoeae as cause of, 6.238*f*, 6.238–239
Neisseria meningitidis as cause of, 6.238
prevalence of, 6.237
prophylaxis for, 6.239
Ophthalmia nodosum, 8.387
Ophthalmic artery, 6.23
anatomy of, 2.21, 2.23*f*, 2.25*f*, 2.106*f*, 2.119, 7.12–13*f*, 7.14, 7.15–16*f*
branches of, 2.21
occlusion of, 7.157, 12.146, 12.147*f*
Ophthalmic artery (OphA), 5.8*f*, 5.12, 5.13*f*, 5.14*f*, 5.14–17, 5.15*f*
aneurysm of, 5.339
optic nerve supplied by, 5.17*f*, 5.26, 10.44
orbit supplied by, 5.12, 5.13*f*, 5.14*f*, 5.14–17, 5.15*f*
terminal, 5.15
Ophthalmic division of cranial nerve V (trigeminal). *See* Cranial nerve V (trigeminal nerve), V_1
Ophthalmic echography. *See* Ultrasonography/ultrasound (echography)
Ophthalmic examination. *See also* Examination, ophthalmic
in children
anterior segment examination, 6.10
Brückner test, 6.9
communication during, 6.4
cycloplegic refraction, 6.10–12
difficult child, 6.5
distance fixation targets, 6.3, 6.4*f*
dynamic retinoscopy, 6.9
fundus, 6.12
general considerations and strategies for, 6.3–5
intraocular pressure measurement, 6.10
1 toy, 1 look rule, 6.3, 6.4*f*
in outpatient setting, 6.3, 6.4*f*
practitioner positioning during, 6.4
pupil testing, 6.10
red reflex, 6.9
"safe" environment for, 6.4
slit-lamp examination, 6.4–5
tonometry, 6.10
visual acuity assessment. *See* Children, visual acuity assessment
visual field testing, 6.10
vocabulary during, 6.4
description of, 3.23
diabetes mellitus–related, 12.93–94, 12.95*t*
Ophthalmic instrumentation. *See also specific instrument; specific type*
errors in, after refractive surgery, 3.251–252
phototoxicity from
cataract surgery and, 11.166
description of, 12.368–369
polarized light applications in, 3.99
Ophthalmic irrigants. *See* Irrigation/aspiration
Ophthalmic lenses. *See* Lenses; *specific type*
Ophthalmic oncologist, 4.42
Ophthalmic pathology. *See also specific structure and specific disorder*
of anterior chamber/trabecular meshwork, 4.97–106
checklist for requesting, 4.25, 4.33, 4.34*t*
communication among health care team members and, 4.25–26
congenital anomalies and, 4.6, 4.7*f*, 4.12*t*
of conjunctiva, 4.47–72
of cornea, 4.73–96
cytology for, 4.34*t*
degeneration and dystrophy and, 4.9–10, 4.12*t*
diagnosis/differential diagnosis and, 4.11–12, 4.12*t*
electron microscopy in, 4.34*t*, 4.42
of eyelids, 4.201–221
fine-needle aspiration biopsy in, 4.34*t*, 4.42–43, 4.43*f*
flow cytometry in, 4.34*t*, 4.36, 4.37*f*
frozen section for, 4.34*t*, 4.43–45, 4.44*f*
immunohistochemistry in, 4.33–35, 4.35*f*
inflammation and, 4.6–9, 4.8*f*, 4.9*f*, 4.12*t*
of lens, 4.115–124
molecular pathology in, 4.34*t*, 4.36–42, 4.38–39*t*, 4.40*f*, 4.41*f*
neoplasia and, 4.10, 4.10*t*, 4.11*f*, 4.12*t*
of optic nerve, 4.241–250
of orbit, 4.223–240
organizational paradigm for, 4.5–12, 4.12*t*
of retina/retinal pigment epithelium, 4.139–180
of sclera, 4.107–112, 4.113*f*
special procedures in, 4.33–45
specimen collection/handling for, 4.25–30, 4.31*t*
topography and, 4.6, 4.12*t*
of uveal tract, 4.181–199, 4.200*f*
of vitreous, 4.125–137
wound repair and, 4.13–23, 4.14*f*
Ophthalmic prisms. *See* Prism(s)
Ophthalmic surgery. *See* Ocular (intraocular) surgery
Ophthalmic ultrasonography. *See* Ultrasonography/ultrasound (echography)
Ophthalmic vein, 5.8*f*, 5.21*f*, 5.22*f*, 5.23*f*, 7.13*f*
inferior, 5.8*f*, 5.21*f*, 5.22, 5.22*f*, 5.23*f*
orbit drained by, 5.21*f*
superior, 5.8*f*, 5.21, 5.21*f*, 5.22*f*, 5.23, 5.23*f*
Ophthalmic viscosurgical devices (OVDs/viscoelastic agents)
for cataract surgery, 11.95–97
advanced cataract and, 11.180
aniridia and, 11.184
capsular block syndrome and, 11.148
capsular rupture during surgery and, 11.142–143
ECCE, 11.197
high hyperopia and, 11.185
ICCE, 11.200
inflamed eye and, 11.191
intumescent cataract and, 11.179–180
IOL implantation and, 11.116, 11.117–118
in keratoconjunctivitis sicca, dry eye therapy before use of, 11.173
phacoemulsification, 11.105, 11.109, 11.110, 11.112, 11.115, 11.116, 11.117–118
posterior polar cataract and, 11.181

pupil expansion and, 11.178
selection of, 11.97
traumatic cataract and, 11.191, 11.192
uveitis and, 11.191
zonular dehiscence with lens subluxation or dislocation and, 11.182
in corneoscleral laceration repair, 8.405*f*, 8.406
description of, 2.360*t*, 2.445
elevated intraocular pressure and, 10.108, 11.136
for goniotomy and trabeculotomy, in children, 10.162–163
phakic IOL implantation and, 13.141
posterior chamber lenses, 13.143
physical properties of, 11.96
toric IOL implantation and, 13.152
Ophthalmic wound healing/repair. *See* Wound(s), healing/repair of
Ophthalmometry/ophthalmometer. *See* Keratometry/keratometer
Ophthalmopathy, thyroid (Graves/dysthyroid). *See* Thyroid eye disease
Ophthalmoplegia
cavernous sinus lesion causing, 5.202–206, 5.204*f*, 5.205*f*
in gaze palsy, 5.228
herpes infection and, 5.350
internuclear (INO), 5.38, 5.189–190, 5.190*f*, 5.247
bilateral/wall-eyed bilateral (WEBINO), 5.189, 5.190*f*
in multiple sclerosis, 5.318
in multiple sclerosis, 5.318
myasthenia gravis and, 5.190, 5.324
in neuromyelitis optica, 5.322
nystagmus in, 5.189, 5.190*f*, 5.247
one-and-a-half syndrome and, 5.191
pursuit dysfunction in, 5.226
in myotonic dystrophy, 5.329
in oculopharyngeal dystrophy, 5.329
in optic neuropathy, 5.126
progressive (chronic progressive) external (CPEO), 5.328–329, 5.329*f*
ptosis in, 5.273, 5.273*t*, 5.328, 5.329*f*
in third nerve palsy (recurrent painful oculomotor neuropathy), 5.197
Ophthalmoplegic migraine, 5.197. *See also* Migraine headache
Ophthalmoscopy/ophthalmoscope
before cataract surgery, 11.80–81
confocal scanning laser, 3.302, 3.302*f*
definition of, 3.296
direct, 3.281, 3.297–3.298*f*, 3.297–298, 3.307
limitations of, 12.21
in low vision evaluation, 5.81
in optic nerve/nerve head/disc evaluation, 10.48, 10.56
retinal disease evaluations using, 12.21
fundus camera, 3.301
in glaucoma evaluation, 10.48, 10.49*t*, 10.56
in infants and children, 10.160
indirect, 3.281, 3.298–300*f*, 3.298–301, 3.307
in choroidal/ciliary body melanoma, 4.265
illumination in, 12.21
in optic nerve/nerve head/disc evaluation, 10.48
posterior vitreous detachment diagnosed using, 12.309, 12.331
retinal disease evaluations using, 12.21–22
laser, in optic nerve/nerve head/disc evaluation, 10.56
retinal disease evaluations using, 12.21–22
scanning laser. *See* Scanning laser ophthalmoscopy/ophthalmoscope
Ophthetic. *See* Proparacaine
Opioid crisis, 1.306–307
OPL. *See* Outer plexiform layer
OPP. *See* Ocular perfusion pressure
Opportunistic infections, 1.269, 12.235–236. *See also* Immunocompromised host; *specific type*
in AIDS patients, 9.328
CMV retinitis, 4.145, 4.146*f*
during cyclophosphamide treatment, 9.109
in HIV infection/AIDS. *See* HIV infection/AIDS
Opsins, rod. *See* Rhodopsin
Opsoclonus (saccadomania)
description of, 5.248–249, 6.153, 6.415
in neuromyelitis optica, 5.322
Optic ataxia, 5.223
Optic atrophy, 4.245*f*, 4.245–246, 4.246*f*, 4.247*f*, 5.81–82, 5.82*f*, 5.145–146, 9.269, 9.270*f*
ascending, 4.245–246
autosomal dominant (ADOA), 5.135, 5.136*f*
Behr, 6.368
bow-tie, 5.25*f*, 5.153
causes of, 6.367, 6.367*t*
cavernous, of Schnabel, 4.246, 4.247*f*
descending, 4.246
in DIDMOAD syndrome, 2.220
dominant, 5.135, 5.136*f*, 6.367–368, 6.368*f*
genes and loci associated with, 12.256*t*
Leber hereditary optic neuropathy, 6.368
in optic tract syndrome, 5.153
recessive, 6.368
traumatic hyphema and, 8.393, 8.394, 8.395*t*
Optic axis, 3.51
Optic canal, 5.5, 5.6*f*, 5.7*f*, 5.10*f*, 5.11, 5.26. *See also* Intracanalicular region of optic nerve
anatomy of, 2.6*f*, 2.10, 7.7–8*f*, 7.11
computed tomography of, 2.11*f*, 2.456*f*
decompression of, for traumatic vision loss, 5.140
medial wall of, 7.7
Optic cap (apical zone), 8.25
Optic chiasm. *See* Chiasm
Optic cup, 2.111, 10.48
in AAION/NAION, 5.120, 5.121*f*, 5.122
anatomy of, 2.159*f*
asymmetry of, 10.48–49, 10.49*f*
description of, 6.282, 6.283*f*
development of, 11.25
enlargement of, 10.47*f*, 10.48, 10.49*f*, 10.49*t*. *See also* Cupping of optic nerve/nerve head/disc
formation of, 2.305
invagination of, 2.153
ratio of, to optic disc (cup-disc ratio), in glaucoma evaluation, 10.48, 10.53
in infants and children, 10.160
vertical elongation of, 10.49, 10.50*f*
Optic cup margin, 2.159*f*

Optic disc (optic nerve head/ONH), 2.83, 5.17*f*, 5.24–25, 5.25*f*. *See also* Optic disc; Optic nerve
anatomy of, 2.48*f*, 5.17*f*, 5.24–25, 5.25*f*
atrophy of. *See* Optic atrophy
blood supply of, 5.17*f*
coloboma of, 4.242, 4.243*f*, 6.339*f*
congenital/developmental abnormalities of, 4.241–242, 4.243*f*, 5.143*f*, 5.143–145, 5.144*f*
transient visual loss and, 5.164
cupping of. *See* Cupping of optic nerve/nerve head/disc
definition of, 2.110
drusen of (ODD), 4.247, 4.247*f*, 5.108*f*, 5.140–143, 5.141*f*, 6.373*f*, 6.373–374
astrocytic hamartoma differentiated from, 5.108*f*, 5.143
autofluorescence in identification of, 5.89, 5.90*f*, 5.141*f*, 5.142
papilledema/pseudopapilledema and, 4.247, 5.107, 5.108*f*, 5.141*f*, 5.142–143
transient visual loss and, 5.141, 5.161, 5.164
ultrasonography in identification of, 5.95, 5.141*f*, 5.142
dysplastic, 5.145
edema of, 2.470*f*, 5.82, 5.83*f*, 5.105–113, 5.107*t*, 5.108*f*, 5.109*f*, 5.110*f*, 5.111*t*. *See also* Papilledema; Pseudopapilledema
in anterior optic neuropathy, 5.104
AAION, 5.120, 5.120*t*, 5.121*f*
NAION, 5.120, 5.120*t*, 5.121*f*, 5.122, 5.123*t*
in bartonellosis, 9.241
in diabetic papillopathy, 5.125, 5.125*f*
fluorescein angiography in evaluation of, 5.89
neuroimaging in evaluation of, 5.71, 5.109
in neuroretinitis, 5.118, 5.118*f*, 5.118–119
in optic atrophy, 4.245, 4.245*f*
in papillitis, 5.113
in papillophlebitis, 5.125, 5.126*f*
examination of
in glaucoma evaluation, 10.32, 10.48–59. *See also* Optic disc (optic nerve head/ONH), in glaucoma
in low vision evaluation, 5.81–82, 5.82*f*, 5.83*f*
excavation of, 5.137*f*
congenital, 5.145
in glaucoma, 5.136, 5.137*f*
in Foster-Kennedy/pseudo-Foster-Kennedy syndrome, 5.122
in glaucoma, 5.136, 5.137*f*, 10.3, 10.48
evaluation of, 10.32, 10.48–59, 10.49*f*, 10.49*t*, 10.50*f*, 10.51*f*, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
imaging and, 10.53–59, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
normal-tension glaucoma and, 10.86
perimetry changes correlated with, 10.74–75
recording findings and, 10.53
hemorrhage of, 10.50, 10.51*f*, 10.85*f*, 10.85–86
open-angle glaucoma and, 10.79–80
visual field changes and, 10.74–75
hemangioblastoma of, 4.284, 4.284*f*, 4.285
hypoplasia of, 5.143*f*, 5.143–144
imaging in evaluation of, 10.53–59, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
in Leber hereditary optic neuropathy, 5.133, 5.134*f*
megalopapilla, 6.366
melanocytoma (magnocellular nevus) of, 4.248, 4.248*f*, 4.257*f*, 4.258, 4.268, 6.367, 6.367*f*
melanoma differentiated from, 4.268
morning glory, 5.145
neovascularization of (NVD), in diabetic retinopathy, papillopathy and, 5.125
nerve fibers entering, 10.42–43, 10.43*f*, 10.45*f*
neuroimaging in evaluation of, 5.71
pallor of, 5.81–82, 5.82*f*. *See also* Optic atrophy
OCT in evaluation of, 5.91*f*
papilledema of
definition of, 6.370
idiopathic intracranial hypertension and, 6.370*f*, 6.370–371
peripapillary staphyloma of, 6.366
pseudopapilledema of, 6.372–373*f*, 374
sarcoid granuloma involving, 5.126*f*, 5.327
swelling of, 6.371*t*
tilted, 5.144, 5.144*f*, 6.365–366, 6.366*f*
topography, 10.53
tumors of, 4.248*f*, 4.248–250, 4.249*f*, 4.250*f*
metastatic, 4.303, 4.307–308
Optic disc pits. *See* Optic pits
Optic foramen, 2.10, 5.7*f*, 7.11
Optic gliomas. *See* Optic nerve glioma
Optic holes. *See* Holes
Optic nerve (cranial nerve II), 4.241–250. *See also* Optic nerve head
anatomy of, 2.8, 2.20*f*, 2.48*f*, 2.109, 2.109*f*, 4.241, 4.242*f*, 5.8*f*, 5.16–18*f*, 5.23*f*, 5.25*f*, 5.26–27, 5.27*f*, 5.43*f*, 5.48*f*, 5.55*f*, 7.12–13*f*, 10.41–46, 10.43–45*f*
anterior/anterior zone of, 10.42
aplasia of, 6.366
atrophy of. *See* Optic atrophy
Behçet disease involvement of, 9.215
blood supply of, 2.119–122, 2.120–122*f*, 5.17*f*, 5.18*f*, 10.44–46, 10.45*f*
coloboma of, 4.242, 4.243*f*, 6.364–365*f*
computed tomography of, 2.456*f*
conduction delay, visual evoked potentials of, 12.52
congenital/developmental abnormalities of, 4.241–242, 4.243*f*, 5.143*f*, 5.143–145, 5.144*f*
transient visual loss and, 5.164
craniosynostosis-related abnormalities of, 6.208–209
decussation of, 6.43
degenerations of, 4.245*f*, 4.245–247, 4.246*f*, 4.247*f*
development of
anomalies of, 6.361–367, 6.362–367*f*
description of, 2.156*f*, 2.157
disorders of, 4.241–250. *See also* Optic neuropathy; *specific type*
color vision affected in, 5.78
hallucinations and, 5.176
illusions and, 5.175
neoplastic, 4.248*f*, 4.248–250, 4.249*f*, 4.250*f*, 4.303, 4.307–308
radiation causing, 5.358, 5.358*f*
relative afferent pupillary defect in, 5.81
dysplastic, 5.145
embryologic development of, 2.156*f*, 2.157

evaluation of
before cataract surgery, 11.81
electrophysiologic testing in, 5.95–97, 5.96*f*
in glaucoma, 10.41–46, 10.43*f*, 10.44*f*, 10.45*f*
in infants and children, 10.160
normal-tension glaucoma and, 10.86
before refractive surgery, 13.44
external (dural) sheath of, 2.114, 2.114*f*
in glaucoma, 10.3, 10.46–59, 10.47*f*, 10.49*f*, 10.50*f*, 10.51*f*, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*. *See also* Optic neuropathy
examination of, 10.41–46, 10.43*f*, 10.44*f*, 10.45*f*
in infants and children, 10.160
normal-tension glaucoma and, 10.86
glioma of. *See* Optic nerve (optic pathway/chiasm) glioma
in granulomatosis with polyangiitis (Wegener granulomatosis), 5.115
hypoplasia of, 5.143*f*, 5.143–144, 6.154, 6.361–362, 6.362*f*
nystagmus in, 5.236
infection of, 4.243*f*, 4.243–244, 4.244*f*
infiltrative lesions of, 5.126*f*, 5.126–127, 5.131–133
inflammation of, 4.243*f*, 4.243–245, 4.244*f*, 4.245*f*, 5.113–118, 5.114*f*, 5.117*t*. *See also* Optic neuritis
intracanalicular region of, 2.115, 4.241
compressive lesions of, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*
transient visual loss and, 5.164
intracranial region of, 2.115, 4.241, 5.26–27
intraocular region of, 2.110–113, 2.111–113*f*, 4.241
intraorbital portion of, 7.11
intraorbital region of, 2.113–115, 2.121, 4.241, 5.26, 10.42
compressive lesions of, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*
laminar area of, 10.42, 10.43, 10.46
lateral geniculate nucleus of, 2.116–117*f*
in leukemia, 4.316, 4.316*f*
leukemic infiltration of, 6.414, 6.414*f*
magnetic resonance imaging of, 2.459*t*, 6.363*f*
meningeal sheaths of, 2.114*f*, 2.114–115
meninges of, 2.115
meningiomas of, 5.65*f*, 5.66*f*, 5.126, 5.127*f*, 5.127–129, 5.128*t*
morning glory disc anomaly of, 6.362–363, 6.364*f*
myelination of, 6.365, 6.365*f*
in pathologic myopia, 12.217–218, 12.218*f*
peripapillary intrachoroidal cavitations, 12.215, 12.215*f*
posterior, 10.42
prelaminar area of, 10.42, 10.43, 10.45*f*, 10.45–46. *See also* Optic nerve head
in primary congenital glaucoma, 6.282–283, 6.283*f*
regional differences in, 2.110*t*
retinal ganglion cells in, 10.41–42
degeneration of, in glaucomatous optic neuropathy, 10.46–47
retinoblastoma involving, 4.176*f*, 4.176–177, 4.177*f*, 4.293
retrolaminar area of, 10.42, 10.43, 10.45*f*, 10.46
sarcoidosis involving, 5.115, 5.126*f*, 5.327
in thyroid eye disease, 4.226, 5.131, 5.132*f*
topography of, 2.109, 4.241, 4.242*f*
trauma to, 5.139*f*, 5.139–140
tumors of, 4.248–250, 250*f*. *See also specific type*
meningioma, 5.127–129, 5.128*f*
metastatic, 4.303, 4.307–308
vascular supply of, 2.121*f*
Optic nerve drusen, 2.473*t*
Optic nerve glioblastomas (malignant optic gliomas of adulthood/MOGAs), 4.249, 5.130–131
Optic nerve glioma
chemotherapy for, 7.82–83
clinical features of, 7.80
diagnosis of, 7.80–82
malignant, 7.82
management of, 7.82–83
surgical excision of, 7.82
Optic nerve head (ONH/optic disc), 2.94, 5.17*f*, 5.24–25, 5.25*f*. *See also* Optic nerve
anatomy of, 5.17*f*, 5.24–25, 5.25*f*
angiomatous lesion of, 12.242
atrophy of. *See* Optic atrophy
avulsion of, 12.365, 12.365*f*
blood supply of, 5.17*f*
coloboma of, 4.242, 4.243*f*
congenital/developmental abnormalities of, 4.241–242, 4.243*f*, 5.143*f*, 5.143–145, 5.144*f*
transient visual loss and, 5.164
cupping of. *See* Cupping of optic nerve/nerve head/disc
description of, 2.109
drusen of (ODD), 4.247, 4.247*f*, 5.108*f*, 5.140–143, 5.141*f*, 12.260
astrocytic hamartoma differentiated from, 5.108*f*, 5.143
autofluorescence in identification of, 5.89, 5.90*f*, 5.141*f*, 5.142
papilledema/pseudopapilledema and, 4.247, 5.107, 5.108*f*, 5.141*f*, 5.142–143
transient visual loss and, 5.141, 5.161, 5.164
ultrasonography in identification of, 5.95, 5.141*f*, 5.142
dysplastic, 5.145
edema of, 5.82, 5.83*f*, 5.105–113, 5.107*t*, 5.108*f*, 5.109*f*, 5.110*f*, 5.111*t*, 12.234, 12.349. *See also* Papilledema; Pseudopapilledema
in anterior optic neuropathy, 5.104
AAION, 5.120, 5.120*t*, 5.121*f*
NAION, 5.120, 5.120*t*, 5.121*f*, 5.122, 5.123*t*
in diabetic papillopathy, 5.125, 5.125*f*
fluorescein angiography in evaluation of, 5.89
neuroimaging in evaluation of, 5.71, 5.109
in neuroretinitis, 5.118, 5.118*f*, 5.118–119
in optic atrophy, 4.245, 4.245*f*
in papillitis, 5.113
in papillophlebitis, 5.125, 5.126*f*
examination of
in glaucoma evaluation, 10.32, 10.48–59. *See also* Optic nerve head (ONH/optic disc), in glaucoma
in low vision evaluation, 5.81–82, 5.82*f*, 5.83*f*
excavation of, 5.137*f*
congenital, 5.145
in glaucoma, 5.136, 5.137*f*

in Foster-Kennedy/pseudo-Foster-Kennedy syndrome, 5.122
in glaucoma, 5.136, 5.137*f*, 10.3, 10.48
evaluation of, 10.32, 10.48–59, 10.49*t*, 10.49–51*f*, 10.55–58*f*
imaging and, 10.53–59, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
normal-tension glaucoma and, 10.86
perimetry changes correlated with, 10.74–75
recording findings and, 10.53
hemorrhage of, 10.50, 10.51*f*, 10.85*f*, 10.85–86
open-angle glaucoma and, 10.79–80
visual field changes and, 10.74–75
hemangioblastoma of, 4.284, 4.284*f*, 4.285
hyperemia of, 12.232
hypoplasia of, 5.143*f*, 5.143–144
imaging in evaluation of, 10.53–59, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
laminar area of, 2.113
in Leber hereditary optic neuropathy, 5.133, 5.134*f*
melanocytoma (magnocellular nevus) of, 4.248, 4.248*f*, 4.257*f*, 4.258, 4.268
melanoma differentiated from, 4.268
morning glory, 5.145
neovascularization of (NVD), 12.128, 12.129*f*, 12.170
in diabetic retinopathy, papillopathy and, 5.125
nerve fibers entering, 10.42–43, 10.43*f*, 10.45*f*
neuroimaging in evaluation of, 5.71
pallor of, 5.81–82, 5.82*f*. *See also* Optic atrophy
OCT in evaluation of, 5.91*f*
in pathologic myopia, 12.217–218, 12.218*f*
prelaminar area of, 2.111
retrolaminar area of, 2.113
sarcoid granuloma involving, 5.126*f*, 5.327
schematic representation of, 2.112*f*
size of, 2.110
spontaneous venous pulsation of, 2.114
subretinal hemorrhage, 12.355*f*
superficial nerve fiber layer of, 2.111, 2.113*f*
tilted, 5.144, 5.144*f*
topography of, 10.53
tumors of, 4.248*f*, 4.248–250, 4.249*f*, 4.250*f*
metastatic, 4.303, 4.307–308
Optic nerve (optic pathway/chiasm) gliomas (OPGs/pilocytic astrocytomas), 4.249, 4.249*f*, 4.295, 5.126, 5.128*t*, 5.129*f*, 5.129–131
in children (juvenile), 4.249
malignant (malignant optic glioma of adulthood/MOGA/glioblastoma), 4.249, 5.130–131
in neurofibromatosis, 5.130, 5.334*t*
Optic nerve pits. *See* Optic pits
Optic nerve sheath, 2.459*t*, 5.8*f*
fenestration of (ONSF), for idiopathic intracranial hypertension, 5.112
inflammation of, 5.119. *See also* Optic perineuritis
Optic nerve sheath meningioma (ONSM), 4.250, 4.250*f*, 5.65*f*, 5.66*f*, 5.126, 5.127*f*, 5.127–129, 5.128*t*, 7.85*f*, 7.86
Optic neuritis, 2.474*t*, 5.107*t*, 5.113–118, 5.114*f*, 5.117*t*, 5.317–318, 6.369, 6.369*f*, 9.223
CMV infection causing, 5.349, 5.349*f*
color vision affected in, 5.78, 5.114
contrast sensitivity affected by, 3.136
corticosteroids for, 5.116
cryptococcal, 5.356
hallucinations and, 5.176
herpes infection and, 5.350
illusions and, 5.175
isolated, 5.113–115, 5.114*f*
in multiple sclerosis, 5.107*t*, 5.114, 5.114*f*, 5.115, 5.116, 5.317–318
NAION differentiated from, 5.123, 5.123*t*
neuroimaging in evaluation of, 5.66*f*, 5.72*t*, 5.114*f*, 5.115
in neuromyelitis optica, 5.107*t*, 5.116–118, 5.117*t*, 5.320–323
retrobulbar, 5.113, 5.114
in cryptococcosis, 5.356
tests in diagnosis of, 5.115
toxoplasmic, 5.352
treatment of, 5.116
Optic neuropathy, 2.474*t*, 5.103–146
amiodarone, 1.106, 5.137
anterior, 5.104
ischemic, 5.107*t*, 5.119–124, 5.120*t*, 5.121*f*, 5.123*t*
autosomal dominant optic atrophy and, 5.135, 5.136*f*
causes of, 5.104–146. *See also specific disorder*
cerebral aneurysms causing, 5.339
classification of, 5.104, 5.105*t*
CMV infection causing, 5.349, 5.349*f*
cocaine use as cause of, 1.199
color vision affected in, 5.78
compressive or infiltrative, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*, 5.131–133. *See also specific cause*
congenital disc and nerve anomalies and, 5.107*t*, 5.143*f*, 5.143–145, 5.144*f*
congenital tilted disc syndrome and, 5.144, 5.144*f*
diabetic papillopathy and, 5.125, 5.125*f*
drusen and, 5.107*t*, 5.108*f*, 5.140–143, 5.141*f*. *See also* Drusen
excavated optic nerve/nerve head/disc anomalies and, 5.145
in giant cell arteritis, 5.120, 5.313
in glaucoma, 5.107*t*, 5.136, 5.137*f*, 10.3, 10.46–59, 10.47*f*, 10.49*f*, 10.50*f*, 10.51*f*, 10.55–58*f*
indications for surgery and, 10.197
optic nerve evaluation and, 10.41–46, 10.43–45*f*
optic nerve/nerve head/disc evaluation/cup changes and
imaging and, 10.53–59, 10.55–58*f*
normal-tension glaucoma and, 10.86
perimetry changes correlated with, 10.74–75
recording findings and, 10.53
patterns of nerve loss and, 10.67–69, 10.68*f*, 10.69*f*, 10.70*f*
phacoantigenic glaucoma and, 10.98
hallucinations and, 5.176
hereditary, 5.107*t*, 5.133–135, 5.134*f*, 5.136*f*
autosomal dominant optic atrophy and, 5.135, 5.136*f*
Leber (LHON), 5.133–135, 5.134*f*, 6.368
description of, 2.185–186
family history of, 2.200
mitochondrial DNA mutations and, 5.133
optic neuritis and, 5.115, 5.133
herpes infection and, 5.350
hypertensive, 12.123, 12.125

idiopathic intracranial hypertension and, 5.110–113, 5.111*t*
of increased intracranial pressure, 5.105–113, 5.107*t*, 5.108*f*, 5.109*f*, 5.110*f*, 5.111*t*. *See also* Papilledema
infiltrative, 5.107*t*, 5.126*f*, 5.126–127, 5.131–133
inflammatory, 5.113–118, 5.114*f*, 5.117*t*. *See also* Optic neuritis
chronic relapsing inflammatory, 5.116
pain in, 5.295–296
intraorbital/intracanalicular lesions and, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*
ischemic, 5.107*t*, 5.119–125, 5.120*t*, 5.121*f*, 5.123*t*
anterior (AION), 5.107*t*, 5.119–124, 5.120*t*, 5.121*f*, 5.123*t*
arteritic (AAION), 5.107*t*, 5.120, 5.120*t*, 5.120–122, 5.121*f*, 5.313
nonarteritic (NAION), 5.107*t*, 5.120, 5.120*t*, 5.121*f*, 5.122–124, 5.123*t*
OCT in evaluation of, 5.91*f*
perioperative, 5.124–125
posterior (PION), 5.107*t*, 5.119, 5.124
Leber hereditary. *See* Leber hereditary optic neuropathy
light-near dissociation caused by, 5.266, 5.266*t*
maculopathy differentiated from, 5.78–79, 5.99–100, 5.100*t*
mechanisms of, 5.104, 5.107*t*
neuroimaging in evaluation of, 5.66*f*, 5.72*t*, 5.114*f*, 5.115
neuromyelitis optica/neuromyelitis optic spectrum disorder (NMO/Devic disease/NMOSD) and, 5.107*t*, 5.116–118, 5.117*t*, 5.320–323
neuroretinitis and, 5.118*f*, 5.118–119
nutritional, 5.107*t*, 5.137–139, 5.138*f*
nystagmus and
childhood/infantile nystagmus syndrome, 5.236
pendular, 5.246
OCT in evaluation of, 5.91, 5.91*f*, 5.92
optic atrophy and, 5.135, 5.136*f*, 5.145–146
optic nerve hypoplasia and, 5.143*f*, 5.143–144
optic nerve/nerve head/disc edema and, 5.104
optic nerve/pathway glioma and, 5.126, 5.128*t*, 5.129*f*, 5.129–131
optic nerve sheath meningioma and, 5.126, 5.127*f*, 5.127–129, 5.128*t*
optic neuritis and, 5.107*t*, 5.113–118, 5.114*f*, 5.117*t*
optic perineuritis and, 5.119
orbital lesions and, 5.126*f*, 5.126–131, 5.127*f*, 5.129*f*
papillitis and, 5.113
papillophlebitis and, 5.125–126, 5.126*f*
perimetric findings in, 5.86
posterior, 5.104
ischemic (PION), 5.107*t*, 5.119, 5.124
radiation (RON), 1.239, 5.358, 5.358*f*
retrobulbar optic neuritis and, 5.113, 5.114
in sarcoidosis, 5.115, 5.126*f*, 5.327
thyroid eye disease and, 5.131, 5.132*f*
toxic, 1.199, 5.107*t*, 5.137–139
traumatic, 5.107*t*, 5.139*f*, 5.139–140, 6.381
visual field patterns in
description of, 5.103, 5.104–106*f*, 5.105*t*, 5.106*f*
versus maculopathy, 5.99, 5.100, 5.100*t*
Optic (optical) axis, 11.9, 11.10*f*
Optic pathway glioma, 6.223, 6.396, 6.396*f*
Optic perineuritis, 5.119
radial (radial keratoneuritis), in *Acanthamoeba* keratitis, 4.79
in sarcoidosis, 5.327
Optic pits (optic nerve/disc pits, optic holes, optic pit maculopathy), 5.145, 6.364–365, 6.365*f*
acquired, 10.49–50
description of, 2.148, 12.328–329, 12.329*f*
Optic radiations (geniculocalcarine pathways)
description of, 2.116, 2.118*f*, 2.122*t*, 5.18*f*, 5.19, 5.24*f*, 5.29, 5.30
lesions of, 5.153, 5.155
in multiple sclerosis, 5.318
Optic stalk, 2.150*f*, 2.157, 2.165*f*
Optic strut, 5.7*f*, 5.16*f*, 5.26, 7.7*f*
Optic tract, 5.23*f*, 5.28–29, 5.55*f*
anatomy of, 2.116
blood supply of, 2.122*t*
lesions of, 5.147*f*, 5.153
in multiple sclerosis, 5.318
visual pathways in, 2.115
Optic tract syndrome, 5.18, 5.153
Optic vesicles
description of, 2.148, 2.165*f*
lens development and, 11.25, 11.26*f*
Optic zone (corneal). *See* Optical zone, corneal
Optical aberrations. *See* Aberrations
Optical axis, 3.51, 3.124, 3.129, 3.129*f*
Optical biometer, for axial length measurement, 3.247, 3.247*f*
Optical clarity, of ophthalmic viscosurgical device, 11.97
Optical coherence tomographic angiography (OCTA)
artifacts in, 12.29, 12.30*f*
choroidal circulation abnormalities, 12.198
choroidal neovascularization on, 12.75–76, 12.76–12.78*f*, 12.192
depth resolution using, 12.29
diabetic retinopathy on, 12.93, 12.94*f*
fluorescein angiography *versus*, 12.29
macular telangiectasia type 2 on, 12.163, 12.164*f*
motion artifacts in, 12.29
projection artifacts in, 12.29, 12.30*f*
pseudoxanthoma elasticum on, 12.199*f*
retinal capillary layers on, 12.16
retinal disease evaluations using, 12.28–29
retinal vasculature on, 12.29, 12.30*f*
severity of, 12.93, 12.94*f*
in uveitis, 9.87
Optical coherence tomography (OCT), 5.90–94, 5.91–94*f*, 8.21–22, 8.22*f*, 8.35*t*, 13.20*f*
in acute idiopathic blind-spot enlargement and multiple evanescent white dot syndrome, 5.92, 5.101
acute idiopathic maculopathy on, 12.228
acute macular neuroretinopathy on, 12.228
in acute posterior multifocal placoid pigment epitheliopathy, 9.164*t*, 9.171, 9.172*f*, 12.221*f*, 12.222
in acute retinal pigment epitheliitis, 9.189
in acute zonal occult outer retinopathy, 5.92, 9.164*t*, 9.191, 9.191*f*, 12.227, 12.227*f*

anterior segment, 8.21–22, 8.22*f*
in glaucoma, 10.77
indications for, 9.85
in keratoconus, 8.165–166
in uveitis evaluations, 9.85
in Behçet disease, 9.216, 9.217*f*
in birdshot chorioretinopathy, 9.164*t*, 9.168, 9.168*f*
cancer-associated retinopathy on, 12.287*f*
before cataract surgery, 11.82
central serous chorioretinopathy evaluations, 12.32
in choroidal hemangioma, 4.281, 4.282*f*
in choroidal melanoma/ciliary body melanoma, 4.265, 4.268
choroidal neovascularization on, 12.192, 12.194
in choroidal nevus, 4.258
coherence length and, 3.101–102
coherence time and, 3.101–102
in corneal biomechanics evaluation, 8.43
before corneal transplantation, 8.418
cystoid macular edema on, 12.132*f*, 12.157, 12.158*f*
definition of, 3.282, 3.303, 12.25
in Dengue fever, 9.267, 9.267*f*
diabetic macular edema on, 12.111*f*
drusen on, 12.65–66
enhanced depth imaging, 12.25
in posterior scleritis, 9.124
in uveitis, 9.85, 9.88*f*
epiretinal membranes on, 12.335, 12.383*f*
eye movement tracking with, 12.27
Fourier-domain, 3.304–305
frequency-domain, 3.304
in glaucoma, 10.77
in idiopathic intracranial hypertension, 5.111–112
in idiopathic macular hole, 4.131–132, 4.132*f*
intraoperative, 8.22
in IOL power determination, 8.22, 11.82, 11.84–85, 11.87
in iris melanoma, 4.260, 4.261*f*
in keratoconus, 8.165–166
low-coherence light in, 12.25
in low vision assessment, 5.90–94, 5.91*f*, 5.92*f*, 5.93*f*, 5.93–94*f*
in macular edema, uveitic, 9.85, 9.88*f*, 9.321
macular hole on, 12.27*f*
in metastatic eye disease, 4.307
in multifocal choroiditis and panuveitis syndrome, 9.164*t*, 9.179, 9.180*f*
in multiple evanescent white dot syndrome, 9.164*t*
myopic macular schisis on, 12.210*f*
nerve fiber layer measurement using, 12.218
nomenclature terminology for, 12.26–27
in optic nerve/nerve head/disc drusen, 5.142, 6.373*f*
in optic nerve/nerve head/disc/retinal nerve fiber layer evaluation, 10.53–56, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
peripapillary intrachoroidal cavitations on, 12.215, 12.215*f*
pigment epithelial detachment on, 12.74*f*
in posterior scleritis, 9.123*f*
posterior vitreous detachment on, 12.309, 12.332
in primary congenital glaucoma evaluations, 6.283
in punctate inner choroiditis, 9.164*t*, 9.182, 9.183*f*
before refractive lens exchange, 13.149–150
retinal disease evaluations using, 12.25–27, 12.27*f*
in serpiginous choroiditis, 9.164*t*, 9.175, 9.176*f*
solar retinopathy on, 12.368*f*
spectral-domain, 3.304
adult-onset vitelliform maculopathy on, 12.67–68, 12.68*f*
alkyl nitrite findings, 12.300, 12.300*f*
chloroquine toxicity monitoring uses of, 12.297
choroidal neovascularization on, 12.73–75, 12.75*f*
diabetic macular edema on, 12.109*f*, 12.125
drusen on, 12.64*f*, 12.65
epiretinal membranes on, 12.335*f*
Gaucher disease on, 12.291
pathologic myopia on, 12.90*f*
for posterior scleritis, 9.124–125
reticular pseudodrusen on, 12.65*f*
retinal layers on, 12.10–11, 12.11, 12.12*f*
retinitis pigmentosa findings, 12.263*f*
sensitivity of, 12.26
swept-source optical coherence tomography *versus*, 12.25–26
in subretinal fibrosis and uveitis syndrome, 9.164*t*, 9.184
swept-source
pathologic myopia findings, 12.209*f*
sensitivity of, 12.26
spectral-domain optical coherence tomography *versus*, 12.25–26
sympathetic ophthalmia findings in, 9.201–202, 9.202*f*
time-domain, 3.303–304, 12.25
uveitis evaluations, 9.85, 9.88*f*
vitreoretinal traction syndrome on, 12.337, 12.337*f*
in Vogt-Koyanagi-Harada syndrome, 9.209, 9.210*f*
volume rendering, 12.27, 12.28*f*
X-linked retinoschisis on, 12.278, 12.278*f*
Optical conjugacy. *See* Conjugacy
Optical infinity, 3.3
Optical instruments. *See specific instrument*
Optical (ocular) medium/media
abnormalities of, 5.99
diplopia and, 5.185
fundus examination in evaluation of, 5.81
perimetry affected by, 5.86
transient visual loss and, 5.164
boundaries between. *See* Optical interfaces
opaque. *See* Cataract; Opacities
refractive index of. *See* Refractive index
Optical (optic) axis, 11.9, 11.10*f*
Optical pachymetry/pachymeter, 8.41. *See also* Pachymetry/pachymeter
Optical pumping, 3.111
Optical systems
aberrations of. *See* Aberrations
afocal. *See* Optics, of human eye
reduced, 3.67–68, 3.68–3.69*f*
Optical zone, corneal, 8.25
arcuate keratotomy and, 13.54–55, 13.56
in photoablation, 13.74*f*
preoperative laser programming and, 13.81
pupil size and, 13.40
radial keratotomy and, 13.50, 13.50*f*, 13.51
IOL power calculations affected by, 13.193

Optically empty vitreous, hereditary hyaloideoretinopathies with, 12.342–343, 12.343*f*
Opticin, 2.298
Opticrom. *See* Cromolyn
Optics
adaptive, 3.281, 3.305–306, 3.306*f*
challenges for, 3.7
definition of, 3.4
Gaussian, 3.40, 3.60
geometric. *See* Geometric optics
of human eye
accommodation, 3.140–141
axes, 3.128–129, 3.129*f*
binocular states, 3.139–140
contrast sensitivity, 3.134–136, 3.135–136*f*
contrast sensitivity function, 3.134–136
developmental hyperopia, 3.143
developmental myopia, 3.142–143
illusions and, 5.174
mathematical models of, 3.125, 3.126*f*
pupil size effects on visual resolution, 3.129–131
refractive errors, 3.141*f*, 3.141–142
refractive states and, 3.136–139, 3.137–3.138*f*, 13.7–9. *See also under Refractive*
schematic eye and, 3.125–128, 3.126*f*, 3.127*t*, 3.128*f*. *See also* Schematic eye
visual acuity, 3.131–134, 3.132–3.133*f*
wavefront analysis and, 13.9–13, 13.10–13*f*
lenticular, 3.8*f*
nonspherical, 3.257
physical. *See* Physical optics
OptiPranolol. *See* Metipranolol
Optisol GS, for donor cornea preservation, 8.414, 8.416*f*
Optivar. *See* Azelastine
OPTN gene, 10.11*t*
Optociliary shunt vessels (retinochoroidal/retinociliary venous collaterals), 5.22
in optic nerve sheath meningioma, 5.127*f*, 5.128
in papilledema, 5.109
Optokinetic nystagmus (OKN) drum, 5.218–219
congenital motor nystagmus and, 6.148–149
convergence-retraction nystagmus and, 5.250
reflexive saccades and, 5.221
smooth-pursuit system and, 5.224–225, 5.225
Optokinetic system/nystagmus (OKN), 5.212, 5.212*t*, 5.218–219
description of, 6.40
dysfunction of, 5.218–219
in congenital nystagmus, 5.235
parietal lobe lesions and, 5.156, 5.219
nonorganic disorders and, 5.301–302
Optotypes, 3.23, 3.124, 3.133*f*
age-appropriate, 6.8
contour interaction bars around, 6.7*f*, 6.8, 6.54
crowding phenomenon for, 6.54
LEA symbols, 6.6, 6.7*f*
in nonorganic disorder evaluation, 5.306
for potential acuity meter testing, 5.88–89
for visual acuity assessment in children, 6.6*t*, 6.6–8, 6.7*f*
OR. *See* Odds ratio
ORA. *See* Ocular Response Analyzer
Ora bays
definition of, 12.10
illustration of, 12.11*f*
retinal tears near, 12.312
Ora serrata
anatomy of, 2.48*f*, 2.99, 2.100*f*, 12.7, 12.11*f*
binocular indirect ophthalmoscopy of, 12.22
definition of, 12.10
description of, 2.83
Oral contraceptives
central retinal vein occlusion risks, 12.134
disseminated intravascular coagulation and, 1.148
hypertension and, 1.67
ocular adverse effects of, 1.309*t*
Oral facial dyskinesias, 5.285
Oral glucose tolerance test (OGTT), diabetes mellitus diagnosis using, 1.34
Oral hypoglycemic agents. *See specific agent*
Orbicularis oculi muscle, 4.201, 4.201*f*, 4.202, 5.52, 8.3, 8.4*f*
anatomy of, 2.28*f*, 2.29, 2.31*f*, 7.153, 7.154*f*, 7.157*f*
blepharospasm and, 5.281
in facial myokymia, 5.284
hemifacial spasm and, 5.283
innervation of, 2.29
orbital, 7.163
palpebral, 2.29
preseptal, 7.163
pretarsal, 2.34*f*, 7.161
segments of, 7.161–163, 7.162*f*
spastic paretic facial contracture and, 5.284
tarsal, 2.42
weakness of, in myasthenia gravis, 5.324
Orbit, 4.223–240. *See also under Orbital*
adipose tissue in, 6.25
amyloid deposits in, 4.228
anatomy of, 2.5–15, 2.6–15*f*, 4.223, 5.6–11, 5.7–8*f*, 5.9*f*, 5.10*f*
assessment of, before refractive surgery, 13.41
sensory and motor components, 5.47–52, 5.48*f*
vascular
arterial supply, 5.12–14, 5.13–14*f*
venous drainage, 5.21, 5.21*f*
arteries of, 2.23*f*, 2.25*f*
bacterial infections of, 7.43
biopsy of
fine-needle aspiration, 4.43
in lymphoproliferative lesions, 4.232
blood supply to, 7.14, 7.15–16*f*
bony/bones of, 4.223, 5.6–11, 5.7*f*, 5.9*f*
anatomy of, 2.6*f*, 2.6–7, 7.6, 7.7–8*f*, 7.130*f*
congenital clefts in, 7.38
canals in, 2.6*f*, 2.11, 5.11
cavernous hemangioma of, 4.6, 4.233, 4.234*f*
cellulitis affecting. *See* Orbital cellulitis
compressive lesions. *See* Orbital decompression
computed tomography of, 2.11*f*, 5.58, 5.58*f*, 5.60, 5.61*t*, 5.72*t*, 5.73*f*, 7.26*f*
congenital/developmental disorders of, 4.223–224, 4.224*f*
connective tissues of, 2.45*f*
cysts of, 4.223–224, 4.224*f*
dermoid, 4.223, 4.224*f*
epidermoid/simple epithelial, 4.223–224

microphthalmia with, 7.37*f*
degenerations of, 4.228
depth of, 2.5
in dermal melanocytosis, 4.64
development of, 2.164, 6.181
dimensions of, 2.5, 7.5, 7.6*t*
diplopia caused by disorders of, 5.206–209, 5.207*f*
disorders of. *See* Orbital disorders
emphysema of, 7.115
entrance to, 2.5
extranodal disease of, 7.92
extraocular muscles in, 2.20, 6.25–28, 6.26–27*f*
fascia of, 6.27
fibro-osseous dysplasia (juvenile ossifying fibroma) of, 4.239, 4.240*f*
fibrous dysplasia of, 4.239, 4.240*f*
fissures in. *See* Orbital fissures
floor of, 5.9*f*
foramina of, 2.10–11
healing/repair of, 4.17
infection/inflammation of, 4.225*f*, 4.225–228, 4.227*f*, 4.228*f*
in aspergillosis, 4.227–228, 4.228*f*
idiopathic. *See* Nonspecific orbital inflammation
imaging studies for, 2.476*t*
nonspecific. *See* Nonspecific orbital inflammation
nonsteroidal anti-inflammatory drugs for, 2.410
pain in, 5.295
lacrimal gland neoplasia and, 4.229–231, 4.230*f*, 4.231*f*
lacrimal sac neoplasia and, 4.229
leukemic infiltration of, 4.316
lymphatic system of, 7.14
lymphoproliferative lesions of, 4.231–232, 4.233*f*
margin of, 2.7*f*, 2.8
melanoma affecting, 4.194
meningioma affecting, 4.250, 5.127
transient visual loss and, 5.164
morphologic measurements of, 6.191, 6.192*f*
MRI in evaluation of, 5.58–59*f*, 5.60–67, 5.61*t*, 5.62*f*, 5.63*t*, 5.63*f*, 5.64*f*, 5.65*f*, 5.65*t*, 5.66*f*, 5.67*f*, 5.72*t*
myositis affecting, 4.224, 4.225*f*, 5.207*f*, 5.207–208
nonspecific orbital inflammation and, 4.225, 4.225*f*
neoplasms of, 2.470*f*
nerves of, 7.14, 7.17, 7.18*f*
parasympathetic, 5.52, 5.54–56, 5.55*f*
sympathetic, 5.52–54, 5.53*f*
periorbital sinuses and, 2.12–15
periorbital structures and. *See* Periorbita
radiation sensitivity of, 1.238
retinoblastoma affecting, 4.294, 4.294*f*
rim of, 2.8
roof of, 2.7*f*, 2.8, 5.9*f*
anatomy of, 7.6
fractures of, 7.112
septa of, 7.12, 7.12*f*
sinus diseases that affect, 7.101–104, 7.102–103*f*
soft tissues of, 4.223, 7.11–18
tumors arising in, 4.233
surgical spaces in, 7.123*f*, 7.123–124
teratoma of, 4.7*f*
in thyroid eye disease, 4.226
tissue expanders in, 7.36
topography of, 4.223, 7.6–8, 7.7–8*f*
trauma of, 2.476*t*
ultrasonography of, 5.70–71, 5.72*t*
vascular system of, 2.22–26, 2.23–26*f*, 5.12–14, 5.13–14*f*, 5.21, 5.21*f*, 7.14, 7.15–16*f*
veins of, 2.26*f*
volume of, 5.7
vortex veins of, 2.22, 2.24*f*, 2.26
walls of
apertures of, 7.9–11, 7.10*f*
bones of, 7.6, 7.7–8*f*
lateral, 2.10, 2.10*f*, 5.9*f*, 7.6, 7.130, 7.131*f*
medial, 2.8, 2.9*f*, 5.7, 5.9*f*, 7.7–8
Orbital apex, 2.5, 2.12*f*
anatomy of, 7.9, 7.10*f*
fractures of, 7.112
Orbital apex syndrome, 5.203, 7.51
Orbital cellulitis
description of, 2.476*t*, 6.170, 6.170*f*, 6.213–215, 6.214*f*, 7.46*t*, 7.46–48, 7.47*f*, 9.158
pain associated with, 5.295
Orbital compartment syndrome (OCS), 7.118–119, 7.120*f*, 7.133
Orbital decompression
definition of, 7.130
description of, 7.61–62
of lateral wall, 7.130, 7.131*f*
orbital compartment syndrome treated with, 7.119
techniques for, 7.130–131
thyroid eye disease treated with, 7.130, 7.131*f*
Orbital diseases, 2.476*t*
Orbital disorders, 4.223–240. *See also specific type*
arteriography of, 7.32
cell-marker studies for, 7.33–34
in children
congenital/developmental anomalies, 4.223–224, 4.224*f*
neoplasms, 4.228, 4.229
compressive lesions, 5.107*t*, 5.126, 5.126*f*, 5.126–131, 5.127*f*, 5.128*t*, 5.129*f*
computed tomography angiography of, 7.32
computed tomography of, 7.26*f*, 7.26–27
congenital, 4.223–224, 4.224*f*
anophthalmia. *See* Anophthalmia/anophthalmos
craniofacial clefts, 7.38–39
microphthalmia, 7.36–38
overview of, 7.35
syndromic craniosynostosis, 7.39, 7.39*f*
tumors, 7.40–42
craniosynostosis. *See* Craniosynostosis
dermoid cysts, 6.223–224, 6.223–224*f*
ectopic lacrimal gland, 6.226
ectopic tissue masses, 6.223–225*f*, 6.223–226
encephalocele, 6.225
evaluation of
biopsy in. *See* Orbit, biopsy of
imaging studies in, 5.71–73, 5.72*t*, 5.73*f*
CT, 5.58, 5.58*f*, 5.60, 5.61*t*, 5.72*t*, 5.73*f*
MRI, 5.44*t*, 5.58–59*f*, 5.60–67, 5.61*t*, 5.62*f*, 5.63*t*, 5.63*f*, 5.64*f*, 5.65*f*, 5.66*f*, 5.67*f*, 5.72*t*
ultrasonography, 5.70–71, 5.72*t*
globe displacement associated with, 7.23–24
history-taking for, 7.21–22

infections, 4.226–228, 4.228*f*. *See also* Orbit, infection/inflammation of
infiltrative, 5.126*f*, 5.126–127
inflammation, 4.224–226, 4.225*f*, 4.226*f*, 6.215–216. *See also* Nonspecific orbital inflammation; Orbit, infection/inflammation of
inspection of, 7.23–25
laboratory studies for, 7.34
magnetic resonance imaging of, 7.27–31, 7.28*f*, 7.29*t*, 7.30*f*
malformations
arteriovenous, 6.222
lymphatic, 6.221–222
vascular, 6.221–222
venous, 6.222
meningocele, 6.225
metastatic tumors, 6.218
microphthalmia with cyst, 6.224, 6.225*f*
mucocele, 6.224
mucormycosis, 6.215, 6.215*f*
neoplasms, 4.228–240. *See also* Orbit, tumors of
benign, 6.219–223
in children, 4.228–229
differential diagnosis of, 6.216–217
hemangiomas, 6.219–221
hematopoietic, 6.218–219
histiocytic, 6.218–219
Langerhans cell histiocytosis, 6.218–219
leukemia, 6.218
lymphoma, 6.218
lymphoproliferative, 6.218–219
metastatic, 6.218
neuroblastoma, 6.218
primary malignant, 6.217–218
rhabdomyosarcoma, 6.217*f*, 6.217–218
sarcomas, 6.218
vascular, 6.219–221, 6.220–221*f*
orbital cellulitis, 6.213–215, 6.214*f*
pain and, 5.295–296, 7.21, 7.133. *See also* Pain
palpation of, 7.25–26
pathology of, 7.33–34
periorbital changes associated with, 7.22, 7.23*t*
physical examination of, 7.22–26
preseptal cellulitis, 6.212–214
progression of, 7.22
space-occupying lesions, 6.216
stereotactic navigation of, 7.32, 7.33*f*
teratoma, 6.225*f*, 6.225–226
tonic pupil caused by, 5.265
transient visual loss and, 5.164
ultrasonography of, 7.31
venography of, 7.32
Orbital Doppler sonography, 5.70–71
Orbital eyelid muscles, 5.52
Orbital fat, 2.28*f*, 2.32, 2.33*f*, 2.459*t*, 8.5*f*
anatomy of, 7.164, 7.164*f*, 7.214
redraping of, with lower eyelid blepharoplasty, 7.272*f*
trauma to, 7.214, 7.214*f*
Orbital fibroblasts, in thyroid eye disease, 4.226
Orbital fissures, 2.11–12, 12*f*, 5.6*f*, 5.7*f*, 5.11
inferior, 5.7*f*, 5.9*f*, 5.11
superior, 5.5, 5.6*f*, 5.7*f*, 5.9*f*, 5.11
ophthalmoplegia caused by lesions of, 5.203
Orbital fistulas, 7.78–79*f*, 7.78–80
Orbital floor
anatomy of, 2.8–9, 2.9*f*, 7.8, 7.9*f*
fractures of, 2.9, 6.127–128, 6.128*f*, 6.379–380, 6.380*f*
in children, 7.115, 7.116*f*
diagnosis of, 7.114–115
hydraulic mechanism theory of, 7.114
management of, 7.115–117
physical examination findings, 7.114–115
surgical management of, 7.115–117
right, 2.9–10*f*
Orbital foramen, 7.130*f*
Orbital fractures
apex, 7.112
blowout. *See* Blowout (indirect) fractures, orbital
diplopia after, 5.206
floor. *See* Orbital floor, fractures
Le Fort, 7.109, 7.110*f*
medial, 7.112–114
midfacial, 7.109, 7.110*f*
naso-orbito-ethmoidal fractures, 7.112, 7.113*f*
roof, 7.112
surgical management of, 7.117
zygomatic, 7.109, 7.111, 7.111*f*
Orbital groove, inferior, 5.9*f*
Orbital hemorrhage, 7.80, 7.80*f*, 7.262
Orbital implants
description of, 7.117, 7.139*f*, 7.139–141
exposure and extrusion of, 7.142*f*, 7.142–143
osseointegrated magnetic, 7.147*f*
Orbital inflammation, 4.224–226, 4.225*f*, 4.225–228, 4.227–228*f*, 6.215–216. *See also* Orbit, infection/inflammation of; *specific type or cause*
differential diagnosis of, 7.44*t*
imaging studies for, 2.476*t*
infectious causes of
aspergillosis, 7.52
cellulitis. *See* Cellulitis
mycobacterial infection, 7.50, 7.50*f*
necrotizing fasciitis, 7.48–50, 7.49*f*
zygomycosis, 7.51–52
noninfectious causes of
giant cell arteritis, 7.62–63
granulomatosis with polyangiitis, 7.63–64, 7.64*f*
immunoglobulin G4–related disease, 7.66*f*, 7.66–67
polyarteritis nodosa, 7.65
sarcoidosis, 7.65*f*, 7.65–66
thyroid eye disease. *See* Thyroid eye disease
vasculitis, 7.62–66, 7.64–65*f*
nonspecific. *See* Nonspecific orbital inflammation
nonsteroidal anti-inflammatory drugs for, 2.410
pain in, 5.295
parasitic causes of, 7.53
Orbital inflammatory syndrome (OIS). *See* Nonspecific orbital inflammation
Orbital layer, of extraocular muscles, 6.24
Orbital lesions, 7.26, 7.26*f*
Orbital malformations
arteriovenous malformations, 7.77*f*, 7.77–78
cavernous venous malformations, 7.75–77, 7.76*f*
distensible venous malformations, 7.74–75, 7.75*f*
lymphatic malformation, 7.73*f*, 7.73–74
Orbital mass, 7.25

Orbital melanocytosis, dermal, 4.64. *See also* Dermal/dermal orbital/oculodermal (nevus of Ota) melanocytosis
Orbital metastases
in adults, 7.105–107
from breast carcinoma, 7.106, 7.106*f*
from bronchogenic carcinoma, 7.106
in children, 7.104–105
description of, 4.228, 4.240
leukemia, 7.104
management of, 7.107
neuroblastoma, in children, 7.22*f*, 7.104, 7.105*f*
Orbital myositis, 6.216. *See also* Orbit, myositis affecting
Orbital pseudotumor, 2.470*f*, 9.158. *See also* Nonspecific orbital inflammation
Orbital rim, 5.7–8
Orbital roof fractures, 6.380, 6.380*f*
Orbital septum, 2.28*f*, 2.29, 2.31
Orbital surgery. *See also* Surgery; specific procedure
complications of, 7.133
decompression. *See* Orbital decompression
entry sites for, 7.124*f*
fine-needle aspiration biopsy, 7.132, 7.132*f*
orbitotomy. *See* Orbitotomy
postoperative care for, 7.131
spaces of, 7.123*f*, 7.123–124
special techniques in orbit, 7.132*f*, 7.132–133
Orbital trauma
battlefield-related, 7.122
cerebrospinal fluid leakage after, 7.184
foreign bodies, 7.117–118, 7.118*f*
fractures. *See* Orbital fractures
mass casualty incidents, 7.122
vision loss with clear media, 7.119, 7.121
Orbital tuberculosis, 7.50
Orbital tumors, 2.476*t*, 4.228–240. *See also specific type*
adipose, 4.238
bony, 4.239, 4.240*f*, 6.222
in children, 4.228, 4.229
choristomas, 7.40
congenital, 7.40–42, 7.42*f*
connective tissue origin, 6.222
dermoid cyst, 7.40–41
dermolipoma, 7.41, 7.42*f*
diplopia and, 5.208
with fibrous differentiation, 4.235*f*, 4.235–236
hamartomas, 7.40
infantile (capillary) hemangioma, 7.71*f*, 7.71–73
lacrimal sac/gland involvement and, 4.229–231, 4.230*f*, 4.231*f*
lymphoproliferative, 4.231–232, 4.233*f*
mesenchymal. *See* Mesenchymal tumors
metastases. *See* Orbital metastases
MRI of, 5.64*f*, 5.65*f*
with muscle differentiation, 4.236–237, 4.237*f*
nerve sheath, 4.237–238, 4.238*f*, 4.239*f*
neural origin, 6.223
pain caused by, 5.296
secondary, 4.228, 4.240, 7.101–104
soft tissue, 4.233
teratoma, 7.42
vascular (vascular malformations/fistulas), 4.233, 4.234*f*
Orbital varices, 7.74
glaucoma associated with, 10.30
Orbital veins, 6.23
Orbititis, sclerosing. *See* Nonspecific orbital inflammation
Orbitopathy
neuroimaging in, 5.72*t*
thyroid/thyroid-associated/Graves. *See* Thyroid eye disease
Orbitotomy
hemostasis after, 7.130
inferior approach
transconjunctival incisions for, 7.126–127, 7.127*f*
transcutaneous incisions for, 7.126, 7.126*f*
lateral approach, 7.128–130, 7.129*f*
medial approach
description of, 7.127
retrocaruncular incision for, 7.128–129*f*
transconjunctival incisions for, 7.128
transcutaneous incisions for, 7.128
superior approach
transconjunctival incisions for, 7.125
transcutaneous incisions for, 7.124–125, 7.125*f*
vertical eyelid splitting, 7.125–126
ORF. *See* Open reading frame
Organ culture storage techniques, for donor cornea, 8.416
Organ transplantation. *See* Transplantation
Organic anions, in aqueous humor, 2.274
Ornithine aminotransferase, 2.314*t*
Orthokeratology, 3.228, 13.70–71
Orthomyxoviruses, 8.240*t*
Orthophoria
abbreviation for, 6.17
definition of, 6.15
Orthoptics
convergence insufficiency treated with, 6.103
fusional vergence affected by, 6.72
for suppression, 6.50
Orthostatic hypotension, 1.67
Orthotropia
definition of, 6.15
treatment of, 6.58
OS. *See* Outer segments
OSA. *See* Obstructive sleep apnea
OSAS. *See* Obstructive sleep apnea syndrome
Oscillary potentials, 12.43*f*, 12.43–44
Oscillations. *See* Saccadic intrusions/oscillations
Oscillopsia, 5.233
in superior oblique myokymia, 5.250, 5.251
vestibular nystagmus and, 5.241, 5.243
Oseltamivir, 1.279
Osmitrol. *See* Mannitol
Osmoglyn. *See* Glycerin
Osmolarity, tear film, 8.39
Osmotic/hyperosmotic agents, 10.174*t*
Osmotic drugs, 2.397–398, 2.398*t*
Osmotic force, transendothelial, 8.9
Osseous choristoma, 4.48, 4.49*f*
Ossifying fibroma, juvenile, of orbit, 4.239, 4.240*f*
OSSN. *See* Ocular surface squamous neoplasia
Osteo-odonto-keratoprosthesis, 8.452
Osteodystrophy, Albright hereditary, 8.191*t*

Osteogenesis imperfecta, 1.140, 8.192*t*, 8.194
blue sclera in, 8.194, 8.194*f*
Osteogenic sarcoma (osteosarcoma), retinoblastoma associated with, 4.302, 4.302*t*
Osteoma
choroidal, 4.198–199, 4.270*f*, 4.271
melanoma differentiated from, 4.270*f*, 4.271
description of, 7.89, 7.91, 7.91*f*
orbital, 4.239
Osteoporosis
bisphosphonates for, 1.190
corticosteroid-induced, 1.175, 9.103
in Cushing syndrome, 1.48
definition of, 1.190
fractures secondary to, 1.190
incidence of, 1.190
Osteosarcoma (osteogenic sarcoma)
description of, 7.91
retinoblastoma associated with, 4.302, 4.302*t*
OT (ocular toxocariasis). *See Toxocara* (toxocariasis)
Ota, nevus of. *See* Nevi/nevus, of Ota
Otoconia, in benign paroxysmal positional vertigo, 5.242–243
Otoliths/otolithic organs, 5.38, 6.40
vestibular-ocular reflex and, 5.214, 5.215
peripheral vestibular nystagmus and, 5.215, 5.216, 5.241, 5.242
skew deviation and, 5.216–217
Otosclerosis, 1.140
Ototoxicity
of aminoglycosides, 5.243
peripheral vestibular dysfunction and, 5.243
Ouabain, 2.287, 2.330
Outer eye. *See* External (outer) eye
Outer ischemic retinal atrophy, 4.151, 4.151*f*
Outer neuroblastic layer, 2.155*f*
Outer nuclear layer (ONL), 2.91–92, 4.140*f*, 4.141*f*, 12.11, 12.12*f*
Outer plexiform layer (OPL), 2.91–92, 4.140*f*, 4.141*f*
histology of, 12.11, 12.12*f*
oxygen supply to, 12.16
paracentral acute middle maculopathy of, 12.143
typical degenerative retinoschisis findings, 12.326
Outer-schisis-layer holes, 12.327, 12.327*f*
Outer segments (OS). *See also* Cone outer segments; Rod(s), outer segments
of cones, 12.11, 12.12*f*
description of, 4.140*f*, 4.141*f*
phagocytosis of, 12.17
of rods, 12.11, 12.12*f*
Outflow facility, 10.19
classification of glaucomas and, 10.3–5, 10.4*t*, 10.6*t*
intraocular pressure and, 10.5, 10.5*f*, 10.13, 10.14*f*, 10.19
laser trabeculoplasty affecting, 10.188
tonography in measurement of, 10.19
Ovarian cancer, paraneoplastic-induced saccadic intrusions and, 5.249
OVDs. *See* Ophthalmic viscosurgical devices
Over-the-counter contact lenses, 3.235
Overcorrection, with photoablation, 13.101–102, 13.108–109
Overdepression in adduction (ODAd)
causes of, 6.17, 6.116*t*, 6.116–118
description of, 6.17
pattern strabismus and, 6.107, 6.108*f*, 6.109
superior oblique muscle overaction as cause of, 6.118, 6.118*f*, 6.137
Overelevation in adduction (OEAd)
causes of, 6.17, 6.116*t*, 6.116–118
description of, 6.17
inferior oblique muscle overaction as cause of, 6.117*f*, 6.117–118
pattern strabismus and, 6.107, 6.108*f*, 6.109
Overrefraction
cataract surgery evaluation and, 11.76
in children, 3.169
contact lenses, 3.217, 3.227
Ox eye (buphthalmos)
in megalocornea, 8.99, 8.100
in primary congenital glaucoma, 8.100, 8.108, 10.151, 10.152*f*, 10.158, 10.166
Oxalate, 12.303
Oxaprozin, 2.409*t*
Oxcarbazepine, 1.207
Oxidative lens damage, 11.19–20
Oxidative stress
in age-related macular degeneration, 2.345
causes of, 2.335
ciliary body and, 2.269
in diabetic retinopathy, 2.345
in glaucoma, 2.345
in vision-threatening ophthalmic diseases, 2.343–346
after vitrectomy, 2.302
Oxitropium bromide, 1.128
Oxy radicals. *See* Free radicals
Oxybuprocaine. *See* Benoxinate
Oxygen
in aqueous humor, 2.278
hyalocyte consumption of, 12.7
leukocyte metabolism of, 9.16
retinal supply of, 12.16*f*, 12.16–17
supplementation of, retinopathy of prematurity and, 12.184
in vitreous, 2.302, 2.303*f*
Oxygen radicals. *See* Free radicals
Oxygen therapy, hyperbaric, oxidative lens damage and, 11.20, 11.65
Oxytocin, 1.47

P

P50, 12.45, 12.47*f*
p53, 1.242, 2.181
p53 gene
in adenoid cystic carcinoma, 4.231
mutations of, 7.209
in ocular surface squamous neoplasia, 4.60
in orbital solitary fibrous tumors, 4.236
in pingueculae/pterygia, 4.57
p63 gene, in pingueculae/pterygia, 4.57
P cells (parvocellular neurons/system), 5.28, 5.32, 10.42
P-Selectin, 9.11–12
P value, 1.7

PABPN1 gene mutation, in oculopharyngeal dystrophy, 5.329
PAC. *See* Primary angle closure
Pacchionian granulations, 5.22
PACD. *See* Posterior amorphous corneal dystrophy
Pacemakers, laser surgery in patient with, 13.37
PACG. *See* Primary angle-closure glaucoma
Pachychoroid, 12.19, 12.76
Pachymetry/pachymeter, 8.41–42, 10.159, 13.21*f*, 13.45–46
  before cataract surgery, 11.84
  in children, 10.159
  forme fruste keratoconus and, 13.176, 13.177*f*
  in Fuchs endothelial dystrophy, 8.158
  intraoperative, 13.79
  for intrastromal corneal ring segment placement, 13.64
  before LASIK, 13.79, 13.125, 13.176, 13.177*f*
    corneal perforation and, 13.111
  before refractive surgery, 13.45–46, 13.78, 13.79, 13.125, 13.176, 13.177*f*
Paclitaxel, 12.301
PACS. *See* Primary angle-closure suspect
PACs. *See* Premature complexes/contractions, atrial
PACT. *See* Prism alternate cover test
Paecilomyces, 8.251
PAFs. *See* Platelet-activating factors
Pagetoid spread
  of melanoma, 4.220
  in primary acquired melanosis, 4.66–68
  of sebaceous carcinoma, 4.216, 4.217*f*
Pain. *See also specific type*
  angina pectoris–related, 1.82–83
  arterial dissection and, 5.342
  cerebral aneurysms causing, 5.339, 5.340
  congenital insensitivity to, with anhidrosis (CIPA), congenital corneal anesthesia and, 8.108
  corneal abrasion causing, 8.398
  cranial nerve palsies and, 5.192
    third nerve (oculomotor) palsy, 5.196, 5.197
  facial, 5.289*t*, 5.296–298
  head, 5.287–295, 5.288*t*. *See also* Headache
  headache causing. *See* Headache
  in Horner syndrome, 5.261, 5.262*f*
  in NAION, 5.123*t*
  neuropathic, 1.40
  ocular, 5.295–296
  in ocular ischemic syndrome, 5.170
  in optic neuropathy
    infiltrative, 5.131
    inflammatory, 5.295–296
    versus maculopathy, 5.100*t*
  orbital, 5.295–296, 7.21, 7.133
    in cellulitis, 5.295
    in myositis, 5.207
    in nonspecific orbital inflammation, 4.224, 5.295
  periorbital, 5.295
    in optic neuritis, 5.78, 5.113–114, 5.123*t*
  in recurrent corneal erosion, 5.295, 8.86, 8.87
  in scleritis, 5.295, 8.319, 8.320, 8.322
  in Tolosa-Hunt syndrome, 5.203
  in trochlear headache/trochleitis, 5.296
  with vision loss, assessment and, 5.78, 5.164
Painful oculomotor neuropathy, recurrent, 5.197
"Painless" thyroiditis, 1.45
Paired-like homeodomain transcription factor 2 gene. *See PITX2* gene
Palatal myoclonus/tremor, pendular nystagmus and, 5.246–247
Palatine bone, 2.6*f*, 5.8, 5.9*f*
Palinopsia, 5.176
Palisades of Vogt, 2.261, 8.10
Palliative chemotherapy, 1.239, 1.241
Pallidotomy, for Parkinson disease, 1.205
Palpebral arteries, 5.13*f*, 5.14*f*, 5.15*f*
  superior and inferior, 5.13*f*
Palpebral conjunctiva, 2.28*f*, 2.36, 2.37*f*, 2.43, 4.47, 4.48*f*, 4.201*f*, 4.201–202, 8.6. *See also* Conjunctiva
Palpebral fissure, 2.26, 2.27*f*, 2.36*f*
  in blepharophimosis–ptosis–epicanthus inversus syndrome (BPES), 6.198
  in Brown syndrome, 6.137
  in cryptophthalmos, 6.191
  dermolipomas of, 6.257
  downward-slanting
    description of, 6.196
    pattern strabismus and, 6.107, 6.108*f*
    syndromes with, 6.196
  growth and development of, 6.181
  inferior rectus muscle alteration effect on, 6.29, 6.30*f*
  in Möbius syndrome, 6.135
  slants of, 6.196
Palpebral lacrimal gland, 2.39
Palpebral muscles, 5.52
Palpebral veins, inferior/superior, 5.21*f*
Palpebral vernal keratoconjunctivitis, 6.248, 6.248*f*, 8.289, 8.290*f*
PALs. *See* Progressive addition lenses
Palsy. *See* Paralysis; *specific type or structure affected*
PAM. *See* Potential acuity estimation/potential acuity meter (PAM) testing; Primary acquired melanosis
2-PAM. *See* Pralidoxime
PAMM. *See* Paracentral acute middle maculopathy
PAMPs. *See* Pathogen-associated molecular patterns
PAN. *See* Periodic alternating nystagmus; Polyarteritis nodosa
Pancoast syndrome/tumor, Horner syndrome and, 5.260, 5.260*t*, 5.261*f*
Pancreas
  β cells of, 1.33
  transplantation of, 1.37–38
Pancuronium, 2.382
Panel D-15 (Farnsworth) test, 12.55*f*, 12.55–56
  in low vision evaluation, 5.79
Panencephalitis, subacute sclerosing (SSPE), 8.239
Panic disorder, 1.198
Panipenem, 1.273
Pannus/micropannus, 4.83, 4.84*f*, 8.52, 8.52*f*
  in band keratopathy, 8.119
  cataract surgery in patient with, 11.79
  in Terrien marginal degeneration, 8.123, 8.123*f*
  in trachoma/chlamydial conjunctivitis, 8.262, 8.262*f*
  in vernal keratoconjunctivitis, 8.290

Panretinal dystrophies
clinical findings of, 12.261, 12.263*f*
Coats reaction associated with, 12.260
nonsyndromic, 12.258–259
syndromic, 12.259
Panretinal photocoagulation (PRP), 3.115. *See also* Photocoagulation; Scatter laser treatment/photocoagulation
adverse effects of, 12.106
angle-closure glaucoma after, 10.143
applications of, 12.376–377, 12.377*f*
central retinal vein occlusion treated with, 12.135
idiopathic retinal vasculitis, aneurysms, and neuroretinitis treated with, 12.156
iris neovascularization and, 12.135
macular edema exacerbation by, 12.379
for neovascular glaucoma, 10.135
nonproliferative diabetic retinopathy treated with, 12.101
oxygen tension affected by, 12.104
proliferative diabetic retinopathy treated with, 12.104, 12.106, 12.106*f*
for radiation retinopathy, 1.239
retinal vein occlusion treated with, 12.126
for retinopathy of prematurity, 6.332, 6.333*f*
Pantoscopic tilt, 3.192, 3.199
Panum's area of single binocular vision, 6.42, 6.42*f*, 6.48
Panuveitis, 6.318*f*, 6.318–319. *See also* Uveitis; *specific cause*
characteristics of, 9.75
definition of, 9.194
Ebola virus, 9.271*f*, 12.247
evaluation of, 9.71*t*
multifocal choroiditis with, 12.226*f*. *See also* Multifocal choroiditis
rhegmatogenous retinal detachment associated with, 9.324
in sarcoidosis, 9.194–199
in sympathetic ophthalmia, 9.199–203
sympathetic ophthalmia and, 4.185
in syphilitic uveitis, 12.241
in toxocariasis, 12.245
in Vogt-Koyanagi-Harada disease/syndrome, 12.233. *See also* Vogt-Koyanagi-Harada (VKH) disease/syndrome
Papanicolaou test ("Pap smear"), cervical cancer screening using, 1.218
Papillae
Bergmeister, 4.126, 4.127*f*
conjunctival, 8.46*t*, 8.47*f*, 8.47*t*, 8.47–48, 8.48*f*
in atopic keratoconjunctivitis, 8.292, 8.293*f*
in floppy eyelid syndrome, 8.82, 8.83*f*
in palpebral vernal keratoconjunctivitis, 8.289, 8.290*f*
Papillary cancer, 1.46
Papillary conjunctivitis
description of, 4.50–51*f*, 8.47*t*, 8.48*f*
giant (GPC), after penetrating keratoplasty, 8.426
in reactive arthritis/Reiter syndrome, 8.305–306
Papillary endothelial hyperplasia, intravascular, 8.345*t*
Papilledema, 2.473*t*, 5.82, 5.83*f*, 5.105–113, 5.107*t*, 5.108*f*, 5.109*f*, 5.110*f*, 5.111*t*. *See also* Optic nerve head (ONH/optic disc), edema of
acute, 5.105–107
chronic, 5.109*f*, 5.109–110, 5.110*f*
in cryptococcal meningitis, 5.356
definition of, 6.370
drusen differentiated from, 5.107, 5.108*f*, 5.141*f*, 5.142–143
idiopathic intracranial hypertension and, 5.110–113, 5.111*t*, 6.370*f*, 6.370–371
pseudopapilledema and, 5.107–109, 5.108*f*
in sarcoidosis, 5.327
transient visual loss and, 5.161, 5.164
ultrasonography in identification of, 5.95
Papillitis, 5.113
Papillomacular bundle/fibers, 2.87, 5.25, 5.103, 5.104*f*
visual field defects and, 5.103, 5.106*f*
Papillomas, 6.250, 7.187, 8.238–239, 8.239*f*
conjunctival, 4.59–60, 4.60*f*, 8.238–239, 8.239*f*, 8.332*t*, 8.332–334, 8.333*f*
eyelid, 4.204, 4.205*f*
Papillomatosis, 4.202
Papillomavirus. *See* Human papillomavirus
Papillopathy, diabetic, 5.125, 5.125*f*
Papillophlebitis, 5.125–126, 5.126*f*
Papillorenal syndrome, dysplastic optic nerve and, 5.145
Papovaviruses/papovavirus infection, 8.238–239, 8.239*f*
Papule
of eyelid, 8.45*t*
in rosacea, 8.71, 8.71*f*
para-Aminobenzenesulfonamide, 2.423
para-Aminoclonidine. *See* Apraclonidine
Paracentesis
anterior chamber/aqueous
in bacterial endogenous endophthalmitis, 9.295
for hyphema, 8.395
technique for, 9.92
in uveitis, 9.90–92
in phacoemulsification, 11.105
in trabeculectomy, 10.201, 10.203*f*
Paracentral acute middle maculopathy (PAMM), 12.143
Paracentral scotoma, 3.315*f*
description of, 12.228, 12.367
in glaucoma, 10.68, 10.70*f*, 10.86
Paracentral stromal inflammation, 8.52
Paracentral zone, of cornea, 8.25, 8.25*f*
Paracrine signaling, of cytokines, 9.21
Paradoxical diplopia, 6.50, 6.50*f*
Paradoxical pupils, 6.335, 6.336*t*
Paraflocculus, 5.33, 5.40
Parafollicular cells, 1.41
Parafovea/parafoveal zone, 2.85, 4.140
characteristics of, 12.10*t*
definition of, 12.9
Parafoveal macula, 12.9*f*
Parakeratosis
in actinic keratosis, 4.211, 4.211*f*
definition of, 4.202
Parallelepiped (corneal light wedge) technique, in gonioscopy, 10.36
Paralysis agitans. *See* Parkinson disease/parkinsonism
Paralysis of accommodation, 3.174
Paralysis (paresis/paretic syndromes). *See also specific type or structure affected*
convergence, 6.105–106

diplopia caused by, 5.186
multiple cranial nerve involvement and, 5.202
restrictive syndromes differentiated from, 5.186, 5.186*f*
in multiple sclerosis, 5.317
Paralytic ectropion, 7.230*f*, 7.254–255
Paralytic strabismus
extraocular muscle surgery for, 6.161
Hering's law of motor correspondence and, 6.38
Paramedian pontine reticular formation (PPRF), 5.33, 5.35, 5.35*f*, 5.219
horizontal gaze and, 5.36–37, 5.37*f*
in one-and-a-half syndrome, 5.191
saccades generated by, 5.219–221
Paramyxoviruses (Paramyxoviridae), 8.239–240, 8.240*t*
Paranasal sinuses, 5.8, 5.10*f*. *See also specific sinus*
adenocarcinoma of, 7.102, 7.103*f*
anatomy of, 7.6, 7.19*f*, 7.19–20
Aspergillus causing infection of, 5.353
development of, 7.19–20
neuroimaging in evaluation of disorders of, 5.72*t*
squamous cell carcinoma of, 7.102, 7.103*f*
tumors from, 7.101–104, 7.102–103*f*
Paranasal sinusitis, 6.213, 6.214*f*
Paraneoplastic disorders
retinopathies, 5.102–103
saccadic intrusions caused by, 5.249
Paraneoplastic retinopathies, 12.286–287
Paraprotein, corneal deposition of, 8.198
Parasellar region
description of, 5.5, 5.6*f*
lesions of
chiasm affected by, 5.146, 5.150
meningiomas, 5.147, 5.150
neuroimaging in evaluation of, 5.72*t*, 5.150–151
nystagmus caused by, 5.247
Parasellar (sphenocavernous) syndrome, 5.202
Parasites, 8.208*t*, 8.252–253
ocular infection caused by, 8.208*t*, 8.252–253. *See also specific organism or type of infection*
cornea and scleral involvement and, 8.208*t*, 8.266–283
eyelid margin involvement and, 8.254–255, 8.255*f*
Mooren ulcer and, 8.314, 8.315
orbital involvement and, 4.228
Parasitic diseases, 7.53
Parasitic infections, 12.244
Parasitology, 8.208*t*, 8.252–253. *See also* Parasites
Parasol plugs, for dry eye, 8.64–65
Parastriate cortex (Brodmann area 18), 5.20*f*, 5.30*f*, 5.30–31. *See also* Visual (calcarine/occipital/striate) cortex
Parasympathetic fibers, lacrimal functional unit innervated by, 8.5*f*
Parasympathetic ganglia/nerves/pathway, 5.52, 5.54–56, 5.55*f*
Parasympatholytic agents, accommodation affected by, 11.23
Parasympathomimetic agents
accommodation affected by, 11.23
description of, 6.289*t*
for glaucoma, 10.173*t*, 10.181–182
Parathyroid hormone/disease, corneal changes and, 8.200–201
Paratope, 9.35
Paratrigeminal syndrome, Raeder, 5.261
Paraxial rays, 3.41, 3.70
Parcaine. *See* Proparacaine
Parecoxib, 1.176
Paredrine. *See* Hydroxyamphetamine
Paremyd. *See* Hydroxyamphetamine hydrobromide/tropicamide
Parental diagnosis. *See* Genetic testing/counseling
Parenteral antihypertensives, 1.64
Paresis. *See* Paralysis; *specific type*
Pareto chart, 1.28, 1.30*f*
Parietal bone, 5.5
Parietal cortex, posterior (PPC), 5.30, 5.30*f*
Parietal eye field, 5.32*f*
Parietal lobe, 5.24*f*
lesions of, 5.156
illusions/hallucinations and, 5.175, 5.177
visual field defects in, 5.84, 5.156, 5.219
Parieto-occipital artery, 5.19*f*, 5.20
Parinaud (dorsal midbrain) syndrome, 5.37, 5.229, 5.230*f*, 7.253
in children, 5.231
convergence-retraction nystagmus in, 5.229, 5.250
eyelid retraction in, 5.229, 5.250, 5.274, 5.275*t*
light-near dissociation in, 5.229, 5.230*f*, 5.266*t*, 5.266–267
multiple sclerosis and, 5.319
Parinaud oculoglandular syndrome (POS), 2.38, 4.51, 6.240*f*, 6.240–241, 8.265–266, 9.241, 12.242. *See also* Cat-scratch disease
Parkinson disease (PD)/parkinsonism
convergence insufficiency associated with, 5.227, 6.103
description of, 1.204–205
exposure keratopathy and, 8.79
facial weakness/paralysis in, 5.278
medications for, tear production affected by, 8.62*t*
Parks-Bielschowsky 3-step test, 6.73, 6.120. *See also* 3-step test
in fourth nerve (trochlear) palsy, 5.198–199
Paroxysmal hemicrania, 5.289*t*, 5.294
Paroxysmal nocturnal hemoglobinuria (PNH), 1.136, 1.148
Parry-Romberg syndrome (progressive facial hemiatrophy), 8.192*t*
Pars plana, 4.115*f*, 4.182, 4.183*f*, 12.10
ciliary body, 2.72, 2.100*f*
in uveitis. *See* Intermediate uveitis; Pars planitis
Pars plana vitrectomy. *See also* Vitrectomy
angle-closure glaucoma after, 10.143
branch retinal vein occlusion treated with, 12.130
for capsular rupture during cataract surgery, 11.143
cataract/cataract surgery after, 11.55, 11.190
central retinal vein occlusion treated with, 12.135
complications of, 12.402*t*, 12.402–403
cystoid macular edema treated with, 12.393, 12.394*f*
description of, 9.150
diabetic macular edema treated with, 12.115, 12.388
diabetic retinopathy complications treated with, 12.107

epiretinal membranes treated with, 12.382, 12.383
for hemolytic/ghost cell glaucoma, 10.106
idiopathic macular holes treated with, 12.384–385, 12.385*f*
indications for, 12.381
intraocular foreign body removed with, 12.361
for intraocular lymphoma diagnosis, 4.312
for IOL decentration/dislocation, 11.145
for malignant/ciliary block glaucoma (aqueous misdirection), 10.141
needle perforation/penetration of globe treated with, 12.396
posteriorly dislocated intraocular lenses treated with, 12.393
postoperative endophthalmitis treated with, 11.162
acute-onset, 12.388–390, 12.390*f*
bleb-associated, 12.390–391, 12.391*f*
chronic, 9.293, 12.390, 12.391*f*
retained lens fragments after phacoemulsification treated with, 11.41, 12.391–393, 12.392*f*
for retinal detachment
cataract surgery/IOL and, 11.166
rhegmatogenous, 12.400*f*, 12.400–401
submacular hemorrhage treated with, 12.385, 12.386*f*
suprachoroidal hemorrhage treated with, 12.394–395, 12.395*f*
sympathetic ophthalmia after, 9.199–200
technique for, 12.381
tractional retinal detachment treated with, 12.387–388
for uveal lymphoid proliferation/infiltration diagnosis, 4.314
uveitis macular edema treated with, 9.322
vitreous opacities treated with, 12.386
Pars planitis, 6.316, 12.231. *See also* Intermediate uveitis; Uveitis
ancillary tests for, 9.148–149
cataracts in, 9.151
clinical characteristics of, 9.147–148
complications of, 9.151
corticosteroids for, 9.149–150
description of, 9.70
differential diagnosis of, 9.148
glaucoma in, 9.151
histologic findings in, 9.148–149
macular edema in, 9.147
medical management of, 9.93
multiple sclerosis and, 5.318
prognosis for, 9.149
treatment of, 9.149–150
Pars plicata, 2.72, 2.73*f*, 2.100*f*, 2.472*f*, 4.115*f*, 4.182, 4.183*f*, 10.15*f*
Part-time occlusion, for amblyopia, 6.58
Partial seizures, 1.206–207
Partial third nerve (oculomotor) palsy, 5.193, 5.193*f*, 5.195–196, 5.196*f*
Partially accommodative esotropia, 6.90–92
Partially polarized light, 3.99
Particle theory of light, 3.94
Parvocellular neurons (P cells/system), 5.28, 5.32, 10.42
Parvoviruses, 1.236
PAS. *See* Peripheral anterior synechiae
PAS (periodic acid-Schiff) stain, 4.31*t*
Passive immunization, 1.223, 1.233
Pataday. *See* Olopatadine
Patanol. *See* Olopatadine
Patau syndrome, 6.386*t*
Patching. *See also* Occlusion therapy
for conjunctivochalasis, 8.86
for corneal defects/abrasions, 8.368, 8.369*f*, 8.369–370, 8.370*f*, 8.398
for dellen, 8.79, 8.92, 8.368
for hyphema, 10.105
for penetrating and perforating ocular trauma, 8.402
for recurrent corneal erosion, 8.87, 8.368
for topical anesthetic abuse diagnosis/management, 8.90
Patellar fossa, 12.7
Pathogen-associated molecular patterns (PAMPs), 9.5
Pathologic (high) myopia
chorioretinal atrophy in, 12.214*f*
choroid in, 12.212–216, 12.214–12.215*f*
choroidal neovascularization in, 12.89, 12.90*f*, 12.211*f*, 12.211–212
definition of, 12.207
factors associated with, 12.207
glaucoma in, 12.218, 12.218*f*
global prevalence of, 12.207
macular holes in, 12.209
ocular expansion related to, 12.216
optic nerve in, 12.217–218, 12.218*f*
prevalence of, 12.207
prevention of, 12.207–208
retina in, 12.208–216, 12.209–215*f*
sclera in, 12.216–217, 12.217*f*
swept-source optical coherence tomography of, 12.209*f*
traction effects on retinal vessels in, 12.209
Pathologic suppression, 6.48
Pathology, ophthalmic. *See* Ophthalmic pathology
Patient
examination of. *See* Examination
perimetry results affected by, 10.59, 10.60
selection/preparation of. *See also* Preoperative assessment/preparation for surgery
for corneal crosslinking, 13.131–132
expectations/motivations and, 13.35–36, 13.36*t*, 13.47
for LASIK, 13.78–80
for monovision, 13.39, 13.165
for multifocal IOLs, 13.155, 13.166–167
for phakic IOLs, 13.140–141
for photoablation, 13.77–80, 13.78*t*
for refractive lens exchange, 13.147–149
for surface ablation, 13.77–78
for toric IOLs, 13.151
Patient education
before cataract surgery, 11.87–88
for medication instillation, 10.184–185
adherence and, 10.186
in children, 10.165
Patient Health Questionnaire-2 (PHQ-2), 1.189–190
Pattern-appearance visual evoked potential, 5.95, 12.53
in nonorganic disorder evaluation, 5.302
Pattern deviation map/plot, 5.86, 5.87*f*, 10.65, 10.65*f*

Pattern dystrophies, 4.170, 4.171*f*, 12.67, 12.272, 12.276*f*, 12.276–277
adult-onset foveomacular vitelliform, 4.170, 4.171*f*
butterfly-type (BPD), 4.170, 12.276, 12.276*f*
Pattern electroretinography (PERG), 12.45–46, 12.46–49*f*
Pattern recognition receptors (PRRs)
dendritic cells' use of, 9.4
description of, 9.5
Toll-like receptors as, 9.58
Pattern-reversal visual evoked potential, 12.52, 12.53*f*
Pattern Standard Deviation (PSD), 10.65
Pattern strabismus
A-
clinical features of, 6.109
clinically significant, 6.109
definition of, 6.107
etiology of, 6.107–109, 6.108*f*
exotropia, 6.108*f*, 6.112
in exotropia, 6.109
horizontal rectus muscle transposition for, 6.112
identification of, 6.109
intorsion as cause of, 6.107, 6.110
medial rectus muscle displacement for, 6.110, 6.111*f*
palpebral fissure slanting associated with, 6.196
superior oblique muscle overaction associated with, 6.107
superior oblique tenotomy for, 6.112
surgical treatment of, 6.112, 6.112*t*
anomalous innervation as cause of, 6.109
λ-
clinical features of, 6.110
surgical treatment of, 6.113
management of, 6.110–113, 6.111*f*, 6.112*t*
ocular torsion as cause of, 6.107
surgical correction of, 6.110–113, 6.111*f*, 6.112*t*
types of, 6.107
V-
bilateral superior oblique palsy and, 6.122
in Brown syndrome, 6.137
clinical features of, 6.109
clinically significant, 6.109
craniofacial anomalies and, 6.107
in craniosynostosis, 6.208
definition of, 6.107
etiology of, 6.107–109, 6.108*f*
exotropia with, 6.108*f*, 6.111
extorsion as cause of, 6.107, 6.110
heterotopy as cause of, 6.28
identification of, 6.109
infantile esotropia associated with, 6.109, 6.112
inferior oblique muscle overaction associated with, 6.107
palpebral fissure slanting associated with, 6.196
clinical features of, 6.109–110
definition of, 6.107
downward-slanting palpebral fissures and, 6.107, 6.108*f*
etiology of, 6.107–109, 6.108*f*
horizontal rectus muscles and, 6.109
identification of, 6.109–110
superior oblique palsy and, 6.122
surgical treatment of, 6.111–112, 6.112*t*
X-
clinical features of, 6.110
surgical treatment of, 6.113
Y-
clinical features of, 6.109–110
surgical treatment of, 6.113
Patti Stripes Square Wave Grating Paddles, 6.8
Patton lines, 12.201
Pauciarticular (oligoarticular)-onset juvenile idiopathic (chronic/rheumatoid) arthritis (oligoarthritis), 6.313, 6.314*t*. *See also* Juvenile idiopathic arthritis
Paving-stone (cobblestone) degeneration, 4.150, 4.150*f*, 12.313, 12.314*f*
PAX genes. *See also specific type*
in aniridia, 4.184, 10.150, 10.155, 11.33
PAX2 gene, mutations of, 2.179
optic nerve dysplasia and, 5.145
PAX6 gene, 2.164, 6.267, 6.338
in aniridia, 2.225–226
description of, 2.179
mutation in
in aniridia, 4.184, 10.150, 10.155, 11.33
in Axenfeld-Rieger syndrome, 8.97*t*, 8.102
in microcornea, 8.95
in Peters anomaly, 8.97*t*, 8.103, 10.150, 11.32
mutations of, 2.226
PBK. *See* Pseudophakic (aphakic) bullous keratopathy
PC. *See* Posterior commissure
PCA. *See* Posterior cerebral artery
PCAB. *See* Pharmacy Compounding Accreditation Board
PCG. *See* Primary congenital glaucoma
PCI. *See* Percutaneous coronary intervention
PCIOLs. *See* Intraocular lenses, posterior chamber
PCNSL. *See* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
PCO. *See* Posterior capsular/capsule opacification
PCoA. *See* Posterior communicating artery
PCP (pneumocystis pneumonia). *See Pneumocystis jirovecii*
PCR. *See* Polymerase chain reaction
PCV. *See* Pneumococcal vaccination; Polypoidal choroidal vasculopathy
PD. *See* Parkinson disease/parkinsonism; Proton density
PD-1. *See* Programmed death 1
PD-L1. *See* Programmed death ligand-1
PDCD. *See* Pre-Descemet corneal dystrophy
PDE. *See* Phosphodiesterase
PDGFs. *See* Platelet-derived growth factors
PDR. *See* Proliferative diabetic retinopathy
PDT. *See* Photodynamic therapy
PE. *See* Pigmented epithelium
Pearson marrow-pancreas syndrome, 2.185
Peau d'orange, 12.87, 12.89*f*
"Peculiar substance," in Meesmann corneal dystrophy, 8.139
PEDs (pigment epithelial detachments). *See* Retinal pigment epithelium (RPE), detachment of
Pediatric cataract. *See* Cataract, pediatric
Pediatric corneal transplantation, 8.450–451
Pediatric glaucoma. *See* Glaucoma, pediatric (childhood/congenital/infantile/juvenile)

Pediatric granulomatous arthritis, 6.318
Pediatric life support (PLS), 1.299
Pediatric low vision. *See* Low vision, in infants
Pediatric uveitis, 9.320
Pediculus (pediculosis/lice)
humanus capitis, 8.255
humanus corporis, 8.255
ocular infection caused by, 8.255
Pedigree analysis, 2.200–201, 2.201*f*
PEDs. *See* Pigment epithelial detachments
Peduncular hallucinosis, 5.176
Pedunculated papillomas, conjunctival, 4.59–60, 4.60*f*
PEEs. *See* Punctate epithelial defects/erosions
Pegaptanib, 2.449, 12.80
Pegged porous orbital implant. *See* Orbital implants
Peginterferon alfa-2b, 7.210
PEHCR. *See* Peripheral exudative hemorrhagic chorioretinopathy
PEK. *See* Punctate epithelial keratitis/keratopathy
Pelizaeus-Merzbacher disease, 12.283*t*
Pelli-Robson chart/test, 3.316*f*, 5.88, 12.56–57, 12.57*f*
Pellucid marginal degeneration (PMD), 4.95, 8.16*f*, 8.168*f*, 8.168–169, 8.169*f*, 8.170*f*
corneal topography in evaluation of, 8.31, 8.33*f*, 8.169, 8.170*f*
refractive lens exchange and, 13.149
refractive surgery contraindicated in, 13.24, 13.44, 13.79, 13.176, 13.176*f*
corneal topography and, 13.24, 13.44, 13.45*f*, 13.79, 13.176, 13.176*f*
"Pellucid suspect" pattern, LASIK contraindicated in, 13.176, 13.176*f*
Pelopsia, 5.175
Pembrolizumab, 7.210
Pemirolast potassium, 2.412*t*
Pemphigoid, mucous membrane (MMP/cicatricial), 4.53–55, 4.54*f*, 8.285, 8.299–303, 8.300*f*, 8.301*f*, 8.301*t*, 8.302*t*
cataract surgery in patient with, 11.173
drug-induced (pseudopemphigoid), 8.91, 8.92, 8.299
mucous membrane grafting for, 8.303, 8.366
staging of, 8.299–300, 8.300*f*, 8.302, 8.302*t*
Penciclovir, 8.215*t*
for herpes simplex virus infections, 8.215*t*
Pendular nystagmus, 5.214, 5.233, 5.234*f*, 5.246–247, 6.147
acquired, 5.246–247
in multiple sclerosis, 5.246, 5.319
Penetrance, 2.219
Penetrating and perforating ocular trauma, 6.376–378, 6.377*f*, 8.396–409. *See also* Lacerations; Trauma
anterior segment, 8.396–409
ancillary tests in, 8.402, 8.402*t*
conjunctival foreign body, 8.397, 8.397*f*, 8.398*f*
conjunctival lacerations, 8.396–397
corneal abrasion, 8.8–9, 8.398*f*
corneal foreign body, 8.399–400, 8.400*f*, 8.401*f*, 8.403
evaluation of, 8.401–402, 8.402*t*
examination in, 8.401–402, 8.402*t*
history in, 8.401
management of
nonsurgical, 8.402–403
postoperative, 8.409
preoperative, 8.403
surgical, 8.403–409, 8.404*f*, 8.405*f*, 8.407*f*, 8.408*f*
ocular signs of, 8.402*t*
uveal prolapse in, repair of, 8.375
definitions of, 8.396
eyelid. *See* Lacerations, eyelid
fibrocellular proliferation and, 4.20–22, 4.21*f*
fibrous ingrowth/angle-closure glaucoma and, 10.142, 10.143*f*
lens damage caused by, 11.55, 11.55*f*, 11.56*f*
glaucoma and, 11.67
Seidel test in identification of, 8.36–37, 8.38*f*
sympathetic ophthalmia secondary to, 12.233. *See also* Trauma
Penetrating keratoplasty (PK/PKP), 8.411, 8.412, 8.419–432, 8.437*t*. *See also* Keratoplasty, penetrating
for *Acanthamoeba* keratitis, 8.279
advantages of, 8.421*t*
arcuate keratotomy and, 13.56–57, 13.58
astigmatism after
control of, 8.431–432, 8.432*f*
refractive surgery for, 13.178–180
suture removal/adjustment and, 8.419*f*, 8.431–432, 8.432*f*
corneal keratoscopy and, 8.28
corneal topography and, 8.32, 8.431–432, 8.432*f*
rejection of, 9.55
success rate for, 9.55
Penetrating wound, 8.396. *See also* Penetrating and perforating ocular trauma
Penicillamine, for Wilson disease, 8.189
Penicillin G
Borrelia burgdorferi treated with, 1.255
for leptospirosis, 9.233
for Lyme disease, 9.231*t*
for syphilis, 1.253, 6.413, 9.225–226, 9.226*t*
Penicillin-resistant *Neisseria gonorrhoeae* (PRNG), 8.259, 8.264
Penicillinase-resistant penicillins, 1.246, 1.271, 2.418
Penicillins, 2.417–419. *See also specific agent*
Pentacam system, for corneal power measurements, 3.248, 3.248*f*
Pentolair. *See* Cyclopentolate
Pentose phosphate pathway (hexose monophosphate [HMP] shunt), 2.289
in glucose/carbohydrate metabolism, in lens, 11.17, 11.18*f*, 11.19
Penumbra, 1.110
Peptidoglycan, in bacterial cell wall, 8.244
Peramivir, 1.279
Percent agreement, 1.25
Perception disorders. *See also* Hallucinations; Illusions; Metamorphopsia
cortical lesions and, 5.158, 5.175
nonvisual causes of, 5.174*t*
parietal lobe lesions and, 5.175, 5.177
retinal/macular disorders and, 5.174–175
Percheron, artery of, 5.20, 5.229–230
Percutaneous coronary intervention (PCI)
angina pectoris treated with, 1.91–92
angioplasty, 1.92
coronary heart disease treated with, 1.100

drug-eluting stents with, 1.92
myocardial infarction treated with, 1.85, 1.94
Perennial allergic conjunctivitis, 6.246–248, 8.288–289
Perfluorocarbon, 2.360*t*, 12.382
Perfluoropropane (C_3F_8), 12.382, 12.401
Perforating and penetrating ocular trauma. *See* Penetrating and perforating ocular trauma
Perforators
of basilar artery, 5.20
of posterior cerebral arteries, 5.20
of superior cerebellar arteries, 5.20
Perforin-granzyme pathway, in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
Performance indicators, 1.28
Perfusion pressure, ocular, glaucoma and, 10.83
PERG. *See* Pattern electroretinography
Peribulbar anesthesia, 2.442, 6.174
for cataract surgery, 11.91
for phakic IOL insertion, 13.141
Pericallosal artery, 5.16*f*
Pericentral scotoma, 5.105*t*
Pericytes, 2.89, 2.317–318, 12.93
Perifovea/perifoveal zone, 2.97, 4.140
characteristics of, 12.10*t*
definition of, 12.9
Perifoveal macula, 12.9*f*
Perimacular folds, in abusive head trauma, 6.382–383
Perimetrist, perimetry results affected by, 10.59, 10.60
Perimetry, 5.84–88, 5.85*f*, 5.87*f*, 10.59–77. *See also* Visual field testing
automated
short-wavelength (SWAP), 10.75
standard (SAP/achromatic), 10.59
static, 5.84, 5.85*f*, 5.85–88, 5.87*f*, 10.59, 10.60–62
artifacts seen on, 10.66*f*, 10.66–67, 10.67*f*
in glaucoma, 10.59, 10.60–62
high false-positive rate in, 10.67, 10.67*f*
incorrect corrective lens used in, 10.66
learning effect and, 10.71
in nonorganic disorder evaluation, 5.306–307, 5.307*f*, 5.308*f*
screening tests, 10.62
threshold tests, 10.61*f*, 10.61–62, 10.63*f*
for central visual field assessment, 5.85, 5.85*f*
factors affecting, 10.59–60
false-negative/positive responses and, 5.86, 10.62, 10.67, 10.67*f*
frequency-doubling technology (FDT), 10.75
in glaucoma suspect screening, 10.89
in glaucoma, 10.59–77
preperimetric glaucoma and, 10.3
in glaucoma suspect screening, 10.62, 10.89
Goldmann, 5.84, 5.85*f*
in nonorganic disorder evaluation, 5.308, 5.308*f*
interpretation in
artifacts and, 10.66*f*, 10.66–67, 10.67*f*
normality *versus* abnormality of field and, 10.62–65, 10.64*f*, 10.65*f*
optic nerve/nerve head/disc changes and, 10.74–75
patterns of field loss and, 10.67–69, 10.68*f*, 10.69*f*, 10.70*f*
quality/reliability and, 10.62
serial fields/detection of visual field progression, 10.71–75, 10.72*f*, 10.73*f*, 10.74*f*
single field, 10.62–67, 10.64*f*, 10.65*f*, 10.66*f*, 10.67*f*
kinetic, 5.84, 5.85*f*, 10.59
in nonorganic disorder evaluation, 5.308, 5.308*f*
in optic neuropathy, 5.86
preperimetric glaucoma and, 10.3
screening, 10.62
static. *See* Perimetry, automated, static
Swedish interactive thresholding algorithm (SITA), 5.86, 10.60–61, 10.62
tangent screen in. *See* Tangent screen
tendency-oriented algorithm (TOP), 10.61
terminology used in, 5.105*t*
threshold, 5.86, 10.61*f*, 10.61–62, 10.63*f*
in uveitis evaluations, 9.90
Perinatal infections. *See* Intrauterine ocular infections
Perineural invasion, pain caused by, 5.298
Perineuritis, optic, 5.119
radial (radial keratoneuritis), in *Acanthamoeba* keratitis, 4.79, 8.277
in sarcoidosis, 5.327
Perinuclear antinuclear antibody testing, 9.160
Periocular corticosteroids, for uveitis, 9.95–96, 9.96–97*f*
Periocular injections, 2.359
Periocular tissues
malpositions/involutional changes and. *See specific type*
prostaglandin analogues affecting pigmentation of, 10.175
Periodic acid-Schiff (PAS) stain, 4.31*t*
Periodic alternating nystagmus (PAN), 5.243*t*, 5.245–246, 6.149
Perioperative ischemic optic neuropathy, 5.124–125
Perioperative management in ocular surgery, preoperative assessment and. *See* Preoperative assessment/preparation for surgery
Periorbita (periorbital structures). *See also specific structure*
cellulitis affecting. *See* Orbital cellulitis; Preseptal cellulitis
description of, 7.11
involutional changes in, 7.259
orbital disorder-related changes in, 7.22, 7.23*t*
sebaceous carcinoma, 7.208
sensory innervation of, 7.18*f*
structures of, 7.19–20
Periorbital ecchymoses, 6.379, 6.384
Periorbital lacerations, 2.32
Periorbital pain, 5.295
in optic neuritis, 5.78, 5.113–114, 5.123*t*
Periorbital sinuses
anatomy of, 2.12–15
computed tomography of, 2.14*f*
orbit and, 2.12–15
Periorbital space-occupying lesions, 2.470*f*
Periorbitopathy, prostaglandin-associated, 10.176
Peripapillary atrophy (PPA), in glaucoma, 10.48, 10.52
Peripapillary choroiditis, 9.201*f*
Peripapillary fibers. *See also* Nerve fiber layer
assessment of, OCT in assessment of, 5.91
gliosis of, 5.109
in ONH edema, 5.82, 5.82*f*, 5.83*f*, 5.105

Peripapillary hemorrhages, 6.373
Peripapillary intrachoroidal cavitations, 12.215, 12.215*f*
Peripapillary microangiopathy, 2.186
Peripapillary staphyloma, 6.366
Peripheral airway disease, 1.124
Peripheral anterior synechiae (PAS), in glaucoma
angle closure and, 10.117, 10.121
inflammation and, 10.138, 10.139*f*
anterior segment/iris neovascularization and, 10.39, 10.39*f*, 10.133, 10.133*f*, 10.134*f*
chamber deepening/goniosynechialysis in management of, 10.220
flat anterior chamber and, 10.144
gonioscopy in identification of, 10.34*f*, 10.39, 10.39*f*
iridocorneal endothelial syndrome and, 4.100–101, 4.101*f*, 10.136, 10.136*f*
plateau iris and, 10.128
Peripheral arterial arcade, 7.171
eyelids supplied by, 8.4*f*
Peripheral arterial cascade, 2.28*f*, 2.34*f*, 2.38
Peripheral arterial disease
hyperlipidemia and, 1.78
hypertension and, 1.66
Peripheral cornea, 2.51
Peripheral corneal guttae (Hassall-Henle bodies/warts), 2.53, 8.115, 8.128
Peripheral corneal transparency abnormalities, 6.255–256*f*, 257
Peripheral curve, 3.205, 3.215*f*, 3.216
Peripheral cystoid degeneration, 4.148, 4.149*f*
description of, 12.314
reticular, 12.326
reticular (RPCD), 4.148, 4.149*f*, 12.326
typical (TPCD), 4.148, 4.149*f*, 12.326
Peripheral exudative hemorrhagic chorioretinopathy (PEHCR), 4.270*f*, 4.271
Peripheral fusion, 6.51–52
Peripheral granuloma
Toxocara, 9.284*f*
in toxocariasis, 12.244, 12.245*f*
Peripheral hypertrophic subepithelial corneal degeneration, 8.124–125, 8.125*f*
Peripheral iridectomy, 9.318
Peripheral (surgical) iridectomy. *See also* Iridectomy
for angle-closure glaucoma, 10.125, 10.220
Peripheral iridoplasty
for angle-closure glaucoma, 10.193–194
for plateau iris, 10.127*f*, 10.128
Peripheral iridotomy, 9.318
Peripheral iris suture fixation, for IOL decentration, 11.145, 11.146*f*
Peripheral keratitis, 8.50*t*
scleritis and, 8.323
ulcerative (PUK), 8.51*f*, 8.311*t*, 8.311–313, 8.312*f*, 9.157
differential diagnosis of, 8.311, 8.311*t*
in rosacea, 8.71
in systemic immune-mediated diseases, 8.51*f*, 8.311*t*, 8.311–313, 8.312*f*
Peripheral multifocal choroiditis, 9.229
Peripheral necrotizing retinochoroiditis, 9.222
Peripheral neovascularization, vitreous hemorrhage associated with, 12.232
Peripheral neurofibromatosis, 10.156. *See also* Neurofibromatosis 1 (NF1/von Recklinghausen)
Peripheral retina
definition of, 12.10
excavations, 12.312–313
Peripheral retinal neovascularization, 12.154*t*
Peripheral retinitis, 9.251*f*
Peripheral stromal inflammation, 8.52
Peripheral suppression, 6.48
Peripheral surgical space, 7.12
Peripheral uveitis. *See* Intermediate uveitis; Pars planitis
Peripheral vacuolar cataracts, 6.298
Peripheral vascular sheathing, in intermediate uveitis, 9.75
Peripheral vestibular nystagmus, 5.216, 5.241*t*, 5.241–243
Peripheral visual field/field deficit, 3.318. *See also* Visual field defects
Peripheral vitreous, 2.296, 12.7
Peripheral zone, corneal, 8.25, 8.25*f*
Peripherin, 2.308, 2.313*t*
Peripherin/*RDS (PRPH2)* gene mutation
in pattern dystrophies, 4.170
in Stargardt disease, 4.168
Periphlebitis
in cytomegalovirus retinitis, 12.235
description of, 9.237
in multiple sclerosis, 5.318, 9.152
in sarcoidosis, 4.187
Peristaltic pump, for phacoemulsification aspiration, 11.103, 11.103*f*
Peritomy, 6.163
Peritomy incision, for Gundersen flap, 8.358, 8.358*f*
Periventricular leukomalacia, 6.187, 6.361–362
PERK (Prospective Evaluation of Radial Keratotomy) study, 13.50
Perkins tonometer, 10.23
description of, 6.10, 6.281
in infants and children, 10.158
infection control and, 10.27
Perls Prussian blue stain, 4.31*t*
Permeability coefficient, 2.357
Pernicious anemia, 1.133
Peroxidation, lipid, in lens opacification, 11.19
Peroxin, 2.314*t*
Peroxisomal disorders, 12.290
Peroxy/peroxyl radicals. *See* Free radicals
Persistent corneal epithelial defects, 8.46*t*, 8.80–82, 8.81*t*, 8.82*f*
after cataract surgery, 11.132, 11.173
glaucoma medication toxicity and, 10.31
after LASIK, 13.112
management of, 8.368
after penetrating/deep anterior lamellar keratoplasty, 8.80, 8.424
after surface ablation, 13.107–108
topical anesthetic use/abuse and, 8.80–81, 8.81*t*, 8.89, 8.89*f*
in toxic keratoconjunctivitis, 8.80–81, 8.81*t*
Persistent fetal vasculature (PFV/persistent hyperplastic primary vitreous/PHPV), 2.470*f*, 4.125–126, 4.126*f*, 4.294–295, 6.298*f*, 6.298–299, 6.301, 11.42, 12.341–342
Bergmeister papilla and. *See* Bergmeister papilla

cataract and, 4.126, 11.42
glaucoma and, 10.144
retinoblastoma differentiated from, 4.294–295
Persistent hyaloid artery/system, 4.125–126, 4.126*f*. *See also* Persistent fetal vasculature
Persistent hyperplastic primary vitreous, 2.293
Persistent positive visual phenomena, 5.177, 5.201, 5.290
Persistent pupillary membrane, 6.264, 6.264*f*, 6.266*f*
Personality disorders, 1.198
Persons with disabilities, referrals for providers of support for, 2.240
Perturbations, 3.119
Pertussis vaccination, 1.225*t*
PET. *See* Positron emission tomography
PET-CT. *See* Positron emission tomography (PET)-computed tomography
Petechiae, 1.140
Peters anomaly, 4.74, 4.75*f*, 4.98, 6.259, 6.260*f*, 8.97*t*, 8.102–104, 8.103*f*, 10.150, 10.154, 11.31–32. *See also* Axenfeld-Rieger syndrome
Axenfeld-Rieger syndrome differentiated from, 10.154*t*
glaucoma and, 4.74, 10.150, 10.154
pediatric keratoplasty for, 8.450
Peters-plus syndrome, 6.259, 8.104
Petroclinoid (Gruber) ligament, 2.133, 5.41
Petrosal nerve, greater superficial, 5.276–277*f*, 5.277
Petrosal sinuses, inferior/superior, 5.22, 5.22*f*, 5.23*f*
Petrous bone, 5.5
inflammation of, sixth nerve (abducens) palsy and, 5.201
Peutz-Jeghers syndrome, 7.197
Pfeiffer syndrome, 6.207
PFV. *See* Persistent fetal vasculature
PG analogues. *See* Prostaglandin (PG) analogues
PG/PGH synthetase (prostaglandin synthetase/prostaglandin G/H synthetase). *See* Cyclooxygenase
PGD. *See* Preimplantation genetic diagnosis
PGF_{2a}. *See* Prostaglandin F_{2a}
PGI_2. *See* Prostaglandins, I_2
PGs. *See* Prostaglandins
PHACE syndrome, 6.220, 6.363
Phaco. *See* Phacoemulsification
Phaco chop technique, 11.114
Phaco fracture technique, 11.112–114, 11.113*f*
Phaco handpiece, 11.98, 11.98*f*
Phaco tip, 11.98*f*, 11.100, 11.101*f*
Phacoanaphylactic endophthalmitis. *See* Phacoantigenic (lens-associated) uveitis
Phacoanaphylactic uveitis. *See* Phacoantigenic (lens-associated) uveitis
Phacoanaphylaxis. *See* Phacoantigenic glaucoma
Phacoantigenic glaucoma, 10.98
Phacoantigenic (lens-associated) uveitis (lens-induced granulomatous/phacoanaphylactic endophthalmitis), 4.118–119, 4.119*f*, 11.66
Phacoantigenic uveitis, 9.136–137
Phacodonesis
cataract surgery and, 11.182
in exfoliation syndrome/pseudoexfoliation, 10.92
Phacodynamics, terminology used in, 11.102–103
Phacoemulsification, 11.90–91, 11.98–118. *See also* Cataract surgery
for advanced cataract, 11.180
anterior capsulotomy for, 11.109–110
in anterior chamber, 11.112
anticoagulant use and, 11.171–172, 11.172*t*
aspiration system for, 11.102, 11.115
burst-mode, 11.101
capsular rupture during, 11.142–143
capsule staining for, 11.178–179, 11.179*f*
capsulorrhexis in, 11.108–110, 11.109*f*
clear corneal incision for, 11.106*f*, 11.106–107
cystoid macular edema after, 11.164, 11.187
elliptical, 11.101
eye marking/time-out before, 11.104–105
flat or shallow anterior chamber and, 11.134–136
intraoperative complications and, 11.134–135
posterior fluid misdirection syndrome and, 11.134–135
postoperative complications and, 11.135–136
foldable IOLs for, 11.116, 11.120, 11.120*f*. *See also* Foldable intraocular lenses
in glaucoma, 11.186
combined with trabeculectomy, 10.213
after filtering surgery, 11.187
intraocular pressure lowered by, 11.186
globe exposure for, 11.105, 11.105*f*
high myopia and, 11.184–185
historical overview of, 11.90–91
hydrodelineation in, 11.110
hydrodissection in, 11.110
incisions for. *See also* Incisions, for cataract surgery
clear corneal incisions, 11.106*f*, 11.106–107
scleral tunnel incisions, 11.107*f*, 11.107–108
instrumentation for, 11.98*f*, 11.98–99
for intumescent cataract extraction, 11.179–180
IOLs for, 11.115–117, 11.118–122. *See also* Foldable intraocular lenses
procedures after insertion of, 11.117–118
at iris plane, 11.112
irrigation in, 11.101–102, 11.115
posterior fluid misdirection and, 11.134–135
toxic solutions exposure and, corneal edema caused by, 11.129, 11.133–134
lens particle glaucoma and, 11.67
locations of, 11.111–112
nuclear rotation in, 11.111
nucleus disassembly/removal in, 11.111, 11.112–114, 11.113*f*
locations for emulsification and, 11.111–112
techniques of, 11.112–114, 11.113*f*
chopping techniques, 11.114
phaco fracture, 11.112–114, 11.113*f*
ocular trauma affecting visualization and, 11.191
paracentesis for, 11.105
after pars plana vitrectomy, 11.190
posterior capsule opacification and, 11.152–153
Nd:YAG laser capsulotomy for, 11.152, 11.153, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser, capsulotomy
in posterior chamber, 11.111–112

for posterior polar cataract, 11.180–181
hydrodissection/nucleus rotation and, 11.111, 11.181
power delivery and, 11.99
advances in, 11.100*f*, 11.100–101
procedure for, 11.104–118
pulsed, 11.100
retained lens fragments after, 11.141
retinal detachment and, 11.127, 11.166–167
scleral tunnel incisions for, 11.107*f*, 11.107–108
supracapsular, 11.110
suprachoroidal effusion/hemorrhage risk and, 11.171
torsional, 11.101
for traumatic cataract, 11.192
in triple procedure, 11.175
ultrasonic technology terminology and, 11.99–100
after vitrectomy
description of, 11.190
for retained lens fragments after, 12.391–393, 12.392*f*
in zonular dehiscence with lens subluxation or dislocation, 11.181–183, 11.182*f*, 11.183*f*
Phacolysis, fluid-based, 11.125
Phacolytic glaucoma (phacolytic uveitis), 4.103, 4.103*f*, 4.122, 9.13, 9.136*f*, 9.136–137, 10.97*f*, 10.97–98, 11.67
Phacomorphic glaucoma, 10.119, 10.128, 10.129*f*, 11.67, 11.68*f*
Phagocytosis
antigen-presenting cells in, 9.30, 9.32*f*
description of, 9.12
mechanisms of, 9.16
of outer segments, 12.17
pathologic changes that affect, 12.17
reactive oxygen intermediates in, 9.16
retinal pigment epithelium cell, 12.17
Phagosomes, 2.99, 2.323, 9.12
Phakic intraocular lenses (PIOLs), 13.8*t*, 13.137, 13.138–147, 13.139*t*, 13.142*f*, 13.143*f*
advantages of, 13.138
for amblyopia/anisometropic amblyopia/strabismus, 13.185–187
ancillary preoperative tests for, 13.141
angle-supported, 13.137, 13.138, 13.139*t*, 13.144
complications of, 13.146–147
anterior chamber, 13.8*t*
for astigmatism after penetrating keratoplasty, 8.432
background of, 13.138
in children, 13.187
complications of, 13.145–147
contraindications for, 13.140
corneal crosslinking with, 13.134, 13.207–208
disadvantages/limitations of, 13.47*t*, 13.138–140
indications for, 13.140
informed consent for, 13.140–141
iris-fixated/supported, 13.8*t*, 13.137, 13.138, 13.139*t*, 13.141–142, 13.142*f*
complications of, 13.145
sizing, 13.142, 13.142*f*
outcomes of, 13.144–145
patient evaluation for, 13.140
patient selection for, 13.140–141
posterior chamber, 13.8*t*, 13.138, 13.142*f*, 13.142–144, 13.143*f*
complications of, 13.145–146
corneal crosslinking with, 13.207–208
sizing, 13.144
retinal detachment and, 13.138, 13.145, 13.146
sulcus-supported, 13.137, 13.139*t*
surgical technique for insertion of, 13.141–144, 13.142*f*, 13.143*f*
Phakic refractive procedures, 13.8*t*
Phakinin, 2.285, 11.16
Phakoma/phakomatoses (neurocutaneous syndromes), 2.227–229, 5.330–333, 333*f*, 5.334*t*. *See also* Neurofibromatosis; *specific type*
definition of, 12.165
retinal, 6.397, 6.399
retinal cavernous hemangioma, 12.168, 12.169*f*
von Hippel–Lindau syndrome, 12.165–168, 12.166–12.167*f*
Wyburn-Mason syndrome, 6.222, 6.394*t*, 6.405*t*, 6.405–406, 12.168
Phakomatous choristoma (Zimmerman tumor), 4.202–203, 4.203*f*
Pharmacodynamics, 2.349–350, 2.367
Pharmacogenetics, 2.233–234, 2.368
Pharmacogenomics
for age-related macular degeneration, 12.63
description of, 2.368
Pharmacokinetics
definition of, 2.349–350
topical eyedrops, 2.355*f*
Pharmacologic anisocoria, 5.258*t*, 5.263
Pharmacologic blockade, fixed, dilated pupil caused by, 5.310
Pharmacologic principles
in elderly patients, 2.351–352
pharmacodynamics, 2.349–350, 2.367
pharmacokinetics. *See* Pharmacokinetics
pharmacotherapeutics, 2.349–350
terminology associated with, 2.349
toxicity, 2.350–351
Pharmacology, 2.349. *See also* Drugs, ocular; *specific agent*
Pharmacotherapeutics. *See also* Drugs, ocular; *specific agent*
compliance with, 2.373
compounded pharmaceuticals, 2.372–373
definition of, 2.349–350
legal aspects of, 2.370–371
noncompliance with, 2.373
Pharmacy Compounding Accreditation Board (PCAB), 2.372
Pharyngitis, 1.247
Pharyngoconjunctival fever, 6.242, 8.233, 8.234
Phenethicillin, 2.417
Phenocopy, 2.218
Phenol red-impregnated cotton thread test, of tear secretion, 8.39
Phenothiazines, 12.297–298, 12.298*f*
cornea verticillata caused by, 8.130
corneal pigmentation caused by, 8.130, 8.132
lens changes caused by, 11.52, 11.52*f*
Phenotype, 2.218

Phentolamine, 1.64
Phenylalanine, in alkaptonuria, 8.184
Phenylephrine
blood pressure affected by, 2.384
description of, 2.379, 2.380*t*
Horner syndrome diagnosis and, 5.258–259
intracameral use of, 2.360*t*, 2.384
for intraoperative floppy iris syndrome, 11.138
Phenytoin, 1.207–208
Pheochromocytoma
hypertension caused by, 1.54
in multiple endocrine neoplasia, 1.50
Φ_e. *See* Radiant flux
Φ_v. *See* Luminous flux
Phialophora, 8.251
Phimosis, capsular, 11.153–154
Nd:YAG laser capsulotomy for, 11.154, 11.154*f*, 11.154–157, 11.156*f*
in pseudoexfoliation/exfoliation syndrome, 11.184
Phleboliths, 7.75
Phlyctenules/phlyctenulosis, 8.46*t*, 8.75, 8.75*f*
in blepharitis, 8.74, 8.75, 8.75*f*, 8.76
PHMB. *See* Polyhexamethylene biguanide
PHN. *See* Postherpetic neuralgia
-phoria (suffix), 6.16
Phorias. *See also* Heterotropias/tropias
refractive surgery and, 13.41
Phoropter. *See also* Trial frames
converging of, 3.37, 3.37*f*
definition of, 3.27, 3.148
minus cylinder
advantages of, 3.148
astigmatism detection using, 3.29
cylinder axis refinement using, 3.29–30, 3.30*f*
with Jackson cross cylinder, 3.29, 3.30–3.31*f*
near-point chart with, 3.37*f*
occluding of, 3.26*f*
operating principles of, 3.27
pictorial representation of, 3.26–3.27*f*
plus cylinder
astigmatism detection using, 3.29
cylinder axis refinement using, 3.30
cylinder power refinement using, 3.31–32
retinoscopy using, 3.159*t*
working distances for, 3.154
Phosphate, in aqueous humor, 2.274
Phosphatidylcholine, in retinal pigment epithelium, 2.324
Phosphatidylethanolamine, in retinal pigment epithelium, 2.324
Phosphenes, optic neuritis causing, 5.176, 5.317
Phosphodiesterase (PDE), 2.308, 2.310*f*
Phosphodiesterase-5 inhibitors, 12.304
Phosphofructokinase, in lens glucose/carbohydrate metabolism, 11.17, 11.18*f*
Phosphoinositide kinase, FYVE finger containing-PIKFYVE *(PIKFYVE)* gene, in Fleck corneal dystrophy, 8.136*t*
Phospholine. *See* Echothiophate
Phospholine iodide, 2.379
Phospholipase A_2 (PLA_2), 2.407, 2.424
arachidonic acid from, 9.19
functions of, 9.21
Phospholipids. *See also* Lipids
arachidonic acid from, 9.19
in tear film. *See* Lipid layer of tear film
Phosphonoformic acid. *See* Foscarnet
Phosphoresence, 3.111
Photic damage/phototoxicity/light toxicity, 12.367–369, 12.368*f*
cataract surgery and, 11.166
ophthalmic instrumentation causing, cataract surgery and, 11.166
Photisms, in optic neuropathy/neuritis, 5.176, 5.317
Photo-oxidation, 2.337
Photoablation, 3.113, 3.113*f*, 3.113*t*, 3.115, 13.29–32, 13.30*f*, 13.73–74, 13.74–75*f*, 13.101–126. *See also* LASEK; LASIK; Surface ablation; Wavefront-guided (custom) laser ablation; Wavefront-optimized laser ablation
aberrations after, 13.11, 13.12, 13.13, 13.102–103, 13.103*f*
application of laser treatment for, 13.91*f*, 13.91–93
bioptics with, 13.157
Bowman layer/stromal bed preparation for, 13.82–90
central islands and, 13.103–104, 13.104*f*
central toxic keratopathy after, 13.105*f*, 13.105–106
complications/adverse effects of, 13.101–126. *See also specific type*
contact lens use after, 13.200
corneal curvatures affected by, 13.9, 13.26–28, 13.27*f*, 13.28*f*
IOL power calculation and, 13.44, 13.193–197, 13.196*f*
corneal ectasia after, 13.124–125
corneal crosslinking for, 13.124, 13.130, 13.131
corneal transplantation after, 13.198
corticosteroids after, 13.92
complications associated with, 13.104–105
pressure-induced stromal keratopathy, 13.119
corneal haze reduction and, 13.33, 13.94, 13.108–109
for diffuse lamellar keratitis, 13.117
elevated intraocular pressure/glaucoma and, 13.41, 13.104–105, 13.182, 13.201
fungal keratitis and, 13.106
herpes simplex keratitis and, 13.174
LASIK, 13.93, 13.94
regression in overcorrection and, 13.101, 13.108–109
regression in undercorrection and, 13.102, 13.108
surface ablation, 13.92, 13.94, 13.108–109
custom, 13.31, 13.46, 13.76–77, 13.97. *See also* Custom (wavefront-guided) ablation
decentered ablation and, 13.104, 13.104*f*
dry eye after, 13.78–79
elevated intraocular pressure after, 13.104–105, 13.180–183, 13.182*f*, 13.200–201
fundamentals of, 13.29–30, 13.30*f*
glaucoma/ocular hypertension and, 13.104–105, 13.180–183, 13.182*f*, 13.200–201
herpes simplex virus keratitis and, 13.173–174
infectious keratitis after, 13.106*f*, 13.106–107, 13.107*f*
diffuse lamellar keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*

keratoconus and, 13.42–43, 13.175*f*, 13.175–178, 13.176*f*, 13.177*f*
laser types for, 13.30–32
outcomes of, 13.95–97
techniques and, 13.73–100
overcorrection and, 13.101–102, 13.108–109
patient selection for, 13.77–80, 13.78*t*
postoperative care for, 13.93–95
immediate postablation measures, 13.92–93
preoperative care for
patient preparation and, 13.81–82
patient selection/relative contraindications and, 13.77–80, 13.78*t*
planning/laser programming and, 13.31, 13.40, 13.81
re-treatment/enhancements and, 13.97–100, 13.99*f*
for overcorrection, 13.101–102
for undercorrection, 13.102
for retinoblastoma, 4.300
surgical technique for, 13.80–95
techniques for, 13.73–100
topography-guided, 13.32, 13.77
outcomes of, 13.97
tracking/centration/ablation and, 13.91*f*, 13.91–92
undercorrection and, 13.102, 13.108
Photoactivation, 3.113
Photochemical injury
description of, 12.367
pinguecula as, 4.56, 4.56*f*
Photochemical interactions, laser–tissue, 3.113*t*, 3.113–114
Photochromic lenses, 3.193, 3.193*f*
Photocoagulation
anesthesia for, 12.375
angle-closure glaucoma after, 10.143
Bruch membrane rupture caused by, 12.378
choroidal detachment caused by, 12.379, 12.379*f*
for choroidal hemangioma, 4.283
clinically significant diabetic macular edema treated with, 12.110
Coats disease treated with, 12.161
complications of, 12.378–379
description of, 3.114
diabetic macular edema treated with, 12.376
for diabetic retinopathy, 4.160, 4.161*f*
Early Treatment Diabetic Retinopathy Study findings for, 12.100
exudative retinal detachment caused by, 12.379
factors that affect, 12.373
foveal burns caused by, 12.378
indications for, 12.375–377
lasers used in
alternative systems, 12.377–378
wavelength of, 12.373–375
lenses for, 12.375, 12.376*f*
macular applications of, 12.375–376
for malignant glaucoma, 10.140
neovascular age-related macular degeneration treated with, 12.79
for neovascular glaucoma, 10.135
ophthalmic applications of, 3.115
parameters for, 12.375–377
principles of, 12.373–379
proliferative diabetic retinopathy treated with
description of, 12.104
in pregnancy, 12.94
retinal arterial macroaneurysms treated with, 12.147
retinal cavernous hemangioma treated with, 12.168
for retinal hemangioblastoma, 4.285
retinal holes caused by, 12.378
retinal lesions caused by, 12.378–379
retinal vascular lesions treated with, 12.377
retinopathy of prematurity treated with, 6.332, 6.333*f*, 12.186*f*
slit-lamp delivery systems, 12.377
vitreous hemorrhage caused by, 12.379
for von Hippel-Lindau syndrome/disease (retinal angiomatosis), 4.284, 12.167
Photodisruption, 3.113, 3.113*f*, 3.113*t*, 3.116–117, 3.117*f*, 13.29
femtosecond laser, 13.29
Photodynamic therapy (PDT), 3.114. *See also* Verteporfin
applications of, 12.380
central serous chorioretinopathy treated with, 12.194
for choroidal hemangioma, 4.283
for choroidal melanoma/ciliary body melanoma, 4.276
choroidal neovascularization treated with, 12.212, 12.213*f*, 12.380
complications of, 12.380
half-fluence, 12.380
neovascular age-related macular degeneration treated with, 12.79
photosensitivity reactions caused by, 12.380
polypoidal choroidal vasculopathy treated with, 12.76
ranibizumab added to, 12.85
for retinal hemangioblastoma, 4.285
steps involved in, 12.380
von Hippel–Lindau disease/syndrome treated with, 12.167
Photography, for recording optic nerve/nerve head/disc evaluation, 10.53
Photokeratoscopy, evaluation of astigmatism after penetrating keratoplasty and, 8.431
Photolysis, laser, 11.125
Photometry, 3.92, 3.108–110, 3.109*t*
Photomicroscopy, specular. *See* Specular microscopy
Photomultiplier, 3.94
Photomydriasis, multifocal IOLs and, 13.156
Photon, 3.95, 3.110
Photophobia, 5.296, 12.46, 12.264
in cone dystrophies, 5.102
after intrastromal corneal ring segment implantation, 13.65, 13.69
in optic neuropathy *versus* maculopathy, 5.100*t*
in primary congenital glaucoma, 10.151, 10.152
in recurrent corneal erosion, 8.86, 8.87
Photopic electroretinogram. *See also* Electroretinography/electroretinogram
in cone dystrophies, 5.102
LA 3.0 (photopic single-flash), in cone dystrophies, 5.102
Photopsias, 5.175. *See also* Floaters
electroretinography findings in, 12.46
in multiple evanescent white dot syndrome, 5.101

in optic neuropathy *versus* maculopathy, 5.100*t*
in posterior vitreous detachment, 12.308
retinal disease causing, 5.175
in rhegmatogenous retinal detachment, 12.320
vertebrobasilar disease causing, 5.336
Photoreceptor(s), 4.140*f*, 5.24, 6.44. *See also* Cones; Rod(s)
age-related changes in, 12.61
atrophy of, in macular degeneration, 4.163–164
cones. *See* Cones
density of, 12.11
depolarized state of, 2.308, 2.309*f*
disorders of. *See* Achromatopsia
distribution of, 12.11
drusen effects on, 12.64
inner segments of, 2.317, 2.321. *See also* Cone inner segments; Rod(s), inner segments
iron damage to, 12.362
in macular degeneration/choroidal neovascularization, 4.163–164
outer segments of, 2.306, 2.307*f*, 2.310*f*, 2.321. *See also* Cone outer segments; Rod(s), outer segments
ratio of, to ganglion cells, 5.24
retinal degeneration caused by gene defects in, 2.312
rods. *See* Rod(s)
as waveguides, 12.33
Photoreceptor cells
anatomy of, 2.86*f*
description of, 2.84
synaptic bodies of, 2.87*f*
Photoreceptor dystrophies
cone, 12.264–265
cone–rod. *See* Cone–rod dystrophies
diffuse, 4.170, 4.172*f*. *See also* Retinitis pigmentosa
rod–cone, 12.261–264, 12.262–264*f*
Photorefractive keratectomy (PRK), 8.412*t*, 13.8*t*, 13.73, 13.74, 13.76. *See also* Keratorefractive surgery; Surface ablation
for accommodative esotropia, 13.188
arcuate keratotomy and, 13.54, 13.58
for astigmatism and refractive errors after penetrating keratoplasty, 8.432
cataract surgery after, 11.177
IOL power calculation and, 11.86
central toxic keratopathy after, 13.105*f*, 13.105–106
in children, 13.187
contraindications/relative contraindications to, 13.171
corneal biomechanics affected by, 13.14
corneal crosslinking with, 13.134, 13.206–207
corneal haze after, 13.94, 13.109, 13.109*f*
corneal wound healing/repair and, 13.32–33, 13.94
corticosteroids after, 13.94
drugs affecting success of, 13.37
dry eye after, 13.79
ectatic disorders after, 8.166
glaucoma/ocular hypertension and, 13.181
herpes simplex virus keratitis and, 13.174
hyperopic, 13.94, 13.96
infectious keratitis after, 13.106–107
intraocular pressure measurement after, 10.25, 13.181
IOL power calculations after, OCT in, 8.22
limbal relaxing incisions and, 13.54, 13.58
myopic, 3.271, 3.271*f*, 13.95
conductive keratoplasty for overcorrection and, 13.129
outcomes of, 13.95
ocular and systemic disease and, 13.171
after penetrating keratoplasty, 13.179, 13.180
postoperative care for, 13.94
after radial keratotomy, 13.52
for recurrent corneal erosions, 8.79, 8.87–88
after retinal detachment surgery, 13.185
topography-guided (T-PRK), corneal crosslinking with, 13.206–207
Photorefractor, initial estimate of refractive error obtained using, 3.28
Photosensitive retinal ganglion cells, 5.24, 5.28
Photosensitivity. *See* Photic damage/phototoxicity/light toxicity
Photosensitizing dye, 3.114
Photostress recovery time, testing, 5.88
in optic neuropathy *versus* maculopathy, 5.100*t*
transient visual loss and, 5.163, 5.164
Phototherapeutic keratectomy (PTK), 8.367, 8.412*t*
for band keratopathy, 6.322
for calcific band keratopathy, 8.120
corneal crosslinking with, 13.206–207
for corneal/epithelial erosions, 11.129
after LASIK, 13.112
recurrent, 8.87
for corneal haze after surface ablation, 13.109
glaucoma/ocular hypertension and, 13.182
herpes simplex virus keratitis and, 13.174
layer-based approach to use of, 8.417*t*
for striae in LASIK flaps, 13.115
Photothermal laser therapy, 13.29
Phototoxicity. *See* Photic damage/phototoxicity/light toxicity
Phototransduction
cone, 2.311
definition of, 2.306
rod, 2.306–308
PHP. *See* Preferential hyperacuity perimetry
PHPV (persistent hyperplastic primary vitreous). *See* Persistent fetal vasculature
PHQ-2. *See* Patient Health Questionnaire-2
Phthiriasis/phthiriasis palpebrum (*Phthirus pubis* infection), 8.253, 8.255
Phthirus pubis (crab/pubic louse), 8.253, 8.254*f*
ocular infection caused by, 8.208*t*, 8.253, 8.255
Phthisis bulbi (phthisical eye), 4.22, 4.23, 4.23*f*
retinoblastoma regression and, 4.301
Phycomycetes infection (phycomycosis/mucormycosis/zygomycosis), 5.355*f*, 5.355–356, 8.251
cornea involved in (keratitis), 4.78
optic nerve involved in, 4.243
orbit involved in, 4.226–227, 4.228*f*, 5.355
Phycomycosis, 7.51
Physical activity. *See* Exercise
Physical examination. *See* Examination, ocular
Physical optics
description of, 3.92–93
geometric optics and, 3.119
light scattering, 3.97–98

reflection, 3.96
refraction, 3.96
Tyndall effect, 3.97
Physiologic cup/physiologic cupping, 10.48. *See also* Cupping of optic nerve/nerve head/disc; Optic cup
Physiologic (simple/essential) anisocoria, 5.256*f*, 5.257, 6.275
Physiologic suppression, 6.48
Physostigmine, 2.378*t*
Phytanic acid α-hydrolase defective/deficiency. *See* Refsum disease
Phytanic acid oxidase defective/deficiency. *See* Refsum disease
Phytanic acid storage disease. *See* Refsum disease
Phytanoyl-CoA hydroxylase, 2.314*t*
Pia mater, optic nerve, 4.241, 4.242*f*, 5.17*f*
Pial arteries, optic nerve supplied by, 10.46
PIC. *See* Punctate inner choroiditis/choroidopathy
PICA. *See* Posterior inferior cerebellar artery
Picornaviruses, ocular infection caused by, 8.208*t*, 8.240*t*
Picture charts, 3.134
Pie in the sky defect, 5.155, 5.155*f*
PIER study, 12.80
Pierre Robin malformation, 8.192*t*
Pierre Robin sequence, 6.183, 6.211
Piezoelectric crystal, in phacoemulsification handpiece, 11.99, 11.100
Piggyback intraocular lenses
definition of, 3.240
description of, 3.226
intralenticular fibrosis after placement of, 3.241
power calculations for, 3.251
refractive lens exchange and, 13.150
Pigment, in retinal pigment epithelium, 12.12*f*, 12.17
Pigment dispersion syndrome, 9.311
Pigment epithelial detachments (PEDs), 6.342. *See also* Retinal pigment epithelium (RPE), detachment of
definition of, 12.64
drusenoid, 12.64, 12.272, 12.274*f*
fibrovascular
anti-VEGF therapy for, 12.201*f*
description of, 12.72–73
retinal pigment epithelial tear risks, 12.82
in hypertensive choroidopathy, 12.123
optical coherence tomography of, 12.74*f*
serous, 12.72–73, 12.74*f*
subfoveal, 12.74–12.75*f*
Pigment epithelium cysts, of iris, 6.272, 6.272*f*
Pigment epithelium–derived factor, 2.332
Pigment granules, 12.348
Pigment/pigmentary dispersion syndrome, 4.105, 4.105*f*, 10.93–96, 10.94–96*f*
anterior chamber and trabecular meshwork affected in, 4.104–105, 4.105*f*
cornea affected in, 8.128
gene for, 10.11*t*
glaucoma and, 4.105, 4.105*f*, 10.93–96, 10.94*f*, 10.95*f*, 10.96*f*
posterior chamber phakic IOLs and, 13.145–146
Pigment spot of sclera, 8.338
Pigmentary glaucoma, 4.105, 4.105*f*, 10.95–96, 10.96*f*
Pigmentary retinopathy. *See also* Retinitis pigmentosa
description of, 9.259, 9.259*f*
hearing loss and. *See* Usher syndrome
Pigmentations/pigment deposits. *See also* Pigmented (melanocytic) lesions
conjunctival, 8.131*f*, 8.131–132, 8.338
corneal, 4.86, 8.118*t*
drug-induced, 8.129*t*, 8.129–132, 8.130*f*, 8.131*f*
iris, prostaglandin analogues/latanoprost and, 10.175
lens
aging and, 11.43, 11.44*f*
blunt injury causing (Vossius ring), 4.18, 11.53
drugs causing, 11.52, 11.52*f*
in pigment dispersion syndrome, 10.93–96, 10.94*f*, 10.95*f*
in pseudoexfoliation/exfoliation syndrome, 10.39, 10.91*f*, 10.91–93, 10.92*f*
retinal/retinal pigment epithelium. *See* Pigmentary retinopathy
trabecular meshwork, 4.104–105, 4.105*f*, 10.18, 10.39
in pigmentary glaucoma, 10.94, 10.95*f*
in pseudoexfoliation/exfoliation syndrome, 10.39, 10.93
Pigmented epithelium (PE). See Ciliary epithelium, pigmented; Iris pigment epithelium; Retinal pigment epithelium
Pigmented (melanocytic) lesions, conjunctival/ocular surface, 4.61–69, 4.63–69*t*, 8.338*t*, 8.338–345. *See also* Melanocytic tumors; *specific type*
benign, 8.338*t*, 8.338–341, 8.339–341*t*
malignant, 8.338*t*, 8.339*t*, 8.343–345, 8.344*f*
preinvasive, 8.338*t*, 8.339*t*, 8.342*f*, 8.342–343
Pigmented paravenous retinopathy, 12.263
PIKFYVE (phosphoinositide kinase, FYVE finger containing-PIKFYVE) gene, in Fleck corneal dystrophy, 8.136*t*
Pilagan. *See* Pilocarpine
Pilar cyst, 7.189
Pili, bacterial, 8.244
Pilocar. *See* Pilocarpine
Pilocarpine, 3.272, 10.173*t*, 10.181–182
accommodation affected by, 11.23
for acute angle closure, 10.124
Adie tonic pupil diagnosed using, 2.377, 5.256*f*, 5.264–265, 5.265*f*
anisocoria evaluation and, 5.256*f*
cataracts caused by, 11.52
characteristics of, 2.378*t*
for dry eye, 8.61*t*, 8.64
in fixed, dilated pupil evaluation, 5.310
in mydriasis evaluation, 5.263
ocular inserts for delivery of, 2.363
ointment, 2.378*t*
primary open-angle glaucoma treated with, 2.377–378
Pilocytic astrocytoma, 6.396
optic. *See* Optic nerve glioma
Pilomatricoma, 6.200, 6.200*f*, 7.194, 7.195*f*
Pilomatrixoma, 7.194
Pilopine/Pilopine gel. *See* Pilocarpine
Piloptic. *See* Pilocarpine
Pilostat. *See* Pilocarpine
Pinch technique, 7.261
Pineal gland, 2.116*f*, 5.24*f*

Pinealoblastoma, primary intracranial, retinoblastoma and, 4.298, 4.302
Pinguecula, 4.56, 4.56*f*, 4.57–58, 8.112, 8.112*f*
conjunctival graft for, 8.356
Pinhole, in camera obscura, 3.5, 3.5*f*
Pinhole apertures
double, 3.285, 3.286*f*
monocular diplopia and, 3.130
Pinhole occluder, visual acuity testing use of, 3.23–24, 3.24*f*, 3.130
Pinhole visual acuity, 3.124, 3.130
Pioglitazone, 12.301
PIOL. *See* Primary intraocular/central nervous system lymphoma
PIOLs. *See* Phakic intraocular lenses
PION. *See* Posterior optic neuropathy, ischemic
PIP5K3 (phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase type III) gene. *See PIKFYVE* (phosphoinositide kinase, FYVE finger containing-PIKFYVE) gene
Piperacillin sodium, 2.419
Piroxicam, 2.409*t*
PISK. *See* Pressure-induced stromal keratopathy
Piston (wavefront aberration), 13.11
Pitavastatin, 1.75*t*
PITS. *See* Pulled-in-two syndrome
Pits
lens, 11.25, 11.26*f*
optic (optic nerve/disc pits, optic holes, optic pit maculopathy), 5.145
acquired, 10.49–50
Pituitary adenoma
chiasmal syndromes caused by, 5.147, 5.148*f*
neuroimaging in evaluation of, 5.72*t*, 5.92*f*, 5.93–94*f*
in pregnancy, 5.147, 5.333
Pituitary apoplexy (Sheehan syndrome), 1.49, 5.149, 5.150*f*
Pituitary fossa, 5.6*f*, 7.8*f*
Pituitary gland, 5.27*f*
adenomas of, 1.47–49
disorders of, in lymphocytic hypophysitis, 5.335
thyrotropin-releasing hormone secretion by, 1.42
PITX2 gene, 6.265, 10.11*t*
in Axenfeld-Rieger syndrome, 8.97*t*, 8.102, 10.150
in glaucoma, 10.11*t*
in Peters anomaly, 8.97*t*, 8.103, 10.150, 11.32
Pixie-ear deformity, 7.274
PK/PKP (penetrating keratoplasty). *See* Keratoplasty, penetrating
PL. *See* Preferential looking
PLA_2. *See* Phospholipase A_2
Placental growth factor, 2.277
Placido-based topography/Placido disk, 3.248, 3.288*f*, 8.27–28, 8.35*t*, 13.7–9, 13.14–16, 13.15*f*, 13.17, 13.20, 13.21*f*, 13.25*f*
computerized, 3.288*f*
in corneal biomechanics evaluation, 8.43
errors in, 3.252
IOL power calculation after refractive surgery and, 13.193
Placode, lens, 11.25, 11.26*f*
Plagiocephaly, 6.204–205
Planck constant, 3.110
Plane mirror setting, on retinoscope, 3.150, 3.151*f*
Plane mirrors, 3.81
Plano/plano power intraocular lenses, 13.150
hard contact lens method for IOL power calculation and, 13.195
Planoconcave lenses, 12.375
Plant alkaloids, 1.240*t*, 1.241
Plants/vegetation, ocular injuries caused by, 8.387
corneal abrasions, 8.399
corneal foreign body, 8.387, 8.399
fungal keratitis and, 4.78, 8.273, 8.387, 8.399
Planum sphenoidale, 5.6*f*
Plaque hemangioma, 6.220, 6.220*f*
Plaque radiotherapy. *See* Radioactive plaque therapy
Plaques
anterior subcapsular fibrous, 4.120, 4.120*f*
demyelinating, in multiple sclerosis, 5.316, 5.316*f*
Hollenhorst (cholesterol emboli), 12.141, 12.142*f*, 12.144
in branch retinal artery occlusion, 4.156
transient visual loss and, 5.165, 5.165*f*, 5.166*t*
optic nerve, 4.244
posterior subcapsular fibrous, 4.120*f*, 4.120–121
senile calcific, scleral, 4.111, 4.111*f*
senile scleral (Cogan), 8.128, 8.129*f*
Plasma, 1.131, 2.273*t*
Plasma cell tumors, 7.95
Plasma cells, 4.9, 9.37, 9.41
monoproliferation of, crystalline corneal deposits and, 8.198
Plasma-derived enzyme systems. *See specific component*
Plasma-derived proteins, in cornea, 9.54
Plasma exchange, for granulomatosis with polyangiitis, 1.172
Plasma formation, 3.116, 3.116*f*
Plasma-induced ablation, 3.113, 3.113*f*, 3.113*t*, 3.115–116, 3.116–3.117*f*
Plasma proteins. *See also* Protein(s)
in aqueous humor, 2.275–276
Plasmid resistance, 1.270–271
Plasmids, 8.243
Plasminogen, 9.18
in ligneous conjunctivitis, 8.294, 8.295
Plasminogen activators, tissue. *See* Tissue plasminogen activator
Plasmodium falciparum, 1.232
Plastic prisms, in minimum deviation position, 3.45, 3.46*f*
Plateau iris/plateau iris syndrome, 10.4*t*, 10.9, 10.32, 10.120, 10.127*f*, 10.127–128
laser iridotomy for, 10.128
Platelet(s)
disorders
essential thrombocytopenia, 1.142–143
thrombocytopenia, 1.141–142
thrombocytosis, 1.142–143
dysfunction of, 1.143–144
function of, laboratory evaluation of, 1.139
Platelet-activating factors (PAFs), in inflammation, 9.12, 9.20*f*, 9.20–21
Platelet aggregation
aspirin effects on, 1.143
inhibition of, 1.89, 1.90*f*, 1.143
Platelet aggregometry, 1.139

Platelet count, 1.139
Platelet degranulation, 9.8
Platelet-derived growth factors (PDGFs), 9.24*t*
Platelet-fibrin embolus, transient visual loss and, 5.165, 5.165*f*, 5.166*t*
Platelet function analyzer, 1.139
Platelet glycoprotein IIb/IIIa inhibitors. *See* Glycoprotein IIb/IIIa inhibitors
Platinum eyelid weights
  for corneal exposure in facial palsy, 5.281
  for exposure keratopathy, 8.80
Platysma muscle, 7.267
Platysmaplasty, 7.276, 7.276*f*
Plavix. *See* Clopidogrel
Pleiotropism, 2.220
Pleistophora, 8.252
Pleomorphic adenoma (benign mixed tumor), 7.98–100, 7.99*f*, 7.192
  of lacrimal gland, 4.229–230, 4.230*f*
Pleomorphic rhabdomyosarcomas, 4.236, 7.88
Pleomorphism
  in Fuchs endothelial corneal dystrophy, 8.156
  specular microscopy in evaluation of, 8.23
    before cataract surgery, 11.84
Plexiform layer *See* Inner plexiform layer; Outer plexiform layer
Plexiform neurofibromas, 5.334*t*, 6.223, 6.395*f*, 6.395–396, 7.83
  eyelid involvement/ptosis and, 5.269*t*
  glaucoma and, 10.30, 10.156
  of orbit, 4.238, 4.238*f*
PLG gene, in ligneous conjunctivitis, 8.294
PLGA. *See* Poly(lactic-*co*-glycolic acid)
Plica semilunaris, 2.27*f*, 2.44, 8.6
  advancement of, 6.171
  hypertrophy of, 6.172*f*
Plication
  conjunctiva, for conjunctivochalasis, 8.86, 8.361
  description of, 6.164*t*
PLS. *See* Pediatric life support
Plurihormonal adenomas, 1.48
Plus cylinder
  astigmatic dial refraction with, 3.162
  description of, 3.148–149
  minus cylinder conversion to, 3.149
  for with movement, 3.155
Plus cylinder lens, 3.17*f*
Plus cylinder phoropter
  astigmatism detection using, 3.29
  cylinder axis refinement using, 3.30
  cylinder power refinement using, 3.31–32
  retinoscopy using, 3.159*t*
Plus disease, 6.326, 6.327*t*, 6.330*f*, 12.176*t*, 12.176–177, 12.178*f*, 12.178*t*, 12.179*f*, 12.184*t*, 12.186, 12.186*f*
Plus lenses. *See also* Convex lenses
  amblyopia treated with, 6.59
  convergence paralysis treated with, 6.106
PMD. *See* Pellucid marginal degeneration
PML. *See* Progressive multifocal leukoencephalopathy
PMMA. *See* Polymethylmethacrylate
PMMA lenses, 6.302
PMNs. *See* Polymorphonuclear leukocytes
PMR. *See* Polymyalgia rheumatica
PND. *See* Prenatal diagnosis
PNET. *See* Primitive neuroectodermal tumor
Pneumatic displacement, 12.85
Pneumatic retinopexy, for rhegmatogenous retinal detachment, 12.324, 12.397–398, 12.398*f*
Pneumatic tonometer (pneumotonometer/pneumatonometer), 10.25–26
  in infants and children, 10.158
  for intraocular pressure measurement after refractive surgery, 13.119, 13.200
Pneumococcal pneumonia, 1.230–231
Pneumococcal polysaccharide vaccine 13-valent, 1.230
Pneumococcal polysaccharide vaccine 23-valent, 1.230
Pneumococcal vaccination (PCV), 1.225*t*
Pneumococcus. *See Streptococcus, pneumoniae*
Pneumocystis jirovecii
  choroiditis caused by, 9.332, 9.332*f*
  description of, 1.266
  pneumocystis pneumonia (PCP) caused by, 9.332
Pneumolysin, 8.245
Pneumonia, pneumococcal, 1.230–231
Pneumotonometer/pneumatonometer, 10.25–26
  in infants and children, 10.158
  for intraocular pressure measurement after refractive surgery, 13.119, 13.200
PNH. *See* Paroxysmal nocturnal hemoglobinuria
PO (pupil-optic nerve) section, 4.29*f*, 4.29–30
POAG. *See* Open-angle glaucoma, primary
POHS. *See* Ocular histoplasmosis syndrome
Point mutations, 2.217. *See also* Mutation
Point spread function (PSF), 3.41, 3.69–70, 3.105, 3.275, 3.275*f*, 3.305. *See also* Blur circles
Poland syndrome, 6.135
Polar amphiphilic phospholipids, 2.249
Polar cataracts, 11.35–36, 11.37*f*
  anterior, 6.55, 6.295, 6.295*f*
  posterior, 11.36
    surgery for, 11.180–181
      hydrodissection/nucleus rotation and, 11.111, 11.181
Polarimetry/polarimeter, scanning laser (GDx/SLP). *See* Scanning laser polarimetry/polarimeter
Polarization
  description of, 9.14
  of light, 3.92, 3.98–99
Polarized lens test, in nonorganic disorder evaluation
  monocular no light perception and, 5.303–305
  monocular reduced vision and, 5.305
Polarized Worth 4-dot test, 6.80
Polio vaccine, 1.229
Poliosis, in staphylococcal blepharitis, 8.74
Poly-Dex. *See* Dexamethasone/neomycin sulfate/polymyxin B sulfate
Poly-Pred. *See* Neomycin sulfate/polymyxin B sulfate/prednisolone acetate
Polyallelism, 2.214
Polyangiitis with granulomatosis (GPA/Wegener granulomatosis)
  definition of, 9.158
  description of, 1.171–172, 7.34, 7.63–64, 7.64*f*, 12.195, 12.196*f*
  diagnosis of, 9.159–160
  eyelid manifestations of, 4.207*t*

laboratory investigations for, 9.125*t*
manifestations of, 9.158–159, 9.159*f*
nasolacrimal duct obstruction associated with, 7.306, 7.306*f*
necrotizing scleritis in, 9.120*f*
ocular involvement in, 9.159
optic neuritis and, 5.115
treatment of, 9.160
vision loss in, 9.159
Polyarteritis nodosa (PAN), 1.170–171, 7.65, 9.125*t*, 9.156–158, 9.157*f*
Cogan syndrome and, 8.309
eyelid manifestations of, 4.207*t*
refractive surgery contraindicated in, 13.191
Polyarthritis, 9.143*f*. *See also* Arthritis
juvenile, 6.313, 6.314*t*
Polyarticular-onset juvenile idiopathic (chronic/rheumatoid) arthritis/polyarthritis, 6.313, 6.314*t*. *See also* Juvenile idiopathic arthritis
Polycarbonate, 3.195–196, 3.314
Polychondritis, relapsing, eyelid manifestations of, 4.207*t*
Polycystic kidney disease, 1.53
Polycythemia vera, transient visual loss and, 5.171
Polydactyly, 6.391, 6.391*f*
Polydioxanone intracanalicular plugs, for dry eye, 8.64
Polydystrophy, pseudo-Hurler (ML III), 8.178
Polyenes, 2.429, 2.430*t*
Polyethylene orbital implant. *See* Orbital implants
Polyhedral cells, in choroidal/ciliary body nevus, 4.191
Polyhexamethylene biguanide (PHMB), 2.437
for *Acanthamoeba* infection, 8.278, 8.279
Polyinosinic acid–polycytidylic acid, 2.447
Poly(lactic-*co*-glycolic acid) (PLGA), 2.360*t*, 2.364
Polymegethism, 8.10
in Fuchs endothelial corneal dystrophy, 8.156
specular microscopy in evaluation of, 8.23
before cataract surgery, 11.84
Polymerase chain reaction (PCR), 4.36–40, 4.38*t*, 4.39*t*, 4.40*f*
for chronic postoperative endophthalmitis, 9.293
clinical use of, 4.40, 4.41–42
disadvantages of, 9.90
fluorescent, 2.239
Goldmann-Witmer coefficient and, 9.91
in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.136
principles of, 2.186–187
real-time quantitative (RT-PCR/qPCR), 4.39*t*
reverse (RT-PCR), 4.38*t*
syphilis diagnosis using, 9.225
thermal cycling in, 2.186
for *Tropheryma whipplei,* 9.245
in uveitis, 9.90–91
Polymethylmethacrylate (PMMA)
contact lenses constructed of, 3.213, 6.302
intraocular lens constructed of, 3.240, 11.116, 11.118–119
capsular opacification and, 11.153
insertion of, 11.116
for manual small-incision cataract surgery, 11.198
phakic intraocular lenses, 13.138, 13.139*t*
intrastromal corneal ring segments made from, 13.59, 13.62
Polymorphic amyloid degeneration, 8.122, 8.123*f*, 8.186*t*
Polymorphism, 8.10
Polymorphisms
definition of, 2.183, 2.218
mutations *versus*, 2.182–183
single-nucleotide, 2.182, 2.193–194, 2.195*f*, 2.218, 2.368
Polymorphonuclear leukocytes (PMNs), 4.7, 4.8*f*, 9.2. *See also* Basophils; Eosinophils; Neutrophil(s)
Polymorphous dystrophy, posterior (PPCD/PPMD/CHED1), 4.93–94, 4.94*f*, 8.135*t*, 8.136*t*, 8.158–160, 8.159*f*, 8.160*f*
glaucoma and, 8.159, 10.31
Polymyalgia rheumatica (PMR), 1.168
Polymyositis, 1.167–168
Polymyxin B sulfate, 2.418*t*, 2.427–428
Polymyxin B sulfate/bacitracin zinc, 2.421*t*
Polymyxin B sulfate/neomycin sulfate/bacitracin zinc, 2.421*t*
Polymyxin B sulfate/neomycin sulfate/gramicidin, 2.421*t*
Polymyxin B sulfate/trimethoprim sulfate, 2.421*t*, 2.427–428, 8.258
Polyneuropathy, familial amyloid (FAP), 4.134, 4.134*f*, 4.206. *See also* Familial amyloidosis
vitreous involvement/opacification in, 4.134, 4.134*f*
Polyol (sorbitol) pathway
in cataract formation, 11.19
description of, 2.289, 2.291
in lens glucose/carbohydrate metabolism, 11.18*f*, 11.19
Polyopia, 5.185
in cataracts, 11.70–71
PolyPhen, 2.194
Polypoidal choroidal vasculopathy (PCV/posterior uveal bleeding syndrome), 4.166*f*, 4.166–168, 4.167*f*
central serous chorioretinopathy *versus*, 12.193
clinical presentation of, 12.75
definition of, 12.75
indocyanine green angiography for, 12.38, 12.38*f*
subretinal hemorrhage associated with, 12.76
verteporfin for, 12.76
Polyposis, familial adenomatous (FAP/Gardner syndrome), 12.285–286
congenital hypertrophy of retinal pigment epithelium in, 2.201, 2.202*f*
retinal manifestations of, 4.144–145, 4.269
Polysporin. *See* Polymyxin B
Polytrim. *See* Polymyxin B sulfate/trimethoprim sulfate
Polyunsaturated fatty acids (PUFAs), 2.324, 2.336–337, 2.340
Polyvinyl alcohol (PVA), 2.357
Pons, 5.27*f*. *See also specific Pontine entries*
horizontal eye movements and, 5.36, 5.37*f*, 5.37–38
Pontine lesions
facial myokymia caused by, 5.284
facial weakness/paralysis caused by, 5.278, 5.278*t*
gaze palsy caused by, 5.191, 5.228, 5.229*f*
Horner syndrome and, 5.260*t*
Millard-Gubler syndrome caused by, 5.192
motility disorders caused by, 5.187*f*, 5.191, 5.192

one-and-a-half syndrome caused by, 5.191
spastic paretic facial contraction caused by, 5.284
Pontine nuclei, 5.33
dorsolateral (DLPN), 5.33, 5.34*f*, 5.35, 5.224
Pontine paramedian reticular formation (PPRF), 5.33, 5.35, 5.35*f*, 5.219
horizontal gaze and, 5.36, 5.37, 5.37*f*
in one-and-a-half syndrome, 5.191
saccades generated by, 5.219–220, 5.221
Pontine pathways, in pursuit system, 5.33, 5.34*f*, 5.224
Pontocaine. *See* Tetracaine
Pooling, fluorescein, 12.35, 12.36*f*. *See also* Hyperfluorescence
Population, for clinical studies
evaluation of, 1.4–5
random assignment of, 1.4
recruitment strategy for, 1.4–5
vulnerable, 1.4
Population-wide immunity, 9.63
Pork tapeworm *(Taenia solium)*, orbital infection caused by, 4.228
PORN. *See* Progressive outer retinal necrosis
Porous implants, 7.139
Porous polyethylene orbital implant. *See* Orbital implants
Porphyria/porphyria cutanea tarda, 8.190
PORT. *See* Punctate outer retinal toxoplasmosis
Port-wine stain (PWS/port-wine nevus/nevus flammeus), 6.199, 6.401, 6.401*t*, 6.402*f*, 8.345*t*, 8.346
increased episcleral venous pressure and, 10.30
in Sturge-Weber syndrome, 5.332*f*, 5.334*t*, 8.346, 10.30, 10.155
Portable electronic applanation devices, 10.25
POS. *See* Parinaud oculoglandular syndrome
Posaconazole, for fungal keratitis, 8.275
Position
of gaze. *See* Gaze, positions of
in schematic eye, 3.127*t*
Positional candidate gene screening, 2.189
Positive angle kappa, 6.67, 6.68*f*
Positive defocus, 3.276, 13.11, 13.11*f*
Positive dysphotopsias, 3.255
IOLs and, 5.174, 11.150
Positive lenses. *See* Convex lenses
Positive likelihood ratio, 1.19
Positive numbers, in vergence equation, 3.10
Positive predictive value (PPV)
of diagnostic and screening test, 1.15–16
pretest probability effects on, 1.20*t*
Positive spherical aberrations, 3.74, 3.74*f*
Positive staining (fluorescein), 8.36
"Positive vitreous pressure," flat or shallow anterior chamber and, 11.134
Positron emission tomography (PET), 5.70
in coronary heart disease diagnosis, 1.88
epilepsy diagnosis using, 1.207
lung cancer screening uses of, 1.220
in sarcoidosis, 5.328
in uveal lymphoma, 12.234
Positron emission tomography–computed tomography (PET-CT), 2.454
Posner goniolens, 10.35
Posner-Schlossman syndrome (glaucomatocyclitic crisis), 9.135, 9.318, 10.100–101
Post-Ebola virus disease syndrome, 9.271
Post-refractive intraocular lens power calculator, online, (ASCRS), 13.52, 13.195–197, 13.196*f*
Post-traumatic stress disorder (PTSD), 1.198
Postcentral gyrus, 5.47*f*
Posterior alveolar nerve, 5.49
Posterior amorphous corneal dystrophy (PACD), 8.135*t*, 8.136*t*, 8.154*f*, 8.154–155
Posterior aqueous diversion syndrome. *See* Malignant glaucoma
Posterior capsular/capsule opacification (PCO)
cataract surgery and, 11.152–153
description of, 3.240, 6.302, 12.260
IOLs and, multifocal IOLs, 13.156, 13.167
Nd:YAG laser capsulotomy for, 11.152, 11.153, 11.154*f*, 11.154–157, 11.156*f*. *See also* Nd:YAG laser, capsulotomy
multifocal IOLs and, 13.156, 13.167
Posterior capsular cataract, 6.387*f*
Posterior capsular rupture, cataract surgery and, 11.142–143
Posterior capsulectomy, 6.303
Posterior cerebral artery (PCA), 2.106*f*, 2.108*f*, 2.139*f*, 5.12, 5.18, 5.18*f*, 5.19*f*, 5.20
aneurysm of, 5.339*f*
cranial nerve relationship and, 5.42*f*
Posterior chamber. *See also* Posterior segment
anatomy of, 2.48
dimensions of, 2.49*t*
phacoemulsification in, 11.111–112
ultrasound biomicroscopy of, 2.471*f*
in uveitis. *See* Posterior uveitis
Posterior ciliary arteries, 2.23–24*f*, 2.120, 5.15–17, 5.17*f*
anatomy of, 12.195*f*
choroid blood supply from, 12.19, 12.20*f*, 12.195*f*
optic nerve supplied by, 10.44
Posterior ciliary nerves, 5.55
Posterior circulation. *See* Vertebrobasilar system
Posterior clinoid, 2.106*f*
Posterior collagenous layer (retrocorneal fibrous membrane/RCFM), 4.84, 4.85*f*
Posterior colobomas, 2.153
Posterior commissure (PC), 5.35, 5.35*f*, 5.55*f*
vertical gaze and, 5.36, 5.36*f*
Posterior communicating artery (PCoA), 5.16*f*, 5.18, 5.18*f*, 5.19*f*, 5.20
anatomy of, 2.106–107*f*, 2.124, 2.139*f*
aneurysms of, 2.125, 5.339*f*
third nerve (oculomotor) palsy and, 5.20, 5.194, 5.194*f*, 5.339
cranial nerve relationship and, 5.42*f*
Posterior cornea
anatomy of, 2.54*f*
defects/depression of, 6.259. *See also* Peters anomaly; Posterior keratoconus
Posterior cranial fossa, 5.6*f*
neuroimaging in evaluation of, 5.72*t*
Posterior embryotoxon, 4.99, 4.99*f*, 4.100*f*, 6.255, 6.255*f*, 8.97*t*, 8.101–102, 8.102*f*. *See also* Anterior segment, dysgenesis of
in Axenfeld-Rieger syndrome, 4.99, 4.99*f*, 4.100*f*, 8.97*t*, 8.102, 10.31, 10.153

isolated, Axenfeld-Rieger syndrome differentiated from, 10.154*t*
Posterior ethmoidal artery, 2.23*f*, 5.12, 5.13*f*, 5.14*f*, 5.16*f*, 7.9
Posterior ethmoidal foramen, 2.6*f*, 2.11, 5.11, 7.7–8*f*
Posterior fixation
definition of, 6.164*t*, 6.167
suture for, 6.164*t*
Posterior fluid misdirection syndrome, 11.134–135
Posterior fossa malformations, hemangiomas, arterial lesions, and eye anomalies. *See* PHACE syndrome
Posterior hyaloid, 2.296, 2.296*f*
Posterior inferior cerebellar artery (PICA), 5.19, 5.19*f*, 5.20
Posterior keratoconus, 4.98, 8.97*t*, 8.104, 8.105*f*
Posterior lacrimal crest, 2.6*f*
Posterior lamellar deficiency, 7.254
Posterior lenticonus/lentiglobus, 4.118, 4.118*f*, 6.296–297, 6.297*f*, 11.30, 11.30*f*
Posterior microphthalmos, 6.263
Posterior nonpigmented epithelium of the iris, 2.159*f*
Posterior optic neuropathy, 5.104. *See also* Optic neuropathy
ischemic (PION), 5.107*t*, 5.119, 5.124
perioperative, 5.124–125
Posterior parietal cortex (PPC), 5.30, 5.30*f*
Posterior persistent fetal vasculature, 12.342
Posterior pigmented epithelium, 2.71–72
Posterior pituitary gland hormones, 1.47
Posterior placoid chorioretinitis, 9.222, 9.223*f*
Posterior polar cataract, 11.36
surgery for, 11.180–181
hydrodissection/nucleus rotation and, 11.111, 11.181
Posterior pole, 2.296–297, 11.9, 11.10*f*, 11.12*f*. *See also* Macula
distortion of, 6.317*f*
familial exudative vitreoretinopathy findings, 6.347, 6.348*f*
granuloma, 12.245
metastatic tumors of, 4.305–306, 4.306*f*, 4.307*f*, 4.308*f*
traction of, 6.334*f*
Posterior polymorphous corneal dystrophy (PPCD/PPMD/CHED1), 4.93–94, 4.94*f*, 8.135*t*, 8.136*t*, 8.158–160, 8.159*f*, 8.160*f*
glaucoma and, 8.159, 10.31
Posterior/posterior lateral choroidal artery, 5.18*f*, 5.19*f*
Posterior pupillary membrane, 11.29*f*
remnant of (Mittendorf dot), 11.29, 11.31, 11.32*f*
Posterior reversible encephalopathy syndrome (PRES), 5.333–335, 5.335*f*
Posterior scleritis, 2.465
B-scan ultrasonography for, 9.124
clinical presentation of, 9.123
optical coherence tomography of, 9.123*f*
spectral-domain optical coherence tomography of, 9.124–125
subtype of, 9.116*t*
vision loss risks, 9.128
Posterior segment
anterior segment surgery complications of, vitrectomy for, 12.388–396
assessment of, before refractive surgery, 13.44
B cells in, 9.57
Behçet disease manifestations of, 9.214–215, 9.215*f*, 12.230
blunt trauma to, 12.353
hereditary dystrophies of. *See* Hereditary dystrophies
inflammation of, 9.83. *See also* Posterior uveitis
laser effects on, 12.374
laser therapy for diseases of. *See* Photocoagulation
metastatic tumors of, 4.305–306, 4.306*f*, 4.307*f*, 4.308*f*
sarcoidosis involvement of, 9.196–197
sympathetic ophthalmia findings in, 9.200, 9.201*f*
syphilis findings in, 9.221*f*, 9.221–222
T cells in, 9.57
toxoplasmosis involvement of, 9.277
trauma to. *See* Trauma
in uveitis. *See* Posterior uveitis
Posterior sub-Tenon injection, of periocular corticosteroids, 9.95–96, 9.96*f*, 9.322
Posterior subcapsular cataract (PSC), 2.283, 4.120*f*, 4.120–121, 4.121*f*, 6.297, 11.46–48, 11.51*f*
characteristics and effects of, 11.47, 11.70*t*
corticosteroids causing, 11.51–52
ischemia causing, 11.68
in myotonic dystrophy, 11.62
race and, 11.6
silicone oil use and, 11.190
uveitis and, 11.64
vitrectomy and, 11.55, 11.190
Posterior subscapsular lens, opacity of, 3.67
Posterior synechiae, 2.380
in anterior uveitis, 9.77, 9.80*f*
in glaucoma
inflammation and, 10.138, 10.138*f*
pupillary block/angle closure and, 10.119
pupillary block/angle closure and, 10.119
in uveitis, lens changes/cataract and, 11.64
Posterior synechialysis, 9.131*f*
Posterior temporal artery, 5.16*f*, 5.19*f*
Posterior uveal bleeding syndrome (polypoidal choroidal vasculopathy/PCV), 4.166*f*, 4.166–168, 4.167*f*, 12.75
Posterior uveal melanoma, 4.106, 4.106*f*, 4.192*f*, 4.192–197, 4.193*f*, 4.194*f*, 4.195*f*, 4.196*f*, 4.253, 4.262–279. *See also* Choroidal melanoma/ciliary body melanoma
classification of, 4.194, 4.271–272, 4.272*t*
clinical characteristics of, 4.262–263, 4.264*f*
diagnosis of, 4.263*f*, 4.264*f*, 4.264–267, 4.266*f*, 4.267*f*
differential, 4.267–271, 4.269*f*, 4.270*f*
glaucoma caused by, 4.105*f*, 4.106, 4.194
metastatic, 4.196, 4.272–274, 4.273*t*, 4.306
prognosis/prognostic factors for, 4.194–197, 4.273*t*, 4.277–279
treatment of, 4.253, 4.274–277, 4.275*f*
Posterior uveitis. *See also* Choroiditis; Retinitis; Uveitis; *specific cause*
in acute posterior multifocal placoid pigment epitheliopathy, 9.169–174, 9.170–173*f*
in acute retinal pigment epitheliitis, 9.189*f*, 9.189–190

in acute zonal occult outer retinopathy, 9.162–164*t* 9.190–192, 9.192*f*
in autoimmune retinopathy, 9.192–193
in birdshot chorioretinopathy, 9.165–169, 9.166–168*f*
characteristics of, 9.70, 9.75
definition of, 6.317, 9.70, 9.153
differential diagnosis of, 6.312*t*
electroretinography findings in, 12.44
evaluation of, 9.72–74*t*
fluocinolone acetonide implant for, 9.97–98
fundus autofluorescence of, 9.89
glaucoma and, 10.139
idiopathic, 9.254
inflammation in, 6.320
in inflammatory chorioretinopathies of unknown etiology. *See* Inflammatory chorioretinopathies
intermediate uveitis, 12.231
laboratory tests for, 6.321*t*
in multifocal choroiditis and panuveitis syndrome, 9.179–181, 9.180*f*
in polyarteritis nodosa, 9.156–158, 9.157*f*
in punctate inner choroiditis, 9.181–184, 9.182–183*f*
signs of, 9.83
in subretinal fibrosis and uveitis syndrome, 9.184–185
in Susac syndrome, 9.160*f*, 9.160–161
symptoms of, 9.76, 9.77*t*
syphilitic, 9.224*f*
in systemic lupus erythematosus. *See* Systemic lupus erythematosus
toxocariasis as cause of, 6.317*f*, 6.317–318
toxoplasmosis as cause of, 6.317, 9.275
Posterior vitrectomy, 6.303
Posterior vitreoschisis, 12.332–333
Posterior vitreous detachment (PVD), 4.128–129, 4.129*f*, 6.347
age-related, 12.307–308
anatomy of, 12.331
atrophic holes presenting with, 12.318
cholesterolosis and, 12.348
conditions associated with, 12.307
definition of, 12.331
description of, 2.300, 2.301*f*
diagnosis of, 12.331
enzymes that induce, 2.304
epiretinal membranes. *See* Epiretinal membranes
examination of, 12.309
fibroglial tissue in, 12.331
floaters associated with, 12.308–309
idiopathic macular holes, 12.337–339, 12.338*f*
imaging of, 12.308*f*
indirect ophthalmoscopy of, 12.309, 12.331
management of, 12.309
myopia macular retinoschisis in, 12.209
nonproliferative diabetic retinopathy progression affected by, 12.102
optical coherence tomography of, 12.309, 12.332
in pars plana vitrectomy for diabetic macular edema, 12.115
pathologic conditions caused by, 12.332
photopsias associated with, 12.308
prevalence of, 12.331
retinal breaks associated with, 12.309
retinal detachment after cataract surgery and, 11.166
retinal tears caused by, 12.307, 12.308*f*, 12.309
risk factors for, 12.309
signs and symptoms of, 12.308
slit-lamp biomicroscopy of, 12.331
ultrasonographic findings in, 2.471*f*
vitrectomy for, 12.333*f*, 12.359
vitreomacular adhesions, 12.336, 12.336*t*
vitreomacular traction syndrome, 12.332, 12.332*f*, 12.336*t*, 12.336–337, 12.337*f*
vitreous hemorrhage associated with, 4.133, 12.309
Postexposure prophylaxis, 1.226, 1.268
Postganglionic fibers, 2.15
Postganglionic Horner syndrome, 5.258, 5.259, 5.260, 5.260*t*, 5.261, 5.262*f*
Postherpetic neuralgia (PHN), 1.261, 1.278, 5.280, 5.298, 8.226*t*, 8.227, 8.229, 8.230
Postherpetic neurotrophic keratopathy, 4.77*f*, 4.78
Postictal paresis (Todd paralysis), 1.207, 5.285
Postictal period, 1.207
Postoperative care of ophthalmic surgery patient
cataract surgery and
antimicrobial prophylaxis, 11.95
after ECCE, 11.198
after ICCE, 11.201
corneal imaging in, 13.23*f*, 13.23–24, 13.24*f*
DSEK and, 8.441, 8.441*f*, 8.442*f*
LASIK and, 13.94–95
penetrating and perforating trauma repair and, 8.409
penetrating keratoplasty and, 8.423–430
refractive/keratorefractive surgery and, 13.93–95, 13.193–201
surface ablation and, 13.93–94
immediate postablation measures and, 13.92–93
trabeculectomy and, 10.208–209
Postoperative endophthalmitis, 12.388–391, 12.390–391*f*. *See also* Uveitis, postoperative
bleb-associated, 10.163, 10.209, 10.209*t*, 10.210*f*
after cataract surgery, 4.119, 4.119*f*, 6.305, 11.127, 11.140, 11.160–163, 11.161*f*
prevention of, 11.93–95, 11.94*f*, 11.161–162
Propionibacterium acnes causing, 4.119, 4.119*f*, 11.140, 11.162
after penetrating keratoplasty, 8.424
prophylaxis for, cataract surgery and, 11.93–95, 11.94*f*, 11.161–162
Propionibacterium acnes causing, 4.119, 4.119*f*, 8.246, 11.140, 11.162
Postoperative nausea and vomiting, 1.289, 6.174
Postpartum period
neuro-ophthalmic disorders and, 5.333–335
reversible cerebral vasoconstriction syndrome and, 5.346
Postpartum thyroiditis, 1.46
Postprandial hypoglycemia, 1.300
Postpubescent children. *See* Children
Postsurgical consecutive esotropia, 6.95
Postsurgical esotropia, 6.102
Postsurgical exotropia, 6.104
Postsurgical necrotizing scleritis, 9.121, 9.121*f*
Posttest probability of disease, 1.19–20
Posttraumatic angle recession, 4.18, 4.19*f*, 4.103–104
glaucoma and, 4.18, 4.103–104, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*

Posttraumatic endophthalmitis, 12.362–363
Postural change, transient visual loss and, 5.161, 5.164, 5.170
Postviral neuroretinitis, 5.118
Postviral optic neuritis, 5.113
Postvitrectomy cataract, 11.55, 11.190
Potassium, in lens, 2.287, 11.21
Potassium balance, in lens, pump-leak theory of maintenance of, 11.21, 11.22*f*
Potassium hydroxide (KOH), ocular injury caused by, 8.376*t*
Potassium-sparing diuretics, 1.59*t*, 1.60
Potential acuity estimation/potential acuity meter (PAM) testing, 5.88–89
  in cataract surgery evaluation, 11.81–82
  in nonorganic disorder evaluation, 5.306
Potential energy, 3.106
Potential, visual evoked/visual evoked cortical/visual evoked response (VEP/VECP/VER), 5.95. *See also* Visual evoked potentials
  in low vision evaluation, 5.95
  in nonorganic disorder evaluation, 5.302
Povidone-iodine solution, 2.428
Power (optical). *See also* Transverse magnification
  contact lenses, 3.220–3.221*f*, 3.220–222
  corneal
    central, 3.243, 3.248
    in schematic eye, 3.127*t*
  definition of, 3.4, 3.8, 3.106, 3.112
  equation for, 3.8
  IOL, determination of, 11.84–87
    biometry in, 11.82–83, 11.83*f*, 11.84–85, 11.87
      hypotony affecting, 11.185
    contact lens method for, 13.195
    formulas for, 11.84, 11.85–87
      regression formulas, 11.85–87
    historical methods for, 11.86–87, 13.194
    improving outcomes of surgery and, 11.87
    incorrect, 11.85
    online post-refractive calculator for (ASCRS), 13.52, 13.195–197, 13.196*f*
    preventing errors in, 11.87
    after radial keratotomy, 13.51, 13.52–53, 13.193
    refraction and, 11.76
    refractive lens exchange and, 13.150
    refractive surgery and, 11.85–87, 11.176, 11.177*f*, 13.44, 13.193–197, 13.196*f*
    topographical method for, after refractive surgery, 13.193, 13.194
    triple procedure and, 11.175
    unexpected refractive results after surgery and, 11.86, 11.150
  lensmaker's equation for comparing, 3.52
  in phacoemulsification, 11.100
    delivery of, 11.99
      advances in, 11.100*f*, 11.100–101
  refractive. *See also* Refractive power; Transverse magnification
    of cornea, 8.25–26, 13.7–9
      measurement of, 8.26–27, 8.27*f*, 13.7–9. *See also* Keratometry/keratometer
  sample size and, 1.5
Power calculations, 1.26
  axial length, 3.243–248
  central corneal power, 3.243, 3.248
  in children, 3.254–255
  in corneal transplant eyes, 3.253–254
  double-*K* method, 3.252
  formulas
    biometric, 3.244–250
    errors in, 3.252
    for post-keratorefractive procedure eye, 3.252–253
    prediction, 3.243–244
    theoretical, 3.243
  geometric optics and, 3.243
  multifocal lenses, 3.258
  piggyback lenses, 3.251
  after refractive surgery, 3.251–253
  in silicone oil–filled eyes, 3.254
  sulcus placement adjustments, 3.250*t*
Power cross, 3.4, 3.16, 3.17*f*, 3.41, 3.77, 3.77–3.78*f*. *See also* Cylinder power
Power maps, 8.28–33, 8.29–33*f*, 13.14–19, 13.15*f*, 13.17*f*, 13.19*f*, 13.44–45, 13.45*f*. *See also* Cornea, topography of
  interpretation of, 8.28–31
  in keratoconus, 8.165, 8.165*f*, 8.167*f*
  in pellucid marginal degeneration, 8.31, 8.33*f*, 8.169, 8.170*f*
  postoperative, 13.23, 13.24*f*
Power per unit area, 3.107
Power prediction formulas, for IOLs, 11.84, 11.85–87
  regression formulas, 11.85–87
Power-versus-meridian graph (PVMG), 3.41, 3.79*f*, 3.79–80
Poxviruses (Poxviridae)/poxvirus infection, 8.236–238
PPA. *See* Peripapillary atrophy
PPC. *See* Posterior parietal cortex
PPCD. *See* Posterior polymorphous corneal dystrophy
PPD test. *See* Purified protein derivative (PPD) test
PPMD. *See* Posterior polymorphous corneal dystrophy
PPRF. *See* Paramedian pontine reticular formation
PPSV23. *See* Pneumococcal vaccination
PPV. *See* Positive predictive value
PR interval, 1.84*f*
PR segment, 1.84*f*
Prader-Willi syndrome, imprinting abnormalities as cause of, 2.180–181
Prager shell, 3.246*f*
Pralidoxime, 2.379
Pramipexole, for Parkinson disease, 1.205
Pravachol. *See* Pravastatin
Pravastatin, 1.75*t*
Prazosin, intraoperative floppy iris syndrome and, 11.74, 11.136–137, 11.137*t*
PRDM5 gene, 6.254
Pre-Descemet corneal dystrophy (PDCD), 8.135*t*, 8.136*t*, 8.155*f*, 8.155–156
Pre-Descemet (Dua's) layer, 4.73, 4.74*f*, 8.9
Pre-exposure prophylaxis, 1.268
Pre–plus disease, 6.326, 6.327*t*, 6.330*f*
Preadolescents. *See* Children
Prealbumin. *See* Transthyretin
Preauricular skin tags, in Goldenhar-Gorlin syndrome, 8.195

Precentral gyrus, 5.49
facial weakness/paralysis caused by lesion of, 5.277
Precorneal tear film. *See also* Tear film (tears)
components of, 2.247
description of, 2.49–50, 2.259
functions of, 2.247
layers of, 2.247, 2.248*f*
Precortical vitreous pocket, 12.7, 12.8*f*
Precursor RNA, 2.176
Pred Forte/Pred Mild. *See* Prednisolone
Pred-G. *See* Prednisolone acetate/gentamicin sulfate
Pred Mild. *See* Prednisolone acetate
Prediabetes, 1.34–35
Prednisol. *See* Prednisolone sodium phosphate
Prednisolone, 1.175*t*
for bacterial keratitis, 8.272
for corneal graft rejection prophylaxis, 8.430, 8.447, 8.448
for cystoid macular edema, after cataract surgery, 11.165
for stromal keratitis, 8.222, 8.223*t*
Prednisolone acetate, 2.356, 2.400*t*, 2.402*t*
Prednisolone acetate/gentamicin sulfate, 2.422*t*
Prednisolone acetate/sulfacetamide sodium, 2.422*t*
Prednisolone sodium phosphate, 2.400*t*
Prednisolone sodium phosphate/sulfacetamide sodium, 2.422*t*
Prednisone
for Behçet disease, 9.217
for giant cell arteritis/AAION, 5.121, 5.314
for herpetic retinitis, 12.238*t*
for hyphema, 8.395
for optic neuritis, 5.116
after penetrating and perforating trauma repair, 8.409
polymyalgia rheumatica treated with, 1.168
potency of, 1.175*t*
for scleritis, 8.324
for uveitis, 9.102–103
Preeclampsia, 1.67, 12.197*f*. *See also* Eclampsia
neuro-ophthalmic signs of, 5.333
Preferential hyperacuity perimetry (PHP), 12.69
Preferential looking (PL), for visual acuity assessment, 6.5, 6.8–9, 6.9*f*, 6.182, 6.300
Preferred Practice Pattern guidelines, 1.26
Preferred retinal loci (PRL), 3.310, 3.313, 3.314*f*, 3.317, 3.325
Pregabalin, for postherpetic neuralgia, 8.230
Preganglionic Horner syndrome, 5.257, 5.259, 5.260, 5.260*t*, 5.261*f*
Pregeniculate visual impairment, 6.186–187
in infantile nystagmus syndrome, 5.235–236
Pregnancy. *See also specific Congenital entries*
angiotensin-converting enzyme inhibitor contraindications in, 1.61
antihypertensive therapy in, 1.68
antiphospholipid syndrome in, 1.163
cerebral venous thrombosis and, 5.346
cocaine use during, 1.199
congenital toxoplasmosis in, 9.275–276, 9.281
diabetic retinopathy in
progression of, 12.93–94
proliferative, 12.94
fluorescein angiography in, 12.36
glaucoma medication use during, 10.185–186
gonococcal infection during, ophthalmia neonatorum and, 8.257*t*, 8.264
herpes simplex virus infection during, 8.213
hypercoagulability associated with, 1.148
hypertension in, 1.67–68
immunizations in, 1.224
maternally transmitted eye infection and. *See also specific type*
keratitis, 8.107, 8.308–309, 8.309*f*
ophthalmia neonatorum and, 8.257*t*, 8.263–265
neuro-ophthalmic disorders and, 5.333–335
pituitary tumors affected during, 5.147, 5.333
refractive surgery contraindicated during, 13.37
reversible cerebral vasoconstriction syndrome and, 5.346
rubella during, 8.240, 8.240*t*
statins contraindications in, 1.77
thyrotropin-releasing hormone levels in, 1.42
thyroxine levels in, 1.42
toxemia. *See* Eclampsia; Preeclampsia
Toxoplasma gondii exposure during, 12.243
Zika virus exposure during, 12.247
Preimplantation genetic diagnosis, 2.221, 2.239–240
Prelaminar nerve/prelaminar area of optic nerve, 10.42, 10.43, 10.45*f*, 10.45–46. *See also* Optic nerve head
Preliterate children, optotypes for visual acuity assessment in, 6.6*t*, 6.6–7, 6.7*f*
Preload, 1.99
Premacular bursa, 12.7, 12.8*f*
Premalignant epidermal lesions, 7.198–199, 7.199*f*
Premalignant eyelid lesions, epidermal (actinic keratosis), 4.210–212, 4.211*f*, 4.212*f*
Premature contractions, 1.101–102
atrial, 1.101
junctional, 1.101
ventricular, 1.101
Prematurity
ocular deviations and, 5.231
retinopathy of. *See* Retinopathy of prematurity
"Premium" IOLs, 11.120–121
contraindication for, capsular decentration and, 11.183
dry eye therapy before use of, 11.173
Premotor neurons, 5.33
Prenatal diagnosis (PND), 2.239
Prentice position
definition of, 3.41, 3.45
pictorial representation of, 3.46*f*
power of prism in, 3.49*f*
Prentice rule
bifocal lens design and, 3.184–190, 3.185–189*f*
contact lenses and, 3.206
definition of, 3.148, 3.184
Prenuclear (supranuclear/cortical) pathways, 5.32*f*, 5.32–34, 5.34*f*, 5.211. *See also specific system*
disorders of, 5.188, 5.188*t*, 5.211–231
diplopia and, 5.188, 5.188*t*
facial weakness/paralysis caused by, 5.276*f*, 5.277–278
gaze preference/palsy and, 5.228–230, 5.229*f*, 5.230*f*
ocular fixation system and, 5.212, 5.212*t*, 5.213–214

optokinetic system/nystagmus and, 5.212, 5.212*t*, 5.218–219
saccades/saccadic system and, 5.32–33, 5.38, 5.212, 5.212*t*, 5.219–223, 5.220*f*
smooth-pursuit system and, 5.32, 5.33, 5.34*f*, 5.212, 5.212*t*, 5.224–226, 5.225*f*
tonic deviations and, 5.230–231
vergence system and, 5.212, 5.212*t*, 5.226–228
vestibular-ocular system and, 5.38–39, 5.39*f*, 5.212, 5.212*t*, 5.214–218, 5.216*t*
Preoperative assessment/preparation for surgery, 1.281–283
cataract surgery, 11.74–76, 11.87–88
antimicrobial prophylaxis and, 11.93–94
in diabetes mellitus, 11.80–81
ECCE, 11.196
ICCE, 11.199
medical evaluation and, 11.170–171
ocular trauma and, 11.190–191
corneal transplantation, 8.418–419
penetrating and perforating trauma repair, 8.403
refractive/keratorefractive surgery, 13.35–48, 13.36*t*. *See also specific procedure*
corneal imaging/ancillary tests and, 13.14–26, 13.44–46, 13.45*f*, 13.79–80. *See also* Cornea, topography of; *specific type*
discussion of findings/informed consent and, 13.36*t*, 13.46–48, 13.47*t*
history and, 13.35–39, 13.36*t*
ocular examination and, 13.36*t*, 13.39–44, 13.42*f*, 13.43*f*
patient expectations/motivations and, 13.35–36, 13.36*t*, 13.47
patient preparation and, 13.81–82
patient selection and, 13.77–80, 13.78*t*
planning and laser programming and, 13.81
trabeculectomy, 10.198–199
Prepapillary vascular loops, 4.126, 12.341, 12.341*f*
Preperimetric glaucoma, 10.3
Pre–plus disease, 6.326, 6.327*t*, 6.330*f*
Prepubescent children. *See* Children
Preretinal macular fibrosis, 12.335
Preretinal tract, 12.7
PRES. *See* Posterior reversible encephalopathy syndrome
Presbyopia, 2.75, 11.23, 13.159–170
age/aging and, 11.23, 13.159
age at onset, 3.175
bifocal contact lenses for, 3.224–225
contact lenses for, 3.223–225. *See also* Contact lenses, bifocal
definition of, 3.124, 3.140, 3.148, 3.175
Goldberg theory of reciprocal zonular action and, 13.162
Helmholtz hypothesis (capsular theory) of accommodation and, 11.22, 13.159–160, 13.160*f*
monovision for, 3.224
with myopia, refractive lens exchange for, 13.148
perimetry results affected by, 10.60
premature, 3.176
progressive addition lenses for, 3.183
Schachar theory of accommodation and, 13.160–162, 13.161*f*
surgical correction of, 13.38–39, 13.159–170
accommodative, 13.162–164, 13.163*f*, 13.164*f*
conductive keratoplasty for, 13.128, 13.128*f*, 13.165
corneal inlays for, 13.59–71, 13.169
corneal intrastromal femtosecond laser treatment for, 13.168
custom/multifocal ablations for, 13.167, 13.168*f*
IOLs for
accommodating lenses, 13.8*t*, 13.154, 13.163–164, 13.164*f*
experimental lenses, 13.170, 13.170*f*
multifocal lenses, 13.165–167, 13.166*f*
keratophakia for, 13.59–62, 13.62*f*
monovision and, 13.39, 13.164–165
nonaccommodative, 13.164–169, 13.166*f*, 13.168*f*
refractive lens exchange for, 13.149
scleral surgery for, 13.162–163, 13.163*f*
theories of accommodation and, 13.159–162, 13.160*f*, 13.161*f*
Preschool-aged children. *See* Children
Preseptal cellulitis, 4.204, 4.204*f*, 6.170, 6.212–214, 7.43–46, 7.44*t*
Haemophilus causing, 8.256
Preseptal palpebral muscles, 5.52
Preservatives, 2.351
in ocular medications
allergic/adverse reactions to, 10.184
preservative-free formulations and, 8.62, 8.63, 8.80, 8.90, 8.90*t*, 8.91, 10.170–175, 10.175*t*
artificial tears/demulcents, 8.62, 8.63
contact dermatoblepharitis and, 8.286
persistent corneal defects/toxic keratoconjunctivitis/keratopathy caused by, 8.80, 8.90, 8.90*t*, 8.91
Press-on prisms
for diplopia, 6.96
induced anisophoria correction using, 3.188
Pressure-induced stromal keratopathy (PISK), after LASIK, 13.119, 13.120*f*
Pressure-insensitive (uveoscleral) outflow, 10.5*f*, 10.13, 10.19
Presumed ocular histoplasmosis syndrome (POHS). *See* Ocular histoplasmosis syndrome
Pretarsal palpebral muscles, 5.52
Pretectal nuclei. *See* Pretectum/pretectal nuclei
Pretectal (Parinaud/dorsal midbrain) syndrome, 5.37, 5.229, 5.230*f*
in children, 5.231
convergence-retraction nystagmus in, 5.229, 5.250
eyelid retraction in, 5.229, 5.250, 5.274, 5.275*t*
light-near dissociation in, 5.229, 5.230*f*, 5.266*t*, 5.266–267
multiple sclerosis and, 5.319
Pretectum/pretectal nuclei, 5.54, 5.55*f*
convergence insufficiency caused by damage to, 5.227
vertical gaze palsy caused by damage to, 5.229
Pretest probability of disease, 1.18–21, 1.20*t*
Prethreshold disease (retinopathy of prematurity), 6.326, 12.178*t*, 12.179, 12.185
Pretibial myxedema, 7.58
Pretrichial brow- and forehead-lift, 7.265*f*, 7.265–266
Preussner formula, for IOL power determination/selection, 11.85

Preventive medicine
immunizations. *See* Immunizations
screenings. *See* Screening
Preverbal children
fixation assessments in, 6.300
visual acuity assessment methods in, 6.8–9, 6.154
Primary aberrant regeneration, 5.198
Primary acquired melanosis (PAM), 4.63*t*, 4.65, 4.66–68, 4.67*f*, 8.327, 8.338*t*, 8.339*t*, 8.342*f*, 8.342–343
melanoma and, 4.66–68, 4.67*f*, 4.68, 4.68*f*, 8.327, 8.342, 8.343
Primary angle closure (PAC), 10.4*t*, 10.117, 10.117*t*, 10.118, 10.120–122. *See also* Angle closure; Primary angle-closure glaucoma
acute, 10.123–125, 10.124*f*
management of, 10.184
chronic, 10.4*t*, 10.126–127
pupillary block causing, 10.118–119
Primary angle-closure glaucoma (PACG), 10.4*t*, 10.117, 10.117*t*, 10.118, 10.120–122. *See also* Angle-closure glaucoma
acute, 10.123–125, 10.124*f*
management of, 10.184
epidemiology of, 10.9–10
prevalence of, 10.9, 10.117
with pupillary block, 10.119
iridotomy/iridectomy for, 10.124, 10.125, 10.191–193, 10.192*f*
risk factors for, 10.9, 10.120–122
subacute/intermittent, 10.125–126
without pupillary block (plateau iris), 10.4*t*, 10.9, 10.120, 10.127*f*, 10.127–128
Primary angle-closure suspect (PACS), 10.4*t*, 10.117, 10.117*t*, 10.122–123
Primary anophthalmia, 7.35
Primary aphakia, 4.117, 11.30. *See also* Aphakia
Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma (PCNSL/PIOL), 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349, 9.303, 9.304*f*
in HIV infection/AIDS, 5.349
Primary coloboma, 11.30–31. *See also* Coloboma
Primary congenital glaucoma (PCG), 4.98, 4.99*f*, 8.95, 8.108–109, 10.4*t*, 10.147, 10.148*t*, 10.151*f*, 10.151–153, 10.152*f*, 10.152*t*. *See also* Glaucoma, pediatric
anterior segment findings in, 6.282, 6.282*f*
axial length in, 6.283
central corneal thickness in, 6.281
clinical manifestations of, 6.279–280, 6.280*f*
cornea affected in, 8.108–109
corneal edema in, 6.279–280, 8.108–109
corneal findings in, 6.280*f*, 6.280–281
corneal opacities and, 6.257*t*, 6.260, 6.261*f*, 8.108–109
definition of, 6.278
diagnostic examination for, 6.280–283, 6.282–283*f*
differential diagnosis of, 6.281*t*, 10.151–152, 10.152*t*
genetics of, 6.277–278, 10.11*t*, 10.150
gonioscopy for, 6.282, 6.282*f*
goniotomy for, 6.285, 6.286*f*
incidence of, 6.278
megalocornea and, 8.95, 8.96*t*, 8.99–100, 8.108
natural history of, 6.283–284
optic nerve findings in, 6.282–283, 6.283*f*
optic nerve/fundus evaluation in, 10.160
optical coherence tomography of, 6.283
pathophysiology of, 6.278
surgical treatment of, 6.285–287, 6.286*f*
tonometry in, 6.281–282
trabeculotomy, 6.286*f*, 6.286–287
treatment of, 10.153
medical, 10.153
surgical, 10.153, 10.160–164, 10.161*f*, 10.162*f*, 10.187
Primary conjunctival melanosis (complexion-associated/hypermelanosis), 4.63*t*, 4.65, 4.66, 4.66*f*. *See also* Complexion-associated melanosis
Primary deviation
definition of, 6.38
secondary deviation *versus*, 6.115
Primary divergence insufficiency, 6.94
Primary endothelial failure
after endothelial keratoplasty (DMEK/DSEK), 8.447
after penetrating keratoplasty, 8.423, 8.423*f*
Primary glaucoma. *See* Glaucoma; Primary angle-closure glaucoma; Primary congenital glaucoma
Primary hypercoagulable states, 1.146–148
Primary hypothyroidism, 1.45
Primary immune response, 9.37–38
Primary intracranial pinealoblastoma, retinoblastoma and, 4.298, 4.302
Primary intraocular/central nervous system lymphoma (PIOL/PCNSL), 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
Primary lens fibers, development of, 11.26–27, 11.27*f*
Primary lipid keratopathy, 8.126
Primary megalocornea, 6.253–254
Primary open-angle glaucoma. *See* Open-angle glaucoma, primary
Primary orbital meningiomas, 7.85
Primary position hypotropia, with Brown syndrome, 6.137
Primary position of gaze, 6.31, 6.64
Primary posterior capsulectomy, 6.303
Primary syphilis, 9.221
Primary telecanthus, 6.203
Primary visual (striate/occipital) cortex, 2.119, 2.119*f*, 2.122*t*, 5.24*f*, 5.29*f*, 5.29–30, 5.30*f*, 5.32*f*. *See also* Visual (calcarine/occipital/striate) cortex
abnormal visual experience effects on, 6.53
disorders of, 5.158, 5.178*t*, 5.178–181
illusions and, 5.175
Primary vitreoretinal lymphoma, 12.233–234. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
age at onset, 9.303
clinical features and findings of, 9.304–305, 9.304–305*f*
diagnostic testing for, 9.305–306
fluorescein angiography findings in, 9.305
histology of, 9.306, 9.307*f*
incidence of, 9.303
Primary vitreous, 2.157, 2.159*f*, 2.297, 4.125
persistent hyperplasia of (PHPV). *See* Persistent fetal vasculature
Primed macrophages, 9.14, 9.15*f*

Primers, 2.186
in polymerase chain reaction, 4.37, 4.40*f*
Primitive neuroectodermal tumor (PNET), 6.357–358
retinoblastoma associated with, 4.298, 4.302, 4.302*t*
Prince rule, 3.179, 3.179*f*
Principal axes, of astigmatism, 3.138–139
Principal line of vision, 3.128
Principal meridians
definition of, 3.4, 3.16
in irregular astigmatism, 3.139
refractive powers of, 3.16
Principal planes
definition of, 3.41
description of, 3.56–57, 3.57*f*
distant objects and, 3.59
Principal points, 3.41, 3.56–57
Prinzmetal angina, 1.83
Prion-associated neurologic disorders, 1.211
Prions/prion diseases, 5.357, 8.254
Prism(s). *See also* Base-down prism; Base-out prisms; Base-up prism
angle of deviation in, 3.45, 3.46*f*
apex of, 3.46
base-down, 3.188
base-in, 3.211
base of, 3.46
base-out, 3.211
convergence insufficiency and, 6.103
convergence paralysis and, 6.106
dissociated vertical deviation and, 6.129
nystagmus treated with, 6.155
base-up, 3.188
convergence insufficiency treated with, 6.103
convergence paralysis treated with, 6.106
diplopia treated with, 6.72
in fourth nerve (trochlear) palsy evaluation, 5.198
Fresnel
advantages of, 3.197
description of, 3.49, 3.49*f*
induced anisophoria correction using, 3.188
Press-On, 3.49
in fusional convergence evaluation, 5.226
horizontal heterophoria correction using, 3.196–197
image position affected by, 3.48*f*
intermittent exotropia treated with, 6.102
for myasthenia gravis, 5.326
in nonorganic disorder evaluation, 5.302–303, 5.303*f*
for nystagmus, 5.236, 6.155
in ocular misalignment evaluation, 5.184
orientation of, 3.46
positioning of, 3.45, 3.46*f*
press-on, 3.188
in relative cyclotropia evaluation, 5.185
slab-off
definition of, 3.148
induced anisophoria correction using, 3.188, 3.188*f*
spectacle lens incorporation of, 3.197, 3.285
therapeutic use of, 3.196–197
uses of, 3.45
vertical heterophoria correction using, 3.197
visual acuity assessment in children using, 6.6
Prism Adaptation Study, 6.93
Prism adaptation test, 6.82
Prism alternate cover test (PACT), 6.65–66, 6.66*f*
in fourth nerve (trochlear) palsy, 5.198
in ocular misalignment, 5.184
Prism and cover test
exodeviation evaluations, 6.100
simultaneous, 6.66–67
Prism diopter
definition of, 3.41, 3.46, 3.47*f*
pictorial representation of, 3.47*f*
Prism dissociation
for binocular balance, 3.168, 3.168*f*
for nonorganic disorder evaluation, 5.303, 5.303*f*
Prism power. *See also* Transverse magnification
definition of, 3.45
nonadditive nature of, 3.46, 3.47*f*
in Prentice position, 3.49*f*
Snell's law used to calculate, 3.48
Prisms (wavefront aberrations), 13.11
PRK. *See* Photorefractive keratectomy
PRL. *See* Preferred retinal loci
PRNG. *See* Penicillin-resistant *Neisseria gonorrhoeae*
Probe amplification, multiplex ligation-dependent (MLPA), 4.39*t*
Probenecid, 2.236
Probes, DNA. *See* DNA probes
Probing
for congenital nasolacrimal duct obstruction, 6.232–234, 6.233*f*, 7.289, 7.291*f*, 7.291–292, 7.298, 7.300
lacrimal system, for meibomian gland dysfunction, 8.68
Procainamide, 12.300
Procaine penicillin
description of, 2.438*t*
for syphilis, 1.253
Procerus muscle, 2.31*f*
Process quality, 1.25
Prodrugs, 2.363
Profilin, 1.167
Programmed death 1 (PD-1), 7.206, 7.211
Programmed death ligand-1 (PD-L1), in external eye defense, 8.12–13*f*
Progressive addition lenses (PALs)
candidates for, 3.183
description of, 3.182–184, 3.183*f*
fitting of, 3.183
hard-design, 3.182, 3.183*f*
prescription for, 3.198
soft-design, 3.182, 3.183*f*
Progressive (chronic progressive) external ophthalmoplegia (CPEO)
description of, 5.328–329, 5.329*f*
ptosis in, 5.273, 5.273*t*, 5.328, 5.329*f*
Progressive facial hemiatrophy (Parry-Romberg syndrome), 8.192*t*
Progressive flattening effect, after radial keratotomy, 13.51
Progressive multifocal leukoencephalopathy (PML), 5.351*f*, 5.351–352
natalizumab causing, 5.318, 5.351
Progressive multiple sclerosis, 5.315
Progressive outer retinal necrosis (PORN), 9.250–254, 9.253*f*, 9.330, 12.236–237, 12.237*f*

Progressive supranuclear palsy (PSP)
convergence insufficiency in, 5.227
facial weakness/paralysis in, 5.278
pursuit dysfunction in, 5.226
saccadic dysfunction in, 5.214, 5.221
Progressive systemic sclerosis. *See* Systemic sclerosis
Projection artifact, 12.29, 12.30*f*
Prokaryotes. *See* Bacteria
Prolactinomas, 1.47, 1.50
Prolate, 3.267
Prolate cornea, 2.48, 3.268, 8.25, 13.9, 13.14, 13.26
Q value and, 13.14
Prolensa. *See* Bromfenac
Proliferative diabetic retinopathy (PDR), 2.301. *See also* Diabetic retinopathy
anti-VEGF therapy for, 12.103–104, 12.386
complications of, 12.103–108
definition of, 12.91–92
description of, 12.91–92
extraretinal fibrovascular proliferation associated with, 12.102
high-risk characteristics of, 12.103
ischemic heart disease and, 1.105
laser surgery for, 12.104–107
management of, 12.103–108
neovascular proliferation associated with, 12.102
neovascularization in, 12.151
nonproliferative diabetic retinopathy progression to, 12.101
nonsurgical management of, 12.103–104
optical coherence tomography angiography of, 12.94*f*
panretinal photocoagulation for, 12.104, 12.106, 12.106*f*
photocoagulation for, 12.94
in pregnancy, 12.94
proangiogenic factors in, 12.102
proliferative sickle cell retinopathy *versus*, 12.151
ranibizumab for, 12.104
scatter photocoagulation for, 12.116
severe carotid artery occlusive disease associated with, 12.98
severity of, 12.95*t*
stages of, 12.102
steroids for, 12.103–104
surgical management of, 12.104–107
tractional retinal detachment caused by, 12.103, 12.108, 12.387–388
treatment of, 2.414
ultrasonographic findings in, 2.471*f*
vitreous hemorrhage caused by, 12.103, 12.103*f*, 12.107–108, 12.386–387
Proliferative sickle cell retinopathy (PSR). *See* Sickle cell retinopathy
Proliferative vitreoretinopathy (PVR), 2.332–333, 4.20, 4.21*f*, 4.131, 4.131*f*, 9.56, 9.324, 12.320, 12.323*f*, 12.323–324
Prone-position test, for primary angle-closure suspect, 10.122
Proparacaine, 2.439*t*, 2.441
for cataract surgery, 11.92
Prophase, 2.174, 2.174*f*
Propine. *See* Dipivefrin
Propionibacterium/Propionibacterium acnes, 8.244*t*, 8.246, 8.246*f*, 12.390
chronic postoperative endophthalmitis caused by, 9.292, 9.292*f*
endophthalmitis/postoperative endophthalmitis caused by, 4.119, 4.119*f*, 8.246, 11.140, 11.162
as normal flora, 8.206*t*, 8.246
ocular infection caused by, 8.246
Propofol, 1.290
Propranolol, for hemangioma, 6.220, 6.221*f*
Proprotein convertase subtilisin kexin 9, 1.77
Proptosis (exophthalmos/exorbitism), 4.223, 5.271, 6.203, 7.23, 7.112
in aspergillosis, 5.353, 5.354*f*
computed tomography of, 7.30*f*
in craniosynostosis, 6.207
definition of, 7.23–24
distensible venous malformations as cause of, 7.75*f*
exposure keratopathy/lagophthalmos and, 8.80
magnetic resonance imaging of, 7.30*f*
nonspecific orbital inflammation as cause of, 6.215
in orbital leukemia, 4.316
in orbital lymphatic malformations, 4.233
in orbital lymphoproliferative lesions, 4.232
in pleomorphic adenoma, 4.230*f*
pulsatile, 7.83
in retinoblastoma, 4.294, 4.294*f*
in rhabdomyosarcoma, 4.236, 4.237*f*
in thyroid eye disease, 4.226, 4.227*f*, 5.131. *See also* Thyroid eye disease
in uveal lymphoid proliferation/infiltration, 4.314
Propylthiouracil, for thyroid secretion suppression, 1.44
PROSE treatment
for graft-vs-host disease, 8.304
for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298
Prosopagnosia, 5.179
Prospective Evaluation of Radial Keratotomy (PERK) study, 13.50
Prostaglandin (PG) analogues, 2.269, 2.393–394, 2.394*t*, 6.289*t*, 6.290, 10.170–176, 10.171*t*, 10.175*f*
adnexal changes associated with, 10.30, 10.165–166
in children, 10.165–166
for glaucoma
cystoid macular edema after cataract surgery and, 11.164, 11.187
inflammatory glaucoma and, 10.100
during pregnancy/lactation, 10.185
for uveitic glaucoma, 9.319
Prostaglandin-associated periorbitopathy, 10.176
Prostaglandin-endoperoxide synthase, 2.408
Prostaglandin F2α receptor gene *(PTGFR),* 2.368
Prostaglandin G/H synthase. *See* Cyclooxygenase
Prostaglandins (PGs)
cystoid macular edema after cataract surgery and, 11.164, 11.187
D_2, connective tissue mast cell synthesis of, 9.3
$F_{2\alpha}$ ($PGF_{2\alpha}$), 2.393
$G_{2\alpha}$, 2.410
in uveitic macular edema, 9.19
Prostamides. *See* Bimatoprost; Prostaglandin (PG) analogues

Prostate cancer
choroidal metastases and, 4.304*t*
digital rectal examination for, 1.221
eye/orbital metastases and, 4.304*t*
metastatic, 7.105*f*, 7.107
screening for, 1.216*t*, 1.221
Prostate-specific antigen (PSA), 1.221
Prostheses, ocular, 7.140–141, 7.147*f*
for graft-vs-host disease, 8.304
for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298
Prostigmin. *See* Neostigmine
Prostigmine, 2.362
Protan red-green color deficiency, 12.54
Protanomalous dichromatism, 12.250*t*
Protanomalous trichromatism, 12.250*t*
Proteases, microbial, in ocular infections, 8.207
Protein(s)
in aqueous humor, 2.275–276
cytoskeletal, 2.285
disorders of metabolism of
corneal changes in, 8.181*f*, 8.181–190, 8.182*t*, 8.183*t*, 8.184*f*, 8.185*f*, 8.186*t*, 8.187*f*, 8.188*f*, 8.189*f*
corneal crystal deposition and, 8.182*t*
lens. *See* Lens proteins
in lens, 2.284–286
membrane, 2.285
in retinal pigment epithelium, 2.323–324
in tear film, 2.252
in vitreous, 2.298
Protein C
deficiency of, 1.147, 12.134
description of, 1.139
Protein S
deficiency of, 1.147, 12.134
description of, 1.139
Proteinase inhibitors, in aqueous humor, 2.276
Proteinases, in aqueous humor, 2.276
Proteinuria, 1.56
Proteoglycans
corneal, 2.53, 8.9
Proteus, 8.247
conjunctivitis caused by, 8.257*t*
description of, 2.419
Prothrombin G20210A gene mutation, 1.147
Prothrombin time (PT), 1.139
Proto-oncogenes
description of, 2.183
Neu, in immunohistochemistry, 4.35
Proton density (PD)
description of, 7.28
magnetic resonance imaging, 5.62, 5.63*f*, 5.63*t*, 5.64*f*, 5.75
Protozoa/protozoal infection. *See also specific causative organism*
ocular, 4.147–148, 4.148*f*, 8.252
Acanthamoeba keratitis, 8.208*t*, 8.252, 8.276–279, 8.277*f*, 8.278*f*
corneal opacity and, 8.16*f*
retinitis, 4.147–148, 4.148*f*
Protozoal uveitis
cysticercosis, 9.285–286, 9.285–286*f*
diffuse unilateral subacute neuroretinitis, 9.287–288*f*, 9.287–289
ocular toxoplasmosis. *See* Toxoplasmosis, ocular
onchocerciasis, 9.289*f*, 9.289–290
toxocariasis, 9.283–284, 9.283–285*f*, 9.284*t*
Protractors, eyelid, spasm of (benign essential blepharospasm/BEB). *See* Blepharospasm
Provera. *See* Medroxyprogesterone
Proximal (instrument) convergence, 6.39
Proximal illumination, for slit-lamp biomicroscopy, 8.18–19
PRP. *See* Panretinal photocoagulation
PRP gene, 5.357
PrP^{C}, 5.357
PrP^{CJD}, 5.357
PRPH2 (*RDS*/peripherin) gene
description of, 12.272, 12.273*f*
mutation
in pattern dystrophies, 4.170
in Stargardt disease, 4.168
PrP^{SC}, 5.357
PRRs. *See* Pattern recognition receptors
PRSS56 gene, 6.263
Prussian blue stain, Perls, 4.31*t*
PSA. *See* Prostate-specific antigen
Psammoma bodies, in optic nerve meningioma, 4.250
PSC. *See* Posterior subcapsular cataract
PSD. *See* Pattern Standard Deviation
Pseudo (double) anterior chamber, after lamellar keratoplasty, 8.435
Pseudo-eyelid retraction, 5.274, 5.275*t*
Pseudo-Foster Kennedy syndrome, 5.122
Pseudo-Hurler polydystrophy (ML III), 6.388*t*, 8.178
Pseudo-internuclear ophthalmoplegia, myasthenic, 5.190, 5.324
Pseudo-POHS. *See* Pseudo–presumed ocular histoplasmosis syndrome
Pseudo–presumed ocular histoplasmosis syndrome (pseudo-POHS), 12.225. *See also* Multifocal choroiditis
Pseudo-Roth spots, in leukemia, 4.315
Pseudo-spasmus nutans, 5.130
Pseudoaccommodating intraocular lenses, 11.122
complications of, 11.151
Pseudoadenomatous hyperplasia (Fuchs adenoma), 4.179, 4.279
Pseudocholinesterase, 2.234, 2.379
Pseudocolobomas, 6.211
Pseudocrystalline/crystalline keratopathy, infectious, 4.79–80, 4.80*f*
after penetrating keratoplasty, 4.79
Pseudodendrites
in *Acanthamoeba* keratitis, 8.277
herpes zoster, 8.227–228
in tyrosinemia, 8.183, 8.184*f*
Pseudodominance, 2.206
Pseudodrusen
characteristics of, 12.200, 12.200*f*
imaging of, 12.200
in pseudoxanthoma elasticum, 12.198

reticular (RPD/subretinal drusenoid deposits), 4.162, 4.163, 4.163*f*, 4.171*f*, 12.65*f*, 12.65–66
scanning laser ophthalmoscopy of, 12.24
Pseudoepiphora, 7.296
Pseudoepitheliomatous hyperplasia, 7.188, 8.332*t*
Pseudoesotropia, 6.85–87, 6.86*f*, 6.99
Pseudoexfoliation/exfoliation syndrome (PXE), 4.101–103, 4.102*f*, 4.124, 10.11*t*, 10.31, 10.91*f*, 10.91–93, 10.92*f*, 10.130, 10.131*f*, 11.65*f*, 11.65–66
cataract surgery in patient with, 11.79, 11.184
glaucoma and (pseudoexfoliation glaucoma), 4.101–103, 4.102*f*, 10.11*t*, 10.31, 10.91, 10.93, 10.130, 10.131*f*
IOL decentration/dislocation and, 11.144
postoperative hyphema and, 11.158
single-nucleotide polymorphisms in, 2.195*f*
zonular incompetence and, 10.92, 10.93, 10.130, 10.131*f*, 11.65–66, 11.181, 11.182*f*, 11.184
Pseudoexotropia
description of, 6.99
in retinopathy of prematurity, 6.334, 6.335*f*
Pseudogliomas, 4.172
Pseudoguttae, inflammatory, 8.52
Pseudohermaphrodites, 2.225
Pseudohorn cysts, 4.209, 4.209*f*
Pseudohyphae, 8.249
Pseudohypopyon, 6.342
in leukemia, 4.315
in retinoblastoma, 4.292, 4.293*f*
Pseudo–internuclear ophthalmoplegia, myasthenic, 5.190, 5.324
Pseudoisochromatic plates
for color vision testing, 12.54, 12.55*f*
in low vision evaluation, 5.78
Pseudolymphoma. *See* Lymphoid hyperplasia
Pseudomembrane, conjunctival, 8.46*t*, 8.47*t*
in epidemic keratoconjunctivitis, 8.234
in ligneous conjunctivitis, 8.294
Pseudomembranous colitis, 1.273, 2.426
Pseudomembranous conjunctivitis, 6.251
Pseudomonas corneal ulcer, 3.231*f*
Pseudomonas/Pseudomonas aeruginosa, 1.251–252, 2.420, 2.422, 8.208*t*, 8.244*t*, 8.247, 8.247*f*, 8.257*t*
ocular infection/conjunctivitis/keratitis caused by, 8.208*t*, 8.247, 8.257*t*, 8.267, 8.268*f*
Pseudoneutralization, 3.159–160
Pseudopapilledema, 5.107–109, 5.108*f*, 6.372–373*f*, 374
drusen and, 4.247, 5.107, 5.108*f*, 5.141*f*, 5.142–143
Pseudopemphigoid (drug-induced pemphigoid), 8.91, 8.92, 8.299
Pseudophakia
retinal detachment risks associated with, 12.319
surgically induced
accommodating IOLs for, 13.163–164, 13.164*f*
cataract surgery and, 11.166–167
Pseudophakic (aphakic) bullous keratopathy (PBK)
after cataract surgery, 4.83–84, 4.84*f*, 11.129, 11.129*f*
IOL design and, 11.149
chronic anterior uveitis in, 9.138*f*
DMET for, 8.449
Pseudophakic cystoid macular edema
definition of, 12.157
imaging of, 12.394*f*
optical coherence tomography of, 12.158*f*
pars plana vitrectomy for, 12.394*f*
Pseudophakic glaucoma, 10.130–132
Pseudophakic refractive procedures, 13.8*t*
Pseudophakodonesis
anterior capsule contraction and, 11.154
IOL dislocation and, 11.145
Pseudoplasticity, of ophthalmic viscosurgical device, 11.96
Pseudopolycoria, 6.268, 6.268*f*
Pseudoproptosis, 6.217, 6.283, 7.24–25
Pseudopterygium, 8.113, 8.124–125, 8.125*f*
Pseudoptosis
description of, 5.270*f*, 5.274, 7.248–249, 7.249*f*
in hypotropia, 6.30
Pseudorosettes, in retinoblastoma, 4.173, 4.173*f*
Pseudostrabismus, 7.177
Pseudosuction, in flap creation, 13.86
Pseudotumor
benign lymphoid (pseudolymphoma). *See* Lymphoid hyperplasia
orbital. *See* Nonspecific orbital inflammation
Pseudotumor cerebri (PTC/idiopathic intracranial hypertension/IIH), 2.391, 5.110–113, 5.111*t*
in children, 5.113
headache and, 5.110, 5.112, 5.113, 5.288
Pseudoxanthoma elasticum (PXE), 1.140
angioid streaks and, 12.87, 12.89*f*
Bruch membrane calcification in, 12.19
optical coherence tomographic angiography of, 12.199*f*
pseudodrusen in, 12.198
PSF. *See* Point spread function
Psoriatic arthritis, 1.156–157
acute anterior uveitis in, 9.133
clinical presentation of, 9.133, 9.134*f*
laboratory tests for, 9.125*t*
PSP. *See* Progressive supranuclear palsy
PSR. *See* Sickle cell retinopathy
Psychiatric disorders. *See* Behavioral/psychiatric disorders; Nonorganic (functional/nonphysiologic) ophthalmic disorders
Psychological counseling, 3.327
Psychophysical testing. *See also specific test*
color vision, 12.54–56, 12.55*f*
contrast sensitivity, 12.56–57, 12.57*f*
dark adaptometry, 12.57–58
tests used in, 12.53–54
Psychotherapy, 1.198
Psychotic disorder. *See* Schizophrenia
Psychotropic drugs, tear production affected by, 8.62*t*
PT. *See* Prothrombin time
PTC. *See* Pseudotumor cerebri
Pterygium, 4.57, 4.57*f*, 4.57–58, 8.111, 8.112–113, 8.113*f*, 8.351, 8.352, 8.352*f*
conjunctival transplantation for, 8.351
excision of, 8.351, 8.352–356, 8.353*t*, 8.354*f*
bacterial scleritis after, 8.282, 8.283*f*
recurrent, 8.351, 8.352, 8.353, 8.353*t*, 8.355
Pterygoid process, of sphenoid bone, 5.5
Pterygoid venous plexus, 2.26*f*, 5.21*f*, 5.22
Pterygomaxillary area, 5.11, 5.56
Pterygopalatine area, 5.11

Pterygopalatine fossa, 2.12, 2.132, 5.12, 7.8, 7.8*f*, 7.10
Pterygopalatine ganglion/nerves, 2.12, 5.11, 5.49
PTGFR. *See* Prostaglandin F2α receptor gene
PTK. *See* Phototherapeutic keratectomy
Ptosis (blepharoptosis), 5.269, 5.269*f*, 5.270*f*, 5.272*f*, 5.272–274, 5.273*t*. *See also* Brow ptosis
acquired, 5.273*t*, 5.273–274
anophthalmic, 7.145, 7.145*f*
aponeurotic, 5.273, 5.273*t*, 7.245, 7.245*f*, 7.245*t*
apparent (pseudoptosis), 5.270*f*, 5.274
apraxia of eyelid opening and, 5.273*t*, 5.274
cerebral, 5.273
in chronic progressive external ophthalmoplegia, 5.273, 5.273*t*, 5.328, 5.329*f*
classification of, 6.197*t*, 7.240, 7.244–252
congenital, 5.269*f*, 5.272*f*, 5.272–273, 6.196–198, 6.197*t*, 6.198*f*
congenital myogenic, 7.244, 7.244*f*, 7.245*t*
definition of, 7.240
in downgaze, 7.243
evaluation of, 5.269*f*, 5.269–271, 5.270*f*, 6.197
ancillary testing, 7.243–244
assessments, 7.242–243
eyelid measurements, 7.241–242, 7.241–242*f*
visual field testing in, 7.243
in Horner syndrome, 5.257, 5.259*f*, 5.272, 5.273*t*
Marcus Gunn jaw-winking, 5.272, 5.272*f*, 7.243, 7.246, 7.247*f*
mechanical, 5.273*t*, 5.274, 7.248, 7.248*f*
in myasthenia gravis, 5.206, 5.270*f*, 5.271, 5.273, 5.273*t*, 5.324
myogenic, 5.273*t*, 7.240, 7.244*f*, 7.244–245
in myotonic dystrophy, 5.273, 5.273*t*, 5.329, 5.330
neurogenic, 5.273, 5.273*t*
acquired, 7.246–248
congenital, 5.272–273, 7.246
myasthenia gravis as cause of, 7.247–248
temporary, 7.247
neuromuscular junction causes of, 5.206, 5.273*t*
nonorganic, 5.310–311
in oculopharyngeal dystrophy, 5.273, 5.273*t*, 5.329
pseudoptosis, 7.248–249, 7.249*f*
reverse, 7.246
"senile," 5.273
steroid-induced, 5.273, 5.273*t*
surgical repair of. *See also specific procedure*
allogenic slings, 7.252
autogenous tensor fascia lata, 7.252
complications of, 7.252
considerations before, 7.249
external levator advancement surgery, 7.249–250, 7.250*f*
Fasanella-Servat procedure, 7.250
frontalis suspension surgery, 7.250, 7.251*f*
internal (transconjunctival) approach, 7.250, 7.251*f*
Müller muscle–conjunctival resection, 7.250
third nerve (oculomotor) palsy causing, 5.272, 5.273*t*
traumatic, 5.273*t*, 5.274, 7.248
PTSD. *See* Post-traumatic stress disorder
Pubic louse *(Phthirus pubis)*, 8.253, 8.254*f*
ocular infection caused by, 8.208*t*, 8.253, 8.255
PubMed, 1.3–4
PUFAs. *See* Polyunsaturated fatty acids
PUK. *See* Peripheral keratitis, ulcerative
Pulfrich phenomenon, 5.175
Pulled-in-two syndrome (PITS), 6.169–170
Pulley system
abnormalities of, 6.107
of extraocular muscles, 6.28, 6.32
Pulmonary diseases. *See also* Lung diseases
asthma, 1.123–124, 1.128–130, 1.129*f*
evaluation of, 1.125–126
obstructive, 1.123–125
chronic obstructive pulmonary disease, 1.124
description of, 1.123
irreversible, 1.124
reversible, 1.123–124
perioperative management for ocular surgery in patients with, 1.284
restrictive, 1.125
symptoms of, 1.124
treatment of
algorithm for, 1.129*f*
anticholinergics, 1.128
β_2-adrenergic agonists, 1.128
bronchodilators, 1.128
corticosteroids, 1.128
inflammation inhibitors, 1.128
leukotriene inhibitors, 1.128
noninvasive pressure support ventilation, 1.126–127
nonpharmacologic, 1.126–127
pharmacologic, 1.127–130
tuberculosis. *See* Tuberculosis
Pulmonary embolism, in activated protein C resistance, 1.147
Pulmonary function tests, 1.126
Pulmonary hypertension
oxygen supplementation in, 1.126
sildenafil for, 1.130
in systemic sclerosis, 1.165
treatment of, 1.165
Pulmonary metastases, ocular metastases associated with, 4.197, 4.198*f*, 4.304, 4.304*t*, 4.308–309, 4.309*f*
Pulsating exophthalmos, 7.112
Pulsation of eye, 7.25
Pulse
gaze-evoked nystagmus and, 5.240
saccadic eye movement and, 5.219, 5.220*f*, 5.221, 5.222
Pulse (term), in phacoemulsification, 11.100
Pulsed-light therapy, intense (IPL)
for meibomian gland dysfunction, 8.69
for rosacea, 8.71
Pulsed phacoemulsification, 11.100
Pulseless disease (Takayasu arteritis), cataract caused by, 11.68
Pulvinar, 5.18*f*, 5.30, 5.34
Pump-leak theory, 11.21, 11.22*f*
Puncta. *See* Punctum
Punctal occlusion/plugs
for dry eye, 8.61*t*, 8.64–65, 8.65*f*
for graft-vs-host disease, 8.304
for mucous membrane pemphigoid, 8.303
for neurotrophic keratopathy/persistent corneal epithelial defects, 8.81, 8.224, 8.230
Punctal plug–mediated drug delivery, 2.366

Punctate epithelial defects/erosions (PEEs)
conjunctival, 8.46*t*
corneal, 8.46*t*, 8.50, 8.50*f*, 8.50*t*
in exposure keratopathy, 8.80
in herpetic eye disease/neurotrophic keratopathy, 8.224
refractive surgery and, 13.42, 13.42*f*
in vernal keratoconjunctivitis, 8.290
Punctate epithelial keratitis/keratopathy (PEK), 6.269, 8.46*t*, 8.50, 8.50*f*, 8.50*t*, 9.334*f*
adenoviruses causing, 8.234
blepharitis/blepharoconjunctivitis and, 8.72, 8.73*t*, 8.74
exposure causing, 8.80
herpes simplex causing, 8.216, 8.216*f*
in herpes zoster, 8.227
microsporidial, 8.280, 8.280*f*
superficial Thygeson (SPK), 8.306–307, 8.307*f*
topical anesthetic abuse causing, 8.89
Punctate inner choroiditis/choroidopathy (PIC), 12.225. *See also* Multifocal choroiditis
characteristics of, 9.162–164*t*
choroidal neovascularization in, 9.182
definition of, 9.181
fluorescein angiography findings in, 9.163*t*, 9.182, 9.183*f*
indocyanine green angiography findings in, 9.163*t*, 9.182, 9.183*f*
manifestations of, 9.181–182, 9.182*f*
optical coherence tomography findings in, 9.164*t*, 9.182, 9.183*f*
Punctate keratitis, 3.232–233, 6.197
in reactive arthritis syndrome, 9.133
Punctate outer retinal toxoplasmosis (PORT), 9.279, 9.279*f*
Punctate staining patterns (fluorescein), 8.36, 8.37*f*
Punctoplasty, 7.301–302
Punctum
of canaliculus, 2.27
in external eye defense, 8.11
lacrimal. *See* Lacrimal punctum
Pupil(s)
abnormalities of, 5.253–267, 6.267–268, 6.268*f*. *See also* Pupillary defects; *specific type*
Adie tonic, 5.256*f*, 5.263*f*, 5.263–265, 5.264*f*, 5.265*f*
light-near dissociation and, 5.263, 5.264*f*, 5.266*t*
pharmacologic testing for, 5.256*f*, 5.264–265, 5.265*f*
age-related changes in, 1.183
anisocoria of, 6.275
Argyll Robertson, 5.267
Argyll Robertson–like, 5.267
congenital miosis of, 6.267–268
constriction of, in near and light reflexes, 5.254, 5.266*t*, 5.266–267. *See also* Pupillary light reflex
corectopia of, 6.268
diameter of, 3.105
dilation of. *See also* Mydriasis/mydriatics
for retinopathy of prematurity examination, 6.331
displacement of (corectopia), 5.255
cataract surgery in patient with, 11.180
in iridocorneal endothelial syndrome, 10.136, 10.137*f*
dyscoria of, 6.267
in ectopia lentis et pupillae, 11.42
entrance, 3.124, 3.130–131
examination of, 5.253–254
before cataract surgery, 11.78
in glaucoma, 10.30, 10.33*t*
in low vision, 5.79*f*, 5.79–81
after penetrating and perforating ocular trauma, 8.401
in ptosis evaluation, 7.243
before refractive surgery, 13.40–41
fixed, dilated, nonorganic causes of, 5.310
growth and development of, 6.181
irregular, 5.255
Marcus Gunn. *See* Marcus Gunn pupil
mydriasis of, 6.268
ovalization of, after angle-supported phakic IOL implantation, 13.146–147
paradoxical, 6.335, 6.336*t*
pharmacologic testing of, 5.256*f*, 5.258–259, 5.259*f*, 5.261*f*, 5.264–265, 5.265*f*
pseudopolycoria of, 6.268, 6.268*f*
reactivity/response of, to light. *See* Pupillary light reflex
secluded, 10.119, 10.138, 10.139*f*
size of
abnormalities in, 5.255–266. *See also* Anisocoria
Airy disc and, 3.106
baseline, 5.254–255
cataract surgery and, 11.78, 11.177–178, 11.178*f*
IOL selection and, 11.78
trauma and, 11.191
uveitis and, 11.188
diffraction effects affected by, 3.105
evaluation of, 5.253–254, 5.256*f*
before refractive surgery, 13.40
glaucoma/glaucoma therapy and, 5.254, 10.30
higher-order aberrations and, 3.106
keratorefractive surgery and, 3.272–273
multifocal IOLs and, 13.156
near point of accommodation and, 3.130
nonorganic causes of changes in, 5.310
perimetry results affected by, 10.60
refractive surgery and, 13.40
visual resolution affected by, 3.129–131
wavefront aberrations and, 13.11
springing, 5.267
substance abuse effects on, 1.199
tadpole, 5.255
tonic (Adie pupil/syndrome), 5.256*f*, 5.263*f*, 5.263–265, 5.264*f*, 5.265*f*, 6.275
light-near dissociation and, 5.263, 5.264*f*, 5.266*t*
pharmacologic testing for, 5.256*f*, 5.264–265, 5.265*f*
trauma affecting, 5.255
in uveitic eye, cataract surgery and, 11.188
wavefront aberrations and, 3.275, 13.11
white. *See* Leukocoria
Pupil expansion devices, 11.177, 11.178*f*
for intraoperative floppy iris syndrome, 11.178
for traumatic inflammation, 11.191
Pupil-involving third nerve (oculomotor) palsy, 5.193, 5.194*f*, 5.194–195, 5.265
in young patients, 5.197
Pupil-optic nerve (PO) section, 4.29*f*, 4.29–30

Pupil reflexes
light reflex, 2.126, 2.127*f*
near reflex, 2.126
pathways for, 2.126, 2.127*f*
Pupil size. *See* Pupil(s), size of
Pupil-sparing third nerve (oculomotor) palsy, 5.195–196, 5.196*f*
complete, 5.195
partial, 5.195–196, 5.196*f*
Pupil testing
in children, 6.10
in nystagmus evaluations, 6.154
Pupillary axis, 3.124, 3.129, 3.129*f*, 3.272
Pupillary block, 10.118–119
absolute, 10.119
angle closure/angle-closure glaucoma with, 10.4*t*, 10.6*t*, 10.118–119
iridotomy/iridectomy for, 10.124, 10.125, 10.191
angle closure/angle-closure glaucoma without, 10.4*t*, 10.6*t*, 10.118–120, 10.119*t*
anterior chamber intraocular lenses and, 10.131–132
in aphakic/pseudophakic eye, 10.130
after cataract surgery, flat or shallow anterior chamber and, 11.135–136
ectopia lentis and, 10.129
after endothelial keratoplasty (DMEK/DSEK), 8.444*f*, 8.444–445
mechanism of angle closure and, 10.118–119
microspherophakia causing, 10.130, 10.131*f*, 11.33
after penetrating keratoplasty, 8.424
phacomorphic glaucoma and, 10.119, 11.67, 11.68*f*
reverse, in pigmentary glaucoma, 10.93
Pupillary-block glaucoma, in retinopathy of prematurity, 12.181
Pupillary capture, after cataract surgery, 11.148, 11.148*f*
IOL decentration and, 11.145
Pupillary defects, 5.253–267. *See also specific type and under Pupils*
afferent, relative (RAPD). *See* Relative afferent pupillary defect
benign episodic unilateral mydriasis, 5.267
examination of patient with, 5.79*f*, 5.79–81, 5.253–254
history in, 5.253
irregularity, 5.255
in myasthenia gravis, 5.324
nonorganic, 5.302, 5.310
reactivity disorders (light-near dissociation), 5.254, 5.266*t*, 5.266–267
in sarcoidosis, 5.327
size/shape/location abnormalities, 5.255–266. *See also* Anisocoria
evaluation of, 5.253–254, 5.256*f*
nonorganic, 5.310
in third nerve (oculomotor) palsy, 5.193, 5.194–196, 5.195*f*, 5.196*f*, 5.265
in young patients, 5.197
Pupillary light reflex (pupillary response to light), 2.126, 2.127*f*, 5.55*f*, 5.255–257. *See also* Pupil(s), examination of
in cataract surgery evaluation, 11.78
in children, 6.10
consensual response in, 5.254
development of, 6.181
direct response in, 5.254
disorders of/light-near dissociation and, 5.254, 5.266*t*, 5.266–267
in Horner syndrome, 5.258
in myotonic dystrophy, 5.330
near response and, 5.254, 5.266
nonorganic disorders and, 5.301, 5.310
pathways for, 5.28, 5.44, 5.44*f*, 5.54, 5.55, 5.55*f*
testing, 5.79*f*, 5.79–81, 5.254, 5.255–257
Pupillary membrane
anterior, 11.29, 11.29*f*
in cataract surgery, 11.188
development and, 11.29, 11.29*f*
posterior, 11.29*f*
remnant of (Mittendorf dot), 11.29, 11.31, 11.32*f*
Pupillary muscles, innervation of, 5.44, 5.44*f*, 5.52, 5.54, 5.55
Pupillary near reflex. *See also* Near reflex
spasm of, 5.227, 5.309–310
Pupillometer, 13.40
Pupilloplasty
for cataracts, 11.71–72
for IOL decentration/dislocation, 11.145
Purified neurotoxin complex, 2.443
Purified protein derivative (PPD) test, 1.256–257, 9.28, 9.238. *See also* Tuberculin skin test
Purine nucleotides/purines, hyperuricemia caused by disorders of metabolism of, 8.188
Purkinje cells, 5.40
Purpura, 1.140
Pursuit eye movements/pursuit pathways/system, 5.32, 5.33, 5.34*f*, 5.212, 5.212*t*, 5.224–226, 5.225*f*
dysfunction/injury of, 5.156, 5.224, 5.225–226
optokinetic nystagmus/system and, 5.156, 5.218, 5.219
Pursuit latency, 6.40
Purtscher flecken, 12.171
Purtscher retinopathy, 12.171–173, 12.173*t*
Purtscherlike retinopathy, 12.171–173, 12.172*f*, 12.173*t*
"Pushing plus," before refractive surgery, 13.39
Pustule, of eyelid, 8.45*t*
PVA. *See* Polyvinyl alcohol
PVD. *See* Posterior vitreous detachment
PVL. *See* Periventricular leukomalacia
PVMG. *See* Power-versus-meridian graph
PVR. *See* Proliferative vitreoretinopathy
PWS. *See* Port-wine stain
PXE. *See* Pseudoexfoliation/exfoliation syndrome; Pseudoxanthoma elasticum
Pyogenic granuloma, 4.55, 4.55*f*, 6.170, 6.171*f*, 6.199, 6.199*f*, 7.142*f*, 7.310–312, 8.345*t*, 8.346, 8.346*f*
after pterygium excision, 8.356
Pyridostigmine, in myasthenia gravis treatment, 5.326
Pyridoxine (vitamin B_6), for homocystinuria, 11.41
Pyrimethamine, for ocular toxoplasmosis, 6.409, 9.281
Pyruvate kinase deficiency, 1.136
Pythium insidiosum, 8.251
keratitis caused by, 8.251, 8.275

Q

Q_e. *See* Radiant energy
Q_λ. *See* Radiant energy
Q factor, 3.267, 3.269, 3.279
Q formula, Hoffer, for IOL power determination/selection, 11.85
Q-switching, 3.112
Q value, 13.14
Q waves, 1.84
QED. *See* Quantum electrodynamics
qPCR. *See* Quantitative (real-time) polymerase chain reaction
QRS complex, 1.84*f*
QT interval
  illustration of, 1.84*f*
  prolongation of, in myocardial infarction, 1.86
Quadrantanopia, 5.105*t*
  hallucinations with, 5.177
  occipital lobe lesions causing, 5.156
  temporal lobe lesions causing, 5.155*f*
Quadripod fractures. *See* Zygomaticomaxillary complex (ZMC) fractures
Quadruple sectoranopia, lateral geniculate body lesions causing, 5.154, 5.154*f*
Quadruple therapy, for toxoplasmic retinochoroiditis, 12.243
Quality indicators, 1.24
Quality/reliability of field, perimetry interpretation and, 10.62
Quantitative (real-time) polymerase chain reaction (qPCR/RT-PCR), 4.39*t*
Quantum electrodynamics (QED)
  definition of, 3.92
  origins of, 3.95–96
  principles of, 3.96
  reflection, 3.96
  refraction, 3.96
Quantum theory, 3.95*f*, 3.110
Quetiapine, 1.200
Quinine, 12.301
Quixin. *See* Levofloxacin

R

R9AP gene, 12.49
RA. *See* Retinoic acid; Rheumatoid arthritis
Rab escort protein 1, 2.314*t*
Rabies virus
  corneal transplantation in transmission of, 8.240, 8.240*t*, 8.416*t*
  ocular infection caused by, 8.240, 8.240*t*
  vaccination against, 1.232
Raccoons, 12.246
Race. *See also* Ethnic background
  age-related macular degeneration and, 12.62
  angle-closure glaucoma and, 10.9, 10.117, 10.120
  cataract development and, 11.6
  choroidal/ciliary body melanoma risk and, 4.262
  complexion-associated melanosis and, 8.341
  corneal thickness and, 10.81, 10.82, 10.90
  glaucoma risk and, 10.7–8, 10.9, 10.81, 10.82, 10.120
  multiple sclerosis and, 5.315
  ocular melanocytosis and, 8.338
  open-angle glaucoma and, 10.7–8, 10.81, 10.82
  optic nerve/nerve head/disc size and, 10.48
  polypoidal choroidal vasculopathy and, 4.168, 12.75
  pseudoexfoliation/exfoliation syndrome and, 10.93
  sarcoidosis and, 5.327
  sickle cell hemoglobinopathies and, 12.149, 12.154
  spasmus nutans and, 5.239
  systemic lupus erythematosus and, 12.230
  Vogt-Koyanagi-Harada disease/syndrome and, 4.186, 12.232
Racemose angioma/hemangioma (Wyburn-Mason syndrome/Bonnet-Dechaume-Blanc syndrome), 4.286*f*, 4.286–287, 5.331, 5.333*f*, 5.334*t*, 6.222, 6.394*t*, 6.405*t*, 6.405–406, 12.168
Racial melanosis (complexion-associated melanosis/CAM), 8.338*t*, 8.339*t*, 8.341, 8.341*f*
Radial axis index, skewed, in keratoconus/corneal ectasia, 8.32*t*, 8.165
Radial ciliary muscle, 2.25*f*
Radial incisions
  for intrastromal corneal ring segment placement, 13.64
  for keratorefractive surgery, 13.27
  for radial keratotomy, 13.50, 13.50*f*
    traumatic rupture of, 13.52
Radial keratoneuritis, in *Acanthamoeba* keratitis, 4.79, 8.277
Radial keratotomy (RK), 13.8*t*, 13.49–53, 13.50–51*f*. *See also* Keratorefractive surgery
  aberrations after, 13.11, 13.12
  additional refractive surgery and, 13.37
  cataract surgery after, 11.79, 11.177, 13.52–53
    IOL power calculation and, 11.86
  complications of, 13.51*f*, 13.51–52
  contact lens use after, 13.52, 13.199, 13.199*f*, 13.199–200
  corneal topography after, 13.50–51
  corneal transplantation/penetrating keratoplasty after, 13.52, 13.198
  herpes simplex virus keratitis and, 13.174
  hyperopic shift and, 11.177, 13.51
  intraocular lens power calculation after, 3.251, 13.51–53, 13.193
  iron lines associated with, 8.117
  ocular surgery after, 13.52–53
  refraction after, 13.50–51
    stability of, 13.51
  surgical technique for, 13.50, 13.50*f*
  visual acuity after, 13.50–51, 13.51–52
Radial perineuritis, in *Acanthamoeba* keratitis, 4.79, 8.277
Radial peripapillary capillary network, 12.16
Radial perivascular lattice degeneration, 4.150
Radial thermokeratoplasty, 13.127
Radial ultrasound biomicroscopy scans, 2.468–469, 2.472*f*
Radiance (L_e), 3.107, 3.107*t*, 3.109
Radiant energy, 3.107*t*
Radiant exitance (M_e), 3.108
Radiant flux, 3.107*t*
Radiant intensity, 3.107, 3.107*t*

Radiation exposure. *See also* Radiation therapy; Ultraviolet (UV) light
anterior segment injury caused by, 8.385–386
cancer caused by, 1.236
cataracts caused by, 11.57–58
ionizing, retinopathy caused by, 12.170*f*, 12.170–171
neuroimaging in evaluation of disorders caused by, 5.72*t*
primary vitreoretinal lymphoma treated with, 12.234
Radiation necrosis, 5.358
Radiation optic neuropathy (RON), 5.358, 5.358*f*
Radiation retinopathy, 2.346, 12.170*f*, 12.170–171
Radiation surgery, 5.357
Radiation therapy (RT), 5.357
basal cell carcinoma treated with, 7.205
brachytherapy, 1.237–238
cancer treated with, 1.237–239
cataracts caused by, 1.239
for choroidal hemangioma, 4.283
for choroidal melanoma/ciliary body melanoma, 4.253, 4.275*f*, 4.275–276
complications of, 5.358, 5.358*f*, 7.205
external beam, 1.237–238
infantile hemangiomas treated with, 7.72
for iris melanoma, 4.261
lacrimal drainage system tumors treated with, 7.317
for lymphoma, 4.312
malignant lacrimal gland tumors treated with, 7.100
for metastatic eye disease, 4.310
monoclonal antibody use in, 1.238
neuro-ophthalmic complications of, 5.358, 5.358*f*
neuromyotonia after, 5.202, 5.358
ocular effects of, 1.238, 1.238*t*
for optic nerve glioma, 5.130, 7.83
for optic nerve sheath meningioma, 5.128, 5.129
optic neuropathy caused by, 1.239
for retinal hemangioblastoma, 4.285
for retinoblastoma, 4.301
secondary tumors and, 4.302, 4.302*t*
retinopathy caused by, 1.239
rhabdomyosarcomas treated with, 7.88–89
for uveal lymphoid proliferation/infiltration, 4.314
Radiculitis, herpes infection and, 5.350
Radioactive iodine (RAI)
hyperthyroidism treated with, 7.60
nasolacrimal duct obstruction caused by, 7.307
for retinoblastoma, 4.301
uptake testing, for Graves disease, 1.42
for uveal melanoma, 4.275
Radioactive plaque therapy (brachytherapy)
for choroidal hemangioma, 4.283
for choroidal melanoma/ciliary body melanoma, 4.253, 4.275*f*, 4.275–276
for iris melanoma, 4.261
for medulloepithelioma, 4.296
for metastatic eye disease, 4.310
for retinal hemangioblastoma, 4.285
for retinoblastoma, 4.301
Radiofrequency
for conductive keratoplasty, 13.128, 13.128*f*
for punctal occlusion, 8.65
Radiofrequency ablation
catheter-based, 1.64–65
for trichiasis, 7.240
Radiography, chest. *See* Chest radiographs
Radiometry, 3.92, 3.107*t*, 3.107–108, 3.110
Radionuclide scintigraphy and scans
in coronary heart disease diagnosis, 1.88
technetium-99m, 1.88
thallium-201, 1.88
Radiosurgery, 5.357
Radius of curvature, corneal, 8.8, 8.27
in cornea plana, 8.100
instantaneous (meridional/tangential power), 13.16–17, 13.17*f*
keratometry in measurement of, 8.27. *See also* Keratometry/keratometer
in schematic eye, 3.127*t*
Raeder paratrigeminal syndrome, 5.261
Ragged red fibers, in chronic progressive external ophthalmoplegia, 5.328, 5.329*f*
RAI. *See* Radioactive iodine
Rainbow glare, after LASIK with femtosecond laser flap creation, 13.123–124
Raindrop Near Vision Inlay, 13.28, 13.169
RAIU. *See* Radioactive iodine, uptake testing
Rake defects, 5.82, 5.82*f*
RAM. *See* Retinal Acuity Meter
Ramsay Hunt syndrome, 5.280
Random assignment, 1.4
Random-Dot E test, 6.81
Random-dot stereopsis tests, 6.81
Randomized controlled trials
features of, 1.14
schematic diagram of, 1.13*f*
Randot test, 6.81
Range of accommodation, 3.140
Ranibizumab, 2.449
bevacizumab and, comparison between, 12.83, 12.84*t*
branch retinal vein occlusion treated with, 12.135
central retinal vein occlusion treated with, 12.135
clinical trials of, 12.82*t*
diabetic macular edema treated with, 12.111–112, 12.112*f*
diabetic retinopathy treated with, 12.102
for macular edema, 4.152
neovascular age-related macular degeneration treated with, 12.80–82, 12.82*t*
photodynamic therapy and, 12.85
proliferative diabetic retinopathy treated with, 12.104
retinal vein occlusion treated with, 12.135
for retinopathy of prematurity, 6.333
Ranitidine, 1.288
RAPD. *See* Relative afferent pupillary defect
Rapid plasma reagin, 9.224
Rapid plasma reagin (RPR) test, 1.252, 12.241
RAPs. *See* Retinal angiomatous proliferations
ras, 2.183
Rasagiline, 1.205
Ray(s)
divergent. *See* Vergence
paraxial, approximation/tracing of. *See* Ray tracing
Ray-deflection autorefractors, 3.289
Ray-deflection principle, 3.282, 3.286

Ray tracing
for concave mirrors, 3.82*f*, 3.83
for convex mirrors, 3.82*f*
definition of, 3.41
description of, 3.64–66, 3.65–3.66*f*
for Galilean telescope, 3.84*f*
for general optical system, 3.69*f*
for Keplerian telescope, 3.84*f*
mirrors and, 3.81, 3.82*f*
nodal points in, 3.67
for wavefront aberrations, 3.277
Rayleigh scattering, 3.92, 3.97
Raynaud phenomenon
cold-induced anterior segment trauma and, 8.385
in systemic lupus erythematosus, 1.159, 1.159*f*
in systemic sclerosis, 1.165–166
treatment of, 1.166
RB. *See* Reticulate body; Retinoblastoma
Rb locus. *See RB1* (retinoblastoma) gene
RB1 (retinoblastoma) gene
description of, 4.172–173, 4.253, 4.289–290, 6.354, 6.358
mutations, 2.227
in pinealoblastoma, 4.298
in retinocytoma, 4.298
secondary malignancies and, 4.302
RBC indexes. *See* Red blood cell (RBC) indexes
RBCD. *See* Reis-Bücklers corneal dystrophy
RBCs. *See* Red blood cells
RBP. *See* Retinol-binding protein
RCFM. *See* Retrocorneal fibrous membrane
RCVS. *See* Reversible cerebral vasoconstriction syndrome
RDH. *See* Retinol dehydrogenase
RDH5 gene, 12.252
RDS/peripherin *(PRPH2)* gene mutation
in pattern dystrophies, 4.170
in Stargardt disease, 4.168
RDW. *See* Red cell distribution width
Reactive arthritis/Reiter syndrome, 6.315*t*
acute anterior uveitis in, 9.132–133
conjunctivitis/episcleritis associated with, 8.305–306
conjunctivitis in, 1.157
description of, 1.155–156*f*, 1.157, 8.305–306
diagnostic criteria for, 9.132–133, 9.133*f*
human leukocyte antigen association with, 9.65*t*, 9.132
iridocyclitis associated with, 1.157
laboratory tests for, 9.125*t*
Reactive lymphoid hyperplasia (RLH), 7.94. *See also* Lymphoid hyperplasia
of conjunctiva, 4.69, 4.70*f*
of orbit, 4.231, 4.232
uveal. *See* Uveal lymphoid proliferation/infiltration/lymphoma (primary choroidal lymphoma)
Reactive nitrogen products, 9.16
Reactive oxygen intermediates (ROIs). *See also* Free radicals
in phagocytosis, 9.16
Reactive oxygen species (ROS)
cell protection from, 2.339
defense mechanisms and, 2.338–339
description of, 2.335
detoxification of, 2.336*f*
generation of, 2.336*f*
in glaucoma, 2.345
oxidative stress caused by, 2.335
pathways of, 2.337*f*
radiation retinopathy caused by, 2.346
retinal vulnerability to, 2.340–341
sources of, 2.336
UV light as source of, 2.339
Reactive thrombocytosis, 1.142
Reading-add power, 3.285
Reading glasses, 3.320
Reading tests, 3.318
Real images, 3.41, 3.60–61
Real objects
definition of, 3.41
virtual objects *versus*, 3.61
Real-time quantitative polymerase chain reaction (RT-PCR/qPCR), 4.39*t*
Reattachment surgery. *See* Retinal detachment, surgery for
Rebamipide, 2.416
Rebif. *See* Beta (β)-interferon
Rebleeding, after traumatic hyphema, 8.394, 8.394*f*, 10.104, 10.105
Rebound headache, analgesic, 5.293
Rebound hypertension, 1.69
Rebound nystagmus, 5.240–241
Rebound tonometry, 10.26
in infants and children, 10.158
Rebubbling, after endothelial keratoplasty, 8.438
Recall bias, 1.11
Receiver operating characteristic (ROC) curve, 1.16–18, 1.18*f*
Receptor tyrosine-protein kinase erbB-2, in immunohistochemistry, 4.35
Recession/resection. *See also specific muscle*
definition of, 6.164*t*
of horizontal rectus muscles
description of, 6.139
for esodeviations, 6.160
monocular, 6.161
for nystagmus correction, 6.157
of inferior rectus muscle
description of, 6.29
eyelid position affected by, 6.173
of lateral rectus muscle
for Duane retraction syndrome, 6.134
for exodeviations, 6.160
for high myopia, 6.143
for intermittent exotropia, 6.102
for third nerve palsy, 6.139
for X-pattern strabismus, 6.113
of medial rectus muscle
for convergence insufficiency, 6.103
for Duane retraction syndrome, 6.133
for esotropia from nystagmus blockage syndrome, 6.155
for infantile esotropia, 6.89
for internuclear ophthalmoplegia, 6.144
for Möbius syndrome, 6.136
for nystagmus, 5.236, 5.237*f*
Recessive diseases, 2.194

Recessive inheritance
autosomal, 2.203–206
description of, 2.202–203
X-linked, 2.208–209, 2.209*t*
Recessive optic atrophy, 6.368
Recognition disorders, 5.178*t*, 5.179, 5.180*f*
Recombinant tissue plasminogen activator (rtPA), 1.113. *See also* Tissue plasminogen activator
Recombination frequency, 2.188
Reconstructive surgery
eyelid. *See* Eyelid(s), surgery/reconstruction of
socket. *See* Anophthalmic socket surgery
Record review, 1.25–26
Recoverin (CAR antigen), 5.102
Recruitment, 6.33
Rectus muscles, 5.8*f*, 5.45, 5.46*f*. *See also specific muscle*
anatomy of, 5.8*f*
capsule of, 6.26
horizontal
anatomy of, 6.20, 6.35*f*
inferior zone of, 6.24
innervation of, 6.34
in pattern strabismus, 6.109–110
primary position of, 6.35, 6.35*f*
recession/resection of
description of, 6.139
for esodeviations, 6.160
monocular, 6.161
for nystagmus correction, 6.157
superior zone of, 6.24
transposition of, 6.110, 6.112
horizontal gaze and, 5.37*f*, 5.38
innervation of
compartmentalization of, 6.24
description of, 5.38, 5.44, 5.44*f*
insertion of, 6.22, 6.23*f*
posterior fixation of, 6.164*t*, 6.167
pulley system for, 6.28
"restrained shortest-path model" of, 6.28
in thyroid eye disease, 4.226, 5.206
tightening procedures for, 6.163–164, 6.164*t*
vertical
anatomy of, 6.20, 6.22*f*
eyelid attachments to, 6.30*f*
insertion of, 6.22
surgery of
for nystagmus, 6.156
for pattern strabismus correction, 6.111
vertical strength of, 6.35
weakening procedures for, 6.163, 6.164*t*
Recurrent corneal erosion, 8.79, 8.86–88
dystrophic, 8.86, 8.87, 8.133, 8.135*t*
in epithelial basement membrane dystrophy, 8.86, 8.87, 8.133, 8.138
in lattice corneal dystrophy type 1, 8.147
in Reis-Bücklers corneal dystrophy, 8.143
management of, 8.368
pain caused by, 5.295, 8.86, 8.87
posttraumatic, 8.86, 8.87
Recurrent erosion corneal dystrophies (EREDs), 8.86, 8.87, 8.133, 8.135*t*. *See also* Recurrent corneal erosion
Recurrent meningeal artery, 5.14, 5.14*f*, 5.15*f*
Recurrent multifocal choroiditis (RMC). *See* Multifocal choroiditis
Recurrent painful oculomotor neuropathy, 5.197
Recurrent pterygia, 4.57, 8.351, 8.352, 8.353, 8.353*t*, 8.355
Recurrent uveitis, 9.76
Red blood cell (RBC) indexes, 1.132
Red blood cells (RBCs)
anemia caused by destruction of, 1.136–137
life span of, 1.131, 1.136
precursors of, 1.131
Red cell distribution width (RDW), 1.132
Red comparison test, in confrontation testing, 5.84
Red cones. *See* L cones
Red eye. *See* Conjunctival hyperemia/congestion; Conjunctivitis
Red-glass test, 6.51, 6.75–76, 6.76*f*
Red-green color deficiency
anomaloscope of, 12.54
description of, 2.232*t*
types of, 12.54
Red-green color vision defects, 2.312
screening/testing for, 5.78. *See also* Red-green test
Red-green dyschromatopsia, 6.368
Red-green test. *See also* Duochrome test
in nonorganic disorder evaluation
monocular no light perception and, 5.303, 5.304*f*
monocular reduced vision and, 5.305
before refractive surgery, 13.39
Red laser, 12.374
Red Maddox rod, 5.184, 5.184*f*. *See also* Maddox rod/Maddox rod test
"Red man syndrome," 2.427
Red nucleus, 2.107*f*, 5.18*f*, 5.34*f*, 5.35*f*, 5.41*f*, 5.55*f*
in Benedikt syndrome, 5.191
Red perception testing, for relative afferent pupillary defect, 5.81
Red reflex. *See also* Retinal reflex
in complete cataract, 11.38
after ECCE, 11.198
in keratoconus, 8.163
in lenticonus/lentiglobus, 4.118, 11.30
media opacity effects on, 6.68
poor, cataract surgery and, 11.178–179, 11.179*f*
refractive error effects on, 6.68
testing of
in children, 6.9
ocular alignment assessments using, 6.67–68
Red target test, kinetic, in confrontation testing, 5.83
Reduced schematic eye, 3.124, 3.126
Reduced vergence
definition of, 3.41, 3.51
intraocular power and, 3.247
Reese-Ellsworth Classification for Intraocular Tumors
description of, 6.354
retinoblastoma and, 4.297
Reference sphere
definition of, 3.41, 3.70, 3.70*f*
in wavefront analysis, 3.274, 3.274*f*
Refixation movements, microsaccadic, 5.213

Reflection
description of, 3.96
law of
definition of, 3.40
description of, 3.80–81
vergence equation for mirrors derived from, 3.88–89, 3.89*f*
light, specular, for slit-lamp biomicroscopy, 8.17*f*, 8.17–18, 8.19*f*
total internal, 3.42, 3.50, 3.50*f*
Reflex, ocular. *See* Vestibular-ocular system/vestibular-ocular reflex; *specific type*
Reflex blepharospasm, 5.281, 7.256
Reflex tearing, 2.358
parasympathetic nerves and, 5.56
tests of, 8.39
Reflexive saccades, 5.219, 5.220
in progressive supranuclear palsy, 5.221
Refractec system. *See* Conductive keratoplasty
Refractile bodies/spots, in papilledema, 5.110, 5.110*f*
Refracting power, 8.27. *See also* Refractive power
in IOL power determination, 11.84
Refracting systems
axial (longitudinal) magnification, 3.63–64
composition of, 3.58
conjugate points, 3.64
Gaussian optics, 3.60
general, 3.58–67
nodal points, 3.66–67, 3.67*f*
ray tracing, 3.64–66, 3.65–66*f*
transverse magnification, 3.62
Refraction. *See also* Refractive errors
in children, glaucoma and, 10.158
clinical
bifocal lenses. *See* Bifocal lenses
in cataract
nonsurgical management and, 11.71
before surgery/IOL power determination, 11.76
cycloplegic, 3.168–169
before refractive surgery, 13.40
laser programming and, 13.40, 13.81
definition of, 3.21
exam room length for, 3.149–150
in glaucoma evaluation, 10.29
in children and adolescents, 10.158
goal of, 3.34
in low vision/vision rehabilitation, 5.78
manifest (noncycloplegic), 3.168–169
after penetrating keratoplasty, 8.431–432, 8.432*f*
refractive surgery and, 13.39, 13.40
IOL power calculation and, 13.194, 13.195
laser programming and, 13.40, 13.81
minus cylinder, 3.148–149
objective (retinoscopy). *See* Retinoscope/retinoscopy
overrefraction, 3.169
plus cylinder, 3.148–149
pseudoneutralization, 3.159–160
after radial keratotomy, 13.50–51
stability of, 13.51
after refractive surgery, IOL power calculation and, 13.194
before refractive surgery, 13.38, 13.39–40
for accommodative esotropia, 13.188
IOL power calculation and, 13.194
laser programming and, 13.31, 13.40, 13.81
retinoscopy. *See* Retinoscope/retinoscopy
subjective refraction. *See* Subjective refraction
terminology associated with, 3.148–149
definition of, 3.96
description of, 3.96
instruments for, 3.283–292
law of (Snell's law), 8.26
low vision, 3.314
manifest. *See* Manifest refraction
at near, 3.36–38
purpose of, 3.148
recommendations for, 3.38
single curved surface, 3.51–54
subjective. *See* Subjective refraction
"Refraction operator," 3.60
Refractive accommodative esotropia, 6.90–92
Refractive amblyopia, 3.175, 6.54–55
Refractive ametropia, 3.137, 3.257
Refractive errors. *See also* Ametropia; *specific type*
accommodation in progression of, 3.144
age-based prevalence of, 3.142*f*
astigmatic. *See* Astigmatism
axial, correction of, 3.12–13
in cornea plana, 8.96*t*, 8.100, 8.101
correction of. *See also* Contact lenses; Intraocular lenses (IOLs), for refractive errors; Refractive surgery; Spectacle lenses
in amblyopia, 6.57–58
in intermittent exotropia, 6.101
from lens dislocation, 6.310
options for, 3.144
epidemiology of, 3.141*f*, 3.141–142
extraocular muscle surgery effects on, 6.173–174
in glaucoma, 10.9, 10.29, 10.122, 10.166
headaches and, 3.25
initial estimate of, 3.27*f*, 3.27–29
myopia. *See* Myopia
optical principles/wavefront analysis and, 13.9–13, 13.10*f*, 13.11*f*, 13.12*f*, 13.13*f*
after penetrating keratoplasty, 8.431–432, 8.432*f*
perimetry results affected by, 10.60
postoperative
overcorrection and, 13.101–102, 13.108–109
re-treatment/enhancements and, 13.97–100, 13.99*f*
undercorrection and, 13.102, 13.108
postsurgical, 3.255
prevention of, 3.144
red reflex affected by, 6.68
unexpected, after cataract surgery, 11.86, 11.149–150
Refractive index
of air, 8.26
of aqueous, 8.26
of cornea, 8.8, 8.26
definition of, 3.4, 3.41
description of, 3.43–44
dispersion effects on, 3.45
equation for, 3.43
errors in, 3.252
of lens, 11.11

in schematic eye, 3.127*t*
of spectacle lens materials, 3.194
of tear (fluid) lens, 3.220, 8.26
Refractive keratotomy. *See* Keratotomy
Refractive lens exchange (RLE), 13.8*t*, 13.137, 13.147–151
advantages of, 13.147
for astigmatism, 13.148–149
complications of, 13.151
disadvantages/limitations of, 13.47*t*, 13.147
for hyperopia, 13.148, 13.150
indications for, 13.147
informed consent for, 13.147–148
IOL power calculations in, 13.150
for myopia, 13.148, 13.150
patient selection for, 13.147–149
for presbyopia, 13.149
retinal detachment and, 13.148
surgical planning/techniques for, 13.149–150
Refractive lenticule extraction (ReLEx), 13.8*t*, 13.27, 13.203–206
complications of, 13.205
indications and preoperative evaluation for, 13.204
LASIK compared with, 13.206
outcomes of, 13.205
re-treatment and, 13.206
surgical technique for, 13.204–205
Refractive multifocal intraocular lenses, zonal, 13.166, 13.166*f*. *See also* Multifocal lenses, intraocular
Refractive power. *See also* Transverse magnification
of cornea, 8.25–26, 13.7–9
measurement of, 8.26–27, 8.27*f*, 13.7–9. *See also* Keratometry/keratometer
in schematic eye, 3.127*t*
of schematic eye, 3.127*t*
Refractive procedure–induced diplopia, 5.209
Refractive states. *See also* Refractive errors
ametropia, 3.136–137, 3.137*f*
astigmatism. *See* Astigmatism
description of, 6.180*f*, 6.180–181
emmetropia, 3.136, 3.137*f*
far point concept of, 3.136
focal point concept of, 3.136
spherical equivalent of, 3.139
Refractive surgery, 13.7, 13.8*t*. *See also* Keratorefractive surgery; Ocular surgery, refractive; *specific procedure*
abbreviations and acronyms used in, 13.3–5
amblyopia/anisometropic amblyopia and, 13.185–187
astigmatism and
corneal topography in detection/management of, 8.32, 13.18–19, 13.22–23, 13.44, 13.45, 13.45*f*
penetrating keratoplasty and, 13.178–180
in autoimmune disease, 13.191
cataract/cataract surgery and, 11.123–124, 11.176–177, 11.177*f*, 13.43–44
IOL power calculation and, 11.85–87, 11.176, 11.177*f*, 13.44, 13.194
preoperative evaluation/planning and, 11.76, 11.79
in children, 13.187–188
in collagen vascular/connective tissue diseases, 13.37, 13.171, 13.191
contact lens use after, 13.198–200, 13.199*f*
contraindications to
corneal topography in identification of, 13.23, 13.24–26, 13.25*f*
in ocular and systemic disease, 13.171
corneal, 13.7, 13.8*t*. *See also* Keratorefractive surgery; Photoablation
collagen shrinkage, 13.8*t*, 13.28, 13.28*f*, 13.127–129, 13.128*f*, 13.129*f*
corneal crosslinking, 13.8*t*, 13.130–135, 13.131*f*, 13.133*f*, 13.133*t*
incisional, 13.8*t*, 13.26–27, 13.27*f*, 13.49–58
inlays/onlays, 13.59–71, 13.169
photoablation, 13.29–32, 13.30*f*, 13.73–74, 13.74–75*f*, 13.101–126
corneal biomechanics affected by, 13.13–14
corneal imaging/evaluation and, 13.14–26, 13.44–45, 13.45*f*. *See also* Cornea, topography of; *specific type*
indications for, 13.22–24, 13.23*f*, 13.24*f*
postoperative, 13.23*f*, 13.23–24, 13.24*f*
preoperative, 13.14–26, 13.44–45, 13.45*f*, 13.79–80
corneal optics and, 13.7–9
corneal shape and, 13.9
corneal topography and, 13.14–19, 13.15–19*f*, 13.24–26, 13.25*f*, 13.44–45, 13.45*f*, 13.79. *See also* Cornea, topography of
astigmatism and, 8.32, 13.18–19, 13.22–23, 13.44, 13.45, 13.45*f*
dry eye and, 13.173
indications for, 13.22–23, 13.23*f*, 13.24*f*
postoperative evaluation and, 13.23*f*, 13.23–24, 13.24*f*
preoperative evaluation and, 13.14–19, 13.15*f*, 13.16*f*, 13.17*f*, 13.18*f*, 13.19*f*, 13.24–26, 13.25*f*, 13.44–45, 13.45*f*, 13.79–80
refractive lens exchange and, 13.149
toric IOLs and, 13.151–152
after corneal transplant, 13.37, 13.178–180
corneal transplant after, 13.197–198
in diabetes mellitus, 13.37, 13.190–191
diplopia caused by, 5.209
donor cornea suitability and, 8.414
emerging technologies in, 13.203–208
excimer laser, 13.8*t*, 13.29, 13.73–77, 13.74–75*f*
glaucoma/ocular hypertension and, 13.180–183, 13.182*f*, 13.200–201
herpes simplex virus infection and, 13.173–174
in HIV infection/AIDS, 13.188–190
incisional, 13.8*t*, 13.26–27, 13.27*f*, 13.49–58
for astigmatism, 13.53–58, 13.54*f*, 13.55*f*, 13.56*f*, 13.57*f*
corneal effects of, 13.9, 13.26–28, 13.27*f*, 13.28*f*
for myopia, 13.49–53, 13.50*f*, 13.51*f*
induced anisophoria corrected using, 3.190
informed consent for, 13.36*t*, 13.46–48, 13.47*t*
instrument error after, 3.251–252
intraocular lens power calculations after, 3.251–253, 13.44, 13.193–197, 13.196*f*
intraocular procedures in, 13.7, 13.8*t*, 13.137–157. *See also* Ocular (intraocular) surgery, refractive
with keratorefractive (corneal) surgery (bioptics), 13.137, 13.157
iron lines associated with, 8.117

irregular astigmatism and, 13.18–19, 13.22–23, 13.44, 13.45
keratoconus and, 13.23, 13.24, 13.25*f*, 13.38, 13.42–43, 13.44, 13.175*f*, 13.175–178, 13.176*f*, 13.177*f*. *See also* Keratoconus
keratometric power measurements affected by, 13.193
laser biophysics and, 13.29–32, 13.30*f*
lenticular. *See specific procedure*
limitations of procedures used in, 13.47*t*
medical history and, 13.36*t*, 13.37
monovision and, 13.39, 13.164–165
in ocular and systemic disease, 13.171–191. *See also specific disorder*
ocular history and, 13.36*t*, 13.37–38
optical considerations/principles in, 13.9–13, 13.10*f*, 13.11*f*, 13.12*f*, 13.13*f*
overview of procedures used in, 13.7, 13.8*t*
patient age and, 13.38–39
patient evaluation for, 13.35–48, 13.36*t*. *See also* Refractive surgery, preoperative evaluation for
after penetrating keratoplasty, 8.432, 13.37, 13.178–180
penetrating keratoplasty after, 13.197–198
postoperative considerations and, 13.193–201
contact lens use after, 13.198–200, 13.199*f*
corneal imaging and, 13.23*f*, 13.23–24, 13.24*f*
corneal transplantation after, 13.197–198
glaucoma and, 13.200–201
IOL power calculations and, 13.193–197, 13.196*f*
retinal detachment repair after, 13.197
preoperative evaluation for, 13.35–48, 13.36*t*
corneal imaging/ancillary tests and, 13.14–26, 13.44–46, 13.45*f*, 13.79–80. *See also* Cornea, topography of; *specific type*
discussion of findings/informed consent and, 13.36*t*, 13.46–48, 13.47*t*
history and, 13.35–39, 13.36*t*
ocular examination and, 13.36*t*, 13.39–44, 13.42*f*, 13.43*f*
patient expectations/motivations and, 13.35–36, 13.36*t*, 13.47
in presbyopia, 13.38–39, 13.159–170
after radial keratotomy, 13.52
retinal disease/detachment and, 13.44, 13.183–185, 13.197
science of, 13.7–33
social/occupational history and, 13.36*t*, 13.36–37
strabismus and, 13.41, 13.185–187
wavefront aberrations/analysis and, 13.9–13, 13.10*f*, 13.11*f*, 13.12*f*, 13.13*f*, 13.31, 13.46
postoperative, 13.102–103, 13.103*f*
Refractor. *See* Phoropter
Refsum disease, 2.204*t*, 2.314*t*, 6.389*t*, 12.283*t*, 12.286, 12.290
Regeneration, 4.13. *See also* Wound(s), healing/repair of
aberrant nerve. *See* Aberrant nerve regeneration
Regional anesthetics, 2.438*t*. *See also* Anesthesia (anesthetics); local
Regional enteritis. *See* Crohn disease
Regional immunity, 9.51, 9.52*t*. *See also* Immunologic microenvironment
Registration, for laser centration, 13.91, 13.91*f*
Regression analysis, 1.12
Regression formulas, for IOL power determination/selection, 11.85–87
Regular astigmatism, 3.124, 3.139, 3.276
corneal topography in detection/management of, 13.17, 13.18*f*
wavefront aberrations produced by, 13.11, 13.11*f*
Regulatory (Treg/suppressor) T cells. *See also* T cell(s)
in corneal transplant tolerance, 8.316
in external eye defense, 8.12–13*f*, 8.13, 8.14
Rehabilitation. *See* Vision rehabilitation
Reichert Phoroptor, 3.173
Reis-Bücklers corneal dystrophy (RBCD/CDB1/atypical granular corneal dystrophy), 4.88, 4.88*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.142*f*, 8.142–143
Reiter syndrome/reactive arthritis, 1.155, 8.305–306
conjunctivitis/episcleritis associated with, 8.305–306
Rejection (corneal transplant), 4.84, 4.85*f*, 8.316–318, 8.428–431
after endothelial keratoplasty (DMEK/DSEK), 8.437*t*, 8.447*f*, 8.447–448
after lamellar keratoplasty, 8.411, 8.435, 8.435*f*
after penetrating keratoplasty, 8.316–318, 8.428–431, 8.437*t*
prevention of, 8.430–431
treatment of, 8.429–430
Rejuvenation, facial. *See also* Facial surgery; *specific procedure*
autologous fat grafting for, 7.271
botulinum toxin for, 7.269–270
dermal fillers for, 7.270*f*, 7.270–271
hyaluronic acid fillers for, 7.270, 7.270*f*
laser skin resurfacing for, 7.268–269
lower face, 7.272–273
nonsurgical, 7.268–271, 7.270*f*
rhytidectomy, 7.273–274, 7.274–275*f*
soft-tissue dermal fillers for, 7.270*f*, 7.270–271
surgical techniques for, 7.271–276, 7.272–275*f*
Relapsing polychondritis, 1.168–169, 9.125*t*
eyelid manifestations of, 4.207*t*
Relapsing-remitting multiple sclerosis, 5.315
Relative afferent pupillary defect (RAPD/Marcus Gunn pupil), 5.253
in acute idiopathic blind-spot enlargement/acute zonal occult outer retinopathy/multiple evanescent white dot syndrome, 5.101
cataract surgery in patient with, 11.78
in NAION, 5.122
in ocular trauma, 8.401
in optic neuropathy *versus* maculopathy, 5.81, 5.99, 5.100*t*
in optic tract syndrome, 5.153
testing for, 5.79*f*, 5.79–81
in glaucoma evaluation, 10.30
nonorganic disorders and, 5.302
Relative risk, 1.22–23, 1.214, 9.64
Relaxation, in MRI, 5.75
Relaxation times, in MRI, 5.62, 5.63*t*, 5.76
Relaxing incisions
for anterior capsule contraction, 11.154*f*, 11.156
for corneal astigmatism after penetrating keratoplasty, 8.432

limbal (LRIs), 13.8*t*, 13.27*f*, 13.53–58, 13.54–57*f*
cataract surgery and, 11.123–124
complications of, 13.58
instrumentation for, 13.55, 13.56*f*
ocular surgery after, 13.58
outcomes of, 13.57
refractive lens exchange and, 13.149
technique for, 13.55–57, 13.56*t*, 13.57*f*
Relentless placoid chorioretinitis, 9.173*f*, 9.173–174
ReLEx. *See* Refractive lenticule extraction
Reliability, 1.24
Relocation of images, 3.62
Renal artery stenosis, angiotensin-converting enzyme inhibitor contraindications in, 1.61
Renal cell carcinoma, metastatic eye disease and, 4.304*t*
Renal coloboma syndrome, dysplastic optic nerve and, 5.145
Renal diseases
chronic, 1.65
contrast agents contraindicated in, 5.60
diabetes mellitus/diabetic retinopathy and. *See* Diabetic retinopathy
retinal degeneration associated with, 12.285
Renal sympathetic nerves, catheter-based radiofrequency ablation of, 1.64–65
Rendu-Osler-Weber disease, 1.140
Renin-angiotensin-aldosterone system
angiotensin II, 1.61
in hypertension, 1.53, 1.54*f*, 1.69
in ocular tissues, 1.69
schematic diagram of, 1.54*f*
Renovascular disease, hypertension caused by, 1.53
Renu with MoistureLoc contact lens solution, *Fusarium* keratitis and, 8.274
Repair, 4.13. *See also* Wound(s), healing/repair of
Reparative macrophages, 9.16
Repetition time (TR), 2.457
Repetitive nerve stimulation, electromyographic, in myasthenia gravis, 5.326
Replicative segregation, 2.184
Rescue breathing, 1.297
Rescula. *See* Unoprostone isopropyl
Resection. *See* Recession/resection
Residence time, 2.354
Residual stromal bed (RSB) thickness, LASIK and, 13.30, 13.45–46, 13.79–80
calculation of, 13.46, 13.79
corneal perforation and, 13.111
ectasia and, 13.79, 13.124
Resistance (drug). *See specific agent and specific organism*
Resistance factor, corneal (CRF), 8.43
Resistant hypertension, 1.54, 1.55*t*, 1.64
Resolution
minimum angle of (MAR), logarithm of (logMAR), cystoid macular edema after cataract surgery and, 11.164
pupil size effects on, 3.129–131
Resolving power. *See* Transverse magnification
Resonator cavity, 3.111
Respiratory burst, 2.336
Respiratory disorders. *See* Pulmonary diseases
Respiratory obstruction, 1.301
Response accommodative convergence/accommodation (AC/A) ratio, 6.71. *See also* Accommodative convergence/accommodation (AC/A) ratio
Restasis. *See* Cyclosporine/cyclosporine A, topical
Resting macrophages, 9.13, 9.15*f*
Resting neutrophils, 9.10
"Restrained shortest-path model," 6.28
Restrictive lung diseases, 1.125
Restrictive strabismus, Hering's law of motor correspondence and, 6.38
Restrictive syndromes, diplopia caused by, 5.186, 5.206–209, 5.207*f*
paretic syndromes differentiated from, 5.186, 5.186*f*
postsurgical, 5.207
posttraumatic, 5.186, 5.206
Resuscitation. *See* Cardiopulmonary resuscitation
RET gene, in multiple endocrine neoplasia, 8.200
Retained lens fragments after phacoemulsification, 12.391–393, 12.392*f*
Retained lens material, cataract surgery and, 11.140–141
Reticular degenerative (bullous) retinoschisis, 4.148, 12.326, 12.327
Reticular formation
mesencephalic (MRF), 5.35*f*
paramedian pontine (PPRF), 5.33, 5.35, 5.35*f*, 5.219
horizontal gaze and, 5.36, 5.37, 5.37*f*
in one-and-a-half syndrome, 5.191
saccades generated by, 5.219–220, 5.221
Reticular peripheral cystoid degeneration (RPCD), 4.148, 4.149*f*, 12.326
Reticular pseudodrusen (RPD/subretinal drusenoid deposits), 4.162, 4.163, 4.163*f*, 4.171*f*, 12.65*f*, 12.65–66
Reticular-type pattern dystrophy, 12.276, 12.276*f*
Reticulate body (RB), 8.249
Reticulocyte count, 1.132
Reticulum cell sarcoma. *See* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
Retina, 4.139–180. *See also under Retinal*
acute necrosis of, 9.250, 9.251–252*f*, 9.330
adhesion of, 2.331–332
anatomy of, 2.49, 2.83, 2.84*f*, 4.139–140, 4.140*f*, 4.141*f*, 5.17*f*, 5.23–25, 5.24*f*, 5.25*f*
angiography of. *See* Fluorescein angiography; Indocyanine green angiography
angiomas of, 12.168
anomalies of, 2.470*f*
antioxidant localization in, 2.344*f*
arterioles of, 2.90
astrocytic hamartoma of, 4.295, 4.296*f*
optic nerve/nerve head/disc drusen differentiated from, 5.108*f*, 5.143
retinoblastoma differentiated from, 4.295, 4.296*f*
atrophy of, ischemia causing. *See also* Retinal ischemia
in diabetic retinopathy, 4.159
in retinal arterial and venous occlusions, 4.156, 4.159
blood–retina barrier, 2.88, 2.90*f*
blood supply to, 12.140. *See also* Retinal blood vessels
blood vessels of, 4.139. *See also specific vessel*
anomalies of, 4.143*f*, 4.143–144, 4.144*f*
description of, 2.90

disease of. *See* Retinal disease, vascular
ischemia and, 4.140, 4.151, 4.151*f*, 4.152–156, 4.153*f*, 4.154*f*, 4.155*f*, 4.156*f*. *See also* Retinal ischemia
in retinoblastoma, 4.292, 4.292*f*, 4.293*f*
capillary hemangioblastoma of, 4.283–285, 4.284*f*. *See also* Retinal angiomatosis
cavernous hemangioma of, 4.285*f*, 4.285–286
cells of, 2.305
amacrine cells, 2.316
bipolar cells, 2.315–318, 2.316*f*
classes of, 2.315–318, 2.316*f*
ganglion cells, 2.317
glial cells, 2.317
horizontal cells, 2.315*f*, 2.316
neurons, 2.315–317, 2.328
vascular cells, 2.317–318
circulation of, 2.90, 12.16*f*, 12.16–17
combined hamartoma of the retina and retinal pigment epithelium, 6.350
congenital disorders of, 4.142*f*, 4.142–145, 4.143*f*, 4.144*f*, 4.145*f*
degenerations of. *See* Retinal degeneration
detachment of. *See* Retinal detachment
development of, 2.155, 2.155*f*, 2.306*f*
diabetes mellitus affecting. *See* Diabetic retinopathy
disorders of. *See* Retinal disease; Retinopathy; *specific type*
drug-induced toxicity of
alkyl nitrites, 12.300, 12.300*f*
chloroquine derivatives, 12.295–297, 12.296*f*
clofazimine, 12.298
deferoxamine, 12.298–299
dideoxyinosine, 12.299
hydroxychloroquine, 12.295–297, 12.296*f*
MEK inhibitors, 12.299, 12.299*f*
nucleoside reverse transcriptase inhibitors, 12.299
phenothiazines, 12.297–298, 12.298*f*
dystrophies of. *See* Retinal dystrophies
edema of. *See* Retinal edema
electro-oculography of, 12.50–51, 12.51–12.52*f*
electrophysiology of, 2.318–319, 12.41–42. *See also specific test*
electroretinography of. *See* Electroretinography/electroretinogram
emboli in, 5.166*t*. *See also* Emboli
transient visual loss caused by, 5.161, 5.162, 5.165, 5.165*f*, 5.165–169, 5.166*t*
embryology of, 2.83, 2.155, 2.155*f*
equatorial, 12.9–10
examination of
before cataract surgery, 11.80–81
imaging in. *See* Retina, imaging techniques in evaluation of
before refractive surgery, 13.44, 13.183
gliosis of, 4.157, 4.158, 4.158*f*
of peripapillary nerve fiber layer, 5.5, 5.109
growth and development of, 6.182, 6.325
gyrate atrophy of, 2.204*t*
hamartomas of, 4.179, 4.180*f*, 4.280, 4.280*f*
optic nerve/nerve head/disc drusen differentiated from, 5.108*f*, 5.143
healing/repair of, 4.17
hemangioblastomas of, 4.283–285, 4.284*f*
in von Hippel–Lindau disease/syndrome, 5.330, 5.331*f*, 5.334*t*, 12.165–166, 12.166*f*, 12.168
histologic sequelae of trauma to, 4.18–20, 4.20*f*
in HIV infection/AIDS. *See* Retinitis
hypertension-related complications of, 1.69–70, 1.70*t*
imaging techniques in evaluation of
angiography. *See* Fluorescein angiography; Indocyanine green angiography
OCT, 5.90–94, 5.92*f*, 5.93*f*, 5.94*f*
immune responses of, 9.57–59
immunologic microenvironment of, 9.57–58
immunoregulatory systems of, 9.59
infection/inflammation of, 4.145–148, 4.146*f*, 4.147*f*, 4.148*f*. *See also* Retinitis; *specific disease*
acute retinal necrosis, 12.236, 12.236*f*
cat-scratch disease, 12.242–243, 12.243*f*
cytomegalovirus retinitis, 12.235–236
diffuse unilateral subacute neuroretinitis, 12.246
endogenous bacterial endophthalmitis, 12.237–239, 12.238*f*
fungal endophthalmitis, 12.239, 12.239*f*
infectious causes, 12.235–247
Lyme disease, 12.245–246
necrotizing herpetic retinitis, 12.236–12.237*f*, 12.236–237, 12.238*t*
noninfectious causes, 12.219–234
progressive outer retinal necrosis syndrome, 12.236–237, 12.237*f*
syphilitic chorioretinitis, 12.241–242, 12.242*f*
toxocariasis, 12.244–245, 12.245*f*
toxoplasmic retinochoroiditis, 12.243–244, 12.244*f*
tuberculosis, 12.240–241, 12.241*f*
West Nile virus chorioretinitis, 12.246, 12.247*f*
white dot syndromes as cause of. *See* White dot syndromes
yeast endophthalmitis, 12.239–240, 12.240*f*
ischemic lesions of. *See* Retinal ischemia
layers of, 2.89*f*, 2.96*f*, 4.139–140, 4.140*f*, 4.141*f*. *See also* Retina, neurosensory
blood supply to, 12.140
external limiting membrane, 12.11, 12.12*f*
ganglion cell layer, 12.11, 12.12*f*
Henle fiber layer, 12.11, 12.12*f*
imaging of, 12.10–11, 12.11, 12.12*f*
inner nuclear layer, 12.11, 12.12*f*
inner plexiform layer, 12.11, 12.12*f*
internal limiting membrane, 12.11, 12.12*f*
middle limiting membrane, 12.11, 12.12*f*
nerve fiber layer, 12.11, 12.12*f*
optical coherence tomography angiography of, 12.29
outer nuclear layer, 12.11, 12.12*f*
outer plexiform layer, 12.11, 12.12*f*, 12.16
oxygen supply to, 12.16
lesions of, 12.378–379
in leukemia, 4.315, 4.315*f*
light-related injury to, 12.367. *See also* Retina, photic injury of
lymphoma of, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma

magnetic resonance imaging of, 2.459*t*
melanoma invading, 4.194, 4.195*f*
mesenchymal tissue, 6.325
metabolic needs of, 12.20
metastasis to, 9.309
microglia in, 9.57
nasal, 5.24*f*, 5.25, 5.27
necrosis of, acute, 4.145, 4.146*f*
neovascularization of. *See also* Neovascularization
in age-related macular degeneration, 4.161*f*, 4.164–166, 4.165*f*
ischemia causing, 4.154, 4.156*f*
in uveitis, 9.324–325
neural
anatomy of, 2.48*f*
development of, 2.155, 2.155*f*
lamination of, 2.155
neuro-ophthalmic elements of, 5.23–25, 5.24*f*, 5.25*f*
neurosensory, 4.139–140, 4.140*f*, 4.141*f*, 12.9–17
anatomy of, 4.139–140, 4.140*f*, 4.141*f*
cells of, 2.305
definition of, 2.84
description of, 2.83
external limiting membrane of, 2.91
ganglion cell layer of, 2.92
glial elements of, 2.88
inner nuclear layer of, 2.92
inner plexiform layer of, 2.92
internal limiting membrane of, 2.92
layers of, 2.84, 2.85*f*. *See also* Retina, layers of
middle limiting membrane of, 2.92
nerve fiber layer of, 2.92
neuronal elements of, 2.84–88, 2.86*f*
ischemia affecting, 4.151*f*, 4.151–152, 4.152*f*
outer nuclear layer of, 2.91–92
outer plexiform layer of, 2.91–92
retinal pigment epithelium and, 2.91
stratification of, 2.91–93, 2.93*f*
vascular elements of, 2.88–90, 2.90–91*f*. *See also* Retinal blood vessels
noninfectious inflammation of
acute idiopathic maculopathy, 12.228–229
acute macular neuroretinopathy, 12.228, 12.229*f*
acute zonal occult outer retinopathy, 12.226–228, 12.227*f*
white dot syndromes. *See* White dot syndromes
oxidative lens damage during surgery on, 11.20
oxygen supply to, 12.16*f*, 12.16–17
in pathologic myopia, 12.207–216, 12.209–12.215*f*
peripheral, 12.10. *See also* Peripheral retina
phakomas of, 6.397, 6.399. *See also* Phakoma/phakomatoses
photic injury of, during cataract surgery, 11.166
pigment epithelium of. *See* Retinal pigment epithelium
psychophysical testing of. *See* Psychophysical testing
reactive oxygen species vulnerability of, 2.340–341
retinal pigment epithelium separation of, 12.17
"Rim" proteins, 2.308
splitting of. *See* Retinoschisis, X-linked
surface of, in exudative retinal detachment, 12.326
temporal, 5.24*f*, 5.25
thickness of
description of, 2.93
in pathologic myopia, 12.208
topography of, 2.93–97, 2.96*f*, 4.139–140, 4.140*f*, 4.141*f*, 12.9*f*, 12.9–10
tuberculosis involvement of, 9.237–238
tumors of, 4.172–180. *See also* Retinoblastoma
glaucoma caused by, 10.98–100, 10.99*f*, 10.138
metastatic, 4.303, 4.308, 4.309*f*
pigmented, 4.279–280, 4.280*f*
in uveitis. *See* Posterior uveitis
vascular occlusion of, 12.231
vasculature of, 6.182, 6.325, 12.180
description of, 2.155, 12.16*f*, 12.16–17
optical coherence tomography angiography of, 12.29, 12.30*f*
veins of, 2.90
venous pressure in, 12.125
visual evoked cortical potentials of, 12.52–53
visual pathways of, 2.115
in von Hippel–Lindau disease. *See* Retinal angiomatosis
zones of, 6.328*f*
Retinal Acuity Meter (RAM), in cataract surgery evaluation, 11.81
Retinal angiography. *See* Fluorescein angiography; Indocyanine green angiography
Retinal angiomatosis (angiomatosis retinae, von Hippel/von Hippel–Lindau syndrome/disease), 4.144, 4.144*f*, 4.283–285, 4.284*f*, 5.330, 5.331*f*, 5.334*t*, 6.400*f*
Retinal angiomatous proliferations (RAPs), 12.72, 12.78*f*
Retinal arterial arcades, inferior/superior, 5.14
Retinal arterial macroaneurysms, 12.147–148, 12.148*f*
Retinal arterioles
obstruction of. *See* Cotton-wool spots
optic nerve supplied by, 5.17*f*, 10.45
Retinal arteriovenous anastomoses, in Takayasu arteritis, 1.170
Retinal artery, 5.17*f*
central (CRA), 5.12, 5.13*f*, 5.14, 5.14*f*, 5.16*f*, 5.17*f*, 10.44–45, 10.45*f*. *See also* Central retinal artery
optic nerve supplied by, 5.17*f*, 5.26, 10.44–45, 10.45*f*
microaneurysms of, 4.154, 4.155*f*
in diabetes mellitus, 4.155*f*, 4.159
in diabetic retinopathy, 4.159
in retinal vein occlusion, 4.158, 4.159
occlusion of. *See* Retinal artery occlusion
Retinal artery occlusion
branch. *See* Branch retinal artery occlusion
capillary retinal arteriole obstruction, 12.140*f*, 12.140–141
central. *See* Central retinal artery occlusion
ciliroretinal artery occlusion, 12.143
ophthalmic artery occlusion, 12.146, 12.147*f*
paracentral acute middle maculopathy, 12.143
transient visual loss and, 5.161
Retinal blur, vergence system and, 5.226
Retinal breaks, 2.471*f*. *See also* Retinal tears
aphakia and, 12.319
asymptomatic, 12.318
classification of, 12.315

cryotherapy of, as prophylactic treatment, 12.317
definition of, 12.314
description of, 12.396
lattice degeneration and, 12.310
Lincoff rules for finding, 12.320, 12.322*f*
posterior vitreous detachment and, 12.309
prophylactic treatment of, 12.317*t*, 12.317–320
pseudophakia and, 12.319
retinal detachment caused by
illustration of, 12.318*f*
prophylactic treatment to prevent, 12.317*t*, 12.317–320
rhegmatogenous, 12.314–315, 12.320, 12.322*f*, 12.324
significance of, 12.314
symptomatic, 12.318
traumatic, 12.315–316, 12.316*f*
vitreoretinal traction as cause of, 12.315
Retinal capillaries
nonperfusion of, in diabetic retinopathy, 12.101
perifoveal, 12.157
Retinal capillary hemangioblastomas, 6.400
Retinal capillary hemangioma, 4.283–285, 4.284*f*
Retinal correspondence
anomalous
afterimage test for, 6.79*f*
definition of, 6.50
diplopia and visual confusion eliminated with, 6.49*f*
eccentric fixation *versus*, 6.51
Maddox rod testing in, 6.68
major amblyoscope for, 6.70
red-glass test findings in, 6.76*f*
after strabismus surgery, 6.50
testing for, 6.50–51
description of, 6.41–42
normal
afterimage test for, 6.79*f*
strabismus and, 6.48, 6.49*f*
testing for, 6.51
"Retinal crystals." *See* Refractile bodies/spots
Retinal degeneration, 4.148–170, 4.171*f*, 4.172*f*, 6.385. *See also* Pigmentary retinopathy; Retinal disease; Retinal dystrophies; Retinopathy; *specific type*
amino acid disorders that cause, 12.293
autoimmune causes of, 12.286–287
cancer-associated retinopathy as cause of, 12.286, 12.287*f*
dental diseases associated with, 12.286
dermatologic diseases associated with, 12.286
gastrointestinal diseases associated with, 12.285–286
gene defects that cause, 2.312, 2.314*t*
hearing loss and. *See* Usher syndrome
ischemic, 4.140, 4.150–160. *See also* Retinal ischemia
lattice, 4.148–150, 4.149*f*
radial perivascular, 4.150
liver diseases associated with, 12.285
melanoma-associated retinopathy as cause of, 12.286
metabolic diseases that cause
abetalipoproteinemia, 12.289–290
albinism, 12.288
central nervous system, 12.288–292
lysosomal, 12.291–292, 12.292*f*
mucopolysaccharidoses, 12.290–291
neuronoid ceroid lipofuscinoses, 12.289, 12.290*f*
Niemann-Pick disease, 12.291
peroxisomal disorders, 12.290
Refsum disease, 12.290
Tay-Sachs disease, 12.291, 12.292*f*
vitamin A deficiency, 12.289–290
Zellweger syndrome, 12.290
mitochondrial disorders that cause, 12.293–294
neuromuscular disorders associated with, 12.285
paraneoplastic retinopathies that cause, 12.286–287
paving-stone (cobblestone), 4.150, 4.150*f*, 12.313, 12.314*f*
peripheral cystoid, 4.148, 4.149*f*
reticular (RPCD), 4.148, 4.149*f*, 12.326
typical (TPCD), 4.148, 4.149*f*, 12.326
renal diseases associated with, 12.285
systemic disorders associated with
Bardet-Biedl syndrome, 12.281, 12.282*t*, 12.284, 12.284*f*
Leber congenital amaurosis, 12.281
list of, 12.282–12.283*t*
overview of, 12.281
Usher syndrome, 12.284
Retinal detachment, 4.130*f*, 4.130–131, 4.131*f*
angle-closure glaucoma and, 10.141
anterior segment trauma and, 8.409
after cataract surgery, 6.304, 11.127, 11.166–167, 12.319
family history as risk factor and, 11.75
Nd:YAG laser capsulotomy and, 11.157, 11.166
central serous chorioretinopathy as cause of, 12.189, 12.191
choroidal hemangioma and, 4.281, 4.283
choroidal melanoma/ciliary body melanoma and, 4.193*f*, 4.194, 4.194*f*, 4.263, 4.264*f*
choroidal nevi and, 4.156–157, 4.257*f*
chronic, 12.324*f*
classification of, 12.320
in Coats disease, 4.143, 4.143*f*, 4.295, 4.295*f*
cobblestone degeneration and, 12.313, 12.314*f*
in cytomegalovirus retinitis, 9.324, 9.329
definition of, 2.98
description of, 2.93, 2.331
diagnostic features of, 12.320, 12.321*t*
differential diagnosis of
description of, 12.320
retinoschisis, 12.326–328
extrafoveal, in retinopathy of prematurity, 6.329*f*
exudative
causes of, 12.320
diagnostic features of, 12.321*t*
in familial exudative vitreoretinopathy, 12.343
glaucoma and, 10.141
imaging of, 12.325*f*
management of, 12.325–326
photocoagulation as cause of, 12.379
retinal surface in, 12.326
subretinal fluid findings in, 12.326
in fellow eye, 12.319
glaucoma and, 10.141
hallucinations caused by, 5.175
lattice degeneration and, 4.148, 4.150, 12.309–311, 12.310–12.311*f*, 12.316*f*, 12.319

lesions not predisposing to, 12.313–314
lesions predisposing to, 12.309–312, 12.310–12.313*f*
in leukemia, 4.315
macular hole as cause of, 12.330, 12.330*f*
macular lesions associated with, 12.328–329
management of, 12.324, 12.324*f*
meridional folds and, 12.312, 12.313*f*
metastatic eye disease and, 4.305–306, 4.306*f*
myopia/high myopia and, 13.44, 13.183–184, 13.184, 13.197
after Nd:YAG laser capsulotomy, 11.157, 11.166
nonrhegmatogenous. *See* Retinal detachment, exudative
optic pit maculopathy and, 12.328–329, 12.329*f*
paving-stone degeneration and, 12.313, 12.314*f*
peripheral cystoid degeneration and, 12.314
phakic IOLs and, 13.138, 13.145, 13.146
iris-fixated lenses, 13.145
posterior chamber lenses, 13.146
posterior vitreous detachment and, cataract surgery and, 11.166
proliferative vitreoretinopathy and, 4.131, 4.131*f*
after refractive lens exchange, 13.148
refractive surgery and, 13.44, 13.183–184, 13.184, 13.197
in retinal angiomatosis/hemangioblastoma/von Hippel–Lindau disease/syndrome, 4.284
retinal pigment epithelial hyperplasia and, 12.313–314
retinal pigment epithelial hypertrophy and, 12.314
retinal tear progression to, 12.347
in retinoblastoma, 4.292, 4.293*f*
retinopathy of prematurity as risk factor for, 6.334
in retinoschisis, 12.328
rhegmatogenous (RRD), 2.332
after cataract surgery, 11.166–167
family history as risk factor and, 11.75
Nd:YAG laser capsulotomy and, 11.157, 11.166
child abuse and, 6.384
chronic, 12.324*f*
chronic peripheral, 9.311
complex, 12.401
definition of, 12.396
description of, 4.130*f*, 4.130–131, 4.131*f*
diagnostic features of, 12.320, 12.321*t*
floaters associated with, 12.320
glaucoma and, 10.141
incidence of, 12.320
intraocular pressure in, 12.320
lattice degeneration associated with, 12.310
"macula-off," 12.401
macular hole as cause of, 12.330, 12.330*f*
management of, 12.324, 12.324*f*, 12.397
pigmented demarcation lines with, 12.324
pneumatic retinopexy for, 12.324, 12.397–398, 12.398*f*
posterior vitreous detachment and, after cataract surgery, 11.166
proliferative vitreoretinopathy associated with, 12.320, 12.323*t*, 12.323*f*, 12.323–324
reattachment surgery for, 12.401–402
retinal breaks as cause of, 12.314–315, 12.396
retinoschisis *versus*, 12.320, 12.322*f*, 12.327*t*, 12.327–328
risk factors for, 9.151, 12.396
scatter photocoagulation as cause of, 12.155
Schwartz (Schwartz-Matsuo) syndrome and, 10.109
scleral buckling for, 12.324, 12.398–400, 12.399*f*
Shafer sign, 12.320
surgical repair of, 12.397–401, 12.398–400*f*
tractional retinal detachment *versus*, 12.325
uveitis as cause of, 9.324
vision loss caused by, 12.128
vitrectomy for, 12.324, 12.400*f*, 12.400–401
word origin of, 12.320
Schwartz (Schwartz-Matsuo) syndrome and, 10.109
scleral buckle for
after cataract surgery, 11.166–167
refractive surgery after, 13.185
scleral perforation as cause of, 6.170
secondary (nonrhegmatogenous). *See* Retinal detachment, exudative
serous, 6.362
in intraocular lymphoma, 12.234
MEK inhibitors as cause of, 12.299
in sickle cell retinopathy, 12.155
in Stickler syndrome, 6.346
subclinical, 12.319–320
surgery for
angle-closure glaucoma after, 10.143
description of, 6.146
LASIK and, 13.185, 13.197
refractive surgery and, 13.185, 13.197
vitrectomy. *See* Retinal detachment, vitrectomy for
tractional, 6.348*f*, 6.360
causes of, 12.320
description of, 12.286
diagnostic features of, 12.321*t*, 12.325
in familial exudative vitreoretinopathy, 12.343
imaging of, 12.387*f*
management of, 12.325
pathophysiology of, 12.387
in proliferative diabetic retinopathy, 12.103, 12.108, 12.387–388
rhegmatogenous retinal detachment *versus*, 12.325
vitrectomy for, 12.325, 12.387–388
trauma and
anterior segment, 8.409
description of, 12.317
in uveal lymphoid proliferation/infiltration, 4.314
vitrectomy for, refractive surgery after, 13.185
vitreoretinal tufts and, 12.311–312, 12.312*f*
vitreous contraction as cause of, 12.349
Retinal dialyses, 4.19–20, 4.20*f*, 12.315
Retinal disease and disorders, 4.139–180. *See also* Macula/macula lutea, diseases of; Retinitis; Retinopathy; *specific type*
acquired, 6.358–360, 6.359*f*
angiography in. *See* Fluorescein angiography; Indocyanine green (ICG) angiography
arterial macroaneurysms, 12.147–148, 12.148*f*
arterial occlusive
branch retinal artery occlusion. *See* Branch retinal artery occlusion

capillary retinal arteriole obstruction, 12.140*f*, 12.140–141
central retinal artery occlusion. *See* Central retinal artery occlusion
cilioretinal artery occlusion, 12.143
ophthalmic artery occlusion, 12.146, 12.147*f*
paracentral acute middle maculopathy, 12.143
after cataract surgery, 11.163–167, 11.164*f*
cataract surgery in patient with, 11.189
Coats disease, 6.358–360, 6.359*f*
combined hamartoma of the retina and retinal pigment epithelium, 6.350
congenital/developmental, 4.142*f*, 4.142–145, 4.143*f*, 4.144*f*, 4.145*f*
degenerative, 4.148–170, 4.171*f*, 4.172*f*. *See also* Retinal degeneration
in diabetes mellitus. *See* Diabetic retinopathy
electrophysiologic testing in, 5.95–97, 5.96*f*. *See also specific test*
ERG in, 5.96*f*, 5.96–97
hallucinations caused by, 5.175
hereditary
achromatopsia, 6.337–338
Aicardi syndrome, 6.338–339, 6.339*f*
congenital stationary night blindness, 6.338
evaluative tests for, 6.335
foveal hypoplasia, 6.338
Leber congenital amaurosis, 6.335–336, 6.337*f*
nystagmus associated with, 6.335
paradoxical pupils associated with, 6.335, 6.336*t*
human immunodeficiency virus complications, 6.348
illusions caused by, 5.174–175
imaging modalities for
adaptive optics imaging, 12.33
fluorescein angiography, 12.33–38, 12.34*f*, 12.36–12.37*f*
fundus autofluorescence, 12.29, 12.31–33
fundus camera imaging, 12.22–23, 12.23*f*
indirect ophthalmoscopy, 12.21–22
indocyanine green angiography, 12.38–39
ophthalmoscopy, 12.21–22
optical coherence tomography, 12.25–27, 12.27*f*. *See also* Optical coherence tomography
optical coherence tomography angiography, 12.28–29
scanning laser ophthalmoscopy, 12.24
ultrasonography, 12.39–40
infectious, 6.348
inflammatory, 4.145–148, 4.146*f*, 4.147*f*, 4.148*f*. *See also* Retinitis; *specific disease*
infectious, 4.145–148, 4.146*f*, 4.147*f*, 4.148*f*
macular dystrophies
Best disease, 6.340–342, 6.342*f*
Stargardt disease, 6.339–340, 6.340–341*f*
neoplastic, 4.172–180. *See also* Retinoblastoma
glaucoma caused by, 10.98–100, 10.99*f*
metastatic, 4.303, 4.308, 4.309*f*
pigmented, 4.279–280, 4.280*f*
nystagmus associated with, 5.236
psychophysical testing in. *See specific test*
refractive surgery and, 13.44, 13.183–185
retinoblastoma. *See* Retinoblastoma
retinopathy of prematurity. *See* Retinopathy of prematurity
tumors, 6.349–358
vascular. *See also* Retinal vasculitis; *specific type*
angle-closure glaucoma and, 10.84, 10.134–135, 10.141, 10.143–144
arterial occlusion. *See* Retinal artery occlusion
branch retinal vein occlusion. *See* Branch retinal vein occlusion (BRVO)
cavernous hemangioma, 4.285*f*, 4.285–286, 12.168, 12.169*f*
central retinal vein occlusion. *See* Central retinal vein occlusion
Coats disease, 12.159–161, 12.160*f*, 12.326
congenital, 4.143*f*, 4.143–144, 4.144*f*
cystoid macular edema. *See* Cystoid macular edema
in diabetes mellitus, 4.159. *See also* Diabetic retinopathy
hypertension, 12.121–125, 12.122–124*f*
macular telangiectasia. *See* Macular telangiectasia
microaneurysms, 4.154, 4.155*f*
in diabetes mellitus, 4.155*f*, 4.159
in diabetic retinopathy, 4.159
in retinal vein occlusion, 4.158, 4.159
ocular ischemic syndrome, 12.138–140, 12.139*f*
Purtscher retinopathy, 12.171–173, 12.173*t*
Purtscherlike retinopathy, 12.171–173, 12.172*f*, 12.173*t*
radiation retinopathy, 12.170*f*, 12.170–171
retinal vein occlusion. *See* Retinal vein occlusion (RVO)
sickle cell retinopathy. *See* Sickle cell retinopathy
systemic arterial hypertension, 12.121–125, 12.122–12.124*f*
Terson syndrome, 12.173
Valsalva retinopathy, 12.171
vasculitis and, 12.155*f*, 12.155–156. *See also* Retinal vasculitis
venous occlusion. *See* Retinal vein occlusion
von Hippel–Lindau disease/syndrome and, 4.144, 4.144*f*, 4.284–285, 5.330, 5.331*f*, 5.334*t*, 12.165–168, 12.166–167*f*
Wyburn-Mason syndrome and, 4.286*f*, 4.286–287, 5.331, 5.333*f*, 5.334*t*, 12.168
vitreoretinopathies
familial exudative, 6.347–348, 6.348*f*
juvenile retinoschisis. *See* Retinoschisis, X-linked
Knobloch syndrome, 6.346*f*, 6.346–347
Norrie disease, 6.347
Stickler syndrome, 6.345–346
Retinal disparity, vergence system and, 5.226
Retinal dystrophies. *See also* Retinal degeneration; *specific type*
classification of, 12.255
congenital sensory nystagmus from, 6.154
hereditary. *See also* Hereditary dystrophies; *specific type*
bilateral symmetric involvement of, 12.258
blindness concerns of patients with, 12.260
cystoid macular edema in, 12.260, 12.260*f*
diagnostic considerations for, 12.258–259
enhanced S-cone disease, 12.266, 12.267*f*

gene therapy for, 12.260, 12.266
genes and loci associated with, 12.256–257*t*
genetic considerations for, 12.259
inheritance patterns for, 12.259
Leber congenital amaurosis, 12.265–266
management of, 12.259–260, 12.260*f*
molecular genetic testing for, 12.259
photoreceptor (diffuse), 4.170, 4.172*f*
rod–cone dystrophies, 12.261–264, 12.262–264*f*
stem cell therapy for, 12.260
infantile nystagmus syndrome and, 5.236
inner, 12.278–279
juvenile, 6.390*f*
nystagmus associated with, 6.391*f*
sporadic, 12.263
X-linked retinoschisis, 12.278*f*, 12.278–279
Retinal edema, 4.152, 4.153*f*, 4.154*f*. *See also* Macular edema
illusions and, 5.174–175
myopia choroidal neovascularization as cause of, 12.212
Retinal folds
in familial exudative vitreoretinopathy, 12.343, 12.345*f*
fixed, 12.326
Retinal ganglion cells (RGCs), 2.335, 12.45. *See also* Ganglion cells/ganglion cell layer
apoptosis of, 6.44
development of, 6.44
Retinal gene therapy, 9.58
Retinal grafts, 12.340
Retinal hemorrhages
in abusive head trauma, 6.382–383, 6.382–383*f*, 12.366, 12.366*f*
in branch retinal vein occlusion, 4.159
in carotid occlusive disease, 12.138
in central retinal vein occlusion, 4.156, 4.158*f*
dot-and-blot, 4.153–154, 4.155*f*, 5.170, 5.171*f*
ischemia causing, 4.153–154, 4.155*f*, 5.170, 5.171*f*
flame, ischemia causing, 4.153, 4.155*f*
ischemia causing, 4.153–154, 4.155*f*, 5.170, 5.171*f*
in leukemia, 4.315, 6.414
Retinal holes
atrophic
definition of, 12.315
lattice degeneration and, 4.150, 12.310, 12.311*f*, 12.316*f*
retinal detachment secondary to, 12.310
description of, 12.378
lattice degeneration and, 4.150, 12.310, 12.311*f*, 12.316*f*
operculated, 12.315–316
Retinal image size, 3.126
Retinal ischemia, 4.140, 4.150–160, 12.140
cataract surgery and, 11.80–81
cellular responses to, 4.151*f*, 4.151–152, 4.152*f*
central and branch retinal artery and vein occlusions causing, 4.151*f*, 4.156–159, 4.157*f*, 4.158*f*
diabetic retinopathy and, 4.155*f*, 4.159–160, 4.160*f*, 4.161*f*
illusions and, 5.175
inner ischemic retinal atrophy and, 4.151, 4.151*f*
in diabetic retinopathy, 4.159
in retinal arterial and venous occlusions, 4.156, 4.159
outer ischemic retinal atrophy and, 4.151, 4.151*f*
stroke and, 5.167, 5.168–169
transient visual loss and, 5.161, 5.164, 5.167, 5.168–169
vascular responses to, 4.152–156, 4.153*f*, 4.154*f*, 4.155*f*, 4.156*f*
Retinal light toxicity. *See* Photic damage/phototoxicity/light toxicity
Retinal (intraocular/primary central nervous system) lymphoma, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
Retinal necrosis, 9.279*f*
Retinal neovascularization. *See also* Neovascularization; Retinal disease, vascular
in age-related macular degeneration, 4.161*f*, 4.164–166, 4.165*f*
ischemia causing, 4.154, 4.156*f*
Retinal nerve fiber layer (RNFL). *See* Nerve fiber layer
Retinal nerve fibers, 4.140. *See also* Nerve fiber layer
distribution of, 10.42–43, 10.43*f*
imaging in evaluation of, 10.53–59, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
loss of, in glaucoma, 10.50–52, 10.51*f*
myelinated, 4.143
Retinal organoids, 2.166–167
Retinal photocoagulation, 3.118
Retinal pigment epithelium (RPE), 4.139, 4.140*f*, 4.141, 4.141*f*, 5.24
abnormalities of
in age-related macular degeneration, 12.66–67
central serous chorioretinopathy as cause of, 12.67
focal atrophy, 12.66
geographic atrophy, 12.64, 12.66, 12.67*f*, 12.68
hyperpigmentation, 12.68
pattern dystrophies, 12.67
acute posterior multifocal placoid pigment epitheliopathy involvement of, 9.171
acute zonal occult outer retinopathy involvement in, 9.190, 9.190*f*
adenomas/adenocarcinomas of, 4.180, 4.279
age-related changes in, 12.62
anatomy of, 2.77*f*, 4.139, 4.140*f*, 4.141, 4.141*f*, 5.24, 12.17–19, 12.18*f*
antioxidants in, 2.341–343
apical membrane of, 2.330
atrophy of, 4.164, 4.164*f*, 12.106*f*, 12.294*f*
in cone dystrophies, 5.102
autophagy in, 2.332
barrier functions of, 12.18
basal surface of, 2.321
biochemical composition of, 2.323–324
birdshot chorioretinopathy findings in, 9.166
burns of, during cataract surgery, 11.166
cells of
11-*cis*-retinal generation by, 2.326
bis-retinoid accumulation in, 12.31
cytoplasm of, 2.99
description of, 2.97, 12.17, 12.20
in epiretinal membranes, 12.334
fluorescein angiography of, 12.34

functions of, 2.98–99
illustration of, 2.322*f*
melanin granules in, 2.321, 2.323
Na^+,K^+-ATPase in, 2.324
number of, 2.321
pigment-laden, 12.66
choriocapillaris and, 2.322*f*
choroidal nevi and, 4.256, 4.257*f*
combined hamartoma of the retina and, 6.350
congenital abnormalities of, 4.142*f*, 4.142–145, 4.143*f*, 4.144*f*, 4.145*f*
hypertrophy (CHRPE), 4.144–145, 4.145*f*, 4.268–269, 4.269*f*, 6.349, 6.349*f*
in familial adenomatous polyposis, 2.201, 2.202*f*
melanoma differentiated from, 4.144, 4.268–269, 4.269*f*
cytokine synthesis by, 9.58
degeneration of, 12.258
depigmentation of, 12.227, 12.293
detachment of (PED/RPED). *See also* Pigment epithelial detachments (PEDs); Retinal detachment
multiple recurrent serosanguineous (polypoidal choroidal vasculopathy), 4.166*f*, 4.166–168, 4.167*f*
in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.135, 4.135*f*, 4.136*f*
development of, 2.157, 2.306*f*, 2.321
in disease, 2.332–333, 2.333*t*
disorders of, 4.139–180. *See also specific type*
drugs that affect
alkyl nitrites, 12.300, 12.300*f*
chloroquine derivatives, 12.295–297, 12.296*f*
chlorpromazine, 12.297
clofazimine, 12.298
deferoxamine, 12.298–299
dideoxyinosine, 12.299
MEK inhibitors, 12.299, 12.299*f*
nucleoside reverse transcriptase inhibitors, 12.299
phenothiazines, 12.297–298
thioridazine, 12.297
electro-oculography of, 12.50
embryology of, 2.97
functions of, 2.97, 12.17–18
genetic defects in, 2.332
geographic atrophy of, 4.164, 4.164*f*
glucose in, 2.323
hamartoma of
combined, 4.179, 4.180*f*, 4.280, 4.280*f*
in Gardner syndrome, 4.145
simple, 4.279, 4.280*f*
healing/repair of, 4.17
histology of, 2.329*f*
hyperpigmentation of, 12.106*f*
hyperplasia of
around retinal tuft, 12.312
retinal detachment and, 12.313–314
hypertrophy of, 12.314
congenital (CHRPE), 4.144–145, 4.145*f*, 4.268–269, 4.269*f*, 6.349, 6.349*f*
in familial adenomatous polyposis, 2.201, 2.202*f*
melanoma differentiated from, 4.144, 4.268–269, 4.269*f*
immune responses of, 9.57–59
immunologic microenvironment of, 9.52*t*, 9.57–58
immunoregulatory systems of, 9.59
in Knobloch syndrome, 6.346
leaks from, 12.190, 12.190*f*
in Leber congenital amaurosis, 6.336
lesions of, 6.349, 6.349*f*
lipids in, 2.324
lipofuscin in, 9.89, 12.32
lipofuscin-like material, 12.270, 12.270*f*
major histocompatibility class II molecule expression by, 9.57
melanin pigment in, 2.331
net ionic fluxes in, 2.330
neurosensory retina and, 2.91
nucleic acids in, 2.324
nummular loss of, 12.204
ocular histoplasmosis syndrome findings in, 9.273
peripapillary changes in, 9.190*f*
phagocytosis of shed photoreceptor outer-segment discs by, 2.328
phosphatidylcholine in, 2.324
phosphatidylethanolamine in, 2.324
physiologic roles of, 2.324–332, 2.325*f*
pigments/pigmentation of, 2.331, 12.214, 12.277
description of, 12.12*f*, 12.17
mottling of, 12.79, 12.87, 12.90*f*
in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.135, 4.135*f*, 4.136*f*, 4.136–137, 4.311, 9.305
progressive atrophy of, 12.66
proteins in, 2.323–324
in retinal adhesion, 2.331–332
retinal separation from, 12.17
in retinitis pigmentosa, 4.170, 4.172*f*
RPE65 expression in, 2.324
rubella as cause of, 9.260
secretions by, 2.332
serpiginous choroiditis findings in, 9.175
siderosis bulbi effects on, 12.362
standing potential, 12.50, 12.51*f*
in Stargardt disease, 4.168–169*f*, 4.169–170, 6.339, 6.341*f*, 12.270, 12.270*f*
structure of, 2.321–323
subretinal fibrosis in, 9.178
tears of
autofluorescence of, 12.31, 12.32*f*
in choroidal neovascularization, 12.31
fibrovascular pigment epithelial detachment as risk for, 12.82
thermal injury to, 12.367
tight junctions in, 2.85
toll-like receptor expression by, 9.57
topography of, 4.140*f*, 4.141, 4.141*f*
transport proteins in, 2.330
tumors of, 4.180
vitamin A regeneration in, 2.326–328, 2.327*f*
water transport in, 12.18
Retinal precipitates, 12.241
Retinal reflex
aberrations of, 3.159
break in, 3.156, 3.157*f*
description of, 3.152–153*f*, 3.152–153

against movement, 3.152, 3.153*f*, 3.155
with movement, 3.152, 3.153*f*, 3.155
skew of, 3.156, 3.157*f*
width of, 3.156, 3.157*f*
Retinal rivalry, 6.47, 6.47*f*
Retinal scars, 4.17
Retinal sclopetaria, 4.22, 12.356–358, 12.357*f*
Retinal tears, 4.20, 4.20*f*, 4.129–130, 4.130*f*. *See also* Retinal breaks
chorioretinal adhesions around, using laser retinopexy, 12.377
classification of, 12.315
flap, 12.315, 12.318–319
giant, 12.315
horseshoe-shaped, 12.316, 12.323*f*
lattice degeneration and, 4.150
mechanisms of, 12.308*f*
ora bays and, 12.312
peripheral retinal excavations and, 12.312–313
posterior vitreous detachment as cause of, 12.307, 12.308*f*, 12.309
retinal detachment, progression of, 12.347
ultrasonography of, 12.39
vitreoretinal/vitreous traction and, 4.129–130
in vitreous hemorrhage, 12.347
Retinal telangiectasia. *See* Coats disease
Retinal transient ischemic attack (RTIA)
stroke and, 5.167, 5.168–169
transient monocular visual loss and, 5.164, 5.167, 5.168–169, 5.171
Retinal tufts, 12.311–312, 12.312*f*
Retinal vascular occlusive disease, in systemic lupus erythematosus, 9.154, 9.155*f*
Retinal vascular sheathing, 12.231*f*
Retinal vasculitis, 1.9, 12.155*f*, 12.155–156
characteristics of, 9.75
diseases associated with, 9.75*t*
human leukocyte antigen association with, 9.65*t*
in posterior uveitis, 9.74*t*
in uveitis. *See* Posterior uveitis
vasculopathy *versus*, 9.75
Retinal vasospasm, transient visual loss and, 5.161, 5.162, 5.171
Retinal vein, 5.17*f*
arcade, 5.21
central (CRV), 2.26*f*, 2.111, 2.120, 5.17*f*, 5.21, 5.21*f*, 10.44, 10.45*f*, 10.46
optic nerve drained by, 5.17*f*, 10.45*f*, 10.46
occlusion of. *See* Retinal vein occlusion
Retinal vein occlusion (RVO)
aflibercept for, 12.135
anti-VEGF drugs for, 12.126, 12.136–137
bevacizumab for, 12.135
branch (BRVO), 4.158–159
aflibercept for, 12.135
at arteriovenous crossing, 12.126
bevacizumab for, 12.135
clinical findings of, 12.125–127, 12.126*f*
corticosteroids for, 12.137–138
diabetes mellitus and, 12.128
fluorescein angiography of, 12.129*f*
glaucoma as risk factor for, 12.125
hypertensive retinopathy and, 12.122
intraretinal hemorrhages associated with, 12.125, 12.126*f*
macular laser surgery for, 12.128
neovascularization in, 4.159, 12.125, 12.128, 12.129*f*
pars plana vitrectomy for, 12.130
pharmacologic management of, 12.135–138
prognosis for, 12.128
ranibizumab for, 12.135
risk factors for, 12.127–128
scatter photocoagulation for, 12.128–130
spontaneous resolution of, 12.125
surgical management of, 12.128–130
treatment of, 12.128–130
triamcinolone for, 12.137
vision loss caused by, 12.128
central (CRVO), 1.148, 4.156–158, 4.158*f*
aflibercept for, 12.135
age and, 12.133
angle-closure glaucoma and, 10.143–144
neovascularization and, 10.134–135
bevacizumab for, 12.135
causes of, 12.133–134
chronic changes caused by, 12.127*f*
cilioretinal artery occlusion caused by, 12.143
clinical findings of, 12.127*f*, 12.130
complications of, 12.135
corticosteroids for, 12.137–138
cystoid macular edema caused by, 12.136*f*
differential diagnosis of, 12.134
diuretic and, 12.134
electroretinography findings in, 12.50
evaluation of, 12.134–135
follow-up for, 12.134
hypercoagulable conditions presenting with, 12.134
hypertensive retinopathy and, 12.122
hyperviscosity retinopathy *versus*, 12.134
intraocular pressure in, 12.133
iris neovascularization in, 12.133, 12.135
ischemic/complete/nonperfused, 4.156, 4.157–158, 4.158*f*, 12.132*f*
macular laser surgery for, 12.135
management of, 12.134–135
neovascularization in, 12.125
nonischemic, 12.130, 12.131*f*
ocular ischemic syndrome *versus*, 12.134
open-angle glaucoma and, 10.84, 12.133
oral contraceptives and, 12.134
panretinal photocoagulation for, 12.135
papillophlebitis and, 5.125–126, 5.126*f*
pars plana vitrectomy for, 12.135
pharmacologic management of, 12.135–138
progression of, follow-up for, 12.134
ranibizumab for, 12.135
retinal microvascular changes in, 12.125, 12.127*f*
risk factors for, 12.133–134
spontaneous resolution of, 12.125
transient visual loss and, 5.170
treatment of, 12.135
vision loss caused by, 12.130
vitreous hemorrhage secondary to, 12.135
cystoid macular edema caused by, 12.135, 12.136*f*
dexamethasone implant for, 12.137
glaucoma as risk factor for, 12.125

improvements in, 12.125
intravitreal corticosteroids for, 12.137–138
ocular examination for, 12.125
panretinal photocoagulation for, 12.126
pharmacologic management of, 12.135–138
ranibizumab for, 12.135
spontaneous resolution of, 12.125
transient visual loss and, 5.170
triamcinolone for, 12.137
Retinitis
in acute retinal necrosis, 4.145, 4.146*f*, 5.350
Chikungunya virus, 9.268, 9.268*f*, 12.247
cytomegalovirus, 1.262, 1.279, 4.145, 4.146*f*, 5.349, 6.411, 12.235–236, 12.238*t*
characteristics of, 9.254–257
in children, 9.255–256
in HIV/AIDS patients, 5.349, 9.256, 9.328–329
imaging of, 9.255*f*
retinal detachments secondary to, 9.324, 9.329
treatment of, 9.256–257
Epstein-Barr virus, 9.257–258, 9.258*f*
foveomacular. *See* Solar retinopathy
herpetic, 4.145, 5.350
necrotizing, 4.145, 12.236–12.237*f*, 12.236–237, 12.238*t*
in neuroretinitis, 12.242
nonnecrotizing herpetic, 9.250–254
pigmentosa. *See* Retinitis pigmentosa
solar. *See* Solar retinopathy
syphilitic, 9.222, 9.224*f*
in toxoplasmosis, 4.147–148, 4.148*f*
Retinitis pigmentosa (RP), 4.170, 4.172*f*, 9.192, 9.310. *See also* Rod–cone dystrophies
autofluorescence imaging of, 12.261
autosomal dominant, 2.207, 2.312
autosomal recessive, 2.312
cataract/cataract surgery in patient with, 11.68
clinical presentation of, 12.261
congenital stationary night blindness *versus*, 12.251
cystoid macular edema associated with, 12.260
description of, 2.180
electroretinography findings in, 12.44, 12.261
electroretinography in, 5.96
fundal findings in, 12.261, 12.262*f*
genes and loci associated with, 12.257*t*
genetics of, 4.170. *See also specific mutation type*
hearing loss and, 12.284. *See also* Usher syndrome
inheritance patterns for, 2.207, 2.211
MAK-associated, 2.229
management of, 12.264
nutritional supplements for, 12.264
retinal pigment epithelium in, 4.170, 4.172*f*
sectorial, 12.263, 12.264*f*
sine pigmento, 12.261
spectral-domain optical coherence tomography findings, 12.263*f*
unilateral, 12.263
visual fields in, 12.263*f*
X-linked, 2.231*f*, 12.50
Retinitis punctata albescens, 12.258, 12.258*f*
Retinoblastoma (RB), 4.172–177, 4.253, 4.289–302, 7.136, 9.308–309
aniridia *versus*, 2.226
bilateral, 6.357*f*
brachytherapy for, 4.301
chemotherapy for, 4.253, 4.299–300, 4.300*f*, 6.356–357
classification of, 4.297, 4.297*t*, 6.354, 6.356*t*
clinical evaluation/diagnosis of, 4.291*f*, 4.291*t*, 4.291–294, 4.292*f*, 4.293*f*, 4.294*f*
differential diagnosis and, 4.294*t*, 4.294–297, 4.295*f*, 4.296*f*
clinical trials in, 4.301
Coats disease *versus*, 4.295, 4.295*f*, 6.352–353, 6.360
conditions associated with, 4.298
cryotherapy for, 4.300
description of, 6.299, 6.351
diagnosis of, 6.352–353*f*, 6.352–354
diffuse infiltrating, 4.292, 6.353
endophytic, 6.352, 6.352*f*
enucleation for, 4.299
evaluation of, 6.353
exophytic, 6.352–353, 6.353*f*
external-beam radiation for, 4.301
extraocular, 6.357
fleurettes in, 4.175, 4.175*f*
Flexner-Wintersteiner rosettes associated with, 6.353
genetics of, 2.226–227, 4.172–173, 4.253, 4.289–291, 4.290*f*, 6.354, 6.355*f*
counseling and, 4.289–291, 4.290*f*
hereditary, 2.226–227
histologic features of, 4.173*f*, 4.173–175, 4.174*f*, 4.175*f*, 6.353–354
intracranial, 4.298
iris affected in, 4.174, 4.174*f*
Knudson's hypothesis and, 2.227
laser therapy for, 4.300
leukocoria associated with, 6.351, 6.351*f*, 6.351*t*
leukocoria in, 4.291, 4.291*f*, 4.291*t*
metastatic, 4.177, 4.177*f*, 4.293–294
monitoring of, 6.358
ocular inflammation in, 4.291, 4.291*t*
optic nerve affected in, 4.176*f*, 4.176–177, 4.177*f*, 4.293
orbit affected in, 4.294, 4.294*f*
pathogenesis of, 4.172–173
persistent fetal vasculature differentiated from, 4.294–295
plaque radiotherapy for, 4.301
presenting signs and symptoms of, 4.291*f*, 4.291*t*, 4.291–294, 4.292*f*, 4.293*f*, 4.294*f*
prognosis for, 4.302, 4.302*t*
progression of, 4.176*f*, 4.176–177, 4.177*f*
radiation therapy for, 4.301
secondary tumors and, 4.302, 4.302*t*
recurrence of, 6.358
retinocytoma and, 4.178, 4.178*f*, 4.298
rosettes in, 4.174–175, 4.175*f*
secondary malignancies and, 4.302, 4.302*t*, 6.358
spontaneous regression of, 4.301, 6.353
sporadic, 2.228
staging of, 4.297
strabismus in, 4.291, 4.291*f*, 4.291*t*
transpupillary thermotherapy for, 4.300
treatment of, 4.299–301, 4.300*f*, 6.356–358
trilateral, 4.298, 6.357
tumorigenesis in, 2.226

ultrasonographic findings in, 2.470*f*
vitreous seeds and, 4.292, 4.293*f*
Retinoblastoma *(RB1)* gene, 4.172–173, 4.253, 4.289–290
in pinealoblastoma, 4.298
in retinocytoma, 4.298
secondary malignancies and, 4.302
Retinochoroidal/retinociliary venous collaterals (optociliary shunt vessels), 5.22
in optic nerve sheath meningioma, 5.127*f*, 5.128
in papilledema, 5.109
Retinochoroidal scar/scarring
description of, 9.278, 9.278*f*
toxoplasmic chorioretinitis and, 4.147, 4.148*f*
Retinochoroiditis
cytomegalovirus, 6.411, 6.411*f*
necrotizing, 12.243
in syphilitic uveitis, 12.241
toxoplasmic, 12.243–244, 12.244*f*
toxoplasmosis, 9.278*f*, 9.278–280, 9.297, 9.330*f*, 9.330–331
Retinochoroidopathies, 9.88. *See also specific disorder*
Retinociliary venous/retinochoroidal collaterals (optociliary shunt vessels), 5.22
in optic nerve sheath meningioma, 5.127*f*, 5.128
in papilledema, 5.109
Retinocytoma, 4.178, 4.178*f*, 4.298
Retinogeniculocortical pathway
abnormal visual experience affecting, 6.44–47, 6.45–46*f*
development of, 6.44–47
Retinoic acid, 2.166
Retinoic acid–inducible gene-I-like (RIG-I-like) receptors, 9.5
Retinoid–binding proteins, interphotoreceptor (IRBP), 4.172
Retinoid cycle, 2.326, 2.327*f*
Retinol, 2.311
Retinol-binding protein, 2.326
Retinol dehydrogenase, 2.327
Retinopathy, 5.99–103, 5.100*t*. *See also* Retinitis; *specific type*
acute zonal occult outer, 12.226–228, 12.227*f*
arteriosclerotic, 12.122
autoimmune, 5.103, 9.192–193, 12.286
cancer-associated (CAR), 5.102, 9.192–193, 12.286, 12.287*f*
ERG in, 5.96, 5.102
central serous (CSR). *See* Central serous chorioretinopathy
CRB1-related, 12.258
crystalline
cause of, 12.302–304, 12.303*t*
drugs that cause, 12.302–304
tamoxifen as cause of, 12.303, 12.304*f*
West African, 12.303–304, 12.305*f*
diabetic. *See* Diabetic retinopathy
HIV-associated, 9.327, 9.328*f*. *See also* HIV infection/AIDS, retinitis in
hypertensive, 1.69, 1.70*t*, 12.121–123, 12.122*f*, 12.124*f*
hyperviscosity, 12.134
in leukemia, 4.315, 4.315*f*
measles, 9.262
melanoma-associated (MAR), 5.102–103, 9.192–193, 12.286
ERG in identification of, 5.96, 5.102–103
neurotrophic keratopathy/persistent corneal epithelial defect and, 8.81, 8.81*t*
occlusive, 12.300–301
in ocular ischemic syndrome, 5.170, 5.171*f*, 12.138
optic neuropathy differentiated from, 5.99–100, 5.100*t*
paraneoplastic, 5.102–103
pigmentary, 12.282–283*t*. *See also* Retinitis pigmentosa
hearing loss and. *See* Usher syndrome
pigmented paravenous, 12.263
Purtscher, 12.171–173, 12.173*t*
Purtscherlike, 12.171–173, 12.172*f*, 12.173*t*
radiation, 1.239, 12.170*f*, 12.170–171
refractive surgery in patient with, 13.190
sickle cell. *See* Sickle cell retinopathy
solar, 12.277, 12.367, 12.368*f*
syndromic/systemic diseases associated with, 12.257*t*
thioridazine as cause of, 12.297
Valsalva, 12.171
venous stasis (VSR), 5.170
Retinopathy of prematurity (ROP), 2.470*f*
aggressive posterior, 6.326, 6.327*t*, 6.330*f*, 6.333, 12.177
angle-closure glaucoma in, 12.181
anti-VEGF agents for, 6.333
bevacizumab for, 6.333
birth weight and, 12.182
blindness caused by, 6.335, 12.182
cicatricial, 6.67, 12.181
classification of, 6.325–326, 6.327*t*, 6.328–330*f*, 6.331*t*, 12.175–179, 12.176*t*, 12.178*t*
clinically significant, 12.184*t*
complications of, 6.334–335
conditions associated with, 12.181–182
cryotherapy for, 6.331
definition of, 12.175
demarcation line in, 6.328*f*
diagnosis of, 6.329, 6.331
diet and, 12.184–185
digital retinal photography for, 6.331
discovery of, 6.325
Early Treatment for Retinopathy of Prematurity classification of, 6.326, 6.331*t*
end stage of, 12.175
epidemiology of, 12.175
extrafoveal retinal detachment in, 6.329*f*
extraretinal fibrovascular proliferation in, 6.329*f*
familial exudative vitreoretinopathy *versus*, 12.344
follow-up examinations for, 6.332*t*
glaucoma and, 10.144
incidence of, in premature infants, 12.182
in infants, 12.175
insulin-like growth factor I in, 6.325, 6.326*t*, 12.182
International Classification of Retinopathy of Prematurity, 6.325, 6.327*t*
late sequelae of, 12.181–182
location of, 6.327*t*
macular dragging associated with, 6.334, 6.334*f*
myopia associated with, 6.334

natural course of, 12.181
neovascularization in, 12.180–181
ocular examination for, 6.329, 6.331, 6.332*t*
oxygen supplementation and, 12.184
panretinal photocoagulation for, 6.332, 6.333*f*
pathophysiology of, 6.325, 6.326*t*, 12.180–182
plus disease, 6.326, 6.327*t*, 6.330*f*
posterior persistent fetal vasculature *versus*, 12.342
pre–plus disease, 6.326, 6.327*t*, 6.330*f*
prethreshold disease, 6.326, 12.178*t*, 12.179, 12.185
prevention of, 12.184–185
pseudoexotropia associated with, 6.334, 6.335*f*
pupillary-block glaucoma in, 12.181
ranibizumab for, 6.333
risk factors for, 6.326–327, 12.184–185
scleral buckling for, 6.335
screening of
birth weight–based criteria for, 12.182
criteria for, 12.182–183
description of, 6.329, 6.331, 6.332*t*
discontinuation of, criteria for, 12.183
fundus photographic, 12.184
intervals for, 12.183
sequelae of, 6.334–335, 12.181–182
severity of, 12.176*t*
spontaneous regression of, 12.181
stage 1, 6.327*t*, 6.328*f*, 12.176, 12.176*f*, 12.180
stage 2, 6.327*t*, 6.328*f*, 12.176, 12.176*f*, 12.180
stage 3, 6.327*t*, 6.329*f*, 12.176, 12.177*f*, 12.180
stage 4, 6.327*t*, 6.329*f*, 12.176, 12.177*f*, 12.180, 12.187–188
stage 5, 6.327*t*, 6.328*f*, 6.335, 12.188
supplemental oxygen as risk factor for, 6.326–327
telemedicine for, 6.331
terminology for, 12.175–176, 12.176*f*
threshold disease, 12.177, 12.178*t*, 12.179, 12.180*f*, 12.181, 12.185
threshold level of, 6.331
treatment of, 6.331–334
anti-VEGF drugs, 12.186–187
bevacizumab, 12.186–187
cryoablation, 12.185–186
intravitreal injections, 12.187
laser surgery, 12.185–186
overview of, 12.185
photocoagulation, 12.186*f*
scleral buckling surgery, 12.187–188
vitrectomy, 12.187–188
type 1, 6.326, 6.331*t*, 6.332
type 2, 6.326, 6.331*t*, 6.332
vascular endothelial growth factor in, 6.325, 6.326*t*
vitrectomy for, 6.335
weight, IGF-1, neonatal ROP algorithm for, 12.182
zones of, 6.325, 6.328*f*
Retinopexy
laser, 12.376–377
pneumatic, for rhegmatogenous retinal detachment, 12.397–398, 12.398*f*
Retinoschisin, 12.279
Retinoschisis
bullous, 12.326
demarcation lines in, 12.328
imaging of, 12.327*f*
outer-schisis-layer holes associated with, 12.327, 12.327*f*
reticular degenerative (bullous), 4.148, 12.326, 12.327
retinal detachments and, 12.326–328, 12.328
rhegmatogenous retinal detachment *versus*, 12.327*t*, 12.327–328
typical degenerative, 4.148, 12.326
X-linked
abusive head trauma as cause of, 6.383
description of, 6.342–343
diagnosis of, 6.344–345*f*
treatment of, 6.344
Retinoscope/retinoscopy
alignment of, 3.151
applications of, 3.150
cataract evaluations, 6.299
before cataract surgery, 11.80
concave mirror setting with, 3.150, 3.151*f*
correcting lens in, 3.153–155, 3.154*f*
definition of, 3.148
dynamic
accommodation measurements using, 6.9
in children, 6.9
examiner positioning during, 3.151
fixation for, 3.152
fogging for, 3.152
initial estimate of refractive error obtained using, 3.28
irregular astigmatism and, 8.163
against movement in, 3.152, 3.153*f*, 3.155
with movement in, 3.152, 3.153*f*, 3.155
neutrality, 3.152, 3.153–3.154*f*, 3.155
pictorial representation of, 3.150*f*
plane mirror setting with, 3.150
plus cylinder phoropter for, 3.159*t*
regular astigmatism application of
cylinder axis, 3.156–158, 3.157–3.158*f*
cylinder power, 3.158
overview of, 3.155–156
retinal reflex, 3.152–3.153*f*, 3.152–153
streak projection system used in, 3.150, 3.273
summary of, 3.159*t*
working distance in, 3.154
Retinoscopic reflex. *See* Retinal reflex
Retinovascular occlusion, intravenous drug use as cause of, 1.199
Retisert. *See* Fluocinolone acetonide implant
Retraction, eyelid, 5.274, 5.275*f*, 5.275*t*
in dorsal midbrain (Parinaud) syndrome, 5.229, 5.250, 5.274, 5.275*t*
pseudoptosis/ptosis and, 5.274, 5.275*t*
in thyroid eye disease, 4.226, 4.227*f*, 5.131, 5.274, 5.275*f*, 5.275*t*
Retro-orbicularis oculi fat (ROOF), 7.168
Retrobulbar anesthesia, 2.442, 6.174. *See also* Anesthesia
for cataract surgery, 11.91, 11.91*f*
hemorrhage and, 11.158, 11.171
for phakic IOL insertion, 13.141
Retrobulbar block, 7.13
Retrobulbar hemorrhage, cataract surgery and, 11.158, 11.171
Retrobulbar meningitis, 2.114
Retrobulbar optic neuritis, 5.113, 5.114
in cryptococcosis, 5.356

Retrocaruncular incision
for medial orbitotomy, 7.128, 7.128*f*
for orbital decompression, 7.130
Retrochiasmal lesions, 5.146, 5.152–159
lateral geniculate body lesions, 5.154, 5.154*f*
in multiple sclerosis, 5.318
occipital lobe lesions, 5.147*f*, 5.156–158, 5.157*f*, 5.158*f*, 5.159*f*
optic tract lesions, 5.147*f*, 5.153
parietal lobe lesions, 5.156
temporal lobe lesions, 5.147*f*, 5.155, 5.155*f*
Retrocorneal fibrous membrane (RCFM/posterior collagenous layer), 2.267, 4.84, 4.85*f*
Retrogeniculate (cerebral/cortical) visual impairment, 6.186. *See also* Cerebral/cortical blindness
Retroillumination, 3.292, 3.293*f*
for slit-lamp biomicroscopy, 8.17*f*, 8.19, 8.20*f*
Retrolaminar nerve/retrolaminar area of optic nerve, 2.113, 10.42, 10.43, 10.45*f*, 10.46
Retrolental fibroplasia. *See* Retinopathy of prematurity
Retrovir. *See* Zidovudine
Retroviruses (Retroviridae), 1.236, 1.266, 8.240*t*, 8.240–241
Rev-Eyes. *See* Dapiprazole
Revascularization. *See also* Percutaneous coronary intervention
for angina pectoris, 1.91–92
Reverse amblyopia, 6.55–56, 6.59–60
Reverse-geometry lens, after radial keratotomy, 13.199
Reverse Marcus Gunn response, in ocular trauma, 8.401
Reverse ptosis, 7.246
Reverse slab-off, induced anisophoria correction using, 3.188–189
Reverse transcriptase, 8.240
Reverse transcriptase–polymerase chain reaction (RT-PCR), 4.38*t*
Reversible cerebral vasoconstriction syndrome (RCVS), 5.346–348, 5.347*f*
Reversible cholinesterase inhibitors, 2.379
Reversible encephalopathy syndrome, posterior (PRES), 5.333–335, 5.335*f*
Reversible obstructive lung diseases, 1.123–124
Revised European-American Lymphoma Classification, 7.91
Reye syndrome, 2.410
ReZoom zonal refractive intraocular lens, 13.166
RF. *See* Rheumatoid factor
RGCs (retinal ganglion cells). *See* Ganglion cells/ganglion cell layer (GCL), retinal; Retinal ganglion cells
RGP contact lenses. *See* Rigid gas-permeable (RGP) contact lenses
RGS9 gene, 12.49
Rhabdomyosarcoma, 7.87*f*, 7.87–89
eyelid, 6.200
orbital, 4.236, 4.237*f*, 6.217*f*, 6.217–218
retinoblastoma associated with, 4.302*t*
Rhabdoviridae, 8.240, 8.240*t*
Rhegmatogenous retinal detachment (RRD), 2.332. *See also* Retinal detachment
child abuse and, 6.384
chronic, 12.324*f*
chronic peripheral, 9.311
complex, 12.401
definition of, 12.396
diagnostic features of, 12.320, 12.321*t*
floaters associated with, 12.320
incidence of, 12.320
intraocular pressure in, 12.320
lattice degeneration associated with, 12.310
"macula-off," 12.401
macular hole as cause of, 12.330, 12.330*f*
management of, 12.324, 12.324*f*, 12.397
pigmented demarcation lines with, 12.324
pneumatic retinopexy for, 12.324, 12.397–398, 12.398*f*
proliferative vitreoretinopathy associated with, 12.320, 12.323*f*, 12.323*t*, 12.323–324
reattachment surgery for, 12.401–402
retinal breaks as cause of, 12.314–315, 12.320, 12.322*f*, 12.396
retinoschisis *versus*, 12.327*t*, 12.327–328
risk factors for, 9.151, 12.396
scatter photocoagulation as cause of, 12.155
scleral buckling for, 12.324, 12.398–400, 12.399*f*
Shafer sign, 12.320
surgical repair of, 12.397–401, 12.398–400*f*
tractional retinal detachment *versus*, 12.325
uveitis as cause of, 9.324
vision loss caused by, 12.128
vitrectomy for, 12.324, 12.400*f*, 12.400–401
word origin of, 12.320
Rheopheresis, 12.71
Rheumatic disorders. *See also specific disorder*
ankylosing spondylitis, 1.154–155
antiphospholipid syndrome, 1.148–149, 1.163–164
dermatomyositis, 1.167*f*, 1.167–168
description of, 1.151
enteropathic arthritis, 1.156
juvenile idiopathic arthritis, 1.157–158, 1.158*t*
ocular involvement in, 1.151
polymyalgia rheumatica, 1.168
polymyositis, 1.167–168
psoriatic arthritis, 1.156–157
reactive arthritis, 1.155–156*f*, 1.157
relapsing polychondritis, 1.168–169
rheumatoid arthritis. *See* Rheumatoid arthritis
sarcoidosis, 1.162–163
Sjögren syndrome, 1.161, 1.166–167
spondyloarthritis. *See* Spondyloarthropathies/spondyloarthritis
systemic lupus erythematosus. *See* Systemic lupus erythematosus
systemic sclerosis, 1.164–166, 1.165*f*
treatment of
corticosteroids, 1.174–176, 1.175*t*
disease-modifying antirheumatic drugs. *See* Disease-modifying antirheumatic drugs
nonsteroidal anti-inflammatory drugs, 1.176
vasculitis. *See* Vasculitis/vasculitides
Rheumatoid arthritis (RA)
cataract surgery in patient with, corneal melting/keratolysis and, 11.132
description of, 9.125*t*
extra-articular manifestations of, 1.152–153
hand deformities associated with, 1.152, 1.152*f*

juvenile. *See* Juvenile idiopathic arthritis
laboratory testing for, 1.153
ocular manifestations of, 1.153
peripheral ulcerative keratitis and, 8.311, 8.312, 8.312*f*
prevalence of, 1.152
refractive surgery contraindicated in, 13.191
scleritis/scleromalacia perforans and, 8.321–322, 8.322*f*
treatment of, 1.153–154
Rheumatoid factor (RF), 1.153
Rheumatoid melt, 8.368
Rhinocerebral zygomycosis, 5.355, 5.355*f*
Rhinophyma, in rosacea, 8.71, 8.71*f*
Rhinosporidium/Rhinosporidium seeberi (rhinosporidiosis), 8.249*t*, 8.251
Rhinoviruses, 8.240*t*
Rhizopus, 8.249*t*, 8.251
ocular infection caused by, 5.355*f*, 5.355–356
Rho guanosine triphosphate hydrolase (Rho GTPase), 2.395
Rho kinase (ROCK), 2.395–396
Rho kinase inhibitors, 2.395–396, 10.182
Rhodopsin, 2.306–308, 2.307*f*, 2.326, 12.252, 12.264
Rhodopsin *(RHO)* gene mutation
description of, 2.312
in retinitis pigmentosa, 4.170
Rhodopsin kinase, 2.313*t*
Rhomboid flaps, for lateral canthal defects, 7.225, 7.226*f*
RHoT. *See* Right hypotropia
Rhytidectomy, 7.273–274, 7.274–275*f*
Riboflavin (vitamin B_2)
in corneal crosslinking, 13.130–131, 13.132–134, 13.133*f*
description of, 3.114
Ribonucleic acid. *See* RNA
Ribosomal RNA (rRNA), mitochondrial DNA-encoded, 2.184
Ribozymes, 2.197–198
Richner-Hanhart syndrome, 6.270, 8.183. *See also* Tyrosinemia
Riddoch phenomenon, 5.158, 5.181
Riders, 11.35
Ridley intraocular lens, 11.118*f*, 11.118–119
RIEG1/RIEG2 genes, 10.11*t*. *See also PITX2* gene
Rieger anomaly/syndrome, 8.102, 10.153. *See also* Axenfeld-Rieger syndrome
gene for, 10.11*t*
Rifabutin, 9.139, 12.305
endothelial pigmentation caused by, 8.132
Rifampin, 1.276
for bartonellosis, 9.243
for cat-scratch disease, 12.243
ocular adverse effects of, 1.308*t*
tuberculosis treated with, 1.257
Rift Valley fever (RVF), 9.265, 9.265*f*
RIG-I-like receptors. *See* Retinoic acid–inducible gene-I-like (RIG-I-like) receptors
Right hypotropia (RHoT), 6.17
Right to Sight, 11.6
Rigid contact lenses (hard contact lenses). *See* Rigid gas-permeable (RGP) contact lenses
Rigid gas-permeable (RGP) contact lenses. *See also* Contact lenses
advantages of, 3.214*t*, 3.215
apical alignment fit of, 3.218–219, 3.219*f*
apical bearing of, 3.218
apical clearance of, 3.218
for astigmatism, 13.17
after refractive surgery, 13.199
base curve of, 3.218, 3.219*f*
central fit of, 3.219
characteristics of, 3.213–214
corneal abnormalities corrected using, 3.226
corneal reshaping uses of, 3.228
disadvantages of, 3.215
discontinuing use of before refractive surgery, 13.38
fitting of, 3.218–221*f*, 3.218–222, 3.220*t*
fluorescein patterns for fitting evaluations, 3.219*f*, 3.219–220
indications for, 3.207*t*, 3.227
interpalpebral fit of, 3.219
keratoconus correction using, 3.226
after LASIK, 13.199, 13.200
for myopia reduction (orthokeratology), 13.70–71
orthokeratology, 3.228
pannus associated with, 3.232
parameters of, 3.220*t*
ptosis secondary to, 3.233
after radial keratotomy, 13.199
after refractive surgery, 13.199
scleral, 3.226–227
soft lenses *versus*, 3.218
tear layer created by, 3.221
tear lens, 3.218, 3.218*f*
Riley-Day syndrome (familial dysautonomia/FD)
congenital corneal anesthesia and, 8.108
description of, 2.204*t*, 2.229, 6.271
Rilonacept, 1.180
"Rim"/RIM proteins, 2.308. *See also specific type*
mutations in, 4.168–169
RimabotulinumtoxinB, 5.281. *See also* Botulinum toxin
Rimantadine, 1.279
Rimexolone, 2.400*t*, 2.403
riMLF. *See* Rostral interstitial nucleus of medial longitudinal fasciculus
Ring infiltrate, in *Acanthamoeba* keratitis, 4.79, 4.79*f*, 8.277, 8.277*f*
Ring melanoma, 4.193, 4.194*f*, 4.262, 4.263*f*
Ring of Elschnig, 10.43
Ring opacity, topical anesthetic abuse and, 8.89, 8.89*f*
"Ring sideroblast," 1.137
Ring sign, in optic nerve sheath meningioma, 5.127*f*
Riolan muscle, 4.201
Ripasudil, 2.396
Rise time, in phacoemulsification, 11.102, 11.103
Risk
absolute reduction of, 1.22
definition of, 1.22
relative, 1.22–23, 1.214
Risk calculators, 1.23
Risk difference, 1.22
Risk factors. *See also specific disorder*
disease and, 1.13
Risk reduction
absolute, 1.22
in diabetes mellitus, 1.35–36

Ritipenem, 1.273
Rituximab, 1.141, 1.180, 1.242, 2.406*t*, 6.322, 7.61, 7.67
for primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.312, 12.234
for scleritis, 8.324
for uveitis, 9.112
Rivaroxaban, 1.149
River blindness (onchocerciasis), 8.252–253, 9.289*f*, 9.289–290
Rizzutti sign, 8.163
RK. *See* Radial keratotomy
RLBP1 gene, 12.252
RLE. *See* Refractive lens exchange
RLF (retrolental fibroplasia). *See* Retinopathy of prematurity
RLH. *See* Reactive lymphoid hyperplasia
RMC (recurrent multifocal choroiditis). *See* Multifocal choroiditis
RMS (root mean square) error, magnitude of wavefront deviation and, 13.9
RNA
messenger
description of, 2.176
intron excision, 2.179
proteins, 2.273
precursor, 2.176
retinal pigment epithelium synthesis of, 2.324
ribosomal, mitochondrial DNA–encoded, 2.184
short interfering, 2.198
transfer, mitochondrial DNA–encoded, 2.184
virus, 8.211. *See also* RNA viruses
RNA viruses, 1.236, 1.237*t*, 8.211, 8.239–241, 8.240*t*. *See also specific virus*
RNFL (retinal nerve fiber layer). *See* Nerve fiber layer
ROC curve. *See* Receiver operating characteristic (ROC) curve
Rochalimaea henselae. See Bartonella (bartonellosis), henselae
ROCK. *See* Rho kinase
Rocuronium, 2.382
Rod(s)
abnormalities of. *See* Night blindness; Night-vision abnormalities
anatomy of, 2.85, 2.86*f*
cones *versus*, 2.306
density of, 12.11–12
in foveal center, 12.11
inner segments of, 2.85, 4.140*f*, 12.11–12, 12.12*f*. *See also* Photoreceptor(s), inner segments
light effects on, 2.318, 2.318*f*
light-sensitive molecules in, 12.12
neuronal elements of, 2.88
number of, 2.84
outer segments of, 2.98*f*, 4.140*f*, 12.11, 12.12*f*. *See also* Photoreceptor(s), outer segments
phototransduction of, 2.306–308
schematic diagram of, 12.14*f*
Rod ABC transporter, 2.313*t*
Rod cGMP-gated channel, 2.313*t*
Rod cGMP phosphodiesterase, 2.313*t*
Rod–cone dystrophies. *See also* Retinitis pigmentosa
in Bardet-Biedl syndrome, 12.284
characteristics of, 12.261–264, 12.262–264*f*
conventional testing of, 12.261
electroretinography evaluations, 12.46, 12.47*f*, 12.261
imaging of, 12.262–264*f*
macula-spared, 12.46, 12.47*f*
Rod monochromatism, 6.337, 12.250, 12.250*t*. *See also* Achromatopsia
Rod outer-segment protein 1, 2.308, 2.313*t*
Rod response. *See* Dark adaptation
Rod transducin, 2.313*t*
Rods (bacteria), 8.244*t*
gram-negative, 8.244*t*, 8.247*f*, 8.247–248
therapy for infection caused by, 8.270*t*
gram-positive, 8.244*t*, 8.245–247, 8.246*f*
Rofecoxib, 1.176
ROIs. *See* Reactive oxygen intermediates
Romycin. *See* Erythromycin
RON. *See* Radiation optic neuropathy
ROOF. *See* Retro-orbicularis oculi fat
Root mean square (RMS) error, magnitude of wavefront deviation and, 13.9
ROP. *See* Retinopathy of prematurity
Ropinirole, 1.205
ROS. *See* Reactive oxygen species
Rosacea, 6.244, 8.69–71, 8.70*f*, 8.71*f*
blepharitis and, 8.70, 8.73*t*
cataract surgery in patient with, 11.172–173
meibomian gland dysfunction and, 8.60, 8.70
Rose bengal stain, 8.37
description of, 2.444
in superior limbic keratoconjunctivitis, 8.84, 8.84*f*
in tear film/dry eye evaluation, 8.37, 8.56
Rosenthal, basilar vein of, 5.22
Rosenthal fibers, in optic nerve gliomas, 4.249, 4.249*f*
Rosette cataract, 11.54, 11.54*f*
Rosettes
in medulloepithelioma, 4.178*f*, 4.179
in primary intracranial pinealoblastoma, 4.298
in retinoblastoma, 4.174–175, 4.175*f*
Rosiglitazone, 12.301
Rostral interstitial nucleus of medial longitudinal fasciculus (riMLF), 5.33, 5.35, 5.35*f*, 5.220
saccadic eye movements and, 5.220
vertical gaze and, 5.36, 5.36*f*, 5.220
Rosuvastatin, 1.75*t*
Roswell Park Memorial Institute (RPMI) tissue culture medium, as tissue fixative, 4.26*t*
Rotation/rotational flap
for lower eyelid defects, 7.224
for wound closure after pterygium excision, 8.354*f*
Rotational corneal autograft, 8.451
Rotational upper eyelid pedicle flap, 7.227*f*
Rotations, ocular
definition of, 6.31
horizontal, 6.31
torsional, 6.31
vertical, 6.31
Rotavirus, 1.230
Roth spots, 4.154, 9.294
Rothmund-Thomson syndrome, 8.192*t*
Rotigotine, 1.205
Rotterdam Study, 10.82, 10.83

Rowland-Payne syndrome, Horner syndrome and, 5.260*t*
RP. *See* Retinitis pigmentosa
RPCD. *See* Reticular peripheral cystoid degeneration
RPD. *See* Reticular pseudodrusen
RPE. *See* Retinal pigment epithelium
RPE65
  description of, 2.324, 2.333*t*
  gene therapy trials with, 2.196
  Leber congenital amaurosis caused by, 2.196, 2.333
RPE65 gene, 6.337, 12.266
RPE65 mutation–associated retinal dystrophy, 9.58
RPED. *See* Retinal pigment epithelium, detachment of
RPMI. *See* Roswell Park Memorial Institute (RPMI) tissue culture medium
RPR. *See* Rapid plasma reagin (RPR) test
RPR test. *See* Rapid plasma reagin (RPR) test
RRD. *See* Rhegmatogenous retinal detachment
rRNA. *See* Ribosomal RNA
RS1 gene, 6.342, 12.279
RSB. *See* Residual stromal bed
RT. *See* Radiation therapy
RT-PCR. *See* Real-time quantitative polymerase chain reaction; Reverse transcriptase–polymerase chain reaction
RTIA. *See* Retinal transient ischemic attack
rtPA (recombinant tissue plasminogen activator). *See* Tissue plasminogen activator
Rubella
  congenital (CRS), 8.240, 8.240*t*
    aphakia and, 4.117
    cataracts and, 11.38–39
    glaucoma and, 10.150*t*
  description of, 6.410*f*, 6.410–411, 9.258–261
Rubeola virus, 8.239, 8.240*t*. *See also* Measles
  ocular infection caused by, 8.239, 8.240*t*
Rubeosis iridis (iris neovascularization), 2.22, 2.72, 4.188, 4.189*f*
  in diabetes mellitus, 4.159, 4.160*f*
  glaucoma and, 4.188, 10.32, 10.39, 10.132*t*, 10.133, 10.133*f*, 10.135*f*. *See also* Neovascular glaucoma
    in children and adolescents, 10.149*t*
    incisional surgery contraindicated in, 10.198
    laser iridotomy contraindicated in, 10.191
  in retinoblastoma, 4.174, 4.174*f*, 4.292
Rubinstein-Taybi syndrome, congenital corneal keloids in, 8.107
Ruby laser. *See* Laser(s)
Ruiz procedure, 13.8*t*
"Rule-1" test, for accommodative control, 3.35
Run charts, 1.28, 1.30*f*
Rundle's curve, 7.58, 7.58*f*
Rush disease, 12.177, 12.178*t*. *See also* Aggressive posterior retinopathy of prematurity (AP-ROP)
Russell bodies, 4.9
"Rust ring," iron foreign body causing, 8.399, 8.400*f*
Ruthenium 106
  for retinoblastoma, 4.301
  for uveal melanoma, 4.275
RVF. *See* Rift Valley fever
RVO. *See* Retinal vein occlusion

S

S-100 protein, in immunohistochemistry, 4.33
  in adenoid cystic carcinoma, 4.231
S-antigen, in experimental autoimmune uveoretinitis, 9.61
S-cone (blue-cone) monochromatism, 2.232*t*, 6.337–338, 12.46, 12.47*f*, 12.250, 12.250*t*
S cones, 2.312, 12.54
SA. *See* Sideroblastic anemia
SA node. *See* Sinoatrial (SA) node
Sabin's tetrad, 9.277
Saccades/saccadic system, 5.32–33, 5.38, 5.212, 5.212*t*, 5.219–223, 5.220*f*, 6.40
  in diplopia, 5.186
  dysfunction of, 5.221–223. *See also* Saccadic intrusions/oscillations
    in internuclear ophthalmoplegia, 5.189
    ocular motor apraxia and, 5.221, 5.222–223
    in progressive supranuclear palsy, 5.214, 5.221
  dysmetric saccades and, 5.222
  hallucinations and, 5.175
  hypermetric saccades and, 5.221, 5.222, 5.248, 5.248*f*
  hypometric saccades and, 5.221, 5.222
  inability to initiate/ocular motor apraxia, 5.221, 5.222–223
  velocity of, 5.219–220, 5.221
Saccadic initiation failure (ocular motor apraxia), 5.221, 5.222–223
Saccadic interval, intrusions and
  normal, 5.247–248, 5.248*f*
  not normal, 5.248*f*, 5.248–249
Saccadic intrusions/oscillations, 5.214, 5.221, 5.233, 5.247–250, 5.248*f*
  intersaccadic intervals and
    normal, 5.247–248, 5.248*f*
    not normal, 5.248*f*, 5.248–249
  macrosaccadic, 5.248, 5.248*f*
  in multiple sclerosis, 5.319
  ocular flutter and, 5.243*t*, 5.248, 5.248*f*, 5.249
  voluntary flutter/"nystagmus" and, 5.249–250
Saccadic latency, 1.210
Saccadic (cogwheel) pursuit, 5.219, 5.224, 5.225, 5.226
Saccadic velocity, 6.73
Saccadomania (opsoclonus), 5.248–249
  in neuromyelitis optica, 5.322
Saccomanno fixative, for tissue preservation, 4.26*t*
Saccular (berry) aneurysm
  description of, 5.338
  subarachnoid hemorrhage caused by, 1.121
Saccule, 5.38, 5.39*f*, 5.214, 5.215, 6.40
Sacroiliitis, in reactive arthritis syndrome, 9.132
Saethre-Chotzen syndrome, 6.207, 6.208*f*
Safinamide, 1.205
SAG gene, 12.253
Sagging eye syndrome, 5.209, 5.228
Sagittal curvature. *See* Axial curvature/axial curvature map
Sagittal depth or vault, of contact lenses, 3.205, 3.215*f*, 3.216
Sagittal plane, 7.27
Sagittal sinus
  inferior, 5.22*f*

superior (SSS), 5.22, 5.22*f*
thrombosis in, 5.346
Sagittal suture, 5.5
SAH. *See* Subarachnoid hemorrhage
SAILOR study, 12.81
Saline solution, for contact lens, 3.229
Salisbury Eye Evaluation project, 11.6
Salivary glands
biopsy of, for Sjögren syndrome, 1.166
in Sjögren syndrome, 8.57, 8.58*t*
Salivatory (salivary) nucleus
description of, 5.51*f*, 5.55, 5.276–277*f*
superior, 8.5*f*
Salmeterol, 1.128
Salmon patch
description of, 6.269
in syphilitic keratitis, 8.107, 8.308, 8.309*f*
Salmon-patch hemorrhage, 12.150, 12.150*f*
Salmon-patch subconjunctival lesion, 7.94*f*
Salmonella, 8.247
Salzmann nodular degeneration, 4.81, 4.82*f*, 8.124*f*, 8.124–125, 8.125*f*
Sampaolesi line
in pigment dispersion syndrome/pigmentary glaucoma, 10.94
in pseudoexfoliation/exfoliation syndrome, 10.39, 10.93
Sample size
evaluation of, 1.5
power and, 1.5
power calculations to determine, 1.26
Sandhoff disease, 2.204*t*, 6.389*t*
Sanfilippo syndrome (MPS III A–D), 2.204*t*, 6.388*t*, 8.175*t*, 12.282*t*, 12.291
Sanger sequencing, 2.189
SAP. *See* Standard automated perimetry
Sarcoid granuloma/nodule, 5.126*f*, 5.327, 8.347
Sarcoidosis, 1.162–163, 4.186–187, 4.187*f*, 5.327–328, 6.318*f*, 6.318–319, 7.65*f*, 7.65–66, 12.134, 12.231, 12.231*f*
angiotensin-converting enzyme levels in, 9.198
anterior uveitis in, 9.195–196
biomicroscopic findings in, 9.196, 9.196*f*
chest radiograph findings in, 9.198
in children, 9.194–195
conjunctival involvement by, 9.195, 9.195*f*
conjunctivitis and, 4.52, 4.52*f*
corneal involvement in, 9.196
cranial nerve VII (facial) involvement and, 5.280, 5.327
definition of, 9.194
diagnosis of, 5.327–328, 9.197–198
early-onset, 9.194, 9.197
epidemiology of, 9.194
etiology of, 9.195
eyelid manifestations of, 4.207*t*
granulomas associated with, 9.195, 9.195*f*, 9.197*f*
histologic findings, 9.194, 9.194*f*
human leukocyte antigen association with, 9.65*t*
imaging of, 9.198
intraocular manifestations of, 5.327
laboratory tests for, 9.125*t*
manifestations of, 9.195–197, 9.195–197*f*
neuro-ophthalmologic manifestations in, 5.327
optic nerve involvement and, 4.187, 4.245, 4.245*f*, 5.115, 5.126*f*, 5.327
panuveitis in, 9.194–199
posterior segment involvement in, 9.196–197
retinal vascular sheathing in, 9.197, 9.198*f*
treatment of, 5.327–328, 9.199
uveal tract affected in, 4.186–187
Sarcoidosis-associated uveitis, 9.148
Sarcoma, 4.10, 4.10*t*, 4.11*f*
Ewing, retinoblastoma associated with, 4.302*t*
granulocytic (chloroma), 4.316, 6.218
Kaposi. *See* Kaposi sarcoma
reticulum cell. *See* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
retinoblastoma associated with, 4.302, 4.302*t*
Satellite lesion, 6.409
Satellites, 2.177
Sattler layer, 2.76, 2.77*f*, 12.19
Sattler veil, 3.232
SBE. *See* Subacute bacterial endocarditis
SC. *See* Sickle cell hemoglobin C; Superior colliculus
SCA. *See* Superior cerebellar artery
Scanning, in ophthalmic examination, 8.20–24, 8.21*f*, 8.22*f*, 8.23*f*, 8.24*f*. *See also specific type*
Scanning laser ophthalmoscopy/ophthalmoscope (SLO), 3.282, 3.301–303
angiography *versus*, 12.24
blue excitation light used by, 12.31
choroidal nevi on, 12.24
description of, 3.301–303
digital resolution of, 12.24
ellipsoidal mirror in, 12.24
epiretinal membrane on, 12.334*f*
in optic nerve/nerve head/disc evaluation, 10.56
pseudodrusen on, 12.24
resolution of, 12.24
retinal disease evaluations, 12.24
wavelengths in, 12.24
Scanning laser polarimetry/polarimeter (GDx/SLP), 3.99, 3.303
in optic nerve/nerve head/disc evaluation, 10.56
Scanning-slit confocal microscope, 8.24. *See also* Confocal microscopy
Scanning-slit lasers, for photoablation, 13.30–31, 13.31
Scanning-slit technology, 8.35*t*
for corneal tomography, 13.19
for pachymetry, 13.45. *See also* Pachymetry/pachymeter
with Placido disk–based topography, 8.34
Scanning training, 3.310, 3.325
Scaphocephaly, 6.205
Scars
keloid
corneal, 8.125
congenital, 8.107–108, 8.125
refractive surgery in patient with history of, 13.77
retinal, 4.17
wound repair and, 4.13, 4.14*f*
Scatter diagrams
description of, 1.28, 1.29*f*
for flow cytometry results, 4.37*f*

Scatter laser treatment/photocoagulation. *See also* Panretinal photocoagulation; Photocoagulation
branch retinal vein occlusion treated with, 12.128–130
sickle cell retinopathy treated with, 12.155
vitreoretinal surgery for, 12.155
Scattering, of light
age-related increase in, 3.98
definition of, 3.96–97
geometric, 3.91, 3.97–98
Mie, 3.92, 3.97–98
Rayleigh, 3.92, 3.97
for slit-lamp biomicroscopy, 8.17*f*, 8.19
Tyndall effect and, 3.97
Scavenging macrophages, 9.13
SCC. *See* Squamous cell carcinoma
SCD. *See* Schnyder corneal dystrophy; Sickle cell anemia/sickle cell disease; Sudden cardiac death
Scedosporium, 8.251
Schachar theory of accommodation, 13.160–162, 13.161*f*
Schaumann bodies, in sarcoidosis, 4.187
Scheie stripe, 10.94, 10.95*f*
Scheie syndrome (MPS IS/MPS1-S), 2.204*t*, 2.214, 6.270, 6.388*t*, 8.174, 8.175*t*, 12.282*t*, 12.290–291
Scheimpflug camera systems
in corneal biomechanics evaluation, 8.43
for corneal tomography, 8.34, 8.34*f*, 8.35*f*, 8.35*t*, 13.19, 13.21*f*
in keratoconus, 8.165*f*, 8.165–166
description of, 3.248, 3.289
Scheimpflug principle, 3.282, 3.289
Scheiner, Christopher, 3.285
Scheiner disk, 3.285, 3.289
Scheiner principle, 3.282, 3.285, 3.286*f*
Schematic eye, 3.125–128, 3.126*f*, 3.127*t*, 3.128*f*
description of, 3.244*f*
reduced, 3.124, 3.126
Schiøtz (indentation) tonometry, 10.19, 10.26
Schirmer tests, 8.38–39, 8.57*t*
type I, 8.38–39
type II, 8.39
Schisis, macular, 12.328
Schizoaffective disorder, 1.195
Schizophrenia
antipsychotic drugs for, 1.200
description of, 1.194–195
drugs for (antipsychotic drugs), oculogyric crisis caused by, 5.231
Schizophreniform disorder, 1.195
Schlaegel lines, 12.225
Schlemm canal, 2.161, 4.98, 6.286, 6.286*f*, 10.5*f*, 10.13, 10.18, 10.18*f*
anatomy of, 2.61, 2.64
collector channels from, 2.64, 2.67*f*
endothelial lining of, 2.66*f*
gonioscopic visualization of, 10.38, 10.38*f*
juxtacanalicular trabecular meshwork and, 2.65*f*
schematic representation of, 2.67*f*
Schlichting dystrophy. *See* Posterior polymorphous corneal dystrophy
Schmidt sign, 2.232*t*
Schnabel, cavernous optic atrophy of, 4.246, 4.247*f*
Schnyder corneal dystrophy (SCD), 6.270, 6.387*f*, 8.135*t*, 8.136*t*, 8.145*t*, 8.151–152, 8.152*f*
crystalline form of, 8.151, 8.152*f*
hyperlipoproteinemia and, 8.151, 8.179
Schocket procedure, 10.214
School-aged children. *See also* Children
eye examination in, glaucoma and, 10.157, 10.157*t*
Schwalbe line, 2.55, 2.59*f*, 2.61, 2.63, 2.99, 4.97, 4.97*f*, 4.98*f*, 6.255, 8.9, 8.101, 10.33*t*, 10.34*f*, 10.36
gonioscopic appearance of, 10.33*t*, 10.34*f*, 10.36
prominent (posterior embryotoxon), 4.99, 4.99*f*, 4.100*f*, 8.97*t*, 8.101–102, 8.102*f*
in Axenfeld-Rieger syndrome, 4.99, 4.99*f*, 4.100*f*, 8.97*t*, 8.102, 10.31, 10.153
isolated, Axenfeld-Rieger syndrome differentiated from, 10.154*t*
Schwann cells, 2.157
Schwannoma (neurilemoma/neurinoma), 6.223
conjunctival/ocular surface, 8.345
of orbit, 4.238, 4.239*f*
of uveal tract, 4.199
vestibular, Bruns nystagmus and, 5.243
Schwannomin, 2.228
Schwartz (Schwartz-Matsuo) syndrome, 9.311, 10.109
Schwinger, Julian, 3.96
Scintigraphy. *See* Radionuclide scintigraphy and scans; *specific type*
Scintillating scotomata/scintillating scotoma with fortification spectrum. *See also* Scotomata
in arteriovenous malformation, 5.343
in migraine headache, 5.161, 5.177, 5.290*f*, 5.290–291, 5.291
Scissors reflex, 3.159
sCJD. *See* Sporadic Creutzfeldt-Jakob disease
Sclera, 4.107*f*, 4.107–112, 4.108*f*, 4.113*f*, 5.17*f*. *See also* Episclera
aging of, 4.111, 4.111*f*
anatomy of, 2.48, 2.48*f*, 2.56–59, 2.265*f*, 4.107*f*, 4.107–108, 4.108*f*, 5.17*f*, 12.20
avascular nature of, 2.57, 2.57*f*
bare, wound closure after pterygium excision and, 8.351, 8.353*t*, 8.353–355, 8.354*f*
recurrence rate and, 8.353*t*
biopsy of, indications for, 9.91
blue, 8.195*t*
in Ehlers-Danlos syndrome, 8.191*t*, 8.193
in keratoglobus, 8.171
in Marfan syndrome, 8.194
in osteogenesis imperfecta, 8.194, 8.194*f*
collagen fibers of, 2.58–59
composition of, 2.265*f*
congenital anomalies of, 4.108–109, 8.95–109, 8.96–98*t*
degenerations of, 4.111*f*, 4.111–112, 4.112*f*, 8.128, 8.129*f*
development of, 2.162
disorders of, 4.107–112, 4.113*f*, 8.46*t*. *See also* Episcleritis; Scleritis; *specific type*
common clinical findings in, 8.46*t*
immune-mediated, 8.318–326
ionizing radiation causing, 8.386
neoplastic, 4.112, 4.113*f*
edema, hyperemia in, 9.117

emissaria of, 2.58
episcleral vessels of, 2.57, 2.57*f*
in glaucoma, 10.31
healing/repair of, 4.16
immunologic microenvironment of, 9.52*t*
indentation of, 12.310*f*
infection/inflammation of, 4.109–110, 4.110*f*, 4.111*f*, 8.282–283, 8.283*f*. *See also* Episcleritis; Scleritis
laceration/penetrating wound of, 12.359. *See also* Corneoscleral lacerations
magnetic resonance imaging of, 2.459*t*
melanoma involving, 4.194, 4.195*f*
in pathologic myopia, 12.216–217, 12.217*f*
perforation of, repair of. *See* Corneoscleral lacerations
permeability of, 12.20
pigment spot of, 8.338
rupture of, 2.57, 12.352, 12.358
stroma of, 2.58, 4.107*f*, 4.107–108, 4.108*f*
surgical perforation of, 6.30, 6.170
thickness of, 12.20, 12.216
thinning of
in infectious uveitis, 9.96
from primary congenital glaucoma, 6.283
in scleritis, 8.321–322, 8.323
topography of, 4.107*f*, 4.107–108, 4.108*f*
traumatic injuries to, 12.352, 12.358
uveal attachment to, 2.66
Scleral buckling/buckle, 12.201
complications of, 12.400
intraocular pressure affected by, 12.399
for retinal detachment
angle-closure glaucoma after, 10.143
after cataract surgery, 11.166–167
refractive surgery after, 13.185
for retinal hemangioblastoma, 4.285
for retinopathy of prematurity, 6.335, 12.187–188
for rhegmatogenous retinal detachment, 12.324, 12.398–400, 12.399*f*
Scleral contact lenses. *See also* Contact lenses, scleral
for dry eye, 8.61*t*, 8.63
for graft-vs-host disease, 8.304, 8.305*f*
for limbal stem cell deficiency, 8.94
Scleral expansion bands, for presbyopia, 13.162, 13.163*f*
Scleral-fixated posterior chamber intraocular lenses
after ICCE, 11.200
insertion of, 11.116–117
after keratoplasty, 11.176
ocular trauma and, 11.193
uveitis and, 11.188
Scleral fixation, 12.393
Scleral flap, for trabeculectomy, 10.200–201, 10.203*f*
closure of, 10.202–204, 10.205*f*
management of, 10.207–208
Scleral grafting, for scleritis, 9.127, 9.128*f*
Scleral plaques
senile (Cogan), 8.128, 8.129*f*
senile/senile calcific, 4.111, 4.111*f*
Scleral spur, 2.159*f*, 4.97–98, 4.98*f*, 6.181, 10.33*t*, 10.34*f*, 10.36
anatomy of, 2.59*f*
cells of, 2.62
formation of, 2.161
Scleral sulcus, internal, 2.61, 4.98
Scleral support ring, for ICCE, 11.199
Scleral surgery. *See also specific procedure*
for presbyopia, 13.162–163, 13.163*f*
Scleral tunnel incisions, for cataract surgery, 11.107*f*, 11.107–108
after radial keratotomy, 11.177, 13.53
Sclerectomy, for glaucoma, deep (nonpenetrating), 10.217–219
Scleritis, 4.109–110, 4.110*f*, 4.111*f*, 7.68, 8.282–283, 8.283*f*, 8.319–326, 8.320*t*, 8.320*f*, 8.321*f*, 8.322*f*, 8.323*f*, 8.324*t*, 8.325*f*
anterior, 8.320, 8.320*f*, 8.320*t*, 8.321*f*
diffuse, 9.116, 9.118
nodular, 9.116, 9.118–119, 9.119*f*
subtype of, 9.116*t*
bisphosphonates and, 1.190
brawny, 4.110, 4.110*f*
cataract surgery in patient with, 11.170–171
classification of, 9.115–116, 9.116*t*
clinical presentation of, 8.319–323, 8.320*f*, 8.320*t*, 8.321*f*, 8.322*f*, 9.117–123*f*, 9.117–124
complications of, 8.323
corticosteroids for, 8.324
diagnosis of, 9.124–126, 9.125*t*
diffuse anterior, 8.320, 8.320*f*, 8.320*t*, 8.321*f*, 8.325*f*
epidemiology of, 9.117
episcleritis *versus*, 9.117
in herpes zoster, 8.227, 8.282
hyperemia in, 9.117, 9.117*f*
immune-mediated, 8.319–326, 8.320*f*, 8.320*t*, 8.321*f*, 8.322*f*, 8.323*f*, 8.324*t*, 8.325*f*
immunomodulatory therapy for, 9.126
incidence of, 9.117
infectious
actinomycetes as cause of, 9.119*f*
clinical presentation of, 9.124
description of, 8.282–283, 8.283*f*, 9.116
microbiological examination for, 9.125
pathophysiology of, 9.123–124
treatment of, 9.127
vision loss risks, 9.128
laboratory evaluation of, 8.323–324, 8.324*t*
management of, 8.324–326, 8.325*f*
manifestations of, 9.115
methylprednisolone for, 9.126–127
necrotizing, 4.110, 4.110*f*, 8.46*t*, 8.320*t*, 8.320–322, 8.321–322*f*, 8.325*f*
anterior, 9.118*f*
clinical presentation of, 9.118*f*, 9.119–122
delayed hypersensitivity response in, 9.116
description of, 9.115
diagnosis of, 9.124
granulomatous, 9.120*f*, 9.120–121
with inflammation, 8.320*t*, 8.320–321, 8.321*f*, 9.120–121, 9.120–121*f*
laboratory tests for, 9.124
mortality rates for, 9.119
pathophysiology of, 9.116
postsurgical, 9.121, 9.121*f*
surgically induced (SINS), 8.282
vaso-occlusive, 9.120, 9.121*f*
vision loss risks, 9.128

without inflammation (scleromalacia perforans), 4.110, 8.320*t*, 8.321–322, 8.322*f*, 9.121–122, 9.122*f*
nodular anterior, 8.320, 8.320*t*, 8.321*f*, 8.325*f*, 9.116, 9.118–119, 9.119*f*
noninfectious, 9.116
nonnecrotizing, 4.110, 8.46*t*
nonsteroidal anti-inflammatory drugs for, 9.126
pain and, 5.295, 8.319, 8.320, 8.322
pathogenesis of, 8.319
pathophysiology of, 9.116
posterior, 8.319, 8.320*t*, 8.322*f*, 8.322–323
B-scan ultrasonography for, 9.124
clinical presentation of, 9.123
optical coherence tomography of, 9.123*f*
spectral-domain optical coherence tomography of, 9.124–125
subtype of, 9.116*t*
vision loss risks, 9.128
prognosis for, 9.127–128
scleral grafting for, 9.127, 9.128*f*
staphylomas and, 4.110, 4.111*f*, 4.112, 8.322
subtypes and prevalence of, 8.319, 8.320*t*
surgical treatment of, 9.127
systemic diseases associated with, 9.115
topical therapy for, 9.126
treatment of, 9.126–127
ultrasonography in identification of, 5.95
vision loss risks, 9.128
Sclerocornea, 6.257*t*, 6.260, 6.261*f*, 8.98*t*, 8.105, 8.106*f*
cornea plana and, 8.96*t*, 8.98*t*, 8.100, 8.105
in Peters anomaly, 4.74, 4.75*f*
Scleroderma. *See* Systemic sclerosis
Sclerokeratitis, 8.323
Scleromalacia perforans, 4.110, 8.320*t*, 8.321–322, 8.322*f*, 9.121–122, 9.122*f*
Sclerosants
for distensible venous malformations, 7.75
for lymphatic malformations, 7.74
Sclerosing (morpheaform) basal cell carcinoma, 4.212–213, 4.213*f*. *See also* Basal cell carcinoma
Sclerosing nonspecific orbital inflammation, 7.70. *See also* Nonspecific orbital inflammation
Sclerosis
multiple. *See* Multiple sclerosis
nuclear, 11.43, 11.45*f*, 11.48*f*, 11.50*f*
smoking and, 11.6–7
systemic. *See* Systemic sclerosis
tuberous (TS/Bourneville disease/syndrome), 5.330, 5.331*f*, 5.334*t*
glaucoma associated with, 10.30
Sclerotic (gliotic) lesions, in multiple sclerosis, 5.316, 5.316*f*
Sclerotic scatter, 3.292–293, 3.293*f*
for slit-lamp biomicroscopy, 8.17*f*, 8.19
Sclerotomy
anterior ciliary (ACS), for presbyopia, 13.162
for suprachoroidal hemorrhage, 11.160
Sclerouveitis, 9.70
SCLO. *See* Confocal scanning laser ophthalmoscopy/ophthalmoscope
Sclopetaria, 4.22
chorioretinitis, 4.22
Scopolamine hydrobromide, 2.380*t*
Scotomas. *See also* Scotomata
absolute, 12.327
central, 12.86, 12.265
central suppression, 4Δ base-out prism test for, 6.79
foveal-sparing, 3.314, 3.315*f*
paracentral, 12.228, 12.367
pictorial representation of, 3.318*f*
retinoschisis as cause of, 12.327
suppression
description of, 6.49
4Δ base-out prism test for, 6.79
Worth 4-dot test for, 6.80*f*, 6.80–81
variations in, 3.317
vision rehabilitation and, 3.317
Scotomata, 5.105*t*
arcuate (Bjerrum), 5.103, 5.105*t*, 5.106*f*, 10.68, 10.68*f*
in arteriovenous malformation, 5.343
arteriovenous malformations causing, 5.291, 5.343
cecocentral, 5.103, 5.105*t*, 5.106*f*
central, 5.103, 5.105*t*, 5.106*f*
in glaucoma, 10.68, 10.68*f*, 10.70*f*, 10.86
"junctional," 5.146–147, 5.148*f*, 5.151*f*
in migraine aura without headache, 5.291
in migraine headache, 5.161, 5.171–172, 5.177, 5.290*f*, 5.290–291, 5.291
as nonorganic disorders, 5.306–308, 5.307*f*, 5.308*f*, 5.309*f*
papillomacular fiber lesions causing, 5.103, 5.106*f*
paracentral, 5.103, 5.105*t*, 5.106*f*, 10.68, 10.70*f*, 10.86
pericentral, 5.105*t*
physiologic (blind spot), 5.24
cortical area corresponding to, 5.29*f*
enlargement of, 5.103, 5.106*f*
acute idiopathic (AIBSE), 5.100–101, 5.101*f*
systemic hypoperfusion causing, 5.157–158, 5.159*f*
Scotopic spectral luminous efficiency function, 3.109
Scrapie, 5.357
Scraping, for specimen collection, 8.210
Screen reading, 3.323, 3.324*f*
Screening. *See also specific test or disorder*
for atherosclerosis, 1.215
for bladder cancer, 1.221
for breast cancer, 1.215–217, 1.216*t*
for cancer, 1.215–221
for cervical cancer, 1.216*t*, 1.217–218
for colorectal cancer, 1.216*t*, 1.218–219
for coronary heart disease, 1.215
costs of, 1.214
for depression, 1.189
for endometrial cancer, 1.216*t*
for gastric cancer, 1.219
for gastrointestinal cancer, 1.219–220
for glaucoma, 1.184
for hypertension, 1.214
for infectious diseases, 1.222–223
for lung cancer, 1.216*t*, 1.220
for melanoma, 1.220–221
nonresearch uses of, 1.213
for pancreatic cancer, 1.220
for prostate cancer, 1.216*t*, 1.221
relative risk of, 1.213
sensitivity of, 1.15–16, 1.17*f*, 1.214

specificity of, 1.15–16, 1.17*f*, 1.213
for syphilis, 1.222–223
for tuberculosis, 1.222
for urologic cancer, 1.221
Sculpting, in phacoemulsification, settings for, 11.111
Scurf, in seborrheic blepharitis, 8.72, 8.72*f*
Scurvy, 1.140
SD-OCT. *See* Spectral-domain optical coherence tomography
SDH. *See* Shape-discrimination hyperacuity
SE (spin echo) technique, 5.62, 5.75
Sea-blue histiocyte syndrome (chronic Niemann-Pick disease), 12.291. *See also* Niemann-Pick disease
Sea fan neovascularization, 12.151, 12.153*f*
Seafood allergy, 2.428
Seasonal conjunctivitis
allergic, 6.246*f*, 6.246–248, 8.288–289
vernal, 8.289–292, 8.290*f*, 8.291*f*
Sebaceous adenoma, 4.210*t*, 4.215, 4.216*f*, 7.191
in tuberous sclerosis, 5.331*f*, 10.30
Sebaceous carcinoma/adenocarcinoma, 4.210*t*, 4.215–218, 4.216*f*, 4.217*f*, 7.206–208, 7.207*f*, 8.327, 8.337*f*, 8.337–338
Sebaceous cysts (epidermal inclusion cysts)
description of, 7.189
of eyelid, 4.208, 4.208*f*
Sebaceous glands of eyelid, 4.201, 4.202, 8.4
tumors/lesions of, 4.210*t*, 4.215–218, 4.216*f*, 4.217*f*, 8.327, 8.337*f*, 8.337–338
benign, 4.215
malignant, 4.210*t*, 4.215–218, 4.216*f*, 4.217*f*
Sebaceous hyperplasia, 4.215, 4.216*f*, 7.191
Seborrheic blepharitis, 8.72, 8.72*f*, 8.73*t*
Seborrheic keratosis, 4.209, 4.209*f*, 4.210*f*, 7.187–188, 7.188, 7.188*f*
Sebum, 7.182
Secluded pupil, 10.119, 10.138, 10.139*f*
"Second corneal apex," 3.272
Second cranial nerve. *See* Optic nerve
Second-generation antipsychotics, 1.199, 1.200*t*
Second-generation cephalosporins, 2.419
Second nodal point, 3.66
Second-order aberrations, 13.11, 13.11*f*
Second-order neuron, 5.52, 5.53*f*, 5.53–54
Horner syndrome caused by lesions of, 5.257, 5.259, 5.260, 5.260*t*, 5.261*f*
Second-order wavefront aberrations, 3.276*f*
Second-order Zernike polynomials, 3.73
Second principal plane, 3.56
"Second sight," 11.43, 11.70
Secondary acquired melanosis, 4.65–66
Secondary anophthalmia, 7.35
Secondary aphakia, 4.117, 11.30. *See also* Aphakia
Secondary childhood glaucoma
acquired condition, 6.284
after cataract surgery, 6.285
classification of, 6.278*t*
nonacquired conditions associated with, 6.284*t*
Secondary coloboma, 11.31. *See also* Coloboma
Secondary deviation
definition of, 6.39
primary deviation *versus*, 6.115
Secondary diagnostic position of gaze, 6.31
Secondary glaucoma. *See* Angle-closure glaucoma, secondary; Glaucoma; Open-angle glaucoma, secondary
Secondary hypercoagulable states, 1.146, 1.148
Secondary hypertension
causes of, 1.53–54, 1.55*t*
in children, 1.68
laboratory tests for, 1.55
Secondary hypothyroidism, 1.45
Secondary immune response, 9.37–38
Secondary lens fibers, development of, 11.27*f*, 11.27–28
microspherophakia and, 11.33
Secondary lipid keratopathy, 8.125, 8.126*f*
Secondary megalocornea, 6.254
Secondary syphilis, 9.221
Secondary vitreous, 2.157, 2.158*f*, 2.293, 4.125
Secretory immunoglobulin A (sIgA), 2.252
Secretory lacrimal apparatus. *See* Lacrimal gland
Sectoral cataracts, 6.297–298
Sectoral iris palsy, 5.254
anisocoria/Adie tonic pupil and, 5.256*f*, 5.263, 5.263*f*
Sectoranopia, lateral geniculate body lesions causing, 5.154, 5.154*f*
Sectorial retinitis pigmentosa, 12.263, 12.264*f*
Secukinumab, 1.180
See-saw (vision loss) nystagmus, 5.243*t*, 5.247, 6.152
SEFs. *See* Supplementary eye fields
Segment removal, in phacoemulsification, settings for, 11.111
Segmental phlebitis, 12.232
Segmental trichiasis, 7.240
Segmented contact lenses, 3.224–225
Segregation, genetic, 2.215–216
Seidel aberrations, 3.41, 3.72, 3.72*f*
Seidel test, 8.36–37, 8.38*f*
after penetrating keratoplasty, 8.423
Seizures. *See also* Epilepsy
arteriovenous malformations causing, 5.343
causes of, 1.303
definition of, 1.303
epileptic, 1.206–209
facial movements/palsy/Todd paralysis and, 5.285
hallucinations and, 5.177
local anesthetic agent as cause of, 1.291
ocular deviations caused by, 5.230
tonic-clonic, 1.306
transient visual loss caused by, 5.161, 5.162, 5.172
Selectins
description of, 9.11
E-, 9.11–12
L-, 9.11–12
P-, 9.11–12
Selection bias, 1.4, 1.11
Selective COX-2 inhibitors, 1.176
Selective laser trabeculoplasty (SLT), 10.188–190, 10.190*f*
Selective serotonin reuptake inhibitors (SSRIs), 1.202, 1.203*t*
Selegiline, 1.205
Selenium
description of, 2.341
supplementation of, in thyroid eye disease, 7.59
Selenoprotein P, 2.276

Self-sealing incision, for cataract surgery, 11.118
beveled/biplanar, clear corneal incision and, 11.106*f*, 11.106–107
Self-tolerance, 9.34
Sella turcica, 2.106*f*, 5.5, 5.6*f*, 5.10*f*
Semi-scleral contact lenses, 3.227
Semicircular advancement flaps, for lower eyelid defects, 7.224
Semicircular canals, 6.40
hair cells of, 5.38, 5.39*f*
vestibular-ocular reflex and, 5.214–215
peripheral vestibular nystagmus and, 5.215, 5.216, 5.241, 5.242
Semicircular flap, for lower eyelid defects, 7.223*f*
Semilunar ganglion (gasserian/trigeminal ganglion), 2.131, 5.42*f*, 5.48, 5.48*f*
herpes simplex/varicella zoster virus latency and, 8.205, 8.207, 8.212, 8.213, 8.226
Senile furrow degeneration, 8.122
Senile lentigo, 7.197
Senile macular degeneration. *See* Age-related macular degeneration/maculopathy
"Senile" ptosis, 5.273
Senile/senile calcific/Cogan plaques, scleral, 4.111, 4.111*f*, 8.128, 8.129*f*
Senior-Løken syndrome, 6.391
Sensation, in cornea, 8.8
esthesiometry in evaluation of, 8.42–43
reduction/absence of
congenital, 8.108
in herpes simplex epithelial keratitis, 8.217–218, 8.226*t*
in herpes zoster, 8.226*t*, 8.228
keratoplasty and, 8.418, 8.424
in neurotrophic keratopathy/persistent corneal epithelial defects, 8.80, 8.224
Sensitivity, of diagnostic and screening test, 1.15–16, 1.17*f*
Sensitivity threshold, in perimetry, 5.86, 5.87*f*, 5.91. *See also* Threshold stimulus/testing (perimetry)
Sensorcaine. *See* Bupivacaine
Sensory adaptation testing
afterimage test, 6.79, 6.79*f*
amblyoscope testing, 6.79–80
Bagolini lenses, 6.77*f*, 6.77–78
description of, 6.75
4Δ base-out prism test, 6.78*f*, 6.78–79
red-glass test, 6.75–76, 6.76*f*
Worth 4-dot test, 6.80*f*, 6.80–81
Sensory binocularity, 6.75
Sensory esotropia, 6.93–94
Sensory exotropia, 6.104
Sensory fusion, 6.43
Sensory nucleus, of cranial nerve V (trigeminal), 5.47, 5.47*f*
Sensory nystagmus, 6.187
Sensory pathways, 5.47*f*, 5.47–49, 5.48*f*. *See also* Cranial nerve V
Sentinel bleed, before aneurysm rupture, 5.340
Sentinel lymph node (SLN) biopsy
in conjunctival/ocular surface melanoma, 8.344
for melanoma, 7.210
for sebaceous carcinoma, 7.208
Sentinel T cells, 9.5
Sentinel vessels, 4.68, 4.69*f*, 4.262, 4.263*f*, 9.125, 10.31
Sepsis
bacterial, pathophysiologic responses to, 9.7
lipopolysaccharide in, 9.7
Septata, keratoconjunctivitis caused by, 8.280
Septate filamentous fungi, 8.249, 8.249*t*, 8.250*f*, 8.251. *See also* Filamentous fungi; Fungi
Septic emboli, 12.141
Septic shock, 1.301
Septic thrombosis
cavernous sinus, 5.345
orbital infection/cellulitis and, 5.345
lateral (transverse) sinus, 5.345
Septo-optic dysplasia (de Morsier syndrome), 5.143–144, 6.361, 6.363*f*
Sequence, 6.183
Sequencing, DNA, next-generation (NGS/massively parallel), 4.39*t*
Seroconversion conjunctivitis, in HIV infection/AIDS, 8.240*t*, 8.241
Serologic tests. *See specific type*
Seronegative spondyloarthropathies. *See also* Spondyloarthropathies/spondyloarthritis; *specific type*
acute anterior uveitis associated with, 9.131–134, 9.133–134*f*
ankylosing spondylitis. *See* Ankylosing spondylitis
definition of, 9.131
Serotonin modulators, 1.203*t*
Serotonin-norepinephrine reuptake inhibitors, 1.203*t*
Serous choroidal detachment, melanoma differentiated from, 4.270–271
Serous pigment epithelial detachment, 12.72–73, 12.74*f*
Serous retinal detachment
description of, 6.362
in intraocular lymphoma, 12.234
MEK inhibitors as cause of, 12.299
tubercular multifocal choroiditis with, 9.236*f*
Serpiginous choroiditis
acute posterior multifocal placoid pigment epitheliopathy *versus*, 9.171
characteristics of, 9.162–164*t*
course of, 9.175
definition of, 9.174
fluorescein angiography findings in, 9.163*t*, 9.175*f*
fundus autofluorescence in, 9.163*t*, 9.176*f*
imaging of, 9.174*f*
indocyanine green angiography findings in, 9.163*t*, 9.175
manifestations of, 9.174–175
multifocal, 9.177
optical coherence tomography findings in, 9.164*t*, 9.175, 9.176*f*
retinal pigment epithelium findings in, 9.175
treatment of, 9.176–177
Serpiginous choroidopathy, 12.220*t*, 12.222–223, 12.223*f*
Serpiginous-like choroiditis, 9.177, 9.236, 9.237*f*
Serratia
description of, 8.247
marcescens, 1.251
Serum, 1.131

Serum drops
for dry eye, 8.61*t*, 8.63
for neurotrophic keratopathy/persistent corneal epithelial defects, 8.81, 8.224
for superior limbic keratoconjunctivitis, 8.84
Sessile papillomas, conjunctival, 4.60
Setting sun sign, 5.231
Seventh cranial nerve. *See* Cranial nerve VII
Seventh nerve (facial) palsy. *See* Facial paralysis/weakness
Sex chromosomes
aneuploidy of, 2.223
mosaicism, 2.225
Sex-determining region, 2.208
Sex (gender), in glaucoma, 10.9, 10.121
SF. *See* Surgeon factor
SF_6. *See* Sulfur hexafluoride
SF3B1 gene, in choroidal/ciliary body melanoma, 4.197, 4.278
sflt-1, 2.259
SFU. *See* Subretinal fibrosis and uveitis syndrome
Shafer sign, 12.320, 12.348
Shaffer gonioscopic grading system, 10.37
Shagreen, crocodile, 8.121
Shagreen patch, in tuberous sclerosis, 5.334*t*
Shaken baby syndrome, 1.299, 12.365–366, 12.366*f*. *See also* Abusive head trauma
Shallow anterior chamber. *See* Anterior chamber, flat or shallow
Shape-discrimination hyperacuity (SDH), 12.69
Sheehan syndrome (pituitary apoplexy), 1.49, 5.149, 5.150*f*
Sherrington's law of reciprocal innervation, 6.33
Shh, 2.166
Shield ulcer, 6.248, 6.249*f*, 8.290, 8.291*f*
Shiga toxin-producing *Escherichia coli*, 1.142
Shigella, 8.207, 8.247
invasive capability of, 8.207
Shimmering, electroretinography findings in, 12.46
Shingles. *See* Herpes zoster
Shingrix, 1.227
Shock. *See also specific type*
assessment of, 1.300
classification of, 1.300–301
definition of, 1.300
respiratory gas exchange failure in, 1.301
treatment of, 1.300–301
Short arm 11 deletion syndrome (11p13 syndrome/*PAX6* gene mutation), 2.225–226
in aniridia, 4.184, 10.150, 11.33
Short ciliary arteries, 2.22, 2.23*f*, 2.120*f*, 5.13*f*, 5.14*f*, 5.15–17, 5.17*f*
optic nerve supplied by, 10.44, 10.45*f*, 10.45–46
Short ciliary nerves, 2.16, 2.76, 5.55*f*
Adie tonic pupil and, 5.263, 5.264, 5.264*f*, 5.265
Short interfering RNA (siRNA), 2.198
Short interspersed elements (SINEs), 2.177
Short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), 5.289*t*, 5.294
Short posterior ciliary artery, 2.24*f*
Short posterior ciliary nerves, 7.12*f*
Short tau inversion recovery (STIR) technique, 5.62–65, 5.63*t*, 5.75
Short-wavelength automated perimetry (SWAP), 10.75
Short-wavelength sensitive cones. *See* S cones
SHRM. *See* Subretinal hyperreflective material
Shunting, for idiopathic intracranial hypertension, 6.371
Shunting surgery
for glaucoma, 10.213–217, 10.214*t*, 10.218*t*, 10.219–220. *See also* Tube shunts
for idiopathic intracranial hypertension, 5.112, 5.113
Sialic acid, in microbial adherence, 8.207
Sialidoses
description of, 6.388*t*
dysmorphic (ML I), 8.178
Sickle cell anemia/sickle cell disease (SCD), 1.135–136, 2.214
hyphema/elevated intraocular pressure and, 8.395, 8.395*t*, 8.396, 10.104, 10.105
ophthalmic manifestations of. *See also* Sickle cell retinopathy
traumatic hyphema and, 8.395*t*, 8.396
elevated intraocular pressure and, 8.395, 8.395*t*, 8.396
surgery for, 8.395, 8.395*t*, 8.396
proliferative sickle cell retinopathy complications in, 12.150
Sickle cell hemoglobin C disease (SC)
ocular findings in, 12.153*f*
proliferative sickle cell retinopathy complications in, 12.150
Sickle cell hemoglobinopathies, 2.229
description of, 12.149
incidence of, 12.149*t*
ocular abnormalities in, 12.154
racial predilection of, 12.149, 12.154
Sickle cell retinopathy
hyphema/elevated intraocular pressure and, 10.104, 10.105
management of, 12.154–155
nonproliferative
branch retinal artery occlusions in, 12.152*f*
characteristics of, 12.149–150
imaging of, 12.150–12.152*f*
retinal arteriolar occlusions in, 12.151*f*
salmon-patch hemorrhage in, 12.150*f*
proliferative
complications of, 12.150
proliferative diabetic retinopathy *versus*, 12.151
scatter photocoagulation for, 12.155
sea fan neovascularization associated with, 12.151, 12.153*f*
stages of, 12.150–151
retinal detachment secondary to, 12.155
scatter photocoagulation for, 12.155
thalassemia as cause of, 12.149
Sickle cell trait/disease, 6.378
Sideroblastic anemia (SA), 1.137
Siderosis/siderosis (hemosiderosis) bulbi
corneal deposits/pigmentation in, 8.118*t*
description of, 4.103, 4.120, 11.58*f*, 11.58–59, 12.362, 12.363*t*
glaucoma and, 4.103, 10.103
Siegrist streaks, 12.123, 12.198
Siepser slipknot technique, for IOL decentration, 11.145, 11.146*f*

sIgA. *See* Secretory immunoglobulin A
Sight substitution devices, 3.325
Sigmoid sinus, 5.22, 5.22*f*
Sigmoidoscopy, flexible, 1.218–219
Signal error information, 5.40
Significance, statistical. *See P* value
Sildenafil, 12.299, 12.304
  adverse ocular effects caused by, 1.130, 1.307, 1.309*t*
  color vision affected by, 5.175
  ocular effects/retinal toxicity of, 5.175
  pulmonary hypertension treated with, 1.130
Silent sinus syndrome, 7.102, 7.103*f*
Silent visual fields, nonorganic disorder evaluation and, 5.308
Silicone foldable intraocular lenses, 11.120. *See also* Foldable intraocular lenses
  IOL opacification and, 11.151
  after ocular trauma, 11.193
  in uveitis, 11.188, 11.188*f*
Silicone oil, 2.360*t*, 12.401
  cataract/cataract surgery and, 11.83, 11.120, 11.190
  intraocular lenses in eyes filled with, 3.254
Silicone plugs, for dry eye, 8.64–65, 8.65*f*. *See also* Lacrimal plugs
Silicone rods, in frontalis suspension surgery, 7.251*f*
Silicone stent, for intubation. *See* Lacrimal intubation
Silodosin, intraoperative floppy iris syndrome and, 11.74, 11.136, 11.137*t*
Silver, 12.306
Silver compounds, corneal deposits of/pigmentation caused by, 8.118*t*, 8.132
Silver nitrate, for gonorrheal ophthalmia neonatorum, 6.239
SIM K. *See* Corneal power simulation measurements
Simbrinza. *See* Brinzolamide/brimonidine tartrate suspension
Simcoe cannula, 11.198, 11.199*f*
Simple (physiologic/essential) anisocoria, 5.256*f*, 5.257
Simple diffusion, glucose transport into lens and, 11.17*f*
Simple (diffuse injection) episcleritis, 4.109, 8.318
Simple epithelial (epidermoid) cysts, of orbit, 4.223–224. *See also* Epithelial cysts
Simple hyperopic astigmatism, 3.138, 3.138*f*
Simple limbal epithelial transplantation (SLET), 8.365
  for chemical injury, 8.384
  in pterygium surgery, 8.355
Simple myopic astigmatism, 3.138, 3.138*f*
Simple partial seizures, 1.206–207
Simultanagnosia, 5.180, 5.181*f*, 5.223
Simultaneous prism and cover test, 6.66–67
Simultaneous vision bifocal contact lenses, 3.225, 3.225*f*
Simvastatin, 1.75*t*, 1.77
  cataract risk and, 11.53
SINEs. *See* Short interspersed elements
Single base-pair mutations, 2.183
Single binocular vision, 6.81–82, 6.82*f*
Single curved surface, refraction by, 3.51–54
Single-flash (LA 3.0/photopic) electroretinogram, in cone dystrophies, 5.102
Single-gene disorders, 2.218
Single-nucleotide polymorphisms (SNPs)
  description of, 2.182, 2.193–194, 2.195*f*, 2.218, 2.368
  oligonucleotide microarray analysis (SOMA), 4.39*t*
Single pedicle flap, 8.359*f*, 8.359–360
Single-photon emission computed tomography (SPECT), 2.454, 5.70
  in coronary heart disease diagnosis, 1.88
  epilepsy diagnosis using, 1.207
Single-vision reading glasses with lowered optical centers, induced anisophoria corrected using, 3.189–190
Singlet oxygen, 2.337*t*
Sino-orbital zygomycosis, 7.51*f*
Sinoatrial (SA) node, in cardiac rhythm, 1.101
SINS. *See* Surgically induced necrotizing scleritis
Sinus(es). *See* Paranasal sinuses; *specific type*
Sinus thrombosis
  cavernous (CST), 5.345, 6.214, 7.48, 7.51
    orbital infection/cellulitis and, 5.345
  lateral (transverse), 5.69*f*, 5.345–346
  superior sagittal, 5.346
Sinusitis
  allergic aspergillosis, 5.353
  in ethmoid sinus, 7.20
  orbital cellulitis and, 7.46
  paranasal, 6.213, 6.214*f*
  sinus surgery for, 7.47
siRNA. *See* Short interfering RNA
Sirolimus, 2.405*t*
SITA. *See* Swedish interactive thresholding algorithm
SITA Fast, 10.61
SITA Standard, 10.61, 10.62
SITE. *See* Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study
Sixth cranial nerve. *See* Cranial nerve VI
Sixth nerve (abducens) palsy, 5.189, 5.200*f*, 5.200–201
  carotid-cavernous fistula and, 5.201, 5.205–206
  cavernous sinus thrombosis and, 5.345
  in cryptococcosis, 5.356
  description of, 6.95–97, 6.96*f*, 6.140, 6.176
  diplopia and, 5.189, 5.200*f*, 5.200–201
  divergence insufficiency/paralysis and, 5.200
  isolated, 5.200, 5.201
  lateral (transverse) sinus thrombosis and, 5.345–346
  in Möbius syndrome, 6.135
  multiple sclerosis and, 5.318
Sjögren syndrome (SS)
  aqueous tear deficiency/dry eye and, 8.39, 8.55*f*, 8.56–58, 8.58*t*
  cataract surgery in patient with, corneal melting/keratolysis and, 11.132
  description of, 1.161, 1.166–167, 8.56–58, 8.58*t*
  peripheral ulcerative keratitis and, 8.312
Sjögren Syndrome Foundation, 8.53
SJS. *See* Stevens-Johnson syndrome
SJS/SJS-TEN. *See* Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis)
SK. *See* Superficial keratectomy
Skeletal disorders. *See also* Connective tissue disorders
  corneal changes in, 8.190–196, 8.191–192*t*, 8.193*f*, 8.194*f*, 8.195*f*, 8.195*t*
Skew, of retinal reflex, 3.156, 3.157*f*
Skew deviation, 5.216–217, 6.125
  alternating, 5.216
  fourth nerve (trochlear) palsy differentiated from, 5.198–199, 5.216

in internuclear ophthalmoplegia, 5.189
in multiple sclerosis, 5.318
vestibular-ocular dysfunction and, 5.216–217
"Skew" rays, 3.51
Skewed radial axis index, in keratoconus/corneal ectasia, 8.32*t*, 8.165
Skiascopy, dynamic. *See* Retinoscope/retinoscopy
Skin
disorders of. *See also* Dermatitis
cataracts associated with, 11.66
corneal changes in, 8.201–203
in xanthogranuloma, 4.187
eyelid, 4.210, 8.3–4
amyloid deposits in, 4.206–207, 4.207*f*, 4.207*t*, 8.186*t*, 8.187
healing/repair of, 4.17
melanoma arising in, 4.220, 4.221*f*
melanoma of, 4.220, 4.221*f*
redundancy of. *See* Dermatochalasis
tumors of. *See* Eyelid(s), tumors of
Fitzpatrick scale for, 7.268
fluorescein angiography effects on, 12.36
laser resurfacing of, 7.268–269
systemic sclerosis manifestations of, 1.164–165, 1.165*f*
Skin cancer. *See also* Melanoma
description of, 1.220–221
metastatic eye disease and, 4.304*t*
predisposing factors for, 7.186
signs of, 7.187
Skin grafts. *See* Flap(s); Graft(s)
Skin tags, in Goldenhar-Gorlin syndrome, 8.195
Skin tests. *See specific type*
"Skip lesions," 4.245, 5.314
Skipped generation, 2.207, 2.219
Skull, 2.106*f*
abnormal shapes of. *See* Craniosynostosis
bony growth of, 6.203
sutures of, 6.203–204, 6.204–205*f*
Skull base, 5.5–6, 5.6–8*f*
Slab-off prism
definition of, 3.148
induced anisophoria correction using, 3.188, 3.188*f*
SLC4A11 (sodium borate transporter, member 11) gene
in congenital hereditary endothelial dystrophy, 8.136*t*
description of, 6.258
SLE. *See* Systemic lupus erythematosus
Sleep, 1.53, 1.66–67
Sleep apnea/sleep deprivation. *See also* Obstructive sleep apnea
floppy eyelids and, 8.79, 8.82
Sleep-associated visual hallucinations, 5.177
Sleep test, for myasthenia gravis, 5.324, 5.325
SLET. *See* Simple limbal epithelial transplantation
Slide preparation, for pathologic examination, 4.30
Sliding flap, for wound closure after pterygium excision, 8.353, 8.354*f*, 8.355
Slit-lamp biomicroscopy/examination, 3.292–293, 3.293*f*, 8.15–20, 8.16*f*, 8.17*f*, 8.18*f*, 8.19*f*, 8.20*f*
in aqueous tear deficiency, 8.56
auxiliary lenses for, 3.295–296, 3.296*t*
in cataract evaluation, 6.300
before cataract surgery, 11.78–80
limitations of, 11.80
in children, 6.4–5, 10.160
in choroidal/ciliary body melanoma, 4.263*f*, 4.265
clinical procedure for, 8.19–20
definition of, 3.282
description of, 3.292–293, 3.293*f*, 3.306
in Duane retraction syndrome, 6.133
in fundus examination, 5.81
in glaucoma, 10.30–32
illumination methods for
direct, 8.16–18, 8.17*f*, 8.18*f*, 8.19*f*
indirect, 8.17*f*, 8.18–19, 8.20*f*
in iris nevus, 4.255
in meibomian gland dysfunction, 8.40
operculated holes on, 12.318
in optic nerve/nerve head/disc evaluation, 10.32, 10.48, 10.53
posterior vitreous detachment diagnosis using, 12.331
in pupillary examination, 5.254, 5.256*f*
in recurrent corneal erosions, 8.87
before refractive surgery, 13.41–44, 13.42*f*, 13.43*f*
slit-beam illumination for, 8.17, 8.18*f*
in striae in LASIK flaps, 13.113, 13.114*t*
in uveitis associated with juvenile idiopathic arthritis, 6.314*f*
Slit-lamp photography. *See* Slit-lamp biomicroscopy/examination
SLK. *See* Superior limbic keratoconjunctivitis
SLN biopsy. *See* Sentinel lymph node (SLN) biopsy
SLO. *See* Scanning laser ophthalmoscopy/ophthalmoscope
Sloan letters
definition of, 3.134
on ETDRS-type eye chart, 3.23*f*
Slow inactivators, 2.233
Slow-reacting substance of anaphylaxis. *See* Leukotrienes
SLP. *See* Scanning laser polarimetry/polarimeter
SLT. *See* Selective laser trabeculoplasty
Sly syndrome (MPS VII), 6.388*t*, 8.175*t*
Small-aperture corneal inlay, 13.61, 13.61*f*
Small-incision cataract surgery, 11.198, 11.199*f*
in eye with functioning filter, 11.187
in glaucoma, 11.186, 11.187
Small-incision lenticule extraction (SMILE), 13.8*t*, 13.28, 13.203–206
complications of, 13.205
disadvantages of, 13.205
indications and preoperative evaluation for, 13.204
LASIK compared with, 13.205, 13.206
outcomes of, 13.205
re-treatment and, 13.206
surgical technique for, 13.204–205
Small-incision phacoemulsification. *See* Phacoemulsification
Small-vessel vasculitis, 1.169*t*, 1.171–173
Smallpox vaccination, ocular complications of, 8.238
SMART. *See* Stroke-like migraine attacks after radiation therapy
Smart System PC-Plus, 6.81
SMAS. *See* Superficial musculoaponeurotic system
SMCD. *See* Subepithelial mucinous corneal dystrophy

SMILE. *See* Small-incision lenticule extraction
Smoking
cessation of
age-related macular degeneration risks, 12.62
cataract development and, 11.6–7, 11.63–64
for chronic obstructive pulmonary disease, 1.126
dry eye and, 8.61
for lung cancer prevention, 1.220
optic neuropathy and, 5.137, 5.138
in thyroid eye disease, 7.59
as coronary heart disease risk factor, 1.73*t*
lung cancer risks, 1.220
pancreatic cancer risks, 1.220
thyroid eye disease and, 6.140
uveitic macular edema risks associated with, 9.321
Smooth-muscle tumors, conjunctival/ocular surface, 8.345
Smooth-pursuit eye movements/system, 5.32, 5.33, 5.34*f*, 5.212, 5.212*t*, 5.224–226, 5.225*f*
description of, 6.40
dysfunction/injury of, 5.156, 5.224, 5.225–226
in infantile esotropia, 6.88
optokinetic nystagmus/system and, 5.156, 5.218, 5.219
Snapback test, 7.231, 7.260
Snellen chart
for bottom-up acuity testing, 5.306
disadvantages of, 3.132–133
letters on, 3.131–134, 3.132*f*
optotypes, 3.133*f*, 3.134
Snellen letters, monofixation syndrome and, 6.51
Snellen visual acuity, 3.124, 3.131, 3.132*f*, 3.134. *See also* Visual acuity
in low vision, 5.78, 5.88
after radial keratotomy, 13.51–52
Snell's law (law of refraction)
definition of, 3.42
description of, 3.44*f*, 3.44–45, 8.26
lensmaker's equation derivation from, 3.85–86
linearization of, 3.60
prism power calculation using, 3.48
vergence equation derivation from, 3.85–86
"SNOOP" mnemonic, in headache evaluation, 5.287
"Snow bank," 6.316*f*
Snow blindness, 8.385
Snowball opacities
in chronic postoperative endophthalmitis, 9.292
in intermediate uveitis, 9.82, 9.147, 9.148*f*, 12.231
Snowbanks, in intermediate uveitis, 9.82, 9.147, 12.231–232, 12.245
"Snowflake" cataract, 11.60, 11.60*f*, 12.326
SNP. *See* Single-nucleotide polymorphisms
SNP oligonucleotide microarray analysis (SOMA), 4.39*t*
SNRPN gene, 2.180–181
SO. *See* Superior oblique (SO) muscle; Sympathetic ophthalmia
Social history
cataract surgery evaluation and, 11.72, 11.76
refractive surgery evaluation and, 13.36*t*, 13.36–37
Socket contraction. *See* Anophthalmic socket surgery
SOD. *See* Superoxide dismutase
Sodium, in lens, 2.287, 11.21
Sodium balance, in lens, pump-leak theory of maintenance of, 11.21, 11.22*f*
Sodium bicarbonate. *See* Bicarbonate
Sodium borate transporter, member 11 *(SLC4A11)* gene, in congenital hereditary endothelial dystrophy, 8.136*t*
Sodium chloride, 2.443
Sodium citrate, for chemical injuries, 8.383
Sodium fluorescein. *See* Fluorescein
Sodium hyaluronate, as viscoelastic, 11.95
elevated intraocular pressure and, 10.108
Sodium hydroxide (NaOH), ocular injury caused by, 8.376*t*
Sodium nitroprusside, 1.64
Sodium-potassium pump (Na^+,K^+-ATPase)
in aqueous humor secretion/suppression, 10.16–17
cold affecting, 8.385
corneal hydration and, 8.9
description of, 2.287, 2.307, 2.324
in Fuchs endothelial corneal dystrophy, 8.156
in lens active transport, 11.21
pump-leak theory and, 11.21, 11.22*f*
Sodium restriction
congestive heart failure managed with, 1.100
hypertension managed with, 1.58*t*
Soemmering ring lens remnant/Soemmering ring cataract, 4.121, 4.122*f*, 11.152
Soft (flexible) contact lenses. *See also* Contact lenses
adjustment of, 3.217*t*
advantages of, 3.214, 3.214*t*
daily-wear, 3.214–215
discontinuing use of before refractive surgery, 13.38
duration of use, 3.214
evaluation of, 3.217*t*
extended-wear, 3.215
fitting of, 3.216–217, 3.217*f*, 3.217–218*t*
hydrogel, 3.213
after LASIK, 13.200
materials used in, 3.213
overrefraction testing, 3.217
parameters for, 3.217, 3.218*t*
after radial keratotomy, 13.199
after refractive surgery, 13.199
rigid gas-permeable lenses *versus*, 3.218
selection of, 3.217*t*
spherical, 3.207*t*
after surface ablation, 13.200
tonometry accuracy and, 10.24
toric, 3.207*t*, 3.222–223
discontinuing use of before refractive surgery, 13.38
after radial keratotomy, 13.200
Soft-design progressive addition lenses, 3.182, 3.183*f*
Soft drusen, 4.162, 4.162*f*, 12.65, 12.68, 12.75, 12.200*f*, 12.272
Soft exudates, 12.122. *See also* Cotton-wool spots
Soft-tissue dermal fillers, 7.157, 7.270*f*, 7.270–271
Soft-tissue tumors, 4.10*t*, 4.11*f*
of orbit, 4.233
retinoblastoma associated with, 4.302, 4.302*t*
Soil contamination, *Bacillus* endophthalmitis and, 8.247, 8.403
Solar elastosis, of eyelid, 4.211–212, 4.212*f*

Solar lentigo, 7.197–198, 7.198*f*, 7.200
Solar retinitis. *See* Solar retinopathy
Solar retinopathy, 12.277, 12.367, 12.368*f*
Solexa technology, in next-generation sequencing. *See* Next-generation sequencing
Solid-state laser. *See also* Laser(s)
  for photoablation, 13.29. *See also* Photoablation
Solitary fibrous tumor, 7.89, 7.90*f*
  of orbit, 4.235*f*, 4.235–236
Soluble guanylate cyclase activators, 1.64
Soluble proteins, in vitreous, 2.298
Soluble vascular endothelial growth factor receptor 1, 2.180
Solute carrier family 4, in congenital hereditary endothelial dystrophy, 8.136*t*
Solutes
  low-molecular-weight, in vitreous, 2.298–299
  pump–leak hypothesis of, in lens, 2.288*f*
Solutions, contact lens, 3.229*t*, 3.229–230
SOM. *See* Superior oblique myokymia
SOMA (SNP oligonucleotide microarray analysis), 4.39*t*
Somatic development, 2.153*f*
Somatic symptom and related disorders (SSDs), 1.196–197
Somatization, 1.196
Somatoform disorders, 1.196–197
Somatoform pain disorder. *See* Somatic symptom and related disorders
Somatotroph adenomas, 1.47–48
Somesthetic cortex (postcentral gyrus), 5.47*f*
Sonidegib, 7.205
Sonography. *See* Ultrasonography/ultrasound (echography)
SOOF. *See* Suborbicularis oculi fat
Sorbitol/sorbitol pathway
  in cataract formation, 11.19, 11.60
  description of, 2.289, 2.291
  in lens glucose/carbohydrate metabolism, 11.18*f*, 11.19
Sorsby macular dystrophy, 12.275*f*, 12.275–276
Sound-induced photisms, 5.176
SP. *See* Swelling pressure
Space maintenance, by ophthalmic viscosurgical device, 11.97
Spaeth gonioscopic grading system, 10.37, 10.37*f*
SPAs. *See* Subperiosteal abscesses
Spasm
  of accommodation (ciliary muscle spasm), 3.176, 5.310
  benign essential blepharospasm (BEB), 5.281–283, 5.282*f*, 5.282*t*
  of convergence, 5.227
  of fixation. *See* Ocular motor apraxia
  habit, 5.285
  hemifacial (HFS), 5.282*t*, 5.283*f*, 5.283–284
  of near reflex, 3.177, 5.227, 5.309–310
Spasmus nutans/spasmus nutans syndrome, 5.239
  description of, 6.151–152
  pseudo-spasmus nutans and, 5.130
Spastic entropion, 7.235*f*, 7.237
Spastic paretic facial contracture, 5.284
Spatial coherence, 3.101
Spatial frequency, 3.124, 3.135, 12.56, 12.57*f*
Specific gravity, of spectacle lens materials, 3.194
Specific (adaptive) immunity. *See* Adaptive immune response/adaptive immunity
Specificity, of diagnostic and screening test, 1.15–16, 1.17*f*, 1.214
Specimen collection/handling, 4.25–30, 4.31*t*, 8.208–211, 8.209*t*, 8.211*f*
  communication with health care team and, 4.25–26
  fixatives for tissue preservation and, 4.26, 4.26*t*
  gross dissection/transillumination and, 4.28*f*, 4.28–30, 4.29*f*
  orientation of globe and, 4.27, 4.27*f*
  processing/staining tissues and, 4.30, 4.31*t*
  special procedures and, 4.33–45
  transillumination and, 4.28*f*, 4.28–29
SPECT. *See* Single-photon emission computed tomography
Spectacle blur, 3.233
Spectacle lenses (spectacles). *See also* Lenses
  absorptive. *See* Sunglasses
  accommodation affected by, 3.178
  accommodative demand through, 3.210*t*
  anisometropia correction with, 3.139
  antireflection coatings on, 3.103, 3.104*f*
  aphakia correction using, 3.191*f*, 3.191–192
  contact lenses *versus*, 3.206, 3.216*t*
  convergence affected by, 3.178, 3.212*f*
  cylindrical correcting. *See* Cylindrical lenses
  dissatisfied wearers of, troubleshooting of, 3.198–199
  glass, 3.195
  history of use of, refractive surgery evaluation and, 13.38
  for hyperopia, 3.211, 3.212*f*
  materials for, 3.194–196
  for myopia, 3.211, 3.212*f*
  optical centers of, 3.211
  prescription for, 3.198
  prism incorporation into, 3.197, 3.285. *See also* Prism(s)
  standard plastic, 3.195
Spectacle telescope, 3.322*f*
Spectinomycin, for gonococcal conjunctivitis, 8.259
Spectral bandwidth, coherence length and, 3.102, 3.103*f*
Spectral-domain optical coherence tomography (SD-OCT), 3.304, 8.22
  adult-onset vitelliform maculopathy on, 12.67–68, 12.68*f*
  alkyl nitrite findings, 12.300, 12.300*f*
  Best disease on, 6.342, 6.343*f*
  central retinal artery occlusion on, 12.144*f*
  chloroquine toxicity monitoring uses of, 12.297
  choroidal neovascularization on, 12.73–75, 12.75*f*
  commotio retinae on, 12.353
  diabetic macular edema on, 12.109*f*, 12.125
  drusen on, 12.64*f*, 12.65
  epiretinal membranes on, 12.335*f*
  Gaucher disease on, 12.291
  juvenile retinoschisis on, 6.344, 6.344*f*
  for multiple evanescent white dot syndrome, 9.188, 9.188*f*
  in optic nerve/nerve head/disc/retinal nerve fiber layer evaluation, 10.54–56, 10.55*f*, 10.56*f*, 10.57*f*, 10.58*f*
  pathologic myopia on, 12.90*f*
  for posterior scleritis, 9.124–125

reticular pseudodrusen on, 12.65*f*
retinal layers on, 12.10–11, 12.11, 12.12*f*
retinitis pigmentosa findings, 12.263*f*
sensitivity of, 12.26
swept-source optical coherence tomography *versus*, 12.25–26
vitreomacular traction on, 12.332*f*
Spectral luminous efficiency function, 3.108–109
Spectroscopy, magnetic resonance (MRS), 5.70
Specular microscope, 3.282, 3.295
Specular microscopy, 8.23, 8.23*f*
before cataract surgery, 11.84
in Fuchs endothelial corneal dystrophy, 8.23*f*, 8.158
in iridocorneal endothelial syndrome diagnosis, 10.137
before phakic IOL insertion, 13.141
Specular reflection, 3.80, 3.293, 3.293*f*
for slit-lamp biomicroscopy, 8.17*f*, 8.17–18, 8.19*f*
Specular transmission. *See* Law of refraction
Speed
of light, 3.43
of retinal reflex, 3.153
Sphenocavernous (parasellar) syndrome, 5.202
Sphenoethmoidal recess, 7.19, 7.20
Sphenoid bone, 5.5, 5.7*f*, 5.8, 5.9*f*
greater wing of, 2.6–7*f*, 2.9–10*f*, 2.11, 7.7–8*f*, 7.9
lesser wing of, 2.6–7*f*, 2.11, 7.7–8*f*, 7.9, 7.11
metastatic tumors of, 7.105
pterygoid process of, 5.5
Sphenoid dysplasia, 6.397
Sphenoid sinus, 2.460*f*, 5.8, 5.9, 5.10*f*
anatomy of, 7.8*f*
development of, 7.20
Sphenoid wing
anatomy of, 5.5, 5.7*f*, 5.9*f*
meningiomas, 7.84*f*, 7.84–86
Sphenopalatine ganglion, 5.51*f*, 5.56, 5.276–277*f*, 8.5*f*
Sphere (refining the), for refraction, 3.165–167, 3.167*f*
Sphere power, refinement of, 3.33
Spherical aberration
description of, 3.42, 3.72, 3.72*f*, 3.74*f*, 3.159, 3.268–269, 3.272, 3.275–276*f*, 3.276, 13.9, 13.12, 13.12*f*, 13.102
after LASIK, 13.12, 13.102
after radial keratotomy, 13.50
after surface ablation, 13.12, 13.102
Spherical aniseikonia, 3.255
Spherical concave lenses
combining of, 3.16
convex lens combined with, 3.17
description of, 3.11
Spherical correcting lenses, ametropia correction using, 3.170, 3.170*f*
Spherical equivalent
definition of, 3.42
description of, 3.76
of refractive state, 3.139
Spherical refractive error, direct initial measurement of, 3.28
Spheroidal degeneration (actinic/climatic droplet/Labrador keratopathy), 4.83, 4.83*f*, 8.115–117, 8.116*f*
Spherophakia, 6.305
Spherule, 2.85
Sphincter muscle (iris), 4.182, 4.182*f*
damage to, 4.18
Adie tonic pupil and, 5.256*f*, 5.263, 5.263*f*
anisocoria and, 5.256*f*, 5.262–263
cataract surgery in patient with, 11.191
in Horner syndrome, 5.258
pupil irregularity and, 5.255
traumatic mydriasis and, 8.388, 8.389*f*
innervation of, 5.52, 5.55
mydriatics affecting, 5.263
Sphingolipidoses, 8.176–178
corneal changes in, 8.176–178, 8.177*f*
Sphingomyelin, 2.284
SPIKES Healthcare Model of Communication, 3.326*f*
Spin echo (SE) technique, 5.62, 5.75
Spin-lattice (longitudinal) relaxation time (T1), 5.62, 5.63*t*, 5.76
Spin-spin (transverse) relaxation time (T2), 5.62, 5.63*t*, 5.76
Spinal cord lesions, Horner syndrome and, 5.260*t*
Spinal nucleus and tract, of cranial nerve V (trigeminal), 5.47, 5.47*f*
Spindle cell(s)
in choroidal/ciliary body melanoma, 4.192*f*, 4.192–193, 4.194, 4.195
in choroidal/ciliary body nevus, 4.191, 4.192*f*
in iris melanoma, 4.190
in iris nevus, 4.189
in neurilemoma, 4.238, 4.239*f*
in nodular fasciitis, 4.112, 4.113*f*
in orbital neurofibroma, 4.237
in orbital rhabdomyosarcoma, 4.236
Spindle cell carcinoma, 4.61, 8.336
Spindle cell melanoma, 4.192*f*, 4.192–193, 4.194, 4.195
Spindle pattern, in pigment dispersion syndrome, 10.94
Spinocerebellar degeneration, 12.282*t*
Spiral CT scanners, 7.27
Spiral of Tillaux, 2.21*f*, 2.99, 5.45, 6.22, 6.23*f*, 6.169
SPK. *See* Thygeson superficial punctate keratitis
Splenectomy, 1.134, 1.141
Splenic sequestration, 1.142
Spliceosomes, 2.179
Splicing
alternative, 2.179
definition of, 2.179
Split bifocal intraocular lens, 3.258, 3.259*f*
Spondylitis, ankylosing (AS), 1.154–155
cataract surgery in patient with, 11.171, 11.171*f*
Spondyloarthropathies/spondyloarthritis. *See also specific type*
ankylosing spondylitis, 1.154–155
definition of, 1.154
enteropathic arthritis, 1.156
inflammatory bowel disease and, 1.156
reactive arthritis, 1.155–156*f*, 1.157
uveitis and, 1.157
Spongiform encephalopathies, transmissible, 5.357
Spontaneous consecutive esotropia, 6.95
Spontaneous emission, 3.110
Spontaneous eye movements, 5.233–251. *See also* Nystagmus
Spontaneous hyphema, 8.393. *See also* Hyphema

Spontaneous nystagmus. *See* Nystagmus
Sporadic Creutzfeldt-Jakob disease (sCJD), 5.357
Sporanox. *See* Itraconazole
Spread of comitance, 5.186
Spreading depression, cortical, 5.177
Springing pupils, 5.267
Squamous cell carcinoma (SCC)
actinic keratosis as cause of, 7.199
of conjunctiva, 4.61, 4.63*f*
in situ, 4.61, 4.63*f*
invasive, 4.61, 4.62*f*, 4.63*f*
of ethmoid sinus, 7.102, 7.103*f*
of eyelid, 4.213, 4.214*f*, 7.205–206, 7.206*f*
actinic keratosis and, 4.211
well-differentiated (keratoacanthoma), 4.209–210, 4.210*t*, 4.211*f*
in situ, 7.199
of lacrimal sac, 7.316*f*, 7.317
ocular surface, 8.332*t*, 8.336, 8.336*f*
management of, 8.330*f*, 8.336–337
in situ, 8.334. *See also* Conjunctival or corneal intraepithelial neoplasia
retinoblastoma associated with, 4.302*t*
Squamous cell papilloma, of conjunctiva, 4.59–60, 4.60*f*
Squamous dysplasia, ocular surface, 8.334. *See also* Conjunctival or corneal intraepithelial neoplasia
Squamous neoplasia, ocular surface (OSSN), 4.60–61, 4.62*f*, 4.63*f*, 8.334–337, 8.335*f*, 8.336*f*
invasive, 8.332*t*, 8.336, 8.336*f*. *See also* Squamous cell carcinoma
management of, 8.330*f*, 8.336–337
noninvasive, 8.334–335, 8.335*f*. *See also* Conjunctival or corneal intraepithelial neoplasia
Square waves/square-wave jerks (SWJs), 5.213, 5.214, 5.247–248, 5.248*f*
SR. *See* Superior rectus (SR) muscle
SRK (SRK/T) formula, 3.249, 3.249*f*, 11.85
SRY. *See* Sex-determining region
SS. *See* Sjögren syndrome
SS-A antigen, antibodies to (anti-Ro antibodies), in Sjögren syndrome, 8.56, 8.58*t*
SS-B antigen, antibodies to (anti-La antibodies), in Sjögren syndrome, 8.56, 8.58*t*
SS-OCT. *See* Swept-source optical coherence tomography
SSc. *See* Systemic sclerosis
SSD. *See* Somatic symptom and related disorders
SSPE. *See* Subacute sclerosing panencephalitis
SSRIs. *See* Selective serotonin reuptake inhibitors
SSS. *See* Superior sagittal sinus
ST segment, 1.84*f*
ST-segment elevation, 1.84–85*f*
ST-segment elevation myocardial infarction (STEMI). *See also* Acute coronary syndromes
description of, 1.83
reperfusion therapies for, 1.94
thrombolysis for, 1.94–95
treatment of, 1.94
Stab incisions, 7.274
Stabbing headache, idiopathic, 5.294
Stains/staining techniques, 4.30, 4.31*t*, 8.36–37, 8.37*f*, 8.38*f*, 8.56
hyperfluorescence and, 12.35
immunohistochemical, 4.33
for infectious keratitis, 8.209*t*, 8.269, 8.273, 8.275
Stand magnifiers, 3.320–321, 3.321*f*
Standard automated perimetry (SAP), 10.59. *See also* Perimetry
Standard plastic lenses, 3.195
Standardization of Uveitis Nomenclature system, 2.66, 9.68–69, 9.69–70*t*, 9.77, 9.80*t*, 9.147, 9.153
Standing potential, 12.50, 12.51*f*
Stapedial/stapedius nerve/muscle, 5.52, 5.276–277*f*
Staphylococcus, 8.244, 8.244*t*
aureus, 2.420, 2.422, 6.213, 6.240
blepharitis/blepharoconjunctivitis caused by, 8.72, 8.74, 8.75, 8.208*t*, 8.256, 8.257*t*
description of, 1.246
endogenous endophthalmitis caused by, 9.294
keratitis caused by, 8.208*t*
after photoablation, 13.106
methicillin-resistant, 1.246
methicillin-resistant (MRSA), 8.244, 8.271
keratitis after photoablation caused by, 13.106
as normal flora, 8.205, 8.206*t*, 8.244
postoperative endophthalmitis caused by, 11.140, 11.161
blepharitis/blepharoconjunctivitis caused by, 8.72, 8.72*f*, 8.72–76, 8.73*f*, 8.73*t*, 8.74*f*, 8.75*f*, 8.208*t*, 8.254, 8.256, 8.257*t*
keratitis and, 8.73*t*, 8.74
marginal infiltrates in, 8.74, 8.74*f*
endogenous bacterial endophthalmitis caused by, 12.238
endophthalmitis caused by, postoperative, 11.161
epidermidis, 1.246–247, 2.422
as normal flora, 8.205, 8.206*t*
ocular infection caused by, 8.208*t*
postoperative endophthalmitis caused by, 11.140, 11.161
uveitis/endophthalmitis after cataract surgery caused by, 11.140, 11.162
keratitis caused by, 8.208*t*, 13.106
as normal flora, 8.205, 8.206*t*, 8.244
ocular infection caused by, 8.208*t*. *See also specific type*
orbital cellulitis caused by, 6.213
phlyctenulosis caused by, 8.75, 8.75*f*
postoperative endophthalmitis caused by, 12.389
preseptal cellulitis caused by, 6.213
resistant strains of, 8.244
uveitis caused by, after cataract surgery, 11.140
Staphylomas
axial length measurement for IOL power determination and, 13.150
in children, 4.112
congenital, 8.98*t*, 8.106*f*, 8.106–107
description of, 3.245, 3.246*f*, 12.209, 12.216, 12.217*f*, 12.330
peripapillary, 6.366
scleral, 4.111–112, 4.112*f*
in scleritis, 4.110, 4.111*f*, 4.112, 8.322
Starburst effects, after radial keratotomy, 13.51
"Stare test," 8.55–56
Stargardt disease (juvenile macular degeneration/fundus flavimaculatus), 2.328, 4.168–169*f*, 4.168–170, 6.339–340, 6.340–341*f*, 12.269
ABCA4 gene mutations as cause of, 12.271

ATP-binding cassette (ABC) transporter protein mutation causing, 4.168–169
clinical findings of, 12.269–270, 12.270*f*
description of, 12.31, 12.44
electroretinography findings in, 12.48*f*
fluorescein angiography findings, 12.269–270, 12.270*f*
fundus autofluorescence findings, 12.270
phenotype of, 12.269
retinal pigment epithelium findings in, 4.168–169*f*, 4.169–170, 12.270, 12.270*f*
visual acuity in, 12.269
"Starry night" sign, in Vogt-Koyanagi-Harada disease, 12.232
STAT6 expression, in orbital solitary fibrous tumors, 4.235
Static dyschromatopsia, 12.249
Static perimetry, automated, 5.84, 5.85*f*, 5.85–88, 5.87*f*
in nonorganic disorder evaluation, 5.306–307, 5.307*f*, 5.308*f*
Staticokinetic dissociation (Riddoch phenomenon), 5.158, 5.181
Statins
adverse effects of, 1.77
age-related macular degeneration and, 1.78–79
angina pectoris treated with, 1.91
cataracts and, 1.79, 11.53
dosing of, 1.75*t*
hypercholesterolemia treated with, 1.75*t*, 1.76–77
ischemic stroke prevention using, 1.115
stroke prevention using, 1.115
Stationary retinal disease. *See specific disorder*
Statistical tests
clinical significance of, 1.7
flow chart of, 1.7
Status epilepticus, 1.303–304
Status epilepticus amauroticus, 5.172
Steady fixation, 6.6
Steepening, in hyperopia surgery, 13.26, 13.79, 13.96
Steinert disease, 2.218, 12.282*t*
Stellate (sutural) cataracts, 11.37, 11.37*f*
Stem cells, 8.8, 8.10–11. *See also* Limbal stem cells
conjunctival, 8.92, 8.362
corneal, 8.8, 8.92
culture of, 8.365
definition of, 2.166
human embryonic, 2.166
induced pluripotent, 2.166
STEMI. *See* ST-segment elevation myocardial infarction
Stenopeic slit effect, 3.130
Stenopeic slit technique, 3.162, 3.162*f*
Stents. *See also* Lacrimal intubation
bicanalicular lacrimal, 7.293, 7.294*f*, 7.301*f*, 7.312
for cerebral aneurysm, 5.342
for congenital nasolacrimal duct obstruction, 6.234–235
lacrimal intubation, 7.292–294, 7.294*f*, 7.303
percutaneous coronary intervention with, 1.92
vertebrobasilar artery, 5.338
Step
gaze-evoked nystagmus and, 5.222, 5.240
saccadic eye movement and, 5.219, 5.220*f*, 5.222
Step innervation, 5.220
Stereo Fly test, 3.99
Stereoacuity. *See also* Stereopsis
development of, 6.182
testing
in monocular no light perception, 5.305
in monocular reduced vision, 5.305, 5.305*t*
in monofixation syndrome, 6.51
in nonorganic disorder evaluation
monocular no light perception and, 5.305
monocular reduced vision and, 5.305, 5.305*t*
sensory adaptation assessments using, 6.81
visual acuity relationship and, 5.305, 5.305*t*
Stereophotography, for recording optic nerve/nerve head/disc evaluation, 10.53
Stereopsis
binocular indirect ophthalmoscopes for, 12.22
contour, 6.81
definition of, 6.43, 6.81
depth perception *versus*, 6.43
development of, 6.43
random-dot tests, 6.81
sensory tests for, 6.100
testing
linear polarizers used in, 3.99
in nonorganic disorder evaluation
monocular no light perception and, 5.305
monocular reduced vision and, 5.305, 5.305*t*
visual acuity relationship and, 5.305, 5.305*t*
Stereotactic navigation, 7.32, 7.33*f*
Stereotactic radiosurgery, for arteriovenous malformations, 1.122
Sterile corneal infiltrates, 3.231*f*, 3.234
Sterile infiltrates, after surface ablation, 13.108, 13.108*f*
Sterile interface inflammation (diffuse lamellar keratitis/DLK), after LASIK, 13.116*f*, 13.116–117, 13.117*t*
infectious keratitis differentiated from, 13.117–118, 13.118*f*, 13.118*t*
pressure-induced stromal keratopathy differentiated from, 13.119
Steroids. *See* Corticosteroid(s)
Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis/SJS-TEN), 1.208, 6.251–252, 6.252*f*, 7.237, 7.238*f*, 7.303, 8.285, 8.295–298, 8.296*f*, 8.297*f*
STGD4 gene, in Stargardt disease, 4.168
Stickler syndrome, 2.302, 6.183, 6.345–346, 12.282*t*, 12.309, 12.342–343, 12.343*f*
Stigmatic imaging, 3.42, 3.69, 3.274
Still disease, 9.141
Stimulated absorption, 3.110
Stimulated emission, 3.111, 3.111*f*
Stimulated macrophages, 9.14–16, 9.15*f*
Stimulatory hypersensitivity, 9.38
Stimulus, perimetry results affected by, 10.60
Stimulus accommodative convergence/accommodation (AC/A) ratio, 6.71. *See also* Accommodative convergence/accommodation (AC/A) ratio
Stimulus deprivation amblyopia, 6.55
STIR (short tau inversion recovery) technique, 5.62–65, 5.63*t*, 5.75
Stocker-Holt variant Meesmann corneal dystrophy, 8.136*t*, 8.139

Stocker lines, 8.113, 8.118*t*. *See also* Iron lines
Stop and chop technique, in phacoemulsification, 11.114
Storiform pattern, in solitary fibrous tumor, 4.235, 4.235*f*
Strabismic amblyopia
  anisometropic amblyopia *versus*, 6.54–55
  clinical features of, 6.54
  critical period for, 6.45
  development of, 6.46–47
  eccentric fixation in, 6.54
  grating acuity associated with, 6.54, 6.56
  occlusion therapy for, 6.58
  pathophysiology of, 6.54
  visual acuity in, 6.54
Strabismus, 2.44. *See also* Deviations; Diplopia
  A-pattern. *See* A-pattern strabismus
  abbreviations for, 6.17
  abnormal visual experience caused by, 6.44
  accommodative convergence/accommodation ratio abnormalities as cause of, 6.39
  acquired, 6.16
  acute paralytic, 6.175
  age at onset, 6.16
  amblyopia treatment as cause of, 6.59–60
  animal models of, 6.46
  in Apert syndrome, 6.208, 6.209*f*
  in Brown syndrome. *See* Brown syndrome
  after cataract surgery, 6.304
  classification terms for, 6.16–17
  comitant/incomitant deviations in, 5.184, 5.186, 5.187
  congenital, 6.16
  congenital nystagmus and, 5.235
  consecutive, 6.16
  convergent, 6.15
  in craniosynostosis, 6.208
  cyclic, 6.93
  cyclovertical, 6.162
  definition of, 6.15
  dissociated strabismus complex, 6.17, 6.105*f*
  divergent, 6.15
  early-onset, 6.154
  extraocular muscle surgery and. *See* Strabismus surgery
  fixus, 5.208
  in Graves eye disease. *See* Strabismus, in thyroid eye disease
  history-taking for, 6.63
  incomitant
    abnormal head position caused by, 6.83
    prism alternate cover test for, 6.66
  infantile
    description of, 6.16
    dissociated vertical deviation associated with, 6.129
    fusion maldevelopment nystagmus syndrome associated with, 6.151, 6.154
    primary inferior oblique muscle overaction associated with, 6.117
  intermittent, 6.182
  latent
    alternate cover test for, 6.65, 6.66*f*
    description of, 6.15
    exodeviation as, 6.99
  manifest
    alternate cover test for, 6.65, 6.66*f*
    description of, 6.15
    exodeviation as, 6.99
    monocular cover-uncover test for, 6.64, 6.65*f*
  normal retinal correspondence and, 6.48–49, 6.49*f*
  nystagmus associated with, 6.154, 6.156–157
  ocular surgery–related, 6.145–146
  paralytic
    extraocular muscle surgery for, 6.161
    Hering's law of motor correspondence and, 6.38
  pattern. *See* Pattern strabismus
  pediatric glaucoma and, 10.166–167
  prefixes associated with, 6.15–16
  refractive surgery and, 13.41, 13.185–187
  restrictive, 6.146
  in retinoblastoma, 4.291, 4.291*f*, 4.291*t*
  screening for, 6.56
  sensory adaptations in
    anomalous retinal correspondence, 6.50–51
    monofixation syndrome, 6.51–52
    suppression, 6.48–50, 6.49*f*
  sensory response to, 6.75
  small-angle, 6.89
  squinting associated with, 6.202
  suffixes associated with, 6.15–16
  suppression in, 5.186
  supranuclear causes of, 5.188*t*
  surgical treatment of. *See* Strabismus surgery
  terminology related to, 6.15–17
  third nerve palsy. *See* Third nerve (oculomotor) palsy
  in thyroid eye disease, 5.206
  torticollis and, 6.63
  types of, 6.17
  V-pattern. *See* V-pattern strabismus
  vertical. *See also* Vertical deviations
    description of, 6.15–16
    diagnostic positions of gaze for, 6.64
  word origin of, 6.15
Strabismus fixus, 6.135
Strabismus surgery. *See also* Extraocular muscle surgery; *specific type or disorder*
  anomalous retinal correspondence after, 6.50
  diplopia after, 5.209
  esotropia treated with, 6.91
  infantile, monofixation syndrome after, 6.51
  pediatric glaucoma and, 10.166–167
  tightening procedures in, 6.164*t*
  weakening procedures in, 6.164*t*. *See also* Weakening procedures
Straddling, 3.158, 3.158*f*
Straight-line rays. *See* Ray(s)
Straight sinus, 5.22, 5.22*f*
Stratum album profundum, 5.33
Stratum griseum profundum, 5.33
Strawberry hemangioma. *See* Hemangiomas
Strawberry tongue, 1.171
Streak reflex. *See* Retinal reflex
Streak retinoscopy, 3.273
Streptococcus, 8.244*t*, 8.244–245, 8.245*f*
  α-hemolytic, infectious pseudocrystalline/crystalline keratopathy caused by, 4.79, 8.268, 8.268*f*
  bacterial conjunctivitis caused by, 6.240

β-hemolytic. *See Streptococcus, pyogenes*
conjunctivitis caused by, 8.208*t*, 8.256, 8.257*t*
in children, 4.52
endogenous endophthalmitis caused by, 9.294
endophthalmitis caused by
bleb-associated, 12.391
endogenous bacterial, 12.238
postoperative, 11.161, 12.389
epidermidis, 2.422
group A β-hemolytic. *See Streptococcus, pyogenes*
keratitis caused by, 8.208*t*
after penetrating keratoplasty, 8.427
after photoablation, 13.106
as normal flora, 8.205, 8.206*t*, 8.244
ocular infection caused by, 8.208*t*. *See also specific type*
pneumoniae (pneumococcus), 1.247–248, 2.422, 6.213, 6.240, 8.245, 8.245*f*
conjunctivitis caused by, 8.256, 8.257*t*
in children, 4.52
keratitis caused by, 8.208*t*
after photoablation, 13.106
as normal flora, 8.205
ocular infection caused by, 8.208*t*
preseptal cellulitis caused by, 6.213
pyogenes, 1.247, 6.213
viridans, 2.426, 12.404
conjunctivitis caused by, 8.256, 8.257*t*
infectious pseudocrystalline keratopathy caused by, 4.79
keratitis caused by, after photoablation, 13.106
Streptokinase, 2.445
Streptomyces caespitosus, 2.414
Streptomycin, 2.426
Stress echocardiography, 1.87
Striae
after conductive keratoplasty, 13.128, 13.129*f*
in LASIK flaps, 13.112–115, 13.114*t*, 13.115*f*
Striate cortex (Brodmann area 17), 2.115, 2.116*f*, 5.24*f*, 5.29*f*, 5.29–30, 5.30*f*, 5.32*f*, 5.34*f*. *See also* Visual (calcarine/occipital/striate) cortex
description of, 6.44
disorders of, 5.158, 5.178*t*, 5.178–181
illusions and, 5.175
monocular visual deprivation in, 6.44, 6.45
Striate melanokeratosis, 4.65, 8.341
"String of pearls," 9.196, 9.292, 9.296*f*
"String sign," in internal carotid artery dissection, 5.262*f*
Stroke
acquired ocular motor apraxia and, 5.223
arterial dissection causing, 5.342
aspirin prophylaxis for, 1.89
cardioembolic, 1.111
carotid artery disease and. *See also* Carotid occlusive disease
description of, 5.167–169
transient visual loss and, 5.167, 5.168, 5.169
carotid duplex ultrasonography for, 1.113
cerebral arteriography for, 1.113
completed, 1.110
computed tomography of, 1.112
cryptogenic, 1.119
deaths caused by, 1.109–110
diagnosis of, 1.111–112
echocardiography evaluations, 1.112
gaze preference and, 5.228
helical computed tomography angiography of, 1.113
hemispheric transient ischemic attack and, 5.167, 5.168–169
homonymous hemianopia caused by, 5.153, 5.156, 5.157, 5.157*f*, 5.158*f*
hypertension and, 1.66, 1.115
imaging studies for, 1.112–113
incidence of, 1.109
internuclear ophthalmoplegia caused by, 5.190
ischemic. *See also* Cerebral ischemia
blood pressure control for prevention of, 1.115
cardioaortic causes of, 1.118–119
carotid duplex ultrasonography for, 1.113
carotid occlusive disease as cause of, 1.115–119
causes of, 1.111
cerebral arteriography for, 1.113
clinical manifestations of, 1.110–111
diagnosis of, 1.111–112
helical computed tomography angiography for, 1.113
imaging studies for, 1.112–113
magnetic resonance angiography evaluations, 1.112–113
magnetic resonance imaging evaluations, 1.112–113
management of, 1.111–112
mechanical thrombectomy for, 1.113–114
multimodal computed tomography for, 1.112
nonarteriosclerotic causes of, 1.111
penumbra, 1.110
prevention of, 1.114–115
recombinant tissue plasminogen activator for, 1.113
reperfusion techniques, 1.114
risk factors for, 1.111
statins for prevention of, 1.115
thrombolytic agents, 1.113
transcranial Doppler ultrasonography for, 1.113
treatment of, 1.113–114
magnetic resonance angiography of, 1.112–113
magnetic resonance imaging of, 1.112–113, 5.65*t*, 5.66, 5.67*f*, 5.75
management of, 1.111–112
mortality rates for, 1.109–110
nonarteriosclerotic causes of, 1.111
occipital lobe lesions caused by, 5.156
in ocular ischemic syndrome patients, 12.139
prevention of, antithrombotic therapy, 1.114–115
retinal transient ischemic attack and, 5.167, 5.168–169
risk factors for, 1.111, 5.168–169
secondary, 1.114–115
severity of, 1.111
transcranial Doppler ultrasonography for, 1.113
transient monocular visual loss and, 5.164, 5.167, 5.168–169
clinical/laboratory evaluation and, 5.166–167
prognosis/treatment and, 5.168–169
vestibular-ocular dysfunction and, 5.217

Stroke-like migraine attacks after radiation therapy (SMART), 5.358
Stroke/stroke length (phacoemulsification), 11.99, 11.100
Stroma
choroidal, 2.77, 4.182
ciliary body, 2.73
conjunctival (substantia propria), 4.47, 4.48*f*, 8.7
age-related changes in, 8.112
in external eye defense, 8.13
immune and inflammatory cells in, 8.13
corneal, 4.73, 4.74*f*, 8.7*f*, 8.8–9, 8.9*f*
anatomy of, 2.53, 8.7*f*, 8.8–9, 8.9*f*
biomechanics and, 13.13–14
collagen fibers in, 2.263, 2.264–265*f*
composition of, 2.53, 2.58
degenerations of, 8.120–126
dystrophies of. *See* Stromal corneal dystrophies
healing/repair of, 4.14, 4.15*f*
inflammation of, 8.50*t*, 8.50–52, 8.51*f*
in systemic infections, 8.279
keratocytes, 2.263
neovascularization of, 8.52
pigmentation of/deposits in, 8.118*t*
drug-induced, 8.129*t*, 8.132
refractive index of, 8.26
glucose delivery to, 2.259
iris, 2.68–69, 4.181
healing/repair of, 4.16
keratocytes of, 2.259
scleral, 4.107*f*, 4.107–108, 4.108*f*
Stromal bed
preparation of, for LASIK, 13.84–90. *See also* LASIK (laser in situ keratomileusis), flap creation for
with femtosecond laser, 13.87–90, 13.88*f*, 13.89*f*, 13.90*t*
with microkeratome, 13.84–87, 13.85*f*, 13.86*f*, 13.87*f*
residual (RSB), thickness of, LASIK and, 13.30, 13.45–46, 13.79–80
calculation of, 13.46, 13.79
corneal perforation and, 13.111
ectasia and, 13.79, 13.124
Stromal corneal dystrophies, 4.91, 4.92*f*, 8.135*t*, 8.149–156. *See also* Epithelial-stromal *TGFBI* dystrophies; *specific type*
congenital/congenital hereditary (CHSD/CSCD), 8.135*t*, 8.136*t*, 8.152, 8.153*f*
Fleck (FCD), 8.135*t*, 8.136*t*, 8.153, 8.154*f*
macular (MCD), 4.91, 4.91*t*, 4.92*f*, 8.135*t*, 8.136*t*, 8.145*t*, 8.149–151, 8.150*f*
posterior amorphous (PACD), 8.135*t*, 8.136*t*, 8.154*f*, 8.154–155
pre-Descemet (PDCD), 8.135*t*, 8.136*t*, 8.155–156, 8.156*f*
recurrence of after corneal transplantation, 8.425
Schnyder (SCD), 8.135*t*, 8.136*t*, 8.145*t*, 8.151–152, 8.152*f*
crystalline form of, 8.151, 8.152*f*
hyperlipoproteinemia and, 8.151, 8.179
Stromal corneal infiltrates
in epidemic keratoconjunctivitis, 8.234*f*, 8.234–235, 8.235*f*
after surface ablation, 13.108, 13.108*f*
Stromal edema, 8.42
after cataract surgery, 11.128*t*, 11.128–130
cold-induced, 8.385
Stromal graft rejection, 8.429. *See also* Rejection
Stromal interstitial keratitis, 9.220, 9.221*f*
Stromal keratitis, 8.46*t*, 8.50*t*, 8.50–52, 8.51*f*
CMV causing, 8.232
in Cogan syndrome, 8.309–310
Epstein-Barr virus causing, 8.230–231, 8.231*f*
herpes simplex virus causing, 4.77*f*, 4.78, 8.219–222, 8.220*f*, 8.221*f*, 8.223*t*
penetrating keratoplasty for, 8.225
recurrence of in graft, 8.225
in herpes zoster ophthalmicus, 8.228, 8.228*f*
microsporidial, 8.280–281
necrotizing, 8.52, 8.219, 8.220–221, 8.221*f*, 8.222, 8.223*t*
nonnecrotizing, 8.51*f*, 8.219, 8.220*f*, 8.221*f*, 8.223*t*
nonsuppurative, 8.46*t*, 8.50, 8.50*t*, 8.51*f*, 8.52
in rosacea, 8.70, 8.70*f*
suppurative, 8.46*t*, 8.50, 8.50*t*, 8.51*f*, 8.52
syphilitic, 8.308–309, 8.309*f*
Stromal keratopathy, pressure-induced (PISK), after LASIK, 13.119, 13.120*f*
Stromal nevi, 4.64, 8.338*t*, 8.340
Stromal puncture, for recurrent corneal erosions, 8.79, 8.87
Stromal thinning. *See also* Cornea, thinning of
in ectatic disorders, 8.133
microsporidial, penetrating keratoplasty for, 8.281
STUMPED mnemonic, for corneal opacities, 6.257*t*, 6.257–258
Sturge-Weber syndrome (SWS/cerebrofacial/encephalotrigeminal/encephalofacial angiomatosis/hemangiomatosis)
choroidal hemangioma in, 4.197, 4.281, 5.332*f*, 5.334*t*
description of, 5.331, 5.332*f*, 5.334*t*, 6.199, 6.251, 6.285, 6.349, 6.394*t*, 6.401*t*, 6.401–403, 6.402*f*, 10.30, 10.155, 12.202
port-wine stain (nevus flammeus) in, 8.346
glaucoma associated with, 5.332*f*, 5.334*t*, 10.30, 10.155
in children, 5.332*f*, 10.155
port-wine stain (port-wine nevus/nevus flammeus) in, 5.332*f*, 5.334*t*, 8.346, 10.30, 10.155
Stye (external hordeolum), 4.203–204, 8.76, 8.76*f*
Sub-Tenon injection
corticosteroid, in cystoid macular edema, after cataract surgery, 11.165
lidocaine, for cataract surgery, 11.92, 11.92*f*
of periocular corticosteroids, 9.95–96, 9.96*f*, 9.322
Sub-Tenon space, 7.124, 12.20
Subacute bacterial endocarditis (SBE), 1.248*t*
Subacute granulomatous thyroiditis, 1.45
Subacute sclerosing panencephalitis (SSPE), 8.239, 9.262–263
Subarachnoid hemorrhage (SAH), 1.121, 6.382, 12.173. *See also* Intracranial hemorrhage
arteriovenous malformations causing, 5.343
ocular hemorrhage with, 5.340, 5.340*f*
ruptured aneurysm causing, 5.340
Subarachnoid ocular motor nerve course, 5.42*f*
cranial nerve palsies and, 5.192
Subarachnoid space, 2.114
optic nerve in, 4.241, 5.17*f*

Subarachnoid surgical space, 7.124
Subcapsular cataract
anterior (subcapsular fibrous plaques), 4.120, 4.120*f*
after posterior chamber phakic IOL insertion, 13.146
posterior (PSC), 2.283, 4.120*f*, 4.120–121, 4.121*f*, 6.297, 11.46–48, 11.51*f*
characteristics and effects of, 11.47, 11.70*t*
corticosteroids causing, 11.51–52
ischemia causing, 11.68
in myotonic dystrophy, 11.62
race and, 11.6
silicone oil use and, 11.190
uveitis and, 11.64
vitrectomy and, 11.55, 11.190
Subclavian artery, 5.13*f*, 5.19
Subclavian steal, 5.337–338
Subclinical depression, 1.189
Subclinical hypothyroidism, 1.45
Subclinical keratoconus. *See* Forme fruste (subclinical keratoconus)
Subclinical retinal detachment, 12.319–320
Subconjunctival disorders, 6.250–252
Subconjunctival fibrosis, medications causing, 8.91
Subconjunctival hemorrhage, 8.115*t*, 8.387–388, 8.388*f*
Subconjunctival lymphomas, 9.308
Subconjunctival nodules, 7.65, 7.65*f*
Subcortical structures. *See also specific structure*
in ocular motility, 5.33–34
Subcutaneous nodules, in sarcoidosis, 4.187, 4.187*f*
Subdural hematoma, 6.382
Subepithelial amyloidosis (gelatinous droplike dystrophy/primary familial amyloidosis), 8.135*t*, 8.136*t*, 8.140–141, 8.141*f*, 8.185–187, 8.186*t*
Subepithelial corneal degenerations, 8.115–120, 8.116*f*, 8.117*f*, 8.118*t*, 8.119*f*
Subepithelial corneal dystrophies. *See* Epithelial dystrophies, epithelial and subepithelial
Subepithelial corneal infiltrates, 8.46*t*
in epidemic keratoconjunctivitis, 8.234*f*, 8.234–235, 8.235*f*
Subepithelial fibrosis, in mucous membrane pemphigoid, 8.299, 8.300*f*, 8.302*t*
Subepithelial graft rejection, 8.428–429, 8.429*f*. *See also* Rejection
Subepithelial keratitis, in reactive arthritis syndrome, 9.133
Subepithelial mucinous corneal dystrophy (SMCD), 8.135*t*
Subepithelial nevi, 4.64, 8.338*t*, 8.340
Subfoveal pigment epithelial detachment, 12.74–12.75*f*
Subhyaloid hemorrhage, 12.173
Subjective refraction, 3.155
astigmatic dial technique in, 3.160–162, 3.161*f*, 3.166
binocular balance, 3.167–168, 3.168*f*
cross cylinder technique, 3.163–165, 3.164*f*, 3.165*t*
cylinder power refinement for, 3.164–165
description of, 3.160
Jackson cross cylinder for, 3.163–165, 3.164*f*
refining the sphere for, 3.165–167, 3.167*f*
stenopeic slit technique in, 3.162, 3.162*f*
Subluxation, IOL, 11.144*f*, 11.144–147, 11.146*f*, 11.147*f*. *See also* Decentration/dislocation
Subluxed/subluxated lens, 10.129–130, 10.130*f*, 10.130*t*, 11.39–40, 11.40*f*. *See also* Ectopia lentis
angle closure/pupillary block and, 10.119, 10.129–130, 10.130*f*, 10.130*t*
cataract surgery in patient with, 11.181–183, 11.182*f*, 11.183*f*
in megalocornea, 8.100
traumatic, 11.40, 11.54*f*, 11.54–55
Submacular hemorrhage
in neovascular age-related macular degeneration, 12.85, 12.385
posttraumatic, 12.354*f*
vitrectomy for, 12.385, 12.386*f*
Submandibular ganglion, 5.276–277*f*
Submental liposuction, 7.275*f*
Suborbicular fat pads, 7.168
Suborbicularis oculi fat (SOOF), 2.28*f*
anatomy of, 7.168
lift/elevation of, 7.224, 7.272
Subperiosteal abscesses (SPAs), 6.213, 6.214*f*, 7.47
Subperiosteal fluid, 7.11
Subperiosteal midface-lift, 7.272, 7.273*f*
Subperiosteal surgical space, 7.123, 7.123*f*
Subretinal drusenoid deposits (reticular pseudodrusen/RPD), 4.162, 4.163, 4.163*f*, 4.171*f*, 12.65, 12.65*f*, 12.200
Subretinal fibrosis
in Coats disease, 6.360
in multifocal choroiditis, 12.226, 12.226*f*
Subretinal fibrosis and uveitis syndrome (SFU)
characteristics of, 9.162–164*t*
definition of, 9.184
differential diagnosis of, 9.184
fluorescein angiography findings in, 9.163*t*, 9.184
manifestations of, 9.184, 9.184*f*
optical coherence tomography findings in, 9.164*t*, 9.184
treatment of, 9.185
Subretinal fluid
in central serous chorioretinopathy, 12.76
in choroidal neovascularization, 12.71
in exudative retinal detachment, 12.326
optic pit and, 12.329*f*
Subretinal hemorrhage
choroidal neovascularization *versus*, 12.211
description of, 6.373
in polypoidal choroidal vasculopathy, 12.76
Subretinal hyperreflective material (SHRM), 12.75
Subretinal infiltrates/subretinal pigment epithelium infiltrates, in primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.135, 4.135*f*, 4.136–137, 4.311, 4.311*f*
Subretinal neovascularization, 12.162, 12.164
Subretinal space, 2.330–331
biopsy of, in intraocular lymphoma, 4.135–136, 4.312
fluorophore accumulation in, 12.32
immunologic microenvironment of, 9.52*t*
retinal pigment epithelium–mediated dehydration of, 12.18
Substance abuse disorders, 1.198–199. *See also specific substance*
Substance P, 9.24*t*
Substantia nigra, 2.107*f*, 5.41*f*
in Benedikt syndrome, 5.191

Substantia propria
conjunctival, 9.3, 9.53
conjunctival (conjunctival stroma), 4.47, 4.48*f*, 8.7
age-related changes in, 8.112
in external eye defense, 8.13
immune and inflammatory cells in, 8.13
corneal. *See* Stroma, corneal
Subtotal exenteration, 7.146
Subtractive interference, 3.100
Succinylcholine, 2.234, 2.379, 2.382
Suction ring
for femtosecond laser flap creation, 13.88*f*, 13.89, 13.89*f*
after glaucoma surgery, 13.182
for microkeratome flap creation, 13.84–85, 13.85*f*, 13.86, 13.86*f*
Sudden cardiac death (SCD)
definition of, 1.85
implantable cardioverter-defibrillator for prevention of, 1.86, 1.105
timing of, 1.85–86
Sufentanil, 1.289
"Sugar" cataracts
aldose reductase in development of, 11.19
description of, 2.289–291
Sugiura sign, 9.206, 9.207*f*, 12.233
Suicide
depression and, 1.195
in older adults, 1.188
Sulamyd. *See* Sulfacetamide
Sulbactam. *See specific antibiotic combination*
Sulcus
internal scleral, 4.98
intraocular lenses supported by, 13.137, 13.139*t*
Sulfacetamide ophthalmic solutions, 2.423
Sulfacetamide sodium, 2.421*t*
Sulfadiazine
for ocular toxoplasmosis, 9.281
for toxoplasmic retinochoroiditis, 12.243
for toxoplasmosis, 6.410
Sulfasalazine, 1.179
Sulfatase deficiency, multiple, 8.177
Sulfite oxidase deficiency, 2.204*t*, 6.310
Sulfonamides, 2.361, 2.423–424. *See also specific agent*
Sulfur hexafluoride (SF_6), 12.382
Sulfuric acid (H_2SO_4), ocular injury caused by, 8.376*t*
Sulfurous acid (H_2SO_3), ocular injuries caused by, 8.376*t*
Sulindac, 2.409*t*
Sumatriptan, refractive surgery in patient taking, 13.37
Sump syndrome, 7.310, 7.310*f*
SUNCT (short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing), 5.289*t*, 5.294
"Sunflower" cataract, in chalcosis/Wilson disease, 8.189, 11.59, 11.62
Sunglasses
contrast sensitivity improvements using, 3.192
graded-density, 3.192–193
polarized, 3.99
ultraviolet-absorbing lenses and, cataract prevention and, 11.58
ultraviolet light absorption by, 3.194
Sunlight. *See* Ultraviolet (UV) light
"Sunset glow" fundus/sign, 9.204, 9.206, 9.207*f*, 12.232*f*, 12.232–233
Sunsetting, 6.185
Superficial basal cell carcinoma. *See* Basal cell carcinoma
Superficial keratectomy (SK), 8.366–367, 8.412*t*
layer-based approach to use of, 8.417*t*
Superficial mimetic muscles, 7.153
Superficial musculoaponeurotic system (SMAS), 2.134
description of, 7.151–153, 7.152*f*
rhytidectomy of, 7.273, 7.274*f*
Superficial nerve fiber layer, 2.111, 2.113*f*
Superficial petrosal nerve, greater, 5.276–277*f*, 5.277
Superficial plexus, 2.57
Superficial punctate keratitis of Thygeson (SPK), 8.306–307, 8.307*f*
Superficial spreading melanoma, 4.220, 4.221*f*
Superficial temporal artery, 2.38, 5.12, 5.15*f*
Superficial vascular plexus, 12.16
Superior cantholysis, 7.223*f*
Superior cerebellar artery (SCA), 2.107*f*, 5.18*f*, 5.19*f*, 5.20
cranial nerve relationship and, 5.42*f*
Superior cervical ganglion, 5.53*f*, 5.54
Horner syndrome caused by lesions of, 5.260*t*
Superior colliculus (SC), 5.18*f*, 5.33–34
saccadic control and, 5.219
Superior conchae, 7.19
Superior eyelid crease, 2.27
Superior limbic keratoconjunctivitis (SLK), 8.83–85, 8.84*f*
Superior marginal arcade, 5.13*f*
Superior muscular artery, 5.14–15
Superior oblique (SO) muscle, 5.8*f*, 5.36*f*, 5.46, 5.46*f*, 7.12–13*f*
action of, 6.34*t*, 6.37*f*
anatomy of, 2.8, 2.17*f*, 2.20*f*, 2.28*f*, 2.107*f*, 5.8*f*, 5.36*f*, 5.46, 5.46*f*
characteristics of, 2.19*t*, 6.21*t*
congenital palsy of, 6.69
depressor function of, 6.73
field of action for, 6.33
innervation of, 2.21, 5.40, 5.44, 6.19
magnetic resonance imaging of, 2.460*f*
myokymia affecting, 5.250–251
origin of, 2.18, 6.20, 6.21*t*
overaction of
A-pattern strabismus associated with, 6.107, 6.111
bilateral, 6.118*f*
description of, 6.17
horizontal deviation associated with, 6.118
overdepression in adduction caused by, 6.118, 6.118*f*, 6.137
palsy of, 6.17
bilateral, 6.122–124
causes of, 6.119
clinical features of, 6.119–122
congenital *versus* acquired, 6.119
description of, 6.69
hypertropia associated with, 6.123
inhibitional palsy of contralateral antagonist, 6.120–121, 6.121*f*

management of, 6.122–124, 6.123*t*
masked bilateral, 6.122
neuroimaging evaluations, 6.119
right, 6.120–121*f*
surgical management of, 6.122–124, 6.123*t*
3-step test for, 6.120
unilateral, 6.119–121, 6.120–121*f*, 6.122–123, 6.123*t*
V-pattern strabismus associated with, 6.109
paralysis of, inferior oblique muscle overaction secondary to, 6.166
right, palsy of, 6.120–121*f*
surgery of, for superior oblique myokymia, 5.251
tenotomy, 6.112, 6.138
tightening of, 6.123, 6.123*t*, 6.167
weakening of
bilateral, 6.166
for Brown syndrome, 6.138, 6.166
for lambda-pattern strabismus, 6.113
for nystagmus, 6.156
surgical procedures for, 6.164*t*, 6.166
tenotomy for, 6.166
unilateral, 6.166
weakness of, 6.119
Superior oblique myokymia (SOM), 5.250–251, 6.145
Superior oblique tendon, 2.17*f*, 7.6
anatomy of, 6.19*f*
tightening of, 6.167
Superior oblique tenotomy, for superior oblique myokymia, 5.251
Superior ophthalmic vein, 2.26*f*, 5.8*f*, 5.21, 5.21*f*, 5.22*f*, 5.23, 5.23*f*, 7.12*f*, 7.14
Superior orbital fissure, 5.5, 5.6*f*, 5.7*f*, 5.9*f*, 5.11, 7.6, 7.7*f*, 7.9, 7.130*f*
anatomy of, 2.6*f*, 2.11, 2.106*f*, 2.132
computed tomography of, 2.11*f*
ophthalmoplegia caused by lesions of, 5.203
Superior orbital vein, 6.23
Superior orbitotomy
transconjunctival incisions for, 7.125
transcutaneous incisions for, 7.124–125, 7.125*f*
vertical eyelid splitting, 7.125–126
Superior palpebral artery, 5.13*f*
Superior palpebral vein, 5.21*f*
Superior petrosal sinus, 5.22, 5.23*f*
Superior punctum, 2.27. *See also* Punctum
Superior rectus (SR) muscle, 5.8*f*, 5.36*f*, 5.45, 5.46*f*, 7.12, 7.13*f*
action of, 6.34*t*, 6.35, 6.36*f*
anatomy of, 2.17*f*, 2.20*f*, 2.28*f*, 2.107*f*, 5.8*f*, 5.36*f*, 5.45, 5.46*f*
characteristics of, 2.19*t*, 6.21*t*
computed tomography of, 2.456*f*
elevator function of, 6.73
innervation of, 5.44, 5.44*f*, 6.19
intorsion of, 6.34
Knapp procedure, 6.127
magnetic resonance imaging of, 2.460*f*
origin of, 6.20, 6.21*t*, 6.22*f*
recession of, 6.30, 6.128, 6.130
resection of, 6.30
surgery considerations for, 6.29–30
transposition of, 6.167
Superior rectus subnucleus, 5.44
Superior rectus tendon, 2.17*f*, 6.19*f*
Superior retinal arcade, 5.14
Superior sagittal sinus (SSS), 5.22, 5.22*f*
thrombosis in, 5.346
Superior salivatory (salivary) nucleus, 5.51*f*, 5.55, 5.276–277*f*, 8.5*f*
Superior segmental hypoplasia, 5.144
Superior sulcus deformity, 7.141*f*
Superior tarsal muscle of Müller, 4.202, 8.3, 8.4*f*
innervation of, 5.53, 5.53*f*, 5.54
Superior turbinate, 2.14*f*
Superior vena cava syndrome, glaucoma associated with, 10.30
Superoxide anion, 2.337*t*, 9.16
Superoxide dismutase (SOD), 2.342
in lens, 11.20
Supertraction crescent, 12.210
Supplemental intraocular lenses (piggybacking), refractive lens exchange and, 13.150
Supplemental oxygen, retinopathy of prematurity risks secondary to, 6.326–327
Supplementary eye fields (SEFs), 5.32*f*, 5.33
Suppression, 5.186
alternating, 6.49
central, 6.48
constant, 6.49
definition of, 6.48
facultative, 6.49
management of, 6.50
nonalternating, 6.49
orthoptic exercises for, 6.50
pathologic, 6.48
peripheral, 6.48
physiologic, 6.48
red-glass test findings in, 6.76*f*
as strabismus adaptation, 6.48–50, 6.49*f*
Suppression scotoma
description of, 6.49
4Δ base-out prism test for, 6.79
Worth 4-dot test for, 6.80*f*, 6.80–81
Suppressor (regulatory/Treg) T cells. *See also* T cell(s)
in corneal transplant tolerance, 8.316
in external eye defense, 8.12–13*f*, 8.13, 8.14
Supracapsular phacoemulsification, 11.110
Suprachoroidal effusion. *See also* Suprachoroidal hemorrhage/choroidal hemorrhage
angle-closure glaucoma and, 10.141, 10.142*f*, 10.144, 10.145, 10.145*f*
cataract surgery and, 11.159
flat or shallow anterior chamber and, 11.134
after filtering surgery, 10.210–211
Suprachoroidal hemorrhage/choroidal hemorrhage, 4.18, 4.19*f*
angle-closure glaucoma and, 10.141
cataract surgery and, 11.159, 11.171
delayed, 11.160
expulsive, 11.159–160
flat or shallow anterior chamber and, 11.134
description of, 12.394–395, 12.395*f*
expulsive, 4.18, 4.19*f*
cataract surgery and, 11.159–160
after filtering surgery, 10.210–211
Suprachoroidal shunts, 10.220

Supraciliary space, 2.76
Supraduction. *See* Elevation of eye
Supramarginal gyrus, 5.32*f*
Supranuclear control systems, for eye movements, 6.40
Supranuclear palsy, progressive (PSP)
convergence insufficiency in, 5.227
facial weakness/paralysis in, 5.278
pursuit dysfunction in, 5.226
saccadic dysfunction in, 5.214, 5.221
Supranuclear (cortical) pathways, 5.32*f*, 5.32–33, 5.33–34, 5.34*f*, 5.211. *See also specific system*
disorders of, 5.188, 5.188*t*, 5.211–231
diplopia and, 5.188, 5.188*t*
facial weakness/paralysis caused by, 5.276*f*, 5.277–278
gaze preference/palsy and, 5.228–230, 5.229*f*, 5.230*f*
ocular fixation system and, 5.212, 5.212*t*, 5.213–214
optokinetic system/nystagmus and, 5.212, 5.212*t*, 5.218–219
saccades/saccadic system and, 5.32–33, 5.38, 5.212, 5.212*t*, 5.219–223, 5.220*f*
smooth-pursuit system and, 5.32, 5.33, 5.34*f*, 5.212, 5.212*t*, 5.224–226, 5.225*f*
tonic deviations and, 5.230–231
vergence system and, 5.212, 5.212*t*, 5.226–228
vestibular-ocular system and, 5.38–39, 5.39*f*, 5.212, 5.212*t*, 5.214–218, 5.216*t*
Supraorbital artery, 2.23*f*, 2.38*f*, 5.12, 5.13*f*, 5.14*f*, 5.15*f*
Supraorbital ethmoids, 7.20
Supraorbital foramen/notch, 2.7*f*, 2.8, 2.10–11, 5.9*f*, 7.6, 7.7*f*
Supraorbital nerve, 5.48, 5.48*f*
Supraorbital vein, 2.26*f*, 5.21*f*
Supratarsal corticosteroid injections, for vernal keratoconjunctivitis, 8.291
Supratrochlear artery, 2.23*f*, 2.38*f*, 5.12, 5.13*f*, 5.14*f*, 5.15*f*
Supratrochlear nerve, 2.131, 5.48
Supratrochlear vein, 5.21*f*
Supraventricular tachycardias, 1.102–103
Surface ablation, 13.8*t*, 13.30, 13.73, 13.74–76. *See also* Photoablation; *specific procedure*
aberrations and, 13.11, 13.12, 13.13, 13.102
advanced (ASA). *See* Photorefractive keratectomy
application of laser treatment and, 13.30, 13.91*f*, 13.91–93
bandage contact lenses after, 13.92, 13.107, 13.200
sterile infiltrates and, 13.108, 13.108*f*
bioptics with, 13.157
calibration of excimer laser for, 13.80
complications/adverse effects of, 13.107–110, 13.108*f*, 13.109*f*
contact lens use after, 13.200
contraindications for, 13.77–78
corneal ectasia after, 13.124
corneal crosslinking for, 13.124, 13.130, 13.131
corneal haze and, 13.33, 13.52, 13.92, 13.108–110, 13.109*f*
corticosteroids in reduction of, 13.33, 13.94, 13.108–109
mitomycin C in reduction of, 13.33, 13.92, 13.109
undercorrection and, 13.102, 13.108
corneal healing/repair and, 13.33
corneal preparation for, 13.82–84, 13.83*f*
corneal transplantation after, 13.198
corticosteroids after, 13.92, 13.94
complications associated with, 13.41, 13.104–105
dry eye after, 13.76
epithelial defect and, 13.107–108
epithelial debridement for, 13.82–84, 13.83*f*
epithelial/persistent epithelial defects after, 13.107–108
debridement for, 13.108
epithelial preservation techniques for, 13.84
glaucoma/ocular hypertension and, 13.104–105, 13.180–183, 13.182*f*, 13.200–201
infectious keratitis and, 13.106–107
intraocular pressure measurement after, 13.104–105, 13.181, 13.200–201
keratoconus and, 13.175
for LASIK enhancement, 13.98–99
limitations of, 13.47*t*
outcomes of, 13.95
postoperative care for, 13.93–94
immediate postablation measures and, 13.92–93
preoperative care for
patient preparation and, 13.81–82
patient selection/relative contraindications and, 13.77–78, 13.78
planning/laser programming and, 13.81
after radial keratotomy, 13.52
re-treatment/enhancements and, 13.98–99
refractive lens exchange and, 13.149
sterile infiltrates and, 13.108, 13.108*f*
surgical technique for, 13.80–95
tracking/centration/ablation and, 13.91*f*, 13.91–92
undercorrection and, 13.102, 13.108
wavefront-guided. *See* Wavefront-guided (custom) laser ablation
Surface-active agents, 2.358
Surface ectoderm, lens development and, 11.25, 11.26*f*
Surface normal, 3.42, 3.44, 3.44*f*
Surface tension, of ophthalmic viscosurgical device, 11.96
Surfactants, 2.358
Surge, in phacoemulsification, 11.102
Surgeon factor (SF), 3.249
Surgery. *See also* Cataract surgery; Laser surgery; Ocular surgery; Orbital surgery; *specific procedure*
anesthetics in, 2.441–442
basal cell carcinoma treated with, 7.204
chalazion treated with, 7.182–183, 7.183*f*
childhood glaucoma treated with, 6.285–288, 6.286*f*, 6.288*f*
diabetic macular edema treated with, 12.114–115
endophthalmitis after, 12.388–391, 12.390–391*f*. *See also* Postoperative endophthalmitis
extraocular muscle. *See* Extraocular muscle surgery
facial rejuvenation techniques, 7.271–276, 7.272–275*f*
high AC/A ratio accommodative esotropia treated with, 6.92
infantile hemangiomas treated with, 7.72
intermittent exotropia treated with, 6.102–103
intraocular foreign bodies removed with, 12.360–362
lens subluxation treated with, 6.310
macular holes managed with, 12.339–340

necrotizing fasciitis treated with, 7.49*f*
neovascular age-related macular degeneration treated with, 12.85–86
open-globe injuries managed with, 12.359–360
optic nerve glioma treated with, 7.82
orbital fractures treated with, 7.117
primary congenital glaucoma treated with, 6.285–288, 6.286*f*, 6.288*f*
ptosis treated with. *See* Ptosis, surgical repair of
rhegmatogenous retinal detachment treated with, 12.397–401, 12.398–400*f*
scleritis treated with, 9.127
sympathetic ophthalmia secondary to, 12.233
uveitis treated with, 9.113
vitreous loss during, 12.349
Surgical instruments
for arcuate keratotomy, 13.55
for intrastromal corneal ring segment placement, 13.63
for limbal relaxing incisions, 13.55, 13.56*f*
for phacoemulsification, 11.98*f*, 11.98–99
Surgical myectomy, 7.257–258
Surgical/operating microscope, 3.294, 3.295*f*
for manual small-incision cataract surgery, 11.198
phototoxicity and, 11.166
Surgically induced necrotizing scleritis (SINS), 8.282
Sursumduction/sursumversion. *See* Elevation of eye
Sursumversion, 6.37
Survival analysis, 1.10
Susac syndrome, 9.160*f*, 9.160–161, 12.156
Suspension, 2.349, 2.356
Suspensory ligaments of lens. *See* Zonular fibers, lens
Sussman goniolens, 10.35
SUSTAIN study, 12.81
Sustained-release drug delivery, 2.363–365
Sustained-release oral preparations, 2.362
Sutural cataracts, 11.37, 11.37*f*
Sutural cysts, 6.224
Suture abscess, after penetrating keratoplasty, 8.426
Sutures (lens), 11.13
development of, 11.27*f*, 11.28*f*, 11.28–29
opacification of (sutural/stellate cataract), 11.37, 11.37*f*
Sutures (surgical)
for cataract surgery
astigmatism and, 11.131–132
posterior chamber IOL fixation and, 11.116–117, 11.119, 11.119*f*
McCannel, for IOL decentration, 11.145
for penetrating keratoplasty, 8.419*f*
corneoscleral laceration repair and, 8.406, 8.407*f*, 8.408*f*
postoperative problems and, 8.426*f*, 8.426–427, 8.431–432, 8.432*f*
removal/adjustment of
after corneal transplant
for astigmatism, 8.419*f*, 8.431–432, 8.432*f*
in children, 8.451
after penetrating and perforating trauma repair, 8.409
for trabeculectomy, laser lysis of, scleral flap closure and, 10.202–203, 10.207–208
Swabbing, for specimen collection, 8.210–211, 8.211
Swan-neck deformity, 1.152, 1.152*f*
SWAP. *See* Short-wavelength automated perimetry
Sweat glands, of eyelid, 4.201, 4.202, 8.4
cyst arising in, 4.208, 4.208*f*
syringoma associated with malformation of, 4.214, 4.215*f*
Swedish interactive thresholding algorithm (SITA) (perimetry), 5.86, 10.60–61, 10.62
short-wavelength automated perimetry (SWAP) using, 10.75
Swelling pressure (SP), 8.9
Swept-source optical coherence tomography (SS-OCT), 8.22
pathologic myopia findings on, 12.209*f*
sensitivity of, 12.26
spectral-domain optical coherence tomography *versus*, 12.25–26
Swinging flashlight test, for relative afferent pupillary defect, 5.79, 5.79*f*, 5.80
before cataract surgery, 11.78
SWJs. *See* Square waves/square-wave jerks
SWS. *See* Sturge-Weber syndrome
SYCAMORE study, 9.100*t*, 9.111
Sylvius, cerebral aqueduct of, 2.107*f*, 5.36*f*, 5.41*f*, 5.192
Symblepharon, 6.146, 7.239
acid burn causing, 8.381, 8.381*f*
cataract surgery in patient with, 11.173
in mucous membrane pemphigoid, 8.299, 8.300, 8.300*f*, 8.302*t*
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297, 8.297*f*
Symbol charts, 6.7
Symmetric convergence, 6.41
Sympathetic fibers, lacrimal functional unit innervated by, 8.5*f*
Sympathetic ganglia/nerves/pathway, 5.52–54, 5.53*f*
Sympathetic ophthalmia (SO), 4.185, 4.186*f*, 7.136–138
anterior segment findings in, 9.200
characteristics of, 12.233
Dalen-Fuchs nodules in, 9.200, 9.202
description of, 9.45–46
diagnosis of, 9.203
enucleation in prevention of, 8.404
fluorescein angiography findings in, 9.200, 9.201*f*
glaucoma/glaucoma surgery and, 10.195, 10.196, 10.198
histologic features of, 9.202
histologic/histopathologic features of, 4.185, 4.186*f*
human leukocyte antigen association with, 9.65*t*
incidence of, 9.199–200
indocyanine green angiography findings in, 9.201, 9.202*f*
manifestations of, 9.200–202, 9.201–202*f*
ocular trauma as cause of, 9.199
optical coherence tomography findings in, 9.201–202, 9.202*f*
panuveitis in, 9.199–203
after pars plana vitrectomy, 9.199–200
posterior segment findings in, 9.200, 9.201*f*
surgical procedures/injuries leading to, 4.185
trauma as cause of, 12.364–365

treatment of, 9.203
Vogt-Koyanagi-Harada disease/syndrome *versus*, 9.203, 12.232
Sympathizing eye, 4.185, 9.199–200. *See also* Sympathetic ophthalmia
Symporters, 2.271
Symptomatic retinal breaks, 12.318
Synaptic body, 2.85
Synaptophysin, in immunohistochemistry, 4.34
Synchysis, in cholesterolosis (synchysis scintillans), 4.133
Synchysis scintillans, 4.133, 12.348
Syncope, 1.299
Syndactyly, in Apert syndrome, 6.206, 6.207*f*
Syndrome, 6.183. *See also specific syndrome*
Syndrome X. *See* Metabolic syndrome
Syndromic congenital craniofacial anomalies. *See* Craniofacial malformations; *specific type*
Syndromic craniosynostosis, 7.39, 7.39*f*. *See also* Craniosynostosis
Syndromic panretinal dystrophies, 12.259
Synechiae
anterior, 9.318
angle closure and, 10.117, 10.121
in glaucoma
angle closure and, 10.117, 10.121
inflammation and, 10.138, 10.139*f*
anterior segment/iris neovascularization and, 10.39, 10.39*f*, 10.133, 10.133*f*, 10.134*f*
chamber deepening/goniosynechialysis in management of, 10.220
flat anterior chamber and, 10.144
gonioscopy in identification of, 10.34*f*, 10.39, 10.39*f*
iridocorneal endothelial syndrome and, 4.100–101, 4.101*f*, 10.136, 10.136*f*
plateau iris and, 10.128
traumatic hyphema and, 8.394, 8.395*t*
posterior
in anterior uveitis, 9.77, 9.80*f*
in glaucoma
inflammation and, 10.138, 10.138*f*
pupillary block/angle closure and, 10.119
pupillary block/angle closure and, 10.119
in uveitis, lens changes/cataract and, 11.64
pupil irregularity and, 5.255
Syneresis, 4.128, 4.129*f*
posterior vitreous detachment and, 4.128–129, 4.129*f*
vitreous, 12.307, 12.316
vitreous hemorrhage and, 4.133
Synergist, 6.33
Synergistic divergence, 6.133
Synkinesis, 7.243, 7.246
facial, 5.271, 5.271*f*, 5.277
near reflex and. *See* Near reflex
Synkinetic near reflex. *See* Near reflex
Syntenic traits, 2.217
Syphilis, 8.107, 8.308–309, 8.309*f*
acquired, 9.221
acute syphilitic posterior placoid chorioretinitis caused by, 12.241
anterior segment findings of, 9.221–222
Argyll Robertson pupil in, 5.267
cerebrospinal fluid testing in, 9.225
chorioretinitis in, 9.222–223*f*, 12.241–242, 12.242*f*
congenital, 1.222, 1.252, 6.269, 6.412–413, 9.220, 9.226
congenital/intrauterine, 8.107, 8.308–309, 8.309*f*
corneal manifestations of, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*
conjunctivitis in, 8.260*t*
definition of, 9.219
diagnosis of/screening/testing for
description of, 1.252–253, 9.224–225
optic neuritis and, 5.115
HIV and, 1.253, 9.219–220, 9.331–332
incidence of, 9.219
keratitis in, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*
latent, 1.252
lumbar puncture for, 1.253
management of, 1.253
neuro-ophthalmic manifestations of, 5.351, 9.223–224
nontreponemal tests for, 9.224–225
ocular involvement in, 1.252–253, 9.221–224, 9.222–224*f*
penicillin G for, 9.225–226, 9.226*t*
polymerase chain reaction diagnosis of, 9.225
posterior segment findings of, 9.221*f*, 9.221–222
primary, 9.221
retinitis in, 9.222, 9.224*f*
screening for, 1.222–223
secondary, 9.221
tertiary, 1.252, 9.221
testing for, 9.84–85, 9.148
transmission of, 1.222, 1.252, 9.219
treatment of, 9.225–227, 9.226*t*
treponemal tests for, 9.224–225
uveitis caused by, 9.84–85, 9.148, 9.219–227, 12.241
Syphilitic choroiditis, 9.177
Syringomas, 4.214, 4.215*f*, 7.192, 7.192*f*
Systematic reviews, 1.14
Systemic diseases
ataxia-telangiectasia, 6.393*t*, 6.403*t*, 6.403*f*, 6.403–404
chromosomal abnormalities, 6.385, 6.386*t*
diabetes mellitus, 6.408–409
familial oculorenal syndromes, 6.391–392, 6.391–392*f*
inborn errors of metabolism. *See* Inborn errors of metabolism
intrauterine infections, 6.409–413
intrauterine/perinatal infections, 6.409–413
Leber congenital amaurosis–like phenotypes in, 6.336
leukemia, 6.413–414
malignant, 6.413–415
neuro-oculocutaneous syndromes. *See* Neuro-oculocutaneous syndromes
neuroblastoma, 6.414–415, 6.415*f*
ocular manifestations of, 6.385–415
von Hippel–Lindau syndrome, 6.393*t*, 6.399–401, 6.400*t*, 6.400*f*
Systemic fibrosis, nephrogenic (NSF), 2.458
gadolinium causing, 5.60
Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study (SITE), 9.100*t*, 9.105, 9.150

Systemic lupus erythematosus (SLE)
antinuclear antibody testing for, 1.160, 1.160*t*, 9.156
articular disease associated with, 1.158
autoantibodies in, 1.161, 9.154
cardiac manifestations of, 1.159–160
cutaneous manifestations of, 1.158, 1.159*f*
definition of, 1.158, 9.153
description of, 9.125*t*, 12.134
diagnosis of, 1.160*t*, 1.160–161
eyelid manifestations of, 4.207*t*
gastrointestinal manifestations of, 1.160
gender predilection of, 1.158
keratoconjunctivitis sicca in, 1.161
lupus choroidopathy in, 9.154, 9.155*f*
lupus retinopathy in, 9.154, 9.155*f*
malar rash associated with, 1.158, 1.159*f*
manifestations of, 9.154–156
ocular manifestations of, 1.161
optic neuritis and, 5.115
pathogenesis of, 9.153–154
procainamide as cause of, 12.300
racial predilection of, 1.158
Raynaud phenomenon associated with, 1.159, 1.159*f*
refractive surgery contraindicated in, 13.191
refractory, 1.161
renal disease associated with, 1.158
retinal vascular occlusive disease in, 9.154, 9.155*f*
signs and symptoms of, 1.158–160, 1.159*f*
thromboembolism in, 1.160
treatment of, 1.161–162, 9.156
vasculitis associated with, 12.230–231, 12.231*f*
Systemic (visceral/nodal) lymphoma. *See also* Lymphomas
secondary eye involvement and, 4.135*f*, 4.135–137, 4.136*f*, 4.314
prognosis for, 4.314
Systemic sarcoidosis. *See* Sarcoidosis
Systemic sclerosis (SSc/scleroderma)
description of, 1.164–166, 1.165*f*
eyelid manifestations of, 4.207*t*
Systolic blood pressure, 1.52, 1.56, 1.214
Systolic dysfunction, 1.98–99

T

T. *See* Transducin
T1 (spin-lattice/longitudinal relaxation time), 5.62, 5.63*t*, 5.76
T1-weighted images, 2.457, 2.460*f*, 5.58*f*, 5.62, 5.62*f*, 5.63*f*, 5.64*f*, 5.65*f*, 5.66*f*, 5.67*f*, 7.28*f*, 7.30*f*
T2 (spin-spin/transverse relaxation time), 5.62, 5.63*t*, 5.76
T2 "shine through" artifact, 5.64*f*, 5.66
T2-weighted images, 2.457–458, 2.460*f*, 5.58*f*, 5.62, 5.62*f*, 5.63*f*, 5.64*f*, 5.66*f*, 5.67*f*, 5.76, 7.28*f*, 7.30*f*
T_3. *See* Triiodothyronine
T_4. *See* Thyroxine
T4/T8 ratio, 1.267
in HIV infection/AIDS. *See* $CD4^+$ T cell(s); $CD8^+$ T cell(s)
T cell(s), 4.9
in anterior uvea, 9.56
in B cell activation, 9.35
$CD4^+$. *See also* Helper T cells; T cells
in AIDS, 9.327
in cytomegalovirus retinitis, 12.235
description of, 12.235
development of, 9.43*f*
in external eye defense, 8.12*f*
in HIV infection/AIDS, 8.241
in immune processing, 9.30–31
in sympathetic ophthalmia, 9.45
in tubulointerstitial nephritis and uveitis syndrome, 9.135
$CD8^+$
cytotoxicity mechanisms of, 9.47*f*
in external eye defense, 8.12*f*
major histocompatibility class I molecules and, 9.30
regulatory (suppressor). *See* Regulatory (Treg/suppressor) T cells
in sympathetic ophthalmia, 9.45
in cell-mediated/cellular immunity. *See* Adaptive immune response, lymphocyte-mediated immune effector responses
clonal expansion of, 9.37
in corneal transplant rejection, 8.316, 8.317
cytotoxic
apoptosis inducement by, 9.46
assassination by, 9.46
autoimmunity and, 9.44
CD8 expression by, 9.36, 9.44
cytotoxicity mechanisms of, 9.46, 9.47*f*
description of, 9.44, 9.46
precursor, 9.46
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.296
suicide induction by, 9.46
delayed hypersensitivity
description of, 9.36, 9.42–44
inflammatory diseases mediated by, 9.44*t*
in sympathetic ophthalmia, 9.45–46
T helper-cell 2, 9.43
in toxocara granuloma, 9.45
description of, 9.21
effector (Teff), in external eye defense, 8.12–13*f*
gamma-delta, 9.5
helper. *See* Helper T cells; T helper cells
in HIV infection/AIDS, 8.241
homing of, 9.38
inhibitors of, for uveitis, 9.108–109
interleukin-2 synthesis and release by, 9.31
killer. *See* Killer cells
in multifocal choroiditis and panuveitis syndrome, 9.179
in posterior segment, 9.57
priming of, 9.30
receptors on. *See* T-cell antigen receptor
regulatory (Treg/suppressor). *See* T regulatory (Treg) cells
in resting state, 9.37
sentinel, 9.5
in Sjögren syndrome, 8.57
subsets of, 9.34–35, 9.42
tuberculosis response by, 9.28

T-cell antigen receptor, in human leukocyte antigen–disease association, 9.66
T-cell inhibitors, 2.404*t*
T-cell lymphomas
central nervous system/intraocular. *See* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
orbital, 4.232. *See also* Lymphomas
T helper cell(s). *See also* T cell(s); *specific T helper cell; specific type*
accessory molecules expressed by, 9.31
in adaptive immune response, 9.30, 9.32*f*
antigen receptor on, 9.30
classification of, 9.32
differentiation of, 9.32–35
priming of, 9.31
subsets of, 9.32
T helper cell-1
in conjunctiva, 9.53
delayed hypersensitivity mechanisms mediated by, 9.42, 9.44*t*, 9.53
description of, 9.32–33
interferon-gamma produced by, 9.35
macrophage activation by, 9.42
T helper cell-2
in conjunctiva, 9.53
cytokines secreted by, 9.43
description of, 9.32
T helper cell-17
in birdshot chorioretinopathy, 9.34
in delayed hypersensitivity, 9.44
description of, 9.33–34
interleukins produced by, 9.34
T-lymphocyte lymphoma. *See* T-cell lymphomas
T lymphocytes. *See* T cell(s)
"T" molecules, antiangiogenic, for corneal transplantation rejection, 8.317
T-PRK. *See* Topography-guided photorefractive keratectomy
T regulatory (Treg) cells. *See also* T cell(s)
adaptive, 9.34
in $CD4^+$ T cell development, 9.43*f*
in corneal transplant tolerance and, 8.316
description of, 9.33
in external eye defense, 8.12–13*f*, 8.13, 8.14
immune responses suppressed by, 9.35
inducible, 9.34
naturally occurring, 9.34
in peripheral tolerance to self-antigens, 9.35
T-VEC. *See* Laherparepvec
T waves, in coronary heart disease, 1.86
TAB. *See* Temporal artery biopsy
Taches de bougie, 9.196
Tachyarrhythmias
atrial fibrillation, 1.102–103, 1.103*f*
atrial flutter, 1.102
in congestive heart failure, 1.99
definition of, 1.102
implantable cardioverter-defibrillators for, 1.104–106
supraventricular tachycardias, 1.102–103
ventricular, 1.104
ventricular fibrillation, 1.104
Tachycardia
narrow complex, 1.102
supraventricular, 1.102–103
ventricular, 1.104
wide complex, 1.102
Tachyphylaxis, 2.389
with α-agonists, 10.178
with β-blockers, 10.177
Tachyzoites, 9.275
Tacrolimus, 1.179, 2.405*t*
for atopic dermatitis, 8.287
for atopic keratoconjunctivitis, 8.294
for contact dermatoblepharitis, 8.287
for corneal graft rejection prophylaxis, 8.430
for graft-vs-host disease, 8.304
for scleritis, 8.324
for Thygeson superficial punctate keratitis, 8.307
for uveitis, 9.108
for vernal keratoconjunctivitis, 8.290*f*, 8.291
TACs. *See* Trigeminal autonomic cephalgias
TACSTD2 gene, in gelatinous droplike corneal dystrophy, 8.136*t*
Tactile tension, for intraocular pressure estimation, 10.26
Tadalafil, 1.309*t*, 12.304
Tadpole pupil, 5.255
Taenia solium (pork tapeworm), 7.53, 9.285
orbital infection caused by, 4.228
Tafluprost, 2.363, 2.393, 2.394*t*, 10.170–176, 10.171*t*, 10.175*t*
Takayasu arteritis (aortic arch arteritis/aortitis syndrome/pulseless disease)
cataract caused by, 11.68
description of, 1.170, 9.125*t*
Talc emboli, 12.141, 12.303
Tamoxifen, 1.309*t*, 12.302–303, 12.304*f*
cataract risk and, 11.53
cornea verticillata caused by, 8.130
maculopathy caused by, 11.53
Tamsulosin, intraoperative floppy iris syndrome and, 11.74, 11.136, 11.137, 11.137*t*
Tandem scanning confocal microscopy, 8.24. *See also* Confocal microscopy
Tangent screen, in nonorganic disorder evaluation, 5.308, 5.309*f*
Tangential curvature, 8.29*f*
Tangential incisions, for keratorefractive surgery, 13.27, 13.27*f*
coupling and, 13.27, 13.27*f*, 13.54
Tangential (transverse) keratotomy, for astigmatism, 13.53, 13.54, 13.54*f*
Tangential map, 8.28, 8.29*f*. *See also* Cornea, topography of
Tangential power (instantaneous radius of curvature), 13.16–17, 13.17*f*
Tangier disease, 8.180–181
Tap/biopsy of vitreous. *See* Vitreous, biopsy of
Tapeworms
dog *(Echinococcus granulosus),* orbital infection caused by, 4.228
pork *(Taenia solium),* orbital infection caused by, 4.228
Taq polymerase, 2.186

Tarantula hairs, ocular inflammation caused by, 8.387
Tardive dyskinesia, 1.200
blepharospasm and, 5.281
facial movements and, 5.285
Target, in microarray, 4.41
Target recognition/selection, smooth pursuit movements and, 5.33, 5.224, 5.225, 5.225*f*
Tarsal conjunctiva, 8.6. *See also* Conjunctiva
in superior limbic keratoconjunctivitis, 8.83, 8.84
Tarsal ectropion, 7.232
Tarsal fracture operation, 7.237, 7.238*f*
Tarsal glands. *See* Meibomian (tarsal) glands
Tarsal kink
congenital, 6.194–195
description of, 7.179, 7.179*f*
Tarsal muscles
in Horner syndrome, 5.257
superior (Müller), 4.202, 8.3, 8.4*f*
innervation of, 5.53, 5.53*f*, 5.54
Tarsal plates/tarsus, 2.34*f*, 2.35, 4.201, 4.201*f*, 4.202, 8.3, 8.4*f*
sebaceous adenocarcinoma arising in, 4.215
Tarsoconjunctival flaps
description of, 7.218
lower eyelid defects reconstructed with, 7.223*f*, 7.224
Tarsoconjunctival grafts, 7.221
for chemical injuries, 8.384
Tarsorrhaphy, 6.207–208, 7.255, 7.255*f*, 8.351, 8.372*f*, 8.372–373
for chemical injuries, 8.383–384
for dry eye, 8.61*t*, 8.65, 8.368
for exposure keratopathy, 8.80
for neurotrophic keratopathy/persistent corneal epithelial defects, 8.82, 8.224, 8.230
for thermal injuries, 8.385
Tarsotomy, for trichiasis/distichiasis, 8.88
Tarsus, 2.28*f*, 2.36, 7.168, 7.169*f*, 8.3, 8.4*f*. *See also* Tarsal plates/tarsus
TASS. *See* Toxic anterior segment syndrome
Tattoo, corneal, 8.118*t*, 8.371*f*, 8.371–372
Tauber staging system, 8.302, 8.302*t*
Taxanes, 12.301
Taxon-specific crystallins, 2.285
Tay-Sachs disease (GM_2 gangliosidosis), 6.389*t*, 8.176–178, 12.291, 12.292*f*
description of, 2.204*t*
ethnic characteristics of, 2.229
Tazobactam. *See specific antibiotic combination*
TB. *See* Tuberculosis
TBCD. *See* Thiel-Behnke corneal dystrophy
TBG. *See* Thyroxine-binding globulin
TBII test. *See* Thyrotropin-binding inhibitory immunoglobulin (TBII) test
TBIs. *See* Traumatic brain injuries
TBUT. *See* Tear breakup time
Tc-99. *See* Technetium-99
TCF4 gene, in Fuchs endothelial corneal dystrophy, 8.136*t*, 8.156
TCOF1 gene, 6.211
TD-OCT. *See* Time-domain optical coherence tomography
TDF. *See* Testis-determining factor
TE. *See* Echo time
TE (time to echo), 5.62, 5.75, 5.76
Tear(s) (artificial), 2.415. *See also* Lubricants
for corneal exposure in facial palsy, 5.280
for dry eye, 8.61*t*, 8.62–63
for exposure keratopathy, 8.80
for hay fever conjunctivitis, 8.288
refractive surgery and, 13.173
for Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.297, 8.298
for Thygeson superficial punctate keratitis, 8.307
Tear(s) (retinal). *See* Retinal tears
Tear breakup, 8.60
Tear breakup time (TBUT), 7.296, 8.36, 8.57*t*, 8.60
fluorescein in evaluation of, 8.36, 8.57*t*, 8.60
refractive surgery and, 13.42, 13.42*f*
Tear-deficiency states. *See also* Dry eye; *specific type*
aqueous, 8.45, 8.53, 8.54*f*, 8.55*f*, 8.55–58, 8.61*t*, 8.61–65, 8.62*t*, 8.65*f*
evaporative dry eye, 8.45, 8.53–54, 8.54*f*, 8.55*f*, 8.58–60, 8.59*f*, 8.60*f*, 8.66*t*, 8.66–67*t*, 8.66–69
refractive surgery and, 13.42, 13.78–79, 13.172–173
stains in evaluation of, 8.37
tests of, 8.38–39
qualitative tests, 8.40*f*, 8.40–41
quantitative tests, 8.39
Tear film (tears), 7.280–281, 8.5–6, 8.6*f*
antimicrobial components of, 2.252
aqueous component of, 2.251–252
composition of, 2.247, 8.5–6, 8.6*f*
corneal topography affected by, 13.14, 13.19
cytokines in, 2.252
description of, 2.49–50, 2.247, 2.259
dysfunction/alterations of, 2.252, 2.256–258. *See also* Dry eye; Dry eye syndrome; Tear-deficiency states
decreased vision/transient visual loss and, 5.164, 13.7
illusions caused by, 5.174
refractive surgery and, 13.172–173
multifocal IOLs, 13.155
seventh nerve lesions causing, 5.276–277*f*
tests of, before refractive surgery, 13.173
electrolytes in, 2.251
evaluation of, 8.38–41, 8.40*f*
stains used in, 8.36–37, 8.37*f*, 8.38*f*, 8.56
in external eye defense, 8.11
functions of, 2.247, 8.6
glucose levels in, 2.252
growth factors in, 2.252
hyperosmolarity, dry eye and, 8.39, 8.53
hypersecretion of (lacrimation). *See* Tearing
instability of, 8.54, 8.54*f*
lacrimal functional unit in maintenance of, 8.5, 8.6
layers of, 2.247, 2.248*f*
lipid layer of, 2.249–250, 2.250*f*
matrix metalloproteinase 9 levels in, 2.252
mucoaqueous layer of, 2.251–253
nonpolar lipids in, 2.250*f*
osmolarity of, 2.257, 8.39
peptide hormones in, 2.254
polar lipids in, 2.250*f*

production of
evaluation of, 8.38–41, 8.40*f*
medications affecting, 8.61–62, 8.62*t*
pharmacologic stimulation of, 8.64
properties of, 2.249*t*
proteins in, 2.252
refractive index of, 8.26
secretion of, 2.252–255
solutes of, 2.252
steroid hormones in, 2.255
thickness of, 2.248, 2.249*t*
Tear function tests. *See specific test*
Tear lake, 2.248*f*, 2.352
Tear lens
definition of, 3.206, 3.211
power of, 3.220
refractive index of, 3.220
rigid gas-permeable contact lens creation of, 3.218, 3.218*f*
Tear meniscus (marginal tear strip)
description of, 2.247, 7.296
inspection of, 8.56
Tear reflex pathway, 2.135
Tear sac. *See* Lacrimal sac
Tear secretion. *See* Tear film (tears), secretion of
"Tear star," 8.117
Tear substitutes, for dry eye syndrome, 2.258
Tearing/epiphora, 8.46*t*. *See also Epiphora; specific cause*
chewing causing (crocodile tears), 5.277
in primary congenital glaucoma, differential diagnosis and, 10.151, 10.152*t*
reflex, parasympathetic nerves and, 5.56
Tecfidera. *See* Dimethyl fumarate
Technetium-99m, 1.88
Technosphere insulin, 1.37
TECNIS Symfony intraocular lens, 3.263, 13.166
Tectonic penetrating keratoplasty
for herpetic eye disease, 8.225
for keratoglobus, 8.171
for peripheral ulcerative keratitis, 8.313
TED. *See* Thyroid eye disease
TEE. *See* Transesophageal echocardiography
Teenagers. *See* Adolescents
Teff cells. *See* Effector T (Teff) cells
Teichoic acid, in bacterial cell wall, 8.244
Teichopsia, 5.177
Teicoplanin, 1.274
Telangiectasias. *See also* Macular telangiectasia
aneurysmal, 12.161
in ataxia-telangiectasia (Louis-Bar syndrome), 5.332*f*, 5.334*t*, 8.115*t*, 8.346
conjunctival, 5.332*f*, 5.334*t*, 8.115*t*, 8.346
juxtafoveal, 12.161
retinal. *See* Coats disease
in rosacea, 8.70, 8.71
Telecanthus, 6.203, 7.23, 7.169, 7.169*f*
Telemedicine, 6.331
Telemicroscopes, 3.322
Teleopsia, 5.175
Telescopes
astronomical. *See* Telescopes, Keplerian
Galilean, 3.40, 3.83–84, 3.84*f*, 3.140, 3.166, 3.255, 3.292, 3.298, 3.322
Keplerian, 3.40, 3.83–84, 3.84*f*, 3.322
low vision managed with, 3.322*t*, 3.322*f*, 3.322–323
spectacle, 3.322*f*
Teller Acuity Cards II, 6.8, 6.9*f*, 6.56, 6.154, 6.187
Telomeric DNA, 2.178
Telophase, 2.174, 2.174*f*
Telorbitism, 7.23
Temperature, anterior segment injury and, 8.384–385, 8.385*f*
Tempering, 3.195
Temporal (giant cell) arteritis. *See* Giant cell arteritis
Temporal artery
deep, 5.15*f*
posterior, 5.16*f*, 5.19*f*
superficial, 5.12, 5.15*f*
Temporal artery biopsy (TAB), in giant cell arteritis/AAION, 4.244*f*, 4.244–245, 5.121, 5.314
Temporal bone, 5.5
Temporal coherence, 3.100*f*, 3.101
Temporal crescent, 5.29*f*, 5.30, 5.156
Temporal flare, 7.253
Temporal fossa, 5.8, 5.10*f*
Temporal lobe, 2.460*f*, 5.24*f*
lesions of, 5.147*f*, 5.155, 5.155*f*
hallucinations and, 5.155, 5.176–177
resection of, for seizures, visual field defects and, 5.155
Temporal nerve, 5.51*f*, 5.52, 5.276–277*f*
Temporal occipital parietal pontine pathway, 5.34*f*
Temporal retina, 5.24*f*, 5.25
Temporal wedge, 5.103
in glaucoma, 10.69
Temporalis muscle, 7.152*f*
"Temporary tarsorrhaphy," 7.255
Temporofacial division, of cranial nerve VII (facial), 5.52
Temporomandibular joint (TMJ) disease, pain and, 5.297
Temporoparietal fascia, 7.151, 7.153
TEN. *See* Toxic epidermal necrolysis
Tenacious proximal fusion
definition of, 6.100
in intermittent exotropia, 6.71, 6.100
Tendency-oriented perimeter (TOP) algorithm, 10.61
Tendon–trochlea complex, 6.20
Tenectomy, 6.164*t*
Tenofovir-emtricitabine, 1.268
Tenon capsule, 8.6
anatomy of, 2.44, 2.45*f*, 6.25–27, 6.27*f*
functions of, 2.57
posterior portion of, 6.27
scarring of, 6.171
surgical penetration of, 6.30
Tenotomy
definition of, 6.164*t*
superior oblique, for superior oblique myokymia, 5.251
superior oblique muscle, 6.112, 6.138
Tension rings, capsular (CTRs), for zonular incompetence, 11.180, 11.181*f*, 11.183
Tension-type headache, 5.292
treatment of, 5.292–293
Tensor tympani, 5.48
Tensor veli palatini, 5.48

Tentorium cerebelli, 5.41*f*
Teprotumumab, 1.44, 7.61
Teratoid medulloepitheliomas, 4.179
Teratoma, 4.6, 4.7*f*, 6.225*f*, 6.225–226, 7.42
Terazosin, intraoperative floppy iris syndrome and, 11.74, 11.136–137, 11.137*t*
Terbinafine, 1.277
Teriflunomide, for multiple sclerosis, 5.321*t*
Terrien marginal degeneration, 8.122–124, 8.123*f*
Terson syndrome, 1.121, 2.471*f*, 5.340, 5.340*f*, 12.366
Tertiary diagnostic position of gaze, 6.31
Tertiary syphilis, 1.252, 9.221
Tertiary vitreous, 2.157, 2.158*f*, 2.293, 4.125
Tesla, 5.60, 5.76
Tessellation, 12.214
Test-retest reliability, 1.24
Testis-determining factor (TDF), 2.208
Tetanic cataract, 11.61–62
Tetanus and diphtheria immunization, 1.225*t*, 1.229–230
Tetracaine, 2.439*t*, 2.441, 8.205
  for cataract surgery, 11.92
Tetracyclines, 2.424–425. *See also specific agent*
  adrenochrome deposition caused by, 8.118*t*, 8.131
  for chalazion, 7.182
  for chemical injuries, 8.383
  for chlamydial conjunctivitis, 8.263
  description of, 1.275–276
  gonococcal infections treated with, 1.251
  for meibomian gland dysfunction, 8.68
  for neurotrophic keratopathy/persistent corneal epithelial defects, 8.81–82
    after surface ablation, 13.108
  ocular adverse effects of, 1.308*t*
  for rosacea, 8.71
  for trachoma, 8.262, 8.263
Tetrafoil, 3.276*f*
Tetrahydrotriamcinolone, 2.402*t*
TetraVisc. *See* Tetracaine
Textural interface opacity, after DSEK, 8.446, 8.446*f*
TGF-βs. *See* Transforming growth factor βs
TGFBI dystrophies, epithelial-stromal, 4.86, 4.88*f*, 4.88–91, 4.89*f*, 4.90*f*, 4.91*t*, 4.91*f*, 8.133, 8.134, 8.135*t*, 8.136*t*, 8.142–149
  granular, 8.135*t*
    type 1 (GCD1/classic), 4.90, 4.90*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.147–148, 8.148*f*
    type 2 (GCD2/Avellino), 4.90, 4.91*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.148–149, 8.149*f*
      amyloid deposits in, 8.148, 8.186*t*
      refractive surgery and, 13.43
  lattice (LCD), 4.88–90, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.145*t*, 8.145–147, 8.146*f*, 8.147*f*. *See also specific type*
  recurrence of after corneal transplantation, 8.425
  Reis-Bücklers (RBCD/CDB1/atypical granular), 4.88, 4.88*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.142*f*, 8.142–143
  Thiel-Behnke (TBCD/CDB2), 4.88, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.143–144, 8.144*f*
Thalamostriate arteries, 5.20
Thalamotomy, for Parkinson disease, 1.205
Thalamus, 2.116*f*, 5.24*f*, 5.33, 5.34
Thalassemia, 1.134–135, 12.149, 12.149*t*
Thallium-201, 1.88
Theophylline, 1.287
Theoretical formulas, for IOL power determination. *See* Power prediction formulas, for IOLs
Theques, 4.63–64
Therapeutic contact lenses, 8.368. *See also* Bandage contact lenses
Therapeutic lifestyle changes (TLCs). *See* Lifestyle modifications
Therapeutic ratio, 1.237
Thermal cautery
  for conjunctivochalasis, 8.86, 8.361
  for punctal occlusion, 8.65
  for superior limbic keratoconjunctivitis, 8.84
Thermal cycling, 2.186
Thermal energy, 3.106
Thermal injury (burns), 6.376
  anterior segment, 8.384–385, 8.385*f*
  cataract surgery incision, 11.131
Thermal interactions, laser–tissue, 3.113–114*t*, 3.113–114*f*, 3.113–115
Thermal laser
  for neovascular age-related macular degeneration, 12.79
  for photocoagulation. *See* Photocoagulation
Thermokeratoplasty, 13.8*t*, 13.28, 13.28*f*, 13.127–128
  laser (LTK), 13.8*t*, 13.127–128
    corneal transplantation after, 13.198
  radial, 13.127
Thermoplastic acrylic gel, for IOLs, 13.170
Thermotherapy, transpupillary (TTT)
  for choroidal/ciliary body melanoma, 4.276
  for metastatic eye disease, 4.310
  for retinoblastoma, 4.300
Thiabendazole, for diffuse unilateral subacute neuroretinitis, 9.288
Thiamine deficiency, optic neuropathy caused by, 5.138
Thiazide-type diuretics
  hypertension treated with, 1.59, 1.59*t*
  side effects of, 1.60
Thiazolidinediones, 1.38
Thick lenses
  formula for, 3.54–55
  power of, 3.55*f*
Thiel-Behnke corneal dystrophy (TBCD/CDB2), 4.88, 4.89*f*, 4.91*t*, 8.135*t*, 8.136*t*, 8.143–144, 8.144*f*
Thimerosal, allergic/sensitivity/toxic reactions and, 8.90*t*, 8.91
Thin-lens approximation, 3.42, 3.54, 3.56
Thioflavin T (ThT) stain, 4.31*t*
Thiopental sodium, 1.290
Thiopurine-S-methyltransferase (TPMT), 9.106
Thioridazine, 12.297
  lens changes caused by, 11.52
Third cranial nerve. *See* Cranial nerve III
Third-generation cephalosporins, 2.420
Third law of motion, 3.293
Third nerve (oculomotor) palsy, 5.188, 5.191, 5.193–194*f*, 5.193–198, 5.196*f*, 5.198*f*
  aberrant nerve regeneration and, 5.197–198, 5.198*f*
    anisocoria and, 5.265–266
    light-near dissociation and, 5.266*t*, 5.267
  acquired, 6.138

amblyopia with, 6.138
aneurysm and, 5.20, 5.194*f*, 5.194–195, 5.196, 5.196*f*, 5.339
anisocoria and, 5.256*f*, 5.265–266
clinical features of, 6.138
complete, 6.139
congenital, 6.138
diplopia and, 5.188, 5.191, 5.193*f*, 5.193–198, 5.194*f*, 5.196*f*, 5.198*f*, 6.139
divisional, 5.197
incomplete, 6.139
isolated, 5.192, 5.194, 5.197
in multiple sclerosis, 5.318
management of, 6.138–140
neuroimaging in evaluation of, 5.70
partial, 5.193, 5.193*f*, 5.195–196, 5.196*f*
ptosis in, 5.272, 5.273*t*
pupil-involving, 5.193, 5.194*f*, 5.194–195, 5.265
in younger patients, 5.197
pupil-sparing, 5.195–196, 5.196*f*
complete, 5.195
partial, 5.195–196, 5.196*f*
spontaneous recovery of, 6.138
surgical management of, 6.139–140
upper eyelid ptosis associated with, 6.138, 6.139*f*
in younger patients, 5.197
Third-order aberrations, 13.12, 13.12*f*
Third-order neuron dysfunction, 7.243–244
Third-order neurons, 5.52, 5.53*f*, 5.54
Horner syndrome caused by lesions of, 5.258, 5.259, 5.260, 5.260*t*, 5.261, 5.262*f*
Third-order wavefront aberrations, 3.276*f*
Third-order Zernike polynomials, 3.73
30° test, 5.95
Three cone opsins. *See* Color vision
Three-dimensional CT, 7.27, 7.27*f*
3-dimensional navigation, 7.33*f*
3-mirror lens, 12.22
3-o'clock staining, 3.233, 3.233*f*
3-piece foldable intraocular lens, insertion of, 11.116
3-step test
description of, 6.73–75, 6.74*f*
in fourth nerve (trochlear) palsy, 5.198–199
unilateral superior oblique muscle palsy diagnosis using, 6.120
3′ untranslated region, 2.176
Three-zone multifocal intraocular lens, 3.259, 3.259*f*
Threshold, sensitivity, 5.86, 5.87*f*, 5.91
Threshold disease (retinopathy of prematurity), 12.177, 12.178*t*, 12.179, 12.180*f*, 12.181, 12.185
Threshold stimulus/testing (perimetry), 5.86, 10.61*f*, 10.61–62, 10.63*f*
Thrombi/thrombus. *See* Thrombosis/thrombotic disorders
Thrombin, 1.138, 2.446, 9.18
Thromboangiitis obliterans (Buerger disease), cataract caused by, 11.68
Thrombocytopenia
idiopathic thrombocytopenic purpura, 1.141–142
nonimmunologic, 1.142
thrombotic thrombocytopenic purpura, 1.142
Thrombocytosis, 1.142–143
Thromboembolism. *See also* Deep venous thrombosis
in systemic lupus erythematosus, 1.160
venous. *See* Venous thromboembolism
Thrombolytic therapy
bleeding complications of, 1.94–95
indications for, 1.150
myocardial infarction treated with, 1.94–95
stroke treated with, 1.113
Thrombophilia, 1.146, 1.147–148. *See also* Hypercoagulable states; Thrombosis/thrombotic disorders
Thrombopoietin receptor agonists, 1.141
Thrombosis/thrombotic disorders. *See also* Hypercoagulable states
atrial, 1.102
cerebral venous (CVT), 5.345–346
in idiopathic intracranial hypertension, 5.111
neuroimaging in, 5.69, 5.69*f*, 5.72*t*, 5.346
comma-shaped, 12.154
in NAION, 5.123
retinal vasculitis *versus*, 12.156
Thrombospondin 1, 2.301
Thrombotic disorders
activated protein C resistance, 1.146–147
description of, 1.146
hypercoagulable states, 1.146–148
primary hypercoagulable states, 1.146–148
Thrombotic thrombocytopenic purpura (TTP), 1.136, 1.142, 12.195
ThT (thioflavin T) stain, 4.31*t*
"Thunderclap headaches," 5.346
Thygeson superficial punctate keratitis (SPK), 6.269, 8.306–307, 8.307*f*
Thymectomy, for myasthenia gravis, 5.326
Thymidine kinase, 2.434
Thymine, 2.176
Thymoma, in myasthenia gravis, 5.326
Thymoxamine hydrochloride, 2.387
Thyroglobulin, antibodies to, 1.42
Thyroid adenomas, 1.46
Thyroid antibody tests, 1.42–43
Thyroid-associated ophthalmopathy/orbitopathy. *See* Thyroid eye disease
Thyroid cancer
medullary, 1.46, 1.50
papillary, 1.46
types of, 1.46, 1.50
Thyroid carcinoma, retinoblastoma associated with, 4.302*t*
Thyroid disease. *See also* Thyroid eye disease
hyperthyroidism, 1.43–44
hypothyroidism, 1.44–45
physiology of, 1.41
superior limbic keratoconjunctivitis and, 8.83, 8.84
thyroiditis, 1.45–46
toxic nodular goiter, 1.44
tumors, 1.46
Thyroid eye disease (TED), 2.476*t*, 4.226, 4.227*f*, 5.131, 5.132*f*, 5.326–327, 6.140–141, 6.141*f*, 6.143*t*, 6.175, 6.215
asymmetric, 7.54*f*
autoimmune hyperthyroidism associated with, 7.57
Clinical Activity Score for, 7.58

clinical features of, 7.57–58
clinical signs of, 7.53–54, 7.54*f*
compressive optic neuropathy associated with, 7.60–61
description of, 1.43–44, 7.24–25, 7.53–54
diagnosis of, 7.55–56
diplopia associated with, 5.186, 5.206, 7.61–62
epidemiology of, 7.57
eye movements/extraocular myopathy and, 4.226, 4.227*f*, 5.206
eyelid abnormalities and, 4.226, 4.227*f*, 5.131, 5.274, 5.275*f*, 5.275*t*
eyelid retraction caused by, 7.253
glaucoma and, 10.30
glucocorticoids for, 7.60–61
hyperthyroidism and, 7.60
key points about, 7.55
myasthenia gravis and, 5.324
neuro-ophthalmic signs of, 5.326–327
neuroimaging in evaluation of, 5.72*t*, 5.206
optic neuropathy in, 5.131, 5.132*f*
orbital decompression for, 7.130, 7.131*f*
pathogenesis of, 7.57
pretibial myxedema associated with, 7.58
prognosis for, 7.58–62
proptosis and, 4.226, 4.227*f*, 5.131
radiographic evidence of, 7.55, 7.56*f*
radiotherapy for, 7.61
rituximab for, 7.61
selenium supplementation in, 7.59
serologic testing for, 7.56
smoking cessation in, 7.59
strabismus and, 5.206
surgery for, 7.61–62
teprotumumab for, 1.44
treatment of, 7.58–62, 7.60*t*
upper eyelid retraction associated with, 7.58
Thyroid follicles, 1.41
Thyroid function tests
description of, 1.41
in subacute thyroiditis, 1.45
thyrotropin-releasing hormone, 1.42
Thyroid gland
biopsy of, 1.43
lymphoma of, 1.46
parafollicular cells of, 1.41
physiology of, 1.41
scanning of, 1.43
tumors of, 1.46
ultrasonography of, 1.43
Thyroid hormones
function of, 1.41
secretory suppression of, 1.44
T_3. *See* Triiodothyronine
T_4. *See* Thyroxine
Thyroid ophthalmopathy/orbitopathy/thyroid-related immune orbitopathy. *See* Thyroid eye disease
Thyroid peroxidase antibody, 1.42
Thyroid-stimulating hormone (TSH), 7.34, 7.56
Thyroid-stimulating immunoglobulins (TSIs), 1.42, 6.140
Thyroid storm, 1.43
Thyroiditis, 1.45–46. *See also specific type*
Thyrotoxic exophthalmos. *See* Thyroid eye disease
Thyrotoxicosis, 1.43. *See also* Hyperthyroidism
Thyrotropin-binding inhibitory immunoglobulin (TBII) test, 7.56
Thyrotropin-releasing hormone (TRH)
secretion of, 1.41
serum levels of, 1.42
tests of, 1.42
Thyroxine (T_4)
deiodination of, 1.41
levels of during pregnancy, 1.42
secretion of, 1.41
serum, measurement of, 1.42
structure of, 1.41
total, 1.42
Thyroxine-binding globulin (TBG), 1.41
TI (interpulse time), 5.75
TIAs. *See* Transient ischemic attacks
Tibia bone tissue keratoprosthesis (TKPro), 8.452
Tic
facial (habit spasm), 5.285
ocular, 6.201–202
Tic douloureux (trigeminal neuralgia), 5.289*t*, 5.297
Ticarcillin sodium, 2.418*t*, 2.419
Ticks
Lyme disease transmitted by, 8.249
tick-borne diseases, 12.245–246
tick-borne encephalitis, 1.232
Tight junctions, 2.51, 2.52*f*, 2.270
in corneal epithelium, 8.8
Tightening procedures
for inferior oblique muscle, 6.166
for oblique muscles, 6.164*t*, 6.166–167
for rectus muscles, 6.163–164, 6.164*t*
for superior oblique muscle, 6.167
TIGR/myocilin *(TIGR/MYOC)* gene, 10.10, 10.11*t*, 10.150
in pediatric glaucoma, 8.108
TIGR protein, 10.10
Tillaux, spiral of. *See* Spiral of Tillaux
Tilt
definition of, 3.42
intraocular lenses, 3.250
Tilted disc syndrome, 12.217
congenital, 5.144, 5.144*f*
description of, 6.365–366, 6.366*f*
Time-domain optical coherence tomography (TD-OCT), 3.303–304, 3.304*f*, 8.22, 10.54
"Time out"
before ECCE, 11.196
before phacoemulsification, 11.104–105
preoperative, 13.82
Time to echo (TE), 5.62, 5.75, 5.76
Time to repetition (TR), 5.62, 5.76
Timentin, 1.273
Timolol, 2.389*t*, 2.390, 10.171*t*, 10.175*t*, 10.176–177
in children, 10.165
in combination preparations, 10.174*t*, 10.182
for glaucoma, 10.171*t*, 10.176–177
in children, 10.165
in combination preparations, 10.174*t*
for infantile hemangiomas, 7.72
Timolol hemihydrate, 2.389*t*, 2.390
Timoptic, 2.389*t*

Timoptic-XE, 2.389*t*
TIMP 1. *See* Tissue inhibitor of matrix metalloproteinase 1
TIMP3, 2.333*t*
TIMP3 gene, 12.275–276
Tinnitus, vestibular nystagmus and, 5.241, 5.241*t*, 5.242
TINU. *See* Tubulointerstitial nephritis and uveitis (TINU) syndrome
TINU syndrome. *See* Tubulointerstitial nephritis and uveitis (TINU) syndrome
Tiotropium bromide, 1.128
TIR. *See* Total internal reflection
Tissue
  laser interactions with, 13.29
  ultraviolet light effects on, 3.194
Tissue addition/subtraction techniques, 13.27–28. *See also specific procedure*
Tissue adhesives
  cyanoacrylate, 8.370–371. *See also* Cyanoacrylate glue/adhesive
  fibrin (fibrin glue/sealant), 8.355. *See also* Fibrin glue/sealant/tissue adhesive
Tissue dendritic cells, 9.4
Tissue inhibitor of matrix metalloproteinase 1 (TIMP 1), in tear film, 8.6*f*
Tissue inhibitor of metalloproteinase, 2.332
Tissue–laser interactions, 13.29
Tissue microarrays (TMAs), 4.40, 4.41*f*
Tissue plasminogen activator (tPA), 1.94, 2.360*t*, 2.371*t*, 2.445, 9.18
Tissue preparation/preservation
  donor corneas, 8.414–416, 8.416*f*
  for pathologic examination, 4.25–30, 4.31*t*
    from conjunctival biopsy, 8.361
    from corneal biopsy, 8.367
    fixatives for, 4.26, 4.26*t*
    processing and, 4.30
    slide preparation and, 4.30
    special procedures and, 4.33–45
    staining and, 4.30, 4.31*t*
Titmus test, 6.81
TK. *See* Transverse keratotomy
TKPro. *See* Tibia bone tissue keratoprosthesis
TLCs (therapeutic lifestyle changes). *See* Lifestyle modifications
TLRs. *See* Toll-like receptors
TMAs. *See* Tissue microarrays
TMEM98 gene, 6.263
TMJ disease. *See* Temporomandibular joint (TMJ) disease
TMP-SMX. *See* Trimethoprim-sulfamethoxazole
TMVL. *See* Transient monocular visual loss
TMVL (transient monocular visual loss). *See* Monocular transient visual loss
TNF. *See* Tumor necrosis factor
TNO test, 6.81
Tobacco use. *See also* Smoking
  cataract development and, 11.6–7, 11.63–64
  optic neuropathy and, 5.137
Tobradex. *See* Dexamethasone/tobramycin
Tobramycin
  for bacterial keratitis, 8.270*t*
  description of, 2.418*t*, 2.421*t*, 2.425
Tobrasol. *See* Tobramycin
Tobrex. *See* Tobramycin
Tocilizumab, 1.180, 2.406*t*, 7.63
α-Tocopherol. *See* Vitamin E
Todd paralysis, 1.207, 5.285
Tofacitinib, 1.180
Togaviruses, 8.240, 8.240*t*
Tolerance (immunologic)
  corneal transplantation and, 8.316
  ocular surface immunoregulation and, 8.11
Toll-like receptors (TLRs)
  dendritic cells' use of, 9.4
  family of, 9.5
  lipopolysaccharide, 9.7
  retinal pigment epithelium expression of, 9.58
  TLR2, 9.8
Tolmetin, 2.409*t*
Tolosa-Hunt syndrome, 5.203
Tomato ketchup fundus, 4.281, 4.283*f*, 6.402*f*
Tomography
  computed. *See* Computed tomography
  corneal, 8.33–36, 8.34*f*, 8.35*f*, 8.35*t*, 13.19–22, 13.20–21*f*, 13.194
    in keratoconus, 8.35, 8.35*f*, 8.165*f*, 8.165–166
    after refractive/keratorefractive surgery, 13.23
      IOL power determination/selection and, 13.194
  optical coherence (OCT). *See* Optical coherence tomography
Tomonaga, Sin-Itiro, 3.96
Tomopenem, 1.273
TON. *See* Traumatic optic neuropathy
Tongue claudication, in giant cell arteritis, 5.313
Tonic cells, 2.317
Tonic-clonic seizures, 1.306
Tonic convergence, 6.40
Tonic deviations, 5.230–231
  in gaze preference, 5.228
Tonic pupil (Adie tonic pupil), 5.256*f*, 5.263*f*, 5.263–265, 5.264*f*, 5.265*f*, 6.275
  light-near dissociation and, 5.263, 5.264*f*, 5.266*t*
  pharmacologic testing for, 5.256*f*, 5.264–265, 5.265*f*
Tonic vergence, 5.226
Tono-Pen, 6.10, 6.281
  for intraocular pressure measurement, 10.25
    in infants and children, 10.158
    after refractive surgery, 13.181
Tonography, in aqueous outflow measurement, 10.19
Tonometry (tonometer), 3.282, 10.22–27, 10.23*f*, 10.24*f*
  applanation. *See* Applanation tonometry/tonometer
  corneal thickness affecting, 10.25, 10.81, 10.82, 10.86, 13.105, 13.181
  dynamic contour, 10.26
  Goldmann (GAT), 10.22–23, 10.23*f*, 10.24*f*. *See also* Goldmann applanation tonometry
  in infants and children, 10.158–159
  infection control and, 10.27
  noncontact (air-puff), 10.26
  Perkins, 10.23
    in infants and children, 10.158
  pneumatic (pneumatonometer/pneumotonometer), 10.25–26
    in infants and children, 10.158
    for intraocular pressure measurement after refractive surgery, 13.119, 13.200

in primary congenital glaucoma evaluations, 6.281–282
after refractive surgery, 13.105, 13.119, 13.181, 13.200–201
LASIK, 13.105
surface ablation, 13.105
Schiøtz (indentation), 10.19, 10.26
sources of error in, 10.23–24, 10.24*t*
TOP algorithm. *See* Tendency-oriented perimeter (TOP) algorithm
Topical anesthesia/anesthetics. *See also* Anesthesia (anesthetics), local
absorption of, 2.355–356
binding of, 2.358
for cataract surgery, 11.92
concentration of, 2.356–357
description of, 2.441–442
eyedrops, 2.352–358
ionic charge of, 2.358
lipid solubility of, 2.357
ointments, 2.358–359
for penetrating and perforating trauma repair, 8.403–404
pH, 2.358
for phakic IOL insertion, 13.141
pharmacokinetics of, 2.355*f*
for photoablation, 13.82
reflex tearing and, 2.358
retention of, 2.352–355
solubility of, 2.356–357
surfactants, 2.358
viscosity of, 2.357
Topiramate, 1.207–208, 1.308*t*
choroidal swelling caused by, 12.201
glaucoma caused by, 6.284
for idiopathic intracranial hypertension, 5.112, 6.371
for migraine prophylaxis, 5.293
myopia caused by, 12.305
ophthalmic/retinal side effects of, glaucoma and, 10.145*f*, 10.145–146
Topographic maps, 8.28–33, 8.29–33*f*, 13.14–19, 13.15*f*, 13.17*f*, 13.19*f*, 13.44–45, 13.45*f*. *See also* Cornea, topography of
interpretation of, 8.28–31
in keratoconus, 8.165, 8.165*f*, 8.167*f*
in pellucid marginal degeneration, 8.31, 8.33*f*, 8.169, 8.170*f*
postoperative, 13.23, 13.24*f*
Topography, 4.6, 4.12*t*
anterior chamber, 4.97*f*, 4.97–98, 4.98*f*
choroidal, 4.181*f*, 4.182–183, 4.183*f*
ciliary body, 4.181*f*, 4.182, 4.183*f*
conjunctival, 4.47, 4.48*f*
corneal, 4.73, 8.15, 8.28–36, 8.29–33*f*, 8.35*t*, 13.14–19, 13.15–19*f*, 13.44–45, 13.45*f*, 13.79. *See also* Cornea, topography of
before cataract surgery, 11.84, 11.86, 11.174
Placido-based, 13.7–9, 13.14–17, 13.15*f*, 13.20–21*f*, 13.25*f*
eyelid, 4.201*f*, 4.201–202
iris, 4.181–182, 4.181–182*f*
lens, 4.115*f*, 4.115–117, 4.116*f*
optic nerve/nerve head/disc, 4.241, 4.242*f*, 10.53
orbital, 4.223
Placido-based. *See* Placido-based topography/Placido disk
retinal, 4.139–140, 4.140*f*, 4.141*f*, 12.9*f*, 12.9–10
retinal pigment epithelium, 4.140*f*, 4.141, 4.141*f*
scleral, 4.107*f*, 4.107–108, 4.108*f*
trabecular meshwork, 4.97*f*, 4.97–98, 4.98*f*
uveal tract, 4.181*f*, 4.181–183, 4.182*f*, 4.183*f*
vitreous, 4.125
Topography-guided photoablation, 13.32, 13.77
outcomes of, 13.97
Topography-guided photorefractive keratectomy (T-PRK), corneal crosslinking and, 13.206–207
Topoisomerase inhibitors, 1.240*t*
TORCH syndrome, 9.260
Torcular Herophili, 5.22, 5.22*f*
Toric contact lenses, soft
discontinuing use of before refractive surgery, 13.38
after radial keratotomy, 13.200
Toric intraocular lenses, 11.124, 13.8*t*, 13.137, 13.148–149, 13.151–153
astigmatism correction using, 3.257
complications of, 11.151, 13.153
contraindication for, capsular decentration and, 11.183
corneal crosslinking with, 13.134, 13.207–208
definition of, 3.4, 3.15
dry eye therapy before use of, 11.173
meridians, 3.78*f*
outcomes of, 13.152–153
overrefraction with, 3.169
paraxial power of, 3.79
patient selection for, 13.151
after penetrating keratoplasty, 8.432, 13.179
planning/surgical technique for, 13.151–152
plate-haptic, 3.257
power-cross representation of, 3.77
power-*versus*-meridian graph of, 3.79*f*
properties of, 3.74
soft, 3.222–223
spherical equivalent of, 3.76
Toric surface
curvature variation of, along meridian, 3.16*f*
definition of, 3.42, 3.71
formation of, 3.15*f*
methods of describing, 3.18
nonocular objects with, 3.15
normal plane and, intersection between, 3.15*f*
Torsades de pointes, 1.104
Torsional deviations, dissociated, 6.17, 6.129
Torsional fusional vergence, 6.72
Torsional nystagmus, 5.245
Torsional phacoemulsification, 11.101
Torticollis
abnormal head position associated with, 6.82
definition of, 6.82
differential diagnosis of, 6.82–84, 6.83*t*
evaluation of, 6.84
facial asymmetry and, 6.82
history-taking for, 6.63
ocular, 6.82–84, 6.83*t*
spasmus nutans and, 5.239
strabismus and, 6.63

Tortuosity, conjunctival vascular, 8.114, 8.115*t*
Total cataract, 11.38
Total exenteration, 7.146, 7.147*f*
Total internal reflection (TIR), 3.42, 3.50, 3.50*f*
Tourette syndrome, 6.202
  facial twitching and, 5.285
Touton giant cells, 4.7, 4.9*f*, 6.271, 9.309
  in juvenile xanthogranuloma, 4.187, 4.188*f*
Toxemia of pregnancy. *See* Eclampsia; Preeclampsia
Toxic anterior segment syndrome (TASS), 2.360, 11.129, 11.133–134
Toxic conjunctivitis, 3.232
Toxic epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis/SJS-TEN), 1.208, 6.251–252, 6.252*f*, 7.237, 7.238*f*, 7.303, 8.285, 8.295–298, 8.296*f*, 8.297*f*
Toxic goiter. *See* Thyroid eye disease
Toxic keratitis, 8.91. *See also* Toxic keratoconjunctivitis
Toxic keratoconjunctivitis, medications causing, 8.80–81, 8.81*t*, 8.90*t*, 8.90–91
Toxic keratopathy
  central, after photoablation, 13.105*f*, 13.105–106
  ulcerative, 8.80–81, 8.81*t*. *See also* Toxic keratoconjunctivitis
Toxic nodular goiter, 1.44
Toxic optic neuropathy, 1.199, 5.107*t*, 5.137–139
Toxic solutions, exposure to during cataract surgery, corneal edema caused by, 11.129, 11.133–134
Toxicity, 2.350–351
  anterior segment injuries and, 8.375–409
  light. *See* Light toxicity/photic damage/phototoxicity
Toxocara (toxocariasis), 4.295, 6.317*f*, 6.317–318, 8.253, 9.283–284, 9.283–285*f*, 9.284*t*, 12.244–245, 12.245*f*
  canis, 6.317, 8.253, 9.45, 9.283, 9.287, 12.244, 12.246
  cati, 6.317, 8.253, 9.283, 12.244, 12.246
  retinoblastoma differentiated from, 4.295
Toxocara granuloma, 9.45
Toxoplasma (toxoplasmosis), 5.352
  chorioretinitis caused by, 4.147–148, 4.148*f*, 6.409, 6.410*f*
  gondii, 1.258–259, 6.409, 9.275–277, 9.276*f*, 9.331
    definition of, 12.243
    retinochoroiditis caused by, 12.243–244, 12.244*f*
  in HIV infection/AIDS, 5.352
  ocular infection/inflammation caused by, 4.147–148, 4.148*f*
  retinal, 4.147–148, 4.148*f*
  uveitis in, 4.147
Toxoplasmosis, 1.258–259
  anterior uveitis caused by, 6.317
  ocular
    in AIDS patients, 9.331
    congenital, 9.276–277, 9.277*f*, 9.281
    diagnosis of, 9.280
    Goldmann-Witmer coefficient for, 9.91
    manifestations of, 6.409–410, 6.410*f*
    punctate outer retinal, 9.279, 9.279*f*
    pyrimethamine for, 9.281
    retinochoroidal scar caused by, 9.278, 9.278*f*
    retinochoroiditis caused by, 9.278, 9.278*f*, 9.280, 9.297, 9.330*f*, 9.330–331
    sulfadiazine for, 9.281
    Toxoplasma gondii as cause of, 9.275–277, 9.276*f*, 9.331
    treatment of, 9.280–282
TP-PA. *See Treponema pallidum* particle agglutination assay
tPA. *See* Tissue plasminogen activator
TPCD. *See* Typical peripheral cystoid degeneration
TPMT. *See* Thiopurine-S-methyltransferase
TR. *See* Repetition time
TR (time to repetition), 5.62, 5.76
Trabecular meshwork, 4.97*f*, 4.97–106, 4.98*f*, 10.5*f*, 10.13, 10.17–18, 10.19*f*
  aging changes to, 2.63
  anatomy of, 2.61*f*
  chemical injury of, glaucoma and, 10.104
  composition of, 2.63
  congenital anomalies of, 4.98–99, 4.99*f*, 4.100*f*
  corneoscleral, 2.63–64
  degenerations of, 4.100–105, 4.101*f*, 4.102*f*, 4.103*f*, 4.104*f*, 4.105*f*
  disorders of, 4.97–106. *See also specific type*
  in glaucoma, 4.105*f*, 4.106, 4.194, 10.94, 10.95*f*
  gonioscopic appearance of, 4.97–98, 4.98*f*, 10.33*t*, 10.34*f*
  juxtacanalicular, 2.64
  layers of, 2.63
  melanoma of, 4.106, 4.106*f*, 4.195*f*
  neovascularization and, 10.133
  nitric oxide production in, 2.395
  pigment in, 4.104–105, 4.105*f*, 10.18, 10.39
    in pigment dispersion syndrome/pigmentary glaucoma, 4.104–105, 4.105*f*, 10.94, 10.95*f*
  in pseudoexfoliation/exfoliation syndrome, 4.102–103, 10.39, 10.93
  topography of, 4.97*f*, 4.97–98, 4.98*f*
  uveal, 2.63
Trabecular meshwork inducible glucocorticoid response/myocilin *(TIGR/MYOC)* gene, 10.10, 10.11*t*, 10.150
  in pediatric glaucoma, 8.108
Trabecular microbypass, cataract surgery and, 11.186
Trabecular outflow, 10.5*f*, 10.13, 10.17–18, 10.18*f*
Trabeculectomy, 6.323, 10.113–115, 10.187, 10.196, 10.197–211. *See also* Filtering procedures
  ab interno, 10.219
  antifibrotic agents used with, 10.205–207, 10.207*f*, 10.208*f*
    bleb-related endophthalmitis and, 10.163, 10.209
  cataract risk and, 11.56
  with cataract surgery, 10.211–213
  in children, 10.161, 10.163
  complications of, 10.209*t*, 10.209–211, 10.210*f*
  contraindications for, 10.198
  in elderly patients, 10.221
  failed, tube shunt implantation after, 10.215
  flap management in, 10.207–208
  indications for, 10.197
  limbus-based, 2.56*f*
  for open-angle glaucoma, 10.113–115
  postoperative considerations in, 10.208–209

preoperative evaluation for, 10.198–199
technique for, 10.199–205
for conjunctival incision/flap, 10.200, 10.201*f*, 10.202*f*
closure and, 10.204, 10.206*f*
management and, 10.207–208
for exposure, 10.199, 10.200*f*
for iridectomy, 10.202, 10.204*f*
for keratectomy, 10.201–202, 10.204*f*
for paracentesis, 10.201, 10.203*f*
for scleral flap, 10.200–201, 10.203*f*
closure and, 10.202–204, 10.205*f*
management and, 10.207–208
Trabeculitis, in glaucomatocyclitic crisis (Posner-Schlossman syndrome), 10.101
Trabeculocytes, 2.63
Trabeculoplasty, 10.113–115, 10.188–191, 10.190*f*
for exfoliation glaucoma, 10.93
for normal-tension glaucoma, 10.88
for open-angle glaucoma, 10.113–115, 10.188–191
for pigmentary glaucoma, 10.96
selective (SLT), 10.188, 10.189, 10.190, 10.190*f*
Trabeculotome, 10.161, 10.162*f*
Trabeculotomy
description of, 10.160, 10.161–162, 10.162*f*, 10.163
for primary congenital glaucoma, 6.286*f*, 6.286–287
Tracheotomy, 1.302
Trachipleistophora, 8.252
Trachoma, 6.241, 8.260–263, 8.261*f*, 8.262*f*
cicatricial conjunctivitis differentiated from, 8.301*t*
Tracking systems (excimer laser), 13.91
Traction test, 7.114. *See also* Forced duction test
Tractional retinal detachment, 6.348*f*, 6.360, 9.237. *See also* Retinal detachment
description of, 12.286
diagnostic features of, 12.321*t*, 12.325
in familial exudative vitreoretinopathy, 12.343
imaging of, 12.387*f*
management of, 12.325
pathophysiology of, 12.387
in proliferative diabetic retinopathy, 12.103, 12.108, 12.387–388
rhegmatogenous retinal detachment *versus*, 12.325
vitrectomy for, 12.325, 12.387–388
Tractus solitarius, nucleus of, 5.55
Trade magnification, 3.321–322
Trait
definition of, 2.202
dominant, 2.202–203
recessive, 2.202
syntenic, 2.217
Tram-tracking/tram-track sign, 7.86
in optic nerve sheath meningioma, 5.127*f*, 5.128*t*
Tranexamic acid, 2.446–447
for hyphema, 8.395
Transconjunctival cryopexy, 12.398
Transconjunctival incisions
for inferior orbitotomy, 7.126–127, 7.127*f*
for medial orbitotomy, 7.128
for superior orbitotomy, 7.125
Transcranial Doppler ultrasonography
carotid stenosis diagnosis using, 1.116
stroke evaluations using, 1.113
Transcription factor 4 *(TCF4)* gene, in Fuchs endothelial corneal dystrophy, 8.136*t*, 8.156
Transcription factors, 2.179
Transcutaneous incisions
for inferior orbitotomy, 7.126, 7.126*f*
for medial orbitotomy, 7.128
for superior orbitotomy, 7.125
Transducin, 2.308
Transendothelial osmotic force, 8.9
Transepithelial ablation, debridement for, 13.83
Transepithelial corneal crosslinking, 13.132–134, 13.133*f*. *See also* Corneal (collagen) crosslinking
Transesophageal echocardiography (TEE), 1.118
Transfer of energy, 3.106
Transfer RNA, mitochondrial DNA–encoded, 2.184
Transferrin, in vitreous, 2.298
Transforming growth factor β–induced gene, dystrophies associated with, 8.133, 8.134, 8.135*t*, 8.136*t*, 8.142–149. *See also TGFBI* dystrophies
Transforming growth factor β–induced (TGFBI) keratoepithelin, in corneal dystrophies, 8.133, 8.134, 8.136*t*. *See also TGFBI* dystrophies
Reis-Bücklers, 8.142
Transforming growth factor βs (TGF-βs), 2.448
characteristics of, 9.24*t*
in external eye defense, 8.12–13*f*
in pseudoexfoliation/exfoliation syndrome, 11.65
in T regulatory cell effector function, 9.35
in tear film, 8.6*f*
Transfusion, for thalassemias, 1.134
Transfusion-transmitted virus (TTV), 1.263
Transient cerebral ischemia
description of, 1.110, 1.115
stroke risks, 1.117–118
Transient hypertension, 1.68
Transient ischemic attacks (TIAs)
description of, 1.119
hemispheric, stroke and, 5.168–169
occipital, binocular transient visual loss and, 5.172
retinal (RTIA)
stroke and, 5.167, 5.168–169
transient monocular visual loss and, 5.164, 5.167, 5.168–169, 5.171
vertebrobasilar, 5.336–337
Transient monocular visual loss (TMVL). *See also* Monocular transient visual loss; Transient visual loss
carotid stenosis as cause of, 1.118
giant cell arteritis presenting as, 1.119
Transient obscurations of vision, 5.161, 5.164. *See also* Transient visual loss
Transient visual loss (TVL), 5.161–172. *See also* Amaurosis, fugax
age of patient and, 5.161
binocular, 5.161, 5.171–172
carotid artery disease causing, 5.162, 5.165–166, 5.167*f*, 5.168
cerebrovascular disease causing, 5.161, 5.162, 5.164–165, 5.326, 5.336
duration of, 5.161
examination of patient with, 5.163
migraine headache and, 5.161, 5.162, 5.171–172, 5.177, 5.291

monocular (TMVL), 5.161, 5.163*t*, 5.163–171. *See also* Monocular transient visual loss
pattern of, 5.162
recovery pattern and, 5.162
Transillumination, 4.28*f*, 4.28–29
in choroidal melanoma/ciliary body melanoma diagnosis, 4.267, 4.267*f*
iris, 6.265
in albinism, 4.142, 4.142*f*
in pathologic examination, 4.28*f*, 4.28–29
Transit amplification, in stem cell differentiation, 8.92
Transitional zone (peripheral zone), corneal, 8.25, 8.25*f*
Transketolase, 2.260
Translation, 2.179
"Translation operator," 3.60
Transmissible spongiform encephalopathies, 1.211, 5.357
Transmission (window) defect
of fluorescence. *See* Hyperfluorescence
hyperfluorescence in, 12.36
Transplant rejection. *See* Rejection
Transplantation. *See also specific type*
amniotic membrane. *See* Amniotic membrane transplantation (AMT)/graft
cardiac, 1.100
conjunctival, 8.351*t*, 8.353*t*, 8.353–355, 8.354*f*, 8.356
autografts/autologous, 8.351*t*, 8.353*t*, 8.353–355, 8.354*f*, 8.356
for chemical injuries, 8.383
indications for, 8.351*t*, 8.353, 8.356
for limbal stem cell deficiency, 8.94
in pterygium surgery, 8.351, 8.353*t*, 8.353–355, 8.354*f*, 8.356
recurrence rate and, 8.353*t*
after tumor removal surgery, 8.329
corneal, 8.316, 8.411–452, 8.412*t*, 8.412–413*t*. *See also* Donor cornea; Keratoplasty; *specific procedure*
allografts/allogeneic, 8.316, 8.411–451, 8.412*t*, 8.412–413*t*
autografts/autologous, 8.411, 8.451–452
cataract/cataract surgery and, 11.56, 11.175, 11.176
for chemical injuries, 8.384
definition of/terminology and, 8.412–413
disease transmission and, 8.414, 8.415*t*, 8.416*t*
Creutzfeldt-Jakob disease, 8.254, 8.416*t*
rabies virus, 8.240, 8.240*t*, 8.416*t*
donor selection and, 8.414, 8.415*t*, 8.416*t*
eye banking and, 8.413–417, 8.415*t*, 8.416*f*, 8.416*t*
immune privilege and, 8.316
indications for, 8.412–413*t*
patient selection and, 8.418
pediatric, 8.450–451
preoperative evaluation/preparation and, 8.418–419
after refractive surgery, 13.197–198
refractive surgery after, 13.37, 13.178–180
rejection and, 4.84, 4.85*f*, 8.316–318, 8.428–431. *See also* Rejection
in triple procedure, 11.175–176
hematopoietic stem cell
allogeneic, for thalassemias, 1.134
complications of, 1.135
sickle cell disease treated with, 1.135
limbal, 8.94, 8.351*t*
for chemical injuries, 8.380, 8.384
indications for, 8.351*t*
liver, 1.226
mucous membrane, 8.351*t*, 8.365–366
indications for, 8.351*t*, 8.366
for mucous membrane pemphigoid, 8.303, 8.366
pancreas, type 1 diabetes mellitus treated with, 1.37–38
rejection and. *See* Rejection
Transport mechanisms
in aqueous humor dynamics, 10.16
lens, 11.21, 11.22*f*
Transposition
definition of, 3.18, 3.77
practice with, 3.78
Transpupillary thermotherapy (TTT), 3.115, 12.380
for choroidal/ciliary body melanoma, 4.276
for metastatic eye disease, 4.310
for retinoblastoma, 4.300
11-*trans*-retinal, 12.31
11-*trans*-retinaldehyde, 12.17
Transscleral cryopexy, 12.398
Transscleral cyclophotocoagulation (cyclodestruction), 10.194, 10.195–196, 10.196
for pediatric glaucoma, 10.163–164
Transthoracic echocardiography (TTE), 1.118
Transthyretin (TTR/prealbumin), 2.326
amyloidosis/amyloid deposits and, 4.134, 4.135, 4.206, 8.187
Transtracheal ventilation, 1.299
Transverse facial artery, 2.38*f*, 5.13*f*, 5.15*f*
Transverse keratotomy (TK), 13.53, 13.54, 13.54*f*
Transverse magnification, 3.42, 3.62, 3.300
Transverse (spin-spin) relaxation time (T2), 5.62, 5.63*t*, 5.76
Transverse scans, 2.464–467, 2.466–467*f*
Transverse sinus, 5.22, 5.22*f*
endovascular stenting of, for idiopathic intracranial hypertension, 5.113
thrombosis in, 5.69*f*, 5.345–346
"Trapdoor"-type fractures, 2.9
Traquair, junctional scotoma of, 5.146–147
Trastuzumab, 1.242
Trauma. *See also* Lacerations; Penetrating and perforating ocular trauma; Wound(s), healing/repair of
abusive head, 6.381–384, 6.382–383*f*, 12.365–366, 12.366*f*
accidental, 6.375–381, 6.377–378*f*, 6.380*f*
amblyopia secondary to, 6.375
angle recession/angle-recession glaucoma and, 4.18, 4.19*f*, 4.103–104, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*
animal and plant substances causing, 8.386–387
anterior segment, 8.375–409, 10.39–40, 10.40*f*, 10.41*f*, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*. *See also* Anterior segment, trauma to
anterior uveitis caused by, 6.316
assessment of, 11.190–191
blunt, 6.378–379, 8.387–396, 8.388–395*f*, 12.315, 12.353–358, 12.354–12.357*f*. *See also* Blunt (concussive) trauma
canalicular, 7.311–312
canthal tendon, 7.214–215
cataract surgery after, 11.190–193, 11.192*f*

chemical injuries, 6.376, 8.375–384, 8.376*t*
chiasmal injury caused by, 5.152
in children, 12.316–317
choroidal rupture, 12.354–12.356*f*, 12.354–355
classification of, 12.351
closed-globe, 12.351–352
commotio retinae, 12.353, 12.354*f*
concussive (blunt), 8.387–396, 8.388*f*, 8.389*f*, 8.390*f*, 8.391*f*, 8.392*f*, 8.393*f*, 8.394*f*, 8.395*t*. *See also* Blunt (concussive) trauma
convergence insufficiency caused by, 5.227
corneal abrasion, 6.376
corneal blood staining and, 8.394, 8.394*f*, 8.395, 8.395*t*, 10.104, 10.104*f*, 10.105
Descemet membrane rupture and, 4.17, 4.18*f*
diplopia after, 5.186, 5.206
ectopia lentis caused by, 11.40
endophthalmitis after, 12.362–363
evaluation of patient after, 12.351–353, 12.352*t*
eyelid. *See* Eyelid(s), surgery/reconstruction of; Eyelid(s), trauma to
fibrocellular proliferation secondary to, 4.20–22, 4.21*f*, 12.315
fourth nerve (trochlear) palsy caused by, 5.199, 5.200
fungal keratitis associated with, 4.78
glaucoma associated with, 4.103–104, 4.104*f*, 10.39–40, 10.40*f*, 10.41*f*, 10.98, 10.103–108, 10.104*f*, 10.106*f*, 10.107*f*
angle closure/angle-closure glaucoma and, 10.142
fibrous ingrowth and, 10.142, 10.143*f*
angle recession and, 4.18, 4.103–104, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*
in children and adolescents, 10.149*t*
lens particle glaucoma and, 10.98, 11.67
open-angle glaucoma and, 10.40*f*, 10.40–41, 10.41*f*, 10.106–108, 10.107*f*
phacoantigenic glaucoma and, 10.98
handheld laser-pointer injury, 12.369
histologic sequelae of, 4.17–23, 4.18*f*, 4.19*f*, 4.20*f*, 4.21*f*, 4.22*f*, 4.23*f*
hyphema, 6.378*f*, 6.378–379
incidence of, 6.375
in infants, 12.316–317
intraocular pressure evaluations, 12.352
lacrimal sac, 7.312
laser-pointer injury, 12.369
LASIK flap dislocation and, 13.115–116
lens damage/cataracts caused by, 4.18, 11.53–59, 11.54*f*, 11.55*f*, 11.56*f*, 11.58*f*, 11.59*f*, 11.190–193, 11.192*f*
glaucoma and, 10.98, 11.67
phacoantigenic uveitis and, 4.118–119, 4.119*f*, 11.66, 11.191
surgery for, 11.192
macular hole caused by, 12.355–357, 12.356*f*
management of, 6.375
microsurgery for, 12.351
Mooren ulcer and, 8.314
nasolacrimal duct, 7.306, 7.312
neuroimaging in evaluation of, 5.72*t*, 5.73*f*, 5.139*f*, 5.140
nonaccidental
abusive head trauma, 6.381–384, 6.382–383*f*, 12.365–366, 12.366*f*
ocular injury secondary to, 6.384
occupational light toxicity, 12.369
ocular infection and, 8.247, 8.403
ocular surface, 8.375–409
Ocular Trauma Score, 12.364, 12.364*t*
open-globe
description of, 12.351–352
intraocular foreign bodies, 12.351–352, 12.360–362, 12.361*f*
lacerating injuries, 12.358
needle perforation/penetration, 12.358, 12.395*f*, 12.395–396
penetrating injuries, 12.358
prognosis for, 12.363–364
scleral rupture, 12.358
optic nerve head avulsion caused by, 12.365, 12.365*f*
optic neuropathy caused by, 5.107*t*, 5.139*f*, 5.139–140, 6.381
orbital. *See* Orbital trauma
orbital floor fractures, 6.127–128, 6.128*f*, 6.379–380, 6.380*f*
orbital roof fractures, 6.380, 6.380*f*
penetrating and perforating, 6.376–378, 6.377*f*, 8.396–409. *See also* Penetrating and perforating ocular trauma; Trauma
photic damage, 12.367–369, 12.368*f*
phototoxicity from ophthalmic instrumentation, 12.368–369
prognosis after, 12.363–364
ptosis caused by, 5.273*t*, 5.274
pupil irregularity caused by, 5.255
restrictive conditions caused by, 5.186, 5.206
retinal breaks caused by, 12.315–316, 12.316*f*
retinal detachments caused by, 12.317
retinal sclopetaria, 12.356–358, 12.357*f*
scleral rupture, 12.352
seventh nerve (facial) palsy caused by, 5.278*t*, 5.280
sixth nerve (abducens) palsy caused by, 5.201
spheroidal degeneration and, 8.116–117
subconjunctival hemorrhage caused by, 8.387–388, 8.388*f*
submacular hemorrhage secondary to, 12.354*f*
surgical, open-angle glaucoma and., 10.108–109
sympathetic ophthalmia and, 4.185, 12.364–365
temperature and radiation causing, 8.384–386, 8.385*f*
thermal injury, 6.376
uveal tract, 4.18, 4.19*f*
vitreous hemorrhage secondary to, 12.357
whiplash, 12.356–357
in young patients, 12.316–317
Traumatic anterior uveitis, 8.389–390
Traumatic brain injuries (TBIs), 1.191
Traumatic breaks in Descemet membrane, 6.262, 6.262*f*
Traumatic corneal endothelial rings, 8.388
Traumatic hyphema, 8.391–396, 8.392–394*f*, 8.395*t*
glaucoma/elevated intraocular pressure and, 8.394, 10.104*f*, 10.104–105
medical management of, 8.394–395
rebleeding after, 8.394, 8.394*f*, 10.104, 10.105
sickle cell disease/retinopathy/elevated intraocular pressure and, 8.395, 8.395*t*, 8.396, 10.104, 10.105
surgery for, 8.395*t*, 8.395–396, 8.396, 10.105

Traumatic miosis, 5.262, 8.389
Traumatic mydriasis, 5.262, 8.388, 8.389*f*
Traumatic optic neuropathy (TON), 5.107*t*, 5.139*f*, 5.139–140, 7.119, 7.121*f*
Traumatic posterior annular keratopathy, 8.388
Traumatic ptosis, 7.248
Traumatic recession of anterior chamber angle, 4.18, 4.19*f*, 4.103–104
  glaucoma and, 4.18, 4.103–104, 10.39–40, 10.40*f*, 10.41*f*, 10.106–108, 10.107*f*
Travatan/Travatan Z. *See* Travoprost
Travel immunizations, 1.232
Travoprost, 2.363, 2.394*t*, 10.170–176, 10.171*t*, 10.175*t*
  in combination preparations, 10.174*t*
Travoprost/timolol maleate, 2.394*t*, 2.397*t*
Treacher Collins/Treacher Collins-Franceschetti syndrome (mandibulofacial dysostosis), 6.196, 6.211, 6.211*f*, 7.38*f*, 8.192*t*
  eyelid manifestations of, 4.207*t*
Tree sap, ocular injuries caused by, 8.387
Trefoil, 3.275–276*f*, 13.9, 13.12, 13.13*f*, 13.103*f*
  after LASIK, 13.103*f*
Treg cells. *See* T regulatory (Treg) cells
Tremor, in Parkinson disease, 1.204
Trend-based analysis, of visual field progression, 10.71
Trephination/trephines, for mechanical keratectomy, 8.367
Treponema pallidum, 1.252–253, 6.240, 6.412, 8.107, 8.309, 9.219, 9.224. *See also* Syphilis
  conjunctivitis caused by, 8.260*t*
  interstitial keratitis caused by, 4.80, 4.81*f*, 8.107, 8.308–309, 8.309*f*
Treponema pallidum particle agglutination assay (TP-PA), 12.241
Treponemal antigen tests, 1.223, 1.253
TRH. *See* Thyrotropin-releasing hormone
Triage, 7.122
Trial contact lens fitting. *See* Fitting (contact lens)
Trial frames. *See also* Phoropter
  for nonorganic disorder evaluation, 5.306
Trial lens, 3.164*f*
Triamcinolone, 1.175*t*, 2.360*t*, 2.371*t*, 2.407, 2.444
  branch retinal vein occlusion treated with, 12.137
  for chalazion, 8.77
  for corneal graft rejection, 8.430
  diabetic macular edema treated with, 12.113
  intravitreal (IVTA), for macular edema/diabetic macular edema, 4.152
  for scleritis, 9.127
  uveal effusion syndrome treated with, 12.203
  for uveitis
    inferior transseptal injection of, 9.96, 9.97*f*
    intravitreal injection of, 9.96*f*, 9.97
    posterior sub-Tenon injection of, 9.95, 9.96*f*
  for vernal keratoconjunctivitis, 8.291
Triazoles, 1.277, 2.429–431, 2.430*t*
  for *Acanthamoeba* keratitis, 8.278
Trichiasis, 7.235, 7.239*f*, 7.239–240, 8.88
  in staphylococcal blepharitis, 8.74
Trichilemmal cyst, 7.189
Trichilemmomas, 4.210*t*, 7.194
Trichinella spiralis, 7.53
Trichinosis, 7.53
Trichoepithelioma, 7.193, 7.194*f*
Trichofolliculoma, 7.193, 7.194*f*
Trichotillomania, 6.201, 6.201*f*, 7.186, 7.186*f*
Trichromatism, 12.249
Tricyclic antidepressants, 1.203*t*
  apraclonidine/brimonidine interactions and, 10.179
Trifluridine, 2.432*t*, 2.433, 8.215*t*
  for herpes simplex virus infections, 8.215*t*, 8.219, 8.222, 8.223*t*
    epithelial keratitis, 8.219
    stromal keratitis, 8.222, 8.223*t*
  for vaccinia infection, 8.238
Trifocal lenses, 3.180–182
Trifocal optics, for multifocal IOL, 13.166
Trigeminal autonomic cephalgias (TACs), 5.293–294
  Horner syndrome and, 5.260*t*, 5.261
Trigeminal ganglion (gasserian/semilunar ganglion), 2.131, 5.42*f*, 5.48, 5.48*f*, 7.14
  herpes simplex/varicella-zoster virus latency and, 8.205, 8.207, 8.212, 8.213, 8.226
Trigeminal lemniscus, 5.47*f*
Trigeminal nerve. *See* Cranial nerve V
Trigeminal neuralgia (tic douloureux), 5.289*t*, 5.297
Trigeminal nucleus, 5.47. *See also* Cranial nerve V
Triglycerides
  lipoprotein transport of, 1.72
  lowering levels of. *See* Lipid-lowering therapy
  nonpharmacologic management of, 1.75
Trihexyphenidyl, 1.205
Triiodothyronine (T_3)
  deiodination of, 1.41
  secretion of, 1.41
  serum, measurement of, 1.42
Trilateral retinoblastoma, 4.298
Trimethoprim-sulfamethoxazole (TMP-SMX), 1.276
  for granulomatosis with polyangiitis, 7.64
  for ocular toxoplasmosis, 9.281–282
  for *Pneumocystis jirovecii* choroiditis, 9.332
  for toxoplasmic retinochoroiditis, 12.243–244
  for Whipple disease, 9.245
Trimethoprim with sulfonamides. *See* Trimethoprim-sulfamethoxazole
Trinucleotides, 2.176, 2.178
TRIO (thyroid-related immune orbitopathy). *See* Thyroid eye disease
Triple procedure, 11.175–176
Trisomy, 2.222
Trisomy 8, in choroidal/ciliary body melanoma, 4.197
Trisomy 13, 6.386*t*
Trisomy 18, 6.386*t*
Trisomy 21 (Down syndrome). *See also* Down syndrome
  genetic errors in, 2.223
  mosaicism, 2.225
  pharmacogenetics and, 2.233–234
Tritanomalous dichromatism, 12.250*t*
Tritanomalous trichromatism, 12.250*t*
Tritanopia (tritan defects/blue-yellow color confusion)
  in optic atrophy, 5.135
  tests for, 5.78–79
Trivariant color vision, 2.312. *See also* Color vision
Trivex, 3.196
tRNA. *See* Transfer RNA

Trochlea, 2.17*f*, 5.46
anatomy of, 6.19*f*
function of, 6.20
Trochlear fossa, 2.7*f*, 2.8
Trochlear headache/trochleitis, 5.296
Trochlear nerve. *See* Cranial nerve IV; Fourth nerve (trochlear) palsy
Tropheryma whipplei, 5.251, 9.243, 9.311
Trophozoites, 9.331
-tropia (suffix), 6.16
Tropias. *See also* Heterotropias/tropias
refractive surgery and, 13.41
Tropicacyl. *See* Tropicamide
Tropicamide, 2.380*t*, 6.11, 6.11*t*
Tropocollagen, 2.294
Troponins
in acute coronary syndrome, 1.87
I, 1.87
T, 1.87
Trusopt. *See* Dorzolamide
Trypan blue, 2.360*t*, 2.444
Trypan blue dye, for capsule staining, 11.178–179, 11.179*f*
TS. *See* Tuberous sclerosis
TSC1/TSC2 genes
description of, 2.228, 6.399
in tuberous sclerosis, 5.334*t*
TSH. *See* Thyroid-stimulating hormone
TSH-R. *See* Thyrotropin (thyroid-stimulating hormone/TSH), receptor for
TSIs. *See* Thyroid-stimulating immunoglobulins
TTE. *See* Transthoracic echocardiography
TTP. *See* Thrombotic thrombocytopenic purpura
TTR. *See* Transthyretin
TTR gene, in amyloidosis, 8.187
TTT. *See* Transpupillary thermotherapy
TTV. *See* Transfusion-transmitted virus
TUBB3 gene, 6.135
Tube-cornea touch, after tube shunt surgery, 10.217, 10.218*t*
Tube shunts (glaucoma drainage devices), 10.196–197, 10.213–217, 10.214*t*, 10.218*t*
cataract extraction combined with, 10.213
complications associated with, 10.217, 10.218*t*
corneal graft failure and, 8.428
description of, 6.146, 6.287, 6.323
in iridocorneal endothelial syndrome, 8.127
LASIK and, 13.182
neovascular glaucoma and, 10.135
pediatric glaucoma and, 10.161, 10.163
strabismus and, 10.166–167
uveitis/uveitic glaucoma and, 10.214
Tube Versus Trabeculectomy study, 10.215
Tubercles
"hard," 4.7, 4.8*f*
in sarcoidosis, 4.52, 4.52*f*
Tubercular serpiginous-like choroiditis, 12.222
Tuberculin skin test, for tuberculosis, 9.28, 9.238
Tuberculoma, 9.237*f*
Tuberculosis. *See also Mycobacterium, tuberculosis*
choroidal involvement in, 9.236–237*f*
diagnosis of, 9.238–239
extrapulmonary, 9.234
fluorescein angiography findings in, 9.236, 9.237*f*
incidence of, 9.234
indocyanine green angiography findings in, 9.236, 9.237*f*
isoniazid for, 9.239–240
latent, 9.240
multidrug-resistant, 9.239
multifocal choroiditis in, 9.236, 9.236*f*
neuro-ophthalmic signs of, 5.350
ocular, 9.235–238, 9.235–238*f*, 12.240–241, 12.241*f*
primary response to, 9.28
pulmonary, 9.234
retinal involvement in, 9.237–238
risk factors for, 9.234
screening for, 1.222
secondary response to, 9.28
serpiginous-like choroiditis associated with, 9.177, 9.236, 9.237*f*
treatment of, 9.239–240
tuberculin skin test for, 9.28, 9.238
uveitis caused by, 9.234–240, 9.235–238*f*
Tuberculous meningitis, 5.350
neuro-ophthalmic signs of, 5.350
Tuberculous scleritis, 8.282
Tuberculum sella, 5.6*f*, 5.27*f*
Tuberin, 5.334*t*
Tuberous sclerosis (TS/Bourneville disease/syndrome)
description of, 2.228–229, 5.330, 5.331*f*, 5.334*t*, 6.393*t*, 6.397–399, 6.398*t*, 6.398*f*
glaucoma associated with, 10.30
Tubulin, 2.285
Tubulointerstitial nephritis and uveitis (TINU) syndrome, 6.316
acute anterior uveitis in, 9.134–135, 9.135*f*
$CD4^+$ T cells in, 9.135
characteristics of, 9.134
diagnostic criteria for, 9.134
human leukocyte antigen association with, 9.65*t*
Tuck, 6.164*t*
Tumbling E chart, 6.7
Tumbling E optotypes, 3.133*f*, 3.134
Tumor(s), 4.10, 4.10*t*, 4.11*f*, 4.12*t*. *See also* Cancer; Eyelid(s), tumors of; Intraocular tumors; Lacrimal gland, tumors of; Mesenchymal tumors; Metastatic eye disease; Neoplasia; Neoplasms; Orbital tumors; *specific tumor and structure or organ affected*
anterior chamber and trabecular meshwork, 4.106, 4.106*f*
anterior segment, 6.271–274
bony, 6.222
in children
orbital, 4.228, 4.229
retinoblastoma, 4.289–302
choristomatous, 6.225–226
choroid and ciliary body, 4.191–197
ciliary body, 6.273*f*, 6.273–274
conjunctival, 4.59–72
connective tissue, 6.222
corneal, 4.96, 6.271
eyelid, 4.209–221, 4.210*t*
iris, 4.189–190, 4.190*f*, 4.191*f*, 6.271–273, 6.272*f*
neural, 6.223
neuroimaging in evaluation of, 5.64*f*, 5.65*f*, 5.72*t*

ocular surface, 8.327–350. *See also* Ocular surface, tumors of
optic nerve/nerve head/disc, 4.248*f*, 4.248–250, 4.249*f*, 4.250*f*
orbital, 4.228–240
scleral, 4.112, 4.113*f*
secondary, 4.303–310. *See also* Metastatic eye disease
orbital, 4.228, 4.240
retinoblastoma and, 4.302, 4.302*t*
thyroid, 1.46
uveal tract, 4.189–199, 4.200*f*
vitreous, 4.135*f*, 4.135–137, 4.136*f*
Tumor-associated calcium signal transducer 2 *(TACSTD2)* gene, in gelatinous droplike corneal dystrophy, 8.136*t*
Tumor necrosis factor (TNF)
α
characteristics of, 9.23*t*
in dry eye, 8.53
immune response suppression by, 9.25
inhibitors, 1.180, 2.405*t*
description of, 6.322
optic neuropathy caused by, 5.137
for scleritis, 8.324, 8.325*t*
inhibitors of
for Behçet disease, 9.217–218
side effects of, 9.139–140
for uveitis, 9.105, 9.110–112, 9.130–131, 9.139
in mucous membrane pemphigoid, 8.299
β, 9.23*t*
in external eye defense, 8.11–13
Tumor suppressor genes, 1.235. *See also specific type*
definition of, 2.183
examples of, 2.183–184
in ocular surface squamous neoplasia, 4.60
in pinguecula/pterygium, 4.57
Tunica vasculosa lentis, 2.154, 2.158*f*, 11.29, 11.29*f*, 12.186, 12.340–341
remnant of
epicapsular star, 11.31, 11.32*f*
Mittendorf dot, 4.126, 11.29, 11.31, 11.32*f*
Turban tumors, 7.193
Turbinates
anatomy of, 7.19
infracture of, 7.294
Turner syndrome, 2.225, 6.386*t*
TVL. *See* Transient visual loss
Twin studies
in age-related cataract, 11.41–42
in glaucoma, 10.10
TWIST gene, 6.206
2-hit hypothesis, 2.184
Two-sided lenses
depth of field, 3.57, 3.58*f*
depth of focus, 3.57, 3.58*f*
description of, 3.54–57
principal planes, 3.56–57, 3.57*f*
"thick-lens formula" for, 3.54–55
Tympanic segment of cranial nerve VII (facial), 5.52
Tyndall effect
definition of, 3.97
scattering of light and, 3.97
Type 1 diabetes mellitus. *See* Diabetes mellitus, type 1
Type 2 diabetes mellitus. *See* Diabetes mellitus, type 2
Typhoid fever vaccination, 1.232
Typical degenerative retinoschisis, 4.148, 12.326
Typical peripheral cystoid degeneration (TPCD), 4.148, 4.149*f*, 12.326
Tyrosine aminotransferase, defective, 8.183
Tyrosinemia, 2.204*t*, 8.183*t*, 8.183–184, 8.184*f*
alkaptonuria and, 8.184
corneal changes in, 8.183–184, 8.184*f*
type II, 6.270
Tyrosinuria, 8.183
Tysabri. *See* Natalizumab

U

UbiA prenyltransferase domain-containing protein 1 *(UBIAD1)* gene, in Schnyder corneal dystrophy, 6.270, 8.136*t*
UBM. *See* Ultrasound biomicroscopy
UC. *See* Uncentral (UC) fixation
UC fixation. *See* Uncentral (UC) fixation
UCVA/UDVA. *See* Uncorrected/uncorrected distance visual acuity
UDAd. *See* Underdepression in adduction
UDP (uridine diphosphate) galactose 4-epimerase deficiency, galactosemia/cataract formation and, 11.61
UEAd. *See* Underelevation in adduction
UFH. *See* Unfractionated heparin
UGH syndrome. *See* Uveitis-glaucoma-hyphema (UGH) syndrome
Uhthoff phenomenon, 5.162, 5.317
UKPDS (United Kingdom Prospective Diabetes Study), 12.96–97
Ulcer(s)
conjunctival, 8.47*t*
corneal. *See* Corneal ulcers; Keratitis
eyelid, 8.45*t*
Mooren, 8.313–316, 8.315*f*
neurotrophic. *See* Neurotrophic keratopathy/ulcers
Ulcerative basal cell carcinoma. *See* Basal cell carcinoma
Ulcerative colitis, 1.156
Ulcerative keratitis/peripheral ulcerative keratitis (PUK), 8.51*f*, 8.311*t*, 8.311–313, 8.312*f*. *See also* Keratitis
differential diagnosis of, 8.311, 8.311*t*
in rosacea, 8.71
in systemic immune-mediated diseases, 8.51*f*, 8.311*t*, 8.311–313, 8.312*f*
Ulcerative keratopathy, toxic, 8.80–81, 8.81*t*. *See also* Toxic keratoconjunctivitis
ULE. *See* Upper eyelid(s), excursion
Ultrafiltration, 2.271
in aqueous humor dynamics/formation, 10.16
Ultrashort laser pulses, 3.117–118
Ultrasonic (term), 11.99
Ultrasonic phacoemulsification, 6.302
Ultrasonography/ultrasound (echography), 5.72*t*
A-scan, 2.463*f*, 2.463*t*, 2.463–464, 3.244–245, 3.245–246*f*, 7.31. *See also* A-scan ultrasonography/echography

for axial length measurement
in IOL power determination/selection, 11.82–83, 11.83*f*, 11.85, 11.87
in primary congenital glaucoma, 10.160
anterior segment (ultrasound biomicroscopy/UBM), 4.265, 8.20–21, 8.21*f*
in choroidal/ciliary body melanoma, 4.265
before corneal transplantation, 8.418
in glaucoma, 10.77, 10.124*f*
pediatric glaucoma and, 10.160
applanation, 3.245, 3.245*f*
applications of, 12.40
for axial length measurement, 3.244–246, 3.245–3.246*f*
in IOL power determination/selection, 11.82–83, 11.83*f*, 11.85, 11.87
hypotony affecting, 11.185
in primary congenital glaucoma, 10.160
B-scan, 7.31. *See also* B-scan ultrasonography/echography
axial scans, 2.464–465, 2.464–465*f*
contact, 12.39, 12.39*f*
dynamic, 2.467–468, 2.469*t*, 2.470–471*f*
in glaucoma, 10.77
pediatric glaucoma and, 10.160
longitudinal scans, 2.464, 2.466*f*, 2.468–469*f*
probe for, 2.463*f*
tissue-specific gain setting for, 2.469*t*
transverse scans, 2.464–467, 2.466–467*f*
types of, 2.464, 2.465*f*
cardiac emboli identification and, 5.168
in carotid artery evaluation, 5.70, 5.167
before cataract surgery, 11.81, 11.82–83, 11.83*f*, 11.87
hypotony and, 11.185
in choroidal hemangioma, 4.281, 4.282*f*
in choroidal melanoma/ciliary body melanoma, 4.265–267, 4.266*f*
in corneal topography/tomography, 8.35*t*
before corneal transplantation, 8.418
definition of, 2.462
devices for, 2.462, 2.463*f*
disease-/disorder-specific findings, 2.470–471*f*
Doppler, 5.70, 7.31
high-frequency, 2.462
immersion, 3.245, 3.246*f*
indications for, 2.462
intraocular foreign-body evaluations, 12.352
in IOL power determination/selection, 11.82–83, 11.83*f*, 11.87
in iris melanoma, 4.260, 4.261*f*
low-frequency, 2.462
in low vision evaluation, 5.95
in lymphoma, 4.311–312
macula imaging on, 2.469*f*
in metastatic eye disease, 4.307, 4.307*f*
in optic nerve/nerve head/disc drusen, 5.95, 5.141*f*, 5.142
versus papilledema, 5.141*f*, 5.142–143
orbital disorders evaluated using, 7.31
in orbital evaluation, 5.70–71, 5.72*t*
orbital foreign bodies on, 7.117
for pachymetry, 8.41. *See also* Pachymetry/pachymeter
for intrastromal corneal ring segment placement, 13.64
before refractive surgery, 13.45
for phacoemulsification, 11.98
terminology related to, 11.99–100
in posterior scleritis, 8.322, 8.322*f*
retinal disease evaluations using, 12.39–40
in retinoblastoma, 4.292
of thyroid gland, 1.43
in uveal lymphoid proliferation/infiltration, 4.314
in uveitis evaluations, 9.89–90
for vitreous hemorrhage, 12.347
Ultrasound biomicroscopy (UBM), 4.265, 8.20–21, 8.21*f*
of anterior chamber, 2.60*f*
anterior chamber evaluations, 12.40
axial scans, 2.468, 2.471*f*
characteristics of, 2.468
in choroidal/ciliary body melanoma, 4.265
ciliary body evaluations, 12.40
before corneal transplantation, 8.418
in glaucoma, 10.77, 10.124*f*
pediatric glaucoma and, 10.160
ocular anatomy on, 2.471–472*f*
radial scans, 2.468–469, 2.472*f*
Ultrathin Descemet stripping endothelial keratoplasty (ultrathin DSEK), 8.439–440
Ultraviolet-A (UVA) light, 3.114, 3.118, 3.193
Ultraviolet-absorbing chromophores/filters, IOLs with, 11.120
Ultraviolet-absorbing lenses, 3.193–194. *See also* Sunglasses
cataract prevention and, 11.58
Ultraviolet-B (UVB) light, 3.118, 3.193–194
Ultraviolet-C (UVC) light, 3.193–194
Ultraviolet (UV) light (ultraviolet [UV] radiation)
blockage of, 2.288*f*, 2.338
in corneal crosslinking, 13.130–131, 13.132, 13.134
definition of, 2.286
eye disorders/injury associated with. *See also* Light toxicity/photic damage/phototoxicity
actinic keratopathy, 4.83, 4.83*f*, 8.116
actinic keratosis, 4.210
anterior segment injury, 8.385–386
basal cell carcinoma, 4.212*f*, 4.212–213, 4.213*f*
cataracts, 11.57–58
corneal haze after surface ablation and, 13.109
eyelid tumors, 4.210, 4.212*f*, 4.212–213, 4.213, 4.213*f*
ocular surface squamous neoplasia, 4.60
pinguecula, 4.56, 4.56*f*, 8.112
pseudoexfoliation, 11.65*f*, 11.65–66
pterygium, 4.57, 4.57*f*, 8.112
spheroidal degeneration (actinic/climatic droplet/Labrador keratopathy), 4.83, 4.83*f*, 8.116
squamous cell carcinoma and, 4.213, 4.214*f*
lenses absorbing. *See also* Sunglasses
cataract prevention and, 11.58
for light-adjustable IOLs, 13.153–154, 13.154*f*
melanomas caused by, 1.220
reactive oxygen species from, 2.339
UM. *See* Unmaintained (UM) fixation
Umbo (clivus), 5.5
anatomy of, 12.9, 12.9*f*
characteristics of, 12.10*t*

Unasyn, 1.273
Uncentral, unsteady, and unmaintained fixation, 6.6
Uncentral (UC) fixation, 6.6
Uncorrected/uncorrected distance visual acuity (UCVA/UDVA), 13.39–40. *See also* Visual acuity
  assessment of before refractive surgery, 13.39–40
  corneal inlays and, 13.61
  hyperopia correction and, 13.96
  intrastromal corneal ring segment placement and, 13.64
    for keratoconus, 13.66
  LASIK and, 13.95, 13.96, 13.97
    in amblyopia/anisometropic amblyopia, 13.186
    in diabetes mellitus, 13.190
    for mixed astigmatism, 13.97
    after penetrating keratoplasty, 13.180
    after retinal detachment surgery, 13.185
    small-incision lenticule extraction compared with, 13.205
  myopia correction and, 13.95
  patient expectations/motivations and, 13.35–36
  photorefractive keratectomy and, 13.95
  radial keratotomy and, 13.50
  refractive lens exchange and, 13.150
  small-incision lenticule extraction and, 13.205
  toric IOL implantation and, 13.152–153
  wavefront-guided/wavefront-optimized/topography-guided ablation and, 13.32, 13.97
Uncrossed diplopia, 6.75
Uncus, 5.45
Undercorrection, with photoablation, 13.102, 13.108
Underdepression in adduction (UDAd), 6.17
Underelevation in adduction (UEAd), 6.17
Undifferentiated anterior uveitis, 9.146–147
Undifferentiated uveitis, 9.84
Unformed hallucinations, 5.158, 5.175, 5.176. *See also* Hallucinations
Unfractionated heparin (UFH), 1.149. *See also* Heparin
Unharmonious anomalous retinal correspondence, 6.76
Unifocal eosinophilic granuloma, 6.219, 6.219*f*
Unilateral aphakia, 3.140, 3.207
Unilateral vision loss, 5.161, 5.163*t*, 5.163–171. *See also* Monocular transient visual loss
  in low vision evaluation, 5.77
  in nonorganic disorders, 5.305, 5.305*t*
  in optic neuritis, 5.113
United Kingdom Prospective Diabetes Study (UKPDS), 12.96–97
Universal Protocol, 1.288–289
Unmaintained (UM) fixation, 6.6
Unoprostone isopropyl, 2.393, 2.394*t*
Unpolarized light, 3.98
Unstable angina pectoris, 1.83
Upbeat nystagmus, 5.243*t*, 5.245
Upgaze (elevation of eye/sursumduction/sursumversion/supraduction)
  description of, 6.37
  disorders/limitation of, 5.228–229
    in Brown syndrome, 5.208
    in dorsal midbrain (Parinaud) syndrome, 5.229, 5.230*f*
    in newborns, 5.230
    saccadic dysfunction and, 5.222
  extraocular muscles controlling, 5.36*f*, 5.46*f*
    inferior oblique muscle, 5.36*f*, 5.46*f*
    superior rectus muscle, 5.36*f*, 5.46*f*
Upper eyelids. *See also* Eyelid(s); *specific disorders*
  anatomy of, 2.26, 7.160*f*
  anophthalmic ptosis of, 7.145*f*
  blepharoplasty of
    brow ptosis and, 7.264
    description of, 7.259
    preoperative evaluation, 7.260
    retraction caused by, 7.253*f*, 7.254
    technique for, 7.261, 7.261*f*
  crease incision of, 7.125, 7.165
  crease of, 7.160, 7.242, 7.244
  defects involving, reconstruction of, 7.220–221, 7.222*f*
  dermatochalasis of, 7.259
  development of, 2.163, 2.164*f*
  drooping of. *See* Ptosis
  entropion of, 7.234
  eversion of, 7.174, 7.176*f*
  excursion of, 7.242
  fold of, 7.160–161
  hematoma of, in orbital roof fractures, 6.380, 6.380*f*
  laceration of, 7.214*f*
  measurements of, 7.242
  milia of, 7.189, 7.189*f*
  muscles of, 2.33–35
  orbital septum, 7.163
  paralysis of, 7.255–256
  in plexiform neurofibromas, 6.395–396
  ptosis of, 7.240
    in third nerve palsy, 6.138, 6.139*f*
  retraction of
    clinical features of, 7.253, 7.254*f*
    in thyroid eye disease, 6.140, 6.141*f*, 7.58
  trichiasis of, 7.239*f*
  vertical splitting of, 7.125–126
  von Graefe sign of, 7.25
Urate crystal deposition, in gout, 8.119, 8.188
Urate keratopathy/band keratopathy, 8.119, 8.188
Urea
  in aqueous humor, 2.275
  therapeutic uses of, 2.397–398, 2.398*t*
Urea-insoluble (membrane structural) lens proteins, 11.15*f*, 11.16–17
Urea-soluble (cytoskeletal) lens proteins, 2.285, 11.15*f*, 11.16–17
Ureaphil. *See* Urea
Ureaplasma urealyticum, 9.132
Urethritis, 1.255
Uric acid
  description of, 2.236
  in gout, 8.188
Uridine diphosphate (UDP) galactose 4-epimerase deficiency, galactosemia/cataract formation and, 11.61
Urinary sphincter disturbances, in multiple sclerosis, 5.317
Urinary stones, 2.392
Urinary tract infections, *Escherichia coli* as cause of, 12.238
Urine alkalinization, 2.392
Urokinase, 2.445

Urologic cancer screening, 1.221
Uroporphyrinogen decarboxylase deficiency, in porphyria, 8.190
Urrets-Zavalia syndrome, 5.263
Urticating hairs, ocular inflammation caused by, 8.387
US Pharmacopeia (USP), 2.372
US Preventive Services Task Force mammography recommendations, 1.217
Usher syndrome, 2.234, 2.313*t*
  clinical features of, 12.283*t*, 12.284
  description of, 12.259
  genes and loci associated with, 12.257*t*
  types of, 12.284
Ustekinumab, 1.180
Utricle, 5.38, 5.39*f*, 5.214, 5.215, 6.40
UV light. *See* Ultraviolet (UV) light
UV light/radiation. *See* Ultraviolet (UV) light
UVA. *See* Ultraviolet-A light
UVB. *See* Ultraviolet-B light
UVC. *See* Ultraviolet-C light
Uvea (uveal tract), 2.157, 2.269, 4.181–199, 4.200*f*. *See also specific structure*
  anatomy of, 2.49, 2.68*f*, 9.67
  anterior
    B cells in, 9.56
    immunologic microenvironment of, 9.52*t*
    metastasis to, 9.309
    T cells in, 9.56
  choroid. *See* Choroid
  ciliary body. *See* Ciliary body
  congenital anomalies of, 4.184, 4.184*f*
  connective tissue mast cells in, 9.3
  degenerations of, 4.188, 4.189*f*
  development of, 2.157
  disorders of, 4.181–199, 4.200*f*. *See also specific disorder*
    neoplastic, 4.189–199, 4.200*f*. *See also* Uvea (uveal tract), tumors of
  healing/repair of, 4.16
  infection/inflammation of, 4.185–187, 4.186*f*, 4.187*f*, 4.188*f*. *See also* Endophthalmitis; Uveitis
  inflammation of. *See* Uveitis
  iris. *See* Iris
  in leukemia, 4.315
  lymphoid proliferation/infiltration/lymphoma of (primary choroidal lymphoma), 4.199, 4.199*f*, 4.313–314
  melanocytoma of, 4.192, 4.257*f*, 4.258, 4.268
    melanoma differentiated from, 4.268
  melanoma of, 4.106, 4.106*f*, 4.192*f*, 4.192–197, 4.193*f*, 4.194*f*, 4.195*f*, 4.196*f*, 4.253, 4.262–279. *See also* Choroidal melanoma/ciliary body melanoma; Iris, melanoma of
    classification of, 4.194, 4.271–272, 4.272*t*
    clinical characteristics of, 4.262–263, 4.264*f*
    diagnosis of, 4.263*f*, 4.264*f*, 4.264–267, 4.266*f*, 4.267*f*
      differential, 4.267–271, 4.269*f*, 4.270*f*
    fine-needle aspiration biopsy in identification/evaluation of, 4.42, 4.43*f*, 4.253
    glaucoma caused by, 4.105*f*, 4.106, 4.194
    metastatic, 4.196, 4.272–274, 4.273*t*, 4.306
    ocular surface/conjunctival involvement and, 4.68, 4.69*f*, 8.343
    prognosis/prognostic factors for, 4.194–197, 4.273*t*, 4.277–279
    treatment of, 4.253, 4.274–277, 4.275*f*
  nevus involving, 4.191, 4.192*f*
  parts of, 2.64, 2.68*f*
  sarcoidosis involving, 4.186–187
  scleral attachment of, 2.66
  topography of, 4.181*f*, 4.181–183, 4.182*f*, 4.183*f*
  traumatic injury of, 4.18, 4.19*f*
  tumors of, 4.189–199, 4.200*f*. *See also specific tumor*
    metastatic, 4.197, 4.198*f*, 4.303, 4.304–306, 4.305*f*, 4.306*f*, 4.307*f*, 4.308*f*, 4.309*t*
      prognosis of, 4.309–310
    miscellaneous, 4.197–199, 4.198*f*, 4.200*f*
    pigmented, 4.279–280, 4.280*f*
Uveal (posterior) bleeding syndrome (polypoidal choroidal vasculopathy/PCV), 4.166*f*, 4.166–168, 4.167*f*
Uveal effusions/uveal effusion syndrome
  angle-closure glaucoma and, 10.138–139
  description of, 12.203, 12.204*f*
Uveal lymphoid hyperplasia, 9.308
Uveal lymphoid proliferation/infiltration/lymphoma (primary choroidal lymphoma), 4.199, 4.199*f*, 4.313–314
Uveal lymphoma, 12.234, 12.235*f*
Uveal melanocytic proliferation, bilateral diffuse, 9.309
Uveal melanoma, 9.308
Uveal thickening, 12.234, 12.235*f*
Uveal trabecular meshwork, 2.63, 10.17, 10.18*f*
Uveitic glaucoma
  angle-closure, 10.134, 10.139, 10.139*f*
  in infants and children, 10.149*t*
  after laser trabeculoplasty, 10.190
  open-angle, 10.100–102, 10.102*f*
  tube shunt/drainage device implantation for, 10.214
Uveitis, 4.185–187. *See also* Endophthalmitis; *specific type*
  acute
    anterior. *See* Anterior uveitis, acute
    definition of, 9.75
    signs and symptoms of, 9.71*t*
  ancillary testing for, 9.84–92, 9.86–87*t*, 9.88–89*f*
  animal models of, 9.61–62
  anterior. *See* Anterior uveitis
  anterior chamber paracentesis for, 9.90–92
  autoimmune. *See* Uveitis, noninfectious/autoimmune
  bacterial. *See* Bacterial uveitis
  band keratopathy caused by, 6.322
  in Behçet disease, 12.230
  biologic drugs for, 6.322
  birdshot
    characteristics of, 12.220*t*, 12.224–225, 12.225*f*
    uveal lymphoma and, 12.234
  blindness caused by, 9.68
  cataract surgery in, 6.323, 11.139–140
  cataracts and, 11.64*f*, 11.64–65, 11.188
    after cataract surgery, 11.139–140
    surgery in patients with, 11.64–65, 11.75, 11.140, 11.170–171, 11.188, 11.188*f*
  in children, 9.320
  chronic
    calcific band keratopathy associated with, 9.313
    definition of, 9.75–76

signs and symptoms of, 9.72*t*
systemic corticosteroids for, 9.102–103
classification of, 2.66, 6.311
anatomical, 9.68–75
clinical features, 9.75–76
Standardization of Uveitis Nomenclature system, 9.68–69, 9.69–70*t*, 9.77, 9.80*t*, 9.147
clinical features of, 9.75–76
CMV, 8.231–232, 8.232
complications of. *See also specific type*
calcific band keratopathy, 9.143*f*, 9.313
cataracts, 9.313–317
choroidal neovascularization, 9.324–325
epiretinal membranes, 9.323
glaucoma, 9.317–321
hypotony, 9.321
macular edema. *See* Uveitis, macular edema caused by
macular hole, 9.323
retinal neovascularization, 9.324–325
rhegmatogenous retinal detachment, 9.323–324
surgical treatment for, 6.322–323
vitreous opacification, 9.323–324
vitritis, 9.323–324
corticosteroids for, 6.320–321
adverse effects of, 9.94, 9.103, 9.143, 9.150
in children, 9.143
dose and duration of, 9.94, 9.102
intermediate, 9.149–150
intravitreal, 9.97–98, 9.102
local, 9.95
nonsteroidal anti-inflammatory drugs and, 9.103
osteoporosis prevention strategies, 9.103
periocular, 9.95–96, 9.96–97*f*
phacoantigenic, 9.137
sustained-release, 9.95
systemic, 9.102–103, 9.150
tapering of, 9.94
topical, 9.94–95, 9.130
definition of, 6.311, 9.67
descriptors of, 9.69*t*
diagnosis of, 6.319
ancillary testing in, 9.84–92, 9.86–87*t*, 9.88–89*f*
cytology, 9.91–92
fluid and tissue sampling tests, 9.90–91
history-taking for, 9.67, 9.83–84
imaging for, 9.67–68, 9.85–90, 9.88–89*f*
laboratory tests, 9.86–87*t*
patient factors in, 9.83*t*, 9.83–84
physical examination in, 9.67
signs, 9.77–83
differential diagnosis of, 6.312*t*, 9.84
diffuse. *See* Panuveitis
drug-induced, 9.139–140*f*, 9.139–141
Ebola virus as cause of, 1.264
endotoxin-induced, 9.8, 9.62
epidemiology of, 6.311, 9.68
equine recurrent, 9.62
evaluation of, 6.319, 9.71–74*t*
fluid and tissue sampling tests
antibody production, 9.91
ocular serology, 9.91
polymerase chain reaction tests, 9.90–91
Fuchs heterochromic (FHU/Fuchs heterochromic iridocyclitis/uveitis syndrome)
cataracts/cataract surgery and, 11.64*f*, 11.64–65
description of, 9.145–146, 9.146*f*
glaucoma and, 10.101–102, 10.102*f*
Goldmann-Witmer coefficient for, 9.41–42
keratic precipitates in, 9.248
medical management of, 9.93
glaucoma and, 10.100–102, 10.102*f*, 10.134, 10.139, 10.139*f*, 10.149*t*. *See also* Uveitic glaucoma; Uveitis-glaucoma-hyphema (UGH) syndrome
in children and adolescents, 10.149*t*
after laser trabeculoplasty, 10.190
tube shunt/drainage device implantation for, 10.214
glaucoma surgery in, 6.323
granulomatous, 9.76
HLA associations in, 9.63–66
HLA-B27 association with, 9.64
imaging tests for, 6.321*t*, 9.67–68, 9.85–90, 9.88–89*f*
color photography, 9.89
electroretinography, 9.90
enhanced depth imaging optical coherence tomography, 9.85, 9.88*f*
fluorescein angiography, 9.88, 9.89*f*
fundus autofluorescence, 9.89
indocyanine green angiography, 9.89
optical coherence tomographic angiography, 9.87
optical coherence tomography, 9.85, 9.88*f*
perimetry, 9.90
ultrasonography, 9.89–90
visual field testing, 9.90
immune recovery, 9.329, 12.235
immunomodulatory medications for, 2.404–406*t*
immunosuppressive therapy for, 6.321–322
indocyanine green angiography of, 12.38–39
infectious. *See* Infectious uveitis; *specific causative agent*
inflammation in, 6.320–322
intermediate. *See* Intermediate uveitis
intraocular lens–associated, 9.137–139, 9.138*f*
intraocular lymphoma and, 4.311, 12.233–234
ischemic, 5.170
laboratory tests for, 6.321*t*
lens-associated/phacoantigenic/phacolytic, 4.103, 4.103*f*, 4.118–119, 4.119*f*, 4.122, 11.66
hypopyon in, 9.6
types of, 9.136*f*, 9.136–137
in Lyme disease, 12.245
macular edema caused by
description of, 9.19, 9.321–322
fluorescein angiography of, 9.88, 9.89*f*
optical coherence tomography of, 9.85, 9.88*f*, 9.321
in phacoemulsification, 9.316
postoperative, 9.316
smoking as risk factor for, 9.321
treatment of, 9.322
masquerade syndromes for, 6.319, 6.320*t*
methotrexate for, 6.322
in multiple sclerosis, 5.318
Mycobacterium tuberculosis, 12.240
nongranulomatous, 9.76
noninfectious/autoimmune, 4.127, 4.128*f*. *See also specific cause*
vitreous infiltrate in, 4.127, 4.128*f*

ocular hypertension associated with, 9.317
panuveitis, 6.318*f*, 6.318–319
pediatric, 9.320
peripheral. *See* Pars planitis
phacoantigenic, 9.136–137
phacolytic, 9.136*f*, 9.136–137
posterior. *See* Posterior uveitis
postoperative
after cataract surgery, 11.139–140
infectious endophthalmitis. *See* Postoperative endophthalmitis
prevalence of, 9.68
Propionibacterium acnes causing, 11.162
prostaglandin analogues causing, 10.166
in reactive arthritis syndrome/Reiter syndrome, 8.305–306
recurrent, 9.76
sarcoidosis-associated, 4.186–187, 9.148
scleritis and, 8.323
signs of, 9.77–83, 9.78*t*, 9.79–82*f*, 9.80*t*, 9.82*t*
spondyloarthritis associated with, 1.157
Standardization of Uveitis Nomenclature system for, 9.68–69, 9.69–70*t*, 9.77, 9.80*t*, 9.147
sympathetic ophthalmia and, 4.185
symptoms of, 9.76, 9.77*t*
syndromes masquerading as, 9.84, 9.303–309. *See also* Masquerade syndromes
syphilitic, 9.84–85, 9.148, 12.241
in toxocariasis, 12.245
in toxoplasmosis, 4.147
traumatic, 8.389–390
treatment of, 6.320–322
carbonic anhydrase inhibitors, 9.113
corticosteroids. *See* Uveitis, corticosteroids for
cycloplegics, 9.113
goals for, 9.93
immunomodulatory therapy. *See* Immunomodulatory therapy, for uveitis
intravenous immunoglobulin, 9.113
mydriatrics, 9.113
nonsteroidal anti-inflammatory drugs, 9.113, 9.315
surgery, 9.113
undifferentiated, 9.84
vision rehabilitation in, 9.325
Vogt-Koyanagi-Harada syndrome and, 4.186
Uveitis-glaucoma-hyphema (UGH) syndrome, 9.10, 9.137–138, 10.108–109
IOL implantation and, 11.149
decentration and, 11.145
transient visual loss and, 5.164
Uveoretinitis, experimental autoimmune, 9.61–62
Uveoscleral drainage/outflow, 10.5*f*, 10.13, 10.19
drugs affecting, 10.165–166, 10.170, 10.178
Uveoscleral pathway, 2.60
Uvula, ventral, 5.39

V

V1 to V6 areas of brain. *See* Visual (calcarine/occipital/striate) cortex
V-neck sign, 1.167
V-pattern strabismus
bilateral superior oblique palsy and, 6.122
in Brown syndrome, 6.137
clinical features of, 6.109
clinically significant, 6.109
craniofacial anomalies and, 6.107
in craniosynostosis, 6.208
definition of, 6.107
etiology of, 6.107–109, 6.108*f*
exotropia with, 6.108*f*, 6.111
extorsion as cause of, 6.107, 6.110
heterotopy as cause of, 6.28
identification of, 6.109
infantile esotropia associated with, 6.109, 6.112
inferior oblique muscle overaction associated with, 6.107
palpebral fissure slanting associated with, 6.196
superior oblique palsy and, 6.122
surgical treatment of, 6.111–112, 6.112*t*
VA. *See* Vertebral artery
Vaccines/vaccinations. *See also* Immunizations; *specific type*
anterior uveitis caused by, 9.140
cancer treatment uses of, 1.242
cholera, 1.232
future types of, 1.232–233
Haemophilus influenzae, 1.231–232, 1.250
hepatitis B, 1.224, 1.226
hepatitis C, 1.226
human papillomavirus, 1.225*t*, 1.231–232, 1.236
influenza, 1.225*t*, 1.226–227
malaria, 1.232
measles/mumps/rubella, 1.225*t*, 1.228–229
meningococcal, 1.231
new types of, 1.232–233
pneumococcal pneumonia, 1.230–231
polio, 1.229
rabies, 1.232
rotavirus, 1.230
tetanus and diphtheria, 1.225*t*, 1.229–230
tuberculosis, 1.222
typhoid fever, 1.232
varicella-zoster, 1.225*t*, 1.227–228
yellow fever, 1.232
Vaccinia-immune globulin (VIG), 8.238
Vaccinia/vaccinia infection, 8.238
Vacuum (phacoemulsification), 11.98, 11.103
Vacuum, speed of light in, 3.43
Vacuum rise time (phacoemulsification), 11.102, 11.103
Vagus nerve stimulation (VNS), 1.208
Valacyclovir, 8.215*t*
for cytomegalovirus, 9.256
description of, 2.432*t*, 2.435
for herpes simplex virus, 1.260, 1.278, 8.215*t*, 8.219, 8.222, 9.249, 9.252
epithelial keratitis, 8.219
refractive surgery and, 13.174
stromal keratitis, 8.222
for herpes zoster, 8.229
for herpetic retinitis, 12.238*t*
varicella-zoster treated with, 1.261
Valcyte. *See* Valganciclovir

Valganciclovir, 1.278–279, 2.432*t*, 2.435, 8.215*t*
for CMV infection, anterior segment, 8.232
for herpes simplex virus infections, 8.215*t*
Valproic acid, 1.203, 1.207
Valsalva maneuver, 6.207
Valsalva retinopathy, 12.171
Valtrex. *See* Valacyclovir
Valtrex HZV. *See* Valacyclovir
Valve of Hasner, 6.230, 6.231*f*
anatomy of, 7.282–283
in congenital nasolacrimal duct obstruction, 7.283, 7.288–289
Valve of Rosenmüller, 6.228, 7.281, 7.281*f*, 7.289, 7.298
Valved tube shunts, 10.214, 10.214*t*
van der Waals forces, 2.331, 2.367
Van Herick method, 10.31–32
van Lint nerve block, for cataract surgery, 11.92, 11.93*f*
Vancomycin, 2.359, 2.360*t*, 2.418*t*, 2.426–427, 12.300
for bacterial keratitis, 8.270*t*
for chronic postoperative endophthalmitis, 9.293
Clostridium difficile treated with, 1.249
after corneoscleral laceration repair, 8.409
description of, 1.273–274
for endophthalmitis, after cataract surgery, 11.162
enterococcal infections resistant to, 1.274
resistance and, 8.244, 8.245
for staphylococcal infections, 8.244
Staphylococcus spp treated with, 1.247
Vancomycin-intermediate *Staphylococcus aureus* inflammatory scoring system, 7.58, 7.59*t*
Vancomycin-resistant enterococci (VRE), 8.245
Variable expressivity, 12.255
Variable-vessel vasculitis, 1.169*t*, 1.173–174
Variant angina pectoris, 1.83
Variant Creutzfeldt-Jakob disease (vCJD), 5.357
Variant lattice dystrophies, 8.135*t*, 8.146–147, 8.147*f*
Varicella (chickenpox), 1.260, 6.242–243, 8.225, 8.226, 9.247–248. *See also* Varicella-zoster virus
conjunctivitis in, 8.225, 8.226
Varicella keratouveitis, 8.226, 8.229
Varicella-zoster
characteristics of, 1.260–261
reactivation of, 1.260–261
vaccination for, 1.225*t*, 1.227–228
Varicella-zoster sine herpete, 5.298, 9.248
Varicella-zoster vaccine, 5.298, 8.229
Varicella-zoster virus (VZV), 6.242–243. *See also* Herpes zoster
acute retinal necrosis caused by, 9.252
anterior uveitis associated with, 9.247–250
conjunctivitis caused by, 8.225–230, 8.226*t*
dermatoblepharitis caused by, 8.208*t*, 8.225–230, 8.226*t*
immunization against, 8.229
infectious scleritis caused by, 9.124
latency/recurrence and, 8.205, 8.207, 8.225–226
necrotizing retinitis caused by, 12.236–237*f*, 12.236–237, 12.238*t*
ocular infection caused by, 8.208*t*, 8.225–230, 8.226*t*, 8.227*f*, 8.228*f*. *See also* Herpes zoster ophthalmicus
herpes simplex virus infection differentiated from, 8.225, 8.226*t*
progressive outer retinal necrosis caused by, 9.253, 9.253*f*
retinitis caused by, 4.145
skin lesions in, 9.248, 9.248*f*
Varices
orbital, glaucoma associated with, 10.30
vortex vein, 4.270*f*, 4.271
Vascular cells, 2.317–318
Vascular dementia, 1.210
Vascular disorders, 1.140–141
Vascular endothelial growth factor (VEGF)
antibodies against, 1.241
in aqueous humor, 2.277–278
choroidal neovascularization concentrations of, 12.80
in corneal angiogenesis/lymphangiogenesis, transplant rejection and, 8.317
description of, 2.448–449
in external eye defense, 8.12*f*
isoforms of, 12.80
in retinal ischemia, 4.152
in retinopathy of prematurity pathophysiology, 6.325, 6.326*t*
VEGF-A, 2.259, 2.278
in vitreous, 2.301
Vascular endothelial growth factor (VEGF) inhibitors, 9.310, 9.322. *See also* Anti-VEGF agents
for corneal transplantation rejection, 8.317
for ocular ischemic syndrome, 9.310
for uveitic macular edema, 9.322
Vascular endothelial growth factor receptors (VEGFRs)
description of, 2.277
VEGFR-1, 2.180, 2.278
VEGFR-2, 2.278
VEGFR-3, 2.278
Vascular eyelid disorders, 6.199
Vascular filling defects, in fluorescein angiography, 12.35
Vascular loops, prepapillary, 4.126
Vascular stroke. *See* Stroke
Vascular system
anatomy of, 5.11–23
arterial, 5.11–20, 5.13–14*f*, 5.15*f*, 5.16*f*, 5.17*f*, 5.18*f*, 5.20*f*
venous, 5.21*f*, 5.21–23, 5.22*f*, 5.23*f*
of anterior optic nerve, 10.44–46, 10.45*f*
of choroid, 4.139–140
retinal ischemia and, 4.140, 4.151, 4.151*f*
disorders of. *See also* Vasculitis/vasculitides
transient visual loss and, 5.163*t*, 5.164–171
imaging of, 5.60*f*, 5.67–71, 5.68*f*, 5.72*t*
of orbit, 5.12–14, 5.13–14*f*, 5.21, 5.21*f*
of retina, 4.139. *See also* Retina, blood vessels of
anomalies of, 4.143*f*, 4.143–144, 4.144*f*
ischemia and, 4.140, 4.151, 4.151*f*, 4.153*f*, 4.154, 4.155*f*
tumors arising in. *See* Vascular tumors
Vascular tufts, conjunctival papillae and, 8.47*f*, 8.47–48
Vascular tumors
of eyelid and conjunctiva, 8.345*t*, 8.345–348, 8.346*f*, 8.347*f*
benign, 8.345*t*, 8.345–347, 8.346*f*
inflammatory, 8.346*f*, 8.346–347
malignant, 8.347*f*, 8.347–348
of orbit, 4.233, 4.234*f*

Vascularized pannus, 8.52, 8.52*f*. *See also* Pannus/micropannus
Vasculature, retinal, 12.16*f*, 12.16–17
Vasculitis/vasculitides. *See also* Arteritis; *specific type*
antineutrophil cytoplasmic antibody–associated, 1.169*t*, 1.171–173
Behçet disease, 1.173–174, 4.187
choroidal, 1.171
classification of, 1.169*t*
Cogan syndrome, 1.174
eosinophilic granulomatosis with polyangiitis, 1.172
giant cell arteritis. *See* Giant cell arteritis
granulomatosis with polyangiitis, 1.171–172, 7.63–64, 7.64*f*
inflammatory, 12.230*t*, 12.230–231, 12.231*f*
Kawasaki disease, 1.171
large-vessel, 1.169*t*, 1.170
lupus, 12.230–231, 12.231*f*
medium-sized–vessel, 1.169*t*, 1.170–171
microscopic polyangiitis, 1.172–173
optic neuritis and, 5.115
overview of, 1.169–170
polyarteritis nodosa, 1.170–171, 7.65
retinal, 12.155*f*, 12.155–156
in uveitis. *See* Posterior uveitis
small-vessel, 1.169*t*, 1.171–173
Takayasu arteritis, 1.170, 9.125*t*, 11.68
transient visual loss caused by, 5.163*t*, 5.169–170
variable-vessel, 1.169*t*, 1.173–174
Vasculopathy
polypoidal choroidal (PCV/posterior uveal bleeding syndrome), 4.166*f*, 4.166–168, 4.167*f*
retinal vasculitis *versus*, 9.75
Vasculotropin, 2.49. *See also* Vascular endothelial growth factor
Vaso-occlusive necrotizing scleritis, 9.120, 9.121*f*
Vasoactive intestinal peptide, 9.24*t*
Vasoactive intestinal polypeptide (VIP), 2.249
in external eye defense, 8.12*f*
Vasocidin. *See* Prednisolone sodium phosphate/sulfacetamide sodium
Vasoconstrictors
for hay fever conjunctivitis, 8.288
for ocular allergies, 6.247*t*
Vasogenic edema, 2.461*t*
Vasopressin, 1.47, 1.301
Vasopressor drugs, 1.301
Vasospasm, retinal, transient visual loss and, 5.161, 5.162, 5.171
Vasovagal episodes. *See* Syncope
Vaughan Williams classification, of antiarrhythmic drugs, 1.102, 1.102*t*
VCAID. *See* Vitreous cavity–associated immune deviation
VCAN gene, 2.297
vCJD. *See* Variant Creutzfeldt-Jakob disease
VDA (Visual Disability Assessment), 11.71
VDRL. *See* Venereal Disease Research Laboratory
VECP (visual evoked cortical potential). *See* Visual evoked potential/cortical potential/response
Vecuronium, 2.382
Vegetation/plants, ocular injuries caused by, 8.387
corneal abrasions, 8.399
corneal foreign body, 8.387, 8.399
fungal keratitis and, 4.78, 8.273, 8.387, 8.399
VEGF. *See* Vascular endothelial growth factor(s)
VEGF Trap. *See* Aflibercept
VEGFR1 gene, 12.82
VEGFR2 gene, 12.82
VEGFRs. *See* Vascular endothelial growth factor receptors
Vein of Galen, 5.22
Vein of Labbé, 5.22
Veins, 5.21*f*, 5.21–23, 5.22*f*, 5.23*f*. *See also specific vein*
Velocardiofacial syndrome, 6.255
Velocity, saccadic, 5.219–220, 5.221
Velocity storage, unstable, periodic alternating nystagmus (PAN) and, 5.246
Venereal Disease Research Laboratory (VDRL), 9.224
Venography, 7.32
in cerebral venous thrombosis, 5.69, 5.69*f*, 5.346
computed tomography (CTV), 5.58, 5.70, 5.72*t*, 5.75
advantages/disadvantages of/contraindications for, 5.61*t*
in cerebral venous thrombosis, 5.346
magnetic resonance (MRV), 5.58, 5.69, 5.69*f*, 5.72*t*, 5.75
advantages/disadvantages of/contraindications for, 5.61*t*
in cerebral venous thrombosis, 5.69, 5.69*f*, 5.346
in idiopathic intracranial hypertension, 5.111
Venomous insect stings, ocular injury/infection caused by, 8.386–387
Venous beading, in nonproliferative diabetic retinopathy, 12.100*f*
Venous malformations
cavernous, 7.75–77, 7.76*f*
combined lymphatic, 7.74
distensible, 7.74–75, 7.75*f*
orbital
description of, 6.222
glaucoma associated with, 10.30
Venous occlusive disease, retinal. *See also* Retinal vein occlusion
branch retinal vein occlusion, 4.158–159
central retinal vein occlusion, 4.156–158, 4.158*f*
angle-closure glaucoma and, 10.143–144
neovascularization and, 10.134–135
open-angle glaucoma and, 10.84
Venous retrobulbar hemorrhage, 11.158. *See also* Retrobulbar hemorrhage
Venous sinuses, 2.136, 2.138, 2.138*f*
imaging in thrombosis of, 5.69, 5.69*f*
Venous stasis retinopathy (VSR), 5.170
Venous system, 5.21*f*, 5.21–23, 5.22*f*, 5.23*f*. *See also specific vein*
Venous thromboembolism
protein C deficiency in, 1.147
protein S deficiency in, 1.147
prothrombin G20210A and, 1.147
Venous thrombosis. *See also* Thrombosis/thrombotic disorders
cerebral (CVT), 5.345–346
in idiopathic intracranial hypertension, 5.111
neuroimaging in, 5.69, 5.69*f*, 5.72*t*, 5.346

Ventral uvula, 5.39
Ventricular contractility, 1.81
Ventricular dysfunction, 1.65
Ventricular fibrillation (VF), 1.104
Ventricular tachyarrhythmias, 1.104
Ventricular tachycardia, 1.104–105
Ventriculography, 1.89
Ventriculoperitoneal shunting, for idiopathic intracranial hypertension, 5.112, 5.113
Venturi pump, for phacoemulsification aspiration, 11.103, 11.104*f*
VEP/VECP/VER. *See* Visual evoked potential/cortical potential/response
VEPs. *See* Visual evoked potentials
Vergence equation
  definition of, 3.4, 3.42
  for dense media, 3.12
  derivation of
    for mirrors, 3.88–89
    from Snell's law, 3.85–86
  description of, 3.9–10, 3.51
  for mirrors, 3.81, 3.88–89, 3.89*f*
  negative numbers in, 3.10
  positive numbers in, 3.10
  problems involving, 3.53
  relocation of images and, 3.62
  schematic diagram of, 3.10*f*
Vergences/vergence system (eye movements), 5.212, 5.212*t*, 5.226–228, 6.40. *See also specific type*
  convergence, 6.39–40
  definition of, 3.4, 3.10, 3.42, 6.37, 6.39, 6.72
  description of, 3.9–10
  divergence, 6.40
  dysfunction of, 5.227–228
  fusional, 6.72, 6.72*t*
  image, 3.51
  object, 3.51
  reduced, 3.41, 3.51
Verhoeff–van Gieson stain, 4.31*t*
Vermis, 5.33, 5.34*f*, 5.40
Vernal conjunctivitis, 2.252
  mast cells in, 9.3
Vernal keratoconjunctivitis (VKC), 6.248–249, 6.248–249*f*, 8.289–292, 8.290*f*, 8.291*f*
  atopic keratoconjunctivitis differentiated from, 8.292–293, 8.293*f*
Vernier acuity, 3.131
Verocay bodies, 4.238, 4.239*f*
Verruca/verruca vulgaris (wart), 7.188, 7.188*f*
  of eyelid, 4.204, 4.205*f*
  papillomavirus causing, 4.204, 4.205*f*, 8.238
Versican, 2.297
Versions, 5.34–35, 5.35*f*. *See also specific type*
  definition of, 6.37
  deorsumversion, 6.37
  dextrocycloversion, 6.38
  dextroversion, 6.37
  in diplopia, 5.184
  in infantile esotropia, 6.37
  levocycloversion, 6.38
  levoversion, 6.37
  smooth-pursuit system and, 5.224
  sursumversion, 6.37
Vertebral artery (VA), 2.108*f*, 5.12, 5.13*f*, 5.19, 5.19*f*
  aneurysms of, 5.339*f*
  dissection of, 5.342
Vertebrobasilar system, 5.19*f*, 5.19–20. *See also* Basilar artery; Vertebral artery
  arterial dissections in, 5.342
  disorders of, 5.336–338, 5.337*f*
    transient visual loss caused by, 5.162, 5.336–337
Verteporfin. *See also* Photodynamic therapy
  central serous chorioretinopathy treated with, 12.194
  complications of, 12.380
  neovascular age-related macular degeneration treated with, 12.79
  polypoidal choroidal vasculopathy treated with, 12.76
  von Hippel–Lindau (VHL) disease/syndrome treated with, 12.167
Vertex, corneal, 8.25, 8.26*f*
Vertex distance, 3.148, 3.170–173, 3.171–172*f*
  measurement of before refractive surgery, 13.40
Vertex normal, 13.15
Vertexometer, 3.171, 3.171*f*
Vertical chopping techniques, in phacoemulsification, 11.114
Vertical deviations. *See also specific type and cause*
  characteristics of, 6.116
  clinical approach to, 6.115–116
  dissociated
    age at onset, 6.129
    clinical features of, 6.129, 6.129*f*
    definition of, 6.129
    description of, 6.17, 6.105, 6.111, 6.115–116
    hypertropia and, 6.115
    inferior oblique anterior transposition for, 6.166
    inferior oblique muscle overaction *versus*, 6.129–130
    management of, 6.130
  with horizontal comitance, 6.125–128
  with horizontal incomitance, 6.116–125
  inferior oblique muscle palsy
    Brown syndrome *versus*, 6.124, 6.125*t*
    clinical features of, 6.124, 6.124*f*, 6.125*t*
    management of, 6.124–125
  monocular elevation deficiency, 6.125–127, 6.126*f*
  orbital floor fractures, 6.127–128, 6.128*f*
  overdepression in adduction
    causes of, 6.17, 6.116*t*, 6.116–118
    description of, 6.17
    pattern strabismus and, 6.107, 6.108*f*, 6.109
    superior oblique muscle overaction as cause of, 6.118, 6.118*f*
  overelevation in adduction
    causes of, 6.17, 6.116*t*, 6.116–118
    description of, 6.17
    inferior oblique muscle overaction as cause of, 6.117*f*, 6.117–118
    pattern strabismus and, 6.107, 6.108*f*, 6.109
  skew deviation, 6.125
  superior oblique muscle palsy
    bilateral, 6.122–124
    causes of, 6.119
    clinical features of, 6.119–122
    congenital *versus* acquired, 6.119
    description of, 6.69

hypertropia associated with, 6.123
inhibitional palsy of contralateral antagonist, 6.120–121, 6.121*f*
management of, 6.122–124, 6.123*t*
masked bilateral, 6.122
neuroimaging evaluations, 6.119
right, 6.120–121*f*
surgical management of, 6.122–124, 6.123*t*
3-step test for, 6.120
unilateral, 6.119–121, 6.120–121*f*, 6.122–123, 6.123*t*
V-pattern strabismus associated with, 6.109
thyroid eye disease as cause of, 6.140
Vertical fusional vergence, 6.72
Vertical gaze
description of, 5.36*f*, 5.36–37
palsy of, 5.228–229
Vertical gaze deviation, seizures and, 1.208
Vertical heterophoria, 3.197
Vertical nystagmus, 6.152
Vertical palpebral fissure, 7.242
Vertical phoria, 3.184
Vertical prism dissociation test, in nonorganic disorder evaluation, 5.303, 5.303*f*
Vertical rectus muscles. *See also* Inferior rectus (IR) muscle; Superior rectus (SR) muscle
anatomy of, 6.20, 6.22*f*
eyelid attachments to, 6.30*f*
insertion of, 6.22
surgery of
for nystagmus, 6.156
for pattern strabismus correction, 6.111
vertical strength of, 6.35
Vertical retraction syndrome, 6.135
Vertical rotations, 6.31
Vertical strabismus, 6.15–16. *See also* Vertical deviations
Vertigo
benign paroxysmal positional, nystagmus and, 5.242–243
vertebrobasilar insufficiency causing, 5.336, 5.337*f*
vestibular nystagmus and, 5.241, 5.241*t*
Vertometer. *See* Lensmeter
Very-low-density lipoproteins (VLDLs), 1.72
Vesicle
of eyelid, 8.45*t*
lens, formation of, 11.25, 11.26*f*
optic, lens development and, 11.25, 11.26*f*
Vestibular nerve/nuclei (VN), 5.34*f*, 5.35, 5.36*f*, 5.38–39
disruption to, 5.216*f*, 5.216–218
nystagmus and, 5.215, 5.241, 5.243
horizontal gaze and, 5.37, 5.38
output of, 5.38–39, 5.39*f*
vertical gaze and, 5.36, 5.36*f*
Vestibular neuronitis, peripheral vestibular dysfunction and, 5.242
Vestibular nystagmus, 5.215, 5.234*f*, 5.241*t*, 5.241–246, 5.243*t*, 5.245*f*
central, 5.216, 5.243*t*, 5.243–246, 5.245*f*
instability (periodic alternating/PAN), 5.243*t*, 5.245–246, 6.149
peripheral, 5.216, 5.241*t*, 5.241–243
Vestibular-ocular reflex (VOR) gain, 5.215–216
in toxic vestibular dysfunction, 5.243
Vestibular-ocular system/vestibular-ocular reflex (VOR), 5.38–39, 5.39*f*, 5.212, 5.212*t*, 5.214–218, 5.216*t*, 6.40. *See also* Vestibular nerve/nuclei
dysfunction of, 5.215, 5.216*f*, 5.216–218
nystagmus and. *See* Vestibular nystagmus
optokinetic system/nystagmus and, 5.218
smooth-pursuit system and, 5.225, 5.225*f*, 5.226
suppression of, 5.225, 5.225*f*
Vestibular schwannoma, Bruns nystagmus and, 5.243
Vestibulocerebellum, 5.39–40
downbeat nystagmus caused by lesions of, 5.244
Vexol. *See* Rimexolone
VF. *See* Ventricular fibrillation
VF-14 (Visual Function Index), 11.71
Vfend. *See* Voriconazole
VFI. *See* Visual Field Index
VHL. *See* von Hippel–Lindau (VHL) disease/syndrome
VHL disease. *See* von Hippel–Lindau (VHL) disease/syndrome
VHL gene, 4.144, 6.399
Vicious circle theory of dry eye syndrome, 2.254, 2.256*f*
Vidarabine, 8.215*t*
description of, 2.432*t*
for herpes simplex virus infections, 8.215*t*, 8.219
Video magnifiers, 3.310, 3.323, 3.324*f*
Videokeratography, IOL power determination/selection after refractive surgery and, 11.86
Videokeratoscopy, 8.28*f*, 8.35*t*. *See also* Keratoscopy
in keratoconus, 8.28, 8.167*f*
Vidian canal, 5.11
Vidian nerve, 5.54, 5.56, 5.276–277*f*
Vieth-Müller circle, 6.41
VIEW 1 study, 12.83
VIEW 2 study, 12.83
VIG. *See* Vaccinia-immune globulin
Vigabatrin, 1.209, 6.399, 12.305
Vigamox. *See* Moxifloxacin
Vimentin, 2.285, 11.16
Vincristine, for retinoblastoma, 4.299
VIP. *See* Vasoactive intestinal polypeptide
Vira-A. *See* Vidarabine
Viral capsid, 8.211, 8.212
Viral conjunctivitis, 6.241–243, 6.243–244*f*
Virchow's law, 6.203, 6.205*f*
Viridans streptococci. *See Streptococcus, viridans*
Virology, 8.208*t*, 8.211–212. *See also* Viruses
Viroptic. *See* Trifluridine
Virtual images
definition of, 3.42
formation of, 3.11, 3.11*f*
Maddox rod and, 3.75, 3.75*f*
real images *versus*, 3.61
Virtual objects
definition of, 3.42
real objects *versus*, 3.61
Virulence (microbial), 8.206–207
Viruses, 8.208*t*, 8.211–212. *See also specific organism or type of infection*
cancer associated with, 1.236, 1.237*t*
conjunctivitis caused by, 4.52
DNA, 1.236, 1.237*t*
eyelid infection caused by, 4.204
neuritis/neuroretinitis caused by, 5.113, 5.118

ocular infection/inflammation caused by, 8.208*t*, 8.211–241
adherence and, 8.207
corneal opacity and, 8.16*f*
isolation techniques for diagnosis of, 8.211
specimen collection for diagnosis of, 8.209*t*
optic nerve infection caused by, 4.244
retinal infection caused by, 4.145, 4.146*f*
RNA, 1.236, 1.237*t*
treatment of infection caused by. *See* Antiviral agents
Visceral larval/larvae migrans (VLM), 6.317, 8.253, 12.244. *See also Toxocara* (toxocariasis)
Visceral toxocariasis, 9.283
Viscocanalostomy, 9.319, 10.217–219
Viscodissection, 11.115. *See also* Viscoelastic agents
for advanced cataract, 11.180
in zonular dehiscence with lens subluxation or dislocation, 11.182
Viscoelastic agents (ophthalmic viscosurgical/OVDs), 8.405*f*, 8.406, 11.95–97
for cataract surgery, 11.95–97
advanced cataract and, 11.180
aniridia and, 11.184
capsular block syndrome and, 11.148
capsular rupture during surgery and, 11.142–143
ECCE, 11.197
high hyperopia and, 11.185
ICCE, 11.200
inflamed eye and, 11.191
intumescent cataract and, 11.179–180
IOL implantation and, 11.116, 11.117–118
in keratoconjunctivitis sicca, dry eye therapy before use of, 11.173
phacoemulsification, 11.105, 11.109, 11.110, 11.112, 11.115, 11.116, 11.117–118
posterior polar cataract and, 11.181
pupil expansion and, 11.178
selection of, 11.97
traumatic cataract and, 11.191, 11.192
uveitis and, 11.191
zonular dehiscence with lens subluxation or dislocation and, 11.182
elevated intraocular pressure and, 10.108, 11.136
for goniotomy and trabeculotomy, in children, 10.162–163
phakic IOL implantation and, 13.141
posterior chamber lenses, 13.143
physical properties of, 11.96
toric IOL implantation and, 13.152
Viscoelasticity, of ophthalmic viscosurgical device, 11.96
Viscomydriasis, 11.97
Viscosity, 2.357
of ophthalmic viscosurgical device, 11.96
Viscosurgical devices, ophthalmic (OVDs). *See* Viscoelastic agents (ophthalmic viscosurgical/OVDs)
Visine-A. *See* Naphazoline hydrochloride/pheniramine maleate
Vision
awareness of, disorders of, 5.178*t*, 5.180–181
binocular. *See* Binocular vision
color. *See* Color vision
defects in. *See* Color vision, defects in
decreased. *See also* Low vision; Vision loss/impairment
evaluation of, 6.187–188
development of
abnormal visual experience effects on, 6.44–47, 6.45–46*f*
amblyopia and, 6.53
description of, 6.44
in young infants, 6.185
difficulties in, 3.312
diurnal fluctuation in, after radial keratotomy, 13.51
double. *See* Diplopia
intraocular lens–related vision disturbances in, 3.255–256, 3.256*f*
island of, in perimetry, 5.84
loss of/low. *See* Blindness; Low vision; Vision loss/impairment
neurophysiology of, 6.43–52
VISION 2020, 11.6
Vision charts
Bailey-Lovie, 3.133, 6.8
for children, 3.38. *See also* Visual acuity, in children
distance from patient to, 3.149
Early Treatment Diabetic Retinopathy Study, 3.133, 3.133*f*, 6.8
ETDRS-type, with Sloan letters, 3.23*f*
pictorial representation of, 3.23*f*
Snellen
disadvantages of, 3.132–133
letters on, 3.131–134, 3.132*f*
optotypes, 3.133*f*, 3.134
Vision loss/impairment, 1.184. *See also* Blindness; Low vision; Visual acuity; Visual field defects; *specific type*
in acute idiopathic blind-spot enlargement, 5.100–101, 5.101*f*
in acute zonal occult outer retinopathy, 5.101
amblyopia as cause of, 6.53, 6.56
arterial dissection and, 5.162, 5.342
arteritic causes of, 12.195
assessment of, 5.77–97. *See also* Low vision, assessment of
nonorganic disorders and, 5.301–311, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*, 5.307*f*, 5.308*f*, 5.309*f*
awareness of, 5.178*t*, 5.180–181
bilateral/binocular, 5.77, 5.171–172
nonorganic disorders and, 5.306–308, 5.307*f*, 5.308*f*, 5.309*f*
branch retinal vein occlusion as cause of, 12.128
in cancer-associated retinopathy, 5.102
carotid dissection and, 5.162, 5.342
cataract and, 11.5, 11.69–71, 11.70*t*
indications for surgery and, 11.72–73
causes of, 12.346
in central retinal artery occlusion, 5.161, 12.143–144
in central retinal vein occlusion, 5.170
cerebral, 6.186–187
chiasmal lesions causing, 5.146–152
childhood glaucoma as cause of, 6.290
in children, 3.327
classification of, 5.99–159. *See also specific causative factor*
in cone dystrophies, 5.102

cortical, 6.186
in Creutzfeldt-Jakob disease, 5.357
delayed visual maturation, 6.186–187
in diffuse unilateral subacute neuroretinitis, 12.246
after endothelial keratoplasty (DMEK/DSEK), 8.438–440
functional. *See* Vision loss/impairment, nonorganic
fungal endophthalmitis as cause of, 12.239
in glaucoma, 10.7, 10.82, 10.84, 10.117. *See also* Visual field defects, in glaucoma
in children, 10.158, 10.166–167
race and, 10.82
after trabeculectomy, 10.199
hallucinations and (Charles Bonnet syndrome), 5.177–178
in idiopathic intracranial hypertension, 5.110–113, 5.111*t*
in infants, 6.186–187
in infants and children. *See* Low vision, in children
in leukemia, 4.315, 4.316
management of, 5.99–159. *See also specific causative factor*
media abnormality causing, 5.99, 5.164
monocular/unilateral, 5.77, 5.161, 5.163*t*, 5.163–171. *See also* Monocular transient visual loss
nonorganic disorders and, 5.302–305, 5.303*f*, 5.304*f*, 5.305*t*
in optic neuritis, 5.113
in multiple evanescent white dot syndrome, 5.101
in neuroretinitis, 5.118*f*, 5.118–119
nonorganic, 5.299*t*, 5.299–312
afferent visual pathways and, 5.301–305, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*
clinical profile of patient with, 5.300
examination techniques in, 5.301–311, 5.302*f*, 5.303*f*, 5.304*f*, 5.305*t*, 5.307*f*, 5.308*f*, 5.309*f*
eyelid position/function and, 5.310–311
malingering and, 5.299
management of, 5.311
ocular motility/alignment and, 5.309–310
organic disorders misdiagnosed as, 5.299, 5.299*t*
pupils/accommodation and, 5.301, 5.310
in nystagmus, 5.235–236, 5.243*t*, 5.247
ophthalmologist's role in, 3.311
in optic neuritis, 5.107*t*, 5.113–118, 5.114*f*, 5.117*t*, 5.317
in optic neuropathy, 5.103–146. *See also* Optic neuropathy
AION, 5.119
arteritic (AAION), 5.120, 5.121*f*
nonarteritic (NAION), 5.91*f*, 5.120*t*, 5.121*f*, 5.122, 5.123
infiltrative, 5.131
versus maculopathy, 5.99–103, 5.100*t*
traumatic, 5.139–140
in optic perineuritis, 5.119
orbital surgery as cause of, 7.133
in papilledema, 5.105–113, 5.107*t*, 5.108*f*, 5.109*f*, 5.110*f*, 5.111*t*
after parasellar tumor therapy, 5.150, 5.151
pregeniculate, 6.186–187
prevalence of, 3.311
pupillary abnormalities and, 5.253–267
quality of life affected by, 3.311
retinopathies causing. *See specific type*
retrochiasmal lesions causing, 5.152–158
retrogeniculate, 6.186
in reversible cerebral vasoconstriction syndrome, 5.346
rhegmatogenous retinal detachment as cause of, 12.128
in sarcoidosis, 5.327
scleritis as cause of, 9.128
spousal effects of, 3.327
symptoms associated with, 5.78
in thyroid eye disease, 5.131, 5.132*f*
time course of, 5.77–78
in toxocariasis, 12.245
after trabeculectomy, 10.199
transient, 2.474*t*, 5.161–172. *See also* Transient visual loss
traumatic, 5.139–140
with clear media, 7.119, 7.121
unilateral/monocular, 5.77, 5.161, 5.163*t*, 5.163–171. *See also* Monocular transient visual loss
nonorganic disorders and, 5.302–305, 5.303*f*, 5.304*f*, 5.305*t*
in optic neuritis, 5.113
in uveal lymphoid proliferation/infiltration, 4.313
vitreous hemorrhage as cause of, 12.346
Vision loss (see-saw) nystagmus, 5.243*t*, 5.247
Vision rehabilitation, 5.159, 6.188–189, 6.189*t*
in age-related macular degeneration, 3.315
for blindness, 3.325
in cataracts, 11.71
ocular trauma and, 11.193
definition of, 3.310
for field loss, 3.325–326
low vision evaluations. *See* Low vision
model of, 3.328*f*
ongoing eye care during, 3.328
patient's goals for, 3.312
psychological counseling included with, 3.327
resources for, 3.329
services added to, 3.327–329
in Stevens-Johnson syndrome (Stevens-Johnson syndrome/toxic epidermal necrolysis overlap and toxic epidermal necrolysis), 8.298
training in, 3.325
in uveitis, 9.325
visual function assessment and. *See* Low vision, assessment of
Vision Rehabilitation for Adults, 3.311
Vismodegib, 7.205
Vistech chart, 3.316*f*
Vistide. *See* Cidofovir
Visual acuity. *See also* Best-corrected visual/Snellen visual acuity; Distance visual acuity; Near visual acuity; Uncorrected/uncorrected distance visual acuity; Vision loss/impairment
in AION, 5.119
arteritic (AAION), 5.120, 5.120*t*
nonarteritic (NAION), 5.120*t*, 5.122, 5.123
in amblyopia
description of, 6.5
refractive surgery and, 13.185–186

assessments of
for amblyopia diagnosis, 6.56
in children. *See* Visual acuity, in children
in nystagmus, 6.153–154
in cataract, 11.69–70, 11.70*t*
indications for surgery and, 11.72–73
preoperative evaluation and, 11.75–76, 11.76
after cataract surgery, 11.126
cystoid macular edema and, 11.163, 11.164
with ECCE, 11.198
endophthalmitis and, 11.161, 11.162
with ICCE, 11.201
incorrect lens power and, 11.85
with manual small-incision surgery, 11.198–199
multifocal IOLs and, 11.121–122
in central serous chorioretinopathy, 12.190
in children, assessment of
age-specific approaches, 6.5
alternative methods, 6.8–9
Central, Steady, and Maintained method of, 6.6
eye charts for, 6.6*t*, 6.6–8, 6.7*f*
fixation and following behavior for, 6.5
fixation behavior, 6.5–6
HOTV test, 6.6, 6.6*t*, 6.7*f*
induced tropia test, 6.6
in nystagmus, 6.8
occluders used in, 6.8
optotypes for, 6.6*t*, 6.6–8, 6.7*f*
preferential looking, 6.5, 6.8–9, 6.9*f*, 6.182, 6.300
preverbal children, 6.8–9, 6.154
sequence of, 6.8
symbol charts for, 6.7
visual evoked potential for, 6.9, 6.182, 6.300
clinical measurement of. *See* Refraction, clinical; Visual acuity, testing
in congenital glaucoma, 10.158
corneal crosslinking and, 13.131
corneal inlays and, 13.61
description of, 3.131–134
development of, 6.182
dynamic, vestibular-ocular reflex evaluation and, 5.216
after endothelial keratoplasty (DMEK/DSEK), 8.438–440
femtosecond laser corneal intrastromal treatment and, 13.168
flap folds/striae and, 13.112, 13.113, 13.114*t*, 13.115
in giant cell arteritis/AAION, 5.120, 5.120*t*
hard contact lens method for IOL power calculation and, 13.195
hyperopia correction and, 13.94
intrastromal corneal ring segment placement and, 13.64, 13.67
for keratoconus, 13.66
irregular astigmatism affecting, 13.17
after keratoprosthesis implantation, 8.452
LASIK and
for amblyopia/anisometropic amblyopia, 13.186
in diabetes mellitus, 13.190
flap folds/striae and, 13.112, 13.113, 13.114*t*, 13.115
for hyperopia/hyperopic astigmatism, 13.97
for mixed astigmatism, 13.97
for myopia, 13.95, 13.97
after penetrating keratoplasty, 13.180
after retinal detachment surgery, 13.185
in Leber hereditary optic neuropathy, 5.133
in low vision, 5.78
photostress testing and, 5.88
with monovision, 13.39, 13.164–165
in morning glory disc anomaly, 6.363
with multifocal IOLs, 13.155–156
myopia correction and, 13.95
in neuromyelitis optica, 5.320
in neuroretinitis, 5.118
in newborn, 6.44
in nystagmus, 5.235
in optic atrophy, 5.135
in optic nerve hypoplasia, 5.143
in optic neuritis, 5.115
in optic neuropathy *versus* maculopathy, 5.99, 5.100*t*
patient expectations/motivations for refractive surgery and, 13.35–36, 13.36, 13.47
after penetrating and perforating ocular trauma, 8.401
with phakic IOLs, 13.144
photorefractive keratectomy and, 13.95
pinhole, 3.124, 3.130
positive visual phenomena and, 5.173
radial keratotomy and, 13.50–51, 13.51–52
ranibizumab effects on, 12.80
refractive lens exchange and, 13.150
after small-incision lenticule extraction, 13.205
Snellen, 3.124, 3.131, 3.132*f*, 3.134
stereoacuity/stereopsis relationship and, 5.305, 5.305*t*
subnormal, 3.25
testing of. *See also* Refraction, clinical
cataract surgery and, 11.75–76, 11.76
in children, 3.38, 10.158
conversion chart for, 3.132*t*
eye charts for, 3.22, 3.23*f*. *See also* Eyecharts
fixation during, 3.313
in low vision evaluations, 3.313
in low vision/vision rehabilitation, 5.78
in manifest refraction process, 3.22–25
at near, 3.24
nonorganic disorders and, 5.306
photostress testing and, 5.88
pinhole occluder used in, 3.23–24, 3.24*f*
refractive surgery and, 13.39–40
amblyopia and, 13.185
Snellen chart for, 3.131, 3.132*f*
terminology used in, 3.131
toric IOL implantation and, 13.152–153
undercorrection after photoablation and, 13.102
wavefront-guided/wavefront-optimized ablation and, 13.32
Visual aids. *See also* Low vision aids
in nonorganic disorder evaluation, 5.306
Visual allesthesia, 5.180
Visual aura. *See* Aura
Visual axis, 3.125, 6.41
Nd:YAG laser capsulotomy location and, 11.155
Visual confusion, 6.47, 6.47*f*
Visual (calcarine/occipital/striate) cortex, 5.24*f*, 5.29*f*, 5.29–31, 5.30*f*, 5.32*f*, 5.34*f*, 6.46*f*
disorders of, 5.158, 5.178*t*, 5.178–181

hallucinations and, 5.158, 5.176–178
illusions and, 5.175
recognition disorders and, 5.178*t*, 5.179, 5.180*f*
vision/visual deficit awareness disorders and, 5.178*t*, 5.180–181
visual-spatial relationship disorders and, 5.178*t*, 5.180
ocular motor control and, 5.32*f*, 5.32–33, 5.34*f*
vascular supply of
arterial supply, 5.20, 5.20*f*
venous drainage, 5.22*f*, 5.22–23, 5.23*f*
Visual confusion, 6.47, 6.47*f*
Visual cycle, 2.326, 2.327*f*
Visual deficits. *See also* Low vision; Vision loss/impairment
disorders of awareness of, 5.178*t*, 5.180–181
Visual deprivation
abnormal visual experience caused by, 6.44
amblyopia
causes of, 6.55
congenital cataracts as cause of, 6.55
congenital nevocellular nevi as cause of, 6.200
corneal blood staining as cause of, 6.379
critical period for, 6.53
reverse amblyopia, 6.55–56
monocular, 6.44, 6.45*f*
Visual Disability Assessment (VDA), 11.71
Visual disorders, 1.191
Visual evoked potential/cortical potential/response (VEP/VECP/VER), 5.95
in low vision evaluation, 5.95
in nonorganic disorder evaluation, 5.302
Visual evoked potentials (VEPs)
albinism evaluations, 12.288
in children, 12.53
delayed, 12.52–53
demyelinating optic neuritis findings, 12.52
description of, 12.52
flash, 12.52
flash stimulation for, 12.53
in nystagmus, 12.53
optic nerve conduction delay diagnosis with, 12.52
pattern-appearance stimulation, 12.53
pattern electroretinography and, 12.45–46
pattern-reversal, 12.52, 12.53*f*
for visual acuity assessment in preverbal children, 6.9, 6.182, 6.300
Visual evoked response. *See* Visual evoked potential/cortical potential/response
Visual field. *See also* Visual field defects
central, 3.315, 3.317, 5.85, 5.85*f*
clinical evaluation of. *See* Visual field testing
cloverleaf, 10.66, 10.66*f*
cortical areas corresponding to, 5.28, 5.29*f*
normality/abnormality of, perimetry interpretation and, 10.62–65, 10.64*f*, 10.65*f*
peripheral, 3.318
quality/reliability of, perimetry interpretation and, 10.62
silent, nonorganic disorder evaluation and, 5.308
Visual field defects
in acute zonal occult outer retinopathy, 12.227
age/aging affecting, 10.81
in AION, 5.119
nonarteritic (NAION), 5.91*f*, 5.122, 5.123*t*
arteriovenous malformations causing, 5.291, 5.343, 5.344*f*
central, 5.85, 5.85*f*
chiasmal lesions causing, 5.146–147, 5.147*f*, 5.148*f*
in congenital tilted disc syndrome, 5.144, 5.144*f*
congruous, 5.29
retrochiasmal lesions producing, 5.153
occipital lobe lesions, 5.156, 5.157*f*
cortical areas/lesions and, 5.28, 5.29*f*
evaluation of, 5.83–88, 5.85*f*, 5.87*f*. *See also* Perimetry; Visual field testing
in glaucoma, 10.59
cataract/media opacities and, 11.186, 11.186*f*
evaluation of, 10.59–77
patterns of loss and, 10.67–69, 10.68*f*, 10.69*f*, 10.70*f*
serial fields/progression and, 10.71–75, 10.72*f*, 10.73*f*, 10.74*f*
single field and, 10.62–67, 10.64*f*, 10.65*f*, 10.66*f*, 10.67*f*
indications for surgery and, 10.197
normal-tension glaucoma and, 10.86
optic nerve/nerve head/disc changes correlated with, 10.74–75
primary open-angle glaucoma (POAG) and, 10.79–80
screening tests for, 10.62
incongruous, 5.29
retrochiasmal lesions producing, 5.153
lateral geniculate body lesions causing, 5.154, 5.154*f*
in Leber hereditary optic neuropathy, 5.133, 5.134*f*
in migraine aura without headache, 5.291
in migraine headache, 5.171–172, 5.290–291
in multiple sclerosis, 5.318
in neuromyelitis optica, 5.320
as nonorganic disorders, 5.306–308, 5.307*f*, 5.308*f*, 5.309*f*
occipital lobe lesions causing, 5.156–158, 5.157*f*, 5.158*f*, 5.159*f*
in optic atrophy, 5.135, 5.136*f*
in optic nerve hypoplasia, 5.143
optic nerve/nerve head/disc drusen causing, 5.141*f*, 5.141–142
in optic neuritis, 5.114, 5.114*f*, 5.123*t*
in optic neuropathy, 5.103, 5.104*f*, 5.105*t*, 5.106*f*
versus maculopathy, 5.99, 5.100, 5.100*t*
optic tract lesions causing, 5.147*f*, 5.153
in papilledema, 5.107, 5.110, 5.110*f*
parietal lobe lesions causing, 5.84, 5.156
perimetric terms and, 5.105*t*
in retrochiasmal lesions, 5.146, 5.153
in reversible cerebral vasoconstriction syndrome, 5.346
in sarcoidosis, 5.327
in stroke, 5.153, 5.156, 5.157, 5.157*f*, 5.158*f*
temporal lobe lesions causing, 5.155, 5.155*f*
in thyroid eye disease, 5.131, 5.132*f*
in tilted disc syndrome, 5.144, 5.144*f*
in toxic/nutritional optic atrophy, 5.137, 5.138*f*
in vertebrobasilar insufficiency, 5.336

Visual Field Index (VFI)/VFI field progression plot, in visual field progression identification, 10.72–74, 10.74*f*
Visual field testing, 5.83–88, 5.85*f*, 5.87*f*, 6.10, 7.243
Amsler grid, 5.84
in aura evaluation, 5.291
before cataract surgery, 11.82
confrontation testing, 5.83–84
in hemispatial neglect, 5.181
in glaucoma, 10.59–77. *See also* Perimetry
artifacts and, 10.66*f*, 10.66–67, 10.67*f*
interpretation in
patterns of field loss and, 10.67–69, 10.68*f*, 10.69*f*, 10.70*f*
of serial fields/progression, 10.71–75, 10.72*f*, 10.73*f*, 10.74*f*
of single field, 10.62–67, 10.64*f*, 10.65*f*, 10.66*f*, 10.67*f*
optic nerve/nerve head/disc changes correlated with, 10.74–75
screening tests in, 10.62
ultrasound biomicroscopy in, 10.77
in low vision patients/vision rehabilitation, 5.83–88, 5.85*f*, 5.87*f*
in nonorganic disorder evaluation, 5.306–308, 5.307*f*, 5.308*f*, 5.309*f*
perimetry, 5.84–88, 5.85*f*, 5.87*f*. *See also* Perimetry
in uveitis, 9.90
Visual function
assessments of
central visual field, 3.315, 3.317
contrast sensitivity, 3.314–315
fixation, 3.313*f*, 3.313–314
peripheral visual field, 3.318
refraction, 3.314, 3.315*f*
visual acuity measurements, 3.313, 3.313*f*
improving. *See* Vision rehabilitation
measuring. *See also* Low vision, assessment of
in cataract evaluation, 11.71
after surgery, 11.126
before surgery, 11.71, 11.72, 11.76–77
indications for surgery and, 11.72
central visual field assessment and, 5.85, 5.85*f*
reduced. *See* Low vision; Vision loss/impairment
Visual Function Index (VF-14), 11.71
Visual history, in manifest refraction process, 3.25
Visual loss/impairment. *See* Vision loss/impairment
Visual neglect, in parietal lobe lesions, 5.84
Visual pathways, 5.5–56. *See also* Retinogeniculocortical pathway
afferent, 5.23–31, 5.24*f*. *See also* Afferent visual pathways
anatomy of, 2.115, 2.116*f*
autonomic pathways and, 5.52–56
parasympathetic, 5.52, 5.54–56, 5.55*f*
sympathetic, 5.52–54, 5.53*f*
blood supply of, 2.119–122, 2.120–122*f*, 2.121*f*, 2.122*t*
bony anatomy of head and, 5.5–11, 5.6*f*, 5.7–8*f*, 5.9*f*, 5.10*f*
central, 6.44
development of, 6.44
efferent (ocular motor), 5.31–46, 5.211. *See also* Ocular motility, control of; Ocular motor pathways
electrophysiologic and psychophysical testing in evaluation of. *See specific test*
locations of lesions of, 5.147*f*
sensory and facial motor pathways, 5.47–52
vascular anatomy of, 2.121*f*, 2.122*t*, 5.11–23
arterial, 5.11–20, 5.13–14*f*, 5.15*f*, 5.16*f*, 5.17*f*, 5.18*f*, 5.20*f*
venous, 5.21*f*, 5.21–23, 5.22*f*, 5.23*f*
visual evoked potential testing in evaluation of, 5.95
white matter of, 6.44
Visual phenomena, persistent positive, 5.177, 5.201, 5.290
Visual processing stream, dorsal, 5.224
Visual prosthesis, 3.310
Visual (optic) radiations (geniculocalcarine pathways), 5.18*f*, 5.19, 5.24*f*, 5.29, 5.30
lesions of, 5.153, 5.155
in multiple sclerosis, 5.318
Visual rehabilitation. *See* Vision rehabilitation
Visual resolution. *See* Resolution
Visual-spatial relationships, disorders of, 5.178*t*, 5.180
Visual stimulus deprivation amblyopia, 6.55. *See also* Visual deprivation, amblyopia
Visual task performance, 3.318–319
VIT1, 2.298
Vitamin A
deficiency of, 8.196–197, 8.197*f*, 12.261, 12.289–290
corneal changes in, 8.196–197, 8.197*f*
Corynebacterium xerosis and, 8.196–197, 8.246
illusions caused by, 5.175
in retinal pigment epithelium, 2.326–328, 2.327*f*
Vitamin B_2 (riboflavin), in corneal crosslinking, 13.130–131, 13.132–134, 13.133*f*
Vitamin B_6 (pyridoxine), for homocystinuria, 11.41
Vitamin B_{12} deficiency
anemia caused by, 1.133
folate deficiency *versus*, 1.134
optic neuropathy caused by, 5.138
Vitamin C. *See also* Ascorbic acid
for chemical injuries, 8.383
corneal wound healing and, 13.33
in phototherapeutic keratectomy, 8.367
Vitamin E, 2.340, 2.342, 2.344*f*
Vitamin K
deficiency of, 1.145
functions of, 1.145
Vitamin K antagonists
for coronary heart disease, 1.90*t*
direct oral anticoagulants *versus*, 1.149
Vitamin K–dependent factors, 1.139
Vitamin supplements, 2.447
Vitamins
for age-related macular degeneration, 12.69, 12.70*t*
deficiencies of
cataracts caused by, 11.63
optic neuropathy caused by, 5.138
supplementary, cataract prevention and, 11.7, 11.20
therapeutic uses of, 2.236
Vitelliform degenerations. *See* Vitelliform macular dystrophy

Vitelliform exudative macular detachment, 12.272, 12.274*f*
Vitelliform macular dystrophy (VMD)
adult-onset, 4.170, 4.171*f*
description of, 12.32
electro-oculography findings in, 12.51
Vitelliform macular dystrophy *(VMD2/BEST1)* gene, 6.340–342, 10.11*t*, 12.271
Vitiliginous chorioretinitis. *See* Birdshot uveitis
Vitrasert. *See* Ganciclovir
Vitreal syneresis, 6.344
Vitrectomy, 2.302
angle-closure glaucoma after, 10.143
for capsular rupture during cataract surgery, 11.142, 11.143
cataract/cataract surgery after, 11.20, 11.55, 11.75, 11.190
complications of, 12.402*t*, 12.402–403
for cystoid macular edema, postoperative, after cataract surgery, 11.165
cystoid macular edema treated with, 12.159, 12.393, 12.394*f*
delayed, 12.360
diabetic macular edema treated with, 12.388
diabetic retinopathy complications treated with, 12.107
diagnostic, 9.92, 9.298
for endophthalmitis, postoperative, 11.162
epiretinal membranes treated with, 12.382, 12.383
for hemolytic/ghost cell glaucoma, 10.106
idiopathic macular holes treated with, 12.384–385, 12.385*f*
immediate, 12.359
indications for, 12.359, 12.381
instrumentation used in, 12.381–382
in intraocular lymphoma, 4.312
for IOL decentration/dislocation, 11.145
for malignant/ciliary block glaucoma (aqueous misdirection), 10.141
needle perforation/penetration of globe treated with, 12.396
open-angle glaucoma risks secondary to, 12.402
open-globe injuries treated with, 12.359–360
oxidative lens damage and, 11.20
pars plana. *See* Pars plana vitrectomy
posterior vitreous detachment treated with, 12.333*f*, 12.359
posteriorly dislocated intraocular lenses treated with, 12.393
postoperative endophthalmitis treated with
acute-onset, 12.388–390, 12.390*f*
bleb-associated, 12.390–391, 12.391*f*
chronic (delayed-onset), 12.390, 12.391*f*
in primary central nervous system lymphoma, 4.312
for retained lens fragments after phacoemulsification, 11.141, 12.391–393, 12.392*f*
for retinal detachment
cataract surgery/IOL insertion and, 11.166
refractive surgery after, 13.185
rhegmatogenous, 12.324, 12.400*f*, 12.400–401
for retinopathy of prematurity, 6.335, 12.187
smaller-gauge instrumentation used in, 12.382
submacular hemorrhage treated with, 12.385, 12.386*f*
suprachoroidal hemorrhage treated with, 12.394–395, 12.395*f*
technique for, 12.381
tractional retinal detachment treated with, 12.325, 12.387–388
in uveal lymphoid proliferation/infiltration, 4.314
visualization aids used in, 12.381–382
for vitreocorneal adherence/persistent corneal edema, 11.130
vitreous hemorrhage treated with, 12.366, 12.386–387
vitreous opacities treated with, 12.348, 12.386
for vitreous prolapse, 11.142, 11.143–144
Vitrectorhexis, 6.302
Vitreocorneal adherence, after cataract surgery, 11.130
Vitreolysis
enzymatic, 2.304
Nd:YAG laser
for cystoid macular edema, after cataract surgery, 11.165
for vitreous prolapse in anterior chamber, 11.143
Vitreomacular adhesions, 12.336, 12.336*t*
Vitreomacular traction (VMT) syndrome
description of, 12.332, 12.332*f*, 12.336*t*, 12.336–337, 12.337*f*
epiretinal membranes *versus*, 12.382–383
vitrectomy for, 12.382–384, 12.384*f*
Vitreopapillary traction, optic nerve/nerve head/disc edema differentiated from, 5.107
Vitreoretinal adhesions, 12.337
Vitreoretinal interface
description of, 2.296, 2.300
disorders of. *See specific type*
Vitreoretinal/retinal (primary central nervous system/intraocular) lymphoma, 4.135*f*, 4.135–137, 4.136*f*, 4.311*f*, 4.311–313, 4.313*f*, 5.349, 12.233–234. *See also* Primary central nervous system/intraocular/vitreoretinal/retinal lymphoma
cytologic studies for, 9.91
primary. *See* Primary vitreoretinal lymphoma
Vitreoretinal surgery. *See also* Vitrectomy
angle-closure glaucoma after, 10.143
after refractive surgery, 13.197
Vitreoretinal tufts, 12.311–312, 12.312*f*
Vitreoretinopathies. *See also specific type*
cataract surgery in patient with, 11.189
familial exudative, 6.347–348, 6.348*f*
juvenile retinoschisis. *See* Retinoschisis, X-linked
Knobloch syndrome, 6.346*f*, 6.346–347
Norrie disease, 6.347
proliferative (PVR), 4.20, 4.21*f*, 4.131, 4.131*f*
Stickler syndrome, 6.345–346
Vitreoschisis. *See* Vitreous detachment
Vitreous, 4.125–137
age-related changes in, 2.278, 2.300–304
amyloidosis involving, 4.134*f*, 4.134–135
anatomy of, 2.102*f*, 4.125, 12.7–9, 12.8*f*, 12.331
as angiogenesis inhibitor, 2.301
ascorbate levels in, 12.9
attachments of, 12.7
biopsy of
for endophthalmitis after cataract surgery, 11.162
indications for, 9.91–92

for primary central nervous system/intraocular/vitreoretinal/retinal lymphoma, 4.135–136, 4.136*f*, 4.312
technique for, 9.92
for uveal lymphoid proliferation/infiltration, 4.314
canals in, 12.7
cataract surgery complications and
endophthalmitis, 11.161
with ICCE, 11.200
posterior vitreous detachment, 11.166
prolapse, 11.142, 11.143–144
vitreocorneal adherence, 11.130
chondroitin sulfate in, 2.297
cisterns in, 12.7
collagen fibers in, 12.7, 12.344
age-related breakdown of, 2.300
description of, 2.101, 2.294–297, 2.295–296*f*
proteins associated with, 2.298
type II, 9.56
composition of, 2.273*t*, 2.294–300, 12.7, 12.331
congenital anomalies of, 4.125–127, 4.126*f*, 4.127*f*
cortical, 2.296
cysts of, 4.126–127
cytomegalovirus retinitis findings, 12.235
definition of, 12.331
degeneration of, 4.128–135, 4.129*f*, 4.130*f*, 4.131*f*, 4.132*f*, 4.133*f*, 4.134*f*, 12.344
detachment of. *See* Vitreous detachment
development of, 2.157, 2.158*f*, 2.293, 4.125
abnormalities of, 4.125–127, 4.126*f*, 4.127*f*
persistent fetal vasculature, 12.341–342
prepapillary vascular loops, 12.341, 12.341*f*
tunica vasculosa lentis, 12.340–341
disorders of, 4.125–137. *See also specific type*
neoplastic, 4.135*f*, 4.135–137, 4.136*f*
enhanced depth imaging optical coherence tomography of, 12.25
familial exudative vitreoretinopathy of, 12.343–344, 12.345*f*
functions of, 2.101
genetic diseases involving, 2.302, 2.304
healing/repair of, 4.17
hereditary hyaloideoretinopathies with optically empty vitreous, 12.342–343, 12.343*f*
hyalocytes in, 2.299*f*, 2.299–300, 12.7
hyaluronan in, 2.297
illustration of, 2.102*f*
immunologic microenvironment of, 9.52*t*, 9.56
infection/inflammation of, 2.302, 4.127, 4.128*f*. *See also* Endophthalmitis; Intermediate uveitis; Vitritis
in leukemia, 4.315
liquefaction of, 2.300–301, 12.316–317, 12.344
low-molecular-weight solutes in, 2.298–299
magnetic resonance imaging of, 2.459*t*, 2.460*f*
myopia effects on, 2.301
opacities/opacification in
amyloidosis, 4.134, 12.348, 12.349*f*
asteroid hyalosis, 12.346*f*, 12.346–347
bilateral, 12.348
cholesterolosis, 12.348
pigment granules, 12.348
from uveitis, 9.323–324
vitrectomy for, 12.386
vitreous degeneration and detachment associated, 12.344
vitreous hemorrhage, 12.347
oxygen movement in, 2.302, 2.303*f*
peripheral, 2.296
polymerase chain reaction testing of, in uveitis evaluations, 9.90–91
posterior attachments of, 2.103*f*
primary, 2.157, 2.159*f*, 2.293, 4.125
primary persistent hyperplasia of (PHPV). *See* Persistent fetal vasculature
proteins in, 2.298
retinal cavernous hemangioma bleeding into, 12.168
secondary, 2.157, 2.158*f*, 2.293, 4.125
soluble proteins in, 2.298
specimen collection from/tap/biopsy of. *See* Vitreous, biopsy of
surgery-related abnormalities of, 12.349–350
syneresis of, 12.307, 12.316
tertiary, 2.157, 2.158*f*, 2.293, 4.125
topography of, 4.125
traction, 12.208
tumors of, 4.135*f*, 4.135–137, 4.136*f*
in uveitis. *See* Intermediate uveitis
vitrectomy effects on, 2.302
void of, 12.7
zonular fibers in, 2.298, 4.125
Vitreous base, 2.101, 2.102*f*
avulsion of, 12.315, 12.316*f*, 12.331
posterior border of, 12.10
posterior vitreous detachment and, 4.130, 4.130*f*
retinal dialyses at, 12.315
vitreous gel attachment to, 12.307
Vitreous block. *See also* Ciliary block glaucoma
after cataract surgery, 11.139
Vitreous body, 2.48, 2.49*t*
anatomy of, 12.8*f*
anterior surface of, 12.7, 12.8*f*
topographic areas of, 12.7
Vitreous cavity
anatomy of, 2.48
ascorbate in, 2.302, 2.303*f*
description of, 2.101
Vitreous cavity–associated immune deviation, 2.299
Vitreous cells
grading scheme for, 9.82, 9.82*t*
in intermediate uveitis, 9.81, 9.82*f*
Vitreous detachment
hallucinations and, 5.175
perifoveal, 12.337
posterior, 2.300, 2.301*f*
posterior (PVD), 4.128–129, 4.129*f*
age-related, 12.307–308
anatomy of, 12.331
atrophic holes presenting with, 12.318
cholesterolosis and, 12.348
conditions associated with, 12.307
definition of, 12.331
diagnosis of, 12.331
epiretinal membranes. *See* Epiretinal membranes
examination of, 12.309
fibroglial tissue in, 12.331

floaters associated with, 12.308–309
idiopathic macular holes, 12.337–339, 12.338*f*
imaging of, 12.308*f*
indirect ophthalmoscopy of, 12.309, 12.331
management of, 12.309
myopia macular retinoschisis in, 12.209
nonproliferative diabetic retinopathy progression affected by, 12.102
optical coherence tomography of, 12.309, 12.332
in pars plana vitrectomy for diabetic macular edema, 12.115
pathologic conditions caused by, 12.332
photopsias associated with, 12.308
prevalence of, 12.331
retinal breaks associated with, 12.309
retinal detachment after cataract surgery and, 11.166
retinal tears caused by, 12.307, 12.308*f*, 12.309
risk factors for, 12.309
signs and symptoms of, 12.308
slit-lamp biomicroscopy of, 12.331
vitrectomy for, 12.333*f*, 12.359
vitreomacular adhesions, 12.336, 12.336*t*
vitreomacular traction syndrome, 12.332, 12.332*f*, 12.336*t*, 12.336–337, 12.337*f*
vitreous hemorrhage associated with, 4.133, 12.309
Vitreous gel
age-related changes in, 12.331
attachment of, to vitreous base, 12.307
composition of, 12.7
Vitreous haze, in intermediate uveitis, 9.81*f*, 9.81–82, 9.82*t*
Vitreous hemorrhage, 2.302, 4.132–133
in central retinal vein occlusion, 12.135
echography for, 12.347
hemolytic/ghost cell glaucoma and, 4.133, 10.105, 10.106
in pars planitis, 9.151
peripheral neovascularization, 12.232
photocoagulation as cause of, 12.379
in polypoidal choroidal vasculopathy, 12.75
posterior vitreous detachment and, 12.309
in proliferative diabetic retinopathy, 12.103, 12.103*f*, 12.107–108, 12.386–387
trauma-related, 12.357
treatment of, 12.309
in Valsalva retinopathy, 12.171
vision loss caused by, 12.346
vitrectomy for, 12.366, 12.386–387
Vitreous humor, 2.48, 2.101
Vitreous pressure, positive, flat or shallow anterior chamber and, 11.134
Vitreous seeds, in retinoblastoma, 4.292, 4.293*f*
Vitreous tap, for specimen collection. *See* Vitreous, biopsy of
Vitreous veils, 6.344
Vitritis, 4.127. *See also* Endophthalmitis
chorioretinitis with, 9.72–73*t*
description of, 9.148
in intraocular (primary central nervous system) lymphoma, 4.135, 4.311
Lyme disease in, 9.229, 9.229*f*
in multiple sclerosis, 5.318
uveitis as cause of, 9.323–324
Vittaforma/Vittaforma corneae, 8.252
corneal infection caused by, 8.280–281
VKC. *See* Vernal keratoconjunctivitis
VKH. *See* Vogt-Koyanagi-Harada (VKH) disease/syndrome
VKH disease. *See* Vogt-Koyanagi-Harada (VKH) disease/syndrome
VKH syndrome. *See* Vogt-Koyanagi-Harada (VKH) disease/syndrome
VLDLs. *See* Very-low-density lipoproteins
VLM. *See* Visceral larval/larvae migrans
VMAs. *See* Vitreomacular adhesions
VMD. *See* Vitelliform macular dystrophy
VMD2 (vitelliform macular dystrophy/*BEST1*) gene, 6.340–342, 10.11*t*, 12.271
VMT. *See* Vitreomacular traction (VMT) syndrome
VN. *See* Vestibular nerve/nuclei
VNS. *See* Vagus nerve stimulation
Vogt
palisades of, 8.10
white limbal girdle of, 8.120, 8.120*f*
Vogt-Koyanagi-Harada (VKH) disease/syndrome, 4.186, 6.319, 12.232*f*, 12.232–233
acute secondary angle-closure glaucoma associated with, 9.318
acute uveitic stage of, 9.205, 9.205*f*
chronic recurrent stage of, 9.207
convalescent stage of, 9.205–206
definition of, 9.204
diagnosis of, 9.206–210, 9.208*t*, 9.209–210*f*
differential diagnosis of, 9.210
enhanced depth imaging optical coherence tomography in, 9.85, 9.88*f*
fluorescein angiography findings in, 9.208–209, 9.209*f*
histologic findings in, 9.204
HLA association with, 9.65*t*
HLA-DR4 and, 9.204
incidence of, 9.204
indocyanine green angiography in, 9.209
integumentary changes in, 9.206
lumbar puncture for, 9.209
manifestations of, 9.205–207, 9.205–207*f*
nivolumab-induced, 9.140*f*
optical coherence tomography findings in, 9.209, 9.210*f*
prodromal stage of, 9.205
prognosis for, 9.211
Sugiura sign in, 9.206, 9.207*f*
sunset-glow fundus in, 9.204, 9.206, 9.207*f*
sympathetic ophthalmia *versus*, 9.203
treatment of, 9.211
ultrasonography of, 9.209
Vogt striae, 6.254
in keratoconus, 8.162*f*, 8.163, 8.164*f*
Vogt triad, 6.397
Volitional saccades, 5.219, 5.220
in progressive supranuclear palsy, 5.221
testing, 5.221
Voltaren. *See* Diclofenac sodium
Volume rendering
B-scans *versus*, 12.27
macular telangiectasia on, 12.31
Voluntary convergence/vergence, 5.226, 6.40
Voluntary flutter, 5.249–250, 5.309

Voluntary "nystagmus," 5.249–250, 5.309
Vomiting. *See* Nausea and vomiting
von Basedow disease. *See* Hyperthyroidism; Thyroid eye disease
von Graefe knife, 11.90
von Graefe sign, 7.25
von Hippel internal ulcer, 4.74, 4.75*f*, 6.259
von Hippel–Lindau (VHL) disease/syndrome, 2.228, 4.144, 4.144*f*, 4.284–285, 5.330, 5.331*f*, 5.334*t*, 6.393*t*, 6.399–401, 6.400*t*, 6.400*f*, 12.165–168, 12.166–167*f*. *See also* Retinal angiomatosis
von Kossa stain, 4.31*t*
von Recklinghausen disease/neurofibromatosis. *See* Neurofibromatosis 1
von Willebrand disease (vWD), 1.144–145
von Willebrand factor (vWF), 1.144–145
VOR. *See* Vestibular-ocular system/vestibular-ocular reflex
VOR gain. *See* Vestibular-ocular reflex (VOR) gain
Voretigene neparvovec, 2.196
Voretigene neparvovec-rzyl, 9.58
Voriconazole, 1.277, 2.430*t*
  for *Acanthamoeba* keratitis, 8.279
  for *Candida* fungal postoperative endophthalmitis, 9.298
  for coccidioidomycosis, 9.302
  fungal endophthalmitis treated with, 12.239
  for fungal keratitis, 8.275
  yeast endophthalmitis treated with, 12.240
Vortex (hurricane) keratopathy (cornea verticillata), 8.90, 8.129*t*, 8.130, 8.176, 8.177*f*
  in chloroquine/hydroxychloroquine toxicity, 8.130
  in Fabry disease, 6.270, 8.176, 8.177*f*
Vortex veins, 2.22, 2.24*f*, 2.26, 5.21
  in choroid, 12.19
  extraocular muscles supplied by, 6.23
  surgical considerations for, 6.30
  varix of, 4.270*f*, 4.271
Vorticose veins, 5.21*f*
Vossius ring, 4.18, 11.53
VRE. *See* Vancomycin-resistant enterococci
VSR. *See* Venous stasis retinopathy
VT. *See* Ventricular tachycardia
Vulnerable populations, 1.4
vWD. *See* von Willebrand disease
vWF. *See* von Willebrand factor
Vyzulta. *See* Latanoprostene bunod
VZV. *See* Varicella-zoster virus

W

Waardenburg-Jonkers corneal dystrophy. *See* Thiel-Behnke corneal dystrophy
Waardenburg syndrome, 2.206, 12.282*t*
  description of, 6.270
  type 1, 6.191, 6.192*f*
Wagner disease, 12.342–343
Wagner hereditary vitreoretinal degeneration, 12.282*t*
Wagner syndrome, 2.302, 2.304
WAGR syndrome, 2.225, 6.267, 10.155, 11.33
Waite-Beetham lines, 8.41, 8.199
Waldenström macroglobulinemia, crystalline corneal deposits in, 8.198, 8.199*f*
Wall-eyed bilateral internuclear ophthalmoplegia (WEBINO), 5.189, 5.190*f*
  in multiple sclerosis, 5.318
Wallenberg syndrome (Wallenberg lateral medullary syndrome), 5.20, 5.180, 5.217, 5.337
  Horner syndrome and, 5.260*t*, 5.337
  MRI in, 5.64*f*
Wallerian degeneration, optic nerve, 4.245–246
Wandering nystagmus, 12.266
Warfarin/warfarin derivatives
  cataract surgery in patient taking, 11.171
  cessation of, before ocular surgery, 1.286
  genetic testing used in dosing of, 1.140
  indications for, 1.150
  ocular adverse effects of, 1.309*t*
  therapeutic uses of, 1.149–150
Wart (verruca/verruca vulgaris)
  of eyelid, 4.204, 4.205*f*
  papillomavirus causing, 4.204, 4.205*f*, 8.238
Wasp stings, ocular injury caused by, 8.386–387
Watchful waiting. *See* Observation
Water and electrolyte balance, in lens, maintenance of, 11.21, 11.22*f*
Water channels (aquaporins), 11.16, 11.20–21
Water-insoluble lens proteins, 11.15, 11.15*f*
  aging affecting, 11.17
Water molds, 8.251
Water-soluble lens proteins, 11.15, 11.15*f*. *See also* Crystallins
  conversion of, to water-insoluble, 11.17
Water transport, in retinal pigment epithelium, 12.18
Watershed defects, 12.198
Watershed zone, 2.120
Watt, 3.106
Watts per square centimeter (W/cm^2), 3.108
Watts per unit area (W/m^2), 3.108
Wave–particle duality of light, 3.94
Wave theory of light, 3.94–95, 3.95*f*
Wavefront(s)
  definition of, 3.42, 3.94
  geometric, 3.70–71, 3.274
  in myopia, 3.73, 3.73*f*
  pictorial representation of, 3.94*f*
Wavefront aberrations. *See also* Aberrations; Wavefront analysis; *specific type*
  coma, 3.40, 3.275*f*, 3.275–276, 13.9, 13.12, 13.12*f*, 13.103*f*
  definition of, 3.274, 3.289
  description of, 3.70–74, 3.71–74*f*
  first-order, 13.11
  fourth-order, 3.276*f*, 13.12, 13.12*f*
  graphical representations of, 13.9–10, 13.10*f*
  higher-order, 13.11–13, 13.12*f*, 13.13*f*
    after LASIK, 13.11, 13.12, 13.102–103, 13.103*f*
    after surface ablation, 13.11, 13.12, 13.13, 13.102
    topography-guided laser ablation and, 13.32, 13.77
    wavefront-guided/wavefront-optimized ablation and, 13.13, 13.31–32, 13.76–77
  hyperopia producing (negative defocus), 13.11
  irregular astigmatism, 13.17–19, 13.18*f*, 13.19*f*. *See also* Irregular astigmatism

keratorefractive surgery and, 13.9–13, 13.10*f*, 13.11*f*, 13.12*f*, 13.13*f*
lower-order, 13.11, 13.11*f*
measurement of, 13.9–10, 13.10*f*
myopia producing (positive defocus), 13.11, 13.11*f*
piston, 13.11
postoperative, 13.102–103, 13.103*f*
prisms, 13.11
pupil position and, 3.275–276
ray tracing for, 3.277
regular astigmatism, 13.17, 13.18*f*. *See also* Regular astigmatism
second-order, 3.276*f*, 13.11, 13.11*f*
spherical, 13.9, 13.12, 13.12*f*, 13.102
after LASIK, 13.12, 13.102
after radial keratotomy, 13.50
after surface ablation, 13.12, 13.102
surfaces of, 3.277
third-order, 3.276*f*, 13.12, 13.12*f*
trefoil, 13.9, 13.12, 13.13*f*, 13.103*f*
types of, 3.275–276, 3.276*f*
Zernike polynomials, 3.277
zero-order, 13.11
Wavefront aberrometry/aberrometers, 3.289–292, 3.290–291*f*. *See also* Wavefront analysis
intraoperative, in IOL power determination/selection
astigmatism and, 11.124
after refractive surgery, 11.86
Wavefront analysis, 13.9–13, 13.10*f*, 13.11*f*, 13.12*f*, 13.13*f*, 13.46. *See also* Wavefront aberrations
definition of, 3.268
Fermat principle as basis of, 3.274
graphical representations and, 13.9–10, 13.10*f*
IOL power determination/selection after refractive surgery and, 13.194
of irregular astigmatism, 3.273–277, 3.274–276*f*
before LASIK, 13.80
after photoablation, 13.102–103, 13.103*f*
reference sphere in, 3.274, 3.274*f*
before wavefront-guided ablation, 13.31, 13.46, 13.80
laser programming and, 13.31, 13.81
Wavefront-guided (custom) laser ablation, 13.31, 13.46, 13.76–77
higher-order aberrations and, 13.13, 13.31–32, 13.76–77
for LASIK re-treatment/enhancement, 13.99
for mixed astigmatism, 13.97
multifocal, 13.167, 13.168*f*
outcomes of, 13.31–32, 13.97
overcorrection and, 13.102
patient selection/relative contraindications and, 13.80
postoperative aberrations and, 13.13, 13.102
preoperative planning/laser programming for, 13.31, 13.46, 13.81
for presbyopia, 13.167, 13.168*f*
wavefront analysis before, 13.31, 13.46, 13.80
Wavefront-guided lasers, 13.31–32, 13.76–77
programming, 13.31, 13.81
Wavefront-mapping systems, 13.81
Wavefront-optimized laser ablation, 13.31, 13.76–77
higher-order aberrations and, 13.13, 13.31–32
outcomes of, 13.31–32, 13.97
postoperative aberrations and, 13.13, 13.102
Wavefront theory, 3.70–74
Wavelength
anterior segment and, 3.118
color associations with, 3.94*t*
laser, 3.115
of light, 3.93, 3.94*t*
Wavescan imaging, 13.21*f*
WDR36 gene, 10.11*t*
Weakening procedures
for inferior oblique muscle
bilateral, 6.165
indications for, 6.118
for superior oblique muscle palsy, 6.123, 6.123*t*
surgical procedures for, 6.164*t*, 6.165–166
for V-pattern strabismus, 6.111
for oblique muscles, 6.164*t*, 6.165–166
for rectus muscles, 6.163, 6.164*t*
Wear-and-tear pigment, 2.98–99
Weber syndrome, 5.191
WEBINO. *See* Wall-eyed bilateral internuclear ophthalmoplegia
Wedl (bladder) cells, 4.121, 4.121*f*, 11.48, 11.152
in phakomatous choristoma, 4.202, 4.203*f*
Wegener granulomatosis (granulomatosis with polyangiitis/GPA)
definition of, 9.158
description of, 1.171–172, 7.34, 7.63–64, 7.64*f*, 12.195, 12.196*f*
diagnosis of, 9.159–160
eyelid manifestations of, 4.207*t*
laboratory investigations for, 9.125*t*
manifestations of, 9.158–159, 9.159*f*
nasolacrimal duct obstruction associated with, 7.306, 7.306*f*
necrotizing scleritis in, 9.120*f*
ocular involvement in, 9.159
optic neuritis and, 5.115
treatment of, 9.160
vision loss in, 9.159
Weight, IGF-1, neonatal ROP (WINROP) algorithm, 12.182
Weight loss
hypertension managed with, 1.58*t*
for idiopathic intracranial hypertension, 5.112
Weight management, coronary heart disease risk modification using, 1.73*t*
Weil disease, 9.232
Weill-Marchesani syndrome, 6.309, 11.33
microspherophakia in, 10.130, 11.33
Weiss ring, 12.308*f*
Welch-Allyn retinoscope, 3.150–151, 3.160
Well-differentiated pleomorphic tumors, 6.217
Well-differentiated squamous cell carcinoma, of eyelid (keratoacanthoma), 4.209–210, 4.210*t*, 4.211*f*
Werner syndrome, 8.192*t*
Wernicke disease, 1.199
WESDR. *See* Wisconsin Epidemiologic Study of Diabetic Retinopathy
West African crystalline retinopathy, 12.303–304, 12.305*f*

West Nile virus (WNV)
chorioretinitis caused by, 12.246, 12.247*f*
description of, 9.263–264, 9.264*f*
Western blot analysis, in Lyme disease, 5.353
"Wet"/exudative age-related macular degeneration. *See* Neovascular ("wet"/exudative) age-related macular degeneration
Wettability, of contact lenses, 3.213, 3.213*f*
Wetting angle, 3.206, 3.213
Wheezing, 1.124
Whiplash injuries, 12.356–357
Whipple disease, 9.243–245, 9.244*f*
eye movement abnormalities in, 5.251
White blood cells (leukocytes). *See also specific type*
immunophenotyping of, flow cytometry for, 4.36
in inflammation, 4.7, 4.8*f*
White dot syndromes. *See also specific type*
acute posterior multifocal placoid pigment epitheliopathy, 12.220*t*, 12.221*f*, 12.221–222
acute zonal occult outer retinopathy *versus*, 9.192
birdshot uveitis, 12.220*t*, 12.224–225, 12.225*f*
characteristics of, 12.220*t*
definition of, 9.161
etiology of, 9.161, 9.165
fluorescein angiography of, 9.88
multifocal choroiditis, 12.220*t*, 12.225–226, 12.226*f*
multifocal choroiditis and panuveitis syndrome, 12.220*t*
multiple evanescent (MEWDS), 5.101, 12.220*t*, 12.223–224, 12.224*f*
fundus autofluorescence in identification of, 5.90
OCT in identification of, 5.92, 5.101
punctate inner choroidopathy, 12.220*t*
serpiginous choroidopathy, 12.220*t*, 12.222–223, 12.223*f*
White eye shunt syndrome, 5.201
White-eyed blowout fracture, 6.380
White limbal girdle of Vogt, 8.120, 8.120*f*
White Maddox rod, 5.184–185, 5.185*f*. *See also* Maddox rod/Maddox rod test
White-matter lesions
in multiple sclerosis, 5.318
neuroimaging in evaluation of, 5.72*t*
White pupil. *See* Leukocoria
White ring, Coats, 8.115, 8.116*f*
"White spot" (hypopigmented macule/ash-leaf spot), in tuberous sclerosis, 5.331*f*, 5.334*t*, 10.30
Whitnall ligament, 2.28*f*, 2.34–35*f*, 7.6, 7.164–166, 7.166*f*, 7.279
Whitnall tubercle, 2.10, 7.279
WHO. *See* World Health Organization
Whole-exome sequencing, 2.189
Whole-genome shotgun sequencing, 2.191*f*
Wide-angle fluorescein angiography
description of, 12.36, 12.37*f*
von Hippel–Lindau syndrome on, 12.167, 12.167*f*
Wide complex tachycardias, 1.102
Wilbrand knee, 5.27–28
Wilcoxon signed rank test, 1.7
Wildervanck syndrome, 6.131
Willis, circle of, 2.138–139, 2.139*f*, 5.18
subarachnoid hemorrhage from, 1.121
Wilms tumor
aniridia and, 4.184, 10.155, 11.33
aniridia *versus*, 2.226
Wilms tumor *(WT1)* gene, aniridia and, 10.155
Wilson disease (hepatolenticular degeneration), 1.136, 2.235, 6.270, 8.189*f*, 8.189–190, 11.62, 12.362
cataracts associated with, 8.189, 11.62
oculogyric crisis in, 5.231
penicillamine for, 8.189
Window defect, hyperfluorescence in, 12.36
WINROP algorithm, 12.182
Wipeout, after trabeculectomy, 10.199
Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), 12.92
With movement, in retinoscopy, 3.152, 3.153*f*, 3.155
"With-the-rule" astigmatism, 8.31*f*
definition of, 3.19, 3.125
description of, 3.139
minus cylinder lens correction of, 3.20*f*
schematic diagram of, 3.20*f*
Withdrawal (abstinence) syndrome. *See also specific drug*
hypertension caused by, 1.68–69
Wnt, 2.166
WNV. *See* West Nile virus
Wolbachia, 9.290
in onchocerciasis, 8.253
Wolf-Hirschhorn syndrome, 6.386*t*
Wolfflin nodules, 6.272
Wolfring, glands of, 4.202, 8.4*f*
Women
congestive heart failure in, 1.95
coronary heart disease in, 1.82
hypertension in, 1.67–68
Work of breathing, dyspnea and, 1.124
Working distance
bifocal segment decentration and, 3.191
in retinoscopy, 3.154
World Health Organization (WHO)
antibiotic-resistant pathogen prioritization by, 1.276–277
behavioral and neurologic disorder focus of, 1.193
cataract epidemiology and, 11.5
immunization guidelines of, 1.224
on lacrimal gland neoplasia classification, 4.229
on lymphoma classification, 4.231
Mental Health Gap Action Program, 1.194
Worm's-eye view, 7.24, 7.25*f*, 7.102*f*
Worth 4-dot test. *See also* Duochrome test
description of, 6.51–52, 6.80*f*, 6.80–81
in nonorganic disorder evaluation
monocular no light perception and, 5.303, 5.304*f*
monocular reduced vision and, 5.305
before refractive surgery, 13.39
Wound(s)
closure of, after cataract surgery
complications associated with, 11.130–131
after ECCE, 11.197–198
after ICCE, 11.200–201
postoperative endophthalmitis and, 11.161
contraction of, 4.13
eyelid/orbit scarring and, 4.17
dehiscence/rupture of, after cataract surgery, 11.131

healing/repair of, 4.13–23, 4.14*f*. *See also specific tissue*
of cornea, 4.13–16, 4.15*f*
keratorefractive surgery and, 13.32–33
delays in, 13.93–94, 13.108
of eyelid/orbit/lacrimal tissues, 4.17
histologic sequelae of trauma and, 4.17–23, 4.18*f*, 4.19*f*, 4.20*f*, 4.21*f*, 4.22*f*, 4.23*f*
of lens, 4.17
promotion of, in chemical injuries, 8.383–384
of retina, 4.17
of sclera, 4.16
of uvea, 4.16
of vitreous, 4.17
tetanus immunizations in, 1.230
Wound leaks
after cataract surgery, 11.118, 11.130–131
flat anterior chamber and, 11.135
angle-closure glaucoma and, 10.144–145
after penetrating keratoplasty, 8.423
after trabeculectomy, 10.209, 10.210, 10.211
Wound misalignment, after penetrating keratoplasty, 8.423
Wright-Giemsa stain, 4.31*t*
Wrong-site surgery, 1.288
WT1 (Wilms tumor) gene, 6.267
aniridia and, 10.155
Wyburn-Mason syndrome (Bonnet-Dechaume-Blanc syndrome/racemose angioma/hemangioma), 4.286*f*, 4.286–287, 5.331, 5.333*f*, 5.334*t*, 6.222, 6.394*t*, 6.405*t*, 6.405–406, 12.168

X

X-inactivation, 2.180
X-linked cone dystrophy, 12.253*f*
X-linked congenital stationary night blindness, 12.252
X-linked disorders. *See also* X-linked inheritance; *specific disorder*
Fabry disease, 8.176–178, 8.177*f*
gene therapy for, 2.194
Hunter syndrome, 8.175*t*
ichthyosis, 8.202
Lisch corneal dystrophy, 8.140
megalocornea, 8.96*t*
ocular findings in, 2.232*t*
X-linked inheritance. *See also* X-linked disorders
description of, 2.208
disorders associated with, 2.210
dominant, 2.209, 2.210*t*
recessive, 2.208–209, 2.209*t*
X-linked ocular albinism, 2.230
X-linked retinitis pigmentosa, electroretinography findings in, 12.50
X-linked retinoschisis (XLRS)
characteristics of, 12.278*f*, 12.278–279
electroretinography findings in, 12.46, 12.47*f*
X-pattern strabismus
clinical features of, 6.110
surgical treatment of, 6.113
Xalacom. *See* Latanoprost, in combination preparations; Latanoprost/timolol maleate
Xalatan. *See* Latanoprost
Xanthelasma, 4.206, 4.206*f*, 7.190, 7.190*f*. *See also* Xanthomas
in dyslipoproteinemia/hyperlipoproteinemia, 4.206, 4.207*t*
Xanthocoria, 6.360
Xanthogranuloma, 7.97
juvenile, 8.347
glaucoma associated with, 10.30
of iris, 4.187, 4.260
uveal tract/uveitis and, 4.187, 4.188*f*
necrobiotic, 8.347
Xanthomas
fibrous (fibrous histiocytoma), 8.347
malignant, 4.112
orbital, 4.235
scleral, 4.112, 4.113*f*
in hyperlipoproteinemias, 4.206, 4.207*t*
Xanthophylls (carotenoids)
description of, 3.119, 12.373, 12.374*f*
in macula, 4.140
Xanthopsia, 12.305
Xeroderma pigmentosum (XP), 2.181–182, 7.202, 7.202*f*, 8.202–203
ocular surface squamous cell carcinoma and, 8.336
Xerophthalmia, 8.196–197. *See also* Vitamin A, deficiency of
dry eye and, 8.54, 8.54*f*
Xerosis
Corynebacterium xerosis and, 8.196–197, 8.246
in vitamin A deficiency, 8.196, 8.197
Xibrom. *See* Bromfenac
XLM. *See* External limiting membrane
XLRS. *See* X-linked retinoschisis
XP. *See* Xeroderma pigmentosum
Xylocaine. *See* Lidocaine
XYZ hypothesis, 8.11

Y

Y-pattern strabismus
clinical features of, 6.109–110
surgical treatment of, 6.113
Y-shaped suture, 2.82
Y-sutures, lens, 11.13
development of, 11.28, 11.28*f*
opacification of (sutural/stellate cataract), 11.37, 11.37*f*
Y–V-plasty
for blepharophimosis–ptosis–epicanthus inversus syndrome, 7.174, 7.175*f*
for epicanthus tarsalis, 7.177, 7.178*f*
YAG lasers. *See* Laser(s)
Yeast endophthalmitis, 12.239–240, 12.240*f*
Yeasts, 5.353, 8.249, 8.249*t*, 8.250*f*, 8.250–251
Candida, 1.258, 1.278*t*
keratitis caused by, 8.208*t*, 8.251, 8.273, 8.274–275
as normal flora, 8.206*t*, 8.250
Yellow fever vaccination, 1.232
Yellow laser, 12.374

Yellow spot. *See* Macula/macula lutea
Yersinia pseudotuberculosis, 6.240
Yoke muscles, 6.38
  eccentric gaze and, 5.38
Young, Thomas, double-slit experiments by, 3.94, 3.101, 3.101*f*, 3.105

Z

z-height/*z*-maps, 13.22, 13.22*f*
Z-plasties, for blepharophimosis–ptosis–epicanthus inversus syndrome, 7.174, 7.175*f*
Z syndrome, 11.151
Zaditor. *See* Ketotifen fumarate
Zanamivir, 1.279
Zeaxanthin, 2.94
  age-related macular degeneration managed with, 12.70*t*
  cataract risk affected by, 11.7
  description of, 12.367
ZEB1 gene, in posterior polymorphous corneal dystrophy, 8.136*t*
Zeis, glands of, 4.201, 8.4, 8.4*f*
  chalazion and, 4.204, 4.206*f*
  chalazion/hordeolum and, 8.76, 8.77
  hordeolum and, 4.203–204
  sebaceous adenocarcinoma arising in, 4.215
Zeiss 4-mirror goniolens, for gonioscopy, 10.33, 10.34*f*, 10.35
  in pediatric glaucoma, 10.159
Zellweger syndrome, 12.283*t*, 12.290
Zentmayer line, 10.94, 10.95*f*
Zernike polynomials, 13.9, 13.11*f*, 13.12*f*, 13.13*f*
  definition of, 3.42, 3.71, 3.139, 3.277
  higher-order aberrations characterized by, 3.139
  low-order, 3.73, 3.73*f*
  second-order, 3.73
  third-order, 3.73
  wavefront aberrations, 3.277
Zero-order aberrations, 13.11
Zeus transport medium, as tissue fixative, 4.26*t*
Zidovudine, 2.432*t*, 2.436
Ziehl-Neelsen stain, 4.31*t*
Zika fever, 9.269–270, 9.270*f*
Zika virus
  chorioretinitis caused by, 12.247
  description of, 1.265–266, 6.413
Zimmerman tumor (phakomatous choristoma), 4.202–203, 4.203*f*
Zinbryta. *See* Daclizumab
Zinc
  age-related macular degeneration managed with, 12.69, 12.70*t*
  in aqueous humor, 2.274
  in intraocular foreign body, 12.362
Zinc finger E box-binding homeobox 1 *(ZEB1)* gene, in posterior polymorphous corneal dystrophy, 8.136*t*
Zinn
  annulus of, 5.8*f*, 5.26, 5.45
  circle of (circle of Zinn-Haller), 2.120, 2.122*f*, 5.17, 10.44, 10.46, 12.217
  zonules of. *See* Zonular fibers, lens
Zioptan. *See* Tafluprost
Zirgan. *See* Ganciclovir
ZMC fractures. *See* Zygomaticomaxillary complex (ZMC) fractures
ZNF469 gene, 6.254
Zollinger-Ellison syndrome, 1.50
Zonal granuloma, 4.119, 4.119*f*
Zonal refractive multifocal intraocular lenses, 13.166, 13.166*f*. *See also* Multifocal lenses, intraocular
Zonulae adherentes, 2.98
Zonulae occludentes (tight junctions)
  in corneal epithelium, 8.8
  description of, 2.98, 12.17
Zonular (lamellar) cataracts, 11.34–35, 11.36*f*
Zonular dehiscence
  angle closure/pupillary block and, 10.119
  cataract surgery and, 11.181–183, 11.182*f*, 11.183*f*
    iris coloboma/corectopia and, 11.180
Zonular fibers
  lens (zonules of Zinn), 2.82–83, 2.83*f*, 2.292, 4.115, 4.117, 11.9, 11.10*f*, 11.12
    absent/abnormal
      cataract surgery and, 11.179–184
        iris coloboma/corectopia and, 11.180
        nucleus rotation and, 11.111
      in glaucoma, 10.33*t*, 10.119
    in accommodation, 13.159, 13.160, 13.160*f*, 13.161, 13.161*f*
    degenerations of, 4.124
    development of, 11.29
    evaluation of
      before cataract surgery, 11.80
      in glaucoma, 10.33*t*
    pigment deposits on, in pigment dispersion syndrome, 10.94, 10.95*f*
    in pseudoexfoliation/exfoliation syndrome, 10.92, 10.93, 10.130, 10.131*f*, 11.65–66, 11.181, 11.182*f*, 11.184
    as tertiary vitreous, 4.125
    topography of, 4.117
  ultrasound biomicroscopy of, 2.472*f*
  vitreous, tertiary, 4.125
  of vitreous, 2.298
Zonular lamella, 11.11
Zonular traction retinal tufts, 12.311, 12.312*f*
Zonules, of Zinn. *See* Zonular fibers, lens
Zostavax, 1.227
Zoster. *See* Herpes zoster; Varicella-zoster
Zoster dermatitis, 8.227, 8.229
Zoster sine herpete, 5.298
Zoster vaccine, 5.298, 8.229
Zosyn, 1.273
Zovirax. *See* Acyclovir
Zygoma. *See* Zygomatic bone
Zygomatic artery, 5.13*f*
Zygomatic bone (zygoma), 2.6*f*, 5.5, 5.7, 5.7*f*, 5.9*f*, 7.7–8*f*
Zygomatic branch of cranial nerve VII (facial), 5.51*f*, 5.52, 5.276–277*f*
Zygomatic fractures, 7.109, 7.111, 7.111*f*
Zygomatic nerve, 5.8*f*, 5.48*f*, 5.49, 5.51*f*
Zygomaticofacial artery, 2.25*f*, 5.15*f*
Zygomaticofacial canal, 7.10
Zygomaticofacial foramen, 2.11, 7.7–8*f*

Zygomaticofacial nerve, 5.49
Zygomaticomaxillary complex (ZMC) fractures, 7.109, 7.111, 7.111*f*
Zygomaticomaxillary suture, 5.8
Zygomaticotemporal artery, 2.25*f*, 5.15*f*
Zygomaticotemporal canal, 7.10
Zygomaticotemporal foramen/foramina, 2.11, 5.11, 7.7*f*
Zygomaticotemporal nerve, 5.49
Zygomycetes, 7.51
Zygomycetes infection (zygomycosis/mucormycosis/phycomycosis), 5.355*f*, 5.355–356, 8.251
  cornea involved in (keratitis), 4.78
  optic nerve involved in, 4.243
  orbit involved in, 4.226–227, 4.228*f*, 5.355
Zygomycosis, 7.51–52
Zygote, 2.215
Zylet. *See* Loteprednol etabonate/tobramycin
Zymar. *See* Gatifloxacin
Zymaxid. *See* Gatifloxacin

Basic and Clinical Science Course

Section 1 Update on General Medicine

Section 2 Fundamentals and Principles of Ophthalmology

Section 3 Clinical Optics

Section 4 Ophthalmic Pathology and Intraocular Tumors

Section 5 Neuro-Ophthalmology

Section 6 Pediatric Ophthalmology and Strabismus

Section 7 Oculofacial Plastic and Orbital Surgery

Section 8 External Disease and Cornea

Section 9 Uveitis and Ocular Inflammation

Section 10 Glaucoma

Section 11 Lens and Cataract

Section 12 Retina and Vitreous

Section 13 Refractive Surgery

Master Index

ISBN 978-1-68104-149-0
Item No. 02850939